nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	gabapentin-22||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
amod||reactions-4/NNS||pseudotumor-like-1/JJ	amod||reactions-4/NNS||periprosthetic-2/JJ	nn||reactions-4/NNS||tissue-3/NN	nsubj||cause-13/VB||reactions-4/NNS	nsubj||lead-16/VB||reactions-4/NNS	advmod||cause-13/VB||around-5/RB	amod||replacements-11/NNS||metal-on-metal-6/JJ	appos||replacements-11/NNS||m-m-8/NNP	amod||replacements-11/NNS||hip-10/JJ	nsubj||cause-13/VB||replacements-11/NNS	aux||cause-13/VB||can-12/MD	root||ROOT-0/null||cause-13/VB	dobj||cause-13/VB||pain-14/NN	conj_and||cause-13/VB||lead-16/VB	nn||surgery-19/NN||revision-18/NN	prep_to||lead-16/VB||surgery-19/NN	pain-14||metal--1||no_rel||pseudotumor-like periprosthetic tissue reactions around metal-on-metal (m-m) hip replacements can cause pain and lead to revision surgery.
nn||use-4/NN||metformin-1/NN	conj_and||metformin-1/NN||lovastatin-3/NN	nn||use-4/NN||lovastatin-3/NN	nsubjpass||improved-13/VBN||use-4/NN	prep_among||use-4/NN||patients-6/NNS	prep_of||patients-6/NNS||type2diabetes-8/NN	prep_of||patients-6/NNS||dyslipidemia-10/NN	conj_and||type2diabetes-8/NN||dyslipidemia-10/NN	auxpass||improved-13/VBN||is-11/VBZ	advmod||improved-13/VBN||significantly-12/RB	root||ROOT-0/null||improved-13/VBN	det||outcomes-16/NNS||the-14/DT	amod||outcomes-16/NNS||clinical-15/JJ	dobj||improved-13/VBN||outcomes-16/NNS	type2diabetes-8||metformin-1||yes||metformin and lovastatin use among patients of type2diabetes and dyslipidemia is significantly improved the clinical outcomes.
det||rate-6/NN||the-1/DT	amod||rate-6/NN||minimum-2/JJ	amod||rate-6/NN||estimated-3/JJ	nn||rate-6/NN||population-4/NN	nn||rate-6/NN||mortality-5/NN	nsubj||8.63-12/CD||rate-6/NN	prep_from||rate-6/NN||melioidosis-8/NNS	prep_in||melioidosis-8/NNS||2006-10/CD	cop||8.63-12/CD||was-11/VBD	root||ROOT-0/null||8.63-12/CD	num||people-15/NNS||100,000-14/CD	prep_per||8.63-12/CD||people-15/NNS	num||%-18/NN||95-17/CD	dep||people-15/NNS||%-18/NN	nn||â-22/FW||ci-19/FW	nn||â-22/FW||=-20/FW	nn||â-22/FW||7.33-21/FW	dep||%-18/NN||â-22/FW	dep||â-22/FW||$-23/$	num||$-23/$||10.11-25/CD	det||cause-32/NN||the-28/DT	amod||cause-32/NN||third-29/JJ	advmod||common-31/JJ||most-30/RBS	amod||cause-32/NN||common-31/JJ	appos||people-15/NNS||cause-32/NN	prep_of||cause-32/NN||death-34/NN	amod||diseases-37/NNS||infectious-36/JJ	prep_from||death-34/NN||diseases-37/NNS	prep_in||diseases-37/NNS||northeast-39/NN	vmod||northeast-39/NN||thailand-40/VBN	prep_after||thailand-40/VBN||humanimmunodeficiencyvirus-42/NNS	discourse||humanimmunodeficiencyvirus-42/NNS||hiv-44/UH	punct||aids-49/NNS||/-46/:	amod||aids-49/NNS||acquiredimmunodeficiencysyndrome-47/JJ	dep||humanimmunodeficiencyvirus-42/NNS||aids-49/NNS	dep||humanimmunodeficiencyvirus-42/NNS||tuberculosis-52/NNP	conj_and||aids-49/NNS||tuberculosis-52/NNP	acquiredimmunodeficiencysyndrome-47||humanimmunodeficiencyvirus-42||no||the minimum estimated population mortality rate from melioidosis in 2006 was 8.63 per 100,000 people (95% ci = 7.33â€“10.11), the third most common cause of death from infectious diseases in northeast thailand after humanimmunodeficiencyvirus (hiv)/acquiredimmunodeficiencysyndrome (aids) and tuberculosis.
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	adjuvant-21||hypersensitivity-12||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
nsubj||aids-9/NNS||predictors-1/NNS	prep_for||predictors-1/NNS||change-3/NN	det||reason-7/NN||any-6/DT	prep_due_to||change-3/NN||reason-7/NN	cop||aids-9/NNS||were-8/VBD	root||ROOT-0/null||aids-9/NNS	prep_at||aids-9/NNS||baseline-11/NN	det||use-14/NN||the-13/DT	conj_and||aids-9/NNS||use-14/NN	det||non-efavirenz-17/NN||a-16/DT	prep_of||use-14/NN||non-efavirenz-17/NN	vmod||non-efavirenz-17/NN||containing-18/VBG	dobj||containing-18/VBG||regimen-19/NN	aids-9||efavirenz--1||yes||predictors for change due to any reason were aids at baseline and the use of a non-efavirenz containing regimen.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	hypertension-21||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	nsubj||explore-21/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||level-12/NN||the-9/DT	amod||level-12/NN||cd127-10/JJ	nn||level-12/NN||expression-11/NN	dobj||investigate-8/VB||level-12/NN	amod||subsets-15/NNS||different-14/JJ	prep_on||investigate-8/VB||subsets-15/NNS	amod||cell-19/NN||cd8-17/JJ	nn||cell-19/NN||t-18/NN	prep_of||subsets-15/NNS||cell-19/NN	xcomp||was-6/VBD||explore-21/VB	conj_and||investigate-8/VB||explore-21/VB	det||relationship-23/NN||the-22/DT	dobj||explore-21/VB||relationship-23/NN	iobj||explore-21/VB||relationship-23/NN	amod||expression-26/NN||cd127-25/JJ	prep_between||relationship-23/NN||expression-26/NN	amod||cells-31/NNS||cd8-28/JJ	nn||cells-31/NNS||memory-29/NN	nn||cells-31/NNS||t-30/NN	prep_on||expression-26/NN||cells-31/NNS	prep_on||expression-26/NN||serumhepatitisbvirus-33/NNS	conj_and||cells-31/NNS||serumhepatitisbvirus-33/NNS	appos||relationship-23/NN||hbv-35/NN	amod||levels-45/NNS||dna-37/JJ	conj_and||dna-37/JJ||hepatitisb-39/JJ	amod||levels-45/NNS||hepatitisb-39/JJ	amod||levels-45/NNS||e-40/JJ	nn||levels-45/NNS||antigen-41/NN	appos||levels-45/NNS||hbeag-43/NN	dep||relationship-23/NN||levels-45/NNS	prep_in||levels-45/NNS||patients-47/NNS	prep_with||patients-47/NNS||chronichepatitisb-49/NN	dep||patients-47/NNS||chb-51/VBN	hbv-35||hepatitisbvirus--1||no||the aim of this study was to investigate the cd127 expression level on different subsets of cd8 t cell and explore the relationship between cd127 expression on cd8 memory t cells and serumhepatitisbvirus (hbv) dna and hepatitisb e antigen (hbeag) levels in patients with chronichepatitisb (chb).
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	sorethroat-25||antibody--1||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||reductase-10/NN||polyol-6/JJ	nn||reductase-10/NN||pathway-7/NN	nn||reductase-10/NN||enzymes-8/NNS	nn||reductase-10/NN||aldose-9/NN	prep_of||role-4/NN||reductase-10/NN	appos||reductase-10/NN||ar-12/NN	amod||dehydrogenase-16/NN||sorbitol-15/JJ	prep_of||role-4/NN||dehydrogenase-16/NN	conj_and||reductase-10/NN||dehydrogenase-16/NN	appos||reductase-10/NN||sdh-18/NN	prepc_in||investigated-2/VBD||mediating-21/VBG	dobj||mediating-21/VBG||injury-22/NN	amod||ischemia-reperfusion-25/JJ||due-23/JJ	dep||ischemia-reperfusion-25/JJ||to-24/TO	amod||injury-22/NN||ischemia-reperfusion-25/JJ	appos||injury-22/NN||ir-27/NN	amod||hearts-35/NNS||type-30/NN	number||type-30/NN||2-31/CD	amod||hearts-35/NNS||diabetic-32/JJ	amod||hearts-35/NNS||bbz-33/JJ	nn||hearts-35/NNS||rat-34/NN	prep_in||mediating-21/VBG||hearts-35/NNS	ischemia--1||sorbitol-15||no_rel||we investigated the role of polyol pathway enzymes aldose reductase (ar) and sorbitol dehydrogenase (sdh) in mediating injury due to ischemia-reperfusion (ir) in type 2 diabetic bbz rat hearts.
poss||data-2/NNS||our-1/PRP$	nsubj||show-3/VBP||data-2/NNS	root||ROOT-0/null||show-3/VBP	mark||induces-19/VBZ||that-4/IN	prepc_despite||induces-19/VBZ||having-7/VBG	amod||effects-10/NNS||adverse-8/JJ	amod||effects-10/NNS||acute-9/JJ	dobj||having-7/VBG||effects-10/NNS	amod||treatment-14/NN||tlr2-12/JJ	nn||treatment-14/NN||agonist-13/NN	nsubj||induces-19/VBZ||treatment-14/NN	det||intervention-18/NN||a-16/DT	amod||intervention-18/NN||therapeutic-17/JJ	prep_as||treatment-14/NN||intervention-18/NN	ccomp||show-3/VBP||induces-19/VBZ	det||expansion-21/NN||an-20/DT	dobj||induces-19/VBZ||expansion-21/NN	det||population-26/NN||the-23/DT	amod||population-26/NN||treg-24/JJ	nn||population-26/NN||cell-25/NN	prep_of||expansion-21/NN||population-26/NN	det||lungs-29/NNS||the-28/DT	prep_in||population-26/NN||lungs-29/NNS	prep_in||population-26/NN||results-31/NNS	conj_and||lungs-29/NNS||results-31/NNS	amod||protection-34/NN||long-term-33/JJ	prep_in||lungs-29/NNS||protection-34/NN	prep_against||protection-34/NN||manifestation-36/NN	prep_of||manifestation-36/NN||allergicasthma-38/NN	amod||provocation-42/NN||subsequent-40/JJ	nn||provocation-42/NN||allergen-41/NN	prep_upon||induces-19/VBZ||provocation-42/NN	allergen-41||allergicasthma-38||no_rel||our data show that, despite having adverse acute effects, tlr2 agonist treatment as a therapeutic intervention induces an expansion of the treg cell population in the lungs and results in long-term protection against manifestation of allergicasthma upon subsequent allergen provocation.
nsubj||is-2/VBZ||this-1/DT	root||ROOT-0/null||is-2/VBZ	mark||resolve-16/VB||because-3/IN	det||features-6/NNS||the-4/DT	amod||features-6/NNS||biochemical-5/JJ	nsubj||resolve-16/VB||features-6/NNS	amod||acidosis-11/NNS||high-8/JJ	amod||acidosis-11/NNS||anion-gap-9/JJ	amod||acidosis-11/NNS||metabolic-10/JJ	prep_of||features-6/NNS||acidosis-11/NNS	det||gap-15/NN||an-13/DT	nn||gap-15/NN||osmolar-14/NN	prep_of||features-6/NNS||gap-15/NN	conj_and||acidosis-11/NNS||gap-15/NN	advcl||is-2/VBZ||resolve-16/VB	number||72-20/CD||24-18/CD	dep||72-20/CD||to-19/TO	num||hours-21/NNS||72-20/CD	prep_within||resolve-16/VB||hours-21/NNS	mark||metabolized-26/VBN||as-22/IN	det||ethyleneglycol-24/NN||the-23/DT	nsubjpass||metabolized-26/VBN||ethyleneglycol-24/NN	auxpass||metabolized-26/VBN||is-25/VBZ	advcl||resolve-16/VB||metabolized-26/VBN	amod||metabolites-29/NNS||toxic-28/JJ	prep_to||metabolized-26/VBN||metabolites-29/NNS	ethyleneglycol-24||acidosis-11||no_rel||this is because the biochemical features of high anion-gap metabolic acidosis and an osmolar gap resolve within 24 to 72 hours as the ethyleneglycol is metabolized to toxic metabolites.
det||study-2/NN||the-1/DT	nsubjpass||planned-4/VBN||study-2/NN	nsubj||determine-6/VB||study-2/NN	auxpass||planned-4/VBN||was-3/VBD	root||ROOT-0/null||planned-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||planned-4/VBN||determine-6/VB	amod||influence-8/NN||cholinergic-7/JJ	dobj||determine-6/VB||influence-8/NN	amod||stages-11/NNS||different-10/JJ	prep_on||determine-6/VB||stages-11/NNS	prep_of||stages-11/NNS||memory-13/NN	dep||stages-11/NNS||acquisition-15/NN	dep||stages-11/NNS||consolidation-17/NN	conj_and||acquisition-15/NN||consolidation-17/NN	dep||stages-11/NNS||recall-19/NN	conj_and||acquisition-15/NN||recall-19/NN	amod||amnesia-22/NN||scopolamine-induced-21/JJ	prep_in||acquisition-15/NN||amnesia-22/NN	nn||impairment-25/NN||memory-24/NN	appos||stages-11/NNS||impairment-25/NN	prep_in||stages-11/NNS||mice-28/NNS	amnesia-22||scopolamine--1||no||the study was planned to determine cholinergic influence on different stages of memory - acquisition, consolidation and recall in scopolamine-induced amnesia (memory impairment) in mice.
nn||policies-3/NNS||results-1/NNS	nn||policies-3/NNS||national-level-2/NN	nsubj||had-6/VBN||policies-3/NNS	nsubj||response-16/NN||policies-3/NNS	aux||had-6/VBN||have-5/VBP	rcmod||policies-3/NNS||had-6/VBN	det||impact-9/NN||a-7/DT	amod||impact-9/NN||major-8/JJ	dobj||had-6/VBN||impact-9/NN	prepc_on||had-6/VBN||chinaâ-11/VBG	dobj||chinaâ-11/VBG||$-12/$	num||$-12/$||™-13/CD	cop||response-16/NN||s-14/VBZ	amod||response-16/NN||hiv/aids-15/JJ	dep||include-17/VBP||response-16/NN	root||ROOT-0/null||include-17/VBP	amod||frees-21/NNS||â-18/JJ	amod||frees-21/NNS||$-19/$	dep||$-19/$||˜four-20/JJ	dobj||include-17/VBP||frees-21/NNS	num||careâ-24/NNS||one-23/CD	dobj||include-17/VBP||careâ-24/NNS	conj_and||frees-21/NNS||careâ-24/NNS	nsubj||include-17/VBP||$-25/$	num||$-25/$||™-26/CD	amod||plans-30/NNS||5-year-28/JJ	nn||plans-30/NNS||action-29/NN	nsubj||include-17/VBP||plans-30/NNS	conj_and||$-25/$||plans-30/NNS	amod||regulation-34/NN||hiv/aids-33/JJ	nsubj||include-17/VBP||regulation-34/NN	conj_and||$-25/$||regulation-34/NN	aids--1||hiv--1||no||results national-level policies that have had a major impact on chinaâ€™s hiv/aids response include â€˜four frees and one careâ€™; 5-year action plans; and hiv/aids regulation.
prep_in||mandated-8/VBD||2006-2/CD	det||agency-7/NN||the-4/DT	nn||agency-7/NN||norwegian-5/NN	nn||agency-7/NN||medicines-6/NNS	nsubj||mandated-8/VBD||agency-7/NN	root||ROOT-0/null||mandated-8/VBD	det||switch-10/NN||a-9/DT	dobj||mandated-8/VBD||switch-10/NN	prep_from||mandated-8/VBD||desloratadine-12/NN	prep_from||mandated-8/VBD||ebastine-14/NN	conj_or||desloratadine-12/NN||ebastine-14/NN	prep_from||mandated-8/VBD||fexofenadine-17/NN	conj_or||desloratadine-12/NN||fexofenadine-17/NN	prep_to||desloratadine-12/NN||cetirizine-19/NN	prep_to||desloratadine-12/NN||loratadine-21/NN	conj_or||cetirizine-19/NN||loratadine-21/NN	prep_in||mandated-8/VBD||patients-23/NNS	amod||rhinitis-26/NNS||allergic-25/JJ	prep_with||patients-23/NNS||rhinitis-26/NNS	appos||rhinitis-26/NNS||ar-28/NN	amod||urticaria-32/NN||chronic-31/JJ	prep_with||patients-23/NNS||urticaria-32/NN	conj_or||rhinitis-26/NNS||urticaria-32/NN	appos||rhinitis-26/NNS||cu-34/NN	urticaria-32||cetirizine-19||yes||in 2006, the norwegian medicines agency mandated a switch from desloratadine, ebastine, or fexofenadine to cetirizine or loratadine in patients with allergic rhinitis (ar) or chronic urticaria (cu).
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tuberculosisinfection-17||bcg-33||no||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
amod||-rrb--6/NNS||legionella-1/JJ	nn||-rrb--6/NNS||pneumophila-2/NN	nn||-rrb--6/NNS||-lrb--3/NN	nn||-rrb--6/NNS||l.-4/NN	nn||-rrb--6/NNS||pneumophila-5/NN	nsubj||replicates-22/VBZ||-rrb--6/NNS	det||agent-10/NN||the-8/DT	amod||agent-10/NN||causative-9/JJ	appos||-rrb--6/NNS||agent-10/NN	det||form-14/NN||a-12/DT	amod||form-14/NN||severe-13/JJ	prep_of||agent-10/NN||form-14/NN	prep_of||form-14/NN||pneumonia-16/NN	vmod||pneumonia-16/NN||called-17/VBN	poss||disease-20/NN||legionnaires-18/NNS	dobj||called-17/VBN||disease-20/NN	root||ROOT-0/null||replicates-22/VBZ	amod||monocytes-25/NNS||human-24/JJ	prep_in||replicates-22/VBZ||monocytes-25/NNS	prep_in||replicates-22/VBZ||macrophages-27/NNS	conj_and||monocytes-25/NNS||macrophages-27/NNS	legionnaires' disease--1||legionella pneumophila--1||no||legionella pneumophila -lrb- l. pneumophila -rrb- , the causative agent of a severe form of pneumonia called legionnaires ' disease , replicates in human monocytes and macrophages .
amod||patients-2/NNS||sixty-1/JJ	nsubjpass||divided-12/VBN||patients-2/NNS	prep_with||patients-2/NNS||psychoticdisorder-4/NN	nsubjpass||assigned-7/VBN||psychoticdisorder-4/NN	auxpass||assigned-7/VBN||were-6/VBD	rcmod||psychoticdisorder-4/NN||assigned-7/VBN	amod||treatment-10/NN||6-month-9/JJ	prep_to||assigned-7/VBN||treatment-10/NN	auxpass||divided-12/VBN||were-11/VBD	root||ROOT-0/null||divided-12/VBN	num||groups-15/NNS||two-14/CD	prep_in||divided-12/VBN||groups-15/NNS	num||haloperidol-18/NN||30-16/CD	amod||haloperidol-18/NN||received-17/VBN	dobj||divided-12/VBN||haloperidol-18/NN	amod||antipsychotic-22/NN||first-20/JJ	nn||antipsychotic-22/NN||generation-21/NN	appos||haloperidol-18/NN||antipsychotic-22/NN	num||olanzapine-27/NN||30-25/CD	amod||olanzapine-27/NN||received-26/VBN	dobj||divided-12/VBN||olanzapine-27/NN	conj_and||haloperidol-18/NN||olanzapine-27/NN	amod||antipsychotic-31/NN||second-29/JJ	nn||antipsychotic-31/NN||generation-30/NN	appos||olanzapine-27/NN||antipsychotic-31/NN	psychoticdisorder-4||antipsychotic-31||no_rel||sixty patients with psychoticdisorder who were assigned to 6-month treatment were divided in two groups 30 received haloperidol (first generation antipsychotic) and 30 received olanzapine (second generation antipsychotic).
nsubj||â-2/VBP||conclusions-1/NNS	ccomp||have-15/VBP||â-2/VBP	dobj||â-2/VBP||$-3/$	prepc_compared_with||$-3/$||with-6/IN	pobj||$-3/$||youth-7/NN	prep_with||youth-7/NN||ngt-9/NN	amod||adolescents-12/NNS||obese-11/JJ	nsubj||have-15/VBP||adolescents-12/NNS	prep_with||adolescents-12/NNS||igt-14/NN	root||ROOT-0/null||have-15/VBP	dobj||have-15/VBP||evidence-16/NN	det||î-19/NN||a-18/DT	prep_of||evidence-16/NN||î-19/NN	punct||î-19/NN||²-20/''	nn||defect-23/NN||cell-22/NN	dep||î-19/NN||defect-23/NN	vmod||defect-23/NN||manifested-24/VBN	amod||secretion-29/NN||impaired-26/VBN	amod||secretion-29/NN||first-phase-27/JJ	nn||secretion-29/NN||insulin-28/NN	prep_in||manifested-24/VBN||secretion-29/NN	det||defect-35/NN||a-32/DT	amod||defect-35/NN||more-33/JJR	amod||defect-35/NN||profound-34/JJ	prep_with||î-19/NN||defect-35/NN	prep_in||defect-35/NN||type2diabetes-37/NNS	vmod||type2diabetes-37/NNS||involving-38/VBG	det||insulin-44/NN||both-39/DT	amod||insulin-44/NN||first-40/JJ	conj_and||first-40/JJ||second-phase-43/NN	amod||insulin-44/NN||second-phase-43/NN	dobj||involving-38/VBG||insulin-44/NN	type2diabetes-37||insulin-44||yes||conclusions â€”compared with youth with ngt, obese adolescents with igt have evidence of a î²-cell defect manifested in impaired first-phase insulin secretion, with a more profound defect in type2diabetes involving both first- and second-phase insulin.
mark||reported-4/VBN||since-1/IN	nsubjpass||reported-4/VBN||cq-2/NN	nsubj||inhibit-6/VB||cq-2/NN	auxpass||reported-4/VBN||is-3/VBZ	advcl||analyzed-39/VBD||reported-4/VBN	aux||inhibit-6/VB||to-5/TO	xcomp||reported-4/VBN||inhibit-6/VB	advmod||inhibit-6/VB||autophagy-7/RB	det||process-11/NN||the-9/DT	amod||process-11/NN||catabolic-10/JJ	dep||necessary-12/JJ||process-11/NN	parataxis||analyzed-39/VBD||necessary-12/JJ	nn||survival-15/NN||cell-14/NN	prep_for||necessary-12/JJ||survival-15/NN	nsubjpass||induced-26/VBN||survival-15/NN	prep_under||survival-15/NN||conditions-17/NNS	nn||starvation-20/NN||cell-19/NN	prep_of||conditions-17/NNS||starvation-20/NN	prep_of||conditions-17/NNS||stress-22/NN	conj_or||starvation-20/NN||stress-22/NN	auxpass||induced-26/VBN||is-25/VBZ	rcmod||survival-15/NN||induced-26/VBN	nn||cells-29/NNS||cancer-28/NN	agent||induced-26/VBN||cells-29/NNS	det||mechanism-33/NN||a-31/DT	amod||mechanism-33/NN||protective-32/JJ	prep_as||induced-26/VBN||mechanism-33/NN	prep_against||mechanism-33/NN||chemotherapeuticagents-35/NNS	nsubj||analyzed-39/VBD||we-37/PRP	advmod||analyzed-39/VBD||also-38/RB	root||ROOT-0/null||analyzed-39/VBD	det||induction-41/NN||the-40/DT	dobj||analyzed-39/VBD||induction-41/NN	prep_of||induction-41/NN||autophagy-43/NN	prep_in||analyzed-39/VBD||ht-29-45/JJ	cancer-28||chemotherapeuticagents-35||no_rel||since cq is reported to inhibit autophagy, the catabolic process necessary for cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective mechanism against chemotherapeuticagents, we also analyzed the induction of autophagy in ht-29.
nsubj||receive-11/VBP||individuals-1/NNS	vmod||individuals-1/NNS||aged-2/VBN	amod||years-6/NNS||18-85â-3/JJ	amod||years-6/NNS||$-4/$	dep||$-4/$||‰-5/JJ	tmod||aged-2/VBN||years-6/NNS	amod||depression-10/NN||unipolar-8/JJ	amod||depression-10/NN||psychotic-9/JJ	prep_with||aged-2/VBN||depression-10/NN	root||ROOT-0/null||receive-11/VBP	prt||receive-11/VBP||up-12/RP	amod||weeks-17/NNS||12â-14/JJ	amod||weeks-17/NNS||$-15/$	dep||$-15/$||‰-16/JJ	prep_to||receive-11/VBP||weeks-17/NNS	amod||treatment-20/NN||open-label-19/JJ	prep_of||weeks-17/NNS||treatment-20/NN	prep_with||treatment-20/NN||sertraline-22/NN	prep_with||treatment-20/NN||olanzapine-24/NN	conj_and||sertraline-22/NN||olanzapine-24/NN	psychotic-9||olanzapine-24||yes||individuals aged 18-85â€‰years with unipolar psychotic depression receive up to 12â€‰weeks of open-label treatment with sertraline and olanzapine.
nsubj||shows-4/VBZ||conclusion-1/NN	det||paper-3/NN||this-2/DT	dep||conclusion-1/NN||paper-3/NN	root||ROOT-0/null||shows-4/VBZ	det||importance-6/NN||the-5/DT	dobj||shows-4/VBZ||importance-6/NN	prepc_of||importance-6/NN||incorporating-8/VBG	preconj||level-11/NN||both-9/DT	amod||level-11/NN||individual-10/JJ	dobj||incorporating-8/VBG||level-11/NN	dobj||incorporating-8/VBG||change-13/NN	conj_and||level-11/NN||change-13/NN	prep_in||level-11/NN||depression-15/NN	prep_as||incorporating-8/VBG||predictors-17/NNS	prep_of||predictors-17/NNS||change-19/NN	nn||consumption-22/NN||alcohol-21/NN	prep_in||change-19/NN||consumption-22/NN	prep_among||incorporating-8/VBG||subjects-24/NNS	vmod||subjects-24/NNS||treated-25/VBN	prep_for||treated-25/VBN||alcoholaddiction-27/NN	alcoholaddiction-27||alcohol-21||no||conclusion this paper shows the importance of incorporating both individual level and change in depression as predictors of change in alcohol consumption among subjects treated for alcoholaddiction.
nsubjpass||investigated-4/VBN||cloperastine-1/NN	nsubjpass||shown-17/VBN||cloperastine-1/NN	nsubj||possess-19/VB||cloperastine-1/NN	aux||investigated-4/VBN||has-2/VBZ	auxpass||investigated-4/VBN||been-3/VBN	root||ROOT-0/null||investigated-4/VBN	amod||types-7/NNS||various-6/JJ	prep_in||investigated-4/VBN||types-7/NNS	prep_of||types-7/NNS||cough-9/NN	dep||investigated-4/VBN||unlike-12/IN	pobj||unlike-12/IN||codeine-13/NN	aux||shown-17/VBN||has-15/VBZ	auxpass||shown-17/VBN||been-16/VBN	conj_and||investigated-4/VBN||shown-17/VBN	aux||possess-19/VB||to-18/TO	xcomp||shown-17/VBN||possess-19/VB	amod||activity-21/NN||dual-20/JJ	dobj||possess-19/VB||activity-21/NN	cough-9||codeine-13||yes||cloperastine has been investigated in various types of cough and, unlike codeine, has been shown to possess dual activity.
amod||lato-3/NN||borreliaburgdorferi-1/JJ	amod||lato-3/NN||sensu-2/JJ	nsubjpass||transmitted-15/VBN||lato-3/NN	appos||lato-3/NN||sl-5/NN	det||agent-10/NN||the-8/DT	amod||agent-10/NN||causative-9/JJ	appos||lato-3/NN||agent-10/NN	prep_of||agent-10/NN||lymeborreliosis-12/NNS	auxpass||transmitted-15/VBN||is-14/VBZ	root||ROOT-0/null||transmitted-15/VBN	agent||transmitted-15/VBN||ticks-17/NNS	det||ixodes-21/NNS||the-19/DT	amod||ixodes-21/NNS||genus-20/JJ	prep_of||ticks-17/NNS||ixodes-21/NNS	prep_as||transmitted-15/VBN||vector-23/NN	lymeborreliosis-12||borreliaburgdorferi-1||no||borreliaburgdorferi sensu lato (sl), the causative agent of lymeborreliosis, is transmitted by ticks of the genus ixodes as vector.
nsubj||play-18/VBP||retinoicacid-1/NN	prep_including||retinoicacid-1/NN||all-4/DT	dep||all-4/DT||trans-6/NNS	vmod||trans-6/NNS||retinoicacid-7/VBN	num||cis-11/CD||9-9/CD	dep||all-4/DT||cis-11/CD	conj_and||trans-6/NNS||cis-11/CD	dep||all-4/DT||13-13/CD	conj_and||trans-6/NNS||13-13/CD	dep||all-4/DT||cis-15/NN	vmod||cis-15/NN||retinoicacid-16/VBN	root||ROOT-0/null||play-18/VBP	amod||roles-20/NNS||important-19/JJ	dobj||play-18/VBP||roles-20/NNS	amod||processes-24/NNS||various-22/JJ	amod||processes-24/NNS||physiological-23/JJ	prep_in||roles-20/NNS||processes-24/NNS	prepc_such_as||roles-20/NNS||in-28/IN	amod||growth-37/NN||embryonic-29/JJ	nn||growth-37/NN||development-30/NN	pobj||in-28/IN||reproduction-32/NN	conj_and||growth-37/NN||reproduction-32/NN	pobj||in-28/IN||vision-34/NN	conj_and||growth-37/NN||vision-34/NN	pobj||in-28/IN||cell-36/NN	conj_and||growth-37/NN||cell-36/NN	pobj||in-28/IN||growth-37/NN	pobj||in-28/IN||differentiation-39/NN	conj_and||growth-37/NN||differentiation-39/NN	pobj||in-28/IN||apoptosis-41/NNS	conj_and||growth-37/NN||apoptosis-41/NNS	pobj||in-28/IN||inflammation-43/NN	conj_and||growth-37/NN||inflammation-43/NN	retinoicacid-16||inflammation-43||no_rel||retinoicacid, including all- trans retinoicacid, 9- cis and 13- cis retinoicacid, play important roles in various physiological processes, such as in embryonic development, reproduction, vision, cell growth, differentiation, apoptosis and inflammation.
prep_in_addition_to||secreted-17/VBD||rantes-4/NNS	amod||±-9/NNS||il-8-6/JJ	amod||±-9/NNS||mip-1î-8/JJ	conj_and||rantes-4/NNS||±-9/NNS	prep_in_addition_to||secreted-17/VBD||±-9/NNS	amod||²-12/NNS||mip-1î-11/JJ	conj_and||rantes-4/NNS||²-12/NNS	prep_in_addition_to||secreted-17/VBD||²-12/NNS	amod||cells-16/NNS||reovirus-infected-14/JJ	nn||cells-16/NNS||melanoma-15/NN	nsubj||secreted-17/VBD||cells-16/NNS	root||ROOT-0/null||secreted-17/VBD	dobj||secreted-17/VBD||eotaxin-18/NN	dobj||secreted-17/VBD||ip-10-20/JJ	conj_and||eotaxin-18/NN||ip-10-20/JJ	det||²-27/NN||the-22/DT	nn||²-27/NN||type-23/NN	num||²-27/NN||1-24/CD	nn||²-27/NN||interferon-25/NN	nn||²-27/NN||ifn-î-26/NN	dobj||secreted-17/VBD||²-27/NN	conj_and||eotaxin-18/NN||²-27/NN	melanoma-15||ifn--1||yes||in addition to rantes, il-8, mip-1î± and mip-1î², reovirus-infected melanoma cells secreted eotaxin, ip-10 and the type 1 interferon ifn-î².
nsubjpass||expressed-4/VBN||mrp7-1/NNS	auxpass||expressed-4/VBN||is-2/VBZ	advmod||expressed-4/VBN||highly-3/RB	root||ROOT-0/null||expressed-4/VBN	amod||cells-7/NNS||non-smallcelllungcancer-6/JJ	prep_in||expressed-4/VBN||cells-7/NNS	amod||mice-11/NNS||mrp7-ko-10/JJ	nsubj||sensitive-14/JJ||mice-11/NNS	cop||sensitive-14/JJ||are-12/VBP	advmod||sensitive-14/JJ||highly-13/RB	conj_and||expressed-4/VBN||sensitive-14/JJ	prep_to||sensitive-14/JJ||paclitaxel-16/NN	xcomp||sensitive-14/JJ||making-18/VBG	amod||target-23/NN||mrp7-19/JJ	det||target-23/NN||an-20/DT	amod||chemotherapeutic-22/JJ||attractive-21/JJ	amod||target-23/NN||chemotherapeutic-22/JJ	dobj||making-18/VBG||target-23/NN	prep_of||target-23/NN||non-smallcelllungcancer-25/NN	paclitaxel-16||non-smallcelllungcancer-25||no_rel||mrp7 is highly expressed in non-smallcelllungcancer cells, and mrp7-ko mice are highly sensitive to paclitaxel, making mrp7 an attractive chemotherapeutic target of non-smallcelllungcancer.
advmod||recommended-35/VBN||furthermore-1/RB	nsubjpass||recommended-35/VBN||development-3/NN	det||policy-6/NN||a-5/DT	prep_of||development-3/NN||policy-6/NN	nsubj||encourages-8/VBZ||policy-6/NN	rcmod||policy-6/NN||encourages-8/VBZ	dobj||encourages-8/VBZ||equality-9/NN	prep_in||equality-9/NN||access-11/NN	nn||care-14/NN||health-13/NN	prep_to||access-11/NN||care-14/NN	det||patients-17/NNS||all-16/DT	prep_for||care-14/NN||patients-17/NNS	prep_with||patients-17/NNS||hiv/aids-19/NNS	prepc_by||encourages-8/VBZ||applying-21/VBG	det||conditions-24/NNS||the-22/DT	amod||conditions-24/NNS||same-23/JJ	dobj||applying-21/VBG||conditions-24/NNS	preconj||men-27/NNS||both-26/DT	prep_to||applying-21/VBG||men-27/NNS	prep_to||applying-21/VBG||women-29/NNS	conj_and||men-27/NNS||women-29/NNS	nn||institutions-33/NNS||health-31/NN	nn||institutions-33/NNS||care-32/NN	prep_in||men-27/NNS||institutions-33/NNS	auxpass||recommended-35/VBN||is-34/VBZ	root||ROOT-0/null||recommended-35/VBN	aids--1||hiv--1||no||furthermore, development of a policy that encourages equality in access to health care for all patients with hiv/aids by applying the same conditions to both men and women in health care institutions is recommended.
nsubj||shown-6/VBN||bortezomib-1/NN	prep_in||bortezomib-1/NN||particular-4/NN	aux||shown-6/VBN||has-5/VBZ	root||ROOT-0/null||shown-6/VBN	amod||efficacy-9/NN||significant-7/JJ	amod||efficacy-9/NN||clinical-8/JJ	dobj||shown-6/VBN||efficacy-9/NN	nn||treatment-12/NN||myeloma-11/NN	prep_in||efficacy-9/NN||treatment-12/NN	myeloma-11||bortezomib-1||yes||bortezomib, in particular has shown significant clinical efficacy in myeloma treatment.
nsubjpass||defined-7/VBN||diabeticretinopathy-1/NN	appos||diabeticretinopathy-1/NN||dr-3/NN	auxpass||defined-7/VBN||is-5/VBZ	advmod||defined-7/VBN||classically-6/RB	root||ROOT-0/null||defined-7/VBN	det||microvasculopathy-10/NN||a-9/DT	prep_as||defined-7/VBN||microvasculopathy-10/NN	nsubj||affects-13/VBZ||microvasculopathy-10/NN	advmod||affects-13/VBZ||primarily-12/RB	rcmod||microvasculopathy-10/NN||affects-13/VBZ	det||vessels-17/NNS||the-14/DT	amod||vessels-17/NNS||small-15/JJ	nn||vessels-17/NNS||blood-16/NN	dobj||affects-13/VBZ||vessels-17/NNS	det||retina-21/NN||the-19/DT	amod||retina-21/NN||inner-20/JJ	prep_of||vessels-17/NNS||retina-21/NN	det||complication-24/NN||a-23/DT	prep_as||affects-13/VBZ||complication-24/NN	prep_of||complication-24/NN||diabetesmellitus-26/NNS	appos||diabetesmellitus-26/NNS||dm-28/NN	diabeticretinopathy-1||diabetesmellitus-26||no||diabeticretinopathy (dr) is classically defined as a microvasculopathy that primarily affects the small blood vessels of the inner retina as a complication of diabetesmellitus (dm).
nsubj||complication-5/NN||intracranialtuberculomas-1/NNS	cop||complication-5/NN||are-2/VBP	det||complication-5/NN||a-3/DT	amod||complication-5/NN||rare-4/JJ	root||ROOT-0/null||complication-5/NN	prep_of||complication-5/NN||tuberculosis-7/NNP	vmod||tuberculosis-7/NNP||occurring-8/VBG	prep_through||occurring-8/VBG||hematogenous-10/NNS	vmod||hematogenous-10/NNS||spread-11/VBN	det||source-15/NN||an-13/DT	amod||source-15/NN||extracranial-14/JJ	prep_from||spread-11/VBN||source-15/NN	advmod||often-18/RB||most-17/RBS	advmod||spread-11/VBN||often-18/RB	amod||origin-21/NN||pulmonary-20/JJ	prep_of||complication-5/NN||origin-21/NN	intracranialtuberculomas-1||tuberculosis-7||no||intracranialtuberculomas are a rare complication of tuberculosis occurring through hematogenous spread from an extracranial source, most often of pulmonary origin.
det||correspondence-2/NN||this-1/DT	nsubj||suggests-26/VBZ||correspondence-2/NN	det||mapping-8/NN||the-6/DT	amod||mapping-8/NN||well-known-7/JJ	prep_together_with||correspondence-2/NN||mapping-8/NN	det||polymerase-12/NN||the-10/DT	amod||polymerase-12/NN||conserved-11/JJ	prep_of||mapping-8/NN||polymerase-12/NN	dep||correspondence-2/NN||motifs-13/NNS	det||regions-17/NNS||the-15/DT	amod||regions-17/NNS||central-16/JJ	prep_to||motifs-13/NNS||regions-17/NNS	det||l-protein-20/NN||the-19/DT	prep_of||regions-17/NNS||l-protein-20/NN	nn||subunit-24/NN||influenza-22/NN	nn||subunit-24/NN||pb1-23/NNS	prep_of||regions-17/NNS||subunit-24/NN	conj_and||l-protein-20/NN||subunit-24/NN	root||ROOT-0/null||suggests-26/VBZ	mark||architecturally-31/JJ||that-27/IN	nsubj||architecturally-31/JJ||l-proteins-28/NNS	nsubj||pa-pb1-pb2-48/JJ||l-proteins-28/NNS	aux||architecturally-31/JJ||might-29/MD	cop||architecturally-31/JJ||be-30/VB	ccomp||suggests-26/VBZ||architecturally-31/JJ	advmod||equivalent-35/JJ||functionally-34/RB	amod||subunits-44/NNS||equivalent-35/JJ	det||concatemer-38/NN||a-37/DT	prep_to||equivalent-35/JJ||concatemer-38/NN	det||orthomyxovirus-42/NNS||the-40/DT	num||orthomyxovirus-42/NNS||three-41/CD	prep_of||concatemer-38/NN||orthomyxovirus-42/NNS	nn||subunits-44/NNS||polymerase-43/NN	dep||pa-pb1-pb2-48/JJ||subunits-44/NNS	det||order-47/NN||the-46/DT	prep_in||subunits-44/NNS||order-47/NN	ccomp||suggests-26/VBZ||pa-pb1-pb2-48/JJ	conj_and||architecturally-31/JJ||pa-pb1-pb2-48/JJ	influenza-22||orthomyxovirus-42||no||this correspondence, together with the well-known mapping of the conserved polymerase motifs to the central regions of the l-protein and influenza pb1 subunit, suggests that l-proteins might be architecturally, and functionally equivalent to a concatemer of the three orthomyxovirus polymerase subunits in the order pa-pb1-pb2.
amod||viral-2/NNS||dual-1/JJ	nsubj||elevated-5/VBD||viral-2/NNS	conj_and||viral-2/NNS||bacterialinfection-4/NNS	nsubj||elevated-5/VBD||bacterialinfection-4/NNS	root||ROOT-0/null||elevated-5/VBD	det||load-8/NN||the-6/DT	amod||load-8/NN||bacterial-7/JJ	dobj||elevated-5/VBD||load-8/NN	prepc_compared_to||elevated-5/VBD||to-10/TO	pobj||elevated-5/VBD||animals-11/NNS	vmod||animals-11/NNS||infected-12/VBN	prep_with||infected-12/VBN||bacteria-14/NNS	advmod||infected-12/VBN||alone-15/RB	bacterialinfection-4||bacterial-7||no||dual viral and bacterialinfection elevated the bacterial load compared to animals infected with bacteria alone.
mark||proposed-5/VBN||as-1/IN	aux||proposed-5/VBN||can-2/MD	advmod||proposed-5/VBN||also-3/RB	auxpass||proposed-5/VBN||be-4/VB	advcl||appears-14/VBZ||proposed-5/VBN	nn||diabetesmellitus-9/NNS||type-7/FW	nn||diabetesmellitus-9/NNS||i-8/FW	prep_for||proposed-5/VBN||diabetesmellitus-9/NNS	nn||interferon-13/NN||type-11/FW	nn||interferon-13/NN||i-12/FW	nsubj||appears-14/VBZ||interferon-13/NN	nsubj||contribute-16/VB||interferon-13/NN	root||ROOT-0/null||appears-14/VBZ	aux||contribute-16/VB||to-15/TO	xcomp||appears-14/VBZ||contribute-16/VB	det||development-19/NN||the-18/DT	prep_to||contribute-16/VB||development-19/NN	nn||progression-24/NN||autoimmunity-21/NN	conj_and||autoimmunity-21/NN||disease-23/NN	nn||progression-24/NN||disease-23/NN	prep_of||development-19/NN||progression-24/NN	amod||autoimmunediseases-27/NNS||multiple-26/JJ	prep_in||contribute-16/VB||autoimmunediseases-27/NNS	mark||maintaining-30/VBG||while-29/IN	advcl||contribute-16/VB||maintaining-30/VBG	det||capacity-32/NN||some-31/DT	dobj||maintaining-30/VBG||capacity-32/NN	aux||control-34/VB||to-33/TO	vmod||capacity-32/NN||control-34/VB	amod||disease-36/NN||established-35/JJ	dobj||control-34/VB||disease-36/NN	advmod||contribute-16/VB||particularly-38/RB	amod||sites-41/NNS||local-40/JJ	prep_at||contribute-16/VB||sites-41/NNS	prep_of||sites-41/NNS||inflammation-43/NN	autoimmunediseases-27||interferon-13||no||as can also be proposed for type i diabetesmellitus, type i interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmunediseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation.
det||study-3/NN||this-2/DT	prep_in||used-5/VBD||study-3/NN	nsubj||used-5/VBD||we-4/PRP	root||ROOT-0/null||used-5/VBD	num||assays-8/NNS||two-6/CD	nn||assays-8/NNS||pcr-7/NN	dobj||used-5/VBD||assays-8/NNS	nsubj||screen-14/VB||assays-8/NNS	num||assay-12/NN||one-10/CD	nn||assay-12/NN||antibody-11/NN	dobj||used-5/VBD||assay-12/NN	conj_and||assays-8/NNS||assay-12/NN	nsubj||screen-14/VB||assay-12/NN	aux||screen-14/VB||to-13/TO	xcomp||used-5/VBD||screen-14/VB	num||samples-17/NNS||25-15/CD	nn||samples-17/NNS||blood-16/NN	dobj||screen-14/VB||samples-17/NNS	amod||children-20/NNS||autistic-19/JJ	prep_from||screen-14/VB||children-20/NNS	vmod||children-20/NNS||born-21/VBN	vmod||children-20/NNS||born-21/VBN	conj_and||born-21/VBN||born-21/VBN	prep_to||born-21/VBN||mothers-23/NNS	prep_with||mothers-23/NNS||cfs-25/NN	num||controls-30/NNS||20-28/CD	amod||controls-30/NNS||mixed-29/VBN	prep_from||born-21/VBN||controls-30/NNS	nn||members-33/NNS||family-32/NN	prep_including||controls-30/NNS||members-33/NNS	det||assayed-37/NN||the-35/DT	nn||assayed-37/NN||children-36/NNS	prep_of||members-33/NNS||assayed-37/NN	prep_including||controls-30/NNS||people-39/NNS	conj_and||members-33/NNS||people-39/NNS	prep_with||people-39/NNS||fibromyalgia-41/NNP	prep_including||controls-30/NNS||people-43/NNS	conj_and||members-33/NNS||people-43/NNS	amod||lymedisease-46/NN||chronic-45/JJ	prep_with||people-43/NNS||lymedisease-46/NN	autistic-19||antibody-11||no_rel||in this study we used two pcr assays and one antibody assay to screen 25 blood samples from autistic children born to mothers with cfs and from 20 mixed controls including family members of the children assayed, people with fibromyalgia and people with chronic lymedisease.
advmod||was-9/VBD||therefore-1/RB	det||aim-5/NN||the-3/DT	amod||aim-5/NN||specific-4/JJ	nsubj||was-9/VBD||aim-5/NN	nsubj||test-11/VB||aim-5/NN	det||study-8/NN||this-7/DT	prep_of||aim-5/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||test-11/VB||to-10/TO	xcomp||was-9/VBD||test-11/VB	det||hypothesis-13/NNS||the-12/DT	dobj||test-11/VB||hypothesis-13/NNS	mark||amplify-22/VB||that-14/IN	amod||use-16/NN||6-week-15/JJ	nsubj||amplify-22/VB||use-16/NN	det||fluoxetine-20/NN||the-18/DT	amod||fluoxetine-20/NN||ssri-19/JJ	prep_of||use-16/NN||fluoxetine-20/NN	aux||amplify-22/VB||would-21/MD	ccomp||test-11/VB||amplify-22/VB	amod||system-25/NN||autonomic-23/JJ	amod||system-25/NN||nervous-24/JJ	dobj||amplify-22/VB||system-25/NN	dep||amplify-22/VB||ans-27/NN	amod||responses-30/NNS||counterregulatory-29/JJ	dobj||amplify-22/VB||responses-30/NNS	prep_to||responses-30/NNS||hypoglycemia-32/NN	prep_in||amplify-22/VB||individuals-34/NNS	prep_with||amplify-22/VB||type1diabetes-36/CD	fluoxetine-20||type1diabetes-36||no_rel||therefore, the specific aim of this study was to test the hypothesis that 6-week use of the ssri fluoxetine would amplify autonomic nervous system (ans) counterregulatory responses to hypoglycemia in individuals with type1diabetes.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	amod||analysis-5/NN||proteomic-4/JJ	prep_by||identified-2/VBD||analysis-5/NN	vmod||analysis-5/NN||using-6/VBG	amod||electrophoresis-8/NNS||2d-dige-7/JJ	dobj||using-6/VBG||electrophoresis-8/NNS	prep||using-6/VBG||combined-9/VBN	pcomp||combined-9/VBN||with-10/IN	amod||spectrometry-17/NN||maldi-tof-tof-11/JJ	conj_and||maldi-tof-tof-11/JJ||esi-linear-13/JJ	amod||spectrometry-17/NN||esi-linear-13/JJ	nn||spectrometry-17/NN||ion-14/NN	nn||spectrometry-17/NN||trap-15/NN	nn||spectrometry-17/NN||mass-16/NN	pobj||with-10/IN||spectrometry-17/NN	det||number-19/NN||a-18/DT	dobj||identified-2/VBD||number-19/NN	poss||expression-26/NN||number-19/NN	prep_of||number-19/NN||proteins-21/NNS	amod||functions-24/NNS||variable-23/JJ	prep_with||proteins-21/NNS||functions-24/NNS	nsubjpass||modulated-28/VBN||expression-26/NN	auxpass||modulated-28/VBN||is-27/VBZ	rcmod||number-19/NN||modulated-28/VBN	agent||modulated-28/VBN||snail1-30/NNS	amod||cells-36/NNS||sw480-adh-32/JJ	amod||cells-36/NNS||human-33/JJ	nn||cells-36/NNS||colon-34/NN	nn||cells-36/NNS||cancer-35/NN	prep_in||snail1-30/NNS||cells-36/NNS	ion-14||cancer-35||no_rel||we identified by proteomic analysis using 2d-dige electrophoresis combined with maldi-tof-tof and esi-linear ion trap mass spectrometry a number of proteins with variable functions whose expression is modulated by snail1 in sw480-adh human colon cancer cells.
mark||shown-5/VBN||although-1/IN	amod||monotherapy-3/NN||docetaxel-2/JJ	nsubj||shown-5/VBN||monotherapy-3/NN	aux||shown-5/VBN||has-4/VBZ	advcl||controversial-38/JJ||shown-5/VBN	amod||benefits-7/NNS||clinical-6/JJ	dobj||shown-5/VBN||benefits-7/NNS	advmod||treated-10/JJ||previously-9/RB	amod||patients-11/NNS||treated-10/JJ	prep_for||shown-5/VBN||patients-11/NNS	amod||non-smallcelllungcancer-14/NN||advanced-13/VBN	prep_with||patients-11/NNS||non-smallcelllungcancer-14/NN	dep||patients-11/NNS||nsclc-16/JJ	det||efficacy-20/NN||the-19/DT	nsubj||controversial-38/JJ||efficacy-20/NN	nn||chemotherapy-24/NN||salvage-22/NN	amod||chemotherapy-24/NN||docetaxel-23/JJ	prep_of||efficacy-20/NN||chemotherapy-24/NN	amod||patients-27/NNS||elderly-26/JJ	prep_for||chemotherapy-24/NN||patients-27/NNS	prep_for||chemotherapy-24/NN||patients-29/NNS	conj_or||patients-27/NNS||patients-29/NNS	amod||status-33/NN||poor-31/JJ	nn||status-33/NN||performance-32/NN	prep_with||patients-27/NNS||status-33/NN	appos||status-33/NN||ps-35/NN	cop||controversial-38/JJ||is-37/VBZ	root||ROOT-0/null||controversial-38/JJ	nsclc-16||docetaxel-23||yes||although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-smallcelllungcancer (nsclc), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with poor performance status (ps) is controversial.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||decreases-4/NNS||significant-3/JJ	nsubj||were-2/VBD||decreases-4/NNS	prep_in||decreases-4/NNS||survival-6/NN	nn||output-9/NN||urine-8/NN	prep_in||decreases-4/NNS||output-9/NN	conj_and||survival-6/NN||output-9/NN	amod||output-12/NN||cardiac-11/JJ	prep_in||decreases-4/NNS||output-12/NN	conj_and||survival-6/NN||output-12/NN	nn||delivery-15/NN||oxygen-14/NN	conj_and||survival-6/NN||delivery-15/NN	conj_and||output-12/NN||delivery-15/NN	amod||min-18/NN||60â-17/JJ	prep_at||output-12/NN||min-18/NN	amod||consumption-21/NN||o2-20/JJ	prep_in||decreases-4/NNS||consumption-21/NN	conj_and||survival-6/NN||consumption-21/NN	amod||min-24/NN||120â-23/JJ	prep_at||consumption-21/NN||min-24/NN	det||group-28/NN||the-26/DT	nn||group-28/NN||pneumonia-27/NN	prep_in||min-24/NN||group-28/NN	prepc_compared_to||group-28/NN||to-30/TO	det||group-35/NN||the-31/DT	amod||group-35/NN||nonâ-32/JJ	amod||group-35/NN||$-33/$	number||$-33/$||pneumonia-34/CD	pobj||group-28/NN||group-35/NN	pneumonia-34||o2-20||yes||there were significant decreases in survival, urine output, cardiac output and oxygen delivery at 60â min and o2 consumption at 120â min in the pneumonia group compared to the nonâ€?pneumonia group.
nn||ebv-3/NN||type-1/NN	num||ebv-3/NN||1-2/CD	nsubj||genotypes-12/NNS||ebv-3/NN	amod||zp-p-6/NN||bzlf1-5/JJ	conj_and||ebv-3/NN||zp-p-6/NN	nsubj||genotypes-12/NNS||zp-p-6/NN	prep_of||zp-p-6/NN||ebv-8/NN	cop||genotypes-12/NNS||were-9/VBD	det||genotypes-12/NNS||the-10/DT	amod||genotypes-12/NNS||predominant-11/JJ	root||ROOT-0/null||genotypes-12/NNS	amod||ebv-15/NN||nonmalignant-14/JJ	prep_in||genotypes-12/NNS||ebv-15/NN	vmod||ebv-15/NN||associated-16/VBN	dobj||associated-16/VBN||diseases-17/NNS	amod||children-20/NNS||chinese-19/JJ	prep_in||diseases-17/NNS||children-20/NNS	amod||variant-23/NN||zp-v3-22/JJ	nsubj||correlates-25/VB||variant-23/NN	aux||correlates-25/VB||may-24/MD	conj_and||genotypes-12/NNS||correlates-25/VB	prep_with||correlates-25/VB||the-27/DT	amod||the-27/DT||developing-28/VBG	amod||diseases-32/NNS||severe-30/JJ	nn||diseases-32/NNS||ebvinfection-31/NN	prep_of||the-27/DT||diseases-32/NNS	prep_such_as||the-27/DT||caebv-36/NN	prep_such_as||the-27/DT||ebv-hlh-38/NN	conj_and||caebv-36/NN||ebv-hlh-38/NN	ebvinfection-31||ebv-15||no||type 1 ebv and bzlf1 zp-p of ebv were the predominant genotypes in nonmalignant ebv associated diseases in chinese children and zp-v3 variant may correlates with the developing of severe ebvinfection diseases, such as caebv and ebv-hlh.
amod||resistance-3/NN||primary-1/JJ	amod||resistance-3/NN||glucocorticoid-2/JJ	nsubj||hereditarydisease-11/NN||resistance-3/NN	appos||resistance-3/NN||omim-5/NN	num||omim-5/NN||138040-6/CD	cop||hereditarydisease-11/NN||is-8/VBZ	det||hereditarydisease-11/NN||a-9/DT	amod||hereditarydisease-11/NN||rare-10/JJ	root||ROOT-0/null||hereditarydisease-11/NN	nsubj||causes-13/VBZ||hereditarydisease-11/NN	rcmod||hereditarydisease-11/NN||causes-13/VBZ	det||insensitivity-17/NN||a-14/DT	amod||insensitivity-17/NN||generalized-15/JJ	amod||insensitivity-17/NN||partial-16/JJ	dobj||causes-13/VBZ||insensitivity-17/NN	amod||action-20/NN||glucocorticoid-19/JJ	prep_to||causes-13/VBZ||action-20/NN	acomp||causes-13/VBZ||due-22/JJ	amod||alterations-25/NNS||genetic-24/JJ	prep_to||due-22/JJ||alterations-25/NNS	det||receptor-29/NN||the-27/DT	amod||receptor-29/NN||glucocorticoid-28/JJ	prep_of||alterations-25/NNS||receptor-29/NN	appos||receptor-29/NN||gr-31/NN	hereditarydisease-11||glucocorticoid-28||no_rel||primary glucocorticoid resistance (omim 138040) is a rare hereditarydisease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (gr).
det||area-3/NN||an-2/DT	prep_in||increased-14/VBN||area-3/NN	advmod||prevalent-8/JJ||where-4/WRB	amod||mrsa-6/NN||pvl-containing-5/JJ	nsubj||prevalent-8/JJ||mrsa-6/NN	cop||prevalent-8/JJ||is-7/VBZ	rcmod||area-3/NN||prevalent-8/JJ	nn||risk-12/NN||skin-10/NN	nn||risk-12/NN||infection-11/NN	nsubjpass||increased-14/VBN||risk-12/NN	auxpass||increased-14/VBN||was-13/VBD	root||ROOT-0/null||increased-14/VBN	amod||carriers-18/NNS||mrsa-16/JJ	amod||carriers-18/NNS||nasal-17/JJ	prep_among||increased-14/VBN||carriers-18/NNS	prepc_compared_with||increased-14/VBN||with-20/IN	amod||carriers-23/NNS||methicillin-susceptible-21/JJ	nn||carriers-23/NNS||s.aureus-22/NN	pobj||increased-14/VBN||carriers-23/NNS	pobj||increased-14/VBN||noncarriers-25/NNS	conj_and||carriers-23/NNS||noncarriers-25/NNS	nn||differential-29/NN||risk-28/NN	nsubj||diminished-30/VBN||differential-29/NN	conj_but||increased-14/VBN||diminished-30/VBN	prep_over||diminished-30/VBN||time-32/NN	mrsa-16||s.aureus-22||no||in an area where pvl-containing mrsa is prevalent , skin infection risk was increased among mrsa nasal carriers compared with methicillin-susceptible s.aureus carriers and noncarriers , but risk differential diminished over time .
advmod||tested-5/VBN||therefore-1/RB	nsubj||tested-5/VBN||we-3/PRP	aux||tested-5/VBN||have-4/VBP	root||ROOT-0/null||tested-5/VBN	det||hypothesis-7/NNS||the-6/DT	dobj||tested-5/VBN||hypothesis-7/NNS	mark||â-19/VBP||that-8/IN	det||allele-11/NN||the-9/DT	amod||allele-11/NN||rare-10/JJ	nsubj||â-19/VBP||allele-11/NN	det||tâ-15/NN||the-13/DT	amod||tâ-15/NN||-164-14/JJ	prep_of||allele-11/NN||tâ-15/NN	num||tâ-15/NN||$-16/$	number||>-18/CD||‰-17/CD	num||$-16/$||>-18/CD	ccomp||tested-5/VBN||â-19/VBP	num||polymorphism-23/NN||$-20/$	number||c-22/CD||‰-21/CD	num||$-20/$||c-22/CD	nsubj||alters-26/VBZ||polymorphism-23/NN	prep_in||polymorphism-23/NN||mttp-25/NN	ccomp||â-19/VBP||alters-26/VBZ	det||risk-28/NN||the-27/DT	dobj||alters-26/VBZ||risk-28/NN	prep_of||risk-28/NN||cardiovasculardisease-30/NN	appos||cardiovasculardisease-30/NN||cvd-32/NN	prepc_depending_on||alters-26/VBZ||on-36/IN	det||levels-39/NNS||the-37/DT	nn||levels-39/NNS||cholesterol-38/NN	pobj||alters-26/VBZ||levels-39/NNS	cholesterol-38||cvd-32||no_rel||therefore, we have tested the hypothesis that the rare allele of the -164tâ€‰>â€‰c polymorphism in mttp alters the risk of cardiovasculardisease (cvd), depending on the cholesterol levels.
det||association-4/NN||the-1/DT	amod||association-4/NN||american-2/JJ	nn||association-4/NN||diabetes-3/NN	nsubj||recommend-14/VBP||association-4/NN	det||association-8/NN||the-6/DT	nn||association-8/NN||european-7/NN	conj_and||association-4/NN||association-8/NN	nsubj||recommend-14/VBP||association-8/NN	det||study-11/NN||the-10/DT	prep_for||association-8/NN||study-11/NN	prep_of||study-11/NN||diabetes-13/NN	root||ROOT-0/null||recommend-14/VBP	dobj||recommend-14/VBP||metformin-15/NN	det||agent-19/NN||the-17/DT	amod||agent-19/NN||initial-18/JJ	prep_as||recommend-14/VBP||agent-19/NN	prep_of||agent-19/NN||choice-21/NN	det||treatment-24/NN||the-23/DT	prep_in||choice-21/NN||treatment-24/NN	prep_of||treatment-24/NN||type2diabetesmellitus-26/CD	type2diabetesmellitus-26||metformin-15||yes||the american diabetes association and the european association for the study of diabetes recommend metformin as the initial agent of choice in the treatment of type2diabetesmellitus.
det||spread-2/NN||the-1/DT	nsubj||suggests-23/VBZ||spread-2/NN	det||h1n1influenzavirus-6/NNS||the-4/DT	num||h1n1influenzavirus-6/NNS||2009-5/CD	prep_of||spread-2/NN||h1n1influenzavirus-6/NNS	det||population-9/NN||the-8/DT	prep_in||h1n1influenzavirus-6/NNS||population-9/NN	advmod||population-9/NN||worldwide-10/RB	det||number-17/NN||the-15/DT	amod||number-17/NN||large-16/JJ	prep_in_addition_to||spread-2/NN||number-17/NN	prep_of||number-17/NN||individuals-19/NNS	advmod||vaccinated-21/VBN||already-20/RB	vmod||individuals-19/NNS||vaccinated-21/VBN	root||ROOT-0/null||suggests-23/VBZ	mark||have-32/VBP||that-24/IN	det||proportion-27/NN||a-25/DT	amod||proportion-27/NN||large-26/JJ	nsubj||have-32/VBP||proportion-27/NN	det||population-30/NN||the-29/DT	prep_of||proportion-27/NN||population-30/NN	advmod||have-32/VBP||now-31/RB	ccomp||suggests-23/VBZ||have-32/VBP	amod||antibodies-34/NNS||cross-protective-33/JJ	dobj||have-32/VBP||antibodies-34/NNS	det||virus-38/NN||the-36/DT	num||virus-38/NN||1918-37/CD	prep_against||antibodies-34/NNS||virus-38/NN	advmod||alleviating-41/VBG||greatly-40/RB	vmod||antibodies-34/NNS||alleviating-41/VBG	dobj||alleviating-41/VBG||concerns-42/NNS	dobj||alleviating-41/VBG||fears-44/NNS	conj_and||concerns-42/NNS||fears-44/NNS	det||exposure/release-48/NN||the-46/DT	amod||exposure/release-48/NN||accidental-47/JJ	prep_regarding||concerns-42/NNS||exposure/release-48/NN	det||virus-52/NN||the-50/DT	num||virus-52/NN||1918-51/CD	prep_of||exposure/release-48/NN||virus-52/NN	det||laboratory-55/NN||the-54/DT	prep_from||virus-52/NN||laboratory-55/NN	det||use-58/NN||the-57/DT	prep_of||exposure/release-48/NN||use-58/NN	conj_and||virus-52/NN||use-58/NN	det||virus-61/NN||the-60/DT	prep_of||use-58/NN||virus-61/NN	det||agent-65/NN||a-63/DT	amod||agent-65/NN||bioterrorist-64/JJ	prep_as||virus-61/NN||agent-65/NN	cross--1||antibodies-34||no_rel||the spread of the 2009 h1n1influenzavirus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.
det||interest-2/NN||the-1/DT	nsubjpass||recommended-7/VBN||interest-2/NN	det||case-5/NN||this-4/DT	prep_of||interest-2/NN||case-5/NN	auxpass||recommended-7/VBN||is-6/VBZ	root||ROOT-0/null||recommended-7/VBN	det||existence-10/NN||the-9/DT	prep_in||recommended-7/VBN||existence-10/NN	num||pathogens-14/NNS||two-12/CD	amod||pathogens-14/NNS||responsible-13/JJ	prep_of||existence-10/NN||pathogens-14/NNS	det||paucity-17/NN||the-16/DT	prep_in||recommended-7/VBN||paucity-17/NN	conj_and||existence-10/NN||paucity-17/NN	det||oflungabscess-21/NNS||the-19/DT	nn||oflungabscess-21/NNS||development-20/NN	prep_of||paucity-17/NN||oflungabscess-21/NNS	det||patient-24/NN||a-23/DT	prep_in||oflungabscess-21/NNS||patient-24/NN	prep_with||patient-24/NN||vap-26/NN	det||treatment-31/NN||the-29/DT	amod||treatment-31/NN||successful-30/JJ	prep_in||recommended-7/VBN||treatment-31/NN	conj_and||existence-10/NN||treatment-31/NN	det||patient-34/NN||the-33/DT	prep_of||treatment-31/NN||patient-34/NN	det||combination-37/NN||the-36/DT	prep_with||recommended-7/VBN||combination-37/NN	amod||drainage-40/NN||controlled-39/VBN	prep_of||combination-37/NN||drainage-40/NN	det||therapy-47/NN||the-42/DT	amod||therapy-47/NN||abscess-43/JJ	conj_and||abscess-43/JJ||appropriate-45/JJ	amod||therapy-47/NN||appropriate-45/JJ	amod||therapy-47/NN||antibiotic-46/JJ	prep_of||drainage-40/NN||therapy-47/NN	abscess-43||antibiotic-46||no_rel||the interest of this case is recommended in the existence of two responsible pathogens, the paucity of the development oflungabscess in a patient with vap, and the successful treatment of the patient with the combination of controlled drainage of the abscess and appropriate antibiotic therapy.
det||incidence-2/NN||the-1/DT	nsubj||lower-9/JJR||incidence-2/NN	conj_and||incidence-2/NN||severity-4/NN	nsubj||lower-9/JJR||severity-4/NN	prep_of||incidence-2/NN||pain-6/NN	cop||lower-9/JJR||was-7/VBD	advmod||lower-9/JJR||significantly-8/RB	root||ROOT-0/null||lower-9/JJR	nn||lk-12/NN||group-11/NN	prep_in||lower-9/JJR||lk-12/NN	prep_than||lower-9/JJR||group-14/NN	dep||lower-9/JJR||l-15/NN	dep||lower-9/JJR||group-17/NN	conj_or||l-15/NN||group-17/NN	xcomp||lower-9/JJR||k-18/VBG	num||seconds-21/NNS||10-20/CD	prep_at||k-18/VBG||seconds-21/NNS	det||injection-24/NN||the-23/DT	prep_after||k-18/VBG||injection-24/NN	amod||mg-29/NN||microemulsion-26/JJ	nn||mg-29/NN||propofol-27/NN	num||mg-29/NN||30-28/CD	prep_of||injection-24/NN||mg-29/NN	parataxis||k-18/VBG||p-31/VB	num||0.05-33/CD||<-32/CD	dobj||p-31/VB||0.05-33/CD	pain-6||propofol-27||yes||the incidence and severity of pain was significantly lower in group lk than group l or group k at 10 seconds after the injection of microemulsion propofol 30 mg (p < 0.05).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effects-10/NNS||the-9/DT	dobj||evaluate-8/VB||effects-10/NNS	amod||injection-13/NN||intra-articular-12/JJ	prep_of||effects-10/NNS||injection-13/NN	prep_of||injection-13/NN||celecoxib-15/NN	det||model-20/NN||a-17/DT	nn||model-20/NN||rabbit-18/NN	nn||model-20/NN||osteoarthritis-19/NNS	prep_in||evaluate-8/VB||model-20/NN	osteoarthritis-19||celecoxib-15||yes||the aim of this study was to evaluate the effects of intra-articular injection of celecoxib in a rabbit osteoarthritis model.
prep_from||had-12/VBD||january-2/NNP	num||january-2/NNP||2004-3/CD	prep_to||had-12/VBD||june-5/NNP	num||june-5/NNP||2005-6/CD	num||patients-9/NNS||254-8/CD	nsubj||had-12/VBD||patients-9/NNS	nsubj||received-25/VBD||patients-9/NNS	prep_with||patients-9/NNS||stemi-11/NNS	root||ROOT-0/null||had-12/VBD	amod||reversal-14/NN||immediate-13/JJ	dobj||had-12/VBD||reversal-14/NN	prep_of||reversal-14/NN||anticoagulation-16/NN	amod||administration-19/NN||protamine-18/JJ	prep_by||had-12/VBD||administration-19/NN	amod||stenting-23/NN||infarct-21/JJ	nn||stenting-23/NN||artery-22/NN	prep_after||administration-19/NN||stenting-23/NN	conj_and||had-12/VBD||received-25/VBD	amod||therapy-27/NN||abciximab-26/JJ	dobj||received-25/VBD||therapy-27/NN	nn||infusion-30/NN||heparin-29/NN	prep_without||received-25/VBD||infusion-30/NN	appos||infusion-30/NN||group-32/NN	num||group-32/NN||1-33/CD	abciximab-26||infarct-21||no_rel||from january 2004 to june 2005, 254 patients with stemi had immediate reversal of anticoagulation by protamine administration after infarct artery stenting and received abciximab therapy without heparin infusion (group 1).
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	cefixime-8||gonorrhoea-21||no_rel||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	oa-13||chondroitinsulfate-44||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
advmod||occurs-5/VBZ||typically-1/RB	amod||steroidmyopathy-4/NN||acute-3/JJ	nsubj||occurs-5/VBZ||steroidmyopathy-4/NN	root||ROOT-0/null||occurs-5/VBZ	prep_with||occurs-5/VBZ||therapy-7/NN	vmod||therapy-7/NN||using-8/VBG	amod||corticosteroids-10/NNS||intravenous-9/JJ	dobj||using-8/VBG||corticosteroids-10/NNS	amod||doses-13/NNS||high-12/JJ	prep_at||using-8/VBG||doses-13/NNS	steroidmyopathy-4||corticosteroids-10||no||typically, acute steroidmyopathy occurs with therapy using intravenous corticosteroids at high doses.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||suppresses-21/VBZ||that-5/IN	det||increase-7/NN||an-6/DT	nsubj||suppresses-21/VBZ||increase-7/NN	prep_in||increase-7/NN||insulin-9/NN	nn||se-11/FW||per-10/FW	advmod||insulin-9/NN||se-11/FW	dep||se-11/FW||i.e.-13/CD	det||absence-17/NN||the-16/DT	prep_in||se-11/FW||absence-17/NN	prep_of||absence-17/NN||zinc-19/NN	ccomp||tested-2/VBD||suppresses-21/VBZ	nn||secretion-23/NN||glucagon-22/NN	dobj||suppresses-21/VBZ||secretion-23/NN	prep_during||suppresses-21/VBZ||euglycemia-25/NN	mark||stimulates-34/VBZ||that-27/IN	det||decrease-29/NN||a-28/DT	nsubj||stimulates-34/VBZ||decrease-29/NN	prep_in||decrease-29/NN||insulin-31/NN	nn||se-33/FW||per-32/FW	advmod||stimulates-34/VBZ||se-33/FW	ccomp||tested-2/VBD||stimulates-34/VBZ	conj_and||suppresses-21/VBZ||stimulates-34/VBZ	nn||secretion-36/NN||glucagon-35/NN	dobj||stimulates-34/VBZ||secretion-36/NN	prep_during||stimulates-34/VBZ||hypoglycemia-38/NN	prep_in||hypoglycemia-38/NN||humans-40/NNS	hypoglycemia-38||zinc-19||no_rel||we tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon secretion during euglycemia and that a decrease in insulin per se stimulates glucagon secretion during hypoglycemia in humans.
nsubjpass||assessed-3/VBN||pain-1/NN	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	xcomp||assessed-3/VBN||using-4/VBG	xcomp||assessed-3/VBN||using-4/VBG	conj_and||using-4/VBG||using-4/VBG	det||scale-8/NN||a-5/DT	amod||scale-8/NN||visual-6/JJ	amod||scale-8/NN||analog-7/JJ	dobj||using-4/VBG||scale-8/NN	num||=-11/NNS||0-10/CD	dep||scale-8/NN||=-11/NNS	neg||pain-13/NN||no-12/DT	dep||=-11/NNS||pain-13/NN	dep||pain-13/NN||100-15/CD	dep||pain-20/NN||=-16/SYM	det||pain-20/NN||the-17/DT	amod||pain-20/NN||worst-18/JJS	amod||pain-20/NN||possible-19/JJ	rcmod||100-15/CD||pain-20/NN	prep_at||using-4/VBG||0-23/NNP	num||0-23/NNP||5-25/CD	num||0-23/NNP||10-27/CD	num||minutes-31/NNS||30-30/CD	npadvmod||using-4/VBG||minutes-31/NNS	prepc_after||using-4/VBG||stopping-33/VBG	det||infusion-36/NN||the-34/DT	amod||infusion-36/NN||remifentanil-35/JJ	dobj||stopping-33/VBG||infusion-36/NN	pain-20||remifentanil-35||yes||pain was assessed using a visual analog scale (0 = no pain; 100 = the worst possible pain) at 0, 5, 10, and 30 minutes after stopping the remifentanil infusion.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||male-7/NN||47-yr-old-6/JJ	prep_of||case-4/NN||male-7/NN	vmod||male-7/NN||presented-9/VBN	amod||cancer-13/NN||sigmoid-11/JJ	nn||cancer-13/NN||colon-12/NN	prep_with||presented-9/VBN||cancer-13/NN	amod||liver-16/NN||multiple-15/JJ	prep_with||presented-9/VBN||liver-16/NN	prep_in||was-24/VBD||liver-16/NN	amod||metastases-19/NNS||peritoneal-18/JJ	prep_with||presented-9/VBN||metastases-19/NNS	conj_and||liver-16/NN||metastases-19/NNS	prep_in||was-24/VBD||metastases-19/NNS	expl||was-24/VBD||there-23/EX	rcmod||liver-16/NN||was-24/VBD	det||response-27/NN||a-25/DT	amod||response-27/NN||complete-26/JJ	nsubj||was-24/VBD||response-27/NN	det||cancer-32/NN||the-29/DT	amod||cancer-32/NN||primary-30/JJ	nn||cancer-32/NN||colon-31/NN	prep_for||response-27/NN||cancer-32/NN	prep_after||was-24/VBD||administration-34/NN	amod||chemotherapy-37/NN||preoperative-36/JJ	prep_of||administration-34/NN||chemotherapy-37/NN	vmod||chemotherapy-37/NN||selected-38/VBN	agent||selected-38/VBN||atp-cra-40/NN	cancer-32||atp--1||no_rel||we report a case of 47-yr-old male, presented with sigmoid colon cancer with multiple liver and peritoneal metastases, in which there was a complete response for the primary colon cancer after administration of preoperative chemotherapy selected by atp-cra.
amod||vasculitis-6/NNS||hydralazine-induced-1/JJ	amod||vasculitis-6/NNS||anti-neutrophil-2/JJ	amod||vasculitis-6/NNS||cytoplasmic-3/JJ	amod||vasculitis-6/NNS||antibody-positive-4/JJ	amod||vasculitis-6/NNS||renal-5/JJ	nsubj||effect-11/NN||vasculitis-6/NNS	nsubj||present-14/VB||vasculitis-6/NNS	cop||effect-11/NN||is-7/VBZ	det||effect-11/NN||a-8/DT	amod||effect-11/NN||rare-9/JJ	amod||effect-11/NN||adverse-10/JJ	root||ROOT-0/null||effect-11/NN	aux||present-14/VB||can-13/MD	conj_and||effect-11/NN||present-14/VB	det||syndrome-19/NN||a-16/DT	amod||syndrome-19/NN||severe-17/JJ	amod||syndrome-19/NN||vasculitic-18/JJ	prep_with||present-14/VB||syndrome-19/NN	amod||involvement-23/NN||multiple-21/JJ	nn||involvement-23/NN||organ-22/NN	prep_with||syndrome-19/NN||involvement-23/NN	antibody--1||vasculitis-6||no_rel||hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis is a rare adverse effect and can present with a severe vasculitic syndrome with multiple organ involvement.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||œsix-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the â€œsix-week extended-dose nevirapineâ€? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
det||drugs-3/NNS||the-1/DT	amod||drugs-3/NNS||adjuvant-2/JJ	nsubj||effective-16/JJ||drugs-3/NNS	dep||drugs-3/NNS||ketamine-5/JJ	dep||drugs-3/NNS||ntg-7/JJ	conj_or||ketamine-5/JJ||ntg-7/JJ	advmod||added-10/VBD||when-9/WRB	rcmod||drugs-3/NNS||added-10/VBD	aux||lidocaine-12/VB||to-11/TO	xcomp||added-10/VBD||lidocaine-12/VB	prep_in||lidocaine-12/VB||ivra-14/NN	cop||effective-16/JJ||were-15/VBD	root||ROOT-0/null||effective-16/JJ	prepc_in||effective-16/JJ||improving-18/VBG	det||quality-21/NN||the-19/DT	amod||quality-21/NN||overall-20/JJ	dobj||improving-18/VBG||quality-21/NN	prep_of||quality-21/NN||anesthesia-23/NN	prepc_in||effective-16/JJ||reducing-25/VBG	conj_and||improving-18/VBG||reducing-25/VBG	amod||pain-27/NN||tourniquet-26/JJ	dobj||reducing-25/VBG||pain-27/NN	prepc_in||effective-16/JJ||increasing-29/VBG	conj_and||improving-18/VBG||increasing-29/VBG	amod||tolerance-31/NN||tourniquet-30/JJ	dobj||increasing-29/VBG||tolerance-31/NN	prepc_in||effective-16/JJ||improving-33/VBG	conj_and||improving-18/VBG||improving-33/VBG	det||analgesia-36/NN||the-34/DT	amod||analgesia-36/NN||postoperative-35/JJ	dobj||improving-33/VBG||analgesia-36/NN	prep_in||analgesia-36/NN||comparison-38/NN	det||group-42/NN||the-40/DT	nn||group-42/NN||control-41/NN	prep_to||improving-33/VBG||group-42/NN	pain-27||lidocaine-12||yes||the adjuvant drugs (ketamine or ntg) when added to lidocaine in ivra were effective in improving the overall quality of anesthesia, reducing tourniquet pain, increasing tourniquet tolerance and improving the postoperative analgesia in comparison to the control group.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||gold-2/JJ	amod||therapy-4/NN||standard-3/JJ	nsubjpass||pegylated-9/VBN||therapy-4/NN	amod||patients-7/NNS||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||patients-7/NNS	auxpass||pegylated-9/VBN||is-8/VBZ	root||ROOT-0/null||pegylated-9/VBN	dobj||pegylated-9/VBN||interferon-10/NN	prep||pegylated-9/VBN||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	det||drug-15/NN||an-13/DT	amod||drug-15/NN||anti-viral-14/JJ	pobj||with-12/IN||drug-15/NN	appos||drug-15/NN||ribavirin-17/NNP	gold-2||chronichepatitisc-6||no_rel||the gold standard therapy for chronichepatitisc patients is pegylated interferon combined with an anti-viral drug (ribavirin).
det||woman-4/NN||a-1/DT	amod||woman-4/NN||70-year-old-2/JJ	amod||woman-4/NN||caucasian-3/JJ	nsubjpass||treated-16/VBN||woman-4/NN	neg||history-9/NN||no-7/DT	amod||history-9/NN||previous-8/JJ	prep_with||woman-4/NN||history-9/NN	prep_of||history-9/NN||hematological-11/NN	prep_of||history-9/NN||liverdiseases-13/NNS	conj_or||hematological-11/NN||liverdiseases-13/NNS	auxpass||treated-16/VBN||was-15/VBD	root||ROOT-0/null||treated-16/VBN	amod||mg-20/NN||ticlopidine-18/JJ	dep||ticlopidine-18/JJ||250-19/CD	prep_with||treated-16/VBN||mg-20/NN	advmod||daily-22/RB||twice-21/RB	npadvmod||immediately-23/RB||daily-22/RB	advmod||treated-16/VBN||immediately-23/RB	det||stroke-27/NN||a-25/DT	nn||stroke-27/NN||vertebrobasilar-26/NN	prep_after||treated-16/VBN||stroke-27/NN	liverdiseases-13||ticlopidine-18||no||a 70-year-old caucasian woman, with no previous history of hematological or liverdiseases, was treated with ticlopidine 250 mg twice daily immediately after a vertebrobasilar stroke.
det||injection-3/NN||an-1/DT	amod||injection-3/NN||intravenous-2/JJ	nsubj||resolved-7/VBD||injection-3/NN	nsubj||normalized-15/VBD||injection-3/NN	amod||antibiotics-6/NNS||anti-staphylococcal-5/JJ	prep_of||injection-3/NN||antibiotics-6/NNS	root||ROOT-0/null||resolved-7/VBD	det||pain-10/NN||the-8/DT	amod||pain-10/NN||back-9/JJ	dobj||resolved-7/VBD||pain-10/NN	nn||pain-13/NN||radicular-12/NN	dobj||resolved-7/VBD||pain-13/NN	conj_and||pain-10/NN||pain-13/NN	conj_and||resolved-7/VBD||normalized-15/VBD	det||findings-18/NNS||the-16/DT	nn||findings-18/NNS||laboratory-17/NN	dobj||normalized-15/VBD||findings-18/NNS	pain-13||antibiotics-6||no_rel||an intravenous injection of anti-staphylococcal antibiotics resolved the back pain and radicular pain and normalized the laboratory findings.
advmod||cultured-4/VBN||when-1/WRB	nsubjpass||cultured-4/VBN||viruses-2/NNS	auxpass||cultured-4/VBN||are-3/VBP	advcl||cause-20/VB||cultured-4/VBN	amod||passage-7/NN||serial-6/JJ	agent||cultured-4/VBN||passage-7/NN	amod||cells-11/NNS||susceptible-9/JJ	nn||cells-11/NNS||host-10/NN	prep_on||passage-7/NN||cells-11/NNS	det||presence-14/NN||the-13/DT	nsubj||cause-20/VB||presence-14/NN	amod||particles-18/NNS||virus-like-16/JJ	nn||particles-18/NNS||di-17/NNP	prep_of||presence-14/NN||particles-18/NNS	aux||cause-20/VB||can-19/MD	root||ROOT-0/null||cause-20/VB	nn||populations-22/NNS||virus-21/NN	dobj||cause-20/VB||populations-22/NNS	aux||rise-24/VB||to-23/TO	vmod||cause-20/VB||rise-24/VB	vmod||cause-20/VB||fall-26/VB	conj_and||rise-24/VB||fall-26/VB	xcomp||cause-20/VB||reflecting-28/VBG	amod||interactions-30/NNS||predator-prey-29/JJ	dobj||reflecting-28/VBG||interactions-30/NNS	prep_between||interactions-30/NNS||di-32/FW	nn||particles-35/NNS||virus-34/NN	prep_between||interactions-30/NNS||particles-35/NNS	conj_and||di-32/FW||particles-35/NNS	virus-34||viruses-2||no||when viruses are cultured by serial passage on susceptible host cells, the presence of virus-like di particles can cause virus populations to rise and fall, reflecting predator-prey interactions between di and virus particles.
advmod||noted-4/VBD||therefore-1/RB	nsubj||noted-4/VBD||we-3/PRP	nsubj||propose-24/VBP||we-3/PRP	root||ROOT-0/null||noted-4/VBD	det||increases-6/NNS||the-5/DT	dobj||noted-4/VBD||increases-6/NNS	prep_of||increases-6/NNS||gal-9-8/NN	prep_of||increases-6/NNS||opn-10/NN	conj_and||gal-9-8/NN||opn-10/NN	prep_in||noted-4/VBD||plasma-12/NN	det||time-16/NN||the-14/DT	amod||time-16/NN||first-15/JJ	prep_for||plasma-12/NN||time-16/NN	det||patient-19/NN||a-18/DT	prep_in||time-16/NN||patient-19/NN	nn||allergy-22/NN||insulin-21/NN	prep_with||patient-19/NN||allergy-22/NN	conj_and||noted-4/VBD||propose-24/VBP	mark||reflects-27/VBZ||that-25/IN	nsubj||reflects-27/VBZ||gal-9-26/JJ	ccomp||propose-24/VBP||reflects-27/VBZ	det||conditions-29/NNS||the-28/DT	dobj||reflects-27/VBZ||conditions-29/NNS	prep_of||conditions-29/NNS||allergy-31/NN	advmod||accurately-33/RB||more-32/RBR	advmod||reflects-27/VBZ||accurately-33/RB	allergy-31||allergy-31||no||therefore, we noted the increases of gal-9 and opn in plasma for the first time in a patient with insulin allergy and propose that gal-9 reflects the conditions of allergy more accurately.
nn||analysis-2/NN||meta-1/NN	nsubj||showed-3/VBD||analysis-2/NN	root||ROOT-0/null||showed-3/VBD	mark||higher-59/JJR||that-4/IN	det||rate-6/NN||the-5/DT	nsubj||higher-59/JJR||rate-6/NN	amod||dna-11/NN||undetected-8/JJ	nn||dna-11/NN||serum-9/NN	nn||dna-11/NN||hbv-10/NN	prep_of||rate-6/NN||dna-11/NN	amod||risk-14/NN||relative-13/JJ	dep||dna-11/NN||risk-14/NN	amod||risk-14/NN||1.73-16/CD	number||%-19/NN||95-18/CD	amod||interval-21/NN||%-19/NN	nn||interval-21/NN||confidence-20/NN	dep||risk-14/NN||interval-21/NN	num||.17-24/CD||1.38-2-23/CD	dep||risk-14/NN||.17-24/CD	conj_and||interval-21/NN||.17-24/CD	dep||0.00001-28/CD||p-26/RB	number||0.00001-28/CD||<-27/CD	dep||.17-24/CD||0.00001-28/CD	dep||risk-14/NN||that-31/DT	conj_and||interval-21/NN||that-31/DT	nn||normalization-35/NN||serum-33/NN	nn||normalization-35/NN||alt-34/NN	prep_of||that-31/DT||normalization-35/NN	amod||risk-38/NN||relative-37/JJ	dep||normalization-35/NN||risk-38/NN	dep||risk-38/NN||1.25-40/CD	number||%-43/NN||95-42/CD	amod||interval-45/NN||%-43/NN	nn||interval-45/NN||confidence-44/NN	dep||risk-14/NN||interval-45/NN	num||.49-48/CD||1.06-1-47/CD	appos||interval-45/NN||.49-48/CD	dep||risk-14/NN||p-50/NN	dep||0.009-52/CD||=-51/SYM	rcmod||p-50/NN||0.009-52/CD	det||group-57/NN||the-55/DT	nn||group-57/NN||entecavir-56/NN	prep_in||dna-11/NN||group-57/NN	cop||higher-59/JJR||were-58/VBD	ccomp||showed-3/VBD||higher-59/JJR	prep_than||higher-59/JJR||those-61/DT	det||group-65/NN||the-63/DT	nn||group-65/NN||adefovir-64/NN	prep_in||those-61/DT||group-65/NN	hbv-10||entecavir-56||yes||meta analysis showed that the rate of undetected serum hbv dna (relative risk, 1.73; 95% confidence interval, 1.38-2.17; p < 0.00001) and that of serum alt normalization (relative risk, 1.25; 95% confidence interval, 1.06-1.49; p = 0.009) in the entecavir group were higher than those in the adefovir group.
nsubj||worse-18/JJR||aureus-1/NN	appos||aureus-1/NN||mrsa-3/NNP	nsubj||increasing-7/VBG||infection-5/NN	aux||increasing-7/VBG||are-6/VBP	rcmod||aureus-1/NN||increasing-7/VBG	nn||outcomes-10/NNS||treatment-9/NN	conj_and||aureus-1/NN||outcomes-10/NNS	nsubj||worse-18/JJR||outcomes-10/NNS	prep_for||outcomes-10/NNS||bacteraemia-12/NN	vmod||bacteraemia-12/NN||caused-13/VBN	agent||caused-13/VBN||mrsa-15/NN	cop||worse-18/JJR||are-16/VBP	advmod||worse-18/JJR||generally-17/RB	root||ROOT-0/null||worse-18/JJR	mark||observed-21/VBD||than-19/IN	nsubj||observed-21/VBD||those-20/DT	ccomp||worse-18/JJR||observed-21/VBD	amod||s-24/NNS||methicillin-susceptible-23/JJ	prep_with||observed-21/VBD||s-24/NNS	mrsa-15||methicillin--1||no_rel||aureus (mrsa) infection are increasing and treatment outcomes for bacteraemia caused by mrsa are generally worse than those observed with methicillin-susceptible s .
det||proteasome-2/NN||the-1/DT	nsubjpass||established-5/VBN||proteasome-2/NN	aux||established-5/VBN||has-3/VBZ	auxpass||established-5/VBN||been-4/VBN	root||ROOT-0/null||established-5/VBN	mark||approved-17/VBN||as-6/IN	det||target-9/NN||a-7/DT	amod||target-9/NN||relevant-8/JJ	nsubjpass||approved-17/VBN||target-9/NN	amod||malignancies-12/NNS||hematologic-11/JJ	prep_in||target-9/NN||malignancies-12/NNS	prep_in||target-9/NN||bortezomib-14/NN	conj_and||malignancies-12/NNS||bortezomib-14/NN	aux||approved-17/VBN||has-15/VBZ	auxpass||approved-17/VBN||been-16/VBN	advcl||established-5/VBN||approved-17/VBN	det||treatment-20/NN||the-19/DT	prep_for||approved-17/VBN||treatment-20/NN	prep_of||treatment-20/NN||multiplemyeloma-22/NN	multiplemyeloma-22||bortezomib-14||yes||the proteasome has been established as a relevant target in hematologic malignancies and bortezomib has been approved for the treatment of multiplemyeloma.
amod||family-2/NN||high-1/JJ	nsubj||increase-21/VB||family-2/NN	vmod||family-2/NN||loading-3/VBG	prep_for||loading-3/VBG||alcoholism-5/NN	amod||onset-8/NN||early-7/JJ	nsubj||increase-21/VB||onset-8/NN	nn||use-11/NN||alcohol-10/NN	prep_of||onset-8/NN||use-11/NN	nn||behaviors-15/NNS||childhood-13/NN	nn||behaviors-15/NNS||disinhibitory-14/NN	prep_of||onset-8/NN||behaviors-15/NNS	conj_and||use-11/NN||behaviors-15/NNS	vmod||onset-8/NN||persisting-17/VBG	prep_into||persisting-17/VBG||adulthood-19/NN	root||ROOT-0/null||increase-21/VB	det||susceptibility-23/NN||the-22/DT	dobj||increase-21/VB||susceptibility-23/NN	prep_to||increase-21/VB||alcoholism-25/NN	alcoholism-25||alcohol-10||no||high family loading for alcoholism, early onset of alcohol use and childhood disinhibitory behaviors, persisting into adulthood, increase the susceptibility to alcoholism.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||explored-4/VBD||study-3/NN	root||ROOT-0/null||explored-4/VBD	det||growth-24/NN||the-5/DT	nn||effect-9/NN||vivo-7/NN	nn||effect-9/NN||immunomodulatory-8/NN	prep_in||interleukin-17-17/JJ||effect-9/NN	prep_on||effect-9/NN||interferon-gamma-11/NN	nn||³-14/NNP||ifn-î-13/NNP	appos||interferon-gamma-11/NN||³-14/NNP	amod||growth-24/NN||interleukin-17-17/JJ	dep||interleukin-17-17/JJ||il-17-19/JJ	conj_and||interleukin-17-17/JJ||transforming-23/JJ	amod||growth-24/NN||transforming-23/JJ	nsubj||evoked-32/VBD||growth-24/NN	number||1-26/CD||factor-beta-25/CD	amod||growth-24/NN||1-26/CD	dep||1-26/CD||tgf-î-28/NNP	number||1-30/CD||²-29/CD	num||tgf-î-28/NNP||1-30/CD	ccomp||explored-4/VBD||evoked-32/VBD	num||water-extracts-35/NNS||two-34/CD	prep_by||evoked-32/VBD||water-extracts-35/NNS	vmod||water-extracts-35/NNS||prepared-36/VBN	nn||leaves-39/NNS||ej-38/NN	prep_from||prepared-36/VBN||leaves-39/NNS	det||tissues-42/NNS||the-41/DT	prep_in||leaves-39/NNS||tissues-42/NNS	amod||mice-48/NNS||normal-44/JJ	conj_and||normal-44/JJ||meth-a-fibrosarcoma-46/JJ	amod||mice-48/NNS||meth-a-fibrosarcoma-46/JJ	nn||mice-48/NNS||bearing-47/NN	prep_of||tissues-42/NNS||mice-48/NNS	interferon--1||fibrosarcoma--1||no_rel||the present study explored the in vivo immunomodulatory effect on interferon-gamma (ifn-î³), interleukin-17 (il-17), and transforming growth factor-beta 1 (tgf-î²1) evoked by two water-extracts prepared from ej leaves in the tissues of normal and meth-a-fibrosarcoma bearing mice.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||study-11/NN||a-3/DT	amod||study-11/NN||prospective-4/JJ	amod||study-11/NN||randomized-6/JJ	amod||study-11/NN||open-label-8/JJ	amod||study-11/NN||multicenter-10/JJ	dobj||conducted-2/VBD||study-11/NN	aux||compare-13/VB||to-12/TO	vmod||conducted-2/VBD||compare-13/VB	dobj||compare-13/VB||busulfan-14/NN	prep||busulfan-14/NN||plus-15/CC	pobj||plus-15/CC||fludarabine-16/NN	appos||fludarabine-16/NN||buflu-18/NNP	nn||plus-22/NN||busulfan-21/NN	prep_with||compare-13/VB||plus-22/NN	advmod||conducted-2/VBD||cyclophosphamide-23/RB	dep||conducted-2/VBD||bucy-25/RB	mark||stem-34/VBP||as-27/IN	det||regimen-30/NN||the-28/DT	nn||regimen-30/NN||conditioning-29/NN	nsubj||stem-34/VBP||regimen-30/NN	amod||hematopoietic-33/NN||allogeneic-32/JJ	prep_in||regimen-30/NN||hematopoietic-33/NN	advcl||conducted-2/VBD||stem-34/VBP	nn||transplantation-36/NN||cell-35/NN	dobj||stem-34/VBP||transplantation-36/NN	appos||transplantation-36/NN||allo-hsct-38/NN	amod||myeloid-42/JJ||acute-41/JJ	amod||leukemia-43/NN||myeloid-42/JJ	prep_for||transplantation-36/NN||leukemia-43/NN	appos||leukemia-43/NN||aml-45/NN	amod||remission-50/NN||first-48/JJ	amod||remission-50/NN||complete-49/JJ	prep_in||stem-34/VBP||remission-50/NN	appos||remission-50/NN||cr1-52/NNP	aml-45||cyclophosphamide-23||yes||we conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (buflu) with busulfan plus cyclophosphamide (bucy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-hsct) for acute myeloid leukemia (aml) in first complete remission (cr1).
nsubjpass||shown-14/VBN||combinations-1/NNS	nsubj||active-18/JJ||combinations-1/NNS	nsubj||mantle-24/VB||combinations-1/NNS	prep_of||combinations-1/NNS||bendamustine-3/NN	prep_with||bendamustine-3/NN||mitoxantrone-5/NN	prep_with||bendamustine-3/NN||rituximab-7/NN	conj_and||mitoxantrone-5/NN||rituximab-7/NN	prep_with||bendamustine-3/NN||rituximab-10/NN	conj_and||mitoxantrone-5/NN||rituximab-10/NN	advmod||shown-14/VBN||alone-11/RB	aux||shown-14/VBN||have-12/VBP	auxpass||shown-14/VBN||been-13/VBN	root||ROOT-0/null||shown-14/VBN	aux||active-18/JJ||to-15/TO	cop||active-18/JJ||be-16/VB	advmod||active-18/JJ||highly-17/RB	xcomp||shown-14/VBN||active-18/JJ	amod||lymphomas-22/NNS||relapsed/refractory-20/JJ	nn||lymphomas-22/NNS||indolent-21/NN	prep_in||active-18/JJ||lymphomas-22/NNS	xcomp||shown-14/VBN||mantle-24/VB	conj_and||active-18/JJ||mantle-24/VB	nn||lymphomas-26/NNS||cell-25/NN	dobj||mantle-24/VB||lymphomas-26/NNS	xcomp||mantle-24/VB||achieving-27/VBG	advmod||lasting-29/JJ||long-28/RB	amod||remissions-31/NNS||lasting-29/JJ	amod||remissions-31/NNS||complete-30/JJ	dobj||achieving-27/VBG||remissions-31/NNS	lymphomas-26||mitoxantrone-5||yes||combinations of bendamustine with mitoxantrone and rituximab and with rituximab alone have been shown to be highly active in relapsed/refractory indolent lymphomas and mantle cell lymphomas achieving long lasting complete remissions.
nsubjpass||misfolded-17/VBN||prions-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||infectious-4/JJ	appos||prions-1/NNS||agent-5/NN	prep_of||agent-5/NN||scrapie-7/NN	amod||disease-11/NN||chronic-9/JJ	nn||disease-11/NN||wasting-10/NN	prep_of||agent-5/NN||disease-11/NN	conj_and||scrapie-7/NN||disease-11/NN	amod||transmissiblespongiformencephalopathies-14/NNS||other-13/JJ	prep_of||agent-5/NN||transmissiblespongiformencephalopathies-14/NNS	conj_and||scrapie-7/NN||transmissiblespongiformencephalopathies-14/NNS	auxpass||misfolded-17/VBN||are-16/VBP	root||ROOT-0/null||misfolded-17/VBN	dobj||misfolded-17/VBN||proteins-18/NNS	nsubj||stable-22/JJ||proteins-18/NNS	nsubj||resistant-24/JJ||proteins-18/NNS	cop||stable-22/JJ||are-20/VBP	advmod||stable-22/JJ||highly-21/RB	rcmod||proteins-18/NNS||stable-22/JJ	rcmod||proteins-18/NNS||resistant-24/JJ	conj_and||stable-22/JJ||resistant-24/JJ	prep_to||stable-22/JJ||degradation-26/NN	transmissiblespongiformencephalopathies-14||prions-1||no||prions, the infectious agent of scrapie, chronic wasting disease and other transmissiblespongiformencephalopathies, are misfolded proteins that are highly stable and resistant to degradation.
amod||vaccines-2/NNS||developing-1/VBG	nsubj||task-15/NN||vaccines-2/NNS	det||prevention-5/NN||the-4/DT	prep_for||vaccines-2/NNS||prevention-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||prevention-5/NN||infection-8/NN	amod||influenzaviruses-11/NNS||h5n1-10/JJ	prep_by||infection-8/NN||influenzaviruses-11/NNS	cop||task-15/NN||is-12/VBZ	det||task-15/NN||an-13/DT	amod||task-15/NN||urgent-14/JJ	root||ROOT-0/null||task-15/NN	h5n1-10||influenzaviruses-11||no||developing vaccines for the prevention of human infection by h5n1 influenzaviruses is an urgent task.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||outcomes-5/NNS||the-4/DT	prep_on||report-2/VBP||outcomes-5/NNS	num||patients-11/NNS||21-7/CD	amod||patients-11/NNS||consecutive-8/JJ	amod||patients-11/NNS||gastric-9/JJ	nn||patients-11/NNS||cancer-10/NN	prep_of||outcomes-5/NNS||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_off||treated-12/VBN||protocol-14/NN	amod||carboplatin-17/NNS||adjuvant-16/JJ	prep_with||treated-12/VBN||carboplatin-17/NNS	dep||carboplatin-17/NNS||area-19/NN	det||ã-25/NN||the-21/DT	nn||ã-25/NN||curve-22/NN	num||ã-25/NN||5-23/CD	nn||ã-25/NN||mg/ml-24/NN	prep_under||area-19/NN||ã-25/NN	dep||ã-25/NN||min-27/NN	prep_with||treated-12/VBN||paclitaxel-30/NN	conj_and||carboplatin-17/NNS||paclitaxel-30/NN	quantmod||$-33/$||175â-32/RB	num||mg/m2-36/NNS||$-33/$	num||$-33/$||200-35/CD	dep||paclitaxel-30/NN||mg/m2-36/NNS	det||weeks-40/NNS||every-38/DT	num||weeks-40/NNS||3-39/CD	tmod||treated-12/VBN||weeks-40/NNS	prepc_followed_by||treated-12/VBN||by-43/IN	amod||analogs-46/NNS||concurrent-44/JJ	nn||analogs-46/NNS||pyrimidine-45/NN	pobj||treated-12/VBN||analogs-46/NNS	dep||â-51/FW||either-48/DT	nn||â-51/FW||capecitabine-49/FW	nn||â-51/FW||1,600-50/FW	dep||analogs-46/NNS||â-51/FW	num||mg/m2/day-55/NNS||$-52/$	num||$-52/$||2,000-54/CD	dep||â-51/FW||mg/m2/day-55/NNS	num||patients-58/NNS||17-57/CD	prep_in||mg/m2/day-55/NNS||patients-58/NNS	number||200-62/CD||5fu-61/CD	num||mg/m2/day-63/NNS||200-62/CD	dep||â-51/FW||mg/m2/day-63/NNS	conj_or||mg/m2/day-55/NNS||mg/m2/day-63/NNS	num||patients-66/NNS||4-65/CD	prep_in||mg/m2/day-63/NNS||patients-66/NNS	pobj||treated-12/VBN||radiation-69/NN	conj_and||analogs-46/NNS||radiation-69/NN	dep||analogs-46/NNS||45â-71/NNS	dep||45â-71/NNS||$-72/$	num||$-72/$||50.4-74/CD	dep||$-72/$||gy-75/NN	cancer-10||adjuvant-16||no_rel||we report on the outcomes of 21 consecutive gastric cancer patients treated off protocol with adjuvant carboplatin (area under the curve 5 mg/ml ã— min) and paclitaxel (175â€“200 mg/m2) every 3 weeks, followed by concurrent pyrimidine analogs (either capecitabine 1,600â€“2,000 mg/m2/day in 17 patients, or 5fu 200 mg/m2/day in 4 patients) and radiation (45â€“50.4 gy).
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||case-6/NN||a-5/DT	dobj||report-4/VBP||case-6/NN	prep_of||case-6/NN||5-8/CD	nn||â-11/NN||fu-10/NN	dep||case-6/NN||â-11/NN	dep||â-11/NN||$-12/$	advmod||encephalopathy-15/JJ||induced-14/RB	amod||manifesting-17/NNS||encephalopathy-15/JJ	npadvmod||as-18/RB||manifesting-17/NNS	dep||seizures-19/CD||as-18/RB	num||$-12/$||seizures-19/CD	dobj||report-4/VBP||delirium-21/NN	conj_and||case-6/NN||delirium-21/NN	det||era-25/NN||an-24/DT	prep_in||delirium-21/NN||era-25/NN	amod||chemotherapy-28/NN||oxaliplatin-containing-27/JJ	prep_of||era-25/NN||chemotherapy-28/NN	oxaliplatin--1||seizures-19||no_rel||here, we report a case of 5- fu â€“induced encephalopathy, manifesting as seizures and delirium, in an era of oxaliplatin-containing chemotherapy.
nsubj||receiving-3/VBG||patients-2/NNS	prepc_in||had-17/VBD||receiving-3/VBG	dobj||receiving-3/VBG||dacarbazine-4/NN	amod||chemotherapy-7/NN||first-line-6/JJ	prep_as||receiving-3/VBG||chemotherapy-7/NN	amod||melanoma-10/NN||metastatic-9/JJ	prep_for||chemotherapy-7/NN||melanoma-10/NN	det||addition-13/NN||the-12/DT	nsubj||had-17/VBD||addition-13/NN	amod||bosentan-16/NN||high-dose-15/JJ	prep_of||addition-13/NN||bosentan-16/NN	root||ROOT-0/null||had-17/VBD	neg||effect-19/NN||no-18/DT	dobj||had-17/VBD||effect-19/NN	prep_on||effect-19/NN||time-21/NN	nn||progression-24/NN||tumor-23/NN	prep_to||had-17/VBD||progression-24/NN	amod||parameters-28/NNS||other-26/JJ	nn||parameters-28/NNS||efficacy-27/NN	prep_to||had-17/VBD||parameters-28/NNS	conj_or||progression-24/NN||parameters-28/NNS	bosentan-16||melanoma-10||no_rel||in patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.
vmod||possible-16/JJ||using-1/VBG	dobj||using-1/VBG||algorithms-2/NNS	aux||shut-4/VB||to-3/TO	vmod||using-1/VBG||shut-4/VB	prt||shut-4/VB||off-5/RP	det||pump-8/NN||the-6/DT	nn||pump-8/NN||insulin-7/NN	dobj||shut-4/VB||pump-8/NN	tmod||predicted-12/VBN||pump-8/NN	advmod||predicted-12/VBN||when-9/WRB	nsubjpass||predicted-12/VBN||hypoglycemia-10/NN	auxpass||predicted-12/VBN||is-11/VBZ	rcmod||pump-8/NN||predicted-12/VBN	nsubj||possible-16/JJ||it-14/PRP	nsubj||prevent-18/VB||it-14/PRP	cop||possible-16/JJ||is-15/VBZ	root||ROOT-0/null||possible-16/JJ	aux||prevent-18/VB||to-17/TO	xcomp||possible-16/JJ||prevent-18/VB	dobj||prevent-18/VB||hypoglycemia-19/NN	num||%-22/NN||75-21/CD	prep_on||prevent-18/VB||%-22/NN	prep_of||%-22/NN||nights-24/NNS	tmod||predicted-36/VBN||nights-24/NNS	num||%-27/NN||84-26/CD	dep||nights-24/NNS||%-27/NN	prep_of||%-27/NN||events-29/NNS	advmod||predicted-36/VBN||when-31/WRB	nsubjpass||predicted-36/VBN||it-32/PRP	nsubj||occur-38/VB||it-32/PRP	aux||predicted-36/VBN||would-33/MD	advmod||predicted-36/VBN||otherwise-34/RB	auxpass||predicted-36/VBN||be-35/VB	rcmod||nights-24/NNS||predicted-36/VBN	aux||occur-38/VB||to-37/TO	xcomp||predicted-36/VBN||occur-38/VB	hypoglycemia-19||insulin-7||no_rel||using algorithms to shut off the insulin pump when hypoglycemia is predicted, it is possible to prevent hypoglycemia on 75% of nights (84% of events) when it would otherwise be predicted to occur.
det||data-2/NNS||the-1/DT	nsubj||show-3/VBP||data-2/NNS	root||ROOT-0/null||show-3/VBP	mark||increased-10/VBD||that-4/IN	amod||animals-7/NNS||fed-6/VBN	prep_in||increased-10/VBD||animals-7/NNS	nsubj||increased-10/VBD||injury-9/NN	nsubj||impacted-19/VBD||injury-9/NN	ccomp||show-3/VBP||increased-10/VBD	nn||output-12/NN||glucose-11/NN	dobj||increased-10/VBD||output-12/NN	advmod||increased-10/VBD||mainly-13/RB	nn||breakdown-16/NN||glycogen-15/NN	prep_from||increased-10/VBD||breakdown-16/NN	advmod||impacted-19/VBD||minimally-18/RB	ccomp||show-3/VBP||impacted-19/VBD	conj_and||increased-10/VBD||impacted-19/VBD	amod||metabolism-21/NN||aminoacid-20/JJ	dobj||impacted-19/VBD||metabolism-21/NN	impacted-19||glucose-11||no_rel||the data show that in fed animals, injury increased glucose output mainly from glycogen breakdown and minimally impacted aminoacid metabolism.
dep||surprisingly-2/RB||not-1/RB	advmod||was-5/VBD||surprisingly-2/RB	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	amod||downregulation-7/NN||clear-6/JJ	nsubj||was-5/VBD||downregulation-7/NN	prep_of||downregulation-7/NN||genes-9/NNS	vmod||genes-9/NNS||associated-10/VBN	nn||synthesis-14/NN||milk-12/NN	amod||synthesis-14/NN||fat-13/JJ	prep_with||associated-10/VBN||synthesis-14/NN	nn||cd36-20/NN||fasn-16/NN	dep||cd36-20/NN||acaca-18/NN	appos||synthesis-14/NN||cd36-20/NN	dep||cd36-20/NN||fabp3-22/NNP	dep||cd36-20/NN||scd-24/NN	amod||regulation-29/NN||lipid-related-27/JJ	nn||regulation-29/NN||transcription-28/NN	prep_with||associated-10/VBN||regulation-29/NN	conj_and||synthesis-14/NN||regulation-29/NN	dep||synthesis-14/NN||srebf1-31/NNS	appos||srebf1-31/NNS||srebf2-33/NNS	scd-24||fat-13||no_rel||not surprisingly, there was clear downregulation of genes associated with milk fat synthesis ( fasn , acaca , cd36 , fabp3 , scd ) and lipid-related transcription regulation ( srebf1 , srebf2 ).
amod||responses-2/NNS||inappropriate-1/JJ	nsubjpass||involved-9/VBN||responses-2/NNS	amod||bacteria-6/NNS||normal-4/JJ	amod||bacteria-6/NNS||intestinal-5/JJ	prep_to||responses-2/NNS||bacteria-6/NNS	aux||involved-9/VBN||may-7/MD	auxpass||involved-9/VBN||be-8/VB	root||ROOT-0/null||involved-9/VBN	det||development-12/NN||the-11/DT	prep_in||involved-9/VBN||development-12/NN	prep_of||development-12/NN||inflammatoryboweldiseases-14/NNS	amod||ibd-16/NN||-lrb--15/JJ	nsubj||ulcerativecolitis-26/VBZ||ibd-16/NN	nn||crohn-19/NNP||e.g.-18/NNP	poss||-rrb--24/NN||crohn-19/NNP	nn||-rrb--24/NN||disease-21/NN	amod||-rrb--24/NN||-lrb--22/JJ	nn||-rrb--24/NN||cd-23/NN	appos||ibd-16/NN||-rrb--24/NN	rcmod||inflammatoryboweldiseases-14/NNS||ulcerativecolitis-26/VBZ	amod||-rrb--30/NNS||-lrb--27/JJ	nn||-rrb--30/NNS||uc-28/NN	amod||-rrb--30/NNS||-rrb--29/JJ	nsubj||mediate-38/VB||-rrb--30/NNS	conj_and||-rrb--30/NNS||variations-32/NNS	nsubj||mediate-38/VB||variations-32/NNS	det||genome-36/NN||the-34/DT	nn||genome-36/NN||host-35/NN	prep_in||-rrb--30/NNS||genome-36/NN	aux||mediate-38/VB||may-37/MD	ccomp||ulcerativecolitis-26/VBZ||mediate-38/VB	det||process-40/NN||this-39/DT	dobj||mediate-38/VB||process-40/NN	cd-23||ibd-16||no_rel||inappropriate responses to normal intestinal bacteria may be involved in the development of inflammatoryboweldiseases -lrb- ibd , e.g. crohn 's disease -lrb- cd -rrb- , ulcerativecolitis -lrb- uc -rrb- -rrb- and variations in the host genome may mediate this process .
amod||rickets-2/JJ||nutritional-1/JJ	amod||diagnosis-3/NN||rickets-2/JJ	nsubjpass||based-5/VBN||diagnosis-3/NN	nsubjpass||normalization-13/VBN||diagnosis-3/NN	auxpass||based-5/VBN||was-4/VBD	root||ROOT-0/null||based-5/VBN	amod||parameters-11/NNS||clinical-7/JJ	amod||parameters-11/NNS||radiologic-8/JJ	conj_and||radiologic-8/JJ||biochemical-10/JJ	amod||parameters-11/NNS||biochemical-10/JJ	prep_on||based-5/VBN||parameters-11/NNS	conj_and||based-5/VBN||normalization-13/VBN	amod||level-17/NN||alkaline-15/JJ	nn||level-17/NN||phosphatase-16/NN	prep_of||normalization-13/VBN||level-17/NN	num||weeks-20/NNS||6-19/CD	prep_after||normalization-13/VBN||weeks-20/NNS	dobj||based-5/VBN||course-21/NN	amod||therapy-25/NN||daily-23/JJ	amod||therapy-25/NN||vitamind-24/JJ	prep_of||course-21/NN||therapy-25/NN	rickets-2||vitamind-24||yes||nutritional rickets diagnosis was based on clinical radiologic and biochemical parameters and normalization of alkaline phosphatase level after 6 weeks course of daily vitamind therapy.
det||initiative-4/NN||the-1/DT	amod||initiative-4/NN||joint-2/JJ	nn||initiative-4/NN||learning-3/NN	nsubj||recommended-10/VBD||initiative-4/NN	prep_on||initiative-4/NN||children-6/NNS	prep_on||initiative-4/NN||aids-8/NNS	conj_and||children-6/NNS||aids-8/NNS	advmod||recommended-10/VBD||recently-9/RB	root||ROOT-0/null||recommended-10/VBD	mark||direct-23/VB||that-11/IN	nsubj||direct-23/VB||programmes-12/NNS	prep_for||programmes-12/NNS||children-14/NNS	vmod||children-14/NNS||affected-15/VBN	agent||affected-15/VBN||hiv-17/NN	agent||affected-15/VBN||aids-19/NNS	conj_and||hiv-17/NN||aids-19/NNS	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||affected-15/VBN||africa-22/NN	ccomp||recommended-10/VBD||direct-23/VB	amod||support-25/NN||more-24/JJR	dobj||direct-23/VB||support-25/NN	prep_to||direct-23/VB||families-27/NNS	aids-19||hiv-17||no||the joint learning initiative on children and aids recently recommended that programmes for children affected by hiv and aids in sub-saharan africa direct more support to families.
det||cause-2/NN||the-1/DT	nsubjpass||vitamind-7/VBN||cause-2/NN	det||hypocalcemia-5/NN||the-4/DT	prep_of||cause-2/NN||hypocalcemia-5/NN	auxpass||vitamind-7/VBN||was-6/VBD	root||ROOT-0/null||vitamind-7/VBN	amod||rickets-9/NNS||deficient-8/JJ	dobj||vitamind-7/VBN||rickets-9/NNS	rickets-9||vitamind-7||yes||the cause of the hypocalcemia was vitamind deficient rickets.
det||epidemic-6/NN||the-1/DT	amod||epidemic-6/NN||humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome-2/JJ	nn||epidemic-6/NN||hiv/aids-4/NN	nsubj||is-7/VBZ||epidemic-6/NN	nsubj||reached-14/VBN||epidemic-6/NN	root||ROOT-0/null||is-7/VBZ	poss||decade-11/NN||its-9/PRP$	amod||decade-11/NN||third-10/JJ	prep_in||is-7/VBZ||decade-11/NN	aux||reached-14/VBN||has-13/VBZ	conj_and||is-7/VBZ||reached-14/VBN	amod||proportions-17/NNS||alarming-16/JJ	prep_to||reached-14/VBN||proportions-17/NNS	advmod||reached-14/VBN||worldwide-18/RB	acquiredimmunodeficiencysyndrome--1||humanimmunodeficiencyvirus--1||no||the humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome (hiv/aids) epidemic is in its third decade and has reached to alarming proportions worldwide.
det||extracts-2/NNS||all-1/DT	nsubj||showed-9/VBD||extracts-2/NNS	nn||flower-7/NN||samanea-5/NN	nn||flower-7/NN||saman-6/NN	prep_except||extracts-2/NNS||flower-7/NN	root||ROOT-0/null||showed-9/VBD	amod||activity-11/NN||antibacterial-10/JJ	dobj||showed-9/VBD||activity-11/NN	num||strains-14/NNS||two-13/CD	prep_against||showed-9/VBD||strains-14/NNS	prep_of||strains-14/NNS||methicillinresistantstaphylococcusaureus-16/NNS	appos||methicillinresistantstaphylococcusaureus-16/NNS||mrsa-18/NNP	amod||values-22/NNS||mid-21/JJ	prep_with||showed-9/VBD||values-22/NNS	vmod||values-22/NNS||ranging-23/VBG	num||î-31/NNS||100-25/CD	number||1/4-27/CD||î-26/CD	num||î-31/NNS||1/4-27/CD	amod||î-31/NNS||g/disc-28/JJ	cc||500-30/CD||and-29/CC	num||î-31/NNS||500-30/CD	prep_between||ranging-23/VBG||î-31/NNS	number||g/disc-33/JJ||1/4-32/CD	amod||î-31/NNS||g/disc-33/JJ	mrsa-18||antibacterial-10||no_rel||all extracts (except samanea saman flower) showed antibacterial activity against two strains of methicillinresistantstaphylococcusaureus (mrsa) with mid values ranging between 100 î¼g/disc and 500 î¼g/disc.
expl||increasing-3/VBG||there-1/EX	aux||increasing-3/VBG||is-2/VBZ	root||ROOT-0/null||increasing-3/VBG	dobj||increasing-3/VBG||evidence-4/NN	nsubj||increasing-3/VBG||evidence-4/NN	amod||effects-7/NNS||anti-tumour-6/JJ	prep_of||evidence-4/NN||effects-7/NNS	prep_of||effects-7/NNS||bisphosphonates-9/NNS	amod||studies-12/NNS||pre-clinical-11/JJ	prep_from||increasing-3/VBG||studies-12/NNS	vmod||increasing-3/VBG||supporting-14/VBG	det||role-16/NN||a-15/DT	dobj||supporting-14/VBG||role-16/NN	det||drugs-19/NNS||these-18/DT	prep_for||role-16/NN||drugs-19/NNS	poss||use-23/NN||their-21/PRP$	amod||use-23/NN||traditional-22/JJ	prep_beyond||supporting-14/VBG||use-23/NN	prep_in||use-23/NN||treatment-25/NN	amod||bonedisease-28/NN||cancer-induced-27/JJ	prep_of||treatment-25/NN||bonedisease-28/NN	bisphosphonates-9||cancer--1||no_rel||there is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bonedisease.
nsubj||analogue-5/NN||adefovir-1/NN	cop||analogue-5/NN||is-2/VBZ	det||analogue-5/NN||an-3/DT	amod||analogue-5/NN||adenosine-4/JJ	root||ROOT-0/null||analogue-5/NN	vmod||analogue-5/NN||approved-6/VBN	det||administration-12/NN||the-8/DT	nn||administration-12/NN||food-9/NN	conj_and||food-9/NN||drug-11/NN	nn||administration-12/NN||drug-11/NN	agent||approved-6/VBN||administration-12/NN	det||treatment-15/NN||the-14/DT	prep_for||administration-12/NN||treatment-15/NN	nn||mutations-19/NNS||chronichepatitisb-17/NNP	prep_of||treatment-15/NN||mutations-19/NNS	vmod||mutations-19/NNS||occurring-20/VBG	det||virus-24/NN||the-22/DT	amod||virus-24/NN||hepatitisb-23/JJ	prep_in||occurring-20/VBG||virus-24/NN	amod||-rrb--27/NNS||-lrb--25/JJ	nn||-rrb--27/NNS||hbv-26/NN	nsubj||transcriptase-29/VBP||-rrb--27/NNS	advmod||transcriptase-29/VBP||reverse-28/RB	rcmod||virus-24/NN||transcriptase-29/VBP	amod||domains-33/NNS||-lrb--30/JJ	nn||domains-33/NNS||rt-31/NN	nn||domains-33/NNS||-rrb--32/NN	nsubjpass||shown-35/VBN||domains-33/NNS	nsubj||confer-37/VB||domains-33/NNS	auxpass||shown-35/VBN||are-34/VBP	ccomp||transcriptase-29/VBP||shown-35/VBN	aux||confer-37/VB||to-36/TO	xcomp||shown-35/VBN||confer-37/VB	dobj||confer-37/VB||resistance-38/NN	prep_to||confer-37/VB||antiviraldrugs-40/NNS	hbv-26||adefovir-1||yes||adefovir is an adenosine analogue approved by the food and drug administration for the treatment of chronichepatitisb. mutations occurring in the hepatitisb virus -lrb- hbv -rrb- reverse transcriptase -lrb- rt -rrb- domains are shown to confer resistance to antiviraldrugs .
amod||control-2/NN||efficient-1/JJ	nsubj||requires-8/VBZ||control-2/NN	prep_of||control-2/NN||tuberculosis-4/NNP	appos||tuberculosis-4/NNP||tb-6/NN	dep||mycobacteriumbovis-20/VBZ||requires-8/VBZ	dobj||requires-8/VBZ||development-9/NN	prep_of||development-9/NN||strategies-11/NNS	nsubj||enhance-14/VB||strategies-11/NNS	aux||enhance-14/VB||can-13/MD	rcmod||strategies-11/NNS||enhance-14/VB	dobj||enhance-14/VB||efficacy-15/NN	det||vaccine-19/NN||the-17/DT	amod||vaccine-19/NN||existing-18/VBG	prep_of||efficacy-15/NN||vaccine-19/NN	root||ROOT-0/null||mycobacteriumbovis-20/VBZ	amod||guerin-23/NN||bacille-21/JJ	nn||guerin-23/NN||calmette-22/NN	nsubj||mycobacteriumbovis-20/VBZ||guerin-23/NN	appos||guerin-23/NN||bcg-25/NN	tuberculosis-4||bcg-25||yes||efficient control of tuberculosis (tb) requires development of strategies that can enhance efficacy of the existing vaccine mycobacteriumbovis bacille calmette guerin (bcg).
nn||patients-2/NNS||results-1/NNS	nsubj||referred-3/VBD||patients-2/NNS	root||ROOT-0/null||referred-3/VBD	det||programme-7/NN||the-5/DT	amod||programme-7/NN||hiv/aids-6/JJ	prep_to||referred-3/VBD||programme-7/NN	amod||care-11/NN||general-9/JJ	amod||care-11/NN||primary-10/JJ	prep_through||referred-3/VBD||care-11/NN	nn||clinics-14/NNS||intervention-13/NN	prep_at||referred-3/VBD||clinics-14/NNS	cop||likely-17/JJ||were-15/VBD	advmod||likely-17/JJ||more-16/RBR	rcmod||clinics-14/NNS||likely-17/JJ	prep_than||likely-17/JJ||those-19/DT	nn||clinics-22/NNS||control-21/NN	prep_at||those-19/DT||clinics-22/NNS	aux||receive-24/VB||to-23/TO	xcomp||likely-17/JJ||receive-24/VB	amod||prophylaxis-26/NNS||co-trimoxazole-25/JJ	dobj||receive-24/VB||prophylaxis-26/NNS	num||%-29/NN||41-28/CD	nsubj||v-34/VBP||%-29/NN	appos||%-29/NN||2253/5523-32/CD	dep||clinics-14/NNS||v-34/VBP	num||%-36/NN||32-35/CD	dobj||v-34/VBP||%-36/NN	appos||%-36/NN||1340/4210-38/CD	dep||%-36/NN||odds-41/NNS	nsubj||interval-48/VBP||ratio-42/NN	num||ratio-42/NN||1.95-43/CD	number||%-46/NN||95-45/CD	amod||confidence-47/NN||%-46/NN	appos||ratio-42/NN||confidence-47/NN	rcmod||odds-41/NNS||interval-48/VBP	number||3.40-51/CD||1.11-49/CD	dep||3.40-51/CD||to-50/TO	dobj||interval-48/VBP||3.40-51/CD	nsubj||likely-58/JJ||tuberculosis-55/NNP	nsubjpass||diagnosed-61/VBN||tuberculosis-55/NNP	cop||likely-58/JJ||was-56/VBD	advmod||likely-58/JJ||more-57/RBR	conj_and||referred-3/VBD||likely-58/JJ	aux||diagnosed-61/VBN||to-59/TO	auxpass||diagnosed-61/VBN||be-60/VB	xcomp||likely-58/JJ||diagnosed-61/VBN	prep_among||diagnosed-61/VBN||patients-63/NNS	prep_with||patients-63/NNS||hiv/aids/art-65/NN	num||%-68/NN||7-67/CD	nsubj||v-72/VBP||%-68/NN	appos||%-68/NN||417/5793-70/CD	dep||patients-63/NNS||v-72/VBP	num||%-74/NN||6-73/CD	dobj||v-72/VBP||%-74/NN	appos||%-74/NN||245/4343-76/CD	dep||%-74/NN||1.25-79/CD	number||1.55-83/CD||1.01-81/CD	dep||1.55-83/CD||to-82/TO	appos||1.25-79/CD||1.55-83/CD	aids--1||hiv--1||no||results patients referred to the hiv/aids programme through general primary care at intervention clinics were more likely than those at control clinics to receive co-trimoxazole prophylaxis (41%, (2253/5523) v 32% (1340/4210); odds ratio 1.95, 95% confidence interval 1.11 to 3.40), and tuberculosis was more likely to be diagnosed among patients with hiv/aids/art (7% (417/5793) v 6% (245/4343); 1.25, 1.01 to 1.55).
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||paucity-4/NN||a-3/DT	nsubj||was-2/VBD||paucity-4/NN	prep_of||paucity-4/NN||evidence-6/NN	prep_on||evidence-6/NN||behaviour-8/NN	aux||avoid-10/VB||to-9/TO	vmod||paucity-4/NN||avoid-10/VB	dobj||avoid-10/VB||hypoglycaemia-11/NN	expl||were-15/VBD||there-14/EX	conj_but||was-2/VBD||were-15/VBD	det||suggestions-17/NNS||some-16/DT	nsubj||were-15/VBD||suggestions-17/NNS	mark||permitted-26/VBN||that-18/IN	dep||desirable-21/JJ||higher-19/JJR	dep||desirable-21/JJ||than-20/IN	amod||levels-23/NNS||desirable-21/JJ	nn||levels-23/NNS||bloodglucose-22/NN	nsubjpass||permitted-26/VBN||levels-23/NNS	nsubj||avoid-30/VB||levels-23/NNS	aux||permitted-26/VBN||might-24/MD	auxpass||permitted-26/VBN||be-25/VB	ccomp||were-15/VBD||permitted-26/VBN	prep_in||permitted-26/VBN||order-28/NN	aux||avoid-30/VB||to-29/TO	xcomp||permitted-26/VBN||avoid-30/VB	dobj||avoid-30/VB||hypoglycaemia-31/NN	glucose--1||hypoglycaemia-31||no_rel||there was a paucity of evidence on behaviour to avoid hypoglycaemia, but there were some suggestions that higher than desirable bloodglucose levels might be permitted in order to avoid hypoglycaemia.
amod||evolutionary-2/JJ||molecular-1/JJ	nsubj||suggested-10/VBD||evolutionary-2/JJ	amod||analyses-5/NNS||genetic-4/JJ	conj_and||evolutionary-2/JJ||analyses-5/NNS	nsubj||suggested-10/VBD||analyses-5/NNS	det||loci-9/NN||the-7/DT	amod||loci-9/NN||examined-8/JJ	prep_of||evolutionary-2/JJ||loci-9/NN	root||ROOT-0/null||suggested-10/VBD	det||history-14/NN||a-11/DT	amod||history-14/NN||unique-12/JJ	amod||history-14/NN||evolutionary-13/JJ	dobj||suggested-10/VBD||history-14/NN	prep_in||suggested-10/VBD||hg-i-16/NN	advmod||shaped-19/VBN||probably-18/RB	prep_in||suggested-10/VBD||shaped-19/VBN	conj_and||hg-i-16/NN||shaped-19/VBN	vmod||hg-i-16/NN||shaped-19/VBN	amod||interactions-22/NNS||complex-21/JJ	agent||shaped-19/VBN||interactions-22/NNS	prep_of||interactions-22/NNS||selection-24/NN	amod||history-27/NN||demographic-26/JJ	prep_in||suggested-10/VBD||history-27/NN	conj_and||hg-i-16/NN||history-27/NN	amod||differentiation-32/NN||high-30/JJ	amod||differentiation-32/NN||geographical-31/JJ	prep_in||suggested-10/VBD||differentiation-32/NN	conj_and||hg-i-16/NN||differentiation-32/NN	vmod||differentiation-32/NN||leading-33/VBG	det||formation-36/NN||the-35/DT	prep_to||leading-33/VBG||formation-36/NN	amod||subhaplogroups-40/NNS||distinct-38/JJ	nn||subhaplogroups-40/NNS||hg-i-39/NN	prep_of||formation-36/NN||subhaplogroups-40/NNS	mark||associated-44/VBN||that-41/IN	nsubjpass||associated-44/VBN||today-42/NN	auxpass||associated-44/VBN||are-43/VBP	ccomp||leading-33/VBG||associated-44/VBN	amod||onset-47/NN||hiv/aids-46/JJ	prep_with||associated-44/VBN||onset-47/NN	aids--1||hiv--1||no||molecular evolutionary and genetic analyses of the examined loci suggested a unique evolutionary history in hg-i, probably shaped by complex interactions of selection, demographic history, and high geographical differentiation leading to the formation of distinct hg-i subhaplogroups that today are associated with hiv/aids onset.
nsubj||one-10/CD||inhibition-1/NN	det||signalling-7/NN||both-3/DT	amod||signalling-7/NN||erbb2-4/JJ	conj_and||erbb2-4/JJ||erbb4-6/JJ	amod||signalling-7/NN||erbb4-6/JJ	prep_of||inhibition-1/NN||signalling-7/NN	aux||one-10/CD||may-8/MD	cop||one-10/CD||be-9/VB	root||ROOT-0/null||one-10/CD	det||reasons-13/NNS||the-12/DT	prep_of||one-10/CD||reasons-13/NNS	advmod||suffer-25/VBP||why-14/WRB	det||patients-16/NNS||those-15/DT	nsubj||receive-18/VBP||patients-16/NNS	nsubj||suffer-25/VBP||patients-16/NNS	rcmod||patients-16/NNS||receive-18/VBP	amod||therapy-20/NN||concurrent-19/JJ	dobj||receive-18/VBP||therapy-20/NN	prep_with||receive-18/VBP||dox-22/NN	prep_with||receive-18/VBP||trastuzumab-24/NN	conj_and||dox-22/NN||trastuzumab-24/NN	advcl||one-10/CD||suffer-25/VBP	prep_from||suffer-25/VBP||chf-27/NN	chf-27||dox-22||no||inhibition of both erbb2 and erbb4 signalling may be one of the reasons why those patients who receive concurrent therapy with dox and trastuzumab suffer from chf.
nsubjpass||known-4/VBN||it-1/PRP	auxpass||known-4/VBN||is-2/VBZ	neg||known-4/VBN||not-3/RB	root||ROOT-0/null||known-4/VBN	advmod||promotes-8/VBZ||how-5/WRB	nsubj||promotes-8/VBZ||ebvinfection-6/NN	advmod||promotes-8/VBZ||potentially-7/RB	ccomp||known-4/VBN||promotes-8/VBZ	nn||-lrb--14/NNS||autoimmunity-9/NN	conj_and||autoimmunity-9/NN||central-11/JJ	nn||-lrb--14/NNS||central-11/JJ	amod||-lrb--14/NNS||nervous-12/JJ	nn||-lrb--14/NNS||system-13/NN	nsubj||cns-15/VBP||-lrb--14/NNS	ccomp||promotes-8/VBZ||cns-15/VBP	amod||damage-18/NN||-rrb--16/JJ	nn||damage-18/NN||tissue-17/NN	nsubj||have-33/VBP||damage-18/NN	prep_in||damage-18/NN||ms.-20/NN	mark||isolates-28/VBZ||ms.-20/NN	advmod||ms.-20/NN||recently-21/RB	nsubjpass||found-25/VBN||it-22/PRP	aux||found-25/VBN||has-23/VBZ	auxpass||found-25/VBN||been-24/VBN	rcmod||ms.-20/NN||found-25/VBN	nsubj||isolates-28/VBZ||ebv-27/NN	ccomp||found-25/VBN||isolates-28/VBZ	amod||regions-32/NNS||different-30/JJ	amod||regions-32/NNS||geographic-31/JJ	prep_from||isolates-28/VBZ||regions-32/NNS	ccomp||cns-15/VBP||have-33/VBP	advmod||conserved-35/JJ||highly-34/RB	amod||epitopes-37/NNS||conserved-35/JJ	amod||epitopes-37/NNS||barf1-36/JJ	dobj||have-33/VBP||epitopes-37/NNS	ebvinfection-6||ebv-27||no||it is not known how ebvinfection potentially promotes autoimmunity and central nervous system -lrb- cns -rrb- tissue damage in ms. recently it has been found that ebv isolates from different geographic regions have highly conserved barf1 epitopes .
amod||treatment-3/NN||local-1/JJ	nn||treatment-3/NN||tacrolimus-2/NN	nsubj||effective-5/JJ||treatment-3/NN	cop||effective-5/JJ||is-4/VBZ	root||ROOT-0/null||effective-5/JJ	det||subgroup-8/NN||a-7/DT	prep_in||effective-5/JJ||subgroup-8/NN	amod||patients-11/NNS||proctitis-10/JJ	prep_of||subgroup-8/NN||patients-11/NNS	tacrolimus-2||proctitis-10||no_rel||local tacrolimus treatment is effective in a subgroup of proctitis patients.
amod||studies-3/NNS||several-1/JJ	amod||studies-3/NNS||recent-2/JJ	nsubj||demonstrated-4/VBD||studies-3/NNS	nsubj||translate-19/VB||studies-3/NNS	nsubj||including-27/VBG||studies-3/NNS	root||ROOT-0/null||demonstrated-4/VBD	mark||limited-13/VBN||that-5/IN	det||activity-8/NN||the-6/DT	amod||activity-8/NN||anticancer-7/JJ	nsubjpass||limited-13/VBN||activity-8/NN	prep_of||activity-8/NN||bisphosphonates-10/NNS	auxpass||limited-13/VBN||is-11/VBZ	neg||limited-13/VBN||not-12/RB	ccomp||demonstrated-4/VBD||limited-13/VBN	prep_to||limited-13/VBN||bone-15/NN	aux||translate-19/VB||can-18/MD	conj_and||demonstrated-4/VBD||translate-19/VB	det||reduction-22/NN||a-21/DT	prep_into||translate-19/VB||reduction-22/NN	nn||recurrence-25/NN||disease-24/NN	prep_in||reduction-22/NN||recurrence-25/NN	conj_and||demonstrated-4/VBD||including-27/VBG	prep_including||demonstrated-4/VBD||reductions-28/NNS	amod||metastases-33/NNS||locoregional-30/JJ	conj_and||locoregional-30/JJ||distant-32/JJ	amod||metastases-33/NNS||distant-32/JJ	prep_in||reductions-28/NNS||metastases-33/NNS	bisphosphonates-10||metastases-33||no_rel||several recent studies demonstrated that the anticancer activity of bisphosphonates is not limited to bone, and can translate into a reduction in disease recurrence, including reductions in locoregional and distant metastases.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-15/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-15/VBN||irondeficiency-9/RB	nsubjpass||evaluated-15/VBN||irondeficiencyanemia-11/NN	conj_and||irondeficiencyanemia-11/NN||anemia-13/NN	nsubjpass||evaluated-15/VBN||anemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	prep_among||evaluated-15/VBN||them-17/PRP	irondeficiencyanemia-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiencyanemia and anemia were evaluated among them.
det||epidemic-2/NN||the-1/DT	nsubjpass||caused-9/VBN||epidemic-2/NN	prep_of||epidemic-2/NN||severeacuterespiratorysyndrome-4/NN	appos||epidemic-2/NN||sars-6/NNS	auxpass||caused-9/VBN||was-8/VBD	root||ROOT-0/null||caused-9/VBN	det||coronavirus-14/NNS||a-11/DT	advmod||emerged-13/JJ||newly-12/RB	amod||coronavirus-14/NNS||emerged-13/JJ	agent||caused-9/VBN||coronavirus-14/NNS	appos||coronavirus-14/NNS||sars-cov-16/NNP	severeacuterespiratorysyndrome-4||coronavirus-14||no||the epidemic of severeacuterespiratorysyndrome (sars) was caused by a newly emerged coronavirus (sars-cov).
aux||investigate-2/VB||to-1/TO	dep||studied-11/VBD||investigate-2/VB	amod||differences-4/NNS||global-3/JJ	dobj||investigate-2/VB||differences-4/NNS	det||epidemiology-7/NN||the-6/DT	prep_in||investigate-2/VB||epidemiology-7/NN	prep_of||epidemiology-7/NN||chickenpox-9/NN	nsubj||studied-11/VBD||we-10/PRP	root||ROOT-0/null||studied-11/VBD	det||population-13/NN||a-12/DT	dobj||studied-11/VBD||population-13/NN	nn||bissau-16/NN||guinea-15/NN	prep_in||population-13/NN||bissau-16/NN	nsubj||has-25/VBZ||bissau-16/NN	prep_in||has-25/VBZ||contrast-20/NN	amod||countries-24/NNS||other-22/JJ	amod||countries-24/NNS||tropical-23/JJ	prep_to||contrast-20/NN||countries-24/NNS	rcmod||bissau-16/NN||has-25/VBZ	det||age-29/NN||an-26/DT	advmod||early-28/JJ||unexpectedly-27/RB	amod||age-29/NN||early-28/JJ	dobj||has-25/VBZ||age-29/NN	prep_of||age-29/NN||infection-31/NN	prep_with||infection-31/NN||vzv-33/NN	amod||age-29/NN||comparable-35/JJ	aux||temperate-37/VB||to-36/TO	xcomp||comparable-35/JJ||temperate-37/VB	dobj||temperate-37/VB||latitudes-38/NNS	chickenpox-9||vzv-33||no||to investigate global differences in the epidemiology of chickenpox we studied a population in guinea bissau, which in contrast to other tropical countries has an unexpectedly early age of infection with vzv, comparable to temperate latitudes.
amod||artery-2/NN||infarct-1/JJ	nsubjpass||used-10/VBN||artery-2/NN	vmod||artery-2/NN||stenting-3/VBG	amod||therapy-7/NN||adjunctive-5/JJ	nn||therapy-7/NN||abciximab-6/NN	prep_with||stenting-3/VBG||therapy-7/NN	auxpass||used-10/VBN||is-8/VBZ	advmod||used-10/VBN||widely-9/RB	root||ROOT-0/null||used-10/VBN	dobj||used-10/VBN||treatment-11/NN	prep_for||used-10/VBN||patients-13/NNS	prep_with||patients-13/NNS||acutemyocardialinfarction-15/NN	appos||acutemyocardialinfarction-15/NN||ami-17/NN	abciximab-6||ami-17||no_rel||infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acutemyocardialinfarction (ami).
num||rats-5/NNS||resultsâ-1/CD	amod||rats-5/NNS||$-2/JJ	nn||rats-5/NNS||zdf-4/NN	nsubj||have-10/VBP||rats-5/NNS	prepc_compared_with||rats-5/NNS||with-7/IN	nn||rats-9/NNS||zcl-8/NN	pobj||rats-5/NNS||rats-9/NNS	root||ROOT-0/null||have-10/VBP	amod||gk-13/NN||lower-11/JJR	amod||gk-13/NN||hepatic-12/JJ	dobj||have-10/VBP||gk-13/NN	nsubj||increased-73/VBD||activity-14/NN	nn||activity-14/NN||-lrb--15/FW	nn||activity-14/NN||11.6-16/FW	nn||activity-14/NN||â-17/FW	nn||activity-14/NN||±-18/FW	nn||activity-14/NN||1.9-19/FW	nn||activity-14/NN||vs.-20/FW	nn||activity-14/NN||32.5-21/FW	nn||activity-14/NN||â-22/FW	nn||activity-14/NN||±-23/FW	nn||activity-14/NN||3.2-24/FW	nn||activity-14/NN||mu/mg-25/FW	nn||activity-14/NN||protein-26/FW	nn||activity-14/NN||-rrb--27/FW	nn||activity-14/NN||marked-29/FW	nn||activity-14/NN||hyperglycemia-30/FW	nn||activity-14/NN||-lrb--31/FW	nn||activity-14/NN||23.9-32/FW	nn||activity-14/NN||â-33/FW	nn||activity-14/NN||±-34/FW	nn||activity-14/NN||1.2-35/FW	nn||activity-14/NN||vs.-36/FW	nn||activity-14/NN||7.4-37/FW	nn||activity-14/NN||â-38/FW	dep||activity-14/NN||±-39/FW	number||-rrb--42/NN||0.3-40/CD	dep||-rrb--42/NN||mmol/l-41/JJ	amod||activity-14/NN||-rrb--42/NN	amod||endogenous-45/NNS||higher-44/JJR	appos||activity-14/NN||endogenous-45/NNS	advmod||activity-14/NN||glucose-46/RB	dep||activity-14/NN||production-47/NN	nn||production-47/NN||-lrb--48/FW	nn||production-47/NN||80-49/FW	nn||production-47/NN||â-50/FW	nn||production-47/NN||±-51/FW	nn||production-47/NN||3-52/FW	nn||production-47/NN||vs.-53/FW	nn||production-47/NN||38-54/FW	nn||production-47/NN||â-55/FW	nn||production-47/NN||±-56/FW	nn||production-47/NN||3-57/FW	nn||production-47/NN||î-58/FW	nn||production-47/NN||1/4-59/FW	nn||production-47/NN||mol-60/FW	nn||production-47/NN||â-61/FW	dep||production-47/NN||·-62/FW	poss||-rrb--71/NN||kgâˆ-63/NNP	number||â-66/NN||1-65/CD	amod||-rrb--71/NN||â-66/NN	punct||-rrb--71/NN||·-67/``	nn||-rrb--71/NN||minâˆ-68/NN	num||-rrb--71/NN||1-70/CD	dep||production-47/NN||-rrb--71/NN	rcmod||gk-13/NN||increased-73/VBD	amod||â-78/NN||glucose-6-phosphatase-74/JJ	nn||â-78/NN||flux-75/NN	nn||â-78/NN||-lrb--76/NN	num||â-78/NN||150-77/CD	iobj||increased-73/VBD||â-78/NN	punct||â-78/NN||±-79/``	nn||â-78/NN||11-80/FW	nn||â-78/NN||vs.-81/FW	nn||â-78/NN||58-82/FW	nn||â-78/NN||â-83/FW	nn||â-78/NN||±-84/FW	nn||â-78/NN||8-85/FW	nn||â-78/NN||î-86/FW	nn||â-78/NN||1/4-87/FW	nn||â-78/NN||mol-88/FW	dep||â-78/NN||â-89/FW	punct||â-78/NN||·-90/''	poss||â-94/NN||kgâˆ-91/NNP	num||â-94/NN||1-93/CD	iobj||increased-73/VBD||â-94/NN	dep||â-94/NN||·-95/SYM	poss||production-113/NN||minâˆ-96/NNP	number||-rrb--99/NN||1-98/CD	amod||production-113/NN||-rrb--99/NN	cc||during-102/IN||and-101/CC	dep||-rrb--99/NN||during-102/IN	det||clamp-105/NN||a-103/DT	amod||clamp-105/NN||hyperglycemic-104/JJ	pobj||during-102/IN||clamp-105/NN	det||failure-108/NN||a-107/DT	appos||clamp-105/NN||failure-108/NN	amod||endogenous-111/NNS||suppress-110/JJ	prep_to||failure-108/NN||endogenous-111/NNS	nn||production-113/NN||glucose-112/NN	iobj||increased-73/VBD||production-113/NN	amod||production-113/NN||-lrb--114/NN	number||-lrb--114/NN||80-115/CD	iobj||increased-73/VBD||â-116/NN	punct||â-116/NN||±-117/``	nn||â-116/NN||7-118/FW	nn||â-116/NN||vs.-119/FW	nn||â-116/NN||âˆ-120/FW	nn||â-116/NN||7-122/FW	nn||â-116/NN||â-123/FW	nn||â-116/NN||±-124/FW	nn||â-116/NN||4-125/FW	nn||â-116/NN||î-126/FW	nn||â-116/NN||1/4-127/FW	nn||â-116/NN||mol-128/FW	dep||â-116/NN||â-129/FW	punct||â-116/NN||·-130/``	poss||â-134/NN||kgâˆ-131/NNP	num||â-134/NN||1-133/CD	dep||â-116/NN||â-134/NN	punct||â-116/NN||·-135/''	poss||incorporation-143/NN||minâˆ-136/NNP	number||-rrb--139/NN||1-138/CD	amod||incorporation-143/NN||-rrb--139/NN	conj_and||-rrb--139/NN||promote-141/JJ	amod||incorporation-143/NN||promote-141/JJ	nn||incorporation-143/NN||glucose-142/NN	dobj||increased-73/VBD||incorporation-143/NN	prep_into||increased-73/VBD||glycogen-145/NN	nn||glycogen-145/NN||-lrb--146/FW	nn||glycogen-145/NN||15-147/FW	nn||glycogen-145/NN||â-148/FW	nn||glycogen-145/NN||±-149/FW	nn||glycogen-145/NN||5-150/FW	nn||glycogen-145/NN||vs.-151/FW	nn||glycogen-145/NN||43-152/FW	nn||glycogen-145/NN||â-153/FW	nn||glycogen-145/NN||±-154/FW	nn||glycogen-145/NN||3-155/FW	dep||glycogen-145/NN||î-156/FW	dep||glycogen-145/NN||1/4-157/CD	xcomp||increased-73/VBD||mol/g-158/VBG	nn||-rrb--160/NNS||liver-159/NN	dobj||mol/g-158/VBG||-rrb--160/NNS	hyperglycemia-30||glucose-142||no||resultsâ $ '' zdf rats compared with zcl rats have lower hepatic gk activity -lrb- 11.6 â ± 1.9 vs. 32.5 â ± 3.2 mu/mg protein -rrb- , marked hyperglycemia -lrb- 23.9 â ± 1.2 vs. 7.4 â ± 0.3 mmol/l -rrb- , higher endogenous glucose production -lrb- 80 â ± 3 vs. 38 â ± 3 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , increased glucose-6-phosphatase flux -lrb- 150 â ± 11 vs. 58 â ± 8 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , and during a hyperglycemic clamp , a failure to suppress endogenous glucose production -lrb- 80 â ± 7 vs. âˆ ' 7 â ± 4 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- and promote glucose incorporation into glycogen -lrb- 15 â ± 5 vs. 43 â ± 3 î 1/4 mol/g liver -rrb- .
nsubj||decreased-8/VBD||consumption-1/NN	det||hpmc-7/NN||the-3/DT	amod||hpmc-7/NN||viscous-4/JJ	amod||hpmc-7/NN||non-fermentable-5/JJ	nn||hpmc-7/NN||fiber-6/NN	prep_of||consumption-1/NN||hpmc-7/NN	root||ROOT-0/null||decreased-8/VBD	amod||wasting-10/NN||diabetic-9/JJ	dobj||decreased-8/VBD||wasting-10/NN	amod||control-14/NN||improved-12/VBN	nn||control-14/NN||glucose-13/NN	dobj||decreased-8/VBD||control-14/NN	conj_and||wasting-10/NN||control-14/NN	amod||insulinresistance-17/NN||reduced-16/VBN	dobj||decreased-8/VBD||insulinresistance-17/NN	conj_and||wasting-10/NN||insulinresistance-17/NN	nn||liver-20/NN||fatty-19/NN	conj_and||wasting-10/NN||liver-20/NN	conj_and||insulinresistance-17/NN||liver-20/NN	det||model-23/NN||a-22/DT	prep_in||insulinresistance-17/NN||model-23/NN	prep_of||insulinresistance-17/NN||obesity-25/NN	prep_with||insulinresistance-17/NN||diabetes-27/NN	insulinresistance-17||glucose-13||no_rel||consumption of the viscous non-fermentable fiber hpmc decreased diabetic wasting, improved glucose control and reduced insulinresistance and fatty liver in a model of obesity with diabetes.
nsubjpass||recorded-5/VBN||symptoms-1/NNS	prep_of||symptoms-1/NNS||commoncold-3/NN	auxpass||recorded-5/VBN||were-4/VBD	root||ROOT-0/null||recorded-5/VBN	det||load-9/NN||the-7/DT	amod||load-9/NN||viral-8/JJ	nsubjpass||determined-17/VBN||load-9/NN	amod||viruses-12/NNS||respiratory-11/JJ	prep_of||load-9/NN||viruses-12/NNS	amod||secretions-15/NNS||nasal-14/JJ	prep_in||viruses-12/NNS||secretions-15/NNS	auxpass||determined-17/VBN||was-16/VBD	conj_and||recorded-5/VBN||determined-17/VBN	num||visits-21/NNS||two-19/CD	amod||visits-21/NNS||consecutive-20/JJ	prep_at||determined-17/VBN||visits-21/NNS	commoncold-3||viruses-12||no||symptoms of commoncold were recorded and the viral load of respiratory viruses in nasal secretions was determined at two consecutive visits.
amod||therapy-3/NN||long-term-1/JJ	nn||therapy-3/NN||oxygen-2/NN	nsubj||treatment-9/NN||therapy-3/NN	appos||therapy-3/NN||ltot-5/NN	cop||treatment-9/NN||is-7/VBZ	det||treatment-9/NN||the-8/DT	root||ROOT-0/null||treatment-9/NN	vmod||treatment-9/NN||proven-10/VBN	aux||improve-12/VB||to-11/TO	xcomp||proven-10/VBN||improve-12/VB	dobj||improve-12/VB||survival-13/NN	iobj||improve-12/VB||survival-13/NN	amod||obstructivepulmonarydisease-16/NN||chronic-15/JJ	prep_in||survival-13/NN||obstructivepulmonarydisease-16/NN	dep||survival-13/NN||copd-18/VBN	dep||survival-13/NN||patients-20/NNS	amod||failure-24/NN||chronic-22/JJ	amod||failure-24/NN||respiratory-23/JJ	prep_with||patients-20/NNS||failure-24/NN	obstructivepulmonarydisease-16||oxygen-2||yes||long-term oxygen therapy (ltot) is the treatment proven to improve survival in chronic obstructivepulmonarydisease (copd) patients with chronic respiratory failure.
det||study-3/NN||this-1/DT	amod||study-3/NN||cross-sectional-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||evaluate-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||evaluate-7/VB||to-6/TO	xcomp||conducted-5/VBN||evaluate-7/VB	det||prevalence-9/NN||the-8/DT	dobj||evaluate-7/VB||prevalence-9/NN	prep_of||prevalence-9/NN||hepatitisbvirus-11/NNS	appos||hepatitisbvirus-11/NNS||hbv-13/NN	amod||virus-17/NN||hepatitisc-16/JJ	prep_of||prevalence-9/NN||virus-17/NN	conj_and||hepatitisbvirus-11/NNS||virus-17/NN	appos||hepatitisbvirus-11/NNS||hcv-19/NN	amod||donors-24/NNS||healthy-22/JJ	nn||donors-24/NNS||blood-23/NN	prep_in||evaluate-7/VB||donors-24/NNS	det||valley-27/NN||the-26/DT	prep_in||donors-24/NNS||valley-27/NN	hbv-13||hepatitisbvirus-11||no||this cross-sectional study was conducted to evaluate the prevalence of hepatitisbvirus (hbv) and hepatitisc virus (hcv) in healthy blood donors in the valley.
advmod||approved-5/VBN||currently-1/RB	nsubjpass||approved-5/VBN||ziprasidone-3/NN	auxpass||approved-5/VBN||is-4/VBZ	root||ROOT-0/null||approved-5/VBN	dep||food-9/NN||the-7/DT	dep||food-9/NN||us-8/PRP	agent||approved-5/VBN||food-9/NN	nn||administration-12/NN||drug-11/NN	agent||approved-5/VBN||administration-12/NN	conj_and||food-9/NN||administration-12/NN	det||treatment-16/NN||the-14/DT	amod||treatment-16/NN||acute-15/JJ	prep_for||approved-5/VBN||treatment-16/NN	prep_of||treatment-16/NN||psychosis-18/NNS	prep_in||psychosis-18/NNS||schizophrenia-20/NN	prep_in||psychosis-18/NNS||mania-22/NN	conj_and||schizophrenia-20/NN||mania-22/NN	prep_in||approved-5/VBN||bipolardisorder-24/NN	schizophrenia-20||ziprasidone-3||yes||currently, ziprasidone is approved by the us food and drug administration for the acute treatment of psychosis in schizophrenia and mania in bipolardisorder.
advmod||+-10/VBD||however-1/RB	amod||p465l-4/NNS||pparg-3/JJ	nsubj||+-10/VBD||p465l-4/NNS	punct||akita-8/NN||/-5/:	amod||akita-8/NN||+-6/JJ	amod||akita-8/NN||ins2-7/JJ	dep||p465l-4/NNS||akita-8/NN	punct||akita-8/NN||/-9/:	root||ROOT-0/null||+-10/VBD	nsubj||aggravated-13/VBN||females-11/NNS	aux||aggravated-13/VBN||have-12/VBP	ccomp||+-10/VBD||aggravated-13/VBN	dobj||aggravated-13/VBN||hyperglycemia-14/NN	amod||islets-17/NNS||smaller-16/JJR	dobj||aggravated-13/VBN||islets-17/NNS	conj_and||hyperglycemia-14/NN||islets-17/NNS	amod||insulin-22/NN||reduced-20/VBN	nn||insulin-22/NN||plasma-21/NN	dobj||aggravated-13/VBN||insulin-22/NN	conj_and||hyperglycemia-14/NN||insulin-22/NN	insulin-22||hyperglycemia-14||no_rel||however, pparg p465l /+ ins2 akita /+ females have aggravated hyperglycemia, smaller islets, and reduced plasma insulin.
nsubj||share-5/VBP||cr-1/NN	amod||exercise-4/NN||endurance-3/JJ	conj_and||cr-1/NN||exercise-4/NN	nsubj||share-5/VBP||exercise-4/NN	root||ROOT-0/null||share-5/VBP	det||function-9/NN||a-6/DT	amod||function-9/NN||potent-7/JJ	amod||function-9/NN||anti-inflammatory-8/JJ	dobj||share-5/VBP||function-9/NN	amod||tissues-12/NNS||adipose-11/JJ	prep_in||function-9/NN||tissues-12/NNS	prepc_in||share-5/VBP||ameliorating-14/VBG	amod||obesity-16/NN||diet-induced-15/JJ	dobj||ameliorating-14/VBG||obesity-16/NN	dobj||ameliorating-14/VBG||insulinresistance-18/NN	conj_and||obesity-16/NN||insulinresistance-18/NN	cr-1||insulinresistance-18||no_rel||cr and endurance exercise share a potent anti-inflammatory function in adipose tissues in ameliorating diet-induced obesity and insulinresistance.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	amod||effects-5/NNS||possible-3/JJ	amod||effects-5/NNS||direct-4/JJ	dobj||investigated-2/VBD||effects-5/NNS	prep_of||effects-5/NNS||salmoncalcitonin-7/NN	prep_on||investigated-2/VBD||proteoglycans-9/NNS	nn||synthesis-12/NN||collagen-type-ii-11/NN	prep_on||investigated-2/VBD||synthesis-12/NN	conj_and||proteoglycans-9/NNS||synthesis-12/NN	amod||cartilage-18/NNS||osteoarthritic-14/JJ	appos||cartilage-18/NNS||oa-16/NN	prep_in||investigated-2/VBD||cartilage-18/NNS	oa-16||salmoncalcitonin-7||no_rel||we investigated possible direct effects of salmoncalcitonin on proteoglycans and collagen-type-ii synthesis in osteoarthritic (oa) cartilage.
nsubj||drugs-14/NNS||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	amod||sulfate-7/NN||glucosamine-6/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-7/NN	nsubj||drugs-14/NNS||sulfate-7/NN	appos||sulfate-7/NN||gs-9/NN	cop||drugs-14/NNS||are-11/VBP	amod||drugs-14/NNS||symptomatic-12/JJ	amod||drugs-14/NNS||slow-acting-13/JJ	root||ROOT-0/null||drugs-14/NNS	prep_for||drugs-14/NNS||osteoarthritis-16/NNS	appos||osteoarthritis-16/NNS||oa-18/NN	advmod||used-21/VBN||widely-20/RB	vmod||osteoarthritis-16/NNS||used-21/VBN	prep_in||used-21/VBN||clinic-23/NN	oa-18||glucosamine-6||yes||chondroitinsulfate (cs) and glucosamine sulfate (gs) are symptomatic slow-acting drugs for osteoarthritis (oa) widely used in clinic.
det||vaccine-5/NN||the-1/DT	amod||vaccine-5/NN||only-2/JJ	advmod||available-4/JJ||currently-3/RB	amod||vaccine-5/NN||available-4/JJ	nsubj||calmette-guerin-14/NN||vaccine-5/NN	prep_against||vaccine-5/NN||tuberculosis-7/NNP	appos||vaccine-5/NN||tb-9/NN	cop||calmette-guerin-14/NN||is-11/VBZ	amod||bacille-13/JJ||mycobacteriumbovis-12/JJ	amod||calmette-guerin-14/NN||bacille-13/JJ	root||ROOT-0/null||calmette-guerin-14/NN	nsubj||inconsistent-21/JJ||calmette-guerin-14/NN	nsubj||protect-24/VB||calmette-guerin-14/NN	appos||calmette-guerin-14/NN||bcg-16/NN	aux||inconsistent-21/JJ||has-20/VBZ	rcmod||calmette-guerin-14/NN||inconsistent-21/JJ	advmod||inconsistent-21/JJ||efficacy-22/RB	aux||protect-24/VB||to-23/TO	xcomp||inconsistent-21/JJ||protect-24/VB	det||disease-27/NN||the-26/DT	prep_against||protect-24/VB||disease-27/NN	prep_in||inconsistent-21/JJ||adults-29/NNS	tb-9||bcg-16||yes||the only currently available vaccine against tuberculosis (tb) is mycobacteriumbovis bacille calmette-guerin (bcg), which has inconsistent efficacy to protect against the disease in adults.
amod||therapies-2/NNS||advanced-1/JJ	nsubj||succeeded-6/VBN||therapies-2/NNS	nsubj||control-8/VB||therapies-2/NNS	vmod||therapies-2/NNS||using-3/VBG	dobj||using-3/VBG||biologicals-4/NNS	aux||succeeded-6/VBN||have-5/VBP	root||ROOT-0/null||succeeded-6/VBN	aux||control-8/VB||to-7/TO	xcomp||succeeded-6/VBN||control-8/VB	amod||opticneuritis-10/NNS||intractable-9/JJ	dobj||control-8/VB||opticneuritis-10/NNS	nn||models-13/NNS||animal-12/NN	prep_in||control-8/VB||models-13/NNS	opticneuritis-10||biologicals-4||no_rel||advanced therapies using biologicals have succeeded to control intractable opticneuritis in animal models.
det||tissues-2/NNS||the-1/DT	nsubj||had-10/VBD||tissues-2/NNS	prep_from||tissues-2/NNS||patients-4/NNS	vmod||patients-4/NNS||revised-5/VBN	amod||wear-9/NN||suspected-7/VBN	amod||wear-9/NN||high-8/JJ	prep_for||revised-5/VBN||wear-9/NN	root||ROOT-0/null||had-10/VBD	det||score-14/NN||a-11/DT	amod||score-14/NN||lower-12/JJR	nn||score-14/NN||alval-13/NN	dobj||had-10/VBD||score-14/NN	amod||lymphocytes-17/NNS||fewer-16/JJR	appos||score-14/NN||lymphocytes-17/NNS	amod||macrophages-21/NN||more-20/JJR	dobj||had-10/VBD||macrophages-21/NN	conj_but||score-14/NN||macrophages-21/NN	nn||particles-24/NNS||metal-23/NN	conj_but||score-14/NN||particles-24/NNS	conj_and||macrophages-21/NN||particles-24/NNS	det||tissues-27/NNS||those-26/DT	prep_than||macrophages-21/NN||tissues-27/NNS	prep_from||had-10/VBD||hips-29/NNS	vmod||hips-29/NNS||revised-30/VBN	prep_for||revised-30/VBN||pain-32/NN	amod||hypersensitivity-36/NN||suspected-34/VBN	nn||hypersensitivity-36/NN||metal-35/NN	prep_for||revised-30/VBN||hypersensitivity-36/NN	conj_and||pain-32/NN||hypersensitivity-36/NN	metal-35||hypersensitivity-36||no_rel||the tissues from patients revised for suspected high wear had a lower alval score, fewer lymphocytes, but more macrophages and metal particles than those tissues from hips revised for pain and suspected metal hypersensitivity.
det||relaxation-3/NN||the-1/DT	nn||relaxation-3/NN||dna-2/NN	nsubj||topoisomerase-10/VBP||relaxation-3/NN	amod||accumulation-7/NN||cleavage-5/JJ	nn||accumulation-7/NN||complex-6/NN	conj_and||relaxation-3/NN||accumulation-7/NN	nsubj||topoisomerase-10/VBP||accumulation-7/NN	prep_of||relaxation-3/NN||m.tuberculosis-9/NNS	root||ROOT-0/null||topoisomerase-10/VBP	nsubjpass||measured-14/VBN||i-11/FW	aux||measured-14/VBN||can-12/MD	auxpass||measured-14/VBN||be-13/VB	ccomp||topoisomerase-10/VBP||measured-14/VBN	amod||assays-17/NNS||genetic-16/JJ	prep_with||measured-14/VBN||assays-17/NNS	nn||coli-20/NNS||e.-19/NN	prep_in||measured-14/VBN||coli-20/NNS	xcomp||measured-14/VBN||facilitating-22/VBG	amod||analysis-24/NN||rapid-23/JJ	dobj||facilitating-22/VBG||analysis-24/NN	poss||activities-27/NNS||its-26/PRP$	prep_of||analysis-24/NN||activities-27/NNS	nsubj||targeting-35/VBG||discovery-30/NN	amod||therapy-34/NN||new-32/JJ	nn||therapy-34/NN||tb-33/NN	prep_of||discovery-30/NN||therapy-34/NN	conj_and||topoisomerase-10/VBP||targeting-35/VBG	det||enzyme-38/NN||this-36/DT	amod||enzyme-38/NN||essential-37/JJ	dobj||targeting-35/VBG||enzyme-38/NN	tb-33||m.tuberculosis-9||no||the dna relaxation and cleavage complex accumulation of m.tuberculosis topoisomerase i can be measured with genetic assays in e. coli , facilitating rapid analysis of its activities , and discovery of new tb therapy targeting this essential enzyme .
nsubj||reduce-3/VB||dronedarone-1/NN	aux||reduce-3/VB||can-2/MD	root||ROOT-0/null||reduce-3/VB	amod||points-11/NNS||unique-4/JJ	advmod||serious-8/JJ||potentially-7/RB	conj_but||unique-4/JJ||serious-8/JJ	amod||points-11/NNS||serious-8/JJ	nn||points-11/NNS||end-10/NN	dobj||reduce-3/VB||points-11/NNS	prep_in||reduce-3/VB||patients-13/NNS	prep_with||reduce-3/VB||atrialfibrillation-15/NN	dronedarone-1||atrialfibrillation-15||no_rel||dronedarone can reduce unique, but potentially serious, end points in patients with atrialfibrillation.
det||domain-3/NN||the-1/DT	amod||domain-3/NN||outer-2/JJ	nsubj||represents-14/VBZ||domain-3/NN	appos||domain-3/NN||od-5/NN	prep_of||domain-3/NN||humanimmunodeficiencyvirus-8/NNS	dep||domain-3/NN||hiv-10/VBN	num||gp120-13/NNS||-1-12/CD	dep||domain-3/NN||gp120-13/NNS	root||ROOT-0/null||represents-14/VBZ	det||target-21/NN||an-15/DT	amod||difficult-19/JJ||attractive-16/JJ	dep||difficult-19/JJ||if-18/IN	amod||target-21/NN||difficult-19/JJ	dobj||represents-14/VBZ||target-21/NN	det||response-26/NN||a-23/DT	amod||response-26/NN||beneficial-24/JJ	amod||response-26/NN||immune-25/JJ	prep_for||target-21/NN||response-26/NN	prep_to||represents-14/VBZ||hivinfection-28/NN	hivinfection-28||hiv-10||no||the outer domain (od) of humanimmunodeficiencyvirus (hiv)-1 gp120 represents an attractive, if difficult, target for a beneficial immune response to hivinfection.
nsubjpass||increased-22/VBN||hypertension-1/NN	conj_and||hypertension-1/NN||triglycerides-3/NN	nsubjpass||increased-22/VBN||triglycerides-3/NN	conj_and||hypertension-1/NN||insulinresistance-5/NN	nsubjpass||increased-22/VBN||insulinresistance-5/NN	dep||hypertension-1/NN||determined-7/VBN	amod||assessment-11/NN||homeostasis-9/JJ	nn||assessment-11/NN||model-10/NN	prep_by||determined-7/VBN||assessment-11/NN	prep_of||assessment-11/NN||insulinresistance-13/NN	amod||protein-17/NN||c-reactive-16/JJ	conj_and||hypertension-1/NN||protein-17/NN	nsubjpass||increased-22/VBN||protein-17/NN	dep||protein-17/NN||crp-19/VBN	auxpass||increased-22/VBN||were-21/VBD	root||ROOT-0/null||increased-22/VBN	prep_in||increased-22/VBN||sle-24/NN	parataxis||increased-22/VBN||p-26/VB	num||0.01-28/CD||<-27/CD	dobj||p-26/VB||0.01-28/CD	mark||differ-43/VB||while-30/IN	nn||lipoprotein-37/NN||smoking-31/NN	dep||lipoprotein-37/NN||ldl-33/NN	amod||lipoprotein-37/NN||high-35/JJ	nn||lipoprotein-37/NN||density-36/NN	nsubj||differ-43/VB||lipoprotein-37/NN	appos||lipoprotein-37/NN||hdl-39/NN	aux||differ-43/VB||did-41/VBD	neg||differ-43/VB||not-42/RB	advcl||increased-22/VBN||differ-43/VB	prep_between||differ-43/VB||groups-45/NNS	triglycerides-3||insulinresistance-13||no_rel||hypertension, triglycerides and insulinresistance (determined by homeostasis model assessment of insulinresistance) and c-reactive protein (crp) were increased in sle ( p < 0.01) while smoking, ldl, high density lipoprotein (hdl) did not differ between groups.
amod||calculations-2/NNS||statistical-1/JJ	nsubjpass||carried-4/VBN||calculations-2/NNS	auxpass||carried-4/VBN||were-3/VBD	root||ROOT-0/null||carried-4/VBN	prepc_out||carried-4/VBN||using-6/VBG	amod||software-9/NN||spss11-7/JJ	num||software-9/NN||.5-8/CD	dobj||using-6/VBG||software-9/NN	nsubj||analyze-11/VB||software-9/NN	aux||analyze-11/VB||to-10/TO	xcomp||using-6/VBG||analyze-11/VB	det||prevalence-13/NN||the-12/DT	dobj||analyze-11/VB||prevalence-13/NN	det||bacteria-16/NNS||the-15/DT	prep_of||prevalence-13/NN||bacteria-16/NNS	vmod||bacteria-16/NNS||involved-17/VBN	amod||caries-20/NNS||secondary-19/JJ	prep_in||involved-17/VBN||caries-20/NNS	caries-20||bacteria-16||no||statistical calculations were carried out using spss11.5 software to analyze the prevalence of the bacteria involved in secondary caries.
advmod||mutate-11/VB||furthermore-1/RB	amod||viruses-6/NNS||other-4/JJ	nn||viruses-6/NNS||rna-5/NN	prep_unlike||mutate-11/VB||viruses-6/NNS	nsubj||mutate-11/VB||hcovs-8/NNS	nsubj||recombine-13/VB||hcovs-8/NNS	aux||mutate-11/VB||can-9/MD	advmod||mutate-11/VB||easily-10/RB	root||ROOT-0/null||mutate-11/VB	conj_and||mutate-11/VB||recombine-13/VB	advmod||infect-17/VB||when-14/WRB	amod||strains-16/NNS||different-15/JJ	nsubj||infect-17/VB||strains-16/NNS	nsubj||give-22/VB||strains-16/NNS	advcl||mutate-11/VB||infect-17/VB	det||cells-20/NNS||the-18/DT	amod||cells-20/NNS||same-19/JJ	dobj||infect-17/VB||cells-20/NNS	advcl||mutate-11/VB||give-22/VB	conj_and||infect-17/VB||give-22/VB	dobj||give-22/VB||rise-23/NN	det||virus-27/NN||a-25/DT	nn||virus-27/NN||novel-26/NN	prep_to||give-22/VB||virus-27/NN	amod||ranges-31/NNS||unpredictable-29/JJ	nn||ranges-31/NNS||host-30/NN	prep_with||give-22/VB||ranges-31/NNS	prep_with||give-22/VB||pathogenicity-33/NN	conj_and||ranges-31/NNS||pathogenicity-33/NN	virus-27||viruses-6||no||furthermore, unlike other rna viruses, hcovs can easily mutate and recombine when different strains infect the same cells and give rise to a novel virus with unpredictable host ranges and pathogenicity.
prep_by||pretreated-5/VBD||contrast-2/NN	nsubj||pretreated-5/VBD||cultures-4/NNS	nsubj||exposed-13/VBN||cultures-4/NNS	root||ROOT-0/null||pretreated-5/VBD	prep_with||pretreated-5/VBD||ammonia-7/NN	num||h-10/NN||24-9/CD	prep_for||pretreated-5/VBD||h-10/NN	advmod||exposed-13/VBN||then-12/RB	conj_and||pretreated-5/VBD||exposed-13/VBN	prep_to||exposed-13/VBN||cytokines-15/NNS	det||h-20/NNS||an-17/DT	amod||h-20/NNS||additional-18/JJ	num||h-20/NNS||24-19/CD	prep_for||cytokines-15/NNS||h-20/NNS	dep||pretreated-5/VBD||showed-22/VBD	det||increase-25/NN||a-23/DT	amod||increase-25/NN||marked-24/JJ	dobj||showed-22/VBD||increase-25/NN	prep_in||showed-22/VBD||astrocyte-27/JJ	amod||astrocyte-27/JJ||swelling-28/VBG	num||%-31/NN||129-30/CD	appos||astrocyte-27/JJ||%-31/NN	ammonia-7||swelling-28||no_rel||by contrast, cultures pretreated with ammonia for 24 h and then exposed to cytokines for an additional 24 h, showed a marked increase in astrocyte swelling (129%).
nsubj||remains-6/VBZ||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||remains-6/VBZ||infection-5/RB	root||ROOT-0/null||remains-6/VBZ	det||problem-11/NN||a-7/DT	amod||problem-11/NN||significant-8/JJ	amod||problem-11/NN||public-9/JJ	nn||problem-11/NN||health-10/NN	xcomp||remains-6/VBZ||problem-11/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection remains a significant public health problem.
num||cases-2/NNS||seven-1/CD	nsubjpass||caused-6/VBN||cases-2/NNS	prep_of||cases-2/NNS||candidaemia-4/NN	auxpass||caused-6/VBN||were-5/VBD	root||ROOT-0/null||caused-6/VBN	nn||dubliniensis-9/NNS||candida-8/NN	agent||caused-6/VBN||dubliniensis-9/NNS	nsubj||prevalent-14/JJ||dubliniensis-9/NNS	cop||prevalent-14/JJ||was-12/VBD	advmod||prevalent-14/JJ||more-13/RBR	rcmod||dubliniensis-9/NNS||prevalent-14/JJ	advmod||prevalent-14/JJ||even-15/RB	amod||lusitaniae-18/NN||candida-17/JJ	prep_than||prevalent-14/JJ||lusitaniae-18/NN	nn||tropicalis-21/NNS||candida-20/NN	prep_than||prevalent-14/JJ||tropicalis-21/NNS	conj_and||lusitaniae-18/NN||tropicalis-21/NNS	num||cases-24/NNS||six-23/CD	dep||lusitaniae-18/NN||cases-24/NNS	dep||cases-24/NNS||each-25/DT	candidaemia-4||candida-20||no||seven cases of candidaemia were caused by candida dubliniensis , which was more prevalent even than candida lusitaniae and candida tropicalis (six cases each).
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||this-4/DT	amod||study-6/NN||seroprevalence-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	det||frequency-11/NN||the-10/DT	dobj||evaluate-9/VB||frequency-11/NN	prep_of||frequency-11/NN||hivinfection-13/NN	nsubj||using-20/VBG||sailors-15/NNS	prep_in||sailors-15/NNS||south-17/NN	prep_of||south-17/NN||iran-19/NN	prepc_among||evaluate-9/VB||using-20/VBG	amod||test-23/NN||rapid-21/JJ	nn||test-23/NN||hiv-22/NN	dobj||using-20/VBG||test-23/NN	hivinfection-13||hiv-22||no||the aim of this seroprevalence study was to evaluate the frequency of hivinfection among sailors in south of iran using rapid hiv test.
prep_during||correlates-10/VBZ||infection-2/NN	amod||viruses-5/NNS||persistence-prone-4/JJ	prep_with||infection-2/NN||viruses-5/NNS	amod||replication-9/NN||prolonged-7/VBN	nn||replication-9/NN||virus-8/NN	nsubj||correlates-10/VBZ||replication-9/NN	root||ROOT-0/null||correlates-10/VBZ	amod||responses-15/NNS||low-12/JJ	nn||responses-15/NNS||neutralizing-13/NN	nn||responses-15/NNS||antibody-14/NN	prep_with||correlates-10/VBZ||responses-15/NNS	virus-8||viruses-5||no||during infection with persistence-prone viruses, prolonged virus replication correlates with low neutralizing antibody responses.
advmod||applied-6/VBN||further-1/RB	det||method-4/NN||this-3/DT	nsubjpass||applied-6/VBN||method-4/NN	nsubj||detect-8/VB||method-4/NN	auxpass||applied-6/VBN||was-5/VBD	root||ROOT-0/null||applied-6/VBN	aux||detect-8/VB||to-7/TO	xcomp||applied-6/VBN||detect-8/VB	dobj||detect-8/VB||metallothioneins-9/NNS	nn||serum-12/NN||blood-11/NN	prep_in||detect-8/VB||serum-12/NN	vmod||serum-12/NN||obtained-13/VBN	vmod||serum-12/NN||obtained-13/VBN	conj_and||obtained-13/VBN||obtained-13/VBN	prep_from||obtained-13/VBN||patients-15/NNS	nn||cancer-18/NN||breast-17/NN	prep_with||patients-15/NNS||cancer-18/NN	nn||cells-22/NNS||neuroblastoma-21/NN	prep_in||obtained-13/VBN||cells-22/NNS	amod||cells-22/NNS||resistant-23/JJ	amod||cells-22/NNS||sensitive-25/JJ	conj_and||resistant-23/JJ||sensitive-25/JJ	aux||cisplatin-27/VB||to-26/TO	xcomp||obtained-13/VBN||cisplatin-27/VB	mark||show-31/VB||in-28/IN	dep||show-31/VB||order-29/NN	aux||show-31/VB||to-30/TO	advcl||cisplatin-27/VB||show-31/VB	det||role-34/NN||the-32/DT	amod||role-34/NN||possible-33/JJ	dobj||show-31/VB||role-34/NN	prep_of||role-34/NN||metallothioneins-36/NNS	prep_in||metallothioneins-36/NNS||carcinogenesis-38/NNS	neuroblastoma-21||cisplatin-27||yes||further, this method was applied to detect metallothioneins in blood serum obtained from patients with breast cancer and in neuroblastoma cells resistant and sensitive to cisplatin in order to show the possible role of metallothioneins in carcinogenesis.
nn||design-2/NN||research-1/NN	nsubjpass||assigned-21/VBN||design-2/NN	poss||patients-8/NNS||methods-4/NNS	amod||patients-8/NNS||$-6/JJ	conj_and||design-2/NN||patients-8/NNS	nsubjpass||assigned-21/VBN||patients-8/NNS	dep||patients-8/NNS||type2diabetes-10/NNS	amod||30â-13/NNS||aged-12/JJ	appos||type2diabetes-10/NNS||30â-13/NNS	num||years-17/NNS||$-14/$	num||$-14/$||75-16/CD	dep||30â-13/NNS||years-17/NNS	auxpass||assigned-21/VBN||were-19/VBD	advmod||assigned-21/VBN||randomly-20/RB	root||ROOT-0/null||assigned-21/VBN	num||days-24/NNS||21-23/CD	prep_within||assigned-21/VBN||days-24/NNS	amod||strategy-32/NN||ami-26/JJ	det||prandial-31/NNS||the-28/DT	num||prandial-31/NNS||1-29/CD	prep_to||ami-26/JJ||prandial-31/NNS	prep_after||days-24/NNS||strategy-32/NN	dep||days-24/NNS||prandial-34/VB	num||doses-39/NNS||three-37/CD	amod||doses-39/NNS||premeal-38/JJ	dep||days-24/NNS||doses-39/NNS	prep_of||doses-39/NNS||insulinlispro-41/NN	vmod||insulinlispro-41/NN||targeting-42/VBG	amod||bloodglucose-45/NN||2-h-43/JJ	amod||bloodglucose-45/NN||postprandial-44/JJ	nsubj||mmol/l-48/NN||bloodglucose-45/NN	dep||mmol/l-48/NN||<-46/SYM	num||mmol/l-48/NN||7.5-47/CD	ccomp||targeting-42/VBG||mmol/l-48/NN	det||strategy-55/NN||the-51/DT	nn||strategy-55/NN||2-52/NN	amod||strategy-55/NN||basal-54/JJ	prep_within||assigned-21/VBN||strategy-55/NN	conj_or||days-24/NNS||strategy-55/NN	dep||strategy-55/NN||basal-57/JJ	dep||strategy-55/NN||nph-60/VBN	advmod||daily-62/JJ||twice-61/RB	advmod||nph-60/VBN||daily-62/JJ	dep||daily-66/RB||insulinglargine-64/NN	advmod||daily-66/RB||once-65/RB	advmod||nph-60/VBN||daily-66/RB	conj_or||daily-62/JJ||daily-66/RB	xcomp||nph-60/VBN||targeting-67/VBG	amod||bloodglucose-69/NN||fasting/premeal-68/JJ	nsubj||mmol/l-72/NN||bloodglucose-69/NN	dep||mmol/l-72/NN||<-70/SYM	num||mmol/l-72/NN||6.7-71/CD	ccomp||targeting-67/VBG||mmol/l-72/NN	type2diabetes-10||insulinlispro-41||yes||research design and methods â€”patients (type2diabetes, aged 30â€“75 years) were randomly assigned within 21 days after ami to the 1 ) prandial strategy (prandial) (three premeal doses of insulinlispro targeting 2-h postprandial bloodglucose <7.5 mmol/l) or the 2 ) basal strategy (basal) (nph twice daily or insulinglargine once daily targeting fasting/premeal bloodglucose <6.7 mmol/l).
mwe||than-2/IN||more-1/JJR	quantmod||50-3/CD||than-2/IN	num||%-4/NN||50-3/CD	nsubj||ribavirin-25/VBZ||%-4/NN	amod||viruses-7/NNS||hepatitisc-6/JJ	prep_of||%-4/NN||viruses-7/NNS	appos||viruses-7/NNS||hcv-9/NN	amod||patients-13/NNS||infected-12/JJ	nsubj||respond-16/VB||patients-13/NNS	aux||respond-16/VB||do-14/VBP	neg||respond-16/VB||not-15/RB	parataxis||ribavirin-25/VBZ||respond-16/VB	det||interferon-20/NN||the-18/DT	amod||interferon-20/NN||classical-19/JJ	prep_to||respond-16/VB||interferon-20/NN	appos||interferon-20/NN||ifn-22/NN	punct||respond-16/VB||/-24/:	root||ROOT-0/null||ribavirin-25/VBZ	dep||ribavirin-25/VBZ||rbv-27/NN	nn||therapy-30/NN||combination-29/NN	dobj||ribavirin-25/VBZ||therapy-30/NN	hepatitisc-6||interferon-20||no_rel||more than 50% of hepatitisc viruses (hcv)-infected patients do not respond to the classical interferon (ifn)/ribavirin (rbv) combination therapy.
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	aza--1||tumors-12||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
det||effects-2/NNS||the-1/DT	nsubjpass||truncated-8/VBN||effects-2/NNS	amod||treatment-6/NN||anti-cd25-4/JJ	nn||treatment-6/NN||mab-5/NN	prep_of||effects-2/NNS||treatment-6/NN	auxpass||truncated-8/VBN||are-7/VBP	root||ROOT-0/null||truncated-8/VBN	prep_in||truncated-8/VBN||cats-10/NNS	advmod||infected-12/VBN||acutely-11/RB	vmod||cats-10/NNS||infected-12/VBN	amod||post-fivinfection-44/NN||fiv-c36-14/JJ	mark||included-37/VBD||as-15/IN	prepc_compared_to||included-37/VBD||to-17/TO	advmod||cats-25/NNS||chronically-18/RB	amod||cats-25/NNS||infected-19/JJ	nn||cats-25/NNS||cats-20/NNS	conj_or||cats-20/NNS||fiv-naã-22/JJ	nn||cats-25/NNS||fiv-naã-22/JJ	amod||cats-25/NNS||¯-23/JJ	nn||cats-25/NNS||ve-24/NN	pobj||included-37/VBD||cats-25/NNS	mark||heightened-32/VBN||as-27/IN	amod||levels-30/NNS||treg-28/VBG	nn||levels-30/NNS||cell-29/NN	nsubjpass||heightened-32/VBN||levels-30/NNS	auxpass||heightened-32/VBN||were-31/VBD	dep||cats-25/NNS||heightened-32/VBN	det||treatment-35/NN||all-34/DT	prep_in||heightened-32/VBN||treatment-35/NN	nsubj||included-37/VBD||groups-36/NNS	dep||fiv-c36-14/JJ||included-37/VBD	det||study-40/NN||the-39/DT	prep_in||included-37/VBD||study-40/NN	num||weeks-43/NNS||two-42/CD	prep_within||included-37/VBD||weeks-43/NNS	prep_with||infected-12/VBN||post-fivinfection-44/NN	fivinfection--1||fiv--1||no||the effects of anti-cd25 mab treatment are truncated in cats acutely infected with fiv-c36 as compared to chronically infected cats or fiv-naã¯ve cats, as treg cell levels were heightened in all treatment groups included in the study within two weeks post-fivinfection.
det||hallmarks-2/NNS||the-1/DT	nsubj||include-6/VBP||hallmarks-2/NNS	amod||hyperglycaemia-5/NN||stress-induced-4/JJ	prep_of||hallmarks-2/NNS||hyperglycaemia-5/NN	root||ROOT-0/null||include-6/VBP	acomp||include-6/VBP||insulinresistance-8/JJ	ccomp||insulinresistance-8/JJ||associated-10/VBN	det||increase-13/NN||an-12/DT	prep_with||associated-10/VBN||increase-13/NN	amod||output-17/NN||hepatic-15/JJ	nn||output-17/NN||glucose-16/NN	prep_in||increase-13/NN||output-17/NN	amod||release-20/NN||insufficient-19/JJ	prep_with||associated-10/VBN||release-20/NN	conj_and||increase-13/NN||release-20/NN	prep_of||release-20/NN||insulin-22/NN	prep_with||associated-10/VBN||regard-24/NN	prep_to||associated-10/VBN||glycaemia-26/NN	hyperglycaemia-5||glucose-16||no||the hallmarks of stress-induced hyperglycaemia include 'insulinresistance' associated with an increase in hepatic glucose output and insufficient release of insulin with regard to glycaemia.
amod||models-2/NNS||prognostic-1/JJ	nsubj||used-3/VBD||models-2/NNS	root||ROOT-0/null||used-3/VBD	amod||analysis-7/NN||multivariate-4/JJ	nn||analysis-7/NN||cox-5/NN	nn||analysis-7/NN||regression-6/NN	dobj||used-3/VBD||analysis-7/NN	amod||analyses-10/NNS||multivariate-9/JJ	prep_for||analysis-7/NN||analyses-10/NNS	prep_of||analyses-10/NNS||survival-12/NN	poss||study-15/NN||our-14/PRP$	nsubj||showed-16/VBD||study-15/NN	parataxis||used-3/VBD||showed-16/VBD	nsubj||p-lvd-18/JJ||that-17/DT	nsubj||i-lvd-22/JJ||that-17/DT	nsubjpass||correlated-26/VBN||that-17/DT	xcomp||showed-16/VBD||p-lvd-18/JJ	xcomp||showed-16/VBD||i-lvd-22/JJ	conj_negcc||p-lvd-18/JJ||i-lvd-22/JJ	auxpass||correlated-26/VBN||was-24/VBD	advmod||correlated-26/VBN||significantly-25/RB	xcomp||showed-16/VBD||correlated-26/VBN	ccomp||p-lvd-18/JJ||correlated-26/VBN	conj_negcc||p-lvd-18/JJ||correlated-26/VBN	nn||invasion-31/NN||lymph-28/NN	nn||invasion-31/NN||vascular-29/NN	nn||invasion-31/NN||space-30/NN	prep_with||correlated-26/VBN||invasion-31/NN	appos||invasion-31/NN||lvsi-33/NNP	nn||metastasis-38/NNS||lymph-36/NN	nn||metastasis-38/NNS||node-37/NN	prep_with||correlated-26/VBN||metastasis-38/NNS	conj_and||invasion-31/NN||metastasis-38/NNS	nn||stage-41/NN||tumor-40/NN	prep_with||correlated-26/VBN||stage-41/NN	conj_and||invasion-31/NN||stage-41/NN	amod||expression-45/NN||cd44-44/JJ	prep_with||correlated-26/VBN||expression-45/NN	conj_and||invasion-31/NN||expression-45/NN	amod||carcinoma-48/NN||endometrial-47/JJ	prep_in||correlated-26/VBN||carcinoma-48/NN	i---1||carcinoma-48||no_rel||prognostic models used multivariate cox regression analysis for multivariate analyses of survival; our study showed that p-lvd, but not i-lvd, was significantly correlated with lymph vascular space invasion (lvsi), lymph node metastasis, tumor stage, and cd44 expression in endometrial carcinoma.
det||subsystems-3/NNS||these-1/DT	num||subsystems-3/NNS||eight-2/CD	nsubj||cover-4/VBP||subsystems-3/NNS	root||ROOT-0/null||cover-4/VBP	nsubj||hiv/aids-8/VBZ||i-6/FW	ccomp||cover-4/VBP||hiv/aids-8/VBZ	nn||reporting-10/NN||case-9/NN	dobj||hiv/aids-8/VBZ||reporting-10/NN	appos||testing-16/NN||ii-13/NN	amod||testing-16/NN||hiv-15/JJ	dep||reporting-10/NN||testing-16/NN	dep||reporting-10/NN||counselling-18/NN	conj_and||testing-16/NN||counselling-18/NN	appos||treatment-24/NN||iii-21/NN	amod||treatment-24/NN||antiretroviral-23/JJ	dep||reporting-10/NN||treatment-24/NN	conj_and||testing-16/NN||treatment-24/NN	appos||treatment-24/NN||art-26/NN	prep_for||treatment-24/NN||adults-29/NNS	amod||art-34/NN||iv-32/JJ	dep||reporting-10/NN||art-34/NN	conj_and||testing-16/NN||art-34/NN	prep_for||art-34/NN||children-36/NNS	appos||interventions-42/NN||v-39/NN	amod||interventions-42/NN||behavioural-41/JJ	dep||reporting-10/NN||interventions-42/NN	conj_and||testing-16/NN||interventions-42/NN	amod||groups-45/NNS||high-risk-44/JJ	prep_for||interventions-42/NN||groups-45/NNS	appos||maintenance-51/NN||vi-48/NN	amod||maintenance-51/NN||methadone-50/JJ	dep||reporting-10/NN||maintenance-51/NN	conj_and||testing-16/NN||maintenance-51/NN	dep||maintenance-51/NN||treatment-52/NN	dep||reporting-10/NN||vii-55/NN	conj_and||testing-16/NN||vii-55/NN	amod||surveillance-60/NN||sentinel-57/JJ	conj_and||sentinel-57/JJ||behavioural-59/JJ	amod||surveillance-60/NN||behavioural-59/JJ	dep||vii-55/NN||surveillance-60/NN	appos||county-67/NN||viii-64/NNP	amod||county-67/NN||local-66/JJ	dep||reporting-10/NN||county-67/NN	conj_and||testing-16/NN||county-67/NN	nn||information-69/NN||background-68/NN	dep||county-67/NN||information-69/NN	aids--1||hiv-15||no||these eight subsystems cover (i) hiv/aids case reporting; (ii) hiv testing and counselling; (iii) antiretroviral treatment (art) for adults; (iv) art for children; (v) behavioural interventions for high-risk groups; (vi) methadone maintenance treatment; (vii) sentinel and behavioural surveillance; and (viii) local county background information.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||ergonovine-17||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
mark||proven-7/VBN||while-1/IN	preconj||itraconazole-3/NN||both-2/DT	nsubj||proven-7/VBN||itraconazole-3/NN	nsubj||effective-10/JJ||itraconazole-3/NN	conj_and||itraconazole-3/NN||terbinafine-5/NN	nsubj||proven-7/VBN||terbinafine-5/NN	nsubj||effective-10/JJ||terbinafine-5/NN	aux||proven-7/VBN||have-6/VBP	advcl||known-17/VBN||proven-7/VBN	aux||effective-10/JJ||to-8/TO	cop||effective-10/JJ||be-9/VB	xcomp||proven-7/VBN||effective-10/JJ	prep_against||effective-10/JJ||onychomycosis-12/NNS	advmod||little-15/JJ||very-14/RB	nsubjpass||known-17/VBN||little-15/JJ	auxpass||known-17/VBN||is-16/VBZ	root||ROOT-0/null||known-17/VBN	poss||efficacy-21/NN||their-19/PRP$	amod||efficacy-21/NN||comparative-20/JJ	prep_about||known-17/VBN||efficacy-21/NN	prepc_in||known-17/VBN||achieving-23/VBG	amod||cure-27/NN||mycological-24/JJ	conj_and||mycological-24/JJ||clinical-26/JJ	amod||cure-27/NN||clinical-26/JJ	dobj||achieving-23/VBG||cure-27/NN	onychomycosis-12||terbinafine-5||yes||while both itraconazole and terbinafine have proven to be effective against onychomycosis, very little is known about their comparative efficacy in achieving mycological and clinical cure.
amod||responses-3/NNS||rotavirus-induced-1/JJ	amod||responses-3/NNS||immune-2/JJ	nsubjpass||characterized-16/VBN||responses-3/NNS	advmod||t-7/NN||especially-5/RB	det||t-7/NN||the-6/DT	num||responses-11/NNS||t-7/NN	conj_and||t-7/NN||b-9/SYM	num||responses-11/NNS||b-9/SYM	nn||responses-11/NNS||cell-10/NN	appos||responses-3/NNS||responses-11/NNS	aux||characterized-16/VBN||have-13/VBP	auxpass||characterized-16/VBN||been-14/VBN	advmod||characterized-16/VBN||extensively-15/RB	root||ROOT-0/null||characterized-16/VBN	advmod||known-22/VBN||however-18/RB	nsubjpass||known-22/VBN||little-20/RB	auxpass||known-22/VBN||is-21/VBZ	parataxis||characterized-16/VBN||known-22/VBN	amod||mechanisms-26/NNS||innate-24/JJ	amod||mechanisms-26/NNS||immune-25/JJ	prep_about||known-22/VBN||mechanisms-26/NNS	vmod||mechanisms-26/NNS||involved-27/VBN	det||control-30/NN||the-29/DT	prep_in||involved-27/VBN||control-30/NN	prep_of||control-30/NN||rotavirusinfection-32/NN	rotavirusinfection-32||rotavirus--1||yes||rotavirus-induced immune responses, especially the t and b cell responses, have been extensively characterized; however, little is known about innate immune mechanisms involved in the control of rotavirusinfection.
nsubj||autoimmunedisease-4/NN||type1diabetesmellitus-1/NNS	cop||autoimmunedisease-4/NN||is-2/VBZ	det||autoimmunedisease-4/NN||an-3/DT	root||ROOT-0/null||autoimmunedisease-4/NN	dep||autoimmunedisease-4/NN||caused-5/VBN	prep_by||caused-5/VBN||destruction-7/NN	amod||cells-11/NNS||pancreatic-9/JJ	nn||cells-11/NNS||beta-10/NN	prep_of||destruction-7/NN||cells-11/NNS	dep||autoimmunedisease-4/NN||characterized-13/VBN	conj_and||caused-5/VBN||characterized-13/VBN	prep_by||characterized-13/VBN||defect-15/NN	nn||secretion-18/NN||insulin-17/NN	prep_in||defect-15/NN||secretion-18/NN	mark||and/or-27/VBZ||while-19/IN	amod||results-21/NNS||type2diabetesmellitus-20/JJ	nsubj||and/or-27/VBZ||results-21/NNS	prep_from||results-21/NNS||abnormalities-23/NNS	nn||secretion-26/NN||insulin-25/NN	prep_in||abnormalities-23/NNS||secretion-26/NN	advcl||characterized-13/VBN||and/or-27/VBZ	nn||action-29/NN||insulin-28/NN	dobj||and/or-27/VBZ||action-29/NN	dobj||and/or-27/VBZ||both-31/DT	conj_or||action-29/NN||both-31/DT	type1diabetesmellitus-1||insulin-28||yes||type1diabetesmellitus is an autoimmunedisease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||32-year-old-2/JJ	nsubj||presented-10/VBD||woman-3/NN	det||history-6/NN||a-5/DT	prep_with||woman-3/NN||history-6/NN	amod||use-9/NN||oralcontraceptive-8/JJ	prep_of||history-6/NN||use-9/NN	root||ROOT-0/null||presented-10/VBD	nn||abdominalpain-15/NN||nausea-12/NN	conj_and||nausea-12/NN||severe-14/JJ	nn||abdominalpain-15/NN||severe-14/JJ	prep_with||presented-10/VBD||abdominalpain-15/NN	prep||abdominalpain-15/NN||but-16/CC	neg||ascites-18/NN||no-17/DT	pobj||but-16/CC||ascites-18/NN	pobj||but-16/CC||stigmata-20/NN	conj_or||ascites-18/NN||stigmata-20/NN	prep_of||ascites-18/NN||cirrhosis-22/NNS	nausea-12||oralcontraceptive-8||no_rel||a 32-year-old woman with a history of oralcontraceptive use presented with nausea and severe abdominalpain but no ascites or stigmata of cirrhosis.
det||respondents-2/NNS||the-1/DT	nsubj||had-9/VBD||respondents-2/NNS	quantmod||than-5/IN||less-4/JJR	num||education-8/NN||than-5/IN	amod||school-7/NN||secondary-6/JJ	dep||than-5/IN||school-7/NN	prep_with||respondents-2/NNS||education-8/NN	root||ROOT-0/null||had-9/VBD	det||attitude-12/NN||a-10/DT	amod||attitude-12/NN||discriminatory-11/JJ	dobj||had-9/VBD||attitude-12/NN	amod||people-15/NNS||hivpositive-14/JJ	prep_toward||attitude-12/NN||people-15/NNS	nsubj||deserving-21/VBG||them-20/PRP	nsubj||suffer-23/VB||them-20/PRP	nsubj||dismissing-25/VBG||them-20/PRP	nsubj||hesitating-30/VBG||them-20/PRP	nsubj||sit-32/VB||them-20/PRP	nsubj||divorcing-42/VBG||them-20/PRP	nsubj||willingness-48/VBG||them-20/PRP	nsubjpass||tested-51/VBN||them-20/PRP	prepc_with_regard_to||had-9/VBD||deserving-21/VBG	aux||suffer-23/VB||to-22/TO	xcomp||deserving-21/VBG||suffer-23/VB	prepc_with_regard_to||had-9/VBD||dismissing-25/VBG	conj_and||deserving-21/VBG||dismissing-25/VBG	det||maid-28/NN||a-26/DT	amod||maid-28/NN||hivpositive-27/JJ	dobj||dismissing-25/VBG||maid-28/NN	prepc_with_regard_to||had-9/VBD||hesitating-30/VBG	conj_and||deserving-21/VBG||hesitating-30/VBG	aux||sit-32/VB||to-31/TO	xcomp||hesitating-30/VBG||sit-32/VB	det||person-37/NN||a-35/DT	amod||person-37/NN||hivpositive-36/JJ	prep_next_to||sit-32/VB||person-37/NN	det||bus-40/NN||the-39/DT	prep_in||sit-32/VB||bus-40/NN	prepc_with_regard_to||had-9/VBD||divorcing-42/VBG	conj_and||deserving-21/VBG||divorcing-42/VBG	det||spouse-45/NN||the-43/DT	amod||spouse-45/NN||infected-44/JJ	dobj||divorcing-42/VBG||spouse-45/NN	prepc_with_regard_to||had-9/VBD||willingness-48/VBG	conj_and||deserving-21/VBG||willingness-48/VBG	aux||tested-51/VBN||to-49/TO	auxpass||tested-51/VBN||get-50/VB	xcomp||willingness-48/VBG||tested-51/VBN	prep_for||tested-51/VBN||hiv-53/NN	nsubjpass||found-57/VBN||hiv-53/NN	nsubj||significant-61/JJ||hiv-53/NN	auxpass||found-57/VBN||was-56/VBD	rcmod||hiv-53/NN||found-57/VBN	aux||significant-61/JJ||to-58/TO	cop||significant-61/JJ||be-59/VB	advmod||significant-61/JJ||statistically-60/RB	xcomp||found-57/VBN||significant-61/JJ	hivpositive-36||hiv-53||no||the respondents with less than secondary school education had a discriminatory attitude toward hivpositive people, with regard to them deserving to suffer, dismissing a hivpositive maid, hesitating to sit next to a hivpositive person in the bus, divorcing the infected spouse, and willingness to get tested for hiv, which was found to be statistically significant.
det||bortezomib-4/NN||the-1/DT	amod||bortezomib-4/NN||proteasome-2/JJ	nn||bortezomib-4/NN||inhibitor-3/NN	nsubj||improved-6/VBN||bortezomib-4/NN	aux||improved-6/VBN||has-5/VBZ	root||ROOT-0/null||improved-6/VBN	det||survival-8/NN||the-7/DT	dobj||improved-6/VBN||survival-8/NN	prep_of||survival-8/NN||patients-10/NNS	prep_with||improved-6/VBN||multiplemyeloma-12/NN	amod||peripheralneuropathy-15/NN||bortezomib-induced-14/JJ	nsubj||emerged-20/VBN||peripheralneuropathy-15/NN	appos||peripheralneuropathy-15/NN||bipn-17/NN	aux||emerged-20/VBN||has-19/VBZ	conj_but||improved-6/VBN||emerged-20/VBN	det||complication-25/NN||a-22/DT	amod||complication-25/NN||serious-23/JJ	amod||complication-25/NN||potential-24/JJ	prep_as||emerged-20/VBN||complication-25/NN	det||therapy-28/NN||this-27/DT	prep_of||complication-25/NN||therapy-28/NN	multiplemyeloma-12||bortezomib-4||yes||the proteasome inhibitor bortezomib has improved the survival of patients with multiplemyeloma but bortezomib-induced peripheralneuropathy (bipn) has emerged as a serious potential complication of this therapy.
nsubj||provide-3/VB||it-1/PRP	aux||provide-3/VB||could-2/MD	root||ROOT-0/null||provide-3/VB	det||alternative-10/NN||a-4/DT	advmod||efficient-6/JJ||more-5/RBR	amod||alternative-10/NN||efficient-6/JJ	advmod||painful-9/JJ||less-8/RBR	conj_and||efficient-6/JJ||painful-9/JJ	amod||alternative-10/NN||painful-9/JJ	dobj||provide-3/VB||alternative-10/NN	advmod||tests-16/NNS||traditionally-12/RB	amod||tests-16/NNS||used-13/JJ	nn||tests-16/NNS||skin-14/NN	nn||tests-16/NNS||prick-15/NN	prep_to||provide-3/VB||tests-16/NNS	vmod||provide-3/VB||making-18/VBG	nsubj||compare-23/VB||it-19/PRP	nsubj||monitor-30/VB||it-19/PRP	nsubj||facilitate-37/VB||it-19/PRP	advmod||feasible-21/JJ||economically-20/RB	dep||compare-23/VB||feasible-21/JJ	aux||compare-23/VB||to-22/TO	xcomp||making-18/VBG||compare-23/VB	nn||sensitivity-25/NN||allergen-24/NN	dobj||compare-23/VB||sensitivity-25/NN	amod||populations-28/NNS||different-27/JJ	prep_of||sensitivity-25/NN||populations-28/NNS	xcomp||making-18/VBG||monitor-30/VB	conj_and||compare-23/VB||monitor-30/VB	amod||responses-32/NNS||individual-31/JJ	dobj||monitor-30/VB||responses-32/NNS	prep_over||monitor-30/VB||time-34/NN	xcomp||making-18/VBG||facilitate-37/VB	conj_and||compare-23/VB||facilitate-37/VB	amod||studies-39/NNS||genetic-38/JJ	dobj||facilitate-37/VB||studies-39/NNS	prep_on||facilitate-37/VB||pollenallergy-41/NN	allergen-24||pollenallergy-41||no_rel||it could provide a more efficient and less painful alternative to traditionally used skin prick tests, making it economically feasible to compare allergen sensitivity of different populations, monitor individual responses over time, and facilitate genetic studies on pollenallergy.
nsubj||oncogene-6/NN||lmp1-1/NNS	cop||oncogene-6/NN||is-2/VBZ	det||oncogene-6/NN||the-3/DT	nn||oncogene-6/NN||tumour-4/NN	amod||oncogene-6/NN||predisposing-5/VBG	root||ROOT-0/null||oncogene-6/NN	nsubj||give-16/VBP||oncogene-6/NN	num||series-10/NN||two-8/CD	amod||series-10/NN||different-9/JJ	prep_in||oncogene-6/NN||series-10/NN	amod||mice-13/NNS||transgenic-12/JJ	prep_of||series-10/NN||mice-13/NNS	advmod||give-16/VBP||separately-15/RB	rcmod||oncogene-6/NN||give-16/VBP	dobj||give-16/VBP||rise-17/NN	preconj||b-celllymphomas-20/NNS||either-19/CC	prep_to||give-16/VBP||b-celllymphomas-20/NNS	prep_to||give-16/VBP||carcinomas-22/NNS	conj_or||b-celllymphomas-20/NNS||carcinomas-22/NNS	rise-17||tumour-4||no_rel||lmp1 is the tumour predisposing oncogene in two different series of transgenic mice which separately give rise to either b-celllymphomas or carcinomas.
advmod||frequent-10/JJ||however-1/RB	det||âˆ-4/NN||the-3/DT	poss||variant-7/NN||âˆ-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||š-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||š-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||š-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||š-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	tropicalspasticparaparesis-17||htlv-1-29||no||however, the âˆ’336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â€š%; healthy asymptomatic htlv-1 carriers, 90â€š%] than in the control group (70â€š%) [ p =0.0197, odds ratio (or)=2.511, 95â€š% confidence interval (ci)=1.218â€“5.179).
det||chc-4/NN||these-1/DT	nn||chc-4/NN||qualitatively-2/NN	amod||chc-4/NN||differing-3/VBG	nsubjpass||found-7/VBN||chc-4/NN	advmod||found-7/VBN||compounds-5/RB	auxpass||found-7/VBN||were-6/VBD	root||ROOT-0/null||found-7/VBN	amod||classes-11/NNS||various-9/JJ	nn||classes-11/NNS||substance-10/NN	prep_across||found-7/VBN||classes-11/NNS	prep_including||classes-11/NNS||alkanes-13/NNS	appos||alkanes-13/NNS||alkenes-15/NNS	appos||alkanes-13/NNS||mono-17/NN	conj_and||alkenes-15/NNS||mono-17/NN	amod||alkanes-24/NNS||di-20/JJ	conj_and||di-20/JJ||trimethyl-branched-23/JJ	amod||alkanes-24/NNS||trimethyl-branched-23/JJ	appos||alkanes-13/NNS||alkanes-24/NNS	alkanes-24||di-20||no_rel||these qualitatively differing chc compounds were found across various substance classes including alkanes, alkenes and mono-, di- and trimethyl-branched alkanes.
nsubj||resulted-4/VBD||treatment-1/NN	prep_with||treatment-1/NN||phenobarbital-3/NN	root||ROOT-0/null||resulted-4/VBD	amod||improvement-7/NN||substantial-6/JJ	prep_in||resulted-4/VBD||improvement-7/NN	det||number-10/NN||the-9/DT	prep_in||resulted-4/VBD||number-10/NN	nn||episodes-13/NNS||seizure-12/NN	prep_of||number-10/NN||episodes-13/NNS	advmod||continued-19/VBD||however-15/RB	amod||movement-18/NN||fine-16/JJ	amod||movement-18/NN||seizure-like-17/JJ	nsubj||continued-19/VBD||movement-18/NN	nsubj||continued-19/VBD||movement-18/NN	parataxis||resulted-4/VBD||continued-19/VBD	parataxis||resulted-4/VBD||continued-19/VBD	conj_and||continued-19/VBD||continued-19/VBD	prt||continued-19/VBD||in-20/RP	preconj||continued-19/VBD||both-21/DT	det||hands-24/NNS||the-23/DT	prep_of||continued-19/VBD||hands-24/NNS	appos||hands-24/NNS||feet-26/NNS	det||tongue-30/NN||the-29/DT	prep_in||continued-19/VBD||tongue-30/NN	det||follow-up-34/NN||the-32/DT	amod||follow-up-34/NN||five-month-33/JJ	prep_until||continued-19/VBD||follow-up-34/NN	seizure-12||phenobarbital-3||no_rel||treatment with phenobarbital resulted in substantial improvement in the number of seizure episodes, however fine seizure-like movement continued in both of the hands, feet and in the tongue until the five-month follow-up.
det||analysis-6/NN||an-2/DT	amod||analysis-6/NN||unsupervised-3/JJ	amod||analysis-6/NN||hierarchical-4/JJ	nn||analysis-6/NN||cluster-5/NN	prep_in||identified-21/VBN||analysis-6/NN	amod||profiles-10/NNS||similar-8/JJ	amod||profiles-10/NNS||genomic-9/JJ	nsubjpass||identified-21/VBN||profiles-10/NNS	amod||clustering-13/NN||close-12/JJ	conj_and||profiles-10/NNS||clustering-13/NN	nsubjpass||identified-21/VBN||clustering-13/NN	det||sts-19/NN||the-15/DT	amod||sts-19/NN||first-16/JJ	conj_and||first-16/JJ||subsequent-18/JJ	amod||sts-19/NN||subsequent-18/JJ	prep_between||clustering-13/NN||sts-19/NN	auxpass||identified-21/VBN||were-20/VBD	root||ROOT-0/null||identified-21/VBN	num||cases-24/NNS||5-23/CD	prep_in||identified-21/VBN||cases-24/NNS	vmod||cases-24/NNS||suggesting-26/VBG	amod||disease-28/NN||metastatic-27/JJ	dobj||suggesting-26/VBG||disease-28/NN	mark||did-38/VBD||whereas-30/IN	det||tumors-32/NNS||the-31/DT	nsubj||did-38/VBD||tumors-32/NNS	nsubj||showed-42/VBD||tumors-32/NNS	det||patients-37/NNS||the-34/DT	amod||patients-37/NNS||remaining-35/VBG	num||patients-37/NNS||8-36/CD	prep_from||tumors-32/NNS||patients-37/NNS	advcl||suggesting-26/VBG||did-38/VBD	neg||cluster-40/NN||not-39/RB	dobj||did-38/VBD||cluster-40/NN	advcl||suggesting-26/VBG||showed-42/VBD	conj_and||did-38/VBD||showed-42/VBD	advmod||correlation-46/NN||only-43/RB	amod||correlation-46/NN||weak-44/JJ	amod||correlation-46/NN||pairwise-45/JJ	dobj||showed-42/VBD||correlation-46/NN	vmod||suggesting-26/VBG||suggesting-48/VBG	dobj||suggesting-48/VBG||development-49/NN	amod||sts-53/NN||second-51/JJ	amod||sts-53/NN||primary-52/JJ	prep_of||development-49/NN||sts-53/NN	tumors-32||sts-53||no||in an unsupervised hierarchical cluster analysis, similar genomic profiles and close clustering between the first and subsequent sts were identified in 5 cases, suggesting metastatic disease, whereas the tumors from the remaining 8 patients did not cluster and showed only weak pairwise correlation, suggesting development of second primary sts.
nsubj||expressed-3/VBD||genes-1/NNS	advmod||expressed-3/VBD||differentially-2/RB	root||ROOT-0/null||expressed-3/VBD	amod||mice-9/NNS||il10-5/JJ	dep||mice-9/NNS||/-7/NNP	prep_in||expressed-3/VBD||mice-9/NNS	mark||associated-21/VBN||as-10/IN	det||result-12/NN||a-11/DT	nsubjpass||associated-21/VBN||result-12/NN	nn||inoculation-19/NN||ef-14/NN	conj_or||ef-14/NN||efâ-16/NN	nn||inoculation-19/NN||efâ-16/NN	amod||inoculation-19/NN||·-17/JJ	nn||inoculation-19/NN||cif-18/NN	prep_of||result-12/NN||inoculation-19/NN	auxpass||associated-21/VBN||were-20/VBD	advcl||expressed-3/VBD||associated-21/VBN	det||inflammatorydisease-26/NN||the-23/DT	amod||inflammatorydisease-26/NN||following-24/VBG	nn||inflammatorydisease-26/NN||pathways-25/NNS	prep_with||associated-21/VBN||inflammatorydisease-26/NN	num||genes-29/NNS||111-28/CD	dep||inflammatorydisease-26/NN||genes-29/NNS	advmod||expressed-31/VBN||differentially-30/RB	vmod||genes-29/NNS||expressed-31/VBN	amod||response-35/NN||immune-34/JJ	appos||inflammatorydisease-26/NN||response-35/NN	num||genes-38/NNS||209-37/CD	appos||response-35/NN||genes-38/NNS	nn||presentation-42/NN||antigen-41/NN	appos||inflammatorydisease-26/NN||presentation-42/NN	conj_and||response-35/NN||presentation-42/NN	num||genes-45/NNS||11-44/CD	dep||presentation-42/NN||genes-45/NNS	advmod||histocompatability-49/NN||particularly-47/RB	amod||histocompatability-49/NN||major-48/JJ	appos||genes-45/NNS||histocompatability-49/NN	amod||ii-52/NN||complex-50/JJ	nn||ii-52/NN||class-51/NN	dep||genes-45/NNS||ii-52/NN	amod||metabolism-56/NN||fattyacid-55/JJ	appos||inflammatorydisease-26/NN||metabolism-56/NN	conj_and||response-35/NN||metabolism-56/NN	num||genes-59/NNS||30-58/CD	appos||metabolism-56/NN||genes-59/NNS	appos||inflammatorydisease-26/NN||detoxification-62/NN	conj_and||response-35/NN||detoxification-62/NN	num||genes-65/NNS||31-64/CD	appos||detoxification-62/NN||genes-65/NNS	fattyacid-55||inflammatorydisease-26||no_rel||genes differentially expressed in il10 -/- mice as a result of ef or efâ·cif inoculation were associated with the following pathways inflammatorydisease (111 genes differentially expressed), immune response (209 genes), antigen presentation (11 genes, particularly major histocompatability complex class ii), fattyacid metabolism (30 genes) and detoxification (31 genes).
nsubj||shown-14/VBN||bevacizumab-1/NN	det||antibody-5/NN||a-3/DT	amod||antibody-5/NN||monoclonal-4/JJ	appos||bevacizumab-1/NN||antibody-5/NN	vmod||antibody-5/NN||directed-6/VBN	det||ligand-9/NN||the-8/DT	prep_against||directed-6/VBN||ligand-9/NN	appos||ligand-9/NN||vegf-11/NN	aux||shown-14/VBN||has-13/VBZ	root||ROOT-0/null||shown-14/VBN	dobj||shown-14/VBN||activity-15/NN	prep_against||activity-15/NN||rcc-17/NN	det||agent-21/NN||a-19/DT	amod||agent-21/NN||single-20/JJ	prep_as||shown-14/VBN||agent-21/NN	prep_in||agent-21/NN||patients-23/NNS	nsubj||failed-26/VBN||patients-23/NNS	aux||failed-26/VBN||had-25/VBD	rcmod||patients-23/NNS||failed-26/VBN	amod||therapy-29/NN||prior-27/JJ	nn||therapy-29/NN||cytokine-28/NN	dobj||failed-26/VBN||therapy-29/NN	dobj||failed-26/VBN||as-31/RB	advmod||therapy-29/NN||as-31/RB	conj_and||therapy-29/NN||as-31/RB	amod||therapy-34/NN||first-32/JJ	nn||therapy-34/NN||line-33/NN	dep||therapy-29/NN||therapy-34/NN	prep_in||therapy-34/NN||combination-36/NN	prep_with||failed-26/VBN||interferon-38/NN	interferon-38||rcc-17||no_rel||bevacizumab, a monoclonal antibody directed against the ligand, vegf, has shown activity against rcc as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-11/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||ipti-sp-9/NN	root||ROOT-0/null||reduces-11/VBZ	nn||morbidity-13/NN||malaria-12/NN	dobj||reduces-11/VBZ||morbidity-13/NN	number||%-19/NN||20-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||33-18/CD	prep_by||reduces-11/VBZ||%-19/NN	malaria-12||pyrimethamine--1||yes||intermittent preventive treatment in infants with sulphadoxine-pyrimethamine (ipti-sp) reduces malaria morbidity by 20% to 33%.
det||importance-2/NN||the-1/DT	nsubjpass||recognized-13/VBN||importance-2/NN	amod||care-5/NN||family-centred-4/JJ	prep_of||importance-2/NN||care-5/NN	prep_for||care-5/NN||children-7/NNS	vmod||children-7/NNS||affected-8/VBN	agent||affected-8/VBN||hiv/aids-10/NNS	aux||recognized-13/VBN||has-11/VBZ	auxpass||recognized-13/VBN||been-12/VBN	root||ROOT-0/null||recognized-13/VBN	det||time-16/NN||some-15/DT	prep_for||recognized-13/VBN||time-16/NN	aids--1||hiv--1||no||the importance of family-centred care for children affected by hiv/aids has been recognized for some time.
det||results-2/NNS||these-1/DT	nsubj||provide-3/VBP||results-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||evidence-5/NN||strong-4/JJ	dobj||provide-3/VBP||evidence-5/NN	aux||recommend-7/VB||to-6/TO	vmod||provide-3/VBP||recommend-7/VB	det||use-10/NN||the-8/DT	amod||use-10/NN||routine-9/JJ	dobj||recommend-7/VB||use-10/NN	amod||treatment-14/NN||titrated-12/JJ	nn||treatment-14/NN||oxygen-13/NN	prep_of||use-10/NN||treatment-14/NN	prep_in||recommend-7/VB||patients-16/NNS	prep_with||patients-16/NNS||breathlessness-18/NNS	det||history-21/NN||a-20/DT	prep_with||patients-16/NNS||history-21/NN	conj_and||breathlessness-18/NNS||history-21/NN	amod||likelihood-24/NN||clinical-23/JJ	prep_in||recommend-7/VB||likelihood-24/NN	conj_or||patients-16/NNS||likelihood-24/NN	amod||obstructivepulmonarydisease-27/NN||chronic-26/JJ	prep_of||likelihood-24/NN||obstructivepulmonarydisease-27/NN	det||setting-31/NN||the-29/DT	amod||setting-31/NN||prehospital-30/JJ	prep_in||recommend-7/VB||setting-31/NN	obstructivepulmonarydisease-27||oxygen-13||yes||these results provide strong evidence to recommend the routine use of titrated oxygen treatment in patients with breathlessness and a history or clinical likelihood of chronic obstructivepulmonarydisease in the prehospital setting.
amod||understanding-2/NN||greater-1/JJR	nsubj||help-20/VB||understanding-2/NN	det||interplay-5/NN||the-4/DT	prep_of||understanding-2/NN||interplay-5/NN	det||factors-9/NNS||the-7/DT	amod||factors-9/NNS||key-8/JJ	prep_between||interplay-5/NN||factors-9/NNS	vmod||factors-9/NNS||involved-10/VBN	det||regulation-13/NN||the-12/DT	prep_in||involved-10/VBN||regulation-13/NN	nn||metabolism-16/NN||iron-15/NN	prep_of||regulation-13/NN||metabolism-16/NN	prep_of||regulation-13/NN||erythropoiesis-18/NNS	conj_and||metabolism-16/NN||erythropoiesis-18/NNS	aux||help-20/VB||will-19/MD	root||ROOT-0/null||help-20/VB	xcomp||help-20/VB||develop-21/VB	advmod||effective-23/JJ||more-22/RBR	amod||therapies-24/NNS||effective-23/JJ	dobj||develop-21/VB||therapies-24/NNS	prep_for||develop-21/VB||disorders-26/NNS	nn||irondeficiency-30/NN||ironoverload-28/NN	prep_of||disorders-26/NNS||irondeficiency-30/NN	nn||synthesis-34/NN||hemoglobin-33/NN	prep_of||disorders-26/NNS||synthesis-34/NN	conj_and||irondeficiency-30/NN||synthesis-34/NN	overload--1||iron-15||no||greater understanding of the interplay between the key factors involved in the regulation of iron metabolism and erythropoiesis will help develop more effective therapies for disorders of ironoverload, irondeficiency, and hemoglobin synthesis.
nn||detemir-2/NN||insulin-1/NN	nsubj||improves-3/VBZ||detemir-2/NN	root||ROOT-0/null||improves-3/VBZ	amod||control-5/NN||glycemic-4/JJ	dobj||improves-3/VBZ||control-5/NN	vmod||control-5/NN||based-7/VBN	amod||reduction-10/NN||hba1c-9/JJ	prep_on||based-7/VBN||reduction-10/NN	nn||levels-14/NNS||fasting-12/NN	nn||levels-14/NNS||glucose-13/NN	prep_on||based-7/VBN||levels-14/NNS	conj_and||reduction-10/NN||levels-14/NNS	prepc_without||improves-3/VBZ||increasing-17/VBG	det||risk-19/NN||the-18/DT	dobj||increasing-17/VBG||risk-19/NN	nn||gain-24/NN||hypoglycemia-21/NN	conj_and||hypoglycemia-21/NN||weight-23/NN	nn||gain-24/NN||weight-23/NN	prep_of||risk-19/NN||gain-24/NN	hypoglycemia-21||glucose-13||yes||insulin detemir improves glycemic control, based on hba1c reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain.
det||study-9/NN||this-1/DT	amod||study-9/NN||prospective-2/JJ	amod||study-9/NN||6-week-4/JJ	amod||study-9/NN||multicenter-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-22/VBD||study-9/NN	vmod||study-9/NN||examined-10/VBN	det||benefits-12/NNS||the-11/DT	dobj||examined-10/VBN||benefits-12/NNS	prepc_of||benefits-12/NNS||initiating-14/VBG	dobj||initiating-14/VBG||treatment-15/NN	nn||valsartan/hydrochlorothiazide-18/NN||combination-17/NN	prep_with||initiating-14/VBG||valsartan/hydrochlorothiazide-18/NN	appos||study-9/NN||hctz-20/NNP	root||ROOT-0/null||compared-22/VBD	amod||monotherapy-26/NN||initial-24/JJ	nn||monotherapy-26/NN||valsartan-25/NN	prep_with||compared-22/VBD||monotherapy-26/NN	num||patients-29/NNS||648-28/CD	prep_for||monotherapy-26/NN||patients-29/NNS	amod||hypertension-34/NN||stage-1-31/JJ	conj_or||stage-1-31/JJ||stage-2-33/JJ	amod||hypertension-34/NN||stage-2-33/JJ	prep_with||compared-22/VBD||hypertension-34/NN	dep||hypertension-34/NN||age-36/NN	dep||years-42/NNS||=-37/SYM	num||years-42/NNS||52.6-38/CD	nn||years-42/NNS||â-39/NNP	nn||years-42/NNS||±-40/NNP	num||years-42/NNS||10-41/CD	rcmod||age-36/NN||years-42/NNS	num||%-45/NN||54-44/CD	dep||age-36/NN||%-45/NN	dep||%-45/NN||male-46/NN	nn||blood-49/NN||baseline-48/NN	dep||age-36/NN||blood-49/NN	rcmod||blood-49/NN||pressure-50/NN	dep||pressure-50/NN||bp-52/NN	amod||stage-66/NN||=-54/JJ	dep||=-54/JJ||161/98-55/CD	amod||stage-66/NN||â-56/JJ	amod||stage-66/NN||$-57/$	dep||$-57/$||‰-58/JJ	amod||stage-66/NN||mmâ-59/JJ	amod||stage-66/NN||$-60/$	number||hg-62/CD||‰-61/CD	num||$-60/$||hg-62/CD	number||%-65/NN||32-64/CD	amod||stage-66/NN||%-65/NN	dobj||pressure-50/NN||stage-66/NN	dep||age-36/NN||1-67/CD	hypertension-34||valsartan-25||yes||this prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (hctz) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52.6â±10 years; 54% male; baseline blood pressure (bp)=161/98â€‰mmâ€‰hg, 32% stage 1).
det||goals-2/NNS||the-1/DT	nsubj||were-6/VBD||goals-2/NNS	det||study-5/NN||this-4/DT	prep_of||goals-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||examine-8/VB||to-7/TO	ccomp||were-6/VBD||examine-8/VB	det||influence-10/NN||the-9/DT	dobj||examine-8/VB||influence-10/NN	amod||type1diabetes-13/NNS||maternal-12/JJ	prep_of||influence-10/NN||type1diabetes-13/NNS	prep_during||examine-8/VB||pregnancy-15/NN	nn||adiposity-18/NN||offspring-17/NN	prep_on||examine-8/VB||adiposity-18/NN	nn||tolerance-21/NN||glucose-20/NN	prep_on||examine-8/VB||tolerance-21/NN	conj_and||adiposity-18/NN||tolerance-21/NN	prep_at||adiposity-18/NN||age-23/NN	num||years-25/NNS||7-24/CD	dep||adiposity-18/NN||years-25/NNS	aux||assess-28/VB||to-27/TO	ccomp||were-6/VBD||assess-28/VB	conj_and||examine-8/VB||assess-28/VB	mark||predict-40/VBP||whether-29/IN	amod||factors-31/NNS||metabolic-30/JJ	nsubj||predict-40/VBP||factors-31/NNS	prep_at||factors-31/NNS||birth-33/NN	amod||leptin-36/NNS||neonatal-35/JJ	appos||birth-33/NN||leptin-36/NNS	appos||birth-33/NN||insulin-38/NN	conj_and||leptin-36/NNS||insulin-38/NN	ccomp||assess-28/VB||predict-40/VBP	amod||outcomes-42/NNS||adverse-41/JJ	dobj||predict-40/VBP||outcomes-42/NNS	insulin-38||type1diabetes-13||no_rel||the goals of this study were to examine the influence of maternal type1diabetes during pregnancy on offspring adiposity and glucose tolerance at age 7 years and to assess whether metabolic factors at birth (neonatal leptin and insulin) predict adverse outcomes.
nsubj||receiving-12/VBG||resistance-1/NN	amod||insecticides-4/NNS||pyrethroid-3/JJ	prep_to||resistance-1/NN||insecticides-4/NNS	det||gambiae-10/NN||the-6/DT	nn||gambiae-10/NN||malaria-7/NN	nn||gambiae-10/NN||vector-8/NN	nn||gambiae-10/NN||anopheles-9/NNS	prep_in||insecticides-4/NNS||gambiae-10/NN	aux||receiving-12/VBG||is-11/VBZ	root||ROOT-0/null||receiving-12/VBG	vmod||receiving-12/VBG||increasing-13/VBG	dobj||increasing-13/VBG||attention-14/NN	mark||threatens-17/VBZ||because-15/IN	nsubj||threatens-17/VBZ||it-16/PRP	advcl||increasing-13/VBG||threatens-17/VBZ	det||sustainability-19/NN||the-18/DT	dobj||threatens-17/VBZ||sustainability-19/NN	nn||programs-24/NNS||malaria-21/NN	nn||programs-24/NNS||vector-22/NN	nn||programs-24/NNS||control-23/NN	prep_of||sustainability-19/NN||programs-24/NNS	amod||africa-27/NN||sub-saharan-26/JJ	prep_in||threatens-17/VBZ||africa-27/NN	insecticides-4||malaria-21||no_rel||resistance to pyrethroid insecticides in the malaria vector anopheles gambiae is receiving increasing attention because it threatens the sustainability of malaria vector control programs in sub-saharan africa.
amod||loads-3/NNS||hbv-1/JJ	amod||loads-3/NNS||viral-2/JJ	root||ROOT-0/null||loads-3/NNS	amod||mutations-12/NNS||genotypes-5/JJ	conj_and||genotypes-5/JJ||precore-7/JJ	amod||mutations-12/NNS||precore-7/JJ	conj_and||genotypes-5/JJ||basal-9/JJ	amod||mutations-12/NNS||basal-9/JJ	nn||mutations-12/NNS||core-10/NN	nn||mutations-12/NNS||promotor-11/NN	appos||loads-3/NNS||mutations-12/NNS	appos||loads-3/NNS||serumhepatitisbsurfaceantigen-14/NN	conj_and||mutations-12/NNS||serumhepatitisbsurfaceantigen-14/NN	dep||serumhepatitisbsurfaceantigen-14/NN||hbsag-16/VBG	amod||protein-21/NN||interferon-gamma-19/JJ	nn||protein-21/NN||inducible-20/NN	appos||loads-3/NNS||protein-21/NN	conj_and||mutations-12/NNS||protein-21/NN	dobj||determined-35/VBN||10-22/CD	dep||10-22/CD||ip-10-24/JJ	nsubjpass||determined-35/VBN||levels-26/NNS	num||snps-31/NNS||four-30/CD	conj_and||levels-26/NNS||snps-31/NNS	nsubjpass||determined-35/VBN||snps-31/NNS	prep_of||snps-31/NNS||il28b-33/CD	auxpass||determined-35/VBN||were-34/VBD	rcmod||protein-21/NN||determined-35/VBN	hbv-1||hepatitisbsurfaceantigen--1||yes||hbv viral loads, genotypes, precore and basal core promotor mutations, serumhepatitisbsurfaceantigen (hbsag) and interferon-gamma inducible protein 10 (ip-10) levels as well as four snps of il28b were determined.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	nn||prevalence-4/NN||baseline-3/NN	dobj||determine-2/VB||prevalence-4/NN	dobj||determine-2/VB||intensity-6/NN	conj_and||prevalence-4/NN||intensity-6/NN	nn||infection-9/NN||sth-8/NN	prep_of||prevalence-4/NN||infection-9/NN	amod||children-14/NNS||east-11/JJ	nn||children-14/NNS||guatemalan-12/NN	nn||children-14/NNS||school-13/NN	prep_in||determine-2/VB||children-14/NNS	conj_and||determine-2/VB||describe-17/VB	det||epidemiology-20/NN||the-18/DT	amod||epidemiology-20/NN||associated-19/JJ	dobj||describe-17/VB||epidemiology-20/NN	prep_of||epidemiology-20/NN||anemia-22/NN	vmod||epidemiology-20/NN||stunting-24/VBG	conj_and||determine-2/VB||wasting-27/VBG	det||population-30/NN||this-29/DT	prep_in||wasting-27/VBG||population-30/NN	wasting-27||sth-8||yes||to determine baseline prevalence and intensity of sth infection in east guatemalan school children, and describe the associated epidemiology of anemia, stunting, and wasting in this population.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	amod||hepatitis-36/NN||viral-35/JJ	prep_for||centre-33/NN||hepatitis-36/NN	interferon--1||chronichepatitisc-11||no_rel||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viral hepatitis.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||explore-8/VB||purpose-2/NN	det||work-5/NN||this-4/DT	prep_of||purpose-2/NN||work-5/NN	root||ROOT-0/null||was-6/VBD	aux||explore-8/VB||to-7/TO	xcomp||was-6/VBD||explore-8/VB	det||knowledge-10/NN||the-9/DT	dobj||explore-8/VB||knowledge-10/NN	dobj||explore-8/VB||acceptance-12/NN	conj_and||knowledge-10/NN||acceptance-12/NN	prep_of||knowledge-10/NN||varicellazostervirus-14/NNS	appos||varicellazostervirus-14/NNS||vzv-16/NN	amod||vaccination-23/NN||herpeszoster-19/JJ	appos||vaccination-23/NN||hz-21/NN	dep||varicellazostervirus-14/NNS||vaccination-23/NN	det||population-28/NN||the-25/DT	amod||population-28/NN||general-26/JJ	amod||population-28/NN||italian-27/JJ	prep_in||vaccination-23/NN||population-28/NN	advmod||distributed-38/VBN||where-30/WRB	det||vaccine-33/NN||the-31/DT	nn||vaccine-33/NN||hz-32/NN	nsubjpass||distributed-38/VBN||vaccine-33/NN	aux||distributed-38/VBN||has-34/VBZ	neg||distributed-38/VBN||not-35/RB	advmod||distributed-38/VBN||yet-36/RB	auxpass||distributed-38/VBN||been-37/VBN	rcmod||population-28/NN||distributed-38/VBN	vmod||varicellazostervirus-14/NNS||using-40/VBG	det||study-43/NN||a-41/DT	amod||study-43/NN||prevalence-42/JJ	dobj||using-40/VBG||study-43/NN	prep_of||study-43/NN||subjects-45/NNS	num||regions-48/NNS||two-47/CD	prep_from||using-40/VBG||regions-48/NNS	prep_in||regions-48/NNS||italy-50/NN	herpeszoster-19||varicellazostervirus-14||no||the purpose of this work was to explore the knowledge and acceptance of varicellazostervirus (vzv)-herpeszoster (hz) vaccination in the general italian population, where the hz vaccine has not yet been distributed, using a prevalence study of subjects from two regions in italy.
nsubj||complications-9/NNS||denguehemorrhagicfever-1/NN	conj_and||denguehemorrhagicfever-1/NN||dengueshocksyndrome-3/NN	nsubj||complications-9/NNS||dengueshocksyndrome-3/NN	appos||denguehemorrhagicfever-1/NN||dhf/dss-5/NNS	cop||complications-9/NNS||are-7/VBP	amod||complications-9/NNS||life-threatening-8/JJ	root||ROOT-0/null||complications-9/NNS	prep_following||complications-9/NNS||infection-11/NN	prep_with||infection-11/NN||one-13/CD	det||serotypes-17/NNS||the-15/DT	num||serotypes-17/NNS||four-16/CD	prep_of||one-13/CD||serotypes-17/NNS	prep_of||serotypes-17/NNS||denguevirus-19/NNS	appos||denguevirus-19/NNS||denv-21/NNP	denguehemorrhagicfever-1||denguevirus-19||no||denguehemorrhagicfever and dengueshocksyndrome (dhf/dss) are life-threatening complications following infection with one of the four serotypes of denguevirus (denv).
det||goals-2/NNS||the-1/DT	nsubj||were-6/VBD||goals-2/NNS	det||study-5/NN||this-4/DT	prep_of||goals-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||examine-8/VB||to-7/TO	ccomp||were-6/VBD||examine-8/VB	det||influence-10/NN||the-9/DT	dobj||examine-8/VB||influence-10/NN	amod||type1diabetes-13/NNS||maternal-12/JJ	prep_of||influence-10/NN||type1diabetes-13/NNS	prep_during||examine-8/VB||pregnancy-15/NN	nn||adiposity-18/NN||offspring-17/NN	prep_on||examine-8/VB||adiposity-18/NN	nn||tolerance-21/NN||glucose-20/NN	prep_on||examine-8/VB||tolerance-21/NN	conj_and||adiposity-18/NN||tolerance-21/NN	prep_at||adiposity-18/NN||age-23/NN	num||years-25/NNS||7-24/CD	dep||adiposity-18/NN||years-25/NNS	aux||assess-28/VB||to-27/TO	ccomp||were-6/VBD||assess-28/VB	conj_and||examine-8/VB||assess-28/VB	mark||predict-40/VBP||whether-29/IN	amod||factors-31/NNS||metabolic-30/JJ	nsubj||predict-40/VBP||factors-31/NNS	prep_at||factors-31/NNS||birth-33/NN	amod||leptin-36/NNS||neonatal-35/JJ	appos||birth-33/NN||leptin-36/NNS	appos||birth-33/NN||insulin-38/NN	conj_and||leptin-36/NNS||insulin-38/NN	ccomp||assess-28/VB||predict-40/VBP	amod||outcomes-42/NNS||adverse-41/JJ	dobj||predict-40/VBP||outcomes-42/NNS	glucose-20||type1diabetes-13||no_rel||the goals of this study were to examine the influence of maternal type1diabetes during pregnancy on offspring adiposity and glucose tolerance at age 7 years and to assess whether metabolic factors at birth (neonatal leptin and insulin) predict adverse outcomes.
nsubjpass||limited-6/VBN||treatment-1/NN	amod||rsvinfection-4/NN||active-3/JJ	prep_for||treatment-1/NN||rsvinfection-4/NN	auxpass||limited-6/VBN||is-5/VBZ	root||ROOT-0/null||limited-6/VBN	det||symptoms-9/NNS||the-8/DT	prep_to||limited-6/VBN||symptoms-9/NNS	prep_of||symptoms-9/NNS||infection-11/NN	det||cause-16/NN||the-14/DT	amod||cause-16/NN||underlying-15/VBG	prep_to||limited-6/VBN||cause-16/NN	conj_negcc||symptoms-9/NNS||cause-16/NN	advmod||critical-22/JJ||therefore-18/RB	nsubj||critical-22/JJ||it-20/PRP	nsubj||reduce-24/VB||it-20/PRP	cop||critical-22/JJ||is-21/VBZ	parataxis||limited-6/VBN||critical-22/JJ	aux||reduce-24/VB||to-23/TO	xcomp||critical-22/JJ||reduce-24/VB	det||transmission-26/NN||the-25/DT	dobj||reduce-24/VB||transmission-26/NN	prep_of||transmission-26/NN||rsv-28/NN	rsvinfection-4||rsv-28||no||treatment for active rsvinfection is limited to the symptoms of infection rather than the underlying cause; therefore, it is critical to reduce the transmission of rsv.
nsubjpass||limited-3/VBN||data-1/NNS	auxpass||limited-3/VBN||are-2/VBP	root||ROOT-0/null||limited-3/VBN	det||use-6/NN||the-5/DT	prep_regarding||limited-3/VBN||use-6/NN	prep_of||use-6/NN||eptifibatide-8/NN	prep_in||eptifibatide-8/NN||patients-10/NNS	nn||myocardialinfarction-15/NN||st-12/NN	nn||myocardialinfarction-15/NN||segment-13/NN	nn||myocardialinfarction-15/NN||elevation-14/NN	prep_with||patients-10/NNS||myocardialinfarction-15/NN	myocardialinfarction-15||eptifibatide-8||yes||data are limited regarding the use of eptifibatide in patients with st segment elevation myocardialinfarction.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	advmod||is-15/VBZ||where-8/WRB	det||wide-14/NNS||the-9/DT	amod||wide-14/NNS||highest-10/JJS	amod||wide-14/NNS||reported-11/JJ	nn||wide-14/NNS||incidence-12/NN	nn||wide-14/NNS||world-13/NN	nsubj||is-15/VBZ||wide-14/NNS	rcmod||melioidosis-7/NNS||is-15/VBZ	det||northeast-18/NN||the-17/DT	prep_in||is-15/VBZ||northeast-18/NN	prep_of||northeast-18/NN||thailand-20/NN	advmod||prevalent-28/JJ||where-22/WRB	amod||soil-24/NN||saline-23/JJ	nsubj||prevalent-28/JJ||soil-24/NN	conj_and||soil-24/NN||water-26/NN	nsubj||prevalent-28/JJ||water-26/NN	cop||prevalent-28/JJ||are-27/VBP	advcl||is-15/VBZ||prevalent-28/JJ	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the causative agent of melioidosis where the highest reported incidence world wide is in the northeast of thailand, where saline soil and water are prevalent.
nsubj||permit-9/VB||t-cell-1/NN	vmod||t-cell-1/NN||based-2/VBN	xcomp||based-2/VBN||ifn-î-3/VBG	amod||assays-6/NNS||³-4/JJ	nn||assays-6/NNS||release-5/NN	dobj||ifn-î-3/VBG||assays-6/NNS	aux||permit-9/VB||do-7/VBP	neg||permit-9/VB||not-8/RB	root||ROOT-0/null||permit-9/VB	dobj||permit-9/VB||distinction-10/NN	amod||-rrb--16/NNP||active-12/JJ	nn||-rrb--16/NNP||tuberculosis-13/NNP	nn||-rrb--16/NNP||-lrb--14/NNP	nn||-rrb--16/NNP||tb-15/NNP	prep_of||distinction-10/NN||-rrb--16/NNP	advmod||treated-19/VBG||successfully-18/RB	prepc_from||permit-9/VB||treated-19/VBG	nn||m.tuberculosisinfection-23/NN||disease-20/NN	conj_or||disease-20/NN||latent-22/NN	nn||m.tuberculosisinfection-23/NN||latent-22/NN	dobj||treated-19/VBG||m.tuberculosisinfection-23/NN	tb-15||m.tuberculosis--1||no||t-cell based ifn-î ³ release assays do not permit distinction of active tuberculosis -lrb- tb -rrb- from successfully treated disease or latent m.tuberculosisinfection .
num||patients-3/NNS||ten-1/CD	amod||patients-3/NNS||male-2/JJ	nsubj||received-26/VBD||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||â-8/VBP||means-7/NNS	parataxis||received-26/VBD||â-8/VBP	amod||sd-10/NN||±-9/JJ	nsubj||bmi-19/VBP||sd-10/NN	amod||â-14/NN||a1c-12/JJ	amod||â-14/NN||7.0-13/JJ	dep||sd-10/NN||â-14/NN	number||1.1-16/CD||±-15/CD	num||%-17/NN||1.1-16/CD	dep||â-14/NN||%-17/NN	ccomp||â-8/VBP||bmi-19/VBP	advmod||bmi-19/VBP||28.3-20/RB	dep||bmi-19/VBP||â-21/VB	number||2.7-23/CD||±-22/CD	num||kg/m2-24/NNS||2.7-23/CD	dobj||â-21/VB||kg/m2-24/NNS	root||ROOT-0/null||received-26/VBD	det||units-29/NNS||either-27/DT	num||units-29/NNS||300-28/CD	dobj||received-26/VBD||units-29/NNS	prep_of||units-29/NNS||insulin-31/NN	prep||received-26/VBD||combined-32/VBN	pcomp||combined-32/VBN||with-33/IN	num||mg-35/NN||400-34/CD	pobj||with-33/IN||mg-35/NN	nn||orally-39/NN||delivery-37/NN	nn||orally-39/NN||agent-38/NN	prep_of||mg-35/NN||orally-39/NN	num||units-42/NNS||15-41/CD	pobj||with-33/IN||units-42/NNS	conj_or||mg-35/NN||units-42/NNS	vmod||units-42/NNS||rhi-43/VBN	advmod||rhi-43/VBN||subcutaneously-44/RB	amod||conditions-48/NNS||isoglycemic-46/JJ	nn||conditions-48/NNS||clamp-47/NN	prep_under||rhi-43/VBN||conditions-48/NNS	type2diabetes-5||insulin-31||yes||ten male patients with type2diabetes (means â± sd; a1c 7.0 â± 1.1%; bmi 28.3 â± 2.7 kg/m2) received either 300 units of insulin combined with 400 mg of delivery agent orally or 15 units rhi subcutaneously under isoglycemic clamp conditions.
nsubj||become-3/VBN||it-1/PRP	aux||become-3/VBN||has-2/VBZ	root||ROOT-0/null||become-3/VBN	acomp||become-3/VBN||clear-4/JJ	mark||leads-16/VBZ||that-5/IN	det||approach-8/NN||an-6/DT	amod||approach-8/NN||individualistic-7/JJ	nsubj||leads-16/VBZ||approach-8/NN	prep_to||approach-8/NN||children-10/NNS	vmod||children-10/NNS||affected-11/VBN	agent||affected-11/VBN||hiv-13/NN	agent||affected-11/VBN||aids-15/NNS	conj_and||hiv-13/NN||aids-15/NNS	ccomp||become-3/VBN||leads-16/VBZ	prep_to||leads-16/VBZ||confusion-18/NN	prep_to||leads-16/VBZ||misdirection-20/NN	conj_and||confusion-18/NN||misdirection-20/NN	det||response-28/NN||the-22/DT	amod||response-28/NN||global-23/JJ	conj_and||global-23/JJ||national-25/JJ	amod||response-28/NN||national-25/JJ	conj_and||global-23/JJ||local-27/JJ	amod||response-28/NN||local-27/JJ	prep_of||confusion-18/NN||response-28/NN	aids-15||hiv-13||no||it has become clear that an individualistic approach to children affected by hiv and aids leads to confusion and misdirection of the global, national and local response.
nsubj||confirmed-2/VBD||we-1/PRP	root||ROOT-0/null||confirmed-2/VBD	dobj||confirmed-2/VBD||pulmonaryaspergillosis-3/NNS	advmod||confirmed-2/VBD||noninvasively-4/RB	det||result-8/NN||a-6/DT	amod||result-8/NN||positive-7/JJ	prep_through||confirmed-2/VBD||result-8/NN	det||culture-11/NN||the-10/DT	prep_from||confirmed-2/VBD||culture-11/NN	amod||fluid-16/NN||bronchial-13/JJ	nn||fluid-16/NN||alveolar-14/NN	nn||fluid-16/NN||lavage-15/NN	prep_of||culture-11/NN||fluid-16/NN	amod||test-20/NN||positive-18/JJ	amod||test-20/NN||serological-19/JJ	appos||fluid-16/NN||test-20/NN	amod||antigen-23/NN||aspergillus-22/JJ	prep_for||test-20/NN||antigen-23/NN	nn||results-26/NNS||radiology-25/NN	prep_for||test-20/NN||results-26/NNS	conj_and||antigen-23/NN||results-26/NNS	pulmonaryaspergillosis-3||aspergillus-22||no||we confirmed pulmonaryaspergillosis noninvasively through a positive result from the culture of bronchial alveolar lavage fluid, positive serological test for aspergillus antigen and radiology results.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	mark||allows-17/VBZ||that-3/IN	det||protrusion-5/NN||the-4/DT	nsubj||allows-17/VBZ||protrusion-5/NN	det||portion-8/NN||some-7/DT	prep_of||protrusion-5/NN||portion-8/NN	det||terminus-12/NNS||the-10/DT	nn||terminus-12/NNS||c-11/NN	prep_of||portion-8/NN||terminus-12/NNS	det||shell-16/NN||the-14/DT	amod||shell-16/NN||spherical-15/JJ	prep_above||terminus-12/NNS||shell-16/NN	ccomp||propose-2/VBP||allows-17/VBZ	dobj||allows-17/VBZ||it-18/PRP	nsubj||cross-link-20/VB||it-18/PRP	aux||cross-link-20/VB||to-19/TO	xcomp||allows-17/VBZ||cross-link-20/VB	amod||polypeptides-24/NNS||other-22/JJ	amod||polypeptides-24/NNS||mutant-23/JJ	prep_with||cross-link-20/VB||polypeptides-24/NNS	nn||bridging-27/NNS||iron-26/NN	prep_through||cross-link-20/VB||bridging-27/NNS	xcomp||cross-link-20/VB||leading-29/VBG	amod||precipitation-33/NN||enhanced-31/JJ	amod||precipitation-33/NN||mutant-32/JJ	prep_to||leading-29/VBG||precipitation-33/NN	prep_by||leading-29/VBG||iron-35/NN	cross--1||iron-35||no_rel||we propose that the protrusion of some portion of the c terminus above the spherical shell allows it to cross-link with other mutant polypeptides through iron bridging, leading to enhanced mutant precipitation by iron.
aux||address-2/VB||to-1/TO	root||ROOT-0/null||address-2/VB	det||problems-5/NNS||the-3/DT	amod||problems-5/NNS||long-term-4/JJ	dobj||address-2/VB||problems-5/NNS	nn||wear-9/NN||bearing-7/NN	nn||wear-9/NN||surface-8/NN	prep_of||problems-5/NNS||wear-9/NN	prep_of||problems-5/NNS||osteolysis-11/NNS	conj_and||wear-9/NN||osteolysis-11/NNS	vmod||osteolysis-11/NNS||associated-12/VBN	amod||metal-polyethylene-15/NN||conventional-14/JJ	prep_with||associated-12/VBN||metal-polyethylene-15/NN	dep||metal-polyethylene-15/NN||m-pe-17/JJ	amod||arthroplasty-21/NN||total-19/JJ	nn||arthroplasty-21/NN||hip-20/NN	dep||metal-polyethylene-15/NN||arthroplasty-21/NN	appos||metal-polyethylene-15/NN||tha-23/NN	appos||metal-polyethylene-15/NN||metal-metal-26/NN	appos||metal-metal-26/NN||m-m-28/NNP	amod||bearings-36/NNS||ceramic-ceramic-32/JJ	appos||bearings-36/NNS||c-c-34/NNP	nsubjpass||introduced-39/VBN||bearings-36/NNS	aux||introduced-39/VBN||have-37/VBP	auxpass||introduced-39/VBN||been-38/VBN	conj_and||address-2/VB||introduced-39/VBN	tha-23||osteolysis-11||no_rel||to address the long-term problems of bearing surface wear and osteolysis associated with conventional metal-polyethylene (m-pe) total hip arthroplasty (tha), metal-metal (m-m), and ceramic-ceramic (c-c) bearings have been introduced.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||identify-16/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	det||consortium-8/NN||the-6/DT	amod||consortium-8/NN||international-7/JJ	agent||conducted-4/VBN||consortium-8/NN	nn||safety-11/NN||blood-10/NN	prep_for||consortium-8/NN||safety-11/NN	appos||safety-11/NN||icbs-13/NNS	aux||identify-16/VB||to-15/TO	xcomp||conducted-4/VBN||identify-16/VB	amod||kits-19/NNS||high-quality-17/JJ	nn||kits-19/NNS||test-18/NN	dobj||identify-16/VB||kits-19/NNS	iobj||identify-16/VB||kits-19/NNS	prep_for||kits-19/NNS||detection-21/NN	prep_of||detection-21/NN||hepatitisbvirus-23/NNS	appos||kits-19/NNS||hbv-25/NN	nn||antigen-28/NN||surface-27/NN	dep||kits-19/NNS||antigen-28/NN	appos||antigen-28/NN||hbsag-30/NN	det||benefit-34/NN||the-33/DT	prep_for||antigen-28/NN||benefit-34/NN	amod||countries-37/NNS||developing-36/VBG	prep_of||benefit-34/NN||countries-37/NNS	hbv-25||hepatitisbvirus-23||no||this study was conducted by the international consortium for blood safety (icbs) to identify high-quality test kits for detection of hepatitisbvirus (hbv) surface antigen (hbsag) for the benefit of developing countries.
det||data-2/NNS||these-1/DT	nsubj||differentiate-3/VB||data-2/NNS	root||ROOT-0/null||differentiate-3/VB	det||mechanism-5/NN||the-4/DT	dobj||differentiate-3/VB||mechanism-5/NN	amod||effects-9/NNS||primary-7/JJ	amod||effects-9/NNS||anti-tumor-8/JJ	prep_for||mechanism-5/NN||effects-9/NNS	amod||±-14/NNS||il-2-11/JJ	amod||±-14/NNS||/-12/JJ	nn||±-14/NNS||î-13/NN	prep_of||effects-9/NNS||±-14/NNS	amod||immunotherapy-17/NN||cd40-16/JJ	dep||mechanism-5/NN||immunotherapy-17/NN	nsubj||independent-21/JJ||immunotherapy-17/NN	cop||independent-21/JJ||are-20/VBP	rcmod||immunotherapy-17/NN||independent-21/JJ	advmod||independent-21/JJ||of-22/IN	dep||of-22/IN||no-23/DT	det||inhibition-28/NN||the-26/DT	amod||inhibition-28/NN||no-dependent-27/JJ	prep_from||independent-21/JJ||inhibition-28/NN	prep_of||inhibition-28/NN||metastases-30/NNS	il-2-11||tumor--1||no_rel||these data differentiate the mechanism for primary anti-tumor effects of il-2/î±-cd40 immunotherapy, which are independent of no, from the no-dependent inhibition of metastases.
nn||samples-2/NNS||plasma-1/NN	nsubjpass||tested-21/VBN||samples-2/NNS	amod||patients-6/NNS||hiv-4/JJ	amod||patients-6/NNS||infected-5/JJ	prep_from||samples-2/NNS||patients-6/NNS	num||individuals-9/NNS||190-8/CD	dep||samples-2/NNS||individuals-9/NNS	prep_with||individuals-9/NNS||clinically-11/NNP	vmod||individuals-9/NNS||defined-12/VBN	dobj||defined-12/VBN||aids-13/NNS	nn||individuals-16/NNS||382-15/NN	dobj||defined-12/VBN||individuals-16/NNS	conj_and||aids-13/NNS||individuals-16/NNS	prep_without||defined-12/VBN||aids-18/NNS	auxpass||tested-21/VBN||were-20/VBD	root||ROOT-0/null||tested-21/VBN	advmod||tested-21/VBN||retrospectively-22/RB	det||presence-25/NN||the-24/DT	prep_for||tested-21/VBN||presence-25/NN	nn||sero-markers-28/NNS||hbv-27/NN	prep_of||presence-25/NN||sero-markers-28/NNS	nn||dna-33/NN||serum-31/NN	nn||dna-33/NN||hbv-32/NN	prep_for||tested-21/VBN||dna-33/NN	conj_and||presence-25/NN||dna-33/NN	vmod||dna-33/NN||screened-35/VBN	nn||infection-38/NN||hcv-37/NN	prep_for||screened-35/VBN||infection-38/NN	agent||screened-35/VBN||testing-40/VBG	amod||antibody-43/NN||anti-hcv-42/JJ	prep_for||testing-40/VBG||antibody-43/NN	nn||rna-46/NN||hcv-45/NN	prep_for||testing-40/VBG||rna-46/NN	conj_and||antibody-43/NN||rna-46/NN	aids-18||hiv-4||no||plasma samples from hiv infected patients (190 individuals with clinically defined aids and 382 individuals without aids) were tested retrospectively for the presence of hbv sero-markers and for serum hbv dna, screened for hcv infection by testing for anti-hcv antibody and hcv rna.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||responsible-24/JJ||that-4/IN	poss||countries-8/NNS||our-6/PRP$	nn||countries-8/NNS||study-7/NN	nsubj||encompass-11/VB||countries-8/NNS	prep_in||responsible-24/JJ||countries-8/NNS	rcmod||countries-8/NNS||encompass-11/VB	num||%-13/NN||70-12/CD	dobj||encompass-11/VB||%-13/NN	det||population-17/NN||the-15/DT	amod||population-17/NN||sub-saharan-16/JJ	prep_of||%-13/NN||population-17/NN	det||epidemic-21/NN||the-19/DT	nn||epidemic-21/NN||hiv/aids-20/NNS	nsubj||responsible-24/JJ||epidemic-21/NN	aux||responsible-24/JJ||could-22/MD	cop||responsible-24/JJ||be-23/VB	ccomp||suggest-3/VBP||responsible-24/JJ	num||individuals-34/NNS||582â-26/CD	amod||individuals-34/NNS||$-27/$	num||$-27/$||‰-28/CD	amod||individuals-34/NNS||200-917â-29/JJ	amod||individuals-34/NNS||$-30/$	number||000-32/CD||‰-31/CD	num||$-30/$||000-32/CD	dep||$-30/$||older-33/JJR	prep_for||responsible-24/JJ||individuals-34/NNS	vmod||individuals-34/NNS||living-35/VBG	advmod||living-35/VBG||alone-36/RB	amod||adults-40/NNS||prime-38/JJ	nn||adults-40/NNS||age-39/NN	nsubj||caregivers-54/NNS||adults-40/NNS	num||individuals-50/NNS||141â-42/CD	amod||individuals-50/NNS||$-43/$	num||$-43/$||‰-44/CD	amod||individuals-50/NNS||000-323â-45/JJ	amod||individuals-50/NNS||$-46/$	number||100-48/CD||‰-47/CD	num||$-46/$||100-48/CD	dep||$-46/$||older-49/JJR	conj_and||adults-40/NNS||individuals-50/NNS	nsubj||caregivers-54/NNS||individuals-50/NNS	cop||caregivers-54/NNS||being-51/VBG	det||caregivers-54/NNS||the-52/DT	amod||caregivers-54/NNS||sole-53/JJ	prepc_without||living-35/VBG||caregivers-54/NNS	amod||children-57/NNS||young-56/JJ	prep_for||caregivers-54/NNS||children-57/NNS	aids--1||hiv--1||no||these findings suggest that in our study countries, which encompass 70% of the sub-saharan population, the hiv/aids epidemic could be responsible for 582â€‰200-917â€‰000 older individuals living alone without prime age adults and 141â€‰000-323â€‰100 older individuals being the sole caregivers for young children.
nsubj||condition-7/NN||mh-1/NN	cop||condition-7/NN||is-2/VBZ	det||condition-7/NN||an-3/DT	amod||condition-7/NN||autosomal-4/JJ	amod||condition-7/NN||dominant-5/JJ	amod||condition-7/NN||hypermetabolic-6/JJ	root||ROOT-0/null||condition-7/NN	nsubj||occurs-9/VBZ||condition-7/NN	rcmod||condition-7/NN||occurs-9/VBZ	advmod||predisposed-12/JJ||genetically-11/RB	amod||subjects-13/NNS||predisposed-12/JJ	prep_in||occurs-9/VBZ||subjects-13/NNS	amod||anesthesia-16/NN||general-15/JJ	prep_during||subjects-13/NNS||anesthesia-16/NN	dep||subjects-13/NNS||induced-18/VBG	advmod||used-21/VBN||commonly-20/RB	amod||anesthetics-23/NNS||used-21/VBN	amod||anesthetics-23/NNS||volatile-22/JJ	prep_by||induced-18/VBG||anesthetics-23/NNS	det||neuromuscular-26/NN||the-25/DT	dep||subjects-13/NNS||neuromuscular-26/NN	conj_and/or||induced-18/VBG||neuromuscular-26/NN	vmod||neuromuscular-26/NN||blocking-27/VBG	nn||succinylcholine-29/NN||agent-28/NN	dobj||blocking-27/VBG||succinylcholine-29/NN	mh-1||succinylcholine-29||no||mh is an autosomal dominant hypermetabolic condition that occurs in genetically predisposed subjects during general anesthesia, induced by commonly used volatile anesthetics and/or the neuromuscular blocking agent succinylcholine.
nsubj||concern-11/NN||infection-1/NN	prep_with||infection-1/NN||hepatitisbvirus-3/NNS	appos||hepatitisbvirus-3/NNS||hbv-5/NN	cop||concern-11/NN||is-7/VBZ	amod||concern-11/NN||major-8/JJ	amod||concern-11/NN||public-9/JJ	nn||concern-11/NN||health-10/NN	root||ROOT-0/null||concern-11/NN	hbv-5||hepatitisbvirus-3||no||infection with hepatitisbvirus (hbv) is major public health concern.
det||rates-3/NNS||the-1/DT	nn||rates-3/NNS||conversion-2/NN	nsubj||different-26/JJ||rates-3/NNS	det||methods-6/NNS||both-5/DT	prep_by||rates-3/NNS||methods-6/NNS	det||rest-9/NN||the-8/DT	prep_during||methods-6/NNS||rest-9/NN	det||period-13/NN||the-11/DT	nn||period-13/NN||treatment-12/NN	prep_of||rest-9/NN||period-13/NN	dep||rates-3/NNS||8-15/CD	dep||rates-3/NNS||12-17/CD	conj_and||8-15/CD||12-17/CD	num||weeks-21/NNS||20-20/CD	dep||rates-3/NNS||weeks-21/NNS	conj_and||8-15/CD||weeks-21/NNS	cop||different-26/JJ||were-23/VBD	neg||different-26/JJ||not-24/RB	advmod||different-26/JJ||significantly-25/RB	root||ROOT-0/null||different-26/JJ	amod||patients-32/NNS||hivpositive-28/JJ	conj_and||hivpositive-28/JJ||hiv-30/JJ	amod||patients-32/NNS||hiv-30/JJ	amod||patients-32/NNS||negative-31/JJ	prep_between||different-26/JJ||patients-32/NNS	hivpositive-28||hiv-30||no||the conversion rates by both methods during the rest of the treatment period (8, 12, and 20 weeks) were not significantly different between hivpositive and hiv negative patients.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tuberculosis--1||isoniazid-27||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
nsubj||factor-8/NN||hyperhomocysteinemia-1/NN	nsubj||develop-16/VB||hyperhomocysteinemia-1/NN	cop||factor-8/NN||is-4/VBZ	det||factor-8/NN||an-5/DT	amod||factor-8/NN||independent-6/JJ	nn||factor-8/NN||risk-7/NN	rcmod||hyperhomocysteinemia-1/NN||factor-8/NN	amod||vasculardisease-11/NN||atherosclerotic-10/JJ	prep_for||factor-8/NN||vasculardisease-11/NN	prep_for||factor-8/NN||thromboembolism-13/NN	conj_and||vasculardisease-11/NN||thromboembolism-13/NN	aux||develop-16/VB||may-15/MD	root||ROOT-0/null||develop-16/VB	amod||patients-19/NNS||hcv-infected-18/JJ	prep_in||develop-16/VB||patients-19/NNS	mark||enzyme-28/VBP||although-20/IN	amod||transferase-24/NN||altered-21/JJ	amod||transferase-24/NN||alanine-22/JJ	amod||transferase-24/NN||amino-23/JJ	nsubj||enzyme-28/VBP||transferase-24/NN	appos||transferase-24/NN||alt-26/NN	advcl||develop-16/VB||enzyme-28/VBP	nsubjpass||associated-32/VBN||levels-29/NNS	auxpass||associated-32/VBN||are-30/VBP	advmod||associated-32/VBN||generally-31/RB	ccomp||enzyme-28/VBP||associated-32/VBN	prep_with||associated-32/VBN||damage-34/NN	nn||cells-37/NNS||liver-36/NN	prep_to||associated-32/VBN||cells-37/NNS	enzyme-28||thromboembolism-13||no_rel||hyperhomocysteinemia, which is an independent risk factor for atherosclerotic vasculardisease and thromboembolism , may develop in hcv-infected patients although altered alanine amino transferase (alt) enzyme levels are generally associated with damage to liver cells.
det||rate-3/NN||a-1/DT	amod||rate-3/NN||high-2/JJ	nsubjpass||observed-9/VBN||rate-3/NN	amod||diagnoses-7/NNS||false-5/JJ	amod||diagnoses-7/NNS||negative-6/JJ	prep_of||rate-3/NN||diagnoses-7/NNS	auxpass||observed-9/VBN||was-8/VBD	root||ROOT-0/null||observed-9/VBN	amod||diseases-12/NNS||infectious-11/JJ	prep_for||observed-9/VBN||diseases-12/NNS	nsubj||showed-15/VBD||diseases-12/NNS	rcmod||diseases-12/NNS||showed-15/VBD	dobj||showed-15/VBD||sensitivities-16/NNS	number||%-19/NN||50-18/CD	amod||conditions-21/NNS||%-19/NN	amod||conditions-21/NNS||hiv/aids-related-20/JJ	prep_under||showed-15/VBD||conditions-21/NNS	num||%-24/NN||33.3-23/CD	appos||conditions-21/NNS||%-24/NN	amod||bronchopneumonia-28/NN||pyogenic-27/JJ	prep_under||showed-15/VBD||bronchopneumonia-28/NN	conj_and||conditions-21/NNS||bronchopneumonia-28/NN	num||%-31/NN||35.3-30/CD	appos||bronchopneumonia-28/NN||%-31/NN	amod||meningitis-35/NNS||pyogenic-34/JJ	prep_under||showed-15/VBD||meningitis-35/NNS	conj_and||conditions-21/NNS||meningitis-35/NNS	num||%-38/NN||40.0-37/CD	appos||meningitis-35/NNS||%-38/NN	amod||septicemia-43/NN||puerperal-42/JJ	prep_under||showed-15/VBD||septicemia-43/NN	conj_and||conditions-21/NNS||septicemia-43/NN	num||%-46/NN||50.0-45/CD	appos||septicemia-43/NN||%-46/NN	aids--1||hiv--1||no||a high rate of false negative diagnoses was observed for infectious diseases, which showed sensitivities under 50% hiv/aids-related conditions (33.3%), pyogenic bronchopneumonia (35.3%), pyogenic meningitis (40.0%), and puerperal septicemia (50.0%).
det||study-2/NN||this-1/DT	nsubjpass||designed-5/VBN||study-2/NN	nsubj||investigate-7/VB||study-2/NN	aux||designed-5/VBN||has-3/VBZ	auxpass||designed-5/VBN||been-4/VBN	root||ROOT-0/null||designed-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||designed-5/VBN||investigate-7/VB	mark||alternative-15/NN||whether-8/IN	det||admixture-10/NN||this-9/DT	nsubj||alternative-15/NN||admixture-10/NN	aux||alternative-15/NN||can-11/MD	cop||alternative-15/NN||be-12/VB	det||alternative-15/NN||a-13/DT	amod||alternative-15/NN||suitable-14/JJ	ccomp||investigate-7/VB||alternative-15/NN	aux||propofol-17/VB||to-16/TO	vmod||alternative-15/NN||propofol-17/VB	prep_in||designed-5/VBN||relation-20/NN	aux||ease-22/VB||to-21/TO	vmod||relation-20/NN||ease-22/VB	prep_of||ease-22/VB||insertion-24/NN	det||pain-35/NN||the-26/DT	nn||stability-30/NN||lma-27/NN	amod||stability-30/NN||haemodynamic-29/JJ	dep||pain-35/NN||stability-30/NN	nn||containment-33/NN||cost-32/NN	dep||stability-30/NN||containment-33/NN	prep_of||insertion-24/NN||pain-35/NN	prep_on||pain-35/NN||injection-37/NN	prep_on||pain-35/NN||recovery-39/NN	conj_and||injection-37/NN||recovery-39/NN	prep_in||ease-22/VB||children-41/NNS	pain-35||propofol-17||yes||this study has been designed to investigate whether this admixture can be a suitable alternative to propofol, in relation to ease of insertion of the lma, haemodynamic stability, cost containment, pain on injection and recovery in children.
det||vitamina-4/NN||the-2/DT	amod||vitamina-4/NN||national-3/JJ	prep_despite||continue-16/VBP||vitamina-4/NN	amod||programmes-8/NNS||antihelminthic-6/JJ	nn||programmes-8/NNS||prophylaxis-7/NNS	conj_and||vitamina-4/NN||programmes-8/NNS	prep_despite||continue-16/VBP||programmes-8/NNS	preconj||geo-helminths-12/NNS||both-10/DT	amod||geo-helminths-12/NNS||intestinal-11/JJ	nsubj||continue-16/VBP||geo-helminths-12/NNS	nsubj||prevalent-19/JJ||geo-helminths-12/NNS	nn||vitaminadeficiency-15/NN||subclinical-14/NN	conj_and||geo-helminths-12/NNS||vitaminadeficiency-15/NN	nsubj||continue-16/VBP||vitaminadeficiency-15/NN	nsubj||prevalent-19/JJ||vitaminadeficiency-15/NN	root||ROOT-0/null||continue-16/VBP	aux||prevalent-19/JJ||to-17/TO	cop||prevalent-19/JJ||be-18/VB	xcomp||continue-16/VBP||prevalent-19/JJ	prep_among||prevalent-19/JJ||children-21/NNS	amod||countries-24/NNS||developing-23/VBG	prep_in||children-21/NNS||countries-24/NNS	vitaminadeficiency-15||vitamina-4||yes||despite the national vitamina and antihelminthic prophylaxis programmes, both intestinal geo-helminths and subclinical vitaminadeficiency continue to be prevalent among children in developing countries.
nsubj||intervention-14/NN||prevention-1/NN	amod||transmission-5/NN||mother-to-child-3/JJ	nn||transmission-5/NN||hiv-4/NN	prep_of||prevention-1/NN||transmission-5/NN	appos||transmission-5/NN||pmtct-7/NN	cop||intervention-14/NN||is-9/VBZ	advmod||intervention-14/NN||still-10/RB	det||intervention-14/NN||the-11/DT	advmod||effective-13/JJ||most-12/RBS	amod||intervention-14/NN||effective-13/JJ	root||ROOT-0/null||intervention-14/NN	prepc_in||intervention-14/NN||combating-16/VBG	amod||hivinfections-18/NNS||new-17/JJ	dobj||combating-16/VBG||hivinfections-18/NNS	hivinfections-18||hiv-4||no||prevention of mother-to-child hiv transmission (pmtct) is still the most effective intervention in combating new hivinfections.
det||virus-5/NN||the-1/DT	amod||virus-5/NN||global-2/JJ	amod||virus-5/NN||human-3/JJ	amod||virus-5/NN||immuno-deficiency-4/JJ	nsubj||continues-10/VBZ||virus-5/NN	nsubj||spread-12/VB||virus-5/NN	nsubj||sexuallytransmittedinfections-24/VBZ||virus-5/NN	appos||virus-5/NN||hiv-7/NN	amod||virus-5/NN||pandemic-9/JJ	root||ROOT-0/null||continues-10/VBZ	aux||spread-12/VB||to-11/TO	xcomp||continues-10/VBZ||spread-12/VB	det||rate-15/NN||a-14/DT	prep_at||spread-12/VB||rate-15/NN	mwe||than-18/IN||more-17/JJR	quantmod||15,000-19/CD||than-18/IN	num||infections-21/NNS||15,000-19/CD	amod||infections-21/NNS||new-20/JJ	prep_of||rate-15/NN||infections-21/NNS	advmod||spread-12/VB||daily-22/RB	conj_and||continues-10/VBZ||sexuallytransmittedinfections-24/VBZ	nsubj||predispose-29/VB||stis-26/NNS	aux||predispose-29/VB||can-28/MD	ccomp||sexuallytransmittedinfections-24/VBZ||predispose-29/VB	dobj||predispose-29/VB||people-30/NNS	prepc_to||predispose-29/VB||acquiring-32/VBG	dobj||acquiring-32/VBG||hivinfection-33/NN	hivinfection-33||hiv-7||no||the global human immuno-deficiency virus (hiv) pandemic continues to spread at a rate of more than 15,000 new infections daily and sexuallytransmittedinfections (stis) can predispose people to acquiring hivinfection.
advmod||reduced-16/VBN||furthermore-1/RB	det||virulence-4/NN||the-3/DT	nsubjpass||reduced-16/VBN||virulence-4/NN	nsubjpass||reduced-29/VBN||virulence-4/NN	det||virus-7/NN||a-6/DT	prep_of||virulence-4/NN||virus-7/NN	vmod||virus-7/NN||lacking-8/VBG	dobj||lacking-8/VBG||c16l-9/NNS	dep||virus-7/NN||vî-11/VBN	dobj||vî-11/VBN||c16-13/NNS	auxpass||reduced-16/VBN||was-15/VBD	root||ROOT-0/null||reduced-16/VBN	det||model-21/NN||a-18/DT	amod||model-21/NN||murine-19/JJ	amod||model-21/NN||intranasal-20/JJ	prep_in||reduced-16/VBN||model-21/NN	prepc_compared_with||reduced-16/VBN||with-23/IN	nn||viruses-25/NNS||control-24/NN	pobj||reduced-16/VBN||viruses-25/NNS	expl||reduced-29/VBN||there-27/EX	auxpass||reduced-29/VBN||were-28/VBD	conj_and||reduced-16/VBN||reduced-29/VBN	nn||titres-31/NNS||virus-30/NN	nsubj||post-infection-37/JJ||titres-31/NNS	amod||days-36/NNS||4â-33/JJ	amod||days-36/NNS||$-34/$	prep_from||titres-31/NNS||days-36/NNS	xcomp||reduced-29/VBN||post-infection-37/JJ	virus-30||viruses-25||no||furthermore, the virulence of a virus lacking c16l (vî”c16) was reduced in a murine intranasal model compared with control viruses and there were reduced virus titres from 4â€…days post-infection.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	ccomp||was-7/VBD||assess-9/VB	det||utility-11/NN||the-10/DT	dobj||assess-9/VB||utility-11/NN	prep_of||utility-11/NN||cd26-13/CD	det||biomarker-16/NN||a-15/DT	prep_as||assess-9/VB||biomarker-16/NN	nn||outcome-19/NN||treatment-18/NN	prep_for||biomarker-16/NN||outcome-19/NN	prep_in||assess-9/VB||chronichepatitisc-21/NN	aux||define-24/VB||to-23/TO	ccomp||was-7/VBD||define-24/VB	conj_and||assess-9/VB||define-24/VB	poss||association-26/NN||its-25/PRP$	dobj||define-24/VB||association-26/NN	amod||cells-30/NNS||hcv-specific-28/JJ	nn||cells-30/NNS||t-29/NN	prep_with||define-24/VB||cells-30/NNS	chronichepatitisc-21||hcv--1||no||the aim of the present study was to assess the utility of cd26 as a biomarker for treatment outcome in chronichepatitisc and to define its association with hcv-specific t cells.
prep_in||important-39/JJ||light-2/NN	det||effectiveness-6/NN||the-4/DT	amod||effectiveness-6/NN||suboptimal-5/JJ	prep_of||light-2/NN||effectiveness-6/NN	nn||methods-11/NNS||vaccines-8/NNS	dep||methods-11/NNS||barrier-10/NN	prep_of||effectiveness-6/NN||methods-11/NNS	nn||strategies-15/NNS||behavior-13/NN	nn||strategies-15/NNS||change-14/NN	prep_of||effectiveness-6/NN||strategies-15/NNS	conj_and||methods-11/NNS||strategies-15/NNS	prep_for||effectiveness-6/NN||prevention-17/NN	prep_of||prevention-17/NN||hivinfection-19/NN	det||effects-25/NNS||the-21/DT	nn||effects-25/NNS||cost-22/NN	conj_and||cost-22/NN||side-24/NN	nn||effects-25/NNS||side-24/NN	prep_of||light-2/NN||effects-25/NNS	conj_and||effectiveness-6/NN||effects-25/NNS	amod||therapy-28/NN||antiretroviral-27/JJ	prep_of||effects-25/NNS||therapy-28/NN	appos||therapy-28/NN||art-30/NN	poss||treatment-34/NN||its-33/PRP$	prep_for||therapy-28/NN||treatment-34/NN	nsubj||important-39/JJ||it-36/PRP	nsubj||urgent-41/JJ||it-36/PRP	nsubj||develop-43/VB||it-36/PRP	nsubj||implement-45/VB||it-36/PRP	cop||important-39/JJ||is-37/VBZ	preconj||important-39/JJ||both-38/DT	root||ROOT-0/null||important-39/JJ	conj_and||important-39/JJ||urgent-41/JJ	aux||develop-43/VB||to-42/TO	xcomp||important-39/JJ||develop-43/VB	xcomp||important-39/JJ||implement-45/VB	conj_and||develop-43/VB||implement-45/VB	det||agenda-49/NN||a-46/DT	amod||agenda-49/NN||rigorous-47/JJ	nn||agenda-49/NN||research-48/NN	dobj||develop-43/VB||agenda-49/NN	aux||investigate-51/VB||to-50/TO	dep||develop-43/VB||investigate-51/VB	det||risks-54/NNS||the-52/DT	amod||risks-54/NNS||potential-53/JJ	dobj||investigate-51/VB||risks-54/NNS	dobj||investigate-51/VB||benefits-56/NNS	conj_and||risks-54/NNS||benefits-56/NNS	prep_of||risks-54/NNS||timh-58/NN	aux||identify-61/VB||to-60/TO	dep||develop-43/VB||identify-61/VB	conj_and||investigate-51/VB||identify-61/VB	poss||role-63/NN||its-62/PRP$	dobj||identify-61/VB||role-63/NN	det||management-66/NN||the-65/DT	prep_in||identify-61/VB||management-66/NN	prep_of||management-66/NN||hiv/aids-68/NNS	conj_and||investigate-51/VB||associated-70/JJ	conj_and||identify-61/VB||associated-70/JJ	dobj||associated-70/JJ||illnesses-71/NNS	prep_in||associated-70/JJ||india-73/NN	hivinfection-19||hiv--1||no||in light of the suboptimal effectiveness of vaccines, barrier methods and behavior change strategies for prevention of hivinfection and the cost and side effects of antiretroviral therapy (art) for its treatment, it is both important and urgent to develop and implement a rigorous research agenda to investigate the potential risks and benefits of timh and to identify its role in the management of hiv/aids and associated illnesses in india.
amod||members-7/NNS||ninety-six/246-1/JJ	num||%-4/NN||39-3/CD	dep||ninety-six/246-1/JJ||%-4/NN	nn||members-7/NNS||family-6/NN	nsubj||hbv-seropositive-18/JJ||members-7/NNS	vmod||members-7/NNS||residing-8/VBG	amod||households-11/NNS||same-10/JJ	prep_at||residing-8/VBG||households-11/NNS	prepc_with||residing-8/VBG||hbsag-13/VBG	amod||participants-15/NNS||positive-14/JJ	dobj||hbsag-13/VBG||participants-15/NNS	cop||hbv-seropositive-18/JJ||were-16/VBD	advmod||hbv-seropositive-18/JJ||also-17/RB	root||ROOT-0/null||hbv-seropositive-18/JJ	number||74-20/CD||-LSB--19/CD	dep||hbv-seropositive-18/JJ||74-20/CD	num||%-23/NN||30.1-22/CD	appos||74-20/CD||%-23/NN	prep_for||74-20/CD||anti-hbc-26/CD	prep_for||74-20/CD||22-28/CD	conj_and||anti-hbc-26/CD||22-28/CD	num||%-31/NN||8.9-30/CD	appos||anti-hbc-26/CD||%-31/NN	det||-RSB--38/NN||both-34/DT	amod||-RSB--38/NN||hbsag-35/JJ	conj_and||hbsag-35/JJ||anti-hbc-37/JJ	amod||-RSB--38/NN||anti-hbc-37/JJ	prep_for||hbv-seropositive-18/JJ||-RSB--38/NN	nsubj||higher-43/JJR||-RSB--38/NN	cop||higher-43/JJR||was-41/VBD	advmod||higher-43/JJR||significantly-42/RB	rcmod||-RSB--38/NN||higher-43/JJR	nn||members-46/NNS||family-45/NN	prep_among||higher-43/JJR||members-46/NNS	num||%-49/NN||39-48/CD	appos||members-46/NNS||%-49/NN	prep_than||higher-43/JJR||that-52/DT	nn||participants-55/NNS||study-54/NN	prep_of||that-52/DT||participants-55/NNS	num||%-58/NN||29-57/CD	appos||participants-55/NNS||%-58/NN	cc||1.56-62/CD||or-61/CC	dep||participants-55/NNS||1.56-62/CD	dep||1.56-62/CD||p-64/NN	number||0.001-66/CD||<-65/CD	dep||p-64/NN||0.001-66/CD	hbv--1||hbsag-35||yes||ninety-six/246 (39%) family members residing at same households with hbsag positive participants were also hbv-seropositive [74 (30.1%) for anti-hbc and 22 (8.9%) for both hbsag and anti-hbc], which was significantly higher among family members (39%) than that of study participants (29%) (or 1.56; p < 0.001).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||approach-5/NN||a-3/DT	amod||approach-5/NN||criteria-based-4/JJ	dobj||used-2/VBD||approach-5/NN	aux||determine-7/VB||to-6/TO	vmod||used-2/VBD||determine-7/VB	nsubj||hiv/aids-9/VBZ||which-8/WDT	nsubj||purposive-27/JJ||which-8/WDT	dobj||determine-7/VB||hiv/aids-9/VBZ	nsubj||conduct-30/VB||hiv/aids-9/VBZ	nsubj||have-11/VBP||stakeholders-10/NNS	ccomp||hiv/aids-9/VBZ||have-11/VBP	det||impact-15/NN||the-12/DT	advmod||significant-14/JJ||most-13/RBS	amod||impact-15/NN||significant-14/JJ	dobj||have-11/VBP||impact-15/NN	amod||research-18/NN||hiv/aids-17/JJ	prep_on||impact-15/NN||research-18/NN	prep_on||impact-15/NN||programs-20/NNS	conj_and||research-18/NN||programs-20/NNS	prep_on||impact-15/NN||funding-22/NN	conj_and||research-18/NN||funding-22/NN	prep_on||impact-15/NN||policy-24/NN	conj_and||research-18/NN||policy-24/NN	amod||purposive-27/JJ||stratified-26/JJ	dobj||determine-7/VB||purposive-27/JJ	conj_and||hiv/aids-9/VBZ||purposive-27/JJ	nsubj||conduct-30/VB||purposive-27/JJ	amod||purposive-27/JJ||sampling-28/VBG	aux||conduct-30/VB||to-29/TO	xcomp||determine-7/VB||conduct-30/VB	dobj||conduct-30/VB||interviews-31/NNS	det||subset-34/NN||a-33/DT	prep_with||conduct-30/VB||subset-34/NN	det||individuals-37/NNS||these-36/DT	prep_of||subset-34/NN||individuals-37/NNS	aids--1||hiv--1||no||we used a criteria-based approach to determine which hiv/aids stakeholders have the most significant impact on hiv/aids research, programs, funding and policy and stratified purposive sampling to conduct interviews with a subset of these individuals.
det||agents-3/NNS||the-1/DT	amod||agents-3/NNS||common-2/JJ	nsubj||dermatophytes-8/NNS||agents-3/NNS	vmod||agents-3/NNS||causing-4/VBG	nn||infections-6/NNS||hair-5/NN	dobj||causing-4/VBG||infections-6/NNS	cop||dermatophytes-8/NNS||are-7/VBP	root||ROOT-0/null||dermatophytes-8/NNS	nn||species-11/NNS||malassezia-10/NN	appos||dermatophytes-8/NNS||species-11/NNS	det||piedra-15/NN||those-13/DT	amod||piedra-15/NN||causing-14/VBG	appos||dermatophytes-8/NNS||piedra-15/NN	conj_and||species-11/NNS||piedra-15/NN	piedra-15||dermatophytes-8||no||the common agents causing hair infections are dermatophytes, malassezia species and those causing piedra.
nn||granulomas-5/NNS||tuberculosis-1/NNP	appos||granulomas-5/NNS||tb-3/NN	nsubj||collections-8/NNS||granulomas-5/NNS	cop||collections-8/NNS||are-6/VBP	amod||collections-8/NNS||organized-7/VBN	root||ROOT-0/null||collections-8/NNS	amod||cells-11/NNS||immune-10/JJ	prep_of||collections-8/NNS||cells-11/NNS	vmod||cells-11/NNS||comprised-12/VBN	prep_of||comprised-12/VBN||macrophages-14/NNS	prep_of||comprised-12/VBN||lymphocytes-16/NNS	conj_and||macrophages-14/NNS||lymphocytes-16/NNS	amod||cells-19/NNS||other-18/JJ	prep_of||comprised-12/VBN||cells-19/NNS	conj_and||macrophages-14/NNS||cells-19/NNS	nsubj||form-21/VBP||cells-19/NNS	rcmod||cells-19/NNS||form-21/VBP	det||lung-24/NN||the-23/DT	prep_in||form-21/VBP||lung-24/NN	det||result-27/NN||a-26/DT	prep_as||lung-24/NN||result-27/NN	amod||response-30/NN||immune-29/JJ	prep_of||result-27/NN||response-30/NN	nn||infection-36/NN||mycobacteriumtuberculosis-32/NNP	appos||infection-36/NN||mtb-34/NN	prep_to||form-21/VBP||infection-36/NN	tuberculosis-1||mtb-34||no||tuberculosis (tb) granulomas are organized collections of immune cells comprised of macrophages, lymphocytes and other cells that form in the lung as a result of immune response to mycobacteriumtuberculosis (mtb) infection.
det||msm-2/NN||the-1/DT	nsubj||likely-32/JJ||msm-2/NN	nsubj||receive-34/VB||msm-2/NN	vmod||msm-2/NN||sampled-3/VBN	amod||pride-6/NN||gay-5/JJ	prep_at||sampled-3/VBN||pride-6/NN	nsubj||reported-8/VBD||pride-6/NN	rcmod||pride-6/NN||reported-8/VBD	ccomp||reported-8/VBD||engaging-9/VBG	prep_in||engaging-9/VBG||uai-11/NN	aux||used-14/VBN||having-13/VBG	ccomp||reported-8/VBD||used-14/VBN	conj_or||engaging-9/VBG||used-14/VBN	det||stimulant-16/NN||any-15/DT	dobj||used-14/VBN||stimulant-16/NN	dep||stimulant-16/NN||cocaine-18/NN	dep||stimulant-16/NN||crack-cocaine-20/NN	conj_or||cocaine-18/NN||crack-cocaine-20/NN	dep||stimulant-16/NN||methamphetamine-23/NN	conj_or||cocaine-18/NN||methamphetamine-23/NN	det||months-29/NNS||the-26/DT	amod||months-29/NNS||last-27/JJ	num||months-29/NNS||12â-28/CD	prep_in||used-14/VBN||months-29/NNS	cop||likely-32/JJ||were-30/VBD	advmod||likely-32/JJ||more-31/RBR	root||ROOT-0/null||likely-32/JJ	aux||receive-34/VB||to-33/TO	xcomp||likely-32/JJ||receive-34/VB	nn||vaccination-36/NN||hepatitis-35/NN	dobj||receive-34/VB||vaccination-36/NN	advmod||receive-34/VB||on-site-37/JJ	hepatitis-35||stimulant-16||no_rel||the msm sampled at gay pride who reported engaging in uai or having used any stimulant (cocaine, crack-cocaine, or methamphetamine) in the last 12â months were more likely to receive hepatitis vaccination on-site.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||ketamine-21||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
amod||regression-2/NN||logistic-1/JJ	nsubj||showed-3/VBD||regression-2/NN	root||ROOT-0/null||showed-3/VBD	mark||age-17/VBG||that-4/IN	det||predictors-13/NNS||the-5/DT	advmod||significant-7/JJ||statistically-6/RB	amod||predictors-13/NNS||significant-7/JJ	dep||<-10/JJ||p-9/RB	dep||significant-7/JJ||<-10/JJ	dep||<-10/JJ||0.05-11/CD	nsubj||age-17/VBG||predictors-13/NNS	nsubj||wanting-22/VBG||predictors-13/NNS	nsubj||cut-24/VB||predictors-13/NNS	nsubj||being-31/VBG||predictors-13/NNS	prep_of||predictors-13/NNS||womanabuse-15/NN	aux||age-17/VBG||were-16/VBD	ccomp||showed-3/VBD||age-17/VBG	mwe||than-19/IN||less-18/JJR	quantmod||49-20/CD||than-19/IN	dobj||age-17/VBG||49-20/CD	ccomp||showed-3/VBD||wanting-22/VBG	conj_and||age-17/VBG||wanting-22/VBG	aux||cut-24/VB||to-23/TO	xcomp||wanting-22/VBG||cut-24/VB	prt||cut-24/VB||down-25/RP	nn||use-28/NN||alcohol-27/NN	prep_on||cut-24/VB||use-28/NN	advmod||being-31/VBG||currently-30/RB	ccomp||showed-3/VBD||being-31/VBG	conj_and||age-17/VBG||being-31/VBG	det||relationship-34/NN||a-33/DT	prep_in||being-31/VBG||relationship-34/NN	alcohol-27||womanabuse-15||no_rel||logistic regression showed that the statistically significant ( p < 0.05) predictors of womanabuse were age less than 49, wanting to cut down on alcohol use and currently being in a relationship.
nsubj||â-2/VBP||results-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	det||patients-8/NNS||the-5/DT	advmod||obese-7/JJ||morbidly-6/RB	amod||patients-8/NNS||obese-7/JJ	nsubj||had-11/VBD||patients-8/NNS	prep_with||patients-8/NNS||diabetes-10/NN	rcmod||$-3/$||had-11/VBD	advmod||higher-13/JJR||significantly-12/RB	amod||levels-14/NNS||higher-13/JJR	dobj||had-11/VBD||levels-14/NNS	prep_of||levels-14/NNS||oxldl-16/NN	prepc_compared_with||had-11/VBD||with-18/IN	det||patients-22/NNS||the-19/DT	advmod||obese-21/JJ||morbidly-20/RB	amod||patients-22/NNS||obese-21/JJ	pobj||had-11/VBD||patients-22/NNS	amod||glucose-26/NN||normal-24/JJ	nn||glucose-26/NN||fasting-25/NN	prep_with||patients-22/NNS||glucose-26/NN	det||subjects-30/NNS||the-28/DT	nn||subjects-30/NNS||control-29/NN	prep_with||patients-22/NNS||subjects-30/NNS	conj_and||glucose-26/NN||subjects-30/NNS	advmod||lower-33/JJR||significantly-32/RB	amod||levels-34/NNS||lower-33/JJR	pobj||had-11/VBD||levels-34/NNS	conj_and||patients-22/NNS||levels-34/NNS	amod||antibodies-38/NNS||igm-36/JJ	amod||antibodies-38/NNS||anti-oxldl-37/JJ	prep_of||levels-34/NNS||antibodies-38/NNS	obese-21||antibodies-38||no_rel||results â€”the morbidly obese patients with diabetes had significantly higher levels of oxldl compared with the morbidly obese patients with normal fasting glucose and the control subjects and significantly lower levels of igm anti-oxldl antibodies.
nn||demand-8/NN||adiponectin-1/NN	dep||demand-8/NN||resistin-3/NN	dep||demand-8/NN||leptin-5/NN	amod||demand-8/NN||insulin-7/JJ	nsubj||epinephrine-17/VBP||demand-8/NN	amod||levels-15/NNS||minimal-10/JJ	conj_and||minimal-10/JJ||maximal-12/JJ	amod||levels-15/NNS||maximal-12/JJ	nn||levels-15/NNS||blood-13/NN	nn||levels-15/NNS||sugar-14/NN	appos||demand-8/NN||levels-15/NNS	root||ROOT-0/null||epinephrine-17/VBP	amod||demand-21/NN||hydrocortisone-20/JJ	nsubjpass||measured-23/VBN||demand-21/NN	auxpass||measured-23/VBN||were-22/VBD	conj_and||epinephrine-17/VBP||measured-23/VBN	num||day-25/NN||1-24/CD	dep||measured-23/VBN||day-25/NN	prep_after||measured-23/VBN||diagnosis-27/NN	amod||sepsis-30/NN||severe-29/JJ	prep_of||diagnosis-27/NN||sepsis-30/NN	prep_of||diagnosis-27/NN||septicshock-32/NN	conj_or||sepsis-30/NN||septicshock-32/NN	num||patients-35/NNS||25-34/CD	prep_in||diagnosis-27/NN||patients-35/NNS	dep||measured-23/VBN||8-37/CD	dep||8-37/CD||female-38/NN	num||male-41/NN||17-40/CD	appos||female-38/NN||male-41/NN	amod||age-44/NN||median-43/JJ	dep||female-38/NN||age-44/NN	num||years-46/NNS||65-45/CD	dep||age-44/NN||years-46/NNS	dep||female-38/NN||range-48/NN	number||87-51/CD||31-49/CD	dep||87-51/CD||to-50/TO	num||years-52/NNS||87-51/CD	dep||range-48/NN||years-52/NNS	septicshock-32||epinephrine-17||yes||adiponectin, resistin, leptin, insulin demand, minimal and maximal blood sugar levels, epinephrine, and hydrocortisone demand were measured 1 day after diagnosis of severe sepsis or septicshock in 25 patients (8 female, 17 male; median age 65 years; range 31 to 87 years).
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	dobj||evaluated-2/VBN||effects-4/NNS	prep_of||effects-4/NNS||bosentan-6/NN	det||antagonist-12/NN||a-8/DT	amod||antagonist-12/NN||dual-9/JJ	nn||antagonist-12/NN||endothelin-10/NN	nn||antagonist-12/NN||receptor-11/NN	dep||effects-4/NNS||antagonist-12/NN	prep_in||effects-4/NNS||patients-15/NNS	vmod||effects-4/NNS||receiving-16/VBG	amod||therapy-19/NN||first-line-17/JJ	nn||therapy-19/NN||dacarbazine-18/NN	dobj||receiving-16/VBG||therapy-19/NN	nn||cutaneousmelanoma-24/NN||stage-21/NN	nn||cutaneousmelanoma-24/NN||iv-22/NN	amod||cutaneousmelanoma-24/NN||metastatic-23/JJ	prep_for||therapy-19/NN||cutaneousmelanoma-24/NN	det||phase-27/NN||a-26/DT	prep_in||evaluated-2/VBN||phase-27/NN	num||phase-27/NN||2-28/CD	amod||study-31/NN||proof-of-concept-30/JJ	dobj||evaluated-2/VBN||study-31/NN	bosentan-6||cutaneousmelanoma-24||no_rel||we evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage iv metastatic cutaneousmelanoma in a phase 2, proof-of-concept study.
nsubjpass||defined-3/VBN||success-1/NN	auxpass||defined-3/VBN||was-2/VBD	root||ROOT-0/null||defined-3/VBN	amod||improvement-6/NN||clinical-5/JJ	prep_as||defined-3/VBN||improvement-6/NN	prep_with||improvement-6/NN||clearance-8/NN	prep_of||clearance-8/NN||bacteraemia-10/NN	prep_among||defined-3/VBN||patients-12/NNS	nsubj||completed-14/VBD||patients-12/NNS	nsubj||received-18/VBD||patients-12/NNS	nsubj||had-25/VBD||patients-12/NNS	rcmod||patients-12/NNS||completed-14/VBD	amod||therapy-16/NN||adequate-15/JJ	dobj||completed-14/VBD||therapy-16/NN	rcmod||patients-12/NNS||received-18/VBD	conj_and||completed-14/VBD||received-18/VBD	neg||antibiotics-23/NN||no-19/DT	advmod||effective-21/JJ||potentially-20/RB	amod||antibiotics-23/NN||effective-21/JJ	amod||antibiotics-23/NN||non-study-22/JJ	dobj||received-18/VBD||antibiotics-23/NN	rcmod||patients-12/NNS||had-25/VBD	conj_and||completed-14/VBD||had-25/VBD	amod||cultures-28/NNS||negative-26/JJ	nn||cultures-28/NNS||blood-27/NN	dobj||had-25/VBD||cultures-28/NNS	num||weeks-30/NNS||6-29/CD	npadvmod||had-25/VBD||weeks-30/NNS	prep_after||had-25/VBD||end-32/NN	prep_of||end-32/NN||therapy-34/NN	bacteraemia-10||antibiotics-23||no_rel||success was defined as clinical improvement with clearance of bacteraemia among patients who completed adequate therapy, received no potentially effective non-study antibiotics and had negative blood cultures 6 weeks after end of therapy.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	sda-43||fat--1||no_rel||using the caenorhabditis elegans â€“ pseudomonasaeruginosa hostâ€“pathogen system, we present genetic evidence that a î”6-desaturase fat-3, through its two 18-carbon productsâ€”gamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)â€”is required for basal innate immunity in vivo.
nsubj||included-2/VBD||we-1/PRP	root||ROOT-0/null||included-2/VBD	num||men-4/NNS||78-3/CD	dobj||included-2/VBD||men-4/NNS	prep_with||included-2/VBD||type2diabetes-6/NNS	nsubjpass||assigned-25/VBN||type2diabetes-6/NNS	dep||type2diabetes-6/NNS||aged-8/VBN	num||years-13/NNS||56.5-9/CD	nn||years-13/NNS||â-10/NN	amod||years-13/NNS||±-11/VBG	num||years-13/NNS||0.6-12/CD	dobj||aged-8/VBN||years-13/NNS	num||±-18/NNS||hba1c-15/CD	num||±-18/NNS||7.1-16/CD	amod||±-18/NNS||â-17/JJ	dep||years-13/NNS||±-18/NNS	number||%-20/NN||0.1-19/CD	amod||±-18/NNS||%-20/NN	auxpass||assigned-25/VBN||were-23/VBD	advmod||assigned-25/VBN||randomly-24/RB	rcmod||type2diabetes-6/NNS||assigned-25/VBN	prep_to||assigned-25/VBN||treatment-27/NN	prep_with||treatment-27/NN||pioglitazone-29/NN	num||mg/day-32/NN||30-31/CD	appos||pioglitazone-29/NN||mg/day-32/NN	prep_with||treatment-27/NN||metformin-35/NN	conj_or||pioglitazone-29/NN||metformin-35/NN	num||mg/day-38/NN||2000-37/CD	appos||pioglitazone-29/NN||mg/day-38/NN	amod||placebo-42/NN||matching-41/VBG	prep_to||assigned-25/VBN||placebo-42/NN	conj_and||treatment-27/NN||placebo-42/NN	prep_in||included-2/VBD||addition-45/NN	aux||glimepiride-47/VB||to-46/TO	vmod||addition-45/NN||glimepiride-47/VB	type2diabetes-6||pioglitazone-29||yes||we included 78 men with type2diabetes (aged 56.5 â± 0.6 years; hba1c 7.1 â± 0.1%) who were randomly assigned to treatment with pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo, in addition to glimepiride.
nsubj||appears-2/VBZ||dr-1/NN	nsubj||problem-8/NN||dr-1/NN	root||ROOT-0/null||appears-2/VBZ	aux||problem-8/NN||to-3/TO	cop||problem-8/NN||be-4/VB	det||problem-8/NN||a-5/DT	amod||problem-8/NN||public-6/JJ	nn||problem-8/NN||health-7/NN	xcomp||appears-2/VBZ||problem-8/NN	det||district-13/NN||the-10/DT	nn||district-13/NN||al-11/NNP	nn||district-13/NN||hasa-12/NN	prep_in||problem-8/NN||district-13/NN	amod||arabia-16/NN||saudi-15/JJ	prep_of||district-13/NN||arabia-16/NN	det||approach-21/NN||a-19/DT	amod||approach-21/NN||planned-20/VBN	nsubjpass||required-23/VBN||approach-21/NN	nsubj||avoid-25/VB||approach-21/NN	auxpass||required-23/VBN||is-22/VBZ	conj_and||appears-2/VBZ||required-23/VBN	aux||avoid-25/VB||to-24/TO	xcomp||required-23/VBN||avoid-25/VB	amod||impairment-28/NN||severe-26/JJ	amod||impairment-28/NN||visual-27/JJ	dobj||avoid-25/VB||impairment-28/NN	prep_in||avoid-25/VB||patients-30/NNS	prep_with||patients-30/NNS||diabetesmellitus-32/NNS	dr-1||diabetesmellitus-32||no||dr appears to be a public health problem in the al hasa district of saudi arabia, and a planned approach is required to avoid severe visual impairment in patients with diabetesmellitus.
nn||rates-2/NNS||success-1/NN	nsubj||%-9/NN||rates-2/NNS	prep_for||rates-2/NNS||daptomycin-4/NN	prep_versus||daptomycin-4/NN||vancomycin/gentamicin-6/NN	cop||%-9/NN||were-7/VBD	num||%-9/NN||45-8/CD	root||ROOT-0/null||%-9/NN	num||%-12/NN||27-11/CD	prep_versus||%-9/NN||%-12/NN	amod||bacteraemia-15/NN||complicated-14/JJ	prep_in||%-12/NN||bacteraemia-15/NN	num||%-18/NN||60-17/CD	prep_versus||%-9/NN||%-18/NN	conj_and||%-12/NN||%-18/NN	num||%-21/NN||45-20/CD	prep_versus||%-18/NN||%-21/NN	amod||bacteraemia-24/NN||uncomplicated-23/JJ	prep_in||%-21/NN||bacteraemia-24/NN	num||%-27/NN||50-26/CD	prep_versus||%-9/NN||%-27/NN	conj_and||%-12/NN||%-27/NN	num||%-30/NN||50-29/CD	prep_versus||%-27/NN||%-30/NN	amod||endocarditis-34/NNS||right-sided-32/JJ	nn||endocarditis-34/NNS||mrsa-33/NN	prep_in||%-30/NN||endocarditis-34/NNS	vancomycin--1||endocarditis-34||no_rel||success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided mrsa endocarditis.
nn||therapy-2/NN||statin-1/NN	nsubj||inhibits-3/VBZ||therapy-2/NN	root||ROOT-0/null||inhibits-3/VBZ	amod||outflow-6/NN||central-4/JJ	amod||outflow-6/NN||sympathetic-5/JJ	dobj||inhibits-3/VBZ||outflow-6/NN	nn||patients-9/NNS||chf-8/NN	prep_in||outflow-6/NN||patients-9/NNS	mark||measured-12/VBN||as-11/IN	advcl||inhibits-3/VBZ||measured-12/VBN	prep_by||measured-12/VBN||msna-14/NN	chf-8||statin-1||no_rel||statin therapy inhibits central sympathetic outflow in chf patients, as measured by msna.
prep_in||improves-10/VBZ||contrast-2/NN	nsubj||improves-10/VBZ||treatment-4/NN	det||int-747-9/NN||the-6/DT	nn||int-747-9/NN||fxr-7/NN	nn||int-747-9/NN||agonist-8/NN	prep_with||treatment-4/NN||int-747-9/NN	root||ROOT-0/null||improves-10/VBZ	amod||injury-12/NN||renal-11/JJ	dobj||improves-10/VBZ||injury-12/NN	prepc_by||improves-10/VBZ||decreasing-14/VBG	dobj||decreasing-14/VBG||proteinuria-15/NN	dobj||decreasing-14/VBG||glomerulosclerosis-17/NNS	conj_and||proteinuria-15/NN||glomerulosclerosis-17/NNS	amod||fibrosis-21/NN||tubulointerstitial-20/JJ	dobj||decreasing-14/VBG||fibrosis-21/NN	conj_and||proteinuria-15/NN||fibrosis-21/NN	prepc_by||improves-10/VBZ||modulating-24/VBG	conj_and||decreasing-14/VBG||modulating-24/VBG	amod||metabolism-27/NN||renal-25/JJ	nn||metabolism-27/NN||lipid-26/NN	dobj||modulating-24/VBG||metabolism-27/NN	amod||infiltration-30/NN||macrophage-29/JJ	dobj||modulating-24/VBG||infiltration-30/NN	conj_and||metabolism-27/NN||infiltration-30/NN	amod||expression-34/NN||renal-33/JJ	dobj||modulating-24/VBG||expression-34/NN	conj_and||metabolism-27/NN||expression-34/NN	prep_of||expression-34/NN||srebps-36/NNS	amod||factors-40/NNS||profibrotic-38/JJ	nn||factors-40/NNS||growth-39/NN	prep_of||expression-34/NN||factors-40/NNS	conj_and||srebps-36/NNS||factors-40/NNS	amod||enzymes-45/NNS||oxidative-43/JJ	nn||enzymes-45/NNS||stress-44/NN	prep_of||expression-34/NN||enzymes-45/NNS	conj_and||srebps-36/NNS||enzymes-45/NNS	det||strain-50/NN||the-47/DT	amod||strain-50/NN||diabetic-48/JJ	amod||strain-50/NN||dba/2j-49/JJ	prep_in||enzymes-45/NNS||strain-50/NN	fibrosis-21||lipid-26||no_rel||in contrast, treatment with the fxr agonist int-747 improves renal injury by decreasing proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis, and modulating renal lipid metabolism, macrophage infiltration, and renal expression of srebps, profibrotic growth factors, and oxidative stress enzymes in the diabetic dba/2j strain.
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	det||discovery-5/NN||the-4/DT	dobj||report-3/VBP||discovery-5/NN	num||rnas-10/NNS||34-7/CD	amod||rnas-10/NNS||novel-8/JJ	amod||rnas-10/NNS||small-9/JJ	prep_of||discovery-5/NN||rnas-10/NNS	num||srnas-12/NNS||-lrb--11/CD	npadvmod||-rrb--13/JJ||srnas-12/NNS	amod||rnas-10/NNS||-rrb--13/JJ	det||bcg-19/NN||the-15/DT	amod||bcg-19/NN||tb-complex-16/JJ	nn||bcg-19/NN||m.-17/NN	nn||bcg-19/NN||bovis-18/NNS	prep_in||rnas-10/NNS||bcg-19/NN	vmod||rnas-10/NNS||using-21/VBG	det||combination-23/NN||a-22/DT	dobj||using-21/VBG||combination-23/NN	amod||approaches-28/NNS||experimental-25/JJ	conj_and||experimental-25/JJ||computational-27/JJ	amod||approaches-28/NNS||computational-27/JJ	prep_of||rnas-10/NNS||approaches-28/NNS	tb--1||bcg-19||yes||here we report the discovery of 34 novel small rnas -lrb- srnas -rrb- in the tb-complex m. bovis bcg , using a combination of experimental and computational approaches .
amod||abnormalities-2/NNS||g1/s-1/JJ	nsubj||crucial-4/JJ||abnormalities-2/NNS	cop||crucial-4/JJ||are-3/VBP	root||ROOT-0/null||crucial-4/JJ	det||progression-7/NN||the-6/DT	prep_for||crucial-4/JJ||progression-7/NN	prep_of||progression-7/NN||malignantmelanoma-9/NN	amod||d1-14/NNS||enhanced-12/JJ	nn||d1-14/NNS||cyclin-13/NN	nsubjpass||observed-24/VBN||d1-14/NNS	amod||expression-17/NN||d3-16/JJ	conj_and||d1-14/NNS||expression-17/NN	nsubjpass||observed-24/VBN||expression-17/NN	amod||expression-17/NN||leading-18/VBG	amod||proliferation-22/NN||increased-20/VBN	nn||proliferation-22/NN||melanocyte-21/NN	prep_to||d1-14/NNS||proliferation-22/NN	auxpass||observed-24/VBN||is-23/VBZ	conj_and||crucial-4/JJ||observed-24/VBN	det||melanoma-27/NN||both-26/DT	prep_in||observed-24/VBN||melanoma-27/NN	amod||nevi-30/NNS||dysplastic-29/JJ	prep_in||observed-24/VBN||nevi-30/NNS	conj_and||melanoma-27/NN||nevi-30/NNS	d3-16||nevi-30||no_rel||g1/s abnormalities are crucial for the progression of malignantmelanoma, and enhanced cyclin d1 and d3 expression leading to increased melanocyte proliferation is observed in both melanoma and dysplastic nevi.
amod||kinase-3/NN||focal-1/JJ	nn||kinase-3/NN||adhesion-2/NN	nsubj||kinase-11/NN||kinase-3/NN	appos||kinase-3/NN||fak-5/NN	cop||kinase-11/NN||is-7/VBZ	det||kinase-11/NN||a-8/DT	amod||kinase-11/NN||non-receptor-9/JJ	nn||kinase-11/NN||tyrosine-10/NN	root||ROOT-0/null||kinase-11/NN	vmod||kinase-11/NN||required-12/VBN	nn||migration-15/NN||cell-14/NN	prep_for||required-12/VBN||migration-15/NN	prep_for||required-12/VBN||proliferation-17/NN	conj_and||migration-15/NN||proliferation-17/NN	prep_for||required-12/VBN||survival-19/NN	conj_and||migration-15/NN||survival-19/NN	adhesion-2||tyrosine-10||no_rel||focal adhesion kinase (fak) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival.
vmod||show-9/VBP||using-1/VBG	det||approach-6/NN||a-2/DT	amod||approach-6/NN||lentivirus-based-3/JJ	amod||approach-6/NN||tetracycline-inducible-4/JJ	nn||approach-6/NN||shrna-5/NN	dobj||using-1/VBG||approach-6/NN	nsubj||show-9/VBP||we-8/PRP	root||ROOT-0/null||show-9/VBP	mark||affects-21/VBZ||that-10/IN	nsubj||affects-21/VBZ||downregulation-11/NN	amod||expression-14/NN||ran-13/JJ	prep_of||downregulation-11/NN||expression-14/NN	amod||lines-20/NNS||aggressive-16/JJ	amod||lines-20/NNS||ovarian-17/JJ	nn||lines-20/NNS||cancer-18/NN	nn||lines-20/NNS||cell-19/NN	prep_in||expression-14/NN||lines-20/NNS	ccomp||show-9/VBP||affects-21/VBZ	amod||proliferation-23/NN||cellular-22/JJ	dobj||affects-21/VBZ||proliferation-23/NN	prepc_by||affects-21/VBZ||inducing-25/VBG	det||apoptosis-29/NNS||a-26/DT	amod||apoptosis-29/NNS||caspase-3-27/JJ	amod||apoptosis-29/NNS||associated-28/JJ	dobj||inducing-25/VBG||apoptosis-29/NNS	cancer-18||tetracycline--1||no_rel||using a lentivirus-based tetracycline-inducible shrna approach, we show that downregulation of ran expression in aggressive ovarian cancer cell lines affects cellular proliferation by inducing a caspase-3 associated apoptosis.
amod||ifn-gamma-responses-2/NNS||increased-1/VBN	nsubj||represents-15/VBZ||ifn-gamma-responses-2/NNS	amod||proliferation-7/NN||antigen-specific-4/JJ	nn||proliferation-7/NN||t-5/NN	nn||proliferation-7/NN||cell-6/NN	conj_and||ifn-gamma-responses-2/NNS||proliferation-7/NN	nsubj||represents-15/VBZ||proliferation-7/NN	det||subset-14/NN||the-9/DT	amod||subset-14/NN||cd8alpha/alpha-10/JJ	amod||subset-14/NN||+-11/JJ	nn||subset-14/NN||t-12/NN	nn||subset-14/NN||cell-13/NN	prep_in||proliferation-7/NN||subset-14/NN	root||ROOT-0/null||represents-15/VBZ	det||marker-18/NN||a-16/DT	amod||marker-18/NN||valuable-17/JJ	dobj||represents-15/VBZ||marker-18/NN	prep_for||marker-18/NN||vaccine-take-20/NN	amod||trials-25/NNS||bcg-based-22/JJ	nn||trials-25/NNS||tb-23/NN	nn||trials-25/NNS||vaccine-24/NN	prep_in||vaccine-take-20/NN||trials-25/NNS	tb-23||bcg--1||yes||increased ifn-gamma-responses and antigen-specific t cell proliferation in the cd8alpha/alpha+ t cell subset represents a valuable marker for vaccine-take in bcg-based tb vaccine trials
nn||telaprevir-2/NN||background-1/NN	nsubj||advancement-12/NN||telaprevir-2/NN	prep_in||telaprevir-2/NN||combination-4/NN	prep_with||combination-4/NN||peginterferon-6/NN	prep_with||combination-4/NN||ribavirin-8/NN	conj_and||peginterferon-6/NN||ribavirin-8/NN	cop||advancement-12/NN||is-9/VBZ	det||advancement-12/NN||a-10/DT	amod||advancement-12/NN||promising-11/JJ	root||ROOT-0/null||advancement-12/NN	amod||treatment-15/NN||chronichepatitisc-14/JJ	prep_in||advancement-12/NN||treatment-15/NN	chronichepatitisc-14||peginterferon-6||yes||background telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronichepatitisc treatment.
det||prognosis-2/NN||the-1/DT	nsubj||iii-9/VBP||prognosis-2/NN	prep_for||prognosis-2/NN||patients-4/NNS	amod||stage-8/NN||advanced-6/JJ	nn||stage-8/NN||figo-7/NN	prep_with||patients-4/NNS||stage-8/NN	root||ROOT-0/null||iii-9/VBP	amod||cancer-12/NN||epithelial-10/JJ	nn||cancer-12/NN||ovarian-11/NN	nsubj||remains-13/VBZ||cancer-12/NN	ccomp||iii-9/VBP||remains-13/VBZ	acomp||remains-13/VBZ||poor-14/JJ	det||treatment-19/NN||the-16/DT	amod||treatment-19/NN||aggressive-17/JJ	amod||treatment-19/NN||standard-18/JJ	prep_despite||poor-14/JJ||treatment-19/NN	xcomp||remains-13/VBZ||consisting-21/VBG	amod||surgery-25/NN||maximal-23/JJ	nn||surgery-25/NN||cytoreductive-24/NN	prep_of||consisting-21/VBG||surgery-25/NN	amod||chemotherapy-28/NN||platinum-based-27/JJ	prep_of||consisting-21/VBG||chemotherapy-28/NN	conj_and||surgery-25/NN||chemotherapy-28/NN	cancer-12||platinum--1||no_rel||the prognosis for patients with advanced figo stage iii epithelial ovarian cancer remains poor despite the aggressive standard treatment, consisting of maximal cytoreductive surgery and platinum-based chemotherapy.
nsubj||showed-2/VBD||studies-1/NNS	root||ROOT-0/null||showed-2/VBD	mark||induce-7/VB||that-3/IN	amod||therapy-5/NN||prolonged-4/VBN	nsubj||induce-7/VB||therapy-5/NN	aux||induce-7/VB||could-6/MD	ccomp||showed-2/VBD||induce-7/VB	amod||variants-14/NNS||lamivudine-8/JJ	nn||variants-14/NNS||resistance-9/NN	nn||variants-14/NNS||hepatitisbvirus-10/NN	appos||variants-14/NNS||hbv-12/NN	dobj||induce-7/VB||variants-14/NNS	amod||motif-17/NN||ymdd-16/JJ	appos||variants-14/NNS||motif-17/NN	hbv-12||hepatitisbvirus-10||no||studies showed that prolonged therapy could induce lamivudine resistance hepatitisbvirus (hbv) variants (ymdd motif).
det||search-5/NN||a-2/DT	amod||search-5/NN||computerized-3/JJ	nn||search-5/NN||medline-4/NN	prep_in||selected-10/VBN||search-5/NN	amod||studies-8/NNS||relevant-7/JJ	nsubjpass||selected-10/VBN||studies-8/NNS	auxpass||selected-10/VBN||were-9/VBD	root||ROOT-0/null||selected-10/VBN	num||authors-13/NNS||two-12/CD	agent||selected-10/VBN||authors-13/NNS	vmod||authors-13/NNS||using-14/VBG	det||â-17/NN||the-15/DT	amod||â-17/NN||keywords-16/JJ	dobj||using-14/VBG||â-17/NN	dep||â-17/NN||$-18/$	num||$-18/$||œdiabetesmellitusâ-19/CD	num||$-18/$||$-20/CD	advmod||â-17/NN||â-22/RB	pobj||â-22/RB||$-23/$	number||$-25/CD||œcataractâ-24/CD	num||$-23/$||$-25/CD	dobj||using-14/VBG||$-28/$	conj_â||â-17/NN||$-28/$	number||$-30/CD||œdiabeticretinopathyâ-29/CD	num||$-28/$||$-30/CD	quantmod||$-33/$||â-32/RB	conj_â||â-17/NN||$-33/$	conj_and||$-28/$||$-33/$	number||$-35/CD||œdiabeticmaculopathyâ-34/CD	num||$-33/$||$-35/CD	diabeticmaculopathy--1||diabetesmellitus--1||no||in a computerized medline search,relevant studies were selected by two authors using the keywords â€œdiabetesmellitusâ€?, â€œcataractâ€?, â€œdiabeticretinopathyâ€? and â€œdiabeticmaculopathyâ€?.
amod||regimens-3/NNS||heterologous-1/JJ	amod||regimens-3/NNS||prime-boost-2/JJ	nsubj||represent-11/VBP||regimens-3/NNS	vmod||regimens-3/NNS||utilizing-4/VBG	dobj||utilizing-4/VBG||bcg-5/NN	det||vaccine-9/NN||a-7/DT	amod||vaccine-9/NN||prime-8/JJ	prep_as||utilizing-4/VBG||vaccine-9/NN	advmod||represent-11/VBP||probably-10/RB	root||ROOT-0/null||represent-11/VBP	det||hope-14/NN||the-12/DT	amod||hope-14/NN||best-13/JJS	dobj||represent-11/VBP||hope-14/NN	det||development-17/NN||the-16/DT	prep_for||hope-14/NN||development-17/NN	amod||tuberculosis-20/JJ||novel-19/JJ	amod||vaccines-24/NNS||tuberculosis-20/JJ	appos||vaccines-24/NNS||tb-22/NN	prep_of||development-17/NN||vaccines-24/NNS	tb-22||bcg-5||yes||heterologous prime-boost regimens utilizing bcg as a prime vaccine probably represent the best hope for the development of novel tuberculosis (tb) vaccines.
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||fe-43||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â€“8 wks.
det||w-4/NN||both-1/DT	number||%-3/NN||10-2/CD	amod||w-4/NN||%-3/NN	nsubj||able-17/JJ||w-4/NN	nsubj||eradicate-19/VB||w-4/NN	nsubj||prevent-23/VB||w-4/NN	nsubj||tolerated-30/JJ||w-4/NN	punct||solutions-9/NNS||/-5/:	dep||solutions-9/NNS||v-6/RB	amod||solutions-9/NNS||fipronil-based-7/JJ	amod||solutions-9/NNS||spot-on-8/JJ	dep||w-4/NN||solutions-9/NNS	amod||vehicles-13/NNS||different-12/JJ	prep_despite||able-17/JJ||vehicles-13/NNS	cop||able-17/JJ||were-15/VBD	advmod||able-17/JJ||equally-16/RB	root||ROOT-0/null||able-17/JJ	aux||eradicate-19/VB||to-18/TO	xcomp||able-17/JJ||eradicate-19/VB	dobj||eradicate-19/VB||tickinfestation-20/NN	aux||prevent-23/VB||to-22/TO	xcomp||able-17/JJ||prevent-23/VB	amod||infestations-25/NNS||new-24/JJ	dobj||prevent-23/VB||infestations-25/NNS	cop||tolerated-30/JJ||were-27/VBD	advmod||tolerated-30/JJ||equally-28/RB	advmod||tolerated-30/JJ||well-29/RB	conj_and||able-17/JJ||tolerated-30/JJ	vehicles-13||tickinfestation-20||no_rel||both 10% w / v fipronil-based spot-on solutions, despite different vehicles, were equally able to eradicate tickinfestation, to prevent new infestations and were equally well tolerated.
nsubjpass||determined-17/VBN||cross-reactivity-1/NN	det||abs-5/NN||these-3/DT	amod||abs-5/NN||anti-sars-4/JJ	prep_of||cross-reactivity-1/NN||abs-5/NN	amod||coronavirus-8/NNS||human-7/JJ	prep_against||abs-5/NN||coronavirus-8/NNS	dep||cross-reactivity-1/NN||hcov-10/VBN	amod||oc43-15/NNS||229e-12/JJ	conj_and||229e-12/JJ||hcov-14/JJ	amod||oc43-15/NNS||hcov-14/JJ	dep||cross-reactivity-1/NN||oc43-15/NNS	auxpass||determined-17/VBN||were-16/VBD	root||ROOT-0/null||determined-17/VBN	agent||determined-17/VBN||western-19/JJ	amod||western-19/JJ||blotting-20/VBG	sars--1||coronavirus-8||no||cross-reactivity of these anti-sars abs against human coronavirus (hcov) 229e and hcov oc43 were determined by western blotting.
nsubjpass||accepted-4/VBN||it-1/PRP	auxpass||accepted-4/VBN||is-2/VBZ	advmod||accepted-4/VBN||widely-3/RB	root||ROOT-0/null||accepted-4/VBN	mark||accomplished-16/VBN||that-5/IN	nn||replacement-8/NN||thyroid-6/NN	nn||replacement-8/NN||hormone-7/NN	nsubjpass||accomplished-16/VBN||replacement-8/NN	prep_for||replacement-8/NN||patients-10/NNS	prep_with||patients-10/NNS||hypothyroidism-12/NN	aux||accomplished-16/VBN||can-13/MD	auxpass||accomplished-16/VBN||be-14/VB	advmod||accomplished-16/VBN||fully-15/RB	ccomp||accepted-4/VBN||accomplished-16/VBN	amod||monotherapy-19/NN||levothyroxine-18/JJ	prep_with||accomplished-16/VBN||monotherapy-19/NN	mark||assessed-22/VBN||as-21/IN	advcl||accomplished-16/VBN||assessed-22/VBN	nn||tests-27/NNS||serum-24/NN	nn||tests-27/NNS||thyroid-25/NN	nn||tests-27/NNS||function-26/NN	prep_by||assessed-22/VBN||tests-27/NNS	hypothyroidism-12||levothyroxine-18||yes||it is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests.
advmod||thereafter-2/RB||soon-1/RB	advmod||reported-17/VBN||thereafter-2/RB	prep_in||reported-17/VBN||1983-5/CD	det||retrovirus-9/NNS||another-7/DT	amod||retrovirus-9/NNS||human-8/JJ	nsubjpass||reported-17/VBN||retrovirus-9/NNS	nsubjpass||implicated-19/VBN||retrovirus-9/NNS	appos||retrovirus-9/NNS||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	auxpass||reported-17/VBN||was-16/VBD	root||ROOT-0/null||reported-17/VBN	conj_and||reported-17/VBN||implicated-19/VBN	det||agent-23/NN||the-21/DT	amod||agent-23/NN||etiologic-22/JJ	prep_as||reported-17/VBN||agent-23/NN	prep_of||agent-23/NN||aids-25/NNS	aids-25||hiv-13||no||soon thereafter, in 1983, another human retrovirus, humanimmunodeficiencyvirus (hiv), was reported and implicated as the etiologic agent of aids.
det||man-4/NN||a-1/DT	amod||man-4/NN||40-year-old-2/JJ	amod||man-4/NN||caucasian-3/JJ	nsubj||presented-13/VBD||man-4/NN	nsubj||left-26/VBD||man-4/NN	amod||rheumatoidarthritis-7/NNS||severe-6/JJ	prep_with||man-4/NN||rheumatoidarthritis-7/NNS	auxpass||treated-9/VBN||being-8/VBG	vmod||rheumatoidarthritis-7/NNS||treated-9/VBN	amod||adalimumab-12/NN||high-dose-11/JJ	prep_with||treated-9/VBN||adalimumab-12/NN	root||ROOT-0/null||presented-13/VBD	poss||facility-16/NN||our-15/PRP$	prep_to||presented-13/VBD||facility-16/NN	det||leg-20/NN||a-18/DT	amod||leg-20/NN||swollen-19/JJ	prep_with||presented-13/VBD||leg-20/NN	amod||groin-24/NN||palpable-22/JJ	amod||groin-24/NN||left-23/JJ	prep_with||presented-13/VBD||groin-24/NN	conj_and||leg-20/NN||groin-24/NN	conj_and||presented-13/VBD||left-26/VBD	amod||lumps-28/NNS||axillary-27/JJ	dobj||left-26/VBD||lumps-28/NNS	det||lesion-33/NN||a-30/DT	amod||lesion-33/NN||left-31/JJ	nn||lesion-33/NN||nipple-32/NN	dobj||left-26/VBD||lesion-33/NN	conj_and||lumps-28/NNS||lesion-33/NN	rheumatoidarthritis-7||adalimumab-12||yes||a 40-year-old caucasian man with severe rheumatoidarthritis being treated with high-dose adalimumab presented to our facility with a swollen leg and palpable left groin and left axillary lumps and a left nipple lesion.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||model-5/NN||a-3/DT	amod||model-5/NN||markov-4/JJ	dobj||used-2/VBD||model-5/NN	vmod||used-2/VBD||simulating-7/VBG	det||progression-9/NN||the-8/DT	dobj||simulating-7/VBG||progression-9/NN	nn||infection-12/NN||hpv-11/NN	prep_from||simulating-7/VBG||infection-12/NN	amod||cancer-15/NN||cervical-14/JJ	prep_to||simulating-7/VBG||cancer-15/NN	prep_to||simulating-7/VBG||genitalwarts-17/NNS	conj_or||cancer-15/NN||genitalwarts-17/NNS	genitalwarts-17||hpv-11||no||we used a markov model, simulating the progression from hpv infection to cervical cancer or genitalwarts.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
det||end-3/NN||the-2/DT	prep_at||superior-10/JJ||end-3/NN	amod||treatment-6/NN||48-week-5/JJ	prep_of||end-3/NN||treatment-6/NN	nsubj||superior-10/JJ||tenofovir-8/NN	nsubj||adefovir-12/VB||tenofovir-8/NN	cop||superior-10/JJ||was-9/VBD	root||ROOT-0/null||superior-10/JJ	aux||adefovir-12/VB||to-11/TO	xcomp||superior-10/JJ||adefovir-12/VB	det||suppression-16/NN||the-14/DT	amod||suppression-16/NN||hbv-dna-15/JJ	prep_at||adefovir-12/VB||suppression-16/NN	nn||rr-20/NN||patients-18/NNS	amod||rr-20/NN||-LSB--19/JJ	prep_in||suppression-16/NN||rr-20/NN	dep||2.59-22/NNS||=-21/SYM	dep||rr-20/NN||2.59-22/NNS	number||%-25/NN||95-24/CD	amod||ci-26/NN||%-25/NN	dep||suppression-16/NN||ci-26/NN	number||.67-29/CD||1.01-6-28/CD	dep||ci-26/NN||.67-29/CD	vmod||ci-26/NN||p-32/VBN	dep||-RSB--35/NNS||=-33/SYM	num||-RSB--35/NNS||0.05-34/CD	ccomp||p-32/VBN||-RSB--35/NNS	hbv--1||adefovir-12||yes||at the end of 48-week treatment, tenofovir was superior to adefovir at the hbv-dna suppression in patients[rr = 2.59; 95%ci(1.01-6.67), p = 0.05].
advmod||are-4/VBP||however-1/RB	expl||are-4/VBP||there-3/EX	root||ROOT-0/null||are-4/VBP	neg||guidelines-7/NNS||no-5/DT	amod||guidelines-7/NNS||official-6/JJ	nsubj||are-4/VBP||guidelines-7/NNS	advmod||treat-12/VB||how-10/WRB	aux||treat-12/VB||to-11/TO	prepc_as_to||guidelines-7/NNS||treat-12/VB	dobj||treat-12/VB||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv/acquiredimmunodeficiencysyndrome-16/NN	appos||hiv/acquiredimmunodeficiencysyndrome-16/NN||aids-18/NNS	appos||hiv/acquiredimmunodeficiencysyndrome-16/NN||plwha-21/NNP	advmod||screen-26/VB||how-24/WRB	aux||screen-26/VB||to-25/TO	prepc_as_to||guidelines-7/NNS||screen-26/VB	conj_or||treat-12/VB||screen-26/VB	advmod||infectious-29/JJ||potentially-28/RB	amod||people-30/NNS||infectious-29/JJ	prep_for||screen-26/VB||people-30/NNS	aids-18||hiv--1||no||however, there are no official guidelines as to how to treat people living with hiv/acquiredimmunodeficiencysyndrome (aids) (plwha) or how to screen for potentially infectious people.
nsubj||unknown-24/JJ||effectiveness-1/NN	prep_of||effectiveness-1/NN||cotrimoxazole-3/NN	appos||effectiveness-1/NN||ctx-5/NN	prepc_compared_with||effectiveness-1/NN||with-8/IN	amod||intermittent-preventive-therapy-13/NN||sulfadoxine-pyrimethamine-9/JJ	appos||intermittent-preventive-therapy-13/NN||sp-11/NN	pobj||effectiveness-1/NN||intermittent-preventive-therapy-13/NN	appos||intermittent-preventive-therapy-13/NN||iptp-15/NN	prep_for||intermittent-preventive-therapy-13/NN||malaria-18/NN	amod||women-22/NNS||hiv-infected-20/JJ	amod||women-22/NNS||pregnant-21/JJ	prep_in||malaria-18/NN||women-22/NNS	cop||unknown-24/JJ||is-23/VBZ	root||ROOT-0/null||unknown-24/JJ	malaria-18||pyrimethamine--1||yes||effectiveness of cotrimoxazole (ctx) compared with sulfadoxine-pyrimethamine (sp) intermittent-preventive-therapy (iptp) for malaria in hiv-infected pregnant women is unknown.
neg||effect-3/NN||no-1/DT	amod||effect-3/NN||significant-2/JJ	nsubj||derived-9/VBD||effect-3/NN	nn||length-6/NN||gene-5/NN	prep_in||effect-3/NN||length-6/NN	prep_in||effect-3/NN||vaccine-8/NN	conj_or||length-6/NN||vaccine-8/NN	root||ROOT-0/null||derived-9/VBD	amod||dvpvs-12/NNS||polioviruses-10/JJ	nsubjpass||observed-22/VBN||dvpvs-12/NNS	amod||viruses-16/NNS||wild-15/JJ	conj_and||dvpvs-12/NNS||viruses-16/NNS	nsubjpass||observed-22/VBN||viruses-16/NNS	amod||virus-20/NN||live-18/JJ	amod||virus-20/NN||attenuated-19/JJ	conj_and||dvpvs-12/NNS||virus-20/NN	nsubjpass||observed-22/VBN||virus-20/NN	auxpass||observed-22/VBN||was-21/VBD	ccomp||derived-9/VBD||observed-22/VBN	det||variations-25/NNS||the-24/DT	prep_on||observed-22/VBN||variations-25/NNS	amod||codon-28/JJ||synonymous-27/JJ	amod||usage-29/NN||codon-28/JJ	prep_of||variations-25/NNS||usage-29/NN	det||genes-33/NNS||the-31/DT	nn||genes-33/NNS||virus-32/NN	prep_in||usage-29/NN||genes-33/NNS	virus-32||viruses-16||no||no significant effect in gene length or vaccine derived polioviruses (dvpvs), wild viruses and live attenuated virus was observed on the variations of synonymous codon usage in the virus genes.
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-28/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||lowbackpain-16/NN||chronic-15/JJ	prep_in||activity-13/NN||lowbackpain-16/NN	appos||lowbackpain-16/NN||cbp-18/NN	nn||osteoarthritis-23/NNS||knee-22/NN	prep_in||treatment-6/NN||osteoarthritis-23/NNS	appos||effects-2/NNS||oa-25/NN	auxpass||investigated-28/VBN||were-27/VBD	root||ROOT-0/null||investigated-28/VBN	xcomp||investigated-28/VBN||using-29/VBG	amod||fmri-31/NNS||serial-30/JJ	dobj||using-29/VBG||fmri-31/NNS	dep||fmri-31/NNS||contrasting-33/VBG	dobj||contrasting-33/VBG||fmri-34/NNS	advmod||weeks-40/NNS||before-36/RB	conj_and||before-36/RB||after-38/IN	advmod||weeks-40/NNS||after-38/IN	pobj||after-38/IN||two-39/CD	prep_between||fmri-34/NNS||weeks-40/NNS	prep_of||fmri-34/NNS||treatment-42/NN	osteoarthritis-23||analgesic-5||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic lowbackpain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
amod||size-3/NN||adipose-1/JJ	nn||size-3/NN||cell-2/NN	nsubjpass||measured-5/VBN||size-3/NN	auxpass||measured-5/VBN||was-4/VBD	ccomp||ai-26/VBP||measured-5/VBN	prep_in||measured-5/VBN||biopsies-7/NNS	det||tissue-12/NN||the-9/DT	amod||tissue-12/NN||abdominal-10/JJ	nn||tissue-12/NN||adipose-11/NN	prep_from||measured-5/VBN||tissue-12/NN	nn||-rrb--21/NNS||insulin-16/NN	nn||-rrb--21/NNS||sensitivity-17/NN	amod||-rrb--21/NNS||-lrb--18/JJ	nn||-rrb--21/NNS||homa-19/NN	nn||-rrb--21/NNS||index-20/NN	prep_from||measured-5/VBN||-rrb--21/NNS	conj_and||tissue-12/NN||-rrb--21/NNS	nsubj||ai-26/VBP||hdl-cholesterol-23/NN	nsubj||apo-28/VBP||hdl-cholesterol-23/NN	conj_and||hdl-cholesterol-23/NN||apo-25/NN	nsubj||ai-26/VBP||apo-25/NN	root||ROOT-0/null||ai-26/VBP	conj_and||ai-26/VBP||apo-28/VBP	number||166-30/CD||b.-29/CD	num||individuals-33/NNS||166-30/CD	amod||individuals-33/NNS||additional-31/JJ	amod||individuals-33/NNS||non-obese-32/JJ	nsubj||underwent-40/VBD||individuals-33/NNS	det||predisposition-37/NN||a-35/DT	amod||predisposition-37/NN||genetic-36/JJ	prep_with||individuals-33/NNS||predisposition-37/NN	prep_for||predisposition-37/NN||type2diabetes-39/CD	ccomp||apo-28/VBP||underwent-40/VBD	det||clamp-44/NN||a-41/DT	amod||clamp-44/NN||euglycemic-42/JJ	amod||clamp-44/NN||hyperinsulinemic-43/JJ	dobj||underwent-40/VBD||clamp-44/NN	aux||measure-46/VB||to-45/TO	vmod||underwent-40/VBD||measure-46/VB	nn||sensitivity-48/NN||insulin-47/NN	dobj||measure-46/VB||sensitivity-48/NN	type2diabetes-39||insulin-47||yes||adipose cell size was measured in biopsies from the abdominal adipose tissue as well as insulin sensitivity -lrb- homa index -rrb- , hdl-cholesterol and apo ai and apo b. 166 additional non-obese individuals with a genetic predisposition for type2diabetes underwent a euglycemic hyperinsulinemic clamp to measure insulin sensitivity .
prep_in||remained-8/VBD||patients-2/NNS	prep_with||patients-2/NNS||type2diabetes-4/CD	amod||treatment-7/NN||long-term-6/JJ	nsubj||remained-8/VBD||treatment-7/NN	nsubj||had-11/VBD||treatment-7/NN	root||ROOT-0/null||remained-8/VBD	xcomp||remained-8/VBD||weight-neutral-9/NN	conj_but||remained-8/VBD||had-11/VBD	amod||effects-14/NNS||persistent-12/JJ	amod||effects-14/NNS||beneficial-13/JJ	dobj||had-11/VBD||effects-14/NNS	prep_on||effects-14/NNS||short-term-16/JJ	prep_on||effects-14/NNS||intermediate-term-18/JJ	conj_and||short-term-16/JJ||intermediate-term-18/JJ	amod||biomarkers-22/NNS||long-term-21/JJ	prep_on||effects-14/NNS||biomarkers-22/NNS	conj_and||short-term-16/JJ||biomarkers-22/NNS	amod||control-25/NN||metabolic-24/JJ	prep_of||biomarkers-22/NNS||control-25/NN	nn||levels-34/NNS||low-density-31/NN	nn||levels-34/NNS||lipoprotein-32/NN	nn||levels-34/NNS||cholesterol-33/NN	prep_on||effects-14/NNS||levels-34/NNS	conj_and||short-term-16/JJ||levels-34/NNS	nn||requirement-37/NN||insulin-36/NN	conj_and||short-term-16/JJ||requirement-37/NN	conj_and||levels-34/NNS||requirement-37/NN	type2diabetes-4||insulin-36||yes||in patients with type2diabetes, long-term treatment remained weight-neutral but had persistent beneficial effects on short-term, intermediate-term, and long-term biomarkers of metabolic control, as well as on low-density lipoprotein cholesterol levels and insulin requirement.
amod||patients-3/NNS||thirty-three-1/JJ	amod||patients-3/NNS||consecutive-2/JJ	nsubj||received-7/VBD||patients-3/NNS	amod||lupusnephritis-6/NNS||proliferative-5/JJ	prep_with||patients-3/NNS||lupusnephritis-6/NNS	root||ROOT-0/null||received-7/VBD	nn||therapy-9/NN||induction-8/NN	dobj||received-7/VBD||therapy-9/NN	iobj||received-7/VBD||therapy-9/NN	number||seven-13/CD||five-11/CD	dep||seven-13/CD||to-12/TO	num||pulses-19/NNS||seven-13/CD	amod||pulses-19/NNS||monthly-14/JJ	amod||pulses-19/NNS||intravenous-15/JJ	appos||pulses-19/NNS||iv-17/NN	prep_with||therapy-9/NN||pulses-19/NNS	prep_of||therapy-9/NN||cyclophosphamide-21/NN	appos||cyclophosphamide-21/NN||cyc-23/NN	amod||therapy-9/NN||plus-25/IN	nn||steroids-27/NNS||iv-26/NN	dep||therapy-9/NN||steroids-27/NNS	vmod||steroids-27/NNS||followed-28/VBN	amod||g/day-33/NN||oral-30/JJ	nn||g/day-33/NN||mmf-31/NN	num||g/day-33/NN||2-32/CD	agent||followed-28/VBN||g/day-33/NN	nn||therapy-36/NN||maintenance-35/NN	prep_as||received-7/VBD||therapy-36/NN	det||time-40/NN||a-38/DT	amod||time-40/NN||median-39/JJ	prep_for||received-7/VBD||time-40/NN	num||months-43/NNS||29-42/CD	prep_of||time-40/NN||months-43/NNS	parataxis||received-7/VBD||range-45/VB	number||71-48/CD||9-46/CD	dep||71-48/CD||to-47/TO	num||months-49/NNS||71-48/CD	tmod||range-45/VB||months-49/NNS	steroids-27||lupusnephritis-6||no_rel||thirty-three consecutive patients with proliferative lupusnephritis received induction therapy with five to seven monthly intravenous (iv) pulses of cyclophosphamide (cyc) plus iv steroids followed by oral mmf 2 g/day as maintenance therapy for a median time of 29 months (range 9 to 71 months).
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||budesonide--1||yes||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||develop-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||system-12/NN||a-9/DT	amod||system-12/NN||partial-10/JJ	amod||system-12/NN||closed-loop-11/JJ	dobj||develop-8/VB||system-12/NN	aux||prevent-15/VB||to-13/TO	advmod||prevent-15/VB||safely-14/RB	vmod||develop-8/VB||prevent-15/VB	amod||hypoglycemia-17/NN||nocturnal-16/JJ	dobj||prevent-15/VB||hypoglycemia-17/NN	prepc_by||prevent-15/VB||suspending-19/VBG	nn||delivery-21/NN||insulin-20/NN	dobj||suspending-19/VBG||delivery-21/NN	tmod||predicted-25/VBN||delivery-21/NN	advmod||predicted-25/VBN||when-22/WRB	nsubjpass||predicted-25/VBN||hypoglycemia-23/NN	auxpass||predicted-25/VBN||is-24/VBZ	rcmod||delivery-21/NN||predicted-25/VBN	prep_in||predicted-25/VBN||type1diabetes-27/CD	insulin-20||hypoglycemia-23||no_rel||the aim of this study was to develop a partial closed-loop system to safely prevent nocturnal hypoglycemia by suspending insulin delivery when hypoglycemia is predicted in type1diabetes.
det||series-3/NN||an-1/DT	amod||series-3/NN||independent-2/JJ	nsubjpass||used-36/VBN||series-3/NN	nsubj||explore-38/VB||series-3/NN	num||samples-7/NNS||33-5/CD	nn||samples-7/NNS||breasttumor-6/NN	prep_of||series-3/NN||samples-7/NNS	prep_from||samples-7/NNS||patients-9/NNS	nsubj||relapsed-11/VBD||patients-9/NNS	nsubj||relapse-20/VB||patients-9/NNS	rcmod||patients-9/NNS||relapsed-11/VBD	dep||relapsed-11/VBD||n-13/VBN	dep||14-15/CD||=-14/SYM	ccomp||n-13/VBN||14-15/CD	aux||relapse-20/VB||did-18/VBD	neg||relapse-20/VB||not-19/RB	rcmod||patients-9/NNS||relapse-20/VB	conj_or||relapsed-11/VBD||relapse-20/VB	dep||relapse-20/VB||n-22/VBN	dep||19-24/CD||=-23/SYM	ccomp||n-22/VBN||19-24/CD	nn||treatment-28/NN||tamoxifen-27/NN	prep_under||relapse-20/VB||treatment-28/NN	det||location-33/NN||a-30/DT	amod||location-33/NN||different-31/JJ	amod||location-33/NN||geographic-32/JJ	prep_from||treatment-28/NN||location-33/NN	auxpass||used-36/VBN||was-34/VBD	advmod||used-36/VBN||subsequently-35/RB	root||ROOT-0/null||used-36/VBN	aux||explore-38/VB||to-37/TO	xcomp||used-36/VBN||explore-38/VB	det||signature-42/NN||the-39/DT	nn||signature-42/NN||gene-40/NN	nn||signature-42/NN||expression-41/NN	dobj||explore-38/VB||signature-42/NN	vmod||signature-42/NN||identified-43/VBN	breasttumor-6||tamoxifen-27||yes||an independent series of 33 breasttumor samples from patients who relapsed ( n = 14) or did not relapse ( n = 19) under tamoxifen treatment from a different geographic location was subsequently used to explore the gene expression signature identified.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||virus-5/NN||recombinant-3/JJ	amod||virus-5/NN||adeno-associated-4/JJ	dobj||used-2/VBD||virus-5/NN	aux||express-7/VB||to-6/TO	vmod||used-2/VBD||express-7/VB	amod||chemerin-9/NN||human-8/JJ	dobj||express-7/VB||chemerin-9/NN	nn||mice-14/NNS||ldl-11/NN	nn||mice-14/NNS||receptor-12/NN	nn||mice-14/NNS||knockout-13/NN	prep_in||chemerin-9/NN||mice-14/NNS	amod||diet-17/NN||high-fat-16/JJ	prep_on||express-7/VB||diet-17/NN	fat--1||virus-5||no_rel||we used recombinant adeno-associated virus to express human chemerin in ldl receptor knockout mice on high-fat diet.
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	dep||effect-10/NN||lactamantibiotics-15/NNS	prep_against||lactamantibiotics-15/NNS||mrsa-17/NN	prep_in||enhanced-7/VBD||vitro-19/NN	prep_in||enhanced-7/VBD||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	nsubjpass||related-27/VBN||vivo-22/NN	aux||related-27/VBN||might-25/MD	auxpass||related-27/VBN||be-26/VB	rcmod||vivo-22/NN||related-27/VBN	det||accumulation-31/NN||the-29/DT	amod||accumulation-31/NN||increased-30/VBN	prep_to||related-27/VBN||accumulation-31/NN	prep_of||accumulation-31/NN||antibiotics-33/NNS	prep_within||antibiotics-33/NNS||mrsa-35/NN	prep_via||mrsa-35/NN||suppression-37/NN	amod||pumpsâ-41/NNS||important-39/JJ	nn||pumpsâ-41/NNS||efflux-40/NN	nn||expression-45/NN||pumpsâ-41/NNS	amod||expression-45/NN||$-42/$	dep||$-42/$||™-43/JJ	nn||expression-45/NN||gene-44/NN	prep_of||suppression-37/NN||expression-45/NN	mrsa-35||antibacterial-9||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactamantibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ€™ gene expression.
amod||hepatitis-2/NN||viral-1/JJ	nsubj||problem-9/NN||hepatitis-2/NN	cop||problem-9/NN||is-3/VBZ	det||problem-9/NN||a-4/DT	amod||problem-9/NN||serious-5/JJ	amod||problem-9/NN||global-6/JJ	amod||problem-9/NN||public-7/JJ	nn||problem-9/NN||health-8/NN	root||ROOT-0/null||problem-9/NN	vmod||problem-9/NN||affecting-10/VBG	dobj||affecting-10/VBG||billions-11/NNS	prep_of||billions-11/NNS||people-13/NNS	advmod||affecting-10/VBG||globally-14/RB	det||hepatitisbvirus-18/NNS||both-17/DT	nsubj||spreading-31/VBG||hepatitisbvirus-18/NNS	appos||hepatitisbvirus-18/NNS||hbv-20/NN	amod||infections-28/NNS||hepatitisc-23/JJ	nn||infections-28/NNS||virus-24/NN	appos||infections-28/NNS||hcv-26/NN	conj_and||hepatitisbvirus-18/NNS||infections-28/NNS	nsubj||spreading-31/VBG||infections-28/NNS	aux||spreading-31/VBG||are-29/VBP	advmod||spreading-31/VBG||rapidly-30/RB	conj_and||problem-9/NN||spreading-31/VBG	det||countries-35/NNS||the-33/DT	amod||countries-35/NNS||developing-34/VBG	prep_in||spreading-31/VBG||countries-35/NNS	amod||education-44/NN||bangladesh-37/JJ	det||lack-41/NN||the-40/DT	prep_due_to||education-44/NN||lack-41/NN	prep_of||lack-41/NN||health-43/NN	prep_including||countries-35/NNS||education-44/NN	appos||education-44/NN||poverty-46/NN	appos||education-44/NN||illiteracy-48/NN	conj_and||poverty-46/NN||illiteracy-48/NN	appos||education-44/NN||lack-50/NN	conj_and||poverty-46/NN||lack-50/NN	amod||vaccination-53/NN||hepatitisb-52/JJ	prep_of||poverty-46/NN||vaccination-53/NN	hbv-20||hepatitisbvirus-18||no||viral hepatitis is a serious global public health problem affecting billions of people globally, and both hepatitisbvirus (hbv) and hepatitisc virus (hcv) infections are rapidly spreading in the developing countries including bangladesh due to the lack of health education, poverty, illiteracy and lack of hepatitisb vaccination.
nn||projects-4/NNS||conclusion-1/NN	amod||projects-4/NNS||international-2/JJ	nn||projects-4/NNS||cooperation-3/NN	nsubj||component-9/NN||projects-4/NNS	aux||component-9/NN||have-5/VBP	cop||component-9/NN||been-6/VBN	det||component-9/NN||an-7/DT	amod||component-9/NN||invaluable-8/JJ	root||ROOT-0/null||component-9/NN	amod||response-15/NN||chinaâ-11/JJ	amod||response-15/NN||$-12/$	number||s-14/CD||™-13/CD	num||$-12/$||s-14/CD	prep_of||component-9/NN||response-15/NN	prep_to||component-9/NN||hiv/aids-17/NNS	nsubj||able-24/JJ||china-20/NN	nsubj||take-26/VB||china-20/NN	nsubj||share-30/VB||china-20/NN	aux||able-24/JJ||has-21/VBZ	advmod||able-24/JJ||now-22/RB	cop||able-24/JJ||been-23/VBN	conj_and||component-9/NN||able-24/JJ	aux||take-26/VB||to-25/TO	xcomp||able-24/JJ||take-26/VB	det||information-28/NN||this-27/DT	dobj||take-26/VB||information-28/NN	xcomp||able-24/JJ||share-30/VB	conj_and||take-26/VB||share-30/VB	poss||experiences-32/NNS||its-31/PRP$	dobj||share-30/VB||experiences-32/NNS	amod||countries-35/NNS||other-34/JJ	prep_with||share-30/VB||countries-35/NNS	det||help-38/NN||the-37/DT	prep_with||able-24/JJ||help-38/NN	det||programmes-43/NNS||these-40/DT	amod||programmes-43/NNS||same-41/JJ	amod||programmes-43/NNS||international-42/JJ	prep_of||help-38/NN||programmes-43/NNS	aids--1||hiv--1||no||conclusion international cooperation projects have been an invaluable component of chinaâ€™s response to hiv/aids, and china has now been able to take this information and share its experiences with other countries with the help of these same international programmes.
nsubjpass||described-3/VBN||it-1/PRP	auxpass||described-3/VBN||was-2/VBD	root||ROOT-0/null||described-3/VBN	mark||due-8/JJ||that-4/IN	det||effect-6/NN||this-5/DT	nsubj||due-8/JJ||effect-6/NN	cop||due-8/JJ||was-7/VBD	ccomp||described-3/VBN||due-8/JJ	det||replacement-11/NN||a-10/DT	prep_to||due-8/JJ||replacement-11/NN	nn||tissue-14/NN||tumor-13/NN	prep_of||replacement-11/NN||tissue-14/NN	nn||depots-17/NNS||collagen-16/NN	prep_by||due-8/JJ||depots-17/NNS	collagen-16||tumor-13||no_rel||it was described that this effect was due to a replacement of tumor tissue by collagen depots.
nsubjpass||approved-13/VBN||paliperidone-1/NN	nsubjpass||became-28/VBD||paliperidone-1/NN	dep||paliperidone-1/NN||9-hydroxy-risperidone-3/JJ	det||metabolite-8/NN||the-6/DT	amod||metabolite-8/NN||active-7/JJ	appos||paliperidone-1/NN||metabolite-8/NN	prep_of||metabolite-8/NN||risperidone-10/NN	auxpass||approved-13/VBN||was-12/VBD	root||ROOT-0/null||approved-13/VBN	prepc_for||approved-13/VBN||treating-15/VBG	dobj||treating-15/VBG||schizophrenia-16/NN	advmod||treating-15/VBG||worldwide-17/RB	num||extended-release-22/NN||2006-19/CD	advmod||paliperidone-21/JJ||as-20/RB	amod||extended-release-22/NN||paliperidone-21/JJ	prep_in||treating-15/VBG||extended-release-22/NN	prep||extended-release-22/NN||per-24/IN	conj_and||approved-13/VBN||became-28/VBD	det||antipsychotic-32/NN||the-29/DT	amod||antipsychotic-32/NN||first-30/JJ	amod||antipsychotic-32/NN||second-generation-31/JJ	xcomp||became-28/VBD||antipsychotic-32/NN	advmod||licensed-34/VBN||specifically-33/RB	vmod||antipsychotic-32/NN||licensed-34/VBN	prepc_for||licensed-34/VBN||treating-36/VBG	dobj||treating-36/VBG||schizoaffectivedisorder-37/NN	prep_in||treating-36/VBG||2009-39/CD	schizophrenia-16||risperidone-10||yes||paliperidone (9-hydroxy-risperidone), the active metabolite of risperidone, was approved for treating schizophrenia worldwide in 2006 as paliperidone extended-release (per), and became the first second-generation antipsychotic specifically licensed for treating schizoaffectivedisorder in 2009.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the causative agent of melioidosis.
mark||+-3/VBD||although-1/IN	nsubj||+-3/VBD||chf-2/NN	advcl||prevented-27/VBN||+-3/VBD	dep||+-3/VBD||f-4/SYM	xcomp||+-3/VBD||feeding-5/VBG	amod||ampkî-8/NNS||increased-6/JJ	amod||ampkî-8/NNS||hepatic-7/JJ	iobj||feeding-5/VBG||ampkî-8/NNS	number||2-10/CD||±-9/CD	num||activity-11/NN||2-10/CD	dobj||feeding-5/VBG||activity-11/NN	det||gain-16/NN||the-13/DT	nn||gain-16/NN||body-14/NN	nn||gain-16/NN||weight-15/NN	nsubjpass||prevented-27/VBN||gain-16/NN	conj_and||gain-16/NN||dyslipidemia-18/NN	nsubjpass||prevented-27/VBN||dyslipidemia-18/NN	det||accumulation-22/NN||the-21/DT	conj_and||gain-16/NN||accumulation-22/NN	nsubjpass||prevented-27/VBN||accumulation-22/NN	amod||triglycerides-25/NNPS||hepatic-24/JJ	prep_of||accumulation-22/NN||triglycerides-25/NNPS	auxpass||prevented-27/VBN||were-26/VBD	root||ROOT-0/null||prevented-27/VBN	det||diet-33/NN||the-29/DT	nn||diet-33/NN||chf-30/NNP	nn||diet-33/NN||+-31/NNP	nn||diet-33/NN||f-32/NNP	agent||prevented-27/VBN||diet-33/NN	det||degree-37/NN||a-35/DT	amod||degree-37/NN||similar-36/JJ	prep_to||prevented-27/VBN||degree-37/NN	det||2âˆ-42/NNP||both-39/DT	nn||2âˆ-42/NNP||ampkî-40/NNP	nn||2âˆ-42/NNP||±-41/NNP	poss||âˆ-45/NN||2âˆ-42/NNP	amod||âˆ-45/NN||/-44/JJ	prep_in||degree-37/NN||âˆ-45/NN	amod||mice-49/NNS||wild-type-48/JJ	prep_to||prevented-27/VBN||mice-49/NNS	conj_and||degree-37/NN||mice-49/NNS	nn||state-53/NN||ad-51/NN	amod||state-53/NN||libitum-fed-52/JJ	prep_in||mice-49/NNS||state-53/NN	triglycerides-25||chf-30||no_rel||although chf+f feeding increased hepatic ampkî±2 activity, the body weight gain, dyslipidemia, and the accumulation of hepatic triglycerides were prevented by the chf+f diet to a similar degree in both ampkî±2âˆ’/âˆ’ and wild-type mice in ad libitum-fed state.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	painful-10||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
amod||exposure-3/NN||long-term-1/JJ	nn||exposure-3/NN||alcohol-2/NN	nsubj||lead-5/VB||exposure-3/NN	aux||lead-5/VB||may-4/MD	root||ROOT-0/null||lead-5/VB	prep_to||lead-5/VB||development-7/NN	prep_of||development-7/NN||alcoholdependence-9/NN	prep_in||lead-5/VB||consequence-11/NN	amod||functions-15/NNS||altered-13/VBN	nn||functions-15/NNS||neurotransmitter-14/NN	prep_of||consequence-11/NN||functions-15/NNS	alcoholdependence-9||alcohol-2||no||long-term alcohol exposure may lead to development of alcoholdependence in consequence of altered neurotransmitter functions.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	det||need-5/NN||a-3/DT	amod||need-5/NN||significant-4/JJ	nsubj||is-2/VBZ||need-5/NN	amod||analysis-9/NN||detailed-7/VBN	amod||analysis-9/NN||mechanistic-8/JJ	prep_for||need-5/NN||analysis-9/NN	det||population-15/NN||the-11/DT	amod||population-15/NN||aging-12/VBG	amod||population-15/NN||hiv-infected-14/JJ	prep_of||analysis-9/NN||population-15/NN	det||risk-18/NN||the-17/DT	prep_regarding||population-15/NN||risk-18/NN	prep_of||risk-18/NN||hivinfection-20/NN	prep_of||risk-18/NN||therapy-22/NN	conj_and||hivinfection-20/NN||therapy-22/NN	mark||maintain-26/VB||in-23/IN	dep||maintain-26/VB||order-24/NN	aux||maintain-26/VB||to-25/TO	advcl||is-2/VBZ||maintain-26/VB	nn||health-28/NN||bone-27/NN	dobj||maintain-26/VB||health-28/NN	hivinfection-20||hiv--1||no||there is a significant need for detailed mechanistic analysis of the aging, hiv-infected population regarding the risk of hivinfection and therapy in order to maintain bone health.
det||number-3/NN||a-1/DT	amod||number-3/NN||considerable-2/JJ	nsubj||responded-13/VBD||number-3/NN	amod||patients-6/NNS||asthmatic-5/JJ	prep_of||number-3/NN||patients-6/NNS	neg||history-9/NN||no-8/DT	prep_with||patients-6/NNS||history-9/NN	nn||intolerance-12/NN||aspirin-11/NN	prep_of||history-9/NN||intolerance-12/NN	root||ROOT-0/null||responded-13/VBD	det||challenge-18/NN||the-15/DT	nn||challenge-18/NN||inhalation-16/NN	nn||challenge-18/NN||aspirin-17/NN	prep_to||responded-13/VBD||challenge-18/NN	asthmatic-5||aspirin-17||no||a considerable number of asthmatic patients with no history of aspirin intolerance responded to the inhalation aspirin challenge.
vmod||present-16/VBP||using-1/VBG	det||$-10/FW||the-2/DT	nn||$-10/FW||caenorhabditis-3/FW	nn||$-10/FW||elegans-4/FW	nn||$-10/FW||â-5/FW	nn||$-10/FW||$-6/FW	nn||$-10/FW||pseudomonasaeruginosa-8/FW	nn||$-10/FW||hostâ-9/FW	dobj||using-1/VBG||$-10/FW	iobj||using-1/VBG||$-10/FW	nn||system-13/NN||pathogen-12/NN	dep||$-10/FW||system-13/NN	nsubj||present-16/VBP||we-15/PRP	root||ROOT-0/null||present-16/VBP	amod||evidence-18/NN||genetic-17/JJ	dobj||present-16/VBP||evidence-18/NN	mark||required-72/VBN||that-19/IN	det||fat-3-24/NNS||a-20/DT	nn||fat-3-24/NNS||î-21/NN	amod||fat-3-24/NNS||6-desaturase-23/JJ	nsubjpass||required-72/VBN||fat-3-24/NNS	poss||productsâ-30/NNS||its-27/PRP$	num||productsâ-30/NNS||two-28/CD	amod||productsâ-30/NNS||18-carbon-29/JJ	prep_through||fat-3-24/NNS||productsâ-30/NNS	dep||fat-3-24/NNS||$-31/$	num||$-31/$||gamma-linolenicacid-33/CD	dep||$-31/$||gla-35/NN	appos||gla-35/NN||183n6-37/NNS	amod||acid-41/NN||stearidonic-40/JJ	dep||fat-3-24/NNS||acid-41/NN	conj_and||$-31/$||acid-41/NN	dep||acid-41/NN||sda-43/NN	appos||sda-43/NN||184n3-45/NNS	det||acid-54/NN||the-50/DT	num||pufas-52/NNS||20-carbon-51/CD	npadvmod||arachidonic-53/JJ||pufas-52/NNS	amod||acid-54/NN||arachidonic-53/JJ	dep||fat-3-24/NNS||acid-54/NN	conj_negcc||$-31/$||acid-54/NN	dep||acid-54/NN||aa-56/NN	appos||aa-56/NN||204n6-58/NNS	amod||$-69/NNS||eicosapentaenoic-61/JJ	amod||$-69/NNS||acid-62/JJ	dep||$-69/NNS||epa-64/NN	appos||epa-64/NN||205n3-66/NNS	nn||$-69/NNS||â-68/NN	conj_negcc||$-31/$||$-69/NNS	conj_and||acid-54/NN||$-69/NNS	auxpass||required-72/VBN||is-71/VBZ	ccomp||present-16/VBP||required-72/VBN	amod||immunity-76/NN||basal-74/JJ	nn||immunity-76/NN||innate-75/NN	prep_for||required-72/VBN||immunity-76/NN	prep_in||immunity-76/NN||vivo-78/NN	carbon--1||gla-35||no_rel||using the caenorhabditis elegans â€“ pseudomonasaeruginosa hostâ€“pathogen system, we present genetic evidence that a î”6-desaturase fat-3, through its two 18-carbon productsâ€”gamma-linolenicacid (gla, 183n6) and stearidonic acid (sda, 184n3), but not the 20-carbon pufas arachidonic acid (aa, 204n6) and eicosapentaenoic acid (epa, 205n3)â€”is required for basal innate immunity in vivo.
prepc_by||develop-10/VB||altering-2/VBG	nn||patterns-5/NNS||gene-3/NN	nn||patterns-5/NNS||expression-4/NN	dobj||altering-2/VBG||patterns-5/NNS	nn||cells-8/NNS||cancer-7/NN	nsubj||develop-10/VB||cells-8/NNS	aux||develop-10/VB||can-9/MD	root||ROOT-0/null||develop-10/VB	amod||phenotypes-12/NNS||specific-11/JJ	dobj||develop-10/VB||phenotypes-12/NNS	nsubj||allow-14/VBP||phenotypes-12/NNS	rcmod||phenotypes-12/NNS||allow-14/VBP	dobj||allow-14/VBP||them-15/PRP	nsubj||proliferate-17/VB||them-15/PRP	nsubj||survive-19/VB||them-15/PRP	nsubj||secure-21/VB||them-15/PRP	nsubj||evade-26/VB||them-15/PRP	nsubj||invade-30/VB||them-15/PRP	nsubj||metastasize-34/VB||them-15/PRP	aux||proliferate-17/VB||to-16/TO	xcomp||allow-14/VBP||proliferate-17/VB	xcomp||allow-14/VBP||survive-19/VB	conj_and||proliferate-17/VB||survive-19/VB	xcomp||allow-14/VBP||secure-21/VB	conj_and||proliferate-17/VB||secure-21/VB	dobj||secure-21/VB||oxygen-22/NN	dobj||secure-21/VB||nutrients-24/NNS	conj_and||oxygen-22/NN||nutrients-24/NNS	xcomp||allow-14/VBP||evade-26/VB	conj_and||proliferate-17/VB||evade-26/VB	amod||recognition-28/NN||immune-27/JJ	dobj||evade-26/VB||recognition-28/NN	xcomp||allow-14/VBP||invade-30/VB	conj_and||proliferate-17/VB||invade-30/VB	amod||tissues-32/NNS||other-31/JJ	dobj||invade-30/VB||tissues-32/NNS	xcomp||allow-14/VBP||metastasize-34/VB	conj_and||proliferate-17/VB||metastasize-34/VB	oxygen-22||metastasize-34||no_rel||by altering gene expression patterns, cancer cells can develop specific phenotypes that allow them to proliferate, survive, secure oxygen and nutrients, evade immune recognition, invade other tissues and metastasize.
nsubjpass||used-4/VBN||liposomalamphotericinb-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	prepc_with||used-4/VBN||increasing-6/VBG	dobj||increasing-6/VBG||frequency-7/NN	aux||treat-9/VB||to-8/TO	vmod||increasing-6/VBG||treat-9/VB	dobj||treat-9/VB||visceralleishmaniasis-10/NNS	appos||visceralleishmaniasis-10/NNS||vl-12/NN	visceralleishmaniasis-10||liposomalamphotericinb-1||yes||liposomalamphotericinb has been used with increasing frequency to treat visceralleishmaniasis (vl).
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	glucose-22||insulinresistance-15||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
nsubjpass||associated-4/VBN||perniciousanaemia-1/NN	auxpass||associated-4/VBN||is-2/VBZ	advmod||associated-4/VBN||undeniably-3/RB	root||ROOT-0/null||associated-4/VBN	prep_with||associated-4/VBN||vitaminb12deficiency-6/CD	det||association-10/NN||the-9/DT	nsubj||unclear-21/JJ||association-10/NN	amod||concentrations-14/NNS||subnormal-12/JJ	amod||concentrations-14/NNS||vitaminb12-13/JJ	prep_between||association-10/NN||concentrations-14/NNS	conj_and||association-10/NN||anaemia-16/NN	nsubj||unclear-21/JJ||anaemia-16/NN	amod||people-19/NNS||older-18/JJR	prep_in||anaemia-16/NN||people-19/NNS	cop||unclear-21/JJ||is-20/VBZ	conj_but||associated-4/VBN||unclear-21/JJ	perniciousanaemia-1||vitaminb12deficiency-6||no||perniciousanaemia is undeniably associated with vitaminb12deficiency, but the association between subnormal vitaminb12 concentrations and anaemia in older people is unclear.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	mark||associated-19/VBN||whether-5/IN	det||mismatch-7/NN||a-6/DT	nsubjpass||associated-19/VBN||mismatch-7/NN	nn||allotypes-10/NNS||igg-9/NN	prep_in||mismatch-7/NN||allotypes-10/NNS	prep_between||allotypes-10/NNS||adalimumab-12/NN	prep_between||allotypes-10/NNS||igg-14/NN	conj_and||adalimumab-12/NN||igg-14/NN	amod||patients-17/NNS||adalimumab-treated-16/JJ	prep_in||adalimumab-12/NN||patients-17/NNS	auxpass||associated-19/VBN||is-18/VBZ	ccomp||investigated-4/VBD||associated-19/VBN	det||development-22/NN||the-21/DT	prep_with||associated-19/VBN||development-22/NN	prep_of||development-22/NN||aaa-24/NN	aaa-24||adalimumab-12||no_rel||therefore, we investigated whether a mismatch in igg allotypes between adalimumab and igg in adalimumab-treated patients is associated with the development of aaa.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||valsartan-15||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
det||responses-3/NNS||the-1/DT	amod||responses-3/NNS||latter-2/JJ	nsubjpass||seen-9/VBN||responses-3/NNS	advmod||seen-9/VBN||however-5/RB	auxpass||seen-9/VBN||were-7/VBD	neg||seen-9/VBN||not-8/RB	root||ROOT-0/null||seen-9/VBN	amod||mice-13/NNS||meth-a-11/JJ	amod||mice-13/NNS||fibrosarcoma-bearing-12/JJ	prep_in||seen-9/VBN||mice-13/NNS	meth--1||fibrosarcoma--1||no_rel||the latter responses, however, were not seen in meth-a fibrosarcoma-bearing mice.
amod||provision-4/NN||main-1/JJ	nn||provision-4/NN||outcome-2/NN	nn||provision-4/NN||measures-3/NNS	nsubj||referred-10/VBD||provision-4/NN	amod||prophylaxis-7/NNS||co-trimoxazole-6/JJ	prep_of||provision-4/NN||prophylaxis-7/NNS	prep_among||prophylaxis-7/NNS||patients-9/NNS	root||ROOT-0/null||referred-10/VBD	det||programme-14/NN||the-12/DT	amod||programme-14/NN||hiv/aids/art-13/JJ	prep_to||referred-10/VBD||programme-14/NN	prep_to||referred-10/VBD||detection-17/NN	conj_and||programme-14/NN||detection-17/NN	prep_of||detection-17/NN||cases-19/NNS	prep_of||cases-19/NNS||tuberculosis-21/NNP	prep_among||referred-10/VBD||those-23/DT	det||programme-26/NN||the-25/DT	prep_in||those-23/DT||programme-26/NN	aids--1||hiv--1||no||main outcome measures provision of co-trimoxazole prophylaxis among patients referred to the hiv/aids/art programme, and detection of cases of tuberculosis among those in the programme.
nsubj||diseases-9/NNS||priondiseases-1/NNS	conj_or||priondiseases-1/NNS||transmissiblespongiformencephalopathies-3/NNS	nsubj||diseases-9/NNS||transmissiblespongiformencephalopathies-3/NNS	appos||priondiseases-1/NNS||tses-5/NNS	cop||diseases-9/NNS||are-7/VBP	amod||diseases-9/NNS||fatal-8/JJ	root||ROOT-0/null||diseases-9/NNS	vmod||diseases-9/NNS||associated-10/VBN	det||conversion-13/NN||the-12/DT	prep_with||associated-10/VBN||conversion-13/NN	det||prionprotein-17/NN||the-15/DT	amod||prionprotein-17/NN||cellular-16/JJ	prep_of||conversion-13/NN||prionprotein-17/NN	dep||prionprotein-17/NN||prpc-19/JJ	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||abnormal-23/JJ	prep_to||associated-10/VBN||prionprotein-24/NN	dep||prionprotein-24/NN||prpsc-26/JJ	transmissiblespongiformencephalopathies-3||prionprotein-24||no||priondiseases or transmissiblespongiformencephalopathies (tses) are fatal diseases associated with the conversion of the cellular prionprotein (prpc) to the abnormal prionprotein (prpsc).
nsubj||mediated-inflammatory-6/NN||celiacdisease-1/NN	cop||mediated-inflammatory-6/NN||is-2/VBZ	det||mediated-inflammatory-6/NN||a-3/DT	nn||mediated-inflammatory-6/NN||t-4/NN	nn||mediated-inflammatory-6/NN||cell-5/NN	root||ROOT-0/null||mediated-inflammatory-6/NN	advmod||caused-8/VBN||enteropathy-7/RB	vmod||mediated-inflammatory-6/NN||caused-8/VBN	det||ingestion-11/NN||the-10/DT	agent||caused-8/VBN||ingestion-11/NN	prep_of||ingestion-11/NN||gluten-13/NN	advmod||predisposed-16/JJ||genetically-15/RB	amod||individuals-17/NNS||predisposed-16/JJ	prep_in||caused-8/VBN||individuals-17/NNS	vmod||individuals-17/NNS||carrying-18/VBG	acomp||carrying-18/VBG||hla-dq2-19/JJ	acomp||carrying-18/VBG||hla-dq8-21/JJ	conj_or||hla-dq2-19/JJ||hla-dq8-21/JJ	celiacdisease-1||gluten-13||no||celiacdisease is a t cell mediated-inflammatory enteropathy caused by the ingestion of gluten in genetically predisposed individuals carrying hla-dq2 or hla-dq8.
nsubj||class-4/NN||thiazolidinediones-1/NNS	cop||class-4/NN||are-2/VBP	det||class-4/NN||a-3/DT	dep||agonists-17/VBZ||class-4/NN	amod||³-11/NN||peroxisome-6/JJ	nn||³-11/NN||proliferator-7/NN	amod||³-11/NN||activated-8/VBN	nn||³-11/NN||receptor-9/NN	nn||³-11/NN||î-10/NN	prep_of||class-4/NN||³-11/NN	nn||³-15/NNS||ppar-13/NN	nn||³-15/NNS||î-14/NN	dep||agonists-17/VBZ||³-15/NNS	root||ROOT-0/null||agonists-17/VBZ	mark||reduce-19/VB||that-18/IN	ccomp||agonists-17/VBZ||reduce-19/VB	dobj||reduce-19/VB||insulinresistance-20/NN	prep_in||reduce-19/VB||type-22/NN	num||patients-25/NNS||2-23/CD	amod||patients-25/NNS||diabetic-24/JJ	nsubj||agonists-17/VBZ||patients-25/NNS	thiazolidinediones-1||insulinresistance-20||no_rel||thiazolidinediones are a class of peroxisome proliferator activated receptor î³ (ppar î³ ) agonists that reduce insulinresistance in type 2 diabetic patients.
amod||escherichiacoli-2/NNS||seventy-1/JJ	nsubj||isolates-3/VBZ||escherichiacoli-2/NNS	root||ROOT-0/null||isolates-3/VBZ	csubjpass||characterized-22/VBN||recovered-4/VBN	amod||chickens-7/NNS||diseased-6/JJ	prep_from||recovered-4/VBN||chickens-7/NNS	vmod||chickens-7/NNS||diagnosed-8/VBN	prep_with||diagnosed-8/VBN||colibacillosis-10/NNS	nn||province-13/NN||henan-12/NN	prep_in||colibacillosis-10/NNS||province-13/NN	appos||province-13/NN||china-15/NN	prep_between||province-13/NN||2004-18/CD	prep_between||province-13/NN||2005-20/CD	conj_and||2004-18/CD||2005-20/CD	auxpass||characterized-22/VBN||were-21/VBD	ccomp||isolates-3/VBZ||characterized-22/VBN	amod||profiles-26/NNS||antimicrobial-24/JJ	nn||profiles-26/NNS||susceptibility-25/NN	prep_for||characterized-22/VBN||profiles-26/NNS	det||method-32/NN||a-28/DT	amod||method-32/NN||broth-29/JJ	nn||method-32/NN||doubling-30/NN	nn||method-32/NN||dilution-31/NN	prep_via||profiles-26/NNS||method-32/NN	colibacillosis-10||escherichiacoli-2||no||seventy escherichiacoli isolates recovered from diseased chickens diagnosed with colibacillosis in henan province, china, between 2004 and 2005 were characterized for antimicrobial susceptibility profiles via a broth doubling dilution method.
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	cr-32||acutemyeloidleukaemia-22||no_rel||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
amod||infection-3/NN||occult-1/JJ	nn||infection-3/NN||hbv-2/NN	nsubjpass||reported-6/VBN||infection-3/NN	aux||reported-6/VBN||has-4/VBZ	auxpass||reported-6/VBN||been-5/VBN	root||ROOT-0/null||reported-6/VBN	amod||populations-9/NNS||different-8/JJ	prep_in||reported-6/VBN||populations-9/NNS	dep||reported-6/VBN||especially-11/RB	prep_among||reported-6/VBN||patients-13/NNS	amod||hcv-17/NN||hepatitisc-15/JJ	prep_with||patients-13/NNS||hcv-17/NN	vmod||hcv-17/NN||related-19/VBN	acomp||related-19/VBN||liverdisease-20/JJ	hepatitisc-15||hcv-17||no||occult hbv infection has been reported in different populations, especially among patients with hepatitisc (hcv) related liverdisease.
amod||viruses-2/NNS||h3n2-1/JJ	nsubj||reduced-9/VBN||viruses-2/NNS	prep_from||viruses-2/NNS||2003-4/CD	det||present-7/NN||the-6/DT	prep_to||2003-4/CD||present-7/NN	aux||reduced-9/VBN||have-8/VBP	root||ROOT-0/null||reduced-9/VBN	dobj||reduced-9/VBN||requirement-10/NN	prep_for||requirement-10/NN||na-12/NNP	advmod||passaged-14/VBD||when-13/WRB	advcl||reduced-9/VBN||passaged-14/VBD	nn||cells-17/NNS||mdck-16/NN	prep_in||passaged-14/VBD||cells-17/NNS	cop||resistant-20/JJ||are-19/VBP	advcl||reduced-9/VBN||resistant-20/JJ	conj_and||passaged-14/VBD||resistant-20/JJ	aux||na-22/VB||to-21/TO	xcomp||resistant-20/JJ||na-22/VB	dobj||na-22/VB||inhibitors-23/NNS	advmod||by-26/IN||possibly-25/RB	rcmod||inhibitors-23/NNS||by-26/IN	det||mechanism-29/NN||a-27/DT	nn||mechanism-29/NN||novel-28/NN	pobj||by-26/IN||mechanism-29/NN	amod||specificity-33/NN||narrow-31/JJ	nn||specificity-33/NN||receptor-32/NN	prep_of||mechanism-29/NN||specificity-33/NN	prep||na-22/VB||such-34/JJ	mark||self-aggregate-40/VB||that-35/IN	nn||particles-37/NNS||virus-36/NN	nsubj||self-aggregate-40/VB||particles-37/NNS	aux||self-aggregate-40/VB||do-38/VBP	neg||self-aggregate-40/VB||not-39/RB	ccomp||na-22/VB||self-aggregate-40/VB	virus-36||viruses-2||no||h3n2 viruses from 2003 to the present have reduced requirement for na when passaged in mdck cells and are resistant to na inhibitors, possibly by a novel mechanism of narrow receptor specificity such that virus particles do not self-aggregate.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	musculardystrophy-24||manganese--1||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	inflammation-38||basic-45||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
det||translation-2/NN||the-1/DT	nsubj||failed-12/VBN||translation-2/NN	nsubj||produce-14/VB||translation-2/NN	amod||agents-5/NNS||neuroprotective-4/JJ	prep_of||translation-2/NN||agents-5/NNS	prep_for||agents-5/NNS||ischemicstroke-7/NN	prep_from||ischemicstroke-7/NN||bench-to-bedside-9/NN	aux||failed-12/VBN||has-10/VBZ	advmod||failed-12/VBN||largely-11/RB	root||ROOT-0/null||failed-12/VBN	aux||produce-14/VB||to-13/TO	xcomp||failed-12/VBN||produce-14/VB	amod||treatments-16/NNS||improved-15/VBN	dobj||produce-14/VB||treatments-16/NNS	det||development-19/NN||the-18/DT	prep_since||produce-14/VB||development-19/NN	nn||plasminogenactivator-22/NN||tissue-21/NN	prep_of||development-19/NN||plasminogenactivator-22/NN	appos||plasminogenactivator-22/NN||tpa-24/NN	tpa-24||ischemicstroke-7||no_rel||the translation of neuroprotective agents for ischemicstroke from bench-to-bedside has largely failed to produce improved treatments since the development of tissue plasminogenactivator (tpa).
nsubj||occur-7/VBP||thousands-1/NNS	nsubj||occur-7/VBP||thousands-1/NNS	amod||deaths-4/NNS||human-3/JJ	prep_of||thousands-1/NNS||deaths-4/NNS	prep_from||deaths-4/NNS||rabies-6/NNP	root||ROOT-0/null||occur-7/VBP	conj_and||occur-7/VBP||occur-7/VBP	advmod||occur-7/VBP||annually-8/RB	det||availability-11/NN||the-10/DT	prep_despite||occur-7/VBP||availability-11/NN	amod||vaccines-14/NNS||effective-13/JJ	prep_of||availability-11/NN||vaccines-14/NNS	prep_following||vaccines-14/NNS||exposure-16/NN	nn||control-21/NN||disease-20/NN	prep_for||occur-7/VBP||control-21/NN	det||reservoir-25/NN||the-23/DT	nn||reservoir-25/NN||animal-24/NN	prep_in||control-21/NN||reservoir-25/NN	rabies-6||vaccines-14||no_rel||thousands of human deaths from rabies occur annually despite the availability of effective vaccines following exposure, and for disease control in the animal reservoir.
det||outbreaks-4/NNS||the-1/DT	amod||outbreaks-4/NNS||recent-2/JJ	nn||outbreaks-4/NNS||nigeria-3/NN	nsubjpass||determined-7/VBN||outbreaks-4/NNS	aux||determined-7/VBN||have-5/VBP	auxpass||determined-7/VBN||been-6/VBN	root||ROOT-0/null||determined-7/VBN	agent||determined-7/VBN||multidrug-9/VBG	acomp||multidrug-9/VBG||resistant-10/JJ	amod||tor-13/NN||atypical-11/JJ	nn||tor-13/NN||el-12/NN	dep||resistant-10/JJ||tor-13/NN	amod||strains-19/NNS||non-o1-15/JJ	amod||strains-19/NNS||/-16/JJ	amod||strains-19/NNS||non-o139-17/JJ	nn||strains-19/NNS||v.cholerae-18/NN	dep||resistant-10/JJ||strains-19/NNS	conj_and||tor-13/NN||strains-19/NNS	nsubj||seems-23/VBZ||it-22/PRP	conj_and||determined-7/VBN||seems-23/VBZ	mark||epidemic/endemic-41/JJ||that-24/IN	det||tor-28/NN||the-25/DT	amod||tor-28/NN||typical-26/JJ	nn||tor-28/NN||el-27/NN	nsubj||epidemic/endemic-41/JJ||tor-28/NN	det||beginning-32/NN||the-31/DT	prep_from||tor-28/NN||beginning-32/NN	amod||pandemic-36/NN||seventh-34/JJ	nn||pandemic-36/NN||cholera-35/NN	prep_of||beginning-32/NN||pandemic-36/NN	cop||epidemic/endemic-41/JJ||is-38/VBZ	neg||longer-40/RBR||no-39/RB	advmod||epidemic/endemic-41/JJ||longer-40/RBR	ccomp||seems-23/VBZ||epidemic/endemic-41/JJ	det||country-44/NN||this-43/DT	prep_in||epidemic/endemic-41/JJ||country-44/NN	cholera-35||v.cholerae-18||no||the recent nigeria outbreaks have been determined by multidrug resistant atypical el tor and non-o1 / non-o139 v.cholerae strains , and it seems that the typical el tor , from the beginning of seventh cholera pandemic , is no longer epidemic/endemic in this country .
det||review-2/NN||this-1/DT	nsubj||links-16/VBZ||review-2/NN	vmod||review-2/NN||carried-4/VBN	prt||carried-4/VBN||out-5/RP	det||initiative-10/NN||the-7/DT	amod||initiative-10/NN||joint-8/JJ	nn||initiative-10/NN||learning-9/NN	prep_for||carried-4/VBN||initiative-10/NN	prep_on||initiative-10/NN||children-12/NNS	prep_on||initiative-10/NN||aids-14/NNS	conj_and||children-12/NNS||aids-14/NNS	root||ROOT-0/null||links-16/VBZ	det||literature-18/NN||the-17/DT	dobj||links-16/VBZ||literature-18/NN	quantmod||$-21/$||â-20/RB	prep_on||links-16/VBZ||$-21/$	number||$-23/CD||œmigrationâ-22/CD	num||$-21/$||$-23/CD	prep_on||links-16/VBZ||â-26/NN	dobj||links-16/VBZ||$-27/$	num||$-27/$||œhiv-28/CD	advmod||$-31/$||aidsâ-30/RB	dobj||links-16/VBZ||$-31/$	conj_and||$-27/$||$-31/$	num||$-31/$||and-32/CD	quantmod||$-35/$||â-34/RB	prep_on||links-16/VBZ||$-35/$	number||$-37/CD||œfamiliesâ-36/CD	num||$-35/$||$-37/CD	aids-14||hiv--1||no||this review, carried out for the joint learning initiative on children and aids, links the literature on â€œmigrationâ€?, on â€œhiv and aidsâ€? and on â€œfamiliesâ€?.
nsubj||causes-2/VBZ||listeriamonocytogenes-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||listeriosis-3/NNS	vmod||listeriosis-3/NNS||characterized-4/VBN	agent||characterized-4/VBN||septicaemia-6/NN	agent||characterized-4/VBN||encephalitis-8/NN	conj_and||septicaemia-6/NN||encephalitis-8/NN	agent||characterized-4/VBN||abortion-11/NN	conj_and||septicaemia-6/NN||abortion-11/NN	agent||characterized-4/VBN||stillbirth-13/NN	conj_or||septicaemia-6/NN||stillbirth-13/NN	listeriosis-3||listeriamonocytogenes-1||no||listeriamonocytogenes causes listeriosis characterized by septicaemia, encephalitis, and abortion or stillbirth.
nsubjpass||prescribed-3/VBN||antibiotics-1/NNS	auxpass||prescribed-3/VBN||were-2/VBD	root||ROOT-0/null||prescribed-3/VBN	advmod||prescribed-3/VBN||acutely-4/RB	num||%-7/NN||66-6/CD	prep_in||prescribed-3/VBN||%-7/NN	appos||%-7/NN||359/543-9/CD	prep_of||%-7/NN||children-12/NNS	prep_with||children-12/NNS||urinarytractinfection-14/NN	num||%-17/NN||69-16/CD	prep_in||prescribed-3/VBN||%-17/NN	conj_and||%-7/NN||%-17/NN	appos||%-17/NN||366/533-19/CD	prep_with||%-17/NN||pneumonia-22/NN	num||%-26/NN||81-25/CD	prep_in||prescribed-3/VBN||%-26/NN	conj_and||%-7/NN||%-26/NN	appos||%-26/NN||52/64-28/CD	prep_with||%-26/NN||bacteraemia-31/NN	pneumonia-22||antibiotics-1||no_rel||antibiotics were prescribed acutely in 66% (359/543) of children with urinarytractinfection, 69% (366/533) with pneumonia, and 81% (52/64) with bacteraemia.
amod||individuals-3/NNS||healthy-2/JJ	prep_in||is-7/VBZ||individuals-3/NNS	nn||synthesis-6/NN||tf-5/NN	nsubj||is-7/VBZ||synthesis-6/NN	root||ROOT-0/null||is-7/VBZ	advcl||is-7/VBZ||inhibited-8/VBD	prep_by||inhibited-8/VBD||insulin-10/NN	mark||impaired-19/JJ||in-13/IN	nsubj||impaired-19/JJ||patients-14/NNS	amod||inhibition-17/NN||type2diabetes-16/JJ	prep_with||patients-14/NNS||inhibition-17/NN	cop||impaired-19/JJ||is-18/VBZ	advcl||is-7/VBZ||impaired-19/JJ	conj_but||inhibited-8/VBD||impaired-19/JJ	type2diabetes-16||insulin-10||yes||in healthy individuals, tf synthesis is inhibited by insulin, but in patients with type2diabetes inhibition is impaired.
amod||research-2/NN||further-1/JJ	nsubjpass||required-4/VBN||research-2/NN	nsubj||define-6/VB||research-2/NN	auxpass||required-4/VBN||is-3/VBZ	root||ROOT-0/null||required-4/VBN	aux||define-6/VB||to-5/TO	xcomp||required-4/VBN||define-6/VB	advmod||effective-8/JJ||clinically-7/RB	amod||methods-9/NNS||effective-8/JJ	dobj||define-6/VB||methods-9/NNS	amod||training-12/NN||health-worker-11/JJ	prep_of||methods-9/NNS||training-12/NN	aux||support-14/VB||to-13/TO	vmod||define-6/VB||support-14/VB	amod||care-16/NN||hiv/aids-15/JJ	dobj||support-14/VB||care-16/NN	amod||environments-22/NNS||mozambique-18/JJ	advmod||resource-constrained-21/JJ||similarly-20/RB	conj_and||mozambique-18/JJ||resource-constrained-21/JJ	amod||environments-22/NNS||resource-constrained-21/JJ	prep_in||support-14/VB||environments-22/NNS	aids--1||hiv--1||no||further research is required to define clinically effective methods of health-worker training to support hiv/aids care in mozambique and similarly resource-constrained environments.
amod||patients-2/NNS||chronichepatitisc-1/JJ	nsubj||fail-4/VBP||patients-2/NNS	nsubj||respond-6/VB||patients-2/NNS	advmod||fail-4/VBP||often-3/RB	root||ROOT-0/null||fail-4/VBP	aux||respond-6/VB||to-5/TO	xcomp||fail-4/VBP||respond-6/VB	amod||therapies-9/NNS||interferon-based-8/JJ	prep_to||respond-6/VB||therapies-9/NNS	chronichepatitisc-1||interferon--1||yes||chronichepatitisc patients often fail to respond to interferon-based therapies.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	anemia-6||irondeficiency-5||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||aim-2/VBP||we-1/PRP	nsubj||study-4/VB||we-1/PRP	root||ROOT-0/null||aim-2/VBP	aux||study-4/VB||to-3/TO	xcomp||aim-2/VBP||study-4/VB	det||modulation-6/NN||the-5/DT	dobj||study-4/VB||modulation-6/NN	det||promoter-9/NN||this-8/DT	prep_of||modulation-6/NN||promoter-9/NN	prep_by||study-4/VB||cisplatin-11/NN	xcomp||study-4/VB||using-12/VBG	det||reporter-16/NN||an-13/DT	amod||reporter-16/NN||improved-14/VBN	nn||reporter-16/NN||fusion-15/NN	dobj||using-12/VBG||reporter-16/NN	amod||cells-20/NNS||ovarian-18/JJ	nn||cells-20/NNS||cancer-19/NN	prep_in||using-12/VBG||cells-20/NNS	nn||xenografts-23/NNS||tumor-22/NN	prep_in||using-12/VBG||xenografts-23/NNS	conj_and||cells-20/NNS||xenografts-23/NNS	amod||approach-27/NN||non-invasive-25/JJ	nn||approach-27/NN||imaging-26/NN	prep_by||using-12/VBG||approach-27/NN	tumor-22||cisplatin-11||no_rel||we aim to study the modulation of this promoter by cisplatin using an improved fusion reporter in ovarian cancer cells and tumor xenografts by non-invasive imaging approach.
nsubj||showed-27/VBD||cell-1/NN	amod||cell-1/NN||swelling-2/VBG	auxpass||increased-4/VBN||was-3/VBD	rcmod||cell-1/NN||increased-4/VBN	nn||-rrb--10/NNS||ammonia-6/NNP	nn||-rrb--10/NNS||-lrb--7/NNP	number||%-9/NN||43-8/CD	amod||-rrb--10/NNS||%-9/NN	agent||increased-4/VBN||-rrb--10/NNS	agent||increased-4/VBN||cytokines-13/NNS	conj_and||-rrb--10/NNS||cytokines-13/NNS	vmod||cytokines-13/NNS||-lrb--14/VBG	num||%-16/NN||37-15/CD	dobj||-lrb--14/VBG||%-16/NN	advmod||-lrb--14/VBG||-rrb--17/RB	num||co-treatment-22/NN||24-19/CD	amod||co-treatment-22/NN||h.-20/JJ	amod||co-treatment-22/NN||simultaneous-21/JJ	prep_at||-lrb--14/VBG||co-treatment-22/NN	prep_with||co-treatment-22/NN||cytokines-24/NNS	prep_with||co-treatment-22/NN||ammonia-26/NN	conj_and||cytokines-24/NNS||ammonia-26/NN	root||ROOT-0/null||showed-27/VBD	neg||swelling-30/NN||no-28/DT	amod||swelling-30/NN||additional-29/JJ	dobj||showed-27/VBD||swelling-30/NN	swelling-30||ammonia-26||no_rel||cell swelling was increased by ammonia -lrb- 43 % -rrb- and by cytokines -lrb- 37 % -rrb- at 24 h. simultaneous co-treatment with cytokines and ammonia showed no additional swelling .
amod||abstinence-2/NN||sexual-1/JJ	nsubj||option-7/NN||abstinence-2/NN	cop||option-7/NN||is-3/VBZ	det||option-7/NN||the-4/DT	dep||available-6/JJ||best-5/JJS	amod||option-7/NN||available-6/JJ	root||ROOT-0/null||option-7/NN	prepc_for||option-7/NN||preventing-9/VBG	det||pregnancy-11/NN||both-10/DT	dobj||preventing-9/VBG||pregnancy-11/NN	dobj||preventing-9/VBG||sexuallytransmittedinfections-13/NNS	conj_and||pregnancy-11/NN||sexuallytransmittedinfections-13/NNS	prep_including||option-7/NN||hiv/aids-16/NNS	aids--1||hiv--1||no||sexual abstinence is the best available option for preventing both pregnancy and sexuallytransmittedinfections, including hiv/aids.
nsubj||affects-5/VBZ||hiv/aids-1/NNS	prep_in||hiv/aids-1/NNS||india-3/NN	advmod||affects-5/VBZ||disproportionately-4/RB	root||ROOT-0/null||affects-5/VBZ	dobj||affects-5/VBZ||women-6/NNS	neg||affects-5/VBZ||not-8/RB	poss||risks-12/NNS||their-10/PRP$	amod||risks-12/NNS||own-11/JJ	prep_by||affects-5/VBZ||risks-12/NNS	prep_by||affects-5/VBZ||those-16/DT	conj_but||risks-12/NNS||those-16/DT	poss||partners-19/NNS||their-18/PRP$	prep_of||those-16/DT||partners-19/NNS	advmod||those-16/DT||generally-21/RB	poss||spouses-23/NNS||their-22/PRP$	dep||those-16/DT||spouses-23/NNS	aids--1||hiv--1||no||hiv/aids in india disproportionately affects women, not by their own risks, but by those of their partners, generally their spouses.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||chloroquine-38||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
amod||arthroplasty-4/NN||metal-on-metal-1/JJ	nn||arthroplasty-4/NN||hip-2/NN	amod||arthroplasty-4/NN||resurfacing-3/VBG	nsubj||offer-10/VB||arthroplasty-4/NN	nn||hra-7/NN||mom-6/NN	appos||arthroplasty-4/NN||hra-7/NN	aux||offer-10/VB||may-9/MD	root||ROOT-0/null||offer-10/VB	amod||advantages-12/NNS||potential-11/JJ	dobj||offer-10/VB||advantages-12/NNS	amod||arthroplasty-16/NN||total-14/JJ	nn||arthroplasty-16/NN||hip-15/NN	prep_over||offer-10/VB||arthroplasty-16/NN	appos||arthroplasty-16/NN||tha-18/NN	amod||patients-22/NNS||certain-21/JJ	prep_for||arthroplasty-16/NN||patients-22/NNS	amod||osteoarthritis-25/NNS||advanced-24/VBN	prep_with||offer-10/VB||osteoarthritis-25/NNS	det||hip-28/NN||the-27/DT	prep_of||osteoarthritis-25/NNS||hip-28/NN	tha-18||osteoarthritis-25||no_rel||metal-on-metal hip resurfacing arthroplasty (mom hra) may offer potential advantages over total hip arthroplasty (tha) for certain patients with advanced osteoarthritis of the hip.
det||outbreak-3/NN||an-2/DT	prep_during||revealed-17/VBD||outbreak-3/NN	amod||sars-7/NNS||severeacuterespiratorysyndrome-5/JJ	prep_of||outbreak-3/NN||sars-7/NNS	prep_in||sars-7/NNS||march-10/NN	num||march-10/NN||2003-11/CD	nsubj||revealed-17/VBD||hybridization-13/NN	det||microarray-16/NN||this-15/DT	prep_to||hybridization-13/NN||microarray-16/NN	root||ROOT-0/null||revealed-17/VBD	det||presence-19/NN||the-18/DT	dobj||revealed-17/VBD||presence-19/NN	det||coronavirus-24/NNS||a-21/DT	advmod||uncharacterized-23/JJ||previously-22/RB	amod||coronavirus-24/NNS||uncharacterized-23/JJ	prep_of||presence-19/NN||coronavirus-24/NNS	det||cultivated-29/NNS||a-26/DT	amod||cultivated-29/NNS||viral-27/JJ	num||cultivated-29/NNS||isolate-28/CD	prep_in||coronavirus-24/NNS||cultivated-29/NNS	det||patient-33/NN||a-31/DT	amod||patient-33/NN||sars-32/JJ	prep_from||revealed-17/VBD||patient-33/NN	sars-32||coronavirus-24||no||during an outbreak of severeacuterespiratorysyndrome (sars) in march 2003, hybridization to this microarray revealed the presence of a previously uncharacterized coronavirus in a viral isolate cultivated from a sars patient.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||difference-5/NN||no-3/DT	amod||difference-5/NN||significant-4/JJ	nsubj||was-2/VBD||difference-5/NN	det||groups-9/NNS||the-7/DT	num||groups-9/NNS||two-8/CD	prep_between||difference-5/NN||groups-9/NNS	prep_with||was-2/VBD||regard-11/NN	det||incidence-14/NN||the-13/DT	prep_to||was-2/VBD||incidence-14/NN	prep_of||incidence-14/NN||complications-16/NNS	det||incidence-21/NN||an-19/DT	amod||incidence-21/NN||increased-20/VBN	prep_except_for||was-2/VBD||incidence-21/NN	nsubj||necessitated-28/VBD||incidence-21/NN	nn||pain-24/NN||breakthrough-23/NN	prep_of||incidence-21/NN||pain-24/NN	prep_of||incidence-21/NN||discomfort-26/NN	conj_and||pain-24/NN||discomfort-26/NN	rcmod||incidence-21/NN||necessitated-28/VBD	det||use-30/NN||the-29/DT	dobj||necessitated-28/VBD||use-30/NN	prep_of||use-30/NN||fentanyl-32/NN	mark||p-41/VBP||as-33/IN	det||treatment-36/NN||a-34/DT	nn||treatment-36/NN||rescue-35/NN	nsubj||p-41/VBP||treatment-36/NN	det||group-40/NN||the-38/DT	amod||group-40/NN||propofol-39/JJ	prep_in||treatment-36/NN||group-40/NN	advcl||necessitated-28/VBD||p-41/VBP	number||0.001-43/CD||<-42/CD	dobj||p-41/VBP||0.001-43/CD	pain-24||fentanyl-32||yes||there was no significant difference between the two groups with regard to the incidence of complications except for an increased incidence of breakthrough pain and discomfort which necessitated the use of fentanyl as a rescue treatment in the propofol group p <0.001.
det||proportion-2/NN||the-1/DT	nsubj||low-12/JJ||proportion-2/NN	prep_of||proportion-2/NN||disclosure-4/NN	amod||diagnosis-7/NN||hiv/aids-6/JJ	prep_of||disclosure-4/NN||diagnosis-7/NN	amod||children-10/NNS||hiv-infected-9/JJ	prep_to||diagnosis-7/NN||children-10/NNS	cop||low-12/JJ||is-11/VBZ	root||ROOT-0/null||low-12/JJ	aids--1||hiv--1||no||the proportion of disclosure of hiv/aids diagnosis to hiv-infected children is low.
det||findings-2/NNS||these-1/DT	nsubj||extend-3/VB||findings-2/NNS	nsubj||possess-12/VB||findings-2/NNS	nsubj||highlight-18/VB||findings-2/NNS	root||ROOT-0/null||extend-3/VB	det||range-6/NN||the-4/DT	nn||range-6/NN||host-5/NN	dobj||extend-3/VB||range-6/NN	det||influenzavirus-10/NNS||the-8/DT	amod||influenzavirus-10/NNS||h5n1-9/JJ	prep_of||range-6/NN||influenzavirus-10/NNS	conj_and||extend-3/VB||possess-12/VB	dobj||possess-12/VB||implications-13/NNS	prep_for||implications-13/NNS||influenzavirus-15/NNS	advmod||possess-12/VB||epidemiology-16/RB	conj_and||extend-3/VB||highlight-18/VB	det||need-20/NN||the-19/DT	dobj||highlight-18/VB||need-20/NN	det||surveillance-24/NN||the-22/DT	amod||surveillance-24/NN||systematic-23/JJ	prep_for||need-20/NN||surveillance-24/NN	prep_of||surveillance-24/NN||h5n1-26/CD	prep_in||highlight-18/VB||animals-28/NNS	det||vicinity-31/NN||the-30/DT	prep_in||animals-28/NNS||vicinity-31/NN	nn||units-35/NNS||backyard-33/NN	nn||units-35/NNS||poultry-34/NN	prep_of||vicinity-31/NN||units-35/NNS	advmod||highlight-18/VB||especially-36/RB	amod||areas-39/NNS||endemic-38/JJ	prep_in||highlight-18/VB||areas-39/NNS	h5n1-26||influenzavirus-15||no||these findings extend the host range of the h5n1 influenzavirus, possess implications for influenzavirus epidemiology and highlight the need for the systematic surveillance of h5n1 in animals in the vicinity of backyard poultry units especially in endemic areas.
nsubj||lead-3/VB||denguevirusinfection-1/NN	aux||lead-3/VB||can-2/MD	root||ROOT-0/null||lead-3/VB	prep_to||lead-3/VB||denguefever-5/NN	appos||denguefever-5/NN||df-7/NN	prep_to||lead-3/VB||denguehemorrhagicfever-10/NN	conj_or||denguefever-5/NN||denguehemorrhagicfever-10/NN	appos||denguefever-5/NN||dhf-12/NN	denguehemorrhagicfever-10||denguevirus--1||no||denguevirusinfection can lead to denguefever (df) or denguehemorrhagicfever (dhf).
det||cancer-2/NN||the-1/DT	nsubj||stem-3/VBP||cancer-2/NN	root||ROOT-0/null||stem-3/VBP	nn||theory-5/NN||cell-4/NN	nsubj||suggests-6/VBZ||theory-5/NN	ccomp||stem-3/VBP||suggests-6/VBZ	nsubj||persist-8/VB||cscs-7/NNS	nsubj||cause-16/VB||cscs-7/NNS	ccomp||suggests-6/VBZ||persist-8/VB	prep_in||persist-8/VB||tumors-10/NNS	det||population-14/NN||a-12/DT	amod||population-14/NN||distinct-13/JJ	prep_as||tumors-10/NNS||population-14/NN	ccomp||suggests-6/VBZ||cause-16/VB	conj_and||persist-8/VB||cause-16/VB	dobj||cause-16/VB||relapse-17/NN	dobj||cause-16/VB||metastasis-19/NNS	conj_and||relapse-17/NN||metastasis-19/NNS	prepc_by||cause-16/VB||giving-21/VBG	dobj||giving-21/VBG||rise-22/NN	amod||tumors-25/NNS||new-24/JJ	prep_to||giving-21/VBG||tumors-25/NNS	rise-22||metastasis-19||no_rel||the cancer stem cell theory suggests cscs persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||lipid-40||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
mark||correlate-16/VBP||although-1/IN	amod||levels-3/NNS||increased-2/VBN	nsubj||correlate-16/VBP||levels-3/NNS	amod||interferon-8/NN||systemic-5/JJ	nn||interferon-8/NN||type-6/NN	nn||interferon-8/NN||i-7/NN	prep_of||levels-3/NNS||interferon-8/NN	amod||±-11/NN||ifnî-10/JJ	dep||interferon-8/NN||±-11/NN	nn||²-14/NN||î-13/NN	dep||interferon-8/NN||²-14/NN	conj_and||±-11/NN||²-14/NN	advcl||demonstrated-36/VBN||correlate-16/VBP	amod||resolution-19/NN||accelerated-18/VBN	prep_with||correlate-16/VBP||resolution-19/NN	prep_of||resolution-19/NN||rotavirusdisease-21/NN	amod||strains-25/NNS||multiple-23/JJ	nn||strains-25/NNS||rotavirus-24/NNS	nsubjpass||demonstrated-36/VBN||strains-25/NNS	nsubj||antagonize-38/VB||strains-25/NNS	amod||rotavirus-29/NNS||rhesus-28/JJ	prep_including||strains-25/NNS||rotavirus-29/NNS	appos||rotavirus-29/NNS||rrv-31/NN	aux||demonstrated-36/VBN||have-34/VBP	auxpass||demonstrated-36/VBN||been-35/VBN	root||ROOT-0/null||demonstrated-36/VBN	aux||antagonize-38/VB||to-37/TO	xcomp||demonstrated-36/VBN||antagonize-38/VB	nn||production-42/NN||type-39/FW	nn||production-42/NN||i-40/FW	nn||production-42/NN||ifn-41/NN	dobj||antagonize-38/VB||production-42/NN	det||variety-45/NN||a-44/DT	prep_in||production-42/NN||variety-45/NN	amod||types-51/NNS||epithelial-47/JJ	conj_and||epithelial-47/JJ||fibroblast-49/JJ	amod||types-51/NNS||fibroblast-49/JJ	nn||types-51/NNS||cell-50/NN	prep_of||variety-45/NN||types-51/NNS	amod||mechanisms-54/NNS||several-53/JJ	prep_through||antagonize-38/VB||mechanisms-54/NNS	prep_including||antagonize-38/VB||degradation-57/NN	amod||factors-62/NNS||multiple-59/JJ	amod||factors-62/NNS||interferon-60/JJ	amod||factors-62/NNS||regulatory-61/JJ	prep_of||degradation-57/NN||factors-62/NNS	det||protein-67/NN||a-64/DT	amod||protein-67/NN||viral-65/JJ	amod||protein-67/NN||nonstructural-66/JJ	prep_by||factors-62/NNS||protein-67/NN	rotavirusdisease-21||rotavirus-29||no||although increased levels of systemic type i interferon (ifnî± and î²) correlate with accelerated resolution of rotavirusdisease, multiple rotavirus strains, including rhesus rotavirus (rrv), have been demonstrated to antagonize type i ifn production in a variety of epithelial and fibroblast cell types through several mechanisms, including degradation of multiple interferon regulatory factors by a viral nonstructural protein.
amod||catheters-2/NNS||antibiotic-impregnated-1/JJ	nsubjpass||associated-4/VBN||catheters-2/NNS	auxpass||associated-4/VBN||were-3/VBD	root||ROOT-0/null||associated-4/VBN	det||decrease-8/NN||a-6/DT	amod||decrease-8/NN||significant-7/JJ	prep_with||associated-4/VBN||decrease-8/NN	preconj||overall-11/JJ||both-10/DT	prep_in||decrease-8/NN||overall-11/JJ	prep_in||decrease-8/NN||staphylococcalinfection-13/JJ	conj_and||overall-11/JJ||staphylococcalinfection-13/JJ	dep||decrease-8/NN||p-15/VBN	dep||0.030-17/CD||=-16/SYM	ccomp||p-15/VBN||0.030-17/CD	dep||decrease-8/NN||p-19/VBN	conj_and||p-15/VBN||p-19/VBN	dep||0.045-21/CD||=-20/SYM	ccomp||p-19/VBN||0.045-21/CD	dep||p-19/VBN||respectively-23/RB	staphylococcalinfection-13||antibiotic--1||no_rel||antibiotic-impregnated catheters were associated with a significant decrease in both overall and staphylococcalinfection ( p = 0.030 and p = 0.045, respectively).
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||propofol-46||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
amod||viruses-3/NNS||several-1/JJ	nn||viruses-3/NNS||hepatitis-2/NN	nsubjpass||associated-19/VBN||viruses-3/NNS	prep_such_as||viruses-3/NNS||hav-6/NN	prep_such_as||viruses-3/NNS||hbv-8/NN	conj_and||hav-6/NN||hbv-8/NN	prep_such_as||viruses-3/NNS||hcv-10/NN	conj_and||hav-6/NN||hcv-10/NN	prep_such_as||viruses-3/NNS||hdv-12/NN	conj_and||hav-6/NN||hdv-12/NN	prep_such_as||viruses-3/NNS||hev-14/NN	conj_and||hav-6/NN||hev-14/NN	prep_such_as||viruses-3/NNS||hgv-16/NN	conj_and||hav-6/NN||hgv-16/NN	aux||associated-19/VBN||have-17/VBP	auxpass||associated-19/VBN||been-18/VBN	root||ROOT-0/null||associated-19/VBN	det||set-22/NN||this-21/DT	prep_with||associated-19/VBN||set-22/NN	prep_of||set-22/NN||symptoms-24/NNS	hbv-8||viruses-3||no||several hepatitis viruses such as hav, hbv, hcv, hdv, hev and hgv have been associated with this set of symptoms.
mark||reached-11/VBN||after-1/IN	det||concentration-6/NN||the-2/DT	nn||concentration-6/NN||target-3/NN	nn||concentration-6/NN||effect-4/NN	nn||concentration-6/NN||site-5/NN	nsubjpass||reached-11/VBN||concentration-6/NN	prep_of||concentration-6/NN||remifentanil-8/NN	aux||reached-11/VBN||had-9/VBD	auxpass||reached-11/VBN||been-10/VBN	advcl||controlled-15/VBD||reached-11/VBN	det||target-14/NN||the-13/DT	nsubj||controlled-15/VBD||target-14/NN	root||ROOT-0/null||controlled-15/VBD	nsubjpass||started-20/VBN||infusion-16/NN	prep_of||infusion-16/NN||propofol-18/NN	auxpass||started-20/VBN||was-19/VBD	dep||controlled-15/VBD||started-20/VBN	amod||pain-23/NN||propofol-induced-22/JJ	nsubjpass||recorded-25/VBN||pain-23/NN	auxpass||recorded-25/VBN||was-24/VBD	dep||controlled-15/VBD||recorded-25/VBN	conj_and||started-20/VBN||recorded-25/VBN	pain-23||propofol-18||yes||after the target effect site concentration of remifentanil had been reached, the target controlled infusion of propofol was started and propofol-induced pain was recorded.
det||three-2/CD||the-1/DT	nsubjpass||intensified-4/VBN||three-2/CD	auxpass||intensified-4/VBN||are-3/VBP	root||ROOT-0/null||intensified-4/VBN	nn||screening-6/NN||tb-5/NN	dobj||intensified-4/VBN||screening-6/NN	appos||screening-6/NN||icf-8/NN	prep_among||intensified-4/VBN||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv-14/NN	det||provision-17/NN||the-16/DT	appos||hiv-14/NN||provision-17/NN	amod||therapy-21/NN||isoniazid-19/JJ	nn||therapy-21/NN||preventive-20/NN	prep_of||provision-17/NN||therapy-21/NN	appos||therapy-21/NN||ipt-23/NN	nn||control-28/NN||tb-26/NN	nn||control-28/NN||infection-27/NN	prep_of||provision-17/NN||control-28/NN	conj_and||therapy-21/NN||control-28/NN	appos||therapy-21/NN||ic-30/NN	tb-26||isoniazid-19||yes||the three are intensified tb screening (icf) among people living with hiv, the provision of isoniazid preventive therapy (ipt) and tb infection control(ic).
det||compound-5/NN||the-2/DT	amod||compound-5/NN||chiral-3/JJ	nn||compound-5/NN||title-4/NN	prep_in||zidovudine-19/VBP||compound-5/NN	nsubj||zidovudine-19/VBP||c14h17clo7s-7/NNS	det||drug-18/NN||an-9/DT	amod||drug-18/NN||interâmediate-10/JJ	det||synthesis-13/NN||the-12/DT	prep_in||interâmediate-10/JJ||synthesis-13/NN	det||aids-16/NNS||the-15/DT	prep_of||synthesis-13/NN||aids-16/NNS	nn||drug-18/NN||treatment-17/NN	appos||c14h17clo7s-7/NNS||drug-18/NN	root||ROOT-0/null||zidovudine-19/VBP	det||ring-23/NN||the-21/DT	amod||ring-23/NN||threose-22/JJ	nsubj||adopts-24/VBZ||ring-23/NN	parataxis||zidovudine-19/VBP||adopts-24/VBZ	det||configuration-27/NN||an-25/DT	nn||configuration-27/NN||envelope-26/NN	dobj||adopts-24/VBZ||configuration-27/NN	det||atom-32/NN||the-30/DT	nn||atom-32/NN||o-31/NN	prep_with||zidovudine-19/VBP||atom-32/NN	det||position-36/NN||the-34/DT	nn||position-36/NN||flap-35/NN	prep_at||zidovudine-19/VBP||position-36/NN	aids-16||zidovudine-19||yes||in the chiral title compound, c14h17clo7s, an interâ­mediate in the synthesis of the aids treatment drug zidovudine, the threose ring adopts an envelope configuration, with the o atom at the flap position.
amod||models-3/NNS||logistic-1/JJ	nn||models-3/NNS||regression-2/NN	nsubjpass||fitted-5/VBN||models-3/NNS	nsubj||assess-7/VB||models-3/NNS	auxpass||fitted-5/VBN||were-4/VBD	root||ROOT-0/null||fitted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||fitted-5/VBN||assess-7/VB	det||association-9/NN||the-8/DT	dobj||assess-7/VB||association-9/NN	amod||geometric-12/JJ||stavudine-11/JJ	amod||ratio-14/NN||geometric-12/JJ	amod||ratio-14/NN||mean-13/JJ	prep_between||association-9/NN||ratio-14/NN	number||1-16/CD||>-15/CD	num||ratio-14/NN||1-16/CD	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	dobj||assess-7/VB||glucose-20/NN	conj_and||association-9/NN||glucose-20/NN	appos||glucose-20/NN||impairedglucosetolerance-22/NN	appos||glucose-20/NN||hyperlactataemia-24/NN	conj_and||impairedglucosetolerance-22/NN||hyperlactataemia-24/NN	appos||glucose-20/NN||hypertriglyceridaemia-26/NN	conj_and||impairedglucosetolerance-22/NN||hypertriglyceridaemia-26/NN	appos||glucose-20/NN||lipoatrophy-29/NN	conj_and||impairedglucosetolerance-22/NN||lipoatrophy-29/NN	fitted-5||glucose-20||no_rel||logistic regression models were fitted to assess the association between stavudine geometric mean ratio > 1 and impaired fasting glucose, impairedglucosetolerance, hyperlactataemia, hypertriglyceridaemia, and lipoatrophy.
amod||sleepapnea-2/NN||obstructive-1/JJ	nsubj||common-4/JJ||sleepapnea-2/NN	cop||common-4/JJ||is-3/VBZ	root||ROOT-0/null||common-4/JJ	prep_in||common-4/JJ||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	poss||association-12/NN||its-11/PRP$	nsubjpass||examined-19/VBN||association-12/NN	prep_with||association-12/NN||insulin-14/NN	prep_with||association-12/NN||insulinresistance-16/NN	conj_and||insulin-14/NN||insulinresistance-16/NN	aux||examined-19/VBN||has-17/VBZ	auxpass||examined-19/VBN||been-18/VBN	conj_and||common-4/JJ||examined-19/VBN	amod||studies-22/NNS||cross-sectional-21/JJ	prep_in||examined-19/VBN||studies-22/NNS	insulin-14||cross--1||no_rel||obstructive sleepapnea is common in patients with type2diabetes, and its association with insulin and insulinresistance has been examined in cross-sectional studies.
advmod||used-27/VBN||however-1/RB	mark||susceptible-7/JJ||because-3/IN	nsubj||susceptible-7/JJ||ferrets-4/NNS	cop||susceptible-7/JJ||are-5/VBP	advmod||susceptible-7/JJ||naturally-6/RB	advcl||used-27/VBN||susceptible-7/JJ	prep_to||susceptible-7/JJ||infection-9/NN	prep_with||infection-9/NN||humaninfluenzaviruses-11/NNS	mark||resembles-17/VBZ||because-13/IN	det||state-16/NN||the-14/DT	nn||state-16/NN||disease-15/NN	nsubj||resembles-17/VBZ||state-16/NN	conj_and||susceptible-7/JJ||resembles-17/VBZ	advcl||used-27/VBN||resembles-17/VBZ	xcomp||resembles-17/VBZ||that-18/DT	prep_of||that-18/DT||humaninfluenza-20/NN	det||animals-23/NNS||these-22/DT	nsubjpass||used-27/VBN||animals-23/NNS	nsubj||study-32/VB||animals-23/NNS	aux||used-27/VBN||have-24/VBP	auxpass||used-27/VBN||been-25/VBN	advmod||used-27/VBN||widely-26/RB	root||ROOT-0/null||used-27/VBN	det||model-30/NN||a-29/DT	prep_as||used-27/VBN||model-30/NN	aux||study-32/VB||to-31/TO	xcomp||used-27/VBN||study-32/VB	amod||pathogenesis-34/NNS||influenzavirus-33/JJ	dobj||study-32/VB||pathogenesis-34/NNS	humaninfluenza-20||influenzaviruses--1||no||however, because ferrets are naturally susceptible to infection with humaninfluenzaviruses and because the disease state resembles that of humaninfluenza, these animals have been widely used as a model to study influenzavirus pathogenesis.
nsubj||were-2/VBD||results-1/NNS	root||ROOT-0/null||were-2/VBD	prepc_compared_to||were-2/VBD||to-4/TO	det||performance-6/NN||the-5/DT	pobj||were-2/VBD||performance-6/NN	num||enzymes-10/NNS||two-8/CD	amod||enzymes-10/NNS||commercial-9/JJ	prep_of||performance-6/NN||enzymes-10/NNS	amod||1000-13/NN||accellerase-12/JJ	dep||enzymes-10/NNS||1000-13/NN	nn||cp-16/NN||spezyme-15/NN	dep||enzymes-10/NNS||cp-16/NN	conj_and||1000-13/NN||cp-16/NN	det||loadings-22/NNS||the-19/DT	amod||loadings-22/NNS||same-20/JJ	nn||loadings-22/NNS||protein-21/NN	prep_at||enzymes-10/NNS||loadings-22/NNS	cp-16||enzymes-10||no_rel||results were compared to the performance of two commercial enzymes (accellerase 1000 and spezyme cp) at the same protein loadings.
mark||improve-5/VB||whether-1/IN	amod||treatment-3/NN||cysteamine-2/JJ	nsubj||improve-5/VB||treatment-3/NN	aux||improve-5/VB||can-4/MD	csubj||unknown-14/JJ||improve-5/VB	amod||functioning-7/NN||cognitive-6/JJ	dobj||improve-5/VB||functioning-7/NN	amod||patients-10/NNS||cystinosis-9/JJ	prep_of||functioning-7/NN||patients-10/NNS	cop||unknown-14/JJ||is-11/VBZ	advmod||unknown-14/JJ||thus-12/RB	advmod||unknown-14/JJ||far-13/RB	root||ROOT-0/null||unknown-14/JJ	cystinosis-9||cysteamine-2||yes||whether cysteamine treatment can improve cognitive functioning of cystinosis patients is thus far unknown.
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||effect-4/NN||the-3/DT	dobj||examine-2/VB||effect-4/NN	amod||iron-7/NN||intravenous-6/JJ	prep_of||effect-4/NN||iron-7/NN	nn||agents-10/NNS||erythropoietin-stimulating-9/NN	prep_of||effect-4/NN||agents-10/NNS	conj_and||iron-7/NN||agents-10/NNS	appos||iron-7/NN||esas-12/NNS	amod||control-16/NN||glycemic-15/JJ	prep_on||examine-2/VB||control-16/NN	prep_on||examine-2/VB||a1c-18/NNS	conj_and||control-16/NN||a1c-18/NNS	prep_of||control-16/NN||patients-20/NNS	nn||kidneydisease-25/NN||diabetes-22/NN	conj_and||diabetes-22/NN||chronic-24/JJ	nn||kidneydisease-25/NN||chronic-24/JJ	prep_with||patients-20/NNS||kidneydisease-25/NN	appos||kidneydisease-25/NN||ckd-27/NN	iron-7||kidneydisease-25||no_rel||to examine the effect of intravenous iron and erythropoietin-stimulating agents (esas) on glycemic control and a1c of patients with diabetes and chronic kidneydisease (ckd).
amod||studies-2/NNS||few-1/JJ	nsubj||documented-4/VBN||studies-2/NNS	aux||documented-4/VBN||have-3/VBP	root||ROOT-0/null||documented-4/VBN	det||contribution-6/NN||the-5/DT	dobj||documented-4/VBN||contribution-6/NN	prep_of||contribution-6/NN||hiv/aids-8/NNS	prep_to||documented-4/VBN||mortality-10/NN	prep_among||documented-4/VBN||children-12/NNS	num||years-15/NNS||15-14/CD	prep_under||children-12/NNS||years-15/NNS	aids--1||hiv--1||no||few studies have documented the contribution of hiv/aids to mortality among children under 15 years.
det||groups-4/NNS||the-1/DT	num||groups-4/NNS||three-2/CD	nn||groups-4/NNS||study-3/NN	nsubj||254-10/VBZ||groups-4/NNS	appos||groups-4/NNS||203-6/CD	prep_with||203-6/CD||aerd-8/NN	root||ROOT-0/null||254-10/VBZ	amod||asthma-13/NN||aspirin-tolerant-12/JJ	prep_with||254-10/VBZ||asthma-13/NN	appos||asthma-13/NN||ata-15/NN	amod||controls-22/NNS||274-19/JJ	amod||controls-22/NNS||normal-20/JJ	amod||controls-22/NNS||healthy-21/JJ	nsubjpass||recruited-27/VBN||controls-22/NNS	appos||controls-22/NNS||nc-24/NN	auxpass||recruited-27/VBN||were-26/VBD	conj_and||254-10/VBZ||recruited-27/VBN	amod||hospital-31/NN||ajou-29/JJ	nn||hospital-31/NN||university-30/NN	prep_from||recruited-27/VBN||hospital-31/NN	appos||hospital-31/NN||korea-33/NN	asthma-13||aspirin--1||no||the three study groups, 203 with aerd, 254 with aspirin-tolerant asthma (ata), and 274 normal healthy controls (nc) were recruited from ajou university hospital, korea.
nsubj||thromboembolism-9/VBP||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||risk-5/NN||the-4/DT	dobj||compare-3/VB||risk-5/NN	amod||venous-8/NNS||non-fatal-7/JJ	prep_of||risk-5/NN||venous-8/NNS	root||ROOT-0/null||thromboembolism-9/VBP	prep_in||thromboembolism-9/VBP||women-11/NNS	vmod||women-11/NNS||receiving-12/VBG	dobj||receiving-12/VBG||oralcontraceptives-13/NNS	vmod||oralcontraceptives-13/NNS||containing-14/VBG	dobj||containing-14/VBG||drospirenone-15/NN	prep_with||containing-14/VBG||that-17/DT	prep_in||that-17/DT||women-19/NNS	vmod||women-19/NNS||receiving-20/VBG	dobj||receiving-20/VBG||oralcontraceptives-21/NNS	vmod||oralcontraceptives-21/NNS||containing-22/VBG	acomp||containing-22/VBG||levonorgestrel-23/JJ	thromboembolism-9||levonorgestrel-23||no||objective to compare the risk of non-fatal venous thromboembolism in women receiving oralcontraceptives containing drospirenone with that in women receiving oralcontraceptives containing levonorgestrel.
nsubj||reviewed-2/VBN||we-1/PRP	nsubj||obtained-17/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	nsubj||isolates-4/VBZ||staphylococcusaureus-3/NNS	ccomp||reviewed-2/VBN||isolates-4/VBZ	det||facility-9/NN||a-6/DT	amod||facility-9/NN||large-7/JJ	nn||facility-9/NN||healthcare-8/NN	prep_from||isolates-4/VBZ||facility-9/NN	prep_in||facility-9/NN||montevideo-11/NN	advmod||a-14/DT||center-13/RB	dep||facility-9/NN||a-14/DT	conj_and||reviewed-2/VBN||obtained-17/VBN	dobj||obtained-17/VBN||information-18/NN	num||hospitals-22/NNS||3-20/CD	amod||hospitals-22/NNS||additional-21/JJ	prep_from||obtained-17/VBN||hospitals-22/NNS	prep_on||hospitals-22/NNS||patients-24/NNS	vmod||patients-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||ca-mrsa-27/NN	mrsa--1||staphylococcusaureus-3||no||we reviewed staphylococcusaureus isolates from a large healthcare facility in montevideo (center a) and obtained information from 3 additional hospitals on patients infected with ca-mrsa.
det||essence-2/NN||the-1/DT	nsubj||is-6/VBZ||essence-2/NN	poss||research-5/NN||our-4/PRP$	prep_of||essence-2/NN||research-5/NN	root||ROOT-0/null||is-6/VBZ	mark||characterized-28/VBN||that-7/IN	nsubjpass||characterized-28/VBN||patients-8/NNS	nsubjpass||characterized-28/VBN||patients-8/NNS	prep_with||patients-8/NNS||t1dm-10/NN	prep_with||patients-8/NNS||ht-12/NN	conj_and||t1dm-10/NN||ht-12/NN	prep_with||patients-8/NNS||microalbuminuria-15/NN	conj_and||t1dm-10/NN||microalbuminuria-15/NN	discourse||microalbuminuria-15/NN||ma-17/UH	conj_and||t1dm-10/NN||diabeticretinopathy-20/NN	conj_and||microalbuminuria-15/NN||diabeticretinopathy-20/NN	discourse||microalbuminuria-15/NN||dr-22/UH	appos||patients-8/NNS||ma/dr-25/NN	auxpass||characterized-28/VBN||are-27/VBP	ccomp||is-6/VBZ||characterized-28/VBN	ccomp||is-6/VBZ||characterized-28/VBN	conj_and||characterized-28/VBN||characterized-28/VBN	det||level-33/NN||a-30/DT	advmod||higher-32/JJR||significantly-31/RB	amod||level-33/NN||higher-32/JJR	agent||characterized-28/VBN||level-33/NN	prep_of||level-33/NN||vegf-35/NN	num||â-38/NN||340.23-37/CD	dep||vegf-35/NN||â-38/NN	punct||â-38/NN||±-39/:	npadvmod||â-41/RB||93.22-40/CD	prep||â-38/NN||â-41/RB	pobj||â-41/RB||$-42/$	num||$-42/$||‰-43/CD	advmod||â-41/RB||pgâ-44/RB	num||$-48/$||$-45/$	number||mlâ-47/CD||‰-46/CD	num||$-45/$||mlâ-47/CD	pobj||â-41/RB||$-48/$	num||$-48/$||1-50/CD	nn||serum-54/NN||blood-53/NN	prep_in||characterized-28/VBN||serum-54/NN	prep_in||serum-54/NN||comparison-56/NN	det||group-59/NN||the-58/DT	prep_with||characterized-28/VBN||group-59/NN	amod||patients-62/NNS||t1dm-61/JJ	prep_of||group-59/NN||patients-62/NNS	prep_without||characterized-28/VBN||ht-64/FW	prep_without||characterized-28/VBN||ma/dr-66/FW	conj_and||ht-64/FW||ma/dr-66/FW	num||â-69/NN||183.6-68/CD	dep||characterized-28/VBN||â-69/NN	punct||â-69/NN||±-70/:	num||â-72/NN||96.6-71/CD	dep||â-69/NN||â-72/NN	num||$-76/NNS||$-73/$	number||pgâ-75/CD||‰-74/CD	num||$-73/$||pgâ-75/CD	dep||â-72/NN||$-76/NNS	punct||â-69/NN||‰-77/:	dep||â-69/NN||mlâ-78/VBN	dobj||mlâ-78/VBN||$-79/$	num||$-79/$||1-81/CD	amod||controls-86/NNS||healthy-85/JJ	prep_with||characterized-28/VBN||controls-86/NNS	num||â-89/NN||145.32-88/CD	dep||controls-86/NNS||â-89/NN	punct||â-89/NN||±-90/:	npadvmod||â-92/RB||75.58-91/CD	prep||â-89/NN||â-92/RB	pobj||â-92/RB||$-93/$	num||$-93/$||‰-94/CD	advmod||â-92/RB||pgâ-95/RB	num||$-99/$||$-96/$	number||mlâ-98/CD||‰-97/CD	num||$-96/$||mlâ-98/CD	pobj||â-92/RB||$-99/$	num||$-99/$||1-101/CD	dr-22||essence-2||no_rel||the essence of our research is that patients with t1dm and ht and with microalbuminuria (ma) and diabeticretinopathy (dr) (ma/dr) are characterized by a significantly higher level of vegf (340.23â±93.22â€‰pgâ€‰mlâ€“1) in blood serum in comparison with the group of t1dm patients without ht and ma/dr (183.6â±96.6â€‰pgâ€‰mlâ€“1) and with healthy controls (145.32â±75.58â€‰pgâ€‰mlâ€“1).
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	bacterialmeningitis-30||immunoglobulin-16||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
det||hypermuscularity-3/NN||the-1/DT	amod||hypermuscularity-3/NN||marked-2/JJ	nsubj||reduces-10/VBZ||hypermuscularity-3/NN	prep_in||hypermuscularity-3/NN||mice-5/NNS	amod||deficiency-9/NN||constitutive-7/JJ	nn||deficiency-9/NN||myostatin-8/NN	prep_with||mice-5/NNS||deficiency-9/NN	root||ROOT-0/null||reduces-10/VBZ	amod||accumulation-12/NN||fat-11/JJ	dobj||reduces-10/VBZ||accumulation-12/NN	dobj||reduces-10/VBZ||hyperglycemia-14/NN	conj_and||accumulation-12/NN||hyperglycemia-14/NN	vmod||accumulation-12/NN||induced-15/VBN	amod||feeding-18/NN||high-fat-17/JJ	agent||induced-15/VBN||feeding-18/NN	nsubj||unclear-23/JJ||it-21/PRP	cop||unclear-23/JJ||is-22/VBZ	conj_but||reduces-10/VBZ||unclear-23/JJ	mark||has-38/VBZ||whether-24/IN	det||increase-27/NN||the-25/DT	amod||increase-27/NN||smaller-26/JJR	nsubj||has-38/VBZ||increase-27/NN	nn||mass-30/NN||muscle-29/NN	prep_in||increase-27/NN||mass-30/NN	vmod||mass-30/NN||caused-31/VBN	amod||loss-34/NN||postdevelopmental-33/JJ	agent||caused-31/VBN||loss-34/NN	nn||activity-37/NN||myostatin-36/NN	prep_of||loss-34/NN||activity-37/NN	ccomp||unclear-23/JJ||has-38/VBZ	amod||effects-41/NNS||beneficial-39/JJ	amod||effects-41/NNS||metabolic-40/JJ	dobj||has-38/VBZ||effects-41/NNS	amod||feeding-44/NN||high-fat-43/JJ	prep_during||has-38/VBZ||feeding-44/NN	hyperglycemia-14||fat-11||no_rel||the marked hypermuscularity in mice with constitutive myostatin deficiency reduces fat accumulation and hyperglycemia induced by high-fat feeding, but it is unclear whether the smaller increase in muscle mass caused by postdevelopmental loss of myostatin activity has beneficial metabolic effects during high-fat feeding.
aux||investigate-2/VB||to-1/TO	advcl||analyzed-37/VBD||investigate-2/VB	det||bases-5/NNS||the-3/DT	amod||bases-5/NNS||molecular-4/JJ	dobj||investigate-2/VB||bases-5/NNS	det||chemosensitivity-9/NN||the-7/DT	nn||chemosensitivity-9/NN||differential-8/NN	prep_of||bases-5/NNS||chemosensitivity-9/NN	nn||marrow-12/NN||bone-11/NN	prep_of||chemosensitivity-9/NN||marrow-12/NN	amod||cells-15/NNS||hematopoietic-13/JJ	nn||cells-15/NNS||stem-14/NN	dep||chemosensitivity-9/NN||cells-15/NNS	appos||cells-15/NNS||hsc-17/NN	nn||patients-22/NNS||cr-20/NN	nn||patients-22/NNS||aml-21/NN	prep_in||cells-15/NNS||patients-22/NNS	det||relationship-26/NN||the-25/DT	prep_of||bases-5/NNS||relationship-26/NN	conj_and||chemosensitivity-9/NN||relationship-26/NN	prep_between||relationship-26/NN||chemosensitivity-28/NN	vmod||investigate-2/VB||mobilizing-30/VBG	nn||rates-34/NNS||activity-31/NN	conj_and||activity-31/NN||relapse-33/NN	nn||rates-34/NNS||relapse-33/NN	dobj||mobilizing-30/VBG||rates-34/NNS	nsubj||analyzed-37/VBD||we-36/PRP	root||ROOT-0/null||analyzed-37/VBD	poss||profile-41/NN||their-38/PRP$	amod||profile-41/NN||am-39/JJ	nn||profile-41/NN||expression-40/NN	dobj||analyzed-37/VBD||profile-41/NN	prepc_by||analyzed-37/VBD||performing-43/VBG	amod||rt-pcr-46/NN||real-44/JJ	nn||rt-pcr-46/NN||time-45/NN	nsubj||genes-50/NNS||rt-pcr-46/NN	nsubj||compared-72/VBD||rt-pcr-46/NN	prep_of||rt-pcr-46/NN||84-48/CD	cop||genes-50/NNS||am-49/VBP	ccomp||performing-43/VBG||genes-50/NNS	amod||pools-54/NNS||cd34-52/JJ	amod||pools-54/NNS||+-53/JJ	prep_in||genes-50/NNS||pools-54/NNS	det||classes-59/NNS||the-56/DT	num||classes-59/NNS||two-57/CD	amod||classes-59/NNS||extreme-58/JJ	prep_from||pools-54/NNS||classes-59/NNS	prep_of||classes-59/NNS||patients-61/NNS	dep||chemosensitive-68/JJ||i.e.-63/FW	dep||chemosensitive-68/JJ||chemoresistant-65/JJ	dep||patients-61/NNS||highly-67/RB	advmod||chemosensitive-68/JJ||highly-67/RB	conj_and||chemosensitive-68/JJ||highly-67/RB	dep||patients-61/NNS||chemosensitive-68/JJ	ccomp||performing-43/VBG||compared-72/VBD	conj_and||genes-50/NNS||compared-72/VBD	dobj||compared-72/VBD||them-73/PRP	amod||controls-76/NNS||normal-75/JJ	prep_with||compared-72/VBD||controls-76/NNS	aml-21||bases-5||no_rel||to investigate the molecular bases of the differential chemosensitivity of bone marrow hematopoietic stem cells (hsc) in cr aml patients, and the relationship between chemosensitivity, mobilizing activity and relapse rates, we analyzed their am expression profile by performing real time rt-pcr of 84 am genes in cd34+ pools from the two extreme classes of patients (i.e., chemoresistant and highly chemosensitive), and compared them with normal controls.
nsubj||have-9/VBP||adults-1/NNS	amod||living-5/NN||african-caribbean-3/JJ	nn||living-5/NN||origin-4/NN	prep_of||adults-1/NNS||living-5/NN	det||uk-8/NN||the-7/DT	prep_in||living-5/NN||uk-8/NN	root||ROOT-0/null||have-9/VBP	amod||increases-11/NNS||smaller-10/JJR	dobj||have-9/VBP||increases-11/NNS	amod||risk-14/NN||type2diabetes-13/JJ	prep_in||increases-11/NNS||risk-14/NN	vmod||increases-11/NNS||raised-16/VBN	xcomp||raised-16/VBN||circulating-17/VBG	dobj||circulating-17/VBG||insulin-18/NN	dobj||circulating-17/VBG||hdl-cholesterol-20/NN	conj_and||insulin-18/NN||hdl-cholesterol-20/NN	amod||triglyceride-24/NN||low-23/JJ	dobj||have-9/VBP||triglyceride-24/NN	conj_and||increases-11/NNS||triglyceride-24/NN	amod||concentrations-28/NNS||c-reactive-26/JJ	nn||concentrations-28/NNS||protein-27/NN	conj_and||increases-11/NNS||concentrations-28/NNS	conj_and||triglyceride-24/NN||concentrations-28/NNS	cholesterol--1||type2diabetes-13||no_rel||adults of african-caribbean origin living in the uk have smaller increases in type2diabetes risk, raised circulating insulin and hdl-cholesterol, and low triglyceride and c-reactive protein concentrations.
amod||doses-2/NNS||pharmacological-1/JJ	nsubj||improve-5/VB||doses-2/NNS	nsubj||lower-9/VB||doses-2/NNS	nsubj||lead-15/VB||doses-2/NNS	nsubj||weight-17/VB||doses-2/NNS	prep_of||doses-2/NNS||fgf21-4/CD	root||ROOT-0/null||improve-5/VB	nn||tolerance-7/NN||glucose-6/NN	dobj||improve-5/VB||tolerance-7/NN	conj_and||improve-5/VB||lower-9/VB	amod||fattyacids-12/NNS||serum-10/JJ	amod||fattyacids-12/NNS||free-11/JJ	dobj||lower-9/VB||fattyacids-12/NNS	conj_and||improve-5/VB||lead-15/VB	aux||weight-17/VB||to-16/TO	xcomp||lead-15/VB||weight-17/VB	dobj||weight-17/VB||loss-18/NN	amod||mice-21/NNS||obese-20/JJ	prep_in||weight-17/VB||mice-21/NNS	obese-20||fattyacids-12||no_rel||pharmacological doses of fgf21 improve glucose tolerance, lower serum free fattyacids, and lead to weight loss in obese mice.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	enzyme-35||di--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
det||wake-3/NN||the-2/DT	prep_in||value-15/NN||wake-3/NN	det||epidemic-7/NN||the-5/DT	nn||epidemic-7/NN||hiv-6/NN	prep_of||wake-3/NN||epidemic-7/NN	amod||views-10/NNS||traditional-9/JJ	nsubj||value-15/NN||views-10/NNS	prep_of||views-10/NNS||children-12/NNS	cop||value-15/NN||'s-13/VBZ	amod||value-15/NN||social-14/JJ	root||ROOT-0/null||value-15/NN	amod||â-18/NN||domestic-17/JJ	prep_as||value-15/NN||â-18/NN	dep||value-15/NN||$-19/$	num||$-19/$||œhelpersâ-20/CD	amod||$-19/$||$-21/$	dep||$-21/$||have-22/JJ	vmod||$-19/$||evolved-23/VBN	nsubjpass||regarded-27/VBN||them-25/PRP	auxpass||regarded-27/VBN||being-26/VBG	prepc_into||evolved-23/VBN||regarded-27/VBN	amod||actors-32/NNS||capable-29/JJ	conj_and||capable-29/JJ||competent-31/JJ	amod||actors-32/NNS||competent-31/JJ	prep_as||regarded-27/VBN||actors-32/NNS	det||care-35/NN||the-34/DT	prep_in||regarded-27/VBN||care-35/NN	prep_in||regarded-27/VBN||support-37/NN	conj_and||care-35/NN||support-37/NN	prep_of||care-35/NN||people-39/NNS	vmod||people-39/NNS||living-40/VBG	prep_with||living-40/VBG||hiv-42/NN	prep_with||living-40/VBG||aids-44/NNS	conj_or||hiv-42/NN||aids-44/NNS	advmod||integral-48/JJ||as-47/RB	dep||value-15/NN||integral-48/JJ	conj_and||$-19/$||integral-48/JJ	nn||survival-51/NN||household-50/NN	prep_to||integral-48/JJ||survival-51/NN	aids-44||hiv-42||no||in the wake of the hiv epidemic, traditional views of children's social value as domestic â€œhelpersâ€? have evolved into them being regarded as capable and competent actors in the care and support of people living with hiv or aids, and as integral to household survival.
nsubj||common-3/JJ||diarrhea-1/NN	cop||common-3/JJ||is-2/VBZ	root||ROOT-0/null||common-3/JJ	amod||patients-6/NNS||hiv/aids-5/JJ	prep_in||common-3/JJ||patients-6/NNS	vmod||patients-6/NNS||caused-8/VBN	det||pathogens-13/NNS||both-10/DT	amod||pathogens-13/NNS||classic-11/JJ	amod||pathogens-13/NNS||enteric-12/JJ	agent||caused-8/VBN||pathogens-13/NNS	amod||agents-17/NNS||different-15/JJ	amod||agents-17/NNS||opportunistic-16/JJ	agent||caused-8/VBN||agents-17/NNS	conj_and||pathogens-13/NNS||agents-17/NNS	aids--1||hiv--1||no||diarrhea is common in hiv/aids patients, caused by both classic enteric pathogens and different opportunistic agents.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	num||infants-4/NNS||12-3/CD	nsubj||were-2/VBD||infants-4/NNS	nsubj||hbsag-7/VBG||infants-4/NNS	nsubj||had-10/VBD||infants-4/NNS	aux||hbsag-7/VBG||were-6/VBD	rcmod||infants-4/NNS||hbsag-7/VBG	acomp||hbsag-7/VBG||positive-8/JJ	rcmod||infants-4/NNS||had-10/VBD	conj_and||hbsag-7/VBG||had-10/VBD	det||genotypes-14/NNS||the-11/DT	amod||genotypes-14/NNS||same-12/JJ	nn||genotypes-14/NNS||hbv-13/NN	dobj||had-10/VBD||genotypes-14/NNS	poss||mothers-17/NNS||their-16/PRP$	prep_as||genotypes-14/NNS||mothers-17/NNS	hbv-13||hbsag-7||yes||there were 12 infants who were hbsag positive and had the same hbv genotypes as their mothers.
amod||ac-2/NN||accelerated-1/VBN	nsubj||regimens-11/NNS||ac-2/NN	conj_and||ac-2/NN||ec-4/NN	nsubj||regimens-11/NNS||ec-4/NN	prep_with||ac-2/NN||pegfilgrastim-6/NN	cop||regimens-11/NNS||are-7/VBP	amod||regimens-11/NNS||safe-8/JJ	conj_and||safe-8/JJ||feasible-10/JJ	amod||regimens-11/NNS||feasible-10/JJ	root||ROOT-0/null||regimens-11/NNS	det||treatment-14/NN||the-13/DT	prep_in||regimens-11/NNS||treatment-14/NN	amod||cancer-18/NN||early-16/JJ	nn||cancer-18/NN||breast-17/NN	prep_of||treatment-14/NN||cancer-18/NN	advmod||neutropenia-21/JJ||less-20/RBR	amod||schedules-26/NNS||neutropenia-21/JJ	amod||3-24/CD||conventional-23/JJ	prep_than||neutropenia-21/JJ||3-24/CD	amod||schedules-26/NNS||weekly-25/JJ	prep_with||cancer-18/NN||schedules-26/NNS	neutropenia-21||pegfilgrastim-6||yes||accelerated ac and ec with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules.
aux||determine-2/VB||to-1/TO	advcl||required-45/VBN||determine-2/VB	mark||associated-6/VBN||if-3/IN	nsubjpass||associated-6/VBN||upregulation-4/NN	auxpass||associated-6/VBN||is-5/VBZ	advcl||determine-2/VB||associated-6/VBN	det||risk-10/NN||an-8/DT	amod||risk-10/NN||increased-9/VBN	prep_with||associated-6/VBN||risk-10/NN	det||acquisition-13/NN||the-12/DT	prep_for||risk-10/NN||acquisition-13/NN	det||hypersensitivityreaction-18/NN||an-15/DT	amod||hypersensitivityreaction-18/NN||adverse-16/JJ	amod||hypersensitivityreaction-18/NN||cm-induced-17/JJ	prep_of||acquisition-13/NN||hypersensitivityreaction-18/NN	mark||associated-23/VBN||if-20/IN	nsubjpass||associated-23/VBN||downregulation-21/NN	auxpass||associated-23/VBN||is-22/VBZ	advcl||determine-2/VB||associated-23/VBN	conj_and||associated-6/VBN||associated-23/VBN	det||risk-26/NN||a-25/DT	prep_without||associated-23/VBN||risk-26/NN	det||acquisition-29/NN||the-28/DT	prep_for||risk-26/NN||acquisition-29/NN	det||hypersensitivityreaction-34/NN||an-31/DT	amod||hypersensitivityreaction-34/NN||adverse-32/JJ	amod||hypersensitivityreaction-34/NN||cm-induced-33/JJ	prep_of||acquisition-29/NN||hypersensitivityreaction-34/NN	amod||studies-37/NNS||further-36/JJ	nsubjpass||required-45/VBN||studies-37/NNS	det||population-41/NN||a-39/DT	amod||population-41/NN||larger-40/JJR	prep_with||studies-37/NNS||population-41/NN	prep_of||population-41/NN||patients-43/NNS	auxpass||required-45/VBN||are-44/VBP	root||ROOT-0/null||required-45/VBN	hypersensitivityreaction-34||hypersensitivityreaction-34||no||to determine if upregulation is associated with an increased risk for the acquisition of an adverse cm-induced hypersensitivityreaction and if downregulation is associated without a risk for the acquisition of an adverse cm-induced hypersensitivityreaction, further studies with a larger population of patients are required.
advmod||investigated-42/VBN||therefore-1/RB	det||effects-4/NNS||the-3/DT	nsubjpass||investigated-42/VBN||effects-4/NNS	amod||inhibitors-8/NNS||histone-6/JJ	nn||inhibitors-8/NNS||deacetylase-7/NN	prep_of||effects-4/NNS||inhibitors-8/NNS	prep_on||inhibitors-8/NNS||growth-10/NN	prep_of||growth-10/NN||neuroblastoma-12/NN	prep_of||growth-10/NN||combination-14/NN	conj_and||neuroblastoma-12/NN||combination-14/NN	det||compounds-17/NNS||these-16/DT	prep_of||growth-10/NN||compounds-17/NNS	prep_with||compounds-17/NNS||doxorubicin-19/NN	prep_with||compounds-17/NNS||cis-platin-21/NN	conj_and||doxorubicin-19/NN||cis-platin-21/NN	prep_with||compounds-17/NNS||etoposide-23/NN	conj_and||doxorubicin-19/NN||etoposide-23/NN	prep_with||compounds-17/NNS||ellipticine-25/NN	conj_and||doxorubicin-19/NN||ellipticine-25/NN	prep_on||inhibitors-8/NNS||mechanisms-29/NNS	conj_and||growth-10/NN||mechanisms-29/NNS	amod||effects-32/NNS||such-31/JJ	prep_of||mechanisms-29/NNS||effects-32/NNS	amod||lines-37/NNS||human-34/JJ	nn||lines-37/NNS||neuroblastona-35/NN	nn||lines-37/NNS||cell-36/NN	prep_in||effects-32/NNS||lines-37/NNS	prep_in||lines-37/NNS||vitro-39/NNP	auxpass||investigated-42/VBN||are-40/VBP	advmod||investigated-42/VBN||also-41/RB	root||ROOT-0/null||investigated-42/VBN	neuroblastoma-12||etoposide-23||yes||therefore, the effects of histone deacetylase inhibitors on growth of neuroblastoma and combination of these compounds with doxorubicin, cis-platin, etoposide and ellipticine as well as mechanisms of such effects in human neuroblastona cell lines in vitro are also investigated.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||lumefantrine--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
amod||publications-2/NNS||recent-1/JJ	nsubj||put-3/VBD||publications-2/NNS	root||ROOT-0/null||put-3/VBD	det||warning-6/NN||a-4/DT	amod||warning-6/NN||serious-5/JJ	dobj||put-3/VBD||warning-6/NN	det||inefficacy-9/NN||the-8/DT	prep_regarding||warning-6/NN||inefficacy-9/NN	amod||sp-13/NN||sulphadoxine-pyrimethamine-11/JJ	prep_of||inefficacy-9/NN||sp-13/NN	det||treatment-19/NN||the-16/DT	amod||treatment-19/NN||intermittent-17/JJ	nn||treatment-19/NN||preventive-18/NN	prep_for||sp-13/NN||treatment-19/NN	prep_of||treatment-19/NN||malaria-21/NN	amod||children-24/NNS||young-23/JJ	prep_in||malaria-21/NN||children-24/NNS	appos||children-24/NNS||ipti-26/NNP	malaria-21||pyrimethamine--1||yes||recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (sp) for the intermittent preventive treatment of malaria in young children (ipti).
det||model-4/NN||a-2/DT	nn||model-4/NN||rabbit-3/NN	prep_in||evaluated-27/VBN||model-4/NN	amod||osteoarthritis-7/NNS||collagenase-induced-6/JJ	prep_of||model-4/NN||osteoarthritis-7/NNS	det||effects-11/NNS||the-9/DT	amod||effects-11/NNS||additive-10/JJ	nsubjpass||evaluated-27/VBN||effects-11/NNS	amod||growthhormone-16/NN||intra-articular-13/JJ	amod||growthhormone-16/NN||recombinant-14/JJ	amod||growthhormone-16/NN||human-15/JJ	prep_of||effects-11/NNS||growthhormone-16/NN	dep||evaluated-27/VBN||gh-18/NN	nn||hyaluronicacid-22/NN||administration-20/NN	dep||hyaluronicacid-22/NN||to-21/TO	nsubjpass||evaluated-27/VBN||hyaluronicacid-22/NN	appos||hyaluronicacid-22/NN||ha-24/NN	auxpass||evaluated-27/VBN||were-26/VBD	root||ROOT-0/null||evaluated-27/VBN	hyaluronicacid-22||osteoarthritis-7||no_rel||in a rabbit model of collagenase-induced osteoarthritis, the additive effects of intra-articular recombinant human growthhormone (gh) administration to hyaluronicacid (ha) were evaluated.
amod||rats-4/NNS||forty-two-1/JJ	amod||rats-4/NNS||male-2/JJ	amod||rats-4/NNS||sprague-dawley-3/JJ	nsubjpass||divided-7/VBN||rats-4/NNS	auxpass||divided-7/VBN||were-5/VBD	advmod||divided-7/VBN||equally-6/RB	root||ROOT-0/null||divided-7/VBN	num||groups-10/NNS||six-9/CD	prep_into||divided-7/VBN||groups-10/NNS	nn||i-12/NNS||group-11/NN	dep||groups-10/NNS||i-12/NNS	appos||i-12/NNS||control-14/NN	amod||chow-19/NN||normal-17/JJ	nn||chow-19/NN||rat-18/NN	dep||groups-10/NNS||chow-19/NN	nn||ii-22/NN||group-21/NN	appos||chow-19/NN||ii-22/NN	amod||oil-26/NN||fresh-24/JJ	nn||oil-26/NN||soy-25/NN	dep||groups-10/NNS||oil-26/NN	nn||iii-29/NN||group-28/NN	appos||oil-26/NN||iii-29/NN	nn||oil-32/NN||soy-31/NN	dep||groups-10/NNS||oil-32/NN	amod||oil-32/NN||heated-33/JJ	dep||heated-33/JJ||once-34/RB	nn||iv-37/NN||group-36/NN	appos||once-34/RB||iv-37/NN	nn||oil-40/NN||soy-39/NN	dep||groups-10/NNS||oil-40/NN	amod||twice-42/JJ||heated-41/JJ	amod||oil-40/NN||twice-42/JJ	nn||v-45/NN||group-44/NN	appos||oil-40/NN||v-45/NN	nn||oil-48/NN||soy-47/NN	dep||groups-10/NNS||oil-48/NN	amod||oil-48/NN||heated-49/JJ	num||times-51/NNS||five-50/CD	dep||heated-49/JJ||times-51/NNS	nn||vi-54/NN||group-53/NN	appos||times-51/NNS||vi-54/NN	nn||oil-57/NN||soy-56/NN	dep||groups-10/NNS||oil-57/NN	amod||oil-57/NN||heated-58/JJ	num||times-60/NNS||ten-59/CD	dep||groups-10/NNS||times-60/NNS	oil-57||ten-59||no_rel||forty-two male sprague-dawley rats were equally divided into six groups group i (control) - normal rat chow, group ii - fresh soy oil, group iii - soy oil heated once, group iv - soy oil heated twice, group v - soy oil heated five times, group vi - soy oil heated ten times.
amod||access-2/NN||reliable-1/JJ	nsubj||improve-7/VB||access-2/NN	amod||services-5/NNS||basic-4/JJ	prep_to||access-2/NN||services-5/NNS	aux||improve-7/VB||can-6/MD	root||ROOT-0/null||improve-7/VB	det||community-9/NN||a-8/DT	poss||resilience-11/NN||community-9/NN	dobj||improve-7/VB||resilience-11/NN	prep_to||improve-7/VB||hiv/aids-13/NNS	aids--1||hiv--1||no||reliable access to basic services can improve a community's resilience to hiv/aids.
det||data-3/NNS||the-1/DT	amod||data-3/NNS||collective-2/JJ	nsubj||suggest-4/VBP||data-3/NNS	root||ROOT-0/null||suggest-4/VBP	mark||drug-10/NN||that-5/IN	nsubj||drug-10/NN||telmisartan-6/NN	cop||drug-10/NN||is-7/VBZ	det||drug-10/NN||a-8/DT	amod||drug-10/NN||promising-9/JJ	ccomp||suggest-4/VBP||drug-10/NN	prepc_for||drug-10/NN||controlling-12/VBG	dobj||controlling-12/VBG||hypertension-13/NN	prepc_for||drug-10/NN||reducing-15/VBG	conj_and||controlling-12/VBG||reducing-15/VBG	nn||risk-17/NN||vascular-16/NN	dobj||reducing-15/VBG||risk-17/NN	amod||patients-21/NNS||high-risk-19/JJ	amod||patients-21/NNS||elderly-20/JJ	prep_in||reducing-15/VBG||patients-21/NNS	amod||diabetes-24/NN||new-onset-23/JJ	prep_with||patients-21/NNS||diabetes-24/NN	hypertension-13||telmisartan-6||yes||the collective data suggest that telmisartan is a promising drug for controlling hypertension and reducing vascular risk in high-risk elderly patients with new-onset diabetes.
nn||modeling-3/NN||growth-1/NN	nn||modeling-3/NN||mixture-2/NN	nsubjpass||applied-8/VBN||modeling-3/NN	appos||modeling-3/NN||gmm-5/NN	auxpass||applied-8/VBN||was-7/VBD	root||ROOT-0/null||applied-8/VBN	prep_to||applied-8/VBN||data-10/NNS	det||study-18/NN||a-12/DT	amod||study-18/NN||randomized-13/JJ	amod||study-18/NN||double-blind-15/JJ	amod||study-18/NN||12-week-17/JJ	prep_from||data-10/NNS||study-18/NN	num||patients-21/NNS||628-20/CD	prep_of||study-18/NN||patients-21/NNS	prep_with||applied-8/VBN||schizophrenia-23/NN	prep_with||applied-8/VBN||schizo-affectivedisorder-25/NN	conj_or||schizophrenia-23/NN||schizo-affectivedisorder-25/NN	vmod||schizophrenia-23/NN||treated-26/VBN	prep_with||treated-26/VBN||risperidone-28/NN	prep_with||treated-26/VBN||olanzapine-30/NN	conj_or||risperidone-28/NN||olanzapine-30/NN	schizophrenia-23||risperidone-28||yes||growth mixture modeling (gmm) was applied to data from a randomized, double-blind, 12-week study of 628 patients with schizophrenia or schizo-affectivedisorder treated with risperidone or olanzapine.
aux||use-2/VB||to-1/TO	advcl||necessary-16/JJ||use-2/VB	dobj||use-2/VB||pyrimethamine-3/NN	det||drug-8/NN||an-5/DT	amod||drug-8/NN||alternative-6/JJ	amod||drug-8/NN||anti-malarial-7/JJ	prep_as||use-2/VB||drug-8/NN	amod||parasites-12/NNS||chloroquine-resistant-10/JJ	nn||parasites-12/NNS||malaria-11/NN	prep_for||drug-8/NN||parasites-12/NNS	nsubj||necessary-16/JJ||it-14/PRP	nsubj||determine-18/VB||it-14/PRP	cop||necessary-16/JJ||was-15/VBD	root||ROOT-0/null||necessary-16/JJ	aux||determine-18/VB||to-17/TO	xcomp||necessary-16/JJ||determine-18/VB	det||enzyme-20/NN||the-19/DT	poss||variation-23/NN||enzyme-20/NN	amod||variation-23/NN||genetic-22/JJ	dobj||determine-18/VB||variation-23/NN	amod||syntase-27/NN||dihydrofolate-25/JJ	amod||syntase-27/NN||reductase-thymidylate-26/JJ	prep_in||variation-23/NN||syntase-27/NN	appos||syntase-27/NN||dhfr-ts-29/NNS	nn||strains-33/NNS||korean-32/NN	prep_among||determine-18/VB||strains-33/NNS	malaria-11||pyrimethamine-3||yes||to use pyrimethamine as an alternative anti-malarial drug for chloroquine-resistant malaria parasites, it was necessary to determine the enzyme's genetic variation in dihydrofolate reductase-thymidylate syntase (dhfr-ts) among korean strains.
nsubjpass||isolated-15/VBN||influenzaviruses-1/NNS	prep_with||influenzaviruses-1/NNS||changes-3/NNS	prep_at||changes-3/NNS||aminoacids-5/NNS	num||aminoacids-5/NNS||627-6/CD	prep_at||changes-3/NNS||701-8/CD	conj_or||aminoacids-5/NNS||701-8/CD	det||protein-12/NN||the-10/DT	amod||protein-12/NN||pb2-11/JJ	prep_of||aminoacids-5/NNS||protein-12/NN	aux||isolated-15/VBN||have-13/VBP	auxpass||isolated-15/VBN||been-14/VBN	root||ROOT-0/null||isolated-15/VBN	amod||cases-18/NNS||human-17/JJ	prep_from||isolated-15/VBN||cases-18/NNS	advmod||pathogenic-21/JJ||highly-20/RB	amod||h5-22/NNS||pathogenic-21/JJ	prep_of||cases-18/NNS||h5-22/NNS	amod||avianinfluenza-25/NN||h7-24/JJ	prep_of||cases-18/NNS||avianinfluenza-25/NN	conj_and||h5-22/NNS||avianinfluenza-25/NN	avianinfluenza-25||influenzaviruses-1||no||influenzaviruses with changes at aminoacids 627 or 701 of the pb2 protein have been isolated from human cases of highly pathogenic h5 and h7 avianinfluenza.
number||thousand-2/CD||one-1/CD	nsubj||enrolled-15/VBD||thousand-2/CD	num||hundred-4/CD||nine-3/CD	dep||thousand-2/CD||hundred-4/CD	amod||patients-7/NNS||thirty-nine-6/JJ	conj_and||thousand-2/CD||patients-7/NNS	nsubj||using-13/VBG||patients-7/NNS	nsubj||enrolled-15/VBD||patients-7/NNS	prep_with||patients-7/NNS||type2diabetes-9/CD	aux||using-13/VBG||were-11/VBD	neg||using-13/VBG||not-12/RB	rcmod||patients-7/NNS||using-13/VBG	dobj||using-13/VBG||insulin-14/NN	root||ROOT-0/null||enrolled-15/VBD	det||research-19/NN||the-17/DT	amod||research-19/NN||translating-18/JJ	prep_in||enrolled-15/VBD||research-19/NN	prep_into||enrolled-15/VBD||action-21/NN	nn||study-24/NN||diabetes-23/NN	prep_for||action-21/NN||study-24/NN	dep||action-21/NN||triad-26/VBN	det||study-30/NN||a-29/DT	appos||action-21/NN||study-30/NN	nn||care-33/NN||diabetes-32/NN	prep_of||study-30/NN||care-33/NN	amod||care-36/NN||managed-35/VBN	prep_in||care-33/NN||care-36/NN	type2diabetes-9||insulin-14||yes||one thousand nine hundred and thirty-nine patients with type2diabetes who were not using insulin enrolled in the translating research into action for diabetes study (triad), a study of diabetes care in managed care.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	viremia-7||cyclophosphamide-50||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	adrenocorticotropin-11||pituitary-23||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
prep_in||analyzed-22/VBN||addition-2/NN	nn||samples-7/NNS||tumour-4/NN	conj_and||tumour-4/NN||serum-6/NN	nn||samples-7/NNS||serum-6/NN	nsubjpass||analyzed-22/VBN||samples-7/NNS	det||sub-cohort-10/NN||a-9/DT	prep_from||samples-7/NNS||sub-cohort-10/NN	num||ori-14/NN||14-12/CD	nn||ori-14/NN||mä-13/NN	prep_of||sub-cohort-10/NN||ori-14/NN	vmod||ori-14/NN||matched-15/VBN	num||patients-20/NNS||14-17/CD	nn||patients-20/NNS||nz-18/NN	nn||patients-20/NNS||european-19/NN	prep_to||matched-15/VBN||patients-20/NNS	auxpass||analyzed-22/VBN||were-21/VBD	root||ROOT-0/null||analyzed-22/VBN	agent||analyzed-22/VBN||immunohistochemistry-24/NN	agent||analyzed-22/VBN||enzyme-26/NN	conj_and||immunohistochemistry-24/NN||enzyme-26/NN	vmod||immunohistochemistry-24/NN||linked-27/VBN	amod||assay-29/NN||immunosorbent-28/JJ	dobj||linked-27/VBN||assay-29/NN	amod||factors-33/NNS||molecular-31/JJ	amod||factors-33/NNS||prognostic-32/JJ	prep_for||linked-27/VBN||factors-33/NNS	enzyme-26||tumour-4||no_rel||in addition, tumour and serum samples from a sub-cohort of 14 mä?ori matched to 14 nz european patients were analyzed by immunohistochemistry and enzyme linked immunosorbent assay for molecular prognostic factors.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prion-9||kuru-6||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipids-32||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
nsubjpass||associated-4/VBN||methazolamide-1/NN	aux||associated-4/VBN||may-2/MD	auxpass||associated-4/VBN||be-3/VB	root||ROOT-0/null||associated-4/VBN	amod||myopia-7/NN||secondary-6/JJ	prep_with||associated-4/VBN||myopia-7/NN	prep_with||associated-4/VBN||angleclosureglaucoma-9/NN	conj_and||myopia-7/NN||angleclosureglaucoma-9/NN	angleclosureglaucoma-9||methazolamide-1||yes||methazolamide may be associated with secondary myopia and angleclosureglaucoma.
amod||achievements-2/NNS||major-1/JJ	nsubjpass||reached-5/VBN||achievements-2/NNS	aux||reached-5/VBN||have-3/VBP	auxpass||reached-5/VBN||been-4/VBN	root||ROOT-0/null||reached-5/VBN	det||treatment-8/NN||the-7/DT	prep_in||reached-5/VBN||treatment-8/NN	prep_of||treatment-8/NN||rheumatoidarthritis-10/NNS	amod||decades-13/NNS||past-12/JJ	prep_during||rheumatoidarthritis-10/NNS||decades-13/NNS	det||recognition-17/NN||the-16/DT	prep_due_to||reached-5/VBN||recognition-17/NN	prep_of||recognition-17/NN||methotrexate-19/NN	det||drug-23/NN||an-21/DT	amod||drug-23/NN||anchor-22/JJ	prep_as||methotrexate-19/NN||drug-23/NN	prep_for||drug-23/NN||treatment-25/NN	prep_of||treatment-25/NN||rheumatoidarthritis-27/NNS	det||notion-32/NN||the-31/DT	prep_due_to||reached-5/VBN||notion-32/NN	det||window-36/NN||a-34/DT	nn||window-36/NN||treatment-35/NN	prep_of||notion-32/NN||window-36/NN	prep_of||window-36/NN||opportunity-38/NN	prep_in||opportunity-38/NN||patients-40/NNS	amod||rheumatoidarthritis-43/NNS||recent-onset-42/JJ	prep_with||patients-40/NNS||rheumatoidarthritis-43/NNS	vmod||rheumatoidarthritis-43/NNS||necessitating-44/VBG	amod||therapy-47/NN||early-45/JJ	amod||therapy-47/NN||aggressive-46/JJ	dobj||necessitating-44/VBG||therapy-47/NN	det||development-52/NN||the-51/DT	prep_due_to||therapy-47/NN||development-52/NN	prep_of||development-52/NN||biologics-54/NNS	dobj||necessitating-44/VBG||due-56/JJ	conj_and||therapy-47/NN||due-56/JJ	aux||remission-58/VB||to-57/TO	vmod||therapy-47/NN||remission-58/VB	det||target-62/NN||a-60/DT	nn||target-62/NN||treatment-61/NN	prep_as||remission-58/VB||target-62/NN	rheumatoidarthritis-43||methotrexate-19||yes||major achievements have been reached in the treatment of rheumatoidarthritis during past decades due to the recognition of methotrexate as an anchor drug for treatment of rheumatoidarthritis, due to the notion of a treatment window of opportunity in patients with recent-onset rheumatoidarthritis necessitating early aggressive therapy, due to the development of biologics and due to remission as a treatment target.
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	gluten-25||celiac-16||no_rel||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
advmod||considered-18/VBN||as-1/RB	prep_with||as-1/RB||sd-nvp-3/NN	det||value-6/NN||the-5/DT	nsubjpass||considered-18/VBN||value-6/NN	prepc_of||value-6/NN||preventing-8/VBG	dobj||preventing-8/VBG||hivinfection-9/NN	det||number-13/NN||a-11/DT	amod||number-13/NN||large-12/JJ	prep_in||preventing-8/VBG||number-13/NN	prep_of||number-13/NN||infants-15/NNS	aux||considered-18/VBN||should-16/MD	auxpass||considered-18/VBN||be-17/VB	root||ROOT-0/null||considered-18/VBN	det||risk-22/NN||the-20/DT	amod||risk-22/NN||high-21/JJ	prep_alongside||considered-18/VBN||risk-22/NN	prep_of||risk-22/NN||resistance-24/NN	vmod||resistance-24/NN||associated-25/VBN	amod||prophylaxis-29/NNS||extended-27/JJ	nn||prophylaxis-29/NNS||nvp-28/NN	prep_with||associated-25/VBN||prophylaxis-29/NNS	hivinfection-9||nvp-28||yes||as with sd-nvp, the value of preventing hivinfection in a large number of infants should be considered alongside the high risk of resistance associated with extended nvp prophylaxis.
det||contribution-2/NN||the-1/DT	nsubjpass||considered-15/VBN||contribution-2/NN	nn||use-5/NN||alcohol-4/NN	prep_of||contribution-2/NN||use-5/NN	det||vulnerability-9/NN||the-7/DT	nn||vulnerability-9/NN||hiv-8/NN	prep_to||use-5/NN||vulnerability-9/NN	prep_of||vulnerability-9/NN||women-11/NNS	auxpass||considered-15/VBN||is-12/VBZ	neg||considered-15/VBN||not-13/RB	advmod||considered-15/VBN||currently-14/RB	root||ROOT-0/null||considered-15/VBN	advmod||designed-22/VBN||when-16/WRB	nn||programs-19/NNS||hiv-17/NN	nn||programs-19/NNS||prevention-18/NN	nsubjpass||designed-22/VBN||programs-19/NNS	nsubjpass||implemented-24/VBN||programs-19/NNS	aux||designed-22/VBN||are-20/VBP	auxpass||designed-22/VBN||being-21/VBG	advcl||considered-15/VBN||designed-22/VBN	advcl||considered-15/VBN||implemented-24/VBN	conj_and||designed-22/VBN||implemented-24/VBN	xcomp||designed-22/VBN||leaving-25/VBG	det||group-27/NN||a-26/DT	dobj||leaving-25/VBG||group-27/NN	amod||women-30/NNS||high-risk-29/JJ	prep_of||group-27/NN||women-30/NNS	vmod||women-30/NNS||uncovered-31/VBN	advmod||needed-34/VBN||much-33/RB	amod||services-35/NNS||needed-34/VBN	agent||uncovered-31/VBN||services-35/NNS	prep_such_as||services-35/NNS||treatment-38/NN	det||range-41/NN||a-40/DT	prep_for||treatment-38/NN||range-41/NN	nn||problems-44/NNS||health-43/NN	prep_of||range-41/NN||problems-44/NNS	prep_including||problems-44/NNS||alcoholdependence-46/NN	alcoholdependence-46||alcohol-4||no||the contribution of alcohol use to the hiv vulnerability of women is not currently considered when hiv prevention programs are being designed and implemented leaving a group of high-risk women uncovered by much needed services such as treatment for a range of health problems including alcoholdependence.
amod||allergicreactions-2/NNS||severe-1/JJ	nsubjpass||reported-7/VBN||allergicreactions-2/NNS	conj_and||allergicreactions-2/NNS||urticaria-4/NN	nsubjpass||reported-7/VBN||urticaria-4/NN	auxpass||reported-7/VBN||are-5/VBP	advmod||reported-7/VBN||rarely-6/RB	root||ROOT-0/null||reported-7/VBN	det||use-10/NN||the-9/DT	prep_following||reported-7/VBN||use-10/NN	prep_of||use-10/NN||neostigminebromide-12/NN	conj_and||reported-7/VBN||never-15/RB	amod||drugs-18/NNS||methylsulfate-containing-17/JJ	prep_with||never-15/RB||drugs-18/NNS	allergicreactions-2||neostigminebromide-12||no||severe allergicreactions and urticaria are rarely reported following the use of neostigminebromide, and never with methylsulfate-containing drugs.
nsubj||increased-8/VBD||animals-1/NNS	vmod||animals-1/NNS||primed-2/VBN	prep||primed-2/VBN||with-3/IN	nsubj||showed-5/VBD||afro-1-4/JJ	parataxis||primed-2/VBN||showed-5/VBD	dobj||showed-5/VBD||i-6/FW	root||ROOT-0/null||increased-8/VBD	amod||production-11/NN||ag85b-specific-9/JJ	amod||production-11/NN||ifn-gamma-10/JJ	dobj||increased-8/VBD||production-11/NN	det||assay-15/NN||the-13/DT	nn||assay-15/NN||wba-14/NN	prep_in||production-11/NN||assay-15/NN	amod||pg/ml-20/NN||median-17/JJ	amod||pg/ml-20/NN||>-18/JJ	num||pg/ml-20/NN||400-19/CD	dep||assay-15/NN||pg/ml-20/NN	num||animals-23/NNS||6-22/CD	prep_for||pg/ml-20/NN||animals-23/NNS	num||week-26/NN||one-25/CD	dep||assay-15/NN||week-26/NN	det||boost-30/NN||the-28/DT	amod||boost-30/NN||first-29/JJ	prep_after||increased-8/VBD||boost-30/NN	amod||tb-antigens-33/NNS||adenoviral-delivered-32/JJ	prep_with||boost-30/NN||tb-antigens-33/NNS	prep||increased-8/VBD||as-34/IN	prep||increased-8/VBD||compared-35/VBN	pcomp||compared-35/VBN||to-36/TO	pobj||to-36/TO||animals-37/NNS	vmod||animals-37/NNS||primed-38/VBN	prep_with||primed-38/VBN||bcg-40/NN	number||200-43/CD||<-42/CD	num||pg/ml-44/NNS||200-43/CD	appos||bcg-40/NN||pg/ml-44/NNS	dobj||primed-38/VBN||ii-47/NN	amod||proliferation-52/NN||stronger-49/JJR	nn||proliferation-52/NN||t-50/NN	nn||proliferation-52/NN||cell-51/NN	npadvmod||primed-38/VBN||proliferation-52/NN	det||subset-59/NN||the-54/DT	amod||subset-59/NN||cd8alpha/alpha-55/JJ	amod||subset-59/NN||+-56/JJ	nn||subset-59/NN||t-57/NN	nn||subset-59/NN||cell-58/NN	prep_in||primed-38/VBN||subset-59/NN	amod||index-62/NN||proliferative-61/JJ	dep||subset-59/NN||index-62/NN	num||%-64/NN||17-63/CD	dep||index-62/NN||%-64/NN	prepc_as||subset-59/NN||compared-67/VBN	pcomp||compared-67/VBN||to-68/TO	amod||animals-70/NNS||bcg-primed-69/JJ	pobj||to-68/TO||animals-70/NNS	amod||index-73/NN||proliferative-72/JJ	dep||subset-59/NN||index-73/NN	number||%-75/NN||5-74/CD	amod||index-73/NN||%-75/NN	amod||cells-80/NNS||cd8alpha/alpha-77/JJ	amod||cells-80/NNS||+-78/JJ	nn||cells-80/NNS||t-79/NN	prep_in||index-73/NN||cells-80/NNS	tb--1||bcg-40||no||animals primed with afro-1 showed i) increased ag85b-specific ifn-gamma production in the wba assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered tb-antigens as compared to animals primed with bcg (<200 pg/ml), ii) stronger t cell proliferation in the cd8alpha/alpha+ t cell subset (proliferative index 17%) as compared to bcg-primed animals (proliferative index 5% in cd8alpha/alpha+ t cells).
nn||abundance-2/NN||virus-1/NN	nsubj||ranged-3/VBD||abundance-2/NN	root||ROOT-0/null||ranged-3/VBD	number||1011-7/CD||106-5/CD	dep||1011-7/CD||to-6/TO	num||viruses/cm3-8/NNS||1011-7/CD	prep_from||ranged-3/VBD||viruses/cm3-8/NNS	prep_of||viruses/cm3-8/NNS||sediments-10/NNS	advmod||-RSB--21/NNP||down-12/RB	num||cm-15/NN||30-14/CD	prep_to||down-12/RB||cm-15/NN	det||cmbsf-20/NN||the-17/DT	nn||cmbsf-20/NN||seafloor-18/NN	nn||cmbsf-20/NN||-LSB--19/NN	prep_below||cm-15/NN||cmbsf-20/NN	appos||sediments-10/NNS||-RSB--21/NNP	virus-1||viruses--1||no||virus abundance ranged from 106 to 1011 viruses/cm3 of sediments (down to 30 cm below the seafloor [cmbsf]).
amod||factor-22/NN||present-2/JJ	det||efalizumab-7/NN||an-3/DT	amod||efalizumab-7/NN||anti-cd11a-4/JJ	nn||efalizumab-7/NN||antibody-5/NN	dep||present-2/JJ||efalizumab-7/NN	det||alefacept-16/NN||an-10/DT	amod||alefacept-16/NN||anti-lfa3-11/JJ	amod||alefacept-16/NN||/-12/JJ	amod||alefacept-16/NN||cd2-13/JJ	nn||alefacept-16/NN||receptor-14/NN	dep||present-2/JJ||alefacept-16/NN	conj_and||efalizumab-7/NN||alefacept-16/NN	num||necrosis-21/NNS||3-19/CD	nn||necrosis-21/NNS||antitumor-20/NN	dep||present-2/JJ||necrosis-21/NNS	conj_and||efalizumab-7/NN||necrosis-21/NNS	prep_at||alpha-23/NN||factor-22/NN	amod||agents-24/NNS||alpha-23/NN	nsubj||available-35/JJ||agents-24/NNS	nn||infliximab-30/NN||adalimumab-26/NN	dep||infliximab-30/NN||etanercept-28/NN	appos||agents-24/NNS||infliximab-30/NN	cop||available-35/JJ||are-32/VBP	advmod||available-35/JJ||now-33/RB	advmod||available-35/JJ||commercially-34/RB	root||ROOT-0/null||available-35/JJ	det||treatment-38/NN||the-37/DT	prep_for||available-35/JJ||treatment-38/NN	preconj||psoriasis-41/NNS||both-40/DT	prep_of||treatment-38/NN||psoriasis-41/NNS	prep_of||treatment-38/NN||psoriaticarthritis-43/NNS	conj_and||psoriasis-41/NNS||psoriaticarthritis-43/NNS	psoriaticarthritis-43||etanercept-28||yes||at present an anti-cd11a antibody (efalizumab), an anti-lfa3/cd2 receptor (alefacept) and 3 antitumor necrosis factor alpha agents (adalimumab, etanercept, infliximab) are now commercially available for the treatment of both psoriasis and psoriaticarthritis.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||sb-56||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	statin-50||tumor-63||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||compare-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||compare-6/VB||to-5/TO	xcomp||conducted-4/VBN||compare-6/VB	det||efficacy-8/NN||the-7/DT	dobj||compare-6/VB||efficacy-8/NN	det||combination-11/NN||a-10/DT	prep_of||efficacy-8/NN||combination-11/NN	prep_of||combination-11/NN||ondansetron-13/NN	prep_of||combination-11/NN||dexamethasone-15/NN	conj_and||ondansetron-13/NN||dexamethasone-15/NN	prep_with||compare-6/VB||that-17/DT	nn||analgesia-36/NN||metoclopramide-19/NN	conj_and||metoclopramide-19/NN||dexamethasone-21/JJ	nn||analgesia-36/NN||dexamethasone-21/JJ	prep_for||dexamethasone-21/JJ||prevention-23/NN	prepc_of||prevention-23/NN||postoperativenauseaandvomiting-25/VBG	dobj||postoperativenauseaandvomiting-25/VBG||ponv-27/NNP	amod||patients-31/NNS||gynecologic-30/JJ	prep_in||ponv-27/NNP||patients-31/NNS	vmod||patients-31/NNS||receiving-32/VBG	amod||analgesia-36/NN||fentanyl-33/JJ	amod||analgesia-36/NN||iv-patient-34/JJ	amod||analgesia-36/NN||controlled-35/VBN	prep_of||that-17/DT||analgesia-36/NN	postoperativenauseaandvomiting-25||metoclopramide-19||yes||this study was conducted to compare the efficacy of a combination of ondansetron and dexamethasone with that of metoclopramide and dexamethasone for prevention of postoperativenauseaandvomiting (ponv) in gynecologic patients receiving fentanyl iv-patient controlled analgesia.
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||support-3/NN	det||inclusion-6/NN||the-5/DT	prep_for||support-3/NN||inclusion-6/NN	amod||antibodies-9/NNS||anti-ccp-8/JJ	prep_of||inclusion-6/NN||antibodies-9/NNS	dobj||provides-2/VBZ||rf-13/NN	conj_and||support-3/NN||rf-13/NN	conj_and||support-3/NN||rf-13/NN	conj_and||rf-13/NN||rf-13/NN	det||criteria-17/NNS||the-15/DT	nn||criteria-17/NNS||classification-16/NN	prep_in||rf-13/NN||criteria-17/NNS	prep_for||criteria-17/NNS||rheumatoidarthritis-19/NNS	prep_for||rf-13/NN||stratification-22/NN	amod||status-26/NN||anti-ccp-24/JJ	nn||status-26/NN||antibody-25/NN	prep_by||provides-2/VBZ||status-26/NN	amod||trials-29/NNS||clinical-28/JJ	prep_in||status-26/NN||trials-29/NNS	rheumatoidarthritis-19||antibody-25||no_rel||this provides support for the inclusion of anti-ccp antibodies as well as rf in the classification criteria for rheumatoidarthritis and for stratification by anti-ccp antibody status in clinical trials.
mark||declined-6/VBN||while-1/IN	poss||incidence-3/NN||its-2/PRP$	nsubj||declined-6/VBN||incidence-3/NN	aux||declined-6/VBN||has-4/VBZ	advmod||declined-6/VBN||steadily-5/RB	advcl||given-50/VBN||declined-6/VBN	det||cessation-9/NN||the-8/DT	prep_since||declined-6/VBN||cessation-9/NN	poss||route-12/NN||its-11/PRP$	prep_of||cessation-9/NN||route-12/NN	prep_of||route-12/NN||transmission-14/NN	nsubj||given-50/VBN||endocannibalism-16/NN	amod||guinea-21/NN||papua-19/JJ	amod||guinea-21/NN||new-20/JJ	prep_in||endocannibalism-16/NN||guinea-21/NN	det||1950s-24/NNS||the-23/DT	prep_in||guinea-21/NN||1950s-24/NNS	det||arrival-27/NN||the-26/DT	appos||endocannibalism-16/NN||arrival-27/NN	nn||disease-34/NN||variant-29/NN	amod||disease-34/NN||creutzfeldtâ-30/JJ	amod||disease-34/NN||$-31/JJ	nn||disease-34/NN||jakob-33/NN	prep_of||arrival-27/NN||disease-34/NN	dep||endocannibalism-16/NN||vcjd-36/VBN	advmod||thought-40/VBN||also-39/RB	vmod||endocannibalism-16/NN||thought-40/VBN	aux||transmitted-43/VBN||to-41/TO	auxpass||transmitted-43/VBN||be-42/VB	xcomp||thought-40/VBN||transmitted-43/VBN	amod||exposure-47/NN||dietary-45/JJ	nn||exposure-47/NN||prion-46/NN	agent||transmitted-43/VBN||exposure-47/NN	aux||given-50/VBN||has-49/VBZ	root||ROOT-0/null||given-50/VBN	iobj||given-50/VBN||kuru-51/PRP	det||relevance-55/NN||a-52/DT	amod||relevance-55/NN||new-53/JJ	amod||relevance-55/NN||global-54/JJ	dobj||given-50/VBN||relevance-55/NN	kuru-51||prion-46||no_rel||while its incidence has steadily declined since the cessation of its route of transmission, endocannibalism, in papua new guinea in the 1950s, the arrival of variant creutzfeldtâ€“jakob disease (vcjd), also thought to be transmitted by dietary prion exposure, has given kuru a new global relevance.
nsubj||agent-10/NN||denguevirus-1/NNS	det||flavivirus-5/NNS||a-3/DT	amod||flavivirus-5/NNS||mosquito-borne-4/JJ	appos||denguevirus-1/NNS||flavivirus-5/NNS	cop||agent-10/NN||is-7/VBZ	det||agent-10/NN||the-8/DT	amod||agent-10/NN||etiological-9/JJ	root||ROOT-0/null||agent-10/NN	prep_of||agent-10/NN||denguefever-12/NN	prep_of||agent-10/NN||denguehemorrhagicfever-14/NN	conj_and||denguefever-12/NN||denguehemorrhagicfever-14/NN	prep_of||agent-10/NN||dengueshocksyndrome-17/NN	conj_and||denguefever-12/NN||dengueshocksyndrome-17/NN	fever--1||dengue--1||no||denguevirus, a mosquito-borne flavivirus, is the etiological agent of denguefever, denguehemorrhagicfever, and dengueshocksyndrome.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||regulators-7/NNS||negative-6/JJ	prep_of||role-4/NN||regulators-7/NNS	prep_of||regulators-7/NNS||interferon-9/NN	vmod||interferon-9/NN||signaling-10/VBG	dep||signaling-10/VBG||known-11/VBN	nsubj||signaling-16/VBG||suppressors-13/NNS	prep_of||suppressors-13/NNS||cytokine-15/NN	prepc_as||known-11/VBN||signaling-16/VBG	dobj||signaling-16/VBG||socs-18/NNS	prepc_in||signaling-16/VBG||mediating-21/VBG	dobj||mediating-21/VBG||interferon-resistance-22/NN	amod||cells-26/NNS||human-24/JJ	nn||cells-26/NNS||melanoma-25/NN	prep_in||mediating-21/VBG||cells-26/NNS	melanoma-25||interferon-9||yes||we investigated the role of negative regulators of interferon signaling known as suppressors of cytokine signaling (socs) in mediating interferon-resistance in human melanoma cells.
nsubj||effective-61/JJ||analysis-1/NN	amod||terbinafine-58/NN||total-3/JJ	num||trials-5/NNS||eight-4/CD	nsubj||state-9/NN||trials-5/NNS	num||patients-8/NNS||1181-7/CD	prep_including||trials-5/NNS||patients-8/NNS	ccomp||total-3/JJ||state-9/NN	mark||likely-17/JJ||that-10/IN	nsubj||likely-17/JJ||treatment-11/NN	nsubj||produce-19/VB||treatment-11/NN	amod||terbinafine-14/NN||continuous-13/JJ	prep_with||treatment-11/NN||terbinafine-14/NN	cop||likely-17/JJ||is-15/VBZ	advmod||likely-17/JJ||more-16/RBR	ccomp||state-9/NN||likely-17/JJ	aux||produce-19/VB||to-18/TO	xcomp||likely-17/JJ||produce-19/VB	amod||cure-23/NN||mycological-20/JJ	conj_and||mycological-20/JJ||clinical-22/JJ	amod||cure-23/NN||clinical-22/JJ	dobj||produce-19/VB||cure-23/NN	prepc_compared_to||produce-19/VB||to-25/TO	amod||itraconazole-27/NN||intermittent-26/JJ	pobj||produce-19/VB||itraconazole-27/NN	nn||2.3-31/NNS||odds-29/NNS	nn||2.3-31/NNS||ratio-30/NN	prep_with||itraconazole-27/NN||2.3-31/NNS	number||%-34/NN||95-33/CD	amod||ci-35/NN||%-34/NN	dep||likely-17/JJ||ci-35/NN	amod||ci-35/NN||1.7-37/CD	num||p-40/NNS||3.0-39/CD	prep_to||ci-35/NN||p-40/NNS	number||0.0001-42/CD||<-41/CD	num||p-40/NNS||0.0001-42/CD	mark||tolerated-51/JJ||though-44/IN	preconj||itraconazole-46/NN||both-45/DT	nsubj||tolerated-51/JJ||itraconazole-46/NN	conj_and||itraconazole-46/NN||terbinafine-48/NN	nsubj||tolerated-51/JJ||terbinafine-48/NN	cop||tolerated-51/JJ||are-49/VBP	advmod||tolerated-51/JJ||well-50/RB	ccomp||likely-17/JJ||tolerated-51/JJ	advmod||effective-54/JJ||highly-53/RB	conj_and||total-3/JJ||effective-54/JJ	amod||terbinafine-58/NN||effective-54/JJ	nn||terbinafine-58/NN||drugs-55/NNS	amod||terbinafine-58/NN||continuous-57/JJ	prep_of||analysis-1/NN||terbinafine-58/NN	cop||effective-61/JJ||is-59/VBZ	advmod||effective-61/JJ||more-60/RBR	root||ROOT-0/null||effective-61/JJ	amod||itraconazole-64/NN||intermittent-63/JJ	prep_than||effective-61/JJ||itraconazole-64/NN	prepc_at||effective-61/JJ||achieving-66/VBG	amod||cure-68/NN||mycological-67/JJ	dobj||achieving-66/VBG||cure-68/NN	amod||onychomycosis-71/NNS||toenail-70/JJ	prep_of||cure-68/NN||onychomycosis-71/NNS	onychomycosis-71||terbinafine-58||yes||analysis of total eight trials including 1181 patients state that treatment with continuous terbinafine is more likely to produce mycological and clinical cure compared to intermittent itraconazole with odds ratio 2.3(95% ci, 1.7 to 3.0 p <0.0001) though both itraconazole and terbinafine are well tolerated and highly effective drugs, continuous terbinafine is more effective than intermittent itraconazole at achieving mycological cure of toenail onychomycosis
nsubjpass||approved-9/VBN||bevacizumab-1/NN	prep_in||bevacizumab-1/NN||combination-3/NN	nn||alfa-6/NN||interferon-5/NN	prep_with||combination-3/NN||alfa-6/NN	auxpass||approved-9/VBN||is-7/VBZ	advmod||approved-9/VBN||now-8/RB	root||ROOT-0/null||approved-9/VBN	mark||ve-13/VBP||for-10/IN	nn||¯-12/NNP||treatment-naã-11/NNP	nsubj||ve-13/VBP||¯-12/NNP	advcl||approved-9/VBN||ve-13/VBP	amod||renalcellcarcinoma-15/NN||advanced-14/VBN	dobj||ve-13/VBP||renalcellcarcinoma-15/NN	appos||renalcellcarcinoma-15/NN||rcc-17/NN	preconj||us-22/PRP||both-20/PDT	det||us-22/PRP||the-21/DT	prep_in||renalcellcarcinoma-15/NN||us-22/PRP	prep_in||renalcellcarcinoma-15/NN||europe-24/NN	conj_and||us-22/PRP||europe-24/NN	rcc-17||interferon-5||yes||bevacizumab in combination with interferon alfa is now approved for treatment-naã¯ve advanced renalcellcarcinoma (rcc) in both the us and europe.
advmod||appears-4/VBZ||even-1/RB	advmod||appears-4/VBZ||when-2/WRB	nsubj||appears-4/VBZ||drug-resistance-3/NN	nsubj||responsible-7/JJ||drug-resistance-3/NN	advcl||represent-20/VB||appears-4/VBZ	aux||responsible-7/JJ||to-5/TO	cop||responsible-7/JJ||be-6/VB	xcomp||appears-4/VBZ||responsible-7/JJ	det||failure-10/NN||the-9/DT	prep_for||responsible-7/JJ||failure-10/NN	aux||control-12/VB||to-11/TO	vmod||failure-10/NN||control-12/VB	amod||hypertension-14/NN||secondary-13/JJ	dobj||control-12/VB||hypertension-14/NN	prep||control-12/VB||in-15/IN	dep||in-15/IN||as-16/RB	nsubj||represent-20/VB||clonidine-18/NN	aux||represent-20/VB||may-19/MD	root||ROOT-0/null||represent-20/VB	det||option-25/NN||a-21/DT	amod||effective-24/JJ||safe-22/JJ	amod||option-25/NN||effective-24/JJ	dobj||represent-20/VB||option-25/NN	det||normalization-28/NN||the-27/DT	prep_in||option-25/NN||normalization-28/NN	prep_of||normalization-28/NN||highbloodpressure-30/NN	highbloodpressure-30||clonidine-18||yes||even when drug-resistance appears to be responsible for the failure to control secondary hypertension in as, clonidine may represent a safe, effective option in the normalization of highbloodpressure.
nn||dendrobatidis-2/NNS||batrachochytrium-1/NN	nsubj||fungus-8/NN||dendrobatidis-2/NNS	appos||dendrobatidis-2/NNS||bd-4/NN	cop||fungus-8/NN||is-6/VBZ	det||fungus-8/NN||a-7/DT	root||ROOT-0/null||fungus-8/NN	nsubj||causes-10/VBZ||fungus-8/NN	rcmod||fungus-8/NN||causes-10/VBZ	det||disease-12/NN||the-11/DT	nsubj||chytridiomycosis-13/VBZ||disease-12/NN	nsubjpass||associated-16/VBN||disease-12/NN	ccomp||causes-10/VBZ||chytridiomycosis-13/VBZ	auxpass||associated-16/VBN||is-15/VBZ	ccomp||causes-10/VBZ||associated-16/VBN	conj_and||chytridiomycosis-13/VBZ||associated-16/VBN	amod||declines-20/NNS||widespread-18/JJ	nn||declines-20/NNS||amphibian-19/NN	prep_with||associated-16/VBN||declines-20/NNS	chytridiomycosis-13||fungus-8||no||batrachochytrium dendrobatidis ( bd ) is a fungus that causes the disease chytridiomycosis and is associated with widespread amphibian declines.
nn||patients-2/NNS||hiv/aids-1/NNS	nsubjpass||colonized-5/VBN||patients-2/NNS	auxpass||colonized-5/VBN||are-3/VBP	advmod||colonized-5/VBN||orally-4/RB	root||ROOT-0/null||colonized-5/VBN	amod||albicans-10/NNS||single-7/JJ	conj_or||single-7/JJ||multiple-9/JJ	amod||albicans-10/NNS||multiple-9/JJ	agent||colonized-5/VBN||albicans-10/NNS	agent||colonized-5/VBN||non-12/NN	conj_and||albicans-10/NNS||non-12/NN	amod||species-16/NNS||albicans-14/JJ	nn||species-16/NNS||candida-15/NN	dep||albicans-10/NNS||species-16/NNS	nsubj||resistant-20/JJ||species-16/NNS	cop||resistant-20/JJ||are-18/VBP	advmod||resistant-20/JJ||frequently-19/RB	rcmod||species-16/NNS||resistant-20/JJ	prep_to||resistant-20/JJ||azoles-22/NNS	conj_and||colonized-5/VBN||occasionally-24/RB	prep_to||occasionally-24/RB||amphotericinb-26/NN	prep_to||occasionally-24/RB||5-fluorocytosine-28/NN	conj_and||amphotericinb-26/NN||5-fluorocytosine-28/NN	prep_to||occasionally-24/RB||micafungin-30/NN	conj_and||amphotericinb-26/NN||micafungin-30/NN	aids--1||hiv--1||no||hiv/aids patients are orally colonized by single or multiple albicans and non- albicans candida species that are frequently resistant to azoles and occasionally to amphotericinb, 5-fluorocytosine and micafungin.
nsubj||likely-16/JJ||patients-1/NNS	nsubj||have-18/VB||patients-1/NNS	amod||obstructivepulmonarydisease-4/NN||chronic-3/JJ	prep_with||patients-1/NNS||obstructivepulmonarydisease-4/NN	nsubj||received-6/VBD||obstructivepulmonarydisease-4/NN	rcmod||obstructivepulmonarydisease-4/NN||received-6/VBD	amod||oxygen-8/NN||titrated-7/JJ	dobj||received-6/VBD||oxygen-8/NN	prepc_according_to||received-6/VBD||to-10/TO	det||protocol-12/NN||the-11/DT	pobj||received-6/VBD||protocol-12/NN	cop||likely-16/JJ||were-13/VBD	advmod||likely-16/JJ||significantly-14/RB	advmod||likely-16/JJ||less-15/RBR	root||ROOT-0/null||likely-16/JJ	aux||have-18/VB||to-17/TO	xcomp||likely-16/JJ||have-18/VB	dobj||have-18/VB||respiratoryacidosis-19/NNS	dep||respiratoryacidosis-19/NNS||mean-21/VB	nsubj||n-35/VBP||difference-22/NN	number||0.12-25/CD||ph-24/CD	prep_in||difference-22/NN||0.12-25/CD	appos||0.12-25/CD||se-27/NNP	num||se-27/NNP||0.05-28/CD	vmod||difference-22/NN||p-31/VBN	dep||0.01-33/CD||=-32/SYM	ccomp||p-31/VBN||0.01-33/CD	ccomp||mean-21/VB||n-35/VBP	dep||28-37/CD||=-36/SYM	ccomp||n-35/VBP||28-37/CD	dobj||have-18/VB||hypercapnia-40/NN	conj_or||respiratoryacidosis-19/NNS||hypercapnia-40/NN	amod||difference-43/NN||mean-42/JJ	dep||hypercapnia-40/NN||difference-43/NN	amod||pressure-47/NN||arterial-45/JJ	nn||pressure-47/NN||carbondioxide-46/NN	prep_in||difference-43/NN||pressure-47/NN	poss||hg-55/NN||âˆ-48/NNP	nn||hg-55/NN||33.6-50/NNP	appos||hg-55/NN||16.3-52/CD	nn||hg-55/NN||mm-54/NN	dep||pressure-47/NN||hg-55/NN	dep||pressure-47/NN||p-57/NN	dep||0.02-59/CD||=-58/SYM	rcmod||p-57/NN||0.02-59/CD	vmod||difference-43/NN||n-61/VBN	dep||29-63/CD||=-62/SYM	ccomp||n-61/VBN||29-63/CD	mark||patients-67/NNS||than-65/IN	cop||patients-67/NNS||were-66/VBD	advcl||likely-16/JJ||patients-67/NNS	nsubj||received-69/VBD||patients-67/NNS	rcmod||patients-67/NNS||received-69/VBD	amod||oxygen-72/NN||high-70/JJ	nn||oxygen-72/NN||flow-71/NN	dobj||received-69/VBD||oxygen-72/NN	respiratoryacidosis-19||carbondioxide-46||no||patients with chronic obstructivepulmonarydisease who received titrated oxygen according to the protocol were significantly less likely to have respiratoryacidosis (mean difference in ph 0.12 (se 0.05); p=0.01; n=28) or hypercapnia (mean difference in arterial carbondioxide pressure âˆ’33.6 (16.3) mm hg; p=0.02; n=29) than were patients who received high flow oxygen.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||considered-10/VBN||that-4/IN	nsubjpass||considered-10/VBN||s.aureus-5/NNS	conj_and||s.aureus-5/NNS||mrsa-7/NNS	nsubjpass||considered-10/VBN||mrsa-7/NNS	aux||considered-10/VBN||should-8/MD	auxpass||considered-10/VBN||be-9/VB	ccomp||suggest-3/VBP||considered-10/VBN	det||priority-13/NN||a-11/DT	amod||priority-13/NN||national-12/JJ	dobj||considered-10/VBN||priority-13/NN	nn||control-16/NN||disease-15/NN	prep_for||priority-13/NN||control-16/NN	mrsa-7||s.aureus-5||no||our findings suggest that s.aureus and mrsa should be considered a national priority for disease control .
det||diagnosis-2/NN||the-1/DT	nsubjpass||made-8/VBN||diagnosis-2/NN	nn||sencephalopathy-6/NN||wernicke-4/NN	prep_of||diagnosis-2/NN||sencephalopathy-6/NN	auxpass||made-8/VBN||was-7/VBD	root||ROOT-0/null||made-8/VBN	prep||made-8/VBN||at-9/IN	pobj||at-9/IN||once-10/RB	amod||reposition-13/NNS||immediate-12/JJ	nsubjpass||started-19/VBN||reposition-13/NNS	prep_of||reposition-13/NNS||thiamine-15/NN	prep_of||reposition-13/NNS||magnesium-17/NN	conj_and||thiamine-15/NN||magnesium-17/NN	auxpass||started-19/VBN||was-18/VBD	conj_and||made-8/VBN||started-19/VBN	wernicke'sencephalopathy--1||thiamine-15||yes||the diagnosis of wernicke'sencephalopathy was made at once and immediate reposition of thiamine and magnesium was started.
det||proportion-2/NN||the-1/DT	nsubj||decreased-14/VBD||proportion-2/NN	prep_of||proportion-2/NN||msm-4/NN	vmod||decreased-14/VBD||presenting-6/VBG	preconj||aids-9/NNS||either-8/DT	prep_with||presenting-6/VBG||aids-9/NNS	nn||illness-12/NN||hiv-11/NN	prep_with||presenting-6/VBG||illness-12/NN	conj_or||aids-9/NNS||illness-12/NN	root||ROOT-0/null||decreased-14/VBD	prep_over||decreased-14/VBD||time-16/NN	mark||increased-24/VBD||while-18/IN	amod||illness-23/NN||asymptomatic-19/JJ	conj_and||asymptomatic-19/JJ||acute-21/JJ	amod||illness-23/NN||acute-21/JJ	amod||illness-23/NN||hiv-22/JJ	nsubj||increased-24/VBD||illness-23/NN	advcl||decreased-14/VBD||increased-24/VBD	dep||increased-24/VBD||p-26/NN	prep_for||p-26/NN||trend-28/NN	amod||p-26/NN||=-29/JJ	dep||=-29/JJ||0.034-30/CD	dep||=-29/JJ||less-32/JJR	conj_or||0.034-30/CD||less-32/JJR	aids-9||hiv-22||no||the proportion of msm, presenting with either aids or hiv illness, decreased over time, while asymptomatic and acute hiv illness increased (p for trend=0.034 or less).
det||studies-3/NNS||a-1/DT	amod||studies-3/NNS||few-2/JJ	nsubj||reported-4/VBD||studies-3/NNS	root||ROOT-0/null||reported-4/VBD	mark||is-7/VBZ||that-5/IN	expl||is-7/VBZ||there-6/EX	ccomp||reported-4/VBD||is-7/VBZ	det||association-10/NN||a-8/DT	amod||association-10/NN||mysterious-9/JJ	nsubj||is-7/VBZ||association-10/NN	det||polymorphism-14/NN||the-12/DT	amod||polymorphism-14/NN||il28b-13/JJ	prep_between||association-10/NN||polymorphism-14/NN	det||hepatitiscvirus-17/NNS||the-16/DT	nsubj||genotype-21/VBP||hepatitiscvirus-17/NNS	appos||hepatitiscvirus-17/NNS||hcv-19/NN	conj_and||reported-4/VBD||genotype-21/VBP	prep_in||genotype-21/VBP||patients-23/NNS	prep_with||patients-23/NNS||chronichepatitisc-25/NN	nsubj||give-30/VB||they-27/PRP	aux||give-30/VB||did-28/VBD	neg||give-30/VB||not-29/RB	conj_but||reported-4/VBD||give-30/VB	det||reason-32/NN||any-31/DT	dobj||give-30/VB||reason-32/NN	det||phenomenon-35/NN||this-34/DT	prep_for||reason-32/NN||phenomenon-35/NN	chronichepatitisc-25||hepatitiscvirus-17||no||a few studies reported that there is a mysterious association between the il28b polymorphism and the hepatitiscvirus (hcv) genotype in patients with chronichepatitisc but they did not give any reason for this phenomenon.
amod||subjects-3/NNS||663-2/JJ	prep_in||performed-12/VBN||subjects-3/NNS	amod||hyperglycemia-6/NN||fasting-5/JJ	prep_with||subjects-3/NNS||hyperglycemia-6/NN	num||ogtt-10/NN||75-8/CD	nn||ogtt-10/NN||g-9/NN	nsubjpass||performed-12/VBN||ogtt-10/NN	nsubj||confirm-14/VB||ogtt-10/NN	auxpass||performed-12/VBN||were-11/VBD	root||ROOT-0/null||performed-12/VBN	aux||confirm-14/VB||to-13/TO	xcomp||performed-12/VBN||confirm-14/VB	det||status-18/NN||the-15/DT	nn||status-18/NN||glucose-16/NN	nn||status-18/NN||tolerant-17/NN	dobj||confirm-14/VB||status-18/NN	nsubjpass||measured-30/VBN||fasting-21/NN	amod||30-minute-24/JJ||post-challenge-23/JJ	appos||fasting-21/NN||30-minute-24/JJ	amod||levels-28/NNS||120-minute-26/JJ	nn||levels-28/NNS||glucose-27/NN	appos||fasting-21/NN||levels-28/NNS	conj_and||30-minute-24/JJ||levels-28/NNS	auxpass||measured-30/VBN||were-29/VBD	conj_and||performed-12/VBN||measured-30/VBN	hyperglycemia-6||glucose-27||no||in 663 subjects with fasting hyperglycemia, 75 g ogtt were performed to confirm the glucose tolerant status, and fasting, post-challenge 30-minute and 120-minute glucose levels were measured.
nsubj||treatment-9/NN||lithium-1/NN	nn||+-4/NNP||li-3/NNP	appos||lithium-1/NN||+-4/NNP	cop||treatment-9/NN||is-6/VBZ	det||treatment-9/NN||a-7/DT	amod||treatment-9/NN||common-8/JJ	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||bipolarmooddisorder-11/NN	det||illness-16/NN||a-13/DT	amod||illness-16/NN||major-14/JJ	amod||illness-16/NN||psychiatric-15/JJ	appos||bipolarmooddisorder-11/NN||illness-16/NN	det||prevalence-20/NN||a-18/DT	nn||prevalence-20/NN||lifetime-19/NN	prep_with||illness-16/NN||prevalence-20/NN	mwe||than-23/IN||more-22/JJR	quantmod||1-24/CD||than-23/IN	num||%-25/NN||1-24/CD	prep_of||prevalence-20/NN||%-25/NN	bipolarmooddisorder-11||lithium-1||yes||lithium (li+) is a common treatment for bipolarmooddisorder, a major psychiatric illness with a lifetime prevalence of more than 1%.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bacilluscalmette-guerin-24||yes||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
advmod||conclude-4/VBP||thus-1/RB	nsubj||conclude-4/VBP||we-3/PRP	root||ROOT-0/null||conclude-4/VBP	mark||considered-15/VBN||that-5/IN	det||use-7/NN||the-6/DT	nsubjpass||considered-15/VBN||use-7/NN	prep_of||use-7/NN||vitamins-9/NNS	dep||vitamins-9/NNS||c-10/SYM	dep||vitamins-9/NNS||e-12/JJ	conj_and||c-10/SYM||e-12/JJ	aux||considered-15/VBN||should-13/MD	auxpass||considered-15/VBN||be-14/VB	ccomp||conclude-4/VBP||considered-15/VBN	det||control-18/NN||the-17/DT	prep_for||considered-15/VBN||control-18/NN	amod||indices-23/NNS||certain-20/JJ	amod||indices-23/NNS||important-21/JJ	amod||indices-23/NNS||biochemical-22/JJ	prep_of||control-18/NN||indices-23/NNS	det||development-26/NN||the-25/DT	prep_during||considered-15/VBN||development-26/NN	prep_of||development-26/NN||preeclampsia-28/NN	advmod||needed-35/VBN||however-30/RB	amod||studies-33/NNS||further-32/JJ	nsubjpass||needed-35/VBN||studies-33/NNS	nsubj||develop-37/VB||studies-33/NNS	auxpass||needed-35/VBN||are-34/VBP	parataxis||conclude-4/VBP||needed-35/VBN	aux||develop-37/VB||to-36/TO	xcomp||needed-35/VBN||develop-37/VB	dobj||develop-37/VB||methods-38/NNS	det||prevention-41/NN||the-40/DT	prep_for||methods-38/NNS||prevention-41/NN	prep_of||prevention-41/NN||preeclampsia-43/NN	prep_in||develop-37/VB||women-45/NNS	amod||risk-48/NN||high-47/JJ	prep_at||women-45/NNS||risk-48/NN	vitamins-9||preeclampsia-43||no_rel||thus, we conclude that the use of vitamins c and e should be considered for the control of certain important biochemical indices during the development of preeclampsia; however, further studies are needed to develop methods for the prevention of preeclampsia in women at high risk.
mark||closed-9/VBD||conclusion-1/NN	nsubj||improve-15/VB||conclusion-1/NN	nsubj||reduce-22/VB||conclusion-1/NN	det||trials-6/NNS||these-2/DT	num||trials-6/NNS||two-3/CD	amod||trials-6/NNS||small-4/JJ	nn||trials-6/NNS||crossover-5/NN	nsubj||suggest-7/VBP||trials-6/NNS	rcmod||conclusion-1/NN||suggest-7/VBP	ccomp||suggest-7/VBP||closed-9/VBD	nn||delivery-11/NN||loop-10/NN	dobj||closed-9/VBD||delivery-11/NN	prep_of||delivery-11/NN||insulin-13/NN	aux||improve-15/VB||may-14/MD	root||ROOT-0/null||improve-15/VB	amod||control-17/NN||overnight-16/JJ	dobj||improve-15/VB||control-17/NN	nn||levels-20/NNS||glucose-19/NN	prep_of||control-17/NN||levels-20/NNS	conj_and||improve-15/VB||reduce-22/VB	det||risk-24/NN||the-23/DT	dobj||reduce-22/VB||risk-24/NN	amod||hypoglycaemia-27/NN||nocturnal-26/JJ	prep_of||risk-24/NN||hypoglycaemia-27/NN	prep_in||reduce-22/VB||adults-29/NNS	prep_with||adults-29/NNS||type1diabetes-31/CD	type1diabetes-31||insulin-13||yes||conclusion these two small crossover trials suggest that closed loop delivery of insulin may improve overnight control of glucose levels and reduce the risk of nocturnal hypoglycaemia in adults with type1diabetes.
nn||mice-2/NNS||swiss-1/NNS	nsubjpass||inoculated-5/VBN||mice-2/NNS	nsubjpass||treated-17/VBN||mice-2/NNS	nsubjpass||followed-31/VBN||mice-2/NNS	nsubj||determine-39/VB||mice-2/NNS	auxpass||inoculated-5/VBN||were-3/VBD	advmod||inoculated-5/VBN||intravenously-4/RB	root||ROOT-0/null||inoculated-5/VBN	num||log10-8/NNS||6-7/CD	prep_with||inoculated-5/VBN||log10-8/NNS	amod||h37rv-15/NNS||mycobacteriumtuberculosis-10/JJ	dep||mycobacteriumtuberculosis-10/JJ||tb-12/NN	nn||h37rv-15/NNS||strain-14/NN	prep_of||log10-8/NNS||h37rv-15/NNS	conj_and||inoculated-5/VBN||treated-17/VBN	conj_and||inoculated-5/VBN||treated-17/VBN	conj_or||treated-17/VBN||treated-17/VBN	amod||combinations-21/NNS||second-line-19/JJ	nn||combinations-21/NNS||drug-20/NN	prep_with||treated-17/VBN||combinations-21/NNS	det||tmc207-27/NN||the-25/DT	amod||tmc207-27/NN||diarylquinoline-26/JJ	prep_with||treated-17/VBN||tmc207-27/NN	prep_without||treated-17/VBN||tmc207-27/NN	advmod||followed-31/VBN||then-30/RB	conj_and||inoculated-5/VBN||followed-31/VBN	prep_without||followed-31/VBN||treatment-33/NN	num||months-37/NNS||3-35/CD	amod||months-37/NNS||more-36/JJR	prep_for||treatment-33/NN||months-37/NNS	aux||determine-39/VB||to-38/TO	xcomp||followed-31/VBN||determine-39/VB	amod||rates-41/NNS||relapse-40/JJ	dobj||determine-39/VB||rates-41/NNS	dep||rates-41/NNS||modified-43/VBN	amod||model-45/NN||cornell-44/JJ	dobj||modified-43/VBN||model-45/NN	tb-12||mycobacteriumtuberculosis-10||no||swiss mice were intravenously inoculated with 6 log10 of mycobacteriumtuberculosis (tb) strain h37rv, treated with second-line drug combinations with or without the diarylquinoline tmc207, and then followed without treatment for 3 more months to determine relapse rates (modified cornell model).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||method-6/NN||a-3/DT	amod||method-6/NN||validated-4/JJ	amod||method-6/NN||mathematical-5/JJ	dobj||used-2/VBD||method-6/NN	aux||estimate-8/VB||to-7/TO	vmod||used-2/VBD||estimate-8/VB	det||rate-10/NN||the-9/DT	dobj||estimate-8/VB||rate-10/NN	amod||hivinfections-13/NNS||new-12/JJ	prep_of||rate-10/NN||hivinfections-13/NNS	nn||incidence-16/NN||hiv-15/NN	appos||hivinfections-13/NNS||incidence-16/NN	amod||africa-20/NN||south-19/JJ	prep_in||estimate-8/VB||africa-20/NN	vmod||africa-20/NN||using-21/VBG	advmod||representative-23/JJ||nationally-22/RB	amod||data-26/NNS||representative-23/JJ	amod||data-26/NNS||hiv-24/JJ	nn||data-26/NNS||prevalence-25/NN	dobj||using-21/VBG||data-26/NNS	vmod||data-26/NNS||collected-27/VBN	prep_in||collected-27/VBN||2002-29/CD	num||2002-29/CD||2005-31/CD	prep_in||collected-27/VBN||2008-33/CD	conj_and||2002-29/CD||2008-33/CD	hivinfections-13||hiv-24||no||we used a validated mathematical method to estimate the rate of new hivinfections (hiv incidence) in south africa using nationally representative hiv prevalence data collected in 2002, 2005 and 2008.
advmod||showed-11/VBD||however-1/RB	det||trial-8/NN||the-3/DT	amod||trial-8/NN||recent-4/JJ	amod||trial-8/NN||rv144-5/JJ	nn||trial-8/NN||hiv-6/NN	nn||trial-8/NN||vaccine-7/NN	nsubj||showed-11/VBD||trial-8/NN	prep_in||trial-8/NN||thailand-10/NN	root||ROOT-0/null||showed-11/VBD	mark||provide-28/VB||that-12/IN	det||strategy-16/NN||a-13/DT	amod||strategy-16/NN||prime/boost-14/JJ	nn||strategy-16/NN||immunization-15/NN	nsubj||provide-28/VB||strategy-16/NN	vmod||strategy-16/NN||involving-17/VBG	vmod||involving-17/VBG||priming-18/VBG	nn||vcp1521-21/NNS||canarypox-20/NN	prep_with||priming-18/VBG||vcp1521-21/NNS	vmod||vcp1521-21/NNS||followed-22/VBN	agent||followed-22/VBN||boosting-24/VBG	prep_with||boosting-24/VBG||rgp120-26/CD	aux||provide-28/VB||could-27/MD	ccomp||showed-11/VBD||provide-28/VB	amod||protection-34/NN||significant-29/JJ	mark||modest-32/JJ||although-31/IN	dep||protection-34/NN||modest-32/JJ	dobj||provide-28/VB||protection-34/NN	prep_from||protection-34/NN||hivinfection-36/NN	hivinfection-36||hiv-6||no||however, the recent rv144 hiv vaccine trial in thailand showed that a prime/boost immunization strategy involving priming with canarypox vcp1521 followed by boosting with rgp120 could provide significant, although modest, protection from hivinfection.
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||rif--1||yes||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
nsubj||disease-14/NN||tuberculosis-1/NNP	vmod||tuberculosis-1/NNP||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mtb-7/NN	cop||disease-14/NN||is-10/VBZ	det||disease-14/NN||the-11/DT	advmod||notified-13/JJ||most-12/RBS	amod||disease-14/NN||notified-13/JJ	root||ROOT-0/null||disease-14/NN	det||world-17/NN||the-16/DT	prep_in||disease-14/NN||world-17/NN	tuberculosis-1||mycobacteriumtuberculosis-5||no||tuberculosis, caused by mycobacteriumtuberculosis (mtb), is the most notified disease in the world.
advmod||investigated-7/VBD||however-1/RB	quantmod||few-5/JJ||only-3/RB	quantmod||few-5/JJ||a-4/DT	num||studies-6/NNS||few-5/JJ	nsubj||investigated-7/VBD||studies-6/NNS	root||ROOT-0/null||investigated-7/VBD	det||impact-10/NN||the-8/DT	amod||impact-10/NN||prognostic-9/JJ	dobj||investigated-7/VBD||impact-10/NN	prep_of||impact-10/NN||expression-12/NN	prep_of||expression-12/NN||opn-14/NN	prep_in||investigated-7/VBD||softtissuesarcomas-16/NNS	appos||softtissuesarcomas-16/NNS||sts-18/NN	advmod||investigated-7/VBD||yet-20/RB	sts-18||softtissuesarcomas-16||no_rel||however, only a few studies investigated the prognostic impact of expression of opn in softtissuesarcomas (sts) yet.
nsubj||drug-5/NN||mesalamine-1/NN	cop||drug-5/NN||is-2/VBZ	det||drug-5/NN||the-3/DT	amod||drug-5/NN||first-line-4/JJ	root||ROOT-0/null||drug-5/NN	det||treatment-8/NN||the-7/DT	prep_for||drug-5/NN||treatment-8/NN	prep_of||treatment-8/NN||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	ulcerativecolitis-10||mesalamine-1||yes||mesalamine is the first-line drug for the treatment of ulcerativecolitis (uc).
det||report-3/NN||this-2/DT	prep_in||described-5/VBD||report-3/NN	nsubj||described-5/VBD||we-4/PRP	nsubj||described-5/VBD||we-4/PRP	root||ROOT-0/null||described-5/VBD	conj_and||described-5/VBD||described-5/VBD	det||differences-8/NNS||the-6/DT	amod||differences-8/NNS||main-7/JJ	dobj||described-5/VBD||differences-8/NNS	prep_between||differences-8/NNS||pml-10/NN	det||era-16/NN||the-14/DT	amod||era-16/NN||haart-15/JJ	prep_after||described-5/VBD||era-16/NN	prep_before||described-5/VBD||era-16/NN	parataxis||described-5/VBD||highlighting-18/VBG	det||patterns-21/NNS||the-19/DT	amod||patterns-21/NNS||new-20/JJ	dobj||highlighting-18/VBG||patterns-21/NNS	prep_of||patterns-21/NNS||presentation-23/NN	det||neurotropism-26/NN||the-25/DT	dobj||highlighting-18/VBG||neurotropism-26/NN	conj_and||patterns-21/NNS||neurotropism-26/NN	amod||polyomaviruses-30/NNS||other-28/JJ	amod||polyomaviruses-30/NNS||human-29/JJ	prep_of||neurotropism-26/NN||polyomaviruses-30/NNS	det||prevalence-35/NN||the-33/DT	amod||prevalence-35/NN||increased-34/VBN	dobj||highlighting-18/VBG||prevalence-35/NN	conj_and||patterns-21/NNS||prevalence-35/NN	amod||syndrome-40/NN||immune-37/JJ	amod||syndrome-40/NN||reconstitution-38/JJ	amod||syndrome-40/NN||inflammatory-39/JJ	prep_of||prevalence-35/NN||syndrome-40/NN	dep||prevalence-35/NN||iris-42/VBZ	det||complication-47/NN||a-46/DT	prep_as||highlighting-18/VBG||complication-47/NN	prep_of||complication-47/NN||pml-49/NN	prep_in||highlighting-18/VBG||patients-51/NNS	prep_under||patients-51/NNS||haart-53/NN	pml-49||polyomaviruses-30||no||in this report we described the main differences between pml before and after the haart era; highlighting the new patterns of presentation, the neurotropism of other human polyomaviruses, and the increased prevalence of immune reconstitution inflammatory syndrome (iris), as a complication of pml in patients under haart.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	obesity-32||leucine-22||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
det||time-4/NN||the-2/DT	amod||time-4/NN||first-3/JJ	prep_for||detected-11/VBN||time-4/NN	preconj||species-9/NNS||both-5/DT	nn||species-9/NNS||v.cholerae-6/NN	conj_and||v.cholerae-6/NN||acanthamoeba-8/NN	nn||species-9/NNS||acanthamoeba-8/NN	nsubjpass||detected-11/VBN||species-9/NNS	auxpass||detected-11/VBN||were-10/VBD	root||ROOT-0/null||detected-11/VBN	amod||samples-16/NNS||same-13/JJ	amod||samples-16/NNS||natural-14/JJ	nn||samples-16/NNS||water-15/NN	prep_in||detected-11/VBN||samples-16/NNS	vmod||samples-16/NNS||collected-17/VBN	amod||areas-22/NNS||different-19/JJ	amod||areas-22/NNS||cholera-20/JJ	amod||areas-22/NNS||endemic-21/JJ	prep_from||collected-17/VBN||areas-22/NNS	prep_in||areas-22/NNS||sudan-24/NN	cholera-20||v.cholerae-6||no||for the first time both v.cholerae and acanthamoeba species were detected in same natural water samples collected from different cholera endemic areas in sudan .
nsubj||â-2/VBP||conclusions-1/NNS	ccomp||have-15/VBP||â-2/VBP	dobj||â-2/VBP||$-3/$	prepc_compared_with||$-3/$||with-6/IN	pobj||$-3/$||youth-7/NN	prep_with||youth-7/NN||ngt-9/NN	amod||adolescents-12/NNS||obese-11/JJ	nsubj||have-15/VBP||adolescents-12/NNS	prep_with||adolescents-12/NNS||igt-14/NN	root||ROOT-0/null||have-15/VBP	dobj||have-15/VBP||evidence-16/NN	det||î-19/NN||a-18/DT	prep_of||evidence-16/NN||î-19/NN	punct||î-19/NN||²-20/''	nn||defect-23/NN||cell-22/NN	dep||î-19/NN||defect-23/NN	vmod||defect-23/NN||manifested-24/VBN	amod||secretion-29/NN||impaired-26/VBN	amod||secretion-29/NN||first-phase-27/JJ	nn||secretion-29/NN||insulin-28/NN	prep_in||manifested-24/VBN||secretion-29/NN	det||defect-35/NN||a-32/DT	amod||defect-35/NN||more-33/JJR	amod||defect-35/NN||profound-34/JJ	prep_with||î-19/NN||defect-35/NN	prep_in||defect-35/NN||type2diabetes-37/NNS	vmod||type2diabetes-37/NNS||involving-38/VBG	det||insulin-44/NN||both-39/DT	amod||insulin-44/NN||first-40/JJ	conj_and||first-40/JJ||second-phase-43/NN	amod||insulin-44/NN||second-phase-43/NN	dobj||involving-38/VBG||insulin-44/NN	type2diabetes-37||insulin-44||yes||conclusions â€”compared with youth with ngt, obese adolescents with igt have evidence of a î²-cell defect manifested in impaired first-phase insulin secretion, with a more profound defect in type2diabetes involving both first- and second-phase insulin.
num||syphilis-2/NNS||50-1/CD	root||ROOT-0/null||syphilis-2/NNS	amod||specimens-5/NNS||positive-4/JJ	nsubjpass||tested-19/VBN||specimens-5/NNS	num||specimens-9/NNS||50-7/CD	amod||specimens-9/NNS||healthy-8/JJ	conj_and||specimens-5/NNS||specimens-9/NNS	nsubjpass||tested-19/VBN||specimens-9/NNS	vmod||specimens-9/NNS||conformed-10/VBN	nn||agglutination-14/NN||treponemapallidum-12/NN	nn||agglutination-14/NN||particle-13/NN	agent||conformed-10/VBN||agglutination-14/NN	appos||agglutination-14/NN||tppa-16/NNP	auxpass||tested-19/VBN||were-18/VBD	dep||syphilis-2/NNS||tested-19/VBN	nn||dot-labeled-22/NN||quantum-21/NN	prep_with||tested-19/VBN||dot-labeled-22/NN	amod||strips-29/NNS||colloidal-24/JJ	amod||strips-29/NNS||gold-labeled-25/JJ	amod||strips-29/NNS||lateral-26/JJ	nn||strips-29/NNS||flow-27/NN	nn||strips-29/NNS||test-28/NN	prep_with||tested-19/VBN||strips-29/NNS	conj_and||dot-labeled-22/NN||strips-29/NNS	advmod||tested-19/VBN||respectively-31/RB	syphilis-2||treponemapallidum-12||no||50 syphilis -positive specimens and 50 healthy specimens conformed by treponemapallidum particle agglutination (tppa) were tested with quantum dot-labeled and colloidal gold-labeled lateral flow test strips, respectively.
nn||deletion-2/NN||nonpolar-1/NN	nsubj||increased-19/VBD||deletion-2/NN	prep_of||deletion-2/NN||sa1665-4/CD	advmod||resistant-9/NN||heterogeneously-7/RB	dep||resistant-9/NN||methicillin-8/JJ	amod||s.aureus-10/NNS||resistant-9/NN	prep_in||deletion-2/NN||s.aureus-10/NNS	vmod||s.aureus-10/NNS||-lrb--11/VBG	nn||-rrb--13/NNS||mrsa-12/NN	dobj||-lrb--11/VBG||-rrb--13/NNS	amod||backgrounds-17/NNS||different-15/JJ	amod||backgrounds-17/NNS||genetic-16/JJ	prep_of||-rrb--13/NNS||backgrounds-17/NNS	root||ROOT-0/null||increased-19/VBD	amod||levels-22/NNS||methicillin-20/JJ	nn||levels-22/NNS||resistance-21/NN	dobj||increased-19/VBD||levels-22/NNS	det||manner-27/NN||a-24/DT	nn||manner-27/NN||strain-25/NN	amod||manner-27/NN||dependent-26/JJ	prep_in||increased-19/VBD||manner-27/NN	mrsa-12||s.aureus-10||no||nonpolar deletion of sa1665 , in heterogeneously methicillin resistant s.aureus -lrb- mrsa -rrb- of different genetic backgrounds , increased methicillin resistance levels in a strain dependent manner .
vmod||aimed-17/VBD||using-1/VBG	amod||functional-3/JJ||event-related-2/JJ	amod||imaging-6/NNS||functional-3/JJ	amod||imaging-6/NNS||magnetic-4/JJ	nn||imaging-6/NNS||resonance-5/NN	dobj||using-1/VBG||imaging-6/NNS	appos||imaging-6/NNS||fmri-8/NNP	det||task-14/NN||the-11/DT	amod||task-14/NN||color-word-12/JJ	nn||task-14/NN||stroop-13/NN	prep_during||using-1/VBG||task-14/NN	nsubj||aimed-17/VBD||we-16/PRP	nsubj||model-19/VB||we-16/PRP	root||ROOT-0/null||aimed-17/VBD	aux||model-19/VB||to-18/TO	xcomp||aimed-17/VBD||model-19/VB	amod||fatigue-21/NN||mental-20/JJ	dobj||model-19/VB||fatigue-21/NN	amod||exposures-25/NNS||repeated-23/VBN	nn||exposures-25/NNS||task-24/NN	prep_with||model-19/VB||exposures-25/NNS	num||cocaineabusers-28/NNS||33-27/CD	prep_in||exposures-25/NNS||cocaineabusers-28/NNS	num||controls-32/NNS||20-30/CD	amod||controls-32/NNS||healthy-31/JJ	prep_in||exposures-25/NNS||controls-32/NNS	conj_and||cocaineabusers-28/NNS||controls-32/NNS	cocaine--1||fatigue-21||no_rel||using event-related functional magnetic resonance imaging (fmri) during the color-word stroop task, we aimed to model mental fatigue with repeated task exposures in 33 cocaineabusers and 20 healthy controls.
amod||symptoms-2/NNS||psychopathological-1/JJ	nsubjpass||considered-9/VBN||symptoms-2/NNS	prep_in||symptoms-2/NNS||patients-4/NNS	prep_with||patients-4/NNS||heroinaddiction-6/NN	auxpass||considered-9/VBN||are-7/VBP	advmod||considered-9/VBN||generally-8/RB	root||ROOT-0/null||considered-9/VBN	aux||part-12/NN||to-10/TO	cop||part-12/NN||be-11/VB	ccomp||considered-9/VBN||part-12/NN	det||addict-16/NN||the-14/DT	nn||addict-16/NN||drug-15/NN	poss||personality-18/NN||addict-16/NN	prep_of||part-12/NN||personality-18/NN	advmod||related-24/VBN||else-21/RB	aux||related-24/VBN||to-22/TO	auxpass||related-24/VBN||be-23/VB	ccomp||considered-9/VBN||related-24/VBN	conj_or||part-12/NN||related-24/VBN	det||presence-27/NN||the-26/DT	prep_to||related-24/VBN||presence-27/NN	amod||comorbidity-30/NN||psychiatric-29/JJ	prep_of||presence-27/NN||comorbidity-30/NN	xcomp||considered-9/VBN||raising-32/VBG	dobj||raising-32/VBG||doubts-33/NNS	mark||possess-43/VBP||whether-35/IN	nsubj||possess-43/VBP||patients-36/NNS	amod||abuse-39/NN||long-term-38/JJ	prep_with||patients-36/NNS||abuse-39/NN	prep_of||abuse-39/NN||opioids-41/NNS	advmod||possess-43/VBP||actually-42/RB	prepc_about||doubts-33/NNS||possess-43/VBP	amod||dimensions-46/NNS||specific-44/JJ	amod||dimensions-46/NNS||psychopathological-45/JJ	dobj||possess-43/VBP||dimensions-46/NNS	heroinaddiction-6||opioids-41||no||psychopathological symptoms in patients with heroinaddiction are generally considered to be part of the drug addict's personality, or else to be related to the presence of psychiatric comorbidity, raising doubts about whether patients with long-term abuse of opioids actually possess specific psychopathological dimensions.
nsubj||present-10/VBP||viruses-1/NNS	det||tropism-6/NN||a-3/DT	amod||tropism-6/NN||limited-4/JJ	amod||tropism-6/NN||cellular-5/JJ	prep_with||viruses-1/NNS||tropism-6/NN	amod||animals-9/NNS||infected-8/JJ	prep_in||tropism-6/NN||animals-9/NNS	root||ROOT-0/null||present-10/VBP	amod||models-12/NNS||useful-11/JJ	dobj||present-10/VBP||models-12/NNS	prepc_for||present-10/VBP||studying-14/VBG	det||mechanisms-16/NNS||the-15/DT	dobj||studying-14/VBG||mechanisms-16/NNS	dobj||regulates-21/VBZ||which-18/WDT	nn||attachment-20/NN||virus-19/NN	nsubj||regulates-21/VBZ||attachment-20/NN	prepc_by||studying-14/VBG||regulates-21/VBZ	det||process-24/NN||the-22/DT	nn||process-24/NN||disease-23/NN	dobj||regulates-21/VBZ||process-24/NN	virus-19||viruses-1||no||viruses with a limited cellular tropism in infected animals present useful models for studying the mechanisms by which virus attachment regulates the disease process.
vmod||performed-10/VBD||using-1/VBG	det||line-7/NN||the-2/DT	amod||line-7/NN||hl60-3/JJ	nn||line-7/NN||multipotent-4/NN	nn||line-7/NN||promyelocyticleukemia-5/NN	nn||line-7/NN||cell-6/NN	dobj||using-1/VBG||line-7/NN	nsubj||performed-10/VBD||we-9/PRP	root||ROOT-0/null||performed-10/VBD	dobj||performed-10/VBD||experiments-11/NNS	nsubj||led-14/VBN||experiments-11/NNS	advmod||led-14/VBN||ultimately-13/RB	rcmod||experiments-11/NNS||led-14/VBN	num||attractors-20/NNS||two-16/CD	amod||attractors-20/NNS||different-17/JJ	nn||attractors-20/NNS||cell-18/NN	nn||attractors-20/NNS||fate-19/NN	prep_to||led-14/VBN||attractors-20/NNS	num||treatments-23/NNS||two-22/CD	prep_by||led-14/VBN||treatments-23/NNS	amod||dosage-26/NN||varying-25/VBG	prep_of||treatments-23/NNS||dosage-26/NN	prep_of||treatments-23/NNS||duration-28/NN	conj_and||dosage-26/NN||duration-28/NN	det||all-trans-retinoicacid-33/NN||the-30/DT	amod||all-trans-retinoicacid-33/NN||differentiation-31/JJ	nn||all-trans-retinoicacid-33/NN||agent-32/NN	prep_of||duration-28/NN||all-trans-retinoicacid-33/NN	appos||all-trans-retinoicacid-33/NN||atra-35/NNP	promyelocyticleukemia-5||atra-35||yes||using the hl60 multipotent promyelocyticleukemia cell line, we performed experiments that ultimately led to two different cell fate attractors by two treatments of varying dosage and duration of the differentiation agent all-trans-retinoicacid (atra).
nsubj||drug-6/NN||atovaquone-proguanil-1/NN	cop||drug-6/NN||is-2/VBZ	num||drug-6/NN||one-3/CD	amod||drug-6/NN||such-4/JJ	nn||drug-6/NN||combination-5/NN	root||ROOT-0/null||drug-6/NN	vmod||drug-6/NN||used-7/VBN	dep||used-7/VBN||both-8/DT	prep_for||used-7/VBN||prophylaxis-10/NNS	prep_for||used-7/VBN||prophylaxis-10/NNS	conj_and||prophylaxis-10/NNS||prophylaxis-10/NNS	prep_in||prophylaxis-10/NNS||travellers-12/NNS	prep_for||prophylaxis-10/NNS||treatment-16/NN	amod||cases-20/NNS||acute-18/JJ	nn||cases-20/NNS||malaria-19/NN	prep_of||treatment-16/NN||cases-20/NNS	nn||hospitals-23/NNS||european-22/NN	prep_in||used-7/VBN||hospitals-23/NNS	prep_in||used-7/VBN||clinics-25/NNS	conj_and||hospitals-23/NNS||clinics-25/NNS	malaria-19||atovaquone--1||yes||atovaquone-proguanil is one such combination drug used both for prophylaxis in travellers, and for treatment of acute malaria cases in european hospitals and clinics.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||ketamine-21||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubj||had-7/VBD||plus-5/NN	advmod||had-7/VBD||assay-6/RB	root||ROOT-0/null||had-7/VBD	det||sensitivity-9/NN||a-8/DT	dobj||had-7/VBD||sensitivity-9/NN	num||%-12/NN||95.3-11/CD	prep_of||sensitivity-9/NN||%-12/NN	num||%-15/NN||100-14/CD	prep_of||sensitivity-9/NN||%-15/NN	conj_and||%-12/NN||%-15/NN	num||%-19/NN||94.4-18/CD	prep_of||sensitivity-9/NN||%-19/NN	conj_and||%-12/NN||%-19/NN	nn||resistance-22/NN||inh-21/NN	prep_for||had-7/VBD||resistance-22/NN	nn||resistance-25/NN||rif-24/NN	prep_for||had-7/VBD||resistance-25/NN	conj_and||resistance-22/NN||resistance-25/NN	prep_for||had-7/VBD||mdr-tb-28/NN	conj_and||resistance-22/NN||mdr-tb-28/NN	advmod||had-7/VBD||respectively-30/RB	tb--1||rif-24||yes||the genotypeâ® mtbdr plus assay had a sensitivity of 95.3%, 100%, and 94.4% for inh resistance, rif resistance, and mdr-tb, respectively.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	falciparummalaria-24||chloroquine-14||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
poss||results-2/NNS||its-1/PRP$	nsubj||lead-4/VB||results-2/NNS	nsubj||lead-4/VB||results-2/NNS	aux||lead-4/VB||will-3/MD	root||ROOT-0/null||lead-4/VB	conj_and||lead-4/VB||lead-4/VB	det||understanding-8/NN||a-6/DT	amod||understanding-8/NN||new-7/JJ	prep_to||lead-4/VB||understanding-8/NN	det||role-11/NN||the-10/DT	prep_of||understanding-8/NN||role-11/NN	prep_of||role-11/NN||heparins-13/NNS	det||prevention-16/NN||the-15/DT	prep_in||heparins-13/NNS||prevention-16/NN	amod||thromboembolism-19/NN||venous-18/JJ	prep_of||prevention-16/NN||thromboembolism-19/NN	poss||effect-23/NN||their-22/PRP$	prep_of||lead-4/VB||effect-23/NN	nn||rates-28/NNS||survival-25/NN	prep_on||lead-4/VB||remission-27/NN	conj_and||rates-28/NNS||remission-27/NN	prep_on||lead-4/VB||rates-28/NNS	prep_on||lead-4/VB||toxicity-30/NN	conj_and||rates-28/NNS||toxicity-30/NN	amod||regimens-33/NNS||chemotherapeutic-32/JJ	prep_of||rates-28/NNS||regimens-33/NNS	thromboembolism-19||heparins-13||yes||its results will lead to a new understanding of the role of heparins in the prevention of venous thromboembolism and of their effect on survival, remission rates and toxicity of chemotherapeutic regimens.
amod||practice-3/NN||everyday-2/JJ	prep_in||experienced-16/VBD||practice-3/NN	nsubj||experienced-16/VBD||patients-5/NNS	prep_with||patients-5/NNS||type-7/NN	num||type-7/NN||1-8/CD	amod||insulins-15/NNS||type2diabetes-10/JJ	advmod||controlled-12/JJ||inadequately-11/RB	amod||insulins-15/NNS||controlled-12/JJ	prep_by||controlled-12/JJ||premix-14/NN	conj_or||patients-5/NNS||insulins-15/NNS	nsubj||experienced-16/VBD||insulins-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||improvement-18/NN||significant-17/JJ	dobj||experienced-16/VBD||improvement-18/NN	amod||control-21/NN||glycaemic-20/JJ	prep_in||experienced-16/VBD||control-21/NN	num||months-24/NNS||12-23/CD	prep_over||control-21/NN||months-24/NNS	prepc_after||experienced-16/VBD||switching-26/VBG	det||regimen-31/NN||a-28/DT	amod||regimen-31/NN||glargine-based-29/JJ	nn||regimen-31/NN||insulin-30/NN	prep_to||switching-26/VBG||regimen-31/NN	type2diabetes-10||insulin-30||yes||in everyday practice, patients with type 1 or type2diabetes inadequately controlled by premix insulins experienced significant improvement in glycaemic control over 12 months after switching to a glargine-based insulin regimen.
amod||mice-7/NNS||interestingly-1/VBN	amod||mice-7/NNS||clade-3/JJ	num||mice-7/NNS||2-4/CD	nn||mice-7/NNS||vlp-5/NN	nn||mice-7/NNS||vaccinated-6/NN	nsubjpass||protected-9/VBN||mice-7/NNS	auxpass||protected-9/VBN||were-8/VBD	root||ROOT-0/null||protected-9/VBN	preconj||1-13/CD||both-11/DT	amod||1-13/CD||clade-12/JJ	prep_against||protected-9/VBN||1-13/CD	num||viruses-17/NNS||2-15/CD	amod||viruses-17/NNS||h5/pr8-16/JJ	prep_against||protected-9/VBN||viruses-17/NNS	conj_and||1-13/CD||viruses-17/NNS	amod||vlp-22/NN||clade-20/JJ	num||vlp-22/NN||1-21/CD	nsubj||vaccinated-23/VBD||vlp-22/NN	conj_but||protected-9/VBN||vaccinated-23/VBD	nsubjpass||protected-27/VBN||mice-24/NNS	auxpass||protected-27/VBN||were-25/VBD	advmod||protected-27/VBN||only-26/RB	ccomp||vaccinated-23/VBD||protected-27/VBN	det||virus-32/NN||the-29/DT	amod||virus-32/NN||clade-30/JJ	dep||clade-30/JJ||1-31/CD	prep_against||protected-27/VBN||virus-32/NN	virus-32||viruses-17||no||interestingly, clade 2 vlp vaccinated mice were protected against both clade 1 and 2 h5/pr8 viruses, but clade 1 vlp vaccinated mice were only protected against the clade 1 virus.
det||design-6/NN||a-2/DT	amod||design-6/NN||double-blinded-3/JJ	amod||design-6/NN||randomized-4/JJ	nn||design-6/NN||crossover-5/NN	prep_in||examined-12/VBN||design-6/NN	amod||function-10/NN||postprandial-8/JJ	amod||function-10/NN||endothelial-9/JJ	nsubjpass||examined-12/VBN||function-10/NN	auxpass||examined-12/VBN||was-11/VBD	root||ROOT-0/null||examined-12/VBN	num||individuals-15/NNS||28-14/CD	prep_in||examined-12/VBN||individuals-15/NNS	amod||type2diabetes-20/NNS||impairedglucosetolerance-17/JJ	conj_or||impairedglucosetolerance-17/JJ||recent-onset-19/JJ	amod||type2diabetes-20/NNS||recent-onset-19/JJ	prep_with||individuals-15/NNS||type2diabetes-20/NNS	det||injection-24/NN||a-22/DT	amod||injection-24/NN||single-23/JJ	prep_after||examined-12/VBN||injection-24/NN	prep_of||injection-24/NN||exenatide-26/NN	prep_of||injection-24/NN||placebo-28/NN	conj_or||exenatide-26/NN||placebo-28/NN	vmod||injection-24/NN||given-29/VBN	advmod||given-29/VBN||just-30/RB	det||meal-34/NN||a-32/DT	amod||meal-34/NN||high-fat-33/JJ	prep_before||given-29/VBN||meal-34/NN	exenatide-26||impairedglucosetolerance-17||no_rel||in a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impairedglucosetolerance or recent-onset type2diabetes after a single injection of exenatide or placebo given just before a high-fat meal.
advmod||correlated-5/VBD||importantly-1/RB	nn||fibrosis-4/NN||scwat-3/NN	nsubj||correlated-5/VBD||fibrosis-4/NN	root||ROOT-0/null||correlated-5/VBD	advmod||correlated-5/VBD||negatively-6/RB	amod||loss-10/NN||fat-8/JJ	amod||loss-10/NN||mass-9/JJ	prep_with||correlated-5/VBD||loss-10/NN	vmod||loss-10/NN||measured-11/VBN	det||points-16/NNS||the-13/DT	num||points-16/NNS||three-14/CD	nn||points-16/NNS||time-15/NN	prep_at||measured-11/VBN||points-16/NNS	prep_after||measured-11/VBN||surgery-18/NN	fat-8||fibrosis-4||no_rel||importantly, scwat fibrosis correlated negatively with fat mass loss measured at the three time points after surgery.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||enhanced-20/VBD||that-5/IN	det||model-12/NN||a-7/DT	nn||model-12/NN||chemically-8/NNP	nn||model-12/NN||induced-9/NNP	nn||model-12/NN||skin-10/NN	nn||model-12/NN||carcinoma-11/NN	prep_in||enhanced-20/VBD||model-12/NN	amod||drainage-16/NN||increased-14/VBN	amod||drainage-16/NN||vegf-c-15/JJ	nsubj||enhanced-20/VBD||drainage-16/NN	nsubj||facilitated-28/VBD||drainage-16/NN	det||tumor-19/NN||the-18/DT	prep_from||drainage-16/NN||tumor-19/NN	ccomp||found-4/VBD||enhanced-20/VBD	dobj||enhanced-20/VBD||lymphangiogenesis-21/NNS	det||node-26/NN||the-23/DT	amod||node-26/NN||sentinel-24/JJ	nn||node-26/NN||lymph-25/NN	prep_in||enhanced-20/VBD||node-26/NN	ccomp||found-4/VBD||facilitated-28/VBD	conj_and||enhanced-20/VBD||facilitated-28/VBD	amod||spread-30/NN||metastatic-29/JJ	dobj||facilitated-28/VBD||spread-30/NN	nn||cells-33/NNS||cancer-32/NN	prep_of||spread-30/NN||cells-33/NNS	det||lymphatics-36/NNS||the-35/DT	prep_via||cells-33/NNS||lymphatics-36/NNS	cancer-32||chemically-8||no_rel||recently, we found that in a chemically induced skin carcinoma model, increased vegf-c drainage from the tumor enhanced lymphangiogenesis in the sentinel lymph node and facilitated metastatic spread of cancer cells via the lymphatics.
nsubj||agent-5/NN||rubellavirus-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||rubella-7/NN	det||illness-12/NN||a-9/DT	amod||illness-12/NN||mild-10/JJ	nn||illness-12/NN||rash-11/NN	prep_of||agent-5/NN||illness-12/NN	conj_and||rubella-7/NN||illness-12/NN	det||agent-18/NN||a-15/DT	amod||agent-18/NN||potent-16/JJ	amod||agent-18/NN||teratogenic-17/JJ	prep_of||agent-5/NN||agent-18/NN	conj_and||rubella-7/NN||agent-18/NN	advmod||contracted-20/VBD||when-19/WRB	advcl||agent-5/NN||contracted-20/VBD	det||woman-24/NN||a-22/DT	amod||woman-24/NN||pregnant-23/JJ	prep_by||contracted-20/VBD||woman-24/NN	rubella-7||rubellavirus-1||no||rubellavirus is the causative agent of rubella, a mild rash illness, and a potent teratogenic agent when contracted by a pregnant woman.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||adenosinemonophosphate-150/NN||a-148/DT	amod||adenosinemonophosphate-150/NN||cyclic-149/JJ	prep_in||agonists-146/NNS||adenosinemonophosphate-150/NN	appos||adenosinemonophosphate-150/NN||camp-152/NN	amod||assay-155/JJ||functional-154/JJ	amod||adenosinemonophosphate-150/NN||assay-155/JJ	amod||cells-163/NNS||chinese-157/JJ	nn||cells-163/NNS||hamster-158/NN	nn||cells-163/NNS||ovary-159/NN	appos||cells-163/NNS||cho-161/NN	prep_in||agonists-146/NNS||cells-163/NNS	vmod||cells-163/NNS||expressing-164/VBG	amod||ar-166/NN||ha2b-165/JJ	dobj||expressing-164/VBG||ar-166/NN	adenosinemonophosphate-150||ar-166||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosinemonophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
nsubj||point-2/VBP||we-1/PRP	root||ROOT-0/null||point-2/VBP	prt||point-2/VBP||out-3/RP	neg||only-5/JJ||not-4/RB	preconj||association-7/NN||only-5/JJ	det||association-7/NN||the-6/DT	dobj||point-2/VBP||association-7/NN	det||epiduralabscess-10/NNS||an-9/DT	prep_of||association-7/NN||epiduralabscess-10/NNS	amod||jointinfection-13/NN||facet-12/JJ	prep_with||epiduralabscess-10/NNS||jointinfection-13/NN	det||indication-19/NN||the-17/DT	amod||indication-19/NN||possible-18/JJ	dobj||point-2/VBP||indication-19/NN	conj_and||association-7/NN||indication-19/NN	amod||cement-22/NN||antibiotic-bone-21/JJ	prep_of||indication-19/NN||cement-22/NN	rcmod||indication-19/NN||beads-23/VBZ	det||treatment-26/NN||the-25/DT	prep_in||beads-23/VBZ||treatment-26/NN	prep_of||treatment-26/NN||epiduralabscesses-28/NNS	epiduralabscess-10||antibiotic--1||no_rel||we point out not only the association of an epiduralabscess with facet jointinfection, but also the possible indication of antibiotic-bone cement beads in the treatment of epiduralabscesses.
det||number-3/NN||a-1/DT	amod||number-3/NN||vast-2/JJ	nsubj||affect-7/VBP||number-3/NN	amod||diseases-6/NNS||infectious-5/JJ	prep_of||number-3/NN||diseases-6/NNS	root||ROOT-0/null||affect-7/VBP	amod||africa-9/NN||east-8/JJ	dobj||affect-7/VBP||africa-9/NN	prep_including||africa-9/NN||hiv/aids-12/NNS	prep_including||africa-9/NN||malaria-14/NNP	conj_and||hiv/aids-12/NNS||malaria-14/NNP	prep_including||africa-9/NN||tuberculosis-17/NNP	conj_and||hiv/aids-12/NNS||tuberculosis-17/NNP	det||diversity-23/NN||the-20/DT	amod||diversity-23/NN||hla-21/JJ	amod||diversity-23/NN||genetic-22/JJ	nsubj||remains-27/VBZ||diversity-23/NN	det||region-26/NN||this-25/DT	prep_in||diversity-23/NN||region-26/NN	conj_but||affect-7/VBP||remains-27/VBZ	advmod||described-29/VBN||incompletely-28/RB	ccomp||remains-27/VBZ||described-29/VBN	aids--1||hiv--1||no||a vast number of infectious diseases affect east africa, including hiv/aids, malaria, and tuberculosis, but the hla genetic diversity in this region remains incompletely described.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||levels-6/NNS||the-5/DT	dobj||investigated-4/VBD||levels-6/NNS	prep_of||levels-6/NNS||proteins-8/NNS	vmod||proteins-8/NNS||mediating-9/VBG	nn||damage-11/NN||dna-10/NN	dobj||mediating-9/VBG||damage-11/NN	vmod||mediating-9/VBG||signaling-12/VBG	cc||signaling-12/VBG||and-13/CC	dobj||signaling-12/VBG||repair-15/NN	amod||cells-19/NNS||rpmi8226-17/JJ	nn||cells-19/NNS||multiplemyeloma-18/NN	prep_in||signaling-12/VBG||cells-19/NNS	poss||8226-lr5-24/NN||its-21/PRP$	amod||8226-lr5-24/NN||melphalan-resistant-22/JJ	amod||8226-lr5-24/NN||derivative-23/JJ	prep_in||signaling-12/VBG||8226-lr5-24/NN	conj_and||cells-19/NNS||8226-lr5-24/NN	multiplemyeloma-18||melphalan--1||yes||here, we investigated the levels of proteins mediating dna damage signaling and -repair in rpmi8226 multiplemyeloma cells and its melphalan-resistant derivative 8226-lr5.
prepc_after||associated-11/VBN||controlling-2/VBG	amod||confounders-5/NNS||potential-4/JJ	prep_for||controlling-2/VBG||confounders-5/NNS	nsubjpass||associated-11/VBN||adherence-7/NN	prep_to||adherence-7/NN||ahei-9/NNS	auxpass||associated-11/VBN||was-10/VBD	root||ROOT-0/null||associated-11/VBN	nn||ratio-17/NN||mets-13/NNS	nn||ratio-17/NN||reversion-14/NN	nn||ratio-17/NN||odds-16/NNP	prep_with||associated-11/VBN||ratio-17/NN	num||ratio-17/NN||1.88-18/CD	vmod||ratio-17/NN||-LSB--19/VBG	num||%-21/NN||95-20/CD	dobj||-LSB--19/VBG||%-21/NN	number||1.04-23/CD||ci-22/CD	num||%-21/NN||1.04-23/CD	dep||$-25/$||â-24/RB	dep||%-21/NN||$-25/$	amod||-RSB--28/NNS||3.41-27/JJ	npadvmod||high-41/RB||-RSB--28/NNS	dep||-RSB--28/NNS||predominantly-31/RB	prep_in||-RSB--28/NNS||participants-33/NNS	amod||obesity-36/NN||central-35/JJ	prep_with||participants-33/NNS||obesity-36/NN	prep_in||-RSB--28/NNS||those-39/DT	conj_and||participants-33/NNS||those-39/DT	prep||those-39/DT||with-40/IN	dep||triglyceride-42/CD||high-41/RB	num||$-25/$||triglyceride-42/CD	triglyceride-42||obesity-36||no_rel||after controlling for potential confounders, adherence to ahei was associated with mets reversion (odds ratio 1.88 [95% ci 1.04â€“3.41]), predominantly in participants with central obesity and in those with high triglyceride.
det||complexes-3/NNS||all-1/DT	num||complexes-3/NNS||three-2/CD	nsubjpass||characterized-5/VBN||complexes-3/NNS	auxpass||characterized-5/VBN||were-4/VBD	root||ROOT-0/null||characterized-5/VBN	amod||crystallography-9/NN||single-crystal-7/JJ	amod||crystallography-9/NN||x-ray-8/JJ	agent||characterized-5/VBN||crystallography-9/NN	nn||spectroscopy-12/NN||ir-11/NN	agent||characterized-5/VBN||spectroscopy-12/NN	conj_and||crystallography-9/NN||spectroscopy-12/NN	mark||investigated-19/VBN||while-14/IN	poss||activities-17/NNS||their-15/PRP$	amod||activities-17/NNS||antiproliferative-16/JJ	nsubjpass||investigated-19/VBN||activities-17/NNS	auxpass||investigated-19/VBN||were-18/VBD	advcl||characterized-5/VBN||investigated-19/VBN	det||series-22/NN||a-21/DT	prep_against||investigated-19/VBN||series-22/NN	amod||lines-29/NNS||human-24/JJ	conj_and||human-24/JJ||mouse-26/NN	amod||lines-29/NNS||mouse-26/NN	nn||lines-29/NNS||cancer-27/NN	nn||lines-29/NNS||cell-28/NN	prep_of||series-22/NN||lines-29/NNS	crystal--1||cancer-27||no_rel||all three complexes were characterized by single-crystal x-ray crystallography and ir spectroscopy, while their antiproliferative activities were investigated against a series of human and mouse cancer cell lines.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	xcomp||investigated-4/VBD||using-5/VBG	amod||technology-8/NN||luciferase-6/JJ	nn||technology-8/NN||immunoprecipitation-7/NN	dobj||using-5/VBG||technology-8/NN	dep||investigated-4/VBD||lips-10/VB	nn||responses-13/NNS||antibody-12/NN	dobj||investigated-4/VBD||responses-13/NNS	num||proteins-17/NNS||seven-15/CD	amod||proteins-17/NNS||htlv-i-16/JJ	prep_to||responses-13/NNS||proteins-17/NNS	amod||controls-20/NNS||non-infected-19/JJ	prep_in||proteins-17/NNS||controls-20/NNS	amod||htlv-i-carriers-23/NNS||asymptomatic-22/JJ	prep_in||proteins-17/NNS||htlv-i-carriers-23/NNS	conj_and||controls-20/NNS||htlv-i-carriers-23/NNS	prep_in||proteins-17/NNS||atll-25/NN	conj_and||controls-20/NNS||atll-25/NN	nn||samples-29/NNS||ham/tsp-27/NN	nn||samples-29/NNS||sera-28/NN	prep_in||proteins-17/NNS||samples-29/NNS	conj_and||controls-20/NNS||samples-29/NNS	ham--1||htlv-i-16||no||therefore, we investigated using luciferase immunoprecipitation technology (lips) antibody responses to seven htlv-i proteins in non-infected controls, asymptomatic htlv-i-carriers, atll and ham/tsp sera samples.
nsubj||uses-2/VBZ||australia-1/NN	root||ROOT-0/null||uses-2/VBZ	det||protocol-4/NN||a-3/DT	dobj||uses-2/VBZ||protocol-4/NN	vmod||protocol-4/NN||combining-5/VBG	amod||rabiesimmunoglobulin-7/NN||human-6/JJ	dobj||combining-5/VBG||rabiesimmunoglobulin-7/NN	dep||rabiesimmunoglobulin-7/NN||hrig-9/VBG	dobj||combining-5/VBG||rabiesvaccine-12/NN	conj_and||rabiesimmunoglobulin-7/NN||rabiesvaccine-12/NN	amod||prophylaxis-15/NNS||post-exposure-14/JJ	prep_for||rabiesvaccine-12/NN||prophylaxis-15/NNS	appos||rabiesvaccine-12/NN||pep-17/NN	nn||lyssavirus-24/NNS||rabies-20/NNP	conj_and||rabies-20/NNP||australian-22/NN	nn||lyssavirus-24/NNS||australian-22/NN	nn||lyssavirus-24/NNS||bat-23/NN	prep_of||rabiesvaccine-12/NN||lyssavirus-24/NNS	appos||lyssavirus-24/NNS||ablv-26/NNP	det||aim-31/NN||the-30/DT	prep_with||lyssavirus-24/NNS||aim-31/NN	prepc_of||aim-31/NN||achieving-33/VBG	det||titre-36/NN||an-34/DT	nn||titre-36/NN||antibody-35/NN	dobj||achieving-33/VBG||titre-36/NN	nn||¥-40/NNP||â-38/NNP	nn||¥-40/NNP||‰-39/NNP	prep_of||titre-36/NN||¥-40/NNP	number||iu/ml-42/JJ||0.5-41/CD	amod||rabiesvaccine-12/NN||iu/ml-42/JJ	dep||world-46/NN||per-45/IN	amod||guidelines-52/NNS||world-46/NN	nn||guidelines-52/NNS||health-47/NN	nn||guidelines-52/NNS||organization-48/NN	dep||guidelines-52/NNS||who-50/WP	prep_as||rabiesvaccine-12/NN||guidelines-52/NNS	advmod||soon-55/RB||as-54/RB	advmod||guidelines-52/NNS||soon-55/RB	prep_as||soon-55/RB||possible-57/JJ	rabies-20||rabiesvaccine-12||yes||australia uses a protocol combining human rabiesimmunoglobulin (hrig) and rabiesvaccine for post-exposure prophylaxis (pep) of rabies and australian bat lyssavirus (ablv), with the aim of achieving an antibody titre of â‰¥0.5 iu/ml, as per world health organization (who) guidelines, as soon as possible.
det||analysis-2/NN||this-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||participants-4/NNS	det||1999â-7/NNS||the-6/DT	prep_in||included-3/VBD||1999â-7/NNS	dep||included-3/VBD||$-8/$	nsubjpass||aged-19/VBN||$-8/$	det||health-12/NN||2004-10/DT	amod||health-12/NN||national-11/JJ	npadvmod||examination-15/RB||health-12/NN	cc||nutrition-14/RB||and-13/CC	advmod||health-12/NN||nutrition-14/RB	dep||survey-16/CD||examination-15/RB	num||$-8/$||survey-16/CD	auxpass||aged-19/VBN||were-18/VBD	rcmod||$-8/$||aged-19/VBN	number||84-22/CD||20-20/CD	dep||84-22/CD||to-21/TO	num||years-23/NNS||84-22/CD	npadvmod||aged-19/VBN||years-23/NNS	det||diagnosis-26/NN||a-25/DT	prep_without||aged-19/VBN||diagnosis-26/NN	prep_of||diagnosis-26/NN||cardiovasculardisease-28/NN	prep_of||diagnosis-26/NN||hypertension-30/NN	conj_or||cardiovasculardisease-28/NN||hypertension-30/NN	prep_of||diagnosis-26/NN||pregnancy-32/NN	conj_or||cardiovasculardisease-28/NN||pregnancy-32/NN	dep||lower-42/JJR||whose-34/WP$	amod||pressure-37/NN||systolic/diastolic-35/JJ	nn||pressure-37/NN||blood-36/NN	nsubj||lower-42/JJR||pressure-37/NN	appos||pressure-37/NN||sbp/dbp-39/NN	cop||lower-42/JJR||was-41/VBD	dep||diagnosis-26/NN||lower-42/JJR	num||mmhg-45/NN||140/90-44/CD	prep_than||lower-42/JJR||mmhg-45/NN	nsubj||were-48/VBD||mmhg-45/NN	rcmod||mmhg-45/NN||were-48/VBD	dep||were-48/VBD||not-49/RB	dep||not-49/RB||on-50/IN	amod||medication-52/NN||antihypertensive-51/JJ	pobj||on-50/IN||medication-52/NN	nsubj||consumed-56/VBD||who-55/WP	dep||were-48/VBD||consumed-56/VBD	conj_and||not-49/RB||consumed-56/VBD	num||drinks-58/NNS||12-57/CD	dobj||consumed-56/VBD||drinks-58/NNS	cc||more-60/JJR||or-59/CC	num||drinks-58/NNS||more-60/JJR	det||months-65/NNS||the-62/DT	amod||months-65/NNS||past-63/JJ	num||months-65/NNS||12-64/CD	prep_during||consumed-56/VBD||months-65/NNS	dep||months-65/NNS||n-67/VBN	dep||3957-69/CD||=-68/SYM	ccomp||n-67/VBN||3957-69/CD	antihypertensive-51||cardiovasculardisease-28||no_rel||this analysis included participants in the 1999â€“2004 national health and nutrition examination survey who were aged 20 to 84 years without a diagnosis of cardiovasculardisease, hypertension or pregnancy, whose systolic/diastolic blood pressure (sbp/dbp) was lower than 140/90 mmhg, who were not on antihypertensive medication, and who consumed 12 drinks or more during the past 12 months (n = 3957).
nsubj||indicate-2/VBP||results-1/NNS	nsubj||elevated-75/VBD||results-1/NNS	root||ROOT-0/null||indicate-2/VBP	amod||reduction-9/NN||significant-3/JJ	nn||reduction-9/NN||-lrb--4/NN	nn||reduction-9/NN||p-5/NN	num||reduction-9/NN||<-6/CD	num||reduction-9/NN||0.05-7/CD	amod||reduction-9/NN||-rrb--8/JJ	dobj||indicate-2/VBP||reduction-9/NN	num||+-12/NNS||na-11/CD	amod||-rrb--73/NNP||+-12/NNS	number||+-14/CD||k-13/CD	dep||+-12/NNS||+-14/CD	amod||activity-17/NN||atpase-16/JJ	dep||+-14/CD||activity-17/NN	det||-lrb--24/NN||the-19/DT	nn||-lrb--24/NN||type-20/NN	num||-lrb--24/NN||1-21/CD	amod||-lrb--24/NN||diabetic-22/JJ	nn||-lrb--24/NN||patients-23/NNS	prep_in||activity-17/NN||-lrb--24/NN	num||â-26/NN||0.38-25/CD	nsubj||±-32/VBD||â-26/NN	nsubj||±-32/VBD||â-26/NN	number||0.08-28/CD||±-27/CD	num||â-26/NN||0.08-28/CD	prep||â-26/NN||vs.-29/FW	num||â-31/NN||0.59-30/CD	pobj||vs.-29/FW||â-31/NN	rcmod||-lrb--24/NN||±-32/VBD	rcmod||-lrb--24/NN||±-32/VBD	conj_and||±-32/VBD||±-32/VBD	num||-rrb--36/NNS||0.07-33/CD	nn||-rrb--36/NNS||um-34/NN	nn||-rrb--36/NNS||pi/mgprotein/h-35/NN	dobj||±-32/VBD||-rrb--36/NNS	prepc_compared_to||±-32/VBD||to-38/TO	det||control-40/NN||the-39/DT	pobj||±-32/VBD||control-40/NN	cc||±-32/VBD||but-41/CC	amod||reduction-44/NN||greater-43/JJR	prep_with||±-32/VBD||reduction-44/NN	det||subgroup-48/NN||the-46/DT	amod||subgroup-48/NN||diabetic-47/JJ	prep_in||reduction-44/NN||subgroup-48/NN	amod||control-52/NN||poor-50/JJ	amod||control-52/NN||glycemic-51/JJ	nn||n-54/NN||control-52/NN	amod||n-54/NN||-lrb--53/JJ	prep_with||subgroup-48/NN||n-54/NN	dep||-rrb--57/NNS||=-55/SYM	num||-rrb--57/NNS||20-56/CD	dep||n-54/NN||-rrb--57/NNS	amod||cases-61/NNS||whom-60/JJ	prep_in||±-32/VBD||cases-61/NNS	nn||-rrb--67/NNS||hypercholesterolemia-63/NNP	nn||-rrb--67/NNS||-lrb--64/NNP	number||%-66/NN||8.8-65/CD	amod||-rrb--67/NNS||%-66/NN	prep_of||cases-61/NNS||-rrb--67/NNS	amod||-lrb--70/JJ||hypertriglyceridemia-69/JJ	amod||-rrb--73/NNP||-lrb--70/JJ	number||%-72/NN||2.9-71/CD	amod||-rrb--73/NNP||%-72/NN	prep_in||reduction-9/NN||-rrb--73/NNP	conj_and||indicate-2/VBP||elevated-75/VBD	amod||-lrb--77/NNS||ldl-cholesterol-76/JJ	dobj||elevated-75/VBD||-lrb--77/NNS	number||%-79/NN||5.9-78/CD	amod||-lrb--77/NNS||%-79/NN	det||-rrb--81/NN||each-80/DT	nsubjpass||found-83/VBN||-rrb--81/NN	auxpass||found-83/VBN||were-82/VBD	rcmod||-lrb--77/NNS||found-83/VBN	hypercholesterolemia-63||cholesterol--1||no||results indicate significant -lrb- p < 0.05 -rrb- reduction in na + k + - atpase activity in the type 1 diabetic patients -lrb- 0.38 â ± 0.08 vs. 0.59 â ± 0.07 um pi/mgprotein/h -rrb- compared to the control but with greater reduction in the diabetic subgroup with poor glycemic control -lrb- n = 20 -rrb- and in whom cases of hypercholesterolemia -lrb- 8.8 % -rrb- , hypertriglyceridemia -lrb- 2.9 % -rrb- and elevated ldl-cholesterol -lrb- 5.9 % each -rrb- were found .
advmod||show-9/VBP||here-1/RB	vmod||show-9/VBP||using-3/VBG	amod||analysis-6/NN||novel-4/JJ	amod||analysis-6/NN||statistical-5/JJ	dobj||using-3/VBG||analysis-6/NN	nsubj||show-9/VBP||we-8/PRP	root||ROOT-0/null||show-9/VBP	mark||exist-15/VBP||that-10/IN	amod||abnormalities-14/NNS||subtle-11/JJ	conj_but||subtle-11/JJ||significant-13/JJ	amod||abnormalities-14/NNS||significant-13/JJ	nsubj||exist-15/VBP||abnormalities-14/NNS	ccomp||show-9/VBP||exist-15/VBP	det||composition-18/NN||the-17/DT	prep_in||exist-15/VBP||composition-18/NN	prep_of||composition-18/NN||fattyacids-20/NNS	appos||fattyacids-20/NNS||fas-22/NN	amod||acid-27/NN||docosapentaenoic-26/JJ	prep_including||exist-15/VBP||acid-27/NN	num||-3-31/NN||225-29/CD	nn||-3-31/NN||n-30/NN	appos||acid-27/NN||-3-31/NN	appos||acid-27/NN||one-34/CD	det||fas-39/NN||the-36/DT	amod||fas-39/NN||omega-3-37/JJ	amod||fas-39/NN||polyunsaturated-38/JJ	prep_of||one-34/CD||fas-39/NN	vmod||fas-39/NN||found-41/VBN	det||cortex-46/NN||the-43/DT	amod||cortex-46/NN||post-mortem-44/JJ	nn||cortex-46/NN||frontopolar-45/NN	prep_in||found-41/VBN||cortex-46/NN	appos||cortex-46/NN||fpc-48/NN	prep_of||cortex-46/NN||subjects-51/NNS	prep_with||found-41/VBN||bipolar-53/NNP	amod||depressivedisorders-56/NNS||major-55/JJ	prep_with||found-41/VBN||depressivedisorders-56/NNS	conj_or||bipolar-53/NNP||depressivedisorders-56/NNS	mark||in-60/IN||although-58/IN	dep||in-60/IN||not-59/RB	advcl||exist-15/VBP||in-60/IN	pobj||in-60/IN||those-61/DT	prep_with||those-61/DT||schizophrenia-63/NN	schizophrenia-63||fattyacids-20||no_rel||here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fattyacids (fas), including docosapentaenoic acid (225 n -3), one of the omega-3 polyunsaturated fas, found in the post-mortem frontopolar cortex (fpc) of subjects with bipolar or major depressivedisorders, although not in those with schizophrenia.
nsubj||agent-5/NN||humanpolyomavirusjc-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	det||form-9/NN||a-7/DT	amod||form-9/NN||deadly-8/JJ	prep_of||agent-5/NN||form-9/NN	amod||dementia-13/NN||sudden-11/JJ	nn||dementia-13/NN||onset-12/NN	prep_of||form-9/NN||dementia-13/NN	amod||leukocoencephalopathy-17/NN||progressive-15/JJ	amod||leukocoencephalopathy-17/NN||multifocal-16/JJ	appos||dementia-13/NN||leukocoencephalopathy-17/NN	appos||leukocoencephalopathy-17/NN||pml-19/NN	pml-19||humanpolyomavirusjc-1||no||humanpolyomavirusjc is the causative agent of a deadly form of sudden onset dementia, progressive multifocal leukocoencephalopathy (pml).
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	impairedglucosetolerance-29||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	det||index-6/NN||a-4/DT	nn||index-6/NN||price-5/NN	nsubjpass||used-20/VBN||index-6/NN	nsubj||estimate-22/VB||index-6/NN	amod||therapy-11/NN||first-8/JJ	nn||therapy-11/NN||line-9/NN	nn||therapy-11/NN||antiretroviral-10/NN	prep_of||index-6/NN||therapy-11/NN	prep_with||therapy-11/NN||data-13/NNS	amod||assistance-16/NN||foreign-15/JJ	prep_on||data-13/NNS||assistance-16/NN	prep_for||assistance-16/NN||hiv-18/NN	auxpass||used-20/VBN||was-19/VBD	ccomp||measures-3/VBZ||used-20/VBN	aux||estimate-22/VB||to-21/TO	xcomp||used-20/VBN||estimate-22/VB	det||associations-24/NNS||the-23/DT	dobj||estimate-22/VB||associations-24/NNS	prep_of||associations-24/NNS||prices-26/NNS	amod||assistance-29/NN||foreign-28/JJ	dobj||estimate-22/VB||assistance-29/NN	conj_and||associations-24/NNS||assistance-29/NN	amod||coverage-32/NN||antiretroviral-31/JJ	prep_with||assistance-29/NN||coverage-32/NN	dep||associations-24/NNS||percentage-34/NN	prep_of||percentage-34/NN||people-36/NNS	amod||hivinfection-39/NN||advanced-38/JJ	prep_with||people-36/NNS||hivinfection-39/NN	vmod||hivinfection-39/NN||receiving-40/VBG	amod||therapy-42/NN||antiretroviral-41/JJ	dobj||receiving-40/VBG||therapy-42/NN	dobj||estimate-22/VB||controlling-45/VBG	conj_and||associations-24/NNS||controlling-45/VBG	amod||spending-50/NN||national-47/JJ	amod||spending-50/NN||public-48/JJ	nn||spending-50/NN||health-49/NN	prep_for||controlling-45/VBG||spending-50/NN	nn||prevalence-53/NN||hiv-52/NN	prep_for||controlling-45/VBG||prevalence-53/NN	conj_and||spending-50/NN||prevalence-53/NN	prep_for||controlling-45/VBG||governance-55/NN	conj_and||spending-50/NN||governance-55/NN	amod||effects-59/NNS||fixed-58/JJ	prep_for||controlling-45/VBG||effects-59/NNS	conj_and||spending-50/NN||effects-59/NNS	prep_for||controlling-45/VBG||countries-61/NNS	prep_for||controlling-45/VBG||years-63/NNS	conj_and||countries-61/NNS||years-63/NNS	hivinfection-39||hiv-52||no||main outcome measures a price index of first line antiretroviral therapy with data on foreign assistance for hiv was used to estimate the associations of prices and foreign assistance with antiretroviral coverage (percentage of people with advanced hivinfection receiving antiretroviral therapy), controlling for national public health spending, hiv prevalence, governance, and fixed effects for countries and years.
det||model-2/NN||the-1/DT	nsubj||predicts-3/VBZ||model-2/NN	root||ROOT-0/null||predicts-3/VBZ	mark||cost-effective-7/JJ||that-4/IN	nsubj||cost-effective-7/JJ||it-5/PRP	nsubj||keep-9/VB||it-5/PRP	cop||cost-effective-7/JJ||is-6/VBZ	ccomp||predicts-3/VBZ||cost-effective-7/JJ	aux||keep-9/VB||to-8/TO	xcomp||cost-effective-7/JJ||keep-9/VB	det||patient-11/NN||a-10/DT	dobj||keep-9/VB||patient-11/NN	prep_with||keep-9/VB||schizophrenia-13/NN	prep_in||schizophrenia-13/NN||germany-15/NN	amod||risperidone-18/NN||branded-17/JJ	prep_on||keep-9/VB||risperidone-18/NN	prepc_instead_of||risperidone-18/NN||switching-21/VBG	dobj||switching-21/VBG||him/her-22/NN	amod||risperidone-25/NN||generic-24/JJ	prep_to||switching-21/VBG||risperidone-25/NN	dep||risperidone-25/NN||assuming-27/VBG	det||reduction-31/NN||a-28/DT	number||%-30/NN||40-29/CD	amod||reduction-31/NN||%-30/NN	dobj||assuming-27/VBG||reduction-31/NN	nn||costs-34/NNS||medication-33/NN	prep_in||reduction-31/NN||costs-34/NNS	mark||exceeds-47/VBZ||if-37/IN	det||probability-40/NN||the-38/DT	amod||probability-40/NN||incremental-39/JJ	nsubj||exceeds-47/VBZ||probability-40/NN	prepc_of||probability-40/NN||becoming-42/VBG	xcomp||becoming-42/VBG||non-compliant-43/NN	amod||substitution-46/NN||generic-45/JJ	prep_after||becoming-42/VBG||substitution-46/NN	advcl||cost-effective-7/JJ||exceeds-47/VBZ	num||%-49/NN||5.2-48/CD	dobj||exceeds-47/VBZ||%-49/NN	schizophrenia-13||risperidone-25||yes||the model predicts that it is cost-effective to keep a patient with schizophrenia in germany on branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5.2%.
det||study-2/NN||this-1/DT	nsubj||assessed-3/VBD||study-2/NN	root||ROOT-0/null||assessed-3/VBD	nn||effects-5/NNS||statin-4/NN	dobj||assessed-3/VBD||effects-5/NNS	dep||activity-11/NN||central-8/JJ	amod||activity-11/NN||sympathetic-10/JJ	prep_on||assessed-3/VBD||activity-11/NN	amod||patients-20/NNS||human-13/JJ	amod||patients-20/NNS||chronic-14/JJ	nn||patients-20/NNS||heart-15/NN	nn||patients-20/NNS||failure-16/NN	nn||patients-20/NNS||chf-18/NN	prep_in||assessed-3/VBD||patients-20/NNS	chf-18||statin-4||no_rel||this study assessed statin effects on (central) sympathetic activity in human chronic heart failure (chf) patients.
advmod||exists-6/VBZ||however-1/RB	advmod||information-5/NN||virtually-3/RB	neg||information-5/NN||no-4/DT	nsubj||exists-6/VBZ||information-5/NN	root||ROOT-0/null||exists-6/VBZ	xcomp||exists-6/VBZ||regarding-7/VBG	det||effects-9/NNS||the-8/DT	dobj||regarding-7/VBG||effects-9/NNS	prep_of||effects-9/NNS||fluoxetine-11/NN	amod||responses-16/NNS||integrated-13/JJ	amod||responses-16/NNS||physiological-14/JJ	nn||responses-16/NNS||counterregulatory-15/NN	prep_on||regarding-7/VBG||responses-16/NNS	prep_during||regarding-7/VBG||hypoglycemia-18/NN	prep_in||hypoglycemia-18/NN||type1diabetes-20/CD	fluoxetine-11||type1diabetes-20||no_rel||however, virtually no information exists regarding the effects of fluoxetine on integrated physiological counterregulatory responses during hypoglycemia in type1diabetes.
amod||providers-3/NNS||primary-1/JJ	nn||providers-3/NNS||care-2/NN	nsubj||aware-6/JJ||providers-3/NNS	aux||aware-6/JJ||should-4/MD	cop||aware-6/JJ||be-5/VB	root||ROOT-0/null||aware-6/JJ	num||developments-10/NNS||two-8/CD	amod||developments-10/NNS||new-9/JJ	prep_of||aware-6/JJ||developments-10/NNS	nn||cessation-15/NN||nicotineaddiction-12/NN	conj_and||nicotineaddiction-12/NN||smoking-14/NN	nn||cessation-15/NN||smoking-14/NN	prep_in||developments-10/NNS||cessation-15/NN	dep||emergence-19/NN||1-16/LS	det||emergence-19/NN||the-18/DT	dep||cessation-15/NN||emergence-19/NN	det||system-25/NN||a-21/DT	amod||system-25/NN||novel-22/JJ	nn||system-25/NN||nicotine-23/NN	nn||system-25/NN||delivery-24/NN	prep_of||emergence-19/NN||system-25/NN	vmod||system-25/NN||known-26/VBN	det||cigarette-34/NN||the-28/DT	amod||cigarette-34/NN||electronic-29/JJ	dep||cigarette-34/NN||e-31/JJ	prep_as||known-26/VBN||cigarette-34/NN	dep||reports-40/NNS||2-37/LS	amod||reports-40/NNS||new-39/JJ	dep||cessation-15/NN||reports-40/NNS	conj_and||emergence-19/NN||reports-40/NNS	amod||nicotine-44/NN||residual-42/JJ	amod||nicotine-44/NN||environmental-43/JJ	prep_of||reports-40/NNS||nicotine-44/NN	amod||toxicants-48/NNS||other-46/JJ	nn||toxicants-48/NNS||biopersistent-47/NN	prep_of||reports-40/NNS||toxicants-48/NNS	conj_and||nicotine-44/NN||toxicants-48/NNS	vmod||nicotine-44/NN||found-49/VBN	nn||smoke-52/NN||cigarette-51/NN	prep_in||found-49/VBN||smoke-52/NN	advmod||described-55/VBN||recently-54/RB	vmod||cessation-15/NN||described-55/VBN	nn||$-61/NNS||â-57/NN	amod||$-61/NNS||$-58/$	dep||$-58/$||œthirdhand-59/JJ	nn||$-61/NNS||smokeâ-60/NN	prep_as||described-55/VBN||$-61/NNS	nicotineaddiction-12||nicotine-44||no||primary care providers should be aware of two new developments in nicotineaddiction and smoking cessation 1) the emergence of a novel nicotine delivery system known as the electronic (e-) cigarette; and 2) new reports of residual environmental nicotine and other biopersistent toxicants found in cigarette smoke, recently described as â€œthirdhand smokeâ€?.
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||acetylsalicylicacid-4||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type1diabetes-49||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
amod||analyses-3/NNS||corresponding-1/JJ	nn||analyses-3/NNS||stratified-2/NN	nsubj||showed-4/VBD||analyses-3/NNS	root||ROOT-0/null||showed-4/VBD	det||risk-8/NN||a-5/DT	amod||risk-8/NN||significant-6/JJ	amod||risk-8/NN||increased-7/VBN	dobj||showed-4/VBD||risk-8/NN	prep_of||risk-8/NN||cvd-10/NN	dep||risk-8/NN||hradditve-12/VB	dep||1.38-14/CD||=-13/SYM	ccomp||ci-18/VBP||1.38-14/CD	num||%-17/NN||95-16/CD	nsubj||ci-18/VBP||%-17/NN	ccomp||hradditve-12/VB||ci-18/VBP	number||1.78-21/CD||1.07-19/CD	dep||1.78-21/CD||to-20/TO	dobj||ci-18/VBP||1.78-21/CD	prep_for||risk-8/NN||individuals-24/NNS	nn||levels-27/NNS||cholesterol-26/NN	prep_with||individuals-24/NNS||levels-27/NNS	vmod||levels-27/NNS||<-28/VBG	num||mg/dl-30/NN||200-29/CD	dobj||<-28/VBG||mg/dl-30/NN	det||study-34/NN||the-32/DT	amod||study-34/NN||epic-potsdam-33/JJ	prep_in||mg/dl-30/NN||study-34/NN	cholesterol-26||cvd-10||no_rel||corresponding stratified analyses showed a significant increased risk of cvd (hradditve = 1.38, 95% ci 1.07 to 1.78) for individuals with cholesterol levels <200 mg/dl in the epic-potsdam study.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	dobj||used-2/VBD||microarrays-3/NNS	aux||assess-5/VB||to-4/TO	vmod||used-2/VBD||assess-5/VB	det||effects-7/NNS||the-6/DT	dobj||assess-5/VB||effects-7/NNS	nn||expression-10/NN||gene-9/NN	prep_on||effects-7/NNS||expression-10/NN	amod||cells-15/NNS||ht29-12/JJ	nn||cells-15/NNS||colon-13/NN	nn||cells-15/NNS||adenocarcinoma-14/NN	prep_in||assess-5/VB||cells-15/NNS	prep_of||cells-15/NNS||exposure-17/NN	det||acid-22/NN||the-19/DT	amod||eicosapentaenoic-21/JJ||n-3fattyacid-20/JJ	amod||acid-22/NN||eicosapentaenoic-21/JJ	prep_to||assess-5/VB||acid-22/NN	appos||acid-22/NN||epa-24/NN	adenocarcinoma-14||n-3fattyacid-20||no_rel||we used microarrays to assess the effects on gene expression in ht29 colon adenocarcinoma cells of exposure to the n-3fattyacid eicosapentaenoic acid (epa).
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	nn||study-4/NN||association-3/NN	dobj||conducted-2/VBD||study-4/NN	num||polymorphisms-9/NNS||66-6/CD	amod||polymorphisms-9/NNS||single-7/JJ	nn||polymorphisms-9/NNS||nucleotide-8/NN	prep_between||study-4/NN||polymorphisms-9/NNS	appos||polymorphisms-9/NNS||snps-11/NNS	det||gene-16/NN||the-14/DT	amod||gene-16/NN||fsip1-15/JJ	prep_of||polymorphisms-9/NNS||gene-16/NN	prep_of||polymorphisms-9/NNS||aia-18/NN	conj_and||gene-16/NN||aia-18/NN	prep_in||conducted-2/VBD||total-20/NN	num||subjects-24/NNS||592-22/CD	nn||subjects-24/NNS||korean-23/NN	prep_of||total-20/NN||subjects-24/NNS	num||aia-27/NN||163-26/CD	prep_including||subjects-24/NNS||aia-27/NN	num||patients-35/NNS||429-29/CD	amod||patients-35/NNS||aspirin-tolerant-30/JJ	nn||patients-35/NNS||asthma-31/NN	appos||patients-35/NNS||ata-33/NN	prep_including||subjects-24/NNS||patients-35/NNS	conj_and||aia-27/NN||patients-35/NNS	asthma-31||aspirin--1||no||we conducted association study between 66 single nucleotide polymorphisms (snps) of the fsip1 gene and aia in total of 592 korean subjects including 163 aia and 429 aspirin-tolerant asthma (ata) patients.
nsubj||inhibited-2/VBD||dexamethasone-1/NN	root||ROOT-0/null||inhibited-2/VBD	amod||ltb4-4/NNS||lps-induced-3/JJ	dobj||inhibited-2/VBD||ltb4-4/NNS	dobj||inhibited-2/VBD||lxa4-6/NNS	conj_and||ltb4-4/NNS||lxa4-6/NNS	amod||suppression-10/NN||lesser-9/JJR	prep_with||inhibited-2/VBD||suppression-10/NN	prep_of||suppression-10/NN||ltb4-12/CD	amod||patients-16/NNS||severe-14/JJ	nn||patients-16/NNS||asthma-15/NN	prep_in||inhibited-2/VBD||patients-16/NNS	parataxis||inhibited-2/VBD||p-18/VB	num||0.05-20/CD||<-19/CD	dobj||p-18/VB||0.05-20/CD	asthma-15||dexamethasone-1||yes||dexamethasone inhibited lps-induced ltb4 and lxa4, with lesser suppression of ltb4 in severe asthma patients (p < 0.05).
det||study-3/NN||the-1/DT	amod||study-3/NN||current-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||evaluate-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	ccomp||approved-19/VBD||conducted-5/VBN	aux||evaluate-7/VB||to-6/TO	xcomp||conducted-5/VBN||evaluate-7/VB	det||efficacy-9/NN||the-8/DT	dobj||evaluate-7/VB||efficacy-9/NN	prep_of||efficacy-9/NN||glatirameracetate-11/NN	appos||glatirameracetate-11/NN||ga-13/NN	det||drug-18/NN||an-16/DT	amod||drug-18/NN||immunomodulatory-17/JJ	nsubj||approved-19/VBD||drug-18/NN	root||ROOT-0/null||approved-19/VBD	det||treatment-22/NN||the-21/DT	prep_for||approved-19/VBD||treatment-22/NN	prep_of||treatment-22/NN||relapsingremittingmultiplesclerosis-24/NNS	prepc_in||approved-19/VBD||preventing-27/VBG	det||death-29/NN||the-28/DT	dobj||preventing-27/VBG||death-29/NN	amod||mice-32/NNS||c57bl/6j-31/JJ	prep_of||death-29/NN||mice-32/NNS	vmod||mice-32/NNS||infected-33/VBN	nn||anka-37/NN||plasmodium-35/NN	nn||anka-37/NN||berghei-36/NN	prep_with||infected-33/VBN||anka-37/NN	relapsingremittingmultiplesclerosis-24||glatirameracetate-11||yes||the current study was conducted to evaluate the efficacy of glatirameracetate (ga), an immunomodulatory drug approved for the treatment of relapsingremittingmultiplesclerosis, in preventing the death of c57bl/6j mice infected with plasmodium berghei anka.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	cancer-14||dm-35||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
nsubj||labelled-5/VBD||signalling-1/NN	amod||18f-4/NNS||radioisotope-3/JJ	prep_of||signalling-1/NN||18f-4/NNS	root||ROOT-0/null||labelled-5/VBD	nsubj||injected-10/VBD||fluorodeoxyglucose-6/NN	dep||fluorodeoxyglucose-6/NN||18f-fdg-8/JJ	ccomp||labelled-5/VBD||injected-10/VBD	prep_in||injected-10/VBD||mice-12/NNS	amod||isomerase-15/NN||glucose-6-phosphate-14/JJ	prep_with||injected-10/VBD||isomerase-15/NN	appos||isomerase-15/NN||g6pi-17/NNP	amod||arthritis-21/NN||induced-20/JJ	nsubjpass||analysed-23/VBN||arthritis-21/NN	auxpass||analysed-23/VBN||was-22/VBD	parataxis||labelled-5/VBD||analysed-23/VBN	agent||analysed-23/VBN||pet/ct-25/NN	arthritis-21||glucose--1||no_rel||signalling of radioisotope 18f labelled fluorodeoxyglucose (18f-fdg) injected in mice with glucose-6-phosphate isomerase (g6pi)-induced arthritis was analysed by pet/ct.
nsubj||host-5/NN||humans-1/NNS	cop||host-5/NN||are-2/VBP	det||host-5/NN||the-3/DT	amod||host-5/NN||only-4/JJ	root||ROOT-0/null||host-5/NN	prep_of||host-5/NN||polioviruses-7/NNS	advmod||host-5/NN||thus-9/RB	det||prospects-11/NNS||the-10/DT	nsubj||look-16/VBP||prospects-11/NNS	amod||eradication-15/NN||global-13/JJ	nn||eradication-15/NN||polio-14/NNP	prep_of||prospects-11/NNS||eradication-15/NN	parataxis||host-5/NN||look-16/VBP	acomp||look-16/VBP||reasonable-17/JJ	polio-14||polioviruses-7||no||humans are the only host of polioviruses, thus the prospects of global polio eradication look reasonable.
nsubj||â-2/VBP||results-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	det||patients-8/NNS||the-5/DT	advmod||obese-7/JJ||morbidly-6/RB	amod||patients-8/NNS||obese-7/JJ	nsubj||had-11/VBD||patients-8/NNS	prep_with||patients-8/NNS||diabetes-10/NN	rcmod||$-3/$||had-11/VBD	advmod||higher-13/JJR||significantly-12/RB	amod||levels-14/NNS||higher-13/JJR	dobj||had-11/VBD||levels-14/NNS	prep_of||levels-14/NNS||oxldl-16/NN	prepc_compared_with||had-11/VBD||with-18/IN	det||patients-22/NNS||the-19/DT	advmod||obese-21/JJ||morbidly-20/RB	amod||patients-22/NNS||obese-21/JJ	pobj||had-11/VBD||patients-22/NNS	amod||glucose-26/NN||normal-24/JJ	nn||glucose-26/NN||fasting-25/NN	prep_with||patients-22/NNS||glucose-26/NN	det||subjects-30/NNS||the-28/DT	nn||subjects-30/NNS||control-29/NN	prep_with||patients-22/NNS||subjects-30/NNS	conj_and||glucose-26/NN||subjects-30/NNS	advmod||lower-33/JJR||significantly-32/RB	amod||levels-34/NNS||lower-33/JJR	pobj||had-11/VBD||levels-34/NNS	conj_and||patients-22/NNS||levels-34/NNS	amod||antibodies-38/NNS||igm-36/JJ	amod||antibodies-38/NNS||anti-oxldl-37/JJ	prep_of||levels-34/NNS||antibodies-38/NNS	obese-21||glucose-26||no_rel||results â€”the morbidly obese patients with diabetes had significantly higher levels of oxldl compared with the morbidly obese patients with normal fasting glucose and the control subjects and significantly lower levels of igm anti-oxldl antibodies.
amod||diagnosis-3/NN||accurate-1/JJ	amod||diagnosis-3/NN||molecular-2/JJ	nsubj||critical-13/JJ||diagnosis-3/NN	amod||diabetesmellitus-8/NNS||monogenic-5/JJ	amod||diabetesmellitus-8/NNS||non-autoimmune-6/JJ	amod||diabetesmellitus-8/NNS||neonatal-7/JJ	prep_of||diagnosis-3/NN||diabetesmellitus-8/NNS	appos||diabetesmellitus-8/NNS||ndm-10/NN	cop||critical-13/JJ||is-12/VBZ	root||ROOT-0/null||critical-13/JJ	amod||care-16/NN||patient-15/JJ	prep_for||critical-13/JJ||care-16/NN	mark||treated-29/VBN||as-18/IN	nsubjpass||treated-29/VBN||patients-19/NNS	vmod||patients-19/NNS||carrying-20/VBG	det||mutation-22/NN||a-21/DT	dobj||carrying-20/VBG||mutation-22/NN	prep_in||mutation-22/NN||kcnj11-24/NNS	prep_in||mutation-22/NN||abcc8-26/NNS	conj_or||kcnj11-24/NNS||abcc8-26/NNS	aux||treated-29/VBN||can-27/MD	auxpass||treated-29/VBN||be-28/VB	advcl||critical-13/JJ||treated-29/VBN	amod||drugs-33/NNS||oral-31/JJ	nn||drugs-33/NNS||sulfonylurea-32/NN	agent||treated-29/VBN||drugs-33/NNS	nn||therapy-37/NN||insulin-36/NN	prep_instead_of||drugs-33/NNS||therapy-37/NN	insulin-36||diabetesmellitus-8||no_rel||accurate molecular diagnosis of monogenic non-autoimmune neonatal diabetesmellitus (ndm) is critical for patient care, as patients carrying a mutation in kcnj11 or abcc8 can be treated by oral sulfonylurea drugs instead of insulin therapy.
det||article-3/NN||this-2/DT	prep_in||review-7/VBP||article-3/NN	nsubj||review-7/VBP||we-5/PRP	advmod||review-7/VBP||briefly-6/RB	root||ROOT-0/null||review-7/VBP	det||development-12/NN||the-8/DT	amod||development-12/NN||preclinical-9/JJ	conj_and||preclinical-9/JJ||clinical-11/JJ	amod||development-12/NN||clinical-11/JJ	dobj||review-7/VBP||development-12/NN	nsubj||beginning-32/VBG||development-12/NN	nsubj||shed-34/VB||development-12/NN	det||drug-15/NN||the-14/DT	prep_of||development-12/NN||drug-15/NN	det||underpinning-18/NN||the-17/DT	prep_as||drug-15/NN||underpinning-18/NN	det||review-22/NN||a-20/DT	amod||review-22/NN||systematic-21/JJ	prep_for||underpinning-18/NN||review-22/NN	det||number-26/NN||the-24/DT	amod||number-26/NN||large-25/JJ	prep_of||review-22/NN||number-26/NN	amod||trials-29/NNS||clinical-28/JJ	prep_of||number-26/NN||trials-29/NNS	aux||beginning-32/VBG||are-31/VBP	rcmod||development-12/NN||beginning-32/VBG	aux||shed-34/VB||to-33/TO	xcomp||beginning-32/VBG||shed-34/VB	det||light-36/NN||some-35/DT	dobj||shed-34/VB||light-36/NN	det||potential-41/NN||the-38/DT	amod||potential-41/NN||full-39/JJ	amod||potential-41/NN||therapeutic-40/JJ	prep_on||shed-34/VB||potential-41/NN	prep_of||potential-41/NN||bortezomib-43/NN	prep_in||bortezomib-43/NN||myeloma-45/NN	myeloma-45||bortezomib-43||yes||in this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma.
det||comparison-3/NN||the-2/DT	prep_in||received-16/VBD||comparison-3/NN	amod||individuals-6/NNS||insulin-treated-5/JJ	prep_of||comparison-3/NN||individuals-6/NNS	prep_with||individuals-6/NNS||lada-8/NN	prep_with||individuals-6/NNS||type2diabetes-10/NNS	conj_and||lada-8/NN||type2diabetes-10/NNS	amod||patients-13/NNS||more-12/JJR	nsubj||received-16/VBD||patients-13/NNS	prep_with||patients-13/NNS||lada-15/NN	ccomp||p-34/NN||received-16/VBD	iobj||received-16/VBD||insulin-17/NN	number||40-19/CD||-lrb--18/CD	dobj||received-16/VBD||40-19/CD	num||%-22/NN||22-21/CD	prep_vs.||40-19/CD||%-22/NN	nn||-rrb--27/NNP||p-24/NN	nn||-rrb--27/NNP||<-25/NN	num||-rrb--27/NNP||0.001-26/CD	nsubj||p-34/NN||-rrb--27/NNP	amod||levels-30/NNS||c-peptide-29/JJ	conj_and||-rrb--27/NNP||levels-30/NNS	nsubj||p-34/NN||levels-30/NNS	cop||p-34/NN||were-31/VBD	amod||p-34/NN||lower-32/JJR	amod||p-34/NN||-lrb--33/JJ	root||ROOT-0/null||p-34/NN	vmod||p-34/NN||<-35/VBG	num||-rrb--37/NNS||0.001-36/CD	dobj||<-35/VBG||-rrb--37/NNS	type2diabetes-10||insulin-17||yes||in the comparison of insulin-treated individuals with lada and type2diabetes , more patients with lada received insulin -lrb- 40 vs. 22 % , p < 0.001 -rrb- and c-peptide levels were lower -lrb- p < 0.001 -rrb- .
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
amod||patients-3/NNS||forty-1/JJ	amod||patients-3/NNS||nsclc-2/JJ	nsubjpass||treated-9/VBN||patients-3/NNS	nsubj||received-17/VBD||patients-3/NNS	aux||treated-9/VBN||had-6/VBD	auxpass||treated-9/VBN||been-7/VBN	advmod||treated-9/VBN||previously-8/RB	rcmod||patients-3/NNS||treated-9/VBN	num||regimens-15/NNS||one-11/CD	conj_or||one-11/CD||more-13/JJR	num||regimens-15/NNS||more-13/JJR	amod||regimens-15/NNS||chemotherapy-14/JJ	prep_with||treated-9/VBN||regimens-15/NNS	root||ROOT-0/null||received-17/VBD	acomp||received-17/VBD||docetaxel-18/JJ	det||dose-21/NN||a-20/DT	prep_at||docetaxel-18/JJ||dose-21/NN	num||mg/m2-24/NNS||25-23/CD	prep_of||dose-21/NN||mg/m2-24/NNS	amod||mg/m2-24/NNS||weekly-25/JJ	prep_on||mg/m2-24/NNS||days-27/NNS	dep||docetaxel-18/JJ||1-28/CD	num||1-28/CD||8-30/CD	dep||docetaxel-18/JJ||15-33/CD	conj_and||1-28/CD||15-33/CD	det||cycle-37/NN||a-35/DT	amod||cycle-37/NN||28-day-36/JJ	prep_of||1-28/CD||cycle-37/NN	nsclc-2||docetaxel-18||yes||forty nsclc patients, who had been previously treated with one or more chemotherapy regimens, received docetaxel at a dose of 25 mg/m2 weekly on days 1, 8, and 15 of a 28-day cycle.
csubj||trial-6/NN||ecog-1/VBG	dobj||ecog-1/VBG||1684-2/CD	cop||trial-6/NN||was-3/VBD	det||trial-6/NN||the-4/DT	amod||trial-6/NN||pivotal-5/JJ	root||ROOT-0/null||trial-6/NN	nsubj||demonstrated-9/VBD||trial-6/NN	advmod||demonstrated-9/VBD||first-8/RB	rcmod||trial-6/NN||demonstrated-9/VBD	det||benefit-13/NN||a-10/DT	advmod||significant-12/JJ||statistically-11/RB	amod||benefit-13/NN||significant-12/JJ	dobj||demonstrated-9/VBD||benefit-13/NN	amod||survival-18/NN||relapse-free-15/JJ	conj_and||relapse-free-15/JJ||overall-17/JJ	amod||survival-18/NN||overall-17/JJ	prep_in||benefit-13/NN||survival-18/NN	amod||interferonalpha-2b-21/NN||adjuvant-20/JJ	prep_for||demonstrated-9/VBD||interferonalpha-2b-21/NN	amod||melanoma-24/NN||high-risk-23/JJ	prep_in||interferonalpha-2b-21/NN||melanoma-24/NN	melanoma-24||adjuvant-20||no_rel||ecog 1684 was the pivotal trial that first demonstrated a statistically significant benefit in relapse-free and overall survival for adjuvant interferonalpha-2b in high-risk melanoma.
nsubj||resulted-8/VBD||treatment-1/NN	amod||strontium-89chloride-4/NN||radionuclide-3/JJ	prep_with||treatment-1/NN||strontium-89chloride-4/NN	appos||treatment-1/NN||89sr-6/NNP	root||ROOT-0/null||resulted-8/VBD	det||response-12/NN||a-10/DT	amod||response-12/NN||partial-11/JJ	prep_in||resulted-8/VBD||response-12/NN	nsubjpass||confirmed-15/VBN||response-12/NN	auxpass||confirmed-15/VBN||was-14/VBD	rcmod||response-12/NN||confirmed-15/VBN	det||relief-19/NN||the-17/DT	amod||relief-19/NN||successful-18/JJ	agent||confirmed-15/VBN||relief-19/NN	nn||modalities-25/NNS||pain-21/NN	conj_and||pain-21/NN||other-23/JJ	nn||modalities-25/NNS||other-23/JJ	nn||modalities-25/NNS||imaging-24/NN	prep_of||relief-19/NN||modalities-25/NNS	pain-21||strontium-89chloride-4||yes||treatment with radionuclide strontium-89chloride (89sr) resulted in a partial response which was confirmed by the successful relief of pain and other imaging modalities.
poss||studies-3/NNS||our-1/PRP$	amod||studies-3/NNS||previous-2/JJ	nsubj||proven-5/VBN||studies-3/NNS	aux||proven-5/VBN||have-4/VBP	root||ROOT-0/null||proven-5/VBN	mark||mediated-14/VBN||that-6/IN	det||enhancement-10/NN||the-7/DT	amod||enhancement-10/NN||complement-mediated-8/JJ	amod||enhancement-10/NN||antibody-dependent-9/JJ	nsubjpass||mediated-14/VBN||enhancement-10/NN	nsubjpass||deposited-29/VBD||enhancement-10/NN	prep_of||enhancement-10/NN||hivinfection-12/NN	auxpass||mediated-14/VBN||is-13/VBZ	ccomp||proven-5/VBN||mediated-14/VBN	det||association-17/NN||the-16/DT	agent||mediated-14/VBN||association-17/NN	amod||type-21/NN||complement-19/JJ	nn||type-21/NN||receptor-20/NN	prep_of||association-17/NN||type-21/NN	dep||bound-23/VBN||2-22/CD	amod||type-21/NN||bound-23/VBN	det||fragment-27/NN||the-25/DT	amod||fragment-27/NN||c3-26/JJ	prep_to||bound-23/VBN||fragment-27/NN	ccomp||proven-5/VBN||deposited-29/VBD	conj_and||mediated-14/VBN||deposited-29/VBD	det||surface-32/NN||the-31/DT	prep_on||deposited-29/VBD||surface-32/NN	nn||virions-35/NNS||hiv-34/NN	prep_of||surface-32/NN||virions-35/NNS	hivinfection-12||hiv-34||no||our previous studies have proven that the complement-mediated antibody-dependent enhancement of hivinfection is mediated by the association of complement receptor type 2 bound to the c3 fragment and deposited on the surface of hiv virions.
det||emergence-2/NN||the-1/DT	nsubj||undermines-8/VBZ||emergence-2/NN	nsubj||undermines-8/VBZ||emergence-2/NN	nn||resistance-5/NN||drug-4/NN	prep_of||emergence-2/NN||resistance-5/NN	prep_in||resistance-5/NN||m.tuberculosis-7/NNS	root||ROOT-0/null||undermines-8/VBZ	conj_and||undermines-8/VBZ||undermines-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||undermines-8/VBZ||efficacy-10/NN	nn||treatment-16/NN||tuberculosis-12/NNP	nn||treatment-16/NN||-lrb--13/NNP	nn||treatment-16/NN||tb-14/NNP	nn||treatment-16/NN||-rrb--15/NNP	prep_of||efficacy-10/NN||treatment-16/NN	prep_in||undermines-8/VBZ||individuals-18/NNS	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||undermines-8/VBZ||programs-23/NNS	prep_in||programs-23/NNS||populations-25/NNS	tb-21||m.tuberculosis-7||no||the emergence of drug resistance in m.tuberculosis undermines the efficacy of tuberculosis -lrb- tb -rrb- treatment in individuals and of tb control programs in populations .
nsubj||seems-2/VBZ||it-1/PRP	root||ROOT-0/null||seems-2/VBZ	mark||prominent-19/JJ||that-3/IN	det||impact-5/NN||the-4/DT	nsubj||prominent-19/JJ||impact-5/NN	amod||polymorphism-8/NN||il28b-7/JJ	prep_of||impact-5/NN||polymorphism-8/NN	det||clearance-12/NN||the-10/DT	amod||clearance-12/NN||spontaneous-11/JJ	prep_on||polymorphism-8/NN||clearance-12/NN	nn||genotype-15/NN||hcv-14/NN	prep_of||clearance-12/NN||genotype-15/NN	num||genotype-15/NN||1-16/CD	cop||prominent-19/JJ||is-17/VBZ	advmod||prominent-19/JJ||more-18/RBR	ccomp||seems-2/VBZ||prominent-19/JJ	prep_than||prominent-19/JJ||hcv-21/NN	nsubj||results-25/VBZ||hcv-21/NN	amod||hcv-21/NN||genotype-22/JJ	dep||genotype-22/JJ||3-23/CD	rcmod||hcv-21/NN||results-25/VBZ	det||observation-28/NN||the-27/DT	prep_in||results-25/VBZ||observation-28/NN	amod||rs12979860-31/NNS||higher-30/JJR	prep_of||observation-28/NN||rs12979860-31/NNS	dep||genotype-40/VBP||c-32/SYM	amod||frequency-34/NN||allele-33/JJ	nsubj||genotype-40/VBP||frequency-34/NN	amod||patients-37/NNS||chronichepatitisc-36/JJ	prep_in||frequency-34/NN||patients-37/NNS	prep_with||patients-37/NNS||hcv-39/NN	ccomp||prominent-19/JJ||genotype-40/VBP	dobj||genotype-40/VBP||3-41/CD	nn||genotype-44/NN||hcv-43/NN	prep_than||genotype-40/VBP||genotype-44/NN	num||genotype-44/NN||1-45/CD	chronichepatitisc-36||hcv-43||no||it seems that the impact of il28b polymorphism on the spontaneous clearance of hcv genotype 1 is more prominent than hcv genotype 3 which results in the observation of higher rs12979860 c allele frequency in chronichepatitisc patients with hcv genotype 3 than hcv genotype 1.
det||pathophysiology-2/NN||the-1/DT	nsubj||multifactorial-6/JJ||pathophysiology-2/NN	nsubj||related-8/VBN||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||anemia-4/NN	cop||multifactorial-6/JJ||is-5/VBZ	root||ROOT-0/null||multifactorial-6/JJ	conj_and||multifactorial-6/JJ||related-8/VBN	amod||factors-11/NNS||various-10/JJ	prep_to||related-8/VBN||factors-11/NNS	prep_including||factors-11/NNS||hemodilution-14/NN	nn||losses-17/NNS||iron-16/NN	appos||hemodilution-14/NN||losses-17/NNS	amod||drugs-20/NNS||anti-platelet-19/JJ	prep_from||losses-17/NNS||drugs-20/NNS	appos||hemodilution-14/NN||activation-22/NN	det||cascade-26/NN||the-24/DT	amod||cascade-26/NN||inflammatory-25/JJ	prep_of||activation-22/NN||cascade-26/NN	amod||losses-29/NNS||urinary-28/JJ	appos||hemodilution-14/NN||losses-29/NNS	prep_of||losses-29/NNS||erythropoietin-31/NN	conj_and||multifactorial-6/JJ||associated-33/VBN	conj_and||related-8/VBN||associated-33/VBN	advmod||associated-33/VBN||renalinsufficiency-34/RB	anemia-4||erythropoietin-31||no_rel||the pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renalinsufficiency.
neg||difference-4/NN||no-1/DT	advmod||significant-3/JJ||statistically-2/RB	amod||difference-4/NN||significant-3/JJ	nsubjpass||found-6/VBN||difference-4/NN	auxpass||found-6/VBN||was-5/VBD	root||ROOT-0/null||found-6/VBN	det||groups-12/NNS||the-8/DT	nn||groups-12/NNS||dexamethasone-9/NN	conj_and||dexamethasone-9/NN||placebo-11/NN	nn||groups-12/NNS||placebo-11/NN	prep_between||found-6/VBN||groups-12/NNS	nn||score-15/NN||pain-14/NN	prep_in||found-6/VBN||score-15/NN	prep_in||found-6/VBN||nausea-17/NN	conj_or||score-15/NN||nausea-17/NN	prep_in||found-6/VBN||vomiting-19/NN	conj_or||score-15/NN||vomiting-19/NN	prep_in||found-6/VBN||irritability-21/NN	conj_or||score-15/NN||irritability-21/NN	amod||postoperatively-26/NN||analgesic-24/JJ	nn||postoperatively-26/NN||requirement-25/NN	prep_in||found-6/VBN||postoperatively-26/NN	conj_or||score-15/NN||postoperatively-26/NN	vomiting-19||dexamethasone-9||yes||no statistically significant difference was found between the dexamethasone and placebo groups in pain score, nausea, vomiting, irritability, or analgesic requirement postoperatively.
nsubj||provide-14/VB||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||non-chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||letrozole-10/NN	aux||provide-14/VB||may-12/MD	advmod||provide-14/VB||also-13/RB	root||ROOT-0/null||provide-14/VB	det||option-18/NN||a-15/DT	amod||option-18/NN||chemotherapy-free-16/JJ	nn||option-18/NN||treatment-17/NN	dobj||provide-14/VB||option-18/NN	amod||patients-21/NNS||postmenopausal-20/JJ	prep_for||option-18/NN||patients-21/NNS	nn||cancer-28/NN||estrogen-23/NN	amod||cancer-28/NN||receptor-positive/erbb2-24/JJ	amod||cancer-28/NN||+-25/JJ	amod||cancer-28/NN||metastatic-26/JJ	nn||cancer-28/NN||breast-27/NN	prep_with||provide-14/VB||cancer-28/NN	cancer-28||estrogen-23||no_rel||lapatinib, in combination with non-chemotherapeuticagents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/erbb2+ metastatic breast cancer.
nsubj||changed-9/VBN||treatment-1/NN	nsubj||il-2-17/JJ||treatment-1/NN	det||melanoma-7/NN||both-3/DT	amod||melanoma-7/NN||early-4/JJ	conj_and||early-4/JJ||advanced-6/JJ	amod||melanoma-7/NN||advanced-6/JJ	prep_for||treatment-1/NN||melanoma-7/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	advmod||changed-9/VBN||little-10/RB	det||introduction-13/NN||the-12/DT	prep_since||changed-9/VBN||introduction-13/NN	prep_of||introduction-13/NN||interferon-15/NN	conj_and||changed-9/VBN||il-2-17/JJ	det||1990s-21/NNS||the-19/DT	amod||1990s-21/NNS||early-20/JJ	prep_in||il-2-17/JJ||1990s-21/NNS	melanoma-7||interferon-15||yes||treatment for both early and advanced melanoma has changed little since the introduction of interferon and il-2 in the early 1990s.
nsubjpass||defined-4/VBN||silicosis-1/NNS	aux||defined-4/VBN||may-2/MD	auxpass||defined-4/VBN||be-3/VB	root||ROOT-0/null||defined-4/VBN	det||disease-7/NN||the-6/DT	prep_as||defined-4/VBN||disease-7/NN	vmod||disease-7/NN||resulting-8/VBG	amod||exposure-12/NN||chronic-10/JJ	amod||exposure-12/NN||occupational-11/JJ	prep_from||resulting-8/VBG||exposure-12/NN	aux||silicadust-14/VB||to-13/TO	xcomp||resulting-8/VBG||silicadust-14/VB	silicosis-1||silicadust-14||no||silicosis may be defined as the disease resulting from chronic occupational exposure to silicadust.
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||need-11/VBP||scores-4/NNS	appos||scores-4/NNS||incidence-6/NN	amod||pain-9/NN||distressing-8/JJ	prep_of||incidence-6/NN||pain-9/NN	ccomp||recorded-28/VBN||need-11/VBP	amod||boluses-14/NNS||supplementary/rescue-13/JJ	prep_of||need-11/VBP||boluses-14/NNS	appos||boluses-14/NNS||dose-16/NN	prep_of||dose-16/NN||bupivacaine-18/NN	vmod||bupivacaine-18/NN||consumed-19/VBN	amod||satisfaction-22/NN||maternal-21/JJ	nsubjpass||recorded-28/VBN||satisfaction-22/NN	amod||scores-26/NNS||neonatal-24/JJ	nn||scores-26/NNS||apgar-25/NN	conj_and||satisfaction-22/NN||scores-26/NNS	nsubjpass||recorded-28/VBN||scores-26/NNS	auxpass||recorded-28/VBN||were-27/VBD	root||ROOT-0/null||recorded-28/VBN	pain-9||bupivacaine-18||yes||verbal analogue pain scores, incidence of distressing pain, need of supplementary/rescue boluses, dose of bupivacaine consumed, maternal satisfaction and neonatal apgar scores were recorded.
det||substudy-6/NN||this-2/DT	amod||substudy-6/NN||randomized-3/JJ	amod||substudy-6/NN||placebo-controlled-5/JJ	prep_in||received-12/VBD||substudy-6/NN	num||patients-9/NNS||122-8/CD	nsubj||received-12/VBD||patients-9/NNS	prep_with||patients-9/NNS||jia-11/NN	root||ROOT-0/null||received-12/VBD	number||3-14/CD||infliximab-13/CD	dobj||received-12/VBD||3-14/CD	xcomp||received-12/VBD||mg/kg-15/VBG	amod||methotrexate-17/NN||+-16/JJ	dobj||mg/kg-15/VBG||methotrexate-17/NN	appos||methotrexate-17/NN||mtx-19/NN	dep||methotrexate-17/NN||n-22/VBN	dep||60-24/CD||=-23/SYM	ccomp||n-22/VBN||60-24/CD	nn||mtx-29/NN||placebo-27/NN	amod||mtx-29/NN||+-28/VBG	dobj||mg/kg-15/VBG||mtx-29/NN	conj_or||methotrexate-17/NN||mtx-29/NN	dep||mtx-29/NN||n-31/VBN	dep||62-33/CD||=-32/SYM	ccomp||n-31/VBN||62-33/CD	prep_at||received-12/VBD||weeks-36/NNS	dep||weeks-36/NNS||0-37/CD	num||0-37/CD||2-39/CD	dep||weeks-36/NNS||6-42/CD	conj_and||0-37/CD||6-42/CD	jia-11||mtx-29||yes||in this randomized, placebo-controlled substudy, 122 patients with jia received infliximab 3 mg/kg + methotrexate (mtx)(n = 60) or placebo + mtx (n = 62) at weeks 0, 2, and 6.
advmod||review-16/VB||here-1/RB	nsubj||discuss-4/VB||we-3/PRP	parataxis||review-16/VB||discuss-4/VB	det||structure-6/NN||the-5/DT	dobj||discuss-4/VB||structure-6/NN	dobj||discuss-4/VB||function-8/NN	conj_and||structure-6/NN||function-8/NN	prep_of||structure-6/NN||3dpol-10/CD	amod||replication-13/NN||picornavirus-12/JJ	prep_during||discuss-4/VB||replication-13/NN	nsubj||review-16/VB||we-15/PRP	nsubj||highlight-33/VB||we-15/PRP	nsubj||discuss-53/VB||we-15/PRP	root||ROOT-0/null||review-16/VB	det||evidence-18/NN||the-17/DT	dobj||review-16/VB||evidence-18/NN	dobj||review-16/VB||consequence-20/NN	conj_and||evidence-18/NN||consequence-20/NN	det||response-25/NN||a-22/DT	nn||response-25/NN||host-23/NN	amod||response-25/NN||immune-24/JJ	prep_of||evidence-18/NN||response-25/NN	prep_to||review-16/VB||epitopes-27/NNS	prep_in||epitopes-27/NNS||3dpol-29/CD	prep_after||review-16/VB||picornavirusinfection-31/NN	conj_and||review-16/VB||highlight-33/VB	dobj||highlight-33/VB||data-34/NNS	vmod||data-34/NNS||showing-35/VBG	det||effects-38/NNS||the-36/DT	amod||effects-38/NNS||antiviral-37/JJ	dobj||showing-35/VBG||effects-38/NNS	amod||3dpol-41/NNS||transgenic-40/JJ	prep_of||effects-38/NNS||3dpol-41/NNS	poss||virus-47/NN||theiler-43/NN	nn||virus-47/NN||murine-45/NN	nn||virus-47/NN||encephalomyelitis-46/NNS	prep_from||showing-35/VBG||virus-47/NN	appos||virus-47/NN||tmev-49/NNP	conj_and||review-16/VB||discuss-53/VB	amod||mechanisms-55/NNS||potential-54/JJ	dobj||discuss-53/VB||mechanisms-55/NNS	dobj||causing-60/VBG||which-57/WDT	nsubj||causing-60/VBG||3dpol-58/NNS	aux||causing-60/VBG||is-59/VBZ	prepc_by||discuss-53/VB||causing-60/VBG	det||effect-63/NN||this-61/DT	amod||effect-63/NN||antiviral-62/JJ	dobj||causing-60/VBG||effect-63/NN	prep_in||effect-63/NN||mice-65/NNS	picornavirusinfection-31||picornavirus-12||no||here, we discuss the structure and function of 3dpol during picornavirus replication, we review the evidence and consequence of a host immune response to epitopes in 3dpol after picornavirusinfection, highlight data showing the antiviral effects of transgenic 3dpol from theiler's murine encephalomyelitis virus (tmev), and discuss potential mechanisms by which 3dpol is causing this antiviral effect in mice.
csubj||help-15/VB||unraveling-1/VBG	det||mechanisms-3/NNS||the-2/DT	nsubj||responsible-4/JJ||mechanisms-3/NNS	xcomp||unraveling-1/VBG||responsible-4/JJ	prepc_for||responsible-4/JJ||multidrug-6/VBG	dobj||multidrug-6/VBG||resistance-7/NN	det||isolates-11/NN||the-9/DT	amod||isolates-11/NN||clinical-10/JJ	prep_in||multidrug-6/VBG||isolates-11/NN	prep_of||isolates-11/NN||vibriocholerae-13/NN	aux||help-15/VB||would-14/MD	root||ROOT-0/null||help-15/VB	nn||evolution-18/NN||understanding-17/NN	prep_in||help-15/VB||evolution-18/NN	det||bacteria-22/NNS||these-20/DT	amod||bacteria-22/NNS||pathogenic-21/JJ	prep_of||evolution-18/NN||bacteria-22/NNS	poss||potential-26/NN||their-24/PRP$	nn||potential-26/NN||epidemic-25/NN	prep_of||evolution-18/NN||potential-26/NN	conj_and||bacteria-22/NNS||potential-26/NN	vibriocholerae-13||bacteria-22||no||unraveling the mechanisms responsible for multidrug resistance in the clinical isolates of vibriocholerae would help in understanding evolution of these pathogenic bacteria and their epidemic potential.
nsubjpass||prepared-22/VBN||objective-1/NN	nsubjpass||evaluated-31/VBN||objective-1/NN	det||attempt-4/NN||an-3/DT	prep_in||objective-1/NN||attempt-4/NN	amod||treatment-7/NN||better-6/JJR	prep_for||attempt-4/NN||treatment-7/NN	prep_of||treatment-7/NN||bacterialinfections-9/NNS	nn||wounds-12/NNS||burn-11/NN	prep_of||treatment-7/NN||wounds-12/NNS	conj_and||bacterialinfections-9/NNS||wounds-12/NNS	nn||formulations-15/NNS||plaster-14/NN	appos||bacterialinfections-9/NNS||formulations-15/NNS	vmod||formulations-15/NNS||containing-16/VBG	amod||concentrations-18/NNS||different-17/JJ	dobj||containing-16/VBG||concentrations-18/NNS	prep_of||concentrations-18/NNS||norfloxacin-20/NN	auxpass||prepared-22/VBN||were-21/VBD	root||ROOT-0/null||prepared-22/VBN	xcomp||prepared-22/VBN||using-23/VBG	dobj||using-23/VBG||polymers-24/NNS	nn||alcohol-29/NN||polyvinylpyrrolidone-26/NN	conj_and||polyvinylpyrrolidone-26/NN||polyvinyl-28/NN	nn||alcohol-29/NN||polyvinyl-28/NN	prep_like||using-23/VBG||alcohol-29/NN	conj_and||prepared-22/VBN||evaluated-31/VBN	amod||parameters-34/NNS||physicochemical-33/JJ	prep_for||evaluated-31/VBN||parameters-34/NNS	amod||release-39/NN||vitro-37/JJ	nn||release-39/NN||drug-38/NN	prep_in||evaluated-31/VBN||release-39/NN	amod||activity-42/NN||antimicrobial-41/JJ	appos||release-39/NN||activity-42/NN	amod||properties-48/NNS||burn-45/JJ	amod||properties-48/NNS||wound-46/VBN	nn||properties-48/NNS||healing-47/NN	prep_in||evaluated-31/VBN||properties-48/NNS	conj_and||release-39/NN||properties-48/NNS	bacterialinfections-9||norfloxacin-20||yes||objective in an attempt for better treatment of bacterialinfections and burn wounds, plaster formulations containing different concentrations of norfloxacin were prepared using polymers like polyvinylpyrrolidone and polyvinyl alcohol and evaluated for physicochemical parameters, in vitro drug release, antimicrobial activity, and burn wound healing properties.
det||report-2/NN||this-1/DT	nsubj||discusses-3/VBZ||report-2/NN	root||ROOT-0/null||discusses-3/VBZ	det||case-5/NN||a-4/DT	dobj||discusses-3/VBZ||case-5/NN	amod||psychosis-8/NNS||acute-7/JJ	prep_of||case-5/NN||psychosis-8/NNS	prep_of||case-5/NN||enuresis-10/NNS	conj_and||psychosis-8/NNS||enuresis-10/NNS	det||alcohol-19/NN||a-12/DT	amod||alcohol-19/NN||patient-13/JJ	prep_on||patient-13/JJ||disulfiram-15/NN	nsubj||ingested-18/VBN||disulfiram-15/NN	aux||ingested-18/VBN||had-17/VBD	rcmod||disulfiram-15/NN||ingested-18/VBN	prep_in||case-5/NN||alcohol-19/NN	enuresis-10||alcohol-19||no_rel||this report discusses a case of acute psychosis and enuresis in a patient on disulfiram who had ingested alcohol.
det||features-3/NNS||the-1/DT	amod||features-3/NNS||pathological-2/JJ	nsubj||show-6/VBP||features-3/NNS	prep_of||features-3/NNS||asbestosis-5/NNS	root||ROOT-0/null||show-6/VBP	det||fibrosis-9/NN||the-7/DT	nn||fibrosis-9/NN||peribronchiolar-8/NN	dobj||show-6/VBP||fibrosis-9/NN	nsubj||suggest-11/VBP||fibrosis-9/NN	rcmod||fibrosis-9/NN||suggest-11/VBP	mark||cause-14/VBP||that-12/IN	nsubj||cause-14/VBP||asbestosfibers-13/NNS	ccomp||suggest-11/VBP||cause-14/VBP	det||inflammation-16/NN||the-15/DT	dobj||cause-14/VBP||inflammation-16/NN	prep_of||inflammation-16/NN||bronchioli-18/NNS	asbestosis-5||asbestosfibers-13||no||the pathological features of asbestosis show the peribronchiolar fibrosis which suggest that asbestosfibers cause the inflammation of bronchioli.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||valganciclovir-19||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||methanol-10||no_rel||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
advmod||known-5/VBN||additionally-1/RB	nsubjpass||known-5/VBN||tam-3/NN	nsubj||promote-7/VB||tam-3/NN	auxpass||known-5/VBN||are-4/VBP	root||ROOT-0/null||known-5/VBN	aux||promote-7/VB||to-6/TO	xcomp||known-5/VBN||promote-7/VB	nn||progression-9/NN||tumor-8/NN	dobj||promote-7/VB||progression-9/NN	amod||types-13/NNS||most-11/JJS	nn||types-13/NNS||cancer-12/NN	prep_for||progression-9/NN||types-13/NNS	prep_including||progression-9/NN||lymphomas-16/NNS	tam-3||lymphomas-16||no_rel||additionally, tam are known to promote tumor progression for most cancer types, including lymphomas.
advmod||screened-19/NN||finally-1/RB	vmod||screened-19/NN||using-3/VBG	det||method-5/NN||this-4/DT	dobj||using-3/VBG||method-5/NN	det||sites-10/NNS||the-7/DT	amod||sites-10/NNS||conservative-8/JJ	nn||sites-10/NNS||target-9/NN	nsubj||screened-19/NN||sites-10/NNS	prep_for||sites-10/NNS||hepatitisbvirus-12/NNS	dep||screened-19/NN||hbv-14/NN	nsubj||screened-19/NN||knockdown-16/NN	cop||screened-19/NN||were-17/VBD	amod||screened-19/NN||systemically-18/JJ	root||ROOT-0/null||screened-19/NN	nn||expression-23/NN||hbv-21/NN	nn||expression-23/NN||antigen-22/NN	conj_and||screened-19/NN||expression-23/NN	vmod||screened-19/NN||shown-24/VBN	aux||suppressed-28/VBN||to-25/TO	auxpass||suppressed-28/VBN||be-26/VB	advmod||suppressed-28/VBN||successfully-27/RB	xcomp||shown-24/VBN||suppressed-28/VBN	det||presence-31/NN||the-30/DT	prep_in||suppressed-28/VBN||presence-31/NN	amod||shrnas-35/NNS||connected-33/JJ	amod||shrnas-35/NNS||multiple-34/JJ	prep_of||presence-31/NN||shrnas-35/NNS	preconj||suppressed-28/VBN||both-36/DT	prep_in||suppressed-28/VBN||vitro-38/NNP	prep_in||suppressed-28/VBN||vivo-41/NN	conj_and||vitro-38/NNP||vivo-41/NN	hbv-21||hepatitisbvirus-12||no||finally, using this method, the conservative target sites for hepatitisbvirus (hbv) knockdown were systemically screened and hbv antigen expression shown to be successfully suppressed in the presence of connected multiple shrnas both in vitro and in vivo .
det||aim-3/NN||the-1/DT	amod||aim-3/NN||main-2/JJ	nsubj||was-7/VBD||aim-3/NN	nsubj||evaluate-9/VB||aim-3/NN	det||study-6/NN||this-5/DT	prep_of||aim-3/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	det||expression-11/NN||the-10/DT	dobj||evaluate-9/VB||expression-11/NN	amod||mirnas-14/NNS||several-13/JJ	prep_of||expression-11/NN||mirnas-14/NNS	dep||mirnas-14/NNS||mir-1-16/JJ	amod||mir-296-24/JJ||mir-30-18/JJ	amod||mir-296-24/JJ||mir-128-20/JJ	amod||mir-296-24/JJ||mir-196-22/JJ	amod||mirnas-14/NNS||mir-296-24/JJ	amod||cells-30/NNS||peripheral-27/JJ	nn||cells-30/NNS||blood-28/NN	nn||cells-30/NNS||mononuclear-29/NN	prep_in||mirnas-14/NNS||cells-30/NNS	dep||expression-11/NN||pbmcs-32/VBZ	amod||individuals-36/NNS||healthy-35/JJ	conj_and||individuals-36/NNS||individuals-36/NNS	conj_and||individuals-36/NNS||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	prep_from||alpha-62/NN||individuals-36/NNS	dep||vitro-39/NN||in-38/IN	amod||ifn-treatment-40/NN||vitro-39/NN	prep_after||individuals-36/NNS||ifn-treatment-40/NN	cc||individuals-36/NNS||and-41/CC	prep_in||individuals-36/NNS||pbmcs-43/NNS	prep_from||pbmcs-43/NNS||patients-45/NNS	amod||chc-49/NN||chronichepatitisc-47/JJ	prep_with||patients-45/NNS||chc-49/NN	advmod||chc-49/NN||before-51/IN	num||hours-54/NNS||12-53/CD	npadvmod||individuals-36/NNS||hours-54/NNS	det||injection-58/NN||the-56/DT	amod||injection-58/NN||first-57/JJ	prep_after||individuals-36/NNS||injection-58/NN	amod||ifn-61/NN||pegylated-60/JJ	prep_of||injection-58/NN||ifn-61/NN	amod||expression-11/NN||alpha-62/NN	chronichepatitisc-47||ifn-61||yes||the main aim of this study was to evaluate the expression of several mirnas (mir-1, mir-30, mir-128, mir-196, mir-296) in peripheral blood mononuclear cells (pbmcs) from healthy individuals after in vitro ifn-treatment and in pbmcs from patients with chronichepatitisc (chc) before and 12 hours after the first injection of pegylated ifn alpha.
det||timing-2/NN||the-1/DT	nsubjpass||calculated-14/VBN||timing-2/NN	nsubjpass||calculated-14/VBN||timing-2/NN	nsubj||determine-20/VB||timing-2/NN	prep_of||timing-2/NN||onset-4/NN	vmod||onset-4/NN||offset-6/VBN	prep_of||timing-2/NN||duration-9/NN	conj_and||onset-4/NN||duration-9/NN	nn||secretion-12/NN||melatonin-11/NN	prep_of||duration-9/NN||secretion-12/NN	auxpass||calculated-14/VBN||were-13/VBD	root||ROOT-0/null||calculated-14/VBN	conj_and||calculated-14/VBN||calculated-14/VBN	prep_after||calculated-14/VBN||stroke-18/NN	prep_before||calculated-14/VBN||stroke-18/NN	aux||determine-20/VB||to-19/TO	xcomp||calculated-14/VBN||determine-20/VB	dobj||determine-20/VB||changes-21/NNS	nn||rhythms-24/NNS||circadian-23/NN	prep_in||determine-20/VB||rhythms-24/NNS	nn||secretion-27/NN||melatonin-26/NN	prep_of||rhythms-24/NNS||secretion-27/NN	stroke-18||melatonin-26||no_rel||the timing of onset, offset, and duration of melatonin secretion were calculated before and after stroke to determine changes in circadian rhythms of melatonin secretion.
aux||identify-2/VB||to-1/TO	advcl||performed-18/VBN||identify-2/VB	amod||locations-5/NNS||new-3/JJ	amod||locations-5/NNS||genomic-4/JJ	dobj||identify-2/VB||locations-5/NNS	vmod||locations-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||irondeficiency-8/NN	det||study-13/NN||a-10/DT	amod||study-13/NN||genome-wide-11/JJ	nn||study-13/NN||association-12/NN	nsubjpass||performed-18/VBN||study-13/NN	appos||study-13/NN||gwas-15/NNS	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	xcomp||performed-18/VBN||using-19/VBG	dobj||using-19/VBG||dna-20/NN	vmod||dna-20/NN||collected-21/VBN	amod||men-24/NNS||white-23/JJ	prep_from||collected-21/VBN||men-24/NNS	vmod||men-24/NNS||aged-25/VBN	number||‰-27/CD||â-26/CD	num||y-30/NN||‰-27/CD	nn||y-30/NN||¥-28/NNP	num||y-30/NN||25-29/CD	dobj||aged-25/VBN||y-30/NN	nn||‰-34/NN||women-32/NNS	nn||‰-34/NN||â-33/NN	dobj||aged-25/VBN||‰-34/NN	conj_and||y-30/NN||‰-34/NN	vmod||y-30/NN||¥-35/VBG	num||y-37/NN||50-36/CD	dobj||¥-35/VBG||y-37/NN	det||study-47/NN||the-39/DT	amod||study-47/NN||hemochromatosis-40/JJ	conj_and||hemochromatosis-40/JJ||ironoverload-42/JJ	amod||study-47/NN||ironoverload-42/JJ	nn||study-47/NN||screening-43/NN	appos||study-47/NN||heirs-45/NNS	prep_in||y-37/NN||study-47/NN	amod||controls-67/NNS||serum-49/JJ	amod||controls-67/NNS||ferritin-50/JJ	appos||controls-67/NNS||sf-52/NN	nn||controls-67/NNS||â-54/NN	amod||controls-67/NNS||‰-55/JJ	amod||controls-67/NNS||$-56/$	number||$-56/$||12-57/CD	nn||controls-67/NNS||âµg-58/NN	punct||replete-66/JJ||/-59/:	amod||cases-62/NNS||l-60/JJ	dep||replete-66/JJ||cases-62/NNS	conj_and||cases-62/NNS||iron-65/NN	dep||replete-66/JJ||iron-65/NN	dep||controls-67/NNS||replete-66/JJ	prep_with||¥-35/VBG||controls-67/NNS	dep||controls-67/NNS||sf-69/VBN	number||100-71/CD||>-70/CD	num||âµg-72/NN||100-71/CD	iobj||sf-69/VBN||âµg-72/NN	punct||l-74/NN||/-73/:	dep||âµg-72/NN||l-74/NN	prep_in||l-74/NN||men-76/NNS	advmod||50-80/CD||sf-78/RB	number||50-80/CD||>-79/CD	appos||l-74/NN||50-80/CD	dep||50-80/CD||âµg-81/NN	punct||l-74/NN||/-82/:	dobj||sf-69/VBN||l-83/NN	prep_in||sf-69/VBN||women-85/NNS	hemochromatosis-40||iron-65||no||to identify new genomic locations associated with irondeficiency, a genome-wide association study (gwas) was performed using dna collected from white men aged â‰¥25 y and women â‰¥50 y in the hemochromatosis and ironoverload screening (heirs) study with serum ferritin (sf) â‰¤ 12 âµg/l (cases) and iron replete controls (sf>100 âµg/l in men, sf>50 âµg/l in women).
amod||infusion-3/NN||ophthalmic-1/JJ	amod||infusion-3/NN||intra-arterial-2/JJ	nsubj||option-11/NN||infusion-3/NN	prep_with||infusion-3/NN||melphalan-5/NN	cop||option-11/NN||is-6/VBZ	det||option-11/NN||an-7/DT	amod||option-11/NN||excellent-8/JJ	amod||option-11/NN||globe-conserving-9/JJ	nn||option-11/NN||treatment-10/NN	root||ROOT-0/null||option-11/NN	amod||cases-15/NNS||advanced-13/VBN	nn||cases-15/NNS||retinoblastoma-14/NN	prep_in||option-11/NN||cases-15/NNS	amod||effects-20/NNS||minimal-17/JJ	amod||effects-20/NNS||systemic-18/JJ	nn||effects-20/NNS||side-19/NN	prep_with||cases-15/NNS||effects-20/NNS	melphalan-5||retinoblastoma-14||no_rel||ophthalmic intra-arterial infusion with melphalan is an excellent globe-conserving treatment option in advanced retinoblastoma cases with minimal systemic side effects.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||approach-5/NN||a-3/DT	amod||approach-5/NN||criteria-based-4/JJ	dobj||used-2/VBD||approach-5/NN	aux||determine-7/VB||to-6/TO	vmod||used-2/VBD||determine-7/VB	nsubj||hiv/aids-9/VBZ||which-8/WDT	nsubj||purposive-27/JJ||which-8/WDT	dobj||determine-7/VB||hiv/aids-9/VBZ	nsubj||conduct-30/VB||hiv/aids-9/VBZ	nsubj||have-11/VBP||stakeholders-10/NNS	ccomp||hiv/aids-9/VBZ||have-11/VBP	det||impact-15/NN||the-12/DT	advmod||significant-14/JJ||most-13/RBS	amod||impact-15/NN||significant-14/JJ	dobj||have-11/VBP||impact-15/NN	amod||research-18/NN||hiv/aids-17/JJ	prep_on||impact-15/NN||research-18/NN	prep_on||impact-15/NN||programs-20/NNS	conj_and||research-18/NN||programs-20/NNS	prep_on||impact-15/NN||funding-22/NN	conj_and||research-18/NN||funding-22/NN	prep_on||impact-15/NN||policy-24/NN	conj_and||research-18/NN||policy-24/NN	amod||purposive-27/JJ||stratified-26/JJ	dobj||determine-7/VB||purposive-27/JJ	conj_and||hiv/aids-9/VBZ||purposive-27/JJ	nsubj||conduct-30/VB||purposive-27/JJ	amod||purposive-27/JJ||sampling-28/VBG	aux||conduct-30/VB||to-29/TO	xcomp||determine-7/VB||conduct-30/VB	dobj||conduct-30/VB||interviews-31/NNS	det||subset-34/NN||a-33/DT	prep_with||conduct-30/VB||subset-34/NN	det||individuals-37/NNS||these-36/DT	prep_of||subset-34/NN||individuals-37/NNS	aids--1||hiv--1||no||we used a criteria-based approach to determine which hiv/aids stakeholders have the most significant impact on hiv/aids research, programs, funding and policy and stratified purposive sampling to conduct interviews with a subset of these individuals.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||approach-4/NN||this-3/DT	dobj||used-2/VBD||approach-4/NN	aux||suppress-6/VB||to-5/TO	vmod||approach-4/NN||suppress-6/VB	amod||arthritis-8/NN||collagen-induced-7/JJ	dobj||suppress-6/VB||arthritis-8/NN	prep_in||failed-15/VBD||arthritis-8/NN	amod||cells-14/NNS||conventional-12/JJ	amod||cells-14/NNS||foxp3-transduced-13/JJ	nsubj||failed-15/VBD||cells-14/NNS	nsubj||show-17/VB||cells-14/NNS	rcmod||arthritis-8/NN||failed-15/VBD	aux||show-17/VB||to-16/TO	xcomp||failed-15/VBD||show-17/VB	det||effect-19/NN||any-18/DT	dobj||show-17/VB||effect-19/NN	collagen--1||arthritis-8||no_rel||we used this approach to suppress collagen-induced arthritis, in which conventional foxp3-transduced cells failed to show any effect.
det||suppression-3/NN||the-1/DT	amod||suppression-3/NN||entecavir-induced-2/JJ	nsubjpass||accompanied-8/VBN||suppression-3/NN	nn||replication-6/NN||hbv-5/NN	prep_of||suppression-3/NN||replication-6/NN	auxpass||accompanied-8/VBN||was-7/VBD	root||ROOT-0/null||accompanied-8/VBN	det||increase-12/NN||a-10/DT	amod||increase-12/NN||rapid-11/JJ	agent||accompanied-8/VBN||increase-12/NN	det||number-15/NN||the-14/DT	prep_in||increase-12/NN||number-15/NN	amod||cells-18/NNS||th17-17/JJ	prep_of||number-15/NN||cells-18/NNS	advmod||accompanied-8/VBN||together-20/RB	det||decrease-23/NN||a-22/DT	prep_with||accompanied-8/VBN||decrease-23/NN	amod||cells-26/NNS||treg-25/VBG	prep_in||decrease-23/NN||cells-26/NNS	nsubj||lead-29/VBP||cells-26/NNS	rcmod||cells-26/NNS||lead-29/VBP	det||reduction-33/NN||a-31/DT	amod||reduction-33/NN||significant-32/JJ	prep_to||lead-29/VBP||reduction-33/NN	amod||ratios-36/NNS||treg/th17-35/JJ	prep_of||reduction-33/NN||ratios-36/NNS	hbv-5||entecavir--1||yes||the entecavir-induced suppression of hbv replication was accompanied by a rapid increase in the number of th17 cells, together with a decrease in treg cells, which lead to a significant reduction of treg/th17 ratios.
det||profiling-3/NN||the-1/DT	amod||profiling-3/NN||global-2/JJ	nsubj||gives-8/VBZ||profiling-3/NN	det||genome-7/NN||the-5/DT	nn||genome-7/NN||vzv-6/NN	prep_of||profiling-3/NN||genome-7/NN	root||ROOT-0/null||gives-8/VBZ	amod||insights-10/NNS||further-9/JJ	dobj||gives-8/VBZ||insights-10/NNS	det||replication-13/NN||the-12/DT	prep_into||gives-8/VBZ||replication-13/NN	prep_into||gives-8/VBZ||pathogenesis-15/NNS	conj_and||replication-13/NN||pathogenesis-15/NNS	det||virus-18/NN||this-17/DT	prep_of||replication-13/NN||virus-18/NN	nsubj||lead-22/VB||virus-18/NN	aux||lead-22/VB||can-21/MD	rcmod||virus-18/NN||lead-22/VB	amod||prevention-25/NN||improved-24/VBN	prep_to||lead-22/VB||prevention-25/NN	prep_to||lead-22/VB||therapy-27/NN	conj_and||prevention-25/NN||therapy-27/NN	prep_of||prevention-25/NN||chickenpox-29/NN	prep_of||prevention-25/NN||shingles-31/NNS	conj_and||chickenpox-29/NN||shingles-31/NNS	shingles-31||vzv-6||no||the global profiling of the vzv genome gives further insights into the replication and pathogenesis of this virus, which can lead to improved prevention and therapy of chickenpox and shingles.
nn||botulinumneurotoxintypea-2/NN||background-1/NN	nsubj||substance-9/NN||botulinumneurotoxintypea-2/NN	appos||botulinumneurotoxintypea-2/NN||bont/a-4/NNP	cop||substance-9/NN||is-6/VBZ	det||substance-9/NN||the-7/DT	amod||substance-9/NN||active-8/JJ	root||ROOT-0/null||substance-9/NN	prep_in||substance-9/NN||preparations-11/NNS	vmod||preparations-11/NNS||used-12/VBN	det||treatment-17/NN||the-14/DT	advmod||effective-16/JJ||highly-15/RB	amod||treatment-17/NN||effective-16/JJ	prep_for||used-12/VBN||treatment-17/NN	prep_of||treatment-17/NN||neurologicdisorders-19/NNS	amod||dystonia-23/NN||cervical-22/JJ	prep_such_as||neurologicdisorders-19/NNS||dystonia-23/NN	prep_such_as||neurologicdisorders-19/NNS||blepharospasm-25/NN	conj_or||dystonia-23/NN||blepharospasm-25/NN	prep_such_as||neurologicdisorders-19/NNS||spasticity-28/NN	conj_or||dystonia-23/NN||spasticity-28/NN	amod||indications-34/NNS||other-33/JJ	prep_for||used-12/VBN||indications-34/NNS	conj_and||treatment-17/NN||indications-34/NNS	nn||hyperhidrosis-40/NNS||axillary-37/NN	conj_and||axillary-37/NN||palmar-39/NN	nn||hyperhidrosis-40/NNS||palmar-39/NN	prep_such_as||indications-34/NNS||hyperhidrosis-40/NNS	amod||disorders-44/NNS||urologic-43/JJ	prep_for||used-12/VBN||disorders-44/NNS	conj_and||treatment-17/NN||disorders-44/NNS	blepharospasm-25||botulinumneurotoxintypea-2||yes||background botulinumneurotoxintypea (bont/a) is the active substance in preparations used for the highly effective treatment of neurologicdisorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders.
csubj||suggests-9/VBZ||examining-1/VBG	det||enzymes-5/NNS||the-2/DT	nn||enzymes-5/NNS||role-3/NN	nn||enzymes-5/NNS||ber-4/NN	nsubj||play-6/VB||enzymes-5/NNS	ccomp||examining-1/VBG||play-6/VB	prep_in||play-6/VB||hivinfection-8/NN	root||ROOT-0/null||suggests-9/VBZ	det||role-11/NN||a-10/DT	dobj||suggests-9/VBZ||role-11/NN	det||pathway-15/NN||the-13/DT	nn||pathway-15/NN||ber-14/NN	prep_for||role-11/NN||pathway-15/NN	nn||integration-18/NN||hiv-17/NN	prep_in||pathway-15/NN||integration-18/NN	hivinfection-8||hiv-17||no||examining the role ber enzymes play in hivinfection suggests a role for the ber pathway in hiv integration.
nsubj||showed-27/VBD||cell-1/NN	amod||cell-1/NN||swelling-2/VBG	auxpass||increased-4/VBN||was-3/VBD	rcmod||cell-1/NN||increased-4/VBN	nn||-rrb--10/NNS||ammonia-6/NNP	nn||-rrb--10/NNS||-lrb--7/NNP	number||%-9/NN||43-8/CD	amod||-rrb--10/NNS||%-9/NN	agent||increased-4/VBN||-rrb--10/NNS	agent||increased-4/VBN||cytokines-13/NNS	conj_and||-rrb--10/NNS||cytokines-13/NNS	vmod||cytokines-13/NNS||-lrb--14/VBG	num||%-16/NN||37-15/CD	dobj||-lrb--14/VBG||%-16/NN	advmod||-lrb--14/VBG||-rrb--17/RB	num||co-treatment-22/NN||24-19/CD	amod||co-treatment-22/NN||h.-20/JJ	amod||co-treatment-22/NN||simultaneous-21/JJ	prep_at||-lrb--14/VBG||co-treatment-22/NN	prep_with||co-treatment-22/NN||cytokines-24/NNS	prep_with||co-treatment-22/NN||ammonia-26/NN	conj_and||cytokines-24/NNS||ammonia-26/NN	root||ROOT-0/null||showed-27/VBD	neg||swelling-30/NN||no-28/DT	amod||swelling-30/NN||additional-29/JJ	dobj||showed-27/VBD||swelling-30/NN	ammonia-26||swelling-30||no_rel||cell swelling was increased by ammonia -lrb- 43 % -rrb- and by cytokines -lrb- 37 % -rrb- at 24 h. simultaneous co-treatment with cytokines and ammonia showed no additional swelling .
nsubjpass||suggested-13/VBN||selection-1/NN	nsubj||give-15/VB||selection-1/NN	nsubj||give-15/VB||selection-1/NN	amod||virus-4/NN||hepatitisb-3/JJ	prep_of||selection-1/NN||virus-4/NN	appos||virus-4/NN||hbv-6/NN	nn||immunity-10/NN||host-9/NN	prep_by||virus-4/NN||immunity-10/NN	aux||suggested-13/VBN||has-11/VBZ	auxpass||suggested-13/VBN||been-12/VBN	root||ROOT-0/null||suggested-13/VBN	aux||give-15/VB||to-14/TO	xcomp||suggested-13/VBN||give-15/VB	xcomp||suggested-13/VBN||give-15/VB	conj_or||give-15/VB||give-15/VB	dobj||give-15/VB||rise-16/NN	prep_to||rise-16/NN||variants-18/NNS	amod||substitutions-21/NNS||aminoacid-20/JJ	prep_with||variants-18/NNS||substitutions-21/NNS	det||determinant-29/NN||the-25/DT	nn||determinant-29/NN||a-27/NNP	prep_around||give-15/VB||determinant-29/NN	prep_at||give-15/VB||determinant-29/NN	det||antigen-33/NN||the-31/DT	nn||antigen-33/NN||surface-32/NN	prep_of||determinant-29/NN||antigen-33/NN	appos||determinant-29/NN||hbsag-35/NN	det||target-40/NN||the-38/DT	amod||target-40/NN||main-39/JJ	dobj||give-15/VB||target-40/NN	nn||neutralization-43/NN||antibody-42/NN	prep_of||target-40/NN||neutralization-43/NN	amod||assays-46/NNS||diagnostic-45/JJ	prep_of||target-40/NN||assays-46/NNS	conj_and||neutralization-43/NN||assays-46/NNS	hbv-6||hbsag-35||yes||selection of hepatitisb virus (hbv) by host immunity has been suggested to give rise to variants with aminoacid substitutions at or around the 'a' determinant of the surface antigen (hbsag), the main target of antibody neutralization and diagnostic assays.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||investigate-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||investigate-4/VB||to-3/TO	xcomp||aimed-2/VBD||investigate-4/VB	det||infection-18/NN||the-5/DT	amod||infection-18/NN||longitudinal-6/JJ	dep||longitudinal-6/JJ||hbsag-7/VBG	dobj||hbsag-7/VBG||change-8/NN	amod||carriers-11/NNS||hbeag-negative-10/JJ	prep_in||hbsag-7/VBG||carriers-11/NNS	nn||genotype-14/NN||hbv-13/NN	prep_with||carriers-11/NNS||genotype-14/NN	num||infection-18/NN||b-15/SYM	conj_or||b-15/SYM||c-17/SYM	num||infection-18/NN||c-17/SYM	dobj||investigate-4/VB||infection-18/NN	hbv-13||hbsag-7||yes||we aimed to investigate the longitudinal hbsag change in hbeag-negative carriers with hbv genotype b or c infection.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||a-3/DT	dobj||present-2/VBP||case-4/NN	det||male-11/NN||a-6/DT	number||old-9/JJ||54-7/CD	npadvmod||old-9/JJ||year-8/NN	amod||male-11/NN||old-9/JJ	amod||male-11/NN||caucasian-10/JJ	prep_of||case-4/NN||male-11/NN	amod||rheumatoidarthritis-14/NNS||refractory-13/JJ	prep_with||present-2/VBP||rheumatoidarthritis-14/NNS	nsubj||developed-16/VBD||rheumatoidarthritis-14/NNS	rcmod||rheumatoidarthritis-14/NNS||developed-16/VBD	amod||multiplex-18/NN||mononeuritis-17/JJ	dobj||developed-16/VBD||multiplex-18/NN	num||weeks-20/NNS||four-19/CD	npadvmod||developed-16/VBD||weeks-20/NNS	prepc_after||developed-16/VBD||starting-22/VBG	amod||therapy-24/NN||adalimumab-23/JJ	dobj||starting-22/VBG||therapy-24/NN	rheumatoidarthritis-14||adalimumab-23||yes||we present a case of a 54 year old caucasian male with refractory rheumatoidarthritis who developed mononeuritis multiplex four weeks after starting adalimumab therapy.
nsubj||analysis-5/NN||this-1/DT	cop||analysis-5/NN||was-2/VBD	det||analysis-5/NN||a-3/DT	amod||analysis-5/NN||combined-4/JJ	root||ROOT-0/null||analysis-5/NN	prep_of||analysis-5/NN||2-7/CD	amod||studies-19/NNS||prospective-8/JJ	amod||multicenter-16/JJ||randomized-10/JJ	amod||multicenter-16/JJ||double-blind-12/JJ	amod||multicenter-16/JJ||8-week-14/JJ	amod||studies-19/NNS||multicenter-16/JJ	amod||studies-19/NNS||parallel-group-18/JJ	nsubj||confirmed-35/VBD||studies-19/NNS	vmod||studies-19/NNS||comparing-20/VBG	amod||gel-24/NN||diclofenacsodium-21/JJ	number||%-23/NN||1-22/CD	amod||gel-24/NN||%-23/NN	dobj||comparing-20/VBG||gel-24/NN	nn||gel-27/NN||placebo-26/NN	prep_with||comparing-20/VBG||gel-27/NN	appos||gel-27/NN||vehicle-29/NN	prep_in||gel-27/NN||patients-32/NNS	prep_with||patients-32/NNS||radiographically-34/NN	rcmod||analysis-5/NN||confirmed-35/VBD	acomp||confirmed-35/VBD||mild-36/JJ	amod||oa-40/NN||moderate-38/JJ	nn||oa-40/NN||hand-39/NN	prep_to||mild-36/JJ||oa-40/NN	oa-40||diclofenacsodium-21||yes||this was a combined analysis of 2 prospective, randomized, double-blind, 8-week, multicenter, parallel-group studies comparing diclofenacsodium 1% gel with placebo gel (vehicle) in patients with radiographically confirmed mild to moderate hand oa.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	amod||effects-6/NNS||possible-3/JJ	amod||effects-6/NNS||combinatory-4/JJ	nn||effects-6/NNS||antitumor-5/NN	dobj||examined-2/VBD||effects-6/NNS	amod||adenoviruses-11/NNS||replication-competent-8/JJ	amod||adenoviruses-11/NNS||type-9/NN	number||type-9/NN||5-10/CD	prep_of||effects-6/NNS||adenoviruses-11/NNS	appos||adenoviruses-11/NNS||ad-13/NN	xcomp||examined-2/VBD||lacking-15/VBG	amod||molecules-17/NNS||e1b-55kda-16/JJ	dobj||lacking-15/VBG||molecules-17/NNS	dep||molecules-17/NNS||ad-dele1b55-19/JJ	dobj||lacking-15/VBG||chemotherapeuticagents-22/NNS	conj_and||molecules-17/NNS||chemotherapeuticagents-22/NNS	num||cells-28/NNS||nine-24/CD	amod||cells-28/NNS||human-25/JJ	amod||cells-28/NNS||esophageal-26/JJ	nn||cells-28/NNS||carcinoma-27/NN	prep_in||chemotherapeuticagents-22/NNS||cells-28/NNS	carcinoma-27||chemotherapeuticagents-22||no_rel||we examined possible combinatory antitumor effects of replication-competent type 5 adenoviruses (ad) lacking e1b-55kda molecules (ad-dele1b55) and chemotherapeuticagents in nine human esophageal carcinoma cells.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	triglycerides-53||age-relatedmaculardegeneration-11||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
det||cohort-3/NN||the-1/DT	amod||cohort-3/NN||medalist-2/JJ	nsubj||has-29/VBZ||cohort-3/NN	det||±-9/NN||a-6/DT	amod||±-9/NN||mean-7/JJ	nn||±-9/NN||â-8/NN	prep_with||cohort-3/NN||±-9/NN	vmod||±-9/NN||sd-10/VBN	nn||duration-12/NN||disease-11/NN	nn||â-22/NN||duration-12/NN	conj_and||duration-12/NN||age-14/NN	nn||â-22/NN||age-14/NN	num||â-17/NN||56.2-16/CD	prep_of||duration-12/NN||â-17/NN	amod||â-22/NN||±-18/JJ	dep||±-18/JJ||5.8-19/CD	dep||±-18/JJ||67.2-21/CD	conj_and||5.8-19/CD||67.2-21/CD	dobj||sd-10/VBN||â-22/NN	number||7.5-24/CD||±-23/CD	num||years-25/NNS||7.5-24/CD	tmod||sd-10/VBN||years-25/NNS	advmod||sd-10/VBN||respectively-27/RB	dep||mean-39/VBP||has-29/VBZ	det||phenotype-32/NN||a-30/DT	amod||phenotype-32/NN||clinical-31/JJ	dobj||has-29/VBZ||phenotype-32/NN	amod||type1diabetes-35/JJ||similar-33/JJ	dep||type1diabetes-35/JJ||to-34/TO	amod||phenotype-32/NN||type1diabetes-35/JJ	appos||phenotype-32/NN||type1diabetes-37/NNP	root||ROOT-0/null||mean-39/VBP	nn||onset-43/NN||â-40/NN	num||onset-43/NN||±-41/CD	nn||onset-43/NN||sd-42/NN	dobj||mean-39/VBP||onset-43/NN	num||±-47/NNS||11.0-45/CD	nn||±-47/NNS||â-46/NN	prep_at||onset-43/NN||±-47/NNS	num||years-49/NNS||6.4-48/CD	nsubj||mean-39/VBP||years-49/NNS	appos||years-49/NNS||bmi-51/NN	num||â-54/NN||26.0-53/CD	prep_at||bmi-51/NN||â-54/NN	number||5.1-56/CD||±-55/CD	num||kg/m2-57/NNS||5.1-56/CD	dep||â-54/NN||kg/m2-57/NNS	nn||dose-60/NN||insulin-59/NN	prep_at||bmi-51/NN||dose-60/NN	conj_and||â-54/NN||dose-60/NN	num||±-64/NNS||0.46-62/CD	nn||±-64/NNS||â-63/NN	prep_of||dose-60/NN||±-64/NNS	number||u/kg-66/JJ||0.2-65/CD	amod||±-64/NNS||u/kg-66/JJ	number||1/4-69/CD||âˆ-68/CD	prep_at||bmi-51/NN||1/4-69/CD	conj_and||â-54/NN||1/4-69/CD	num||%-71/NN||94-70/CD	npadvmod||positive-72/JJ||%-71/NN	amod||1/4-69/CD||positive-72/JJ	amod||dr4-76/NNS||dr3-74/JJ	amod||dr4-76/NNS||and/or-75/JJ	prep_for||1/4-69/CD||dr4-76/NNS	num||%-80/NN||29.5-79/CD	prep_at||bmi-51/NN||%-80/NN	conj_and||â-54/NN||%-80/NN	amod||autoantibodies-91/NNS||positive-81/JJ	det||decarboxylase-87/NN||either-83/DT	amod||decarboxylase-87/NN||ia2-84/JJ	conj_or||ia2-84/JJ||glutamicacid-86/JJ	amod||decarboxylase-87/NN||glutamicacid-86/JJ	prep_for||positive-81/JJ||decarboxylase-87/NN	appos||decarboxylase-87/NN||gad-89/NN	dep||%-80/NN||autoantibodies-91/NNS	type1diabetes-37||insulin-59||yes||the medalist cohort, with a mean â± sd disease duration and age of 56.2 â± 5.8 and 67.2 â± 7.5 years, respectively, has a clinical phenotype similar to type1diabetes (type1diabetes) mean â± sd onset at 11.0 â± 6.4 years, bmi at 26.0 â± 5.1 kg/m2, insulin dose of 0.46 â± 0.2 u/kg, âˆ¼94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamicacid decarboxylase (gad) autoantibodies.
nsubj||applied-2/VBD||we-1/PRP	root||ROOT-0/null||applied-2/VBD	det||statistic-5/NN||a-3/DT	amod||statistic-5/NN||scan-4/JJ	dobj||applied-2/VBD||statistic-5/NN	parataxis||applied-2/VBD||p-7/VB	num||0.05-9/CD||<-8/CD	dobj||p-7/VB||0.05-9/CD	aux||detect-12/VB||to-11/TO	vmod||applied-2/VBD||detect-12/VB	amod||clusters-14/NNS||listeriosis-13/JJ	dobj||detect-12/VB||clusters-14/NNS	vmod||clusters-14/NNS||caused-15/VBN	det||subtype-20/NN||a-17/DT	amod||subtype-20/NN||specific-18/JJ	nn||subtype-20/NN||listeriamonocytogenes-19/NNS	agent||caused-15/VBN||subtype-20/NN	listeriosis-13||listeriamonocytogenes-19||no||we applied a scan statistic (p < 0.05) to detect listeriosis clusters caused by a specific listeriamonocytogenes subtype.
nn||group-3/NN||control-2/NN	prep_in||developed-25/VBN||group-3/NN	amod||education-7/NN||oral-5/JJ	nn||education-7/NN||health-6/NN	nsubjpass||developed-25/VBN||education-7/NN	conj_and||education-7/NN||dentalplaque-9/NN	nsubjpass||developed-25/VBN||dentalplaque-9/NN	vmod||education-7/NN||dying-10/VBG	prepc_followed_by||dying-10/VBG||by-12/IN	pcomp||dying-10/VBG||toothbrushing-13/VBG	nn||dentifrice-16/NN||fluoride-15/NN	prep_with||toothbrushing-13/VBG||dentifrice-16/NN	vmod||dentifrice-16/NN||supervised-17/VBN	advmod||supervised-17/VBN||directly-18/RB	det||assistant-22/NN||a-20/DT	amod||assistant-22/NN||dental-21/JJ	agent||supervised-17/VBN||assistant-22/NN	auxpass||developed-25/VBN||was-24/VBD	root||ROOT-0/null||developed-25/VBN	num||times-27/NNS||four-26/CD	dobj||developed-25/VBN||times-27/NNS	prep_per||times-27/NNS||year-29/NN	dentalplaque-9||fluoride-15||yes||in control group, oral health education and dentalplaque dying followed by toothbrushing with fluoride dentifrice supervised directly by a dental assistant, was developed four times per year.
mark||demonstrated-9/VBD||although-1/IN	det||randomized-4/NN||a-3/DT	prep_in||demonstrated-9/VBD||randomized-4/NN	amod||prasugrel-8/NN||double-blind-6/JJ	nn||prasugrel-8/NN||trial-7/NN	nsubj||demonstrated-9/VBD||prasugrel-8/NN	advcl||associated-23/VBN||demonstrated-9/VBD	dobj||demonstrated-9/VBD||superiority-10/NN	amod||endpoints-14/NNS||multiple-12/JJ	amod||endpoints-14/NNS||cardiovascular-13/JJ	prep_for||demonstrated-9/VBD||endpoints-14/NNS	prepc_compared_with||demonstrated-9/VBD||with-16/IN	amod||clopidogrel-18/NN||standard-dose-17/JJ	pobj||demonstrated-9/VBD||clopidogrel-18/NN	nsubjpass||associated-23/VBN||it-20/PRP	auxpass||associated-23/VBN||was-21/VBD	advmod||associated-23/VBN||also-22/RB	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||bleeding-27/NN	prep_with||associated-23/VBN||risk-28/NN	amod||bleeding-32/NN||fatal-31/JJ	prep_including||risk-28/NN||bleeding-32/NN	bleeding-32||clopidogrel-18||no||although in a randomized, double-blind trial prasugrel demonstrated superiority for multiple cardiovascular endpoints compared with standard-dose clopidogrel, it was also associated with an increased bleeding risk, including fatal bleeding.
advmod||components-8/NNS||indeed-1/RB	nsubj||components-8/NNS||isoniazid-3/NN	conj_and||isoniazid-3/NN||rifampicin-5/NN	nsubj||components-8/NNS||rifampicin-5/NN	cop||components-8/NNS||are-6/VBP	amod||components-8/NNS||important-7/JJ	root||ROOT-0/null||components-8/NNS	det||regimen-11/NN||any-10/DT	prep_of||components-8/NNS||regimen-11/NN	det||treatment-14/NN||the-13/DT	prep_for||regimen-11/NN||treatment-14/NN	prep_of||treatment-14/NN||drug-16/NN	amod||tb-18/JJ||susceptible-17/JJ	amod||drug-16/NN||tb-18/JJ	tb-18||rifampicin-5||yes||indeed, isoniazid and rifampicin are important components of any regimen for the treatment of drug susceptible tb.
nsubj||immunomodulator-5/NN||tacrolimus-1/NNS	cop||immunomodulator-5/NN||is-2/VBZ	det||immunomodulator-5/NN||a-3/DT	amod||immunomodulator-5/NN||potent-4/JJ	root||ROOT-0/null||immunomodulator-5/NN	nsubj||effective-8/JJ||immunomodulator-5/NN	cop||effective-8/JJ||is-7/VBZ	rcmod||immunomodulator-5/NN||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||inflammatoryboweldisease-13/NN	appos||inflammatoryboweldisease-13/NN||ibd-15/NN	tacrolimus-1||inflammatoryboweldisease-13||no_rel||tacrolimus is a potent immunomodulator that is effective in the treatment of inflammatoryboweldisease (ibd).
nsubjpass||known-3/VBN||antibodies-1/NNS	nsubj||essential-6/JJ||antibodies-1/NNS	auxpass||known-3/VBN||are-2/VBP	root||ROOT-0/null||known-3/VBN	aux||essential-6/JJ||to-4/TO	cop||essential-6/JJ||be-5/VB	xcomp||known-3/VBN||essential-6/JJ	prepc_in||essential-6/JJ||controlling-8/VBG	dobj||controlling-8/VBG||salmonellainfection-9/NN	poss||role-14/NN||their-12/PRP$	amod||role-14/NN||exact-13/JJ	nsubj||remains-15/VBZ||role-14/NN	conj_but||known-3/VBN||remains-15/VBZ	acomp||remains-15/VBZ||elusive-16/JJ	salmonellainfection-9||antibodies-1||no_rel||antibodies are known to be essential in controlling salmonellainfection, but their exact role remains elusive.
nsubj||neurovirulent-8/JJ||some-1/DT	det||viruses-5/NNS||the-3/DT	amod||viruses-5/NNS||isolated-4/VBN	prep_of||some-1/DT||viruses-5/NNS	cop||neurovirulent-8/JJ||were-6/VBD	advmod||neurovirulent-8/JJ||more-7/RBR	root||ROOT-0/null||neurovirulent-8/JJ	prep||neurovirulent-8/JJ||then-9/RB	det||virus-12/NN||either-10/DT	amod||virus-12/NN||parental-11/JJ	pobj||then-9/RB||virus-12/NN	virus-12||viruses-5||no||some of the isolated viruses were more neurovirulent then either parental virus.
nn||types-7/NNS||fibrosis-1/NN	nn||types-7/NNS||amount-2/NN	conj_and||amount-2/NN||distribution-4/NN	nn||types-7/NNS||distribution-4/NN	conj_and||amount-2/NN||collagen-6/NN	nn||types-7/NNS||collagen-6/NN	nsubj||present-16/VBP||types-7/NNS	nsubj||present-16/VBP||types-7/NNS	dep||types-7/NNS||i-9/FW	dep||types-7/NNS||iii-11/NN	conj_and||i-9/FW||iii-11/NN	dep||types-7/NNS||vi-14/NN	conj_and||i-9/FW||vi-14/NN	root||ROOT-0/null||present-16/VBP	conj_and||present-16/VBP||present-16/VBP	amod||characteristics-18/NNS||distinct-17/JJ	dobj||present-16/VBP||characteristics-18/NNS	amod||subjects-23/NNS||lean-20/JJ	conj_and||lean-20/JJ||obese-22/JJ	amod||subjects-23/NNS||obese-22/JJ	prep_in||present-16/VBP||subjects-23/NNS	nn||localization-28/NN||wat-26/NN	nn||localization-28/NN||depots-27/NN	prep_with||present-16/VBP||localization-28/NN	dep||localization-28/NN||subcutaneous-30/JJ	dep||localization-28/NN||omental-32/JJ	conj_or||subcutaneous-30/JJ||omental-32/JJ	collagen-6||fibrosis-1||no_rel||fibrosis amount, distribution and collagen types (i, iii, and vi) present distinct characteristics in lean and obese subjects and with wat depots localization (subcutaneous or omental).
nsubjpass||associated-3/VBN||htlv-1infection-1/JJ	auxpass||associated-3/VBN||is-2/VBZ	root||ROOT-0/null||associated-3/VBN	prep_with||associated-3/VBN||hivinfection-5/NN	amod||data-9/NNS||longitudinal-8/JJ	nsubj||indicate-10/VBP||data-9/NNS	conj_and||associated-3/VBN||indicate-10/VBP	nsubj||factor-16/NN||hivinfection-11/NN	aux||factor-16/NN||may-12/MD	cop||factor-16/NN||be-13/VB	det||factor-16/NN||a-14/DT	nn||factor-16/NN||risk-15/NN	ccomp||indicate-10/VBP||factor-16/NN	prepc_for||factor-16/NN||acquiring-18/VBG	acomp||acquiring-18/VBG||htlv-1-19/JJ	conj_but||associated-3/VBN||not-22/RB	advmod||versa-24/RB||vice-23/RB	dep||not-22/RB||versa-24/RB	htlv-1infection-1||htlv-1-19||no||htlv-1infection is associated with hivinfection, and longitudinal data indicate hivinfection may be a risk factor for acquiring htlv-1, but not vice versa.
nsubjpass||found-3/VBN||albendazole-1/NN	nsubj||effective-8/JJ||albendazole-1/NN	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	aux||effective-8/JJ||to-4/TO	cop||effective-8/JJ||be-5/VB	advmod||effective-8/JJ||equally-6/RB	advmod||effective-8/JJ||as-7/RB	xcomp||found-3/VBN||effective-8/JJ	prep_as||effective-8/JJ||metronidazole-10/NN	det||treatment-13/NN||the-12/DT	prep_in||metronidazole-10/NN||treatment-13/NN	prep_of||treatment-13/NN||giardiasis-15/NNS	prep_in||giardiasis-15/NNS||humans-17/NNS	dep||effective-8/JJ||rr-19/NN	num||rr-19/NN||0.97-20/CD	number||%-23/NN||95-22/CD	amod||ci-24/NN||%-23/NN	dep||rr-19/NN||ci-24/NN	amod||rr-19/NN||0.93-26/CD	dep||rr-19/NN||1.01-28/FW	giardiasis-15||albendazole-1||yes||albendazole was found to be equally as effective as metronidazole in the treatment of giardiasis in humans (rr 0.97; 95% ci, 0.93, 1.01).
nsubj||metalloid-5/NN||arsenic-1/NN	cop||metalloid-5/NN||is-2/VBZ	det||metalloid-5/NN||a-3/DT	amod||metalloid-5/NN||toxic-4/JJ	root||ROOT-0/null||metalloid-5/NN	nsubj||causes-7/VBZ||metalloid-5/NN	nsubj||binds-11/VBZ||metalloid-5/NN	nsubj||cysteine-13/VB||metalloid-5/NN	rcmod||metalloid-5/NN||causes-7/VBZ	nn||cancer-9/NN||skin-8/NN	dobj||causes-7/VBZ||cancer-9/NN	rcmod||metalloid-5/NN||binds-11/VBZ	conj_and||causes-7/VBZ||binds-11/VBZ	aux||cysteine-13/VB||to-12/TO	xcomp||binds-11/VBZ||cysteine-13/VB	discourse||cysteine-13/VB||residuesâ-14/UH	dep||residuesâ-14/UH||$-15/UH	det||property-18/NN||a-17/DT	dobj||cysteine-13/VB||property-18/NN	nsubjpass||used-22/VBN||property-18/NN	nsubj||infer-24/VB||property-18/NN	aux||used-22/VBN||could-20/MD	auxpass||used-22/VBN||be-21/VB	rcmod||property-18/NN||used-22/VBN	aux||infer-24/VB||to-23/TO	xcomp||used-22/VBN||infer-24/VB	nn||responsiveness-26/NNS||arsenic-25/NN	dobj||infer-24/VB||responsiveness-26/NNS	det||protein-30/NN||a-28/DT	nn||protein-30/NN||target-29/NN	prep_of||responsiveness-26/NNS||protein-30/NN	cancer-9||arsenic-25||no_rel||arsenic is a toxic metalloid that causes skin cancer and binds to cysteine residuesâ€”a property that could be used to infer arsenic responsiveness of a target protein.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||useful-6/JJ||that-3/IN	nsubj||useful-6/JJ||d-penicillamine-4/NN	cop||useful-6/JJ||is-5/VBZ	ccomp||conclude-2/VBP||useful-6/JJ	det||treatment-9/NN||the-8/DT	prep_in||useful-6/JJ||treatment-9/NN	prep_of||treatment-9/NN||cystinuria-11/NN	cystinuria-11||d-penicillamine-4||yes||we conclude that d-penicillamine is useful in the treatment of cystinuria.
num||%-2/NN||64-1/CD	nsubj||had-6/VBD||%-2/NN	det||patients-5/NNS||all-4/DT	prep_of||%-2/NN||patients-5/NNS	root||ROOT-0/null||had-6/VBD	det||condition-10/NN||a-7/DT	amod||condition-10/NN||pre-existing-8/JJ	nn||condition-10/NN||immunosuppressive-9/NN	dobj||had-6/VBD||condition-10/NN	num||%-13/NN||10-12/CD	nsubj||hivpositive-15/JJ||%-13/NN	cop||hivpositive-15/JJ||were-14/VBD	conj_and||had-6/VBD||hivpositive-15/JJ	num||%-18/NN||48-17/CD	nsubj||seronegative-21/JJ||%-18/NN	cop||seronegative-21/JJ||were-19/VBD	advmod||seronegative-21/JJ||hiv-20/RB	conj_and||had-6/VBD||seronegative-21/JJ	num||%-24/NN||42-23/CD	nsubj||had-25/VBD||%-24/NN	conj_and||had-6/VBD||had-25/VBD	det||status-29/NN||an-26/DT	amod||status-29/NN||unknown-27/JJ	nn||status-29/NN||hiv-28/NN	dobj||had-25/VBD||status-29/NN	hivpositive-15||hiv-28||no||64% of all patients had a pre-existing immunosuppressive condition; 10% were hivpositive, 48% were hiv seronegative and 42% had an unknown hiv status.
advmod||reveal-3/VBP||here-1/RB	nsubj||reveal-3/VBP||we-2/PRP	root||ROOT-0/null||reveal-3/VBP	det||difference-6/NN||a-4/DT	amod||difference-6/NN||fundamental-5/JJ	dobj||reveal-3/VBP||difference-6/NN	prep_between||difference-6/NN||hbv-8/NN	det||hepatitisbvirus-13/NNS||the-10/DT	amod||hepatitisbvirus-13/NNS||related-11/JJ	nn||hepatitisbvirus-13/NNS||duck-12/NN	dobj||reveal-3/VBP||hepatitisbvirus-13/NNS	conj_and||difference-6/NN||hepatitisbvirus-13/NNS	appos||hepatitisbvirus-13/NNS||dhbv-15/NNP	det||mechanism-20/NN||the-18/DT	amod||mechanism-20/NN||recycling-19/VBG	prep_in||hepatitisbvirus-13/NNS||mechanism-20/NN	hbv-8||hepatitisbvirus-13||no||here we reveal a fundamental difference between hbv and the related duck hepatitisbvirus (dhbv) in the recycling mechanism.
det||objective-3/NN||the-1/DT	nn||objective-3/NN||study-2/NN	nsubj||was-4/VBD||objective-3/NN	nsubj||explore-6/VB||objective-3/NN	root||ROOT-0/null||was-4/VBD	aux||explore-6/VB||to-5/TO	xcomp||was-4/VBD||explore-6/VB	det||mechanism-9/NN||the-7/DT	amod||mechanism-9/NN||immunomodulatory-8/JJ	dobj||explore-6/VB||mechanism-9/NN	prep_of||mechanism-9/NN||action-11/NN	amod||2b-15/NNS||ifn-î-13/JJ	amod||2b-15/NNS||±-14/JJ	prep_for||action-11/NN||2b-15/NNS	prepc_by||explore-6/VB||measuring-17/VBG	amod||cell-21/NN||serum-18/JJ	amod||cell-21/NN||regulatory-19/JJ	nn||cell-21/NN||t-20/NN	dobj||measuring-17/VBG||cell-21/NN	appos||cell-21/NN||treg-23/NN	nn||²-30/NNP||serum-26/NNP	nn||²-30/NNP||transforming-27/NNP	nn||²-30/NNP||growth-28/NN	nn||²-30/NNP||factor-î-29/NNP	dobj||measuring-17/VBG||²-30/NNP	conj_and||cell-21/NN||²-30/NNP	nn||²-33/NNP||tgf-î-32/NNP	appos||²-30/NNP||²-33/NNP	amod||-10-40/NN||interleukin-36/JJ	appos||-10-40/NN||il-38/NN	dobj||measuring-17/VBG||-10-40/NN	conj_and||cell-21/NN||-10-40/NN	amod||levels-44/NNS||autoantibody-43/JJ	dobj||measuring-17/VBG||levels-44/NNS	conj_and||cell-21/NN||levels-44/NNS	prep_in||levels-44/NNS||patients-46/NNS	prep_with||patients-46/NNS||melanoma-48/NN	vmod||cell-21/NN||treated-49/VBN	det||phase-53/NN||the-51/DT	nn||phase-53/NN||induction-52/NN	prep_with||treated-49/VBN||phase-53/NN	det||regimen-60/NN||the-55/DT	amod||regimen-60/NN||high-dose-56/JJ	nn||regimen-60/NN||ifn-î-57/NNP	nn||regimen-60/NN||±-58/NNP	amod||regimen-60/NN||2b-59/JJ	prep_of||phase-53/NN||regimen-60/NN	melanoma-48||ifn--1||yes||the study objective was to explore the immunomodulatory mechanism of action for ifn-î± 2b by measuring serum regulatory t cell (treg), serum transforming growth factor-î² (tgf-î²), interleukin (il)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose ifn-î± 2b regimen.
det||approach-3/NN||a-1/DT	amod||approach-3/NN||similar-2/JJ	nsubj||helpful-6/JJ||approach-3/NN	nsubj||identify-8/VB||approach-3/NN	aux||helpful-6/JJ||can-4/MD	cop||helpful-6/JJ||be-5/VB	root||ROOT-0/null||helpful-6/JJ	aux||identify-8/VB||to-7/TO	xcomp||helpful-6/JJ||identify-8/VB	advmod||relevant-10/JJ||biologically-9/RB	amod||targets-14/NNS||relevant-10/JJ	advmod||meaningful-13/JJ||clinically-12/RB	conj_and||relevant-10/JJ||meaningful-13/JJ	amod||targets-14/NNS||meaningful-13/JJ	dobj||identify-8/VB||targets-14/NNS	amod||infection-20/NN||m.tuberculosis-16/JJ	appos||infection-20/NN||mtb-18/NN	prep_in||identify-8/VB||infection-20/NN	nn||development-26/NN||diagnosis-22/NN	conj_or||diagnosis-22/NN||tb-24/NN	nn||development-26/NN||tb-24/NN	nn||development-26/NN||vaccine-25/NN	prep_for||infection-20/NN||development-26/NN	advmod||defined-30/JJ||clinically-28/RB	advmod||defined-30/JJ||well-29/RB	amod||populations-31/NNS||defined-30/JJ	prep_in||identify-8/VB||populations-31/NNS	tuberculosis--1||mtb-18||no||a similar approach can be helpful to identify biologically relevant and clinically meaningful targets in m.tuberculosis (mtb) infection for diagnosis or tb vaccine development in clinically well defined populations.
amod||trials-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||trials-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	det||benefits-6/NNS||the-5/DT	dobj||shown-4/VBN||benefits-6/NNS	amod||inhibitors-9/NNS||acetylcholinesterase-8/JJ	prep_of||benefits-6/NNS||inhibitors-9/NNS	prep_such_as||benefits-6/NNS||donepezil-13/JJ	prep_such_as||benefits-6/NNS||galantamine-15/JJ	conj_and||donepezil-13/JJ||galantamine-15/JJ	det||n-19/NN||an-18/DT	prep_such_as||benefits-6/NNS||n-19/NN	conj_and||donepezil-13/JJ||n-19/NN	amod||antagonist-23/NN||methyl-d-aspartate-21/JJ	nn||antagonist-23/NN||receptor-22/NN	dep||n-19/NN||antagonist-23/NN	appos||antagonist-23/NN||memantine-25/NN	prep_in||benefits-6/NNS||patients-28/NNS	prepc_with||patients-28/NNS||alzheimerâ-30/VBG	num||disease-34/NN||$-31/$	number||s-33/CD||™-32/CD	num||$-31/$||s-33/CD	dobj||alzheimerâ-30/VBG||disease-34/NN	appos||disease-34/NN||ad-36/NN	alzheimer--1||donepezil-13||yes||clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an n -methyl-d-aspartate receptor antagonist, memantine, in patients with alzheimerâ€™s disease (ad).
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||amoxicillin-20||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
nsubj||displayed-6/VBD||replacement-1/NN	prep_of||replacement-1/NN||lamivudine-3/NN	prep_by||lamivudine-3/NN||adefovir-5/NN	root||ROOT-0/null||displayed-6/VBD	neg||advantage-8/NN||no-7/DT	dobj||displayed-6/VBD||advantage-8/NN	det||lack-11/NN||the-10/DT	prep_despite||displayed-6/VBD||lack-11/NN	nn||mutations-14/NNS||resistance-13/NN	prep_of||lack-11/NN||mutations-14/NNS	advmod||displayed-6/VBD||thus-16/RB	neg||decrease-18/NN||no-17/DT	nsubjpass||observed-22/VBN||decrease-18/NN	prep_in||decrease-18/NN||viremia-20/NN	auxpass||observed-22/VBN||was-21/VBD	parataxis||displayed-6/VBD||observed-22/VBN	nn||treatment-25/NN||adefovir-24/NN	prep_under||observed-22/VBN||treatment-25/NN	viremia-20||adefovir-24||no_rel||replacement of lamivudine by adefovir displayed no advantage despite the lack of resistance mutations, thus no decrease in viremia was observed under adefovir treatment.
amod||resistance-3/NN||primary-1/JJ	amod||resistance-3/NN||glucocorticoid-2/JJ	nsubj||hereditarydisease-11/NN||resistance-3/NN	appos||resistance-3/NN||omim-5/NN	num||omim-5/NN||138040-6/CD	cop||hereditarydisease-11/NN||is-8/VBZ	det||hereditarydisease-11/NN||a-9/DT	amod||hereditarydisease-11/NN||rare-10/JJ	root||ROOT-0/null||hereditarydisease-11/NN	nsubj||causes-13/VBZ||hereditarydisease-11/NN	rcmod||hereditarydisease-11/NN||causes-13/VBZ	det||insensitivity-17/NN||a-14/DT	amod||insensitivity-17/NN||generalized-15/JJ	amod||insensitivity-17/NN||partial-16/JJ	dobj||causes-13/VBZ||insensitivity-17/NN	amod||action-20/NN||glucocorticoid-19/JJ	prep_to||causes-13/VBZ||action-20/NN	acomp||causes-13/VBZ||due-22/JJ	amod||alterations-25/NNS||genetic-24/JJ	prep_to||due-22/JJ||alterations-25/NNS	det||receptor-29/NN||the-27/DT	amod||receptor-29/NN||glucocorticoid-28/JJ	prep_of||alterations-25/NNS||receptor-29/NN	appos||receptor-29/NN||gr-31/NN	hereditarydisease-11||glucocorticoid-28||no_rel||primary glucocorticoid resistance (omim 138040) is a rare hereditarydisease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (gr).
nn||detemir-2/NN||insulin-1/NN	nsubj||analog-7/NN||detemir-2/NN	cop||analog-7/NN||is-3/VBZ	det||analog-7/NN||a-4/DT	amod||analog-7/NN||basal-5/JJ	nn||analog-7/NN||insulin-6/NN	root||ROOT-0/null||analog-7/NN	nsubj||provides-9/VBZ||analog-7/NN	rcmod||analog-7/NN||provides-9/VBZ	amod||options-12/NNS||effective-10/JJ	amod||options-12/NNS||therapeutic-11/JJ	dobj||provides-9/VBZ||options-12/NNS	prep_for||options-12/NNS||patients-14/NNS	prep_with||patients-14/NNS||type-16/NN	num||type-16/NN||1-17/CD	prep_with||patients-14/NNS||type2diabetes-19/NNS	conj_and||type-16/NN||type2diabetes-19/NNS	type2diabetes-19||insulin-6||yes||insulin detemir is a basal insulin analog that provides effective therapeutic options for patients with type 1 and type2diabetes.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||data-4/NNS||limited-3/VBN	nsubj||is-2/VBZ||data-4/NNS	prep_on||data-4/NNS||lamivudine-6/NN	amod||patients-10/NNS||renal-8/JJ	nn||patients-10/NNS||transplant-9/NN	prep_in||data-4/NNS||patients-10/NNS	nn||infection-13/NN||hbv-12/NN	prep_with||data-4/NNS||infection-13/NN	neg||report-17/NN||no-15/DT	amod||report-17/NN||published-16/VBN	nsubj||is-2/VBZ||report-17/NN	conj_and||data-4/NNS||report-17/NN	prep_from||report-17/NN||india-19/NN	hbv-12||lamivudine-6||yes||there is limited data on lamivudine in renal transplant patients with hbv infection and no published report from india.
nsubj||fos-like-10/JJ||genes-1/NNS	det||upregulation-5/NN||the-3/DT	amod||upregulation-5/NN||strongest-4/JJS	prep_with||genes-1/NNS||upregulation-5/NN	nn||activation-8/NN||receptor-7/NN	prep_after||upregulation-5/NN||activation-8/NN	cop||fos-like-10/JJ||were-9/VBD	root||ROOT-0/null||fos-like-10/JJ	dep||fos-like-10/JJ||antigen-11/NN	num||antigen-11/NN||1-12/CD	appos||antigen-11/NN||fosl1-14/NNP	advmod||egr1-22/NN||early-17/RB	nn||egr1-22/NN||growth-18/NN	nn||egr1-22/NN||response-19/NN	num||egr1-22/NN||1-20/CD	appos||antigen-11/NN||egr1-22/NN	appos||antigen-11/NN||osteopontin-25/NN	appos||osteopontin-25/NN||opn-27/NN	amod||protein-34/NN||insulin-like-30/JJ	nn||protein-34/NN||growth-31/NN	nn||protein-34/NN||factor-32/NN	amod||protein-34/NN||binding-33/JJ	appos||antigen-11/NN||protein-34/NN	conj_and||osteopontin-25/NN||protein-34/NN	dep||protein-34/NN||3-35/CD	appos||protein-34/NN||igfbp3-37/NNP	amod||phosphatase-41/NN||dual-specificity-40/JJ	appos||antigen-11/NN||phosphatase-41/NN	conj_and||osteopontin-25/NN||phosphatase-41/NN	dep||phosphatase-41/NN||4-42/CD	appos||4-42/CD||dusp4-44/NNP	amod||l6-50/NNS||tumor-associated-48/JJ	nn||l6-50/NNS||antigen-49/NN	appos||antigen-11/NN||l6-50/NNS	conj_and||osteopontin-25/NN||l6-50/NNS	appos||l6-50/NNS||taal6-52/NNP	insulin--1||tumor--1||no_rel||genes with the strongest upregulation after receptor activation were fos-like antigen 1 ( fosl1 ), early growth response 1 ( egr1 ), osteopontin ( opn ), insulin-like growth factor binding protein 3 ( igfbp3 ), dual-specificity phosphatase 4 ( dusp4 ), and tumor-associated antigen l6 ( taal6 ).
amod||anesthesia-3/NN||ketamine/xylazine-1/JJ	nn||anesthesia-3/NN||cocktail-2/NN	nsubj||caused-4/VBD||anesthesia-3/NN	root||ROOT-0/null||caused-4/VBD	det||hypertension-7/NN||a-5/DT	amod||hypertension-7/NN||transient-6/JJ	dobj||caused-4/VBD||hypertension-7/NN	det||cats-10/NNS||the-9/DT	prep_in||caused-4/VBD||cats-10/NNS	nsubj||inhibited-13/VBD||ea-12/NN	nsubj||shortened-18/VBN||ea-12/NN	parataxis||caused-4/VBD||inhibited-13/VBD	det||hypertension-16/NN||this-14/DT	amod||hypertension-16/NN||anesthetic-induced-15/JJ	dobj||inhibited-13/VBD||hypertension-16/NN	parataxis||caused-4/VBD||shortened-18/VBN	conj_and||inhibited-13/VBD||shortened-18/VBN	det||time-22/NN||the-19/DT	amod||time-22/NN||post-anesthesia-20/JJ	nn||time-22/NN||recovery-21/NN	dobj||shortened-18/VBN||time-22/NN	hypertension-16||ea-12||yes||ketamine/xylazine cocktail anesthesia caused a transient hypertension in the cats; ea inhibited this anesthetic-induced hypertension and shortened the post-anesthesia recovery time.
det||end-3/NN||the-2/DT	prep_by||comparable-25/JJ||end-3/NN	det||day-8/NN||the-5/DT	amod||day-8/NN||first-6/JJ	nn||day-8/NN||postoperative-7/NN	prep_of||end-3/NN||day-8/NN	det||proportion-11/NN||the-10/DT	nsubj||comparable-25/JJ||proportion-11/NN	nn||responders-14/NNS||treatment-13/NN	prep_of||proportion-11/NN||responders-14/NNS	vmod||responders-14/NNS||based-15/VBN	nn||satisfaction-18/NN||treatment-17/NN	prep_on||based-15/VBN||satisfaction-18/NN	amod||variable-22/NN||primary-20/JJ	amod||variable-22/NN||efficacy-21/JJ	appos||satisfaction-18/NN||variable-22/NN	cop||comparable-25/JJ||was-24/VBD	root||ROOT-0/null||comparable-25/JJ	det||groups-28/NNS||the-27/DT	prep_between||comparable-25/JJ||groups-28/NNS	num||%-31/NN||78.1-30/CD	dep||groups-28/NNS||%-31/NN	dep||%-31/NN||combination-32/NN	dep||%-35/NN||71.9-34/CD	advmod||%-31/NN||%-35/NN	dep||%-31/NN||tramadol-36/NN	dep||tramadol-36/NN||p-38/NN	dep||0.24-40/CD||=-39/SYM	rcmod||p-38/NN||0.24-40/CD	amod||intensity-45/NN||mean-43/JJ	nn||intensity-45/NN||pain-44/NN	nsubjpass||reduced-66/VBN||intensity-45/NN	dep||intensity-45/NN||rated-47/VBN	det||scale-51/NN||a-49/DT	amod||scale-51/NN||numerical-50/JJ	prep_on||rated-47/VBN||scale-51/NN	prep_from||scale-51/NN||0-53/CD	dep||pain-56/NN||=-54/SYM	neg||pain-56/NN||no-55/DT	rcmod||0-53/CD||pain-56/NN	number||=-59/NN||10-58/CD	amod||pain-62/NN||=-59/NN	dep||imaginable-61/JJ||worst-60/JJS	amod||pain-62/NN||imaginable-61/JJ	prep_to||rated-47/VBN||pain-62/NN	aux||reduced-66/VBN||had-64/VBD	auxpass||reduced-66/VBN||been-65/VBN	conj_and||comparable-25/JJ||reduced-66/VBN	number||â-69/CD||1.7-68/CD	num||2.0-71/CD||â-69/CD	number||2.0-71/CD||±-70/CD	prep_to||reduced-66/VBN||2.0-71/CD	det||groups-74/NNS||both-73/DT	prep_for||reduced-66/VBN||groups-74/NNS	pain-62||tramadol-36||yes||by the end of the first postoperative day, the proportion of treatment responders based on treatment satisfaction (primary efficacy variable) was comparable between the groups (78.1% combination, 71.9% tramadol; p = 0.24) and mean pain intensity (rated on a numerical scale from 0 = no pain to 10 = worst imaginable pain) had been reduced to 1.7 â± 2.0 for both groups.
nsubj||has-2/VBZ||eslicarbazepine-1/NN	root||ROOT-0/null||has-2/VBZ	amod||affinity-4/NN||similar-3/JJ	dobj||has-2/VBZ||affinity-4/NN	amod||channels-8/NNS||inactivated-6/JJ	nn||channels-8/NNS||sodium-7/NN	prep_to||affinity-4/NN||channels-8/NNS	dep||affinity-4/NN||channels-10/NNS	advmod||neurons-14/NNS||just-12/RB	amod||neurons-14/NNS||activated-13/VBN	prep_in||channels-10/NNS||neurons-14/NNS	advmod||carbamazepine-17/JJ||as-16/RB	amod||affinity-4/NN||carbamazepine-17/JJ	amod||affinity-4/NN||greater-20/JJR	conj_and||carbamazepine-17/JJ||greater-20/JJR	advmod||has-2/VBZ||efficacy-21/RB	nn||models-24/NNS||animal-23/NN	prep_in||has-2/VBZ||models-24/NNS	prep_of||models-24/NNS||seizure-26/NN	prep_than||seizure-26/NN||oxcarbazepine-28/NN	seizure-26||carbamazepine-17||no_rel||eslicarbazepine has similar affinity to inactivated sodium channels (channels in just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than oxcarbazepine.
advmod||suppressed-5/VBD||furthermore-1/RB	nn||potently-4/NN||capsaicin-3/NN	nsubj||suppressed-5/VBD||potently-4/NN	root||ROOT-0/null||suppressed-5/VBD	det||growth-7/NN||the-6/DT	dobj||suppressed-5/VBD||growth-7/NN	amod||tumors-12/NNS||h69-9/JJ	amod||tumors-12/NNS||human-10/JJ	amod||tumors-12/NNS||sclc-11/JJ	prep_of||growth-7/NN||tumors-12/NNS	prep_in||tumors-12/NNS||vivo-14/NN	amod||models-23/NNS||ascertained-16/JJ	nn||assays-19/NNS||cam-18/NN	prep_by||ascertained-16/JJ||assays-19/NNS	amod||mice-22/NNS||nude-21/JJ	prep_by||ascertained-16/JJ||mice-22/NNS	conj_and||assays-19/NNS||mice-22/NNS	prep_as||suppressed-5/VBD||models-23/NNS	tumors-12||capsaicin-3||no_rel||furthermore, capsaicin potently suppressed the growth of h69 human sclc tumors in vivo as ascertained by cam assays and nude mice models.
root||ROOT-0/null||participants-1/NNS	num||women-3/NNS||25-2/CD	dep||participants-1/NNS||women-3/NNS	prep_with||women-3/NNS||body-5/NN	amod||index-7/NN||mass-6/JJ	dep||participants-1/NNS||index-7/NN	appos||index-7/NN||bmi-9/NN	amod||index-7/NN||>-11/JJ	dep||>-11/JJ||25-12/CD	amod||intracranialhypertension-34/NN||active-15/JJ	dep||active-15/JJ||papilloedema-17/NN	amod||h2o-24/NN||intracranial-19/JJ	nn||h2o-24/NN||pressure-20/NN	nn||h2o-24/NN||>-21/NN	num||h2o-24/NN||25-22/CD	nn||h2o-24/NN||cm-23/NN	dep||active-15/JJ||h2o-24/NN	conj_and||papilloedema-17/NN||h2o-24/NN	dep||intracranialhypertension-34/NN||chronic-27/NN	num||months-31/NNS||three-30/CD	prep_over||intracranialhypertension-34/NN||months-31/NNS	amod||intracranialhypertension-34/NN||idiopathic-33/JJ	prep_with||participants-1/NNS||intracranialhypertension-34/NN	papilloedema-17||intracranialhypertension-34||no||participants 25 women with body mass index (bmi) >25, with active (papilloedema and intracranial pressure >25 cm h2o), chronic (over three months) idiopathic intracranialhypertension.
det||reduction-3/NN||a-1/DT	amod||reduction-3/NN||significant-2/JJ	nsubjpass||observed-11/VBN||reduction-3/NN	amod||cholesterol-6/NN||total-5/JJ	prep_in||reduction-3/NN||cholesterol-6/NN	nn||concentrations-9/NNS||ldl-cholesterol-8/NN	prep_in||reduction-3/NN||concentrations-9/NNS	conj_and||cholesterol-6/NN||concentrations-9/NNS	auxpass||observed-11/VBN||was-10/VBD	root||ROOT-0/null||observed-11/VBN	det||month-15/NN||the-13/DT	amod||month-15/NN||first-14/JJ	prep_during||observed-11/VBN||month-15/NN	prep_of||month-15/NN||treatment-17/NN	xcomp||observed-11/VBN||suggesting-19/VBG	mark||used-29/VBN||that-20/IN	det||administration-22/NN||the-21/DT	nsubjpass||used-29/VBN||administration-22/NN	nn||lecithin-25/NN||soy-24/NN	prep_of||administration-22/NN||lecithin-25/NN	advmod||used-29/VBN||daily-26/RB	aux||used-29/VBN||may-27/MD	auxpass||used-29/VBN||be-28/VB	ccomp||suggesting-19/VBG||used-29/VBN	det||treatment-33/NN||a-31/DT	amod||treatment-33/NN||supplemental-32/JJ	prep_as||used-29/VBN||treatment-33/NN	prep_in||treatment-33/NN||hypercholesterolemia-35/NN	hypercholesterolemia-35||cholesterol-6||no||a significant reduction in total cholesterol and ldl-cholesterol concentrations was observed during the first month of treatment, suggesting that the administration of soy lecithin daily may be used as a supplemental treatment in hypercholesterolemia.
det||strains-4/NNS||these-1/DT	amod||strains-4/NNS||h1n1-2/JJ	nn||strains-4/NNS||siv-3/NN	nsubjpass||related-7/VBN||strains-4/NNS	auxpass||related-7/VBN||were-5/VBD	advmod||related-7/VBN||closely-6/RB	root||ROOT-0/null||related-7/VBN	amod||influenzaviruses-11/NNS||other-9/JJ	nn||influenzaviruses-11/NNS||subtype-10/NN	prep_to||related-7/VBN||influenzaviruses-11/NNS	dep||related-7/VBN||especially-13/RB	prep_to||related-7/VBN||humaninfluenzaviruses-15/NNS	humaninfluenza--1||influenzaviruses-11||no||these h1n1 siv strains were closely related to other subtype influenzaviruses, especially to humaninfluenzaviruses.
det||incidence-2/NN||the-1/DT	nsubj||lower-9/JJR||incidence-2/NN	amod||pain-6/NN||microemulsion-4/JJ	amod||pain-6/NN||propofol-induced-5/JJ	prep_of||incidence-2/NN||pain-6/NN	cop||lower-9/JJR||was-7/VBD	advmod||lower-9/JJR||significantly-8/RB	root||ROOT-0/null||lower-9/JJR	det||group-25/NN||the-11/DT	nn||group-25/NN||lr-12/NN	num||lr-12/NN||0.3-13/CD	conj_and||lr-12/NN||lr-15/NN	nn||group-25/NN||lr-15/NN	num||lr-15/NN||0.5-16/CD	advmod||lr-12/NN||lr-18/RB	conj_and||lr-12/NN||lr-18/RB	nn||group-25/NN||lr-18/RB	num||groups-20/NNS||1.0-19/CD	npadvmod||than-21/IN||groups-20/NNS	advmod||lr-12/NN||than-21/IN	det||ls-24/NN||the-23/DT	prep_in||lr-12/NN||ls-24/NN	prep_in||lower-9/JJR||group-25/NN	num||%-28/NN||37.5-27/CD	dep||group-25/NN||%-28/NN	num||%-31/NN||12.5-30/CD	dep||group-25/NN||%-31/NN	conj_and||%-28/NN||%-31/NN	num||vs-35/NN||10-33/CD	nn||vs-35/NN||%-34/NN	dep||group-25/NN||vs-35/NN	conj_and||%-28/NN||vs-35/NN	num||%-37/NN||65-36/CD	dep||vs-35/NN||%-37/NN	advmod||vs-35/NN||respectively-39/RB	pain-6||propofol--1||yes||the incidence of microemulsion propofol-induced pain was significantly lower in the lr 0.3, lr 0.5 and lr 1.0 groups than in the ls group (37.5%, 12.5% and 10% vs 65%, respectively).
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	hyperglycemia-24||insulin-2||yes||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
advmod||remains-6/VBZ||however-1/RB	nsubj||remains-6/VBZ||stigma-3/NN	conj_and||stigma-3/NN||discrimination-5/NN	nsubj||remains-6/VBZ||discrimination-5/NN	root||ROOT-0/null||remains-6/VBZ	amod||obstacles-8/NNS||major-7/JJ	xcomp||remains-6/VBZ||obstacles-8/NNS	prep_for||remains-6/VBZ||people-10/NNS	vmod||people-10/NNS||living-11/VBG	prep_with||living-11/VBG||hiv/aids-13/NNS	vmod||hiv/aids-13/NNS||trying-14/VBG	nn||services-17/NNS||access-16/NN	prep_to||trying-14/VBG||services-17/NNS	aids--1||hiv--1||no||however, stigma and discrimination remains major obstacles for people living with hiv/aids trying to access services.
aux||examine-2/VB||to-1/TO	advcl||received-14/VBD||examine-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||phosphate-binding-4/JJ	dobj||examine-2/VB||efficacy-5/NN	nsubj||received-14/VBD||rats-7/NNS	amod||function-11/NN||normal-9/JJ	amod||function-11/NN||renal-10/JJ	prep_with||rats-7/NNS||function-11/NN	prep_with||rats-7/NNS||chronicrenalfailure-13/NN	conj_and||function-11/NN||chronicrenalfailure-13/NN	root||ROOT-0/null||received-14/VBD	nn||carbonate-16/NN||lanthanum-15/NN	dobj||received-14/VBD||carbonate-16/NN	nn||hydroxide-19/NN||aluminum-18/NN	dobj||received-14/VBD||hydroxide-19/NN	conj_or||carbonate-16/NN||hydroxide-19/NN	dobj||received-14/VBD||calciumcarbonate-21/NN	conj_or||carbonate-16/NN||calciumcarbonate-21/NN	nn||hydrochloride-25/NN||sevelamer-24/NN	dobj||received-14/VBD||hydrochloride-25/NN	conj_or||carbonate-16/NN||hydrochloride-25/NN	amod||models-29/NNS||several-27/JJ	amod||models-29/NNS||experimental-28/JJ	prep_in||received-14/VBD||models-29/NNS	chronicrenalfailure-13||calciumcarbonate-21||yes||to examine the phosphate-binding efficacy, rats with normal renal function and chronicrenalfailure received lanthanum carbonate, aluminum hydroxide, calciumcarbonate, or sevelamer hydrochloride in several experimental models.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||accurate-7/JJ||that-3/IN	det||tests-5/NNS||both-4/DT	nsubj||accurate-7/JJ||tests-5/NNS	nsubj||detect-9/VB||tests-5/NNS	cop||accurate-7/JJ||are-6/VBP	ccomp||conclude-2/VBP||accurate-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||accurate-7/JJ||detect-9/VB	nn||tuberculosis-11/NNP||latent-10/NNP	dobj||detect-9/VB||tuberculosis-11/NNP	mark||have-17/VBP||although-13/IN	amod||assays-16/NNS||interferon-gamma-14/JJ	nn||assays-16/NNS||release-15/NN	nsubj||have-17/VBP||assays-16/NNS	dep||tuberculosis-11/NNP||have-17/VBP	amod||specificity-19/NN||higher-18/JJR	dobj||have-17/VBP||specificity-19/NN	nn||testing-23/NN||tuberculin-21/NN	nn||testing-23/NN||skin-22/NN	prep_than||have-17/VBP||testing-23/NN	amod||populations-26/NNS||bcg-vaccinated-25/JJ	prep_in||testing-23/NN||populations-26/NNS	advmod||received-32/VBN||particularly-28/RB	mark||received-32/VBN||if-29/IN	nsubjpass||received-32/VBN||bcg-30/NN	auxpass||received-32/VBN||is-31/VBZ	advcl||have-17/VBP||received-32/VBN	prep_after||received-32/VBN||infancy-34/NN	tuberculosis-11||bcg-30||no||we conclude that both tests are accurate to detect latent tuberculosis, although interferon-gamma release assays have higher specificity than tuberculin skin testing in bcg-vaccinated populations, particularly if bcg is received after infancy.
amod||infection-5/NN||hepatitisbvirus-1/JJ	appos||infection-5/NN||hbv-3/NN	nsubj||has-17/VBZ||infection-5/NN	prep_in||infection-5/NN||patients-7/NNS	prep_on||patients-7/NNS||hemodialysis-9/NNS	amod||transplantation-12/NN||renal-11/JJ	prep_on||patients-7/NNS||transplantation-12/NN	conj_and||hemodialysis-9/NNS||transplantation-12/NN	appos||infection-5/NN||rt-14/NN	advmod||has-17/VBZ||usually-16/RB	root||ROOT-0/null||has-17/VBZ	det||course-20/NN||an-18/DT	amod||course-20/NN||unfavorable-19/JJ	dobj||has-17/VBZ||course-20/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection in patients on hemodialysis and renal transplantation (rt) usually has an unfavorable course.
amod||syndrome-2/NN||ehlers-danlos-1/JJ	nsubj||group-9/NN||syndrome-2/NN	appos||syndrome-2/NN||eds-4/NN	cop||group-9/NN||is-6/VBZ	det||group-9/NN||a-7/DT	amod||group-9/NN||rare-8/JJ	root||ROOT-0/null||group-9/NN	amod||connectivetissuedisorder-12/NN||inheritable-11/JJ	prep_of||group-9/NN||connectivetissuedisorder-12/NN	amod||collagen-15/NN||defective-14/JJ	prep_of||connectivetissuedisorder-12/NN||collagen-15/NN	collagen-15||connectivetissuedisorder-12||no_rel||ehlers-danlos syndrome (eds) is a rare group of inheritable connectivetissuedisorder of defective collagen.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	cancer-55||fluorouracil--1||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipids-32||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
det||combination-2/NN||this-1/DT	nsubj||deserves-3/VBZ||combination-2/NN	root||ROOT-0/null||deserves-3/VBZ	amod||study-5/NN||further-4/JJ	dobj||deserves-3/VBZ||study-5/NN	prep_in||deserves-3/VBZ||bone-7/NN	prep_in||deserves-3/VBZ||jointinfection-9/NN	conj_and||bone-7/NN||jointinfection-9/NN	vmod||bone-7/NN||caused-10/VBN	amod||bacteria-16/NNS||antibiotic-12/JJ	npadvmod||positive-15/JJ||resistant-13/NN	npadvmod||positive-15/JJ||gram-14/NN	amod||bacteria-16/NNS||positive-15/JJ	agent||caused-10/VBN||bacteria-16/NNS	antibiotic-12||jointinfection-9||no_rel||this combination deserves further study in bone and jointinfection caused by antibiotic resistant gram positive bacteria.
amod||a2-3/NNS||pregnancy-associated-1/JJ	nn||a2-3/NNS||plasmaprotein-2/NN	nsubj||factor-11/NN||a2-3/NNS	appos||a2-3/NNS||pappa2-5/NNP	cop||factor-11/NN||is-7/VBZ	det||factor-11/NN||an-8/DT	amod||factor-11/NN||insulin-like-9/JJ	nn||factor-11/NN||growth-10/NN	root||ROOT-0/null||factor-11/NN	amod||protein-13/NN||binding-12/JJ	nsubj||protease-17/VBP||protein-13/NN	appos||protein-13/NN||igfbp-15/NN	rcmod||factor-11/NN||protease-17/VBP	ccomp||protease-17/VBP||expressed-18/VBN	det||placenta-21/NN||the-20/DT	prep_in||expressed-18/VBN||placenta-21/NN	ccomp||protease-17/VBP||upregulated-23/VBN	conj_and||expressed-18/VBN||upregulated-23/VBN	prep_in||upregulated-23/VBN||pregnancies-25/NNS	vmod||pregnancies-25/NNS||complicated-26/VBN	agent||complicated-26/VBN||pre-eclampsia-28/NN	pre-eclampsia-28||plasmaprotein-2||no_rel||pregnancy-associated plasmaprotein a2 (pappa2) is an insulin-like growth factor binding protein (igfbp) protease expressed in the placenta and upregulated in pregnancies complicated by pre-eclampsia.
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	obese--1||carbohydrate--1||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
amod||vasculitis-6/NNS||hydralazine-induced-1/JJ	amod||vasculitis-6/NNS||anti-neutrophil-2/JJ	amod||vasculitis-6/NNS||cytoplasmic-3/JJ	amod||vasculitis-6/NNS||antibody-positive-4/JJ	amod||vasculitis-6/NNS||renal-5/JJ	nsubj||effect-11/NN||vasculitis-6/NNS	nsubj||present-14/VB||vasculitis-6/NNS	cop||effect-11/NN||is-7/VBZ	det||effect-11/NN||a-8/DT	amod||effect-11/NN||rare-9/JJ	amod||effect-11/NN||adverse-10/JJ	root||ROOT-0/null||effect-11/NN	aux||present-14/VB||can-13/MD	conj_and||effect-11/NN||present-14/VB	det||syndrome-19/NN||a-16/DT	amod||syndrome-19/NN||severe-17/JJ	amod||syndrome-19/NN||vasculitic-18/JJ	prep_with||present-14/VB||syndrome-19/NN	amod||involvement-23/NN||multiple-21/JJ	nn||involvement-23/NN||organ-22/NN	prep_with||syndrome-19/NN||involvement-23/NN	vasculitis-6||hydralazine--1||no_rel||hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis is a rare adverse effect and can present with a severe vasculitic syndrome with multiple organ involvement.
amod||lupuserythematosus-2/NNS||systemic-1/JJ	nsubj||autoimmunedisease-9/NN||lupuserythematosus-2/NNS	appos||lupuserythematosus-2/NNS||sle-4/NN	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||systemic-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	vmod||autoimmunedisease-9/NN||characterized-10/VBN	amod||interferons-15/NNS||increased-12/VBN	nn||interferons-15/NNS||type-13/NN	amod||interferons-15/NNS||i-14/VBG	agent||characterized-10/VBN||interferons-15/NNS	dep||autoimmunedisease-9/NN||ifns-17/NNS	nn||inflammation-21/NN||multiorgan-20/NN	conj_and||autoimmunedisease-9/NN||inflammation-21/NN	advmod||targeting-23/VBG||frequently-22/RB	vmod||inflammation-21/NN||targeting-23/VBG	det||skin-25/NN||the-24/DT	dobj||targeting-23/VBG||skin-25/NN	interferons-15||autoimmunedisease-9||no_rel||systemic lupuserythematosus (sle) is a systemic autoimmunedisease characterized by increased type i interferons (ifns) and multiorgan inflammation frequently targeting the skin.
nsubj||occurs-18/VBZ||infection-1/NN	nsubj||occurs-18/VBZ||infection-1/NN	amod||titers-4/NNS||high-3/JJ	prep_with||infection-1/NN||titers-4/NNS	prep_of||titers-4/NNS||ebv-6/NN	amod||cells-12/NNS||mixed-8/JJ	amod||cells-12/NNS||primary-10/JJ	amod||cells-12/NNS||b-11/JJ	prep_of||ebv-6/NN||cells-12/NNS	amod||stages-15/NNS||different-14/JJ	prep_in||cells-12/NNS||stages-15/NNS	prep_of||stages-15/NNS||differentiation-17/NN	root||ROOT-0/null||occurs-18/VBZ	conj_and||occurs-18/VBZ||occurs-18/VBZ	amod||ebvinfection-21/NN||primary-20/JJ	prep_during||occurs-18/VBZ||ebvinfection-21/NN	det||setting-25/NN||the-24/DT	prep_in||occurs-18/VBZ||setting-25/NN	nsubj||predisposes-30/VBZ||setting-25/NN	nn||cell-immunocompromise-28/NN||t-27/NN	prep_of||setting-25/NN||cell-immunocompromise-28/NN	rcmod||setting-25/NN||predisposes-30/VBZ	prep_to||predisposes-30/VBZ||development-32/NN	amod||diseases-35/NNS||ebv-lymphoproliferative-34/JJ	prep_of||development-32/NN||diseases-35/NNS	ebvinfection-21||ebv-6||no||infection with high titers of ebv of mixed, primary b cells in different stages of differentiation occurs during primary ebvinfection and in the setting of t cell-immunocompromise that predisposes to development of ebv-lymphoproliferative diseases.
nsubj||increases-6/VBZ||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||increases-6/VBZ||infection-5/RB	root||ROOT-0/null||increases-6/VBZ	det||risk-8/NN||the-7/DT	dobj||increases-6/VBZ||risk-8/NN	nn||carcinoma-13/NN||liverdisease-10/NN	conj_and||liverdisease-10/NN||hepatocellular-12/NN	nn||carcinoma-13/NN||hepatocellular-12/NN	prep_of||risk-8/NN||carcinoma-13/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection increases the risk of liverdisease and hepatocellular carcinoma.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	formaldehyde-14||cancer-21||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
nn||discussions-2/NNS||group-1/NN	nsubjpass||conducted-7/VBN||discussions-2/NNS	amod||interviews-5/NNS||semistructured-4/JJ	conj_and||discussions-2/NNS||interviews-5/NNS	nsubjpass||conducted-7/VBN||interviews-5/NNS	auxpass||conducted-7/VBN||were-6/VBD	root||ROOT-0/null||conducted-7/VBN	prep_with||conducted-7/VBN||40-9/CD	ccomp||conducted-7/VBN||lay-10/VB	dobj||lay-10/VB||counselors-11/NNS	dobj||lay-10/VB||57-13/CD	conj_and||counselors-11/NNS||57-13/CD	advmod||observed-15/JJ||directly-14/RB	amod||supporters-20/NNS||observed-15/JJ	nn||supporters-20/NNS||therapy-16/NN	appos||supporters-20/NNS||dot-18/NNP	dep||57-13/CD||supporters-20/NNS	num||tb-24/NN||13-23/CD	dobj||lay-10/VB||tb-24/NN	conj_and||counselors-11/NNS||tb-24/NN	ccomp||conducted-7/VBN||hiv/acquiredimmunedeficiencysyndrome-26/VB	conj_and||lay-10/VB||hiv/acquiredimmunedeficiencysyndrome-26/VB	dep||hiv/acquiredimmunedeficiencysyndrome-26/VB||aids-28/VB	nn||managers-31/NNS||program-30/NN	dobj||hiv/acquiredimmunedeficiencysyndrome-26/VB||managers-31/NNS	det||province-36/NN||the-33/DT	amod||province-36/NN||free-34/JJ	nn||province-36/NN||state-35/NN	prep_in||hiv/acquiredimmunedeficiencysyndrome-26/VB||province-36/NN	prep_between||province-36/NN||september-38/NNP	num||september-38/NNP||2007-39/CD	ccomp||conducted-7/VBN||march-41/VB	conj_and||lay-10/VB||march-41/VB	dobj||march-41/VB||2008-42/CD	acquiredimmunedeficiencysyndrome--1||hiv--1||no||group discussions and semistructured interviews were conducted with 40 lay counselors, 57 directly observed therapy (dot) supporters, and 13 tb and hiv/acquiredimmunedeficiencysyndrome (aids) program managers in the free state province between september 2007 and march 2008.
nsubj||has-2/VBZ||nigeria-1/NN	root||ROOT-0/null||has-2/VBZ	det||incidence-6/NN||a-3/DT	amod||incidence-6/NN||high-4/JJ	nn||incidence-6/NN||tuberculosis-5/NNP	dobj||has-2/VBZ||incidence-6/NN	amod||studies-10/NNS||genotyping-9/VBG	nsubj||necessary-20/JJ||studies-10/NNS	prep_of||studies-10/NNS||mycobacteriumtuberculosiscomplex-12/NN	appos||mycobacteriumtuberculosiscomplex-12/NN||mtc-14/NN	det||country-18/NN||the-17/DT	prep_in||mycobacteriumtuberculosiscomplex-12/NN||country-18/NN	cop||necessary-20/JJ||are-19/VBP	conj_and||has-2/VBZ||necessary-20/JJ	mark||improve-24/VB||in-21/IN	dep||improve-24/VB||order-22/NN	aux||improve-24/VB||to-23/TO	advcl||necessary-20/JJ||improve-24/VB	poss||understanding-26/NN||our-25/PRP$	dobj||improve-24/VB||understanding-26/NN	det||epidemic-29/NN||the-28/DT	prep_of||understanding-26/NN||epidemic-29/NN	tuberculosis-5||mycobacteriumtuberculosiscomplex-12||no||nigeria has a high tuberculosis incidence, and genotyping studies of mycobacteriumtuberculosiscomplex (mtc) in the country are necessary in order to improve our understanding of the epidemic.
nsubj||jcvirusinfection-9/NN||progressivemultifocalleukoencephalopathy-1/NN	appos||progressivemultifocalleukoencephalopathy-1/NN||pml-3/NN	cop||jcvirusinfection-9/NN||is-5/VBZ	det||jcvirusinfection-9/NN||an-6/DT	amod||jcvirusinfection-9/NN||opportunistic-7/JJ	nn||jcvirusinfection-9/NN||brain-8/NN	root||ROOT-0/null||jcvirusinfection-9/NN	nsubjpass||shown-13/VBN||jcvirusinfection-9/NN	nsubjpass||associated-16/VBN||jcvirusinfection-9/NN	aux||shown-13/VBN||has-11/VBZ	auxpass||shown-13/VBN||been-12/VBN	rcmod||jcvirusinfection-9/NN||shown-13/VBN	aux||associated-16/VBN||to-14/TO	auxpass||associated-16/VBN||be-15/VB	xcomp||shown-13/VBN||associated-16/VBN	amod||treatment-19/NN||natalizumab-18/JJ	prep_with||associated-16/VBN||treatment-19/NN	progressivemultifocalleukoencephalopathy-1||jcvirus--1||no||progressivemultifocalleukoencephalopathy (pml) is an opportunistic brain jcvirusinfection that has been shown to be associated with natalizumab treatment.
nsubj||present-3/VB||vitaminb12deficiency-1/NNS	nsubj||asymptomatic-21/JJ||vitaminb12deficiency-1/NNS	aux||present-3/VB||may-2/MD	root||ROOT-0/null||present-3/VB	amod||anaemia-6/NN||macrocytic-5/JJ	prep_as||present-3/VB||anaemia-6/NN	appos||anaemia-6/NN||subacutecombineddegeneration-8/NN	det||cord-12/NN||the-10/DT	amod||cord-12/NN||spinal-11/JJ	prep_of||subacutecombineddegeneration-8/NN||cord-12/NN	prep_as||present-3/VB||neuropathy-16/NN	conj_or||anaemia-6/NN||neuropathy-16/NN	cop||asymptomatic-21/JJ||is-19/VBZ	advmod||asymptomatic-21/JJ||often-20/RB	conj_but||present-3/VB||asymptomatic-21/JJ	amod||people-24/NNS||older-23/JJR	prep_in||asymptomatic-21/JJ||people-24/NNS	subacutecombineddegeneration-8||vitaminb12deficiency-1||no||vitaminb12deficiency may present as macrocytic anaemia, subacutecombineddegeneration of the spinal cord, or as neuropathy, but is often asymptomatic in older people.
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||exposed-23/VBD||understand-3/VB	det||mechanisms-7/NNS||the-4/DT	amod||mechanisms-7/NNS||cellular-5/JJ	amod||mechanisms-7/NNS||pathogenetic-6/JJ	dobj||understand-3/VB||mechanisms-7/NNS	prep_of||mechanisms-7/NNS||fetalalcoholspectrumdisorder-9/NN	dep||mechanisms-7/NNS||fasd-11/VBN	det||benefit-16/NN||the-14/DT	amod||benefit-16/NN||therapeutic-15/JJ	dobj||understand-3/VB||benefit-16/NN	conj_and||mechanisms-7/NNS||benefit-16/NN	nn||treatment-20/NN||stem-18/NN	nn||treatment-20/NN||cell-19/NN	prep_of||benefit-16/NN||treatment-20/NN	nsubj||exposed-23/VBD||we-22/PRP	nsubj||studied-48/VBD||we-22/PRP	root||ROOT-0/null||exposed-23/VBD	amod||rats-25/NNS||pregnant-24/JJ	dobj||exposed-23/VBD||rats-25/NNS	prep_to||exposed-23/VBD||ethanol-27/NN	vmod||ethanol-27/NN||followed-28/VBN	amod||administration-31/NN||intravenous-30/JJ	agent||followed-28/VBN||administration-31/NN	amod||cells-35/NNS||neural-33/JJ	nn||cells-35/NNS||stem-34/NN	prep_of||administration-31/NN||cells-35/NNS	appos||cells-35/NNS||nscs-37/NNS	vmod||cells-35/NNS||complexed-39/VBN	prep_with||complexed-39/VBN||atelocollagen-41/NN	det||rats-46/NNS||the-43/DT	amod||rats-46/NNS||new-44/JJ	amod||rats-46/NNS||born-45/VBN	prep_to||complexed-39/VBN||rats-46/NNS	conj_and||exposed-23/VBD||studied-48/VBD	dobj||studied-48/VBD||recovery-49/NN	amod||numbers-53/NNS||gabaergic-51/JJ	nn||numbers-53/NNS||interneuron-52/NN	prep_of||recovery-49/NN||numbers-53/NNS	amod||density-57/NN||synaptic-55/JJ	nn||density-57/NN||protein-56/NN	dobj||studied-48/VBD||density-57/NN	conj_and||recovery-49/NN||density-57/NN	det||cortex-62/NN||the-59/DT	nn||cortex-62/NN||anterior-60/NN	nn||cortex-62/NN||cingulate-61/NN	prep_in||density-57/NN||cortex-62/NN	prep_in||density-57/NN||hippocampus-64/NNS	conj_and||cortex-62/NN||hippocampus-64/NNS	prep_in||density-57/NN||amygdala-66/NN	conj_and||cortex-62/NN||amygdala-66/NN	ethanol-27||fetalalcoholspectrumdisorder-9||no_rel||to better understand the cellular pathogenetic mechanisms of fetalalcoholspectrumdisorder (fasd) and the therapeutic benefit of stem cell treatment, we exposed pregnant rats to ethanol followed by intravenous administration of neural stem cells (nscs) complexed with atelocollagen to the new born rats and studied recovery of gabaergic interneuron numbers and synaptic protein density in the anterior cingulate cortex, hippocampus and amygdala.
nsubj||form-4/NN||neurosyphilis-1/NNS	cop||form-4/NN||is-2/VBZ	det||form-4/NN||a-3/DT	root||ROOT-0/null||form-4/NN	amod||infection-7/NN||tertiarysyphilis-6/JJ	prep_of||form-4/NN||infection-7/NN	vmod||infection-7/NN||caused-8/VBN	det||treponemapallidum-13/NN||the-10/DT	amod||treponemapallidum-13/NN||spirochete-11/JJ	nn||treponemapallidum-13/NN||bacterium-12/NN	agent||caused-8/VBN||treponemapallidum-13/NN	neurosyphilis-1||bacterium-12||no||neurosyphilis is a form of tertiarysyphilis infection caused by the spirochete bacterium treponemapallidum.
nsubj||suggest-2/VBP||we-1/PRP	root||ROOT-0/null||suggest-2/VBP	mark||considered-13/VBN||that-3/IN	amod||neuropathy-6/NN||chronic-4/JJ	amod||neuropathy-6/NN||immune-mediated-5/JJ	nsubjpass||considered-13/VBN||neuropathy-6/NN	vmod||neuropathy-6/NN||associated-7/VBN	amod||virusinfection-10/NN||hepatitisb-9/JJ	prep_with||associated-7/VBN||virusinfection-10/NN	aux||considered-13/VBN||should-11/MD	auxpass||considered-13/VBN||be-12/VB	ccomp||suggest-2/VBP||considered-13/VBN	det||diagnosis-17/NN||the-15/DT	nn||diagnosis-17/NN||differential-16/NN	prep_in||considered-13/VBN||diagnosis-17/NN	prep_of||diagnosis-17/NN||patients-19/NNS	prep_with||patients-19/NNS||hepatitisb-21/NN	hepatitisb-21||hepatitisbvirus--1||no||we suggest that chronic immune-mediated neuropathy associated with hepatitisb virusinfection should be considered in the differential diagnosis of patients with hepatitisb.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||protective-2/JJ	nsubjpass||reversed-21/VBN||effect-3/NN	number||³-6/CD||ppar-î-5/CD	num||ligands-7/NNS||³-6/CD	prep_of||effect-3/NN||ligands-7/NNS	dep||12,14-prostaglandin-13/JJ||pioglitazone-9/JJ	conj_or||12,14-prostaglandin-13/JJ||15-deoxy-î-11/JJ	amod||j2-14/NNS||15-deoxy-î-11/JJ	amod||j2-14/NNS||12,14-prostaglandin-13/JJ	appos||ligands-7/NNS||j2-14/NNS	amod||injury-19/NN||gastric-17/JJ	amod||injury-19/NN||ischemia-reperfusion-18/JJ	prep_on||ligands-7/NNS||injury-19/NN	auxpass||reversed-21/VBN||was-20/VBD	root||ROOT-0/null||reversed-21/VBN	det||co-administration-24/NN||the-23/DT	agent||reversed-21/VBN||co-administration-24/NN	amod||antagonist-28/NN||ppar-î-26/JJ	amod||antagonist-28/NN||³-27/JJ	prep_with||co-administration-24/NN||antagonist-28/NN	pioglitazone-9||ischemia--1||no_rel||the protective effect of ppar-î³ ligands, pioglitazone or 15-deoxy-î”12,14-prostaglandin j2, on gastric ischemia-reperfusion injury was reversed by the co-administration with ppar-î³ antagonist.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	prep_of||treatment-7/NN||gastroesophagealrefluxdisease-9/NN	dep||treatment-7/NN||gerd-11/VBN	prep_with||review-2/VB||emphasis-14/NN	prep_on||emphasis-14/NN||protonpumpinhibitors-16/NNS	appos||protonpumpinhibitors-16/NNS||ppis-18/NNS	advmod||review-2/VB||particularly-21/RB	amod||esomeprazole-24/NN||delayed-release-23/JJ	prep_on||review-2/VB||esomeprazole-24/NN	aux||identify-28/VB||to-27/TO	conj_and||review-2/VB||identify-28/VB	dobj||identify-28/VB||properties-29/NNS	amod||effects-32/NNS||adverse-31/JJ	nsubj||observed-35/VBD||effects-32/NNS	prep_of||effects-32/NNS||ppis-34/NNS	conj_and||review-2/VB||observed-35/VBD	det||treatment-38/NN||the-37/DT	prep_in||observed-35/VBD||treatment-38/NN	prep_of||treatment-38/NN||gerd-40/NN	prep_in||observed-35/VBD||children-42/NNS	prep_in||observed-35/VBD||adolescents-44/NNS	conj_and||children-42/NNS||adolescents-44/NNS	gerd-40||protonpumpinhibitors-16||no_rel||to review the literature on the treatment of gastroesophagealrefluxdisease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
mark||remains-5/VBZ||although-1/IN	amod||loss-4/NN||orlistat-induced-2/JJ	nn||loss-4/NN||weight-3/NN	nsubj||remains-5/VBZ||loss-4/NN	advcl||produces-9/VBZ||remains-5/VBZ	acomp||remains-5/VBZ||modest-6/JJ	nsubj||produces-9/VBZ||it-8/PRP	root||ROOT-0/null||produces-9/VBZ	amod||reductions-11/NNS||meaningful-10/JJ	dobj||produces-9/VBZ||reductions-11/NNS	nn||factors-14/NNS||risk-13/NN	prep_in||produces-9/VBZ||factors-14/NNS	amod||conditions-17/NNS||obesity-related-16/JJ	prep_for||factors-14/NNS||conditions-17/NNS	prep_such_as||conditions-17/NNS||diabetes-20/NN	prep_such_as||conditions-17/NNS||cardiovasculardisease-22/NN	conj_and||diabetes-20/NN||cardiovasculardisease-22/NN	obesity--1||orlistat--1||yes||although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovasculardisease.
vmod||performed-9/VBD||using-1/VBG	amod||methods-3/NNS||statistical-2/JJ	dobj||using-1/VBG||methods-3/NNS	amod||evolution-6/NN||molecular-5/JJ	prep_of||methods-3/NNS||evolution-6/NN	nsubj||performed-9/VBD||we-8/PRP	nsubj||found-33/VBD||we-8/PRP	root||ROOT-0/null||performed-9/VBD	det||analysis-12/NN||a-10/DT	amod||analysis-12/NN||comprehensive-11/JJ	dobj||performed-9/VBD||analysis-12/NN	amod||sequences-16/NNS||jcvirus-14/JJ	amod||sequences-16/NNS||vp1-15/JJ	prep_of||analysis-12/NN||sequences-16/NNS	vmod||sequences-16/NNS||isolated-17/VBN	num||patients-21/NNS||55-19/CD	nn||patients-21/NNS||pml-20/NN	prep_from||isolated-17/VBN||patients-21/NNS	num||sequences-24/NNS||253-23/CD	prep_from||isolated-17/VBN||sequences-24/NNS	conj_and||patients-21/NNS||sequences-24/NNS	vmod||sequences-24/NNS||isolated-25/VBN	det||urine-28/NN||the-27/DT	prep_from||isolated-25/VBN||urine-28/NN	amod||individuals-31/NNS||healthy-30/JJ	prep_of||urine-28/NN||individuals-31/NNS	conj_and||performed-9/VBD||found-33/VBD	mark||acquired-46/VBN||that-34/IN	det||subset-36/NN||a-35/DT	nsubjpass||acquired-46/VBN||subset-36/NN	prep_of||subset-36/NN||aminoacids-38/NNS	vmod||aminoacids-38/NNS||found-39/VBN	advmod||found-39/VBN||exclusively-40/RB	amod||sequences-44/NNS||pml-42/JJ	amod||sequences-44/NNS||vp1-43/JJ	prep_among||found-39/VBN||sequences-44/NNS	auxpass||acquired-46/VBN||is-45/VBZ	ccomp||found-33/VBD||acquired-46/VBN	amod||evolution-49/NN||adaptive-48/JJ	prep_via||acquired-46/VBN||evolution-49/NN	pml-42||jcvirus-14||no||using statistical methods of molecular evolution, we performed a comprehensive analysis of jcvirus vp1 sequences isolated from 55 pml patients and 253 sequences isolated from the urine of healthy individuals and found that a subset of aminoacids found exclusively among pml vp1 sequences is acquired via adaptive evolution.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||study-8/VB||objective-2/NN	det||investigation-5/NN||this-4/DT	prep_of||objective-2/NN||investigation-5/NN	root||ROOT-0/null||was-6/VBD	aux||study-8/VB||to-7/TO	xcomp||was-6/VBD||study-8/VB	det||relationship-10/NN||the-9/DT	dobj||study-8/VB||relationship-10/NN	det||symptoms-13/NNS||the-12/DT	prep_between||relationship-10/NN||symptoms-13/NNS	amod||gonococcalinfections-16/NNS||female-15/JJ	prep_of||symptoms-13/NNS||gonococcalinfections-16/NNS	nn||level-20/NN||serum-18/NN	nn||level-20/NN||progesterone-19/NN	prep_of||symptoms-13/NNS||level-20/NN	conj_and||gonococcalinfections-16/NNS||level-20/NN	det||genotypes-23/NNS||the-22/DT	prep_between||relationship-10/NN||genotypes-23/NNS	conj_and||symptoms-13/NNS||genotypes-23/NNS	amod||type-28/NN||neisseriagonorrhoeae-25/JJ	amod||type-28/NN||multi-antigen-26/JJ	nn||type-28/NN||sequence-27/NN	prep_of||genotypes-23/NNS||type-28/NN	appos||type-28/NN||ng-mast-30/NN	prep_in||study-8/VB||wuhan-33/NN	appos||wuhan-33/NN||china-35/NN	gonococcalinfections-16||neisseriagonorrhoeae-25||no||the objective of this investigation was to study the relationship between the symptoms of female gonococcalinfections and serum progesterone level and the genotypes of neisseriagonorrhoeae multi-antigen sequence type (ng-mast) in wuhan, china.
advmod||tested-16/VBN||overall-1/RB	num||%-4/NN||79-3/CD	nsubjpass||tested-16/VBN||%-4/NN	nn||44â-7/NNS||range-6/NN	dep||%-4/NN||44â-7/NNS	num||%-11/NN||$-8/$	num||$-8/$||100-10/CD	dep||44â-7/NNS||%-11/NN	prep_of||%-4/NN||infants-14/NNS	auxpass||tested-16/VBN||were-15/VBD	root||ROOT-0/null||tested-16/VBN	prep_for||tested-16/VBN||hiv-18/NN	num||%-21/NN||11-20/CD	nsubj||hivpositive-33/JJ||%-21/NN	nn||3â-24/NNS||range-23/NN	dep||%-21/NN||3â-24/NNS	num||%-28/NN||$-25/$	num||$-25/$||18-27/CD	dep||3â-24/NNS||%-28/NN	prep_of||%-21/NN||them-31/PRP	cop||hivpositive-33/JJ||were-32/VBD	conj_and||tested-16/VBN||hivpositive-33/JJ	hivpositive-33||hiv-18||no||overall, 79% (range 44â€“100%) of infants were tested for hiv and 11% (range 3â€“18%) of them were hivpositive.
nn||group-2/NN||opc-1/NN	nsubj||felt-3/VBD||group-2/NN	nsubj||had-26/VBD||group-2/NN	nsubj||likely-55/JJ||group-2/NN	nsubj||require-57/VB||group-2/NN	root||ROOT-0/null||felt-3/VBD	amod||pain-5/NN||less-4/JJR	dobj||felt-3/VBD||pain-5/NN	amod||discomfort-8/NN||significant-7/JJ	dep||pain-5/NN||discomfort-8/NN	number||%-10/NN||26-9/CD	amod||discomfort-8/NN||%-10/NN	advmod||discomfort-8/NN||vs-11/RB	num||%-13/NN||58-12/CD	dep||discomfort-8/NN||%-13/NN	advmod||â-19/NN||pâ-15/RB	dep||â-19/NN||$-16/$	num||â-19/NN||‰-17/CD	amod||â-19/NN||=-18/JJ	appos||discomfort-8/NN||â-19/NN	dep||â-19/NN||$-20/$	number||.003-22/CD||‰-21/CD	num||$-20/$||.003-22/CD	conj_and||felt-3/VBD||had-26/VBD	amod||sleep-28/NN||more-27/JJR	dobj||had-26/VBD||sleep-28/NN	num||vs-31/NN||5.8-30/CD	dep||sleep-28/NN||vs-31/NN	number||â-33/CD||3.4-32/CD	num||hours-36/NNS||â-33/CD	amod||hours-36/NNS||$-34/$	dep||$-34/$||‰-35/JJ	dep||vs-31/NN||hours-36/NNS	advmod||â-42/NN||pâ-38/RB	dep||â-42/NN||$-39/$	num||â-42/NN||‰-40/CD	amod||â-42/NN||<-41/JJ	appos||vs-31/NN||â-42/NN	dep||â-42/NN||$-43/$	number||.001-45/CD||‰-44/CD	num||$-43/$||.001-45/CD	amod||preparation-50/NN||cervical-49/JJ	prep_during||had-26/VBD||preparation-50/NN	cop||likely-55/JJ||were-53/VBD	advmod||likely-55/JJ||more-54/RBR	conj_but||felt-3/VBD||likely-55/JJ	aux||require-57/VB||to-56/TO	xcomp||likely-55/JJ||require-57/VB	nn||iol-59/NN||oxytocin-58/NN	dobj||require-57/VB||iol-59/NN	num||vs-62/NN||88-61/CD	dep||iol-59/NN||vs-62/NN	number||%-64/NN||59-63/CD	amod||vs-62/NN||%-64/NN	advmod||â-70/NN||pâ-66/RB	dep||â-70/NN||$-67/$	num||â-70/NN||‰-68/CD	amod||â-70/NN||=-69/JJ	appos||vs-62/NN||â-70/NN	dep||â-70/NN||$-71/$	number||.001-73/CD||‰-72/CD	num||$-71/$||.001-73/CD	oxytocin-58||pain-5||no_rel||opc group felt less pain (significant discomfort 26% vs 58%, pâ€‰=â€‰.003), and had more sleep (5.8 vs 3.4â€‰hours, pâ€‰<â€‰.001), during cervical preparation, but were more likely to require oxytocin iol (88 vs 59%, pâ€‰=â€‰.001).
nsubjpass||transmitted-11/VBN||lymedisease-1/NN	vmod||lymedisease-1/NN||caused-3/VBN	amod||species-6/NNS||various-5/JJ	agent||caused-3/VBN||species-6/NNS	prep_of||species-6/NNS||borrelia-8/NN	auxpass||transmitted-11/VBN||is-10/VBZ	root||ROOT-0/null||transmitted-11/VBN	amod||ticks-14/NNS||ixodes-13/JJ	agent||transmitted-11/VBN||ticks-14/NNS	nn||america-17/NN||north-16/NN	prep_in||ticks-14/NNS||america-17/NN	prep_in||ticks-14/NNS||europe-19/NN	conj_and||america-17/NN||europe-19/NN	lymedisease-1||borrelia-8||no||lymedisease, caused by various species of borrelia , is transmitted by ixodes ticks in north america and europe.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	crystal-4||rta-22||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
nsubj||drugs-14/NNS||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	amod||sulfate-7/NN||glucosamine-6/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-7/NN	nsubj||drugs-14/NNS||sulfate-7/NN	appos||sulfate-7/NN||gs-9/NN	cop||drugs-14/NNS||are-11/VBP	amod||drugs-14/NNS||symptomatic-12/JJ	amod||drugs-14/NNS||slow-acting-13/JJ	root||ROOT-0/null||drugs-14/NNS	prep_for||drugs-14/NNS||osteoarthritis-16/NNS	appos||osteoarthritis-16/NNS||oa-18/NN	advmod||used-21/VBN||widely-20/RB	vmod||osteoarthritis-16/NNS||used-21/VBN	prep_in||used-21/VBN||clinic-23/NN	oa-18||chondroitinsulfate-1||yes||chondroitinsulfate (cs) and glucosamine sulfate (gs) are symptomatic slow-acting drugs for osteoarthritis (oa) widely used in clinic.
amod||infection-2/NN||symptomatic-1/JJ	nsubj||range-9/VB||infection-2/NN	prep_by||infection-2/NN||denguevirus-4/NNS	appos||denguevirus-4/NNS||denv-6/NNP	aux||range-9/VB||can-8/MD	ccomp||understood-33/VBN||range-9/VB	prep_from||range-9/VB||denguefever-11/NN	appos||denguefever-11/NN||df-13/NN	prep_to||range-9/VB||denguehaemorrhagicfever-16/NN	appos||denguehaemorrhagicfever-16/NN||dhf-18/NN	advmod||range-9/VB||however-21/RB	det||determinants-24/NNS||the-23/DT	nsubjpass||understood-33/VBN||determinants-24/NNS	nn||progression-29/NN||df-26/NN	conj_or||df-26/NN||dhf-28/NN	nn||progression-29/NN||dhf-28/NN	prep_of||determinants-24/NNS||progression-29/NN	auxpass||understood-33/VBN||are-30/VBP	neg||understood-33/VBN||not-31/RB	advmod||understood-33/VBN||completely-32/RB	root||ROOT-0/null||understood-33/VBN	denguefever-11||denguevirus-4||no||symptomatic infection by denguevirus (denv) can range from denguefever (df) to denguehaemorrhagicfever (dhf), however, the determinants of df or dhf progression are not completely understood.
predet||patients-3/NNS||both-1/PDT	det||patients-3/NNS||the-2/DT	nsubj||were-4/VBD||patients-3/NNS	root||ROOT-0/null||were-4/VBD	prep_on||were-4/VBD||anticoagulants-6/NNS	prep_on||were-4/VBD||warfarin-8/NN	conj_and||anticoagulants-6/NNS||warfarin-8/NN	prep_on||were-4/VBD||heparin-10/NN	conj_and||anticoagulants-6/NNS||heparin-10/NN	prep_in||were-4/VBD||one-12/CD	prep_in||were-4/VBD||aspirin-14/NN	conj_and||one-12/CD||aspirin-14/NN	conj_and||one-12/CD||clopidogrel-16/NN	conj_and||aspirin-14/NN||clopidogrel-16/NN	det||other-19/JJ||the-18/DT	prep_in||aspirin-14/NN||other-19/JJ	nn||profile-23/NN||abnormalcoagulation-22/NN	prep_with||were-4/VBD||profile-23/NN	det||former-26/JJ||the-25/DT	prep_in||profile-23/NN||former-26/JJ	abnormalcoagulation-22||clopidogrel-16||no||both the patients were on anticoagulants, warfarin and heparin in one and aspirin and clopidogrel in the other, with abnormalcoagulation profile in the former.
nsubj||alternative-5/NN||daptomycin-1/NN	cop||alternative-5/NN||was-2/VBD	det||alternative-5/NN||an-3/DT	amod||alternative-5/NN||effective-4/JJ	root||ROOT-0/null||alternative-5/NN	aux||vancomycin/gentamicin-7/VB||to-6/TO	vmod||alternative-5/NN||vancomycin/gentamicin-7/VB	nn||bacteraemia-10/NN||mrsa-9/NN	prep_for||vancomycin/gentamicin-7/VB||bacteraemia-10/NN	amod||endocarditis-13/NNS||right-sided-12/JJ	prep_for||vancomycin/gentamicin-7/VB||endocarditis-13/NNS	conj_or||bacteraemia-10/NN||endocarditis-13/NNS	mrsa-9||daptomycin-1||no_rel||daptomycin was an effective alternative to vancomycin/gentamicin for mrsa bacteraemia or right-sided endocarditis.
det||comparison-2/NN||a-1/DT	nsubjpass||made-17/VBN||comparison-2/NN	num||techniques-8/NNS||five-4/CD	amod||techniques-8/NNS||rapid-5/JJ	amod||techniques-8/NNS||viral-6/JJ	amod||techniques-8/NNS||diagnostic-7/JJ	prep_of||comparison-2/NN||techniques-8/NNS	prepc_for||techniques-8/NNS||identifying-10/VBG	dobj||identifying-10/VBG||influenzavirus-11/NNS	amod||aspirates-14/NNS||nasopharyngeal-13/JJ	prep_in||identifying-10/VBG||aspirates-14/NNS	aux||made-17/VBN||has-15/VBZ	auxpass||made-17/VBN||been-16/VBN	root||ROOT-0/null||made-17/VBN	prep_on||made-17/VBN||patients-19/NNS	amod||illnesses-22/NNS||influenza-like-21/JJ	prep_with||patients-19/NNS||illnesses-22/NNS	influenza--1||influenzavirus-11||no||a comparison of five rapid viral diagnostic techniques for identifying influenzavirus in nasopharyngeal aspirates has been made on patients with influenza-like illnesses.
det||signal-5/NN||the-1/DT	amod||signal-5/NN||therapeutic-2/JJ	nn||signal-5/NN||class-3/NN	amod||signal-5/NN||specific-4/JJ	nsubjpass||found-13/VBN||signal-5/NN	prep_of||signal-5/NN||bradycardia-7/NN	vmod||bradycardia-7/NN||associated-8/VBN	prep_with||associated-8/VBN||propranololhydrochloride-10/NN	auxpass||found-13/VBN||was-11/VBD	neg||found-13/VBN||not-12/RB	root||ROOT-0/null||found-13/VBN	acomp||found-13/VBN||potent-14/JJ	advmod||potent-14/JJ||enough-15/RB	aux||cause-17/VB||to-16/TO	xcomp||potent-14/JJ||cause-17/VB	dobj||cause-17/VB||bradycardia-18/NN	bradycardia-18||propranololhydrochloride-10||no||the therapeutic class specific signal of bradycardia associated with propranololhydrochloride was not found potent enough to cause bradycardia.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	oa-17||nsaids-57||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
amod||mutations-4/NNS||mody1-1/JJ	conj_and||mody1-1/JJ||mody3-3/JJ	amod||mutations-4/NNS||mody3-3/JJ	nsubj||interact-6/VB||mutations-4/NNS	nsubj||give-10/VB||mutations-4/NNS	aux||interact-6/VB||may-5/MD	root||ROOT-0/null||interact-6/VB	prep_by||interact-6/VB||chance-8/NN	aux||give-10/VB||to-9/TO	xcomp||interact-6/VB||give-10/VB	det||form-14/NN||a-11/DT	advmod||severe-13/JJ||more-12/RBR	amod||form-14/NN||severe-13/JJ	dobj||give-10/VB||form-14/NN	prep_of||form-14/NN||diabetes-16/NN	amod||age-19/NN||younger-18/JJR	dep||form-14/NN||age-19/NN	nn||need-24/NN||presentation-21/NN	conj_and||presentation-21/NN||early-23/JJ	nn||need-24/NN||early-23/JJ	prep_at||age-19/NN||need-24/NN	nn||therapy-27/NN||insulin-26/NN	prep_of||need-24/NN||therapy-27/NN	aux||control-29/VB||to-28/TO	vmod||age-19/NN||control-29/VB	dobj||control-29/VB||hyperglycemia-30/NN	hyperglycemia-30||insulin-26||yes||mody1 and mody3 mutations may interact by chance to give a more severe form of diabetes (younger age at presentation and early need of insulin therapy to control hyperglycemia).
nsubj||drug-7/NN||lansoprazole-1/NN	cop||drug-7/NN||is-2/VBZ	det||drug-7/NN||an-3/DT	amod||drug-7/NN||acid-4/JJ	amod||drug-7/NN||proton-pump-5/JJ	nn||drug-7/NN||inhibiting-6/NN	root||ROOT-0/null||drug-7/NN	nsubjpass||used-10/VBN||drug-7/NN	auxpass||used-10/VBN||is-9/VBZ	rcmod||drug-7/NN||used-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||used-10/VBN||treatment-13/NN	prep_of||treatment-13/NN||duodenal-15/NNS	prep_of||treatment-13/NN||gastriculcers-17/NNS	conj_or||duodenal-15/NNS||gastriculcers-17/NNS	nn||infection-21/NN||h.-19/NN	nn||infection-21/NN||pylori-20/NN	prep_of||treatment-13/NN||infection-21/NN	conj_or||duodenal-15/NNS||infection-21/NN	prep_of||treatment-13/NN||gastroesophagealrefluxdisease-23/NN	conj_or||duodenal-15/NNS||gastroesophagealrefluxdisease-23/NN	amod||syndrome-26/NN||zollinger-ellison-25/JJ	prep_of||treatment-13/NN||syndrome-26/NN	conj_or||duodenal-15/NNS||syndrome-26/NN	gastroesophagealrefluxdisease-23||lansoprazole-1||yes||lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastriculcers , h. pylori infection , gastroesophagealrefluxdisease or zollinger-ellison syndrome .
advmod||î-7/VBP||furthermore-1/RB	nn||/-6/NNP||ppar-3/NN	nn||/-6/NNP||î-4/NN	nn||/-6/NNP||²-5/NNP	nsubj||î-7/VBP||/-6/NNP	root||ROOT-0/null||î-7/VBP	amod||ligands-9/NNS||´-8/JJ	nsubj||prevent-10/VB||ligands-9/NNS	nsubj||avoid-18/VB||ligands-9/NNS	nsubj||suppress-26/VB||ligands-9/NNS	ccomp||î-7/VBP||prevent-10/VB	amod||inflammation-12/NN||fattyacid-induced-11/JJ	dobj||prevent-10/VB||inflammation-12/NN	amod||cells-16/NNS||skeletal-14/JJ	nn||cells-16/NNS||muscle-15/NN	prep_in||prevent-10/VB||cells-16/NNS	ccomp||î-7/VBP||avoid-18/VB	conj_and||prevent-10/VB||avoid-18/VB	det||development-20/NN||the-19/DT	dobj||avoid-18/VB||development-20/NN	amod||hypertrophy-23/NN||cardiac-22/JJ	prep_of||development-20/NN||hypertrophy-23/NN	ccomp||î-7/VBP||suppress-26/VB	conj_and||prevent-10/VB||suppress-26/VB	amod||inflammation-28/NN||macrophage-derived-27/JJ	dobj||suppress-26/VB||inflammation-28/NN	prep_in||suppress-26/VB||atherosclerosis-30/NNS	atherosclerosis-30||fattyacid--1||no_rel||furthermore, ppar î² / î´ ligands prevent fattyacid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis.
advmod||brought-13/VBD||moreover-1/RB	nsubj||brought-13/VBD||data-3/NNS	det||interaction-6/NN||the-5/DT	prep_on||data-3/NNS||interaction-6/NN	prep_of||interaction-6/NN||microbiota-8/NN	prep_with||microbiota-8/NN||food-10/NN	prep_with||microbiota-8/NN||obesity-12/NN	conj_and||food-10/NN||obesity-12/NN	root||ROOT-0/null||brought-13/VBD	amod||hypothesis-15/NNS||new-14/JJ	dobj||brought-13/VBD||hypothesis-15/NNS	det||relationship-20/NN||the-17/DT	amod||relationship-20/NN||obesity/fat-18/JJ	nn||relationship-20/NN||diet-19/NN	prep_for||brought-13/VBD||relationship-20/NN	prep_with||brought-13/VBD||inflammation-22/NN	inflammation-22||fat--1||no_rel||moreover, data on the interaction of microbiota with food and obesity brought new hypothesis for the obesity/fat diet relationship with inflammation.
nsubj||prevalent-4/JJ||hyperglycemia-1/NN	cop||prevalent-4/JJ||is-2/VBZ	advmod||prevalent-4/JJ||highly-3/RB	root||ROOT-0/null||prevalent-4/JJ	amod||adults-7/NNS||chinese-6/JJ	prep_among||prevalent-4/JJ||adults-7/NNS	advmod||diagnosed-10/VBN||newly-9/RB	amod||hiv/aids-11/NNS||diagnosed-10/VBN	prep_with||adults-7/NNS||hiv/aids-11/NNS	aids--1||hiv--1||no||hyperglycemia is highly prevalent among chinese adults with newly diagnosed hiv/aids.
nsubjpass||determined-66/VBN||levels-1/NNS	amod||factor-7/NN||angiopoietin-2-3/JJ	nn||factor-7/NN||von-5/NNP	amod||factor-7/NN||willebrand-6/JJ	prep_of||levels-1/NNS||factor-7/NN	appos||factor-7/NN||vwf-9/NN	nn||propeptide-13/NN||vwf-12/NN	appos||levels-1/NNS||propeptide-13/NN	amod||molecule-1-21/NN||soluble-15/JJ	amod||molecule-1-21/NN||p-selectin-16/JJ	amod||molecule-1-21/NN||soluble-18/JJ	nn||molecule-1-21/NN||intercellular-19/NN	nn||molecule-1-21/NN||adhesion-20/NN	appos||levels-1/NNS||molecule-1-21/NN	dep||molecule-1-21/NN||icam-1-23/JJ	amod||kinase-1-32/NN||soluble-26/JJ	amod||kinase-1-32/NN||endoglin-27/JJ	amod||kinase-1-32/NN||soluble-29/JJ	amod||kinase-1-32/NN||fms-like-30/JJ	nn||kinase-1-32/NN||tyrosine-31/NN	appos||molecule-1-21/NN||kinase-1-32/NN	dep||kinase-1-32/NN||flt-1-34/JJ	amod||protein-41/NN||soluble-37/JJ	amod||protein-41/NN||tie-2-38/JJ	amod||protein-41/NN||c-reactive-40/JJ	appos||molecule-1-21/NN||protein-41/NN	appos||protein-41/NN||procalcitonin-43/NN	num||protein-49/NN||10-45/CD	amod||protein-49/NN||kda-46/JJ	amod||protein-49/NN||interferon-47/JJ	amod||protein-49/NN||gamma-induced-48/JJ	appos||molecule-1-21/NN||protein-49/NN	dep||protein-49/NN||ip-10-51/JJ	amod||receptor-57/NN||soluble-55/JJ	amod||receptor-57/NN||triggering-56/VBG	appos||molecule-1-21/NN||receptor-57/NN	conj_and||protein-49/NN||receptor-57/NN	vmod||receptor-57/NN||expressed-58/VBN	amod||cells-1-61/NN||myeloid-60/JJ	prep_on||expressed-58/VBN||cells-1-61/NN	dep||protein-49/NN||trem-1-63/JJ	auxpass||determined-66/VBN||were-65/VBD	root||ROOT-0/null||determined-66/VBN	agent||determined-66/VBN||elisa-68/NN	interferon-47||adhesion-20||no_rel||levels of angiopoietin-2, von willebrand factor (vwf), vwf propeptide, soluble p-selectin, soluble intercellular adhesion molecule-1 (icam-1), soluble endoglin, soluble fms-like tyrosine kinase-1 (flt-1), soluble tie-2, c-reactive protein, procalcitonin, 10 kda interferon gamma-induced protein (ip-10), and soluble triggering receptor expressed on myeloid cells-1 (trem-1) were determined by elisa.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||trial-5/NN||this-4/DT	prep_of||aim-2/NN||trial-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||treatment-10/NN||on-demand-9/JJ	dobj||compare-8/VB||treatment-10/NN	det||agent-20/NN||a-12/DT	amod||agent-20/NN||pectin-based-13/JJ	amod||agent-20/NN||raft-forming-15/JJ	amod||agent-20/NN||natural-17/JJ	amod||agent-20/NN||anti-reflux-19/JJ	prep_with||treatment-10/NN||agent-20/NN	appos||agent-20/NN||pra-22/NN	prep_with||compare-8/VB||that-25/DT	amod||mg-29/NN||esomeprazole-27/JJ	dep||esomeprazole-27/JJ||20-28/CD	prep_of||that-25/DT||mg-29/NN	appos||mg-29/NN||eso20-31/NNP	prep_in||compare-8/VB||patients-34/NNS	amod||gerd-37/NN||mild/moderate-36/JJ	prep_with||patients-34/NNS||gerd-37/NN	gerd-37||esomeprazole-27||yes||the aim of this trial was to compare on-demand treatment with a pectin-based, raft-forming, natural, anti-reflux agent (pra) with that of esomeprazole 20 mg (eso20) in patients with mild/moderate gerd.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||rif-10||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
det||context-3/NN||this-2/DT	prep_within||is-6/VBZ||context-3/NN	expl||is-6/VBZ||there-5/EX	root||ROOT-0/null||is-6/VBZ	nsubj||is-6/VBZ||consensus-7/NN	nsubj||strengthening-9/VBG||consensus-7/NN	rcmod||consensus-7/NN||strengthening-9/VBG	det||capacity-11/NN||the-10/DT	dobj||strengthening-9/VBG||capacity-11/NN	prep_of||capacity-11/NN||families-13/NNS	aux||care-15/VB||to-14/TO	vmod||strengthening-9/VBG||care-15/VB	mark||one-19/CD||for-16/IN	nsubj||one-19/CD||children-17/NNS	cop||one-19/CD||is-18/VBZ	advcl||care-15/VB||one-19/CD	det||strategies-24/NNS||the-21/DT	advmod||important-23/JJ||most-22/RBS	amod||strategies-24/NNS||important-23/JJ	prep_of||one-19/CD||strategies-24/NNS	prepc_for||strategies-24/NNS||mitigating-26/VBG	det||impacts-28/NNS||the-27/DT	dobj||mitigating-26/VBG||impacts-28/NNS	det||epidemic-32/NN||the-30/DT	amod||epidemic-32/NN||hiv/aids-31/JJ	prep_of||impacts-28/NNS||epidemic-32/NN	poss||lives-36/NNS||children-34/NNS	prep_on||epidemic-32/NN||lives-36/NNS	amod||countries-39/NNS||high-prevalence-38/JJ	prep_in||mitigating-26/VBG||countries-39/NNS	aids--1||hiv--1||no||within this context, there is consensus that strengthening the capacity of families to care for children is one of the most important strategies for mitigating the impacts of the hiv/aids epidemic on children's lives in high-prevalence countries.
det||epidemic-9/NN||the-1/DT	amod||epidemic-9/NN||global-2/JJ	amod||epidemic-9/NN||humanimmunodeficiencyvirusinfection/acquired-3/JJ	amod||epidemic-9/NN||immuno-deficiency-4/JJ	nn||epidemic-9/NN||syndrome-5/NN	appos||epidemic-9/NN||hiv/aids-7/NNS	nsubj||one-11/CD||epidemic-9/NN	cop||one-11/CD||is-10/VBZ	root||ROOT-0/null||one-11/CD	det||threats-15/NNS||the-13/DT	amod||threats-15/NNS||biggest-14/JJS	prep_of||one-11/CD||threats-15/NNS	amod||life-18/NN||human-17/JJ	prep_to||threats-15/NNS||life-18/NN	humanimmunodeficiencyvirusinfection--1||hiv--1||no||the global humanimmunodeficiencyvirusinfection/acquired immuno-deficiency syndrome (hiv/aids) epidemic is one of the biggest threats to human life.
det||differences-2/NNS||these-1/DT	nsubj||seem-3/VBP||differences-2/NNS	root||ROOT-0/null||seem-3/VBP	acomp||seem-3/VBP||independent-4/JJ	amod||use-7/NN||antibiotic-6/JJ	prep_of||seem-3/VBP||use-7/NN	amod||co-infection-10/NN||viral-9/JJ	prep_of||seem-3/VBP||co-infection-10/NN	conj_or||use-7/NN||co-infection-10/NN	antibiotic-6||co-infection-10||no_rel||these differences seem independent of antibiotic use or viral co-infection.
det||viruses-2/NNS||the-1/DT	nsubjpass||detected-4/VBN||viruses-2/NNS	nsubjpass||detected-4/VBN||viruses-2/NNS	auxpass||detected-4/VBN||were-3/VBD	root||ROOT-0/null||detected-4/VBN	conj_and||detected-4/VBN||detected-4/VBN	advmod||detected-4/VBN||directly-5/RB	nn||plasma-8/NN||blood-7/NN	prep_from||detected-4/VBN||plasma-8/NN	xcomp||detected-4/VBN||using-9/VBG	dobj||using-9/VBG||pyrosequencing-10/NN	amod||virusisolation-14/NN||prior-13/JJ	prep_without||detected-4/VBN||virusisolation-14/NN	amod||amplification-19/NN||minimal-17/JJ	nn||amplification-19/NN||pcr-18/NN	prep_with||detected-4/VBN||amplification-19/NN	virusisolation-14||viruses-2||no||the viruses were detected directly from blood plasma using pyrosequencing, without prior virusisolation and with minimal pcr amplification.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||chloroquine-38||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
nsubj||genotyped-2/VBD||we-1/PRP	root||ROOT-0/null||genotyped-2/VBD	num||type2diabetesâ-4/NNS||34-3/CD	dobj||genotyped-2/VBD||type2diabetesâ-4/NNS	prep||type2diabetesâ-4/NNS||$-5/$	advmod||in-9/IN||associated-7/RB	npadvmod||in-9/IN||variants-8/NNS	dep||2,843-10/CD||in-9/IN	num||$-5/$||2,843-10/CD	nn||participants-12/NNS||dpp-11/NN	dep||$-5/$||participants-12/NNS	amod||risk-15/NN||high-14/JJ	prep_at||participants-12/NNS||risk-15/NN	amod||representative-22/NN||type2diabetes-17/JJ	num||groups-21/NNS||five-19/CD	amod||groups-21/NNS||ethnic-20/JJ	prep_from||type2diabetes-17/JJ||groups-21/NNS	prep_of||risk-15/NN||representative-22/NN	nsubjpass||randomized-31/VBN||representative-22/NN	det||population-26/NN||the-24/DT	nn||population-26/NN||u.s.-25/NN	prep_of||representative-22/NN||population-26/NN	aux||randomized-31/VBN||had-29/VBD	auxpass||randomized-31/VBN||been-30/VBN	rcmod||representative-22/NN||randomized-31/VBN	nn||metformin-35/NN||placebo-33/NN	prep_to||randomized-31/VBN||metformin-35/NN	nn||intervention-39/NN||lifestyle-38/NN	prep_to||randomized-31/VBN||intervention-39/NN	conj_or||metformin-35/NN||intervention-39/NN	type2diabetes-17||metformin-35||yes||we genotyped 34 type2diabetesâ $ `` associated variants in 2,843 dpp participants at high risk of type2diabetes from five ethnic groups representative of the u.s. population , who had been randomized to placebo , metformin , or lifestyle intervention .
det||fact-3/NN||the-2/DT	prep_despite||apparent-18/JJ||fact-3/NN	mark||suffer-10/VBP||that-4/IN	nsubj||suffer-10/VBP||men-5/NNS	conj_and||men-5/NNS||women-7/NNS	nsubj||suffer-10/VBP||women-7/NNS	prep_with||men-5/NNS||hiv/aids-9/NNS	dep||fact-3/NN||suffer-10/VBP	det||illness-13/NN||the-11/DT	amod||illness-13/NN||same-12/JJ	dobj||suffer-10/VBP||illness-13/NN	amod||disparities-16/NNS||clear-15/JJ	nsubj||apparent-18/JJ||disparities-16/NNS	cop||apparent-18/JJ||are-17/VBP	root||ROOT-0/null||apparent-18/JJ	det||women-23/NNS||the-20/DT	amod||women-23/NNS||negative-21/JJ	nn||women-23/NNS||reaction-22/NN	prep_in||apparent-18/JJ||women-23/NNS	nn||living-26/NN||men-25/NNS	prep_in||apparent-18/JJ||living-26/NN	conj_and||women-23/NNS||living-26/NN	amod||experience-29/NN||hiv/aids-28/JJ	prep_with||apparent-18/JJ||experience-29/NN	prep_in||experience-29/NN||society-31/NN	aids--1||hiv--1||no||despite the fact that men and women with hiv/aids suffer the same illness, clear disparities are apparent in the negative reaction women and men living with hiv/aids experience in society.
pobj||up-13/RP||conclusions-1/NNS	nsubj||drug-29/NN||conclusions-1/NNS	det||results-3/NNS||the-2/DT	nsubj||reflect-7/VBP||results-3/NNS	det||study-6/NN||this-5/DT	prep_of||results-3/NNS||study-6/NN	rcmod||conclusions-1/NNS||reflect-7/VBP	det||results-9/NNS||the-8/DT	dobj||reflect-7/VBP||results-9/NNS	amod||trials-12/NNS||clinical-11/JJ	prep_of||results-9/NNS||trials-12/NNS	prep||reflect-7/VBP||up-13/RP	det||time-16/NN||the-15/DT	prep_to||up-13/RP||time-16/NN	prep_of||time-16/NN||approval-18/NN	nsubjpass||confirmed-22/VBN||it-20/PRP	auxpass||confirmed-22/VBN||was-21/VBD	rcmod||conclusions-1/NNS||confirmed-22/VBN	conj_and||reflect-7/VBP||confirmed-22/VBN	det||carvedilol-24/NN||that-23/DT	dobj||confirmed-22/VBN||carvedilol-24/NN	cop||drug-29/NN||is-25/VBZ	det||drug-29/NN||a-26/DT	advmod||useful-28/JJ||highly-27/RB	amod||drug-29/NN||useful-28/JJ	root||ROOT-0/null||drug-29/NN	det||treatment-32/NN||the-31/DT	prep_in||drug-29/NN||treatment-32/NN	prep_of||treatment-32/NN||hypertension-34/NN	hypertension-34||carvedilol-24||yes||conclusions the results of this study reflect the results of clinical trials up to the time of approval and it was confirmed that carvedilol is a highly useful drug in the treatment of hypertension.
det||inhibitors-3/NNS||the-1/DT	amod||inhibitors-3/NNS||c-met-2/JJ	nsubj||demonstrated-4/VBD||inhibitors-3/NNS	root||ROOT-0/null||demonstrated-4/VBD	amod||efficacy-6/NN||anti-proliferative-5/JJ	dobj||demonstrated-4/VBD||efficacy-6/NN	advmod||combined-8/VBN||when-7/WRB	advcl||demonstrated-4/VBD||combined-8/VBN	nn||therapy-12/NN||androgen-10/NN	nn||therapy-12/NN||ablation-11/NN	prep_with||combined-8/VBN||therapy-12/NN	amod||cancer-16/NN||advanced-14/JJ	nn||cancer-16/NN||prostate-15/NN	prep_for||therapy-12/NN||cancer-16/NN	androgen-10||cancer-16||no_rel||the c-met inhibitors demonstrated anti-proliferative efficacy when combined with androgen ablation therapy for advanced prostate cancer.
amod||analysis-4/NN||univariate-1/JJ	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubj||showed-5/VBD||analysis-4/NN	root||ROOT-0/null||showed-5/VBD	neg||association-7/NN||no-6/DT	dobj||showed-5/VBD||association-7/NN	amod||ratio-12/NN||stavudine-9/JJ	amod||ratio-12/NN||geometric-10/VBN	amod||ratio-12/NN||mean-11/JJ	prep_between||association-7/NN||ratio-12/NN	amod||ratio-12/NN||>-13/JJ	dep||>-13/JJ||1-14/CD	amod||glucose-18/NN||impaired-16/VBN	amod||glucose-18/NN||fasting-17/JJ	prep_between||association-7/NN||glucose-18/NN	conj_and||ratio-12/NN||glucose-18/NN	nsubj||ratio-21/VBZ||odds-20/NNS	dep||glucose-18/NN||ratio-21/VBZ	dep||2.00-25/CD||or-23/CC	dep||ratio-21/VBZ||2.00-25/CD	num||%-28/NN||95-27/CD	appos||2.00-25/CD||%-28/NN	vmod||%-28/NN||ci-29/VBN	dobj||ci-29/VBN||0.44-30/CD	prep_to||ci-29/VBN||9.19-32/CD	prep_between||association-7/NN||impairedglucosetolerance-35/NN	conj_and||ratio-12/NN||impairedglucosetolerance-35/NN	cc||0.07-43/NNS||or-37/CC	num||0.07-43/NNS||1.14-38/CD	num||0.07-43/NNS||95-40/CD	nn||0.07-43/NNS||%-41/NN	nn||0.07-43/NNS||ci-42/NN	dep||impairedglucosetolerance-35/NN||0.07-43/NNS	prep_to||0.07-43/NNS||19.42-45/CD	conj_and||ratio-12/NN||hyperlactataemia-48/NN	conj_and||impairedglucosetolerance-35/NN||hyperlactataemia-48/NN	cc||2.19-51/CD||or-50/CC	dep||hyperlactataemia-48/NN||2.19-51/CD	num||%-54/NN||95-53/CD	appos||2.19-51/CD||%-54/NN	number||0.63-56/CD||ci-55/CD	num||%-54/NN||0.63-56/CD	prep_to||%-54/NN||7.66-58/CD	conj_and||ratio-12/NN||hypertriglyceridaemia-61/NN	conj_and||impairedglucosetolerance-35/NN||hypertriglyceridaemia-61/NN	cc||ci-68/VBP||or-63/CC	nsubj||ci-68/VBP||1.75-64/CD	number||%-67/NN||95-66/CD	amod||1.75-64/CD||%-67/NN	dep||hypertriglyceridaemia-61/NN||ci-68/VBP	number||7.04-71/CD||0.44-69/CD	dep||7.04-71/CD||to-70/TO	dobj||ci-68/VBP||7.04-71/CD	conj_and||ratio-12/NN||lipoatrophy-75/NN	conj_and||impairedglucosetolerance-35/NN||lipoatrophy-75/NN	cc||0.83-78/CD||or-77/CC	dep||lipoatrophy-75/NN||0.83-78/CD	number||%-81/NN||95-80/CD	amod||ci-82/NN||%-81/NN	appos||0.83-78/CD||ci-82/NN	num||2.79-85/CD||0.25-83/CD	dep||2.79-85/CD||to-84/TO	dep||0.83-78/CD||2.79-85/CD	impairedglucosetolerance-35||glucose-18||no_rel||univariate logistic regression analysis showed no association between stavudine geometric mean ratio >1 and impaired fasting glucose (odds ratio (or) 2.00, 95% ci 0.44 to 9.19), impairedglucosetolerance (or 1.14, 95% ci 0.07 to 19.42), hyperlactataemia (or 2.19, 95%ci 0.63 to 7.66), hypertriglyceridaemia (or 1.75, 95%ci 0.44 to 7.04), and lipoatrophy (or 0.83, 95% ci 0.25 to 2.79).
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	hypoglycemia-84||glucagon-1||yes||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
prep_at||increased-13/VBD||center-2/NN	dep||center-2/NN||a-3/DT	det||proportion-6/NN||the-5/DT	nsubj||increased-13/VBD||proportion-6/NN	amod||infections-9/NNS||s.aureus-8/JJ	prep_of||proportion-6/NN||infections-9/NNS	vmod||infections-9/NNS||caused-10/VBN	agent||caused-10/VBN||ca-mrsa-12/NN	root||ROOT-0/null||increased-13/VBD	number||%-19/NN||4-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||23-18/CD	prep_from||increased-13/VBD||%-19/NN	num||years-22/NNS||2-21/CD	prep_over||increased-13/VBD||years-22/NNS	det||proportion-25/NN||the-24/DT	nsubj||decreased-33/VBD||proportion-25/NN	vmod||proportion-25/NN||caused-26/VBN	amod||-rrb--32/NNS||healthcare-associated-28/JJ	nn||-rrb--32/NNS||mrsa-29/NN	nn||-rrb--32/NNS||-lrb--30/NN	amod||-rrb--32/NNS||ha-mrsa-31/JJ	agent||caused-26/VBN||-rrb--32/NNS	parataxis||increased-13/VBD||decreased-33/VBD	number||%-39/NN||25-35/CD	dep||%-39/NN||%-36/NN	dep||%-39/NN||to-37/TO	number||%-39/NN||5-38/CD	prep_from||decreased-33/VBD||%-39/NN	mrsa-29||s.aureus-8||no||at center a , the proportion of s.aureus infections caused by ca-mrsa increased from 4 % to 23 % over 2 years ; the proportion caused by healthcare-associated mrsa -lrb- ha-mrsa -rrb- decreased from 25 % to 5 % .
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||way-15/NN||that-4/IN	det||use-6/NN||the-5/DT	nsubj||way-15/NN||use-6/NN	amod||filters-10/NNS||ostrich-8/JJ	amod||filters-10/NNS||antibody-impregnated-9/JJ	prep_of||use-6/NN||filters-10/NNS	aux||way-15/NN||might-11/MD	cop||way-15/NN||be-12/VB	det||way-15/NN||a-13/DT	amod||way-15/NN||powerful-14/JJ	ccomp||suggest-3/VBP||way-15/NN	aux||prevent-17/VB||to-16/TO	vmod||way-15/NN||prevent-17/VB	det||transmission-19/NN||the-18/DT	dobj||prevent-17/VB||transmission-19/NN	prep_of||transmission-19/NN||h5n1-21/CD	antibody--1||h5n1-21||no_rel||these results suggest that the use of ostrich antibody-impregnated filters might be a powerful way to prevent the transmission of h5n1.
nsubj||had-6/VBD||one-1/CD	det||women-5/NNS||every-3/DT	num||women-5/NNS||three-4/CD	prep_in||one-1/CD||women-5/NNS	root||ROOT-0/null||had-6/VBD	dobj||had-6/VBD||anaemia-7/NN	dobj||had-6/VBD||deficiency-9/NN	conj_and||anaemia-7/NN||deficiency-9/NN	prep_of||anaemia-7/NN||folicacid-11/NN	mark||had-17/VBD||while-12/IN	nsubj||had-17/VBD||one-13/CD	det||two-16/CD||every-15/DT	prep_in||one-13/CD||two-16/CD	advcl||had-6/VBD||had-17/VBD	dobj||had-17/VBD||irondeficiency-18/NN	vmod||had-17/VBD||suggesting-20/VBG	mark||constitute-28/VBP||that-21/IN	nsubj||constitute-28/VBP||deficiencies-22/NNS	preconj||folicacid-25/NN||both-24/DT	prep_of||deficiencies-22/NNS||folicacid-25/NN	prep_of||deficiencies-22/NNS||iron-27/NN	conj_and||folicacid-25/NN||iron-27/NN	ccomp||suggesting-20/VBG||constitute-28/VBP	det||deficiencies-32/NNS||the-29/DT	amod||deficiencies-32/NNS||major-30/JJ	nn||deficiencies-32/NNS||micronutrient-31/NN	dobj||constitute-28/VBP||deficiencies-32/NNS	nn||women-35/NNS||ethiopian-34/NN	prep_in||deficiencies-32/NNS||women-35/NNS	irondeficiency-18||folicacid-25||no||one in every three women had anaemia and deficiency of folicacid while one in every two had irondeficiency, suggesting that deficiencies of both folicacid and iron constitute the major micronutrient deficiencies in ethiopian women.
det||findings-2/NNS||these-1/DT	nsubj||suggest-5/VBP||findings-2/NNS	advmod||suggest-5/VBP||now-3/RB	advmod||suggest-5/VBP||strongly-4/RB	root||ROOT-0/null||suggest-5/VBP	mark||determined-14/VBN||that-6/IN	det||pathogenesis-10/NNS||the-7/DT	amod||pathogenesis-10/NNS||characteristic-8/JJ	amod||pathogenesis-10/NNS||peripheral-9/JJ	nsubjpass||determined-14/VBN||pathogenesis-10/NNS	prep_of||pathogenesis-10/NNS||vcjd-12/NN	auxpass||determined-14/VBN||is-13/VBZ	ccomp||suggest-5/VBP||determined-14/VBN	nn||type-18/NN||prion-16/NN	nn||type-18/NN||strain-17/NN	agent||determined-14/VBN||type-18/NN	advmod||type-18/NN||alone-19/RB	advmod||type-18/NN||rather-20/RB	prep_than||type-18/NN||route-22/NN	prep_of||route-22/NN||infection-24/NN	vcjd-12||prion-16||no_rel||these findings now strongly suggest that the characteristic peripheral pathogenesis of vcjd is determined by prion strain type alone rather than route of infection.
amod||test-4/NN||bed-eia-1/JJ	amod||test-4/NN||hiv-1-2/JJ	nn||test-4/NN||incidence-3/NN	nsubjpass||described-10/VBN||test-4/NN	appos||test-4/NN||bed-ceia-6/NNP	aux||described-10/VBN||has-8/VBZ	auxpass||described-10/VBN||been-9/VBN	root||ROOT-0/null||described-10/VBN	det||tool-13/NN||a-12/DT	prep_as||described-10/VBN||tool-13/NN	amod||rs-18/NN||discriminate-15/JJ	amod||rs-18/NN||recent-16/JJ	prep_to||tool-13/NN||rs-18/NN	amod||seroconversion-25/NN||long-term-21/JJ	appos||seroconversion-25/NN||lts-23/NN	prep_from||described-10/VBN||seroconversion-25/NN	amod||infection-28/NN||hiv-1-27/JJ	prep_of||seroconversion-25/NN||infection-28/NN	xcomp||described-10/VBN||contributing-30/VBG	det||understanding-34/NN||a-32/DT	amod||understanding-34/NN||better-33/JJR	prep_to||contributing-30/VBG||understanding-34/NN	det||dynamics-37/NNS||the-36/DT	prep_of||understanding-34/NN||dynamics-37/NNS	det||epidemic-41/NN||the-39/DT	amod||epidemic-41/NN||hiv/aids-40/JJ	prep_of||dynamics-37/NNS||epidemic-41/NN	prep_over||epidemic-41/NN||time-43/NN	aids--1||hiv--1||no||bed-eia hiv-1 incidence test (bed-ceia) has been described as a tool to discriminate recent (rs) from long-term (lts) seroconversion of hiv-1 infection, contributing to a better understanding of the dynamics of the hiv/aids epidemic over time.
det||emergence-3/NN||the-1/DT	amod||emergence-3/NN||recent-2/JJ	nsubj||raised-12/VBN||emergence-3/NN	det||influenzavirus-7/NNS||the-5/DT	amod||influenzavirus-7/NNS||h5n1-6/JJ	prep_of||emergence-3/NN||influenzavirus-7/NNS	nn||reservoirs-10/NNS||avian-9/NN	prep_from||influenzavirus-7/NNS||reservoirs-10/NNS	aux||raised-12/VBN||has-11/VBZ	root||ROOT-0/null||raised-12/VBN	dobj||raised-12/VBN||concern-13/NN	amod||strains-17/NNS||future-15/JJ	nn||strains-17/NNS||influenza-16/NN	prep_about||raised-12/VBN||strains-17/NNS	amod||virulence-20/NN||high-19/JJ	prep_of||strains-17/NNS||virulence-20/NN	nsubj||infect-25/VB||virulence-20/NN	amod||virulence-20/NN||emerging-21/VBG	aux||infect-25/VB||could-23/MD	advmod||infect-25/VB||easily-24/RB	rcmod||virulence-20/NN||infect-25/VB	dobj||infect-25/VB||humans-26/NNS	influenza-16||influenzavirus-7||no||the recent emergence of the h5n1 influenzavirus from avian reservoirs has raised concern about future influenza strains of high virulence emerging that could easily infect humans.
poss||recommendations-2/NNS||their-1/PRP$	nsubj||included-3/VBD||recommendations-2/NNS	root||ROOT-0/null||included-3/VBD	dep||make-12/VB||1-5/LS	det||country-10/NN||every-7/DT	amod||country-10/NN||dengue-8/JJ	amod||country-10/NN||endemic-9/JJ	nsubj||make-12/VB||country-10/NN	aux||make-12/VB||should-11/MD	dep||included-3/VBD||make-12/VB	dobj||make-12/VB||reporting-13/NN	amod||cases-16/NNS||dengue-15/JJ	prep_of||reporting-13/NN||cases-16/NNS	det||government-19/NN||the-18/DT	prep_to||make-12/VB||government-19/NN	amod||government-19/NN||mandatory-20/JJ	dep||developed-30/VBN||2-23/LS	amod||systems-27/NNS||electronic-25/JJ	nn||systems-27/NNS||reporting-26/NN	nsubjpass||developed-30/VBN||systems-27/NNS	nsubjpass||used-32/VBN||systems-27/NNS	aux||developed-30/VBN||should-28/MD	auxpass||developed-30/VBN||be-29/VB	parataxis||make-12/VB||developed-30/VBN	parataxis||make-12/VB||used-32/VBN	conj_and||developed-30/VBN||used-32/VBN	nsubj||include-43/VB||3-35/NNP	amod||data-41/NNS||minimum-38/JJ	nn||data-41/NNS||dengue-39/NN	nn||data-41/NNS||surveillance-40/NN	prep_at||3-35/NNP||data-41/NNS	aux||include-43/VB||should-42/MD	conj_and||included-3/VBD||include-43/VB	dobj||include-43/VB||incidence-44/NN	nn||rates-47/NNS||hospitalization-46/NN	appos||incidence-44/NN||rates-47/NNS	appos||rates-47/NNS||deaths-49/NNS	nn||group-52/NN||age-51/NN	prep_by||include-43/VB||group-52/NN	dep||completed-61/VBN||4-55/LS	amod||studies-58/NNS||additional-57/JJ	nsubjpass||completed-61/VBN||studies-58/NNS	nsubj||check-63/VB||studies-58/NNS	aux||completed-61/VBN||should-59/MD	auxpass||completed-61/VBN||be-60/VB	conj_and||included-3/VBD||completed-61/VBN	aux||check-63/VB||to-62/TO	xcomp||completed-61/VBN||check-63/VB	det||sensitivity-65/NN||the-64/DT	dobj||check-63/VB||sensitivity-65/NN	det||system-68/NN||the-67/DT	prep_of||sensitivity-65/NN||system-68/NN	dep||share-75/VB||5-71/CD	nsubj||share-75/VB||laboratories-73/NNS	aux||share-75/VB||should-74/MD	conj_and||included-3/VBD||share-75/VB	dobj||share-75/VB||expertise-76/NN	dobj||share-75/VB||data-78/NNS	conj_and||expertise-76/NN||data-78/NNS	appos||tests-83/NNS||6-81/CD	dep||expertise-76/NN||tests-83/NNS	nsubj||identify-85/VBP||tests-83/NNS	rcmod||tests-83/NNS||identify-85/VBP	nsubjpass||used-89/VBN||denguevirus-86/NNS	aux||used-89/VBN||should-87/MD	auxpass||used-89/VBN||be-88/VB	ccomp||identify-85/VBP||used-89/VBN	prep_in||used-89/VBN||patients-91/NNS	prep_with||patients-91/NNS||fever-93/NN	num||days-96/NNS||four-95/CD	prep_for||fever-93/NN||days-96/NNS	cc||less-98/JJR||or-97/CC	num||days-96/NNS||less-98/JJR	nn||tests-101/NNS||antibody-100/NN	nsubjpass||used-104/VBN||tests-101/NNS	nsubj||diagnose-109/VB||tests-101/NNS	aux||used-104/VBN||should-102/MD	auxpass||used-104/VBN||be-103/VB	conj_and||included-3/VBD||used-104/VBN	prep_after||used-104/VBN||day-106/NN	num||day-106/NN||4-107/CD	aux||diagnose-109/VB||to-108/TO	xcomp||used-104/VBN||diagnose-109/VB	dobj||diagnose-109/VB||dengue-110/NN	appos||detection-117/NN||7-114/CD	amod||detection-117/NN||early-116/JJ	nsubj||goals-125/NNS||detection-117/NN	conj_and||detection-117/NN||prediction-119/NN	nsubj||goals-125/NNS||prediction-119/NN	amod||outbreaks-122/NNS||dengue-121/JJ	prep_of||prediction-119/NN||outbreaks-122/NNS	aux||goals-125/NNS||should-123/MD	cop||goals-125/NNS||be-124/VB	conj_and||included-3/VBD||goals-125/NNS	amod||systems-129/NNS||national-127/JJ	nn||systems-129/NNS||surveillance-128/NN	prep_for||goals-125/NNS||systems-129/NNS	dengue-121||denguevirus-86||no||their recommendations included (1) every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence, hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system; (5) laboratories should share expertise and data; (6) tests that identify denguevirus should be used in patients with fever for four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction of dengue outbreaks should be goals for national surveillance systems.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	inflammation-30||loteprednoletabonate-8||yes||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	dobj||report-2/VBP||transmission-3/NN	amod||virus-6/NN||tick-borneencephalitis-5/JJ	prep_of||transmission-3/NN||virus-6/NN	appos||virus-6/NN||tbev-8/NNP	prep_in||virus-6/NN||july-11/NNP	num||july-11/NNP||2008-12/CD	amod||milk-16/NN||nonpasteurized-14/JJ	nn||milk-16/NN||goat-15/NN	prep_through||report-2/VBP||milk-16/NN	num||humans-19/NNS||6-18/CD	prep_to||milk-16/NN||humans-19/NNS	num||pigs-23/NNS||4-21/CD	amod||pigs-23/NNS||domestic-22/JJ	prep_through||report-2/VBP||pigs-23/NNS	conj_and||milk-16/NN||pigs-23/NNS	det||m-29/NN||an-25/DT	amod||m-29/NN||alpine-26/JJ	nn||m-29/NN||pasture-27/NN	num||m-29/NN||1,500-28/CD	prep_in||pigs-23/NNS||m-29/NN	nn||level-32/NN||sea-31/NN	prep_above||pigs-23/NNS||level-32/NN	tick-borneencephalitis-5||tbev-8||no||we report transmission of tick-borneencephalitis virus (tbev) in july 2008 through nonpasteurized goat milk to 6 humans and 4 domestic pigs in an alpine pasture 1,500 m above sea level.
det||effects-4/NNS||the-1/DT	amod||seasonal-3/JJ||observed-2/JJ	amod||effects-4/NNS||seasonal-3/JJ	nsubjpass||attributed-8/VBN||effects-4/NNS	aux||attributed-8/VBN||could-5/MD	neg||attributed-8/VBN||not-6/RB	auxpass||attributed-8/VBN||be-7/VB	root||ROOT-0/null||attributed-8/VBN	amod||antibiotics-11/NNS||recent-10/JJ	prep_to||attributed-8/VBN||antibiotics-11/NNS	amod||co-infection-14/NN||viral-13/JJ	prep_to||attributed-8/VBN||co-infection-14/NN	conj_or||antibiotics-11/NNS||co-infection-14/NN	antibiotics-11||co-infection-14||no_rel||the observed seasonal effects could not be attributed to recent antibiotics or viral co-infection.
nn||patches-2/NNS||niacin-1/NN	nsubjpass||applied-18/VBN||patches-2/NNS	nsubj||forearm-20/VB||patches-2/NNS	num||concentrations-5/NNS||3-4/CD	prep_of||patches-2/NNS||concentrations-5/NNS	num||m-8/NN||0.001-7/CD	dep||concentrations-5/NNS||m-8/NN	num||m-11/NN||0.01-10/CD	dep||concentrations-5/NNS||m-11/NN	conj_and||m-8/NN||m-11/NN	num||m-15/NN||0.1-14/CD	dep||concentrations-5/NNS||m-15/NN	conj_and||m-8/NN||m-15/NN	auxpass||applied-18/VBN||were-17/VBD	root||ROOT-0/null||applied-18/VBN	aux||forearm-20/VB||to-19/TO	xcomp||applied-18/VBN||forearm-20/VB	dobj||forearm-20/VB||skin-21/NN	det||response-26/NN||the-24/DT	amod||response-26/NN||flush-25/JJ	nsubjpass||rated-28/VBN||response-26/NN	auxpass||rated-28/VBN||was-27/VBD	conj_and||applied-18/VBN||rated-28/VBN	prep_at||rated-28/VBN||5-30/CD	prep_at||rated-28/VBN||10-32/CD	conj_and||5-30/CD||10-32/CD	num||minutes-36/NNS||15-35/CD	prep_at||rated-28/VBN||minutes-36/NNS	conj_and||5-30/CD||minutes-36/NNS	advmod||rated-28/VBN||respectively-38/RB	det||scale-43/NN||a-41/DT	amod||scale-43/NN||4-point-42/JJ	prep_with||rated-28/VBN||scale-43/NN	flush-25||niacin-1||no||niacin patches of 3 concentrations (0.001m, 0.01m, and 0.1m) were applied to forearm skin, and the flush response was rated at 5, 10, and 15 minutes, respectively, with a 4-point scale.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-23/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	dep||antibiotics-7/NNS||penicilling-9/NN	appos||penicilling-9/NN||methicillin-11/NN	appos||penicilling-9/NN||erythromycin-13/NN	conj_and||methicillin-11/NN||erythromycin-13/NN	appos||penicilling-9/NN||ciprofloxacin-15/NN	conj_and||methicillin-11/NN||ciprofloxacin-15/NN	appos||penicilling-9/NN||clindamycin-17/NN	conj_and||methicillin-11/NN||clindamycin-17/NN	appos||penicilling-9/NN||clarithromycin-19/NN	conj_and||methicillin-11/NN||clarithromycin-19/NN	auxpass||observed-23/VBN||was-22/VBD	conj_and||contained-5/VBD||observed-23/VBN	det||isolates-27/NN||the-25/DT	nn||isolates-27/NN||mrsa-26/NN	prep_in||observed-23/VBN||isolates-27/NN	predet||uk-31/NN||both-29/PDT	det||uk-31/NN||the-30/DT	prep_in||isolates-27/NN||uk-31/NN	amod||cohorts-34/NNS||maltese-33/JJ	prep_in||isolates-27/NN||cohorts-34/NNS	conj_and||uk-31/NN||cohorts-34/NNS	clarithromycin-19||mrsa-26||no_rel||the largest mar profile contained six antibiotics (penicilling, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||paucity-4/NN||a-3/DT	nsubj||was-2/VBD||paucity-4/NN	prep_of||paucity-4/NN||evidence-6/NN	prep_on||evidence-6/NN||behaviour-8/NN	aux||avoid-10/VB||to-9/TO	vmod||paucity-4/NN||avoid-10/VB	dobj||avoid-10/VB||hypoglycaemia-11/NN	expl||were-15/VBD||there-14/EX	conj_but||was-2/VBD||were-15/VBD	det||suggestions-17/NNS||some-16/DT	nsubj||were-15/VBD||suggestions-17/NNS	mark||permitted-26/VBN||that-18/IN	dep||desirable-21/JJ||higher-19/JJR	dep||desirable-21/JJ||than-20/IN	amod||levels-23/NNS||desirable-21/JJ	nn||levels-23/NNS||bloodglucose-22/NN	nsubjpass||permitted-26/VBN||levels-23/NNS	nsubj||avoid-30/VB||levels-23/NNS	aux||permitted-26/VBN||might-24/MD	auxpass||permitted-26/VBN||be-25/VB	ccomp||were-15/VBD||permitted-26/VBN	prep_in||permitted-26/VBN||order-28/NN	aux||avoid-30/VB||to-29/TO	xcomp||permitted-26/VBN||avoid-30/VB	dobj||avoid-30/VB||hypoglycaemia-31/NN	hypoglycaemia-31||glucose--1||yes||there was a paucity of evidence on behaviour to avoid hypoglycaemia, but there were some suggestions that higher than desirable bloodglucose levels might be permitted in order to avoid hypoglycaemia.
amod||studies-3/NNS||previous-2/JJ	prep_in||demonstrated-6/VBD||studies-3/NNS	nsubj||demonstrated-6/VBD||we-5/PRP	root||ROOT-0/null||demonstrated-6/VBD	mark||reduce-10/VB||that-7/IN	nsubj||reduce-10/VB||bne-8/NN	aux||reduce-10/VB||could-9/MD	ccomp||demonstrated-6/VBD||reduce-10/VB	det||dna-17/NN||the-11/DT	amod||hepatitisbvirus-13/JJ||supernatant-12/JJ	amod||dna-17/NN||hepatitisbvirus-13/JJ	appos||dna-17/NN||hbv-15/NN	dobj||reduce-10/VB||dna-17/NN	amod||cells-22/NNS||hbv-producing-19/JJ	amod||cells-22/NNS||hepg2-20/JJ	num||cells-22/NNS||2.2.15-21/CD	prep_in||dna-17/NN||cells-22/NNS	hbv-15||hepatitisbvirus-13||no||in previous studies, we demonstrated that bne could reduce the supernatant hepatitisbvirus (hbv) dna in hbv-producing hepg2 2.2.15 cells.
nsubj||agent-5/NN||pioglitazone-1/NN	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||an-3/DT	amod||agent-5/NN||insulin-sensitizing-4/JJ	root||ROOT-0/null||agent-5/NN	amod||agent-5/NN||available-6/JJ	prep_for||available-6/JJ||treatment-8/NN	prep_of||treatment-8/NN||type2diabetes-10/CD	type2diabetes-10||pioglitazone-1||yes||pioglitazone is an insulin-sensitizing agent available for treatment of type2diabetes.
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||yes||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
nsubjpass||transmitted-6/VBN||qfever-1/NN	vmod||qfever-1/NN||caused-2/VBN	agent||caused-2/VBN||coxiellaburnetii-4/NNS	auxpass||transmitted-6/VBN||is-5/VBZ	root||ROOT-0/null||transmitted-6/VBN	prep_to||transmitted-6/VBN||humans-8/NNS	agent||transmitted-6/VBN||inhalation-10/NN	prep_of||inhalation-10/NN||aerosols-12/NNS	nn||products-16/NNS||animal-14/NN	nn||products-16/NNS||birth-15/NN	prep_from||aerosols-12/NNS||products-16/NNS	qfever-1||coxiellaburnetii-4||no||qfever caused by coxiellaburnetii is transmitted to humans by inhalation of aerosols from animal birth products.
nn||use-3/NN||injection-1/NN	nn||use-3/NN||drug-2/NN	nsubj||contribute-12/VBP||use-3/NN	appos||use-3/NN||idu-5/NN	amod||transmission-10/NN||heterosexual-8/JJ	nn||transmission-10/NN||virus-9/NN	conj_and||use-3/NN||transmission-10/NN	nsubj||contribute-12/VBP||transmission-10/NN	dep||contribute-12/VBP||both-11/DT	root||ROOT-0/null||contribute-12/VBP	det||epidemics-18/NN||the-14/DT	amod||epidemics-18/NN||growing-15/VBG	amod||epidemics-18/NN||mixed-16/JJ	nn||epidemics-18/NN||hiv-17/NN	prep_to||contribute-12/VBP||epidemics-18/NN	amod||europe-21/NN||eastern-20/JJ	prep_in||epidemics-18/NN||europe-21/NN	amod||asia-24/NN||central-23/JJ	prep_in||epidemics-18/NN||asia-24/NN	conj_and||europe-21/NN||asia-24/NN	virus-9||idu-5||yes||injection drug use (idu) and heterosexual virus transmission both contribute to the growing mixed hiv epidemics in eastern europe and central asia.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||higher-2/JJR	nsubj||was-7/VBD||incidence-3/NN	amod||patients-6/NNS||diabeticfoot-5/JJ	prep_of||incidence-3/NN||patients-6/NNS	root||ROOT-0/null||was-7/VBD	det||age-11/NN||the-9/DT	amod||age-11/NN||mean-10/JJ	prep_in||was-7/VBD||age-11/NN	nsubjpass||controlled-19/VBN||age-11/NN	amod||±-14/NNS||57â-13/JJ	prep_of||age-11/NN||±-14/NNS	num||years-16/NNS||3.4-15/CD	dep||age-11/NN||years-16/NNS	auxpass||controlled-19/VBN||was-18/VBD	rcmod||age-11/NN||controlled-19/VBN	nn||therapy-22/NN||combination-21/NN	prep_with||controlled-19/VBN||therapy-22/NN	nn||antidiabetics-27/NNS||insulin-24/NN	conj_and||insulin-24/NN||oral-26/JJ	nn||antidiabetics-27/NNS||oral-26/JJ	prep_of||therapy-22/NN||antidiabetics-27/NNS	num||%-30/NN||63.0-29/CD	dep||antidiabetics-27/NNS||%-30/NN	nn||516-34/NNP||n-32/NNP	nn||516-34/NNP||=-33/NNP	appos||%-30/NN||516-34/NNP	insulin-24||diabeticfoot-5||no_rel||the higher incidence of diabeticfoot patients was in the mean age of 57â±3.4 years that was controlled with combination therapy of insulin and oral antidiabetics (63.0%, n=516).
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	det||role-5/NN||a-4/DT	dobj||suggest-3/VBP||role-5/NN	amod||conditions-9/NNS||nasal-7/JJ	amod||conditions-9/NNS||inflammatory-8/JJ	prep_of||role-5/NN||conditions-9/NNS	prep_in||conditions-9/NNS||susceptibility-11/NN	nn||infection-14/NN||influenza-13/NN	prep_to||suggest-3/VBP||infection-14/NN	dep||suggest-3/VBP||especially-16/RB	prep_by||suggest-3/VBP||avianinfluenzaviruses-18/NNS	nsubj||inefficient-23/JJ||avianinfluenzaviruses-18/NNS	cop||inefficient-23/JJ||is-21/VBZ	advmod||inefficient-23/JJ||generally-22/RB	rcmod||avianinfluenzaviruses-18/NNS||inefficient-23/JJ	prepc_in||inefficient-23/JJ||infecting-25/VBG	amod||airway-28/NN||human-26/JJ	amod||airway-28/NN||upper-27/JJ	dobj||infecting-25/VBG||airway-28/NN	influenza-13||influenzaviruses--1||no||our data suggest a role of nasal inflammatory conditions in susceptibility to influenza infection, especially by avianinfluenzaviruses, which is generally inefficient in infecting human upper airway.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||ketamine-34||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
aux||test-2/VB||to-1/TO	advcl||detected-7/VBD||test-2/VB	det||hypothesis-4/NNS||this-3/DT	dobj||test-2/VB||hypothesis-4/NNS	nsubj||detected-7/VBD||we-6/PRP	root||ROOT-0/null||detected-7/VBD	xcomp||detected-7/VBD||î-8/VB	number||2,3-10/CD||±-9/CD	dobj||î-8/VB||2,3-10/CD	nn||acid-17/NN||î-13/NN	amod||acid-17/NN||±-14/JJ	amod||acid-17/NN||2,6-linked-15/JJ	amod||acid-17/NN||sialic-16/JJ	dobj||î-8/VB||acid-17/NN	conj_and||2,3-10/CD||acid-17/NN	amod||polyp-21/NN||human-19/JJ	amod||polyp-21/NN||nasal-20/JJ	prep_in||acid-17/NN||polyp-21/NN	amod||tissues-26/NNS||normal-23/JJ	amod||tissues-26/NNS||nasal-24/JJ	amod||tissues-26/NNS||mucosal-25/JJ	dobj||î-8/VB||tissues-26/NNS	conj_and||2,3-10/CD||tissues-26/NNS	nn||staining-29/NN||lectin-28/NN	prep_by||tissues-26/NNS||staining-29/NN	amod||explants-32/NNS||infected-31/JJ	conj_and||2,3-10/CD||explants-32/NNS	conj_and||tissues-26/NNS||explants-32/NNS	det||tissues-35/NNS||those-34/DT	prep_of||explants-32/NNS||tissues-35/NNS	amod||h5n1-38/NNS||avianinfluenzaviruses-37/JJ	prep_with||î-8/VB||h5n1-38/NNS	amod||influenzaviruses-41/NNS||seasonal-40/JJ	prep_with||î-8/VB||influenzaviruses-41/NNS	conj_and||h5n1-38/NNS||influenzaviruses-41/NNS	h5n1-38||influenzaviruses-41||no||to test this hypothesis, we detected î±2,3- and î±2,6-linked sialic acid in human nasal polyp and normal nasal mucosal tissues by lectin staining and infected explants of those tissues with avianinfluenzaviruses h5n1 and seasonal influenzaviruses.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||no||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provides-11/VBZ||that-4/IN	det||combination-6/NN||the-5/DT	nsubj||provides-11/VBZ||combination-6/NN	amod||olmesartanmedoxomil-10/NN||amlodipine-8/JJ	amod||olmesartanmedoxomil-10/NN||+-9/JJ	prep_of||combination-6/NN||olmesartanmedoxomil-10/NN	ccomp||suggest-3/VBP||provides-11/VBZ	det||option-16/NN||a-12/DT	amod||option-16/NN||safe-13/JJ	conj_and||safe-13/JJ||effective-15/JJ	amod||option-16/NN||effective-15/JJ	dobj||provides-11/VBZ||option-16/NN	det||treatment-19/NN||the-18/DT	prep_for||option-16/NN||treatment-19/NN	prep_of||treatment-19/NN||hypertension-21/NN	prepc_in||provides-11/VBZ||challenging-23/VBG	amod||populations-25/NNS||patient-24/JJ	dobj||challenging-23/VBG||populations-25/NNS	hypertension-21||amlodipine-8||yes||these results suggest that the combination of amlodipine+olmesartanmedoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
det||activity-5/NN||the-1/DT	dep||vitro-3/NN||in-2/IN	amod||activity-5/NN||vitro-3/NN	amod||activity-5/NN||anticandidal-4/JJ	nsubj||racemosus-8/VBZ||activity-5/NN	prep_of||activity-5/NN||asparagus-7/NNS	dep||investigated-14/VBN||racemosus-8/VBZ	nsubj||extract-12/VB||roots-9/NNS	conj_and||roots-9/NNS||tubers-11/NNS	nsubj||extract-12/VB||tubers-11/NNS	ccomp||racemosus-8/VBZ||extract-12/VB	auxpass||investigated-14/VBN||was-13/VBD	root||ROOT-0/null||investigated-14/VBN	prep_against||investigated-14/VBN||candidaalbicans-16/NNS	nn||tropicalis-19/NNS||candida-18/NN	prep_against||investigated-14/VBN||tropicalis-19/NNS	conj_and||candidaalbicans-16/NNS||tropicalis-19/NNS	nn||krusei-22/NNS||candida-21/NN	prep_against||investigated-14/VBN||krusei-22/NNS	conj_and||candidaalbicans-16/NNS||krusei-22/NNS	nn||guillermondii-25/NNS||candida-24/NN	prep_against||investigated-14/VBN||guillermondii-25/NNS	conj_and||candidaalbicans-16/NNS||guillermondii-25/NNS	nn||parapsilosis-28/NNS||candida-27/NN	prep_against||investigated-14/VBN||parapsilosis-28/NNS	conj_and||candidaalbicans-16/NNS||parapsilosis-28/NNS	prep_against||investigated-14/VBN||candida-30/NN	conj_and||candidaalbicans-16/NNS||candida-30/NN	nsubjpass||investigated-14/VBN||stellatoida-31/NN	nsubjpass||isolated-35/VBN||stellatoida-31/NN	auxpass||isolated-35/VBN||are-34/VBP	rcmod||stellatoida-31/NN||isolated-35/VBN	amod||patients-38/NNS||vaginalthrush-37/JJ	prep_from||isolated-35/VBN||patients-38/NNS	vaginalthrush-37||albicans--1||no||the in vitro anticandidal activity of asparagus racemosus roots and tubers extract was investigated against candidaalbicans, candida tropicalis, candida krusei, candida guillermondii, candida parapsilosis and candida stellatoida, which are isolated from vaginalthrush patients.
det||variables-4/NNS||the-2/DT	amod||variables-4/NNS||studied-3/JJ	prep_among||associated-10/VBN||variables-4/NNS	det||following-7/NN||the-6/DT	nsubjpass||associated-10/VBN||following-7/NN	auxpass||associated-10/VBN||were-8/VBD	advmod||associated-10/VBN||positively-9/RB	root||ROOT-0/null||associated-10/VBN	det||presence-13/NN||the-12/DT	prep_with||associated-10/VBN||presence-13/NN	dep||h.-16/NN||anti--15/NN	amod||antibodies-18/NNS||h.-16/NN	nn||antibodies-18/NNS||pylori-17/NN	prep_of||presence-13/NN||antibodies-18/NNS	amod||age-22/NN||multivariable-20/JJ	nn||age-22/NN||analyses-21/NNS	prep_in||antibodies-18/NNS||age-22/NN	num||years-25/NNS||8-24/CD	prep_above||age-22/NN||years-25/NNS	dep||-lrb--27/NN||old-26/JJ	amod||age-22/NN||-lrb--27/NN	amod||ci-34/NN||=-29/JJ	dep||=-29/JJ||1.72-30/CD	number||%-33/NN||95-32/CD	amod||1.72-30/CD||%-33/NN	amod||age-22/NN||ci-34/NN	conj_or||-lrb--27/NN||ci-34/NN	number||1.23-36/CD||=-35/CD	num||â-37/NN||1.23-36/CD	dep||-lrb--27/NN||â-37/NN	dep||-rrb--41/NN||$-38/$	num||$-38/$||2.40-40/CD	amod||antibodies-18/NNS||-rrb--41/NN	det||1.32-113/NN||a-43/DT	dep||sibling-45/VBG||larger-44/JJR	amod||1.32-113/NN||sibling-45/VBG	nn||1.32-113/NN||number-46/NN	dep||1.66-50/VBG||-lrb--47/NN	conj_or||1.66-50/VBG||=-49/NN	amod||1.32-113/NN||=-49/NN	amod||1.32-113/NN||1.66-50/VBG	number||%-53/NN||95-52/CD	amod||1.32-113/NN||%-53/NN	nn||1.32-113/NN||ci-54/NN	amod||1.32-113/NN||=-55/JJ	num||â-57/NN||1.26-56/CD	dep||=-55/JJ||â-57/NN	dep||-rrb--61/NN||$-58/$	num||$-58/$||2.18-60/CD	amod||â-57/NN||-rrb--61/NN	nn||attendance-64/NN||nursery-63/NN	appos||â-57/NN||attendance-64/NN	dep||1.49-68/VBG||-lrb--65/NN	amod||attendance-64/NN||=-67/NN	conj_or||1.49-68/VBG||=-67/NN	amod||attendance-64/NN||1.49-68/VBG	num||%-71/NN||95-70/CD	appos||â-57/NN||%-71/NN	conj_and||attendance-64/NN||%-71/NN	vmod||%-71/NN||ci-72/VBN	dep||â-75/NN||=-73/SYM	num||â-75/NN||1.04-74/CD	ccomp||ci-72/VBN||â-75/NN	dep||-rrb--79/NN||$-76/$	num||$-76/$||2.12-78/CD	amod||%-71/NN||-rrb--79/NN	conj_and||attendance-64/NN||location-81/NN	conj_or||%-71/NN||location-81/NN	det||house-84/NN||the-83/DT	prep_of||location-81/NN||house-84/NN	det||-lrb--89/NN||an-86/DT	amod||-lrb--89/NN||unpaved-87/JJ	nn||-lrb--89/NN||street-88/NN	prep_at||house-84/NN||-lrb--89/NN	conj_and||attendance-64/NN||=-91/NNP	conj_or||%-71/NN||=-91/NNP	num||=-91/NNP||2.03-92/CD	num||%-95/NN||95-94/CD	appos||â-57/NN||%-95/NN	conj_and||attendance-64/NN||%-95/NN	nn||â-99/FW||ci-96/FW	nn||â-99/FW||=-97/FW	nn||â-99/FW||1.44-98/FW	dep||%-95/NN||â-99/FW	dep||-rrb--103/NN||$-100/$	num||$-100/$||2.87-102/CD	amod||â-99/FW||-rrb--103/NN	appos||â-57/NN||absence-105/NN	conj_and||attendance-64/NN||absence-105/NN	det||toilet-109/NN||a-107/DT	amod||toilet-109/NN||flush-108/JJ	prep_of||absence-105/NN||toilet-109/NN	amod||1.32-113/NN||-lrb--110/NN	conj_or||-lrb--110/NN||=-112/NN	amod||1.32-113/NN||=-112/NN	appos||antibodies-18/NNS||1.32-113/NN	num||%-116/NN||95-115/CD	appos||antibodies-18/NNS||%-116/NN	vmod||%-116/NN||ci-117/VBN	dep||â-120/NN||=-118/SYM	num||â-120/NN||1.00-119/CD	ccomp||ci-117/VBN||â-120/NN	dep||-rrb--124/NN||$-121/$	num||$-121/$||1.74-123/CD	amod||presence-13/NN||-rrb--124/NN	antibodies-18||flush-108||no_rel||among the studied variables , the following were positively associated with the presence of anti- h. pylori antibodies in multivariable analyses age above 8 years old -lrb- or = 1.72 , 95 % ci = 1.23 â $ `` 2.40 -rrb- , a larger sibling number -lrb- or = 1.66 , 95 % ci = 1.26 â $ `` 2.18 -rrb- , nursery attendance -lrb- or = 1.49 , 95 % ci = 1.04 â $ `` 2.12 -rrb- , location of the house at an unpaved street -lrb- or = 2.03 , 95 % ci = 1.44 â $ `` 2.87 -rrb- and absence of a flush toilet -lrb- or = 1.32 , 95 % ci = 1.00 â $ `` 1.74 -rrb- .
det||findings-3/NNS||some-1/DT	amod||findings-3/NNS||key-2/JJ	nsubjpass||presented-14/VBN||findings-3/NNS	nsubj||show-16/VB||findings-3/NNS	det||trial-8/NN||a-5/DT	advmod||trial-8/NN||recently-6/RB	amod||trial-8/NN||unpublished-7/JJ	prep_of||findings-3/NNS||trial-8/NN	nn||knees-11/NNS||oa-10/NN	prep_in||trial-8/NN||knees-11/NNS	auxpass||presented-14/VBN||are-12/VBP	advmod||presented-14/VBN||also-13/RB	root||ROOT-0/null||presented-14/VBN	aux||show-16/VB||to-15/TO	xcomp||presented-14/VBN||show-16/VB	dobj||show-16/VB||equivalence-17/JJ	amod||medicine-20/NN||ayurvedic-19/JJ	prep_between||equivalence-17/JJ||medicine-20/NN	prep_between||equivalence-17/JJ||celecoxib-22/NN	conj_and||medicine-20/NN||celecoxib-22/NN	prep_between||equivalence-17/JJ||glucosamine-24/NN	conj_and||medicine-20/NN||glucosamine-24/NN	nsubj||speculate-28/VBP||we-27/PRP	conj_and||presented-14/VBN||speculate-28/VBP	mark||way-35/NN||that-29/IN	amod||trials-31/NNS||equivalence-30/JJ	nsubj||way-35/NN||trials-31/NNS	aux||way-35/NN||may-32/MD	cop||way-35/NN||be-33/VB	det||way-35/NN||a-34/DT	ccomp||speculate-28/VBP||way-35/NN	advmod||way-35/NN||forward-36/RB	oa-10||celecoxib-22||yes||some key findings of a recently unpublished trial in oa knees are also presented to show equivalence between ayurvedic medicine and celecoxib and glucosamine, and we speculate that equivalence trials may be a way forward.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||loperamide-27||no||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
det||focus-2/NN||the-1/DT	nsubj||is-3/VBZ||focus-2/NN	root||ROOT-0/null||is-3/VBZ	det||use-6/NN||the-5/DT	prep_on||is-3/VBZ||use-6/NN	prep_of||use-6/NN||cmr-8/NN	det||diagnosis-11/NN||the-10/DT	prep_in||cmr-8/NN||diagnosis-11/NN	prep_of||diagnosis-11/NN||coronaryarterydisease-13/NN	prep_with||is-3/VBZ||summaries-15/NNS	nn||literature-18/NN||validation-17/NN	prep_of||summaries-15/NNS||literature-18/NN	nn||viability-21/NN||cmr-20/NN	prep_in||literature-18/NN||viability-21/NN	amod||perfusion-24/NN||myocardial-23/JJ	prep_in||literature-18/NN||perfusion-24/NN	conj_and||viability-21/NN||perfusion-24/NN	amod||cmr-28/NN||dobutamine-27/JJ	prep_in||literature-18/NN||cmr-28/NN	conj_and||viability-21/NN||cmr-28/NN	dobutamine-27||coronaryarterydisease-13||no_rel||the focus is on the use of cmr in the diagnosis of coronaryarterydisease with summaries of validation literature in cmr viability, myocardial perfusion, and dobutamine cmr.
advmod||hepatitisbvirus-8/VBZ||recently-1/RB	det||-rrb--7/NN||a-3/DT	amod||-rrb--7/NN||complex-4/JJ	amod||-rrb--7/NN||-lrb--5/JJ	nn||-rrb--7/NN||x/c-6/NN	nsubj||hepatitisbvirus-8/VBZ||-rrb--7/NN	root||ROOT-0/null||hepatitisbvirus-8/VBZ	nn||recombinant-12/NNP||-lrb--9/NNP	nn||recombinant-12/NNP||hbv-10/NNP	nn||recombinant-12/NNP||-rrb--11/NNP	nsubjpass||proposed-20/VBN||recombinant-12/NNP	advmod||reported-15/VBN||first-14/RB	vmod||recombinant-12/NNP||reported-15/VBN	prep_in||reported-15/VBN||2000-17/CD	auxpass||proposed-20/VBN||was-19/VBD	ccomp||hepatitisbvirus-8/VBZ||proposed-20/VBN	det||genotype-24/NN||a-22/DT	amod||genotype-24/NN||new-23/JJ	prep_as||proposed-20/VBN||genotype-24/NN	mark||refuted-29/VBN||although-26/IN	nsubjpass||refuted-29/VBN||this-27/DT	auxpass||refuted-29/VBN||was-28/VBD	advcl||isolates-59/VBZ||refuted-29/VBN	advmod||refuted-29/VBN||immediately-30/RB	mark||differ-34/VBP||because-31/IN	det||strains-33/NNS||the-32/DT	nsubj||differ-34/VBP||strains-33/NNS	advcl||refuted-29/VBN||differ-34/VBP	mwe||than-37/IN||less-36/JJR	quantmod||8â-38/CD||than-37/IN	prep_by||differ-34/VBP||8â-38/CD	num||%-41/NN||$-39/$	num||$-39/$||š-40/CD	dobj||differ-34/VBP||%-41/NN	amod||distance-44/NN||nucleotide-43/JJ	prep_in||%-41/NN||distance-44/NN	amod||c.-47/NN||genotype-46/JJ	prep_from||differ-34/VBP||c.-47/NN	number||â-50/CD||13.5-49/CD	num||-lrb--54/NNS||â-50/CD	dep||%-53/NN||$-51/$	num||$-51/$||š-52/CD	amod||-lrb--54/NNS||%-53/NN	prep_over||c.-47/NN||-lrb--54/NNS	num||-rrb--56/NNS||38/281-55/CD	nsubj||isolates-59/VBZ||-rrb--56/NNS	prep_of||-rrb--56/NNS||hbv-58/NN	parataxis||hepatitisbvirus-8/VBZ||isolates-59/VBZ	det||long-62/JJ||the-61/DT	prep_from||isolates-59/VBZ||long-62/JJ	det||cohort-64/NN||an-63/DT	nsubjpass||assigned-69/VBN||cohort-64/NN	prep_in||cohort-64/NN||china-66/NN	auxpass||assigned-69/VBN||were-67/VBD	neg||assigned-69/VBN||not-68/RB	rcmod||long-62/JJ||assigned-69/VBN	det||genotype-73/NN||a-71/DT	amod||genotype-73/NN||specific-72/JJ	prep_to||assigned-69/VBN||genotype-73/NN	xcomp||assigned-69/VBN||using-75/VBG	amod||tools-78/NNS||current-76/JJ	nn||tools-78/NNS||genotyping-77/NN	dobj||using-75/VBG||tools-78/NNS	aux||analyse-80/VB||to-79/TO	vmod||using-75/VBG||analyse-80/VB	nn||sequences-83/NNS||surface-81/NN	nn||sequences-83/NNS||orf-82/NN	dobj||analyse-80/VB||sequences-83/NNS	nsubj||have-87/VBP||these-86/DT	parataxis||hepatitisbvirus-8/VBZ||have-87/VBP	conj_and||isolates-59/VBZ||have-87/VBP	amod||similarity-93/NN||98â-89/JJ	dep||%-92/NN||$-90/$	num||$-90/$||š-91/CD	amod||similarity-93/NN||%-92/NN	prep_about||have-87/VBP||similarity-93/NN	det||recombinants-97/NNS||the-95/DT	nn||recombinants-97/NNS||x/c-96/NN	prep_to||have-87/VBP||recombinants-97/NNS	hbv-58||hepatitisbvirus-8||no||recently , a complex -lrb- x/c -rrb- hepatitisbvirus -lrb- hbv -rrb- recombinant , first reported in 2000 , was proposed as a new genotype ; although this was refuted immediately because the strains differ by less than 8â $ š % in nucleotide distance from genotype c. over 13.5 â $ š % -lrb- 38/281 -rrb- of hbv isolates from the long an cohort in china were not assigned to a specific genotype , using current genotyping tools to analyse surface orf sequences , and these have about 98â $ š % similarity to the x/c recombinants .
advmod||suggest-15/VBP||indeed-1/RB	amod||lines-4/NNS||several-3/JJ	nsubj||suggest-15/VBP||lines-4/NNS	prep_of||lines-4/NNS||evidence-6/NN	prep_including||evidence-6/NN||epidemiologic-8/NN	prep_including||evidence-6/NN||preclinical-10/JJ	conj_and||epidemiologic-8/NN||preclinical-10/JJ	amod||data-14/NNS||clinical-13/JJ	prep_including||evidence-6/NN||data-14/NNS	conj_and||epidemiologic-8/NN||data-14/NNS	root||ROOT-0/null||suggest-15/VBP	mark||and/or-20/VBD||that-16/IN	amod||levels-19/NNS||reduced-17/VBN	amod||levels-19/NNS||vitamind-18/JJ	nsubj||and/or-20/VBD||levels-19/NNS	ccomp||suggest-15/VBP||and/or-20/VBD	nsubj||factor-28/NN||dysregulation-21/NN	amod||homeostasis-24/NNS||vitamind-23/JJ	prep_of||dysregulation-21/NN||homeostasis-24/NNS	cop||factor-28/NN||is-25/VBZ	det||factor-28/NN||a-26/DT	nn||factor-28/NN||risk-27/NN	ccomp||and/or-20/VBD||factor-28/NN	det||development-31/NN||the-30/DT	prep_for||factor-28/NN||development-31/NN	prep_of||development-31/NN||multiplesclerosis-33/NNS	det||hand-37/NN||the-35/DT	num||hand-37/NN||one-36/CD	prep_on||multiplesclerosis-33/NNS||hand-37/NN	mark||associated-46/VBN||that-40/IN	amod||levels-43/NNS||vitamind-41/JJ	nn||levels-43/NNS||serum-42/NN	nsubjpass||associated-46/VBN||levels-43/NNS	auxpass||associated-46/VBN||are-44/VBP	advmod||associated-46/VBN||inversely-45/RB	ccomp||suggest-15/VBP||associated-46/VBN	conj_and||and/or-20/VBD||associated-46/VBN	nn||activity-49/NN||disease-48/NN	prep_with||associated-46/VBN||activity-49/NN	prep_with||associated-46/VBN||progression-51/NN	conj_and||activity-49/NN||progression-51/NN	det||hand-55/NN||the-53/DT	amod||hand-55/NN||other-54/JJ	prep_on||associated-46/VBN||hand-55/NN	vitamind-41||multiplesclerosis-33||no_rel||indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamind levels and/or dysregulation of vitamind homeostasis is a risk factor for the development of multiplesclerosis on the one hand, and that vitamind serum levels are inversely associated with disease activity and progression on the other hand.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||ketamine-34||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-6/NN||the-3/DT	amod||case-6/NN||first-4/JJ	amod||case-6/NN||known-5/JJ	dobj||present-2/VBP||case-6/NN	det||patient-9/NN||a-8/DT	prep_of||case-6/NN||patient-9/NN	amod||squamouscellcarcinoma-12/NN||cervical-11/JJ	prep_with||present-2/VBP||squamouscellcarcinoma-12/NN	vmod||squamouscellcarcinoma-12/NN||complicated-13/VBN	agent||complicated-13/VBN||paraneoplasticsyndromes-15/NNS	det||secretion-21/NN||both-17/DT	amod||secretion-21/NN||dermatomyositis-18/JJ	conj_and||dermatomyositis-18/JJ||inappropriate-20/JJ	amod||secretion-21/NN||inappropriate-20/JJ	prep_of||paraneoplasticsyndromes-15/NNS||secretion-21/NN	amod||hormone-24/NN||antidiuretic-23/JJ	prep_of||secretion-21/NN||hormone-24/NN	appos||hormone-24/NN||siadh-26/NN	dermatomyositis-18||hormone-24||no_rel||we present the first known case of a patient with cervical squamouscellcarcinoma complicated by paraneoplasticsyndromes of both dermatomyositis and inappropriate secretion of antidiuretic hormone (siadh).
aux||determine-2/VB||to-1/TO	advcl||lesions-19/VBZ||determine-2/VB	det||effect-4/NN||the-3/DT	dobj||determine-2/VB||effect-4/NN	amod||treatment-10/NN||chondroitinsulphate-6/JJ	appos||treatment-10/NN||cs-8/NN	prep_of||effect-4/NN||treatment-10/NN	nn||loss-14/NN||cartilage-12/NN	nn||loss-14/NN||volume-13/NN	prep_on||treatment-10/NN||loss-14/NN	amod||marrow-18/NN||subchondral-16/JJ	nn||marrow-18/NN||bone-17/NN	nsubj||lesions-19/VBZ||marrow-18/NN	root||ROOT-0/null||lesions-19/VBZ	dobj||lesions-19/VBZ||bml-21/NN	dobj||lesions-19/VBZ||synovitis-24/NNS	conj_and||bml-21/NN||synovitis-24/NNS	nn||symptoms-27/NNS||disease-26/NN	dobj||lesions-19/VBZ||symptoms-27/NNS	conj_and||bml-21/NN||symptoms-27/NNS	prep_in||lesions-19/VBZ||patients-29/NNS	nn||osteoarthritis-32/NNS||knee-31/NN	prep_with||patients-29/NNS||osteoarthritis-32/NNS	appos||osteoarthritis-32/NNS||oa-34/NN	oa-34||chondroitinsulphate-6||yes||to determine the effect of chondroitinsulphate (cs) treatment on cartilage volume loss, subchondral bone marrow lesions (bml), synovitis and disease symptoms in patients with knee osteoarthritis (oa).
det||vildagliptin-8/NN||the-1/DT	amod||peptidase-iv-3/JJ||dipeptidyl-2/JJ	amod||vildagliptin-8/NN||peptidase-iv-3/JJ	dep||peptidase-iv-3/JJ||dpp-4-5/JJ	nn||vildagliptin-8/NN||inhibitor-7/NN	nsubjpass||shown-12/VBN||vildagliptin-8/NN	nsubj||protect-14/VB||vildagliptin-8/NN	aux||shown-12/VBN||has-9/VBZ	advmod||shown-12/VBN||also-10/RB	auxpass||shown-12/VBN||been-11/VBN	root||ROOT-0/null||shown-12/VBN	aux||protect-14/VB||to-13/TO	xcomp||shown-12/VBN||protect-14/VB	prep_from||protect-14/VB||hypoglycemia-16/NN	prepc_by||protect-14/VB||enhancing-18/VBG	nn||counterregulation-20/NN||glucagon-19/NN	dobj||enhancing-18/VBG||counterregulation-20/NN	hypoglycemia-16||glucagon-19||yes||the dipeptidyl peptidase-iv (dpp-4) inhibitor vildagliptin has also been shown to protect from hypoglycemia by enhancing glucagon counterregulation.
vmod||assessed-10/VBN||using-1/VBG	num||samples-3/NNS||128-2/CD	dobj||using-1/VBG||samples-3/NNS	det||methods-8/NNS||the-5/DT	num||methods-8/NNS||five-6/CD	nn||methods-8/NNS||pcr-7/NN	nsubjpass||assessed-10/VBN||methods-8/NNS	auxpass||assessed-10/VBN||were-9/VBD	root||ROOT-0/null||assessed-10/VBN	det||protocol-16/NN||an-13/DT	amod||protocol-16/NN||in-house-14/JJ	nn||protocol-16/NN||pcr-15/NN	prep_including||assessed-10/VBN||protocol-16/NN	det||mtb-21/NN||the-18/DT	amod||mtb-21/NN||cobas-19/JJ	nn||mtb-21/NN||amplicor-20/NN	prep_including||assessed-10/VBN||mtb-21/NN	conj_and||protocol-16/NN||mtb-21/NN	det||mtb-26/NN||the-23/DT	amod||mtb-26/NN||cobas-24/JJ	nn||mtb-26/NN||taqman-25/NN	prep_including||assessed-10/VBN||mtb-26/NN	conj_and||protocol-16/NN||mtb-26/NN	det||pcr-32/NN||the-28/DT	amod||pcr-32/NN||advansure-29/JJ	amod||pcr-32/NN||tb/ntm-30/JJ	amod||pcr-32/NN||real-time-31/JJ	prep_including||assessed-10/VBN||pcr-32/NN	conj_and||protocol-16/NN||pcr-32/NN	det||kit-38/NN||the-35/DT	amod||kit-38/NN||real-q-36/JJ	nn||kit-38/NN||m.tuberculosis-37/NNS	prep_including||assessed-10/VBN||kit-38/NN	conj_and||protocol-16/NN||kit-38/NN	tb--1||mtb-26||no||using 128 samples , the five pcr methods were assessed , including an in-house pcr protocol , the cobas amplicor mtb , the cobas taqman mtb , the advansure tb/ntm real-time pcr , and the real-q m.tuberculosis kit .
nsubjpass||treated-27/VBN||individuals-1/NNS	dep||individuals-1/NNS||n-3/VBN	dep||113-5/CD||=-4/SYM	ccomp||n-3/VBN||113-5/CD	amod||depressivedisorder-22/NN||dsm-iv-8/JJ	amod||manual-13/NN||diagnostic-10/JJ	conj_and||diagnostic-10/JJ||statistical-12/JJ	amod||manual-13/NN||statistical-12/JJ	dep||dsm-iv-8/JJ||manual-13/NN	amod||disorders-16/NNS||mental-15/JJ	prep_of||manual-13/NN||disorders-16/NNS	amod||edition-19/NN||fourth-18/JJ	appos||disorders-16/NNS||edition-19/NN	amod||depressivedisorder-22/NN||major-21/JJ	prep_with||individuals-1/NNS||depressivedisorder-22/NN	appos||depressivedisorder-22/NN||mdd-24/NN	auxpass||treated-27/VBN||were-26/VBD	root||ROOT-0/null||treated-27/VBN	prep_with||treated-27/VBN||escitalopram-29/NN	appos||escitalopram-29/NN||esc-31/NN	prep_with||treated-27/VBN||venlafaxine-34/NN	conj_or||escitalopram-29/NN||venlafaxine-34/NN	appos||escitalopram-29/NN||ven-36/NN	num||weeks-40/NNS||8-39/CD	prep_over||treated-27/VBN||weeks-40/NNS	escitalopram-29||depressivedisorder-22||no_rel||individuals ( n =113) with dsm-iv (diagnostic and statistical manual of mental disorders, fourth edition) major depressivedisorder (mdd) were treated with escitalopram (esc) or venlafaxine (ven) over 8 weeks.
vmod||support-6/VBP||taken-1/VBN	advmod||taken-1/VBN||together-2/RB	det||data-5/NNS||these-4/DT	nsubj||support-6/VBP||data-5/NNS	root||ROOT-0/null||support-6/VBP	amod||inhibition-8/NN||sglt2-7/JJ	dobj||support-6/VBP||inhibition-8/NN	det||treatment-13/NN||a-10/DT	amod||treatment-13/NN||viable-11/JJ	amod||treatment-13/NN||insulin-independent-12/JJ	prep_as||support-6/VBP||treatment-13/NN	prep_of||treatment-13/NN||type2diabetes-15/CD	type2diabetes-15||insulin--1||yes||taken together, these data support sglt2 inhibition as a viable insulin-independent treatment of type2diabetes.
advmod||overwhelmed-7/VBN||when-1/WRB	det||level-5/NN||this-2/DT	amod||level-5/NN||first-3/JJ	amod||level-5/NN||regulatory-4/JJ	nsubjpass||overwhelmed-7/VBN||level-5/NN	auxpass||overwhelmed-7/VBN||is-6/VBZ	advcl||occurs-20/VBZ||overwhelmed-7/VBN	nsubj||is-10/VBZ||that-9/WDT	parataxis||overwhelmed-7/VBN||is-10/VBZ	prep_by||is-10/VBZ||exogenous-13/NNS	xcomp||is-10/VBZ||glucose-14/VBG	dobj||glucose-14/VBG||supplementation-15/NN	amod||hyperglycaemia-19/NN||persistent-18/JJ	nsubj||occurs-20/VBZ||hyperglycaemia-19/NN	root||ROOT-0/null||occurs-20/VBZ	amod||consequences-23/NNS||intricate-22/JJ	prep_with||occurs-20/VBZ||consequences-23/NNS	vmod||consequences-23/NNS||related-24/VBN	det||glucose-27/NN||the-26/DT	prep_to||related-24/VBN||glucose-27/NN	vmod||glucose-27/NN||acting-28/VBG	det||substrate-32/NN||a-30/DT	amod||substrate-32/NN||metabolic-31/JJ	prep_as||acting-28/VBG||substrate-32/NN	det||mediator-37/NN||an-35/DT	nn||mediator-37/NN||intracellular-36/NN	prep_as||acting-28/VBG||mediator-37/NN	conj_and||substrate-32/NN||mediator-37/NN	hyperglycaemia-19||glucose-27||no||when this first regulatory level is overwhelmed (that is, by exogenous glucose supplementation), persistent hyperglycaemia occurs with intricate consequences related to the glucose acting as a metabolic substrate and as an intracellular mediator.
det||wells-3/NNS||the-1/DT	nn||wells-3/NNS||quantum-2/NN	nsubj||has-11/VBZ||wells-3/NNS	nsubj||shows-18/VBZ||wells-3/NNS	vmod||wells-3/NNS||grown-4/VBN	det||gan-10/NN||the-6/DT	amod||gan-10/NN||nano-epitaxially-7/JJ	amod||gan-10/NN||lateral-8/JJ	nn||gan-10/NN||overgrown-9/NN	prep_on||grown-4/VBN||gan-10/NN	root||ROOT-0/null||has-11/VBZ	det||field-15/NN||a-12/DT	dep||piezoelectric-14/JJ||weaker-13/JJR	amod||field-15/NN||piezoelectric-14/JJ	dobj||has-11/VBZ||field-15/NN	advmod||shows-18/VBZ||hence-17/RB	conj_and||has-11/VBZ||shows-18/VBZ	det||shift-22/NN||a-19/DT	amod||shift-22/NN||minimal-20/JJ	nn||shift-22/NN||peak-21/NN	dobj||shows-18/VBZ||shift-22/NN	prep_with||shows-18/VBZ||application-24/NN	amod||current-28/NN||higher-26/JJR	nn||current-28/NN||injection-27/NN	prep_of||application-24/NN||current-28/NN	gan-10||wells-3||no_rel||the quantum wells grown on the nano-epitaxially lateral overgrown gan has a weaker piezoelectric field and hence shows a minimal peak shift with application of higher injection current.
amod||efficacy-4/NN||limited-2/JJ	amod||efficacy-4/NN||clinical-3/JJ	prep_despite||remains-14/VBZ||efficacy-4/NN	nsubj||remains-14/VBZ||treatment-6/NN	prep_with||treatment-6/NN||dacarbazine-8/NN	prep_with||treatment-6/NN||temozolomide-10/NN	conj_or||dacarbazine-8/NN||temozolomide-10/NN	appos||treatment-6/NN||tmz-12/NN	root||ROOT-0/null||remains-14/VBZ	det||therapy-17/NN||the-15/DT	amod||therapy-17/NN||standard-16/JJ	xcomp||remains-14/VBZ||therapy-17/NN	amod||melanoma-20/NN||metastatic-19/JJ	prep_for||therapy-17/NN||melanoma-20/NN	melanoma-20||temozolomide-10||yes||despite limited clinical efficacy, treatment with dacarbazine or temozolomide (tmz) remains the standard therapy for metastatic melanoma.
det||study-2/NN||this-1/DT	nsubj||diagnosed-23/VBD||study-2/NN	vmod||study-2/NN||sought-3/VBN	aux||compare-5/VB||to-4/TO	xcomp||sought-3/VBN||compare-5/VB	det||safety-7/NN||the-6/DT	dobj||compare-5/VB||safety-7/NN	iobj||compare-5/VB||safety-7/NN	dobj||compare-5/VB||efficacy-9/NN	iobj||compare-5/VB||efficacy-9/NN	conj_and||safety-7/NN||efficacy-9/NN	prep_of||safety-7/NN||placeboxetine-11/NN	appos||safety-7/NN||pb-13/NN	amod||capsules-18/NNS||hydrochloride-15/JJ	amod||capsules-18/NNS||extended-16/VBN	nn||capsules-18/NNS||release-17/NN	dep||safety-7/NN||capsules-18/NNS	prep_with||capsules-18/NNS||sertralinehydrochloride-20/NN	prep_in||capsules-18/NNS||patients-22/NNS	root||ROOT-0/null||diagnosed-23/VBD	amod||depressivedisorder-26/NN||major-25/JJ	prep_with||diagnosed-23/VBD||depressivedisorder-26/NN	num||hospitals-30/NNS||15-28/CD	amod||hospitals-30/NNS||general-29/JJ	prep_in||diagnosed-23/VBD||hospitals-30/NNS	amod||india-33/NN||south-32/JJ	prep_in||hospitals-30/NNS||india-33/NN	depressivedisorder-26||sertralinehydrochloride-20||yes||this study sought to compare the safety and efficacy of placeboxetine (pb) hydrochloride extended release capsules with sertralinehydrochloride in patients diagnosed with major depressivedisorder in 15 general hospitals in south india.
root||ROOT-0/null||objective-1/NN	aux||determine-3/VB||to-2/TO	dep||objective-1/NN||determine-3/VB	dep||objective-1/NN||determine-3/VB	conj_and||determine-3/VB||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||glucosamine-7/NN	prep_of||effect-5/NN||chondroitin-9/NN	conj_or||glucosamine-7/NN||chondroitin-9/NN	det||two-13/CD||the-12/DT	prep_of||effect-5/NN||two-13/CD	conj_or||glucosamine-7/NN||two-13/CD	prep_in||determine-3/VB||combination-15/NN	amod||pain-18/NN||joint-17/JJ	prep_on||combination-15/NN||pain-18/NN	amod||progression-22/NN||radiological-21/JJ	prep_on||determine-3/VB||progression-22/NN	prep_of||progression-22/NN||disease-24/NN	prep_in||determine-3/VB||osteoarthritis-26/NNS	det||hip-29/NN||the-28/DT	prep_of||osteoarthritis-26/NNS||hip-29/NN	prep_of||osteoarthritis-26/NNS||knee-31/NN	conj_or||hip-29/NN||knee-31/NN	osteoarthritis-26||chondroitin-9||yes||objective to determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee.
nsubj||report-4/NN||this-1/DT	cop||report-4/NN||is-2/VBZ	det||report-4/NN||a-3/DT	root||ROOT-0/null||report-4/NN	det||technique-7/NN||a-6/DT	prep_of||report-4/NN||technique-7/NN	prep_in||used-12/VBN||technique-7/NN	nsubjpass||used-12/VBN||r-tpa-10/NN	nsubj||target-18/VB||r-tpa-10/NN	auxpass||used-12/VBN||is-11/VBZ	rcmod||technique-7/NN||used-12/VBN	det||space-16/NN||the-14/DT	amod||space-16/NN||intrachoroidal-15/JJ	prep_in||used-12/VBN||space-16/NN	aux||target-18/VB||to-17/TO	xcomp||used-12/VBN||target-18/VB	det||clot-21/NN||the-19/DT	amod||clot-21/NN||organized-20/JJ	dobj||target-18/VB||clot-21/NN	amod||hemorrhage-24/NN||suprachoroidal-23/JJ	prep_of||clot-21/NN||hemorrhage-24/NN	advmod||target-18/VB||prior-25/RB	aux||drainage-27/VB||to-26/TO	dep||prior-25/RB||drainage-27/VB	r-tpa-10||hemorrhage-24||no_rel||this is a report of a technique in which r-tpa is used in the intrachoroidal space to target the organized clot of suprachoroidal hemorrhage prior to drainage.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||isoniazid-12||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||reduced-2/VBD||riluzole-1/NN	root||ROOT-0/null||reduced-2/VBD	det||number-5/NN||the-3/DT	amod||number-5/NN||average-4/JJ	dobj||reduced-2/VBD||number-5/NN	det||arrhythmias-8/NNS||all-7/DT	prep_of||number-5/NN||arrhythmias-8/NNS	prep_in||arrhythmias-8/NNS||phase-10/NN	num||phase-10/NN||2-11/CD	dep||arrhythmias-8/NNS||pvcs-13/NNS	number||+-16/CD||484-15/CD	prep_from||pvcs-13/NNS||+-16/CD	punct||+-58/JJ||/-17/:	poss||âˆ-53/NN||âˆ-18/NNP	number||32-22/CD||119-20/CD	dep||32-22/CD||to-21/TO	num||âˆ-53/NN||32-22/CD	amod||âˆ-53/NN||+-23/JJ	punct||âˆ-25/NNP||/-24/:	dep||âˆ-53/NN||âˆ-25/NNP	dep||âˆ-25/NNP||13-27/CD	amod||arrhythmias-31/NNS||non-29/JJ	amod||arrhythmias-31/NNS||sustained-30/JJ	dep||âˆ-25/NNP||arrhythmias-31/NNS	number||+-34/CD||8.9-33/CD	num||0.5-45/NNS||+-34/CD	punct||4.4-38/NN||/-35/:	poss||4.4-38/NN||âˆ-36/NNP	dep||0.5-45/NNS||4.4-38/NN	num||+-41/NNS||0.7-40/CD	prep_to||4.4-38/NN||+-41/NNS	punct||4.4-38/NN||/-42/:	nn||0.5-45/NNS||âˆ-43/NN	prep_from||arrhythmias-31/NNS||0.5-45/NNS	amod||arrhythmias-48/NNS||sustained-47/JJ	dep||0.5-45/NNS||arrhythmias-48/NNS	num||+-51/NNS||3.9-50/CD	prep_from||âˆ-25/NNP||+-51/NNS	punct||âˆ-25/NNP||/-52/:	npadvmod||+-58/JJ||âˆ-53/NN	number||0.5-57/CD||2.2-55/CD	dep||0.5-57/CD||to-56/TO	num||âˆ-53/NN||0.5-57/CD	dep||+-16/CD||+-58/JJ	punct||+-58/JJ||/-59/:	vmod||pvcs-13/NNS||âˆ-60/VBN	dobj||âˆ-60/VBN||0.4-62/CD	nsubj||reduced-66/VBD||lidocaine-65/NN	parataxis||reduced-2/VBD||reduced-66/VBD	det||number-69/NN||the-67/DT	amod||number-69/NN||average-68/JJ	dobj||reduced-66/VBD||number-69/NN	amod||arrhythmias-74/NNS||non-sustained-71/JJ	conj_and||non-sustained-71/JJ||sustained-73/JJ	amod||arrhythmias-74/NNS||sustained-73/JJ	prep_of||number-69/NN||arrhythmias-74/NNS	num||+-78/NNS||0.4-77/CD	prep_to||number-69/NN||+-78/NNS	punct||0.3-82/NN||/-79/:	nn||0.3-82/NN||âˆ-80/NN	dep||+-78/NNS||0.3-82/NN	num||+-85/NNS||0.4-84/CD	dep||+-78/NNS||+-85/NNS	conj_and||0.3-82/NN||+-85/NNS	punct||0.3-82/NN||/-86/:	rcmod||+-78/NNS||âˆ-87/VBP	dobj||âˆ-87/VBP||0.3-89/CD	advmod||âˆ-87/VBP||respectively-90/RB	dobj||reduced-66/VBD||pvcs-94/NNS	conj_negcc||number-69/NN||pvcs-94/NNS	aux||390-97/VB||to-96/TO	dep||pvcs-94/NNS||390-97/VB	nn||âˆ-100/NNP||+-98/NNP	nn||âˆ-100/NNP||/-99/NNP	poss||234-102/NN||âˆ-100/NNP	dobj||390-97/VB||234-102/NN	pvcs-94||lidocaine-65||yes||riluzole reduced the average number of all arrhythmias in phase 2 (pvcs from 484+/âˆ’119 to 32+/âˆ’13; non sustained arrhythmias from 8.9+/âˆ’4.4 to 0.7+/âˆ’0.5; sustained arrhythmias from 3.9+/âˆ’2.2 to 0.5+/âˆ’0.4); lidocaine reduced the average number of non-sustained and sustained arrhythmias (to 0.4+/âˆ’0.3 and 0.4+/âˆ’0.3 respectively) but not pvcs (to 390+/âˆ’234).
advmod||are-4/VBP||however-1/RB	expl||are-4/VBP||there-3/EX	root||ROOT-0/null||are-4/VBP	neg||guidelines-7/NNS||no-5/DT	amod||guidelines-7/NNS||official-6/JJ	nsubj||are-4/VBP||guidelines-7/NNS	advmod||treat-12/VB||how-10/WRB	aux||treat-12/VB||to-11/TO	prepc_as_to||guidelines-7/NNS||treat-12/VB	dobj||treat-12/VB||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv/acquiredimmunodeficiencysyndrome-16/NN	appos||hiv/acquiredimmunodeficiencysyndrome-16/NN||aids-18/NNS	appos||hiv/acquiredimmunodeficiencysyndrome-16/NN||plwha-21/NNP	advmod||screen-26/VB||how-24/WRB	aux||screen-26/VB||to-25/TO	prepc_as_to||guidelines-7/NNS||screen-26/VB	conj_or||treat-12/VB||screen-26/VB	advmod||infectious-29/JJ||potentially-28/RB	amod||people-30/NNS||infectious-29/JJ	prep_for||screen-26/VB||people-30/NNS	acquiredimmunodeficiencysyndrome--1||hiv--1||no||however, there are no official guidelines as to how to treat people living with hiv/acquiredimmunodeficiencysyndrome (aids) (plwha) or how to screen for potentially infectious people.
nsubj||leads-8/VBZ||conclusions-1/NNS	prepc_compared_with||conclusions-1/NNS||with-3/IN	pobj||conclusions-1/NNS||insulinglargine-4/NN	nn||degludec-7/NN||insulin-6/NN	appos||insulinglargine-4/NN||degludec-7/NN	root||ROOT-0/null||leads-8/VBZ	prep_to||leads-8/VBZ||improvements-10/NNS	det||status-17/NN||both-12/DT	amod||status-17/NN||mental-13/JJ	conj_and||mental-13/JJ||physical-15/JJ	amod||status-17/NN||physical-15/JJ	nn||status-17/NN||health-16/NN	prep_in||improvements-10/NNS||status-17/NN	prep_for||status-17/NN||patients-19/NNS	amod||therapy-24/NN||type2diabetes-21/JJ	amod||therapy-24/NN||initiating-22/JJ	nn||therapy-24/NN||insulin-23/NN	prep_with||patients-19/NNS||therapy-24/NN	type2diabetes-21||insulin-23||yes||conclusions compared with insulinglargine, insulin degludec leads to improvements in both mental and physical health status for patients with type2diabetes initiating insulin therapy.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	viremia-7||etoposide-20||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
det||renaldisease-4/NN||the-1/DT	amod||renaldisease-4/NN||first-2/JJ	det||renaldisease-4/NN||that-3/DT	nsubj||manifestation-9/NN||renaldisease-4/NN	aux||manifestation-9/NN||can-5/MD	cop||manifestation-9/NN||be-6/VB	det||manifestation-9/NN||the-7/DT	amod||manifestation-9/NN||first-8/JJ	root||ROOT-0/null||manifestation-9/NN	prep_of||manifestation-9/NN||hivinfection-11/NN	det||second-14/NN||the-13/DT	prep_of||manifestation-9/NN||second-14/NN	conj_and||hivinfection-11/NN||second-14/NN	mark||develop-19/VB||that-15/IN	amod||patients-17/NNS||hiv-infected-16/JJ	nsubj||develop-19/VB||patients-17/NNS	aux||develop-19/VB||may-18/MD	ccomp||manifestation-9/NN||develop-19/VB	amod||renaldiseases-23/NNS||immune-20/JJ	amod||renaldiseases-23/NNS||complex-21/JJ	amod||renaldiseases-23/NNS||related-22/JJ	dobj||develop-19/VB||renaldiseases-23/NNS	prep_of||some-25/DT||renaldiseases-23/NNS	nsubj||treatable-31/JJ||some-25/DT	aux||treatable-31/JJ||may-28/MD	cop||treatable-31/JJ||be-29/VB	advmod||treatable-31/JJ||potentially-30/RB	rcmod||renaldiseases-23/NNS||treatable-31/JJ	hivinfection-11||hiv--1||no||the first that renaldisease can be the first manifestation of hivinfection and the second that hiv-infected patients may develop immune complex related renaldiseases, some of which may be potentially treatable.
det||review-3/NN||a-1/DT	amod||review-3/NN||comprehensive-2/JJ	nsubj||identified-8/VBD||review-3/NN	det||literature-7/NN||the-5/DT	amod||literature-7/NN||medical-6/JJ	prep_of||review-3/NN||literature-7/NN	root||ROOT-0/null||identified-8/VBD	num||publications-10/NNS||five-9/CD	dobj||identified-8/VBD||publications-10/NNS	vmod||publications-10/NNS||evaluating-11/VBG	dobj||evaluating-11/VBG||levofloxacin-12/NN	det||treatment-15/NN||the-14/DT	prep_for||evaluating-11/VBG||treatment-15/NN	advmod||complicated-18/VBN||either-17/RB	amod||pyelonephritis-22/NNS||complicated-18/VBN	nn||pyelonephritis-22/NNS||urinarytractinfections-19/NNS	conj_or||urinarytractinfections-19/NNS||acute-21/JJ	nn||pyelonephritis-22/NNS||acute-21/JJ	prep_of||treatment-15/NN||pyelonephritis-22/NNS	urinarytractinfections-19||levofloxacin-12||yes||a comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinarytractinfections or acute pyelonephritis.
det||liverabscess-2/NNS||a-1/DT	nsubj||arise-4/VB||liverabscess-2/NNS	aux||arise-4/VB||may-3/MD	root||ROOT-0/null||arise-4/VB	det||insult-7/NN||any-6/DT	prep_following||arise-4/VB||insult-7/NN	aux||gut-9/VB||to-8/TO	vmod||insult-7/NN||gut-9/VB	dobj||gut-9/VB||integrity-10/NN	xcomp||gut-9/VB||allowing-11/VBG	amod||drainage-13/NN||portal-12/JJ	dobj||allowing-11/VBG||drainage-13/NN	prep_of||drainage-13/NN||bacteria-15/NNS	prep_to||allowing-11/VBG||hepatocytes-17/NNS	liverabscess-2||bacteria-15||no||a liverabscess may arise following any insult to gut integrity allowing portal drainage of bacteria to hepatocytes.
det||rin-8/NN||the-1/DT	amod||rin-8/NN||current-2/JJ	nn||rin-8/NN||vaccine-3/NN	dep||rin-8/NN||bacille-5/NN	num||rin-8/NN||calmette-guã-6/CD	nn||rin-8/NN||©-7/NNP	nsubj||protect-19/VB||rin-8/NN	appos||rin-8/NN||bcg-10/NN	advmod||employed-15/VBN||albeit-13/IN	advmod||albeit-13/IN||widely-14/RB	vmod||rin-8/NN||employed-15/VBN	aux||protect-19/VB||does-17/VBZ	neg||protect-19/VB||not-18/RB	root||ROOT-0/null||protect-19/VB	amod||disease-23/NN||adult-21/JJ	amod||disease-23/NN||pulmonary-22/JJ	prep_against||protect-19/VB||disease-23/NN	amod||vaccines-27/NNS||new-26/JJ	nsubjpass||needed-30/VBN||vaccines-27/NNS	nsubj||reduce-32/VB||vaccines-27/NNS	auxpass||needed-30/VBN||are-28/VBP	advmod||needed-30/VBN||urgently-29/RB	conj_and||protect-19/VB||needed-30/VBN	aux||reduce-32/VB||to-31/TO	xcomp||needed-30/VBN||reduce-32/VB	det||incidence-34/NN||the-33/DT	dobj||reduce-32/VB||incidence-34/NN	prep_of||incidence-34/NN||tb-36/NN	advmod||reduce-32/VB||worldwide-37/RB	tb-36||bcg-10||no||the current vaccine, bacille calmette-guã©rin (bcg), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of tb worldwide.
mark||localized-7/JJ||although-1/IN	amod||nf90-3/NNS||detectable-2/JJ	dep||localized-7/JJ||nf90-3/NNS	nn||proteins-6/NNS||rha-5/NN	conj_and||nf90-3/NNS||proteins-6/NNS	dep||localized-7/JJ||proteins-6/NNS	advcl||revealed-16/VBD||localized-7/JJ	det||nucleus-10/NN||the-9/DT	prep_to||localized-7/JJ||nucleus-10/NN	amod||cells-13/NNS||uninfected-12/JJ	prep_of||nucleus-10/NN||cells-13/NNS	nsubj||revealed-16/VBD||immunofluorescence-15/NN	root||ROOT-0/null||revealed-16/VBD	amod||nf90-18/NNS||cytoplasmic-17/JJ	dobj||revealed-16/VBD||nf90-18/NNS	amod||cells-21/NNS||denguevirus-infected-20/JJ	prep_in||revealed-16/VBD||cells-21/NNS	vmod||revealed-16/VBD||leading-23/VBG	dobj||leading-23/VBG||us-24/PRP	nsubj||hypothesize-26/VB||us-24/PRP	aux||hypothesize-26/VB||to-25/TO	xcomp||leading-23/VBG||hypothesize-26/VB	mark||has-29/VBZ||that-27/IN	nsubj||has-29/VBZ||nf90-28/NNS	ccomp||hypothesize-26/VB||has-29/VBZ	det||role-32/NN||a-30/DT	amod||role-32/NN||functional-31/JJ	dobj||has-29/VBZ||role-32/NN	dep||role-32/NN||s-34/PRP	amod||infections-38/NNS||dengue-37/JJ	prep_in||has-29/VBZ||infections-38/NNS	dengue-37||denguevirus--1||no||although detectable nf90 and rha proteins localized to the nucleus of uninfected cells, immunofluorescence revealed cytoplasmic nf90 in denguevirus-infected cells, leading us to hypothesize that nf90 has a functional role(s) in dengue infections.
prep_in||improves-5/VBZ||vivo-2/NN	nsubj||improves-5/VBZ||ascorbate-4/NN	nsubj||produces-12/VBZ||ascorbate-4/NN	root||ROOT-0/null||improves-5/VBZ	poss||effect-8/NN||albuterol-6/NNP	dobj||improves-5/VBZ||effect-8/NN	prep_on||improves-5/VBZ||heaves-10/NNP	conj_and||improves-5/VBZ||produces-12/VBZ	det||enhancement-15/NN||a-13/DT	amod||enhancement-15/NN||10-fold-14/JJ	dobj||produces-12/VBZ||enhancement-15/NN	amod||activity-18/NN||albuterol-17/JJ	prep_of||enhancement-15/NN||activity-18/NN	prep_in||produces-12/VBZ||â-20/NN	dobj||improves-5/VBZ||$-21/$	num||$-21/$||œasthmaticâ-22/CD	amod||$-21/$||$-23/$	number||$-23/$||sheep-24/CD	asthmatic--1||albuterol-17||yes||in vivo , ascorbate improves albuterol's effect on heaves and produces a 10-fold enhancement of albuterol activity in â€œasthmaticâ€? sheep.
advmod||overeat-12/VB||conversely-1/RB	nsubj||overeat-12/VB||patients-3/NNS	nsubj||compensate-14/VB||patients-3/NNS	nsubj||gain-22/VB||patients-3/NNS	dep||exceeds-6/VBZ||whose-4/WP$	nsubj||exceeds-6/VBZ||hyperglycemia-5/NN	dep||patients-3/NNS||exceeds-6/VBZ	det||threshold-10/NN||the-7/DT	amod||threshold-10/NN||renal-8/JJ	nn||threshold-10/NN||glucose-9/NN	dobj||exceeds-6/VBZ||threshold-10/NN	aux||overeat-12/VB||may-11/MD	root||ROOT-0/null||overeat-12/VB	aux||compensate-14/VB||to-13/TO	xcomp||overeat-12/VB||compensate-14/VB	prep_for||compensate-14/VB||calories-16/NNS	vmod||calories-16/NNS||lost-17/VBN	prep_in||lost-17/VBN||urine-19/NN	advmod||gain-22/VB||so-21/RB	xcomp||overeat-12/VB||gain-22/VB	conj_and||compensate-14/VB||gain-22/VB	dobj||gain-22/VB||weight-23/NN	advmod||ablates-27/VBZ||when-24/WRB	nn||therapy-26/NN||drug-25/NN	nsubj||ablates-27/VBZ||therapy-26/NN	advcl||gain-22/VB||ablates-27/VBZ	dobj||ablates-27/VBZ||glycosuria-28/NN	hyperglycemia-5||glucose-9||no||conversely, patients whose hyperglycemia exceeds the renal glucose threshold may overeat to compensate for calories lost in urine and so gain weight when drug therapy ablates glycosuria.
num||strategy-4/NN||one-1/CD	amod||strategy-4/NN||potential-2/JJ	nn||strategy-4/NN||vaccine-3/NN	nsubj||involves-10/VBZ||strategy-4/NN	det||fight-7/NN||the-6/DT	prep_in||strategy-4/NN||fight-7/NN	prep_against||fight-7/NN||meningococcaldisease-9/NN	root||ROOT-0/null||involves-10/VBZ	det||exploitation-12/NN||the-11/DT	dobj||involves-10/VBZ||exploitation-12/NN	amod||components-15/NNS||outer-membrane-14/JJ	prep_of||exploitation-12/NN||components-15/NNS	nn||lactamica-18/NN||neisseria-17/NN	prep_of||components-15/NNS||lactamica-18/NN	det||bacterium-22/NN||a-20/DT	amod||bacterium-22/NN||commensal-21/JJ	appos||lactamica-18/NN||bacterium-22/NN	advmod||related-24/VBN||closely-23/RB	amod||bacterium-22/NN||related-24/VBN	det||meningococcus-27/NNS||the-26/DT	prep_to||involves-10/VBZ||meningococcus-27/NNS	appos||meningococcus-27/NNS||neisseriameningitidis-29/NNS	meningococcaldisease-9||meningococcus-27||no||one potential vaccine strategy in the fight against meningococcaldisease involves the exploitation of outer-membrane components of neisseria lactamica , a commensal bacterium closely related to the meningococcus, neisseriameningitidis .
nsubj||predict-3/VB||atp-cra-1/NN	aux||predict-3/VB||could-2/MD	root||ROOT-0/null||predict-3/VB	amod||response-5/NN||clinical-4/JJ	dobj||predict-3/VB||response-5/NN	nn||chemotherapy-10/NN||paclitaxel-7/NN	conj_and||paclitaxel-7/NN||cisplatin-9/NN	nn||chemotherapy-10/NN||cisplatin-9/NN	prep_to||predict-3/VB||chemotherapy-10/NN	amod||accuracy-13/NN||high-12/JJ	prep_with||predict-3/VB||accuracy-13/NN	amod||patients-18/NNS||advanced-15/JJ	amod||patients-18/NNS||gastric-16/JJ	nn||patients-18/NNS||cancer-17/NN	prep_in||accuracy-13/NN||patients-18/NNS	cancer-17||cisplatin-9||no_rel||atp-cra could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients.
advmod||approved-8/VBN||recently-1/RB	det||administration-6/NN||the-2/DT	nn||administration-6/NN||food-3/NN	conj_and||food-3/NN||drug-5/NN	nn||administration-6/NN||drug-5/NN	nsubj||approved-8/VBN||administration-6/NN	aux||approved-8/VBN||has-7/VBZ	root||ROOT-0/null||approved-8/VBN	det||use-10/NN||the-9/DT	dobj||approved-8/VBN||use-10/NN	amod||ato-14/NN||arsenictrioxide-12/JJ	prep_of||use-10/NN||ato-14/NN	prep_of||use-10/NN||trisenox-17/NN	conj_or||ato-14/NN||trisenox-17/NN	det||treatment-20/NN||the-19/DT	prep_for||approved-8/VBN||treatment-20/NN	prep_of||treatment-20/NN||apl-22/NN	prepc_based_on||approved-8/VBN||on-25/IN	amod||studies-27/NNS||clinical-26/JJ	pobj||approved-8/VBN||studies-27/NNS	vmod||studies-27/NNS||showing-28/VBG	det||remission-31/NN||a-29/DT	amod||remission-31/NN||complete-30/JJ	dobj||showing-28/VBG||remission-31/NN	advmod||showing-28/VBG||especially-33/RB	amod||patients-36/NNS||relapsed-35/JJ	prep_in||showing-28/VBG||patients-36/NNS	apl-22||arsenictrioxide-12||yes||recently the food and drug administration has approved the use of arsenictrioxide (ato) or trisenox for the treatment of apl, based on clinical studies showing a complete remission, especially in relapsed patients.
prepc_compared_with||lower-10/JJR||with-2/IN	pobj||lower-10/JJR||adolescents-3/NNS	prep_with||adolescents-3/NNS||ngt-5/NN	amod||insulin-8/NN||first-phase-7/JJ	nsubj||lower-10/JJR||insulin-8/NN	cop||lower-10/JJR||was-9/VBD	root||ROOT-0/null||lower-10/JJR	det||function-38/NN||those-12/DT	prep_with||igt-16/JJ||ifg-14/NN	amod||function-38/NN||igt-16/JJ	conj_and||igt-16/JJ||ifg/igt-19/JJ	amod||function-38/NN||ifg/igt-19/JJ	amod||deterioration-22/NN||further-21/JJ	prep_with||ifg/igt-19/JJ||deterioration-22/NN	prep_in||deterioration-22/NN||those-24/DT	prep_with||those-24/DT||type2diabetes-26/CD	dep||ifg/igt-19/JJ||p-28/NNP	number||0.001-30/CD||<-29/CD	num||p-28/NNP||0.001-30/CD	advmod||²-35/JJ||î-34/RB	conj_and||igt-16/JJ||²-35/JJ	amod||function-38/NN||²-35/JJ	nn||function-38/NN||cell-37/NN	prep_in||lower-10/JJR||function-38/NN	advmod||function-38/NN||relative-39/JJ	nn||sensitivity-42/NN||insulin-41/NN	prep_to||relative-39/JJ||sensitivity-42/NN	nn||-RSB--49/NNP||glucose-44/NN	nn||-RSB--49/NNP||disposition-45/NN	nn||-RSB--49/NNP||index-46/NN	nn||-RSB--49/NNP||-LSB--47/NNP	nn||-RSB--49/NNP||gdi-48/NNP	nsubj||lower-53/JJR||-RSB--49/NNP	cop||lower-53/JJR||was-51/VBD	advmod||lower-53/JJR||also-52/RB	rcmod||sensitivity-42/NN||lower-53/JJR	prep_in||lower-53/JJR||those-55/DT	prep_with||those-55/DT||ifg-57/NN	prep_with||those-55/DT||igt-59/NN	conj_and||ifg-57/NN||igt-59/NN	prep_with||those-55/DT||ifg/igt-62/NN	conj_and||ifg-57/NN||ifg/igt-62/NN	dep||ifg-57/NN||40-64/CD	dep||ifg-57/NN||47-66/CD	conj_and||40-64/CD||47-66/CD	num||%-70/NN||47-69/CD	dep||ifg-57/NN||%-70/NN	conj_and||40-64/CD||%-70/NN	advmod||%-70/NN||respectively-72/RB	det||decrease-78/NN||a-76/DT	amod||decrease-78/NN||further-77/JJ	prep_with||lower-10/JJR||decrease-78/NN	num||%-81/NN||80-80/CD	appos||decrease-78/NN||%-81/NN	prep_in||decrease-78/NN||those-84/DT	prep_with||those-84/DT||type2diabetes-86/NNS	appos||type2diabetes-86/NNS||p-88/NNP	number||0.001-90/CD||<-89/CD	num||p-88/NNP||0.001-90/CD	type2diabetes-86||insulin-41||yes||compared with adolescents with ngt, first-phase insulin was lower in those with ifg, igt, and ifg/igt with further deterioration in those with type2diabetes ( p < 0.001), and î²-cell function relative to insulin sensitivity (glucose disposition index [gdi]) was also lower in those with ifg, igt, and ifg/igt (40, 47, and 47%, respectively), with a further decrease (80%) in those with type2diabetes ( p < 0.001).
det||effect-2/NN||the-1/DT	nsubj||range-18/VBP||effect-2/NN	prep_of||effect-2/NN||faeces-4/NNS	num||patients-8/NNS||26-6/CD	nn||patients-8/NNS||cd-7/NN	prep_of||faeces-4/NNS||patients-8/NNS	amod||disease-11/NN||active-10/JJ	prep_with||patients-8/NNS||disease-11/NN	amod||years-16/NNS||mean-13/JJ	nn||years-16/NNS||age-14/NN	num||years-16/NNS||5.5-15/CD	dep||patients-8/NNS||years-16/NNS	root||ROOT-0/null||range-18/VBP	num||â-20/NN||2.1-19/CD	dobj||range-18/VBP||â-20/NN	prep||â-20/NN||$-21/$	amod||years-24/NNS||12.0-23/JJ	npadvmod||1.0-41/RB||years-24/NNS	num||coeliacdisease-29/NN||18-27/CD	amod||coeliacdisease-29/NN||symptom-free-28/JJ	npadvmod||patients-33/RB||coeliacdisease-29/NN	dep||coeliacdisease-29/NN||sfcd-31/JJ	dep||age-36/NN||patients-33/RB	amod||age-36/NN||mean-35/JJ	dep||years-24/NNS||age-36/NN	num||age-36/NN||5.5-37/CD	dep||age-36/NN||years-38/NNS	appos||age-36/NN||range-40/NN	dep||â-42/CD||1.0-41/RB	num||$-21/$||â-42/CD	dep||$-21/$||$-43/$	amod||years-46/NNS||12.3-45/JJ	npadvmod||blood-88/RB||years-46/NNS	dep||$-54/$||on-48/IN	det||diet-51/NN||a-49/DT	amod||diet-51/NN||gluten-free-50/JJ	pobj||on-48/IN||diet-51/NN	prep_for||on-48/IN||1â-53/CD	dep||years-46/NNS||$-54/$	number||years-57/NNS||2-56/CD	nn||production-81/NN||years-57/NNS	num||children-62/NNS||20-60/CD	amod||children-62/NNS||healthy-61/JJ	conj_and||years-57/NNS||children-62/NNS	nn||production-81/NN||children-62/NNS	amod||age-65/NN||mean-64/JJ	dep||children-62/NNS||age-65/NN	num||years-67/NNS||5.3-66/CD	dep||age-65/NN||years-67/NNS	nn||â-71/NN||range-69/NN	num||â-71/NN||1.8-70/CD	appos||years-57/NNS||â-71/NN	dep||â-71/NN||$-72/$	amod||years-75/NNS||10.8-74/JJ	npadvmod||of-79/RB||years-75/NNS	advmod||years-75/NNS||on-77/RB	pobj||on-77/RB||induction-78/CD	dep||cytokine-80/CD||of-79/RB	num||$-72/$||cytokine-80/CD	npadvmod||antigen-84/JJ||production-81/NN	cc||surface-83/CD||and-82/CC	num||production-81/NN||surface-83/CD	amod||expression-85/NNS||antigen-84/JJ	npadvmod||in-86/RB||expression-85/NNS	dep||peripheral-87/CD||in-86/RB	num||$-54/$||peripheral-87/CD	dep||mononuclear-89/CD||blood-88/RB	num||$-43/$||mononuclear-89/CD	nsubjpass||determined-95/VBN||cells-90/NNS	appos||cells-90/NNS||pbmcs-92/NNS	auxpass||determined-95/VBN||were-94/VBD	rcmod||$-43/$||determined-95/VBN	coeliacdisease-29||gluten--1||no||the effect of faeces of 26 cd patients with active disease (mean age 5.5 years, range 2.1â€“12.0 years), 18 symptom-free coeliacdisease (sfcd) patients (mean age 5.5 years, range 1.0â€“12.3 years) on a gluten-free diet for 1â€“2 years; and 20 healthy children (mean age 5.3 years, range 1.8â€“10.8 years) on induction of cytokine production and surface antigen expression in peripheral blood mononuclear cells (pbmcs) were determined.
advmod||conclude-4/VBP||thus-1/RB	nsubj||conclude-4/VBP||we-3/PRP	root||ROOT-0/null||conclude-4/VBP	mark||considered-15/VBN||that-5/IN	det||use-7/NN||the-6/DT	nsubjpass||considered-15/VBN||use-7/NN	prep_of||use-7/NN||vitamins-9/NNS	dep||vitamins-9/NNS||c-10/SYM	dep||vitamins-9/NNS||e-12/JJ	conj_and||c-10/SYM||e-12/JJ	aux||considered-15/VBN||should-13/MD	auxpass||considered-15/VBN||be-14/VB	ccomp||conclude-4/VBP||considered-15/VBN	det||control-18/NN||the-17/DT	prep_for||considered-15/VBN||control-18/NN	amod||indices-23/NNS||certain-20/JJ	amod||indices-23/NNS||important-21/JJ	amod||indices-23/NNS||biochemical-22/JJ	prep_of||control-18/NN||indices-23/NNS	det||development-26/NN||the-25/DT	prep_during||considered-15/VBN||development-26/NN	prep_of||development-26/NN||preeclampsia-28/NN	advmod||needed-35/VBN||however-30/RB	amod||studies-33/NNS||further-32/JJ	nsubjpass||needed-35/VBN||studies-33/NNS	nsubj||develop-37/VB||studies-33/NNS	auxpass||needed-35/VBN||are-34/VBP	parataxis||conclude-4/VBP||needed-35/VBN	aux||develop-37/VB||to-36/TO	xcomp||needed-35/VBN||develop-37/VB	dobj||develop-37/VB||methods-38/NNS	det||prevention-41/NN||the-40/DT	prep_for||methods-38/NNS||prevention-41/NN	prep_of||prevention-41/NN||preeclampsia-43/NN	prep_in||develop-37/VB||women-45/NNS	amod||risk-48/NN||high-47/JJ	prep_at||women-45/NNS||risk-48/NN	vitamins-9||preeclampsia-43||no_rel||thus, we conclude that the use of vitamins c and e should be considered for the control of certain important biochemical indices during the development of preeclampsia; however, further studies are needed to develop methods for the prevention of preeclampsia in women at high risk.
nsubj||retrovirus-13/NNS||humanimmunodeficiencyvirus-1/NNS	nsubj||is-29/VBZ||humanimmunodeficiencyvirus-1/NNS	appos||humanimmunodeficiencyvirus-1/NNS||hiv-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||humanimmunodeficiencyvirus-1/NNS||agent-8/NN	prep_of||agent-8/NN||aids-10/NNS	cop||retrovirus-13/NNS||is-11/VBZ	det||retrovirus-13/NNS||a-12/DT	root||ROOT-0/null||retrovirus-13/NNS	nn||genome-16/NN||rna-15/NN	prep_with||retrovirus-13/NNS||genome-16/NN	det||â-20/NN||a-18/DT	amod||â-20/NN||unique-19/JJ	conj_and||retrovirus-13/NNS||â-20/NN	num||enzymeâ-25/NNS||$-21/$	number||reverse-23/CD||²-22/CD	num||$-21/$||reverse-23/CD	amod||enzymeâ-25/NNS||transcriptase-24/JJ	dep||â-20/NN||enzymeâ-25/NNS	dep||â-20/NN||$-26/$	num||$-26/$||²-27/CD	conj_and||retrovirus-13/NNS||is-29/VBZ	num||types-32/NNS||two-31/CD	prep_of||is-29/VBZ||types-32/NNS	prep_of||is-29/VBZ||hiv-1-34/JJ	conj_and||types-32/NNS||hiv-1-34/JJ	prep_of||is-29/VBZ||2-36/CD	conj_and||types-32/NNS||2-36/CD	aids-10||hiv-3||no||humanimmunodeficiencyvirus (hiv), the causative agent of aids is a retrovirus with rna genome and a unique â€²reverse transcriptase enzymeâ€² and is of two types, hiv-1 and 2.
preconj||influenzaviruses-2/NNS||both-1/DT	nsubjpass||documented-9/VBN||influenzaviruses-2/NNS	nn||pollutants-5/NNS||air-4/NN	conj_and||influenzaviruses-2/NNS||pollutants-5/NNS	nsubjpass||documented-9/VBN||pollutants-5/NNS	aux||documented-9/VBN||have-6/VBP	auxpass||documented-9/VBN||been-7/VBN	advmod||documented-9/VBN||well-8/RB	root||ROOT-0/null||documented-9/VBN	amod||hazards-12/NNS||major-11/JJ	prep_as||documented-9/VBN||hazards-12/NNS	amod||health-15/NN||human-14/JJ	prep_to||documented-9/VBN||health-15/NN	amod||studies-20/NNS||few-18/JJ	amod||studies-20/NNS||epidemiologic-19/JJ	nsubj||assessed-22/VBN||studies-20/NNS	aux||assessed-22/VBN||have-21/VBP	conj_but||documented-9/VBN||assessed-22/VBN	nn||modification-24/NN||effect-23/NN	dobj||assessed-22/VBN||modification-24/NN	prep_of||modification-24/NN||influenza-26/NN	nn||effects-29/NNS||health-28/NN	prep_on||assessed-22/VBN||effects-29/NNS	amod||pollutants-33/NNS||ambient-31/JJ	nn||pollutants-33/NNS||air-32/NN	prep_of||effects-29/NNS||pollutants-33/NNS	influenza-26||influenzaviruses-2||no||both influenzaviruses and air pollutants have been well documented as major hazards to human health, but few epidemiologic studies have assessed effect modification of influenza on health effects of ambient air pollutants.
det||virus-4/NN||the-1/DT	nn||virus-4/NN||hepatitis-2/NN	nn||virus-4/NN||delta-3/NN	nsubj||virus-14/NN||virus-4/NN	appos||virus-4/NN||hdv-6/NN	cop||virus-14/NN||is-8/VBZ	det||virus-14/NN||a-9/DT	amod||virus-14/NN||small-10/JJ	amod||virus-14/NN||defective-12/JJ	nn||virus-14/NN||rna-13/NN	root||ROOT-0/null||virus-14/NN	nsubj||requires-16/VBZ||virus-14/NN	rcmod||virus-14/NN||requires-16/VBZ	det||presence-18/NN||the-17/DT	dobj||requires-16/VBZ||presence-18/NN	det||hepatitisbvirus-21/NNS||the-20/DT	prep_of||presence-18/NN||hepatitisbvirus-21/NNS	appos||hepatitisbvirus-21/NNS||hbv-23/NN	poss||cycle-28/NN||its-26/PRP$	nn||cycle-28/NN||life-27/NN	prep_for||hepatitisbvirus-21/NNS||cycle-28/NN	hbv-23||hepatitisbvirus-21||no||the hepatitis delta virus (hdv) is a small, defective rna virus that requires the presence of the hepatitisbvirus (hbv) for its life cycle.
det||report-2/NN||this-1/DT	nsubj||argues-3/VBZ||report-2/NN	ccomp||is-42/VBZ||argues-3/VBZ	mark||high-36/JJ||that-4/IN	prep||high-36/JJ||given-5/VBN	pcomp||given-5/VBN||over-6/IN	num||%-8/NN||70-7/CD	pobj||over-6/IN||%-8/NN	prep_of||%-8/NN||women-10/NNS	rcmod||women-10/NNS||have-11/VBP	dobj||have-11/VBP||access-12/NN	quantmod||one-16/CD||at-14/IN	mwe||at-14/IN||least-15/JJS	pobj||at-14/IN||least-15/JJS	prep_to||have-11/VBP||one-16/CD	amod||visit-19/NN||antenatal-17/JJ	nn||visit-19/NN||care-18/NN	nsubj||high-36/JJ||visit-19/NN	det||region-22/NN||the-21/DT	prep_in||visit-19/NN||region-22/NN	prep_in||visit-19/NN||acceptance-24/NN	conj_and||region-22/NN||acceptance-24/NN	prep_of||region-22/NN||hiv-26/NN	vmod||hiv-26/NN||testing-27/VBG	prepc_after||testing-27/VBG||receiving-29/VBG	vmod||receiving-29/VBG||counselling-30/VBG	prep_on||counselling-30/VBG||pmtct-32/NN	aux||high-36/JJ||could-33/MD	cop||high-36/JJ||be-34/VB	advmod||high-36/JJ||as-35/RB	ccomp||argues-3/VBZ||high-36/JJ	num||%-39/NN||90-38/CD	prep_as||high-36/JJ||%-39/NN	expl||is-42/VBZ||there-41/EX	root||ROOT-0/null||is-42/VBZ	det||opportunity-44/NN||an-43/DT	nsubj||is-42/VBZ||opportunity-44/NN	aux||strengthen-46/VB||to-45/TO	vmod||opportunity-44/NN||strengthen-46/VB	amod||services-48/NNS||pmtct-47/JJ	dobj||strengthen-46/VB||services-48/NNS	advmod||eliminate-51/VB||eventually-50/RB	vmod||opportunity-44/NN||eliminate-51/VB	conj_and||strengthen-46/VB||eliminate-51/VB	amod||hivinfections-54/NNS||new-52/JJ	amod||hivinfections-54/NNS||paediatric-53/JJ	dobj||eliminate-51/VB||hivinfections-54/NNS	det||countries-58/NNS||the-56/DT	nn||countries-58/NNS||asean-57/NN	prep_in||hivinfections-54/NNS||countries-58/NNS	hivinfections-54||hiv-26||no||this report argues that given over 70% of women have access to at least one antenatal care visit in the region and acceptance of hiv testing after receiving counselling on pmtct could be as high as 90%, there is an opportunity to strengthen pmtct services and eventually eliminate new paediatric hivinfections in the asean countries.
nsubj||bioequivalent-3/JJ||fosaprepitant-1/NN	nsubj||aprepitant-5/VB||fosaprepitant-1/NN	nsubj||offer-9/VB||fosaprepitant-1/NN	cop||bioequivalent-3/JJ||is-2/VBZ	root||ROOT-0/null||bioequivalent-3/JJ	aux||aprepitant-5/VB||to-4/TO	xcomp||bioequivalent-3/JJ||aprepitant-5/VB	aux||offer-9/VB||could-8/MD	conj_and||bioequivalent-3/JJ||offer-9/VB	amod||benefits-11/NNS||potential-10/JJ	dobj||offer-9/VB||benefits-11/NNS	prep_for||offer-9/VB||patients-13/NNS	nsubj||unable-17/JJ||patients-13/NNS	nsubj||tolerate-19/VB||patients-13/NNS	aux||unable-17/JJ||may-15/MD	cop||unable-17/JJ||be-16/VB	rcmod||patients-13/NNS||unable-17/JJ	aux||tolerate-19/VB||to-18/TO	xcomp||unable-17/JJ||tolerate-19/VB	amod||administration-21/NN||oral-20/JJ	dobj||tolerate-19/VB||administration-21/NN	prep_of||administration-21/NN||antiemetics-23/NNS	det||episode-26/NN||an-25/DT	prep_during||tolerate-19/VB||episode-26/NN	prep_of||episode-26/NN||nausea-28/NN	prep_of||episode-26/NN||vomiting-30/NN	conj_or||nausea-28/NN||vomiting-30/NN	vomiting-30||aprepitant-5||yes||fosaprepitant is bioequivalent to aprepitant, and could offer potential benefits for patients who may be unable to tolerate oral administration of antiemetics during an episode of nausea or vomiting.
amod||deficiencies-4/NNS||immunoglobulin-1/JJ	amod||deficiencies-4/NNS||class-switch-2/JJ	nn||deficiencies-4/NNS||recombination-3/NN	nsubj||immunodeficiencies-11/NNS||deficiencies-4/NNS	appos||deficiencies-4/NNS||ig-csr-ds-6/NNS	cop||immunodeficiencies-11/NNS||are-8/VBP	amod||immunodeficiencies-11/NNS||rare-9/JJ	amod||immunodeficiencies-11/NNS||primary-10/JJ	root||ROOT-0/null||immunodeficiencies-11/NNS	vmod||immunodeficiencies-11/NNS||characterized-12/VBN	amod||production-20/NN||defective-14/JJ	nn||production-20/NN||switched-15/NNS	nn||production-20/NN||isotype-16/NN	appos||production-20/NN||igg/iga/ige-18/NN	agent||characterized-12/VBN||production-20/NN	immunodeficiencies-11||immunoglobulin-1||yes||immunoglobulin class-switch recombination deficiencies (ig-csr-ds) are rare primary immunodeficiencies characterized by defective switched isotype (igg/iga/ige) production.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	interleukin-2-6||autoimmunediseases-19||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||formoterol--1||yes||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
nn||consumption-2/NN||alcohol-1/NN	nsubjpass||linked-5/VBN||consumption-2/NN	nsubj||nonadherence-7/VB||consumption-2/NN	nsubj||antiretroviral-9/VB||consumption-2/NN	auxpass||linked-5/VBN||is-3/VBZ	advmod||linked-5/VBN||causally-4/RB	root||ROOT-0/null||linked-5/VBN	aux||nonadherence-7/VB||to-6/TO	xcomp||linked-5/VBN||nonadherence-7/VB	aux||antiretroviral-9/VB||to-8/TO	xcomp||nonadherence-7/VB||antiretroviral-9/VB	dobj||antiretroviral-9/VB||treatment-10/NN	nsubj||causes-14/VBZ||treatment-10/NN	prep_in||causes-14/VBZ||turn-13/NN	rcmod||treatment-10/NN||causes-14/VBZ	det||increase-16/NN||an-15/DT	dobj||causes-14/VBZ||increase-16/NN	amod||mortality-19/NN||hiv/aids-18/JJ	prep_in||increase-16/NN||mortality-19/NN	aids--1||hiv--1||no||alcohol consumption is causally linked to nonadherence to antiretroviral treatment that in turn causes an increase in hiv/aids mortality.
det||constellation-2/NN||the-1/DT	nsubjpass||classified-27/VBN||constellation-2/NN	prep_of||constellation-2/NN||dyslipidemia-4/NN	amod||levels-9/NNS||hypertriglyceridemia-6/JJ	conj_and||hypertriglyceridemia-6/JJ||low-8/JJ	amod||levels-9/NNS||low-8/JJ	dep||dyslipidemia-4/NN||levels-9/NNS	amod||cholesterol-13/NN||high-density-11/JJ	nn||cholesterol-13/NN||lipoprotein-12/NN	prep_of||levels-9/NNS||cholesterol-13/NN	amod||pressure-18/NN||elevated-16/JJ	nn||pressure-18/NN||blood-17/NN	prep_of||constellation-2/NN||pressure-18/NN	conj_and||dyslipidemia-4/NN||pressure-18/NN	prep_of||constellation-2/NN||impairedglucosetolerance-20/NN	conj_and||dyslipidemia-4/NN||impairedglucosetolerance-20/NN	amod||obesity-24/NN||central-23/JJ	prep_of||constellation-2/NN||obesity-24/NN	conj_and||dyslipidemia-4/NN||obesity-24/NN	auxpass||classified-27/VBN||is-25/VBZ	advmod||classified-27/VBN||now-26/RB	root||ROOT-0/null||classified-27/VBN	amod||syndrome-30/NN||metabolic-29/JJ	prep_as||classified-27/VBN||syndrome-30/NN	advmod||called-33/VBN||also-32/RB	vmod||syndrome-30/NN||called-33/VBN	nn||x.-35/NN||syndrome-34/NN	dobj||called-33/VBN||x.-35/NN	cholesterol-13||impairedglucosetolerance-20||no_rel||the constellation of dyslipidemia (hypertriglyceridemia and low levels of high-density lipoprotein cholesterol), elevated blood pressure, impairedglucosetolerance, and central obesity is now classified as metabolic syndrome, also called syndrome x.
amod||models-2/NNS||mathematical-1/JJ	nsubj||shown-4/VBN||models-2/NNS	nsubj||helpful-8/JJ||models-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	aux||helpful-8/JJ||to-5/TO	cop||helpful-8/JJ||be-6/VB	advmod||helpful-8/JJ||extremely-7/RB	xcomp||shown-4/VBN||helpful-8/JJ	prepc_in||helpful-8/JJ||understanding-10/VBG	det||dynamics-12/NNS||the-11/DT	dobj||understanding-10/VBG||dynamics-12/NNS	amod||diseases-16/NNS||different-14/JJ	nn||diseases-16/NNS||virus-15/NN	prep_of||dynamics-12/NNS||diseases-16/NNS	prep_including||shown-4/VBN||hepatitisb-19/NNP	nn||hdv-25/NNP||hepatitis-21/NNP	dep||hdv-25/NNP||d-22/SYM	nn||hdv-25/NNP||virus-23/NNP	nn||hdv-25/NNP||-lrb--24/NNPS	nsubj||virus-30/NN||hdv-25/NNP	advmod||virus-30/NN||-rrb--26/RB	cop||virus-30/NN||is-27/VBZ	det||virus-30/NN||a-28/DT	nn||virus-30/NN||satellite-29/NN	rcmod||hepatitisb-19/NNP||virus-30/NN	det||-rrb--37/NNP||the-32/DT	nn||-rrb--37/NNP||hepatitisb-33/NN	nn||-rrb--37/NNP||virus-34/NN	nn||-rrb--37/NNP||-lrb--35/NNP	nn||-rrb--37/NNP||hbv-36/NNP	prep_of||virus-30/NN||-rrb--37/NNP	hepatitisb-33||hepatitisbvirus--1||no||mathematical models have shown to be extremely helpful in understanding the dynamics of different virus diseases , including hepatitisb. hepatitis d virus -lrb- hdv -rrb- is a satellite virus of the hepatitisb virus -lrb- hbv -rrb- .
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	amod||patients-12/NNS||stemi-11/JJ	prep_in||evaluate-9/VB||patients-12/NNS	dep||patients-12/NNS||undergoing-13/VBG	amod||intervention-17/NN||primary-14/JJ	amod||intervention-17/NN||percutaneous-15/JJ	amod||intervention-17/NN||coronary-16/JJ	dobj||undergoing-13/VBG||intervention-17/NN	appos||intervention-17/NN||pci-19/NN	prep_with||intervention-17/NN||abciximab-22/NN	dep||patients-12/NNS||stenting-24/VBG	conj_and||undergoing-13/VBG||stenting-24/VBG	mark||safe-33/JJ||whether-25/IN	amod||reversal-27/NN||immediate-26/JJ	nsubj||safe-33/JJ||reversal-27/NN	prep_of||reversal-27/NN||anticoagulation-29/NN	prep_by||anticoagulation-29/NN||protamine-31/NN	cop||safe-33/JJ||is-32/VBZ	ccomp||stenting-24/VBG||safe-33/JJ	dep||patients-12/NNS||associated-35/JJ	conj_and||undergoing-13/VBG||associated-35/JJ	det||reduction-38/NN||a-37/DT	prep_with||associated-35/JJ||reduction-38/NN	det||occurrence-41/NN||the-40/DT	prep_in||reduction-38/NN||occurrence-41/NN	amod||complications-44/NNS||bleeding-43/VBG	prep_of||occurrence-41/NN||complications-44/NNS	bleeding-43||protamine-31||no_rel||the aim of the current study was to evaluate in stemi patients undergoing primary percutaneous coronary intervention (pci) with abciximab and stenting whether immediate reversal of anticoagulation by protamine is safe and associated with a reduction in the occurrence of bleeding complications.
prep_in||fused-14/VBN||acutepromyelocyticleukemia-2/NN	appos||acutepromyelocyticleukemia-2/NN||apl-4/NN	det||protein-12/NN||the-7/DT	amod||protein-12/NN||promyelocyticleukemia-8/JJ	nn||protein-12/NN||pml-10/NN	nsubjpass||fused-14/VBN||protein-12/NN	auxpass||fused-14/VBN||is-13/VBZ	root||ROOT-0/null||fused-14/VBN	det||alpha-19/NN||the-16/DT	amod||alpha-19/NN||retinoicacid-17/JJ	nn||alpha-19/NN||receptor-18/NN	prep_to||fused-14/VBN||alpha-19/NN	appos||alpha-19/NN||rar-21/NN	acutepromyelocyticleukemia-2||retinoicacid-17||yes||in acutepromyelocyticleukemia (apl), the promyelocyticleukemia (pml) protein is fused to the retinoicacid receptor alpha (rar).
aux||discuss-2/VB||to-1/TO	advcl||attended-37/VBD||discuss-2/VB	amod||symptoms-4/NNS||potential-3/JJ	nsubj||predicting-8/VBG||symptoms-4/NNS	amod||factors-7/NNS||other-6/JJ	conj_and||symptoms-4/NNS||factors-7/NNS	nsubj||predicting-8/VBG||factors-7/NNS	dep||discuss-2/VB||predicting-8/VBG	dobj||predicting-8/VBG||response-9/NN	prep_to||predicting-8/VBG||treatment-11/NN	amod||plaster-14/NN||lidocaine-13/JJ	prep_with||predicting-8/VBG||plaster-14/NN	det||indications-17/NNS||the-16/DT	prep_for||plaster-14/NN||indications-17/NNS	prep_of||indications-17/NNS||lowbackpain-19/NN	amod||components-22/NNS||neuropathic-21/JJ	prep_with||lowbackpain-19/NN||components-22/NNS	conj_and||discuss-2/VB||neuropathicpain-24/VB	advcl||attended-37/VBD||neuropathicpain-24/VB	amod||trauma-29/NN||surgical-26/JJ	conj_and||surgical-26/JJ||nonsurgical-28/JJ	amod||trauma-29/NN||nonsurgical-28/JJ	prep_after||neuropathicpain-24/VB||trauma-29/NN	num||specialists-33/NNS||44-31/CD	nn||specialists-33/NNS||pain-32/NN	nsubj||attended-37/VBD||specialists-33/NNS	num||countries-36/NNS||17-35/CD	prep_from||specialists-33/NNS||countries-36/NNS	root||ROOT-0/null||attended-37/VBD	det||meeting-41/NN||a-38/DT	amod||meeting-41/NN||two-day-39/JJ	nn||meeting-41/NN||conference-40/NN	dobj||attended-37/VBD||meeting-41/NN	prep_in||attended-37/VBD||december-43/NNP	num||december-43/NNP||2009-44/CD	pain-32||lidocaine-13||yes||to discuss potential symptoms and other factors predicting response to treatment with lidocaine plaster for the indications of lowbackpain with neuropathic components and neuropathicpain after surgical and nonsurgical trauma, 44 pain specialists from 17 countries attended a two-day conference meeting in december 2009.
det||nucleoprotein-2/NN||the-1/DT	nsubj||isolates-18/VBZ||nucleoprotein-2/NN	appos||nucleoprotein-2/NN||n-4/NN	conj_and||nucleoprotein-2/NN||glycoprotein-7/NN	nsubj||isolates-18/VBZ||glycoprotein-7/NN	appos||glycoprotein-7/NN||g-9/NN	num||rabiesvirus-14/NNS||11-12/CD	nn||rabiesvirus-14/NNS||korean-13/NN	prep_of||glycoprotein-7/NN||rabiesvirus-14/NNS	appos||nucleoprotein-2/NN||rabv-16/NNP	root||ROOT-0/null||isolates-18/VBZ	csubjpass||subjected-30/VBN||collected-19/VBN	prep_from||collected-19/VBN||animals-21/NNS	vmod||animals-21/NNS||diagnosed-22/VBN	prep_with||diagnosed-22/VBN||rabies-24/NNP	prep_between||rabies-24/NNP||2008-26/CD	prep_between||rabies-24/NNP||2009-28/CD	conj_and||2008-26/CD||2009-28/CD	auxpass||subjected-30/VBN||were-29/VBD	ccomp||isolates-18/VBZ||subjected-30/VBN	amod||analyses-35/NNS||molecular-32/JJ	conj_and||molecular-32/JJ||phylogenetic-34/JJ	amod||analyses-35/NNS||phylogenetic-34/JJ	prep_to||subjected-30/VBN||analyses-35/NNS	rabies-24||rabiesvirus-14||no||the nucleoprotein (n) and glycoprotein (g) of 11 korean rabiesvirus (rabv) isolates collected from animals diagnosed with rabies between 2008 and 2009 were subjected to molecular and phylogenetic analyses.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	leptomeningealmetastases-40||immunoglobulin-16||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
nsubj||take-9/VBP||individuals-1/NNS	vmod||individuals-1/NNS||living-2/VBG	prep_with||living-2/VBG||hiv/aids-4/NNS	amod||africa-7/NN||sub-saharan-6/JJ	prep_in||hiv/aids-4/NNS||africa-7/NN	advmod||take-9/VBP||generally-8/RB	root||ROOT-0/null||take-9/VBP	mwe||than-11/IN||more-10/JJR	quantmod||90-12/CD||than-11/IN	num||%-13/NN||90-12/CD	dobj||take-9/VBP||%-13/NN	amod||doses-16/NNS||prescribed-15/JJ	prep_of||%-13/NN||doses-16/NNS	amod||therapy-19/NN||antiretroviral-18/JJ	prep_of||doses-16/NNS||therapy-19/NN	appos||therapy-19/NN||art-21/NN	aids--1||hiv--1||no||individuals living with hiv/aids in sub-saharan africa generally take more than 90% of prescribed doses of antiretroviral therapy (art).
det||report-4/NN||the-1/DT	amod||report-4/NN||first-2/JJ	nn||report-4/NN||case-3/NN	nsubj||gave-17/VBD||report-4/NN	amod||efficacy-7/NN||clomipramine-6/JJ	prep_of||report-4/NN||efficacy-7/NN	det||ocd-11/NN||the-9/DT	nn||ocd-11/NN||management-10/NN	prep_in||efficacy-7/NN||ocd-11/NN	mwe||than-13/IN||more-12/JJR	quantmod||40-14/CD||than-13/IN	num||years-15/NNS||40-14/CD	npadvmod||ago-16/RB||years-15/NNS	advmod||gave-17/VBD||ago-16/RB	root||ROOT-0/null||gave-17/VBD	amod||hope-19/NN||new-18/JJ	dobj||gave-17/VBD||hope-19/NN	det||treatment-22/NN||the-21/DT	prep_for||gave-17/VBD||treatment-22/NN	det||disorder-26/NN||this-24/DT	amod||disorder-26/NN||debilitating-25/VBG	prep_of||treatment-22/NN||disorder-26/NN	ocd-11||clomipramine-6||yes||the first case report of clomipramine efficacy in the management ocd more than 40 years ago gave new hope for the treatment of this debilitating disorder.
root||ROOT-0/null||asking-1/VBG	poss||willingness-4/NN||clients-2/NNS	dobj||asking-1/VBG||willingness-4/NN	nn||testing-7/NN||hiv-6/NN	prep_for||willingness-4/NN||testing-7/NN	aux||conducted-10/VBN||should-8/MD	auxpass||conducted-10/VBN||be-9/VB	dep||asking-1/VBG||conducted-10/VBN	det||service-13/NN||all-12/DT	agent||conducted-10/VBN||service-13/NN	nsubj||asking-1/VBG||providers-14/NNS	det||clients-18/NNS||the-17/DT	poss||behaviors-21/NNS||clients-18/NNS	nn||behaviors-21/NNS||risk-20/NN	prep_irrespective_of||providers-14/NNS||behaviors-21/NNS	prep_for||providers-14/NNS||hivinfection-23/NN	det||type-26/NN||the-25/DT	prep_for||providers-14/NNS||type-26/NN	conj_or||hivinfection-23/NN||type-26/NN	prep_of||providers-14/NNS||services-28/NNS	nsubj||need-30/VBP||they-29/PRP	rcmod||services-28/NNS||need-30/VBP	hivinfection-23||hiv-6||no||asking clients' willingness for hiv testing should be conducted by all service providers irrespective of the clients' risk behaviors for hivinfection or the type of services they need.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	dep||was-6/VBD||compare-8/VB	det||effects-10/NNS||the-9/DT	dobj||compare-8/VB||effects-10/NNS	prep_of||effects-10/NNS||fishoil-12/NN	prep_of||effects-10/NNS||montelukast-14/NN	conj_and||fishoil-12/NN||montelukast-14/NN	advmod||compare-8/VB||alone-16/RB	dep||was-6/VBD||in-18/IN	conj_and||compare-8/VB||in-18/IN	pobj||in-18/IN||combination-19/NN	amod||inflammation-23/NN||airway-22/JJ	prep_on||was-6/VBD||inflammation-23/NN	prep_on||was-6/VBD||bronchoconstriction-25/NN	conj_and||inflammation-23/NN||bronchoconstriction-25/NN	vmod||inflammation-23/NN||induced-26/VBN	amod||hyperpnea-30/NN||eucapnic-28/JJ	amod||hyperpnea-30/NN||voluntary-29/JJ	agent||induced-26/VBN||hyperpnea-30/NN	appos||hyperpnea-30/NN||evh-32/NN	prep_in||hyperpnea-30/NN||asthmatics-35/NNS	asthmatics-35||montelukast-14||yes||the purpose of this study was to compare the effects of fishoil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (evh) in asthmatics.
det||methylphenidate-4/NN||the-1/DT	nn||methylphenidate-4/NN||stimulant-2/NN	nn||methylphenidate-4/NN||drug-3/NN	nsubj||used-19/JJ||methylphenidate-4/NN	dep||methylphenidate-4/NN||mph-6/NN	det||atomoxetine-12/NN||the-9/DT	amod||atomoxetine-12/NN||non-stimulant-10/JJ	nn||atomoxetine-12/NN||drug-11/NN	conj_and||methylphenidate-4/NN||atomoxetine-12/NN	nsubj||used-19/JJ||atomoxetine-12/NN	appos||atomoxetine-12/NN||atx-14/NN	cop||used-19/JJ||are-16/VBP	dep||used-19/JJ||both-17/DT	advmod||used-19/JJ||widely-18/RB	root||ROOT-0/null||used-19/JJ	amod||treatment-22/NN||adhd-21/JJ	prep_for||used-19/JJ||treatment-22/NN	poss||effects-27/NNS||their-25/PRP$	nn||effects-27/NNS||differential-26/NN	nsubj||remain-32/VBP||effects-27/NNS	amod||function-31/NN||human-29/JJ	nn||function-31/NN||brain-30/NN	prep_on||effects-27/NNS||function-31/NN	conj_but||used-19/JJ||remain-32/VBP	acomp||remain-32/VBP||unclear-33/JJ	adhd-21||methylphenidate-4||yes||the stimulant drug methylphenidate (mph) and the non-stimulant drug atomoxetine (atx) are both widely used for adhd treatment, but their differential effects on human brain function remain unclear.
aux||determine-2/VB||to-1/TO	csubj||administered-11/VBN||determine-2/VB	det||effects-8/NNS||the-3/DT	amod||effects-8/NNS||pharmacokinetic-4/JJ	conj_and||pharmacokinetic-4/JJ||pharmacodynamic-6/JJ	amod||effects-8/NNS||pharmacodynamic-6/JJ	amod||effects-8/NNS||dose-response-7/JJ	dobj||determine-2/VB||effects-8/NNS	prep_of||effects-8/NNS||insulinglargine-10/NN	root||ROOT-0/null||administered-11/VBN	advmod||administered-11/VBN||subcutaneously-12/RB	prep_in||administered-11/VBN||individuals-14/NNS	prep_with||individuals-14/NNS||type2diabetes-16/CD	type2diabetes-16||insulinglargine-10||yes||to determine the pharmacokinetic and pharmacodynamic dose-response effects of insulinglargine administered subcutaneously in individuals with type2diabetes.
nsubj||â-2/VBP||objective-1/NN	nsubj||saturated-18/VBD||objective-1/NN	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	aux||examine-6/VB||to-5/TO	vmod||â-2/VBP||examine-6/VB	det||effects-9/NNS||the-7/DT	amod||effects-9/NNS||acute-8/JJ	dobj||examine-6/VB||effects-9/NNS	prep_of||effects-9/NNS||consumption-11/NN	prep_of||consumption-11/NN||monounsaturated-13/NN	dep||monounsaturated-13/NN||mufas-15/NNS	conj_and||â-2/VBP||saturated-18/VBD	dobj||saturated-18/VBD||fattyacids-19/NNS	dep||fattyacids-19/NNS||safas-21/NNS	amod||function-25/NN||endothelial-24/JJ	prep_on||saturated-18/VBD||function-25/NN	prep_in||saturated-18/VBD||subjects-27/NNS	prep_with||subjects-27/NNS||type2diabetes-29/CD	fattyacids-19||type2diabetes-29||no_rel||objective â€”to examine the acute effects of consumption of monounsaturated (mufas) and saturated fattyacids (safas) on endothelial function in subjects with type2diabetes.
amod||speed-3/NN||short-distance-1/JJ	nn||speed-3/NN||walking-2/NN	nsubjpass||associated-5/VBN||speed-3/NN	auxpass||associated-5/VBN||is-4/VBZ	root||ROOT-0/null||associated-5/VBN	amod||risk-8/NN||metabolic-7/JJ	prep_with||associated-5/VBN||risk-8/NN	nn||atherosclerosis-11/NNS||subclinical-10/NN	prep_with||associated-5/VBN||atherosclerosis-11/NNS	conj_and||risk-8/NN||atherosclerosis-11/NNS	amod||adults-14/NNS||older-13/JJR	prep_in||risk-8/NN||adults-14/NNS	amod||cvd-17/NN||overt-16/JJ	prep_without||associated-5/VBN||cvd-17/NN	atherosclerosis-11||speed-3||no||short-distance walking speed is associated with metabolic risk and subclinical atherosclerosis in older adults without overt cvd.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||trial-8/NN||a-4/DT	amod||trial-8/NN||prospective-5/JJ	nn||trial-8/NN||phase-6/NN	nn||trial-8/NN||ii-7/NN	prep_on||report-2/VBP||trial-8/NN	num||patients-11/NNS||32-10/CD	prep_of||trial-8/NN||patients-11/NNS	nsubj||underwent-13/VBD||patients-11/NNS	rcmod||patients-11/NNS||underwent-13/VBD	amod||transplantation-18/NN||unrelated-14/JJ	nn||transplantation-18/NN||donor-15/NN	nn||transplantation-18/NN||hematopoietic-16/NN	nn||transplantation-18/NN||cell-17/NN	dobj||underwent-13/VBD||transplantation-18/NN	det||sirolimus-24/NNS||a-21/DT	nn||sirolimus-24/NNS||tacrolimus-22/NNS	prep_with||underwent-13/VBD||sirolimus-24/NNS	nn||globulin-28/NN||rabbit-26/NN	amod||globulin-28/NN||anti-thymoctye-27/JJ	prep_with||underwent-13/VBD||globulin-28/NN	conj_and||sirolimus-24/NNS||globulin-28/NN	vmod||sirolimus-24/NNS||gvhd-29/VBN	amod||regimen-31/NN||prophylactic-30/JJ	dobj||gvhd-29/VBN||regimen-31/NN	gvhd-29||tacrolimus-22||yes||we report on a prospective phase ii trial of 32 patients who underwent unrelated donor hematopoietic cell transplantation, with a tacrolimus, sirolimus and rabbit anti-thymoctye globulin gvhd prophylactic regimen.
nsubj||recruited-2/VBD||we-1/PRP	root||ROOT-0/null||recruited-2/VBD	num||patients-4/NNS||25-3/CD	dobj||recruited-2/VBD||patients-4/NNS	prep_with||recruited-2/VBD||type1diabetes-6/NNS	dep||type1diabetes-6/NNS||mean-8/VB	nn||â-11/NN||age-9/NN	num||â-11/NN||51-10/CD	dobj||mean-8/VB||â-11/NN	number||10-13/CD||±-12/CD	num||years-14/NNS||10-13/CD	tmod||mean-8/VB||years-14/NNS	dep||mean-8/VB||mean-16/VB	nn||duration-18/NN||disease-17/NN	dobj||mean-16/VB||duration-18/NN	num||years-23/NNS||26-19/CD	nn||years-23/NNS||â-20/NNP	nn||years-23/NNS||±-21/NNP	num||years-23/NNS||13-22/CD	tmod||mean-8/VB||years-23/NNS	num||type-28/NN||31-26/CD	amod||type-28/NN||insulin-treated-27/JJ	prep_with||recruited-2/VBD||type-28/NN	conj_and||type1diabetes-6/NNS||type-28/NN	num||patients-31/NNS||2-29/CD	amod||patients-31/NNS||diabetic-30/JJ	dep||type-28/NN||patients-31/NNS	dep||type-28/NN||mean-33/VB	nn||â-36/NN||age-34/NN	num||â-36/NN||66-35/CD	dobj||mean-33/VB||â-36/NN	number||8-38/CD||±-37/CD	num||years-39/NNS||8-38/CD	tmod||mean-33/VB||years-39/NNS	dep||mean-33/VB||mean-41/VB	nn||duration-43/NN||disease-42/NN	dobj||mean-41/VB||duration-43/NN	num||years-48/NNS||19-44/CD	nn||years-48/NNS||â-45/NNP	nn||years-48/NNS||±-46/NNP	num||years-48/NNS||9-47/CD	tmod||mean-33/VB||years-48/NNS	nsubj||received-52/VBD||who-51/WP	nsubj||sitagliptin-69/VBN||who-51/WP	prep_with||recruited-2/VBD||received-52/VBD	conj_and||type1diabetes-6/NNS||received-52/VBD	dobj||received-52/VBD||sitagliptin-53/NN	prep_with||received-52/VBD||metformin-55/NN	det||combination-59/NN||a-57/DT	amod||combination-59/NN||fixed-dose-58/JJ	prep_as||metformin-55/NN||combination-59/NN	num||mg-62/NN||50/1000-61/CD	npadvmod||once-63/RB||mg-62/NN	dep||received-52/VBD||once-63/RB	advmod||daily-66/JJ||twice-65/RB	dep||received-52/VBD||daily-66/JJ	conj_or||once-63/RB||daily-66/JJ	conj_and||type1diabetes-6/NNS||sitagliptin-69/VBN	conj_or||received-52/VBD||sitagliptin-69/VBN	nsubj||mg-72/VBP||100-71/CD	parataxis||sitagliptin-69/VBN||mg-72/VBP	advmod||mg-72/VBP||once-73/RB	advmod||mg-72/VBP||daily-74/RB	mark||metformin-79/VB||if-76/IN	nsubj||metformin-79/VB||intolerant-77/NN	aux||metformin-79/VB||to-78/TO	advcl||mg-72/VBP||metformin-79/VB	xcomp||mg-72/VBP||metformin-79/VB	amod||therapy-86/NN||ongoing-84/JJ	nn||therapy-86/NN||insulin-85/NN	prep_in_addition_to||sitagliptin-69/VBN||therapy-86/NN	num||â-89/NN||46-88/CD	prep_for||therapy-86/NN||â-89/NN	number||19-91/CD||±-90/CD	num||weeks-92/NNS||19-91/CD	dobj||sitagliptin-69/VBN||weeks-92/NNS	num||±-96/NNS||56-94/CD	nn||±-96/NNS||â-95/NN	dobj||sitagliptin-69/VBN||±-96/NNS	conj_and||weeks-92/NNS||±-96/NNS	num||weeks-98/NNS||14-97/CD	dep||±-96/NNS||weeks-98/NNS	advmod||±-96/NNS||respectively-100/RB	type1diabetes-6||insulin-85||yes||we recruited 25 patients with type1diabetes (mean age 51 â± 10 years, mean disease duration 26 â± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 â± 8 years, mean disease duration 19 â± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 â± 19 weeks and 56 â± 14 weeks, respectively.
neg||associations-2/NNS||no-1/DT	nsubjpass||found-4/VBN||associations-2/NNS	auxpass||found-4/VBN||were-3/VBD	root||ROOT-0/null||found-4/VBN	nn||characteristics-9/NNS||ta-6/NN	conj_and||ta-6/NN||tb-8/NN	nn||characteristics-9/NNS||tb-8/NN	prep_between||found-4/VBN||characteristics-9/NNS	nn||abilities-14/NNS||speech-11/NN	conj_and||speech-11/NN||language-13/NN	nn||abilities-14/NNS||language-13/NN	prep_between||found-4/VBN||abilities-14/NNS	conj_and||characteristics-9/NNS||abilities-14/NNS	prep_in||found-4/VBN||children-16/NNS	prep_with||children-16/NNS||ds-18/NN	ds-18||tb-8||no_rel||no associations were found between ta and tb characteristics and speech and language abilities in children with ds.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||role-4/NN||the-3/DT	dobj||review-2/VB||role-4/NN	prep_of||role-4/NN||tmz-6/NN	det||management-9/NN||the-8/DT	prep_in||review-2/VB||management-9/NN	amod||astrocytomas-12/NNS||malignant-11/JJ	prep_of||management-9/NN||astrocytomas-12/NNS	nn||grades-17/NNS||world-14/NN	nn||grades-17/NNS||health-15/NN	nn||grades-17/NNS||organization-16/NN	nsubj||iii-18/VBP||grades-17/NNS	nsubj||iv-20/VBP||grades-17/NNS	dep||management-9/NN||iii-18/VBP	dep||management-9/NN||iv-20/VBP	conj_and||iii-18/VBP||iv-20/VBP	advmod||diagnosed-24/JJ||newly-23/RB	amod||astrocytomas-34/NNS||diagnosed-24/JJ	dep||diagnosed-24/JJ||n-26/NN	conj_and||diagnosed-24/JJ||recurrent-29/JJ	amod||astrocytomas-34/NNS||recurrent-29/JJ	dep||recurrent-29/JJ||r-31/NN	amod||astrocytomas-34/NNS||anaplastic-33/JJ	prep_including||management-9/NN||astrocytomas-34/NNS	appos||astrocytomas-34/NNS||aa-36/NN	prep_including||management-9/NN||glioblastomas-39/NNS	conj_and||astrocytomas-34/NNS||glioblastomas-39/NNS	astrocytomas-34||tmz-6||yes||to review the role of tmz in the management of malignant astrocytomas (world health organization grades iii and iv) including newly diagnosed (n) and recurrent (r) anaplastic astrocytomas (aa) and glioblastomas.
aux||compare-2/VB||to-1/TO	csubj||adjuncts-16/VBZ||compare-2/VB	conj_and||compare-2/VB||evaluate-4/VB	csubj||adjuncts-16/VBZ||evaluate-4/VB	det||effect-6/NN||the-5/DT	dobj||compare-2/VB||effect-6/NN	prepc_of||effect-6/NN||adding-8/VBG	npadvmod||as-15/RB||ketamine-9/NN	conj_or||ketamine-9/NN||nitroglycerin-11/NN	npadvmod||as-15/RB||nitroglycerin-11/NN	appos||ketamine-9/NN||ntg-13/NN	advmod||adding-8/VBG||as-15/RB	root||ROOT-0/null||adjuncts-16/VBZ	aux||lidocaine-18/VB||to-17/TO	xcomp||adjuncts-16/VBZ||lidocaine-18/VB	amod||anesthesia-22/NN||intravenous-20/JJ	amod||anesthesia-22/NN||regional-21/JJ	prep_for||lidocaine-18/VB||anesthesia-22/NN	appos||anesthesia-22/NN||ivra-24/NNP	prep_on||anesthesia-22/NN||intraoperative-27/NN	xcomp||adjuncts-16/VBZ||postoperative-29/VB	conj_and||lidocaine-18/VB||postoperative-29/VB	nn||times-37/NNS||analgesia-30/NN	conj_and||analgesia-30/NN||sensorial-32/NN	nn||times-37/NNS||sensorial-32/NN	conj_and||analgesia-30/NN||motor-34/NN	nn||times-37/NNS||motor-34/NN	nn||times-37/NNS||block-35/NN	nn||times-37/NNS||onset-36/NN	dobj||postoperative-29/VB||times-37/NNS	xcomp||adjuncts-16/VBZ||tourniquet-40/VB	conj_and||lidocaine-18/VB||tourniquet-40/VB	dobj||tourniquet-40/VB||pain-41/NN	pain-41||lidocaine-18||yes||to compare and evaluate the effect of adding ketamine or nitroglycerin (ntg) as adjuncts to lidocaine for intravenous regional anesthesia (ivra) on intraoperative and postoperative analgesia, sensorial and motor block onset times, and tourniquet pain.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	atorvastatin-21||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
amod||time-2/NN||median-1/JJ	nsubj||days-13/NNS||time-2/NN	prep_to||time-2/NN||detection-4/NN	prep_of||detection-4/NN||tuberculosis-6/NNP	det||test-10/NN||the-8/DT	nn||test-10/NN||mtb/rif-9/NN	prep_for||tuberculosis-6/NNP||test-10/NN	cop||days-13/NNS||was-11/VBD	num||days-13/NNS||0-12/CD	root||ROOT-0/null||days-13/NNS	dep||$-17/$||iqr-15/RB	pobj||iqr-15/RB||0â-16/CD	dep||days-13/NNS||$-17/$	num||$-17/$||1-19/CD	prepc_compared_with||days-13/NNS||with-23/IN	num||day-25/NN||1-24/CD	pobj||days-13/NNS||day-25/NN	appos||day-25/NN||0â-27/NNP	num||0â-27/NNP||$-28/$	num||$-28/$||1-30/CD	prep_for||day-25/NN||microscopy-33/NN	num||days-36/NNS||30-35/CD	pobj||days-13/NNS||days-36/NNS	conj_and||day-25/NN||days-36/NNS	appos||days-36/NNS||23â-38/NNP	num||23â-38/NNP||$-39/$	num||$-39/$||43-41/CD	amod||culture-45/NN||solid-44/JJ	prep_for||days-36/NNS||culture-45/NN	num||days-49/NNS||16-48/CD	pobj||days-13/NNS||days-49/NNS	conj_and||day-25/NN||days-49/NNS	appos||days-49/NNS||13â-51/NNP	num||13â-51/NNP||$-52/$	num||$-52/$||21-54/CD	amod||culture-58/NN||liquid-57/JJ	prep_for||days-49/NNS||culture-58/NN	tuberculosis-6||rif--1||yes||median time to detection of tuberculosis for the mtb/rif test was 0 days (iqr 0â€“1), compared with 1 day (0â€“1) for microscopy, 30 days (23â€“43) for solid culture, and 16 days (13â€“21) for liquid culture.
nn||testosterone-2/NN||serum-1/NN	nsubjpass||associated-7/VBN||testosterone-2/NN	auxpass||associated-7/VBN||was-3/VBD	advmod||associated-7/VBN||strongly-4/RB	conj_and||strongly-4/RB||significantly-6/RB	advmod||associated-7/VBN||significantly-6/RB	root||ROOT-0/null||associated-7/VBN	nn||risk-11/NN||breast-9/NN	nn||risk-11/NN||cancer-10/NN	prep_with||associated-7/VBN||risk-11/NN	testosterone-2||cancer-10||no_rel||serum testosterone was strongly and significantly associated with breast cancer risk.
nn||acetylsalicylicacid-4/NN||background-1/NN	conj_and||background-1/NN||aim-3/NN	nn||acetylsalicylicacid-4/NN||aim-3/NN	nsubj||drug-16/NN||acetylsalicylicacid-4/NN	num||-RSB--9/NNS||asa-6/CD	nn||-RSB--9/NNS||-LSB--7/NNP	nn||-RSB--9/NNS||aspirin-8/NN	appos||acetylsalicylicacid-4/NN||-RSB--9/NNS	cop||drug-16/NN||is-11/VBZ	det||drug-16/NN||a-12/DT	advmod||used-14/VBN||commonly-13/RB	amod||drug-16/NN||used-14/VBN	amod||drug-16/NN||over-the-counter-15/JJ	root||ROOT-0/null||drug-16/NN	det||treatment-19/NN||the-18/DT	prep_for||drug-16/NN||treatment-19/NN	prep_of||treatment-19/NN||pain-21/NN	prep_of||treatment-19/NN||fever-23/NN	conj_or||pain-21/NN||fever-23/NN	prep_of||treatment-19/NN||colds-26/NNS	conj_or||pain-21/NN||colds-26/NNS	nsubj||limited-38/JJ||data-29/NNS	det||safety-32/NN||the-31/DT	prep_on||data-29/NNS||safety-32/NN	det||use-35/NN||this-34/DT	prep_of||safety-32/NN||use-35/NN	cop||limited-38/JJ||are-36/VBP	advmod||limited-38/JJ||very-37/RB	conj_but||drug-16/NN||limited-38/JJ	pain-21||aspirin-8||yes||background and aim acetylsalicylicacid (asa [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited.
amod||ranibizumab-2/NN||intravitreal-1/JJ	nsubj||demonstrated-3/VBD||ranibizumab-2/NN	root||ROOT-0/null||demonstrated-3/VBD	amod||benefit-7/NN||anatomic-4/JJ	conj_and||anatomic-4/JJ||functional-6/JJ	amod||benefit-7/NN||functional-6/JJ	dobj||demonstrated-3/VBD||benefit-7/NN	prep_in||demonstrated-3/VBD||patients-9/NNS	amod||detachment-15/NN||symptomatic-11/JJ	amod||detachment-15/NN||drusenoid-12/JJ	nn||detachment-15/NN||pigment-13/NN	nn||detachment-15/NN||epithelial-14/NN	prep_with||patients-9/NNS||detachment-15/NN	amod||neovascularization-18/NN||choroidal-17/JJ	prep_without||demonstrated-3/VBD||neovascularization-18/NN	prep_in||neovascularization-18/NN||age-relatedmaculardegeneration-20/NN	ranibizumab-2||age-relatedmaculardegeneration-20||no_rel||intravitreal ranibizumab demonstrated anatomic and functional benefit in patients with symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-relatedmaculardegeneration.
det||result-3/NN||a-2/DT	prep_as||inhibits-6/VBZ||result-3/NN	nsubj||inhibits-6/VBZ||fad-5/NN	root||ROOT-0/null||inhibits-6/VBZ	amod||transport-9/NN||insulin-stimulated-7/JJ	amod||transport-9/NN||aminoacid-8/JJ	dobj||inhibits-6/VBZ||transport-9/NN	nsubj||have-13/VB||transport-9/NN	aux||have-13/VB||may-12/MD	rcmod||transport-9/NN||have-13/VB	amod||implications-15/NNS||important-14/JJ	dobj||have-13/VB||implications-15/NNS	amod||transport-19/NN||placental-17/JJ	nn||transport-19/NN||nutrient-18/NN	prep_for||implications-15/NNS||transport-19/NN	amod||growth-22/NN||fetal-21/JJ	prep_for||implications-15/NNS||growth-22/NN	conj_and||transport-19/NN||growth-22/NN	prep_in||transport-19/NN||pregnancycomplications-24/NNS	vmod||pregnancycomplications-24/NNS||associated-25/VBN	amod||levels-30/NNS||altered-27/JJ	amod||levels-30/NNS||maternal-28/JJ	nn||levels-30/NNS||adiponectin-29/NN	prep_with||associated-25/VBN||levels-30/NNS	insulin--1||pregnancycomplications-24||no_rel||as a result, fad inhibits insulin-stimulated aminoacid transport, which may have important implications for placental nutrient transport and fetal growth in pregnancycomplications associated with altered maternal adiponectin levels.
det||sites-2/NNS||the-1/DT	nsubj||showed-45/VBD||sites-2/NNS	vmod||sites-2/NNS||stratified-3/VBN	prepc_according_to||stratified-3/VBN||to-5/TO	amod||type-8/NN||normal-6/JJ	nn||type-8/NN||tissue-7/NN	pobj||stratified-3/VBN||type-8/NN	amod||fg-12/NN||fibro-glandular-10/JJ	dep||type-8/NN||fg-12/NN	amod||fa-17/NN||fibro-adipose-15/JJ	dep||type-8/NN||fa-17/NN	conj_and||fg-12/NN||fa-17/NN	dep||type-8/NN||adipose-21/NN	conj_and||fg-12/NN||adipose-21/NN	dep||adipose-21/NN||a-23/SYM	nn||type-28/NN||disease-27/NN	pobj||stratified-3/VBN||type-28/NN	conj_or||type-8/NN||type-28/NN	amod||carcinoma-32/NN||invasive-30/JJ	amod||carcinoma-32/NN||ductal-31/JJ	dep||type-8/NN||carcinoma-32/NN	appos||carcinoma-32/NN||idc-34/NN	amod||carcinoma-38/NN||ductal-37/JJ	dep||type-8/NN||carcinoma-38/NN	conj_and||carcinoma-32/NN||carcinoma-38/NN	prep_in||carcinoma-38/NN||situ-40/NN	appos||situ-40/NN||dcis-42/NNS	root||ROOT-0/null||showed-45/VBD	mark||exhibited-48/VBD||that-46/IN	nsubj||exhibited-48/VBD||fg-47/NN	ccomp||showed-45/VBD||exhibited-48/VBD	amod||s-53/NN||increased-49/JJ	nn||s-53/NN||<-50/NN	nn||s-53/NN||î-51/NN	num||s-53/NN||1/4-52/CD	nsubj||showed-58/VBD||s-53/NN	amod||s-53/NN||>-55/JJ	amod||s-53/NN||a-57/DT	conj_and||>-55/JJ||a-57/DT	ccomp||exhibited-48/VBD||showed-58/VBD	amod||²-62/NN||increased-59/VBN	amod||²-62/NN||-LSB--60/JJ	nn||²-62/NN||î-61/NN	dobj||showed-58/VBD||²-62/NN	amod||-RSB--65/NNS||carotene-64/JJ	dep||²-62/NN||-RSB--65/NNS	amod||tissues-68/NNS||normal-67/JJ	prep_within||-RSB--65/NNS||tissues-68/NNS	carotene-64||carcinoma-38||no_rel||the sites stratified according to normal tissue type (fibro-glandular (fg), fibro-adipose (fa), and adipose (a)) or disease type (invasive ductal carcinoma (idc) and ductal carcinoma in situ (dcis)) showed that fg exhibited increased < î¼s' > and a showed increased [î²-carotene] within normal tissues.
nsubjpass||determined-3/VBN||fcu-1/NN	auxpass||determined-3/VBN||was-2/VBD	root||ROOT-0/null||determined-3/VBN	num||patients-6/NNS||36-5/CD	prep_in||determined-3/VBN||patients-6/NNS	prep_with||determined-3/VBN||gout-8/NN	auxpass||treated-10/VBN||being-9/VBG	vmod||gout-8/NN||treated-10/VBN	prep_with||treated-10/VBN||allopurinol-12/NN	gout-8||allopurinol-12||yes||fcu was determined in 36 patients with gout being treated with allopurinol.
nn||culture-3/NN||tissue-2/NN	prep_in||inhibited-10/VBD||culture-3/NN	amod||acid-5/NN||phosphonoacetic-4/JJ	nsubj||inhibited-10/VBD||acid-5/NN	appos||acid-5/NN||paa-7/NN	advmod||inhibited-10/VBD||specifically-9/RB	root||ROOT-0/null||inhibited-10/VBD	nn||synthesis-12/NN||dna-11/NN	dobj||inhibited-10/VBD||synthesis-12/NN	prep_of||synthesis-12/NN||humancytomegalovirus-14/NNS	appos||humancytomegalovirus-14/NNS||cmv-16/NN	amod||cmv-20/NN||murine-19/JJ	prep_of||synthesis-12/NN||cmv-20/NN	conj_and||humancytomegalovirus-14/NNS||cmv-20/NN	nn||cmv-23/NN||simian-22/NN	prep_of||synthesis-12/NN||cmv-23/NN	conj_and||humancytomegalovirus-14/NNS||cmv-23/NN	prep_of||synthesis-12/NN||epstein-barrvirus-25/NNS	conj_and||humancytomegalovirus-14/NNS||epstein-barrvirus-25/NNS	amod||saimiri-29/NNS||herpesvirus-28/JJ	prep_of||synthesis-12/NN||saimiri-29/NNS	conj_and||humancytomegalovirus-14/NNS||saimiri-29/NNS	cmv-23||humancytomegalovirus-14||no||in tissue culture phosphonoacetic acid (paa) specifically inhibited dna synthesis of humancytomegalovirus (cmv), murine cmv, simian cmv, epstein-barrvirus, and herpesvirus saimiri.
nsubj||manifests-5/VBZ||ecthymagangrenosum-1/NN	nsubjpass||associated-18/VBN||ecthymagangrenosum-1/NN	appos||ecthymagangrenosum-1/NN||eg-3/NN	root||ROOT-0/null||manifests-5/VBZ	det||lesion-9/NN||a-7/DT	nn||lesion-9/NN||skin-8/NN	prep_as||manifests-5/VBZ||lesion-9/NN	xcomp||manifests-5/VBZ||affecting-10/VBG	dobj||affecting-10/VBG||patients-11/NNS	vmod||affecting-10/VBG||suffering-12/VBG	amod||neutropenia-14/NN||extreme-13/JJ	dobj||suffering-12/VBG||neutropenia-14/NN	auxpass||associated-18/VBN||is-16/VBZ	advmod||associated-18/VBN||commonly-17/RB	conj_and||manifests-5/VBZ||associated-18/VBN	prep_with||associated-18/VBN||pseudomonasaeruginosa-20/NN	amod||patients-23/NNS||immunocompromised-22/JJ	prep_in||pseudomonasaeruginosa-20/NN||patients-23/NNS	ecthymagangrenosum-1||pseudomonasaeruginosa-20||no||ecthymagangrenosum (eg) manifests as a skin lesion affecting patients suffering extreme neutropenia and is commonly associated with pseudomonasaeruginosa in immunocompromised patients.
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||artemether--1||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
det||study-2/NN||the-1/DT	prep_on||based-8/VBN||study-2/NN	nsubj||linked-17/VBN||study-2/NN	det||article-6/NN||this-5/DT	nsubjpass||based-8/VBN||article-6/NN	auxpass||based-8/VBN||is-7/VBZ	rcmod||study-2/NN||based-8/VBN	amod||experiences-10/NNS||explored-9/JJ	dobj||based-8/VBN||experiences-10/NNS	amod||women-13/NNS||hivpositive-12/JJ	prep_of||experiences-10/NNS||women-13/NNS	poss||partners-16/NNS||their-15/PRP$	prep_of||experiences-10/NNS||partners-16/NNS	conj_and||women-13/NNS||partners-16/NNS	root||ROOT-0/null||linked-17/VBN	prep_to||linked-17/VBN||prevention-19/NN	prep_of||prevention-19/NN||mother-21/NN	nn||transmission-24/NN||child-23/NN	prep_to||linked-17/VBN||transmission-24/NN	amod||programs-30/NNS||hiv-26/JJ	appos||programs-30/NNS||pmtct-28/NN	prep_of||transmission-24/NN||programs-30/NNS	amod||district-33/NN||chiradzulu-32/JJ	prep_in||linked-17/VBN||district-33/NN	amod||malawi-36/NNS||southern-35/JJ	appos||district-33/NN||malawi-36/NNS	hivpositive-12||hiv-26||no||the study on which this article is based explored experiences of hivpositive women and their partners linked to prevention of mother to child transmission of hiv (pmtct) programs in chiradzulu district, southern malawi.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||here-2/RB	root||ROOT-0/null||show-3/VBP	mark||higher-25/JJR||that-4/IN	det||frequency-7/NN||the-5/DT	amod||frequency-7/NN||average-6/JJ	nsubj||higher-25/JJR||frequency-7/NN	amod||cells-14/NNS||total-9/JJ	conj_and||total-9/JJ||cd8-11/JJ	amod||cells-14/NNS||cd8-11/JJ	amod||cells-14/NNS||+-12/JJ	nn||cells-14/NNS||nkt-13/NN	prep_of||frequency-7/NN||cells-14/NNS	prep_in||cells-14/NNS||pbmcs-16/NNS	num||subjects-22/NNS||128-18/CD	amod||latent-20/JJ||healthy-19/JJ	amod||subjects-22/NNS||latent-20/JJ	amod||subjects-22/NNS||ebv-infected-21/JJ	prep_from||pbmcs-16/NNS||subjects-22/NNS	cop||higher-25/JJR||is-23/VBZ	advmod||higher-25/JJR||significantly-24/RB	ccomp||show-3/VBP||higher-25/JJR	prep||higher-25/JJR||than-26/IN	pcomp||than-26/IN||in-27/IN	num||patients-32/NNS||17-28/CD	amod||patients-32/NNS||acute-29/JJ	nn||patients-32/NNS||ebv-30/NN	nn||patients-32/NNS||infectiousmononucleosis-31/NN	pobj||in-27/IN||patients-32/NNS	num||patients-37/NNS||16-34/CD	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	pobj||in-27/IN||patients-37/NNS	conj_and||patients-32/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	pobj||in-27/IN||subjects-44/NNS	conj_and||patients-32/NNS||subjects-44/NNS	infectiousmononucleosis-31||ebv-30||no||we here show that the average frequency of total and cd8+ nkt cells in pbmcs from 128 healthy latent ebv-infected subjects is significantly higher than in 17 acute ebv infectiousmononucleosis patients, 16 ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
nsubj||has-2/VBZ||oxaliplatin/docetaxel-1/NN	root||ROOT-0/null||has-2/VBZ	dobj||has-2/VBZ||activity-3/NN	amod||non-smallcelllungcancer-6/NN||metastatic-5/JJ	prep_in||activity-3/NN||non-smallcelllungcancer-6/NN	nsubj||seems-10/VBZ||it-9/PRP	nsubj||inferior-13/JJ||it-9/PRP	nsubj||cisplatin/docetaxel-15/VB||it-9/PRP	conj_but||has-2/VBZ||seems-10/VBZ	aux||inferior-13/JJ||to-11/TO	cop||inferior-13/JJ||be-12/VB	xcomp||seems-10/VBZ||inferior-13/JJ	aux||cisplatin/docetaxel-15/VB||to-14/TO	xcomp||inferior-13/JJ||cisplatin/docetaxel-15/VB	non-smallcelllungcancer-6||docetaxel--1||yes||oxaliplatin/docetaxel has activity in metastatic non-smallcelllungcancer, but it seems to be inferior to cisplatin/docetaxel.
nsubj||included-2/VBD||we-1/PRP	root||ROOT-0/null||included-2/VBD	num||men-4/NNS||78-3/CD	dobj||included-2/VBD||men-4/NNS	prep_with||included-2/VBD||type2diabetes-6/NNS	nsubjpass||assigned-25/VBN||type2diabetes-6/NNS	dep||type2diabetes-6/NNS||aged-8/VBN	num||years-13/NNS||56.5-9/CD	nn||years-13/NNS||â-10/NN	amod||years-13/NNS||±-11/VBG	num||years-13/NNS||0.6-12/CD	dobj||aged-8/VBN||years-13/NNS	num||±-18/NNS||hba1c-15/CD	num||±-18/NNS||7.1-16/CD	amod||±-18/NNS||â-17/JJ	dep||years-13/NNS||±-18/NNS	number||%-20/NN||0.1-19/CD	amod||±-18/NNS||%-20/NN	auxpass||assigned-25/VBN||were-23/VBD	advmod||assigned-25/VBN||randomly-24/RB	rcmod||type2diabetes-6/NNS||assigned-25/VBN	prep_to||assigned-25/VBN||treatment-27/NN	prep_with||treatment-27/NN||pioglitazone-29/NN	num||mg/day-32/NN||30-31/CD	appos||pioglitazone-29/NN||mg/day-32/NN	prep_with||treatment-27/NN||metformin-35/NN	conj_or||pioglitazone-29/NN||metformin-35/NN	num||mg/day-38/NN||2000-37/CD	appos||pioglitazone-29/NN||mg/day-38/NN	amod||placebo-42/NN||matching-41/VBG	prep_to||assigned-25/VBN||placebo-42/NN	conj_and||treatment-27/NN||placebo-42/NN	prep_in||included-2/VBD||addition-45/NN	aux||glimepiride-47/VB||to-46/TO	vmod||addition-45/NN||glimepiride-47/VB	type2diabetes-6||metformin-35||yes||we included 78 men with type2diabetes (aged 56.5 â± 0.6 years; hba1c 7.1 â± 0.1%) who were randomly assigned to treatment with pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo, in addition to glimepiride.
advmod||provide-4/VBP||here-1/RB	nsubj||provide-4/VBP||we-3/PRP	root||ROOT-0/null||provide-4/VBP	det||review-7/NN||a-5/DT	amod||review-7/NN||comprehensive-6/JJ	dobj||provide-4/VBP||review-7/NN	poss||knowledge-11/NN||our-9/PRP$	amod||knowledge-11/NN||current-10/JJ	prep_on||review-7/NN||knowledge-11/NN	det||role-14/NN||the-13/DT	nsubj||mediating-29/VBG||role-14/NN	nn||molecules-19/NNS||junctional-16/NN	conj_and||junctional-16/NN||adhesion-18/NN	nn||molecules-19/NNS||adhesion-18/NN	prep_of||role-14/NN||molecules-19/NNS	amod||factors-22/NNS||soluble-21/JJ	prep_of||role-14/NN||factors-22/NNS	conj_and||molecules-19/NNS||factors-22/NNS	amod||enzymes-25/NNS||proteolytic-24/JJ	prep_of||role-14/NN||enzymes-25/NNS	conj_and||molecules-19/NNS||enzymes-25/NNS	amod||pathways-28/NNS||signaling-27/JJ	prep_of||role-14/NN||pathways-28/NNS	conj_and||molecules-19/NNS||pathways-28/NNS	prepc_about||provide-4/VBP||mediating-29/VBG	det||attachment-31/NN||the-30/DT	dobj||mediating-29/VBG||attachment-31/NN	nn||cells-34/NNS||tumor-33/NN	prep_of||attachment-31/NN||cells-34/NNS	nn||cells-38/NNS||brain-36/NN	nn||cells-38/NNS||endothelial-37/NN	prep_to||mediating-29/VBG||cells-38/NNS	det||migration-42/NN||the-40/DT	amod||migration-42/NN||transendothelial-41/JJ	prep_to||mediating-29/VBG||migration-42/NN	conj_and||cells-38/NNS||migration-42/NN	amod||cells-45/NNS||metastatic-44/JJ	prep_of||migration-42/NN||cells-45/NNS	enzymes-25||adhesion-18||no_rel||here, we provide a comprehensive review on our current knowledge about the role of junctional and adhesion molecules, soluble factors, proteolytic enzymes and signaling pathways mediating the attachment of tumor cells to brain endothelial cells and the transendothelial migration of metastatic cells.
mark||drugs-5/NNS||although-1/IN	nsubj||drugs-5/NNS||ppis-2/NNS	nsubj||effective-7/JJ||ppis-2/NNS	cop||drugs-5/NNS||are-3/VBP	amod||drugs-5/NNS||safe-4/JJ	advcl||shown-22/VBN||drugs-5/NNS	amod||drugs-5/NNS||effective-7/JJ	conj_and||drugs-5/NNS||effective-7/JJ	advcl||shown-22/VBN||effective-7/JJ	nn||esophagitis-11/NNS||healing-9/NN	nn||esophagitis-11/NNS||erosive-10/NN	prep_in||effective-7/JJ||esophagitis-11/NNS	conj_and||drugs-5/NNS||in-14/IN	advcl||shown-22/VBN||in-14/IN	amod||symptoms-16/NNS||relieving-15/VBG	pobj||in-14/IN||symptoms-16/NNS	nsubj||shown-22/VBN||studies-18/NNS	prep_with||studies-18/NNS||esomeprazole-20/NN	aux||shown-22/VBN||have-21/VBP	root||ROOT-0/null||shown-22/VBN	mark||has-26/VBZ||that-23/IN	det||drug-25/NN||this-24/DT	nsubj||has-26/VBZ||drug-25/NN	ccomp||shown-22/VBN||has-26/VBZ	prep_as||has-26/VBZ||powerful-28/JJ	det||ability-30/NN||an-29/DT	dobj||has-26/VBZ||ability-30/NN	aux||inhibit-32/VB||to-31/TO	vmod||ability-30/NN||inhibit-32/VB	amod||secretion-34/NN||acid-33/JJ	dobj||inhibit-32/VB||secretion-34/NN	prep_as||inhibit-32/VB||omeprazole-36/NN	esophagitis-11||omeprazole-36||yes||although ppis are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole.
nsubjpass||collected-3/VBN||strains-1/NNS	nsubjpass||tested-19/VBN||strains-1/NNS	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	num||patients-11/NNS||1824-5/CD	amod||patients-11/NNS||diagnosed-6/JJ	nn||patients-11/NNS||sputum-7/NN	amod||patients-11/NNS||smear-8/JJ	amod||patients-11/NNS||positive-9/JJ	nn||patients-11/NNS||pulmonarytb-10/NN	prep_from||collected-3/VBN||patients-11/NNS	amod||province-14/NN||jiangsu-13/JJ	prep_in||patients-11/NNS||province-14/NN	prep_of||province-14/NN||china-16/NN	advmod||tested-19/VBN||then-18/RB	conj_and||collected-3/VBN||tested-19/VBN	nn||susceptibility-22/NN||drug-21/NN	prep_for||tested-19/VBN||susceptibility-22/NN	prep_against||susceptibility-22/NN||rifampicin-24/NN	prep_against||susceptibility-22/NN||isoniazid-26/NN	conj_and||rifampicin-24/NN||isoniazid-26/NN	prep_against||susceptibility-22/NN||ethambutol-28/NN	conj_and||rifampicin-24/NN||ethambutol-28/NN	prep_against||susceptibility-22/NN||streptomycin-30/NN	conj_and||rifampicin-24/NN||streptomycin-30/NN	pulmonarytb-10||ethambutol-28||no_rel||strains were collected from 1824 diagnosed sputum smear positive pulmonarytb patients in jiangsu province of china and then tested for drug susceptibility against rifampicin, isoniazid, ethambutol and streptomycin.
nsubjpass||preceded-3/VBN||hypoglycemia-1/NN	auxpass||preceded-3/VBN||was-2/VBD	root||ROOT-0/null||preceded-3/VBN	det||ingestion-6/NN||the-5/DT	agent||preceded-3/VBN||ingestion-6/NN	preconj||placebo-10/NN||either-8/DT	amod||placebo-10/NN||oral-9/JJ	prep_of||ingestion-6/NN||placebo-10/NN	prep_of||ingestion-6/NN||glucose-12/NN	conj_or||placebo-10/NN||glucose-12/NN	number||g-15/CD||28-14/CD	dep||placebo-10/NN||g-15/CD	prep||preceded-3/VBN||given-17/VBN	pcomp||given-17/VBN||at-18/IN	num||min-20/NN||30-19/CD	pobj||at-18/IN||min-20/NN	hypoglycemia-1||glucose-12||yes||hypoglycemia was preceded by the ingestion of either oral placebo or glucose (28 g) given at 30 min.
quantmod||two-thirds-3/NNS||fewer-1/JJR	quantmod||two-thirds-3/NNS||than-2/IN	nsubj||knew-4/VBD||two-thirds-3/NNS	root||ROOT-0/null||knew-4/VBD	mark||develop-27/VB||that-5/IN	quantmod||10-7/CD||about-6/RB	num||%-8/NN||10-7/CD	nsubj||develop-27/VB||%-8/NN	prep_of||%-8/NN||people-10/NNS	det||u.s.a.-13/NN||the-12/DT	prep_in||people-10/NNS||u.s.a.-13/NN	nsubj||have-15/VBP||u.s.a.-13/NN	rcmod||u.s.a.-13/NN||have-15/VBP	nn||-rrb--20/NNP||latent-16/NN	nn||-rrb--20/NNP||tuberculosisinfection-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||ltbi-19/NNP	dobj||have-15/VBP||-rrb--20/NNP	det||system-25/NN||a-22/DT	amod||system-25/NN||normal-23/JJ	amod||system-25/NN||immune-24/JJ	dobj||have-15/VBP||system-25/NN	conj_and||-rrb--20/NNP||system-25/NN	aux||develop-27/VB||will-26/MD	ccomp||knew-4/VBD||develop-27/VB	nn||disease-29/NN||tb-28/NN	dobj||develop-27/VB||disease-29/NN	mark||part-36/NN||that-32/IN	nsubj||part-36/NN||bcg-33/NN	cop||part-36/NN||is-34/VBZ	neg||part-36/NN||not-35/RB	ccomp||knew-4/VBD||part-36/NN	conj_or||develop-27/VB||part-36/NN	det||program-41/NN||the-38/DT	amod||program-41/NN||routine-39/JJ	nn||program-41/NN||vaccination-40/NN	prep_of||part-36/NN||program-41/NN	det||u.s.a.-44/NN||the-43/DT	prep_in||program-41/NN||u.s.a.-44/NN	mark||complicates-47/VBZ||because-45/IN	nsubj||complicates-47/VBZ||it-46/PRP	advcl||part-36/NN||complicates-47/VBZ	dobj||complicates-47/VBZ||surveillance-48/NN	amod||infection-52/NN||new-50/JJ	nn||infection-52/NN||tb-51/NN	prep_for||surveillance-48/NN||infection-52/NN	tuberculosisinfection-17||bcg-33||yes||fewer than two-thirds knew that about 10 % of people in the u.s.a. who have latent tuberculosisinfection -lrb- ltbi -rrb- and a normal immune system will develop tb disease , or that bcg is not part of the routine vaccination program in the u.s.a. because it complicates surveillance for new tb infection .
nsubj||complication-5/NN||pneumomediastinum-1/NN	cop||complication-5/NN||is-2/VBZ	det||complication-5/NN||an-3/DT	amod||complication-5/NN||uncommon-4/JJ	root||ROOT-0/null||complication-5/NN	nsubj||occurs-9/VBZ||complication-5/NN	nsubj||occur-20/VB||complication-5/NN	prep_of||complication-5/NN||cocaineabuse-7/NN	rcmod||complication-5/NN||occurs-9/VBZ	advmod||commonly-11/RB||more-10/RBR	advmod||occurs-9/VBZ||commonly-11/RB	advmod||smoked-15/VBN||when-12/WRB	nsubjpass||smoked-15/VBN||cocaine-13/NN	auxpass||smoked-15/VBN||is-14/VBZ	advcl||commonly-11/RB||smoked-15/VBN	aux||occur-20/VB||can-18/MD	advmod||occur-20/VB||also-19/RB	rcmod||complication-5/NN||occur-20/VB	conj_but||occurs-9/VBZ||occur-20/VB	advmod||insufflated-25/JJ||when-21/WRB	nsubj||insufflated-25/JJ||cocaine-22/NN	cop||insufflated-25/JJ||is-23/VBZ	advmod||insufflated-25/JJ||nasally-24/RB	advcl||occur-20/VB||insufflated-25/JJ	cocaineabuse-7||cocaine-22||no||pneumomediastinum is an uncommon complication of cocaineabuse that occurs more commonly when cocaine is smoked, but can also occur when cocaine is nasally insufflated.
nsubjpass||related-4/VBN||obesity-1/NN	nsubj||hdl-6/VB||obesity-1/NN	auxpass||related-4/VBN||was-2/VBD	advmod||related-4/VBN||inversely-3/RB	root||ROOT-0/null||related-4/VBN	aux||hdl-6/VB||to-5/TO	xcomp||related-4/VBN||hdl-6/VB	dobj||hdl-6/VB||cholesterol-7/NN	amod||changes-10/NNS||hs-crp-9/JJ	dobj||hdl-6/VB||changes-10/NNS	conj_and||cholesterol-7/NN||changes-10/NNS	amod||a1c-15/NNS||higher-13/JJR	nn||a1c-15/NNS||baseline-14/NN	dobj||hdl-6/VB||a1c-15/NNS	conj_and||cholesterol-7/NN||a1c-15/NNS	amod||reductions-20/NNS||smaller-17/JJR	nn||reductions-20/NNS||apolipoprotein-18/NN	amod||reductions-20/NNS||b-19/JJ	prep_to||a1c-15/NNS||reductions-20/NNS	cholesterol-7||obesity-1||no_rel||obesity was inversely related to hdl cholesterol and hs-crp changes, and higher baseline a1c to smaller apolipoprotein b reductions.
det||article-2/NN||this-1/DT	nsubj||presents-3/VBZ||article-2/NN	root||ROOT-0/null||presents-3/VBZ	det||method-5/NN||a-4/DT	dobj||presents-3/VBZ||method-5/NN	aux||calculate-7/VB||to-6/TO	vmod||method-5/NN||calculate-7/VB	det||percentage-9/NN||the-8/DT	nsubj||attributable-13/JJ||percentage-9/NN	amod||deaths-12/NNS||hiv/aids-11/JJ	prep_of||percentage-9/NN||deaths-12/NNS	xcomp||calculate-7/VB||attributable-13/JJ	nn||consumption-16/NN||alcohol-15/NN	prep_to||attributable-13/JJ||consumption-16/NN	det||uncertainty-20/NN||the-18/DT	amod||uncertainty-20/NN||associated-19/VBN	prep_to||attributable-13/JJ||uncertainty-20/NN	conj_and||consumption-16/NN||uncertainty-20/NN	aids--1||hiv--1||no||this article presents a method to calculate the percentage of hiv/aids deaths attributable to alcohol consumption and the associated uncertainty.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||review-5/NN||this-4/DT	prep_of||purpose-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||analyze-8/VB||to-7/TO	ccomp||is-6/VBZ||analyze-8/VB	dobj||analyze-8/VB||some-9/DT	det||data-13/NNS||the-11/DT	amod||data-13/NNS||current-12/JJ	prep_of||some-9/DT||data-13/NNS	prep_of||data-13/NNS||hdaci-15/NNS	amod||targets-18/NNS||possible-17/JJ	prep_as||analyze-8/VB||targets-18/NNS	nn||development-21/NN||drug-20/NN	prep_of||targets-18/NNS||development-21/NN	aux||provide-24/VB||to-23/TO	ccomp||is-6/VBZ||provide-24/VB	conj_and||analyze-8/VB||provide-24/VB	det||insight-26/NN||some-25/DT	dobj||provide-24/VB||insight-26/NN	det||problems-30/NNS||the-28/DT	amod||problems-30/NNS||current-29/JJ	prep_into||provide-24/VB||problems-30/NNS	amod||cancer-33/NN||pancreatic-32/JJ	prep_with||problems-30/NNS||cancer-33/NN	prep_into||provide-24/VB||points-35/NNS	conj_and||problems-30/NNS||points-35/NNS	prep_of||points-35/NNS||interest-37/NN	amod||study-40/NN||further-39/JJ	prep_for||provide-24/VB||study-40/NN	prep_of||study-40/NN||hdaci-42/NNS	amod||molecules-45/NNS||potential-44/JJ	prep_as||hdaci-42/NNS||molecules-45/NNS	amod||therapy-50/NN||pancreatic-47/JJ	nn||therapy-50/NN||cancer-48/NN	nn||therapy-50/NN||adjuvant-49/NN	prep_for||molecules-45/NNS||therapy-50/NN	cancer-48||adjuvant-49||no_rel||the purpose of this review is to analyze some of the current data of hdaci as possible targets of drug development and to provide some insight into the current problems with pancreatic cancer and points of interest for further study of hdaci as potential molecules for pancreatic cancer adjuvant therapy.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effects-4/NNS||the-3/DT	dobj||investigated-2/VBD||effects-4/NNS	amod||hyperglycemia-7/NN||neonatal-6/JJ	prep_of||effects-4/NNS||hyperglycemia-7/NN	amod||‰-11/NNS||bloodglucose-9/JJ	nn||‰-11/NNS||â-10/NN	nsubj||¥-12/VBZ||‰-11/NNS	dep||hyperglycemia-7/NN||¥-12/VBZ	num||mmol/l-14/NN||10-13/CD	dobj||¥-12/VBZ||mmol/l-14/NN	vmod||mmol/l-14/NN||treated-16/VBN	prep_with||treated-16/VBN||insulin-18/NN	nn||¥-22/NNP||â-20/NNP	nn||¥-22/NNP||‰-21/NNP	prep_for||insulin-18/NN||¥-22/NNP	num||hours-24/NNS||12-23/CD	dep||insulin-18/NN||hours-24/NNS	nn||outcome-30/NN||growth-27/NN	conj_and||growth-27/NN||neurobehavioral-29/NN	nn||outcome-30/NN||neurobehavioral-29/NN	prep_on||investigated-2/VBD||outcome-30/NN	num||years-33/NNS||2-32/CD	prep_at||investigated-2/VBD||years-33/NNS	prep_of||years-33/NNS||age-35/NN	hyperglycemia-7||glucose--1||no||we investigated the effects of neonatal hyperglycemia (bloodglucose â‰¥ 10 mmol/l, treated with insulin for â‰¥ 12 hours) on growth and neurobehavioral outcome at 2 years of age.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	advmod||studied-2/VBD||prospectively-3/RB	num||groups-5/NNS||three-4/CD	dobj||studied-2/VBD||groups-5/NNS	iobj||studied-2/VBD||groups-5/NNS	prep_of||groups-5/NNS||patients-7/NNS	appos||groups-5/NNS||1-9/CD	num||group-12/NN||one-11/CD	dep||groups-5/NNS||group-12/NN	num||patients-15/NNS||35-14/CD	prep_of||group-12/NN||patients-15/NNS	prep_with||patients-15/NNS||fibroticdisorders-17/NNS	prep_of||group-12/NN||16-19/CD	conj_and||patients-15/NNS||16-19/CD	amod||pulmonaryfibrosis-22/NNS||idiopathic-21/JJ	prep_with||16-19/CD||pulmonaryfibrosis-22/NNS	appos||pulmonaryfibrosis-22/NNS||ipf-24/NN	prep_of||group-12/NN||19-27/CD	conj_and||patients-15/NNS||19-27/CD	amod||pneumonias-31/NNS||fibrotic-29/JJ	amod||pneumonias-31/NNS||interstitial-30/JJ	prep_with||19-27/CD||pneumonias-31/NNS	vmod||group-12/NN||associated-32/VBN	nn||disorders-36/NNS||collagen-34/NN	nn||disorders-36/NNS||tissue-35/NN	prep_with||associated-32/VBN||disorders-36/NNS	dep||group-12/NN||ctd-ips-38/NNS	dep||group-45/NN||2-42/LS	num||group-45/NN||one-44/CD	dep||group-12/NN||group-45/NN	num||patients-48/NNS||14-47/CD	prep_of||group-45/NN||patients-48/NNS	prep_with||patients-48/NNS||pulmonarysarcoidosis-50/NNS	appos||patients-48/NNS||3-54/CD	num||subjects-58/NNS||11-56/CD	amod||subjects-58/NNS||normal-57/JJ	prep_of||group-45/NN||subjects-58/NNS	conj_and||patients-48/NNS||subjects-58/NNS	pulmonarysarcoidosis-50||collagen-34||no_rel||we studied prospectively three groups of patients (1) one group of 35 patients with fibroticdisorders, 16 with idiopathic pulmonaryfibrosis (ipf) and 19 with fibrotic interstitial pneumonias associated with collagen tissue disorders (ctd-ips); (2) one group of 14 patients with pulmonarysarcoidosis; and (3) 11 normal subjects.
nsubjpass||found-9/VBN||differences-1/NNS	nsubjpass||found-9/VBN||differences-1/NNS	amod||sequence-4/NN||nucleotide-3/JJ	prep_in||differences-1/NNS||sequence-4/NN	amod||env-7/NN||herv-w-6/JJ	prep_of||sequence-4/NN||env-7/NN	auxpass||found-9/VBN||were-8/VBD	root||ROOT-0/null||found-9/VBN	conj_and||found-9/VBN||found-9/VBN	prep_between||found-9/VBN||patients-11/NNS	prep_with||patients-11/NNS||sz-13/NN	prep_with||patients-11/NNS||bd-15/NN	conj_and||sz-13/NN||bd-15/NN	prepc_as||found-9/VBN||compared-17/VBN	pcomp||compared-17/VBN||with-18/IN	pobj||with-18/IN||hc-19/NN	prep_between||found-9/VBN||sz-25/NN	prep_between||found-9/VBN||bd-27/NN	conj_and||sz-25/NN||bd-27/NN	sz-25||hc-19||no_rel||differences in nucleotide sequence of herv-w env were found between patients with sz and bd as compared with hc, as well as between sz and bd.
det||participants-2/NNS||the-1/DT	nsubj||expressed-3/VBD||participants-2/NNS	root||ROOT-0/null||expressed-3/VBD	det||set-6/NN||a-4/DT	amod||set-6/NN||consistent-5/JJ	dobj||expressed-3/VBD||set-6/NN	nn||beliefs-9/NNS||health-8/NN	prep_of||set-6/NN||beliefs-9/NNS	prep_about||expressed-3/VBD||practices-11/NNS	vmod||practices-11/NNS||relating-12/VBG	prep_to||relating-12/VBG||hiv/aids-14/NNS	aids--1||hiv--1||no||the participants expressed a consistent set of health beliefs about practices relating to hiv/aids.
det||1-year-3/NN||the-2/DT	prep_within||reported-10/VBD||1-year-3/NN	nn||diagnosis-7/NN||disease-6/NN	prep_prior_to||1-year-3/NN||diagnosis-7/NN	nsubj||reported-10/VBD||controls-9/NNS	root||ROOT-0/null||reported-10/VBD	advmod||more-12/JJR||slightly-11/RB	amod||infections-14/NNS||more-12/JJR	amod||infections-14/NNS||strep-tococcal-13/JJ	dobj||reported-10/VBD||infections-14/NNS	appos||infections-14/NNS||p-16/NNP	number||0.2-18/CD||<-17/CD	num||p-16/NNP||0.2-18/CD	dobj||reported-10/VBD||infections-21/NNS	conj_and||infections-14/NNS||infections-21/NNS	prep_with||infections-21/NNS||diarrhea-23/NN	prep_with||infections-21/NNS||vomiting-25/NN	conj_and||diarrhea-23/NN||vomiting-25/NN	dep||infections-14/NNS||p-27/VBN	num||0.3-29/CD||<-28/CD	dobj||p-27/VBN||0.3-29/CD	amod||use-34/NN||antibiotic-33/JJ	dobj||reported-10/VBD||use-34/NN	conj_and||infections-14/NNS||use-34/NN	appos||use-34/NN||p-36/NNP	number||0.09-38/CD||<-37/CD	num||p-36/NNP||0.09-38/CD	mark||significant-48/JJ||although-41/IN	nsubj||significant-48/JJ||none-42/NN	det||results-45/NNS||these-44/DT	prep_of||none-42/NN||results-45/NNS	cop||significant-48/JJ||were-46/VBD	advmod||significant-48/JJ||statistically-47/RB	dep||use-34/NN||significant-48/JJ	strep--1||antibiotic-33||no_rel||within the 1-year prior to disease diagnosis, controls reported slightly more strep-tococcal infections (p<0.2), infections with diarrhea and vomiting (p<0.3), and antibiotic use (p<0.09), although none of these results were statistically significant.
nsubjpass||shown-29/VBN||alefacept-1/NN	nsubj||result-31/VB||alefacept-1/NN	nsubj||has-37/VBZ||alefacept-1/NN	det||antigen-6/NN||a-3/DT	amod||antigen-6/NN||lymphocyte-4/JJ	amod||antigen-6/NN||function-associated-5/JJ	dep||alefacept-1/NN||antigen-6/NN	appos||antigen-6/NN||lfa-8/NN	nsubj||ig-11/VBP||-3-10/CD	rcmod||antigen-6/NN||ig-11/VBP	nn||protein-13/NN||fusion-12/NN	dobj||ig-11/VBP||protein-13/NN	nsubj||binds-15/VBZ||protein-13/NN	rcmod||protein-13/NN||binds-15/VBZ	prep_to||binds-15/VBZ||cd2-17/NNS	prep_to||binds-15/VBZ||functions-19/NNS	conj_and||cd2-17/NNS||functions-19/NNS	det||antagonist-22/NN||an-21/DT	prep_as||antigen-6/NN||antagonist-22/NN	amod||activation-25/NN||t-cell-24/JJ	prep_to||antagonist-22/NN||activation-25/NN	aux||shown-29/VBN||has-27/VBZ	auxpass||shown-29/VBN||been-28/VBN	root||ROOT-0/null||shown-29/VBN	aux||result-31/VB||to-30/TO	xcomp||shown-29/VBN||result-31/VB	prep_in||result-31/VB||improvement-33/NN	prep_in||improvement-33/NN||psoriasis-35/NNS	conj_but||shown-29/VBN||has-37/VBZ	amod||effectiveness-39/NN||limited-38/JJ	dobj||has-37/VBZ||effectiveness-39/NN	prep_in||effectiveness-39/NN||psa-41/NN	psoriasis-35||alefacept-1||yes||alefacept (a lymphocyte function-associated antigen (lfa)-3 ig fusion protein that binds to cd2 and functions as an antagonist to t-cell activation) has been shown to result in improvement in psoriasis but has limited effectiveness in psa.
det||involvement-9/NN||a-1/DT	amod||involvement-9/NN||patient-2/JJ	amod||chest-7/NN||extensive-4/JJ	conj_and||extensive-4/JJ||painful-6/JJ	amod||chest-7/NN||painful-6/JJ	prep_with||patient-2/JJ||chest-7/NN	nn||involvement-9/NN||wall-8/NN	nsubjpass||treated-19/VBN||involvement-9/NN	det||cancer-14/NN||a-11/DT	amod||cancer-14/NN||metastatic-12/JJ	nn||cancer-14/NN||borderline-13/NN	prep_from||involvement-9/NN||cancer-14/NN	det||ovary-17/NN||the-16/DT	prep_of||cancer-14/NN||ovary-17/NN	auxpass||treated-19/VBN||was-18/VBD	root||ROOT-0/null||treated-19/VBN	det||carboplatin-22/JJ||a-21/DT	prep_with||treated-19/VBN||carboplatin-22/JJ	amod||regimen-26/NN||paclitaxel-24/JJ	amod||regimen-26/NN||chemotherapy-25/JJ	prep_with||treated-19/VBN||regimen-26/NN	conj_plus||carboplatin-22/JJ||regimen-26/NN	painful-6||paclitaxel-24||no_rel||a patient with extensive and painful chest wall involvement from a metastatic borderline cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy regimen.
det||patients-2/NNS||the-1/DT	nsubj||received-19/VBD||patients-2/NNS	det||group-9/NN||the-4/DT	amod||preemptive-6/JJ||multimodal-5/JJ	amod||group-9/NN||preemptive-6/JJ	nn||group-9/NN||pain-7/NN	nn||group-9/NN||relief-8/NN	prep_in||patients-2/NNS||group-9/NN	det||group-13/NN||the-11/DT	nn||group-13/NN||study-12/NN	dep||group-9/NN||group-13/NN	nn||121-17/NNP||n-15/NNP	nn||121-17/NNP||=-16/NNP	appos||group-13/NN||121-17/NNP	root||ROOT-0/null||received-19/VBD	amod||blockade-22/NN||regional-20/JJ	nn||blockade-22/NN||nerve-21/NN	dobj||received-19/VBD||blockade-22/NN	number||%-25/NN||0.25-24/CD	amod||bupivacaine-26/NN||%-25/NN	prep_with||received-19/VBD||bupivacaine-26/NN	prep||received-19/VBD||combined-27/VBN	pcomp||combined-27/VBN||with-28/IN	amod||mg/kg-34/NN||preoperative-29/JJ	advmod||administered-31/JJ||rectally-30/RB	amod||mg/kg-34/NN||administered-31/JJ	nn||mg/kg-34/NN||paracetamol-32/NN	num||mg/kg-34/NN||45-33/CD	pobj||with-28/IN||mg/kg-34/NN	amod||min-40/NN||diclofenac-36/JJ	num||min-40/NN||1-37/CD	amod||min-40/NN||mg/kg-38/JJ	dep||mg/kg-38/JJ||60-39/CD	pobj||with-28/IN||min-40/NN	conj_or||mg/kg-34/NN||min-40/NN	prep_before||mg/kg-34/NN||surgery-42/NN	prep_for||surgery-42/NN||cases-44/NNS	nsubj||were-46/VBD||cases-44/NNS	nsubj||undergo-48/VB||cases-44/NNS	rcmod||cases-44/NNS||were-46/VBD	aux||undergo-48/VB||to-47/TO	xcomp||were-46/VBD||undergo-48/VB	amod||surgery-51/NN||lower-49/JJR	nn||surgery-51/NN||abdominal-50/NN	dobj||undergo-48/VB||surgery-51/NN	pain-7||paracetamol-32||yes||the patients in the multimodal preemptive pain relief group (the study group, n = 121) received regional nerve blockade with 0.25% bupivacaine combined with preoperative rectally administered paracetamol 45 mg/kg or diclofenac 1 mg/kg 60 min before surgery for cases that were to undergo lower abdominal surgery.
prep_in||favorable-29/JJ||addition-2/NN	det||parameters-6/NNS||all-4/DT	amod||parameters-6/NNS||metabolic-5/JJ	nsubj||favorable-29/JJ||parameters-6/NNS	nn||weight-10/NN||body-9/NN	prep_including||parameters-6/NNS||weight-10/NN	amod||circumference-13/NN||waist-12/JJ	prep_including||parameters-6/NNS||circumference-13/NN	conj_and||weight-10/NN||circumference-13/NN	prep_including||parameters-6/NNS||bloodglucose-15/NN	conj_and||weight-10/NN||bloodglucose-15/NN	amod||lipoprotein-18/NN||high-density-17/JJ	prep_including||parameters-6/NNS||lipoprotein-18/NN	conj_and||weight-10/NN||lipoprotein-18/NN	prep_including||parameters-6/NNS||triglyceride-20/NN	conj_and||weight-10/NN||triglyceride-20/NN	nn||pressure-23/NN||blood-22/NN	prep_including||parameters-6/NNS||pressure-23/NN	conj_and||weight-10/NN||pressure-23/NN	prep_including||parameters-6/NNS||insulin-26/NN	conj_and||weight-10/NN||insulin-26/NN	cop||favorable-29/JJ||were-28/VBD	root||ROOT-0/null||favorable-29/JJ	det||group-33/NN||the-31/DT	nn||group-33/NN||ketonuria-32/NN	prep_in||favorable-29/JJ||group-33/NN	prep||favorable-29/JJ||than-34/IN	pcomp||than-34/IN||in-35/IN	det||group-38/NN||the-36/DT	amod||group-38/NN||non-ketonuria-37/JJ	pobj||in-35/IN||group-38/NN	advmod||adjustment-42/NN||even-40/RB	mark||adjustment-42/NN||after-41/IN	advcl||favorable-29/JJ||adjustment-42/NN	prep_for||adjustment-42/NN||age-44/NN	nn||use-47/NN||tobacco-46/NN	prep_for||adjustment-42/NN||use-47/NN	conj_and||age-44/NN||use-47/NN	nn||consumption-51/NN||alcohol-50/NN	prep_for||adjustment-42/NN||consumption-51/NN	conj_and||age-44/NN||consumption-51/NN	bloodglucose-15||high--1||yes||in addition, all metabolic parameters (including body weight, waist circumference, bloodglucose, high-density lipoprotein, triglyceride, blood pressure, and insulin) were favorable in the ketonuria group than in the non-ketonuria group, even after adjustment for age, tobacco use, and alcohol consumption.
det||study-3/NN||this-2/DT	prep_in||higher-15/JJR||study-3/NN	det||prevalence-6/NN||the-5/DT	nsubj||higher-15/JJR||prevalence-6/NN	nn||infections-12/NNS||cryptosporidium-8/NN	conj_and||cryptosporidium-8/NN||s.-10/NN	nn||infections-12/NNS||s.-10/NN	nn||infections-12/NNS||stercoralis-11/NNS	prep_of||prevalence-6/NN||infections-12/NNS	cop||higher-15/JJR||was-13/VBD	advmod||higher-15/JJR||significantly-14/RB	root||ROOT-0/null||higher-15/JJR	prep_among||higher-15/JJR||people-17/NNS	prep_with||people-17/NNS||hiv/aids-19/NNS	aids--1||hiv--1||no||in this study , the prevalence of cryptosporidium and s. stercoralis infections was significantly higher among people with hiv/aids .
nsubj||enteropathy-7/NN||coeliacdisease-1/NN	appos||coeliacdisease-1/NN||cd-3/NN	cop||enteropathy-7/NN||is-5/VBZ	det||enteropathy-7/NN||an-6/DT	root||ROOT-0/null||enteropathy-7/NN	vmod||enteropathy-7/NN||characterized-8/VBN	det||response-13/NN||an-10/DT	amod||response-13/NN||aberrant-11/JJ	amod||response-13/NN||immune-12/JJ	agent||characterized-8/VBN||response-13/NN	amod||proteins-16/NNS||cereal-gluten-15/JJ	prep_to||characterized-8/VBN||proteins-16/NNS	coeliacdisease-1||gluten--1||no||coeliacdisease (cd) is an enteropathy characterized by an aberrant immune response to cereal-gluten proteins.
poss||results-2/NNS||our-1/PRP$	nsubj||support-3/VBP||results-2/NNS	nsubj||need-21/VBP||results-2/NNS	root||ROOT-0/null||support-3/VBP	det||assumption-5/NN||the-4/DT	dobj||support-3/VBP||assumption-5/NN	prep_of||assumption-5/NN||non-inferiority-7/NN	prep_of||non-inferiority-7/NN||ibuprofen-9/NN	prepc_compared_to||ibuprofen-9/NN||to-11/TO	pobj||ibuprofen-9/NN||ciprofloxacin-12/NN	prep_for||ciprofloxacin-12/NN||treatment-14/NN	amod||uti-18/NN||symptomatic-16/JJ	amod||uti-18/NN||uncomplicated-17/JJ	prep_of||treatment-14/NN||uti-18/NN	conj_but||support-3/VBP||need-21/VBP	dobj||need-21/VBP||confirmation-22/NN	amod||trials-25/NNS||further-24/JJ	prep_by||need-21/VBP||trials-25/NNS	uti-18||ciprofloxacin-12||yes||our results support the assumption of non-inferiority of ibuprofen compared to ciprofloxacin for treatment of symptomatic uncomplicated uti, but need confirmation by further trials.
advmod||develop-4/VBP||here-1/RB	nsubj||develop-4/VBP||we-3/PRP	ccomp||followed-21/VBD||develop-4/VBP	det||technique-7/NN||a-5/DT	amod||technique-7/NN||new-6/JJ	dobj||develop-4/VBP||technique-7/NN	aux||recover-9/VB||to-8/TO	vmod||technique-7/NN||recover-9/VB	dobj||recover-9/VB||viruses-10/NNS	amod||waters-13/NNS||natural-12/JJ	prep_from||recover-9/VB||waters-13/NNS	vmod||waters-13/NNS||using-14/VBG	amod||flocculation-16/NN||iron-based-15/JJ	dobj||using-14/VBG||flocculation-16/NN	amod||filtration-19/NN||large-pore-size-18/JJ	dobj||using-14/VBG||filtration-19/NN	conj_and||flocculation-16/NN||filtration-19/NN	root||ROOT-0/null||followed-21/VBD	prep_by||followed-21/VBD||resuspension-23/NN	amod||precipitates-26/NNS||virus-containing-25/JJ	prep_of||resuspension-23/NN||precipitates-26/NNS	det||ph-29/NN||a-28/DT	prep_in||followed-21/VBD||ph-29/NN	num||buffer-31/NN||6-30/CD	nsubj||followed-21/VBD||buffer-31/NN	virus--1||viruses-10||no||here, we develop a new technique to recover viruses from natural waters using iron-based flocculation and large-pore-size filtration, followed by resuspension of virus-containing precipitates in a ph 6 buffer.
nsubj||linked-2/VBD||we-1/PRP	root||ROOT-0/null||linked-2/VBD	amod||results-5/NNS||positivehiv-3/JJ	nn||results-5/NNS||pcr-4/NN	dobj||linked-2/VBD||results-5/NNS	amod||testing-11/NN||subsequent-7/JJ	nn||testing-11/NN||hiv-8/NN	amod||testing-11/NN||viral-9/JJ	nn||testing-11/NN||load-10/NN	prep_to||linked-2/VBD||testing-11/NN	aux||determine-13/VB||to-12/TO	vmod||linked-2/VBD||determine-13/VB	det||proportion-15/NN||the-14/DT	dobj||determine-13/VB||proportion-15/NN	prep_of||proportion-15/NN||infants-17/NNS	nsubjpass||linked-21/VBN||infants-17/NNS	auxpass||linked-21/VBN||were-19/VBD	advmod||linked-21/VBN||successfully-20/RB	rcmod||infants-17/NNS||linked-21/VBN	nn||care-24/NN||hiv-23/NN	prep_to||linked-21/VBN||care-24/NN	positivehiv-3||hiv-23||no||we linked positivehiv pcr results to subsequent hiv viral load testing to determine the proportion of infants who were successfully linked to hiv care.
det||study-7/NN||this-1/DT	amod||study-7/NN||26-week-2/JJ	amod||study-7/NN||double-blind-4/JJ	amod||study-7/NN||parallel-group-6/JJ	root||ROOT-0/null||study-7/NN	vmod||study-7/NN||randomized-8/VBN	amod||patients-10/NNS||655-9/JJ	dobj||randomized-8/VBN||patients-10/NNS	advmod||controlled-13/JJ||inadequately-12/RB	amod||monotherapy-25/NNS||controlled-13/JJ	amod||monotherapy-25/NNS||type2diabetes-14/JJ	num||arms-17/NNS||four-16/CD	prep_to||type2diabetes-14/JJ||arms-17/NNS	num||alogliptin-20/NN||25-18/CD	nn||alogliptin-20/NN||mg-19/NN	nsubj||-lrb--21/VBZ||alogliptin-20/NN	rcmod||arms-17/NNS||-lrb--21/VBZ	amod||monotherapy-25/NNS||a25-22/JJ	amod||monotherapy-25/NNS||-rrb--23/JJ	nn||monotherapy-25/NNS||q.d.-24/NN	prep_with||randomized-8/VBN||monotherapy-25/NNS	number||mg-28/CD||30-27/CD	num||monotherapy-34/NN||mg-28/CD	amod||monotherapy-34/NN||pioglitazone-29/JJ	amod||monotherapy-34/NN||-lrb--30/JJ	amod||monotherapy-34/NN||p30-31/JJ	amod||monotherapy-34/NN||-rrb--32/JJ	nn||monotherapy-34/NN||q.d.-33/NN	prep_with||randomized-8/VBN||monotherapy-34/NN	conj_or||monotherapy-25/NNS||monotherapy-34/NN	num||a12-39/NNS||12.5-37/CD	amod||a12-39/NNS||-lrb--38/JJ	prep_with||randomized-8/VBN||a12-39/NNS	conj_or||monotherapy-25/NNS||a12-39/NNS	num||-rrb--41/NNS||.5-40/CD	dep||a12-39/NNS||-rrb--41/NNS	num||q.d.-46/NN||25-43/CD	nn||q.d.-46/NN||mg-44/NN	nn||q.d.-46/NN||alogliptin-45/NN	prep_with||randomized-8/VBN||q.d.-46/NN	conj_or||monotherapy-25/NNS||q.d.-46/NN	prep||q.d.-46/NN||plus-47/CC	amod||therapy-54/NN||pioglitazone-48/JJ	nn||therapy-54/NN||-lrb--49/NNP	amod||therapy-54/NN||p30-50/JJ	amod||therapy-54/NN||-rrb--51/JJ	nn||therapy-54/NN||q.d.-52/NN	nn||therapy-54/NN||combination-53/NN	pobj||plus-47/CC||therapy-54/NN	type2diabetes-14||pioglitazone-48||yes||this 26-week , double-blind , parallel-group study randomized 655 patients with inadequately controlled type2diabetes to four arms 25 mg alogliptin -lrb- a25 -rrb- q.d. monotherapy , 30 mg pioglitazone -lrb- p30 -rrb- q.d. monotherapy , or 12.5 -lrb- a12 .5 -rrb- or 25 mg alogliptin q.d. plus pioglitazone -lrb- p30 -rrb- q.d. combination therapy .
advmod||effective-6/JJ||thus-1/RB	nn||treatment-4/NN||ibuprofen-3/NN	nsubj||effective-6/JJ||treatment-4/NN	cop||effective-6/JJ||was-5/VBD	root||ROOT-0/null||effective-6/JJ	prepc_in||effective-6/JJ||attenuating-8/VBG	amod||inflammation-10/NN||hrhf-induced-9/JJ	dobj||attenuating-8/VBG||inflammation-10/NN	amod||degeneration-15/NN||early-12/JJ	nn||degeneration-15/NN||articular-13/NN	nn||degeneration-15/NN||cartilage-14/NN	dobj||attenuating-8/VBG||degeneration-15/NN	conj_and||inflammation-10/NN||degeneration-15/NN	inflammation-10||ibuprofen-3||yes||thus, ibuprofen treatment was effective in attenuating hrhf-induced inflammation and early articular cartilage degeneration.
amod||concordance-2/NN||inter-laboratory-1/JJ	nsubj||better-5/JJR||concordance-2/NN	cop||better-5/JJR||was-3/VBD	advmod||better-5/JJR||slightly-4/RB	root||ROOT-0/null||better-5/JJR	prep_for||better-5/JJR||psv-7/NN	dep||better-5/JJR||than-8/IN	nn||assays-11/NNS||vi-10/NN	prep_for||better-5/JJR||assays-11/NNS	det||viruses-14/NNS||some-13/DT	prep_with||assays-11/NNS||viruses-14/NNS	amod||viruses-19/NNS||other-18/JJ	prep_for||limited-24/VBN||viruses-19/NNS	nsubjpass||limited-24/VBN||agreement-20/NN	nsubjpass||depended-26/VBN||agreement-20/NN	prep_between||agreement-20/NN||laboratories-22/NNS	auxpass||limited-24/VBN||was-23/VBD	conj_but||better-5/JJR||limited-24/VBN	conj_but||better-5/JJR||depended-26/VBN	conj_and||limited-24/VBN||depended-26/VBN	predet||virus-30/NN||both-28/PDT	det||virus-30/NN||the-29/DT	prep_on||limited-24/VBN||virus-30/NN	det||reagent-34/NN||the-32/DT	amod||reagent-34/NN||neutralizing-33/VBG	prep_on||limited-24/VBN||reagent-34/NN	conj_and||virus-30/NN||reagent-34/NN	virus-30||viruses-19||no||inter-laboratory concordance was slightly better for psv than for vi assays with some viruses, but for other viruses agreement between laboratories was limited and depended on both the virus and the neutralizing reagent.
det||vulnerability-3/NN||this-1/DT	amod||vulnerability-3/NN||increased-2/VBN	nsubj||due-6/JJ||vulnerability-3/NN	aux||due-6/JJ||may-4/MD	cop||due-6/JJ||be-5/VB	root||ROOT-0/null||due-6/JJ	amod||symptom-9/NN||more-8/JJR	prep_to||due-6/JJ||symptom-9/NN	vmod||symptom-9/NN||â-10/VBN	dobj||â-10/VBN||$-11/$	num||$-11/$||œnoiseâ-12/CD	dep||$-11/$||$-13/$	quantmod||euglycemia-18/CD||more-15/JJR	quantmod||euglycemia-18/CD||symptoms-16/IN	quantmod||euglycemia-18/CD||during-17/IN	npadvmod||more-37/JJR||euglycemia-18/CD	appos||euglycemia-18/CD||making-21/NN	npadvmod||harder-23/JJR||it-22/PRP	amod||making-21/NN||harder-23/JJR	amod||driving-28/NN||detect-25/JJ	nn||driving-28/NN||hypoglycemia-26/NN	nn||driving-28/NN||while-27/NN	prep_to||harder-23/JJR||driving-28/NN	advmod||driving-28/NN||possibly-30/RB	amod||utilization-33/NN||greater-31/JJR	nn||utilization-33/NN||carbohydrate-32/NN	dep||driving-28/NN||utilization-33/NN	prep_rendering||euglycemia-18/CD||them-36/PRP	dep||hypoglycemia-41/CD||more-37/JJR	dep||more-37/JJR||vulnerable-38/CD	prep_to||more-37/JJR||experiencing-40/NNP	num||$-13/$||hypoglycemia-41/CD	amod||counterregulation-45/NN||less-43/JJR	amod||counterregulation-45/NN||hormonal-44/JJ	dobj||â-10/VBN||counterregulation-45/NN	conj_and||$-11/$||counterregulation-45/NN	appos||counterregulation-45/NN||leading-47/VBG	amod||hypoglycemia-51/NN||more-49/JJR	amod||hypoglycemia-51/NN||profound-50/JJ	prep_to||leading-47/VBG||hypoglycemia-51/NN	amod||neuroglycopenia-55/NN||more-54/JJR	dobj||â-10/VBN||neuroglycopenia-55/NN	conj_and||$-11/$||neuroglycopenia-55/NN	vmod||â-10/VBN||rendering-57/VBG	nsubj||driving-63/VBG||them-58/PRP	advmod||vulnerable-60/JJ||more-59/RBR	dep||driving-63/VBG||vulnerable-60/JJ	prep_to||vulnerable-60/JJ||impaired-62/JJ	xcomp||rendering-57/VBG||driving-63/VBG	hypoglycemia-51||carbohydrate-32||no_rel||this increased vulnerability may be due to more symptom â€œnoiseâ€? (more symptoms during euglycemia), making it harder to detect hypoglycemia while driving; possibly greater carbohydrate utilization, rendering them more vulnerable to experiencing hypoglycemia; less hormonal counterregulation, leading to more profound hypoglycemia; and more neuroglycopenia, rendering them more vulnerable to impaired driving.
det||frequency-3/NN||an-1/DT	amod||frequency-3/NN||increased-2/VBN	nsubj||occurs-7/VBZ||frequency-3/NN	amod||flares-6/NNS||gout-5/JJ	prep_of||frequency-3/NN||flares-6/NNS	root||ROOT-0/null||occurs-7/VBZ	det||period-11/NN||a-9/DT	amod||period-11/NN||prolonged-10/VBN	prep_for||occurs-7/VBZ||period-11/NN	nn||initiation-14/NN||treatment-13/NN	prep_after||period-11/NN||initiation-14/NN	dep||period-11/NN||as-16/RB	det||lowering-20/NN||any-18/DT	amod||lowering-20/NN||aggressive-19/JJ	prep_with||period-11/NN||lowering-20/NN	nn||urate-23/NN||serum-22/NN	prep_of||lowering-20/NN||urate-23/NN	amod||prophylaxis-27/NNS||prolonged-26/VBN	nsubjpass||required-34/VBN||prophylaxis-27/NNS	prep_with||prophylaxis-27/NNS||colchicine-29/NN	prep_with||prophylaxis-27/NNS||nsaids-31/NNS	conj_or||colchicine-29/NN||nsaids-31/NNS	auxpass||required-34/VBN||is-32/VBZ	advmod||required-34/VBN||usually-33/RB	conj_and||occurs-7/VBZ||required-34/VBN	gout-5||colchicine-29||yes||an increased frequency of gout flares occurs for a prolonged period after treatment initiation, as with any aggressive lowering of serum urate, and prolonged prophylaxis with colchicine or nsaids is usually required.
advmod||was-8/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-8/VBD||aim-4/NN	nsubj||assess-10/VB||aim-4/NN	det||study-7/NN||this-6/DT	prep_of||aim-4/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||assess-10/VB||to-9/TO	xcomp||was-8/VBD||assess-10/VB	det||effectiveness-12/NN||the-11/DT	dobj||assess-10/VB||effectiveness-12/NN	amod||-rrb--43/NN||chloroquine-14/JJ	nn||strains-18/NNS||p.-16/NN	nn||strains-18/NNS||vivax-17/NN	prep_against||chloroquine-14/JJ||strains-18/NNS	prep_in||strains-18/NNS||one-20/CD	det||areas-25/NNS||the-22/DT	amod||areas-25/NNS||malaria-23/JJ	amod||areas-25/NNS||endemic-24/JJ	prep_of||one-20/CD||areas-25/NNS	nn||district-31/NN||ethiopia-27/NN	advmod||district-31/NN||namely-29/RB	nn||district-31/NN||halaba-30/NN	prep_of||areas-25/NNS||district-31/NN	vmod||strains-18/NNS||located-33/VBN	amod||nations-36/NNS||south-35/JJ	prep_in||located-33/VBN||nations-36/NNS	prep_in||located-33/VBN||nationalities-38/NNS	conj_and||nations-36/NNS||nationalities-38/NNS	nn||-rrb--43/NN||peoples-39/NNS	nn||-rrb--43/NN||region-40/NN	amod||-rrb--43/NN||-lrb--41/VBG	nn||-rrb--43/NN||snnpr-42/NN	prep_of||effectiveness-12/NN||-rrb--43/NN	amod||ethiopia-46/NN||south-45/JJ	prep_of||effectiveness-12/NN||ethiopia-46/NN	num||patients-50/NNS||87-48/CD	nn||patients-50/NNS||malaria-49/NN	prep_among||ethiopia-46/NN||patients-50/NNS	vmod||patients-50/NNS||enrolled-51/VBN	det||study-54/NN||the-53/DT	prep_in||enrolled-51/VBN||study-54/NN	quantmod||80-57/CD||only-56/RB	appos||study-54/NN||80-57/CD	prep_of||80-57/CD||them-59/PRP	vmod||80-57/CD||completed-60/VBN	det||follow-up-63/NN||the-61/DT	amod||follow-up-63/NN||28-days-62/JJ	dobj||completed-60/VBN||follow-up-63/NN	malaria-49||chloroquine-14||yes||therefore , the aim of this study was to assess the effectiveness of chloroquine against p. vivax strains in one of the malaria endemic areas of ethiopia , namely halaba district , located in south nations and nationalities peoples region -lrb- snnpr -rrb- of south ethiopia among 87 malaria patients enrolled in the study , only 80 of them completed the 28-days follow-up .
amod||response-2/NN||humoral-1/JJ	nsubjpass||evaluated-4/VBN||response-2/NN	auxpass||evaluated-4/VBN||was-3/VBD	root||ROOT-0/null||evaluated-4/VBN	agent||evaluated-4/VBN||elisa-6/NN	num||patients-10/NNS||117-8/CD	nn||patients-10/NNS||tb-9/NN	prep_in||evaluated-4/VBN||patients-10/NNS	num||ltbi-13/NNS||45-12/CD	prep_in||evaluated-4/VBN||ltbi-13/NNS	conj_and||patients-10/NNS||ltbi-13/NNS	num||controls-17/NNS||67-15/CD	amod||controls-17/NNS||bcg-vaccinated-16/JJ	prep_in||evaluated-4/VBN||controls-17/NNS	conj_and||patients-10/NNS||controls-17/NNS	predet||those-21/DT||all-20/PDT	prep_including||evaluated-4/VBN||those-21/DT	nsubj||had-23/VBD||those-21/DT	rcmod||those-21/DT||had-23/VBD	amod||assay-25/NN||t-cell-24/JJ	dobj||had-23/VBD||assay-25/NN	prep_in||had-23/VBD||comparison-28/NN	det||kit-33/NN||a-30/DT	amod||kit-33/NN||commercial-31/JJ	nn||kit-33/NN||igg-32/NN	prep_with||comparison-28/NN||kit-33/NN	tb-9||bcg--1||yes||humoral response was evaluated by elisa in 117 tb patients, 45 ltbi and 67 bcg-vaccinated controls, including all those who had t-cell assay, in comparison with a commercial igg kit.
root||ROOT-0/null||hiv-1-1/JJ	dep||hiv-1-1/JJ||humanimmunodeficiencyvirus-3/NNS	npadvmod||env-9/JJ||type-4/NN	number||env-9/JJ||1-5/CD	amod||env-9/JJ||aids-acquiredimmunodeficiencysyndrome-7/JJ	amod||humanimmunodeficiencyvirus-3/NNS||env-9/JJ	dep||hiv-1-1/JJ||envelope-11/NN	appos||envelope-11/NN||gp160-13/NNS	num||glycoprotein-17/NN||160,000-15/CD	amod||glycoprotein-17/NN||d-16/JJ	dep||hiv-1-1/JJ||glycoprotein-17/NN	appos||glycoprotein-17/NN||gp120-19/NNS	num||glycoprotein-23/NN||120,000-21/CD	amod||glycoprotein-23/NN||d-22/JJ	dep||hiv-1-1/JJ||glycoprotein-23/NN	appos||glycoprotein-23/NN||gp41-25/NNS	num||glycoprotein-29/NN||41,000-27/CD	amod||glycoprotein-29/NN||d-28/JJ	dep||hiv-1-1/JJ||glycoprotein-29/NN	appos||glycoprotein-29/NN||lanl-31/NN	nn||alamos-34/NNS||los-33/NN	dep||hiv-1-1/JJ||alamos-34/NNS	amod||laboratories-36/NNS||national-35/JJ	dep||alamos-34/NNS||laboratories-36/NNS	advmod||alamos-34/NNS||pdb-38/RB	nn||bank-42/NN||protein-40/NN	nn||bank-42/NN||data-41/NN	dep||hiv-1-1/JJ||bank-42/NN	appos||bank-42/NN||hvtn-44/NN	nn||trial-49/NN||step-46/NN	nn||trial-49/NN||hiv-47/NN	nn||trial-49/NN||vaccine-48/NN	dep||hiv-1-1/JJ||trial-49/NN	appos||trial-49/NN||aa-51/NN	dep||hiv-1-1/JJ||aminoacids-53/NNS	appos||aminoacids-53/NNS||msa-55/NN	amod||alignment-59/NN||multiple-57/JJ	nn||alignment-59/NN||sequence-58/NN	dep||hiv-1-1/JJ||alignment-59/NN	appos||alignment-59/NN||asa-61/NN	amod||area-65/NN||accessible-63/JJ	nn||area-65/NN||surface-64/NN	dep||hiv-1-1/JJ||area-65/NN	appos||area-65/NN||snps-67/NNS	amod||polymorphisms-71/NNS||single-69/JJ	nn||polymorphisms-71/NNS||nucleotide-70/NN	dep||hiv-1-1/JJ||polymorphisms-71/NNS	appos||polymorphisms-71/NNS||haart-73/NN	advmod||active-76/JJ||highly-75/RB	amod||therapy-78/NN||active-76/JJ	amod||therapy-78/NN||antiretroviral-77/JJ	dep||hiv-1-1/JJ||therapy-78/NN	appos||therapy-78/NN||ccr5-80/NNS	amod||type-85/NN||c-c-82/JJ	amod||type-85/NN||chemokine-83/JJ	nn||type-85/NN||receptor-84/NN	dep||hiv-1-1/JJ||type-85/NN	dep||type-85/NN||5-86/CD	advmod||type-85/NN||cns-88/RB	amod||system-92/NN||central-90/JJ	amod||system-92/NN||nervous-91/JJ	dep||hiv-1-1/JJ||system-92/NN	appos||system-92/NN||hive-94/NN	dep||hiv-1-1/JJ||hivencephalitis-96/NNS	appos||hivencephalitis-96/NNS||p-98/NN	dep||hiv-1-1/JJ||polarity-100/NN	appos||polarity-100/NN||np-102/NN	dep||hiv-1-1/JJ||non-polarity-104/NN	appos||non-polarity-104/NN||ctl-106/NN	amod||t-109/NN||cytotoxic-108/JJ	dep||hiv-1-1/JJ||t-109/NN	amod||niaid-112/JJ||lymphocyte-110/JJ	amod||t-109/NN||niaid-112/JJ	amod||institute-115/NN||national-114/JJ	dep||hiv-1-1/JJ||institute-115/NN	nn||diseases-120/NNS||allergy-117/NN	conj_and||allergy-117/NN||infectious-119/JJ	nn||diseases-120/NNS||infectious-119/JJ	prep_of||institute-115/NN||diseases-120/NNS	hivencephalitis-96||hiv-47||no||hiv-1 - humanimmunodeficiencyvirus type 1, aids-acquiredimmunodeficiencysyndrome, env - envelope, gp160 - 160,000d glycoprotein, gp120 - 120,000d glycoprotein, gp41 - 41,000d glycoprotein, lanl - los alamos national laboratories, pdb - protein data bank, hvtn - step hiv vaccine trial, aa - aminoacids, msa - multiple sequence alignment, asa - accessible surface area, snps- single nucleotide polymorphisms, haart - highly active antiretroviral therapy, ccr5 - c-c chemokine receptor type 5, cns - central nervous system, hive - hivencephalitis, p - polarity, np - non-polarity, ctl - cytotoxic t lymphocyte, niaid - national institute of allergy and infectious diseases.
nn||infections-2/NNS||skin-1/NN	nsubj||likely-5/JJ||infections-2/NNS	nsubj||likely-5/JJ||infections-2/NNS	nsubj||develop-7/VB||infections-2/NNS	cop||likely-5/JJ||were-3/VBD	advmod||likely-5/JJ||more-4/RBR	root||ROOT-0/null||likely-5/JJ	conj_but||likely-5/JJ||likely-5/JJ	aux||develop-7/VB||to-6/TO	xcomp||likely-5/JJ||develop-7/VB	nn||carriers-10/NNS||mrsa-9/NN	prep_in||develop-7/VB||carriers-10/NNS	prep||likely-5/JJ||than-11/IN	pcomp||than-11/IN||in-12/IN	amod||carriers-15/NNS||methicillin-susceptible-13/JJ	nn||carriers-15/NNS||s.aureus-14/NN	pobj||in-12/IN||carriers-15/NNS	pobj||in-12/IN||noncarriers-17/NNS	conj_or||carriers-15/NNS||noncarriers-17/NNS	prep_of||carriers-15/NNS||s.aureus-19/NNS	det||year-24/NN||the-21/DT	amod||year-24/NN||first-22/JJ	nn||year-24/NN||follow-up-23/NN	prep_during||likely-5/JJ||year-24/NN	neg||likely-5/JJ||not-27/RB	amod||years-30/NNS||subsequent-29/JJ	prep_in||likely-5/JJ||years-30/NNS	mrsa-9||s.aureus-19||no||skin infections were more likely to develop in mrsa carriers than in methicillin-susceptible s.aureus carriers or noncarriers of s.aureus during the first follow-up year , but not in subsequent years .
nsubj||one-7/CD||acetaminophen-1/NN	det||pain-reliever-4/NN||a-3/DT	appos||acetaminophen-1/NN||pain-reliever-4/NN	cop||one-7/CD||is-6/VBZ	root||ROOT-0/null||one-7/CD	det||medications-13/NNS||the-9/DT	advmod||used-12/VBN||most-10/RBS	advmod||used-12/VBN||widely-11/RB	amod||medications-13/NNS||used-12/VBN	prep_of||one-7/CD||medications-13/NNS	det||world-16/NN||the-15/DT	prep_in||medications-13/NNS||world-16/NN	pain--1||acetaminophen-1||yes||acetaminophen, a pain-reliever, is one of the most widely used medications in the world.
nsubj||likely-9/JJ||persons-1/NNS	nsubjpass||older-16/JJR||persons-1/NNS	nsubjpass||admitted-18/VBN||persons-1/NNS	prep_without||persons-1/NNS||hiv/aids-3/NNS	vmod||hiv/aids-3/NNS||hospitalized-4/VBN	prep_with||hospitalized-4/VBN||cryptococcosis-6/NNS	cop||likely-9/JJ||were-7/VBD	advmod||likely-9/JJ||more-8/RBR	root||ROOT-0/null||likely-9/JJ	prep_than||likely-9/JJ||those-11/DT	prep_with||those-11/DT||hiv/aids-13/NNS	aux||older-16/JJR||to-14/TO	auxpass||older-16/JJR||be-15/VB	cop||older-16/JJR||be-15/VB	xcomp||likely-9/JJ||older-16/JJR	xcomp||likely-9/JJ||admitted-18/VBN	conj_and||older-16/JJR||admitted-18/VBN	amod||cryptococcosis-21/NNS||pulmonary-20/JJ	prep_for||admitted-18/VBN||cryptococcosis-21/NNS	aids--1||hiv--1||no||persons without hiv/aids hospitalized with cryptococcosis were more likely than those with hiv/aids to be older and admitted for pulmonary cryptococcosis.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	num||patients-4/NNS||100-3/CD	dobj||assessed-2/VBD||patients-4/NNS	nn||±-9/NN||age-6/NN	num||±-9/NN||75-7/CD	nn||±-9/NN||â-8/NN	dep||patients-4/NNS||±-9/NN	num||years-11/NNS||5-10/CD	dep||±-9/NN||years-11/NNS	nn||±-16/NN||duration-13/NN	num||±-16/NN||21-14/CD	nn||±-16/NN||â-15/NN	appos||±-9/NN||±-16/NN	num||years-18/NNS||13-17/CD	dep||±-16/NN||years-18/NNS	num||type2diabetes-22/NNS||68-20/CD	nn||type2diabetes-22/NNS||%-21/NN	appos||±-9/NN||type2diabetes-22/NNS	num||%-25/NN||89-24/CD	appos||±-9/NN||%-25/NN	prep_on||%-25/NN||insulin-27/NN	num||months-31/NNS||12-30/CD	prep_over||assessed-2/VBD||months-31/NNS	type2diabetes-22||insulin-27||yes||we assessed 100 patients (age 75 â± 5 years, duration 21 â± 13 years, 68% type2diabetes, 89% on insulin) over 12 months.
det||ease-2/NN||the-1/DT	nsubj||makes-9/VBZ||ease-2/NN	prep_of||ease-2/NN||conversion-4/NN	det||formulations-7/NNS||the-6/DT	prep_between||conversion-4/NN||formulations-7/NNS	advmod||makes-9/VBZ||also-8/RB	root||ROOT-0/null||makes-9/VBZ	xcomp||makes-9/VBZ||lamotrigine-10/VB	det||option-14/NN||an-11/DT	amod||option-14/NN||attractive-12/JJ	nn||option-14/NN||treatment-13/NN	dobj||lamotrigine-10/VB||option-14/NN	prep_for||lamotrigine-10/VB||patients-16/NNS	amod||seizures-21/NNS||primary-18/JJ	amod||seizures-21/NNS||generalized-19/JJ	amod||seizures-21/NNS||tonic-clonic-20/JJ	prep_with||patients-16/NNS||seizures-21/NNS	seizures-21||lamotrigine-10||yes||the ease of conversion between the formulations also makes lamotrigine an attractive treatment option for patients with primary generalized tonic-clonic seizures.
amod||factors-3/NNS||independent-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubj||weight-18/NN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||diabetes-8/NN	nn||women-11/NNS||korean-10/NN	prep_in||diabetes-8/NN||women-11/NNS	amod||gdm-14/NN||previous-13/JJ	prep_with||women-11/NNS||gdm-14/NN	cop||weight-18/NN||are-15/VBP	amod||weight-18/NN||pre-pregnancy-16/JJ	nn||weight-18/NN||body-17/NN	root||ROOT-0/null||weight-18/NN	amod||age-21/NN||gestational-20/JJ	appos||weight-18/NN||age-21/NN	prep_at||age-21/NN||diagnosis-23/NN	nn||hyperglycemia-26/NN||antepartum-25/NN	conj_and||weight-18/NN||hyperglycemia-26/NN	amod||test-31/NN||oral-28/JJ	nn||test-31/NN||glucose-29/NN	nn||test-31/NN||tolerance-30/NN	prep_on||hyperglycemia-26/NN||test-31/NN	amod||response-35/NN||low-33/JJ	nn||response-35/NN||insulin-34/NN	conj_and||weight-18/NN||response-35/NN	amod||load-39/NN||oral-37/JJ	nn||load-39/NN||glucose-38/NN	prep_to||response-35/NN||load-39/NN	nn||history-43/NN||family-42/NN	conj_and||weight-18/NN||history-43/NN	prep_of||history-43/NN||diabetes-45/NN	hyperglycemia-26||insulin-34||yes||independent risk factors for the development of diabetes in korean women with previous gdm are pre-pregnancy body weight, gestational age at diagnosis, antepartum hyperglycemia on oral glucose tolerance test, low insulin response to oral glucose load, and family history of diabetes.
det||incidence-2/NN||the-1/DT	nsubj||disappeared-6/VBD||incidence-2/NN	amod||pain-5/NN||moderate-4/JJ	prep_of||incidence-2/NN||pain-5/NN	root||ROOT-0/null||disappeared-6/VBD	advmod||disappeared-6/VBD||completely-7/RB	det||group-11/NN||the-9/DT	nn||group-11/NN||combination-10/NN	prep_in||disappeared-6/VBD||group-11/NN	num||%-14/NN||0-13/CD	appos||group-11/NN||%-14/NN	prepc_compared_to||disappeared-6/VBD||to-17/TO	pobj||disappeared-6/VBD||that-18/DT	det||group-24/NN||the-20/DT	amod||group-24/NN||remifentanil-21/JJ	conj_and||remifentanil-21/JJ||lidocaine-23/JJ	amod||group-24/NN||lidocaine-23/JJ	prep_in||that-18/DT||group-24/NN	num||%-27/NN||32.5-26/CD	dep||group-24/NN||%-27/NN	num||%-30/NN||20-29/CD	dep||group-24/NN||%-30/NN	conj_and||%-27/NN||%-30/NN	advmod||%-27/NN||respectively-32/RB	nn||0.05-36/NNP||p-34/NNP	nn||0.05-36/NNP||<-35/NNP	appos||%-27/NN||0.05-36/NNP	pain-5||remifentanil-21||yes||the incidence of moderate pain disappeared completely in the combination group (0%) compared to that in the remifentanil and lidocaine group (32.5% and 20%, respectively, p < 0.05).
det||spectrum-2/NN||the-1/DT	nsubj||suggests-32/VBZ||spectrum-2/NN	det||activity-6/NN||the-4/DT	amod||activity-6/NN||antiviral-5/JJ	prep_of||spectrum-2/NN||activity-6/NN	vmod||activity-6/NN||exhibited-7/VBN	agent||exhibited-7/VBN||ha-9/NN	preconj||viruses-15/NNS||both-11/DT	nn||viruses-15/NNS||rna-12/NN	conj_and||rna-12/NN||dna-14/NN	nn||viruses-15/NNS||dna-14/NN	prep_against||ha-9/NN||viruses-15/NNS	vmod||spectrum-2/NN||known-17/VBN	aux||have-19/VB||to-18/TO	xcomp||known-17/VBN||have-19/VB	amod||structures-21/NNS||different-20/JJ	dobj||have-19/VB||structures-21/NNS	prep||structures-21/NNS||with-23/IN	prep||structures-21/NNS||without-25/IN	conj_or||with-23/IN||without-25/IN	pobj||without-25/IN||envelope-26/NN	nn||strategies-30/NNS||replication-29/NN	dobj||have-19/VB||strategies-30/NNS	conj_and||structures-21/NNS||strategies-30/NNS	root||ROOT-0/null||suggests-32/VBZ	det||mechanism-36/NN||a-33/DT	amod||mechanism-36/NN||non-34/JJ	amod||mechanism-36/NN||specific-35/JJ	dobj||suggests-32/VBZ||mechanism-36/NN	prep_of||mechanism-36/NN||action-38/NN	advmod||involving-41/VBG||probably-40/RB	vmod||mechanism-36/NN||involving-41/VBG	nn||steps-45/NNS||cell-42/NN	amod||steps-45/NNS||membrane-virus-43/JJ	nn||steps-45/NNS||interaction-44/NN	dobj||involving-41/VBG||steps-45/NNS	virus--1||viruses-15||no||the spectrum of the antiviral activity exhibited by ha against both rna and dna viruses, known to have different structures (with or without envelope) and replication strategies, suggests a non specific mechanism of action, probably involving cell membrane-virus interaction steps.
advmod||explants-16/VBZ||accordingly-1/RB	det||avianinfluenzaviruses-5/NNS||both-3/DT	amod||avianinfluenzaviruses-5/NNS||h5n1-4/JJ	nsubj||explants-16/VBZ||avianinfluenzaviruses-5/NNS	amod||influenzaviruses-8/NNS||seasonal-7/JJ	conj_and||avianinfluenzaviruses-5/NNS||influenzaviruses-8/NNS	nsubj||explants-16/VBZ||influenzaviruses-8/NNS	vmod||influenzaviruses-8/NNS||replicated-9/VBN	advmod||efficiently-11/RB||more-10/RBR	advmod||replicated-9/VBN||efficiently-11/RB	amod||tissues-15/NNS||nasal-13/JJ	nn||tissues-15/NNS||polyp-14/NN	prep_in||replicated-9/VBN||tissues-15/NNS	root||ROOT-0/null||explants-16/VBZ	h5n1-4||influenzaviruses-8||no||accordingly, both h5n1 avianinfluenzaviruses and seasonal influenzaviruses replicated more efficiently in nasal polyp tissues explants.
nsubjpass||used-4/VBN||sitagliptin-1/NN	aux||used-4/VBN||may-2/MD	auxpass||used-4/VBN||be-3/VB	root||ROOT-0/null||used-4/VBN	det||stages-8/NNS||the-6/DT	amod||stages-8/NNS||early-7/JJ	prep_in||used-4/VBN||stages-8/NNS	prep_of||stages-8/NNS||type2diabetes-10/NNS	prep_in||type2diabetes-10/NNS||combination-12/NN	amod||treatments-17/NNS||metformin-14/JJ	conj_or||metformin-14/JJ||other-16/JJ	amod||treatments-17/NNS||other-16/JJ	prep_with||used-4/VBN||treatments-17/NNS	prep_in||used-4/VBN||subjects-19/NNS	amod||control-23/NN||inadequate-21/JJ	amod||control-23/NN||glycemic-22/JJ	prep_with||subjects-19/NNS||control-23/NN	det||treatments-26/NNS||these-25/DT	prep_on||control-23/NN||treatments-26/NNS	advmod||treatments-26/NNS||alone-27/RB	type2diabetes-10||sitagliptin-1||yes||sitagliptin may be used in the early stages of type2diabetes in combination with metformin or other treatments in subjects with inadequate glycemic control on these treatments alone.
det||inducer-6/NN||the-2/DT	advmod||used-4/VBN||clinically-3/RB	amod||inducer-6/NN||used-4/VBN	nn||inducer-6/NN||differentiation-5/NN	prep_unlike||target-43/VB||inducer-6/NN	nsubj||target-43/VB||all-7/DT	amod||shows-12/NNS||transretinoicacid-9/JJ	amod||shows-12/NNS||tenovin-6-11/JJ	dep||all-7/DT||shows-12/NNS	vmod||shows-12/NNS||limited-13/VBN	dobj||limited-13/VBN||effects-14/NNS	prepc_on||limited-13/VBN||promyelocyticleukemiaâ-16/VBG	dobj||promyelocyticleukemiaâ-16/VBG||$-17/$	amod||±-22/NNS||retinoicacid-19/JJ	nn||±-22/NNS||receptor-20/NN	nn||±-22/NNS||î-21/NN	npadvmod||that-38/RB||±-22/NNS	number||±-25/CD||pml-rar-î-24/CD	dep||±-22/NNS||±-25/CD	nn||formation-32/NN||stability-27/NN	conj_and||stability-27/NN||promyelocyticleukemia-29/NN	nn||formation-32/NN||promyelocyticleukemia-29/NN	amod||formation-32/NN||nuclear-30/JJ	nn||formation-32/NN||body-31/NN	dep||±-25/CD||formation-32/NN	amod||cells-35/NNS||nb4-34/JJ	prep_in||±-25/CD||cells-35/NNS	appos||cells-35/NNS||suggesting-37/NNP	dep||tenovin-6-39/CD||that-38/RB	num||$-17/$||tenovin-6-39/CD	aux||target-43/VB||does-40/VBZ	neg||target-43/VB||not-41/RB	advmod||target-43/VB||directly-42/RB	root||ROOT-0/null||target-43/VB	amod||activity-46/NN||pml-rar-î-44/JJ	amod||activity-46/NN||±-45/JJ	dobj||target-43/VB||activity-46/NN	promyelocyticleukemia-29||transretinoicacid-9||yes||unlike the clinically used differentiation inducer all- transretinoicacid, tenovin-6 shows limited effects on promyelocyticleukemiaâ€“retinoicacid receptor î± (pml-rar-î±) stability and promyelocyticleukemia nuclear body formation in nb4 cells, suggesting that tenovin-6 does not directly target pml-rar-î± activity.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
nsubj||explored-2/VBD||we-1/PRP	root||ROOT-0/null||explored-2/VBD	nn||perceptions-4/NNS||community-3/NN	dobj||explored-2/VBD||perceptions-4/NNS	prep_of||perceptions-4/NNS||hiv-6/NN	prep_of||perceptions-4/NNS||aids-8/NNS	conj_and||hiv-6/NN||aids-8/NNS	det||problem-11/NN||a-10/DT	prep_as||explored-2/VBD||problem-11/NN	poss||inter-linkage-14/NN||its-13/PRP$	prep_as||explored-2/VBD||inter-linkage-14/NN	conj_and||problem-11/NN||inter-linkage-14/NN	prep_with||explored-2/VBD||culture-16/NN	prep_with||explored-2/VBD||insecurity-18/NN	conj_and||culture-16/NN||insecurity-18/NN	nn||district-21/NN||pader-20/NN	prep_in||explored-2/VBD||district-21/NN	aids-8||hiv-6||no||we explored community perceptions of hiv and aids as a problem and its inter-linkage with culture and insecurity in pader district.
nn||scores-2/NNS||nausea-1/NN	nsubj||severe-12/JJ||scores-2/NNS	nsubj||similar-14/JJ||scores-2/NNS	prep_at||scores-2/NNS||baseline-4/NN	conj_and||scores-2/NNS||0â-6/NNS	nsubj||severe-12/JJ||0â-6/NNS	num||minutes-10/NNS||$-7/$	num||$-7/$||30-9/CD	dep||0â-6/NNS||minutes-10/NNS	cop||severe-12/JJ||were-11/VBD	root||ROOT-0/null||severe-12/JJ	conj_and||severe-12/JJ||similar-14/JJ	prep_between||severe-12/JJ||groups-16/NNS	advmod||had-35/VBD||however-18/RB	amod||$-22/$||31â-21/JJ	prep_at||had-35/VBD||$-22/$	num||$-22/$||60-24/CD	conj_and||$-22/$||61â-26/NNS	prep_at||had-35/VBD||61â-26/NNS	num||minutes-30/NNS||$-27/$	num||$-27/$||120-29/CD	dep||61â-26/NNS||minutes-30/NNS	nsubj||had-35/VBD||patients-32/NNS	vmod||patients-32/NNS||receiving-33/VBG	dobj||receiving-33/VBG||prochlorperazine-34/NN	parataxis||severe-12/JJ||had-35/VBD	amod||control-37/NN||better-36/JJR	dobj||had-35/VBD||control-37/NN	nn||=-47/FW||nausea-39/FW	nn||=-47/FW||-lrb--40/FW	nn||=-47/FW||24.9-41/FW	nn||=-47/FW||vs.-42/FW	nn||=-47/FW||43.7-43/FW	nn||=-47/FW||mm-44/FW	dep||=-47/FW||p-46/FW	prep_of||control-37/NN||=-47/FW	dep||=-47/FW||0.03-48/CD	nn||=-56/FW||16.8-50/FW	nn||=-56/FW||vs.-51/FW	nn||=-56/FW||34.3-52/FW	nn||=-56/FW||mm-53/FW	dep||=-56/FW||p-55/FW	dep||=-47/FW||=-56/FW	num||-rrb--58/NNS||0.05-57/CD	dep||=-56/FW||-rrb--58/NNS	nausea-39||prochlorperazine-34||yes||nausea scores at baseline and 0â $ `` 30 minutes were severe and similar between groups ; however , at 31â $ `` 60 and 61â $ `` 120 minutes , patients receiving prochlorperazine had better control of nausea -lrb- 24.9 vs. 43.7 mm , p = 0.03 ; 16.8 vs. 34.3 mm , p = 0.05 -rrb- .
det||findings-2/NNS||these-1/DT	nsubj||indicate-3/VBP||findings-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||contain-19/VBP||that-4/IN	amod||women-18/NNS||cvl-5/JJ	amod||hiv-8/NN||healthy-7/JJ	prep_from||cvl-5/JJ||hiv-8/NN	appos||hiv-8/NN||+-10/NNP	prep_from||cvl-5/JJ||hiv-13/NN	conj_and||hiv-8/NN||hiv-13/NN	appos||hiv-8/NN||âˆ-15/NN	nsubj||contain-19/VBP||women-18/NNS	ccomp||indicate-3/VBP||contain-19/VBP	amod||mechanisms-24/NNS||innate-20/JJ	conj_and||innate-20/JJ||adaptive-22/JJ	amod||mechanisms-24/NNS||adaptive-22/JJ	nn||mechanisms-24/NNS||defense-23/NN	dobj||contain-19/VBP||mechanisms-24/NNS	nsubj||inhibit-26/VBP||mechanisms-24/NNS	rcmod||mechanisms-24/NNS||inhibit-26/VBP	dobj||inhibit-26/VBP||hivinfection-27/NN	hivinfection-27||hiv-13||no||these findings indicate that cvl from healthy hiv(+) and hiv(âˆ’) women contain innate and adaptive defense mechanisms that inhibit hivinfection.
amod||hypogonadism-2/NN||biochemical-1/JJ	nsubjpass||defined-4/VBN||hypogonadism-2/NN	auxpass||defined-4/VBN||was-3/VBD	root||ROOT-0/null||defined-4/VBN	det||level-10/NN||a-6/DT	amod||level-10/NN||total-7/JJ	nn||level-10/NN||serum-8/NN	nn||level-10/NN||testosterone-9/NN	prep_as||defined-4/VBN||level-10/NN	num||nmol/l-13/NN||8-12/CD	prep_below||defined-4/VBN||nmol/l-13/NN	hypogonadism-2||testosterone-9||yes||biochemical hypogonadism was defined as a total serum testosterone level below 8 nmol/l.
nsubj||drives-2/VBZ||bcgvaccine-1/NN	root||ROOT-0/null||drives-2/VBZ	det||immunity-9/NN||a-3/DT	amod||immunity-9/NN||strong-4/JJ	nn||immunity-9/NN||t-5/NN	nn||immunity-9/NN||helper-6/NN	num||immunity-9/NN||1-7/CD	amod||immunity-9/NN||cellular-8/JJ	dobj||drives-2/VBZ||immunity-9/NN	nsubj||essential-12/JJ||immunity-9/NN	cop||essential-12/JJ||is-11/VBZ	rcmod||immunity-9/NN||essential-12/JJ	det||protection-15/NN||the-14/DT	prep_for||essential-12/JJ||protection-15/NN	prep_against||protection-15/NN||mycobacteria-17/NN	advmod||suggest-22/VBP||however-19/RB	amod||studies-21/NNS||recent-20/JJ	nsubj||suggest-22/VBP||studies-21/NNS	parataxis||drives-2/VBZ||suggest-22/VBP	mark||have-27/VB||that-23/IN	nn||vaccination-25/NN||bcg-24/NN	nsubj||have-27/VB||vaccination-25/NN	aux||have-27/VB||can-26/MD	ccomp||suggest-22/VBP||have-27/VB	amod||effects-30/NNS||non-specific-28/JJ	amod||effects-30/NNS||beneficial-29/JJ	nsubj||unrelated-31/JJ||effects-30/NNS	xcomp||have-27/VB||unrelated-31/JJ	prep_to||have-27/VB||tuberculosis-33/NNP	tuberculosis-33||bcg-24||no||bcgvaccine drives a strong t helper 1 cellular immunity which is essential for the protection against mycobacteria, however recent studies suggest that bcg vaccination can have non-specific beneficial effects unrelated to tuberculosis.
det||objective-3/NN||the-1/DT	amod||objective-3/NN||main-2/JJ	nsubj||is-8/VBZ||objective-3/NN	nsubj||monitor-10/VB||objective-3/NN	det||study-7/NN||the-5/DT	amod||study-7/NN||current-6/JJ	prep_of||objective-3/NN||study-7/NN	ccomp||â-36/VBP||is-8/VBZ	aux||monitor-10/VB||to-9/TO	xcomp||is-8/VBZ||monitor-10/VB	det||status-13/NN||the-11/DT	amod||status-13/NN||auditory-12/JJ	dobj||monitor-10/VB||status-13/NN	det||group-16/NN||a-15/DT	prep_in||status-13/NN||group-16/NN	prep_of||group-16/NN||adults-18/NNS	prep_with||monitor-10/VB||aids-20/NNS	vmod||monitor-10/VB||receiving-22/VBG	advmod||active-24/JJ||highly-23/RB	amod||therapy-26/NN||active-24/JJ	amod||therapy-26/NN||antiretroviral-25/JJ	dobj||receiving-22/VBG||therapy-26/NN	appos||therapy-26/NN||haart-28/NN	dep||therapy-26/NN||3tc-31/NNP	dep||3tc-31/NNP||lamivudine-33/NN	nsubj||â-36/VBP||d4t-35/NNS	root||ROOT-0/null||â-36/VBP	dobj||â-36/VBP||$-37/$	npadvmod||outpatient-47/JJ||stavudine-39/NN	conj_and||stavudine-39/NN||efavirenz-42/NN	npadvmod||outpatient-47/JJ||efavirenz-42/NN	quantmod||hospital-46/NN||in-44/IN	quantmod||hospital-46/NN||a-45/DT	num||stavudine-39/NN||hospital-46/NN	amod||clinic-48/NNS||outpatient-47/JJ	npadvmod||in-49/RB||clinic-48/NNS	dep||gauteng-50/CD||in-49/RB	num||$-37/$||gauteng-50/CD	aids-20||d4t-35||yes||the main objective of the current study is to monitor the auditory status in a group of adults with aids, receiving highly active antiretroviral therapy (haart) (3tc -lamivudine, d4t â€“ stavudine, and efavirenz) in a hospital outpatient clinic in gauteng.
nsubjpass||identified-11/VBN||criteria-1/NNS	nn||setting-4/NN||priority-3/NN	prep_for||criteria-1/NNS||setting-4/NN	amod||interventions-7/NNS||hiv/aids-6/JJ	prep_of||setting-4/NN||interventions-7/NNS	prep_in||interventions-7/NNS||thailand-9/NN	auxpass||identified-11/VBN||were-10/VBD	root||ROOT-0/null||identified-11/VBN	nn||discussions-14/NNS||group-13/NN	prep_in||identified-11/VBN||discussions-14/NNS	nn||makers-17/NNS||policy-16/NN	prep_with||identified-11/VBN||makers-17/NNS	appos||makers-17/NNS||people-19/NNS	vmod||people-19/NNS||living-20/VBG	amod||-rrb--25/NNS||hiv/aids-22/JJ	amod||-rrb--25/NNS||-lrb--23/JJ	nn||-rrb--25/NNS||plwha-24/NN	prep_with||living-20/VBG||-rrb--25/NNS	nn||members-29/NNS||community-28/NN	nsubj||-lrb--30/VBD||members-29/NNS	conj_and||identified-11/VBN||-lrb--30/VBD	amod||volunteers-34/NNS||i.e.-31/JJ	nn||volunteers-34/NNS||village-32/NN	nn||volunteers-34/NNS||health-33/NN	nsubj||vhvs-36/VBZ||volunteers-34/NNS	advmod||vhvs-36/VBZ||-lrb--35/RB	ccomp||-lrb--30/VBD||vhvs-36/VBZ	amod||-rrb--38/NNS||-rrb--37/JJ	dobj||vhvs-36/VBZ||-rrb--38/NNS	aids--1||hiv--1||no||criteria for priority setting of hiv/aids interventions in thailand were identified in group discussions with policy makers , people living with hiv/aids -lrb- plwha -rrb- , and community members -lrb- i.e. village health volunteers -lrb- vhvs -rrb- -rrb- .
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
amod||miru-vntr-2/NN||standard-1/JJ	nsubj||reveal-8/VB||miru-vntr-2/NN	nsubj||useful-26/JJ||miru-vntr-2/NN	nsubj||explore-28/VB||miru-vntr-2/NN	vmod||miru-vntr-2/NN||typing-3/VBG	prep||typing-3/VBG||combined-4/VBN	pcomp||combined-4/VBN||with-5/IN	pobj||with-5/IN||spoligotyping-6/NN	aux||reveal-8/VB||can-7/MD	root||ROOT-0/null||reveal-8/VB	advmod||meaningful-10/JJ||epidemiologically-9/RB	amod||diversity-12/NN||meaningful-10/JJ	amod||diversity-12/NN||clonal-11/JJ	dobj||reveal-8/VB||diversity-12/NN	det||lineage-18/NN||a-14/DT	amod||lineage-18/NN||dominant-15/JJ	nn||lineage-18/NN||m.tuberculosis-16/NNS	nn||lineage-18/NN||strain-17/NN	prep_behind||reveal-8/VB||lineage-18/NN	det||country-23/NN||a-20/DT	amod||country-23/NN||high-21/JJ	amod||country-23/NN||tb-burden-22/JJ	prep_in||lineage-18/NN||country-23/NN	cop||useful-26/JJ||is-25/VBZ	conj_and||reveal-8/VB||useful-26/JJ	aux||explore-28/VB||to-27/TO	xcomp||useful-26/JJ||explore-28/VB	amod||ramifications-31/NNS||international-29/JJ	amod||ramifications-31/NNS||phylogenetical-30/JJ	dobj||explore-28/VB||ramifications-31/NNS	tb--1||m.tuberculosis-16||no||standard miru-vntr typing combined with spoligotyping can reveal epidemiologically meaningful clonal diversity behind a dominant m.tuberculosis strain lineage in a high tb-burden country and is useful to explore international phylogenetical ramifications .
prep_before||%-25/NN||treatment-2/NN	det||1â-18/NN||the-3/DT	amod||1â-18/NN||village-level-4/JJ	amod||1â-18/NN||prevalence-5/JJ	nn||trachoma-8/NN||follicular-7/NN	prep_of||prevalence-5/JJ||trachoma-8/NN	number||9-12/CD||1-10/CD	dep||9-12/CD||to-11/TO	num||olds-14/NNS||9-12/CD	nn||olds-14/NNS||year-13/NN	prep_in||trachoma-8/NN||olds-14/NNS	dep||tf-16/NN||-lrb--15/NN	amod||olds-14/NNS||tf-16/NN	nn||1â-18/NN||%-17/NN	nsubj||%-25/NN||1â-18/NN	dep||-rrb--22/NN||$-19/$	num||$-19/$||9-21/CD	amod||1â-18/NN||-rrb--22/NN	cop||%-25/NN||was-23/VBD	num||%-25/NN||15.4-24/CD	root||ROOT-0/null||%-25/NN	nsubj||%-30/NN||c.trachomatis-27/NNS	cop||%-30/NN||was-28/VBD	num||%-30/NN||9.7-29/CD	conj_and||%-25/NN||%-30/NN	trachoma-8||c.trachomatis-27||no||before treatment the village-level prevalence of follicular trachoma in 1 to 9 year olds -lrb- tf % 1â $ `` 9 -rrb- was 15.4 % and c.trachomatis was 9.7 % .
nn||sizes-2/NNS||effect-1/NN	nsubjpass||analyzed-29/VBN||sizes-2/NNS	nn||thresholds-5/NNS||pain-4/NN	prep_on||sizes-2/NNS||thresholds-5/NNS	prep_to||thresholds-5/NNS||stimuli-7/NNS	vmod||stimuli-7/NNS||consisting-8/VBG	prep_of||consisting-8/VBG||heat-10/NN	amod||pressure-15/NN||cold-12/JJ	amod||pressure-15/NN||blunt-14/JJ	prep_of||consisting-8/VBG||pressure-15/NN	conj_and||heat-10/NN||pressure-15/NN	amod||pressure-18/NN||punctuate-17/JJ	prep_of||consisting-8/VBG||pressure-18/NN	conj_and||heat-10/NN||pressure-18/NN	amod||current-21/NN||electrical-20/JJ	prep_of||consisting-8/VBG||current-21/NN	conj_and||heat-10/NN||current-21/NN	vmod||sizes-2/NNS||administered-23/VBN	num||subjects-26/NNS||125-25/CD	prep_to||administered-23/VBN||subjects-26/NNS	auxpass||analyzed-29/VBN||were-28/VBD	root||ROOT-0/null||analyzed-29/VBN	num||variants-33/NNS||29-31/CD	amod||variants-33/NNS||common-32/JJ	nsubj||modulating-39/VBG||variants-33/NNS	num||genes-37/NNS||eight-35/CD	amod||genes-37/NNS||human-36/JJ	prep_in||variants-33/NNS||genes-37/NNS	advmod||modulating-39/VBG||reportedly-38/RB	prepc_for||analyzed-29/VBN||modulating-39/VBG	nn||procedures-45/NNS||pain-40/NN	conj_and||pain-40/NN||gender-42/NN	nn||procedures-45/NNS||gender-42/NN	conj_and||pain-40/NN||sensitization-44/NN	nn||procedures-45/NNS||sensitization-44/NN	dobj||modulating-39/VBG||procedures-45/NNS	vmod||modulating-39/VBG||using-46/VBG	dobj||using-46/VBG||capsaicin-47/NN	dobj||using-46/VBG||menthol-49/NN	conj_or||capsaicin-47/NN||menthol-49/NN	pain-40||menthol-49||yes||effect sizes on pain thresholds to stimuli consisting of heat, cold, blunt pressure, punctuate pressure and electrical current, administered to 125 subjects, were analyzed for 29 common variants in eight human genes reportedly modulating pain, gender and sensitization procedures using capsaicin or menthol.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||m.tuberculosis-23||no||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
neg||effects-3/NNS||no-1/DT	amod||effects-3/NNS||significant-2/JJ	nsubjpass||observed-5/VBN||effects-3/NNS	auxpass||observed-5/VBN||were-4/VBD	root||ROOT-0/null||observed-5/VBN	det||levels-8/NNS||the-7/DT	prep_on||observed-5/VBN||levels-8/NNS	prep_of||levels-8/NNS||tgf-î-10/NNP	num||tgf-î-10/NNP||²-11/CD	num||tgf-î-10/NNP||il-10-13/CD	nsubj||treated-21/VBN||autoantibodies-16/NNS	prep_in||autoantibodies-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||melanoma-20/NN	conj_and||observed-5/VBN||treated-21/VBN	amod||2b-25/NNS||ifn-î-23/JJ	amod||2b-25/NNS||±-24/JJ	prep_with||treated-21/VBN||2b-25/NNS	melanoma-20||ifn--1||yes||no significant effects were observed on the levels of tgf-î², il-10, and autoantibodies in patients with melanoma treated with ifn-î± 2b.
expl||convincing-4/VBG||there-1/EX	aux||convincing-4/VBG||are-2/VBP	advmod||convincing-4/VBG||now-3/RB	root||ROOT-0/null||convincing-4/VBG	dobj||convincing-4/VBG||data-5/NNS	nsubj||convincing-4/VBG||data-5/NNS	nn||ii-8/NN||phase-7/NN	prep_from||convincing-4/VBG||ii-8/NN	nn||trials-18/NNS||multicenter-10/NN	nn||trials-18/NNS||phase-11/NN	nn||trials-18/NNS||iii-12/NN	nn||trials-18/NNS||randomized-13/NN	amod||trials-18/NNS||double-blind-15/JJ	amod||trials-18/NNS||placebo-controlled-17/JJ	prep_from||convincing-4/VBG||trials-18/NNS	conj_and||ii-8/NN||trials-18/NNS	mark||induces-21/VBZ||that-19/IN	nsubj||induces-21/VBZ||methylnaltrexone-20/NN	ccomp||convincing-4/VBG||induces-21/VBZ	dobj||induces-21/VBZ||laxation-22/NN	prep_in||laxation-22/NN||patients-24/NNS	amod||use-28/NN||long-term-26/JJ	amod||use-28/NN||opioid-27/JJ	prep_with||patients-24/NNS||use-28/NN	prepc_without||induces-21/VBZ||affecting-30/VBG	amod||analgesia-32/NN||central-31/JJ	dobj||affecting-30/VBG||analgesia-32/NN	dobj||affecting-30/VBG||precipitation-34/NN	conj_or||analgesia-32/NN||precipitation-34/NN	prep_of||analgesia-32/NN||opioidwithdrawal-36/NN	opioidwithdrawal-36||opioid-27||no||there are now convincing data from phase ii and multicenter phase iii randomized, double-blind, placebo-controlled trials that methylnaltrexone induces laxation in patients with long-term opioid use without affecting central analgesia or precipitation of opioidwithdrawal.
mark||used-12/VBN||although-1/IN	det||vaccine-5/NN||an-2/DT	amod||vaccine-5/NN||attenuated-3/JJ	nn||vaccine-5/NN||vzv-4/NN	nsubjpass||used-12/VBN||vaccine-5/NN	appos||vaccine-5/NN||v-oka-7/NNP	aux||used-12/VBN||has-9/VBZ	auxpass||used-12/VBN||been-10/VBN	advmod||used-12/VBN||widely-11/RB	advcl||seen-24/VBN||used-12/VBN	prep_in||used-12/VBN||children-14/NNS	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||children-14/NNS||states-18/NNS	nn||outbreaks-21/NNS||chickenpox-20/NN	nsubjpass||seen-24/VBN||outbreaks-21/NNS	auxpass||seen-24/VBN||are-22/VBP	advmod||seen-24/VBN||still-23/RB	root||ROOT-0/null||seen-24/VBN	det||vaccine-29/NN||the-27/DT	nn||vaccine-29/NN||shingles-28/NNS	nsubj||reduces-31/VBZ||vaccine-29/NN	advmod||reduces-31/VBZ||only-30/RB	conj_and||seen-24/VBN||reduces-31/VBZ	det||risk-33/NN||the-32/DT	dobj||reduces-31/VBZ||risk-33/NN	prep_of||risk-33/NN||shingles-35/NNS	num||%-38/NN||50-37/CD	prep_by||reduces-31/VBZ||%-38/NN	chickenpox-20||vzv-4||no||although an attenuated vzv vaccine (v-oka) has been widely used in children in the united states, chickenpox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%.
det||inducer-6/NN||the-2/DT	advmod||used-4/VBN||clinically-3/RB	amod||inducer-6/NN||used-4/VBN	nn||inducer-6/NN||differentiation-5/NN	prep_unlike||target-43/VB||inducer-6/NN	nsubj||target-43/VB||all-7/DT	amod||shows-12/NNS||transretinoicacid-9/JJ	amod||shows-12/NNS||tenovin-6-11/JJ	dep||all-7/DT||shows-12/NNS	vmod||shows-12/NNS||limited-13/VBN	dobj||limited-13/VBN||effects-14/NNS	prepc_on||limited-13/VBN||promyelocyticleukemiaâ-16/VBG	dobj||promyelocyticleukemiaâ-16/VBG||$-17/$	amod||±-22/NNS||retinoicacid-19/JJ	nn||±-22/NNS||receptor-20/NN	nn||±-22/NNS||î-21/NN	npadvmod||that-38/RB||±-22/NNS	number||±-25/CD||pml-rar-î-24/CD	dep||±-22/NNS||±-25/CD	nn||formation-32/NN||stability-27/NN	conj_and||stability-27/NN||promyelocyticleukemia-29/NN	nn||formation-32/NN||promyelocyticleukemia-29/NN	amod||formation-32/NN||nuclear-30/JJ	nn||formation-32/NN||body-31/NN	dep||±-25/CD||formation-32/NN	amod||cells-35/NNS||nb4-34/JJ	prep_in||±-25/CD||cells-35/NNS	appos||cells-35/NNS||suggesting-37/NNP	dep||tenovin-6-39/CD||that-38/RB	num||$-17/$||tenovin-6-39/CD	aux||target-43/VB||does-40/VBZ	neg||target-43/VB||not-41/RB	advmod||target-43/VB||directly-42/RB	root||ROOT-0/null||target-43/VB	amod||activity-46/NN||pml-rar-î-44/JJ	amod||activity-46/NN||±-45/JJ	dobj||target-43/VB||activity-46/NN	promyelocyticleukemia-29||transretinoicacid-9||yes||unlike the clinically used differentiation inducer all- transretinoicacid, tenovin-6 shows limited effects on promyelocyticleukemiaâ€“retinoicacid receptor î± (pml-rar-î±) stability and promyelocyticleukemia nuclear body formation in nb4 cells, suggesting that tenovin-6 does not directly target pml-rar-î± activity.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
det||point-3/NN||this-2/DT	prep_at||demonstrates-9/VBZ||point-3/NN	det||evidence-7/NN||the-5/DT	amod||evidence-7/NN||best-6/JJS	nsubj||demonstrates-9/VBZ||evidence-7/NN	advmod||demonstrates-9/VBZ||powerfully-8/RB	root||ROOT-0/null||demonstrates-9/VBZ	nn||patients-13/NNS||stroke-10/NN	conj_and||stroke-10/NN||tia-12/NN	nn||patients-13/NNS||tia-12/NN	nsubjpass||prescribed-16/VBN||patients-13/NNS	aux||prescribed-16/VBN||should-14/MD	auxpass||prescribed-16/VBN||be-15/VB	ccomp||demonstrates-9/VBZ||prescribed-16/VBN	amod||therapy-20/NN||high-17/JJ	nn||therapy-20/NN||dose-18/NN	nn||therapy-20/NN||statin-19/NN	dobj||prescribed-16/VBN||therapy-20/NN	amod||prevention-24/NN||secondary-22/JJ	nn||prevention-24/NN||stroke-23/NN	prep_for||therapy-20/NN||prevention-24/NN	statin-19||stroke-23||no_rel||at this point, the best evidence powerfully demonstrates stroke and tia patients should be prescribed high dose statin therapy for secondary stroke prevention.
amod||cells-3/NNS||ebv-infected-1/JJ	nn||cells-3/NNS||b-2/NN	nsubj||present-5/JJ||cells-3/NNS	cop||present-5/JJ||are-4/VBP	root||ROOT-0/null||present-5/JJ	prep_in||present-5/JJ||blood-7/NN	amod||infectiousmononucleosis-10/NNS||acute-9/JJ	prep_during||present-5/JJ||infectiousmononucleosis-10/NNS	appos||infectiousmononucleosis-10/NNS||im-12/NN	advmod||large-16/JJ||surprisingly-15/RB	amod||numbers-17/NNS||large-16/JJ	prep_in||infectiousmononucleosis-10/NNS||numbers-17/NNS	infectiousmononucleosis-10||ebv--1||no||ebv-infected b cells are present in blood during acute infectiousmononucleosis (im) in surprisingly large numbers.
amod||ablation-2/NN||mfge8-1/JJ	nsubj||derived-37/VBD||ablation-2/NN	vmod||ablation-2/NN||induced-3/VBN	amod||priondisease-5/NN||accelerated-4/JJ	dobj||induced-3/VBN||priondisease-5/NN	amod||clearance-8/NN||reduced-7/VBN	dobj||induced-3/VBN||clearance-8/NN	conj_and||priondisease-5/NN||clearance-8/NN	amod||bodies-12/NNS||cerebellar-10/JJ	amod||bodies-12/NNS||apoptotic-11/JJ	prep_of||clearance-8/NN||bodies-12/NNS	prep_in||clearance-8/NN||vivo-14/NN	amod||accumulation-21/NN||excessive-19/JJ	amod||accumulation-21/NN||prpsc-20/JJ	dobj||induced-3/VBN||accumulation-21/NN	conj_and||priondisease-5/NN||accumulation-21/NN	amod||titers-25/NNS||increased-23/VBN	nn||titers-25/NNS||prion-24/NN	conj_and||priondisease-5/NN||titers-25/NNS	conj_and||accumulation-21/NN||titers-25/NNS	amod||ã-29/NN||prion-infected-27/JJ	amod||ã-29/NN||c57bl/6-28/JJ	prep_in||titers-25/NNS||ã-29/NN	amod||mice-32/NNS||129sv-31/JJ	conj_and||priondisease-5/NN||mice-32/NNS	conj_and||accumulation-21/NN||mice-32/NNS	amod||slices-36/NNS||organotypic-34/JJ	nn||slices-36/NNS||cerebellar-35/NN	conj_and||accumulation-21/NN||slices-36/NNS	conj_and||mice-32/NNS||slices-36/NNS	root||ROOT-0/null||derived-37/VBD	dobj||derived-37/VBD||therefrom-38/NN	priondisease-5||prion-24||no||mfge8 ablation induced accelerated priondisease and reduced clearance of cerebellar apoptotic bodies in vivo, as well as excessive prpsc accumulation and increased prion titers in prion-infected c57bl/6 ã— 129sv mice and organotypic cerebellar slices derived therefrom.
mark||metabolized-3/VBN||although-1/IN	advmod||metabolized-3/VBN||mainly-2/RB	advcl||effect-16/NN||metabolized-3/VBN	det||liver-6/NN||the-5/DT	prep_in||metabolized-3/VBN||liver-6/NN	amod||tests-11/NNS||abnormal-8/JJ	nn||tests-11/NNS||liver-9/NN	nn||tests-11/NNS||function-10/NN	nsubj||effect-16/NN||tests-11/NNS	cop||effect-16/NN||were-12/VBD	det||effect-16/NN||a-13/DT	amod||effect-16/NN||rare-14/JJ	amod||effect-16/NN||adverse-15/JJ	root||ROOT-0/null||effect-16/NN	amod||trials-19/NNS||clinical-18/JJ	prep_during||effect-16/NN||trials-19/NNS	nsubj||found-22/VBD||we-21/PRP	conj_and||effect-16/NN||found-22/VBD	neg||literature-24/NN||no-23/DT	dobj||found-22/VBD||literature-24/NN	amod||hepatitis-27/NN||albendazole-induced-26/JJ	prep_about||found-22/VBD||hepatitis-27/NN	xcomp||found-22/VBD||requiring-28/VBG	dobj||requiring-28/VBG||admission-29/NN	hepatitis-27||albendazole--1||no_rel||although mainly metabolized in the liver, abnormal liver function tests were a rare adverse effect during clinical trials and we found no literature about albendazole-induced hepatitis requiring admission.
mark||are-3/VBP||although-1/IN	expl||are-3/VBP||there-2/EX	advcl||focused-19/VBN||are-3/VBP	det||number-6/NN||an-4/DT	amod||number-6/NN||increasing-5/VBG	nsubj||are-3/VBP||number-6/NN	prep_of||number-6/NN||studies-8/NNS	amod||stigma-11/NN||hiv-related-10/JJ	prep_on||studies-8/NNS||stigma-11/NN	prep_in||stigma-11/NN||nigeria-13/NN	advmod||little-16/JJ||very-15/RB	amod||research-17/NN||little-16/JJ	nsubj||focused-19/VBN||research-17/NN	aux||focused-19/VBN||has-18/VBZ	root||ROOT-0/null||focused-19/VBN	advmod||perpetuate-27/VBP||how-21/WRB	nn||differences-23/NNS||power-22/NN	nsubj||perpetuate-27/VBP||differences-23/NNS	prepc_based_on||differences-23/NNS||on-25/IN	pobj||differences-23/NNS||gender-26/NN	prepc_on||focused-19/VBN||perpetuate-27/VBP	det||stigmatization-29/NN||the-28/DT	dobj||perpetuate-27/VBP||stigmatization-29/NN	prep_of||stigmatization-29/NN||people-31/NNS	vmod||people-31/NNS||living-32/VBG	prep_with||living-32/VBG||hiv/aids-34/NNS	appos||hiv/aids-34/NNS||plwha-36/NNP	advmod||affect-43/VBP||how-39/WRB	det||differences-42/NNS||these-40/DT	nn||differences-42/NNS||gender-41/NN	nsubj||affect-43/VBP||differences-42/NNS	prepc_on||focused-19/VBN||affect-43/VBP	conj_and||perpetuate-27/VBP||affect-43/VBP	det||care-45/NN||the-44/DT	dobj||affect-43/VBP||care-45/NN	mark||receive-48/VBP||that-46/IN	nsubj||receive-48/VBP||plwha-47/NN	dep||perpetuate-27/VBP||receive-48/VBP	nn||institutions-52/NNS||health-50/NN	nn||institutions-52/NNS||care-51/NN	prep_in||receive-48/VBP||institutions-52/NNS	aids--1||hiv--1||no||although there are an increasing number of studies on hiv-related stigma in nigeria, very little research has focused on how power differences based on gender perpetuate the stigmatization of people living with hiv/aids (plwha) and how these gender differences affect the care that plwha receive in health care institutions.
num||patients-2/NNS||nine-1/CD	npadvmod||seropositive-3/JJ||patients-2/NNS	root||ROOT-0/null||seropositive-3/JJ	prep_for||seropositive-3/JJ||hepatitisb-5/NN	dep||received-8/VBD||e-6/SYM	nsubj||received-8/VBD||antigen-7/NN	dep||seropositive-3/JJ||received-8/VBD	nn||monotherapy-10/NN||entecavir-9/NN	nsubjpass||analyzed-34/VBN||monotherapy-10/NN	num||months-13/NNS||12-12/CD	prep_for||monotherapy-10/NN||months-13/NNS	det||percentages-16/NNS||the-15/DT	prep_for||monotherapy-10/NN||percentages-16/NNS	conj_and||months-13/NNS||percentages-16/NNS	prep_of||percentages-16/NNS||tregs-18/NNS	amod||cells-21/NNS||th17-20/JJ	prep_of||percentages-16/NNS||cells-21/NNS	conj_and||tregs-18/NNS||cells-21/NNS	det||productions-28/NNS||the-25/DT	amod||productions-28/NNS||hbv-specific-26/JJ	amod||productions-28/NNS||il-17-27/JJ	prep_of||percentages-16/NNS||productions-28/NNS	conj_and||tregs-18/NNS||productions-28/NNS	det||patients-31/NNS||these-30/DT	prep_in||productions-28/NNS||patients-31/NNS	auxpass||analyzed-34/VBN||were-32/VBD	advmod||analyzed-34/VBN||longitudinally-33/RB	ccomp||received-8/VBD||analyzed-34/VBN	hepatitisb-5||entecavir-9||yes||nine patients seropositive for hepatitisb e antigen received entecavir monotherapy for 12 months and the percentages of tregs and th17 cells as well as the hbv-specific il-17 productions in these patients were longitudinally analyzed.
prep_in||are-11/VBP||addition-2/NN	det||best-6/JJS||the-5/DT	prep_to||are-11/VBP||best-6/JJS	poss||knowledge-9/NN||our-8/PRP$	prep_of||best-6/JJS||knowledge-9/NN	expl||are-11/VBP||there-10/EX	root||ROOT-0/null||are-11/VBP	neg||cases-14/NNS||no-12/DT	amod||cases-14/NNS||reported-13/VBN	nsubj||are-11/VBP||cases-14/NNS	prep_of||cases-14/NNS||patients-16/NNS	amod||virusinfection-19/NN||chronichepatitisc-18/JJ	prep_with||patients-16/NNS||virusinfection-19/NN	vmod||cases-14/NNS||developing-20/VBG	amod||anemia-22/NN||aplastic-21/JJ	dobj||developing-20/VBG||anemia-22/NN	vmod||anemia-22/NN||associated-23/VBN	amod||alpha-27/NN||pegylated-25/JJ	amod||alpha-27/NN||interferon-26/JJ	amod||treatment-29/NN||alpha-27/NN	amod||treatment-29/NN||2a-28/JJ	prep_with||associated-23/VBN||treatment-29/NN	chronichepatitisc-18||interferon-26||yes||in addition, to the best of our knowledge there are no reported cases of patients with chronichepatitisc virusinfection developing aplastic anemia associated with pegylated interferon alpha 2a treatment.
nsubj||exposed-3/VBD||experiments-1/NNS	nsubj||result-18/VB||experiments-1/NNS	rcmod||experiments-1/NNS||exposed-3/VBD	nsubj||â-8/VBP||influenzavirus-4/NNS	appos||influenzavirus-4/NNS||h5n1-6/NNP	ccomp||exposed-3/VBD||â-8/VBP	dobj||â-8/VBP||$-9/$	advmod||susceptible-14/CD||infected-11/RB	dep||susceptible-14/CD||cats-12/CD	dep||susceptible-14/CD||to-13/TO	dep||dogs-15/CD||susceptible-14/CD	num||$-9/$||dogs-15/CD	aux||result-18/VB||did-16/VBD	neg||result-18/VB||not-17/RB	root||ROOT-0/null||result-18/VB	prep_in||result-18/VB||intraspecies-20/NNS	nn||transmission-23/NN||interspecies-22/NNS	prep_in||result-18/VB||transmission-23/NN	conj_or||intraspecies-20/NNS||transmission-23/NN	h5n1-6||influenzavirus-4||no||experiments that exposed influenzavirus (h5n1)â€“infected cats to susceptible dogs did not result in intraspecies or interspecies transmission.
amod||models-2/NNS||mathematical-1/JJ	nsubj||shown-4/VBN||models-2/NNS	nsubj||helpful-8/JJ||models-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	aux||helpful-8/JJ||to-5/TO	cop||helpful-8/JJ||be-6/VB	advmod||helpful-8/JJ||extremely-7/RB	xcomp||shown-4/VBN||helpful-8/JJ	prepc_in||helpful-8/JJ||understanding-10/VBG	det||dynamics-12/NNS||the-11/DT	dobj||understanding-10/VBG||dynamics-12/NNS	amod||diseases-16/NNS||different-14/JJ	nn||diseases-16/NNS||virus-15/NN	prep_of||dynamics-12/NNS||diseases-16/NNS	prep_including||shown-4/VBN||hepatitisb-19/NNP	nn||hdv-25/NNP||hepatitis-21/NNP	dep||hdv-25/NNP||d-22/SYM	nn||hdv-25/NNP||virus-23/NNP	nn||hdv-25/NNP||-lrb--24/NNPS	nsubj||virus-30/NN||hdv-25/NNP	advmod||virus-30/NN||-rrb--26/RB	cop||virus-30/NN||is-27/VBZ	det||virus-30/NN||a-28/DT	nn||virus-30/NN||satellite-29/NN	rcmod||hepatitisb-19/NNP||virus-30/NN	det||-rrb--36/NN||the-32/DT	amod||-rrb--36/NN||hepatitisbvirus-33/JJ	amod||-rrb--36/NN||-lrb--34/JJ	nn||-rrb--36/NN||hbv-35/NN	prep_of||virus-30/NN||-rrb--36/NN	hbv-35||hepatitisbvirus-33||no||mathematical models have shown to be extremely helpful in understanding the dynamics of different virus diseases , including hepatitisb. hepatitis d virus -lrb- hdv -rrb- is a satellite virus of the hepatitisbvirus -lrb- hbv -rrb- .
det||total-2/NN||a-1/DT	nsubj||referred-6/VBD||total-2/NN	nsubjpass||challenged-25/VBN||total-2/NN	number||consecutively-5/CD||580-4/CD	prep_of||total-2/NN||consecutively-5/CD	root||ROOT-0/null||referred-6/VBD	amod||patients-8/NNS||adult-7/JJ	dobj||referred-6/VBD||patients-8/NNS	det||history-11/NN||a-10/DT	prep_with||referred-6/VBD||history-11/NN	amod||allergicreactions-15/NNS||non-serious-13/JJ	nn||allergicreactions-15/NNS||cutaneous-14/NNS	prep_of||history-11/NN||allergicreactions-15/NNS	prep_to||referred-6/VBD||penicillin-17/NN	neg||ige-22/NN||no-21/DT	prep_with||challenged-25/VBN||ige-22/NN	auxpass||challenged-25/VBN||were-24/VBD	conj_but||referred-6/VBD||challenged-25/VBN	amod||doses-28/NNS||therapeutic-27/JJ	prep_with||challenged-25/VBN||doses-28/NNS	nn||v-31/NN||penicillin-30/NN	prep_of||doses-28/NNS||v-31/NN	appos||v-31/NN||phenoxymethylpenicillin-33/NN	prep_of||doses-28/NNS||penicilling-36/NN	conj_or||v-31/NN||penicilling-36/NN	appos||penicilling-36/NN||benzylpenicillin-38/NN	prep_of||doses-28/NNS||both-42/DT	conj_or||v-31/NN||both-42/DT	allergicreactions-15||benzylpenicillin-38||no||a total of 580 consecutively referred adult patients with a history of non-serious cutaneous allergicreactions to penicillin, but with no ige, were challenged with therapeutic doses of penicillin v (phenoxymethylpenicillin), penicilling (benzylpenicillin), or both.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||‰-20/NNS||kd-18/NN	nn||‰-20/NNS||â-19/NN	dobj||log-17/VB||‰-20/NNS	amod||‰-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||‰-38/VBG	number||4-40/CD||¥-39/CD	dobj||‰-38/VBG||4-40/CD	kd-36||sertraline-33||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â‰¤ 2), but higher sorption behavior can be expected for sertraline (log kd â‰¥ 4).
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||artemether--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||significant-2/JJ	nsubj||estimated-9/VBD||correlation-3/NN	nsubj||mr-15/VBP||correlation-3/NN	advmod||visible-6/JJ||microscopically-5/RB	amod||droplets-8/NNS||visible-6/JJ	nn||droplets-8/NNS||lipid-7/NN	prep_between||correlation-3/NN||droplets-8/NNS	root||ROOT-0/null||estimated-9/VBD	amod||staining-13/NN||nile-11/JJ	amod||staining-13/NN||red-12/JJ	prep_by||estimated-9/VBD||staining-13/NN	conj_and||estimated-9/VBD||mr-15/VBP	amod||signals-18/NNS||visible-16/JJ	nn||signals-18/NNS||lipid-17/NN	nsubjpass||observed-20/VBN||signals-18/NNS	auxpass||observed-20/VBN||was-19/VBD	ccomp||mr-15/VBP||observed-20/VBN	amod||carcinomas-24/NNS||metastatic-22/JJ	nn||carcinomas-24/NNS||lung-23/NN	prep_in||observed-20/VBN||carcinomas-24/NNS	dep||carcinomas-24/NNS||p-26/VBN	dep||0.01-28/CD||=-27/SYM	ccomp||p-26/VBN||0.01-28/CD	vmod||estimated-9/VBD||indicating-31/VBG	mark||mr-35/VBP||that-32/IN	det||proton-34/NN||the-33/DT	nsubj||mr-35/VBP||proton-34/NN	ccomp||indicating-31/VBG||mr-35/VBP	amod||signals-38/NNS||visible-36/JJ	nn||signals-38/NNS||lipid-37/NN	nsubj||arise-39/VBP||signals-38/NNS	ccomp||mr-35/VBP||arise-39/VBP	amod||droplets-43/NNS||cytoplasmic-41/JJ	nn||droplets-43/NNS||lipid-42/NN	prep_from||arise-39/VBP||droplets-43/NNS	lipid-42||carcinomas-24||no_rel||a significant correlation between microscopically visible lipid droplets estimated by nile red staining and mr visible lipid signals was observed in metastatic lung carcinomas ( p = 0.01), indicating that the proton mr visible lipid signals arise from cytoplasmic lipid droplets.
prep_in||examined-55/VBN||total-2/NN	nn||lines-5/NNS||cell-4/NN	nsubjpass||examined-55/VBN||lines-5/NNS	num||carcinomas-9/NNS||three-7/CD	nn||carcinomas-9/NNS||endometrium-8/NN	prep_from||lines-5/NNS||carcinomas-9/NNS	nn||an3-15/NNS||ishikawa-11/NN	amod||an3-15/NNS||hec-1-a-13/JJ	nsubj||ca-16/MD||an3-15/NNS	dep||carcinomas-9/NNS||ca-16/MD	num||carcinomas-21/NNS||three-19/CD	amod||carcinomas-21/NNS||cervical-20/JJ	appos||carcinomas-9/NNS||carcinomas-21/NNS	nn||siha-27/NN||hela-23/NN	dep||siha-27/NN||caski-25/NN	appos||carcinomas-21/NNS||siha-27/NN	num||chorioncarcinomas-31/NNS||three-30/CD	appos||carcinomas-9/NNS||chorioncarcinomas-31/NNS	conj_and||carcinomas-21/NNS||chorioncarcinomas-31/NNS	nn||bewo-37/NN||jeg-33/NN	dep||bewo-37/NN||jar-35/NN	appos||chorioncarcinomas-31/NNS||bewo-37/NN	num||cancers-42/NNS||two-40/CD	nn||cancers-42/NNS||ovarian-41/NN	appos||carcinomas-9/NNS||cancers-42/NNS	conj_and||carcinomas-21/NNS||cancers-42/NNS	amod||oaw-42-46/JJ||bg-1-44/JJ	dep||cancers-42/NNS||oaw-42-46/JJ	num||teratocarcinoma-50/NN||one-49/CD	appos||carcinomas-9/NNS||teratocarcinoma-50/NN	conj_and||carcinomas-21/NNS||teratocarcinoma-50/NN	dep||teratocarcinoma-50/NN||pa-1-52/JJ	auxpass||examined-55/VBN||were-54/VBD	root||ROOT-0/null||examined-55/VBN	ca-16||carcinomas-21||no_rel||in total, cell lines from three endometrium carcinomas (ishikawa, hec-1-a, an3 ca), three cervical carcinomas (hela, caski, siha), three chorioncarcinomas (jeg, jar, bewo), two ovarian cancers (bg-1, oaw-42) and one teratocarcinoma (pa-1) were examined.
aux||test-2/VB||to-1/TO	root||ROOT-0/null||test-2/VB	advmod||develop-5/VB||further-4/RB	conj_and||test-2/VB||develop-5/VB	det||policy-8/NN||a-6/DT	nn||policy-8/NN||healthcare-7/NN	nsubj||using-14/VBG||policy-8/NN	amod||framework-13/NN||clinical-10/JJ	nn||framework-13/NN||decision-11/NN	nn||framework-13/NN||support-12/NN	conj_and||policy-8/NN||framework-13/NN	nsubj||using-14/VBG||framework-13/NN	dep||develop-5/VB||using-14/VBG	dobj||using-14/VBG||growthhormone-15/NN	appos||growthhormone-15/NN||gh-17/NN	nn||syndrome-21/NN||turner-20/NN	prep_for||growthhormone-15/NN||syndrome-21/NN	appos||syndrome-21/NN||ts-23/NN	det||study-29/NN||a-26/DT	amod||study-29/NN||complex-27/JJ	nn||study-29/NN||case-28/NN	prep_as||using-14/VBG||study-29/NN	growthhormone-15||ts-23||no_rel||to test and further develop a healthcare policy and clinical decision support framework using growthhormone (gh) for turner syndrome (ts) as a complex case study.
amod||nsaids-2/NNS||non-selective-1/JJ	nsubj||increase-3/VBP||nsaids-2/NNS	root||ROOT-0/null||increase-3/VBP	det||risk-5/NN||the-4/DT	dobj||increase-3/VBP||risk-5/NN	amod||âˆ-8/NN||pepticulcerdisease-7/JJ	prep_of||risk-5/NN||âˆ-8/NN	number||5-fold-10/JJ||1/4-9/CD	amod||âˆ-8/NN||5-fold-10/JJ	prep_of||risk-5/NN||that-13/DT	conj_and||âˆ-8/NN||that-13/DT	amod||4-fold-17/NNS||upper-15/JJ	amod||4-fold-17/NNS||gibleeding-16/VBG	prep_of||that-13/DT||4-fold-17/NNS	mark||associated-27/VBN||whereas-19/IN	amod||cyclo-oxygenase-2-21/JJ||selective-20/JJ	amod||inhibitors-25/NNS||cyclo-oxygenase-2-21/JJ	dep||cyclo-oxygenase-2-21/JJ||cox-23/NN	nsubjpass||associated-27/VBN||inhibitors-25/NNS	auxpass||associated-27/VBN||are-26/VBP	advcl||increase-3/VBP||associated-27/VBN	det||toxicity-33/NN||a-29/DT	advmod||lower-31/JJR||significantly-30/RB	amod||toxicity-33/NN||lower-31/JJR	nn||toxicity-33/NN||gi-32/NN	prep_with||associated-27/VBN||toxicity-33/NN	amod||agents-36/NNS||non-selective-35/JJ	prep_than||toxicity-33/NN||agents-36/NNS	nsaids-2||gibleeding-16||no_rel||non-selective nsaids increase the risk of pepticulcerdisease âˆ¼5-fold, and that of upper gibleeding 4-fold, whereas selective cyclo-oxygenase-2 (cox) inhibitors are associated with a significantly lower gi toxicity than non-selective agents.
num||patients-3/NNS||twenty-1/CD	amod||patients-3/NNS||young-2/JJ	nsubjpass||enrolled-11/VBN||patients-3/NNS	prep_with||patients-3/NNS||pcos-5/NNS	nsubj||received-8/VBN||pcos-5/NNS	aux||received-8/VBN||had-7/VBD	rcmod||pcos-5/NNS||received-8/VBN	dobj||received-8/VBN||metformin-9/NN	auxpass||enrolled-11/VBN||were-10/VBD	root||ROOT-0/null||enrolled-11/VBN	pcos-5||metformin-9||no_rel||twenty young patients with pcos who had received metformin were enrolled.
mark||understand-4/VB||in-1/IN	dep||understand-4/VB||order-2/NN	aux||understand-4/VB||to-3/TO	advcl||analysed-27/VBD||understand-4/VB	mark||serve-9/VB||whether-5/IN	det||snp-7/NN||this-6/DT	nsubj||serve-9/VB||snp-7/NN	nsubj||evaluate-11/VB||snp-7/NN	aux||serve-9/VB||may-8/MD	ccomp||understand-4/VB||serve-9/VB	aux||evaluate-11/VB||to-10/TO	xcomp||serve-9/VB||evaluate-11/VB	det||contribution-13/NN||the-12/DT	dobj||evaluate-11/VB||contribution-13/NN	det||gene-17/NN||the-15/DT	amod||gene-17/NN||ccl2-16/JJ	prep_of||contribution-13/NN||gene-17/NN	det||expression-20/NN||the-19/DT	prep_to||evaluate-11/VB||expression-20/NN	nn||disease-23/NN||tb-22/NN	prep_of||expression-20/NN||disease-23/NN	nsubj||analysed-27/VBD||we-25/PRP	advmod||analysed-27/VBD||further-26/RB	root||ROOT-0/null||analysed-27/VBD	dobj||analysed-27/VBD||distribution-28/NN	poss||alleles-31/NNS||its-30/PRP$	prep_of||distribution-28/NN||alleles-31/NNS	prep_of||distribution-28/NN||genotypes-33/NNS	conj_and||alleles-31/NNS||genotypes-33/NNS	num||cases-37/NNS||301-35/CD	nn||cases-37/NNS||tb-36/NN	prep_in||analysed-27/VBD||cases-37/NNS	num||controls-41/NNS||338-39/CD	amod||controls-41/NNS||non-infected-40/JJ	prep_versus||cases-37/NNS||controls-41/NNS	det||bcg-44/NN||all-43/DT	dep||controls-41/NNS||bcg-44/NN	vmod||bcg-44/NN||vaccinated-45/VBN	vmod||controls-41/NNS||representing-47/VBG	det||population-51/NN||a-48/DT	amod||population-51/NN||high-risk-49/JJ	amod||population-51/NN||pediatric-50/JJ	dobj||representing-47/VBG||population-51/NN	nn||china-54/NN||north-53/NN	prep_of||population-51/NN||china-54/NN	tb-36||bcg-44||yes||in order to understand whether this snp may serve to evaluate the contribution of the ccl2 gene to the expression of tb disease, we further analysed distribution of its alleles and genotypes in 301 tb cases versus 338 non-infected controls (all bcg vaccinated) representing a high-risk pediatric population of north china.
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||yes||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
det||genotypes-2/NNS||some-1/DT	nsubjpass||related-5/VBN||genotypes-2/NNS	auxpass||related-5/VBN||were-3/VBD	advmod||related-5/VBN||directly-4/RB	root||ROOT-0/null||related-5/VBN	prep_with||related-5/VBN||humaninfluenzaviruses-7/NNS	nsubj||include-10/VBP||humaninfluenzaviruses-7/NNS	rcmod||humaninfluenzaviruses-7/NNS||include-10/VBP	dobj||include-10/VBP||strains-11/NNS	mark||derived-15/VBD||that-12/IN	amod||genes-14/NNS||harbored-13/JJ	nsubj||derived-15/VBD||genes-14/NNS	ccomp||include-10/VBP||derived-15/VBD	prep_from||derived-15/VBD||humaninfluenzaviruses-17/NNS	humaninfluenza--1||influenzaviruses--1||no||some genotypes were directly related with humaninfluenzaviruses, which include strains that harbored genes derived from humaninfluenzaviruses.
det||article-2/NN||this-1/DT	nsubj||reviews-5/VBZ||article-2/NN	nsubj||focuses-16/VBZ||article-2/NN	nsubj||proposes-25/VBZ||article-2/NN	nsubj||hypothesized-30/VBN||article-2/NN	advmod||reviews-5/VBZ||first-3/JJ	dep||first-3/JJ||briefly-4/NN	root||ROOT-0/null||reviews-5/VBZ	det||prevalence-7/NN||the-6/DT	dobj||reviews-5/VBZ||prevalence-7/NN	amod||factors-10/NNS||associated-9/VBN	dobj||reviews-5/VBZ||factors-10/NNS	conj_and||prevalence-7/NN||factors-10/NNS	amod||ptsd-13/NN||accident-related-12/JJ	prep_of||factors-10/NNS||ptsd-13/NN	advmod||focuses-16/VBZ||then-15/RB	conj_and||reviews-5/VBZ||focuses-16/VBZ	det||model-20/NN||a-18/DT	amod||model-20/NN||conceptual-19/JJ	prep_on||focuses-16/VBZ||model-20/NN	nn||memory-23/NN||fear-22/NN	prep_of||model-20/NN||memory-23/NN	conj_and||reviews-5/VBZ||proposes-25/VBZ	det||new-27/JJ||a-26/DT	dobj||proposes-25/VBZ||new-27/JJ	advmod||hypothesized-30/VBN||rationally-29/RB	conj_and||reviews-5/VBZ||hypothesized-30/VBN	amod||intervention-33/NN||translational-31/JJ	nn||intervention-33/NN||preventive-32/NN	dobj||hypothesized-30/VBN||intervention-33/NN	prep_for||intervention-33/NN||ptsd-35/NN	prepc_through||hypothesized-30/VBN||promoting-37/VBG	amod||neurogenesis-39/NNS||hippocampal-38/JJ	dobj||promoting-37/VBG||neurogenesis-39/NNS	amod||supplementation-42/NN||omega-3fattyacid-41/JJ	prep_by||promoting-37/VBG||supplementation-42/NN	omega-3fattyacid-41||ptsd-35||no_rel||this article first briefly reviews the prevalence and associated factors of accident-related ptsd, then focuses on a conceptual model of fear memory and proposes a new, rationally hypothesized translational preventive intervention for ptsd through promoting hippocampal neurogenesis by omega-3fattyacid supplementation.
det||polymorphism-4/NN||a-1/DT	amod||polymorphism-4/NN||single-2/JJ	nn||polymorphism-4/NN||nucleotide-3/NN	nsubjpass||shown-36/VBN||polymorphism-4/NN	nsubj||determinant-40/NN||polymorphism-4/NN	appos||polymorphism-4/NN||snp-6/NN	prep_in||polymorphism-4/NN||codon-9/NN	num||codon-9/NN||129-10/CD	det||gene-15/NN||the-12/DT	amod||gene-15/NN||human-13/JJ	nn||gene-15/NN||prion-14/NN	prep_of||codon-9/NN||gene-15/NN	vmod||shown-36/VBN||leading-17/VBG	det||change-20/NN||a-19/DT	prep_to||leading-17/VBG||change-20/NN	prep_from||change-20/NN||methionine-22/NN	aux||valine-24/VB||to-23/TO	xcomp||leading-17/VBG||valine-24/VB	prep_at||valine-24/VB||residue-26/NN	num||residue-26/NN||129-27/CD	prep_of||residue-26/NN||prionprotein-29/NN	appos||prionprotein-29/NN||prp-31/NN	aux||shown-36/VBN||has-34/VBZ	auxpass||shown-36/VBN||been-35/VBN	root||ROOT-0/null||shown-36/VBN	aux||determinant-40/NN||to-37/TO	cop||determinant-40/NN||be-38/VB	det||determinant-40/NN||a-39/DT	xcomp||shown-36/VBN||determinant-40/NN	det||susceptibility-43/NN||the-42/DT	prep_in||determinant-40/NN||susceptibility-43/NN	aux||priondisease-45/VB||to-44/TO	vmod||susceptibility-43/NN||priondisease-45/VB	priondisease-45||prion-14||no||a single nucleotide polymorphism (snp) in codon 129 of the human prion gene, leading to a change from methionine to valine at residue 129 of prionprotein (prp), has been shown to be a determinant in the susceptibility to priondisease.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
advmod||review-21/VBP||here-1/RB	det||attempt-5/NN||an-4/DT	prep_in||review-21/VBP||attempt-5/NN	aux||understand-7/VB||to-6/TO	vmod||attempt-5/NN||understand-7/VB	det||role-9/NN||the-8/DT	dobj||understand-7/VB||role-9/NN	nn||interferons-13/NNS||type-11/FW	nn||interferons-13/NNS||i-12/FW	prep_of||role-9/NN||interferons-13/NNS	det||pathogenesis-16/NNS||the-15/DT	prep_in||interferons-13/NNS||pathogenesis-16/NNS	prep_of||pathogenesis-16/NNS||autoimmunity-18/NN	nsubj||review-21/VBP||we-20/PRP	root||ROOT-0/null||review-21/VBP	det||advances-24/NNS||the-22/DT	amod||advances-24/NNS||recent-23/JJ	dobj||review-21/VBP||advances-24/NNS	det||genetics-27/NNS||the-26/DT	prep_in||advances-24/NNS||genetics-27/NNS	prep_of||genetics-27/NNS||autoimmunediseases-29/NNS	vmod||autoimmunediseases-29/NNS||focusing-30/VBG	det||association-33/NN||the-32/DT	prep_on||focusing-30/VBG||association-33/NN	prep_of||association-33/NN||genes-35/NNS	vmod||genes-35/NNS||involved-36/VBN	nn||pathways-41/NNS||type-38/NN	nn||pathways-41/NNS||i-39/NN	nn||pathways-41/NNS||interferon-40/NN	prep_in||involved-36/VBN||pathways-41/NNS	autoimmunediseases-29||interferon-40||no||here, in an attempt to understand the role of type i interferons in the pathogenesis of autoimmunity, we review the recent advances in the genetics of autoimmunediseases focusing on the association of genes involved in type i interferon pathways.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	prep_of||role-4/NN||spycep-6/NN	amod||necrotizingfasciitis-9/NNS||s.pyogenes-8/JJ	prep_in||spycep-6/NN||necrotizingfasciitis-9/NNS	amod||infection-13/NN||respiratory-11/JJ	nn||infection-13/NN||tract-12/NN	prep_in||spycep-6/NN||infection-13/NN	conj_and||necrotizingfasciitis-9/NNS||infection-13/NN	prep_in||investigated-2/VBD||mice-15/NNS	vmod||mice-15/NNS||using-16/VBG	amod||strains-18/NNS||isogenic-17/JJ	dobj||using-16/VBG||strains-18/NNS	vmod||strains-18/NNS||differing-19/VBG	advmod||differing-19/VBG||only-20/RB	nn||expression-23/NN||spycep-22/NN	prep_in||differing-19/VBG||expression-23/NN	necrotizingfasciitis-9||s.pyogenes-8||no||we investigated the role of spycep in s.pyogenes necrotizingfasciitis and respiratory tract infection in mice using isogenic strains differing only in spycep expression .
nsubj||revealed-9/VBD||investigation-1/NN	det||role-5/NN||the-3/DT	amod||role-5/NN||functional-4/JJ	prep_of||investigation-1/NN||role-5/NN	amod||antibodies-8/NNS||anti-sap-7/JJ	prep_of||role-5/NN||antibodies-8/NNS	root||ROOT-0/null||revealed-9/VBD	mark||reduced-24/VBD||that-10/IN	nsubj||reduced-24/VBD||incubation-11/NN	prep_of||incubation-11/NN||gbs-13/NN	det||presence-16/NN||the-15/DT	prep_in||gbs-13/NN||presence-16/NN	prep_of||presence-16/NN||sera-18/NN	prep_from||sera-18/NN||animals-20/NNS	vmod||animals-20/NNS||immunized-21/VBN	prep_with||immunized-21/VBN||sap-23/NNP	ccomp||revealed-9/VBD||reduced-24/VBD	det||capacity-26/NN||the-25/DT	dobj||reduced-24/VBD||capacity-26/NN	det||bacterium-29/NN||the-28/DT	prep_of||capacity-26/NN||bacterium-29/NN	aux||degrade-31/VB||to-30/TO	vmod||bacterium-29/NN||degrade-31/VB	dobj||degrade-31/VB||pullulan-32/NN	gbs-13||antibodies-8||no_rel||investigation of the functional role of anti-sap antibodies revealed that incubation of gbs in the presence of sera from animals immunized with sap reduced the capacity of the bacterium to degrade pullulan.
det||time-3/NN||the-1/DT	amod||time-3/NN||median-2/JJ	nsubj||days-10/NNS||time-3/NN	prep_to||time-3/NN||recurrence-5/NN	prep_of||recurrence-5/NN||uti-7/NN	cop||days-10/NNS||was-8/VBD	num||days-10/NNS||84.5-9/CD	root||ROOT-0/null||days-10/NNS	det||group-14/NN||the-12/DT	nn||group-14/NN||cranberry-13/NN	prep_for||days-10/NNS||group-14/NN	num||days-17/NNS||91-16/CD	conj_and||days-10/NNS||days-17/NNS	det||group-21/NN||the-19/DT	nn||group-21/NN||trimethoprim-20/NN	prep_for||days-17/NNS||group-21/NN	dep||days-10/NNS||u-23/VBN	dep||166-25/NNS||=-24/SYM	ccomp||u-23/VBN||166-25/NNS	ccomp||u-23/VBN||p-27/VB	dep||0.479-29/CD||=-28/SYM	ccomp||p-27/VB||0.479-29/CD	uti-7||trimethoprim-20||yes||the median time to recurrence of uti was 84.5 days for the cranberry group and 91 days for the trimethoprim group ( u = 166, p = 0.479).
nsubjpass||documented-7/VBN||resistance-1/NN	amod||drugs-4/NNS||antituberculosis-3/JJ	prep_to||resistance-1/NN||drugs-4/NNS	aux||documented-7/VBN||has-5/VBZ	auxpass||documented-7/VBN||been-6/VBN	root||ROOT-0/null||documented-7/VBN	det||1940s-10/NNS||the-9/DT	prep_since||documented-7/VBN||1940s-10/NNS	tmod||introduced-19/VBN||1940s-10/NNS	advmod||introduced-19/VBN||when-12/WRB	det||medicines-15/NNS||the-13/DT	amod||medicines-15/NNS||first-14/JJ	nsubjpass||introduced-19/VBN||medicines-15/NNS	prep_for||medicines-15/NNS||tuberculosis-17/NNP	auxpass||introduced-19/VBN||were-18/VBD	rcmod||1940s-10/NNS||introduced-19/VBN	tuberculosis-17||antituberculosis-3||yes||resistance to antituberculosis drugs has been documented since the 1940s, when the first medicines for tuberculosis were introduced.
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tb--1||isoniazid-27||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
nsubj||compared-2/VBD||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performances-4/NNS||the-3/DT	nsubj||assays-14/VBZ||performances-4/NNS	num||test-10/NN||3-6/CD	amod||test-10/NN||multiple-7/JJ	amod||test-10/NN||allergen-8/JJ	amod||test-10/NN||simultaneous-9/JJ	prep_of||performances-4/NNS||test-10/NN	appos||test-10/NN||mast-12/NN	ccomp||compared-2/VBD||assays-14/VBZ	nn||screen-17/NN||rida-15/NN	nn||screen-17/NN||allergy-16/NN	dobj||assays-14/VBZ||screen-17/NN	nn||germany-23/NN||r-biopharm-19/NN	dep||germany-23/NN||darmstadt-21/NN	appos||screen-17/NN||germany-23/NN	amod||system-29/NN||mast-26/JJ	nn||system-29/NN||optigen-27/NN	nn||system-29/NN||allergy-28/NN	appos||screen-17/NN||system-29/NN	amod||diagnostics-33/NNS||hitachi-31/JJ	nn||diagnostics-33/NNS||chemical-32/NN	nsubj||ca-38/MD||diagnostics-33/NNS	nn||view-36/NN||mountain-35/NN	appos||diagnostics-33/NNS||view-36/NN	dep||screen-17/NN||ca-38/MD	amod||allergy-43/NN||polycheck-42/VBG	dobj||assays-14/VBZ||allergy-43/NN	conj_and||screen-17/NN||allergy-43/NN	nn||gmbh-46/NN||biocheck-45/NN	appos||allergy-43/NN||gmbh-46/NN	dep||gmbh-46/NN||munster-48/NN	dep||gmbh-46/NN||germany-50/NN	allergy-43||allergy-43||no||we compared the performances of 3 multiple allergen simultaneous test (mast) assays rida allergy screen (r-biopharm, darmstadt, germany), mast optigen allergy system (hitachi chemical diagnostics, mountain view, ca), and polycheck allergy (biocheck gmbh, munster, germany).
prep_out_of||checked-7/VBN||these-3/DT	nsubjpass||checked-7/VBN||278-5/NNP	auxpass||checked-7/VBN||were-6/VBD	root||ROOT-0/null||checked-7/VBN	agent||checked-7/VBN||rt-pcr-9/NN	prep_for||rt-pcr-9/NN||influenzaviruses-11/NNS	num||negative-17/NN||157-13/CD	amod||negative-17/NN||positive-14/JJ	conj_and||positive-14/JJ||121-16/JJ	amod||negative-17/NN||121-16/JJ	dep||influenzaviruses-11/NNS||negative-17/NN	prep_of||negative-17/NN||whom-20/WP	dep||influenzaviruses-11/NNS||141-22/CD	conj_and||negative-17/NN||141-22/CD	nn||flu-25/NN||pdm-24/NN	prep_with||141-22/CD||flu-25/NN	dep||influenzaviruses-11/NNS||132-27/CD	conj_and||negative-17/NN||132-27/CD	prep_with||132-27/CD||ilis-29/NNS	nn||origin-33/NN||non-31/NN	nn||origin-33/NN||pdm-32/NN	prep_of||ilis-29/NNS||origin-33/NN	num||untyped-36/NN||5-35/CD	appos||origin-33/NN||untyped-36/NN	flu-25||influenzaviruses-11||no||out of these, 278 were checked by rt-pcr for influenzaviruses (157 positive and 121 negative, of whom, 141 with pdm flu and 132 with ilis of non pdm origin, 5 untyped).
amod||efficacy-2/NN||good-1/JJ	nsubjpass||found-7/VBN||efficacy-2/NN	nn||results-5/NNS||safety-4/NN	conj_and||efficacy-2/NN||results-5/NNS	nsubjpass||found-7/VBN||results-5/NNS	auxpass||found-7/VBN||were-6/VBD	root||ROOT-0/null||found-7/VBN	amod||methylphenidate-10/NN||immediate-release-9/JJ	prep_for||found-7/VBN||methylphenidate-10/NN	prep_in||methylphenidate-10/NN||patients-12/NNS	prep_with||patients-12/NNS||adhd-14/NN	adhd-14||methylphenidate-10||yes||good efficacy and safety results were found for immediate-release methylphenidate in patients with adhd.
det||review-2/NN||this-1/DT	nsubj||examine-4/VB||review-2/NN	nsubj||discuss-20/VB||review-2/NN	aux||examine-4/VB||will-3/MD	root||ROOT-0/null||examine-4/VB	det||pharmacokinetics-6/NNS||the-5/DT	dobj||examine-4/VB||pharmacokinetics-6/NNS	dobj||examine-4/VB||dosing-8/NN	conj_and||pharmacokinetics-6/NNS||dosing-8/NN	dobj||examine-4/VB||efficacy-10/NN	conj_and||pharmacokinetics-6/NNS||efficacy-10/NN	nn||data-14/NNS||safety-13/NN	dobj||examine-4/VB||data-14/NNS	conj_and||pharmacokinetics-6/NNS||data-14/NNS	amod||mesalamine-17/NN||extended-release-16/JJ	prep_of||data-14/NNS||mesalamine-17/NN	conj_and||examine-4/VB||discuss-20/VB	det||role-23/NN||the-21/DT	amod||role-23/NN||potential-22/JJ	dobj||discuss-20/VB||role-23/NN	prepc_of||role-23/NN||improving-25/VBG	nn||compliance-27/NN||medication-26/NN	dobj||improving-25/VBG||compliance-27/NN	amod||costs-30/NNS||decreasing-29/VBG	dobj||improving-25/VBG||costs-30/NNS	conj_and||compliance-27/NN||costs-30/NNS	nn||maintenance-33/NN||uc-32/NN	prep_in||compliance-27/NN||maintenance-33/NN	uc-32||mesalamine-17||yes||this review will examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, and discuss the potential role of improving medication compliance and decreasing costs in uc maintenance.
nsubj||dissimilar-8/JJ||bacteria-1/NNS	vmod||bacteria-1/NNS||associated-2/VBN	amod||disease-5/NN||periodontal-4/JJ	prep_with||associated-2/VBN||disease-5/NN	cop||dissimilar-8/JJ||are-6/VBP	neg||dissimilar-8/JJ||not-7/RB	root||ROOT-0/null||dissimilar-8/JJ	prep_to||dissimilar-8/JJ||those-10/DT	vmod||those-10/DT||known-11/VBN	aux||associated-14/VBN||to-12/TO	auxpass||associated-14/VBN||be-13/VB	xcomp||known-11/VBN||associated-14/VBN	amod||bacterialinfections-17/NNS||genito-urinary-16/JJ	prep_with||associated-14/VBN||bacterialinfections-17/NNS	amod||outcomes-21/NNS||adverse-19/JJ	nn||outcomes-21/NNS||pregnancy-20/NN	prep_with||associated-14/VBN||outcomes-21/NNS	conj_and||bacterialinfections-17/NNS||outcomes-21/NNS	bacterialinfections-17||bacteria-1||no||bacteria associated with periodontal disease are not dissimilar to those known to be associated with genito-urinary bacterialinfections and adverse pregnancy outcomes.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||determine-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	dobj||determine-9/VB||relationship-10/NN	nn||activity-13/NN||disease-12/NN	prep_between||relationship-10/NN||activity-13/NN	amod||markers-16/NNS||systemic-15/JJ	dobj||determine-9/VB||markers-16/NNS	conj_and||relationship-10/NN||markers-16/NNS	nn||degradation-19/NN||cartilage-18/NN	prep_of||markers-16/NNS||degradation-19/NN	amod||telopeptides-24/NNS||urinary-21/JJ	amod||telopeptides-24/NNS||c-terminal-22/JJ	amod||telopeptides-24/NNS||cross-linking-23/JJ	dobj||determine-9/VB||telopeptides-24/NNS	conj_and||relationship-10/NN||telopeptides-24/NNS	nn||collagen-28/NN||type-26/NN	nn||collagen-28/NN||ii-27/NN	prep_of||telopeptides-24/NNS||collagen-28/NN	appos||collagen-28/NN||uctx-ii-30/NNP	nn||degradation-35/NN||bone-34/NN	dobj||determine-9/VB||degradation-35/NN	conj_and||relationship-10/NN||degradation-35/NN	advmod||telopeptides-40/NNS||urinary-37/RB	amod||telopeptides-40/NNS||c-terminal-38/JJ	amod||telopeptides-40/NNS||cross-linking-39/JJ	dobj||determine-9/VB||telopeptides-40/NNS	conj_and||relationship-10/NN||telopeptides-40/NNS	nn||collagen-44/NN||type-42/FW	nn||collagen-44/NN||i-43/FW	prep_of||telopeptides-40/NNS||collagen-44/NN	appos||collagen-44/NN||uctx-i-46/NNP	amod||progression-50/NN||structural-49/JJ	dobj||determine-9/VB||progression-50/NN	conj_and||relationship-10/NN||progression-50/NN	prep_of||progression-50/NN||osteoarthritis-52/NNS	appos||osteoarthritis-52/NNS||oa-54/NN	amod||efficacy-59/NN||potential-57/JJ	amod||efficacy-59/NN||therapeutic-58/JJ	dobj||determine-9/VB||efficacy-59/NN	conj_and||relationship-10/NN||efficacy-59/NN	nn||collagen-63/NN||type-61/NN	nn||collagen-63/NN||ii-62/NN	prep_of||efficacy-59/NN||collagen-63/NN	appos||collagen-63/NN||collii-65/NNP	prep_in||determine-9/VB||combination-68/NN	prep_with||determine-9/VB||glucosamine-70/NN	prep_with||determine-9/VB||chondroitinsulfate-72/NN	conj_and||glucosamine-70/NN||chondroitinsulfate-72/NN	appos||glucosamine-70/NN||gc-74/NN	oa-54||chondroitinsulfate-72||yes||the purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary c-terminal cross-linking telopeptides of type ii collagen (uctx-ii), and bone degradation, urinary c-terminal cross-linking telopeptides of type i collagen (uctx-i), structural progression of osteoarthritis (oa) and potential therapeutic efficacy of type ii collagen (collii) in combination with glucosamine and chondroitinsulfate (gc).
advmod||shown-8/VBN||however-1/RB	amod||analyses-6/NNS||proteomic-3/JJ	conj_and||proteomic-3/JJ||transcriptomic-5/JJ	amod||analyses-6/NNS||transcriptomic-5/JJ	nsubj||shown-8/VBN||analyses-6/NNS	aux||shown-8/VBN||have-7/VBP	root||ROOT-0/null||shown-8/VBN	mark||upregulated-17/VBN||that-9/IN	det||number-11/NN||a-10/DT	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nsubjpass||upregulated-17/VBN||number-11/NN	nn||genes-14/NNS||usp-13/NN	prep_of||number-11/NN||genes-14/NNS	auxpass||upregulated-17/VBN||are-15/VBP	advmod||upregulated-17/VBN||significantly-16/RB	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	ccomp||shown-8/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	conj_and||upregulated-17/VBN||upregulated-17/VBN	amod||conditions-20/NNS||hypoxic-19/JJ	prep_under||upregulated-17/VBN||conditions-20/NNS	prep_in||upregulated-17/VBN||response-23/NN	prep_to||upregulated-17/VBN||nitricoxide-25/NN	prep_to||upregulated-17/VBN||carbonmonoxide-27/NN	conj_and||nitricoxide-25/NN||carbonmonoxide-27/NN	prep_during||upregulated-17/VBN||m.tuberculosisinfection-33/NN	amod||lines-37/NNS||macrophage-35/JJ	nn||lines-37/NNS||cell-36/NN	prep_of||m.tuberculosisinfection-33/NN||lines-37/NNS	nitricoxide-25||tuberculosisinfection--1||no_rel||however , proteomic and transcriptomic analyses have shown that a number of usp genes are significantly upregulated under hypoxic conditions and in response to nitricoxide and carbonmonoxide , as well as during m.tuberculosisinfection of macrophage cell lines .
amod||virus-2/NN||chronichepatitisc-1/JJ	nsubj||cause-11/NN||virus-2/NN	appos||virus-2/NN||hcv-4/NN	advmod||cause-11/NN||infection-6/RB	cop||cause-11/NN||is-7/VBZ	det||cause-11/NN||a-8/DT	amod||cause-11/NN||major-9/JJ	amod||cause-11/NN||worldwide-10/JJ	root||ROOT-0/null||cause-11/NN	prep_of||cause-11/NN||liverdisease-13/NN	prep_including||cause-11/NN||cirrhosis-16/NNS	nn||carcinoma-19/NN||hepatocellular-18/NN	prep_including||cause-11/NN||carcinoma-19/NN	conj_and||cirrhosis-16/NNS||carcinoma-19/NN	chronichepatitisc-1||hcv-4||no||chronichepatitisc virus (hcv) infection is a major worldwide cause of liverdisease, including cirrhosis and hepatocellular carcinoma.
det||article-4/NN||the-2/DT	amod||article-4/NN||following-3/JJ	prep_in||review-7/VBP||article-4/NN	nsubj||review-7/VBP||we-6/PRP	root||ROOT-0/null||review-7/VBP	det||presentation-10/NN||the-8/DT	amod||presentation-10/NN||clinical-9/JJ	dobj||review-7/VBP||presentation-10/NN	prep_of||presentation-10/NN||bipolardisorder-12/NN	poss||epidemiology-15/NN||its-14/PRP$	prep_of||presentation-10/NN||epidemiology-15/NN	conj_and||bipolardisorder-12/NN||epidemiology-15/NN	det||pharmacokinetics-19/NNS||the-18/DT	prep_of||presentation-10/NN||pharmacokinetics-19/NNS	conj_and||bipolardisorder-12/NN||pharmacokinetics-19/NNS	dobj||review-7/VBP||mechanism-21/NN	conj_and||presentation-10/NN||mechanism-21/NN	prep_of||mechanism-21/NN||action-23/NN	prep_for||action-23/NN||divalproex-25/NN	bipolardisorder-12||divalproex-25||yes||in the following article, we review the clinical presentation of bipolardisorder, its epidemiology, and the pharmacokinetics and mechanism of action for divalproex.
det||probability-3/NN||the-1/DT	amod||probability-3/NN||cumulative-2/JJ	nsubj||%-23/NN||probability-3/NN	prep_of||probability-3/NN||hivinfection-5/NN	nsubjpass||tested-15/VBN||hivinfection-5/NN	prep_among||hivinfection-5/NN||babies-7/NNS	amod||regimen-12/NN||single-9/JJ	nn||regimen-12/NN||dose-10/NN	nn||regimen-12/NN||nevirapine-11/NN	prep_on||babies-7/NNS||regimen-12/NN	auxpass||tested-15/VBN||were-14/VBD	rcmod||hivinfection-5/NN||tested-15/VBN	prepc_at||tested-15/VBN||>-17/VBG	dep||months-20/NNS||=-18/SYM	num||months-20/NNS||18-19/CD	ccomp||>-17/VBG||months-20/NNS	cop||%-23/NN||was-21/VBD	num||%-23/NN||15.0-22/CD	root||ROOT-0/null||%-23/NN	num||%-26/NN||95-25/CD	dep||%-23/NN||%-26/NN	vmod||%-26/NN||ci-27/VBN	num||.1-29/CD||9.8-22-28/CD	dobj||ci-27/VBN||.1-29/CD	prep_in||%-23/NN||2007-32/CD	mark||%-38/NN||whereas-34/IN	nsubj||%-38/NN||it-35/PRP	cop||%-38/NN||was-36/VBD	num||%-38/NN||8.2-37/CD	advcl||%-23/NN||%-38/NN	num||%-41/NN||95-40/CD	dep||%-38/NN||%-41/NN	vmod||%-41/NN||ci-42/VBN	num||.97-44/CD||5.55-11-43/CD	dobj||ci-42/VBN||.97-44/CD	prep_among||%-38/NN||babies-47/NNS	nsubjpass||tested-53/VBN||babies-47/NNS	amod||regimen-50/NN||zidovudine-49/JJ	prep_on||babies-47/NNS||regimen-50/NN	auxpass||tested-53/VBN||were-52/VBD	rcmod||babies-47/NNS||tested-53/VBN	prepc_at||tested-53/VBN||>-55/VBG	dep||days-58/NNS||=-56/SYM	num||days-58/NNS||45-57/CD	ccomp||>-55/VBG||days-58/NNS	prep_in||>-55/VBG||2009-60/CD	hivinfection-5||nevirapine-11||yes||the cumulative probability of hivinfection among babies on single dose nevirapine regimen who were tested at >=18 months was 15.0% (95% ci 9.8-22.1) in 2007, whereas it was 8.2% (95% ci 5.55-11.97) among babies on zidovudine regimen who were tested at >=45 days in 2009.
det||potential-7/NN||an-1/DT	advmod||high-3/JJ||unexpectedly-2/RB	amod||potential-7/NN||high-3/JJ	amod||potential-7/NN||seroprevalence-4/JJ	conj_and||seroprevalence-4/JJ||pathogenic-6/JJ	amod||potential-7/NN||pathogenic-6/JJ	nsubjpass||observed-16/VBN||potential-7/NN	amod||parvovirusb19-10/NNS||human-9/JJ	prep_of||potential-7/NN||parvovirusb19-10/NNS	appos||potential-7/NN||b19v-12/NNP	aux||observed-16/VBN||have-14/VBP	auxpass||observed-16/VBN||been-15/VBN	root||ROOT-0/null||observed-16/VBN	amod||countries-20/NNS||certain-18/JJ	amod||countries-20/NNS||malaria-endemic-19/JJ	prep_in||observed-16/VBN||countries-20/NNS	prep_in||countries-20/NNS||parallel-22/NN	amod||use-25/NN||local-24/JJ	prep_with||observed-16/VBN||use-25/NN	prep_of||use-25/NN||chloroquine-27/NN	appos||chloroquine-27/NN||cq-29/NN	amod||treatment-33/NN||first-line-32/JJ	prep_as||observed-16/VBN||treatment-33/NN	prep_for||treatment-33/NN||malaria-35/NN	malaria-35||chloroquine-27||yes||an unexpectedly high seroprevalence and pathogenic potential of human parvovirusb19 (b19v) have been observed in certain malaria-endemic countries in parallel with local use of chloroquine (cq) as first-line treatment for malaria.
poss||observations-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||observations-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||associated-14/VBN||that-4/IN	det||âˆ-7/NN||either-5/DT	amod||âˆ-7/NN||mcp-1-6/JJ	poss||variant-11/NN||âˆ-7/NN	num||variant-11/NN||2518-9/CD	nn||variant-11/NN||g-10/NN	nsubjpass||associated-14/VBN||variant-11/NN	aux||associated-14/VBN||can-12/MD	auxpass||associated-14/VBN||be-13/VB	ccomp||indicate-3/VBP||associated-14/VBN	det||findings-18/NNS||some-16/DT	amod||findings-18/NNS||clinical-17/JJ	prep_with||associated-14/VBN||findings-18/NNS	prep_in||findings-18/NNS||patients-20/NNS	prep_with||patients-20/NNS||sle-22/NN	mcp--1||sle-22||no_rel||our observations indicate that either mcp-1 âˆ’2518 g variant can be associated with some clinical findings in patients with sle.
nsubj||fungaldisease-5/NN||histoplasmosis-1/NNS	cop||fungaldisease-5/NN||is-2/VBZ	det||fungaldisease-5/NN||a-3/DT	amod||fungaldisease-5/NN||systemic-4/JJ	root||ROOT-0/null||fungaldisease-5/NN	advmod||known-8/VBN||also-7/RB	vmod||fungaldisease-5/NN||known-8/VBN	nn||sdisease-12/NN||darling-10/NN	prep_as||known-8/VBN||sdisease-12/NN	rcmod||fungaldisease-5/NN||caused-14/VBN	det||histoplasmacapsulatum-19/NN||the-16/DT	amod||histoplasmacapsulatum-19/NN||dimorphic-17/JJ	nn||histoplasmacapsulatum-19/NN||fungus-18/NN	prep_by||caused-14/VBN||histoplasmacapsulatum-19/NN	histoplasmosis-1||histoplasmacapsulatum-19||no||histoplasmosis is a systemic fungaldisease, also known as darling'sdisease, caused by the dimorphic fungus histoplasmacapsulatum .
nsubj||suggests-2/VBZ||evidence-1/NN	root||ROOT-0/null||suggests-2/VBZ	mark||characterized-9/VBN||that-3/IN	det||epidemic-7/NN||the-4/DT	nn||epidemic-7/NN||mozambican-5/NN	nn||epidemic-7/NN||hiv-6/NN	nsubjpass||characterized-9/VBN||epidemic-7/NN	nsubj||hiv-41/VB||epidemic-7/NN	auxpass||characterized-9/VBN||is-8/VBZ	ccomp||suggests-2/VBZ||characterized-9/VBN	det||preponderance-12/NN||a-11/DT	agent||characterized-9/VBN||preponderance-12/NN	amod||infections-15/NNS||heterosexual-14/JJ	prep_of||preponderance-12/NN||infections-15/NNS	det||world-19/NN||the-18/DT	poss||shortages-25/NNS||world-19/NN	advmod||severe-22/JJ||most-21/RBS	amod||shortages-25/NNS||severe-22/JJ	nn||shortages-25/NNS||health-23/NN	nn||shortages-25/NNS||worker-24/NN	prep_among||preponderance-12/NN||shortages-25/NNS	advmod||poor-28/JJ||relatively-27/RB	amod||knowledge-29/NN||poor-28/JJ	prep_among||preponderance-12/NN||knowledge-29/NN	conj_and||shortages-25/NNS||knowledge-29/NN	prep_of||knowledge-29/NN||hiv/aids-31/NNS	det||population-35/NN||the-33/DT	amod||population-35/NN||general-34/JJ	prep_in||hiv/aids-31/NNS||population-35/NN	amod||access-39/NN||lagging-38/VBG	prep_among||preponderance-12/NN||access-39/NN	conj_and||shortages-25/NNS||access-39/NN	aux||hiv-41/VB||to-40/TO	xcomp||characterized-9/VBN||hiv-41/VB	amod||services-45/NNS||preventive-42/JJ	conj_and||preventive-42/JJ||therapeutic-44/JJ	amod||services-45/NNS||therapeutic-44/JJ	dobj||hiv-41/VB||services-45/NNS	prepc_compared_to||hiv-41/VB||to-47/TO	nn||nations-49/NNS||counterpart-48/NN	pobj||hiv-41/VB||nations-49/NNS	amod||africa-52/NN||southern-51/JJ	prep_in||nations-49/NNS||africa-52/NN	aids--1||hiv-41||no||evidence suggests that the mozambican hiv epidemic is characterized by a preponderance of heterosexual infections, among the world's most severe health worker shortages, relatively poor knowledge of hiv/aids in the general population, and lagging access to hiv preventive and therapeutic services compared to counterpart nations in southern africa.
det||role-2/NN||the-1/DT	nsubjpass||investigated-13/VBN||role-2/NN	prep_of||role-2/NN||sibutramine-4/NN	prep_in||sibutramine-4/NN||osa-6/NN	det||patients-10/NNS||the-8/DT	amod||patients-10/NNS||obese-9/JJ	prep_in||osa-6/NN||patients-10/NNS	aux||investigated-13/VBN||has-11/VBZ	auxpass||investigated-13/VBN||been-12/VBN	ccomp||are-18/VBP||investigated-13/VBN	advmod||investigated-13/VBN||however-15/RB	expl||are-18/VBP||there-17/EX	root||ROOT-0/null||are-18/VBP	nsubj||are-18/VBP||concerns-19/NNS	amod||risk-23/NN||associated-21/JJ	amod||risk-23/NN||cardiovascular-22/JJ	prep_regarding||concerns-19/NNS||risk-23/NN	obese-9||sibutramine-4||yes||the role of sibutramine in osa in the obese patients has been investigated, however, there are concerns regarding associated cardiovascular risk.
det||patients-3/NNS||the-1/DT	amod||patients-3/NNS||asthmatic-2/JJ	nsubjpass||considered-18/VBN||patients-3/NNS	nsubj||have-20/VB||patients-3/NNS	det||igg-7/NN||a-5/DT	amod||igg-7/NN||positive-6/JJ	prep_with||patients-3/NNS||igg-7/NN	prep_for||igg-7/NN||mycoplasma-9/NN	amod||pcr-12/NN||negative-11/JJ	prep_for||igg-7/NN||pcr-12/NN	conj_and||mycoplasma-9/NN||pcr-12/NN	amod||antibody-16/NN||negative-14/JJ	nn||antibody-16/NN||igm-15/NN	conj_and||mycoplasma-9/NN||antibody-16/NN	conj_and||pcr-12/NN||antibody-16/NN	auxpass||considered-18/VBN||were-17/VBD	root||ROOT-0/null||considered-18/VBN	aux||have-20/VB||to-19/TO	xcomp||considered-18/VBN||have-20/VB	amod||history-22/NN||remote-21/JJ	dobj||have-20/VB||history-22/NN	prep_of||history-22/NN||mycoplasmainfection-24/NN	mycoplasmainfection-24||mycoplasma-9||no||the asthmatic patients with a positive igg for mycoplasma and negative pcr and negative igm antibody were considered to have remote history of mycoplasmainfection.
det||pandemic-5/NN||a-2/DT	amod||pandemic-5/NN||manifest-3/JJ	nn||pandemic-5/NN||influenza-4/NN	prep_during||is-10/VBZ||pandemic-5/NN	advmod||is-10/VBZ||however-7/RB	expl||is-10/VBZ||there-9/EX	root||ROOT-0/null||is-10/VBZ	acomp||is-10/VBZ||large-scale-11/JJ	xcomp||is-10/VBZ||spreading-12/VBG	det||influenzavirus-15/NNS||the-14/DT	prep_of||spreading-12/VBG||influenzavirus-15/NNS	influenza-4||influenzavirus-15||no||during a manifest influenza pandemic, however, there is large-scale spreading of the influenzavirus.
amod||determinants-2/NNS||relevant-1/JJ	nsubjpass||discussed-12/VBN||determinants-2/NNS	det||spread-6/NN||the-4/DT	amod||spread-6/NN||future-5/JJ	prep_of||determinants-2/NNS||spread-6/NN	prep_of||spread-6/NN||hiv-8/NN	prep_among||hiv-8/NN||ivdu-10/NN	auxpass||discussed-12/VBN||are-11/VBP	root||ROOT-0/null||discussed-12/VBN	det||factors-18/NNS||the-15/DT	amod||factors-18/NNS||major-16/JJ	nn||factors-18/NNS||risk-17/NN	prep_including||discussed-12/VBN||factors-18/NNS	prep_for||factors-18/NNS||hivseropositivity-20/NN	det||modes-23/NNS||the-22/DT	prep_including||discussed-12/VBN||modes-23/NNS	conj_and||factors-18/NNS||modes-23/NNS	nn||transmission-26/NN||hiv-25/NN	prep_of||modes-23/NNS||transmission-26/NN	prep_including||discussed-12/VBN||aspects-29/NNS	conj_and||factors-18/NNS||aspects-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||aspects-29/NNS||history-33/NN	prep_of||history-33/NN||hivinfection-35/NN	prep_in||hivinfection-35/NN||ivdu-37/NN	hivseropositivity-20||hiv-25||no||relevant determinants of the future spread of hiv among ivdu are discussed, including the major risk factors for hivseropositivity, the modes of hiv transmission, and aspects of the natural history of hivinfection in ivdu.
nsubj||thromboembolism-10/VBP||objective-1/NN	aux||examine-3/VB||to-2/TO	vmod||objective-1/NN||examine-3/VB	det||risk-5/NN||the-4/DT	dobj||examine-3/VB||risk-5/NN	amod||venous-9/NNS||non-fatal-7/JJ	amod||venous-9/NNS||idiopathic-8/JJ	prep_of||risk-5/NN||venous-9/NNS	root||ROOT-0/null||thromboembolism-10/VBP	amod||users-13/NNS||current-12/JJ	prep_in||thromboembolism-10/VBP||users-13/NNS	det||oralcontraceptive-17/NN||a-15/DT	amod||oralcontraceptive-17/NN||combined-16/VBN	prep_of||users-13/NNS||oralcontraceptive-17/NN	vmod||oralcontraceptive-17/NN||containing-18/VBG	dobj||containing-18/VBG||drospirenone-19/NN	advmod||containing-27/VBG||relative-21/JJ	amod||users-24/NNS||current-23/JJ	prep_to||relative-21/JJ||users-24/NNS	prep_of||users-24/NNS||preparations-26/NNS	vmod||containing-18/VBG||containing-27/VBG	dobj||containing-27/VBG||levonorgestrel-28/NN	thromboembolism-10||levonorgestrel-28||no||objective to examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oralcontraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel.
prep_by||was-5/VBD||comparison-2/NN	expl||was-5/VBD||there-4/EX	root||ROOT-0/null||was-5/VBD	number||%-7/NN||65-6/CD	amod||staining-9/NN||%-7/NN	amod||staining-9/NN||positive-8/JJ	nsubj||was-5/VBD||staining-9/NN	nn||receptor-12/NN||estrogen-11/NN	prep_for||staining-9/NN||receptor-12/NN	num||%-15/NN||61-14/CD	nsubj||was-5/VBD||%-15/NN	conj_and||staining-9/NN||%-15/NN	amod||receptor-18/NN||progesterone-17/JJ	prep_for||%-15/NN||receptor-18/NN	num||%-21/NN||67-20/CD	nsubj||was-5/VBD||%-21/NN	conj_and||staining-9/NN||%-21/NN	amod||p53-24/NN||nuclear-23/JJ	prep_for||%-21/NN||p53-24/NN	num||%-28/NN||39-27/CD	nsubj||was-5/VBD||%-28/NN	conj_and||staining-9/NN||%-28/NN	amod||sections-36/NNS||c-erb-b2-30/JJ	det||breast-34/NN||the-32/DT	amod||breast-34/NN||invasive-33/JJ	prep_with||c-erb-b2-30/JJ||breast-34/NN	nn||sections-36/NNS||cancer-35/NN	prep_for||%-28/NN||sections-36/NNS	cancer-35||estrogen-11||no_rel||by comparison, there was 65% positive staining for estrogen receptor, 61% for progesterone receptor, 67% for nuclear p53, and 39% for c-erb-b2 with the invasive breast cancer sections.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||aimed-4/VBD||study-3/NN	nsubj||know-6/VB||study-3/NN	root||ROOT-0/null||aimed-4/VBD	aux||know-6/VB||to-5/TO	xcomp||aimed-4/VBD||know-6/VB	det||seroprevalence-8/NN||the-7/DT	dobj||know-6/VB||seroprevalence-8/NN	prep_of||seroprevalence-8/NN||hepatitisbvirus-10/NNS	appos||hepatitisbvirus-10/NNS||hbv-12/NN	amod||virus-16/NN||hepatitisc-15/JJ	prep_of||seroprevalence-8/NN||virus-16/NN	conj_and||hepatitisbvirus-10/NNS||virus-16/NN	appos||hepatitisbvirus-10/NNS||hcv-18/NN	nn||donors-22/NNS||blood-21/NN	prep_among||know-6/VB||donors-22/NNS	amod||services-27/NNS||regional-24/JJ	nn||services-27/NNS||blood-25/NN	nn||services-27/NNS||transfusion-26/NN	prep_in||know-6/VB||services-27/NNS	prep_of||services-27/NNS||nepal-29/NN	hbv-12||hepatitisbvirus-10||no||the present study aimed to know the seroprevalence of hepatitisbvirus (hbv) and hepatitisc virus (hcv) among blood donors in regional blood transfusion services of nepal.
amod||glatirameracetate-2/NN||daily-1/JJ	nsubj||treatment-14/NN||glatirameracetate-2/NN	dep||treatment-14/NN||ga-4/NN	amod||ml-10/NN||20â-6/JJ	nn||ml-10/NN||mg/1-7/NN	num||ml-10/NN||.0-8/CD	nn||ml-10/NN||â-9/NN	nsubj||treatment-14/NN||ml-10/NN	cop||treatment-14/NN||is-11/VBZ	det||treatment-14/NN||a-12/DT	amod||treatment-14/NN||first-line-13/JJ	root||ROOT-0/null||treatment-14/NN	prep_for||treatment-14/NN||relapsing-remittingmultiplesclerosis-16/NNS	appos||relapsing-remittingmultiplesclerosis-16/NNS||rrms-18/NNS	relapsing-remittingmultiplesclerosis-16||glatirameracetate-2||yes||daily glatirameracetate (ga) 20â mg/1.0â ml is a first-line treatment for relapsing-remittingmultiplesclerosis (rrms).
advmod||obtained-11/VBN||furthermore-1/RB	det||reduction-6/NN||a-3/DT	number||%-5/NN||50-4/CD	amod||reduction-6/NN||%-5/NN	nsubjpass||obtained-11/VBN||reduction-6/NN	amod||complications-9/NNS||bleeding-8/VBG	prep_in||reduction-6/NN||complications-9/NNS	auxpass||obtained-11/VBN||was-10/VBD	root||ROOT-0/null||obtained-11/VBN	amod||enoxaparin-15/NN||fondaparinux-13/JJ	nn||enoxaparin-15/NN||vs-14/NN	prep_with||obtained-11/VBN||enoxaparin-15/NN	xcomp||obtained-11/VBN||leading-17/VBG	det||reduction-21/NN||a-19/DT	nn||reduction-21/NN||risk-20/NN	prep_to||leading-17/VBG||reduction-21/NN	prep_for||reduction-21/NN||death-23/NN	enoxaparin-15||bleeding-8||no_rel||furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs enoxaparin, leading to a risk reduction for death.
det||setting-2/NN||the-1/DT	nsubj||allow-6/VB||setting-2/NN	nsubj||propose-4/VBP||we-3/PRP	rcmod||setting-2/NN||propose-4/VBP	aux||allow-6/VB||would-5/MD	root||ROOT-0/null||allow-6/VB	dobj||allow-6/VB||translation-7/NN	det||knowledge-11/NN||the-9/DT	amod||knowledge-11/NN||molecular-10/JJ	prep_of||translation-7/NN||knowledge-11/NN	det||pathways-15/NNS||the-13/DT	amod||pathways-15/NNS||metastatic-14/JJ	prep_of||knowledge-11/NN||pathways-15/NNS	vmod||pathways-15/NNS||mediated-16/VBN	agent||mediated-16/VBN||platelets-18/NNS	det||selectinsâ-21/NN||the-20/DT	agent||mediated-16/VBN||selectinsâ-21/NN	conj_and||platelets-18/NNS||selectinsâ-21/NN	xcomp||mediated-16/VBN||$-22/VBG	det||targets-26/NNS||all-24/DT	amod||targets-26/NNS||potential-25/JJ	dobj||$-22/VBG||targets-26/NNS	nn||$-29/NNP||heparinâ-28/NNP	prep_of||targets-26/NNS||$-29/NNP	det||endpoint-42/NN||a-32/DT	amod||endpoint-42/NN||â-33/JJ	amod||endpoint-42/NN||$-34/$	dep||$-34/$||œtime-35/JJ	nn||$-38/NNP||appearanceâ-37/NNP	prep_to||$-34/$||$-38/NNP	nn||metastases-41/NNS||brain-40/NN	prep_of||$-38/NNP||metastases-41/NNS	prep_in||$-22/VBG||endpoint-42/NN	heparin--1||metastases-41||no_rel||the setting we propose would allow translation of the molecular knowledge of the metastatic pathways mediated by platelets and the selectinsâ€”all potential targets of heparinâ€”in a â€œtime to appearanceâ€? of brain metastases endpoint.
nn||resistance-2/NN||drug-1/NN	nsubjpass||investigated-21/VBN||resistance-2/NN	nsubj||isolates-8/VBZ||levels-3/NNS	conj_and||levels-3/NNS||patterns-5/NNS	nsubj||isolates-8/VBZ||patterns-5/NNS	prep_among||levels-3/NNS||mycobacteriumtuberculosis-7/NNS	rcmod||resistance-2/NN||isolates-8/VBZ	advmod||diagnosed-11/JJ||newly-10/RB	amod||patients-16/NNS||diagnosed-11/JJ	advmod||treated-14/JJ||previously-13/RB	conj_and||diagnosed-11/JJ||treated-14/JJ	amod||patients-16/NNS||treated-14/JJ	amod||patients-16/NNS||tuberculosis-15/JJ	prep_from||isolates-8/VBZ||patients-16/NNS	nn||uganda-19/NN||mbarara-18/NN	prep_in||patients-16/NNS||uganda-19/NN	auxpass||investigated-21/VBN||were-20/VBD	root||ROOT-0/null||investigated-21/VBN	tuberculosis-15||mycobacteriumtuberculosis-7||no||drug resistance levels and patterns among mycobacteriumtuberculosis isolates from newly diagnosed and previously treated tuberculosis patients in mbarara uganda were investigated.
nsubj||continues-4/VBZ||background-1/NN	nsubj||commit-6/VB||background-1/NN	prep_as||background-1/NN||china-3/NN	ccomp||become-23/VBN||continues-4/VBZ	aux||commit-6/VB||to-5/TO	xcomp||continues-4/VBZ||commit-6/VB	amod||access-9/NN||universal-8/JJ	prep_to||commit-6/VB||access-9/NN	amod||services-17/NNS||hiv/aids-11/JJ	nn||services-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||services-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||services-17/NNS||care-16/NN	prep_to||commit-6/VB||services-17/NNS	poss||policies-21/NNS||its-19/PRP$	amod||policies-21/NNS||hiv/aids-20/JJ	nsubj||become-23/VBN||policies-21/NNS	aux||become-23/VBN||have-22/VBP	root||ROOT-0/null||become-23/VBN	advmod||information-25/NN||increasingly-24/RB	xcomp||become-23/VBN||information-25/NN	vmod||information-25/NN||driven-26/VBN	aids--1||hiv--1||no||background as china continues to commit to universal access to hiv/aids prevention, treatment and care services, its hiv/aids policies have become increasingly information driven.
vmod||target-24/NN||considering-1/VBG	mark||conferred-4/VBD||that-2/IN	nsubj||conferred-4/VBD||hpebp4-3/NNS	nsubjpass||expressed-13/VBN||hpebp4-3/NNS	ccomp||considering-1/VBG||conferred-4/VBD	amod||resistance-6/NN||cellular-5/JJ	dobj||conferred-4/VBD||resistance-6/NN	amod||treatment-9/NN||rituximab-8/JJ	prep_to||conferred-4/VBD||treatment-9/NN	auxpass||expressed-13/VBN||was-11/VBD	advmod||expressed-13/VBN||preferentially-12/RB	ccomp||considering-1/VBG||expressed-13/VBN	conj_and||conferred-4/VBD||expressed-13/VBN	nn||tissue-16/NN||lymphoma-15/NN	prep_in||expressed-13/VBN||tissue-16/NN	nsubj||target-24/NN||it-18/PRP	aux||target-24/NN||could-19/MD	cop||target-24/NN||be-20/VB	det||target-24/NN||a-21/DT	amod||target-24/NN||potential-22/JJ	amod||target-24/NN||valuable-23/JJ	root||ROOT-0/null||target-24/NN	amod||therapy-27/NN||adjuvant-26/JJ	prep_for||target-24/NN||therapy-27/NN	prep_for||therapy-27/NN||b-celllymphoma-29/NN	b-celllymphoma-29||rituximab-8||yes||considering that hpebp4 conferred cellular resistance to rituximab treatment and was preferentially expressed in lymphoma tissue, it could be a potential valuable target for adjuvant therapy for b-celllymphoma.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||inh-27||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
root||ROOT-0/null||in-1/IN	pobj||in-1/IN||patients-2/NNS	vmod||patients-2/NNS||submitted-3/VBN	amod||resection-6/NN||ileal-5/JJ	prep_to||submitted-3/VBN||resection-6/NN	prep_for||resection-6/NN||crohn-8/NN	amod||non-invasive-11/JJ||sdisease-10/JJ	amod||crohn-8/NN||non-invasive-11/JJ	amod||ultrasonography-15/NN||small-12/JJ	nn||ultrasonography-15/NN||intestine-13/NN	nn||ultrasonography-15/NN||contrast-14/NN	dobj||submitted-3/VBN||ultrasonography-15/NN	num||ultrasonography-15/NN||1-16/CD	agent||submitted-3/VBN||assessing-19/VBG	nsubj||detects-25/VBZ||thickness-20/NN	nsubj||assessing-38/VBG||thickness-20/NN	amod||anastomosis-23/NNS||ileo-colonic-22/JJ	prep_of||thickness-20/NN||anastomosis-23/NNS	advmod||detects-25/VBZ||accurately-24/RB	advcl||assessing-19/VBG||detects-25/VBZ	amod||recurrence-32/NN||initial-26/JJ	amod||recurrence-32/NN||minimal-28/JJ	nn||recurrence-32/NN||crohn-29/NN	amod||recurrence-32/NN||sdisease-31/JJ	dobj||detects-25/VBZ||recurrence-32/NN	dep||assessing-38/VBG||2-35/LS	mark||assessing-38/VBG||by-37/IN	advcl||assessing-19/VBG||assessing-38/VBG	conj_and||detects-25/VBZ||assessing-38/VBG	det||thickness-40/NN||both-39/DT	dobj||assessing-38/VBG||thickness-40/NN	amod||anastomosis-43/NNS||ileo-colonic-42/JJ	prep_of||thickness-40/NN||anastomosis-43/NNS	dobj||assessing-38/VBG||extension-45/NN	conj_and||thickness-40/NN||extension-45/NN	amod||lesions-48/NNS||intramural-47/JJ	prep_of||extension-45/NN||lesions-48/NNS	amod||grades-52/NNS||neo-terminal-50/JJ	nn||grades-52/NNS||ileum-51/NN	prep_of||lesions-48/NNS||grades-52/NNS	det||severity-54/NN||the-53/DT	dep||assessing-38/VBG||severity-54/NN	det||recurrence-58/NN||the-56/DT	amod||recurrence-58/NN||post-surgical-57/JJ	prep_of||severity-54/NN||recurrence-58/NN	crohn'sdisease--1||contrast-14||no_rel||in patients submitted to ileal resection for crohn'sdisease non-invasive small intestine contrast ultrasonography 1) by assessing thickness of ileo-colonic anastomosis accurately detects initial, minimal crohn'sdisease recurrence, and 2) by assessing both thickness of ileo-colonic anastomosis and extension of intramural lesions of neo-terminal ileum grades the severity of the post-surgical recurrence.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	det||meta-analysis-5/NNS||this-4/DT	prep_of||purpose-2/NN||meta-analysis-5/NNS	root||ROOT-0/null||is-6/VBZ	aux||compare-8/VB||to-7/TO	xcomp||is-6/VBZ||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	amod||terbinafine-13/NN||continuous-12/JJ	prep_of||efficacy-10/NN||terbinafine-13/NN	amod||itraconazole-16/NN||intermittent-15/JJ	prep_with||compare-8/VB||itraconazole-16/NN	det||treatment-19/NN||the-18/DT	prep_in||compare-8/VB||treatment-19/NN	amod||onychomycosis-22/NNS||toenail-21/JJ	prep_of||treatment-19/NN||onychomycosis-22/NNS	onychomycosis-22||terbinafine-13||yes||the purpose of this meta-analysis is to compare the efficacy of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis.
det||study-3/NN||this-2/DT	prep_in||investigated-5/VBD||study-3/NN	nsubj||investigated-5/VBD||we-4/PRP	root||ROOT-0/null||investigated-5/VBD	det||properties-8/NNS||the-6/DT	amod||properties-8/NNS||antimicrobial-7/JJ	dobj||investigated-5/VBD||properties-8/NNS	det||essentialoil-11/NN||the-10/DT	prep_of||properties-8/NNS||essentialoil-11/NN	amod||communis-14/NNS||myrtus-13/JJ	prep_of||essentialoil-11/NN||communis-14/NNS	amod||strains-17/NNS||clinical-16/JJ	prep_against||investigated-5/VBD||strains-17/NNS	prep_of||strains-17/NNS||m.tuberculosis-19/NNS	nn||paratuberculosis-22/NNS||m.-21/NN	prep_of||strains-17/NNS||paratuberculosis-22/NNS	conj_and||m.tuberculosis-19/NNS||paratuberculosis-22/NNS	essentialoil-11||paratuberculosis-22||no_rel||in this study we investigated the antimicrobial properties of the essentialoil of myrtus communis against clinical strains of m.tuberculosis and m. paratuberculosis .
nsubj||share-5/VBP||cr-1/NN	amod||exercise-4/NN||endurance-3/JJ	conj_and||cr-1/NN||exercise-4/NN	nsubj||share-5/VBP||exercise-4/NN	root||ROOT-0/null||share-5/VBP	det||function-9/NN||a-6/DT	amod||function-9/NN||potent-7/JJ	amod||function-9/NN||anti-inflammatory-8/JJ	dobj||share-5/VBP||function-9/NN	amod||tissues-12/NNS||adipose-11/JJ	prep_in||function-9/NN||tissues-12/NNS	prepc_in||share-5/VBP||ameliorating-14/VBG	amod||obesity-16/NN||diet-induced-15/JJ	dobj||ameliorating-14/VBG||obesity-16/NN	dobj||ameliorating-14/VBG||insulinresistance-18/NN	conj_and||obesity-16/NN||insulinresistance-18/NN	cr-1||obesity-16||no_rel||cr and endurance exercise share a potent anti-inflammatory function in adipose tissues in ameliorating diet-induced obesity and insulinresistance.
det||cyld-4/NN||the-1/DT	nn||cyld-4/NN||tumor-2/NN	nn||cyld-4/NN||suppressor-3/NN	nsubj||enzyme-8/NN||cyld-4/NN	cop||enzyme-8/NN||is-5/VBZ	det||enzyme-8/NN||a-6/DT	amod||enzyme-8/NN||deubiquitinating-7/VBG	root||ROOT-0/null||enzyme-8/NN	nsubj||inhibits-10/VBZ||enzyme-8/NN	rcmod||enzyme-8/NN||inhibits-10/VBZ	dobj||inhibits-10/VBZ||activation-11/NN	nsubj||has-20/VBZ||activation-11/NN	det||îº-16/NN||the-13/DT	nn||îº-16/NN||nf-14/NN	prep_of||activation-11/NN||îº-16/NN	dep||activation-11/NN||b-17/SYM	rcmod||activation-11/NN||has-20/VBZ	amod||roles-22/NNS||key-21/JJ	dobj||has-20/VBZ||roles-22/NNS	prep_in||roles-22/NNS||inflammation-24/NN	prep_in||roles-22/NNS||apoptosis-26/NNS	conj_and||inflammation-24/NN||apoptosis-26/NNS	tumor-2||enzyme-8||no_rel||the tumor suppressor cyld is a deubiquitinating enzyme that inhibits activation of the nf- îº b, which has key roles in inflammation and apoptosis.
advmod||are-4/VBP||however-1/RB	expl||are-4/VBP||there-3/EX	root||ROOT-0/null||are-4/VBP	amod||reports-6/NNS||few-5/JJ	nsubj||are-4/VBP||reports-6/NNS	det||impact-9/NN||the-8/DT	prep_of||reports-6/NNS||impact-9/NN	prep_of||impact-9/NN||non-adherence-11/NN	aux||haart-13/VB||to-12/TO	vmod||reports-6/NNS||haart-13/VB	prep_on||haart-13/VB||mortality-15/NN	nn||hiv/aids-18/NNS||community-17/NN	prep_from||mortality-15/NN||hiv/aids-18/NNS	nn||programmes-22/NNS||treatment-19/NN	conj_and||treatment-19/NN||care-21/NN	nn||programmes-22/NNS||care-21/NN	dobj||haart-13/VB||programmes-22/NNS	amod||countries-25/NNS||developing-24/VBG	prep_in||programmes-22/NNS||countries-25/NNS	aids--1||hiv--1||no||however, there are few reports of the impact of non-adherence to haart on mortality from community hiv/aids treatment and care programmes in developing countries.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||case-6/NN||a-5/DT	dobj||report-4/VBP||case-6/NN	prep_of||case-6/NN||5-8/CD	nn||â-11/NN||fu-10/NN	dep||case-6/NN||â-11/NN	dep||â-11/NN||$-12/$	advmod||encephalopathy-15/JJ||induced-14/RB	amod||manifesting-17/NNS||encephalopathy-15/JJ	npadvmod||as-18/RB||manifesting-17/NNS	dep||seizures-19/CD||as-18/RB	num||$-12/$||seizures-19/CD	dobj||report-4/VBP||delirium-21/NN	conj_and||case-6/NN||delirium-21/NN	det||era-25/NN||an-24/DT	prep_in||delirium-21/NN||era-25/NN	amod||chemotherapy-28/NN||oxaliplatin-containing-27/JJ	prep_of||era-25/NN||chemotherapy-28/NN	delirium-21||fu-10||no_rel||here, we report a case of 5- fu â€“induced encephalopathy, manifesting as seizures and delirium, in an era of oxaliplatin-containing chemotherapy.
nsubjpass||shown-20/VBN||mycophenolatemofetil-1/NN	nsubj||cause-22/VB||mycophenolatemofetil-1/NN	nn||®-4/NNP||cellceptâ-3/NNP	appos||mycophenolatemofetil-1/NN||®-4/NNP	det||drug-11/NN||a-7/DT	advmod||used-9/VBN||commonly-8/RB	amod||drug-11/NN||used-9/VBN	amod||drug-11/NN||immunosuppressive-10/JJ	appos||mycophenolatemofetil-1/NN||drug-11/NN	amod||transplantation-15/NN||solid-13/JJ	nn||transplantation-15/NN||organ-14/NN	prep_in||drug-11/NN||transplantation-15/NN	aux||shown-20/VBN||has-17/VBZ	advmod||shown-20/VBN||recently-18/RB	auxpass||shown-20/VBN||been-19/VBN	root||ROOT-0/null||shown-20/VBN	aux||cause-22/VB||to-21/TO	xcomp||shown-20/VBN||cause-22/VB	dobj||cause-22/VB||graft-versus-hostdisease-23/NN	dep||graft-versus-hostdisease-23/NN||gvhd-25/VBN	prep_like||cause-22/VB||changes-29/NNS	det||tract-33/NN||the-31/DT	amod||tract-33/NN||gastrointestinal-32/JJ	prep_in||changes-29/NNS||tract-33/NN	graft-versus-hostdisease-23||mycophenolatemofetil-1||yes||mycophenolatemofetil (cellceptâ®), a commonly used immunosuppressive drug in solid organ transplantation, has recently been shown to cause graft-versus-hostdisease (gvhd)-like changes in the gastrointestinal tract.
amod||controversy-2/NN||much-1/JJ	nsubj||exists-3/VBZ||controversy-2/NN	root||ROOT-0/null||exists-3/VBZ	xcomp||exists-3/VBZ||concerning-4/VBG	det||efficacy-6/NN||the-5/DT	nsubj||due-21/JJ||efficacy-6/NN	amod||cardioverter-defibrillators-11/NNS||primary-8/JJ	amod||cardioverter-defibrillators-11/NNS||prophylactic-9/JJ	nn||cardioverter-defibrillators-11/NNS||implantable-10/NN	prep_of||efficacy-6/NN||cardioverter-defibrillators-11/NNS	appos||cardioverter-defibrillators-11/NNS||icds-13/NNS	prep_in||cardioverter-defibrillators-11/NNS||patients-16/NNS	amod||fraction-20/NN||low-18/JJ	nn||fraction-20/NN||ejection-19/NN	prep_with||patients-16/NNS||fraction-20/NN	xcomp||concerning-4/VBG||due-21/JJ	prep_to||due-21/JJ||coronaryarterydisease-23/NN	appos||coronaryarterydisease-23/NN||cad-25/NN	prep_to||due-21/JJ||dilatedcardiomyopathy-28/NN	conj_or||coronaryarterydisease-23/NN||dilatedcardiomyopathy-28/NN	appos||coronaryarterydisease-23/NN||dcm-30/NN	dcm-30||dilatedcardiomyopathy-28||no_rel||much controversy exists concerning the efficacy of primary prophylactic implantable cardioverter-defibrillators (icds) in patients with low ejection fraction due to coronaryarterydisease (cad) or dilatedcardiomyopathy (dcm).
det||change-3/NN||the-1/DT	amod||change-3/NN||recent-2/JJ	nsubjpass||accompanied-20/VBN||change-3/NN	nn||policy-6/NN||treatment-5/NN	prep_of||change-3/NN||policy-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||policy-6/NN||malaria-9/NN	prep_from||malaria-9/NN||sulfadoxine-pyrime-thamine-11/NN	prep_to||sulfadoxine-pyrime-thamine-11/NN||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	prep_in||artemether-lumefantrine-13/NN||kenya-18/NN	auxpass||accompanied-20/VBN||was-19/VBD	root||ROOT-0/null||accompanied-20/VBN	amod||recommendations-25/NNS||revised-22/VBN	nn||recommendations-25/NNS||malaria-23/NN	nn||recommendations-25/NNS||diagnosis-24/NN	nsubj||promoting-26/VBG||recommendations-25/NNS	agent||accompanied-20/VBN||promoting-26/VBG	amod||treatment-29/NN||presumptive-27/JJ	amod||treatment-29/NN||antimalarial-28/JJ	dobj||promoting-26/VBG||treatment-29/NN	amod||children-32/NNS||young-31/JJ	prep_in||treatment-29/NN||children-32/NNS	amod||diagnosis-35/NN||parasitological-34/JJ	dobj||promoting-26/VBG||diagnosis-35/NN	conj_and||treatment-29/NN||diagnosis-35/NN	prep_in||diagnosis-35/NN||patients-37/NNS	num||years-39/NNS||5-38/CD	dep||promoting-26/VBG||years-39/NNS	dep||promoting-26/VBG||older-41/JJR	conj_and||years-39/NNS||older-41/JJR	malaria-23||artemether--1||yes||the recent change of treatment policy for uncomplicated malaria from sulfadoxine-pyrime-thamine to artemether-lumefantrine (al) in kenya was accompanied by revised malaria diagnosis recommendations promoting presumptive antimalarial treatment in young children and parasitological diagnosis in patients 5 years and older.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	zinc--1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
det||case-2/NN||the-1/DT	nsubj||describes-5/VBZ||case-2/NN	vmod||case-2/NN||presented-3/VBN	advmod||presented-3/VBN||here-4/RB	root||ROOT-0/null||describes-5/VBZ	det||effectiveness-7/NN||the-6/DT	dobj||describes-5/VBZ||effectiveness-7/NN	prep_of||effectiveness-7/NN||clozapine-9/NN	det||patient-14/NN||a-11/DT	amod||patient-14/NN||young-12/JJ	amod||patient-14/NN||female-13/JJ	prep_in||describes-5/VBZ||patient-14/NN	amod||bpd-17/NN||severe-16/JJ	prep_with||patient-14/NN||bpd-17/NN	nsubj||had-25/VBD||bpd-17/NN	nsubjpass||treated-35/VBN||bpd-17/NN	amod||features-21/NNS||psychotic-20/JJ	prep_without||bpd-17/NN||features-21/NNS	rcmod||bpd-17/NN||had-25/VBD	nn||periods-29/NNS||repeated-26/VBN	conj_and||repeated-26/VBN||prolonged-28/VBN	nn||periods-29/NNS||prolonged-28/VBN	dobj||had-25/VBD||periods-29/NNS	prep_of||periods-29/NNS||hospitalization-31/NN	auxpass||treated-35/VBN||was-33/VBD	advmod||treated-35/VBN||successfully-34/RB	rcmod||bpd-17/NN||treated-35/VBN	conj_and||had-25/VBD||treated-35/VBN	det||dose-39/NN||a-37/DT	amod||dose-39/NN||moderate-38/JJ	prep_with||treated-35/VBN||dose-39/NN	prep_of||dose-39/NN||clozapine-41/NN	det||failure-45/NN||a-44/DT	prep_following||describes-5/VBZ||failure-45/NN	aux||improve-47/VB||to-46/TO	vmod||failure-45/NN||improve-47/VB	amod||medications-51/NNS||other-49/JJ	amod||medications-51/NNS||psychotropic-50/JJ	prep_with||improve-47/VB||medications-51/NNS	psychotic-20||clozapine-41||yes||the case presented here describes the effectiveness of clozapine in a young female patient with severe bpd (without psychotic features), who had repeated and prolonged periods of hospitalization and was successfully treated with a moderate dose of clozapine, following a failure to improve with other psychotropic medications.
amod||vaccines-3/NNS||modified-1/VBN	amod||vaccines-3/NNS||live-2/JJ	nsubjpass||developed-6/VBN||vaccines-3/NNS	nsubj||decrease-8/VB||vaccines-3/NNS	aux||developed-6/VBN||have-4/VBP	auxpass||developed-6/VBN||been-5/VBN	root||ROOT-0/null||developed-6/VBN	aux||decrease-8/VB||to-7/TO	xcomp||developed-6/VBN||decrease-8/VB	det||losses-11/NNS||the-9/DT	amod||losses-11/NNS||economic-10/JJ	dobj||decrease-8/VB||losses-11/NNS	vmod||losses-11/NNS||caused-12/VBN	det||virus-15/NN||this-14/DT	agent||caused-12/VBN||virus-15/NN	virus-15||vaccines-3||no_rel||modified live vaccines have been developed to decrease the economic losses caused by this virus.
aux||minimize-2/VB||to-1/TO	root||ROOT-0/null||minimize-2/VB	dobj||minimize-2/VB||hypoglycemia-3/NN	prep_in||minimize-2/VB||subjects-5/NNS	prep_with||subjects-5/NNS||type1diabetes-7/CD	amod||delivery-11/NN||automated-9/VBN	nn||delivery-11/NN||glucagon-10/NN	prep_by||minimize-2/VB||delivery-11/NN	det||system-17/NN||a-13/DT	amod||system-17/NN||closed-loop-14/JJ	nn||system-17/NN||insulin-15/NN	nn||system-17/NN||delivery-16/NN	prep_in||delivery-11/NN||system-17/NN	type1diabetes-7||insulin-15||yes||to minimize hypoglycemia in subjects with type1diabetes by automated glucagon delivery in a closed-loop insulin delivery system.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||investigate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||investigate-9/VB||to-8/TO	xcomp||was-7/VBD||investigate-9/VB	det||effects-11/NNS||the-10/DT	dobj||investigate-9/VB||effects-11/NNS	amod||antipsychotic-14/NN||selected-13/VBN	prep_of||effects-11/NNS||antipsychotic-14/NN	prep_of||effects-11/NNS||cognition-16/NN	conj_and||antipsychotic-14/NN||cognition-16/NN	vmod||antipsychotic-14/NN||enhancing-17/VBG	dobj||enhancing-17/VBG||drugs-18/NNS	advmod||drugs-18/NNS||namely-20/RB	dep||namely-20/RB||haloperidol-21/JJ	advmod||drugs-18/NNS||risperidone-23/JJ	conj_and||namely-20/RB||risperidone-23/JJ	advmod||drugs-18/NNS||donepezil-25/JJ	conj_and||namely-20/RB||donepezil-25/JJ	advmod||in-29/IN||modafinil-28/RB	advmod||drugs-18/NNS||in-29/IN	conj_and||namely-20/RB||in-29/IN	det||model-32/NN||an-30/DT	nn||model-32/NN||animal-31/NN	pobj||in-29/IN||model-32/NN	advmod||used-34/VBN||widely-33/RB	vmod||model-32/NN||used-34/VBN	amod||research-38/NN||preclinical-36/JJ	nn||research-38/NN||schizophrenia-37/NN	prep_in||used-34/VBN||research-38/NN	schizophrenia-37||risperidone-23||yes||the aim of the present study was to investigate the effects of selected antipsychotic and cognition enhancing drugs, namely haloperidol, risperidone, donepezil, and modafinil in an animal model widely used in preclinical schizophrenia research.
advmod||determined-4/VBD||here-1/RB	nsubj||determined-4/VBD||we-3/PRP	root||ROOT-0/null||determined-4/VBD	det||mode-6/NN||the-5/DT	dobj||determined-4/VBD||mode-6/NN	nn||death-9/NN||cell-8/NN	prep_of||mode-6/NN||death-9/NN	num||lines-14/NNS||11-11/CD	nn||lines-14/NNS||melanoma-12/NN	nn||lines-14/NNS||cell-13/NN	prep_in||death-9/NN||lines-14/NNS	prep_upon||determined-4/VBD||exposure-16/NN	prep_to||determined-4/VBD||tmz-18/NN	prep_to||determined-4/VBD||fotemustine-20/NN	conj_and||tmz-18/NN||fotemustine-20/NN	melanoma-12||tmz-18||yes||here, we determined the mode of cell death in 11 melanoma cell lines upon exposure to tmz and fotemustine.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||role-6/NN||the-5/DT	dobj||investigated-4/VBD||role-6/NN	prep_of||role-6/NN||melatonin-8/NN	det||regulation-11/NN||the-10/DT	prep_in||investigated-4/VBD||regulation-11/NN	nn||invasion-16/NN||breast-13/NN	nn||invasion-16/NN||cancer-14/NN	nn||invasion-16/NN||cell-15/NN	prep_of||regulation-11/NN||invasion-16/NN	cancer-14||melatonin-8||no_rel||here, we investigated the role of melatonin in the regulation of breast cancer cell invasion.
advmod||associated-2/VBN||dyskinesias-1/RB	root||ROOT-0/null||associated-2/VBN	amod||movements-5/NNS||involuntary-4/JJ	prep_with||associated-2/VBN||movements-5/NNS	amod||contractions-9/NNS||painful-7/JJ	nn||contractions-9/NNS||muscle-8/NN	prep_with||associated-2/VBN||contractions-9/NNS	conj_and||movements-5/NNS||contractions-9/NNS	cop||complication-15/NN||are-10/VBP	det||complication-15/NN||a-11/DT	amod||complication-15/NN||common-12/JJ	conj_and||common-12/JJ||severe-14/JJ	amod||complication-15/NN||severe-14/JJ	auxpass||associated-2/VBN||complication-15/NN	amod||levodopa-18/NN||standard-17/JJ	prep_of||complication-15/NN||levodopa-18/NN	appos||levodopa-18/NN||l-dopa-20/NNP	dep||l-dopa-20/NNP||l-3-22/NN	num||l-3-22/NN||,4-23/CD	dep||l-dopa-20/NNP||dihydroxyphenylalanine-25/NN	nsubjpass||associated-2/VBN||therapy-27/NN	nn||sdisease-31/NN||parkinson-29/NN	prep_for||therapy-27/NN||sdisease-31/NN	parkinson'sdisease--1||levodopa-18||yes||dyskinesias associated with involuntary movements and painful muscle contractions are a common and severe complication of standard levodopa (l-dopa, l-3,4-dihydroxyphenylalanine) therapy for parkinson'sdisease.
advmod||provided-8/VBN||moreover-1/RB	amod||information-4/NN||little-3/JJ	nsubjpass||provided-8/VBN||information-4/NN	prep_on||information-4/NN||hiv/aids-6/NNS	auxpass||provided-8/VBN||was-7/VBD	root||ROOT-0/null||provided-8/VBN	det||communities-11/NNS||the-10/DT	prep_to||provided-8/VBN||communities-11/NNS	advmod||have-15/VBP||so-12/RB	mark||have-15/VBP||that-13/IN	nsubj||have-15/VBP||we-14/PRP	advcl||provided-8/VBN||have-15/VBP	dobj||have-15/VBP||disadvantage-16/NN	amod||epidemic-20/NN||controlling-18/VBG	amod||epidemic-20/NN||hiv/aids-19/JJ	prep_of||disadvantage-16/NN||epidemic-20/NN	det||region-23/NN||the-22/DT	prep_in||epidemic-20/NN||region-23/NN	aids--1||hiv--1||no||moreover, little information on hiv/aids was provided to the communities so that we have disadvantage of controlling hiv/aids epidemic in the region.
num||women-2/NNS||three-1/CD	nsubjpass||admitted-5/VBN||women-2/NNS	auxpass||admitted-5/VBN||were-3/VBD	advmod||admitted-5/VBN||consecutively-4/RB	root||ROOT-0/null||admitted-5/VBN	poss||unit-11/NN||our-7/PRP$	amod||unit-11/NN||medical-8/JJ	amod||unit-11/NN||intensive-9/JJ	nn||unit-11/NN||care-10/NN	prep_to||admitted-5/VBN||unit-11/NN	prep_for||unit-11/NN||thyrotoxicosis-13/NNS	det||ingestion-16/NN||the-15/DT	nsubj||containing-21/VBG||ingestion-16/NN	amod||pills-19/NNS||dietary-18/JJ	prep_of||ingestion-16/NN||pills-19/NNS	advmod||containing-21/VBG||accidentally-20/RB	prepc_after||admitted-5/VBN||containing-21/VBG	amod||levels-23/NNS||high-22/JJ	dobj||containing-21/VBG||levels-23/NNS	prep_of||levels-23/NNS||thyroxin-25/NN	thyrotoxicosis-13||thyroxin-25||yes||three women were consecutively admitted to our medical intensive care unit for thyrotoxicosis after the ingestion of dietary pills accidentally containing high levels of thyroxin.
amod||species-4/NNS||hypoxia-evoked-1/JJ	amod||species-4/NNS||reactive-2/JJ	nn||species-4/NNS||oxygen-3/NN	root||ROOT-0/null||species-4/NNS	appos||species-4/NNS||ros-6/NN	amod||oxidative-10/JJ||driven-9/JJ	amod||stress-11/NN||oxidative-10/JJ	dep||species-4/NNS||stress-11/NN	cop||mechanism-15/NN||is-12/VBZ	det||mechanism-15/NN||an-13/DT	amod||mechanism-15/NN||underlying-14/VBG	rcmod||stress-11/NN||mechanism-15/NN	amod||cell-19/NN||retinal-17/JJ	nn||cell-19/NN||ganglion-18/NN	prep_of||mechanism-15/NN||cell-19/NN	appos||cell-19/NN||rgc-21/NN	dep||species-4/NNS||death-23/NN	nsubj||leads-25/VBZ||death-23/NN	rcmod||death-23/NN||leads-25/VBZ	amod||disorders-28/NNS||blinding-27/VBG	prep_to||leads-25/VBZ||disorders-28/NNS	hypoxia--1||oxygen-3||no_rel||hypoxia-evoked reactive oxygen species (ros)-driven oxidative stress is an underlying mechanism of retinal ganglion cell (rgc) death that leads to blinding disorders.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||factors-5/NNS||the-3/DT	amod||factors-5/NNS||clinical-4/JJ	dobj||evaluated-2/VBN||factors-5/NNS	nsubj||affect-7/VBP||factors-5/NNS	rcmod||factors-5/NNS||affect-7/VBP	det||pain-9/NN||the-8/DT	dobj||affect-7/VBP||pain-9/NN	prep_on||affect-7/VBP||injection-11/NN	prep_of||injection-11/NN||propofol-13/NN	aux||develop-15/VB||to-14/TO	vmod||evaluated-2/VBN||develop-15/VB	det||strategy-17/NN||a-16/DT	dobj||develop-15/VB||strategy-17/NN	aux||prevent-19/VB||to-18/TO	vmod||strategy-17/NN||prevent-19/VB	vmod||strategy-17/NN||reduce-21/VB	conj_or||prevent-19/VB||reduce-21/VB	dobj||prevent-19/VB||pain-22/NN	pain-22||propofol-13||yes||we evaluated the clinical factors that affect the pain on injection of propofol to develop a strategy to prevent or reduce pain.
nsubjpass||associated-4/VBN||fospropofol-1/NN	aux||associated-4/VBN||has-2/VBZ	auxpass||associated-4/VBN||been-3/VBN	root||ROOT-0/null||associated-4/VBN	amod||pain-7/NN||less-6/JJR	prep_with||associated-4/VBN||pain-7/NN	nn||site-10/NN||injection-9/NN	prep_at||pain-7/NN||site-10/NN	prep_than||associated-4/VBN||propofol-12/NN	pain-7||propofol-12||yes||fospropofol has been associated with less pain at injection site than propofol.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	nsubj||mmp-2-15/JJ||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||expression-11/NN||the-9/DT	nn||expression-11/NN||gene-10/NN	dobj||determine-8/VB||expression-11/NN	prep_of||expression-11/NN||enos-13/NNS	xcomp||was-6/VBD||mmp-2-15/JJ	conj_and||determine-8/VB||mmp-2-15/JJ	det||lungs-18/NNS||the-17/DT	prep_in||mmp-2-15/JJ||lungs-18/NNS	det||model-22/NN||a-20/DT	nn||model-22/NN||rat-21/NN	prep_of||lungs-18/NNS||model-22/NN	prep_of||model-22/NN||pulmonaryhypertension-24/NN	nn||treatment-27/NN||bosentan-26/NN	prep_after||mmp-2-15/JJ||treatment-27/NN	pulmonaryhypertension-24||bosentan-26||yes||the purpose of this study was to determine the gene expression of enos and mmp-2 in the lungs of a rat model of pulmonaryhypertension after bosentan treatment.
det||trial-2/NN||the-1/DT	nsubj||trial-12/NN||trial-2/NN	cop||trial-12/NN||was-3/VBD	det||trial-12/NN||a-4/DT	amod||trial-12/NN||prospective-5/JJ	amod||trial-12/NN||randomized-7/JJ	amod||trial-12/NN||double-blind-9/JJ	amod||trial-12/NN||placebo-controlled-10/JJ	nn||trial-12/NN||intervention-11/NN	root||ROOT-0/null||trial-12/NN	vmod||trial-12/NN||enrolling-13/VBG	dobj||enrolling-13/VBG||patients-14/NNS	prep_with||enrolling-13/VBG||hypercholesterolemia-16/NN	dep||hypercholesterolemia-16/NN||defined-18/VBN	det||‰-25/NN||a-20/DT	amod||‰-25/NN||baseline-21/JJ	amod||‰-25/NN||total-22/JJ	nn||‰-25/NN||cholesterol-23/NN	nn||‰-25/NN||â-24/NN	prep_as||defined-18/VBN||‰-25/NN	vmod||‰-25/NN||¥-26/VBG	num||100â-39/NNS||200â-27/CD	amod||100â-39/NNS||$-28/$	number||mg/dl-30/CD||‰-29/CD	num||$-28/$||mg/dl-30/CD	amod||100â-39/NNS||and/or-31/JJ	nn||100â-39/NNS||baseline-32/NN	nn||100â-39/NNS||low-density-33/NN	nn||100â-39/NNS||lipoprotein-34/NN	nn||100â-39/NNS||cholesterol-35/NN	nn||100â-39/NNS||â-36/NN	amod||100â-39/NNS||‰-37/JJ	nn||100â-39/NNS||¥-38/NN	dobj||¥-26/VBG||100â-39/NNS	npadvmod||mg/dl-42/JJ||$-40/$	num||$-40/$||‰-41/CD	amod||100â-39/NNS||mg/dl-42/JJ	hypercholesterolemia-16||cholesterol-35||no||the trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol â‰¥200â€‰mg/dl and/or baseline low-density lipoprotein cholesterol â‰¥100â€‰mg/dl).
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||determine-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	det||effects-11/NNS||the-10/DT	dobj||determine-9/VB||effects-11/NNS	prep_of||effects-11/NNS||glucosamine-13/NN	nsubjpass||administered-20/VBN||glucosamine-13/NN	nsubjpass||administered-20/VBN||glucosamine-13/NN	appos||glucosamine-13/NN||glcn-15/NN	auxpass||administered-20/VBN||is-19/VBZ	rcmod||glucosamine-13/NN||administered-20/VBN	rcmod||glucosamine-13/NN||administered-20/VBN	conj_and||administered-20/VBN||administered-20/VBN	det||treatment-23/NN||the-22/DT	prep_in||administered-20/VBN||treatment-23/NN	prep_of||treatment-23/NN||osteoarthritis-25/NNS	poss||2-30/CD||its-29/PRP$	prep_of||administered-20/VBN||2-30/CD	appos||effects-11/NNS||n-acetyl-33/NN	amod||²-37/NNS||l-phenylalanylamido-2-deoxy-î-36/JJ	dep||determine-9/VB||²-37/NNS	amod||derivative-43/NN||d-glucose-39/JJ	appos||derivative-43/NN||napa-41/NNP	dep||²-37/NNS||derivative-43/NN	nn||kinases-46/NNS||ikk-45/NN	prep_on||derivative-43/NN||kinases-46/NNS	dep||²-37/NNS||consequently-49/RB	conj_and||derivative-43/NN||consequently-49/RB	amod||activation-53/NN||nf-îºb-52/JJ	prep_on||consequently-49/RB||activation-53/NN	amod||chondrocytes-56/NNS||human-55/JJ	prep_in||consequently-49/RB||chondrocytes-56/NNS	osteoarthritis-25||glucosamine-13||yes||the aim of the present study was to determine the effects of glucosamine (glcn), which is administered in the treatment of osteoarthritis, and of its 2-(n-acetyl)-l-phenylalanylamido-2-deoxy-î²-d-glucose (napa) derivative on ikk kinases and, consequently, on nf-îºb activation in human chondrocytes.
advmod||evaluated-41/VBN||spirometry-1/RB	amod||gas-5/NN||arterial-3/JJ	nn||gas-5/NN||blood-4/NN	nsubjpass||evaluated-41/VBN||gas-5/NN	amod||gas-5/NN||six-7/CD	amod||test-11/NN||minute-9/JJ	nn||test-11/NN||walk-10/NN	conj_and||gas-5/NN||test-11/NN	nsubjpass||evaluated-41/VBN||test-11/NN	appos||test-11/NN||bode-13/NNP	nn||index-17/NN||body-15/NN	nn||index-17/NN||mass-16/NN	dep||bode-13/NNP||index-17/NN	dep||bode-13/NNP||obstruction-19/NN	conj_and||index-17/NN||obstruction-19/NN	dep||bode-13/NNP||dyspnea-21/NN	conj_and||index-17/NN||dyspnea-21/NN	nn||capacity-25/NN||exercise-24/NN	dep||bode-13/NNP||capacity-25/NN	conj_and||index-17/NN||capacity-25/NN	advmod||questionnaire-35/NN||st-29/RB	amod||questionnaire-35/NN||georgeâ-30/JJ	amod||questionnaire-35/NN||$-31/$	number||s-33/CD||™-32/CD	num||$-31/$||s-33/CD	amod||questionnaire-35/NN||respiratory-34/JJ	conj_and||gas-5/NN||questionnaire-35/NN	nsubjpass||evaluated-41/VBN||questionnaire-35/NN	prep_about||questionnaire-35/NN||quality-37/NN	prep_of||quality-37/NN||life-39/NN	auxpass||evaluated-41/VBN||were-40/VBD	root||ROOT-0/null||evaluated-41/VBN	dyspnea-21||gas-5||no_rel||spirometry, arterial blood gas, six- minute walk test, bode (body mass index, obstruction, dyspnea, and exercise capacity), and st georgeâ€™s respiratory questionnaire about quality of life were evaluated.
nsubj||unknown-24/JJ||effectiveness-1/NN	prep_of||effectiveness-1/NN||cotrimoxazole-3/NN	appos||effectiveness-1/NN||ctx-5/NN	prepc_compared_with||effectiveness-1/NN||with-8/IN	amod||intermittent-preventive-therapy-13/NN||sulfadoxine-pyrimethamine-9/JJ	appos||intermittent-preventive-therapy-13/NN||sp-11/NN	pobj||effectiveness-1/NN||intermittent-preventive-therapy-13/NN	appos||intermittent-preventive-therapy-13/NN||iptp-15/NN	prep_for||intermittent-preventive-therapy-13/NN||malaria-18/NN	amod||women-22/NNS||hiv-infected-20/JJ	amod||women-22/NNS||pregnant-21/JJ	prep_in||malaria-18/NN||women-22/NNS	cop||unknown-24/JJ||is-23/VBZ	root||ROOT-0/null||unknown-24/JJ	malaria-18||pyrimethamine--1||no||effectiveness of cotrimoxazole (ctx) compared with sulfadoxine-pyrimethamine (sp) intermittent-preventive-therapy (iptp) for malaria in hiv-infected pregnant women is unknown.
det||investigation-2/NN||an-1/DT	nsubj||throw-13/VB||investigation-2/NN	amod||impairments-6/NNS||topiramate-induced-4/JJ	nn||impairments-6/NNS||cognitive-5/NN	prep_of||investigation-2/NN||impairments-6/NNS	nn||members-9/NNS||family-8/NN	prep_in||impairments-6/NNS||members-9/NNS	prep_with||members-9/NNS||epilepsy-11/NN	aux||throw-13/VB||may-12/MD	root||ROOT-0/null||throw-13/VB	dobj||throw-13/VB||light-14/NN	det||subject-17/NN||the-16/DT	prep_on||throw-13/VB||subject-17/NN	epilepsy-11||topiramate--1||yes||an investigation of topiramate-induced cognitive impairments in family members with epilepsy may throw light on the subject.
det||protein-3/NN||the-1/DT	amod||protein-3/NN||expressed-2/JJ	nsubj||able-5/JJ||protein-3/NN	nsubj||bind-7/VB||protein-3/NN	cop||able-5/JJ||was-4/VBD	root||ROOT-0/null||able-5/JJ	aux||bind-7/VB||to-6/TO	xcomp||able-5/JJ||bind-7/VB	det||antibody-11/NN||a-8/DT	nn||antibody-11/NN||rabbit-9/NN	nn||antibody-11/NN||polyclonal-10/NN	dobj||bind-7/VB||antibody-11/NN	amod||h5n1-19/NN||nonstructural-13/JJ	nn||h5n1-19/NN||protein-14/NN	appos||h5n1-19/NN||ns1-16/NNP	nn||h5n1-19/NN||avianinfluenzavirus-18/NNS	prep_of||antibody-11/NN||h5n1-19/NN	h5n1-19||avianinfluenzavirus-18||no||the expressed protein was able to bind a rabbit polyclonal antibody of nonstructural protein (ns1) avianinfluenzavirus h5n1.
nsubjpass||involved-3/VBN||nk-1r-1/JJ	auxpass||involved-3/VBN||is-2/VBZ	root||ROOT-0/null||involved-3/VBN	det||pathogenesis-6/NNS||the-5/DT	prep_in||involved-3/VBN||pathogenesis-6/NNS	prep_of||pathogenesis-6/NNS||asthma-8/NN	det||budesonide-11/NN||that-10/DT	nsubj||downregulate-13/VB||budesonide-11/NN	aux||downregulate-13/VB||may-12/MD	conj_and||involved-3/VBN||downregulate-13/VB	det||expression-15/NN||the-14/DT	dobj||downregulate-13/VB||expression-15/NN	prep_of||expression-15/NN||nk-1r-17/CD	det||asmcs-20/NNS||the-19/DT	prep_in||downregulate-13/VB||asmcs-20/NNS	prep_in||downregulate-13/VB||airways-22/NNS	conj_and||asmcs-20/NNS||airways-22/NNS	amod||rats-25/NNS||asthmatic-24/JJ	prep_of||asmcs-20/NNS||rats-25/NNS	nsubj||alleviate-29/VB||rats-25/NNS	aux||alleviate-29/VB||may-28/MD	rcmod||rats-25/NNS||alleviate-29/VB	amod||inflammation-32/NN||neurogenic-30/JJ	nn||inflammation-32/NN||airway-31/NN	dobj||alleviate-29/VB||inflammation-32/NN	asthmatic-24||budesonide-11||no||nk-1r is involved in the pathogenesis of asthma and that budesonide may downregulate the expression of nk-1r in the asmcs and airways of asthmatic rats, which may alleviate neurogenic airway inflammation.
det||study-3/NN||this-2/DT	prep_in||demonstrate-5/VBP||study-3/NN	nsubj||demonstrate-5/VBP||we-4/PRP	root||ROOT-0/null||demonstrate-5/VBP	mark||inhibits-27/VBZ||that-6/IN	det||combination-8/NN||the-7/DT	nsubj||inhibits-27/VBZ||combination-8/NN	amod||+-11/NN||zn2-10/JJ	prep_of||combination-8/NN||+-11/NN	prep_of||combination-8/NN||pt-13/NN	conj_and||+-11/NN||pt-13/NN	amod||concentrations-16/NNS||low-15/JJ	prep_at||+-11/NN||concentrations-16/NNS	num||+-21/NNS||2-18/CD	amod||+-21/NNS||âµm-19/JJ	amod||+-21/NNS||zn2-20/JJ	dep||concentrations-16/NNS||+-21/NNS	num||pt-25/NN||2-23/CD	nn||pt-25/NN||âµm-24/NN	dep||concentrations-16/NNS||pt-25/NN	conj_and||+-21/NNS||pt-25/NN	ccomp||demonstrate-5/VBP||inhibits-27/VBZ	det||replication-29/NN||the-28/DT	dobj||inhibits-27/VBZ||replication-29/NN	prep_of||replication-29/NN||sars-coronavirus-31/NNS	appos||sars-coronavirus-31/NNS||sars-cov-33/NNP	amod||virus-38/NN||equine-36/JJ	nn||virus-38/NN||arteritis-37/NNS	prep_of||replication-29/NN||virus-38/NN	conj_and||sars-coronavirus-31/NNS||virus-38/NN	appos||sars-coronavirus-31/NNS||eav-40/NN	nn||culture-44/NN||cell-43/NN	prep_in||inhibits-27/VBZ||culture-44/NN	sars--1||sars-cov-33||no||in this study we demonstrate that the combination of zn2+ and pt at low concentrations (2 âµm zn2+ and 2 âµm pt) inhibits the replication of sars-coronavirus (sars-cov) and equine arteritis virus (eav) in cell culture.
amod||anticoagulation-2/NN||oral-1/JJ	nsubj||prevents-3/VBZ||anticoagulation-2/NN	root||ROOT-0/null||prevents-3/VBZ	dobj||prevents-3/VBZ||strokes-4/NNS	prep_in||strokes-4/NNS||patients-6/NNS	prep_with||patients-6/NNS||atrialfibrillation-8/NN	nsubj||remain-14/VBP||reasons-12/NNS	prep_for||receive-26/VBP||reasons-12/NNS	rcmod||reasons-12/NNS||remain-14/VBP	acomp||remain-14/VBP||unclear-15/JJ	mwe||than-18/IN||less-17/JJR	quantmod||40-19/CD||than-18/IN	num||%-20/NN||40-19/CD	nsubj||receive-26/VBP||%-20/NN	det||patients-23/NNS||all-22/DT	prep_of||%-20/NN||patients-23/NNS	prep_with||patients-23/NNS||atrialfibrillation-25/NN	conj_but||prevents-3/VBZ||receive-26/VBP	dobj||receive-26/VBP||warfarin-27/NN	atrialfibrillation-25||warfarin-27||yes||oral anticoagulation prevents strokes in patients with atrialfibrillation but, for reasons that remain unclear, less than 40% of all patients with atrialfibrillation receive warfarin.
nsubj||results-7/VBZ||infection-1/NN	prep_with||infection-1/NN||mycobacteriumtuberculosis-3/NNS	appos||mycobacteriumtuberculosis-3/NNS||mtb-5/NN	root||ROOT-0/null||results-7/VBZ	amod||outcomes-11/NNS||different-9/JJ	amod||outcomes-11/NNS||clinical-10/JJ	prep_in||results-7/VBZ||outcomes-11/NNS	vmod||outcomes-11/NNS||ranging-12/VBG	amod||containment-15/NN||asymptomatic-14/JJ	prep_from||ranging-12/VBG||containment-15/NN	advmod||progressing-18/VBG||rapidly-17/RB	prepc_to||ranging-12/VBG||progressing-18/VBG	dobj||progressing-18/VBG||tuberculosis-19/NNP	appos||tuberculosis-19/NNP||tb-21/NN	tuberculosis-19||mycobacteriumtuberculosis-3||no||infection with mycobacteriumtuberculosis ( mtb ) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (tb).
advmod||undisputable-7/JJ||however-1/RB	det||data-4/NNS||these-3/DT	nsubj||undisputable-7/JJ||data-4/NNS	cop||undisputable-7/JJ||are-5/VBP	neg||undisputable-7/JJ||not-6/RB	root||ROOT-0/null||undisputable-7/JJ	amod||questions-11/NNS||many-10/JJ	nsubj||remain-22/VBP||questions-11/NNS	nsubjpass||answered-25/VBN||questions-11/NNS	det||capacity-17/NN||the-13/DT	amod||capacity-17/NN||preventive-14/JJ	conj_and||preventive-14/JJ||therapeutic-16/JJ	amod||capacity-17/NN||therapeutic-16/JJ	prep_regarding||questions-11/NNS||capacity-17/NN	prep_of||capacity-17/NN||vitamind-19/NN	prep_in||vitamind-19/NN||multiplesclerosis-21/NNS	conj_and||undisputable-7/JJ||remain-22/VBP	aux||answered-25/VBN||to-23/TO	auxpass||answered-25/VBN||be-24/VB	xcomp||remain-22/VBP||answered-25/VBN	vitamind-19||multiplesclerosis-21||no_rel||however, these data are not undisputable, and many questions regarding the preventive and therapeutic capacity of vitamind in multiplesclerosis remain to be answered.
nsubj||revised-3/VBD||moh-1/NN	nsubj||defined-14/VBD||moh-1/NN	nsubj||initiated-20/VBD||moh-1/NN	advmod||revised-3/VBD||subsequently-2/RB	root||ROOT-0/null||revised-3/VBD	det||tms-5/NN||the-4/DT	poss||scope-7/NN||tms-5/NN	dobj||revised-3/VBD||scope-7/NN	prep_of||scope-7/NN||work-9/NN	amod||care-12/NN||hiv/aids-11/JJ	prep_in||revised-3/VBD||care-12/NN	conj_and||revised-3/VBD||defined-14/VBD	amod||guidelines-17/NNS||new-15/JJ	amod||guidelines-17/NNS||clinical-16/JJ	dobj||defined-14/VBD||guidelines-17/NNS	conj_and||revised-3/VBD||initiated-20/VBD	det||re-training-23/NN||a-21/DT	amod||re-training-23/NN||nationwide-22/JJ	dobj||initiated-20/VBD||re-training-23/NN	amod||program-27/NN||clinical-25/JJ	nn||program-27/NN||mentoring-26/NN	dobj||initiated-20/VBD||program-27/NN	conj_and||re-training-23/NN||program-27/NN	det||professionals-31/NNS||these-29/DT	nn||professionals-31/NNS||health-30/NN	prep_for||initiated-20/VBD||professionals-31/NNS	aids--1||hiv--1||no||moh subsequently revised the tms' scope of work in hiv/aids care, defined new clinical guidelines, and initiated a nationwide re-training and clinical mentoring program for these health professionals.
nsubjpass||associated-9/VBN||atopicasthma-1/NN	auxpass||associated-3/VBN||was-2/VBD	rcmod||atopicasthma-1/NN||associated-3/VBN	prep_with||associated-3/VBN||eosinophilia-5/NN	prep_with||associated-3/VBN||non-atopicasthma-7/NN	conj_and||eosinophilia-5/NN||non-atopicasthma-7/NN	auxpass||associated-9/VBN||was-8/VBD	root||ROOT-0/null||associated-9/VBN	nn||³-12/NNP||ifn-î-11/NNP	prep_with||associated-9/VBN||³-12/NNP	amod||monocytes-15/NNS||elevated-14/JJ	prep_with||associated-9/VBN||monocytes-15/NNS	conj_and||³-12/NNP||monocytes-15/NNS	prep_in||associated-9/VBN||blood-17/NN	atopicasthma-1||ifn--1||no_rel||atopicasthma was associated with eosinophilia and non-atopicasthma was associated with ifn-î³ and elevated monocytes in blood.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	aspirin--1||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||records-3/NNS||the-1/DT	amod||records-3/NNS||clinical-2/JJ	nsubjpass||reviewed-18/VBN||records-3/NNS	num||patients-7/NNS||207-5/CD	amod||patients-7/NNS||asthmatic-6/JJ	prep_of||records-3/NNS||patients-7/NNS	nsubj||underwent-9/VBD||patients-7/NNS	rcmod||patients-7/NNS||underwent-9/VBD	nn||challenges-11/NNS||inhalation-10/NN	dobj||underwent-9/VBD||challenges-11/NNS	preconj||aspirin-14/NN||both-13/DT	prep_with||underwent-9/VBD||aspirin-14/NN	prep_with||underwent-9/VBD||methacholine-16/NN	conj_and||aspirin-14/NN||methacholine-16/NN	auxpass||reviewed-18/VBN||were-17/VBD	root||ROOT-0/null||reviewed-18/VBN	advmod||reviewed-18/VBN||retrospectively-19/RB	asthmatic-6||aspirin-14||no||the clinical records of 207 asthmatic patients who underwent inhalation challenges with both aspirin and methacholine were reviewed retrospectively.
nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	nsubj||retrieved-4/VBD||data-3/NNS	nsubj||compare-38/VB||data-3/NNS	ccomp||analyzed-2/VBD||retrieved-4/VBD	det||search-8/NN||a-6/DT	amod||search-8/NN||pubmed-7/JJ	prep_through||retrieved-4/VBD||search-8/NN	amod||trials-13/NNS||randomized-10/JJ	amod||trials-13/NNS||placebo-controlled-12/JJ	prep_of||search-8/NN||trials-13/NNS	amod||injectables-18/NNS||first-generation-15/JJ	amod||injectables-18/NNS||antipsychotic-16/JJ	amod||injectables-18/NNS||long-acting-17/JJ	prep_of||trials-13/NNS||injectables-18/NNS	dep||injectables-18/NNS||haloperidoldecanoate-20/NN	amod||decanoate-23/NN||bromperidol-22/JJ	dep||injectables-18/NNS||decanoate-23/NN	conj_and||haloperidoldecanoate-20/NN||decanoate-23/NN	dep||injectables-18/NNS||fluphenazinedecanoate-26/NN	conj_and||haloperidoldecanoate-20/NN||fluphenazinedecanoate-26/NN	det||database-32/NN||a-30/DT	nn||database-32/NN||company-31/NN	prep_of||trials-13/NNS||database-32/NN	conj_and||injectables-18/NNS||database-32/NN	amod||palmitate-35/NN||paliperidone-34/JJ	prep_of||database-32/NN||palmitate-35/NN	aux||compare-38/VB||to-37/TO	xcomp||retrieved-4/VBD||compare-38/VB	det||ratio-41/NN||the-39/DT	amod||ratio-41/NN||benefit-risk-40/JJ	dobj||compare-38/VB||ratio-41/NN	prep_in||compare-38/VB||patients-43/NNS	prep_with||patients-43/NNS||schizophrenia-45/NN	schizophrenia-45||fluphenazinedecanoate-26||yes||we analyzed data retrieved through a pubmed search of randomized, placebo-controlled trials of first-generation antipsychotic long-acting injectables (haloperidoldecanoate, bromperidol decanoate, and fluphenazinedecanoate), and a company database of paliperidone palmitate, to compare the benefit-risk ratio in patients with schizophrenia.
amod||variants-2/NNS||genetic-1/JJ	conj_or||variants-2/NNS||variants-2/NNS	nsubjpass||analyzed-8/VBN||variants-2/NNS	nsubjpass||analyzed-8/VBN||variants-2/NNS	nsubj||assess-10/VB||variants-2/NNS	nsubj||assess-10/VB||variants-2/NNS	prep_in||variants-2/NNS||ask1-6/CD	prep_near||variants-2/NNS||ask1-6/CD	auxpass||analyzed-8/VBN||were-7/VBD	root||ROOT-0/null||analyzed-8/VBN	aux||assess-10/VB||to-9/TO	xcomp||analyzed-8/VBN||assess-10/VB	det||role-12/NN||the-11/DT	dobj||assess-10/VB||role-12/NN	det||gene-15/NN||this-14/DT	prep_of||role-12/NN||gene-15/NN	nn||action-18/NN||insulin-17/NN	prep_in||gene-15/NN||action-18/NN	prep_in||gene-15/NN||type2diabetes-20/NN	conj_and||action-18/NN||type2diabetes-20/NN	type2diabetes-20||insulin-17||yes||genetic variants in or near ask1 were analyzed to assess the role of this gene in insulin action and type2diabetes.
amod||patients-2/NNS||forty-eight-1/JJ	nsubjpass||enrolled-18/VBN||patients-2/NNS	nsubjpass||treated-24/VBN||patients-2/NNS	nn||ve-6/NNP||chemo-naã-4/NNP	nn||ve-6/NNP||¯-5/NNP	prep_with||patients-2/NNS||ve-6/NNP	advmod||confirmed-9/VBN||histologically-8/RB	vmod||ve-6/NNP||confirmed-9/VBN	advmod||ve-6/NNP||locally-11/RB	amod||cancer-16/NN||advanced-12/VBN	conj_or||advanced-12/VBN||metastatic-14/JJ	amod||cancer-16/NN||metastatic-14/JJ	amod||cancer-16/NN||gastric-15/JJ	dep||ve-6/NNP||cancer-16/NN	auxpass||enrolled-18/VBN||were-17/VBD	root||ROOT-0/null||enrolled-18/VBN	det||study-21/NN||the-20/DT	prep_for||enrolled-18/VBN||study-21/NN	auxpass||treated-24/VBN||were-23/VBD	conj_and||enrolled-18/VBN||treated-24/VBN	nn||chemotherapy-27/NN||combination-26/NN	prep_with||treated-24/VBN||chemotherapy-27/NN	amod||mg/m2-31/NNS||paclitaxel-29/JJ	dep||paclitaxel-29/JJ||175-30/CD	prep_of||chemotherapy-27/NN||mg/m2-31/NNS	prep_of||chemotherapy-27/NN||cisplatin-33/NN	conj_and||mg/m2-31/NNS||cisplatin-33/NN	num||mg/m2-35/NNS||75-34/CD	dobj||enrolled-18/VBN||mg/m2-35/NNS	prep_for||enrolled-18/VBN||maximum-37/NN	num||cycles-40/NNS||six-39/CD	prep_of||maximum-37/NN||cycles-40/NNS	prepc_after||enrolled-18/VBN||obtaining-42/VBG	dobj||obtaining-42/VBG||specimen-43/NN	prep_for||obtaining-42/VBG||atp-cra-45/NN	cancer-16||atp--1||no_rel||forty-eight patients with chemo-naã¯ve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for atp-cra.
nn||syndrome-3/NN||introduction-1/NN	nn||syndrome-3/NN||brugada-2/NN	nsubjpass||associated-8/VBN||syndrome-3/NN	appos||syndrome-3/NN||brs-5/NN	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	prep_with||associated-8/VBN||loss-10/NN	aux||+-13/VB||na-12/TO	prep_of||loss-10/NN||+-13/VB	nn||function-15/NN||channel-14/NN	dobj||+-13/VB||function-15/NN	amod||risks-18/NNS||increased-17/VBN	prep_of||loss-10/NN||risks-18/NNS	conj_and||+-13/VB||risks-18/NNS	det||ventriculartachycardia-21/NN||a-20/DT	prep_of||risks-18/NNS||ventriculartachycardia-21/NN	dep||ventriculartachycardia-21/NN||exacerbated-22/VBN	prep_by||exacerbated-22/VBN||flecainide-24/NN	dep||ventriculartachycardia-21/NN||reduced-26/VBN	conj_but||exacerbated-22/VBN||reduced-26/VBN	prep_by||reduced-26/VBN||quinidine-28/NN	ventriculartachycardia-21||quinidine-28||yes||introduction brugada syndrome (brs) is associated with loss of na+ channel function and increased risks of a ventriculartachycardia exacerbated by flecainide but reduced by quinidine.
det||form-4/NN||the-1/DT	amod||form-4/NN||primary-2/JJ	amod||form-4/NN||circulating-3/JJ	nsubj||-RSB--15/VBZ||form-4/NN	prep_of||form-4/NN||vitamind-6/NN	amod||-LSB--9/NN||25-hydroxy-vitamind-8/JJ	appos||vitamind-6/NN||-LSB--9/NN	num||-LSB--9/NN||25-10/CD	discourse||vitamind-6/NN||oh-12/UH	dep||vitamind-6/NN||d-14/SYM	root||ROOT-0/null||-RSB--15/VBZ	auxpass||associated-18/VBN||is-17/VBZ	dep||-RSB--15/VBZ||associated-18/VBN	amod||outcomes-22/NNS||multiple-20/JJ	amod||outcomes-22/NNS||medical-21/JJ	prep_with||associated-18/VBN||outcomes-22/NNS	prep_including||-RSB--15/VBZ||rickets-25/NNS	prep_including||-RSB--15/VBZ||osteoporosis-27/NNS	conj_and||rickets-25/NNS||osteoporosis-27/NNS	prep_including||-RSB--15/VBZ||multiplesclerosis-29/NNS	conj_and||rickets-25/NNS||multiplesclerosis-29/NNS	prep_including||-RSB--15/VBZ||cancer-31/NN	conj_and||rickets-25/NNS||cancer-31/NN	rickets-25||vitamind-6||yes||the primary circulating form of vitamind, 25-hydroxy-vitamind [25(oh)d], is associated with multiple medical outcomes, including rickets, osteoporosis, multiplesclerosis and cancer.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	vasculitis-11||antibody--1||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	cross--1||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	amod||sodiumvalproate-7/NN||intravenous-6/JJ	prep_of||effect-4/NN||sodiumvalproate-7/NN	prep_in||assess-2/VB||patients-9/NNS	amod||episodes-13/NNS||acute-11/JJ	amod||episodes-13/NNS||manic-12/JJ	prep_with||patients-9/NNS||episodes-13/NNS	prep_of||episodes-13/NNS||bipolardisorder-15/NN	bipolardisorder-15||sodiumvalproate-7||yes||to assess the effect of intravenous sodiumvalproate in patients with acute manic episodes of bipolardisorder.
prep_in||conducted-6/VBD||2007/2008-2/CD	det||authors-5/NNS||the-4/DT	nsubj||conducted-6/VBD||authors-5/NNS	root||ROOT-0/null||conducted-6/VBD	det||trial-17/NN||an-7/DT	amod||trial-17/NN||investigator-initiated-8/JJ	amod||trial-17/NN||non-commercial-10/JJ	amod||trial-17/NN||double-blind-12/JJ	amod||trial-17/NN||randomised-14/JJ	amod||trial-17/NN||controlled-15/JJ	nn||trial-17/NN||pilot-16/NN	dobj||conducted-6/VBD||trial-17/NN	dep||trial-17/NN||hwi-01-19/JJ	aux||assess-22/VB||to-21/TO	vmod||conducted-6/VBD||assess-22/VB	det||equivalence-25/NN||the-23/DT	amod||equivalence-25/NN||clinical-24/JJ	dobj||assess-22/VB||equivalence-25/NN	prep_of||equivalence-25/NN||ibuprofen-27/NN	prep_of||equivalence-25/NN||ciprofloxacin-29/NN	conj_and||ibuprofen-27/NN||ciprofloxacin-29/NN	det||treatment-32/NN||the-31/DT	prep_in||assess-22/VB||treatment-32/NN	amod||urinarytractinfection-35/NN||uncomplicated-34/JJ	prep_of||treatment-32/NN||urinarytractinfection-35/NN	appos||urinarytractinfection-35/NN||uti-37/NN	urinarytractinfection-35||ciprofloxacin-29||yes||in 2007/2008, the authors conducted an investigator-initiated, non-commercial, double-blind, randomised controlled pilot trial (hwi-01) to assess the clinical equivalence of ibuprofen and ciprofloxacin in the treatment of uncomplicated urinarytractinfection (uti).
det||production-4/NN||the-1/DT	amod||production-4/NN||long-2/JJ	nn||production-4/NN||term-3/NN	nsubj||contribute-13/VB||production-4/NN	amod||antibodies-8/NNS||ige-6/JJ	amod||antibodies-8/NNS||anti-influenzavirus-7/JJ	prep_of||production-4/NN||antibodies-8/NNS	vmod||antibodies-8/NNS||induced-9/VBN	agent||induced-9/VBN||vaccination-11/NN	aux||contribute-13/VB||may-12/MD	root||ROOT-0/null||contribute-13/VB	amod||immunity-16/NN||protective-15/JJ	prep_to||contribute-13/VB||immunity-16/NN	prep_against||immunity-16/NN||influenza-18/NN	influenza-18||influenzavirus--1||no||the long term production of ige anti-influenzavirus antibodies induced by vaccination may contribute to protective immunity against influenza.
det||view-6/NN||the-4/DT	amod||view-6/NN||traditional-5/JJ	prep_in_addition_to||suggests-28/VBZ||view-6/NN	mark||involved-16/VBN||that-7/IN	amod||levels-9/NNS||elevated-8/JJ	nsubjpass||involved-16/VBN||levels-9/NNS	nn||ammonia-14/NN||blood-11/NN	conj_and||blood-11/NN||brain-13/NN	nn||ammonia-14/NN||brain-13/NN	prep_of||levels-9/NNS||ammonia-14/NN	auxpass||involved-16/VBN||are-15/VBP	dep||view-6/NN||involved-16/VBN	det||mechanism-19/NN||the-18/DT	prep_in||involved-16/VBN||mechanism-19/NN	nn||edema-22/NN||brain-21/NN	prep_of||mechanism-19/NN||edema-22/NN	prep_in||involved-16/VBN||alf-24/NN	amod||evidence-27/NN||emerging-26/VBG	nsubj||suggests-28/VBZ||evidence-27/NN	root||ROOT-0/null||suggests-28/VBZ	mark||contribute-33/VBP||that-29/IN	amod||cytokines-31/NNS||inflammatory-30/JJ	nsubj||contribute-33/VBP||cytokines-31/NNS	advmod||contribute-33/VBP||also-32/RB	ccomp||suggests-28/VBZ||contribute-33/VBP	det||process-36/NN||this-35/DT	prep_to||contribute-33/VBP||process-36/NN	edema-22||ammonia-14||no_rel||in addition to the traditional view that elevated levels of blood and brain ammonia are involved in the mechanism of brain edema in alf, emerging evidence suggests that inflammatory cytokines also contribute to this process.
nsubjpass||prescribed-4/VBN||furosemide-1/NN	auxpass||prescribed-4/VBN||is-2/VBZ	advmod||prescribed-4/VBN||commonly-3/RB	root||ROOT-0/null||prescribed-4/VBN	advmod||ill-7/JJ||critically-6/RB	amod||patients-8/NNS||ill-7/JJ	prep_in||prescribed-4/VBN||patients-8/NNS	amod||injury-12/NN||acute-10/JJ	nn||injury-12/NN||kidney-11/NN	prep_with||patients-8/NNS||injury-12/NN	appos||injury-12/NN||aki-14/NN	aki-14||furosemide-1||yes||furosemide is commonly prescribed in critically ill patients with acute kidney injury (aki).
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||trial-8/NN||a-4/DT	amod||trial-8/NN||prospective-5/JJ	nn||trial-8/NN||phase-6/NN	nn||trial-8/NN||ii-7/NN	prep_on||report-2/VBP||trial-8/NN	num||patients-11/NNS||32-10/CD	prep_of||trial-8/NN||patients-11/NNS	nsubj||underwent-13/VBD||patients-11/NNS	rcmod||patients-11/NNS||underwent-13/VBD	amod||transplantation-18/NN||unrelated-14/JJ	nn||transplantation-18/NN||donor-15/NN	nn||transplantation-18/NN||hematopoietic-16/NN	nn||transplantation-18/NN||cell-17/NN	dobj||underwent-13/VBD||transplantation-18/NN	det||sirolimus-24/NNS||a-21/DT	nn||sirolimus-24/NNS||tacrolimus-22/NNS	prep_with||underwent-13/VBD||sirolimus-24/NNS	nn||globulin-28/NN||rabbit-26/NN	amod||globulin-28/NN||anti-thymoctye-27/JJ	prep_with||underwent-13/VBD||globulin-28/NN	conj_and||sirolimus-24/NNS||globulin-28/NN	vmod||sirolimus-24/NNS||gvhd-29/VBN	amod||regimen-31/NN||prophylactic-30/JJ	dobj||gvhd-29/VBN||regimen-31/NN	gvhd-29||tacrolimus-22||yes||we report on a prospective phase ii trial of 32 patients who underwent unrelated donor hematopoietic cell transplantation, with a tacrolimus, sirolimus and rabbit anti-thymoctye globulin gvhd prophylactic regimen.
nsubj||blinded-11/NN||this-1/DT	cop||blinded-11/NN||is-2/VBZ	det||blinded-11/NN||a-3/DT	amod||blinded-11/NN||prospective-4/JJ	amod||blinded-11/NN||randomised-6/JJ	amod||blinded-11/NN||controlled-8/JJ	amod||blinded-11/NN||patient-10/JJ	root||ROOT-0/null||blinded-11/NN	nsubj||evaluates-23/VBZ||blinded-11/NN	nn||blinded-14/NN||observer-13/NN	conj_and||blinded-11/NN||blinded-14/NN	nsubj||evaluates-23/VBZ||blinded-14/NN	amod||trial-20/NN||single-16/JJ	nn||trial-20/NN||centre-17/NN	nn||trial-20/NN||phase-18/NN	nn||trial-20/NN||i-ii-19/NN	appos||blinded-11/NN||trial-20/NN	rcmod||blinded-11/NN||evaluates-23/VBZ	det||safety-25/NN||the-24/DT	dobj||evaluates-23/VBZ||safety-25/NN	amod||gel-29/NN||a-partâ-27/JJ	amod||gel-29/NN||®-28/JJ	prep_of||safety-25/NN||gel-29/NN	mark||prophylaxis-33/VBZ||as-30/IN	det||adhesion-32/NN||an-31/DT	nsubj||prophylaxis-33/VBZ||adhesion-32/NN	advcl||evaluates-23/VBZ||prophylaxis-33/VBZ	amod||surgery-38/NN||major-35/JJ	amod||surgery-38/NN||abdominal-36/JJ	nn||surgery-38/NN||wall-37/NN	prep_after||prophylaxis-33/VBZ||surgery-38/NN	prep_in||surgery-38/NN||comparison-41/NN	det||group-46/NN||an-43/DT	amod||group-46/NN||untreated-44/JJ	nn||group-46/NN||control-45/NN	prep_to||prophylaxis-33/VBZ||group-46/NN	i---1||adhesion-32||no_rel||this is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase i-ii trial, which evaluates the safety of a-partâ® gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group.
amod||anti-inflammatorydrugs-2/NNS||non-steroidal-1/JJ	nsubj||drugs-8/NNS||anti-inflammatorydrugs-2/NNS	cop||drugs-8/NNS||are-3/VBP	det||drugs-8/NNS||the-4/DT	advmod||prescribed-7/JJ||most-5/RBS	advmod||prescribed-7/JJ||commonly-6/RB	amod||drugs-8/NNS||prescribed-7/JJ	root||ROOT-0/null||drugs-8/NNS	prep_for||drugs-8/NNS||arthritis-10/NN	prep_for||drugs-8/NNS||inflammation-12/NN	conj_and||arthritis-10/NN||inflammation-12/NN	amod||protection-16/NN||cardiovascular-15/JJ	prep_for||drugs-8/NNS||protection-16/NN	conj_and||arthritis-10/NN||protection-16/NN	arthritis-10||anti-inflammatorydrugs-2||no_rel||non-steroidal anti-inflammatorydrugs are the most commonly prescribed drugs for arthritis, inflammation, and cardiovascular protection.
amod||drugs-2/NNS||chemotherapeutic-1/JJ	nsubjpass||delivered-11/VBN||drugs-2/NNS	advmod||developed-5/JJ||newly-4/RB	amod||antibodies-8/NNS||developed-5/JJ	amod||antibodies-8/NNS||therapeutic-6/JJ	amod||antibodies-8/NNS||monoclonal-7/JJ	conj_and||drugs-2/NNS||antibodies-8/NNS	nsubjpass||delivered-11/VBN||antibodies-8/NNS	auxpass||delivered-11/VBN||are-9/VBP	advmod||delivered-11/VBN||adequately-10/RB	root||ROOT-0/null||delivered-11/VBN	advmod||solid-14/JJ||most-13/RBS	amod||tumors-17/NNS||solid-14/JJ	conj_and||solid-14/JJ||systemic-16/JJ	amod||tumors-17/NNS||systemic-16/JJ	prep_to||delivered-11/VBN||tumors-17/NNS	tumors-17||antibodies-8||no_rel||chemotherapeutic drugs and newly developed therapeutic monoclonal antibodies are adequately delivered to most solid and systemic tumors.
det||review-3/NN||this-2/DT	prep_in||explore-6/VB||review-3/NN	nsubj||explore-6/VB||we-5/PRP	root||ROOT-0/null||explore-6/VB	det||link-11/NN||a-7/DT	advmod||unrecognised-9/JJ||previously-8/RB	amod||link-11/NN||unrecognised-9/JJ	amod||link-11/NN||genetic-10/JJ	dobj||explore-6/VB||link-11/NN	prep_between||link-11/NN||ts-13/NN	det||series-17/NN||a-15/DT	amod||series-17/NN||competing-16/VBG	dobj||explore-6/VB||series-17/NN	conj_and||link-11/NN||series-17/NN	nsubj||links-56/VBZ||series-17/NN	amod||complexes-20/NNS||trans-synaptic-19/JJ	prep_of||series-17/NN||complexes-20/NNS	dep||series-17/NN||neurexins-22/NNS	appos||neurexins-22/NNS||nrxns-24/NNS	appos||neurexins-22/NNS||neuroligins-27/NNS	appos||neuroligins-27/NNS||nlgns-29/NNS	amod||proteins-35/NNS||leucine-rich-32/JJ	nn||proteins-35/NNS||repeat-33/NN	nn||proteins-35/NNS||transmembrane-34/NN	appos||neurexins-22/NNS||proteins-35/NNS	dep||proteins-35/NNS||lrrtms-37/VBZ	amod||neuronals-43/NNS||leucine-40/JJ	amod||neuronals-43/NNS||rich-41/JJ	nn||neuronals-43/NNS||repeat-42/NN	appos||neurexins-22/NNS||neuronals-43/NNS	appos||neuronals-43/NNS||lrrns-45/NNS	nn||precursor-49/NN||cerebellin-48/NN	dep||series-17/NN||precursor-49/NN	conj_and||neurexins-22/NNS||precursor-49/NN	dep||precursor-49/NN||2-50/CD	appos||2-50/CD||cbln2-52/NNP	rcmod||series-17/NN||links-56/VBZ	dobj||links-56/VBZ||it-57/PRP	nn||disorder-61/NN||autism-59/NN	nn||disorder-61/NN||spectrum-60/NN	prep_with||links-56/VBZ||disorder-61/NN	amod||pathways-64/NNS||neurodevelopmental-63/JJ	prep_through||disorder-61/NN||pathways-64/NNS	leucine-40||ts-13||no_rel||in this review, we explore a previously unrecognised genetic link between ts and a competing series of trans-synaptic complexes (neurexins (nrxns), neuroligins (nlgns), leucine-rich repeat transmembrane proteins (lrrtms), leucine rich repeat neuronals (lrrns) and cerebellin precursor 2 (cbln2)) that links it with autism spectrum disorder through neurodevelopmental pathways.
det||incidence-2/NN||the-1/DT	nsubj||lower-9/JJR||incidence-2/NN	amod||pain-6/NN||microemulsion-4/JJ	amod||pain-6/NN||propofol-induced-5/JJ	prep_of||incidence-2/NN||pain-6/NN	cop||lower-9/JJR||was-7/VBD	advmod||lower-9/JJR||significantly-8/RB	root||ROOT-0/null||lower-9/JJR	det||group-25/NN||the-11/DT	nn||group-25/NN||lr-12/NN	num||lr-12/NN||0.3-13/CD	conj_and||lr-12/NN||lr-15/NN	nn||group-25/NN||lr-15/NN	num||lr-15/NN||0.5-16/CD	advmod||lr-12/NN||lr-18/RB	conj_and||lr-12/NN||lr-18/RB	nn||group-25/NN||lr-18/RB	num||groups-20/NNS||1.0-19/CD	npadvmod||than-21/IN||groups-20/NNS	advmod||lr-12/NN||than-21/IN	det||ls-24/NN||the-23/DT	prep_in||lr-12/NN||ls-24/NN	prep_in||lower-9/JJR||group-25/NN	num||%-28/NN||37.5-27/CD	dep||group-25/NN||%-28/NN	num||%-31/NN||12.5-30/CD	dep||group-25/NN||%-31/NN	conj_and||%-28/NN||%-31/NN	num||vs-35/NN||10-33/CD	nn||vs-35/NN||%-34/NN	dep||group-25/NN||vs-35/NN	conj_and||%-28/NN||vs-35/NN	num||%-37/NN||65-36/CD	dep||vs-35/NN||%-37/NN	advmod||vs-35/NN||respectively-39/RB	pain-6||propofol--1||yes||the incidence of microemulsion propofol-induced pain was significantly lower in the lr 0.3, lr 0.5 and lr 1.0 groups than in the ls group (37.5%, 12.5% and 10% vs 65%, respectively).
nsubj||observed-3/VBD||we-1/PRP	advmod||observed-3/VBD||serendipitous-2/RB	root||ROOT-0/null||observed-3/VBD	det||tolerability-6/NN||an-4/DT	nn||tolerability-6/NN||increase-5/NN	dobj||observed-3/VBD||tolerability-6/NN	det||response-10/NN||a-8/DT	amod||response-10/NN||rapid-9/JJ	dobj||observed-3/VBD||response-10/NN	conj_and||tolerability-6/NN||response-10/NN	prep_to||response-10/NN||therapy-12/NN	det||onset-16/NN||an-14/DT	amod||onset-16/NN||early-15/JJ	dobj||observed-3/VBD||onset-16/NN	conj_and||tolerability-6/NN||onset-16/NN	amod||activity-20/NN||antidepressant-18/JJ	nn||activity-20/NN||fluvoxamine-19/NN	prep_of||onset-16/NN||activity-20/NN	advmod||associated-22/VBN||when-21/WRB	advcl||observed-3/VBD||associated-22/VBN	prep_with||associated-22/VBN||amisulpride-24/NN	prep_in||associated-22/VBN||patients-26/NNS	amod||depressivedisorder-29/NN||major-28/JJ	prep_with||associated-22/VBN||depressivedisorder-29/NN	fluvoxamine-19||depressivedisorder-29||no_rel||we serendipitous observed an increase tolerability, a rapid response to therapy and an early onset of antidepressant fluvoxamine activity when associated with amisulpride in patients with major depressivedisorder.
det||action-3/NN||the-1/DT	amod||action-3/NN||insulinotropic-2/JJ	nsubjpass||impaired-14/VBN||action-3/NN	det||polypeptide-9/NN||the-5/DT	amod||polypeptide-9/NN||incretin-6/JJ	amod||polypeptide-9/NN||glucose-dependent-7/JJ	amod||polypeptide-9/NN||insulinotropic-8/JJ	prep_of||action-3/NN||polypeptide-9/NN	appos||polypeptide-9/NN||gip-11/NN	auxpass||impaired-14/VBN||is-13/VBZ	root||ROOT-0/null||impaired-14/VBN	prep_in||impaired-14/VBN||type2diabetes-16/CD	mark||preserved-28/VBN||while-18/IN	det||effect-20/NN||the-19/DT	nsubjpass||preserved-28/VBN||effect-20/NN	amod||peptide-1-23/NN||glucagon-like-22/JJ	prep_of||effect-20/NN||peptide-1-23/NN	dep||peptide-1-23/NN||glp-1-25/JJ	auxpass||preserved-28/VBN||is-27/VBZ	advcl||impaired-14/VBN||preserved-28/VBN	type2diabetes-16||glucagon--1||no_rel||the insulinotropic action of the incretin glucose-dependent insulinotropic polypeptide (gip) is impaired in type2diabetes, while the effect of glucagon-like peptide-1 (glp-1) is preserved.
nsubj||activate-6/VB||infections-1/NNS	amod||viruses-4/NNS||respiratory-3/JJ	prep_with||infections-1/NNS||viruses-4/NNS	aux||activate-6/VB||can-5/MD	root||ROOT-0/null||activate-6/VB	det||response-10/NN||the-7/DT	amod||response-10/NN||innate-8/JJ	amod||response-10/NN||immune-9/JJ	dobj||activate-6/VB||response-10/NN	det||mechanism-16/NN||an-12/DT	amod||mechanism-16/NN||important-13/JJ	nn||mechanism-16/NN||host-14/NN	nn||mechanism-16/NN||defence-15/NN	dep||response-10/NN||mechanism-16/NN	det||stage-20/NN||the-18/DT	amod||stage-20/NN||early-19/JJ	prep_in||mechanism-16/NN||stage-20/NN	prep_of||stage-20/NN||viralinfection-22/NN	viralinfection-22||viruses-4||no||infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viralinfection.
dep||is-3/VBZ||fludarabine-1/JJ	root||ROOT-0/null||is-3/VBZ	nsubj||is-3/VBZ||one-4/CD	det||agents-10/NNS||the-6/DT	advmod||active-8/JJ||most-7/RBS	amod||agents-10/NNS||active-8/JJ	amod||agents-10/NNS||single-9/JJ	prep_of||one-4/CD||agents-10/NNS	det||treatment-13/NN||the-12/DT	prep_in||agents-10/NNS||treatment-13/NN	prep_of||treatment-13/NN||chroniclymphocyticleukemia-15/NN	appos||chroniclymphocyticleukemia-15/NN||cll-17/NN	chroniclymphocyticleukemia-15||fludarabine-1||yes||fludarabine, is one of the most active single agents in the treatment of chroniclymphocyticleukemia (cll).
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	hypertension-28||diuretic-32||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
nsubj||presumptive-5/VB||the-2/DT	dep||rejected-11/VBN||presumptive-5/VB	dobj||presumptive-5/VB||malaria-6/NN	nsubjpass||rejected-11/VBN||diagnosis-9/NN	auxpass||rejected-11/VBN||was-10/VBD	ccomp||=-28/VBZ||rejected-11/VBN	advmod||frequently-13/RB||more-12/RBR	advmod||rejected-11/VBN||frequently-13/RB	prep_in||frequently-13/RB||hivpositive-15/NN	appos||hivpositive-15/NN||20/31-17/CD	dep||rejected-11/VBN||than-19/IN	prep_in||rejected-11/VBN||hiv-21/NN	advmod||patients-23/VBN||negative-22/JJ	vmod||hiv-21/NN||patients-23/VBN	dobj||patients-23/VBN||2/10-25/CD	nsubj||=-28/VBZ||p-27/NN	root||ROOT-0/null||=-28/VBZ	dobj||=-28/VBZ||0.023-29/CD	hivpositive-15||hiv-21||no||" the ""presumptive malaria"" diagnosis was rejected more frequently in hivpositive (20/31) than in hiv negative patients (2/10, p = 0.023)."
amod||research-2/NN||further-1/JJ	nsubj||critical-23/JJ||research-2/NN	det||prevalence-5/NN||the-4/DT	prep_on||research-2/NN||prevalence-5/NN	amod||acceptance-8/NN||hiv-related-7/JJ	prep_of||prevalence-5/NN||acceptance-8/NN	prep_of||prevalence-5/NN||stigma-10/NN	conj_and||acceptance-8/NN||stigma-10/NN	prep_among||prevalence-5/NN||caregivers-12/NNS	prep_among||prevalence-5/NN||implications-14/NNS	conj_and||caregivers-12/NNS||implications-14/NNS	amod||stigma-17/NN||such-16/JJ	prep_of||caregivers-12/NNS||stigma-17/NN	nn||development-20/NN||child-19/NN	prep_for||stigma-17/NN||development-20/NN	aux||critical-23/JJ||will-21/MD	cop||critical-23/JJ||be-22/VB	root||ROOT-0/null||critical-23/JJ	mark||responds-28/VBZ||as-24/IN	det||community-27/NN||the-25/DT	nn||community-27/NN||policy-26/NN	nsubj||responds-28/VBZ||community-27/NN	advcl||critical-23/JJ||responds-28/VBZ	det||crisis-34/NN||the-30/DT	amod||crisis-34/NN||global-31/JJ	amod||crisis-34/NN||hiv/aids-32/JJ	amod||crisis-34/NN||orphan-33/JJ	prep_to||responds-28/VBZ||crisis-34/NN	aids--1||hiv--1||no||further research on the prevalence of hiv-related acceptance and stigma among caregivers and implications of such stigma for child development will be critical as the policy community responds to the global hiv/aids orphan crisis.
nsubj||examine-2/VBP||we-1/PRP	root||ROOT-0/null||examine-2/VBP	dobj||examine-2/VBP||relationships-3/NNS	nn||trends-6/NNS||market-5/NN	prep_between||relationships-3/NNS||trends-6/NNS	nn||organization-10/NN||world-8/NN	nn||organization-10/NN||health-9/NN	nsubj||hiv/aids-14/VBZ||organization-10/NN	nsubj||unitaid-71/VBD||organization-10/NN	dep||organization-10/NN||who-12/WP	conj_and||examine-2/VBP||hiv/aids-14/VBZ	nn||guidelines-16/NNS||treatment-15/NN	dobj||hiv/aids-14/VBZ||guidelines-16/NNS	nsubj||prequalification-19/VBP||guidelines-16/NNS	rcmod||guidelines-16/NNS||prequalification-19/VBP	dobj||prequalification-19/VBP||programme-20/NN	nsubj||prequal-23/VBP||who-22/WP	dep||programme-20/NN||prequal-23/VBP	amod||states-27/NNS||united-26/VBN	dobj||prequalification-19/VBP||states-27/NNS	conj_and||programme-20/NN||states-27/NNS	dep||states-27/NNS||us-29/PRP	dep||programme-20/NN||food-31/NN	nn||administration-34/NN||drug-33/NN	dobj||prequalification-19/VBP||administration-34/NN	conj_and||programme-20/NN||administration-34/NN	appos||administration-34/NN||fda-36/NN	dep||administration-34/NN||approvals-38/NNS	amod||policies-42/NNS||procurement-41/JJ	dobj||hiv/aids-14/VBZ||policies-42/NNS	conj_and||guidelines-16/NNS||policies-42/NNS	nsubj||prequalification-19/VBP||policies-42/NNS	det||fund-46/NN||the-44/DT	amod||fund-46/NN||global-45/JJ	prep_of||policies-42/NNS||fund-46/NN	aux||fight-48/VB||to-47/TO	vmod||fund-46/NN||fight-48/VB	dobj||fight-48/VB||aids-49/NNS	appos||aids-49/NNS||tuberculosis-51/NNP	dobj||fight-48/VB||malaria-54/NN	conj_and||aids-49/NNS||malaria-54/NN	appos||malaria-54/NN||gfatm-56/NNP	nsubj||plan-63/NN||us-59/PRP	poss||plan-63/NN||president-60/NN	nn||plan-63/NN||emergency-62/NN	xcomp||fight-48/VB||plan-63/NN	nn||relief-66/NN||aids-65/NNS	prep_for||plan-63/NN||relief-66/NN	appos||relief-66/NN||pepfar-68/NN	conj_and||examine-2/VBP||unitaid-71/VBD	conj_and||hiv/aids-14/VBZ||unitaid-71/VBD	aids-65||hiv--1||no||we examine relationships between market trends and world health organization (who) hiv/aids treatment guidelines; who prequalification programme (who prequal) and united states (us) food and drug administration (fda) approvals; and procurement policies of the global fund to fight aids, tuberculosis, and malaria (gfatm), us president's emergency plan for aids relief (pepfar) and unitaid.
det||finding-2/NN||the-1/DT	nsubj||reinforces-20/VBZ||finding-2/NN	mark||give-11/VB||that-3/IN	num||%-5/NN||23.9-4/CD	nsubj||give-11/VB||%-5/NN	amod||records-8/NNS||matched-7/VBN	prep_of||%-5/NN||records-8/NNS	aux||give-11/VB||did-9/VBD	neg||give-11/VB||not-10/RB	dep||finding-2/NN||give-11/VB	dobj||give-11/VB||hiv-12/NN	dobj||give-11/VB||acquiredimmunodeficiencysyndrome-14/NN	conj_or||hiv-12/NN||acquiredimmunodeficiencysyndrome-14/NN	det||cause-17/NN||the-16/DT	prep_as||give-11/VB||cause-17/NN	prep_of||cause-17/NN||death-19/NN	root||ROOT-0/null||reinforces-20/VBZ	det||need-22/NN||the-21/DT	dobj||reinforces-20/VBZ||need-22/NN	aux||search-24/VB||to-23/TO	vmod||need-22/NN||search-24/VB	amod||databases-27/NNS||all-cause-25/JJ	nn||databases-27/NNS||mortality-26/NN	dobj||search-24/VB||databases-27/NNS	dobj||search-24/VB||alerts-29/NNS	conj_and||databases-27/NNS||alerts-29/NNS	amod||underestimation-32/NN||possible-31/JJ	prep_for||databases-27/NNS||underestimation-32/NN	nn||rates-35/NNS||death-34/NN	prep_of||underestimation-32/NN||rates-35/NNS	acquiredimmunodeficiencysyndrome-14||hiv-12||no||the finding that 23.9% of matched records did not give hiv or acquiredimmunodeficiencysyndrome as the cause of death reinforces the need to search all-cause mortality databases and alerts for possible underestimation of death rates.
nsubj||lungdisease-5/NN||silicosis-1/NNS	cop||lungdisease-5/NN||is-2/VBZ	det||lungdisease-5/NN||a-3/DT	amod||lungdisease-5/NN||chronic-4/JJ	root||ROOT-0/null||lungdisease-5/NN	vmod||lungdisease-5/NN||characterized-6/VBN	amod||lesions-11/NNS||granulomatous-8/JJ	conj_and||granulomatous-8/JJ||fibrotic-10/JJ	amod||lesions-11/NNS||fibrotic-10/JJ	agent||characterized-6/VBN||lesions-11/NNS	nsubj||occurs-14/VBZ||lesions-11/NNS	rcmod||lesions-11/NNS||occurs-14/VBZ	acomp||occurs-14/VBZ||due-15/JJ	prep_to||due-15/JJ||accumulation-17/NN	amod||particles-22/NNS||respirable-19/JJ	nn||particles-22/NNS||silica-20/NN	nn||particles-22/NNS||mineral-21/NN	prep_of||accumulation-17/NN||particles-22/NNS	silicosis-1||silica-20||no||silicosis is a chronic lungdisease characterized by granulomatous and fibrotic lesions, which occurs due to accumulation of respirable silica mineral particles.
amod||coronavirus-2/NNS||severeacuterespiratorysyndrome-associated-1/JJ	nsubj||spreads-6/VBZ||coronavirus-2/NNS	nsubj||has-9/VBZ||coronavirus-2/NNS	appos||coronavirus-2/NNS||sars-cov-4/NNP	root||ROOT-0/null||spreads-6/VBZ	advmod||spreads-6/VBZ||rapidly-7/RB	conj_and||spreads-6/VBZ||has-9/VBZ	det||rate-13/NN||a-10/DT	amod||rate-13/NN||high-11/JJ	amod||rate-13/NN||case-mortality-12/JJ	dobj||has-9/VBZ||rate-13/NN	severeacuterespiratorysyndrome--1||sars-cov-4||no||severeacuterespiratorysyndrome-associated coronavirus (sars-cov) spreads rapidly and has a high case-mortality rate.
nn||binding-2/NN||virus-1/NN	nsubjpass||conducted-7/VBN||binding-2/NN	nsubj||determine-9/VB||binding-2/NN	nn||experiments-5/NNS||infection-4/NN	conj_and||binding-2/NN||experiments-5/NNS	nsubjpass||conducted-7/VBN||experiments-5/NNS	nsubj||determine-9/VB||experiments-5/NNS	auxpass||conducted-7/VBN||were-6/VBD	root||ROOT-0/null||conducted-7/VBN	aux||determine-9/VB||to-8/TO	xcomp||conducted-7/VBN||determine-9/VB	advmod||important-11/JJ||functionally-10/RB	amod||glycans-12/NNS||important-11/JJ	dobj||determine-9/VB||glycans-12/NNS	prep_for||determine-9/VB||influenzavirusinfection-14/NN	det||focus-18/NN||a-17/DT	prep_with||determine-9/VB||focus-18/NN	advmod||emerged-21/VBN||recently-20/RB	amod||viruses-23/NNS||emerged-21/VBN	amod||viruses-23/NNS||swine-22/JJ	prep_on||focus-18/NN||viruses-23/NNS	virusinfection--1||viruses-23||no||virus binding and infection experiments were conducted to determine functionally important glycans for influenzavirusinfection, with a focus on recently emerged swine viruses.
det||adults-3/NNS||these-2/DT	prep_of||had-10/VBD||adults-3/NNS	nsubj||hiv-infected-7/JJ||56-5/CD	cop||hiv-infected-7/JJ||were-6/VBD	dep||had-10/VBD||hiv-infected-7/JJ	nsubj||had-10/VBD||120-9/CD	root||ROOT-0/null||had-10/VBD	det||member-13/NN||a-11/DT	nn||member-13/NN||family-12/NN	dobj||had-10/VBD||member-13/NN	prep_with||member-13/NN||hiv/aids-15/NNS	nsubj||were-19/VBD||146-18/CD	conj_and||had-10/VBD||were-19/VBD	prep_in||were-19/VBD||households-21/NNS	amod||members-24/NNS||hiv-infected-23/JJ	prep_without||were-19/VBD||members-24/NNS	aids--1||hiv--1||no||of these adults, 56 were hiv-infected, 120 had a family member with hiv/aids, and 146 were in households without hiv-infected members.
nsubjpass||collected-3/VBN||strains-1/NNS	nsubjpass||tested-19/VBN||strains-1/NNS	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	num||patients-11/NNS||1824-5/CD	amod||patients-11/NNS||diagnosed-6/JJ	nn||patients-11/NNS||sputum-7/NN	amod||patients-11/NNS||smear-8/JJ	amod||patients-11/NNS||positive-9/JJ	nn||patients-11/NNS||pulmonarytb-10/NN	prep_from||collected-3/VBN||patients-11/NNS	amod||province-14/NN||jiangsu-13/JJ	prep_in||patients-11/NNS||province-14/NN	prep_of||province-14/NN||china-16/NN	advmod||tested-19/VBN||then-18/RB	conj_and||collected-3/VBN||tested-19/VBN	nn||susceptibility-22/NN||drug-21/NN	prep_for||tested-19/VBN||susceptibility-22/NN	prep_against||susceptibility-22/NN||rifampicin-24/NN	prep_against||susceptibility-22/NN||isoniazid-26/NN	conj_and||rifampicin-24/NN||isoniazid-26/NN	prep_against||susceptibility-22/NN||ethambutol-28/NN	conj_and||rifampicin-24/NN||ethambutol-28/NN	prep_against||susceptibility-22/NN||streptomycin-30/NN	conj_and||rifampicin-24/NN||streptomycin-30/NN	streptomycin-30||pulmonarytb-10||no_rel||strains were collected from 1824 diagnosed sputum smear positive pulmonarytb patients in jiangsu province of china and then tested for drug susceptibility against rifampicin, isoniazid, ethambutol and streptomycin.
mark||reported-7/VBN||since-1/IN	nn||infectivity-3/NN||prion-2/NN	nsubjpass||reported-7/VBN||infectivity-3/NN	aux||reported-7/VBN||had-4/VBD	neg||reported-7/VBN||never-5/RB	auxpass||reported-7/VBN||been-6/VBN	advcl||originating-13/VBG||reported-7/VBN	prep_in||reported-7/VBN||milk-9/NN	nn||products-12/NNS||dairy-11/NN	nsubj||originating-13/VBG||products-12/NNS	root||ROOT-0/null||originating-13/VBG	prep_from||originating-13/VBG||transmissiblespongiformencephalopathy-15/NN	appos||transmissiblespongiformencephalopathy-15/NN||tse-17/NN	amod||flocks-22/NNS||affected-20/JJ	nn||flocks-22/NNS||ruminant-21/NN	nsubj||enter-24/VB||flocks-22/NNS	advmod||enter-24/VB||currently-23/RB	parataxis||originating-13/VBG||enter-24/VB	dep||enter-24/VB||unrestricted-25/VBN	det||chain-32/NN||the-27/DT	nn||chain-32/NN||animal-28/NN	conj_and||animal-28/NN||human-30/NN	nn||chain-32/NN||human-30/NN	nn||chain-32/NN||food-31/NN	prep_into||unrestricted-25/VBN||chain-32/NN	transmissiblespongiformencephalopathy-15||prion-2||no||since prion infectivity had never been reported in milk, dairy products originating from transmissiblespongiformencephalopathy (tse)-affected ruminant flocks currently enter unrestricted into the animal and human food chain.
amod||publications-2/NNS||recent-1/JJ	nsubj||put-3/VBD||publications-2/NNS	root||ROOT-0/null||put-3/VBD	det||warning-6/NN||a-4/DT	amod||warning-6/NN||serious-5/JJ	dobj||put-3/VBD||warning-6/NN	det||inefficacy-9/NN||the-8/DT	prep_regarding||warning-6/NN||inefficacy-9/NN	amod||sp-13/NN||sulphadoxine-pyrimethamine-11/JJ	prep_of||inefficacy-9/NN||sp-13/NN	det||treatment-19/NN||the-16/DT	amod||treatment-19/NN||intermittent-17/JJ	nn||treatment-19/NN||preventive-18/NN	prep_for||sp-13/NN||treatment-19/NN	prep_of||treatment-19/NN||malaria-21/NN	amod||children-24/NNS||young-23/JJ	prep_in||malaria-21/NN||children-24/NNS	appos||children-24/NNS||ipti-26/NNP	malaria-21||pyrimethamine--1||no||recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (sp) for the intermittent preventive treatment of malaria in young children (ipti).
nsubjpass||reported-3/VBN||chemerin-1/NN	auxpass||reported-3/VBN||was-2/VBD	root||ROOT-0/null||reported-3/VBN	aux||modulate-5/VB||to-4/TO	ccomp||reported-3/VBN||modulate-5/VB	nn||sensitivity-7/NN||insulin-6/NN	dobj||modulate-5/VB||sensitivity-7/NN	amod||cells-13/NNS||adipocytes-9/JJ	conj_and||adipocytes-9/JJ||skeletal-11/JJ	amod||cells-13/NNS||skeletal-11/JJ	nn||cells-13/NNS||muscle-12/NN	prep_in||sensitivity-7/NN||cells-13/NNS	prep_in||modulate-5/VB||vitro-15/NN	aux||exacerbate-18/VB||to-17/TO	ccomp||reported-3/VBN||exacerbate-18/VB	conj_and||modulate-5/VB||exacerbate-18/VB	dobj||exacerbate-18/VB||glucoseintolerance-19/NN	amod||models-23/NNS||several-21/JJ	nn||models-23/NNS||mouse-22/NN	prep_in||exacerbate-18/VB||models-23/NNS	prep_in||models-23/NNS||vivo-25/NN	insulin-6||glucoseintolerance-19||no_rel||chemerin was reported to modulate insulin sensitivity in adipocytes and skeletal muscle cells in vitro and to exacerbate glucoseintolerance in several mouse models in vivo.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	virus-44||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
advmod||lower-9/JJR||moreover-1/RB	det||severity-4/NN||the-3/DT	nsubj||lower-9/JJR||severity-4/NN	prep_of||severity-4/NN||pain-6/NN	cop||lower-9/JJR||was-7/VBD	advmod||lower-9/JJR||significantly-8/RB	root||ROOT-0/null||lower-9/JJR	prep_in||lower-9/JJR||groups-11/NNS	nsubj||received-13/VBD||groups-11/NNS	nsubj||compared-22/VBN||groups-11/NNS	rcmod||groups-11/NNS||received-13/VBD	acomp||received-13/VBD||remifentanil-14/JJ	det||groups-20/NNS||the-16/DT	amod||groups-20/NNS||cold-17/JJ	conj_and||cold-17/JJ||combination-19/NN	amod||groups-20/NNS||combination-19/NN	prep_in||remifentanil-14/JJ||groups-20/NNS	advmod||compared-22/VBN||when-21/WRB	advcl||received-13/VBD||compared-22/VBN	det||group-26/NN||the-24/DT	nn||group-26/NN||control-25/NN	prep_with||compared-22/VBN||group-26/NN	pain-6||remifentanil-14||yes||moreover, the severity of pain was significantly lower in groups that received remifentanil in the cold and combination groups when compared with the control group.
nsubj||diseases-5/NNS||priondiseases-1/NNS	cop||diseases-5/NNS||are-2/VBP	amod||diseases-5/NNS||fatal-3/JJ	nn||diseases-5/NNS||neurodegenerative-4/NN	root||ROOT-0/null||diseases-5/NNS	vmod||diseases-5/NNS||associated-6/VBN	det||conversion-9/NN||the-8/DT	prep_with||associated-6/VBN||conversion-9/NN	amod||prionprotein-12/NN||cellular-11/JJ	prep_of||conversion-9/NN||prionprotein-12/NN	dep||prionprotein-12/NN||prpc-14/JJ	det||system-20/NN||the-17/DT	amod||system-20/NN||central-18/JJ	amod||system-20/NN||nervous-19/JJ	prep_in||prionprotein-12/NN||system-20/NN	det||isoform-24/NN||the-22/DT	amod||isoform-24/NN||infectious-23/JJ	prep_into||associated-6/VBN||isoform-24/NN	dep||isoform-24/NN||prpsc-26/JJ	prionprotein-12||priondiseases-1||no_rel||priondiseases are fatal neurodegenerative diseases associated with the conversion of cellular prionprotein (prpc) in the central nervous system into the infectious isoform (prpsc).
num||weeks-3/NNS||12-2/CD	prep_at||%-14/NN||weeks-3/NNS	det||proportions-6/NNS||the-5/DT	nsubj||%-14/NN||proportions-6/NNS	prep_of||proportions-6/NNS||subjects-8/NNS	nsubj||had-10/VBD||subjects-8/NNS	rcmod||subjects-8/NNS||had-10/VBD	dobj||had-10/VBD||hypocalcemia-11/NN	cop||%-14/NN||were-12/VBD	num||%-14/NN||5.4-13/CD	root||ROOT-0/null||%-14/NN	num||%-17/NN||19.5-16/CD	conj_and||%-14/NN||%-17/NN	det||calciumacetate-20/NN||the-19/DT	prep_for||%-14/NN||calciumacetate-20/NN	det||groups-24/NNS||the-22/DT	nn||groups-24/NNS||placebo-23/NN	prep_for||%-14/NN||groups-24/NNS	conj_and||calciumacetate-20/NN||groups-24/NNS	advmod||%-14/NN||respectively-26/RB	mark||%-37/NN||while-28/IN	det||proportions-30/NNS||the-29/DT	nsubj||%-37/NN||proportions-30/NNS	prep_of||proportions-30/NNS||those-32/DT	prep_with||those-32/DT||hypercalcemia-34/NN	cop||%-37/NN||were-35/VBD	num||%-37/NN||13.5-36/CD	advcl||%-14/NN||%-37/NN	num||%-40/NN||0-39/CD	advcl||%-14/NN||%-40/NN	conj_and||%-37/NN||%-40/NN	advmod||%-37/NN||respectively-42/RB	hypocalcemia-11||calciumacetate-20||yes||at 12 weeks, the proportions of subjects who had hypocalcemia were 5.4% and 19.5% for the calciumacetate and the placebo groups, respectively, while the proportions of those with hypercalcemia were 13.5% and 0%, respectively.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
amod||dysfunction-2/NN||endothelial-1/JJ	nsubj||present-5/JJ||dysfunction-2/NN	nsubjpass||induced-15/VBN||dysfunction-2/NN	cop||present-5/JJ||is-3/VBZ	advmod||present-5/JJ||frequently-4/RB	root||ROOT-0/null||present-5/JJ	prep_in||present-5/JJ||individuals-7/NNS	prep_with||individuals-7/NNS||insulinresistance-9/NN	prep_with||individuals-7/NNS||type2diabetes-11/NNS	conj_or||insulinresistance-9/NN||type2diabetes-11/NNS	aux||induced-15/VBN||can-13/MD	auxpass||induced-15/VBN||be-14/VB	conj_and||present-5/JJ||induced-15/VBN	amod||meals-20/NNS||high-fat-17/JJ	conj_or||high-fat-17/JJ||high-carbohydrate-19/JJ	amod||meals-20/NNS||high-carbohydrate-19/JJ	agent||induced-15/VBN||meals-20/NNS	fat--1||insulinresistance-9||no_rel||endothelial dysfunction is frequently present in individuals with insulinresistance or type2diabetes and can be induced by high-fat or high-carbohydrate meals.
amod||autoinjectors-2/NNS||adrenaline-1/JJ	nsubjpass||prescribed-7/VBN||autoinjectors-2/NNS	nsubj||facilitate-9/VB||autoinjectors-2/NNS	appos||autoinjectors-2/NNS||aais-4/NNS	auxpass||prescribed-7/VBN||are-6/VBP	root||ROOT-0/null||prescribed-7/VBN	aux||facilitate-9/VB||to-8/TO	xcomp||prescribed-7/VBN||facilitate-9/VB	det||administration-12/NN||the-10/DT	nn||administration-12/NN||intramuscular-11/NN	dobj||facilitate-9/VB||administration-12/NN	prep_of||administration-12/NN||adrenaline-14/NN	prep_in||facilitate-9/VB||patients-16/NNS	vmod||patients-16/NNS||diagnosed-17/VBN	amod||anaphylaxis-20/NNS||life-threatening-19/JJ	prep_with||diagnosed-17/VBN||anaphylaxis-20/NNS	anaphylaxis-20||adrenaline-14||yes||adrenaline autoinjectors (aais) are prescribed to facilitate the intramuscular administration of adrenaline in patients diagnosed with life-threatening anaphylaxis.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||pyrazinamide-48||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubj||report-5/NN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	nsubj||reveals-7/VBZ||report-5/NN	rcmod||report-5/NN||reveals-7/VBZ	det||existence-9/NN||the-8/DT	dobj||reveals-7/VBZ||existence-9/NN	nsubj||differentiate-15/VB||existence-9/NN	det||profile-13/NN||a-11/DT	nn||profile-13/NN||microrna-12/NN	prep_of||existence-9/NN||profile-13/NN	rcmod||existence-9/NN||differentiate-15/VB	amod||clls-19/NNS||refractory-16/JJ	conj_and||refractory-16/JJ||sensitive-18/JJ	amod||clls-19/NNS||sensitive-18/JJ	dobj||differentiate-15/VB||clls-19/NNS	dep||clls-19/NNS||either-21/DT	dep||either-21/DT||before-22/RB	dep||clls-19/NNS||after-24/IN	conj_and||either-21/DT||after-24/IN	amod||mono-therapy-26/NN||fludarabine-25/JJ	pobj||after-24/IN||mono-therapy-26/NN	clls-19||fludarabine-25||yes||this is the first report that reveals the existence of a microrna profile that differentiate refractory and sensitive clls, either before and after fludarabine mono-therapy.
advmod||prescribed-18/VBN||however-1/RB	num||%-4/NN||20-3/CD	nsubjpass||prescribed-18/VBN||%-4/NN	num||â-7/NN||2686/13-6/CD	dep||%-4/NN||â-7/NN	dep||â-7/NN||$-8/$	number||557-10/CD||‰-9/CD	num||$-8/$||557-10/CD	prep_of||%-4/NN||children-13/NNS	prep_without||children-13/NNS||bacterialinfection-15/NN	auxpass||prescribed-18/VBN||were-16/VBD	advmod||prescribed-18/VBN||also-17/RB	root||ROOT-0/null||prescribed-18/VBN	dobj||prescribed-18/VBN||antibiotics-19/NNS	bacterialinfection-15||antibiotics-19||no_rel||however, 20% (2686/13â€‰557) of children without bacterialinfection were also prescribed antibiotics.
nsubj||virus-12/NN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	cop||virus-12/NN||is-5/VBZ	det||virus-12/NN||a-6/DT	amod||virus-12/NN||complex-7/JJ	amod||virus-12/NN||42-nm-8/JJ	advmod||double-stranded-10/JJ||predominantly-9/RB	amod||virus-12/NN||double-stranded-10/JJ	nn||virus-12/NN||dna-11/NN	root||ROOT-0/null||virus-12/NN	amod||surface-15/NN||distinct-14/JJ	prep_with||virus-12/NN||surface-15/NN	nn||antigens-18/NNS||core-17/NN	prep_with||virus-12/NN||antigens-18/NNS	conj_and||surface-15/NN||antigens-18/NNS	det||polymerase-23/NN||an-20/DT	amod||polymerase-23/NN||endogenous-21/JJ	nn||polymerase-23/NN||dna-22/NN	prep_with||virus-12/NN||polymerase-23/NN	conj_and||surface-15/NN||polymerase-23/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) is a complex 42-nm predominantly double-stranded dna virus with distinct surface and core antigens and an endogenous dna polymerase.
det||aim-2/NN||the-1/DT	nsubj||was-3/VBD||aim-2/NN	nsubj||investigate-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||investigate-5/VB||to-4/TO	xcomp||was-3/VBD||investigate-5/VB	det||efficacy-7/NN||the-6/DT	dobj||investigate-5/VB||efficacy-7/NN	amod||therapy-10/NN||icd-only-9/JJ	prep_of||efficacy-7/NN||therapy-10/NN	amod||prevention-13/NN||primary-12/JJ	prep_in||investigate-5/VB||prevention-13/NN	prep_in||investigate-5/VB||patients-15/NNS	prep_with||patients-15/NNS||cad-17/NN	prep_with||patients-15/NNS||dcm-19/NN	conj_or||cad-17/NN||dcm-19/NN	dcm-19||cad-17||no_rel||the aim was to investigate the efficacy of icd-only therapy in primary prevention in patients with cad or dcm.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	nsubj||was-2/VBD||increase-3/NN	nn||use-6/NN||cam-5/NN	prep_in||increase-3/NN||use-6/NN	det||diagnosis-9/NN||the-8/DT	prep_after||was-2/VBD||diagnosis-9/NN	prep_of||diagnosis-9/NN||cancer-11/NN	advmod||was-2/VBD||mainly-12/RB	amod||medicine-15/NN||chinese-14/JJ	prep_for||was-2/VBD||medicine-15/NN	prep_for||was-2/VBD||vitamins-17/NNS	conj_and||medicine-15/NN||vitamins-17/NNS	vitamins-17||cancer-11||no_rel||there was increase in cam use after the diagnosis of cancer mainly for chinese medicine and vitamins.
nn||infections-5/NNS||hepatitisbvirus-1/NNS	appos||infections-5/NNS||hbv-3/NN	nsubj||play-6/VBP||infections-5/NNS	root||ROOT-0/null||play-6/VBP	det||role-9/NN||an-7/DT	amod||role-9/NN||important-8/JJ	dobj||play-6/VBP||role-9/NN	det||development-12/NN||the-11/DT	prep_in||role-9/NN||development-12/NN	nn||carcinoma-15/NN||hepatocellular-14/NN	prep_of||development-12/NN||carcinoma-15/NN	appos||carcinoma-15/NN||hcc-17/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infections play an important role in the development of hepatocellular carcinoma (hcc).
det||re-introduction-3/NN||the-1/DT	amod||re-introduction-3/NN||intentional-2/JJ	nsubj||is-19/VBZ||re-introduction-3/NN	prep_of||re-introduction-3/NN||variolavirus-5/NNS	appos||variolavirus-5/NNS||varv-7/NNP	det||agent-11/NN||the-10/DT	appos||variolavirus-5/NNS||agent-11/NN	prep_of||agent-11/NN||smallpox-13/NN	det||population-18/NN||the-16/DT	amod||population-18/NN||human-17/JJ	prep_into||variolavirus-5/NNS||population-18/NN	root||ROOT-0/null||is-19/VBZ	amod||concern-22/NN||great-21/JJ	prep_of||is-19/VBZ||concern-22/NN	poss||potential-26/NN||its-24/PRP$	amod||potential-26/NN||bio-terroristic-25/JJ	prep_due||concern-22/NN||potential-26/NN	smallpox-13||variolavirus-5||no||the intentional re-introduction of variolavirus (varv), the agent of smallpox, into the human population is of great concern due its bio-terroristic potential.
nsubj||pathogen-19/NN||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||mtb-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-8/NN	prep_of||agent-8/NN||tuberculosis-10/NNP	appos||tuberculosis-10/NNP||tb-12/NN	cop||pathogen-19/NN||is-15/VBZ	det||pathogen-19/NN||a-16/DT	amod||pathogen-19/NN||facultative-17/JJ	nn||pathogen-19/NN||intracellular-18/NN	root||ROOT-0/null||pathogen-19/NN	nsubj||persist-22/VB||pathogen-19/NN	aux||persist-22/VB||can-21/MD	rcmod||pathogen-19/NN||persist-22/VB	det||host-25/NN||the-24/DT	prep_within||persist-22/VB||host-25/NN	tb-12||mtb-3||no||mycobacteriumtuberculosis ( mtb ), the causative agent of tuberculosis (tb), is a facultative intracellular pathogen that can persist within the host.
nn||triglyceride-3/NN||plasma-1/NN	amod||triglyceride-3/NN||total-2/JJ	nsubj||level-7/VBP||triglyceride-3/NN	appos||triglyceride-3/NN||tg-5/NN	root||ROOT-0/null||level-7/VBP	nsubjpass||studied-11/VBN||variations-8/NNS	aux||studied-11/VBN||have-9/VBP	auxpass||studied-11/VBN||been-10/VBN	ccomp||level-7/VBP||studied-11/VBN	prep_in||studied-11/VBN||patients-13/NNS	amod||virus-16/NN||hepatitisc-15/JJ	prep_with||patients-13/NNS||virus-16/NN	appos||virus-16/NN||hcv-18/NN	amod||chronichepatitis-22/NNS||related-21/VBN	dep||patients-13/NNS||chronichepatitis-22/NNS	dep||chronichepatitis-22/NNS||ch-c-24/JJ	chronichepatitis-22||triglyceride-3||no_rel||plasma total triglyceride (tg) level variations have been studied in patients with hepatitisc virus (hcv)-related chronichepatitis (ch-c).
root||ROOT-0/null||supervisors-1/NNS	neg||only-3/JJ||not-2/RB	dep||supervisors-1/NNS||only-3/JJ	conj_but||supervisors-1/NNS||had-4/VBD	aux||support-6/VB||to-5/TO	xcomp||had-4/VBD||support-6/VB	dobj||support-6/VB||chws-7/NNS	poss||attempts-10/NNS||their-9/PRP$	prep_in||support-6/VB||attempts-10/NNS	aux||offer-12/VB||to-11/TO	xcomp||had-4/VBD||offer-12/VB	nn||counselling-14/NN||peer-13/NN	dobj||offer-12/VB||counselling-14/NN	prep_to||offer-12/VB||mothers-16/NNS	nsubj||hivpositive-20/JJ||mothers-16/NNS	cop||hivpositive-20/JJ||were-18/VBD	advmod||hivpositive-20/JJ||potentially-19/RB	rcmod||mothers-16/NNS||hivpositive-20/JJ	nsubj||had-25/VBD||they-23/PRP	nsubj||deal-27/VB||they-23/PRP	advmod||had-25/VBD||also-24/RB	conj_but||supervisors-1/NNS||had-25/VBD	aux||deal-27/VB||to-26/TO	xcomp||had-25/VBD||deal-27/VB	prepc_with||deal-27/VB||supporting-29/VBG	amod||counsellors-32/NNS||hiv-positive-30/JJ	nn||counsellors-32/NNS||peer-31/NN	dobj||supporting-29/VBG||counsellors-32/NNS	hivpositive-20||hiv--1||no||supervisors not only had to support chws in their attempts to offer peer counselling to mothers who were potentially hivpositive, but they also had to deal with supporting hiv-positive peer counsellors.
advmod||fourfold-7/VBN||however-1/RB	det||response-5/NN||the-3/DT	nn||response-5/NN||glucagon-4/NN	nsubjpass||fourfold-7/VBN||response-5/NN	auxpass||fourfold-7/VBN||was-6/VBD	root||ROOT-0/null||fourfold-7/VBN	advmod||greater-10/JJR||fivefold-9/RB	prep_to||fourfold-7/VBN||greater-10/JJR	advmod||increase-16/VB||when-11/WRB	csubj||increase-16/VB||circulating-12/VBG	dobj||circulating-12/VBG||insulin-13/NN	aux||increase-16/VB||did-14/VBD	neg||increase-16/VB||not-15/RB	ccomp||greater-10/JJR||increase-16/VB	nn||hypoglycemia-20/NN||equivalent-19/NN	prep_despite||increase-16/VB||hypoglycemia-20/NN	amod||suppression-23/NN||c-peptide-22/JJ	prep_despite||increase-16/VB||suppression-23/NN	conj_and||hypoglycemia-20/NN||suppression-23/NN	hypoglycemia-20||glucagon-4||yes||however, the glucagon response was fourfold to fivefold greater when circulating insulin did not increase, despite equivalent hypoglycemia and c-peptide suppression.
advmod||-rrb--7/NNS||-lrb--1/RB	det||-rrb--7/NNS||a-2/DT	num||hepatitisbvirus-4/NNS||-rrb--3/CD	npadvmod||-lrb--5/JJ||hepatitisbvirus-4/NNS	amod||-rrb--7/NNS||-lrb--5/JJ	nn||-rrb--7/NNS||hbv-6/NN	nsubj||cause-12/NN||-rrb--7/NNS	cop||cause-12/NN||is-8/VBZ	advmod||cause-12/NN||now-9/RB	det||cause-12/NN||the-10/DT	amod||cause-12/NN||major-11/JJ	root||ROOT-0/null||cause-12/NN	amod||hepatitis-16/NN||infectious-14/JJ	amod||hepatitis-16/NN||viral-15/JJ	prep_of||cause-12/NN||hepatitis-16/NN	amod||personnel-20/NNS||u.s.-18/JJ	amod||personnel-20/NNS||military-19/JJ	prep_in||hepatitis-16/NN||personnel-20/NNS	advmod||hepatitis-16/NN||probably-22/RB	advmod||hepatitis-16/NN||also-23/RB	det||population-27/NN||the-25/DT	amod||population-27/NN||civilian-26/JJ	prep_in||hepatitis-16/NN||population-27/NN	conj_and||personnel-20/NNS||population-27/NN	num||years-30/NNS||15-29/CD	prep_over||population-27/NN||years-30/NNS	prep_of||years-30/NNS||age-32/NN	hbv-6||hepatitisbvirus-4||no||-lrb- a -rrb- hepatitisbvirus -lrb- hbv -rrb- is now the major cause of infectious viral hepatitis in u.s. military personnel and probably also in the civilian population over 15 years of age .
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||analogy-3/NN	amod||proteins-6/NNS||membrane-associated-5/JJ	prep_with||provides-2/VBZ||proteins-6/NNS	vmod||proteins-6/NNS||mediating-7/VBG	det||build-up-9/NN||the-8/DT	dobj||mediating-7/VBG||build-up-9/NN	prep_of||build-up-9/NN||â-11/NN	amod||build-up-9/NN||$-12/$	dep||$-12/$||œvirus-13/JJ	vmod||build-up-9/NN||factoriesâ-14/VBN	dobj||factoriesâ-14/VBN||$-15/$	quantmod||cells-17/CD||in-16/IN	num||$-15/$||cells-17/CD	vmod||$-15/$||infected-18/VBN	amod||viruses-23/NNS||diverse-20/JJ	amod||viruses-23/NNS||positive-strand-21/JJ	nn||viruses-23/NNS||rna-22/NN	prep_with||infected-18/VBN||viruses-23/NNS	amod||viruses-26/NNS||alpha-like-25/JJ	dep||viruses-23/NNS||viruses-26/NNS	amod||viruses-29/NNS||picorna-like-28/JJ	dep||viruses-23/NNS||viruses-29/NNS	conj_and||viruses-26/NNS||viruses-29/NNS	dep||viruses-23/NNS||flaviviruses-31/NNS	conj_and||viruses-26/NNS||flaviviruses-31/NNS	dep||viruses-23/NNS||nidoviruses-34/NNS	conj_and||viruses-26/NNS||nidoviruses-34/NNS	amod||viruses-39/NNS||negative-strand-37/JJ	nn||viruses-39/NNS||rna-38/NN	prep_with||infected-18/VBN||viruses-39/NNS	conj_and||viruses-23/NNS||viruses-39/NNS	appos||viruses-23/NNS||bunyaviruses-41/NNS	virus--1||viruses-39||no||this provides analogy with membrane-associated proteins mediating the build-up of â€œvirus factoriesâ€? in cells infected with diverse positive-strand rna viruses (alpha-like viruses, picorna-like viruses, flaviviruses, and nidoviruses) and negative-strand rna viruses (bunyaviruses).
det||observations-2/NNS||these-1/DT	nsubj||suggest-3/VBP||observations-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||complex-17/JJ||that-4/IN	det||pathogenesis-6/NNS||the-5/DT	nsubj||complex-17/JJ||pathogenesis-6/NNS	amod||hypertension-9/NN||postmenopausal-8/JJ	prep_of||pathogenesis-6/NNS||hypertension-9/NN	poss||complications-14/NNS||its-11/PRP$	nn||complications-14/NNS||target-12/NN	nn||complications-14/NNS||organ-13/NN	prep_of||pathogenesis-6/NNS||complications-14/NNS	conj_and||hypertension-9/NN||complications-14/NNS	cop||complex-17/JJ||is-15/VBZ	advmod||complex-17/JJ||more-16/RBR	ccomp||suggest-3/VBP||complex-17/JJ	mark||projected-19/VBD||than-18/IN	advcl||complex-17/JJ||projected-19/VBD	ccomp||complex-17/JJ||projected-19/VBD	mark||induces-27/VBZ||that-22/IN	nsubj||induces-27/VBZ||loss-23/NN	amod||estrogens-26/NNS||endogenous-25/JJ	prep_of||loss-23/NN||estrogens-26/NNS	advcl||complex-17/JJ||induces-27/VBZ	ccomp||complex-17/JJ||induces-27/VBZ	conj_and||projected-19/VBD||induces-27/VBZ	amod||changes-29/NNS||epigenetic-28/JJ	dobj||induces-27/VBZ||changes-29/NNS	nsubj||alter-31/VBP||changes-29/NNS	rcmod||changes-29/NNS||alter-31/VBP	amod||susceptibility-33/NN||genetic-32/JJ	dobj||alter-31/VBP||susceptibility-33/NN	amod||complications-36/NNS||end-organ-35/JJ	prep_to||alter-31/VBP||complications-36/NNS	nn||se-38/FW||per-37/FW	advmod||resulting-39/VBG||se-38/FW	xcomp||alter-31/VBP||resulting-39/VBG	amod||mechanisms-42/NNS||pathogenetic-41/JJ	prep_in||resulting-39/VBG||mechanisms-42/NNS	prep_beyond||resulting-39/VBG||correction-44/NN	nn||replacement-47/NN||hormone-46/NN	prep_by||resulting-39/VBG||replacement-47/NN	hypertension-9||estrogens-26||no_rel||these observations suggest that the pathogenesis of postmenopausal hypertension and its target organ complications is more complex than projected, and that loss of endogenous estrogens induces epigenetic changes that alter genetic susceptibility to end-organ complications per se resulting in pathogenetic mechanisms beyond correction by hormone replacement.
aux||investigate-2/VB||to-1/TO	root||ROOT-0/null||investigate-2/VB	mark||decrease-7/VB||if-3/IN	amod||analogs-6/NNS||long-acting-4/JJ	nn||analogs-6/NNS||insulin-5/NN	nsubj||decrease-7/VB||analogs-6/NNS	advcl||investigate-2/VB||decrease-7/VB	det||risk-9/NN||the-8/DT	dobj||decrease-7/VB||risk-9/NN	prep_of||risk-9/NN||diabeticketoacidosis-11/NNS	appos||diabeticketoacidosis-11/NNS||dka-13/NN	amod||individuals-17/NNS||young-16/JJ	prep_in||diabeticketoacidosis-11/NNS||individuals-17/NNS	prep_with||individuals-17/NNS||type1diabetes-19/CD	insulin-5||dka-13||no_rel||to investigate if long-acting insulin analogs decrease the risk of diabeticketoacidosis (dka) in young individuals with type1diabetes.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	det||progression-4/NN||the-3/DT	dobj||determine-2/VB||progression-4/NN	nn||weight-7/NN||body-6/NN	prep_of||progression-4/NN||weight-7/NN	appos||weight-7/NN||bw-9/NN	nn||composition-13/NN||body-12/NN	prep_of||progression-4/NN||composition-13/NN	conj_and||weight-7/NN||composition-13/NN	appos||weight-7/NN||bc-15/NN	prep_in||determine-2/VB||patients-18/NNS	amod||t2d-22/NNS||type2diabetesmellitus-20/JJ	prep_with||patients-18/NNS||t2d-22/NNS	nn||therapy-26/NN||insulin-25/NN	prep_on||t2d-22/NNS||therapy-26/NN	det||consequences-29/NNS||the-28/DT	prep_with||patients-18/NNS||consequences-29/NNS	conj_and||t2d-22/NNS||consequences-29/NNS	nn||strength-32/NN||muscle-31/NN	prep_on||consequences-29/NNS||strength-32/NN	appos||strength-32/NN||ms-34/NN	det||reflect-38/NN||a-37/DT	prep_as||determine-2/VB||reflect-38/NN	amod||increases-43/NNS||free-40/JJ	amod||increases-43/NNS||fat-41/JJ	nn||increases-43/NNS||mass-42/NN	prep_of||reflect-38/NN||increases-43/NNS	type2diabetesmellitus-20||insulin-25||yes||to determine the progression of body weight (bw) and body composition (bc) in patients with type2diabetesmellitus (t2d) on insulin therapy and the consequences on muscle strength (ms) as a reflect of free fat mass increases.
num||years-2/NNS||thirty-1/CD	npadvmod||later-3/RB||years-2/NNS	advmod||elucidated-32/VBN||later-3/RB	amod||studies-8/NNS||classic-6/JJ	amod||studies-8/NNS||controlled-7/JJ	prep_in||elucidated-32/VBN||studies-8/NNS	vmod||studies-8/NNS||conducted-9/VBN	prep_in||conducted-9/VBN||puppies-11/NNS	amod||rats-14/NNS||young-13/JJ	prep_in||conducted-9/VBN||rats-14/NNS	conj_and||puppies-11/NNS||rats-14/NNS	det||role-18/NN||the-16/DT	amod||role-18/NN||definitive-17/JJ	nsubjpass||elucidated-32/VBN||role-18/NN	prep_of||role-18/NN||calcium-20/NN	prep_of||role-18/NN||phosphate-22/NN	conj_and||calcium-20/NN||phosphate-22/NN	prep_of||role-18/NN||vitamind-24/NN	conj_and||calcium-20/NN||vitamind-24/NN	prep_in||role-18/NN||prevention-26/NN	prep_in||role-18/NN||therapy-28/NN	conj_and||prevention-26/NN||therapy-28/NN	prep_of||prevention-26/NN||rickets-30/NNS	auxpass||elucidated-32/VBN||was-31/VBD	root||ROOT-0/null||elucidated-32/VBN	rickets-30||vitamind-24||yes||thirty years later, in classic controlled studies conducted in puppies and young rats, the definitive role of calcium, phosphate and vitamind in prevention and therapy of rickets was elucidated.
agent||reported-56/VBN||employing-2/VBG	det||approach-6/NN||an-3/DT	amod||approach-6/NN||unbiased-4/JJ	amod||approach-6/NN||metagenomic-5/JJ	dobj||employing-2/VBG||approach-6/NN	nsubj||allows-9/VBZ||approach-6/NN	rcmod||approach-6/NN||allows-9/VBZ	det||detection-11/NN||the-10/DT	dobj||allows-9/VBZ||detection-11/NN	preconj||unexpected-14/JJ||both-13/DT	amod||agents-19/NNS||unexpected-14/JJ	advmod||unknown-17/JJ||previously-16/RB	conj_and||unexpected-14/JJ||unknown-17/JJ	amod||agents-19/NNS||unknown-17/JJ	amod||agents-19/NNS||infectious-18/JJ	prep_of||detection-11/NN||agents-19/NNS	det||detection-22/NN||the-21/DT	nsubjpass||reported-56/VBN||detection-22/NN	num||viruses-25/NNS||three-24/CD	prep_of||detection-22/NN||viruses-25/NNS	amod||virus-30/NN||aphid-27/JJ	amod||virus-30/NN||lethal-28/JJ	nn||virus-30/NN||paralysis-29/NN	appos||viruses-25/NNS||virus-30/NN	appos||virus-30/NN||alpv-32/NNP	amod||virus-38/NN||israel-35/JJ	amod||virus-38/NN||acute-36/JJ	nn||virus-38/NN||paralysis-37/NN	appos||viruses-25/NNS||virus-38/NN	conj_and||virus-30/NN||virus-38/NN	appos||virus-38/NN||iapv-40/NNP	nn||virus-46/NN||lake-44/NN	nn||virus-46/NN||sinai-45/NN	appos||viruses-25/NNS||virus-46/NN	conj_and||virus-30/NN||virus-46/NN	appos||virus-46/NN||lsv-48/NN	prep_in||viruses-25/NNS||honeybees-52/NNS	prep_from||honeybees-52/NNS||spain-54/NN	auxpass||reported-56/VBN||is-55/VBZ	root||ROOT-0/null||reported-56/VBN	det||article-59/NN||this-58/DT	prep_in||reported-56/VBN||article-59/NN	virus-46||viruses-25||no||by employing an unbiased metagenomic approach, which allows the detection of both unexpected and previously unknown infectious agents, the detection of three viruses, aphid lethal paralysis virus (alpv), israel acute paralysis virus (iapv), and lake sinai virus (lsv), in honeybees from spain is reported in this article.
amod||lines-2/NNS||several-1/JJ	nsubj||support-5/VBP||lines-2/NNS	prep_of||lines-2/NNS||evidence-4/NN	root||ROOT-0/null||support-5/VBP	det||notion-7/NN||the-6/DT	dobj||support-5/VBP||notion-7/NN	mark||predispose-13/VB||that-8/IN	amod||viscosity-11/NN||elevated-9/JJ	nn||viscosity-11/NN||blood-10/NN	nsubj||predispose-13/VB||viscosity-11/NN	aux||predispose-13/VB||may-12/MD	ccomp||support-5/VBP||predispose-13/VB	prep_to||predispose-13/VB||insulinresistance-15/NN	prep_to||predispose-13/VB||type2diabetesmellitus-17/NNS	conj_and||insulinresistance-15/NN||type2diabetesmellitus-17/NNS	prepc_by||predispose-13/VB||limiting-19/VBG	dobj||limiting-19/VBG||delivery-20/NN	prep_of||delivery-20/NN||glucose-22/NN	prep_of||delivery-20/NN||insulin-24/NN	conj_and||glucose-22/NN||insulin-24/NN	prep_of||delivery-20/NN||oxygen-27/NN	conj_and||glucose-22/NN||oxygen-27/NN	advmod||active-30/JJ||metabolically-29/RB	amod||tissues-31/NNS||active-30/JJ	prep_to||glucose-22/NN||tissues-31/NNS	insulin-24||type2diabetesmellitus-17||no_rel||several lines of evidence support the notion that elevated blood viscosity may predispose to insulinresistance and type2diabetesmellitus by limiting delivery of glucose, insulin, and oxygen to metabolically active tissues.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptsd-33||ptg-48||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
aux||gain-2/VB||to-1/TO	advcl||undertook-20/VBD||gain-2/VB	dobj||gain-2/VB||insight-3/NN	nn||signatures-7/NNS||gene-5/NN	nn||signatures-7/NNS||expression-6/NN	prep_into||gain-2/VB||signatures-7/NNS	nsubj||distinguish-10/VB||signatures-7/NNS	aux||distinguish-10/VB||can-9/MD	rcmod||signatures-7/NNS||distinguish-10/VB	dobj||distinguish-10/VB||atopicdermatitis-11/NNS	amod||controls-14/NNS||non-atopic-13/JJ	prep_from||distinguish-10/VB||controls-14/NNS	nn||biopsies-17/NNS||skin-16/NN	prep_without||distinguish-10/VB||biopsies-17/NNS	nsubj||undertook-20/VBD||we-19/PRP	root||ROOT-0/null||undertook-20/VBD	det||study-23/NN||a-21/DT	amod||study-23/NN||comparative-22/JJ	dobj||undertook-20/VBD||study-23/NN	nn||expression-26/NN||gene-25/NN	prep_of||study-23/NN||expression-26/NN	prep_in||undertook-20/VBD||fdks-28/NNS	amod||donors-31/NNS||adult-30/JJ	prep_from||fdks-28/NNS||donors-31/NNS	prep_with||undertook-20/VBD||atopicdermatitis-33/NNS	amod||donors-36/NNS||non-atopic-35/JJ	prep_with||undertook-20/VBD||donors-36/NNS	conj_and||atopicdermatitis-33/NNS||donors-36/NNS	atopicdermatitis-33||atopic--1||no||to gain insight into gene expression signatures that can distinguish atopicdermatitis from non-atopic controls without skin biopsies, we undertook a comparative study of gene expression in fdks from adult donors with atopicdermatitis and non-atopic donors.
det||ability-2/NN||the-1/DT	nsubj||serves-9/VBZ||ability-2/NN	nn||mycobacteriumtuberculosis-5/NNS||culture-4/NN	prep_to||ability-2/NN||mycobacteriumtuberculosis-5/NNS	amod||specimens-8/NNS||clinical-7/JJ	prep_from||mycobacteriumtuberculosis-5/NNS||specimens-8/NNS	root||ROOT-0/null||serves-9/VBZ	det||standard-13/NN||the-11/DT	amod||standard-13/NN||gold-12/JJ	prep_as||serves-9/VBZ||standard-13/NN	det||diagnosis-16/NN||the-15/DT	prep_for||standard-13/NN||diagnosis-16/NN	prep_of||diagnosis-16/NN||tuberculosis-18/NNP	tuberculosis-18||mycobacteriumtuberculosis-5||no||the ability to culture mycobacteriumtuberculosis from clinical specimens serves as the gold standard for the diagnosis of tuberculosis.
mark||drug-11/NN||although-1/IN	nsubj||drug-11/NN||warfarin-2/NN	cop||drug-11/NN||is-3/VBZ	det||drug-11/NN||an-4/DT	amod||drug-11/NN||effective-5/JJ	amod||drug-11/NN||oral-6/JJ	nn||drug-11/NN||anticoagulation-7/NN	appos||drug-11/NN||oac-9/NN	advcl||scarce-32/JJ||drug-11/NN	aux||reduce-13/VB||to-12/TO	vmod||drug-11/NN||reduce-13/VB	det||risk-15/NN||the-14/DT	dobj||reduce-13/VB||risk-15/NN	prep_of||risk-15/NN||thromboembolism-17/NN	prep_in||reduce-13/VB||patients-19/NNS	amod||atrialfibrillation-22/NN||non-valvular-21/JJ	prep_with||patients-19/NNS||atrialfibrillation-22/NN	appos||atrialfibrillation-22/NN||nvaf-24/NN	amod||data-30/NNS||long-27/JJ	nn||data-30/NNS||term-28/NN	nn||data-30/NNS||follow-up-29/NN	nsubj||scarce-32/JJ||data-30/NNS	nsubj||certain-35/JJ||data-30/NNS	cop||scarce-32/JJ||are-31/VBP	root||ROOT-0/null||scarce-32/JJ	aux||certain-35/JJ||to-33/TO	cop||certain-35/JJ||be-34/VB	xcomp||scarce-32/JJ||certain-35/JJ	mark||maintained-42/VBN||whether-36/IN	det||level-40/NN||the-37/DT	nn||level-40/NN||target-38/NN	nn||level-40/NN||inr-39/NN	nsubjpass||maintained-42/VBN||level-40/NN	auxpass||maintained-42/VBN||is-41/VBZ	ccomp||certain-35/JJ||maintained-42/VBN	amod||patients-45/NNS||warfarin-treated-44/JJ	prep_in||maintained-42/VBN||patients-45/NNS	prep_in||patients-45/NNS||korea-47/NN	atrialfibrillation-22||warfarin-2||yes||although warfarin is an effective oral anticoagulation (oac) drug to reduce the risk of thromboembolism in patients with non-valvular atrialfibrillation (nvaf), long term follow-up data are scarce to be certain whether the target inr level is maintained in warfarin-treated patients in korea.
nsubj||saw-3/VBD||we-1/PRP	advmod||saw-3/VBD||also-2/RB	root||ROOT-0/null||saw-3/VBD	det||tendency-5/NN||a-4/DT	dobj||saw-3/VBD||tendency-5/NN	nn||cases-8/NNS||tb-7/NN	prep_for||tendency-5/NN||cases-8/NNS	vmod||cases-8/NNS||infected-9/VBN	nn||africanum-12/NN||m.-11/NN	prep_with||infected-9/VBN||africanum-12/NN	aux||increased-15/VBN||to-13/TO	aux||increased-15/VBN||have-14/VB	xcomp||infected-9/VBN||increased-15/VBN	nn||±-17/NNP||tnf-î-16/NNP	dobj||increased-15/VBN||±-17/NNP	amod||production-20/NN||il-10-19/JJ	dobj||increased-15/VBN||production-20/NN	conj_and||±-17/NNP||production-20/NN	prepc_compared_to||increased-15/VBN||to-22/TO	pobj||increased-15/VBN||those-23/DT	vmod||those-23/DT||infected-24/VBN	prep_with||infected-24/VBN||m.tuberculosis-26/NNS	tb-7||m.tuberculosis-26||no||we also saw a tendency for tb cases infected with m. africanum to have increased tnf-î ± and il-10 production compared to those infected with m.tuberculosis .
det||source-3/NN||the-1/DT	amod||source-3/NN||potential-2/JJ	nsubjpass||found-14/VBN||source-3/NN	prep_of||source-3/NN||antioxidant-5/NN	prep_of||source-3/NN||antibacterialagents-7/NNS	conj_and||antioxidant-5/NN||antibacterialagents-7/NNS	advmod||source-3/NN||especially-9/RB	nn||treatments-12/NNS||mrsainfection-11/NN	prep_for||source-3/NN||treatments-12/NNS	auxpass||found-14/VBN||were-13/VBD	root||ROOT-0/null||found-14/VBN	nn||kockiana-17/NN||b.-16/NN	prep_in||found-14/VBN||kockiana-17/NN	nn||pulcherrima-20/NN||c.-19/NN	prep_in||found-14/VBN||pulcherrima-20/NN	conj_and||kockiana-17/NN||pulcherrima-20/NN	nn||tergemina-23/NN||c.-22/NN	prep_in||found-14/VBN||tergemina-23/NN	conj_and||kockiana-17/NN||tergemina-23/NN	nn||pterocarpum-26/NN||p.-25/NN	prep_in||found-14/VBN||pterocarpum-26/NN	conj_and||kockiana-17/NN||pterocarpum-26/NN	mrsainfection-11||antibacterialagents-7||no_rel||the potential source of antioxidant and antibacterialagents , especially for mrsainfection treatments were found in b. kockiana , c. pulcherrima , c. tergemina and p. pterocarpum .
aux||determine-2/VB||to-1/TO	advcl||screened-15/VBD||determine-2/VB	det||cause-4/NN||the-3/DT	dobj||determine-2/VB||cause-4/NN	nn||cases-7/NNS||spottedfever-6/NN	prep_of||cause-4/NN||cases-7/NNS	det||states-12/NNS||the-9/DT	amod||states-12/NNS||southern-10/JJ	amod||states-12/NNS||united-11/VBN	prep_in||determine-2/VB||states-12/NNS	nsubj||screened-15/VBD||we-14/PRP	root||ROOT-0/null||screened-15/VBD	nn||ticks-18/NNS||gulf-16/NN	nn||ticks-18/NNS||coast-17/NN	dobj||screened-15/VBD||ticks-18/NNS	nn||maculatum-21/NN||amblyomma-20/NN	appos||ticks-18/NNS||maculatum-21/NN	vmod||ticks-18/NNS||collected-23/VBN	prep_in||collected-23/VBN||arkansas-25/NNS	prep_for||arkansas-25/NNS||rickettsiae-27/NN	spottedfever-6||rickettsiae-27||no||to determine the cause of spottedfever cases in the southern united states, we screened gulf coast ticks ( amblyomma maculatum ) collected in arkansas for rickettsiae.
amod||infection-9/NN||occult-1/JJ	conj_or||occult-1/JJ||latent-3/JJ	amod||infection-9/NN||latent-3/JJ	amod||infection-9/NN||hepatitisb-4/JJ	nn||infection-9/NN||virus-5/NN	appos||infection-9/NN||hbv-7/NN	nsubjpass||defined-11/VBN||infection-9/NN	auxpass||defined-11/VBN||is-10/VBZ	root||ROOT-0/null||defined-11/VBN	prep_as||defined-11/VBN||infection-13/NN	amod||dna-17/NN||detectable-15/JJ	nn||dna-17/NN||hbv-16/NN	prep_with||defined-11/VBN||dna-17/NN	amod||antigen-21/NN||undetectable-19/JJ	nn||antigen-21/NN||surface-20/NN	prep_with||defined-11/VBN||antigen-21/NN	conj_and||dna-17/NN||antigen-21/NN	appos||dna-17/NN||hbsag-23/NN	poss||blood-28/NN||patients-26/NNS	prep_in||dna-17/NN||blood-28/NN	hbv-16||hbsag-23||yes||occult or latent hepatitisb virus (hbv) infection is defined as infection with detectable hbv dna and undetectable surface antigen (hbsag) in patients' blood.
nsubj||determined-3/VBD||we-1/PRP	advmod||determined-3/VBD||therefore-2/RB	root||ROOT-0/null||determined-3/VBD	det||frequency-5/NN||the-4/DT	dobj||determined-3/VBD||frequency-5/NN	nn||seropositivity-8/NN||igg-7/NN	prep_of||frequency-5/NN||seropositivity-8/NN	prep_against||determined-3/VBD||scrubtyphus-10/NNS	appos||scrubtyphus-10/NNS||orientiatsutsugamushi-12/NNP	prep_against||determined-3/VBD||murinetyphus-15/NNS	conj_and||scrubtyphus-10/NNS||murinetyphus-15/NNS	appos||scrubtyphus-10/NNS||rickettsiatyphi-17/NNP	prep_as||determined-3/VBD||indices-21/NNS	amod||exposure-24/NN||prior-23/JJ	prep_of||indices-21/NNS||exposure-24/NN	det||pathogens-27/NNS||these-26/DT	prep_to||determined-3/VBD||pathogens-27/NNS	advmod||adults-32/NNS||randomly-30/RB	amod||adults-32/NNS||selected-31/VBN	prep_in||determined-3/VBD||adults-32/NNS	prep_in||adults-32/NNS||urban-34/JJ	amod||city-38/NN||peri-urban-36/JJ	nn||city-38/NN||vientiane-37/NN	prep_in||adults-32/NNS||city-38/NN	conj_and||urban-34/JJ||city-38/NN	dep||adults-32/NNS||nâ-40/VBN	num||â-44/NN||$-41/$	number||=-43/CD||š-42/CD	num||$-41/$||=-43/CD	dobj||nâ-40/VBN||â-44/NN	amod||â-44/NN||$-45/$	number||,002-47/CD||š2-46/CD	num||$-45/$||,002-47/CD	advmod||‰-50/JJ||â-49/RB	dep||$-45/$||‰-50/JJ	number||35-52/CD||¥-51/CD	num||years-53/NNS||35-52/CD	tmod||nâ-40/VBN||years-53/NNS	scrubtyphus-10||orientiatsutsugamushi-12||no||we therefore determined the frequency of igg seropositivity against scrubtyphus ( orientiatsutsugamushi ) and murinetyphus ( rickettsiatyphi ), as indices of prior exposure to these pathogens, in randomly selected adults in urban and peri-urban vientiane city (nâ€š=â€š2,002, â‰¥35 years).
det||patients-2/NNS||both-1/DT	nsubj||received-4/VBD||patients-2/NNS	advmod||received-4/VBD||subsequently-3/RB	root||ROOT-0/null||received-4/VBD	amod||chemotherapeuticagents-6/NNS||other-5/JJ	dobj||received-4/VBD||chemotherapeuticagents-6/NNS	prep_without||received-4/VBD||evidence-8/NN	prep_of||evidence-8/NN||hypersensitivityreaction-10/NN	prep_of||evidence-8/NN||immune-mediatedthrombocytopenia-12/NN	conj_or||hypersensitivityreaction-10/NN||immune-mediatedthrombocytopenia-12/NN	immune-mediatedthrombocytopenia-12||hypersensitivityreaction-10||no||both patients subsequently received other chemotherapeuticagents without evidence of hypersensitivityreaction or immune-mediatedthrombocytopenia.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	indomethacin-23||ischemia--1||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
nsubj||observe-4/VB||we-1/PRP	aux||observe-4/VB||did-2/VBD	neg||observe-4/VB||not-3/RB	root||ROOT-0/null||observe-4/VB	det||difference-7/NN||a-5/DT	amod||difference-7/NN||significant-6/JJ	dobj||observe-4/VB||difference-7/NN	det||distribution-10/NN||the-9/DT	prep_in||observe-4/VB||distribution-10/NN	amod||âˆ-13/NN||mcp-1-12/JJ	poss||variants-20/NNS||âˆ-13/NN	num||variants-20/NNS||2518-15/CD	det||g-18/NN||a-16/DT	amod||g-18/NN||>-17/JJ	npadvmod||polymorphic-19/JJ||g-18/NN	amod||variants-20/NNS||polymorphic-19/JJ	prep_of||distribution-10/NN||variants-20/NNS	prep_in||variants-20/NNS||patients-22/NNS	nn||individuals-27/NNS||sle-24/NN	conj_and||sle-24/NN||healthy-26/JJ	nn||individuals-27/NNS||healthy-26/JJ	prep_with||patients-22/NNS||individuals-27/NNS	mcp--1||sle-24||no_rel||we did not observe a significant difference in the distribution of mcp-1 âˆ’2518 a>g polymorphic variants in patients with sle and healthy individuals.
amod||obstructivepulmonarydisease-2/NN||chronic-1/JJ	nsubj||one-7/CD||obstructivepulmonarydisease-2/NN	dep||obstructivepulmonarydisease-2/NN||copd-4/VBN	cop||one-7/CD||is-6/VBZ	root||ROOT-0/null||one-7/CD	det||complications-12/NNS||the-9/DT	amod||complications-12/NNS||main-10/JJ	amod||complications-12/NNS||late-11/JJ	prep_of||one-7/CD||complications-12/NNS	amod||poisoning-15/NN||sulfurmustard-14/JJ	prep_of||complications-12/NNS||poisoning-15/NN	sulfurmustard-14||obstructivepulmonarydisease-2||no_rel||chronic obstructivepulmonarydisease (copd) is one of the main late complications of sulfurmustard poisoning.
det||findings-2/NNS||these-1/DT	nsubj||potentiate-3/VBP||findings-2/NNS	nsubj||ad5-10-12/JJ||findings-2/NNS	nsubj||aids-19/VBZ||findings-2/NNS	root||ROOT-0/null||potentiate-3/VBP	amod||usage-5/NN||clinical-4/JJ	dobj||potentiate-3/VBP||usage-5/NN	det||combination-8/NN||the-7/DT	prep_of||usage-5/NN||combination-8/NN	prep_of||combination-8/NN||trail-10/NN	conj_and||potentiate-3/VBP||ad5-10-12/JJ	prep_in||ad5-10-12/JJ||eradication-14/NN	amod||macrophage-17/NN||hiv-infected-16/JJ	prep_of||eradication-14/NN||macrophage-17/NN	conj_and||potentiate-3/VBP||aids-19/VBZ	aids-19||hiv--1||no||these findings potentiate clinical usage of the combination of trail and ad5-10 in eradication of hiv-infected macrophage and aids.
amod||sensitivity-2/NN||higher-1/JJR	nsubjpass||achieved-4/VBN||sensitivity-2/NN	auxpass||achieved-4/VBN||was-3/VBD	root||ROOT-0/null||achieved-4/VBN	amod||specificity-12/NN||hiv/aids-6/JJ	conj_and||hiv/aids-6/JJ||tuberculosis-8/JJ	amod||specificity-12/NN||tuberculosis-8/JJ	conj_but||hiv/aids-6/JJ||lower-11/JJR	amod||specificity-12/NN||lower-11/JJR	prep_for||achieved-4/VBN||specificity-12/NN	advmod||false-16/JJ||relatively-14/RB	advmod||false-16/JJ||more-15/RBR	amod||positives-17/NNS||false-16/JJ	prep_with||specificity-12/NN||positives-17/NNS	aids--1||hiv--1||no||higher sensitivity was achieved for hiv/aids and tuberculosis, but lower specificity with relatively more false positives.
det||proportions-2/NNS||the-1/DT	nsubj||%-8/NN||proportions-2/NNS	amod||resistance-5/NN||mono-drug-4/JJ	prep_of||proportions-2/NNS||resistance-5/NN	cop||%-8/NN||were-6/VBD	num||%-8/NN||28.73-7/CD	root||ROOT-0/null||%-8/NN	prep_for||%-8/NN||isoniazid-10/NN	num||%-13/NN||19.41-12/CD	conj_and||%-8/NN||%-13/NN	prep_for||%-13/NN||rifampicin-15/NN	num||%-18/NN||29.33-17/CD	conj_and||%-8/NN||%-18/NN	prep_for||%-18/NN||streptomycin-20/NN	num||%-24/NN||13.98-23/CD	conj_and||%-8/NN||%-24/NN	prep_for||%-24/NN||ethambutol-26/NN	advmod||%-8/NN||respectively-28/RB	mono--1||streptomycin-20||no_rel||the proportions of mono-drug resistance were 28.73% for isoniazid, 19.41% for rifampicin, 29.33% for streptomycin, and 13.98% for ethambutol, respectively.
nsubj||reduce-16/VB||conclusions-1/NNS	nsubj||have-20/VB||conclusions-1/NNS	nsubj||ompared-3/VBD||c-2/SYM	rcmod||conclusions-1/NNS||ompared-3/VBD	prep_with||ompared-3/VBD||placebo-5/NN	prep_with||ompared-3/VBD||glucosamine-7/NN	conj_and||placebo-5/NN||glucosamine-7/NN	prep_with||ompared-3/VBD||chondroitin-9/NN	conj_and||placebo-5/NN||chondroitin-9/NN	poss||combination-13/NN||their-12/PRP$	prep_with||ompared-3/VBD||combination-13/NN	conj_and||placebo-5/NN||combination-13/NN	aux||reduce-16/VB||do-14/VBP	neg||reduce-16/VB||not-15/RB	root||ROOT-0/null||reduce-16/VB	amod||pain-18/NN||joint-17/JJ	dobj||reduce-16/VB||pain-18/NN	conj_or||reduce-16/VB||have-20/VB	det||impact-22/NN||an-21/DT	dobj||have-20/VB||impact-22/NN	prep_on||impact-22/NN||narrowing-24/NN	amod||space-27/NN||joint-26/JJ	prep_of||narrowing-24/NN||space-27/NN	pain-18||chondroitin-9||yes||conclusions c ompared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space.
nsubjpass||known-8/VBN||resistance-1/NN	nsubjpass||associated-11/VBN||resistance-1/NN	prep_to||resistance-1/NN||chloroquine-3/NN	nn||strains-6/NNS||malaria-5/NN	prep_of||chloroquine-3/NN||strains-6/NNS	auxpass||known-8/VBN||is-7/VBZ	root||ROOT-0/null||known-8/VBN	aux||associated-11/VBN||to-9/TO	auxpass||associated-11/VBN||be-10/VB	xcomp||known-8/VBN||associated-11/VBN	det||protein-15/NN||a-13/DT	nn||protein-15/NN||parasite-14/NN	prep_with||associated-11/VBN||protein-15/NN	vmod||protein-15/NN||named-16/VBN	dobj||named-16/VBN||pfcrt-17/NN	det||form-21/NN||the-19/DT	amod||form-21/NN||mutated-20/JJ	appos||pfcrt-17/NN||form-21/NN	nsubj||able-25/JJ||which-23/WDT	nsubj||reduce-27/VB||which-23/WDT	cop||able-25/JJ||is-24/VBZ	prepc_of||form-21/NN||able-25/JJ	aux||reduce-27/VB||to-26/TO	xcomp||able-25/JJ||reduce-27/VB	amod||accumulation-29/NN||chloroquine-28/JJ	dobj||reduce-27/VB||accumulation-29/NN	det||vacuole-33/NN||the-31/DT	amod||vacuole-33/NN||digestive-32/JJ	prep_in||reduce-27/VB||vacuole-33/NN	det||pathogen-36/NN||the-35/DT	prep_of||vacuole-33/NN||pathogen-36/NN	malaria-5||chloroquine-28||yes||resistance to chloroquine of malaria strains is known to be associated with a parasite protein named pfcrt, the mutated form of which is able to reduce chloroquine accumulation in the digestive vacuole of the pathogen.
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	nausea-19||ondansetron-8||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	falciparummalaria-24||pyrimethamine--1||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
det||±-3/NN||the-1/DT	nn||±-3/NN||î-2/NN	root||ROOT-0/null||±-3/NN	amod||bartonella-7/NN||proteobacterial-5/JJ	nn||bartonella-7/NN||genus-6/NN	nsubj||comprises-8/VBZ||bartonella-7/NN	dep||±-3/NN||comprises-8/VBZ	num||species-10/NNS||21-9/CD	dobj||comprises-8/VBZ||species-10/NNS	nsubj||cause-12/VBP||species-10/NNS	rcmod||species-10/NNS||cause-12/VBP	amod||bacteremia-15/NN||host-specific-13/JJ	amod||bacteremia-15/NN||intraerythrocytic-14/JJ	dobj||cause-12/VBP||bacteremia-15/NN	prep_as||cause-12/VBP||hallmark-17/NN	prep_of||hallmark-17/NN||infection-19/NN	poss||reservoirs-24/NNS||their-21/PRP$	amod||reservoirs-24/NNS||respective-22/JJ	amod||reservoirs-24/NNS||mammalian-23/JJ	prep_in||infection-19/NN||reservoirs-24/NNS	det||bartonellaquintana-30/NN||the-27/DT	amod||bartonellaquintana-30/NN||human-specific-28/JJ	nn||bartonellaquintana-30/NN||pathogens-29/NNS	prep_including||cause-12/VBP||bartonellaquintana-30/NN	prep_including||cause-12/VBP||bartonellabacilliformis-32/NNS	conj_and||bartonellaquintana-30/NN||bartonellabacilliformis-32/NNS	nsubj||cause-34/VBP||bartonellabacilliformis-32/NNS	rcmod||bartonellabacilliformis-32/NNS||cause-34/VBP	dobj||cause-34/VBP||trenchfever-35/NN	dobj||cause-34/VBP||oroyafever-37/NN	conj_and||trenchfever-35/NN||oroyafever-37/NN	advmod||cause-34/VBP||respectively-39/RB	oroyafever-37||bartonellabacilliformis-32||no||the î±-proteobacterial genus bartonella comprises 21 species that cause host-specific intraerythrocytic bacteremia as hallmark of infection in their respective mammalian reservoirs, including the human-specific pathogens bartonellaquintana and bartonellabacilliformis that cause trenchfever and oroyafever, respectively.
prep_in||produced-7/VBD||2003-2/CD	det||government-6/NN||the-4/DT	amod||government-6/NN||chinese-5/JJ	nsubj||produced-7/VBD||government-6/NN	root||ROOT-0/null||produced-7/VBD	amod||estimates-9/NNS||national-8/JJ	dobj||produced-7/VBD||estimates-9/NNS	prep_with||produced-7/VBD||support-11/NN	det||programme-17/NN||the-13/DT	amod||programme-17/NN||joint-14/JJ	amod||programme-17/NN||united-15/JJ	nn||programme-17/NN||nations-16/NNS	prep_from||produced-7/VBD||programme-17/NN	prep_on||programme-17/NN||hiv/aids-19/NNS	det||centers-29/NNS||the-21/DT	nn||organization-24/NN||world-22/NN	nn||organization-24/NN||health-23/NN	nn||centers-29/NNS||organization-24/NN	det||states-28/NNS||the-26/DT	amod||states-28/NNS||united-27/VBN	appos||hiv/aids-19/NNS||states-28/NNS	conj_and||centers-29/NNS||states-28/NNS	nn||centers-29/NNS||states-28/NNS	appos||hiv/aids-19/NNS||centers-29/NNS	nn||control-32/NN||disease-31/NN	prep_for||centers-29/NNS||control-32/NN	prep_for||centers-29/NNS||prevention-34/NN	conj_and||control-32/NN||prevention-34/NN	aids--1||hiv--1||no||in 2003, the chinese government produced national estimates with support from the joint united nations programme on hiv/aids, the world health organization and the united states centers for disease control and prevention.
nsubj||promising-15/VBG||capecitabine-1/NN	conj_plus||capecitabine-1/NN||docetaxel-3/NN	nsubj||promising-15/VBG||docetaxel-3/NN	appos||docetaxel-3/NN||xt-5/NN	conj_and||capecitabine-1/NN||trastuzumab-8/NN	nsubj||promising-15/VBG||trastuzumab-8/NN	prep_with||trastuzumab-8/NN||xt-10/NN	appos||xt-10/NN||hxt-12/NN	aux||promising-15/VBG||are-14/VBP	root||ROOT-0/null||promising-15/VBG	amod||regimens-17/NNS||non-anthracycline-16/JJ	dobj||promising-15/VBG||regimens-17/NNS	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||preoperative-20/JJ	prep_for||promising-15/VBG||treatment-21/NN	prep_of||treatment-21/NN||women-23/NNS	amod||cancer-29/NN||her2-negative-25/JJ	conj_and||her2-negative-25/JJ||her2-positive-27/JJ	amod||cancer-29/NN||her2-positive-27/JJ	nn||cancer-29/NN||breast-28/NN	prep_with||women-23/NNS||cancer-29/NN	advmod||promising-15/VBG||respectively-31/RB	cancer-29||capecitabine-1||no_rel||capecitabine plus docetaxel (xt) and trastuzumab with xt (hxt) are promising non-anthracycline regimens for the preoperative treatment of women with her2-negative and her2-positive breast cancer, respectively.
amod||analysis-2/NN||immunohistological-1/JJ	nsubj||confirmed-6/VBD||analysis-2/NN	det||granulomas-5/NNS||these-4/DT	prep_of||analysis-2/NN||granulomas-5/NNS	root||ROOT-0/null||confirmed-6/VBD	det||abundance-9/NN||the-7/DT	amod||abundance-9/NN||disproportionate-8/JJ	dobj||confirmed-6/VBD||abundance-9/NN	det||proteins-12/NNS||the-11/DT	prep_of||abundance-9/NN||proteins-12/NNS	vmod||proteins-12/NNS||involved-13/VBN	nn||metabolism-16/NN||lipid-15/NN	prep_in||involved-13/VBN||metabolism-16/NN	prep_in||involved-13/VBN||cells-18/NNS	vmod||cells-18/NNS||surrounding-19/VBG	det||caseum-21/NN||the-20/DT	dobj||surrounding-19/VBG||caseum-21/NN	advmod||biochemical-36/VBP||namely-23/RB	nn||member-31/NN||adipophilin-25/NN	amod||member-31/NN||acyl-coa-27/JJ	nn||member-31/NN||synthetase-28/NN	amod||member-31/NN||long-chain-29/JJ	nn||member-31/NN||family-30/NN	nsubj||biochemical-36/VBP||member-31/NN	num||member-31/NN||1-32/CD	amod||c.-35/NN||saposin-34/JJ	conj_and||member-31/NN||c.-35/NN	nsubj||biochemical-36/VBP||c.-35/NN	parataxis||confirmed-6/VBD||biochemical-36/VBP	dobj||biochemical-36/VBP||analysis-37/NN	det||species-41/NN||the-39/DT	nn||species-41/NN||lipid-40/NN	prep_of||analysis-37/NN||species-41/NN	det||caseum-44/NN||the-43/DT	prep_within||biochemical-36/VBP||caseum-44/NN	nsubj||implicated-56/VBN||caseum-44/NN	vmod||caseum-44/NN||identified-45/VBN	dobj||identified-45/VBN||cholesterol-46/NN	amod||esters-49/NNS||cholesteryl-48/JJ	dobj||identified-45/VBN||esters-49/NNS	conj_and||cholesterol-46/NN||esters-49/NNS	dobj||identified-45/VBN||triacylglycerols-51/NNS	conj_and||cholesterol-46/NN||triacylglycerols-51/NNS	dobj||identified-45/VBN||lactosylceramide-53/NN	conj_and||cholesterol-46/NN||lactosylceramide-53/NN	rcmod||caseum-44/NN||implicated-56/VBN	amod||lipids-59/NNS||low-density-57/JJ	amod||lipids-59/NNS||lipoprotein-derived-58/JJ	dobj||implicated-56/VBN||lipids-59/NNS	det||source-64/NN||the-61/DT	advmod||likely-63/JJ||most-62/RBS	amod||source-64/NN||likely-63/JJ	prep_as||implicated-56/VBN||source-64/NN	granulomas-5||cholesterol-46||no_rel||immunohistological analysis of these granulomas confirmed the disproportionate abundance of the proteins involved in lipid metabolism in cells surrounding the caseum ; namely , adipophilin , acyl-coa synthetase long-chain family member 1 and saposin c. biochemical analysis of the lipid species within the caseum identified cholesterol , cholesteryl esters , triacylglycerols and lactosylceramide , which implicated low-density lipoprotein-derived lipids as the most likely source .
det||context-3/NN||this-2/DT	prep_in||be-15/VB||context-3/NN	nsubj||be-15/VB||one-5/CD	nsubj||investigate-17/VB||one-5/CD	det||control-13/NN||the-7/DT	amod||control-13/NN||pathways-8/JJ	amod||control-13/NN||available-9/JJ	nn||vector-12/NN||malaria-11/NN	prep_for||available-9/JJ||vector-12/NN	prep_of||one-5/CD||control-13/NN	aux||be-15/VB||would-14/MD	root||ROOT-0/null||be-15/VB	aux||investigate-17/VB||to-16/TO	xcomp||be-15/VB||investigate-17/VB	amod||classes-19/NNS||alternative-18/JJ	dobj||investigate-17/VB||classes-19/NNS	prep_of||classes-19/NNS||insecticides-21/NNS	amod||mode-24/NN||different-23/JJ	prep_with||investigate-17/VB||mode-24/NN	prep_of||mode-24/NN||action-26/NN	prep_than||investigate-17/VB||that-28/DT	prep_of||that-28/DT||pyrethroids-30/NNS	malaria-11||pyrethroids-30||no_rel||in this context, one of the pathways available for malaria vector control would be to investigate alternative classes of insecticides with different mode of action than that of pyrethroids.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||holds-22/VBZ||that-4/IN	det||specificity-8/NN||the-5/DT	amod||specificity-8/NN||unique-6/JJ	amod||specificity-8/NN||biochemical-7/JJ	nsubj||holds-22/VBZ||specificity-8/NN	nn||spectroscopy-11/NN||raman-10/NN	prep_of||specificity-8/NN||spectroscopy-11/NN	vmod||specificity-8/NN||combined-13/VBN	amod||enhancement-17/NN||reproducible-15/JJ	amod||enhancement-17/NN||spectral-16/JJ	prep_with||combined-13/VBN||enhancement-17/NN	amod||na-20/NNS||silver-19/JJ	agent||combined-13/VBN||na-20/NNS	ccomp||suggest-3/VBP||holds-22/VBZ	amod||promise-24/NN||great-23/JJ	dobj||holds-22/VBZ||promise-24/NN	det||platform-28/NN||a-26/DT	amod||platform-28/NN||superior-27/JJ	prep_as||promise-24/NN||platform-28/NN	amod||detection-33/NN||rapid-30/JJ	conj_and||rapid-30/JJ||sensitive-32/JJ	amod||detection-33/NN||sensitive-32/JJ	prep_for||platform-28/NN||detection-33/NN	prep_for||platform-28/NN||identification-35/NN	conj_and||detection-33/NN||identification-35/NN	nn||pneumoniae-38/NN||m.-37/NN	prep_of||promise-24/NN||pneumoniae-38/NN	prep_with||holds-22/VBZ||potential-41/NN	amod||application-44/NN||point-of-care-43/JJ	prep_for||potential-41/NN||application-44/NN	silver-19||pneumoniae-38||no_rel||our findings suggest that the unique biochemical specificity of raman spectroscopy , combined with reproducible spectral enhancement by silver na , holds great promise as a superior platform for rapid and sensitive detection and identification of m. pneumoniae , with potential for point-of-care application .
nsubj||performed-3/VBD||we-1/PRP	advmod||performed-3/VBD||successfully-2/RB	root||ROOT-0/null||performed-3/VBD	nsubj||stem-5/VBP||autologous-4/NNS	ccomp||performed-3/VBD||stem-5/VBP	nn||transplantation-7/NN||cell-6/NN	dobj||stem-5/VBP||transplantation-7/NN	vmod||transplantation-7/NN||using-8/VBG	det||regimen-10/NN||a-9/DT	dobj||using-8/VBG||regimen-10/NN	vmod||regimen-10/NN||consisting-11/VBG	prep_of||consisting-11/VBG||mcnu-13/JJ	dep||mcnu-13/JJ||ranimustine-15/JJ	prep_of||consisting-11/VBG||etoposide-18/JJ	conj_and||mcnu-13/JJ||etoposide-18/JJ	prep_of||consisting-11/VBG||cytarabine-20/JJ	conj_and||mcnu-13/JJ||cytarabine-20/JJ	prep_of||consisting-11/VBG||melphalan-23/JJ	conj_and||mcnu-13/JJ||melphalan-23/JJ	det||patient-27/NN||a-25/DT	amod||patient-27/NN||japanese-26/JJ	prep_in||melphalan-23/JJ||patient-27/NN	amod||lymphoma-32/NN||relapsed-29/JJ	amod||lymphoma-32/NN||aids-related-30/JJ	amod||lymphoma-32/NN||plasmablastic-31/JJ	prep_with||consisting-11/VBG||lymphoma-32/NN	det||cavity-36/NN||the-34/DT	amod||cavity-36/NN||oral-35/JJ	prep_of||lymphoma-32/NN||cavity-36/NN	lymphoma-32||cytarabine-20||yes||we successfully performed autologous stem cell transplantation using a regimen consisting of mcnu (ranimustine), etoposide, cytarabine, and melphalan in a japanese patient with relapsed aids-related plasmablastic lymphoma of the oral cavity.
amod||-rrb--6/NNS||legionella-1/JJ	nn||-rrb--6/NNS||pneumophila-2/NN	nn||-rrb--6/NNS||-lrb--3/NN	nn||-rrb--6/NNS||l.-4/NN	nn||-rrb--6/NNS||pneumophila-5/NN	nsubj||replicates-22/VBZ||-rrb--6/NNS	det||agent-10/NN||the-8/DT	amod||agent-10/NN||causative-9/JJ	appos||-rrb--6/NNS||agent-10/NN	det||form-14/NN||a-12/DT	amod||form-14/NN||severe-13/JJ	prep_of||agent-10/NN||form-14/NN	prep_of||form-14/NN||pneumonia-16/NN	vmod||pneumonia-16/NN||called-17/VBN	poss||disease-20/NN||legionnaires-18/NNS	dobj||called-17/VBN||disease-20/NN	root||ROOT-0/null||replicates-22/VBZ	amod||monocytes-25/NNS||human-24/JJ	prep_in||replicates-22/VBZ||monocytes-25/NNS	prep_in||replicates-22/VBZ||macrophages-27/NNS	conj_and||monocytes-25/NNS||macrophages-27/NNS	legionnaires' disease--1||pneumophila-5||no||legionella pneumophila -lrb- l. pneumophila -rrb- , the causative agent of a severe form of pneumonia called legionnaires ' disease , replicates in human monocytes and macrophages .
nsubj||agent-7/NN||midazolam-1/NN	cop||agent-7/NN||was-2/VBD	det||agent-7/NN||the-3/DT	advmod||common-5/JJ||most-4/RBS	amod||agent-7/NN||common-5/JJ	nn||agent-7/NN||induction-6/NN	root||ROOT-0/null||agent-7/NN	vmod||agent-7/NN||used-8/VBN	num||patients-11/NNS||97-10/CD	appos||agent-7/NN||patients-11/NNS	mark||musclerelaxant-18/NN||while-14/IN	nsubj||musclerelaxant-18/NN||suxamethonium-15/NN	cop||musclerelaxant-18/NN||was-16/VBD	det||musclerelaxant-18/NN||the-17/DT	advcl||agent-7/NN||musclerelaxant-18/NN	prep_of||musclerelaxant-18/NN||choice-20/NN	num||patients-23/NNS||109-22/CD	appos||choice-20/NN||patients-23/NNS	musclerelaxant-18||suxamethonium-15||no||midazolam was the most common induction agent used (97 patients), while suxamethonium was the musclerelaxant of choice (109 patients).
nsubjpass||established-7/VBN||pharmacokinetics-1/NNS	amod||analogs-5/NNS||short-acting-3/JJ	nn||analogs-5/NNS||insulin-4/NN	prep_of||pharmacokinetics-1/NNS||analogs-5/NNS	auxpass||established-7/VBN||were-6/VBD	root||ROOT-0/null||established-7/VBN	agent||established-7/VBN||assessing-9/VBG	dobj||assessing-9/VBG||injection-10/NN	amod||doses-13/NNS||small-12/JJ	prep_of||injection-10/NN||doses-13/NNS	amod||subjects-16/NNS||lean-15/JJ	prep_in||doses-13/NNS||subjects-16/NNS	amod||doses-13/NNS||healthy-18/JJ	amod||doses-13/NNS||with-20/IN	conj_or||healthy-18/JJ||with-20/IN	pobj||with-20/IN||type1diabetes-21/CD	type1diabetes-21||insulin-4||yes||pharmacokinetics of short-acting insulin analogs were established by assessing injection of small doses in lean subjects, healthy or with type1diabetes.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	advmod||report-2/VBP||here-3/RB	det||cases-6/NNS||the-5/DT	prep_on||report-2/VBP||cases-6/NNS	num||patients-11/NNS||two-8/CD	amod||patients-11/NNS||pediatric-9/JJ	nn||patients-11/NNS||osteosarcoma-10/NN	prep_of||cases-6/NNS||patients-11/NNS	amod||excretion-15/NN||delayed-13/JJ	nn||excretion-15/NN||mtx-14/NN	prep_with||patients-11/NNS||excretion-15/NN	nsubjpass||managed-20/VBN||who-17/WP	auxpass||managed-20/VBN||were-18/VBD	advmod||managed-20/VBN||successfully-19/RB	prep_on||report-2/VBP||managed-20/VBN	conj_and||cases-6/NNS||managed-20/VBN	xcomp||managed-20/VBN||using-21/VBG	amod||measures-23/NNS||supportive-22/JJ	dobj||using-21/VBG||measures-23/NNS	osteosarcoma-10||mtx-14||yes||we report here on the cases of two pediatric osteosarcoma patients with delayed mtx excretion and who were successfully managed using supportive measures.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	hereditaryhemochromatosis--1||iron-47||no||we present data drawn from four different conditionsâ€”irondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâ€”both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
nsubj||measured-2/VBD||we-1/PRP	root||ROOT-0/null||measured-2/VBD	nn||concentrations-5/NNS||plasma-3/NN	nn||concentrations-5/NNS||glucagon-4/NN	dobj||measured-2/VBD||concentrations-5/NNS	prep_in||measured-2/VBD||patients-7/NNS	prep_with||measured-2/VBD||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||infused-10/VBN	det||glulisine-15/NN||the-12/DT	amod||glulisine-15/NN||zinc-free-13/JJ	nn||glulisine-15/NN||insulin-14/NN	prep_with||infused-10/VBN||glulisine-15/NN	num||occasions-18/NNS||three-17/CD	prep_on||glulisine-15/NN||occasions-18/NNS	type1diabetes-9||zinc--1||no_rel||we measured plasma glucagon concentrations in patients with type1diabetes infused with the zinc-free insulin glulisine on three occasions.
amod||africa-3/NN||sub-saharan-2/JJ	prep_in||is-6/VBZ||africa-3/NN	nsubj||is-6/VBZ||kenya-5/NN	root||ROOT-0/null||is-6/VBZ	prep_among||is-6/VBZ||countries-8/NNS	vmod||countries-8/NNS||affected-9/VBN	det||pandemic-15/NN||the-11/DT	nn||pandemic-15/NN||hiv-12/NN	conj_and||hiv-12/NN||aids-14/NNS	nn||pandemic-15/NN||aids-14/NNS	agent||affected-9/VBN||pandemic-15/NN	nsubj||led-17/VBD||pandemic-15/NN	rcmod||pandemic-15/NN||led-17/VBD	det||declaration-20/NN||the-19/DT	prep_to||led-17/VBD||declaration-20/NN	prep_of||declaration-20/NN||aids-22/NNS	det||disaster-26/NN||a-24/DT	amod||disaster-26/NN||national-25/JJ	prep_as||led-17/VBD||disaster-26/NN	prep_in||disaster-26/NN||1999-28/CD	aids-22||hiv-12||no||in sub-saharan africa, kenya is among countries affected by the hiv and aids pandemic which led to the declaration of aids as a national disaster in 1999.
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	hc--1||neuropathicpain-36||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||sitagliptin-16/NN||the-9/DT	amod||peptidase-iv-11/JJ||dipeptidyl-10/JJ	amod||sitagliptin-16/NN||peptidase-iv-11/JJ	dep||peptidase-iv-11/JJ||dpp-iv-13/JJ	nn||sitagliptin-16/NN||inhibitor-15/NN	dobj||evaluate-8/VB||sitagliptin-16/NN	prep_with||sitagliptin-16/NN||respect-18/NN	prep_to||evaluate-8/VB||mode-20/NN	prep_of||mode-20/NN||inhibition-22/NN	poss||duration-27/NN||its-24/PRP$	advmod||duration-27/NN||in-25/RB	amod||duration-27/NN||vivo-26/JJ	prep_to||evaluate-8/VB||duration-27/NN	conj_and||mode-20/NN||duration-27/NN	prep_of||duration-27/NN||inhibition-29/NN	prep_of||duration-27/NN||efficacy-31/NN	conj_and||inhibition-29/NN||efficacy-31/NN	amod||model-35/NN||type2diabetes-33/JJ	nn||model-35/NN||animal-34/NN	prep_in||evaluate-8/VB||model-35/NN	type2diabetes-33||sitagliptin-16||yes||the aim of this study was to evaluate the dipeptidyl peptidase-iv (dpp-iv) inhibitor sitagliptin with respect to mode of inhibition and its in vivo duration of inhibition and efficacy in type2diabetes animal model.
amod||isolates-2/NNS||multidrug-resistant-1/JJ	root||ROOT-0/null||isolates-2/NNS	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	prep_of||isolates-2/NNS||s.aureus-5/NNS	nn||-rrb--8/NNP||-lrb--6/NNP	nn||-rrb--8/NNP||mrsa-7/NNP	nsubj||emerged-16/VBN||-rrb--8/NNP	vmod||-rrb--8/NNP||exhibiting-9/VBG	amod||susceptibilities-11/NNS||decreased-10/VBN	dobj||exhibiting-9/VBG||susceptibilities-11/NNS	prep_to||exhibiting-9/VBG||glycopeptides-13/NNS	aux||emerged-16/VBN||has-14/VBZ	advmod||emerged-16/VBN||also-15/RB	dep||isolates-2/NNS||emerged-16/VBN	vmod||isolates-2/NNS||representing-18/VBG	det||challenge-21/NN||a-19/DT	amod||challenge-21/NN||crucial-20/JJ	dobj||representing-18/VBG||challenge-21/NN	amod||therapy-24/NN||antimicrobial-23/JJ	prep_for||isolates-2/NNS||therapy-24/NN	nn||control-27/NN||infection-26/NN	prep_for||isolates-2/NNS||control-27/NN	conj_and||therapy-24/NN||control-27/NN	mrsa-7||s.aureus-5||no||multidrug-resistant isolates of methicillin-resistant s.aureus -lrb- mrsa -rrb- exhibiting decreased susceptibilities to glycopeptides has also emerged , representing a crucial challenge for antimicrobial therapy and infection control .
det||adult-2/NN||all-1/DT	nsubj||hiv/aids-3/VBZ||adult-2/NN	dep||may-21/MD||hiv/aids-3/VBZ	dobj||hiv/aids-3/VBZ||patients-4/NNS	nsubj||started-6/VBD||patients-4/NNS	prep_to||started-6/VBD||patients-4/NNS	rcmod||patients-4/NNS||started-6/VBD	amod||treatment-9/NN||antiretroviral-8/JJ	prep_on||started-6/VBD||treatment-9/NN	nn||hospitals-14/NNS||shashemene-11/NN	conj_and||shashemene-11/NN||assela-13/NN	nn||hospitals-14/NNS||assela-13/NN	prep_in||treatment-9/NN||hospitals-14/NNS	prep_from||started-6/VBD||january-16/NNP	num||january-16/NNP||1-17/CD	num||january-16/NNP||2006-19/CD	root||ROOT-0/null||may-21/MD	nsubj||may-21/MD||31-22/CD	appos||31-22/CD||2006-24/CD	auxpass||included-26/VBN||were-25/VBD	rcmod||2006-24/CD||included-26/VBN	rcmod||2006-24/CD||followed-28/VBN	conj_and||included-26/VBN||followed-28/VBN	prt||followed-28/VBN||up-29/RP	num||years-32/NNS||2-31/CD	prep_for||followed-28/VBN||years-32/NNS	aids--1||hiv--1||no||all adult hiv/aids patients who started on antiretroviral treatment in shashemene and assela hospitals from january 1, 2006 to may 31, 2006 were included and followed up for 2 years.
nsubj||vulnerable-7/JJ||hepatitisbvirus-1/NNS	nsubj||editing-9/VB||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||vulnerable-7/JJ||dna-5/RB	cop||vulnerable-7/JJ||is-6/VBZ	root||ROOT-0/null||vulnerable-7/JJ	aux||editing-9/VB||to-8/TO	xcomp||vulnerable-7/JJ||editing-9/VB	amod||deaminases-13/NNS||human-11/JJ	nn||deaminases-13/NNS||cytidine-12/NN	prep_by||editing-9/VB||deaminases-13/NNS	det||family-20/NN||the-15/DT	amod||family-20/NN||apobec3-16/JJ	dep||family-20/NN||a3a-h-18/JJ	prep_of||deaminases-13/NNS||family-20/NN	advmod||editing-9/VB||albeit-21/IN	advmod||lower-24/JJR||much-23/RB	amod||levels-25/NNS||lower-24/JJR	prep_to||albeit-21/IN||levels-25/NNS	nn||cdna-28/NN||hiv-27/NN	prep_than||levels-25/NNS||cdna-28/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) dna is vulnerable to editing by human cytidine deaminases of the apobec3 (a3a-h) family albeit to much lower levels than hiv cdna.
advmod||explants-16/VBZ||accordingly-1/RB	det||avianinfluenzaviruses-5/NNS||both-3/DT	amod||avianinfluenzaviruses-5/NNS||h5n1-4/JJ	nsubj||explants-16/VBZ||avianinfluenzaviruses-5/NNS	amod||influenzaviruses-8/NNS||seasonal-7/JJ	conj_and||avianinfluenzaviruses-5/NNS||influenzaviruses-8/NNS	nsubj||explants-16/VBZ||influenzaviruses-8/NNS	vmod||influenzaviruses-8/NNS||replicated-9/VBN	advmod||efficiently-11/RB||more-10/RBR	advmod||replicated-9/VBN||efficiently-11/RB	amod||tissues-15/NNS||nasal-13/JJ	nn||tissues-15/NNS||polyp-14/NN	prep_in||replicated-9/VBN||tissues-15/NNS	root||ROOT-0/null||explants-16/VBZ	avianinfluenza--1||influenzaviruses-8||no||accordingly, both h5n1 avianinfluenzaviruses and seasonal influenzaviruses replicated more efficiently in nasal polyp tissues explants.
det||formulation-3/NN||the-1/DT	amod||formulation-3/NN||extended-release-2/JJ	nsubjpass||approved-10/VBN||formulation-3/NN	prep_of||formulation-3/NN||lamotrigine-5/NN	appos||formulation-3/NN||ltg-xr-7/NN	auxpass||approved-10/VBN||was-9/VBD	root||ROOT-0/null||approved-10/VBN	amod||therapy-13/NN||adjunctive-12/JJ	prep_for||approved-10/VBN||therapy-13/NN	prep_in||therapy-13/NN||patients-15/NNS	amod||seizures-20/NNS||primary-17/JJ	amod||seizures-20/NNS||generalized-18/JJ	amod||seizures-20/NNS||tonic-clonic-19/JJ	prep_with||approved-10/VBN||seizures-20/NNS	prep_in||seizures-20/NNS||2010-22/CD	seizures-20||lamotrigine-5||yes||the extended-release formulation of lamotrigine (ltg-xr) was approved for adjunctive therapy in patients with primary generalized tonic-clonic seizures in 2010.
nsubj||first-12/JJ||sitagliptin-1/NN	det||inhibitor-8/NN||a-3/DT	advmod||selective-5/JJ||highly-4/RB	amod||inhibitor-8/NN||selective-5/JJ	amod||inhibitor-8/NN||dipeptidyl-6/JJ	amod||inhibitor-8/NN||peptidase-4-7/JJ	appos||sitagliptin-1/NN||inhibitor-8/NN	cop||first-12/JJ||is-10/VBZ	det||first-12/JJ||the-11/DT	root||ROOT-0/null||first-12/JJ	det||class-16/NN||a-14/DT	amod||class-16/NN||new-15/JJ	prep_in||first-12/JJ||class-16/NN	amod||agents-20/NNS||oral-18/JJ	amod||agents-20/NNS||antihyperglycemic-19/JJ	prep_of||class-16/NN||agents-20/NNS	appos||agents-20/NNS||ahas-22/NNS	det||treatment-26/NN||the-25/DT	prep_for||agents-20/NNS||treatment-26/NN	prep_of||treatment-26/NN||patients-28/NNS	prep_with||patients-28/NNS||type2diabetes-30/CD	type2diabetes-30||sitagliptin-1||yes||sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (ahas) for the treatment of patients with type2diabetes.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bacilluscalmette-guerin-24||yes||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
det||design-6/NN||a-2/DT	amod||design-6/NN||double-blinded-3/JJ	amod||design-6/NN||randomized-4/JJ	nn||design-6/NN||crossover-5/NN	prep_in||examined-12/VBN||design-6/NN	amod||function-10/NN||postprandial-8/JJ	amod||function-10/NN||endothelial-9/JJ	nsubjpass||examined-12/VBN||function-10/NN	auxpass||examined-12/VBN||was-11/VBD	root||ROOT-0/null||examined-12/VBN	num||individuals-15/NNS||28-14/CD	prep_in||examined-12/VBN||individuals-15/NNS	amod||type2diabetes-20/NNS||impairedglucosetolerance-17/JJ	conj_or||impairedglucosetolerance-17/JJ||recent-onset-19/JJ	amod||type2diabetes-20/NNS||recent-onset-19/JJ	prep_with||individuals-15/NNS||type2diabetes-20/NNS	det||injection-24/NN||a-22/DT	amod||injection-24/NN||single-23/JJ	prep_after||examined-12/VBN||injection-24/NN	prep_of||injection-24/NN||exenatide-26/NN	prep_of||injection-24/NN||placebo-28/NN	conj_or||exenatide-26/NN||placebo-28/NN	vmod||injection-24/NN||given-29/VBN	advmod||given-29/VBN||just-30/RB	det||meal-34/NN||a-32/DT	amod||meal-34/NN||high-fat-33/JJ	prep_before||given-29/VBN||meal-34/NN	fat--1||impairedglucosetolerance-17||no_rel||in a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impairedglucosetolerance or recent-onset type2diabetes after a single injection of exenatide or placebo given just before a high-fat meal.
num||percent-2/NN||seventeen-1/CD	nsubj||resistant-8/JJ||percent-2/NN	det||cultures-6/NNS||all-4/DT	amod||cultures-6/NNS||positive-5/JJ	prep_of||percent-2/NN||cultures-6/NNS	cop||resistant-8/JJ||were-7/VBD	root||ROOT-0/null||resistant-8/JJ	preconj||isoniazid-11/NN||both-10/DT	prep_to||resistant-8/JJ||isoniazid-11/NN	prep_to||resistant-8/JJ||rifampin-13/NN	conj_and||isoniazid-11/NN||rifampin-13/NN	dep||resistant-18/NN||i.e.-15/FW	dep||resistant-18/NN||multidrug-17/JJ	dep||isoniazid-11/NN||resistant-18/NN	num||%-22/NN||16-21/CD	nsubjpass||infected-39/VBN||%-22/NN	prep_of||%-22/NN||patients-24/NNS	vmod||patients-24/NNS||dying-25/VBG	det||phase-29/NN||the-27/DT	nn||phase-29/NN||initiation-28/NN	prep_during||dying-25/VBG||phase-29/NN	poss||course-34/NN||their-31/PRP$	amod||course-34/NN||first-32/JJ	advmod||first-32/JJ||ever-33/RB	prep_of||phase-29/NN||course-34/NN	nn||treatment-37/NN||tuberculosis-36/NNP	prep_of||course-34/NN||treatment-37/NN	auxpass||infected-39/VBN||were-38/VBD	parataxis||resistant-8/JJ||infected-39/VBN	amod||bacilli-42/NNS||multidrug-resistant-41/JJ	prep_with||infected-39/VBN||bacilli-42/NNS	tuberculosis-36||isoniazid-11||yes||seventeen percent of all positive cultures were resistant to both isoniazid and rifampin (i.e., multidrug resistant); 16% of patients dying during the initiation phase of their first ever course of tuberculosis treatment were infected with multidrug-resistant bacilli.
vmod||report-4/VBP||herein-1/VBN	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||case-6/NN||a-5/DT	dobj||report-4/VBP||case-6/NN	prep_of||case-6/NN||pv-8/NN	vmod||pv-8/NN||associated-9/VBN	prep_with||associated-9/VBN||uc-11/NN	amod||localization-14/NN||unusual-13/JJ	prep_with||associated-9/VBN||localization-14/NN	nsubj||showed-16/VBD||localization-14/NN	rcmod||localization-14/NN||showed-16/VBD	det||response-19/NN||a-17/DT	amod||response-19/NN||good-18/JJ	dobj||showed-16/VBD||response-19/NN	amod||therapy-27/NN||systemic-21/JJ	amod||therapy-27/NN||corticosteroid-22/NN	conj_and||corticosteroid-22/NN||antibiotic-24/JJ	amod||therapy-27/NN||antibiotic-24/JJ	conj_and||corticosteroid-22/NN||sulfasalazine-26/JJ	amod||therapy-27/NN||sulfasalazine-26/JJ	prep_to||showed-16/VBD||therapy-27/NN	uc-11||sulfasalazine-26||yes||herein, we report a case of pv associated with uc with unusual localization that showed a good response to systemic corticosteroid, antibiotic and sulfasalazine therapy.
nsubjpass||assessed-5/VBN||diabetes-1/NN	conj_and||diabetes-1/NN||hypertension-3/NN	nsubjpass||assessed-5/VBN||hypertension-3/NN	auxpass||assessed-5/VBN||were-4/VBD	root||ROOT-0/null||assessed-5/VBN	amod||diagnosis-8/NN||clinical-7/JJ	agent||assessed-5/VBN||diagnosis-8/NN	agent||assessed-5/VBN||dyslipidemia-10/NN	conj_and||diagnosis-8/NN||dyslipidemia-10/NN	amod||triglycerides-13/NNPS||high-12/JJ	dep||diagnosis-8/NN||triglycerides-13/NNPS	amod||hdl-cholesterol-16/NN||low-15/JJ	dep||diagnosis-8/NN||hdl-cholesterol-16/NN	conj_and||triglycerides-13/NNPS||hdl-cholesterol-16/NN	dep||diagnosis-8/NN||hypercholesterolemia-19/NN	conj_and||triglycerides-13/NNPS||hypercholesterolemia-19/NN	nn||analyses-23/NNS||lipid-22/NN	agent||assessed-5/VBN||analyses-23/NNS	hypercholesterolemia-19||cholesterol--1||no||diabetes and hypertension were assessed by clinical diagnosis and dyslipidemia (high triglycerides, low hdl-cholesterol, and hypercholesterolemia) by lipid analyses.
prep_in||support-6/VBP||summary-2/NN	det||findings-5/NNS||these-4/DT	nsubj||support-6/VBP||findings-5/NNS	root||ROOT-0/null||support-6/VBP	det||model-8/NN||a-7/DT	dobj||support-6/VBP||model-8/NN	prep_in||disrupted-26/VBN||model-8/NN	prep_for||model-8/NN||tb-10/NN	det||relationship-15/NN||the-13/DT	amod||relationship-15/NN||stable-14/JJ	nsubjpass||disrupted-26/VBN||relationship-15/NN	det||host-19/NN||the-17/DT	amod||host-19/NN||human-18/JJ	prep_between||relationship-15/NN||host-19/NN	poss||m.tuberculosis-24/NNS||its-21/PRP$	advmod||m.tuberculosis-24/NNS||locally-22/RB	amod||m.tuberculosis-24/NNS||adapted-23/JJ	prep_between||relationship-15/NN||m.tuberculosis-24/NNS	conj_and||host-19/NN||m.tuberculosis-24/NNS	auxpass||disrupted-26/VBN||is-25/VBZ	rcmod||model-8/NN||disrupted-26/VBN	agent||disrupted-26/VBN||hivinfection-28/NN	tb-10||m.tuberculosis-24||no||in summary , these findings support a model for tb in which the stable relationship between the human host and its locally adapted m.tuberculosis is disrupted by hivinfection .
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	prep_such_as||disorders-27/NNS||disseminatedintravascularcoagulation-30/NN	appos||disseminatedintravascularcoagulation-30/NN||dic-32/NN	prep_such_as||disorders-27/NNS||shock-35/NN	conj_and||disseminatedintravascularcoagulation-30/NN||shock-35/NN	prep_such_as||disorders-27/NNS||pancreatitis-38/NNS	conj_and||disseminatedintravascularcoagulation-30/NN||pancreatitis-38/NNS	trypsin-2||pancreatitis-38||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminatedintravascularcoagulation (dic), shock, and pancreatitis.
amod||expression-4/NN||mpges-1-1/JJ	conj_and||mpges-1-1/JJ||cox-3/JJ	amod||expression-4/NN||cox-3/JJ	nsubjpass||evaluated-6/VBN||expression-4/NN	nsubjpass||evaluated-6/VBN||expression-4/NN	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	conj_and||evaluated-6/VBN||evaluated-6/VBN	agent||evaluated-6/VBN||immunohistochemistry-8/NN	nn||tissue-11/NN||muscle-10/NN	prep_in||immunohistochemistry-8/NN||tissue-11/NN	amod||individuals-14/NNS||healthy-13/JJ	prep_from||evaluated-6/VBN||individuals-14/NNS	prep_from||evaluated-6/VBN||patients-17/NNS	conj_and||individuals-14/NNS||patients-17/NNS	prep_with||patients-17/NNS||polymyositis-19/NNS	prep_with||patients-17/NNS||dermatomyositis-21/NNS	conj_or||polymyositis-19/NNS||dermatomyositis-21/NNS	amod||treatment-27/NN||conventional-25/JJ	nn||treatment-27/NN||immunosuppressive-26/NN	prep_after||evaluated-6/VBN||treatment-27/NN	prep_before||evaluated-6/VBN||treatment-27/NN	polymyositis-19||immunosuppressive-26||no_rel||mpges-1 and cox expression was evaluated by immunohistochemistry in muscle tissue from healthy individuals and from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
amod||immunomodulators-2/NNS||concomitant-1/JJ	nsubj||reduced-10/VBD||immunomodulators-2/NNS	det||form-5/NN||the-4/DT	prep_in||immunomodulators-2/NNS||form-5/NN	prep_of||form-5/NN||methotrexate-7/NN	prep_of||form-5/NN||azathioprine-9/NN	conj_or||methotrexate-7/NN||azathioprine-9/NN	root||ROOT-0/null||reduced-10/VBD	det||immunogenicity-12/NN||the-11/DT	dobj||reduced-10/VBD||immunogenicity-12/NN	amod||antibodies-15/NNS||therapeutic-14/JJ	prep_of||immunogenicity-12/NN||antibodies-15/NNS	prep_in||reduced-10/VBD||rheumatoidarthritis-17/NNS	prep_in||reduced-10/VBD||crohndisease-19/NN	conj_and||rheumatoidarthritis-17/NNS||crohndisease-19/NN	prep_in||reduced-10/VBD||juvenileidiopathicarthritis-22/NNS	conj_and||rheumatoidarthritis-17/NNS||juvenileidiopathicarthritis-22/NNS	rheumatoidarthritis-17||methotrexate-7||yes||concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoidarthritis, crohndisease, and juvenileidiopathicarthritis.
amod||infections-2/NNS||hospital-acquired-1/JJ	nsubj||cause-17/NN||infections-2/NNS	nsubj||impose-23/VB||infections-2/NNS	prep_with||infections-2/NNS||staphylococcusaureus-4/NNS	advmod||s.aureus-8/NNS||especially-6/RB	amod||s.aureus-8/NNS||methicillin-resistant-7/JJ	appos||infections-2/NNS||s.aureus-8/NNS	amod||infections-12/NNS||-lrb--9/JJ	nn||infections-12/NNS||mrsa-10/NN	nn||infections-12/NNS||-rrb--11/NN	dep||s.aureus-8/NNS||infections-12/NNS	cop||cause-17/NN||are-14/VBP	det||cause-17/NN||a-15/DT	amod||cause-17/NN||major-16/JJ	root||ROOT-0/null||cause-17/NN	prep_of||cause-17/NN||illness-19/NN	prep_of||cause-17/NN||death-21/NN	conj_and||illness-19/NN||death-21/NN	conj_and||cause-17/NN||impose-23/VB	amod||costs-26/NNS||serious-24/JJ	amod||costs-26/NNS||economic-25/JJ	dobj||impose-23/VB||costs-26/NNS	prep_on||impose-23/VB||patients-28/NNS	prep_on||impose-23/VB||hospitals-30/NNS	conj_and||patients-28/NNS||hospitals-30/NNS	mrsa-10||s.aureus-8||no||hospital-acquired infections with staphylococcusaureus , especially methicillin-resistant s.aureus -lrb- mrsa -rrb- infections , are a major cause of illness and death and impose serious economic costs on patients and hospitals .
det||exception-3/NN||the-2/DT	prep_with||effective-11/JJ||exception-3/NN	amod||angioplasty-6/NN||primary-5/JJ	prep_of||exception-3/NN||angioplasty-6/NN	nsubj||effective-11/JJ||fondaparinux-8/NN	nsubjpass||associated-20/VBN||fondaparinux-8/NN	cop||effective-11/JJ||is-9/VBZ	advmod||effective-11/JJ||as-10/RB	root||ROOT-0/null||effective-11/JJ	prep_as||effective-11/JJ||enoxaparin-13/NN	prep_as||effective-11/JJ||ufh-15/NN	conj_or||enoxaparin-13/NN||ufh-15/NN	auxpass||associated-20/VBN||is-18/VBZ	advmod||associated-20/VBN||also-19/RB	conj_but||effective-11/JJ||associated-20/VBN	det||reduction-24/NN||a-22/DT	amod||reduction-24/NN||considerable-23/JJ	prep_with||associated-20/VBN||reduction-24/NN	amod||complications-27/NNS||bleeding-26/VBG	prep_in||reduction-24/NN||complications-27/NNS	advmod||effective-11/JJ||thus-30/RB	conj_and||effective-11/JJ||thus-30/RB	det||benefit-36/NN||an-32/DT	amod||benefit-36/NN||undeniable-33/JJ	amod||benefit-36/NN||net-34/JJ	amod||benefit-36/NN||clinical-35/JJ	conj_and||effective-11/JJ||benefit-36/NN	dobj||effective-11/JJ||benefit-36/NN	fondaparinux-8||bleeding-26||no_rel||with the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or ufh, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit.
nn||diagnosis-2/NN||pbc-1/NN	nsubjpass||established-4/VBN||diagnosis-2/NN	auxpass||established-4/VBN||was-3/VBD	root||ROOT-0/null||established-4/VBN	prepc_according_to||established-4/VBN||to-6/TO	det||profile-10/NN||the-7/DT	amod||profile-10/NN||cholestatic-8/JJ	amod||profile-10/NN||biochemical-9/JJ	pobj||established-4/VBN||profile-10/NN	amod||antibodies-13/NNS||anti-mitochondrial-12/JJ	appos||profile-10/NN||antibodies-13/NNS	appos||profile-10/NN||ama-15/NN	nn||histology-20/NN||positivity-17/NN	conj_and||positivity-17/NN||liver-19/NN	nn||histology-20/NN||liver-19/NN	dep||profile-10/NN||histology-20/NN	dep||histology-20/NN||first-22/JJ	dep||profile-10/NN||ama-26/NN	conj_and||histology-20/NN||ama-26/NN	conj_and||histology-20/NN||antinuclear-28/NN	conj_and||ama-26/NN||antinuclear-28/NN	appos||ama-26/NN||ana-30/NN	amod||antibodies-33/NNS||pbc-specific-32/JJ	dep||ama-26/NN||antibodies-33/NNS	dep||ama-26/NN||second-35/JJ	antibodies-33||pbc-1||no_rel||pbc diagnosis was established according to the cholestatic biochemical profile, anti-mitochondrial antibodies (ama) positivity and liver histology (first), and ama and antinuclear (ana) pbc-specific antibodies (second).
amod||mice-3/NNS||sglt2-1/JJ	nn||mice-3/NNS||knockout-2/NN	nsubjpass||protected-5/VBN||mice-3/NNS	nsubjpass||reduced-13/VBN||mice-3/NNS	auxpass||protected-5/VBN||were-4/VBD	root||ROOT-0/null||protected-5/VBN	amod||hyperglycemia-8/NN||hfd-induced-7/JJ	prep_from||protected-5/VBN||hyperglycemia-8/NN	prep_from||protected-5/VBN||glucoseintolerance-10/NN	conj_and||hyperglycemia-8/NN||glucoseintolerance-10/NN	aux||reduced-13/VBN||had-12/VBD	conj_and||protected-5/VBN||reduced-13/VBN	nn||concentrations-16/NNS||plasma-14/NN	nn||concentrations-16/NNS||insulin-15/NN	dobj||reduced-13/VBN||concentrations-16/NNS	prepc_compared_with||reduced-13/VBN||with-18/IN	pobj||reduced-13/VBN||controls-19/NNS	hyperglycemia-8||insulin-15||yes||sglt2 knockout mice were protected from hfd-induced hyperglycemia and glucoseintolerance and had reduced plasma insulin concentrations compared with controls.
aux||aid-2/VB||to-1/TO	advcl||report-25/VBP||aid-2/VB	det||diagnosis-5/NN||the-3/DT	amod||diagnosis-5/NN||clinical-4/JJ	dobj||aid-2/VB||diagnosis-5/NN	prep_of||diagnosis-5/NN||typhoidfever-7/NN	prep_in||aid-2/VB||india-9/NN	advmod||have-18/VBP||where-11/WRB	amod||hospitals-13/NNS||most-12/JJS	nsubj||have-18/VBP||hospitals-13/NNS	amod||centres-17/NNS||primary-15/JJ	nn||centres-17/NNS||health-16/NN	conj_and||hospitals-13/NNS||centres-17/NNS	nsubj||have-18/VBP||centres-17/NNS	advcl||aid-2/VB||have-18/VBP	neg||facilities-20/NNS||no-19/DT	dobj||have-18/VBP||facilities-20/NNS	prep_for||facilities-20/NNS||culture-22/NN	nsubj||report-25/VBP||we-24/PRP	root||ROOT-0/null||report-25/VBP	det||development-28/NN||the-27/DT	prep_on||report-25/VBP||development-28/NN	det||kit-35/NN||a-30/DT	amod||kit-35/NN||novel-31/JJ	conj_and||novel-31/JJ||rapid-33/JJ	amod||kit-35/NN||rapid-33/JJ	amod||kit-35/NN||immunodiagnostic-34/JJ	prep_of||development-28/NN||kit-35/NN	det||detection-39/NN||the-37/DT	amod||detection-39/NN||direct-38/JJ	prep_for||kit-35/NN||detection-39/NN	nn||antibodies-46/NNS||salmonellatyphiâ-41/NNP	nn||antibodies-46/NNS||$-42/NNP	amod||antibodies-46/NNS||specific-44/JJ	nn||antibodies-46/NNS||igg-45/NN	prep_of||detection-39/NN||antibodies-46/NNS	prep_against||report-25/VBP||s-48/PRP	typhoidfever-7||salmonellatyphi--1||no||to aid the clinical diagnosis of typhoidfever in india, where most hospitals and primary health centres have no facilities for culture, we report on the development of a novel and rapid immunodiagnostic kit for the direct detection of salmonellatyphiâ€”specific igg antibodies against s .
amod||trials-4/NNS||controlled-2/JJ	amod||trials-4/NNS||clinical-3/JJ	prep_in||effective-8/JJ||trials-4/NNS	nsubj||effective-8/JJ||sertindole-5/NN	cop||effective-8/JJ||was-6/VBD	advmod||effective-8/JJ||more-7/RBR	root||ROOT-0/null||effective-8/JJ	prep_than||effective-8/JJ||placebo-10/NN	prepc_in||effective-8/JJ||reducing-12/VBG	amod||symptoms-16/NNS||positive-13/JJ	conj_and||positive-13/JJ||negative-15/JJ	amod||symptoms-16/NNS||negative-15/JJ	dobj||reducing-12/VBG||symptoms-16/NNS	mark||effective-22/JJ||whereas-18/IN	nsubj||effective-22/JJ||it-19/PRP	cop||effective-22/JJ||was-20/VBD	advmod||effective-22/JJ||as-21/RB	advcl||effective-8/JJ||effective-22/JJ	prep_as||effective-22/JJ||haloperidol-24/NN	prep_as||effective-22/JJ||risperidone-26/NN	conj_and||haloperidol-24/NN||risperidone-26/NN	det||symptoms-30/NNS||the-28/DT	amod||symptoms-30/NNS||positive-29/JJ	prep_against||effective-22/JJ||symptoms-30/NNS	prep_of||symptoms-30/NNS||schizophrenia-32/NN	schizophrenia-32||haloperidol-24||yes||in controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia.
advmod||had-5/VBD||moreover-1/RB	neg||patient-4/NN||no-3/DT	nsubj||had-5/VBD||patient-4/NN	root||ROOT-0/null||had-5/VBD	det||titre-8/NN||an-6/DT	amod||titre-8/NN||anti-hbsab-7/JJ	dobj||had-5/VBD||titre-8/NN	num||reactivation-14/NN||10-10/CD	amod||reactivation-14/NN||iu/l-11/JJ	conj_or||iu/l-11/JJ||hbv-13/JJ	amod||reactivation-14/NN||hbv-13/JJ	prep_below||titre-8/NN||reactivation-14/NN	amod||seroreversion-17/NN||hbsag-16/JJ	dep||reactivation-14/NN||seroreversion-17/NN	amod||detection-22/NN||positive-19/JJ	nn||detection-22/NN||hbv-20/NN	nn||detection-22/NN||dna-21/NN	dep||reactivation-14/NN||detection-22/NN	conj_or||seroreversion-17/NN||detection-22/NN	hbv-20||hbsag-16||yes||moreover, no patient had an anti-hbsab titre below 10 iu/l or hbv reactivation (hbsag seroreversion or positive hbv dna detection).
amod||yields-12/NNS||interferon-1/JJ	amod||therapy-4/NN||ribavirin-3/JJ	conj_and||interferon-1/JJ||therapy-4/NN	amod||yields-12/NNS||therapy-4/NN	amod||virus-7/NN||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||virus-7/NN	discourse||virus-7/NN||hcv-9/UH	nn||yields-12/NNS||infection-11/NN	nsubj||sustained-13/VBD||yields-12/NNS	root||ROOT-0/null||sustained-13/VBD	amod||rates-19/NNS||virological-14/JJ	nn||rates-19/NNS||response-15/NN	discourse||rates-19/NNS||svr-17/UH	dobj||sustained-13/VBD||rates-19/NNS	prep_of||rates-19/NNS||50â-21/NNS	dep||%-25/NN||$-22/$	num||$-22/$||80-24/CD	amod||50â-21/NNS||%-25/NN	chronichepatitisc-6||interferon-1||yes||interferon and ribavirin therapy for chronichepatitisc virus (hcv) infection yields sustained virological response (svr) rates of 50â€“80%.
aux||examine-2/VB||to-1/TO	advcl||performed-10/VBN||examine-2/VB	det||question-4/NN||this-3/DT	dobj||examine-2/VB||question-4/NN	amod||clamps-8/NNS||euglycemic-6/JJ	nn||clamps-8/NNS||glucose-7/NN	nsubjpass||performed-10/VBN||clamps-8/NNS	auxpass||performed-10/VBN||were-9/VBD	root||ROOT-0/null||performed-10/VBN	advmod||performed-10/VBN||twice-11/RB	amod||order-15/NN||random-14/JJ	prep_in||performed-10/VBN||order-15/NN	num||youth-19/NN||11-18/CD	prep_in||performed-10/VBN||youth-19/NN	prep_with||youth-19/NN||type1diabetes-21/CD	nn||15.1-24/NNS||age-23/NN	nsubj||â-25/VBP||15.1-24/NNS	dep||youth-19/NN||â-25/VBP	number||3-27/CD||±-26/CD	num||years-28/NNS||3-27/CD	tmod||â-25/VBP||years-28/NNS	amod||â-32/NN||a1c-30/JJ	num||â-32/NN||7.6-31/CD	nsubj||±-33/VBG||â-32/NN	vmod||â-25/VBP||±-33/VBG	num||%-35/NN||0.6-34/CD	dobj||±-33/VBG||%-35/NN	num||lispro-40/NN||0.2-38/CD	amod||lispro-40/NN||units/kg-39/VBG	prep_with||youth-19/NN||lispro-40/NN	num||glargine-44/NN||0.4-42/CD	amod||glargine-44/NN||units/kg-43/VBG	prep_with||youth-19/NN||glargine-44/NN	conj_and||lispro-40/NN||glargine-44/NN	vmod||lispro-40/NN||given-46/VBN	preconj||given-46/VBN||either-47/CC	prep_as||given-46/VBN||separate-49/JJ	det||injection-55/NN||a-52/DT	amod||injection-55/NN||single-53/JJ	amod||injection-55/NN||mixed-54/JJ	prep_as||given-46/VBN||injection-55/NN	conj_or||separate-49/JJ||injection-55/NN	glargine-44||type1diabetes-21||no_rel||to examine this question, euglycemic glucose clamps were performed twice, in random order, in 11 youth with type1diabetes (age 15.1 â± 3 years, a1c 7.6 â± 0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either as separate or as a single mixed injection.
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	insulin-59||cancer-54||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
amod||patients-2/NNS||female-1/JJ	nsubj||received-9/VBD||patients-2/NNS	vmod||patients-2/NNS||fulfilling-3/VBG	amod||criteria-6/NNS||rome-4/JJ	nn||criteria-6/NNS||ii-5/NN	dobj||fulfilling-3/VBG||criteria-6/NNS	prep_for||fulfilling-3/VBG||ibs-8/NN	root||ROOT-0/null||received-9/VBD	num||mg-11/NN||6-10/CD	dobj||received-9/VBD||mg-11/NN	prep_of||mg-11/NN||tegaserod-13/NN	advmod||day-16/NN||twice-14/RB	det||day-16/NN||a-15/DT	tmod||received-9/VBD||day-16/NN	num||weeks-19/NNS||4-18/CD	prep_for||received-9/VBD||weeks-19/NNS	ibs-8||tegaserod-13||yes||female patients fulfilling rome ii criteria for ibs received 6 mg of tegaserod twice a day for 4 weeks.
det||results-3/NNS||the-1/DT	nn||results-3/NNS||trial-2/NN	nsubj||provide-5/VB||results-3/NNS	aux||provide-5/VB||would-4/MD	root||ROOT-0/null||provide-5/VB	dobj||provide-5/VB||evidence-6/NN	det||efficacy-9/NN||the-8/DT	prep_on||provide-5/VB||efficacy-9/NN	prep_of||efficacy-9/NN||domperidone-11/NN	nsubjpass||used-16/VBN||domperidone-11/NN	auxpass||used-16/VBN||is-14/VBZ	advmod||used-16/VBN||largely-15/RB	rcmod||domperidone-11/NN||used-16/VBN	amod||practice-19/NN||clinical-18/JJ	prep_in||used-16/VBN||practice-19/NN	det||lack-22/NN||the-21/DT	prep_despite||used-16/VBN||lack-22/NN	amod||evaluation-25/NN||proper-24/JJ	prep_of||lack-22/NN||evaluation-25/NN	det||profile-30/NN||a-27/DT	amod||profile-30/NN||controversial-28/JJ	nn||profile-30/NN||safety-29/NN	prep_of||lack-22/NN||profile-30/NN	conj_and||evaluation-25/NN||profile-30/NN	dep||used-16/VBN||as-32/RB	prepc_compared_to||used-16/VBN||to-34/TO	prep_despite||used-16/VBN||ondansetron-35/NN	nsubjpass||authorized-41/VBN||which-37/WDT	auxpass||authorized-41/VBN||is-38/VBZ	neg||authorized-41/VBN||not-39/RB	advmod||authorized-41/VBN||yet-40/RB	dep||used-16/VBN||authorized-41/VBN	prep_in||authorized-41/VBN||italy-43/NN	prep_despite||authorized-41/VBN||evidence-45/NN	xcomp||authorized-41/VBN||supporting-46/VBG	poss||efficacy-48/NN||its-47/PRP$	dobj||supporting-46/VBG||efficacy-48/NN	prepc_in||supporting-46/VBG||treating-50/VBG	dobj||treating-50/VBG||vomiting-51/NN	vomiting-51||ondansetron-35||yes||the trial results would provide evidence on the efficacy of domperidone, which is largely used in clinical practice despite the lack of proper evaluation and a controversial safety profile, as compared to ondansetron, which is not yet authorized in italy despite evidence supporting its efficacy in treating vomiting.
det||regions-3/NNS||both-2/DT	prep_in||infected-11/VBN||regions-3/NNS	det||majority-6/NN||the-5/DT	nsubjpass||infected-11/VBN||majority-6/NN	prep_of||majority-6/NN||subjects-8/NNS	aux||infected-11/VBN||had-9/VBD	auxpass||infected-11/VBN||been-10/VBN	root||ROOT-0/null||infected-11/VBN	prep_with||infected-11/VBN||varicella-13/NN	advmod||165-17/CD||only-16/RB	nn||subjects-22/NNS||165-17/CD	num||%-20/NN||5.2-19/CD	appos||subjects-22/NNS||%-20/NN	nsubj||reported-23/VBD||subjects-22/NNS	conj_and||infected-11/VBN||reported-23/VBD	xcomp||reported-23/VBD||receiving-24/VBG	det||vaccination-27/NN||the-25/DT	nn||vaccination-27/NN||vzv-26/NN	dobj||receiving-24/VBG||vaccination-27/NN	varicella-13||vzv-26||no||in both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the vzv vaccination.
det||hypermuscularity-3/NN||the-1/DT	amod||hypermuscularity-3/NN||marked-2/JJ	nsubj||reduces-10/VBZ||hypermuscularity-3/NN	prep_in||hypermuscularity-3/NN||mice-5/NNS	amod||deficiency-9/NN||constitutive-7/JJ	nn||deficiency-9/NN||myostatin-8/NN	prep_with||mice-5/NNS||deficiency-9/NN	root||ROOT-0/null||reduces-10/VBZ	amod||accumulation-12/NN||fat-11/JJ	dobj||reduces-10/VBZ||accumulation-12/NN	dobj||reduces-10/VBZ||hyperglycemia-14/NN	conj_and||accumulation-12/NN||hyperglycemia-14/NN	vmod||accumulation-12/NN||induced-15/VBN	amod||feeding-18/NN||high-fat-17/JJ	agent||induced-15/VBN||feeding-18/NN	nsubj||unclear-23/JJ||it-21/PRP	cop||unclear-23/JJ||is-22/VBZ	conj_but||reduces-10/VBZ||unclear-23/JJ	mark||has-38/VBZ||whether-24/IN	det||increase-27/NN||the-25/DT	amod||increase-27/NN||smaller-26/JJR	nsubj||has-38/VBZ||increase-27/NN	nn||mass-30/NN||muscle-29/NN	prep_in||increase-27/NN||mass-30/NN	vmod||mass-30/NN||caused-31/VBN	amod||loss-34/NN||postdevelopmental-33/JJ	agent||caused-31/VBN||loss-34/NN	nn||activity-37/NN||myostatin-36/NN	prep_of||loss-34/NN||activity-37/NN	ccomp||unclear-23/JJ||has-38/VBZ	amod||effects-41/NNS||beneficial-39/JJ	amod||effects-41/NNS||metabolic-40/JJ	dobj||has-38/VBZ||effects-41/NNS	amod||feeding-44/NN||high-fat-43/JJ	prep_during||has-38/VBZ||feeding-44/NN	hyperglycemia-14||fat-11||no_rel||the marked hypermuscularity in mice with constitutive myostatin deficiency reduces fat accumulation and hyperglycemia induced by high-fat feeding, but it is unclear whether the smaller increase in muscle mass caused by postdevelopmental loss of myostatin activity has beneficial metabolic effects during high-fat feeding.
det||ability-2/NN||the-1/DT	nsubj||suggests-20/VBZ||ability-2/NN	prep_of||ability-2/NN||ride-4/NN	aux||enhance-6/VB||to-5/TO	vmod||ride-4/NN||enhance-6/VB	dobj||enhance-6/VB||infectivity-7/NN	amod||vzv-10/NN||cell-free-9/JJ	prep_of||infectivity-7/NN||vzv-10/NN	det||range-14/NN||a-12/DT	amod||range-14/NN||wide-13/JJ	prep_over||enhance-6/VB||range-14/NN	nn||times-17/NNS||incubation-16/NN	prep_of||range-14/NN||times-17/NNS	prep_of||range-14/NN||temperatures-19/NNS	conj_and||times-17/NNS||temperatures-19/NNS	root||ROOT-0/null||suggests-20/VBZ	mark||useful-25/JJ||that-21/IN	nsubj||useful-25/JJ||ride-22/NN	aux||useful-25/JJ||may-23/MD	cop||useful-25/JJ||be-24/VB	ccomp||suggests-20/VBZ||useful-25/JJ	prepc_for||useful-25/JJ||increasing-27/VBG	det||stability-29/NN||the-28/DT	dobj||increasing-27/VBG||stability-29/NN	nn||vaccines-34/NNS||varicella-31/NN	conj_or||varicella-31/NN||zoster-33/NN	nn||vaccines-34/NNS||zoster-33/NN	prep_of||stability-29/NN||vaccines-34/NNS	zoster-33||vzv-10||no||the ability of ride to enhance infectivity of cell-free vzv over a wide range of incubation times and temperatures suggests that ride may be useful for increasing the stability of varicella or zoster vaccines.
det||emergence-2/NN||the-1/DT	nsubj||undermines-8/VBZ||emergence-2/NN	nsubj||undermines-8/VBZ||emergence-2/NN	nn||resistance-5/NN||drug-4/NN	prep_of||emergence-2/NN||resistance-5/NN	prep_in||resistance-5/NN||m.tuberculosis-7/NNS	root||ROOT-0/null||undermines-8/VBZ	conj_and||undermines-8/VBZ||undermines-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||undermines-8/VBZ||efficacy-10/NN	nn||treatment-16/NN||tuberculosis-12/NNP	nn||treatment-16/NN||-lrb--13/NNP	nn||treatment-16/NN||tb-14/NNP	nn||treatment-16/NN||-rrb--15/NNP	prep_of||efficacy-10/NN||treatment-16/NN	prep_in||undermines-8/VBZ||individuals-18/NNS	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||undermines-8/VBZ||programs-23/NNS	prep_in||programs-23/NNS||populations-25/NNS	tuberculosis-12||m.tuberculosis-7||no||the emergence of drug resistance in m.tuberculosis undermines the efficacy of tuberculosis -lrb- tb -rrb- treatment in individuals and of tb control programs in populations .
prep_in||is-11/VBZ||view-2/NN	det||goal-5/NN||the-4/DT	prep_of||view-2/NN||goal-5/NN	amod||elimination-8/NN||measles-7/JJ	prep_of||goal-5/NN||elimination-8/NN	nsubj||is-11/VBZ||it-10/PRP	nsubj||assess-16/VB||it-10/PRP	root||ROOT-0/null||is-11/VBZ	amod||importance-14/NN||great-13/JJ	prep_of||is-11/VBZ||importance-14/NN	aux||assess-16/VB||to-15/TO	xcomp||is-11/VBZ||assess-16/VB	det||circulation-18/NN||the-17/DT	dobj||assess-16/VB||circulation-18/NN	amod||measlesvirus-21/NNS||wild-type-20/JJ	prep_of||circulation-18/NN||measlesvirus-21/NNS	appos||measlesvirus-21/NNS||mv-23/NN	measles-7||measlesvirus-21||no||in view of the goal of measles elimination, it is of great importance to assess the circulation of wild-type measlesvirus (mv).
nsubj||factors-28/NNS||female-1/NN	dep||female-1/NN||p-3/VBN	dep||0.037-5/CD||=-4/SYM	ccomp||p-3/VBN||0.037-5/CD	amod||allergies-9/NNS||preexisting-8/VBG	conj_and||female-1/NN||allergies-9/NNS	nsubj||factors-28/NNS||allergies-9/NNS	dep||allergies-9/NNS||p-11/VBN	dep||0.004-13/CD||=-12/SYM	ccomp||p-11/VBN||0.004-13/CD	amod||level-17/NN||lower-16/JJR	conj_and||female-1/NN||level-17/NN	nsubj||factors-28/NNS||level-17/NN	amod||dehydrogenase-20/NN||lactate-19/JJ	prep_of||level-17/NN||dehydrogenase-20/NN	dep||female-1/NN||p-22/VBN	dep||0.003-24/CD||=-23/SYM	ccomp||p-22/VBN||0.003-24/CD	cop||factors-28/NNS||were-26/VBD	nn||factors-28/NNS||risk-27/NN	root||ROOT-0/null||factors-28/NNS	number||1/2-31/CD||grade-30/CD	num||hypersensitivityreactions-32/NNS||1/2-31/CD	prep_for||factors-28/NNS||hypersensitivityreactions-32/NNS	amod||count-37/NN||higher-35/JJR	amod||count-37/NN||neutrophil-36/JJ	nsubj||were-52/VBD||count-37/NN	dep||count-37/NN||p-39/VBN	dep||0.043-41/CD||=-40/SYM	ccomp||p-39/VBN||0.043-41/CD	amod||count-46/NN||lower-44/JJR	nn||count-46/NN||monocyte-45/NN	conj_and||count-37/NN||count-46/NN	nsubj||were-52/VBD||count-46/NN	dep||count-46/NN||p-48/VBN	dep||0.007-50/CD||=-49/SYM	ccomp||p-48/VBN||0.007-50/CD	conj_and||factors-28/NNS||were-52/VBD	number||3/4-55/CD||grade-54/CD	num||reactions-56/NNS||3/4-55/CD	prep_for||were-52/VBD||reactions-56/NNS	hypersensitivityreactions-32||allergies-9||no||female (p=0.037), preexisting allergies (p=0.004) and lower level of lactate dehydrogenase (p=0.003) were risk factors for grade 1/2 hypersensitivityreactions, and higher neutrophil count (p=0.043) and lower monocyte count (p=0.007) were for grade 3/4 reactions.
nsubj||included-7/VBD||reasons-1/NNS	nsubj||widowhood-30/VBD||reasons-1/NNS	nn||use-6/NN||drug-3/NN	conj_and||drug-3/NN||alcohol-5/NN	nn||use-6/NN||alcohol-5/NN	prep_for||reasons-1/NNS||use-6/NN	root||ROOT-0/null||included-7/VBD	aux||avoid-9/VB||to-8/TO	ccomp||included-7/VBD||avoid-9/VB	dobj||avoid-9/VB||symptoms-10/NNS	prep_of||symptoms-10/NNS||withdrawal-12/NN	aux||suppress-15/VB||to-14/TO	dep||avoid-9/VB||suppress-15/VB	amod||pain-17/NN||emotional-16/JJ	dobj||suppress-15/VB||pain-17/NN	aux||overcome-20/VB||to-19/TO	dep||avoid-9/VB||overcome-20/VB	det||shame-22/NN||the-21/DT	dobj||overcome-20/VB||shame-22/NN	nn||work-25/NN||sex-24/NN	prep_of||shame-22/NN||work-25/NN	appos||work-25/NN||pleasure-27/NN	conj_and||included-7/VBD||widowhood-30/VBD	alcohol-5||pain-17||no_rel||reasons for drug and alcohol use included to avoid symptoms of withdrawal, to suppress emotional pain, to overcome the shame of sex work, pleasure, and widowhood.
det||emulsion-3/NN||the-1/DT	nn||emulsion-3/NN||lipid-2/NN	nsubj||safe-8/JJ||emulsion-3/NN	nsubj||tolerated-11/JJ||emulsion-3/NN	vmod||emulsion-3/NN||enriched-4/VBN	prep_with||enriched-4/VBN||omega-3fattyacids-6/JJ	cop||safe-8/JJ||was-7/VBD	root||ROOT-0/null||safe-8/JJ	advmod||tolerated-11/JJ||well-10/RB	conj_and||safe-8/JJ||tolerated-11/JJ	amod||administration-14/NN||short-term-13/JJ	prep_in||safe-8/JJ||administration-14/NN	prep_to||safe-8/JJ||patients-16/NNS	prep_with||patients-16/NNS||ards-18/NNS	omega-3fattyacids-6||ards-18||no_rel||the lipid emulsion enriched with omega-3fattyacids was safe and well tolerated in short-term administration to patients with ards.
amod||maculardystrophy-3/NN||untreatable-1/JJ	amod||maculardystrophy-3/NN||hereditary-2/JJ	nsubj||presents-7/VBZ||maculardystrophy-3/NN	appos||maculardystrophy-3/NN||hmd-5/NN	root||ROOT-0/null||presents-7/VBZ	det||burden-10/NN||a-8/DT	amod||burden-10/NN||major-9/JJ	dobj||presents-7/VBZ||burden-10/NN	prep_to||presents-7/VBZ||society-12/NN	prep_in||society-12/NN||terms-14/NNS	det||disability-19/NN||the-16/DT	amod||disability-19/NN||resulting-17/VBG	nn||disability-19/NN||patient-18/NN	prep_of||terms-14/NNS||disability-19/NN	det||cost-22/NN||the-21/DT	prep_of||terms-14/NNS||cost-22/NN	conj_and||disability-19/NN||cost-22/NN	det||system-27/NN||the-24/DT	nn||system-27/NN||healthcare-25/NN	nn||system-27/NN||provision-26/NN	prep_to||cost-22/NN||system-27/NN	hmd-5||maculardystrophy-3||no_rel||untreatable hereditary maculardystrophy (hmd) presents a major burden to society in terms of the resulting patient disability and the cost to the healthcare provision system.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||administration-4/NN||the-3/DT	dobj||evaluate-2/VB||administration-4/NN	prep_of||administration-4/NN||antipyretics-6/NNS	prep_to||evaluate-2/VB||children-8/NNS	prep_with||children-8/NNS||upperrespiratorytractinfections-10/NNS	appos||upperrespiratorytractinfections-10/NNS||urti-12/NNP	poss||parents-16/NNS||their-15/PRP$	prep_by||evaluate-2/VB||parents-16/NNS	prep_by||evaluate-2/VB||guardians-18/NNS	conj_or||parents-16/NNS||guardians-18/NNS	prep_without||evaluate-2/VB||consultation-20/NN	prep_with||consultation-20/NN||physicians-22/NNS	conj_and||evaluate-2/VB||compare-25/VB	amod||characteristics-29/NNS||epidemiological-26/JJ	conj_and||epidemiological-26/JJ||clinical-28/JJ	amod||characteristics-29/NNS||clinical-28/JJ	dobj||compare-25/VB||characteristics-29/NNS	prep_of||characteristics-29/NNS||patients-31/NNS	nsubj||received-33/VBD||patients-31/NNS	rcmod||patients-31/NNS||received-33/VBD	dobj||received-33/VBD||antipyretics-34/NNS	dep||evaluate-2/VB||of-36/IN	pcomp||of-36/IN||untreated-37/VBG	dobj||untreated-37/VBG||patients-38/NNS	antipyretics-34||upperrespiratorytractinfections-10||no_rel||to evaluate the administration of antipyretics to children with upperrespiratorytractinfections (urti) by their parents or guardians without consultation with physicians, and compare epidemiological and clinical characteristics of patients who received antipyretics and of untreated patients.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||identified-6/VBD||study-4/NN	nsubj||identified-6/VBD||we-5/PRP	root||ROOT-0/null||identified-6/VBD	dobj||identified-6/VBD||genes-7/NNS	nsubj||predict-12/VB||genes-7/NNS	dobj||identified-6/VBD||mirnas-9/NNS	conj_and||genes-7/NNS||mirnas-9/NNS	nsubj||predict-12/VB||mirnas-9/NNS	aux||predict-12/VB||may-11/MD	rcmod||genes-7/NNS||predict-12/VB	amod||resistance-14/NN||clinical-13/JJ	dobj||predict-12/VB||resistance-14/NN	prep_of||resistance-14/NN||cll-16/NN	aux||fludarabine-18/VB||to-17/TO	vmod||predict-12/VB||fludarabine-18/VB	vmod||predict-12/VB||describe-21/VB	conj_and||fludarabine-18/VB||describe-21/VB	det||mechanism-25/NN||an-22/DT	amod||mechanism-25/NN||interesting-23/JJ	amod||mechanism-25/NN||oncogenic-24/JJ	dobj||fludarabine-18/VB||mechanism-25/NN	nn||patients-28/NNS||cll-27/NN	prep_in||fludarabine-18/VB||patients-28/NNS	amod||patients-28/NNS||resistant-29/JJ	aux||fludarabine-31/VB||to-30/TO	xcomp||resistant-29/JJ||fludarabine-31/VB	dobj||altered-42/VBN||which-33/WDT	det||myc-36/NN||the-34/DT	amod||myc-36/NN||complete-35/JJ	nsubjpass||altered-42/VBN||myc-36/NN	amod||network-40/NN||specific-38/JJ	amod||network-40/NN||regulatory-39/JJ	dep||myc-36/NN||network-40/NN	auxpass||altered-42/VBN||was-41/VBD	prepc_by||fludarabine-31/VB||altered-42/VBN	dep||fludarabine-18/VB||dna-44/NN	dep||fludarabine-18/VB||rna-46/NN	conj_and||dna-44/NN||rna-46/NN	dep||dna-44/NN||levels-47/NNS	amod||targets-51/NNS||transcriptional-50/JJ	dep||fludarabine-18/VB||targets-51/NNS	conj_and||dna-44/NN||targets-51/NNS	cll-27||fludarabine-31||yes||in the present study we identified genes and mirnas that may predict clinical resistance of cll to fludarabine, and describe an interesting oncogenic mechanism in cll patients resistant to fludarabine by which the complete myc -specific regulatory network was altered (dna and rna levels, and transcriptional targets).
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||also-2/RB	root||ROOT-0/null||show-3/VBP	mark||respond-13/VB||that-4/IN	preconj||huh7-6/NNS||both-5/DT	nsubj||respond-13/VB||huh7-6/NNS	amod||lines-10/NNS||a549-8/JJ	nn||lines-10/NNS||cell-9/NN	conj_and||huh7-6/NNS||lines-10/NNS	nsubj||respond-13/VB||lines-10/NNS	aux||respond-13/VB||do-11/VBP	neg||respond-13/VB||not-12/RB	ccomp||show-3/VBP||respond-13/VB	prep_to||respond-13/VB||hantavirusinfection-15/NN	xcomp||respond-13/VB||confirming-17/VBG	mark||involved-30/VBN||that-18/IN	det||pathways-23/NNS||the-19/DT	amod||pathways-23/NNS||cytoplasmic-20/JJ	nn||pathways-23/NNS||rna-21/NN	nn||pathways-23/NNS||helicase-22/NN	nsubjpass||involved-30/VBN||pathways-23/NNS	vmod||pathways-23/NNS||possessed-24/VBN	det||cells-27/NNS||these-26/DT	agent||possessed-24/VBN||cells-27/NNS	auxpass||involved-30/VBN||are-28/VBP	neg||involved-30/VBN||not-29/RB	ccomp||confirming-17/VBG||involved-30/VBN	amod||recognition-33/NN||hantavirus-32/JJ	prep_in||involved-30/VBN||recognition-33/NN	hantavirusinfection-15||hantavirus-32||no||we also show that both huh7 and a549 cell lines do not respond to hantavirusinfection, confirming that the cytoplasmic rna helicase pathways possessed by these cells are not involved in hantavirus recognition.
amod||thromboembolism-2/NN||venous-1/JJ	nsubj||complication-8/NN||thromboembolism-2/NN	cop||complication-8/NN||is-3/VBZ	det||complication-8/NN||a-4/DT	advmod||frequently-6/RB||relatively-5/RB	advmod||occurring-7/VBG||frequently-6/RB	amod||complication-8/NN||occurring-7/VBG	root||ROOT-0/null||complication-8/NN	advmod||ill-11/JJ||critically-10/RB	amod||patients-12/NNS||ill-11/JJ	prep_in||complication-8/NN||patients-12/NNS	vmod||patients-12/NNS||admitted-13/VBN	det||icu-16/NN||the-15/DT	prep_to||admitted-13/VBN||icu-16/NN	amod||treatment-19/NN||prophylactic-18/JJ	prep_despite||admitted-13/VBN||treatment-19/NN	amod||heparin-25/NN||subcutaneous-21/JJ	amod||heparin-25/NN||low-22/JJ	amod||heparin-25/NN||molecular-23/JJ	nn||heparin-25/NN||weight-24/NN	prep_with||admitted-13/VBN||heparin-25/NN	thromboembolism-2||heparin-25||yes||venous thromboembolism is a relatively frequently occurring complication in critically ill patients admitted to the icu despite prophylactic treatment with subcutaneous low molecular weight heparin.
det||total-2/NN||a-1/DT	nsubj||underwent-27/VBD||total-2/NN	num||adolescents-6/NNS||24-4/CD	amod||adolescents-6/NNS||obese-5/JJ	prep_of||total-2/NN||adolescents-6/NNS	prep_with||adolescents-6/NNS||ngt-8/NN	conj_and||total-2/NN||13-10/CD	nsubj||underwent-27/VBD||13-10/CD	prep_with||13-10/CD||ifg-12/NN	conj_and||total-2/NN||29-14/CD	nsubj||underwent-27/VBD||29-14/CD	prep_with||29-14/CD||igt-16/NN	conj_and||total-2/NN||11-18/CD	nsubj||underwent-27/VBD||11-18/CD	amod||ifg/igt-21/NN||combined-20/JJ	prep_with||11-18/CD||ifg/igt-21/NN	conj_and||total-2/NN||30-24/CD	nsubj||underwent-27/VBD||30-24/CD	prep_with||30-24/CD||type2diabetes-26/CD	root||ROOT-0/null||underwent-27/VBD	dobj||underwent-27/VBD||evaluation-28/NN	amod||production-32/NN||hepatic-30/JJ	nn||production-32/NN||glucose-31/NN	prep_of||evaluation-28/NN||production-32/NN	amod||glucose-37/NN||-LSB--34/JJ	nn||glucose-37/NN||6,6-2h2-35/NN	nn||glucose-37/NN||-RSB--36/NN	appos||production-32/NN||glucose-37/NN	amod||disposal-42/NN||insulin-stimulated-40/JJ	nn||disposal-42/NN||glucose-41/NN	appos||production-32/NN||disposal-42/NN	dep||disposal-42/NN||r-44/SYM	dep||r-44/SYM||d-45/SYM	amod||clamp-48/NN||euglycemic-47/JJ	appos||r-44/SYM||clamp-48/NN	amod||secretion-56/NN||first-51/JJ	conj_and||first-51/JJ||second-phase-54/JJ	amod||secretion-56/NN||second-phase-54/JJ	nn||secretion-56/NN||insulin-55/NN	appos||production-32/NN||secretion-56/NN	conj_and||disposal-42/NN||secretion-56/NN	amod||clamp-59/NN||hyperglycemic-58/JJ	appos||secretion-56/NN||clamp-59/NN	nn||composition-63/NN||body-62/NN	appos||production-32/NN||composition-63/NN	conj_and||disposal-42/NN||composition-63/NN	amod||absorptiometry-67/NN||dual-energy-65/JJ	amod||absorptiometry-67/NN||x-ray-66/JJ	appos||composition-63/NN||absorptiometry-67/NN	amod||adiposity-71/NN||abdominal-70/JJ	appos||production-32/NN||adiposity-71/NN	conj_and||disposal-42/NN||adiposity-71/NN	dep||adiposity-71/NN||computed-73/VBN	advmod||computed-73/VBN||tomography-74/RB	amod||oxidation-79/NN||substrate-78/JJ	appos||production-32/NN||oxidation-79/NN	conj_and||disposal-42/NN||oxidation-79/NN	amod||calorimetry-82/NN||indirect-81/JJ	appos||oxidation-79/NN||calorimetry-82/NN	type2diabetes-26||insulin-55||yes||a total of 24 obese adolescents with ngt, 13 with ifg, 29 with igt, 11 with combined ifg/igt, and 30 with type2diabetes underwent evaluation of hepatic glucose production ([6,6-2h2]glucose), insulin-stimulated glucose disposal ( r d, euglycemic clamp), first- and second-phase insulin secretion (hyperglycemic clamp), body composition (dual-energy x-ray absorptiometry), abdominal adiposity (computed tomography), and substrate oxidation (indirect calorimetry).
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||review-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||review-8/VB||to-7/TO	xcomp||was-6/VBD||review-8/VB	det||safety-10/NN||the-9/DT	dobj||review-8/VB||safety-10/NN	dobj||review-8/VB||efficacy-12/NN	conj_and||safety-10/NN||efficacy-12/NN	prep_of||safety-10/NN||growthhormone-14/NN	appos||growthhormone-14/NN||gh-16/NN	num||children-20/NNS||eight-19/CD	prep_in||review-8/VB||children-20/NNS	nsubjpass||treated-26/VBN||children-20/NNS	nn||syndrome-23/NN||hurler-22/NN	prep_with||children-20/NNS||syndrome-23/NN	auxpass||treated-26/VBN||were-25/VBD	rcmod||children-20/NNS||treated-26/VBN	poss||institution-29/NN||our-28/PRP$	prep_at||treated-26/VBN||institution-29/NN	prep_with||treated-26/VBN||gh-31/NN	nn||deficiency-36/NN||shortstature-33/NN	conj_or||shortstature-33/NN||gh-35/NN	nn||deficiency-36/NN||gh-35/NN	prep_for||gh-31/NN||deficiency-36/NN	prep_between||deficiency-36/NN||2005-38/CD	prep_between||deficiency-36/NN||2008-40/CD	conj_and||2005-38/CD||2008-40/CD	shortstature-33||growthhormone-14||yes||the goal of this study was to review the safety and efficacy of growthhormone (gh) in eight children with hurler syndrome who were treated at our institution with gh for shortstature or gh deficiency between 2005 and 2008.
num||assays-6/NNS||two-1/CD	amod||assays-6/NNS||commercial-2/JJ	nn||assays-6/NNS||interferon-3/NN	nn||assays-6/NNS||gamma-4/NN	nn||assays-6/NNS||release-5/NN	nsubj||become-33/VBN||assays-6/NNS	amod||®-12/NNP||-lrb--7/JJ	nn||®-12/NNP||igras-8/NNS	nn||®-12/NNP||-rrb--9/NNP	nn||®-12/NNP||-lrb--10/NNP	nn||®-12/NNP||quantiferonâ-11/NNP	nsubj||tb-23/VBP||®-12/NNP	nn||gold-15/NN||tb-14/NN	dep||®-12/NNP||gold-15/NN	nn||®-21/NNS||tube-17/NN	conj_and||tube-17/NN||t-19/NN	nn||®-21/NNS||t-19/NN	nn||®-21/NNS||spotâ-20/NN	prep_in||gold-15/NN||®-21/NNS	rcmod||assays-6/NNS||tb-23/VBP	acomp||tb-23/VBP||-rrb--24/JJ	aux||detect-26/VB||to-25/TO	xcomp||-rrb--24/JJ||detect-26/VB	det||contact-28/NN||a-27/DT	dobj||detect-26/VB||contact-28/NN	prep_with||detect-26/VB||m.tuberculosis-30/NNS	aux||become-33/VBN||have-31/VBP	advmod||become-33/VBN||recently-32/RB	root||ROOT-0/null||become-33/VBN	acomp||become-33/VBN||available-34/JJ	tb-23||m.tuberculosis-30||no||two commercial interferon gamma release assays -lrb- igras -rrb- -lrb- quantiferonâ ® - tb gold in tube and t spotâ ® - tb -rrb- to detect a contact with m.tuberculosis have recently become available .
amod||causes-3/NNS||known-1/JJ	amod||causes-3/NNS||genetic-2/JJ	nsubjpass||ruled-8/VBN||causes-3/NNS	amod||hypercholesterolemia-6/NN||severe-5/JJ	prep_of||causes-3/NNS||hypercholesterolemia-6/NN	auxpass||ruled-8/VBN||were-7/VBD	root||ROOT-0/null||ruled-8/VBN	prt||ruled-8/VBN||out-9/RP	agent||ruled-8/VBN||sequencing-11/VBG	det||genes-14/NNS||the-12/DT	amod||genes-14/NNS||responsible-13/JJ	dobj||sequencing-11/VBG||genes-14/NNS	nn||pcsk9-20/NN||ldlrap-16/NN	dep||pcsk9-20/NN||ldlr-18/NN	dep||genes-14/NNS||pcsk9-20/NN	dep||pcsk9-20/NN||apoe-22/JJ	dep||pcsk9-20/NN||apob-24/JJ	conj_and||apoe-22/JJ||apob-24/JJ	nsubjpass||ruled-30/VBN||sitosterolemia-28/NN	auxpass||ruled-30/VBN||was-29/VBD	conj_and||ruled-8/VBN||ruled-30/VBN	prt||ruled-30/VBN||out-31/RP	agent||ruled-30/VBN||documenting-33/VBG	det||ratio-38/NN||a-34/DT	amod||ratio-38/NN||normal-35/JJ	nn||ratio-38/NN||plasma-36/NN	nn||ratio-38/NN||sitosterolcholesterol-37/NN	dobj||documenting-33/VBG||ratio-38/NN	hypercholesterolemia-6||cholesterol--1||no||known genetic causes of severe hypercholesterolemia were ruled out by sequencing the responsible genes ( ldlrap , ldlr , pcsk9 , apoe and apob ), and sitosterolemia was ruled out by documenting a normal plasma sitosterolcholesterol ratio.
nsubj||concluded-2/VBD||we-1/PRP	root||ROOT-0/null||concluded-2/VBD	mark||agent-23/NN||that-3/IN	amod||activity-7/NN||mrn-100-4/JJ	amod||activity-7/NN||possesses-5/JJ	amod||activity-7/NN||anti-hiv-6/JJ	nsubj||agent-23/NN||activity-7/NN	prep_in||activity-7/NN||vitro-9/NN	det||increase-13/NN||an-12/DT	prep_without||mrn-100-18/JJ||increase-13/NN	amod||proliferation-16/NN||lymphocyte-15/JJ	prep_in||increase-13/NN||proliferation-16/NN	prep_in||activity-7/NN||mrn-100-18/JJ	conj_and||vitro-9/NN||mrn-100-18/JJ	aux||agent-23/NN||may-19/MD	cop||agent-23/NN||be-20/VB	det||agent-23/NN||a-21/DT	amod||agent-23/NN||useful-22/JJ	ccomp||concluded-2/VBD||agent-23/NN	prepc_for||agent-23/NN||treating-25/VBG	dobj||treating-25/VBG||patients-26/NNS	prep_with||treating-25/VBG||acquiredimmunodeficiencysyndrome-28/NN	acquiredimmunodeficiencysyndrome-28||hiv--1||no||we concluded that mrn-100 possesses anti-hiv activity in vitro and without an increase in lymphocyte proliferation, mrn-100 may be a useful agent for treating patients with acquiredimmunodeficiencysyndrome.
amod||transition-2/NN||sustained-1/JJ	nsubjpass||achieved-16/VBN||transition-2/NN	det||antigen-8/NN||the-4/DT	amod||antigen-8/NN||inactive-5/JJ	nn||antigen-8/NN||hepatitisb-6/NN	nn||antigen-8/NN||surface-7/NN	prep_to||transition-2/NN||antigen-8/NN	dep||transition-2/NN||hbsag-10/VBG	nn||state-13/NN||carrier-12/NN	dep||transition-2/NN||state-13/NN	aux||achieved-16/VBN||can-14/MD	auxpass||achieved-16/VBN||be-15/VB	root||ROOT-0/null||achieved-16/VBN	quantmod||30-19/CD||about-18/RB	num||%-20/NN||30-19/CD	prep_in||achieved-16/VBN||%-20/NN	amod||patients-38/NNS||hepatitisb-22/JJ	dep||â-28/VBP||e-23/SYM	nsubj||â-28/VBP||antigen-24/NN	appos||antigen-24/NN||hbeag-26/NN	ccomp||hepatitisb-22/JJ||â-28/VBP	dobj||â-28/VBP||$-29/$	advmod||of-36/IN||positive-31/RB	num||%-35/NN||patients-32/CD	conj_and||patients-32/CD||20-34/CD	num||%-35/NN||20-34/CD	npadvmod||of-36/IN||%-35/NN	dep||hbeag-negative-37/CD||of-36/IN	num||$-29/$||hbeag-negative-37/CD	prep_of||%-20/NN||patients-38/NNS	hepatitisb-22||hbsag-10||yes||sustained transition to the inactive hepatitisb surface antigen (hbsag) carrier state can be achieved in about 30% of hepatitisb e antigen (hbeag)â€“positive patients and 20% of hbeag-negative patients.
poss||study-2/NN||our-1/PRP$	nsubj||showed-3/VBD||study-2/NN	root||ROOT-0/null||showed-3/VBD	mark||effective-19/JJ||that-4/IN	number||%-6/NN||1-5/CD	amod||tropicamide-7/NN||%-6/NN	nsubj||effective-19/JJ||tropicamide-7/NN	poss||mechanism-13/NN||its-10/PRP$	amod||mechanism-13/NN||parasympathetic-11/JJ	amod||mechanism-13/NN||antagonistic-12/JJ	prep_with||tropicamide-7/NN||mechanism-13/NN	prep_of||mechanism-13/NN||action-15/NN	cop||effective-19/JJ||was-17/VBD	advmod||effective-19/JJ||more-18/RBR	ccomp||showed-3/VBD||effective-19/JJ	prepc_at||effective-19/JJ||inducing-21/VBG	dobj||inducing-21/VBG||pupillarydilation-22/NN	number||%-25/NN||2.5-24/CD	amod||phenylephrine-26/NN||%-25/NN	prep_than||inducing-21/VBG||phenylephrine-26/NN	det||combination-30/NN||the-29/DT	nsubj||effective-41/JJ||combination-30/NN	number||%-33/NN||1-32/CD	amod||tropicamide-34/NN||%-33/NN	prep_of||combination-30/NN||tropicamide-34/NN	number||%-37/NN||2.5-36/CD	amod||phenylephrine-38/NN||%-37/NN	prep_of||combination-30/NN||phenylephrine-38/NN	conj_and||tropicamide-34/NN||phenylephrine-38/NN	cop||effective-41/JJ||was-39/VBD	advmod||effective-41/JJ||more-40/RBR	conj_and||showed-3/VBD||effective-41/JJ	amod||drops-44/NNS||multiple-43/JJ	prep_than||effective-41/JJ||drops-44/NNS	amod||drops-48/NNS||single-46/JJ	nn||drops-48/NNS||eye-47/NN	prep_of||drops-44/NNS||drops-48/NNS	pupillarydilation-22||tropicamide-34||no||our study showed that 1% tropicamide, with its parasympathetic antagonistic mechanism of action, was more effective at inducing pupillarydilation than 2.5% phenylephrine, and the combination of 1% tropicamide and 2.5% phenylephrine was more effective than multiple drops of single eye drops.
num||2005-4/CD||2002-2/CD	dep||2005-4/CD||to-3/TO	prep_from||identified-9/VBD||2005-4/CD	num||reviews-8/NNS||two-6/CD	nn||reviews-8/NNS||literature-7/NN	appos||2005-4/CD||reviews-8/NNS	root||ROOT-0/null||identified-9/VBD	det||number-11/NN||a-10/DT	dobj||identified-9/VBD||number-11/NN	nsubj||appeared-16/VBD||number-11/NN	nsubj||neglected-20/JJ||number-11/NN	amod||issues-14/NNS||reproductive-health-13/JJ	prep_of||number-11/NN||issues-14/NNS	rcmod||number-11/NN||appeared-16/VBD	aux||neglected-20/JJ||to-17/TO	cop||neglected-20/JJ||be-18/VB	advmod||neglected-20/JJ||relatively-19/RB	xcomp||appeared-16/VBD||neglected-20/JJ	prep_in||neglected-20/JJ||relation-22/NN	amod||information-26/NN||hiv/aids-24/JJ	amod||information-26/NN||contraceptive-25/JJ	prep_to||neglected-20/JJ||information-26/NN	vmod||information-26/NN||tailored-27/VBN	det||needs-30/NNS||the-29/DT	prep_to||tailored-27/VBN||needs-30/NNS	amod||people-33/NNS||hiv-positive-32/JJ	prep_of||needs-30/NNS||people-33/NNS	amod||hiv-36/NN||voluntary-35/JJ	dobj||identified-9/VBD||hiv-36/NN	conj_and||number-11/NN||hiv-36/NN	nsubj||appeared-16/VBD||hiv-36/NN	nsubj||neglected-20/JJ||hiv-36/NN	vmod||hiv-36/NN||counselling-37/VBG	vmod||hiv-36/NN||testing-39/VBG	conj_and||counselling-37/VBG||testing-39/VBG	amod||care-42/NN||antenatal-41/JJ	prep_during||counselling-37/VBG||care-42/NN	prep_during||counselling-37/VBG||labour-44/NN	conj_and||care-42/NN||labour-44/NN	prep_during||counselling-37/VBG||delivery-47/NN	conj_and||care-42/NN||delivery-47/NN	nn||options-50/NNS||parenting-49/NN	dobj||identified-9/VBD||options-50/NNS	conj_and||number-11/NN||options-50/NNS	nsubj||appeared-16/VBD||options-50/NNS	nsubj||neglected-20/JJ||options-50/NNS	amod||people-53/NNS||hiv-positive-52/JJ	prep_for||options-50/NNS||people-53/NNS	dep||conception-62/NN||pregnancy-55/NNP	amod||-lrb--59/NNS||unprotected-57/JJ	nn||-lrb--59/NNS||intercourse-58/NN	prep_through||pregnancy-55/NNP||-lrb--59/NNS	advmod||assisted-61/VBN||i.e.-60/RB	amod||conception-62/NN||assisted-61/VBN	prep_besides||people-53/NNS||conception-62/NN	amod||adoption-65/NN||legal-64/JJ	dobj||identified-9/VBD||adoption-65/NN	conj_and||number-11/NN||adoption-65/NN	nsubj||appeared-16/VBD||adoption-65/NN	nsubj||neglected-20/JJ||adoption-65/NN	amod||care-68/NN||foster-67/JJ	conj_and||number-11/NN||care-68/NN	conj_or||adoption-65/NN||care-68/NN	nsubj||identified-9/VBD||-rrb--69/NNP	amod||pregnancy-72/NN||unwanted-71/JJ	nsubj||identified-9/VBD||pregnancy-72/NN	conj_and||-rrb--69/NNP||pregnancy-72/NN	amod||care-76/NN||abortion-related-75/JJ	nsubj||identified-9/VBD||care-76/NN	conj_and||-rrb--69/NNP||care-76/NN	aids--1||hiv-36||no||from 2002 to 2005 , two literature reviews identified a number of reproductive-health issues that appeared to be relatively neglected in relation to hiv/aids contraceptive information tailored to the needs of hiv-positive people ; voluntary hiv counselling and testing during antenatal care , labour , and delivery ; parenting options for hiv-positive people besides pregnancy through unprotected intercourse -lrb- i.e. assisted conception and legal adoption or foster care -rrb- ; unwanted pregnancy ; and abortion-related care .
nsubj||panzootic-7/JJ||avianinfluenzaviruses-1/NNS	nsubj||pose-9/VBP||avianinfluenzaviruses-1/NNS	prep_such_as||avianinfluenzaviruses-1/NNS||h5n1-4/CD	cop||panzootic-7/JJ||are-5/VBP	advmod||panzootic-7/JJ||currently-6/RB	root||ROOT-0/null||panzootic-7/JJ	conj_and||panzootic-7/JJ||pose-9/VBP	det||threat-12/NN||a-10/DT	amod||threat-12/NN||pandemic-11/JJ	dobj||pose-9/VBP||threat-12/NN	h5n1-4||influenzaviruses--1||no||avianinfluenzaviruses such as h5n1 are currently panzootic and pose a pandemic threat.
mark||²-3/VBZ||although-1/IN	nsubj||²-3/VBZ||î-2/NN	advcl||display-14/VBP||²-3/VBZ	nn||numbers-6/NNS||cell-5/NN	nsubj||recover-7/VB||numbers-6/NNS	ccomp||²-3/VBZ||recover-7/VB	parataxis||²-3/VBZ||recover-7/VB	prep_by||recover-7/VB||birth-9/NN	amod||mice-13/NNS||adult-11/JJ	amod||mice-13/NNS||smo-deficient-12/JJ	nsubj||display-14/VBP||mice-13/NNS	root||ROOT-0/null||display-14/VBP	dobj||display-14/VBP||glucoseintolerance-15/NN	amod||sensitivity-19/NN||increased-17/VBN	nn||sensitivity-19/NN||insulin-18/NN	dobj||display-14/VBP||sensitivity-19/NN	conj_and||glucoseintolerance-15/NN||sensitivity-19/NN	amod||production-25/NN||reduced-22/VBN	amod||production-25/NN||total-23/JJ	nn||production-25/NN||insulin-24/NN	dobj||display-14/VBP||production-25/NN	conj_and||glucoseintolerance-15/NN||production-25/NN	insulin-24||glucoseintolerance-15||no_rel||although î²-cell numbers recover by birth, adult smo-deficient mice display glucoseintolerance, increased insulin sensitivity, and reduced total insulin production.
nsubj||continues-5/VBZ||typhoidfever-1/NN	nsubj||problem-11/NN||typhoidfever-1/NN	vmod||typhoidfever-1/NN||caused-2/VBN	agent||caused-2/VBN||salmonellatyphi-4/NNS	root||ROOT-0/null||continues-5/VBZ	aux||problem-11/NN||to-6/TO	cop||problem-11/NN||be-7/VB	det||problem-11/NN||a-8/DT	amod||problem-11/NN||major-9/JJ	nn||problem-11/NN||health-10/NN	xcomp||continues-5/VBZ||problem-11/NN	det||use-16/NN||the-15/DT	prep_in_spite_of||problem-11/NN||use-16/NN	prep_of||use-16/NN||antibiotics-18/NNS	det||development-21/NN||the-20/DT	prep_in_spite_of||problem-11/NN||development-21/NN	conj_and||use-16/NN||development-21/NN	amod||drugs-25/NNS||newer-23/JJR	amod||drugs-25/NNS||antibacterial-24/JJ	prep_of||development-21/NN||drugs-25/NNS	typhoidfever-1||salmonellatyphi-4||no||typhoidfever caused by salmonellatyphi continues to be a major health problem in spite of the use of antibiotics and the development of newer antibacterial drugs.
ccomp||evoked-15/VBD||short-2/JJ	number||ms-5/CD||60-4/CD	dep||short-2/JJ||ms-5/CD	amod||pulses-11/NNS||high-8/JJ	nn||pulses-11/NNS||intensity-9/NN	nn||pulses-11/NNS||laser-10/NN	nsubj||evoked-15/VBD||pulses-11/NNS	appos||pulses-11/NNS||sp-13/NN	ccomp||evoked-40/VBD||evoked-15/VBD	xcomp||evoked-15/VBD||monomodal-16/VB	dobj||monomodal-16/VB||pricking-19/NN	dep||pricking-19/NN||pain-22/NN	nsubjpass||enhanced-26/VBN||pain-22/NN	auxpass||enhanced-26/VBN||was-24/VBD	neg||enhanced-26/VBN||not-25/RB	rcmod||pain-22/NN||enhanced-26/VBN	amod||capsaicin-29/NN||topical-28/JJ	agent||enhanced-26/VBN||capsaicin-29/NN	advmod||longer-32/JJR||whereas-31/RB	amod||pricking-19/NN||longer-32/JJR	amod||pulses-36/NNS||lower-34/JJR	nn||pulses-36/NNS||power-35/NN	nsubj||evoked-40/VBD||pulses-36/NNS	appos||pulses-36/NNS||lp-38/NN	root||ROOT-0/null||evoked-40/VBD	xcomp||evoked-40/VBD||monomodal-41/VB	dobj||monomodal-41/VB||burning-44/NN	iobj||monomodal-41/VB||burning-44/NN	dep||burning-44/NN||pain-47/NN	nsubjpass||enhanced-50/VBN||pain-47/NN	auxpass||enhanced-50/VBN||was-49/VBD	rcmod||pain-47/NN||enhanced-50/VBN	amod||capsaicin-53/NN||topical-52/JJ	agent||enhanced-50/VBN||capsaicin-53/NN	pain-47||capsaicin-53||yes||" short (60 ms), high intensity laser pulses (sp) evoked monomodal ""pricking"" pain which was not enhanced by topical capsaicin, whereas longer, lower power pulses (lp) evoked monomodal ""burning"" pain which was enhanced by topical capsaicin."
nsubj||bacillus-2/VBZ||mycobacteriumbovis-1/NNS	ccomp||matter-30/NN||bacillus-2/VBZ	amod||rin-6/NN||calmette-3/JJ	nn||rin-6/NN||guã-4/NN	nn||rin-6/NN||©-5/NN	nsubj||vaccine-13/NN||rin-6/NN	appos||rin-6/NN||bcg-8/NN	cop||vaccine-13/NN||is-10/VBZ	det||vaccine-13/NN||a-11/DT	amod||vaccine-13/NN||sole-12/JJ	ccomp||bacillus-2/VBZ||vaccine-13/NN	advmod||used-15/VBN||currently-14/RB	vmod||vaccine-13/NN||used-15/VBN	prep_for||used-15/VBN||tb-17/NN	advmod||used-15/VBN||however-19/RB	det||efficacy-22/NN||the-21/DT	nsubj||matter-30/NN||efficacy-22/NN	prep_of||efficacy-22/NN||bcg-24/NN	prep_in||bcg-24/NN||adults-26/NNS	cop||matter-30/NN||is-27/VBZ	advmod||matter-30/NN||still-28/RB	det||matter-30/NN||a-29/DT	root||ROOT-0/null||matter-30/NN	prep_of||matter-30/NN||debate-32/NN	tb-17||bcg-24||yes||mycobacteriumbovis bacillus calmette guã©rin (bcg) is a sole vaccine currently used for tb, however, the efficacy of bcg in adults is still a matter of debate.
aux||discuss-2/VB||to-1/TO	advcl||attended-37/VBD||discuss-2/VB	amod||symptoms-4/NNS||potential-3/JJ	nsubj||predicting-8/VBG||symptoms-4/NNS	amod||factors-7/NNS||other-6/JJ	conj_and||symptoms-4/NNS||factors-7/NNS	nsubj||predicting-8/VBG||factors-7/NNS	dep||discuss-2/VB||predicting-8/VBG	dobj||predicting-8/VBG||response-9/NN	prep_to||predicting-8/VBG||treatment-11/NN	amod||plaster-14/NN||lidocaine-13/JJ	prep_with||predicting-8/VBG||plaster-14/NN	det||indications-17/NNS||the-16/DT	prep_for||plaster-14/NN||indications-17/NNS	prep_of||indications-17/NNS||lowbackpain-19/NN	amod||components-22/NNS||neuropathic-21/JJ	prep_with||lowbackpain-19/NN||components-22/NNS	conj_and||discuss-2/VB||neuropathicpain-24/VB	advcl||attended-37/VBD||neuropathicpain-24/VB	amod||trauma-29/NN||surgical-26/JJ	conj_and||surgical-26/JJ||nonsurgical-28/JJ	amod||trauma-29/NN||nonsurgical-28/JJ	prep_after||neuropathicpain-24/VB||trauma-29/NN	num||specialists-33/NNS||44-31/CD	nn||specialists-33/NNS||pain-32/NN	nsubj||attended-37/VBD||specialists-33/NNS	num||countries-36/NNS||17-35/CD	prep_from||specialists-33/NNS||countries-36/NNS	root||ROOT-0/null||attended-37/VBD	det||meeting-41/NN||a-38/DT	amod||meeting-41/NN||two-day-39/JJ	nn||meeting-41/NN||conference-40/NN	dobj||attended-37/VBD||meeting-41/NN	prep_in||attended-37/VBD||december-43/NNP	num||december-43/NNP||2009-44/CD	pain-32||lidocaine-13||yes||to discuss potential symptoms and other factors predicting response to treatment with lidocaine plaster for the indications of lowbackpain with neuropathic components and neuropathicpain after surgical and nonsurgical trauma, 44 pain specialists from 17 countries attended a two-day conference meeting in december 2009.
nsubjpass||commenced-4/VBN||she-1/PRP	nsubjpass||commenced-13/VBD||she-1/PRP	auxpass||commenced-4/VBN||was-2/VBD	advmod||commenced-4/VBN||initially-3/RB	root||ROOT-0/null||commenced-4/VBN	amod||lincomycin-7/NN||intravenous-6/JJ	prep_on||commenced-4/VBN||lincomycin-7/NN	poss||bloodstreaminfection-10/NN||her-9/PRP$	prep_for||lincomycin-7/NN||bloodstreaminfection-10/NN	advmod||commenced-13/VBD||subsequently-12/RB	conj_and||commenced-4/VBN||commenced-13/VBD	prep_on||commenced-13/VBD||immunosuppression-15/NN	prep_after||commenced-13/VBD||cessation-17/NN	prep_of||cessation-17/NN||hydralazine-19/NN	hydralazine-19||bloodstreaminfection-10||no_rel||she was initially commenced on intravenous lincomycin for her bloodstreaminfection and subsequently commenced on immunosuppression after cessation of hydralazine.
nsubj||equivalent-13/JJ||s-1-1/JJ	det||preparation-5/NN||an-3/DT	amod||preparation-5/NN||oral-4/JJ	appos||s-1-1/JJ||preparation-5/NN	vmod||preparation-5/NN||evolved-6/VBN	prep_from||evolved-6/VBN||uracil-8/NN	prep_from||evolved-6/VBN||tegafur-10/NN	conj_and||uracil-8/NN||tegafur-10/NN	aux||equivalent-13/JJ||has-12/VBZ	root||ROOT-0/null||equivalent-13/JJ	advmod||equivalent-13/JJ||efficacy-14/RB	prep_to||equivalent-13/JJ||uracil-16/NN	prep_to||equivalent-13/JJ||tegafur/leucovorin-18/NN	conj_and||uracil-16/NN||tegafur/leucovorin-18/NN	prepc_for||equivalent-13/JJ||treating-20/VBG	dobj||treating-20/VBG||patients-21/NNS	amod||cancer-25/NN||advanced-23/JJ	amod||cancer-25/NN||colorectal-24/JJ	prep_with||equivalent-13/JJ||cancer-25/NN	aux||regimen-31/NN||might-27/MD	cop||regimen-31/NN||be-28/VB	det||regimen-31/NN||a-29/DT	amod||regimen-31/NN||suitable-30/JJ	conj_and||equivalent-13/JJ||regimen-31/NN	det||setting-35/NN||an-33/DT	amod||setting-35/NN||adjuvant-34/JJ	prep_in||regimen-31/NN||setting-35/NN	cancer-25||leucovorin--1||no_rel||s-1, an oral preparation evolved from uracil and tegafur, has equivalent efficacy to uracil and tegafur/leucovorin for treating patients with advanced colorectal cancer and might be a suitable regimen in an adjuvant setting.
nn||smegmati-2/NNS||mycobacterium-1/NN	nsubj||s-3/VBZ||smegmati-2/NNS	root||ROOT-0/null||s-3/VBZ	nsubj||mycobacteria-10/NN||ms-5/NN	cop||mycobacteria-10/NN||is-7/VBZ	det||mycobacteria-10/NN||a-8/DT	amod||mycobacteria-10/NN||nonpathogenic-9/JJ	ccomp||s-3/VBZ||mycobacteria-10/NN	amod||growth-13/NN||rapid-12/JJ	prep_of||mycobacteria-10/NN||growth-13/NN	nsubj||shares-16/VBZ||growth-13/NN	rcmod||growth-13/NN||shares-16/VBZ	amod||characteristics-18/NNS||many-17/JJ	dobj||shares-16/VBZ||characteristics-18/NNS	prep_with||shares-16/VBZ||mycobacteriumtuberculosis-20/NNS	appos||mycobacteriumtuberculosis-20/NNS||mtb-22/NN	det||agent-28/NN||the-25/DT	amod||agent-28/NN||major-26/JJ	nn||agent-28/NN||causative-27/NN	appos||mycobacteriumtuberculosis-20/NNS||agent-28/NN	prep_of||agent-28/NN||tuberculosis-30/NNP	tuberculosis-30||mtb-22||no||mycobacterium smegmati s (ms) is a nonpathogenic mycobacteria of rapid growth, which shares many characteristics with mycobacteriumtuberculosis (mtb), the major causative agent of tuberculosis.
nsubj||knowledge-4/NN||it-1/PRP	cop||knowledge-4/NN||is-2/VBZ	amod||knowledge-4/NN||common-3/JJ	root||ROOT-0/null||knowledge-4/NN	mark||causes-8/VBZ||that-5/IN	nn||exposure-7/NN||asbestos-6/NN	nsubj||causes-8/VBZ||exposure-7/NN	dep||knowledge-4/NN||causes-8/VBZ	amod||diseases-10/NNS||asbestos-related-9/JJ	dobj||causes-8/VBZ||diseases-10/NNS	prep_such_as||diseases-10/NNS||asbestosis-13/NNS	nn||cancer-16/NN||lung-15/NN	prep_such_as||diseases-10/NNS||cancer-16/NN	conj_and||asbestosis-13/NNS||cancer-16/NN	amod||mesothelioma-19/NN||malignant-18/JJ	prep_such_as||diseases-10/NNS||mesothelioma-19/NN	conj_and||asbestosis-13/NNS||mesothelioma-19/NN	appos||knowledge-4/NN||mm-21/NN	neg||only-24/RB||not-23/RB	dep||knowledge-4/NN||only-24/RB	dep||only-24/RB||in-25/IN	conj||knowledge-4/NN||people-26/NNS	nsubj||handled-29/VBN||people-26/NNS	aux||handled-29/VBN||have-28/VBP	rcmod||people-26/NNS||handled-29/VBN	dobj||handled-29/VBN||asbestos-30/NN	det||environment-34/NN||the-32/DT	nn||environment-34/NN||work-33/NN	prep_in||handled-29/VBN||environment-34/NN	cc||in-38/IN||but-36/CC	dep||in-38/IN||also-37/RB	dep||handled-29/VBN||in-38/IN	nsubj||living-40/VBG||residents-39/NNS	pcomp||in-38/IN||living-40/VBG	amod||factories-42/NNS||near-41/JJ	dobj||living-40/VBG||factories-42/NNS	mark||handle-44/VBP||that-43/IN	ccomp||handled-29/VBN||handle-44/VBP	dobj||handle-44/VBP||asbestos-45/NN	asbestosis-13||asbestos-45||no||it is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (mm) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos.
amod||insufficiency-2/NN||vitamind-1/JJ	nsubj||present-11/JJ||insufficiency-2/NN	nsubj||hypovitaminosisd-16/JJ||insufficiency-2/NN	number||20-7/CD||5-4/CD	dep||20-7/CD||to-5/TO	number||20-7/CD||<-6/CD	num||ng/ml-8/NNS||20-7/CD	appos||insufficiency-2/NN||ng/ml-8/NNS	cop||present-11/JJ||was-10/VBD	root||ROOT-0/null||present-11/JJ	num||%-14/NN||75-13/CD	prep_in||present-11/JJ||%-14/NN	conj_and||present-11/JJ||hypovitaminosisd-16/JJ	number||40-21/CD||20-18/CD	dep||40-21/CD||to-19/TO	number||40-21/CD||<-20/CD	num||ng/ml-22/NNS||40-21/CD	dep||hypovitaminosisd-16/JJ||ng/ml-22/NNS	num||%-26/NN||24-25/CD	prep_in||present-11/JJ||%-26/NN	prep_of||%-26/NN||participants-28/NNS	hypovitaminosisd-16||vitamind-1||yes||vitamind insufficiency (5 to <20 ng/ml) was present in 75% and hypovitaminosisd (20 to <40 ng/ml) in 24% of participants.
det||polymorphism-3/NN||a-1/DT	nn||polymorphism-3/NN||deletion-2/NN	nsubjpass||implicated-14/VBN||polymorphism-3/NN	nsubj||play-16/VB||polymorphism-3/NN	amod||mu-1-7/NN||glutathione-5/JJ	amod||mu-1-7/NN||s-transferase-6/JJ	prep_in||polymorphism-3/NN||mu-1-7/NN	dep||polymorphism-3/NN||gstm1-null-9/JJ	aux||implicated-14/VBN||has-11/VBZ	advmod||implicated-14/VBN||previously-12/RB	auxpass||implicated-14/VBN||been-13/VBN	root||ROOT-0/null||implicated-14/VBN	aux||play-16/VB||to-15/TO	xcomp||implicated-14/VBN||play-16/VB	det||role-18/NN||a-17/DT	dobj||play-16/VB||role-18/NN	iobj||play-16/VB||role-18/NN	prep_in||role-18/NN||rheumatoidarthritis-20/NNS	appos||role-18/NN||ra-22/NN	dep||role-18/NN||risk-24/NN	dep||role-18/NN||progression-26/NN	conj_and||risk-24/NN||progression-26/NN	mark||examined-33/VBN||although-28/IN	neg||investigations-31/NNS||no-29/DT	amod||investigations-31/NNS||prior-30/JJ	nsubj||examined-33/VBN||investigations-31/NNS	aux||examined-33/VBN||have-32/VBP	dep||risk-24/NN||examined-33/VBN	poss||associations-35/NNS||its-34/PRP$	dobj||examined-33/VBN||associations-35/NNS	amod||antibody-39/NN||anticitrullinated-37/JJ	nn||antibody-39/NN||protein-38/NN	prep_with||examined-33/VBN||antibody-39/NN	appos||antibody-39/NN||acpa-41/NNP	advmod||examined-33/VBN||positivity-43/RB	rheumatoidarthritis-20||antibody-39||no_rel||a deletion polymorphism in glutathione s-transferase mu-1 (gstm1-null) has previously been implicated to play a role in rheumatoidarthritis (ra) risk and progression, although no prior investigations have examined its associations with anticitrullinated protein antibody (acpa) positivity.
nsubjpass||used-3/VBN||calcitonin-1/NN	auxpass||used-3/VBN||is-2/VBZ	root||ROOT-0/null||used-3/VBN	det||treatment-6/NN||a-5/DT	prep_as||used-3/VBN||treatment-6/NN	aux||reduce-8/VB||to-7/TO	ccomp||used-3/VBN||reduce-8/VB	det||concentration-12/NN||the-9/DT	nn||concentration-12/NN||blood-10/NN	nn||concentration-12/NN||calcium-11/NN	dobj||reduce-8/VB||concentration-12/NN	prep_in||reduce-8/VB||hypercalcemia-14/NN	aux||improve-17/VB||to-16/TO	ccomp||used-3/VBN||improve-17/VB	conj_and||reduce-8/VB||improve-17/VB	nn||mass-19/NN||bone-18/NN	dobj||improve-17/VB||mass-19/NN	prep_in||improve-17/VB||osteoporosis-21/NN	hypercalcemia-14||calcitonin-1||yes||calcitonin is used as a treatment to reduce the blood calcium concentration in hypercalcemia and to improve bone mass in osteoporosis.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	i---1||carcinoma-44||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
amod||levels-2/NNS||low-1/JJ	nsubjpass||reported-11/VBN||levels-2/NNS	nn||arginine-5/NN||serum-4/NN	prep_of||levels-2/NNS||arginine-5/NN	nn||dysfunction-8/NNS||endothelium-7/NN	prep_of||levels-2/NNS||dysfunction-8/NNS	conj_and||arginine-5/NN||dysfunction-8/NNS	aux||reported-11/VBN||have-9/VBP	auxpass||reported-11/VBN||been-10/VBN	root||ROOT-0/null||reported-11/VBN	prep_in||reported-11/VBN||melas-13/NNS	det||treatment-16/NN||this-15/DT	nsubj||increase-18/VB||treatment-16/NN	nsubj||promote-24/VB||treatment-16/NN	aux||increase-18/VB||may-17/MD	conj_and||reported-11/VBN||increase-18/VB	advmod||increase-18/VB||no-19/RB	amod||cells-22/NNS||endothelial-21/JJ	prep_in||no-19/RB||cells-22/NNS	conj_and||reported-11/VBN||promote-24/VB	conj_and||increase-18/VB||promote-24/VB	dobj||promote-24/VB||vasodilation-25/NN	amod||cerebralischemia-28/NN||decreasing-27/VBG	dobj||promote-24/VB||cerebralischemia-28/NN	conj_and||vasodilation-25/NN||cerebralischemia-28/NN	dobj||promote-24/VB||strokes-30/NNS	conj_and||vasodilation-25/NN||strokes-30/NNS	strokes-30||arginine-5||no_rel||low levels of serum arginine and endothelium dysfunction have been reported in melas and this treatment may increase no in endothelial cells and promote vasodilation, decreasing cerebralischemia and strokes.
nsubj||resistant-15/JJ||prions-1/NNS	det||agents-5/NNS||the-3/DT	amod||agents-5/NNS||infectious-4/JJ	appos||prions-1/NNS||agents-5/NNS	nsubj||cause-7/VBP||agents-5/NNS	rcmod||agents-5/NNS||cause-7/VBP	dobj||cause-7/VBP||transmissiblespongiformencephalopathies-8/NNS	appos||transmissiblespongiformencephalopathies-8/NNS||tses-10/NNS	cop||resistant-15/JJ||are-13/VBP	advmod||resistant-15/JJ||relatively-14/RB	root||ROOT-0/null||resistant-15/JJ	prep_to||resistant-15/JJ||destruction-17/NN	amod||treatments-25/NNS||physical-19/JJ	amod||treatments-25/NNS||enzymatic-21/JJ	conj_and||enzymatic-21/JJ||chemical-24/JJ	amod||treatments-25/NNS||chemical-24/JJ	prep_by||resistant-15/JJ||treatments-25/NNS	transmissiblespongiformencephalopathies-8||prions-1||no||prions, the infectious agents that cause transmissiblespongiformencephalopathies (tses), are relatively resistant to destruction by physical, enzymatic, and chemical treatments.
nsubj||disease-6/NN||leprosy-1/NNP	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||chronic-4/JJ	nn||disease-6/NN||granulomatous-5/NNS	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	agent||caused-7/VBN||mycobacteriumleprae-9/NN	advmod||present-12/JJ||clinically-11/RB	amod||type-20/NN||present-12/JJ	dep||present-12/JJ||either-13/CC	dep||tuberculoid-15/JJ||as-14/IN	conj||present-12/JJ||tuberculoid-15/JJ	conj||present-12/JJ||borderline-17/JJ	conj_or||tuberculoid-15/JJ||borderline-17/JJ	conj||present-12/JJ||lepromatous-19/JJ	conj_or||tuberculoid-15/JJ||lepromatous-19/JJ	appos||mycobacteriumleprae-9/NN||type-20/NN	tuberculoid-15||borderline-17||no||leprosy is a chronic granulomatous disease caused by mycobacteriumleprae , clinically present either as tuberculoid, borderline or lepromatous type.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	pimecrolimus-7||lupus-16||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
amod||concentration-3/NN||endogenous-1/JJ	nn||concentration-3/NN||formaldehyde-2/NN	nsubj||increased-4/VBD||concentration-3/NN	root||ROOT-0/null||increased-4/VBD	advmod||increased-4/VBD||significantly-5/RB	det||lines-12/NNS||the-7/DT	amod||lines-12/NNS||cultured-8/JJ	nn||lines-12/NNS||breast-9/NN	nn||lines-12/NNS||cancer-10/NN	nn||lines-12/NNS||cell-11/NN	prep_in||increased-4/VBD||lines-12/NNS	prep_in||lines-12/NNS||vitro-14/NNP	det||marrow-19/NN||the-17/DT	nn||marrow-19/NN||bone-18/NN	prep_in||increased-4/VBD||marrow-19/NN	prepc_of||marrow-19/NN||breast-21/VBG	amod||model-26/NN||mrmt-1-22/JJ	nn||model-26/NN||bone-23/NN	nn||model-26/NN||cancer-24/NN	nn||model-26/NN||pain-25/NN	dobj||breast-21/VBG||model-26/NN	prep_in||breast-21/VBG||rats-28/NNS	prep_in||breast-21/VBG||tissues-31/NNS	conj_and||rats-28/NNS||tissues-31/NNS	nn||cancer-34/NN||breast-33/NN	prep_from||tissues-31/NNS||cancer-34/NN	nn||patients-38/NNS||lung-36/NN	nn||patients-38/NNS||cancer-37/NN	prep_from||tissues-31/NNS||patients-38/NNS	conj_and||cancer-34/NN||patients-38/NNS	prep_in||breast-21/VBG||vivo-40/NN	pain-25||formaldehyde-2||no_rel||endogenous formaldehyde concentration increased significantly in the cultured breast cancer cell lines in vitro , in the bone marrow of breast mrmt-1 bone cancer pain model in rats and in tissues from breast cancer and lung cancer patients in vivo .
nsubj||way-21/NN||treatment-1/NN	det||combination-4/NN||a-3/DT	prep_with||treatment-1/NN||combination-4/NN	num||metoclopramide-8/NN||20-6/CD	nn||metoclopramide-8/NN||mg-7/NN	prep_of||combination-4/NN||metoclopramide-8/NN	num||dexamethasone-12/NN||5-10/CD	nn||dexamethasone-12/NN||mg-11/NN	prep_of||combination-4/NN||dexamethasone-12/NN	conj_and||metoclopramide-8/NN||dexamethasone-12/NN	cop||way-21/NN||is-13/VBZ	det||way-21/NN||an-14/DT	amod||way-21/NN||effective-15/JJ	conj_and||effective-15/JJ||safe-17/JJ	amod||way-21/NN||safe-17/JJ	conj_and||effective-15/JJ||inexpensive-20/JJ	amod||way-21/NN||inexpensive-20/JJ	root||ROOT-0/null||way-21/NN	aux||prevent-23/VB||to-22/TO	vmod||way-21/NN||prevent-23/VB	dobj||prevent-23/VB||ponv-24/NNP	dep||ponv-24/NNP||when-25/WRB	prepc_compared_to||prevent-23/VB||to-27/TO	pobj||prevent-23/VB||treatment-28/NN	num||ondansetron-32/NN||4-30/CD	nn||ondansetron-32/NN||mg-31/NN	prep_with||treatment-28/NN||ondansetron-32/NN	num||dexamethasone-36/NN||5-34/CD	nn||dexamethasone-36/NN||mg-35/NN	prep_with||treatment-28/NN||dexamethasone-36/NN	conj_and||ondansetron-32/NN||dexamethasone-36/NN	ponv-24||metoclopramide-8||yes||treatment with a combination of 20 mg metoclopramide and 5 mg dexamethasone is an effective, safe, and inexpensive way to prevent ponv when compared to treatment with 4 mg ondansetron and 5 mg dexamethasone.
det||role-3/NN||the-1/DT	amod||role-3/NN||potential-2/JJ	nsubjpass||confirmed-22/VBN||role-3/NN	prep_of||role-3/NN||insects-5/NNS	det||spread-8/NN||the-7/DT	prep_in||insects-5/NNS||spread-8/NN	prep_of||spread-8/NN||b.anthracis-10/NNS	prep_to||b.anthracis-10/NNS||humans-12/NNS	amod||animals-15/NNS||domestic-14/JJ	prep_of||spread-8/NN||animals-15/NNS	conj_and||b.anthracis-10/NNS||animals-15/NNS	det||outbreak-19/NN||an-17/DT	nn||outbreak-19/NN||anthrax-18/NN	prep_during||animals-15/NNS||outbreak-19/NN	aux||confirmed-22/VBN||has-20/VBZ	auxpass||confirmed-22/VBN||been-21/VBN	root||ROOT-0/null||confirmed-22/VBN	amod||studies-25/NNS||many-24/JJ	agent||confirmed-22/VBN||studies-25/NNS	anthrax-18||b.anthracis-10||no||the potential role of insects in the spread of b.anthracis to humans and domestic animals during an anthrax outbreak has been confirmed by many studies .
nsubj||confirm-2/VBP||we-1/PRP	root||ROOT-0/null||confirm-2/VBP	mark||caused-5/VBD||that-3/IN	nsubj||caused-5/VBD||y.pestis-4/NNS	ccomp||confirm-2/VBP||caused-5/VBD	det||blackdeath-7/NN||the-6/DT	dobj||caused-5/VBD||blackdeath-7/NN	dobj||caused-5/VBD||later-9/RB	advmod||blackdeath-7/NN||later-9/RB	conj_and||blackdeath-7/NN||later-9/RB	dep||blackdeath-7/NN||epidemics-10/NNS	det||continent-15/NN||the-12/DT	amod||continent-15/NN||entire-13/JJ	nn||continent-15/NN||european-14/NN	prep_on||epidemics-10/NNS||continent-15/NN	det||course-18/NN||the-17/DT	prep_over||caused-5/VBD||course-18/NN	num||centuries-21/NNS||four-20/CD	prep_of||course-18/NN||centuries-21/NNS	blackdeath-7||y.pestis-4||no||we confirm that y.pestis caused the blackdeath and later epidemics on the entire european continent over the course of four centuries .
nsubj||have-2/VBP||rotaviruses-1/NNS	root||ROOT-0/null||have-2/VBP	det||range-6/NN||a-3/DT	amod||range-6/NN||wide-4/JJ	nn||range-6/NN||host-5/NN	dobj||have-2/VBP||range-6/NN	vmod||range-6/NN||infecting-7/VBG	det||range-10/NN||a-8/DT	amod||range-10/NN||broad-9/JJ	dobj||infecting-7/VBG||range-10/NN	nn||species-13/NNS||animal-12/NN	prep_of||range-10/NN||species-13/NNS	advmod||known-18/VBN||however-15/RB	nsubjpass||known-18/VBN||little-16/RB	auxpass||known-18/VBN||is-17/VBZ	parataxis||have-2/VBP||known-18/VBN	prep_about||known-18/VBN||rotavirusinfection-20/NN	amod||animals-23/NNS||exotic-22/JJ	prep_in||rotavirusinfection-20/NN||animals-23/NNS	rotavirusinfection-20||rotaviruses-1||yes||rotaviruses have a wide host range infecting a broad range of animal species, however little is known about rotavirusinfection in exotic animals.
amod||age-2/NN||increasing-1/VBG	nsubjpass||associated-4/VBN||age-2/NN	auxpass||associated-4/VBN||is-3/VBZ	root||ROOT-0/null||associated-4/VBN	amod||function-8/NN||impaired-6/VBN	amod||function-8/NN||immune-7/JJ	prep_with||associated-4/VBN||function-8/NN	conj_and||associated-4/VBN||in-10/IN	amod||infection-13/NN||chronic-11/JJ	nn||infection-13/NN||hcv-12/NN	pobj||in-10/IN||infection-13/NN	advmod||in-10/IN||specifically-14/RB	amod||fibrosis-18/NN||progressive-17/JJ	prep_with||associated-4/VBN||fibrosis-18/NN	prep_with||associated-4/VBN||liverfailure-20/NN	conj_and||fibrosis-18/NN||liverfailure-20/NN	prep_with||associated-4/VBN||hcc-22/NN	conj_and||fibrosis-18/NN||hcc-22/NN	amod||responses-25/NNS||impaired-24/VBN	prep_with||associated-4/VBN||responses-25/NNS	conj_and||fibrosis-18/NN||responses-25/NNS	amod||therapy-28/NN||antiviral-27/JJ	prep_to||responses-25/NNS||therapy-28/NN	antiviral-27||liverfailure-20||no_rel||increasing age is associated with impaired immune function and in chronic hcv infection specifically, with progressive fibrosis, liverfailure, hcc and impaired responses to antiviral therapy.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||feasibility-4/NN||the-3/DT	dobj||investigated-2/VBD||feasibility-4/NN	prepc_of||feasibility-4/NN||using-6/VBG	amod||radiation-10/NN||low-intensity-7/JJ	amod||radiation-10/NN||pulsed-9/JJ	dobj||using-6/VBG||radiation-10/NN	amod||ultrasound-13/NN||focused-12/JJ	prep_of||radiation-10/NN||ultrasound-13/NN	dep||using-6/VBG||fus-15/NN	aux||suppress-19/VB||to-17/TO	advmod||suppress-19/VB||non-invasively-18/RB	vmod||using-6/VBG||suppress-19/VB	amod||activity-21/NN||epileptic-20/JJ	dobj||suppress-19/VB||activity-21/NN	det||model-25/NN||an-23/DT	nn||model-25/NN||animal-24/NN	prep_in||activity-21/NN||model-25/NN	nsubjpass||induced-32/VBN||model-25/NN	appos||model-25/NN||rat-27/NN	auxpass||induced-32/VBN||was-31/VBD	rcmod||model-25/NN||induced-32/VBN	det||injection-36/NN||the-34/DT	amod||injection-36/NN||intraperitonial-35/JJ	agent||induced-32/VBN||injection-36/NN	prep_of||injection-36/NN||pentylenetetrazol-38/NN	appos||pentylenetetrazol-38/NN||ptz-40/NN	epileptic-20||pentylenetetrazol-38||no||we investigated the feasibility of using low-intensity, pulsed radiation of focused ultrasound (fus) to non-invasively suppress epileptic activity in an animal model (rat), which was induced by the intraperitonial injection of pentylenetetrazol (ptz).
advmod||see-3/VBP||here-1/RB	nsubj||see-3/VBP||we-2/PRP	root||ROOT-0/null||see-3/VBP	mark||occurs-10/VBZ||that-4/IN	amod||patients-7/NNS||obese-6/JJ	prep_in||occurs-10/VBZ||patients-7/NNS	nsubj||occurs-10/VBZ||hyperandrogenism-9/NN	ccomp||see-3/VBP||occurs-10/VBZ	det||result-13/NN||a-12/DT	prep_as||occurs-10/VBZ||result-13/NN	prep_of||result-13/NN||hyperinsulinemia-15/NN	amod||conversion-20/NN||peripheral-19/JJ	prep_as||occurs-10/VBZ||conversion-20/NN	conj_and||result-13/NN||conversion-20/NN	prep_of||conversion-20/NN||estrogens-22/NNS	prep_into||occurs-10/VBZ||androgens-24/NNS	det||tissue-29/NN||the-26/DT	amod||tissue-29/NN||excessive-27/JJ	nn||tissue-29/NN||adipose-28/NN	prep_in||androgens-24/NNS||tissue-29/NN	androgens-24||obese-6||no_rel||here we see that in obese patients, hyperandrogenism occurs as a result of hyperinsulinemia as well as peripheral conversion of estrogens into androgens in the excessive adipose tissue.
nsubj||represent-3/VB||paracetamol-1/NNP	aux||represent-3/VB||may-2/MD	root||ROOT-0/null||represent-3/VB	det||alternative-5/NN||an-4/DT	dobj||represent-3/VB||alternative-5/NN	amod||surgery-16/NN||ketorolac-7/JJ	nn||prevention-10/NN||pain-9/NN	prep_for||ketorolac-7/JJ||prevention-10/NN	dep||mildly-12/RB||after-11/IN	amod||surgery-16/NN||mildly-12/RB	advmod||painful-15/JJ||moderately-14/RB	prep_to||mildly-12/RB||painful-15/JJ	prep_to||represent-3/VB||surgery-16/NN	prep_in||represent-3/VB||situations-18/NNS	advmod||unsuitable-25/JJ||where-19/WRB	det||use-21/NN||the-20/DT	nsubj||unsuitable-25/JJ||use-21/NN	prep_of||use-21/NN||nsaids-23/NNS	cop||unsuitable-25/JJ||is-24/VBZ	rcmod||situations-18/NNS||unsuitable-25/JJ	pain-9||paracetamol-1||yes||paracetamol may represent an alternative to ketorolac for pain prevention after mildly to moderately painful surgery in situations where the use of nsaids is unsuitable.
aux||answer-2/VB||to-1/TO	advcl||necessary-14/JJ||answer-2/VB	amod||questions-5/NNS||many-3/JJ	amod||questions-5/NNS||existing-4/VBG	dobj||answer-2/VB||questions-5/NNS	prep_about||answer-2/VB||fungaldiseases-7/NNS	amod||proteins-12/NNS||fungi-9/JJ	nn||proteins-12/NNS||cell-10/NN	nn||proteins-12/NNS||wall-11/NN	nsubj||necessary-14/JJ||proteins-12/NNS	nsubjpass||examined-17/VBN||proteins-12/NNS	cop||necessary-14/JJ||are-13/VBP	root||ROOT-0/null||necessary-14/JJ	aux||examined-17/VBN||to-15/TO	auxpass||examined-17/VBN||be-16/VB	xcomp||necessary-14/JJ||examined-17/VBN	fungaldiseases-7||fungi-9||no||to answer many existing questions about fungaldiseases, fungi cell wall proteins are necessary to be examined.
amod||diagnosis-3/NN||early-1/JJ	nn||diagnosis-3/NN||infant-2/NN	nsubj||service-12/NN||diagnosis-3/NN	appos||diagnosis-3/NN||eid-5/NN	prep_of||diagnosis-3/NN||hivinfection-8/NN	cop||service-12/NN||is-9/VBZ	det||service-12/NN||an-10/DT	amod||service-12/NN||important-11/JJ	root||ROOT-0/null||service-12/NN	aux||reduce-14/VB||to-13/TO	vmod||service-12/NN||reduce-14/VB	amod||morbidity-16/NN||paediatric-15/JJ	dobj||reduce-14/VB||morbidity-16/NN	dobj||reduce-14/VB||mortality-18/NN	conj_and||morbidity-16/NN||mortality-18/NN	advmod||reduce-14/VB||related-19/VBN	prep_to||related-19/VBN||hiv/aids-21/NNS	hivinfection-8||hiv--1||no||early infant diagnosis (eid) of hivinfection is an important service to reduce paediatric morbidity and mortality related to hiv/aids.
det||involvement-9/NN||a-1/DT	amod||involvement-9/NN||patient-2/JJ	amod||chest-7/NN||extensive-4/JJ	conj_and||extensive-4/JJ||painful-6/JJ	amod||chest-7/NN||painful-6/JJ	prep_with||patient-2/JJ||chest-7/NN	nn||involvement-9/NN||wall-8/NN	nsubjpass||treated-19/VBN||involvement-9/NN	det||cancer-14/NN||a-11/DT	amod||cancer-14/NN||metastatic-12/JJ	nn||cancer-14/NN||borderline-13/NN	prep_from||involvement-9/NN||cancer-14/NN	det||ovary-17/NN||the-16/DT	prep_of||cancer-14/NN||ovary-17/NN	auxpass||treated-19/VBN||was-18/VBD	root||ROOT-0/null||treated-19/VBN	det||carboplatin-22/JJ||a-21/DT	prep_with||treated-19/VBN||carboplatin-22/JJ	amod||regimen-26/NN||paclitaxel-24/JJ	amod||regimen-26/NN||chemotherapy-25/JJ	prep_with||treated-19/VBN||regimen-26/NN	conj_plus||carboplatin-22/JJ||regimen-26/NN	cancer-14||carboplatin-22||no_rel||a patient with extensive and painful chest wall involvement from a metastatic borderline cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy regimen.
nsubj||contributing-14/VBG||lack-1/NN	prep_of||lack-1/NN||awareness-3/NN	det||transmission-6/NN||the-5/DT	prep_about||awareness-3/NN||transmission-6/NN	nn||screening-12/NN||hcv-8/NN	conj_and||hcv-8/NN||regular-10/JJ	nn||screening-12/NN||regular-10/JJ	nn||screening-12/NN||blood-11/NN	prep_of||transmission-6/NN||screening-12/NN	aux||contributing-14/VBG||is-13/VBZ	root||ROOT-0/null||contributing-14/VBG	det||deal-17/NN||a-15/DT	amod||deal-17/NN||great-16/JJ	dobj||contributing-14/VBG||deal-17/NN	det||spread-20/NN||the-19/DT	prep_towards||deal-17/NN||spread-20/NN	prep_of||spread-20/NN||hepatitisc-22/NN	hepatitisc-22||hcv-8||no||lack of awareness about the transmission of hcv and regular blood screening is contributing a great deal towards the spread of hepatitisc.
det||combination-2/NN||a-1/DT	nsubj||reduced-9/VBD||combination-2/NN	nn||exercise-7/NN||cr-4/NN	conj_and||cr-4/NN||endurance-6/JJ	nn||exercise-7/NN||endurance-6/JJ	prep_of||combination-2/NN||exercise-7/NN	advmod||reduced-9/VBD||further-8/RB	root||ROOT-0/null||reduced-9/VBD	acomp||reduced-9/VBD||obesity-10/JJ	acomp||reduced-9/VBD||insulinresistance-12/JJ	conj_and||obesity-10/JJ||insulinresistance-12/JJ	det||condition-15/NN||the-14/DT	prep_under||reduced-9/VBD||condition-15/NN	amod||diet-18/NN||high-fat-17/JJ	prep_of||condition-15/NN||diet-18/NN	cr-4||insulinresistance-12||no_rel||a combination of cr and endurance exercise further reduced obesity and insulinresistance under the condition of high-fat diet.
det||level-3/NN||a-1/DT	amod||level-3/NN||satisfactory-2/JJ	nsubjpass||found-16/VBN||level-3/NN	prep_of||level-3/NN||knowledge-5/NN	prep_about||knowledge-5/NN||hiv/aids-7/NNS	det||attitude-12/NN||a-9/DT	advmod||positive-11/JJ||relatively-10/RB	amod||attitude-12/NN||positive-11/JJ	prep_of||level-3/NN||attitude-12/NN	conj_and||knowledge-5/NN||attitude-12/NN	prep_toward||attitude-12/NN||plwha-14/NN	auxpass||found-16/VBN||was-15/VBD	root||ROOT-0/null||found-16/VBN	aids--1||hiv--1||no||a satisfactory level of knowledge about hiv/aids and a relatively positive attitude toward plwha was found.
num||sequences-4/NNS||eight-1/CD	amod||sequences-4/NNS||new-2/JJ	amod||sequences-4/NNS||full-length-3/JJ	nsubjpass||analyzed-19/VBN||sequences-4/NNS	advmod||pathogenic-7/JJ||highly-6/RB	amod||avianinfluenzaviruses-8/NNS||pathogenic-7/JJ	prep_from||sequences-4/NNS||avianinfluenzaviruses-8/NNS	appos||avianinfluenzaviruses-8/NNS||h5n1-10/NNP	num||states-14/NNS||4-13/CD	prep_from||sequences-4/NNS||states-14/NNS	amod||nigeria-17/NN||southwest-16/JJ	prep_in||states-14/NNS||nigeria-17/NN	auxpass||analyzed-19/VBN||were-18/VBD	root||ROOT-0/null||analyzed-19/VBN	h5n1-10||influenzaviruses--1||no||eight new full-length sequences from highly pathogenic avianinfluenzaviruses (h5n1) from 4 states in southwest nigeria were analyzed.
det||epidemic-6/NN||the-1/DT	amod||epidemic-6/NN||humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome-2/JJ	nn||epidemic-6/NN||hiv/aids-4/NN	nsubj||is-7/VBZ||epidemic-6/NN	nsubj||reached-14/VBN||epidemic-6/NN	root||ROOT-0/null||is-7/VBZ	poss||decade-11/NN||its-9/PRP$	amod||decade-11/NN||third-10/JJ	prep_in||is-7/VBZ||decade-11/NN	aux||reached-14/VBN||has-13/VBZ	conj_and||is-7/VBZ||reached-14/VBN	amod||proportions-17/NNS||alarming-16/JJ	prep_to||reached-14/VBN||proportions-17/NNS	advmod||reached-14/VBN||worldwide-18/RB	acquiredimmunodeficiencysyndrome--1||hiv--1||no||the humanimmunodeficiencyvirus/acquiredimmunodeficiencysyndrome (hiv/aids) epidemic is in its third decade and has reached to alarming proportions worldwide.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||statin-50||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ion-44||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
det||study-3/NN||this-2/DT	prep_in||nvestigated-21/JJ||study-3/NN	nsubj||nvestigated-21/JJ||effects-5/NNS	prep_of||effects-5/NNS||omeprazole-7/NN	nn||quality-10/NN||voice-9/NN	prep_over||omeprazole-7/NN||quality-10/NN	nn||dysphonia-14/NN||muscle-12/NN	nn||dysphonia-14/NN||tension-13/NN	prep_in||quality-10/NN||dysphonia-14/NN	amod||reflux-17/NN||laryngopharyngeal-16/JJ	prep_with||dysphonia-14/NN||reflux-17/NN	cop||nvestigated-21/JJ||was-18/VBD	advmod||nvestigated-21/JJ||ä-19/RB	advmod||nvestigated-21/JJ||±-20/RB	root||ROOT-0/null||nvestigated-21/JJ	reflux-17||omeprazole-7||yes||in this study, effects of omeprazole over voice quality in muscle tension dysphonia with laryngopharyngeal reflux was ä±nvestigated.
det||lesion-2/NN||the-1/DT	nsubjpass||improved-4/VBN||lesion-2/NN	auxpass||improved-4/VBN||was-3/VBD	root||ROOT-0/null||improved-4/VBN	nn||avoidance-7/NN||sun-6/NN	prep_after||improved-4/VBN||avoidance-7/NN	prep_after||improved-4/VBN||treatment-9/NN	conj_and||avoidance-7/NN||treatment-9/NN	amod||virusinfection-12/NN||hepatitisc-11/JJ	prep_of||avoidance-7/NN||virusinfection-12/NN	det||combination-15/NN||a-14/DT	prep_with||improved-4/VBN||combination-15/NN	prep_of||combination-15/NN||interferon-17/NN	prep_of||combination-15/NN||ribavirin-19/NN	conj_and||interferon-17/NN||ribavirin-19/NN	virusinfection-12||ribavirin-19||yes||the lesion was improved after sun avoidance and treatment of hepatitisc virusinfection with a combination of interferon and ribavirin.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||investigate-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||relationship-10/NN||the-9/DT	dobj||investigate-8/VB||relationship-10/NN	prep_between||relationship-10/NN||a2ars-12/CD	det||system-16/NN||the-14/DT	amod||system-16/NN||dopaminergic-15/JJ	dobj||investigate-8/VB||system-16/NN	conj_and||relationship-10/NN||system-16/NN	det||striata-19/NN||the-18/DT	prep_in||system-16/NN||striata-19/NN	amod||patients-25/NNS||drug-naã-21/JJ	nn||patients-25/NNS||¯-22/NNP	nn||patients-25/NNS||ve-23/NN	nn||patients-25/NNS||pd-24/NN	prep_of||striata-19/NN||patients-25/NNS	nn||patients-28/NNS||pd-27/NN	prep_of||striata-19/NN||patients-28/NNS	conj_and||patients-25/NNS||patients-28/NNS	prep_with||system-16/NN||dyskinesia-30/NN	dobj||investigate-8/VB||alteration-33/NN	conj_and||relationship-10/NN||alteration-33/NN	det||receptors-36/NNS||these-35/DT	prep_of||alteration-33/NN||receptors-36/NNS	nn||therapy-39/NN||antiparkinsonian-38/NN	prep_after||investigate-8/VB||therapy-39/NN	dyskinesia-30||dopaminergic-15||no_rel||the purpose of this study was to investigate the relationship between a2ars and the dopaminergic system in the striata of drug-naã¯ve pd patients and pd patients with dyskinesia, and alteration of these receptors after antiparkinsonian therapy.
nsubj||heparin-6/NN||enoxaparin-1/NN	cop||heparin-6/NN||is-2/VBZ	det||heparin-6/NN||the-3/DT	advmod||heparin-6/NN||only-4/RB	amod||heparin-6/NN||low-molecular-weight-5/JJ	root||ROOT-0/null||heparin-6/NN	nsubjpass||licensed-9/VBN||heparin-6/NN	auxpass||licensed-9/VBN||is-8/VBZ	rcmod||heparin-6/NN||licensed-9/VBN	det||prophylaxis-14/NNS||both-11/DT	amod||prophylaxis-14/NNS||venous-12/JJ	nn||prophylaxis-14/NNS||thromboembolism-13/NN	prep_for||licensed-9/VBN||prophylaxis-14/NNS	prep_for||licensed-9/VBN||treatment-16/NN	conj_and||prophylaxis-14/NNS||treatment-16/NN	thromboembolism-13||enoxaparin-1||yes||enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment.
det||drug-2/NN||the-1/DT	nsubjpass||studied-6/VBN||drug-2/NN	nsubj||has-19/VBZ||drug-2/NN	aux||studied-6/VBN||has-3/VBZ	advmod||studied-6/VBN||also-4/RB	auxpass||studied-6/VBN||been-5/VBN	root||ROOT-0/null||studied-6/VBN	prep_in||studied-6/VBN||combination-8/NN	prep_with||studied-6/VBN||rituximab-10/NN	amod||therapy-13/NN||initial-12/JJ	prep_as||studied-6/VBN||therapy-13/NN	amod||lymphomas-16/NNS||indolent-15/JJ	prep_for||therapy-13/NN||lymphomas-16/NNS	conj_and||studied-6/VBN||has-19/VBZ	amod||activity-21/NN||excellent-20/JJ	dobj||has-19/VBZ||activity-21/NN	amod||toxicity-24/NN||less-23/JJR	prep_with||activity-21/NN||toxicity-24/NN	prep_than||toxicity-24/NN||r-chop-26/NN	amod||â-29/NN||rituximab-28/JJ	dep||r-chop-26/NN||â-29/NN	npadvmod||cyclophosphamide-32/JJ||$-30/$	amod||â-29/NN||cyclophosphamide-32/JJ	nn||-LSB--40/FW||hydroxydaunorubicin-34/FW	nn||-LSB--40/FW||-LSB--35/FW	nn||-LSB--40/FW||adriamycin-36/FW	nn||-LSB--40/FW||-RSB--37/FW	dep||-LSB--40/FW||oncovin-39/FW	dep||r-chop-26/NN||-LSB--40/FW	conj_and||â-29/NN||-LSB--40/FW	amod||-LSB--40/FW||vincristine-41/FW	dep||vincristine-41/FW||-RSB--42/FW	dep||r-chop-26/NN||prednisone/prednisolone-45/NN	conj_and||â-29/NN||prednisone/prednisolone-45/NN	lymphomas-16||hydroxydaunorubicin-34||yes||the drug has also been studied in combination with rituximab as initial therapy for indolent lymphomas, and has excellent activity with less toxicity than r-chop (rituximab â€“ cyclophosphamide, hydroxydaunorubicin [adriamycin], oncovin [vincristine], and prednisone/prednisolone).
amod||5-fluorouracil-2/NN||adjuvant-1/JJ	root||ROOT-0/null||5-fluorouracil-2/NN	appos||5-fluorouracil-2/NN||5fu-4/NNP	vmod||5-fluorouracil-2/NN||based-7/VBN	nsubjpass||considered-11/VBN||chemo-radiotherapy-8/NN	auxpass||considered-11/VBN||is-9/VBZ	advmod||considered-11/VBN||currently-10/RB	ccomp||based-7/VBN||considered-11/VBN	det||standard-13/NN||a-12/DT	dobj||considered-11/VBN||standard-13/NN	prep_of||standard-13/NN||care-15/NN	det||treatment-18/NN||the-17/DT	prep_for||5-fluorouracil-2/NN||treatment-18/NN	amod||cancer-21/NN||gastric-20/JJ	prep_of||treatment-18/NN||cancer-21/NN	adjuvant-1||cancer-21||no_rel||adjuvant 5-fluorouracil (5fu)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer.
nsubj||likely-9/JJ||persons-1/NNS	nsubjpass||older-16/JJR||persons-1/NNS	nsubjpass||admitted-18/VBN||persons-1/NNS	prep_without||persons-1/NNS||hiv/aids-3/NNS	vmod||hiv/aids-3/NNS||hospitalized-4/VBN	prep_with||hospitalized-4/VBN||cryptococcosis-6/NNS	cop||likely-9/JJ||were-7/VBD	advmod||likely-9/JJ||more-8/RBR	root||ROOT-0/null||likely-9/JJ	prep_than||likely-9/JJ||those-11/DT	prep_with||those-11/DT||hiv/aids-13/NNS	aux||older-16/JJR||to-14/TO	auxpass||older-16/JJR||be-15/VB	cop||older-16/JJR||be-15/VB	xcomp||likely-9/JJ||older-16/JJR	xcomp||likely-9/JJ||admitted-18/VBN	conj_and||older-16/JJR||admitted-18/VBN	amod||cryptococcosis-21/NNS||pulmonary-20/JJ	prep_for||admitted-18/VBN||cryptococcosis-21/NNS	aids--1||hiv--1||no||persons without hiv/aids hospitalized with cryptococcosis were more likely than those with hiv/aids to be older and admitted for pulmonary cryptococcosis.
nsubj||has-2/VBZ||insulin-1/NN	root||ROOT-0/null||has-2/VBZ	amod||effects-4/NNS||mitogenic-3/JJ	dobj||has-2/VBZ||effects-4/NNS	mark||factor-12/NN||although-6/IN	nsubj||factor-12/NN||hyperglycemia-7/NN	aux||factor-12/NN||may-8/MD	cop||factor-12/NN||be-9/VB	det||factor-12/NN||a-10/DT	nn||factor-12/NN||risk-11/NN	advcl||has-2/VBZ||factor-12/NN	prep_for||factor-12/NN||cancer-14/NN	prep_in||cancer-14/NN||type2diabetes-16/CD	insulin-1||cancer-14||no_rel||insulin has mitogenic effects, although hyperglycemia may be a risk factor for cancer in type2diabetes.
amod||features-2/NNS||clinical-1/JJ	nsubj||alert-24/VB||features-2/NNS	prep_of||features-2/NNS||headache-4/NN	amod||consciousness-7/NN||altered-6/JJ	prep_of||features-2/NNS||consciousness-7/NN	conj_and||headache-4/NN||consciousness-7/NN	amod||deficit-11/NN||focal-9/JJ	amod||deficit-11/NN||neurological-10/JJ	prep_of||features-2/NNS||deficit-11/NN	conj_and||headache-4/NN||deficit-11/NN	prep_of||features-2/NNS||seizures-14/NNS	conj_and||headache-4/NN||seizures-14/NNS	dep||features-2/NNS||developing-15/VBG	prep||developing-15/VBG||during-16/IN	dep||features-2/NNS||immediately-18/RB	conj_or||developing-15/VBG||immediately-18/RB	prep_after||immediately-18/RB||treatment-20/NN	prep_with||immediately-18/RB||l-asparaginase-22/NN	aux||alert-24/VB||should-23/MD	root||ROOT-0/null||alert-24/VB	det||physician-27/NN||the-25/DT	amod||physician-27/NN||treating-26/JJ	dobj||alert-24/VB||physician-27/NN	det||possibility-30/NN||the-29/DT	prep_to||alert-24/VB||possibility-30/NN	prep_of||possibility-30/NN||csvt-32/NN	l-asparaginase-22||headache-4||no_rel||clinical features of headache, altered consciousness, focal neurological deficit, and seizures developing during or immediately after treatment with l-asparaginase should alert the treating physician to the possibility of csvt.
nsubj||demonstrated-2/VBD||rats-1/NNS	root||ROOT-0/null||demonstrated-2/VBD	amod||shifts-4/NNS||immediate-3/JJ	dobj||demonstrated-2/VBD||shifts-4/NNS	nn||timing-7/NN||melatonin-6/NN	prep_in||demonstrated-2/VBD||timing-7/NN	prep_after||demonstrated-2/VBD||stroke-9/NN	melatonin-6||stroke-9||no_rel||rats demonstrated immediate shifts in melatonin timing after stroke.
nsubjpass||recommended-4/VBN||quinine-1/NN	auxpass||recommended-4/VBN||is-2/VBZ	advmod||recommended-4/VBN||still-3/RB	root||ROOT-0/null||recommended-4/VBN	det||therapy-8/NN||an-6/DT	amod||therapy-8/NN||effective-7/JJ	prep_as||recommended-4/VBN||therapy-8/NN	amod||cases-11/NNS||severe-10/JJ	prep_for||therapy-8/NN||cases-11/NNS	prep_of||cases-11/NNS||plasmodiumfalciparummalaria-13/NN	det||parasite-17/NN||the-16/DT	nsubj||developed-19/VBN||parasite-17/NN	aux||developed-19/VBN||has-18/VBZ	conj_but||recommended-4/VBN||developed-19/VBN	dobj||developed-19/VBN||resistance-20/NN	det||drug-23/NN||the-22/DT	prep_to||developed-19/VBN||drug-23/NN	det||cases-26/NNS||some-25/DT	prep_in||drug-23/NN||cases-26/NNS	plasmodiumfalciparummalaria-13||quinine-1||yes||quinine is still recommended as an effective therapy for severe cases of plasmodiumfalciparummalaria, but the parasite has developed resistance to the drug in some cases.
prepc_depending_on||assign-10/VB||on-2/IN	det||annotation-5/NN||the-3/DT	amod||annotation-5/NN||available-4/JJ	pobj||assign-10/VB||annotation-5/NN	det||variantclassifier-8/NN||the-7/DT	nsubj||assign-10/VB||variantclassifier-8/NN	aux||assign-10/VB||may-9/MD	root||ROOT-0/null||assign-10/VB	det||polymorphism-12/NN||each-11/DT	dobj||assign-10/VB||polymorphism-12/NN	det||variety-16/NN||a-14/DT	amod||variety-16/NN||large-15/JJ	prep_to||assign-10/VB||variety-16/NN	nn||types-19/NNS||feature-18/NN	prep_of||variety-16/NN||types-19/NNS	prep_such_as||variety-16/NN||intergenic-23/NN	prep_such_as||variety-16/NN||genic-25/NN	conj_or||intergenic-23/NN||genic-25/NN	amod||region-29/NN||upstream-27/JJ	nn||region-29/NN||promoter-28/NN	dep||variety-16/NN||region-29/NN	amod||region-32/NN||intronic-31/JJ	dep||variety-16/NN||region-32/NN	conj_or||region-29/NN||region-32/NN	amod||region-35/NN||exonic-34/JJ	dep||variety-16/NN||region-35/NN	conj_or||region-29/NN||region-35/NN	amod||region-39/NN||downstream-37/JJ	nn||region-39/NN||transcript-38/NN	dep||variety-16/NN||region-39/NN	conj_or||region-29/NN||region-39/NN	poss||site-44/NN||5-41/CD	amod||site-44/NN||splice-43/JJ	dep||variety-16/NN||site-44/NN	poss||site-49/NN||3-46/CD	amod||site-49/NN||splice-48/JJ	dep||variety-16/NN||site-49/NN	conj_or||site-44/NN||site-49/NN	poss||region-54/NN||5-51/CD	amod||region-54/NN||untranslated-53/JJ	dep||variety-16/NN||region-54/NN	appos||region-54/NN||utr-56/NN	poss||utr-61/NN||3-59/CD	dep||variety-16/NN||utr-61/NN	conj_or||region-54/NN||utr-61/NN	amod||sequence-64/NN||coding-63/JJ	dep||variety-16/NN||sequence-64/NN	conj_or||region-54/NN||sequence-64/NN	appos||sequence-64/NN||cds-66/NN	amod||domain-71/NN||impacted-69/JJ	nn||domain-71/NN||protein-70/NN	dep||variety-16/NN||domain-71/NN	dep||domain-71/NN||substitution-73/NN	dep||domain-71/NN||insertion-75/NN	conj_or||substitution-73/NN||insertion-75/NN	dep||domain-71/NN||deletion-77/NN	conj_or||substitution-73/NN||deletion-77/NN	amod||substitution-73/NN||synonymous-79/JJ	amod||substitution-73/NN||non-synonymous-81/JJ	conj_or||synonymous-79/JJ||non-synonymous-81/JJ	prep_to||assign-10/VB||conserved-83/JJ	amod||variety-16/NN||conserved-83/JJ	conj_and||variety-16/NN||conserved-83/JJ	amod||variety-16/NN||unconserved-85/JJ	conj_and||variety-16/NN||unconserved-85/JJ	conj_or||conserved-83/JJ||unconserved-85/JJ	amod||insertion-91/NN||frameshift-88/JJ	conj_or||frameshift-88/JJ||aminoacid-90/JJ	amod||insertion-91/NN||aminoacid-90/JJ	prep_to||assign-10/VB||insertion-91/NN	conj_and||variety-16/NN||insertion-91/NN	conj_and||variety-16/NN||deletion-93/NN	conj_or||insertion-91/NN||deletion-93/NN	dep||deletion-93/NN||indel-95/JJ	aminoacid-90||impacted-69||no_rel||depending on the available annotation, the variantclassifier may assign each polymorphism to a large variety of feature types, such as intergenic or genic; upstream promoter region, intronic region, exonic region or downstream transcript region; 5' splice site or 3' splice site; 5' untranslated region (utr), 3' utr or coding sequence (cds); impacted protein domain; substitution, insertion or deletion; synonymous or non-synonymous; conserved or unconserved; and frameshift or aminoacid insertion or deletion (indel).
nsubjpass||associated-4/VBN||phn-1/NN	auxpass||associated-4/VBN||was-2/VBD	advmod||associated-4/VBN||significantly-3/RB	root||ROOT-0/null||associated-4/VBN	nn||intensity-7/NN||pain-6/NN	prep_with||associated-4/VBN||intensity-7/NN	nn||smoking-13/NN||presentation-9/NN	dep||smoking-13/NN||age-11/NN	prep_at||intensity-7/NN||smoking-13/NN	dep||smoking-13/NN||trauma-15/FW	amod||prescription-19/NN||missed-17/VBN	amod||prescription-19/NN||antiviral-18/JJ	prep_with||associated-4/VBN||prescription-19/NN	conj_and||intensity-7/NN||prescription-19/NN	amod||model-24/NN||generalized-21/JJ	nn||model-24/NN||estimating-22/NN	nn||model-24/NN||equations-23/NNS	appos||prescription-19/NN||model-24/NN	antiviral-18||pain-6||no_rel||phn was significantly associated with pain intensity at presentation, age, smoking, trauma and missed antiviral prescription (generalized estimating equations model).
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	alcohol-22||gout-8||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-4/NN||no-3/DT	nsubj||was-2/VBD||association-4/NN	prep_between||association-4/NN||intensity-6/NN	nn||prescription-11/NN||pain-8/NN	conj_and||pain-8/NN||nsaid-10/NN	nn||prescription-11/NN||nsaid-10/NN	prep_of||intensity-6/NN||prescription-11/NN	amod||prescription-16/NN||previous-14/JJ	amod||prescription-16/NN||nsaid-15/JJ	nsubj||predicted-17/VBD||prescription-16/NN	conj_but||was-2/VBD||predicted-17/VBD	det||prescription-20/NN||another-18/DT	amod||prescription-20/NN||such-19/JJ	dobj||predicted-17/VBD||prescription-20/NN	nsaid-15||pain-8||no_rel||there was no association between intensity of pain and nsaid prescription, but previous nsaid prescription predicted another such prescription.
det||relationship-2/NN||this-1/DT	nsubjpass||disconnected-6/VBN||relationship-2/NN	nsubj||part-12/NN||relationship-2/NN	auxpass||disconnected-6/VBN||is-4/VBZ	advmod||disconnected-6/VBN||apparently-5/RB	rcmod||relationship-2/NN||disconnected-6/VBN	nn||sensitivity-9/NN||insulin-8/NN	prep_from||disconnected-6/VBN||sensitivity-9/NN	aux||part-12/NN||may-10/MD	cop||part-12/NN||be-11/VB	root||ROOT-0/null||part-12/NN	det||obesity-18/NN||some-14/DT	amod||obesity-18/NN||pathogenetic-15/JJ	amod||obesity-18/NN||mechanisms-16/JJ	amod||obesity-18/NN||underlying-17/JJ	prep_of||part-12/NN||obesity-18/NN	prep_of||part-12/NN||type2diabetes-20/NNS	conj_and||obesity-18/NN||type2diabetes-20/NNS	type2diabetes-20||insulin-8||yes||this relationship which is apparently disconnected from insulin sensitivity may be part of some pathogenetic mechanisms underlying obesity and type2diabetes.
prep_in||potent-7/JJ||conclusion-2/NN	nsubj||potent-7/JJ||clevudine-4/NN	nsubj||lower-12/JJR||clevudine-4/NN	cop||potent-7/JJ||is-5/VBZ	advmod||potent-7/JJ||more-6/RBR	root||ROOT-0/null||potent-7/JJ	amod||suppression-10/NN||viral-9/JJ	prep_for||potent-7/JJ||suppression-10/NN	conj_and||potent-7/JJ||lower-12/JJR	amod||resistance-15/NN||antiviral-14/JJ	prep_for||lower-12/JJR||resistance-15/NN	prep_at||resistance-15/NN||week-17/NN	num||week-17/NN||48-18/CD	mark||¯-25/VBZ||than-19/IN	nsubj||¯-25/VBZ||lamivudine-20/NN	prep_in||lamivudine-20/NN||treatment-22/NN	prep_of||treatment-22/NN||naã-24/NN	advcl||potent-7/JJ||¯-25/VBZ	nn||patients-27/NNS||ve-26/NN	dobj||¯-25/VBZ||patients-27/NNS	prepc_with||¯-25/VBZ||hbeag-29/VBG	amod||chronichepatitisb-31/NN||positive-30/JJ	dobj||hbeag-29/VBG||chronichepatitisb-31/NN	chronichepatitisb-31||lamivudine-20||no_rel||in conclusion, clevudine is more potent for viral suppression and lower for antiviral resistance at week 48 than lamivudine in treatment of naã¯ve patients with hbeag positive chronichepatitisb.
det||method-2/NN||a-1/DT	nsubjpass||used-23/VBN||method-2/NN	prepc_for||method-2/NN||genotyping-4/VBG	prepc_for||method-2/NN||subtyping-6/VBG	conj_and||genotyping-4/VBG||subtyping-6/VBG	dobj||genotyping-4/VBG||hbv-7/NN	amod||gene-11/NN||partial-9/JJ	amod||gene-11/NN||hbsag-10/VBG	prep_by||hbv-7/NN||gene-11/NN	vmod||gene-11/NN||sequencing-12/VBG	vmod||sequencing-12/VBG||using-13/VBG	dobj||using-13/VBG||primers-14/NNS	nsubj||complementary-17/JJ||primers-14/NNS	cop||complementary-17/JJ||are-16/VBP	rcmod||primers-14/NNS||complementary-17/JJ	advmod||known-20/VBN||all-19/RB	amod||genotypes-21/NNS||known-20/VBN	prep_to||complementary-17/JJ||genotypes-21/NNS	auxpass||used-23/VBN||was-22/VBD	root||ROOT-0/null||used-23/VBN	hbv-7||hbsag-10||yes||a method for genotyping and subtyping hbv by partial hbsag gene sequencing using primers that are complementary to all known genotypes was used.
nn||grinders-3/NNS||quartz-1/NN	nn||grinders-3/NNS||stone-2/NN	nsubj||group-7/NN||grinders-3/NNS	cop||group-7/NN||are-4/VBP	num||group-7/NN||one-5/CD	amod||group-7/NN||such-6/JJ	root||ROOT-0/null||group-7/NN	prep_of||group-7/NN||workers-9/NNS	nsubjpass||exposed-12/VBN||workers-9/NNS	nsubjpass||exposed-12/VBN||workers-9/NNS	auxpass||exposed-12/VBN||are-11/VBP	rcmod||workers-9/NNS||exposed-12/VBN	rcmod||workers-9/NNS||exposed-12/VBN	conj_and||exposed-12/VBN||exposed-12/VBN	prep_to||exposed-12/VBN||silica-14/NN	advmod||exposed-12/VBN||thereby-16/RB	prep_at||exposed-12/VBN||risk-18/NN	amod||silicosis-21/NNS||developing-20/VBG	prep_of||risk-18/NN||silicosis-21/NNS	silicosis-21||silica-14||no||quartz stone grinders are one such group of workers who are exposed to silica and thereby at risk of developing silicosis.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||identified-6/VBD||study-4/NN	nsubj||identified-6/VBD||we-5/PRP	root||ROOT-0/null||identified-6/VBD	dobj||identified-6/VBD||genes-7/NNS	nsubj||predict-12/VB||genes-7/NNS	dobj||identified-6/VBD||mirnas-9/NNS	conj_and||genes-7/NNS||mirnas-9/NNS	nsubj||predict-12/VB||mirnas-9/NNS	aux||predict-12/VB||may-11/MD	rcmod||genes-7/NNS||predict-12/VB	amod||resistance-14/NN||clinical-13/JJ	dobj||predict-12/VB||resistance-14/NN	prep_of||resistance-14/NN||cll-16/NN	aux||fludarabine-18/VB||to-17/TO	vmod||predict-12/VB||fludarabine-18/VB	vmod||predict-12/VB||describe-21/VB	conj_and||fludarabine-18/VB||describe-21/VB	det||mechanism-25/NN||an-22/DT	amod||mechanism-25/NN||interesting-23/JJ	amod||mechanism-25/NN||oncogenic-24/JJ	dobj||fludarabine-18/VB||mechanism-25/NN	nn||patients-28/NNS||cll-27/NN	prep_in||fludarabine-18/VB||patients-28/NNS	amod||patients-28/NNS||resistant-29/JJ	aux||fludarabine-31/VB||to-30/TO	xcomp||resistant-29/JJ||fludarabine-31/VB	dobj||altered-42/VBN||which-33/WDT	det||myc-36/NN||the-34/DT	amod||myc-36/NN||complete-35/JJ	nsubjpass||altered-42/VBN||myc-36/NN	amod||network-40/NN||specific-38/JJ	amod||network-40/NN||regulatory-39/JJ	dep||myc-36/NN||network-40/NN	auxpass||altered-42/VBN||was-41/VBD	prepc_by||fludarabine-31/VB||altered-42/VBN	dep||fludarabine-18/VB||dna-44/NN	dep||fludarabine-18/VB||rna-46/NN	conj_and||dna-44/NN||rna-46/NN	dep||dna-44/NN||levels-47/NNS	amod||targets-51/NNS||transcriptional-50/JJ	dep||fludarabine-18/VB||targets-51/NNS	conj_and||dna-44/NN||targets-51/NNS	cll-27||fludarabine-31||yes||in the present study we identified genes and mirnas that may predict clinical resistance of cll to fludarabine, and describe an interesting oncogenic mechanism in cll patients resistant to fludarabine by which the complete myc -specific regulatory network was altered (dna and rna levels, and transcriptional targets).
det||data-2/NNS||the-1/DT	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||restricted-9/VBN||that-4/IN	amod||replication-6/NN||ad5pb_rsv_nis-5/JJ	nsubjpass||restricted-9/VBN||replication-6/NN	nsubj||androgen-11/VB||replication-6/NN	auxpass||restricted-9/VBN||is-7/VBZ	advmod||restricted-9/VBN||stringently-8/RB	ccomp||indicate-3/VBP||restricted-9/VBN	aux||androgen-11/VB||to-10/TO	xcomp||restricted-9/VBN||androgen-11/VB	amod||cells-15/NNS||positive-12/JJ	nn||cells-15/NNS||prostate-13/NN	nn||cells-15/NNS||cancer-14/NN	dobj||androgen-11/VB||cells-15/NNS	dobj||androgen-11/VB||results-17/NNS	conj_and||cells-15/NNS||results-17/NNS	amod||expression-21/NN||effective-19/JJ	nn||expression-21/NN||nis-20/NN	prep_in||androgen-11/VB||expression-21/NN	prep_in||androgen-11/VB||uptake-23/NN	conj_and||expression-21/NN||uptake-23/NN	prep_of||expression-21/NN||radioiodine-25/NN	androgen-11||cancer-14||no_rel||the data indicate that ad5pb_rsv_nis replication is stringently restricted to androgen positive prostate cancer cells and results in effective nis expression and uptake of radioiodine.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	cholesterol-8||tia-31||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	amod||acquiredimmunedeficiencysyndrome-17/NN||humanimmunodeficiencyvirus-13/JJ	appos||acquiredimmunedeficiencysyndrome-17/NN||hiv-15/NN	prep_of||face-11/NN||acquiredimmunedeficiencysyndrome-17/NN	appos||acquiredimmunedeficiencysyndrome-17/NN||aids-19/NNS	prepc_by||changed-9/VBN||leading-22/VBG	amod||decreases-25/NNS||dramatic-24/JJ	prep_to||leading-22/VBG||decreases-25/NNS	amod||morbidity-28/NN||hiv-related-27/JJ	prep_in||decreases-25/NNS||morbidity-28/NN	prep_in||decreases-25/NNS||mortality-30/NN	conj_and||morbidity-28/NN||mortality-30/NN	det||developed-33/JJ||the-32/DT	prep_in||leading-22/VBG||developed-33/JJ	prepc_by||changed-9/VBN||developing-37/VBG	conj_and||leading-22/VBG||developing-37/VBG	dobj||developing-37/VBG||world-38/NN	acquiredimmunedeficiencysyndrome-17||hiv-15||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquiredimmunedeficiencysyndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
quantmod||99-2/CD||almost-1/RB	num||%-3/NN||99-2/CD	nsubj||heard-8/VBN||%-3/NN	det||respondents-6/NNS||the-5/DT	prep_of||%-3/NN||respondents-6/NNS	aux||heard-8/VBN||had-7/VBD	root||ROOT-0/null||heard-8/VBN	prep_of||heard-8/VBN||hiv/aids-10/NNS	num||%-14/NN||89-13/CD	nsubj||identify-16/VB||%-14/NN	aux||identify-16/VB||could-15/MD	conj_and||heard-8/VBN||identify-16/VB	dobj||identify-16/VB||ways-17/NNS	nsubj||protect-19/VB||ways-17/NNS	aux||protect-19/VB||to-18/TO	xcomp||identify-16/VB||protect-19/VB	dobj||protect-19/VB||oneself-20/PRP	advmod||hiv/aids-24/NNS||sexually-22/RB	amod||hiv/aids-24/NNS||transmitted-23/JJ	prep_against||protect-19/VB||hiv/aids-24/NNS	aids--1||hiv--1||no||almost 99% of the respondents had heard of hiv/aids, and 89% could identify ways to protect oneself against sexually transmitted hiv/aids.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||describe-8/VB||goal-2/NN	det||study-5/NN||this-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||describe-8/VB||to-7/TO	xcomp||was-6/VBD||describe-8/VB	advmod||reflected-32/VBD||how-9/WRB	nsubj||reflected-32/VBD||activists-10/NNS	vmod||activists-10/NNS||engaged-11/VBN	prep_in||engaged-11/VBN||campaigns-13/NNS	aux||change-15/VB||to-14/TO	xcomp||engaged-11/VBN||change-15/VB	nn||policies-17/NNS||alcohol-16/NN	dobj||change-15/VB||policies-17/NNS	dep||change-15/VB||in-18/IN	amod||areas-21/NNS||inner-19/JJ	nn||areas-21/NNS||city-20/NN	pobj||in-18/IN||areas-21/NNS	vmod||areas-21/NNS||framed-22/VBN	nn||problems-24/NNS||alcohol-23/NN	dobj||framed-22/VBN||problems-24/NNS	mark||not-29/RB||whether-27/IN	cc||not-29/RB||or-28/CC	dep||change-15/VB||not-29/RB	conj_and||in-18/IN||not-29/RB	poss||frameworks-31/NN||their-30/PRP$	dep||not-29/RB||frameworks-31/NN	ccomp||describe-8/VB||reflected-32/VBD	amod||models-34/NNS||major-33/JJ	dobj||reflected-32/VBD||models-34/NNS	vmod||models-34/NNS||used-35/VBN	det||field-38/NN||the-37/DT	prep_in||used-35/VBN||field-38/NN	det||alcoholism-43/NN||the-42/DT	prep_such_as||field-38/NN||alcoholism-43/NN	det||model-47/NN||a-45/DT	nn||model-47/NN||disease-46/NN	prep_as||alcoholism-43/NN||model-47/NN	det||perspective-52/NN||an-49/DT	nn||perspective-52/NN||alcohol-50/NN	nn||perspective-52/NN||problems-51/NNS	prep_as||alcoholism-43/NN||perspective-52/NN	conj_or||model-47/NN||perspective-52/NN	det||approach-58/NN||a-55/DT	amod||approach-58/NN||public-56/JJ	nn||approach-58/NN||health-57/NN	prep_as||alcoholism-43/NN||approach-58/NN	conj_or||model-47/NN||approach-58/NN	nn||problems-61/NNS||alcohol-60/NN	prep_to||used-35/VBN||problems-61/NNS	alcoholism-43||alcohol-60||no||the goal of this study was to describe how activists engaged in campaigns to change alcohol policies in inner city areas framed alcohol problems, and whether or not their frameworks reflected major models used in the field, such as the alcoholism as a disease model, an alcohol problems perspective, or a public health approach to alcohol problems.
nsubj||compensated-10/VBN||patients-1/NNS	nsubj||overt-12/VB||patients-1/NNS	det||syndrome-4/NN||the-3/DT	prep_with||patients-1/NNS||syndrome-4/NN	nn||unresponsiveness-7/NNS||tsh-6/NN	prep_of||syndrome-4/NN||unresponsiveness-7/NNS	aux||compensated-10/VBN||may-8/MD	aux||compensated-10/VBN||have-9/VB	root||ROOT-0/null||compensated-10/VBN	conj_or||compensated-10/VBN||overt-12/VB	dobj||overt-12/VB||hypothyroidism-13/NN	det||spectrum-17/NN||a-15/DT	amod||spectrum-17/NN||wide-16/JJ	prep_with||overt-12/VB||spectrum-17/NN	amod||alterations-22/NNS||clinical-19/JJ	conj_and||clinical-19/JJ||morphological-21/JJ	amod||alterations-22/NNS||morphological-21/JJ	prep_of||spectrum-17/NN||alterations-22/NNS	prepc_depending_on||overt-12/VB||on-24/IN	det||degree-26/NN||the-25/DT	pobj||overt-12/VB||degree-26/NN	prep_of||degree-26/NN||impairment-28/NN	nn||function-34/NN||tsh-receptor-30/NNP	appos||function-34/NN||tsh-r-32/NN	prep_of||impairment-28/NN||function-34/NN	hypothyroidism-13||tsh-6||no_rel||patients with the syndrome of tsh unresponsiveness may have compensated or overt hypothyroidism with a wide spectrum of clinical and morphological alterations depending on the degree of impairment of tsh-receptor (tsh-r) function.
num||patients-3/NNS||thirty-1/CD	amod||patients-3/NNS||hiv-positive-2/JJ	nsubj||aids-8/VBZ||patients-3/NNS	vmod||patients-3/NNS||enrolled-4/VBN	det||family-7/NN||the-6/DT	prep_in||enrolled-4/VBN||family-7/NN	ccomp||provided-22/VBN||aids-8/VBZ	nn||services-12/NNS||care-9/VB	conj_and||care-9/VB||education-11/NN	nn||services-12/NNS||education-11/NN	dobj||aids-8/VBZ||services-12/NNS	parataxis||aids-8/VBZ||faces-14/VBZ	npadvmod||aids-8/VBZ||program-16/NN	prep_in||aids-8/VBZ||kisumu-18/JJ	nsubjpass||provided-22/VBN||kenya-20/NN	auxpass||provided-22/VBN||were-21/VBD	root||ROOT-0/null||provided-22/VBN	det||loan-25/NN||a-23/DT	amod||loan-25/NN||micro-financed-24/JJ	dobj||provided-22/VBN||loan-25/NN	aux||receive-27/VB||to-26/TO	vmod||provided-22/VBN||receive-27/VB	det||pump-30/NN||an-28/DT	nn||pump-30/NN||irrigation-29/NN	dobj||receive-27/VB||pump-30/NN	nn||guidance-33/NN||farming-32/NN	dobj||receive-27/VB||guidance-33/NN	conj_and||pump-30/NN||guidance-33/NN	prep_from||receive-27/VB||kickstart-35/NN	det||developer-38/NN||the-37/DT	appos||kickstart-35/NN||developer-38/NN	det||pump-41/NN||the-40/DT	prep_of||developer-38/NN||pump-41/NN	aids-8||hiv--1||no||thirty hiv-positive patients enrolled in the family aids care and education services (faces) program in kisumu, kenya were provided a micro-financed loan to receive an irrigation pump and farming guidance from kickstart, the developer of the pump.
amod||influenzaviruses-2/NNS||isolated-1/JJ	nsubjpass||compared-4/VBN||influenzaviruses-2/NNS	auxpass||compared-4/VBN||were-3/VBD	root||ROOT-0/null||compared-4/VBN	amod||influenzaviruses-7/NNS||seasonal-6/JJ	prep_with||compared-4/VBN||influenzaviruses-7/NNS	det||season-12/NN||the-9/DT	num||season-12/NN||2008-10/CD	nn||season-12/NN||influenza-11/NN	prep_from||compared-4/VBN||season-12/NN	influenza-11||influenzaviruses-7||no||isolated influenzaviruses were compared with seasonal influenzaviruses from the 2008 influenza season.
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||mycobacteriumtuberculosis-36||no||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
det||vaccine-4/NN||the-1/DT	amod||vaccine-4/NN||mtb72f-2/JJ	nn||vaccine-4/NN||subunit-3/NN	nsubjpass||hoped-14/VBN||vaccine-4/NN	nsubj||provide-16/VB||vaccine-4/NN	prep_for||vaccine-4/NN||tuberculosis-6/NNP	advmod||in-9/IN||currently-8/RB	rcmod||vaccine-4/NN||in-9/IN	amod||trials-11/NNS||clinical-10/JJ	pobj||in-9/IN||trials-11/NNS	auxpass||hoped-14/VBN||is-13/VBZ	root||ROOT-0/null||hoped-14/VBN	aux||provide-16/VB||to-15/TO	xcomp||hoped-14/VBN||provide-16/VB	amod||protection-18/NN||improved-17/VBN	dobj||provide-16/VB||protection-18/NN	prepc_compared_to||provide-16/VB||to-20/TO	det||bcgvaccine-23/NN||the-21/DT	amod||bcgvaccine-23/NN||current-22/JJ	pobj||provide-16/VB||bcgvaccine-23/NN	tuberculosis-6||bcgvaccine-23||no||the mtb72f subunit vaccine for tuberculosis, currently in clinical trials, is hoped to provide improved protection compared to the current bcgvaccine.
amod||s.aureus-3/NNS||hospital-associated-1/JJ	amod||s.aureus-3/NNS||methicillin-resistant-2/JJ	nsubj||-lrb--4/VBD||s.aureus-3/NNS	root||ROOT-0/null||-lrb--4/VBD	nn||carriage-7/NNP||mrsa-5/NNP	nn||carriage-7/NNP||-rrb--6/NNP	nsubjpass||associated-9/VBN||carriage-7/NNP	auxpass||associated-9/VBN||is-8/VBZ	ccomp||-lrb--4/VBD||associated-9/VBN	det||risk-13/NN||an-11/DT	amod||risk-13/NN||increased-12/VBN	prep_with||associated-9/VBN||risk-13/NN	prep_of||risk-13/NN||infection-15/NN	prep_of||risk-13/NN||morbidity-17/NN	conj_and||infection-15/NN||morbidity-17/NN	prep_of||risk-13/NN||mortality-19/NN	conj_and||infection-15/NN||mortality-19/NN	mrsa-5||s.aureus-3||no||hospital-associated methicillin-resistant s.aureus -lrb- mrsa -rrb- carriage is associated with an increased risk of infection , morbidity and mortality .
advmod||appears-7/VBZ||furthermore-1/RB	det||effectiveness-4/NN||the-3/DT	nsubj||appears-7/VBZ||effectiveness-4/NN	nsubj||greater-10/JJR||effectiveness-4/NN	prep_of||effectiveness-4/NN||vildagliptin-6/NN	root||ROOT-0/null||appears-7/VBZ	aux||greater-10/JJR||to-8/TO	cop||greater-10/JJR||be-9/VB	xcomp||appears-7/VBZ||greater-10/JJR	advmod||used-14/VBN||when-11/WRB	nsubjpass||used-14/VBN||insulin-12/NN	auxpass||used-14/VBN||is-13/VBZ	ccomp||greater-10/JJR||used-14/VBN	det||regimen-18/NN||a-16/DT	amod||regimen-18/NN||basal-17/JJ	prep_as||used-14/VBN||regimen-18/NN	advmod||opposed-20/VBN||as-19/RB	amod||regimen-18/NN||opposed-20/VBN	auxpass||used-23/VBN||being-22/VBG	prepc_to||greater-10/JJR||used-23/VBN	aux||reduce-25/VB||to-24/TO	xcomp||used-23/VBN||reduce-25/VB	amod||hyperglycemia-27/NN||postprandial-26/JJ	dobj||reduce-25/VB||hyperglycemia-27/NN	mark||plays-35/VBZ||since-29/IN	nsubj||plays-35/VBZ||improvement-30/NN	nn||secretion-33/NN||insulin-32/NN	prep_in||improvement-30/NN||secretion-33/NN	advmod||plays-35/VBZ||likely-34/RB	advcl||appears-7/VBZ||plays-35/VBZ	det||role-38/NN||a-36/DT	amod||role-38/NN||minor-37/JJ	dobj||plays-35/VBZ||role-38/NN	tmod||administered-46/VBN||role-38/NN	advmod||administered-46/VBN||when-39/WRB	advmod||high-41/JJ||relatively-40/RB	amod||doses-42/NNS||high-41/JJ	nsubjpass||administered-46/VBN||doses-42/NNS	prep_of||doses-42/NNS||insulin-44/NN	auxpass||administered-46/VBN||are-45/VBP	rcmod||role-38/NN||administered-46/VBN	prep_before||administered-46/VBN||meals-48/NNS	hyperglycemia-27||insulin-44||yes||furthermore, the effectiveness of vildagliptin appears to be greater when insulin is used as a basal regimen as opposed to being used to reduce postprandial hyperglycemia, since improvement in insulin secretion likely plays a minor role when relatively high doses of insulin are administered before meals.
nsubj||equivalent-13/JJ||s-1-1/JJ	det||preparation-5/NN||an-3/DT	amod||preparation-5/NN||oral-4/JJ	appos||s-1-1/JJ||preparation-5/NN	vmod||preparation-5/NN||evolved-6/VBN	prep_from||evolved-6/VBN||uracil-8/NN	prep_from||evolved-6/VBN||tegafur-10/NN	conj_and||uracil-8/NN||tegafur-10/NN	aux||equivalent-13/JJ||has-12/VBZ	root||ROOT-0/null||equivalent-13/JJ	advmod||equivalent-13/JJ||efficacy-14/RB	prep_to||equivalent-13/JJ||uracil-16/NN	prep_to||equivalent-13/JJ||tegafur/leucovorin-18/NN	conj_and||uracil-16/NN||tegafur/leucovorin-18/NN	prepc_for||equivalent-13/JJ||treating-20/VBG	dobj||treating-20/VBG||patients-21/NNS	amod||cancer-25/NN||advanced-23/JJ	amod||cancer-25/NN||colorectal-24/JJ	prep_with||equivalent-13/JJ||cancer-25/NN	aux||regimen-31/NN||might-27/MD	cop||regimen-31/NN||be-28/VB	det||regimen-31/NN||a-29/DT	amod||regimen-31/NN||suitable-30/JJ	conj_and||equivalent-13/JJ||regimen-31/NN	det||setting-35/NN||an-33/DT	amod||setting-35/NN||adjuvant-34/JJ	prep_in||regimen-31/NN||setting-35/NN	cancer-25||adjuvant-34||no_rel||s-1, an oral preparation evolved from uracil and tegafur, has equivalent efficacy to uracil and tegafur/leucovorin for treating patients with advanced colorectal cancer and might be a suitable regimen in an adjuvant setting.
nsubj||effective-18/JJ||methotrexate-1/NN	nsubj||brings-20/VBZ||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	det||treatment-8/NN||the-6/DT	amod||treatment-8/NN||primary-7/JJ	appos||methotrexate-1/NN||treatment-8/NN	det||juvenileidiopathicarthritis-12/NNS||the-10/DT	amod||juvenileidiopathicarthritis-12/NNS||articular-type-11/JJ	prep_for||treatment-8/NN||juvenileidiopathicarthritis-12/NNS	appos||juvenileidiopathicarthritis-12/NNS||jia-14/NN	cop||effective-18/JJ||is-17/VBZ	root||ROOT-0/null||effective-18/JJ	conj_and||effective-18/JJ||brings-20/VBZ	amod||improvement-23/NN||radiological-22/JJ	prep_about||brings-20/VBZ||improvement-23/NN	juvenileidiopathicarthritis-12||mtx-3||yes||methotrexate (mtx), the primary treatment for the articular-type juvenileidiopathicarthritis (jia), is effective and brings about radiological improvement.
nsubj||pathogen-19/NN||mycobacteriumtuberculosis-1/NNS	appos||mycobacteriumtuberculosis-1/NNS||mtb-3/NN	det||agent-8/NN||the-6/DT	amod||agent-8/NN||causative-7/JJ	appos||mycobacteriumtuberculosis-1/NNS||agent-8/NN	prep_of||agent-8/NN||tuberculosis-10/NNP	appos||tuberculosis-10/NNP||tb-12/NN	cop||pathogen-19/NN||is-15/VBZ	det||pathogen-19/NN||a-16/DT	amod||pathogen-19/NN||facultative-17/JJ	nn||pathogen-19/NN||intracellular-18/NN	root||ROOT-0/null||pathogen-19/NN	nsubj||persist-22/VB||pathogen-19/NN	aux||persist-22/VB||can-21/MD	rcmod||pathogen-19/NN||persist-22/VB	det||host-25/NN||the-24/DT	prep_within||persist-22/VB||host-25/NN	tuberculosis-10||mtb-3||no||mycobacteriumtuberculosis ( mtb ), the causative agent of tuberculosis (tb), is a facultative intracellular pathogen that can persist within the host.
amod||overexpression-2/NN||nac-5-htr4-1/JJ	nsubj||upregulated-3/VBD||overexpression-2/NN	root||ROOT-0/null||upregulated-3/VBD	dobj||upregulated-3/VBD||nac-cart-4/NN	vmod||nac-cart-4/NN||provoked-6/VBN	dobj||provoked-6/VBN||anorexia-7/NN	dobj||provoked-6/VBN||hyperactivity-9/NN	conj_and||anorexia-7/NN||hyperactivity-9/NN	nac--1||anorexia-7||no_rel||nac-5-htr4 overexpression upregulated nac-cart, provoked anorexia and hyperactivity.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||20-yr-old-2/JJ	nsubj||came-9/VBD||woman-3/NN	det||history-6/NN||a-5/DT	prep_with||woman-3/NN||history-6/NN	prep_of||history-6/NN||type1diabetes-8/CD	root||ROOT-0/null||came-9/VBD	det||department-13/NN||the-11/DT	nn||department-13/NN||emergency-12/NN	prep_to||came-9/VBD||department-13/NN	num||months-15/NNS||7-14/CD	npadvmod||came-9/VBD||months-15/NNS	prepc_after||came-9/VBD||discontinuing-17/VBG	nn||therapy-19/NN||insulin-18/NN	dobj||discontinuing-17/VBG||therapy-19/NN	type1diabetes-8||insulin-18||yes||a 20-yr-old woman with a history of type1diabetes came to the emergency department 7 months after discontinuing insulin therapy.
det||results-2/NNS||the-1/DT	nsubj||show-6/VBP||results-2/NNS	det||study-5/NN||this-4/DT	prep_of||results-2/NNS||study-5/NN	root||ROOT-0/null||show-6/VBP	mark||added-9/VBD||that-7/IN	nsubj||added-9/VBD||remifentanil-8/NN	nsubj||propofol-11/VB||remifentanil-8/NN	ccomp||show-6/VBP||added-9/VBD	aux||propofol-11/VB||to-10/TO	xcomp||added-9/VBD||propofol-11/VB	nn||sensitization-15/NN||anesthesia-12/NN	nn||sensitization-15/NN||causes-13/NNS	nn||sensitization-15/NN||pain-14/NN	dobj||propofol-11/VB||sensitization-15/NN	det||period-20/NN||the-17/DT	amod||period-20/NN||immediate-18/JJ	nn||period-20/NN||postoperative-19/NN	prep_in||sensitization-15/NN||period-20/NN	pain-14||propofol-11||yes||the results of this study show that remifentanil added to propofol anesthesia causes pain sensitization in the immediate postoperative period.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||used-8/VBN||that-4/IN	nsubjpass||used-8/VBN||saliva-5/NN	aux||used-8/VBN||can-6/MD	auxpass||used-8/VBN||be-7/VB	ccomp||suggest-3/VBP||used-8/VBN	det||biomarker-13/NN||an-10/DT	amod||biomarker-13/NN||appropriate-11/JJ	amod||biomarker-13/NN||clinical-12/JJ	prep_as||used-8/VBN||biomarker-13/NN	prepc_for||used-8/VBN||monitoring-15/VBG	nn||species-17/NNS||arsenic-16/NN	dobj||monitoring-15/VBG||species-17/NNS	nn||patients-20/NNS||apl-19/NN	prep_in||monitoring-15/VBG||patients-20/NNS	apl-19||arsenic-16||yes||these results suggest that saliva can be used as an appropriate clinical biomarker for monitoring arsenic species in apl patients.
amod||artery-2/NN||infarct-1/JJ	nsubjpass||used-10/VBN||artery-2/NN	vmod||artery-2/NN||stenting-3/VBG	amod||therapy-7/NN||adjunctive-5/JJ	nn||therapy-7/NN||abciximab-6/NN	prep_with||stenting-3/VBG||therapy-7/NN	auxpass||used-10/VBN||is-8/VBZ	advmod||used-10/VBN||widely-9/RB	root||ROOT-0/null||used-10/VBN	dobj||used-10/VBN||treatment-11/NN	prep_for||used-10/VBN||patients-13/NNS	prep_with||patients-13/NNS||acutemyocardialinfarction-15/NN	appos||acutemyocardialinfarction-15/NN||ami-17/NN	abciximab-6||infarct-1||no_rel||infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acutemyocardialinfarction (ami).
det||objectives-2/NNS||the-1/DT	nsubj||were-6/VBD||objectives-2/NNS	nsubj||assess-10/VB||objectives-2/NNS	det||study-5/NN||this-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||assess-10/VB||to-7/TO	dep||assess-10/VB||1-8/LS	xcomp||were-6/VBD||assess-10/VB	det||family-12/NN||the-11/DT	dobj||assess-10/VB||family-12/NN	xcomp||assess-10/VB||impact-13/NN	prep_of||impact-13/NN||rotavirusgastroenteritis-15/NNS	amod||interviews-18/NNS||qualitative-17/JJ	prep_through||rotavirusgastroenteritis-15/NNS||interviews-18/NNS	mark||compare-24/VBP||with-19/IN	nsubj||compare-24/VBP||parents-20/NNS	dep||parents-20/NNS||2-22/CD	dep||rotavirusgastroenteritis-15/NNS||compare-24/VBP	det||severity-27/NN||the-25/DT	amod||severity-27/NN||clinical-26/JJ	dobj||compare-24/VBP||severity-27/NN	amod||gastroenteritis-32/NNS||rotavirus-positive-29/JJ	conj_and||rotavirus-positive-29/JJ||negative-31/JJ	amod||gastroenteritis-32/NNS||negative-31/JJ	prep_of||severity-27/NN||gastroenteritis-32/NNS	dep||test-36/VB||3-34/LS	dep||assess-10/VB||test-36/VB	det||questionnaire-38/NN||a-37/DT	dobj||test-36/VB||questionnaire-38/NN	xcomp||test-36/VB||asking-39/VBG	dobj||asking-39/VBG||parents-40/NNS	nsubj||rank-42/VB||parents-40/NNS	aux||rank-42/VB||to-41/TO	xcomp||asking-39/VBG||rank-42/VB	det||importance-44/NN||the-43/DT	dobj||rank-42/VB||importance-44/NN	amod||factors-47/NNS||various-46/JJ	prep_of||importance-44/NN||factors-47/NNS	vmod||factors-47/NNS||associated-48/VBN	det||case-51/NN||a-50/DT	prep_with||associated-48/VBN||case-51/NN	prep_of||case-51/NN||rotavirusgastroenteritis-53/NNS	rotavirusgastroenteritis-53||rotavirus--1||no||the objectives of this study were to 1) assess the family impact of rotavirusgastroenteritis through qualitative interviews with parents; 2) compare the clinical severity of rotavirus-positive and negative gastroenteritis; 3) test a questionnaire asking parents to rank the importance of various factors associated with a case of rotavirusgastroenteritis.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	amod||sodiumvalproate-7/NN||intravenous-6/JJ	prep_of||effect-4/NN||sodiumvalproate-7/NN	prep_in||assess-2/VB||patients-9/NNS	amod||episodes-13/NNS||acute-11/JJ	amod||episodes-13/NNS||manic-12/JJ	prep_with||patients-9/NNS||episodes-13/NNS	prep_of||episodes-13/NNS||bipolardisorder-15/NN	sodiumvalproate-7||bipolardisorder-15||no_rel||to assess the effect of intravenous sodiumvalproate in patients with acute manic episodes of bipolardisorder.
amod||age-2/NN||mean-1/JJ	nsubj||was-5/VBD||age-2/NN	prep_at||age-2/NN||diagnosis-4/NN	root||ROOT-0/null||was-5/VBD	dep||y-14/NN||males-7/NNS	conj_and||males-7/NNS||females-9/NNS	dep||y-14/NN||females-9/NNS	num||y-14/NN||36.6-11/CD	conj_and||36.6-11/CD||38.1-13/CD	num||y-14/NN||38.1-13/CD	dep||was-5/VBD||y-14/NN	prep_for||y-14/NN||uc-16/NN	dep||was-5/VBD||33.4-18/CD	conj_and||y-14/NN||33.4-18/CD	conj_and||y-14/NN||36.2-20/CD	conj_and||33.4-18/CD||36.2-20/CD	vmod||33.4-18/CD||y-21/VBN	prep_for||y-21/VBN||cd-23/NN	cd-23||uc-16||no_rel||mean age at diagnosis was (males and females) 36.6 and 38.1y for uc and 33.4 and 36.2y for cd.
det||study-4/NN||this-1/DT	amod||study-4/NN||prospective-2/JJ	nn||study-4/NN||cohort-3/NN	nsubj||conducted-5/VBD||study-4/NN	root||ROOT-0/null||conducted-5/VBD	prep_in||conducted-5/VBD||zambia-7/NN	vmod||zambia-7/NN||evaluated-8/VBN	det||safety-10/NN||the-9/DT	dobj||evaluated-8/VBN||safety-10/NN	prep_of||safety-10/NN||artemether-lumefantrine-12/NN	appos||artemether-lumefantrine-12/NN||al-14/NNP	amod||women-18/NNS||pregnant-17/JJ	prep_in||evaluated-8/VBN||women-18/NNS	prep_with||evaluated-8/VBN||malaria-20/NN	malaria-20||lumefantrine--1||yes||this prospective cohort study conducted in zambia evaluated the safety of artemether-lumefantrine (al) in pregnant women with malaria.
amod||agonists-3/NNS||glp-1-1/JJ	nn||agonists-3/NNS||receptor-2/NN	nsubjpass||developed-13/VBN||agonists-3/NNS	nsubjpass||approved-17/VBN||agonists-3/NNS	prep_such_as||agonists-3/NNS||exenatide-7/NN	prep_such_as||agonists-3/NNS||liraglutide-9/NN	conj_and||exenatide-7/NN||liraglutide-9/NN	aux||developed-13/VBN||have-11/VBP	auxpass||developed-13/VBN||been-12/VBN	root||ROOT-0/null||developed-13/VBN	auxpass||approved-17/VBN||are-15/VBP	advmod||approved-17/VBN||already-16/RB	conj_and||developed-13/VBN||approved-17/VBN	det||treatment-20/NN||the-19/DT	prep_for||approved-17/VBN||treatment-20/NN	prep_of||treatment-20/NN||type2diabetes-22/CD	type2diabetes-22||exenatide-7||yes||glp-1 receptor agonists, such as exenatide and liraglutide, have been developed and are already approved for the treatment of type2diabetes.
nsubjpass||collected-3/VBN||blood-1/NN	auxpass||collected-3/VBN||was-2/VBD	root||ROOT-0/null||collected-3/VBN	prep_from||collected-3/VBN||patients-5/NNS	amod||melanoma-8/NN||uveal-7/JJ	prep_with||collected-3/VBN||melanoma-8/NN	vmod||melanoma-8/NN||enrolled-9/VBN	det||trial-14/NN||an-11/DT	amod||trial-14/NN||adjuvant-12/JJ	nn||trial-14/NN||therapy-13/NN	prep_on||enrolled-9/VBN||trial-14/NN	prep_in||treated-19/VBN||trial-14/NN	nsubjpass||treated-19/VBN||they-17/PRP	auxpass||treated-19/VBN||were-18/VBD	rcmod||trial-14/NN||treated-19/VBN	advmod||treated-19/VBN||sequentially-20/RB	prep_with||treated-19/VBN||dacarbazine-22/JJ	prep_with||treated-19/VBN||interferon-alfa-2b-24/JJ	conj_and||dacarbazine-22/JJ||interferon-alfa-2b-24/JJ	melanoma-8||dacarbazine-22||yes||blood was collected from patients with uveal melanoma enrolled on an adjuvant therapy trial in which they were treated sequentially with dacarbazine and interferon-alfa-2b.
nsubj||trial-7/NN||e1684-1/NNS	cop||trial-7/NN||was-2/VBD	det||trial-7/NN||the-3/DT	amod||trial-7/NN||pivotal-4/JJ	amod||trial-7/NN||adjuvant-5/JJ	nn||trial-7/NN||melanoma-6/NN	root||ROOT-0/null||trial-7/NN	prep_for||trial-7/NN||establishment-9/NN	amod||interferon-12/NN||high-dose-11/JJ	prep_of||establishment-9/NN||interferon-12/NN	appos||trial-7/NN||ifn-14/NN	amod||therapy-18/NN||effective-17/JJ	prep_as||trial-7/NN||therapy-18/NN	amod||patients-22/NNS||high-risk-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_of||therapy-18/NN||patients-22/NNS	melanoma-21||ifn-14||yes||e1684 was the pivotal adjuvant melanoma trial for establishment of high-dose interferon (ifn) as effective therapy of high-risk melanoma patients.
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	tuberculosis-22||bcg-1||yes||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
det||prevalences-2/NNS||the-1/DT	nsubj||33.1-24/NNP||prevalences-2/NNS	amod||antibody-6/NN||anti-hbv-4/JJ	nn||antibody-6/NN||core-5/NN	prep_of||prevalences-2/NNS||antibody-6/NN	dep||antibody-6/NN||anti-hbc-8/JJ	prep_of||prevalences-2/NNS||hepatitisbvirussurfaceantigen-11/NN	conj_and||antibody-6/NN||hepatitisbvirussurfaceantigen-11/NN	appos||hepatitisbvirussurfaceantigen-11/NN||hbsag-13/NN	amod||antibody-19/NN||anti-hbv-17/JJ	nn||antibody-19/NN||surface-18/NN	prep_of||prevalences-2/NNS||antibody-19/NN	conj_and||antibody-6/NN||antibody-19/NN	appos||antibody-19/NN||anti-hbs-21/NNS	cop||33.1-24/NNP||were-23/VBD	root||ROOT-0/null||33.1-24/NNP	conj_and||33.1-24/NNP||10.4-26/CD	num||%-30/NN||56.1-29/CD	conj_and||33.1-24/NNP||%-30/NN	advmod||33.1-24/NNP||respectively-32/RB	hbv--1||hepatitisbvirussurfaceantigen-11||yes||the prevalences of anti-hbv core antibody (anti-hbc), hepatitisbvirussurfaceantigen (hbsag), and anti-hbv surface antibody (anti-hbs) were 33.1, 10.4, and 56.1%, respectively.
det||study-2/NN||this-1/DT	nsubj||evaluate-4/VB||study-2/NN	aux||evaluate-4/VB||will-3/MD	root||ROOT-0/null||evaluate-4/VB	nn||therapy-8/NN||novel-5/NN	nn||therapy-8/NN||stem/progenitor-6/NN	nn||therapy-8/NN||cell-7/NN	dobj||evaluate-4/VB||therapy-8/NN	nn||treatment-12/NN||combination-10/NN	nn||treatment-12/NN||cytokine-11/NN	prep_with||evaluate-4/VB||treatment-12/NN	det||analogue-17/NN||the-14/DT	amod||analogue-17/NN||long-acting-15/JJ	nn||analogue-17/NN||erythropoietin-16/NN	prep_of||treatment-12/NN||analogue-17/NN	prep_of||treatment-12/NN||darbepoetin-19/NN	conj_and||analogue-17/NN||darbepoetin-19/NN	amod||colony-stimulatingfactor-23/NN||granulocyte-22/JJ	prep_of||treatment-12/NN||colony-stimulatingfactor-23/NN	conj_and||analogue-17/NN||colony-stimulatingfactor-23/NN	dep||analogue-17/NN||g-csf-25/JJ	prep_in||evaluate-4/VB||patients-28/NNS	prep_with||patients-28/NNS||acutemyocardialinfarction-30/NN	erythropoietin-16||acutemyocardialinfarction-30||no_rel||this study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulatingfactor (g-csf) in patients with acutemyocardialinfarction.
det||patients-3/NNS||the-2/DT	nsubj||revealed-6/VBD||patients-3/NNS	prep_in||introduced-17/VBN||patients-3/NNS	rcmod||patients-3/NNS||revealed-6/VBD	dobj||revealed-6/VBD||hypothyroidism-7/NN	appos||hypothyroidism-7/NN||hypot-9/NN	det||substitution-15/NN||an-12/DT	amod||substitution-15/NN||appropriate-13/JJ	amod||substitution-15/NN||l-t4-14/JJ	nsubjpass||introduced-17/VBN||substitution-15/NN	auxpass||introduced-17/VBN||was-16/VBD	root||ROOT-0/null||introduced-17/VBN	advmod||introduced-17/VBN||immediately-18/RB	hypothyroidism-7||t4--1||yes||in the patients, who revealed hypothyroidism (hypot), an appropriate l-t4 substitution was introduced immediately.
aux||study-2/VB||to-1/TO	advcl||mg-46/VBP||study-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||potential-4/JJ	dobj||study-2/VB||efficacy-5/NN	dobj||study-2/VB||tolerability-7/NN	conj_and||efficacy-5/NN||tolerability-7/NN	det||formula-12/NN||a-9/DT	amod||formula-12/NN||natural-10/JJ	amod||formula-12/NN||multiherbal-11/JJ	prep_of||efficacy-5/NN||formula-12/NN	appos||formula-12/NN||immumax-14/NN	xcomp||study-2/VB||containing-16/VBG	amod||mg-19/NN||echinaceaextract-17/JJ	dep||echinaceaextract-17/JJ||120-18/CD	dobj||containing-16/VBG||mg-19/NN	amod||powder-22/NN||garlic-21/JJ	nsubj||mg-46/VBP||powder-22/NN	num||mg-24/NN||100-23/CD	dep||powder-22/NN||mg-24/NN	nn||oil-28/NN||nigella-26/NN	nn||oil-28/NN||sativa-27/NN	conj_and||powder-22/NN||oil-28/NN	nsubj||mg-46/VBP||oil-28/NN	num||mg-30/NN||200-29/CD	dep||oil-28/NN||mg-30/NN	nn||ginseng-34/NN||panax-33/NN	conj_and||powder-22/NN||ginseng-34/NN	nsubj||mg-46/VBP||ginseng-34/NN	number||50-36/CD||extract-35/CD	num||mg-37/NNP||50-36/CD	dep||ginseng-34/NN||mg-37/NNP	nn||mg-41/NN||vitaminc-39/NNP	num||mg-41/NN||50-40/CD	dep||ginseng-34/NN||mg-41/NN	conj_plus||mg-37/NNP||mg-41/NN	amod||7.5-45/NN||elemental-43/JJ	nn||7.5-45/NN||zinc-44/NN	dep||ginseng-34/NN||7.5-45/NN	conj_and||mg-37/NNP||7.5-45/NN	root||ROOT-0/null||mg-46/VBP	det||treatment-49/NN||the-48/DT	prep_in||mg-46/VBP||treatment-49/NN	prep_of||treatment-49/NN||patients-51/NNS	vmod||patients-51/NNS||suffering-52/VBG	det||commoncold-55/NN||the-54/DT	prep_from||suffering-52/VBG||commoncold-55/NN	commoncold-55||vitaminc-39||yes||to study the potential efficacy and tolerability of a natural multiherbal formula (immumax) containing echinaceaextract 120 mg, garlic powder 100 mg, nigella sativa oil 200 mg, and panax ginseng extract 50 mg plus vitaminc 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the commoncold.
det||case-2/NN||the-1/DT	nsubjpass||described-27/VBN||case-2/NN	det||male-8/NN||a-4/DT	num||years-6/NNS||nine-5/CD	npadvmod||old-7/JJ||years-6/NNS	amod||male-8/NN||old-7/JJ	prep_of||case-2/NN||male-8/NN	det||history-13/NN||a-10/DT	num||history-13/NN||6-11/CD	nn||history-13/NN||year-12/NN	prep_with||male-8/NN||history-13/NN	amod||infection-17/NN||chronic-15/JJ	nn||infection-17/NN||hbv-16/NN	prep_of||male-8/NN||infection-17/NN	det||years-22/NNS||those-20/DT	num||years-22/NNS||5-21/CD	prep_of||male-8/NN||years-22/NNS	amod||treatment-25/NN||antiviral-24/JJ	prep_with||male-8/NN||treatment-25/NN	auxpass||described-27/VBN||is-26/VBZ	root||ROOT-0/null||described-27/VBN	antiviral-24||hbv-16||no_rel||the case of a nine years old male with a 6 year history of chronic hbv infection, of those 5 years with antiviral treatment is described.
nsubjpass||demonstrated-5/VBN||efficacy-1/NN	prep_of||efficacy-1/NN||iv-ibuprofen-3/NN	auxpass||demonstrated-5/VBN||was-4/VBD	root||ROOT-0/null||demonstrated-5/VBN	agent||demonstrated-5/VBN||measuring-7/VBG	det||patient-9/NN||the-8/DT	poss||assessment-12/NN||patient-9/NN	nn||assessment-12/NN||self-11/NN	dobj||measuring-7/VBG||assessment-12/NN	prep_of||assessment-12/NN||pain-14/NN	vmod||pain-14/NN||using-15/VBG	det||scale-19/NN||a-16/DT	amod||scale-19/NN||visual-17/JJ	amod||scale-19/NN||analog-18/JJ	dobj||using-15/VBG||scale-19/NN	dep||scale-19/NN||vas-21/NN	dep||vas-21/NN||assessed-23/NNP	dep||vas-21/NN||assessed-23/NNP	conj_and||assessed-23/NNP||assessed-23/NNP	prep_with||assessed-23/NNP||movement-25/NN	prep_at||assessed-23/NNP||rest-28/NN	det||scale-34/NN||a-31/DT	amod||scale-34/NN||verbal-32/JJ	nn||scale-34/NN||response-33/NN	dobj||using-15/VBG||scale-34/NN	conj_and||scale-19/NN||scale-34/NN	appos||scale-34/NN||vrs-36/NN	pain-14||ibuprofen--1||yes||efficacy of iv-ibuprofen was demonstrated by measuring the patient's self assessment of pain using a visual analog scale (vas; assessed with movement and at rest) and a verbal response scale (vrs).
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	salivaryhypersecretion-29||paliperidone-6||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
det||increase-2/NN||an-1/DT	nsubj||unlikely-8/JJ||increase-2/NN	nsubj||reduce-10/VB||increase-2/NN	nn||testing-5/NN||hiv-4/NN	prep_in||increase-2/NN||testing-5/NN	advmod||unlikely-8/JJ||alone-6/RB	cop||unlikely-8/JJ||is-7/VBZ	root||ROOT-0/null||unlikely-8/JJ	aux||reduce-10/VB||to-9/TO	xcomp||unlikely-8/JJ||reduce-10/VB	nn||incidence-12/NN||hiv-11/NN	dobj||reduce-10/VB||incidence-12/NN	advmod||incidence-12/NN||substantially-13/RB	det||$-18/NNS||nsw-15/DT	amod||$-18/NNS||gay-16/JJ	num||$-18/NNS||menâ-17/CD	prep_in||incidence-12/NN||$-18/NNS	advmod||need-27/VBP||however-20/RB	det||high-24/JJ||the-22/DT	advmod||high-24/JJ||relatively-23/RB	dep||need-27/VBP||high-24/JJ	nn||levels-26/NNS||testing-25/NN	nsubj||need-27/VBP||levels-26/NNS	nsubj||continue-29/VB||levels-26/NNS	nsubj||prevent-31/VB||levels-26/NNS	dep||incidence-12/NN||need-27/VBP	aux||continue-29/VB||to-28/TO	xcomp||need-27/VBP||continue-29/VB	aux||prevent-31/VB||to-30/TO	xcomp||continue-29/VB||prevent-31/VB	det||increase-33/NN||an-32/DT	dobj||prevent-31/VB||increase-33/NN	prep_in||increase-33/NN||hivinfections-35/NNS	hivinfections-35||hiv-11||no||an increase in hiv testing alone is unlikely to reduce hiv incidence substantially in nsw gay menâ€“ however, the relatively high testing levels need to continue to prevent an increase in hivinfections.
neg||difference-4/NN||no-1/DT	advmod||significant-3/JJ||statistically-2/RB	amod||difference-4/NN||significant-3/JJ	nsubjpass||found-6/VBN||difference-4/NN	auxpass||found-6/VBN||was-5/VBD	root||ROOT-0/null||found-6/VBN	det||groups-12/NNS||the-8/DT	nn||groups-12/NNS||dexamethasone-9/NN	conj_and||dexamethasone-9/NN||placebo-11/NN	nn||groups-12/NNS||placebo-11/NN	prep_between||found-6/VBN||groups-12/NNS	nn||score-15/NN||pain-14/NN	prep_in||found-6/VBN||score-15/NN	prep_in||found-6/VBN||nausea-17/NN	conj_or||score-15/NN||nausea-17/NN	prep_in||found-6/VBN||vomiting-19/NN	conj_or||score-15/NN||vomiting-19/NN	prep_in||found-6/VBN||irritability-21/NN	conj_or||score-15/NN||irritability-21/NN	amod||postoperatively-26/NN||analgesic-24/JJ	nn||postoperatively-26/NN||requirement-25/NN	prep_in||found-6/VBN||postoperatively-26/NN	conj_or||score-15/NN||postoperatively-26/NN	nausea-17||dexamethasone-9||yes||no statistically significant difference was found between the dexamethasone and placebo groups in pain score, nausea, vomiting, irritability, or analgesic requirement postoperatively.
det||strategies-4/NNS||the-2/DT	nn||strategies-4/NNS||prevention-3/NN	prep_of||involve-7/VBP||strategies-4/NNS	nsubj||involve-7/VBP||primordial-6/JJ	root||ROOT-0/null||involve-7/VBP	dobj||involve-7/VBP||improvement-8/NN	amod||status-11/NN||socioeconomic-10/JJ	prep_in||improvement-8/NN||status-11/NN	prep_in||improvement-8/NN||literacy-13/NN	conj_and||status-11/NN||literacy-13/NN	amod||financing-17/NN||adequate-15/JJ	nn||financing-17/NN||healthcare-16/NN	dobj||involve-7/VBP||financing-17/NN	conj_and||improvement-8/NN||financing-17/NN	amod||insurance-21/NN||public-19/JJ	nn||insurance-21/NN||health-20/NN	conj_and||improvement-8/NN||insurance-21/NN	conj_and||financing-17/NN||insurance-21/NN	amod||programme-27/NN||effective-23/JJ	amod||programme-27/NN||national-24/JJ	amod||programme-27/NN||cvd-25/JJ	nn||programme-27/NN||control-26/NN	appos||financing-17/NN||programme-27/NN	nn||policies-31/NNS||smoking-29/NN	nn||policies-31/NNS||control-30/NN	appos||financing-17/NN||policies-31/NNS	amod||control-34/NN||legislative-33/JJ	appos||financing-17/NN||control-34/NN	amod||fats-37/NNS||saturated-36/JJ	prep_of||control-34/NN||fats-37/NNS	amod||fats-40/NNS||trans-39/JJ	appos||financing-17/NN||fats-40/NNS	appos||financing-17/NN||salt-42/NN	conj_and||fats-40/NNS||salt-42/NN	appos||financing-17/NN||alcohol-44/NN	conj_and||fats-40/NNS||alcohol-44/NN	dobj||involve-7/VBP||development-47/NN	conj_and||improvement-8/NN||development-47/NN	prep_of||development-47/NN||facilities-49/NNS	prepc_for||involve-7/VBP||increasing-51/VBG	amod||activity-53/NN||physical-52/JJ	dobj||increasing-51/VBG||activity-53/NN	amod||planning-57/NN||better-55/JJR	amod||planning-57/NN||urban-56/JJ	prep_through||increasing-51/VBG||planning-57/NN	prep_through||increasing-51/VBG||school-based-59/NN	conj_and||planning-57/NN||school-based-59/NN	nn||interventions-62/NNS||worksite-61/NN	prep_through||increasing-51/VBG||interventions-62/NNS	conj_and||planning-57/NN||interventions-62/NNS	alcohol-44||cvd-25||no_rel||of the prevention strategies, primordial involve improvement in socioeconomic status and literacy, adequate healthcare financing and public health insurance, effective national cvd control programme, smoking control policies, legislative control of saturated fats, trans fats, salt and alcohol, and development of facilities for increasing physical activity through better urban planning and school-based and worksite interventions.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	neg||correlation-4/NN||no-3/DT	dobj||found-2/VBD||correlation-4/NN	amod||rates-8/NNS||high-6/JJ	nn||rates-8/NNS||mdr-7/NN	prep_between||correlation-4/NN||rates-8/NNS	nn||incidence-11/NN||tb-10/NN	dobj||found-2/VBD||incidence-11/NN	conj_and||correlation-4/NN||incidence-11/NN	amod||rates-15/NNS||hiv/tb-13/JJ	amod||rates-15/NNS||co-infection-14/JJ	appos||incidence-11/NN||rates-15/NNS	dobj||found-2/VBD||year-18/NN	conj_or||correlation-4/NN||year-18/NN	prep_of||year-18/NN||introduction-20/NN	prep_of||introduction-20/NN||rifampin-22/NN	tb-10||rifampin-22||yes||we found no correlation between high mdr rates and tb incidence, hiv/tb co-infection rates, or year of introduction of rifampin.
mark||use-4/VB||in-1/IN	dep||use-4/VB||order-2/NN	aux||use-4/VB||to-3/TO	advcl||important-19/JJ||use-4/VB	det||combination-6/NN||a-5/DT	dobj||use-4/VB||combination-6/NN	prep_of||combination-6/NN||ivermectin-8/NN	prep_of||combination-6/NN||albendazole-10/NN	conj_and||ivermectin-8/NN||albendazole-10/NN	det||elimination-13/NN||the-12/DT	prep_for||use-4/VB||elimination-13/NN	prep_of||elimination-13/NN||lymphaticfilariasis-15/NNS	nsubj||important-19/JJ||it-17/PRP	nsubj||assess-21/VB||it-17/PRP	cop||important-19/JJ||is-18/VBZ	root||ROOT-0/null||important-19/JJ	aux||assess-21/VB||to-20/TO	xcomp||important-19/JJ||assess-21/VB	det||risk-24/NN||the-22/DT	amod||risk-24/NN||potential-23/JJ	dobj||assess-21/VB||risk-24/NN	amod||events-28/NNS||increased-26/VBN	amod||events-28/NNS||adverse-27/JJ	prep_of||risk-24/NN||events-28/NNS	prep_in||events-28/NNS||individuals-30/NNS	vmod||individuals-30/NNS||infected-31/VBN	preconj||lymphaticfilariasis-34/NNS||both-33/DT	prep_with||infected-31/VBN||lymphaticfilariasis-34/NNS	prep_with||infected-31/VBN||onchocerciasis-36/NNS	conj_and||lymphaticfilariasis-34/NNS||onchocerciasis-36/NNS	onchocerciasis-36||ivermectin-8||yes||in order to use a combination of ivermectin and albendazole for the elimination of lymphaticfilariasis, it is important to assess the potential risk of increased adverse events in individuals infected with both lymphaticfilariasis and onchocerciasis.
amod||appearance-2/NN||palmitate-1/JJ	nsubjpass||determined-11/VBN||appearance-2/NN	nn||rates-5/NNS||oxidation-4/NN	conj_and||appearance-2/NN||rates-5/NNS	nsubjpass||determined-11/VBN||rates-5/NNS	amod||rate-9/NN||glycerol-7/JJ	nn||rate-9/NN||appearance-8/NN	conj_and||appearance-2/NN||rate-9/NN	nsubjpass||determined-11/VBN||rate-9/NN	auxpass||determined-11/VBN||were-10/VBD	root||ROOT-0/null||determined-11/VBN	amod||offspring-15/NN||eleven-13/VBN	amod||offspring-15/NN||healthy-14/JJ	prep_in||determined-11/VBN||offspring-15/NN	num||parents-18/NNS||two-17/CD	prep_of||offspring-15/NN||parents-18/NNS	prep_with||parents-18/NNS||t2d-20/CD	amod||history-24/NN||positive-22/JJ	nn||history-24/NN||family-23/NN	appos||offspring-15/NN||history-24/NN	nn||+-27/NNP||fh-26/NNP	dep||history-24/NN||+-27/NNP	num||subjects-32/NNS||13-30/CD	amod||subjects-32/NNS||healthy-31/JJ	prep_in||determined-11/VBN||subjects-32/NNS	conj_and||offspring-15/NN||subjects-32/NNS	amod||relatives-35/NNS||first-degree-34/JJ	prep_without||subjects-32/NNS||relatives-35/NNS	prep_with||relatives-35/NNS||t2d-37/NNS	dep||t2d-37/NNS||fh-39/RB	num||subjects-44/NNS||12-43/CD	prep_in||determined-11/VBN||subjects-44/NNS	conj_and||offspring-15/NN||subjects-44/NNS	prep_with||subjects-44/NNS||t2d-46/CD	prepc_at||determined-11/VBN||fasting-48/VBG	amod||clamp-53/NN||normoglycemic-51/JJ	amod||clamp-53/NN||hyperinsulinemic-52/JJ	prep_during||determined-11/VBN||clamp-53/NN	amod||intake-58/NN||continuous-56/JJ	amod||intake-58/NN||oral-57/JJ	prep_during||determined-11/VBN||intake-58/NN	conj_and||clamp-53/NN||intake-58/NN	det||meal-63/NN||a-60/DT	amod||meal-63/NN||standard-61/JJ	amod||meal-63/NN||liquid-62/JJ	prep_of||intake-58/NN||meal-63/NN	aux||achieve-65/VB||to-64/TO	vmod||intake-58/NN||achieve-65/VB	vmod||intake-58/NN||achieve-65/VB	conj_and||achieve-65/VB||achieve-65/VB	amod||postprandial-67/JJ||steady-66/JJ	amod||nefa-68/NNS||postprandial-67/JJ	dobj||achieve-65/VB||nefa-68/NNS	dobj||achieve-65/VB||triacylglycerols-70/NNS	conj_and||nefa-68/NNS||triacylglycerols-70/NNS	appos||nefa-68/NNS||tg-72/NN	nn||infusion-78/NN||insulin-77/NN	prep_with||achieve-65/VB||infusion-78/NN	prep_without||achieve-65/VB||infusion-78/NN	aux||maintain-80/VB||to-79/TO	vmod||achieve-65/VB||maintain-80/VB	amod||glycemia-82/NN||similar-81/JJ	dobj||maintain-80/VB||glycemia-82/NN	det||groups-86/NNS||all-84/DT	num||groups-86/NNS||three-85/CD	prep_in||maintain-80/VB||groups-86/NNS	t2d-46||insulin-77||yes||palmitate appearance and oxidation rates and glycerol appearance rate were determined in eleven healthy offspring of two parents with t2d (positive family history, fh+), 13 healthy subjects without first-degree relatives with t2d (fh-) and 12 subjects with t2d at fasting, during normoglycemic hyperinsulinemic clamp and during continuous oral intake of a standard liquid meal to achieve steady postprandial nefa and triacylglycerols (tg) without and with insulin infusion to maintain similar glycemia in all three groups.
nsubj||thromboembolism-10/VBP||objective-1/NN	aux||examine-3/VB||to-2/TO	vmod||objective-1/NN||examine-3/VB	det||risk-5/NN||the-4/DT	dobj||examine-3/VB||risk-5/NN	amod||venous-9/NNS||non-fatal-7/JJ	amod||venous-9/NNS||idiopathic-8/JJ	prep_of||risk-5/NN||venous-9/NNS	root||ROOT-0/null||thromboembolism-10/VBP	amod||users-13/NNS||current-12/JJ	prep_in||thromboembolism-10/VBP||users-13/NNS	det||oralcontraceptive-17/NN||a-15/DT	amod||oralcontraceptive-17/NN||combined-16/VBN	prep_of||users-13/NNS||oralcontraceptive-17/NN	vmod||oralcontraceptive-17/NN||containing-18/VBG	dobj||containing-18/VBG||drospirenone-19/NN	advmod||containing-27/VBG||relative-21/JJ	amod||users-24/NNS||current-23/JJ	prep_to||relative-21/JJ||users-24/NNS	prep_of||users-24/NNS||preparations-26/NNS	vmod||containing-18/VBG||containing-27/VBG	dobj||containing-27/VBG||levonorgestrel-28/NN	thromboembolism-10||drospirenone-19||no||objective to examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oralcontraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel.
amod||receptors-3/NNS||adenosine-1/JJ	amod||receptors-3/NNS||a2a-2/JJ	nsubjpass||thought-8/VBN||receptors-3/NNS	nsubj||interact-10/VB||receptors-3/NNS	appos||receptors-3/NNS||a2ars-5/NNP	auxpass||thought-8/VBN||are-7/VBP	root||ROOT-0/null||thought-8/VBN	aux||interact-10/VB||to-9/TO	xcomp||thought-8/VBN||interact-10/VB	advmod||interact-10/VB||negatively-11/RB	det||receptor-16/NN||the-13/DT	amod||receptor-16/NN||dopamine-14/JJ	amod||receptor-16/NN||d2-15/JJ	prep_with||interact-10/VB||receptor-16/NN	appos||receptor-16/NN||d2r-18/NNP	dep||thought-8/VBN||so-21/IN	amod||antagonists-24/NNS||selective-22/JJ	amod||antagonists-24/NNS||a2ar-23/JJ	nsubj||attracted-26/VBN||antagonists-24/NNS	aux||attracted-26/VBN||have-25/VBP	parataxis||thought-8/VBN||attracted-26/VBN	dobj||attracted-26/VBN||attention-27/NN	nn||treatments-30/NNS||novel-29/NN	prep_as||attracted-26/VBN||treatments-30/NNS	prep_for||treatments-30/NNS||parkinson-32/NN	dep||parkinson-32/NN||sdisease-34/NN	appos||parkinson-32/NN||pd-36/NN	parkinson'sdisease--1||dopamine-14||no_rel||adenosine a2a receptors (a2ars) are thought to interact negatively with the dopamine d2 receptor (d2r), so selective a2ar antagonists have attracted attention as novel treatments for parkinson'sdisease (pd).
amod||doses-2/NNS||large-1/JJ	nsubj||have-5/VBP||doses-2/NNS	nsubj||retain-12/VBP||doses-2/NNS	prep_of||doses-2/NNS||glargine-4/NN	root||ROOT-0/null||have-5/VBP	amod||effects-7/NNS||minimal-6/JJ	dobj||have-5/VBP||effects-7/NNS	nn||flux-10/NN||glucose-9/NN	prep_on||effects-7/NNS||flux-10/NN	conj_and||have-5/VBP||retain-12/VBP	det||action-16/NN||a-13/DT	advmod||hepatospecific-15/JJ||relatively-14/RB	amod||action-16/NN||hepatospecific-15/JJ	dobj||retain-12/VBP||action-16/NN	prep_in||action-16/NN||type2diabetes-18/CD	type2diabetes-18||glargine-4||yes||large doses of glargine have minimal effects on glucose flux and retain a relatively hepatospecific action in type2diabetes.
nsubj||focus-10/VB||efforts-1/NNS	aux||increase-3/VB||to-2/TO	vmod||efforts-1/NNS||increase-3/VB	amod||initiation-5/NN||early-4/JJ	dobj||increase-3/VB||initiation-5/NN	amod||care-8/NN||hiv/aids-7/JJ	prep_of||initiation-5/NN||care-8/NN	aux||focus-10/VB||should-9/MD	root||ROOT-0/null||focus-10/VB	prepc_on||focus-10/VB||addressing-12/VBG	poss||concerns-15/NNS||patient-13/NN	dobj||addressing-12/VBG||concerns-15/NNS	prep_such_as||concerns-15/NNS||stigma-18/NN	nn||effects-22/NNS||drug-20/NN	nn||effects-22/NNS||side-21/NN	prep_such_as||concerns-15/NNS||effects-22/NNS	conj_and||stigma-18/NN||effects-22/NNS	prep_such_as||concerns-15/NNS||disclosure-24/NN	conj_and||stigma-18/NN||disclosure-24/NN	aids--1||hiv--1||no||efforts to increase early initiation of hiv/aids care should focus on addressing patient's concerns such as stigma, drug side effects and disclosure.
det||study-2/NN||this-1/DT	nsubjpass||designed-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||designed-4/VBN||was-3/VBD	root||ROOT-0/null||designed-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||designed-4/VBN||evaluate-6/VB	det||efficacy-8/NN||the-7/DT	dobj||evaluate-6/VB||efficacy-8/NN	dobj||evaluate-6/VB||safety-10/NN	conj_and||efficacy-8/NN||safety-10/NN	amod||mmc-14/NN||mitomycin-c-12/JJ	prep_of||efficacy-8/NN||mmc-14/NN	vmod||mmc-14/NN||augmented-16/VBN	xcomp||augmented-16/VBN||needling-17/VBG	dobj||needling-17/VBG||procedure-18/NN	det||management-21/NN||the-20/DT	prep_in||needling-17/VBG||management-21/NN	amod||bleb-24/NN||failed-23/VBN	prep_of||management-21/NN||bleb-24/NN	prep_after||evaluate-6/VB||trabeculectomy-26/NN	amod||glaucoma-29/NN||congenital-28/JJ	prep_in||evaluate-6/VB||glaucoma-29/NN	glaucoma-29||mmc-14||yes||this study was designed to evaluate the efficacy and safety of mitomycin-c (mmc) augmented needling procedure in the management of failed bleb after trabeculectomy in congenital glaucoma.
nsubjpass||carried-9/VBN||analysis-1/NN	det||spectrum-5/NN||the-3/DT	amod||spectrum-5/NN||different-4/JJ	prep_of||analysis-1/NN||spectrum-5/NN	prep_of||spectrum-5/NN||ois/co-infections-7/NNS	auxpass||carried-9/VBN||were-8/VBD	root||ROOT-0/null||carried-9/VBN	prt||carried-9/VBN||out-10/RP	num||hiv-13/NN||204-12/CD	prep_with||carried-9/VBN||hiv-13/NN	amod||patients-15/NNS||sero-positive-14/JJ	dobj||carried-9/VBN||patients-15/NNS	nsubj||visited-24/VBD||patients-15/NNS	num||males-18/NNS||142-17/CD	dep||patients-15/NNS||males-18/NNS	num||females-21/NNS||62-20/CD	dep||patients-15/NNS||females-21/NNS	conj_and||males-18/NNS||females-21/NNS	rcmod||patients-15/NNS||visited-24/VBD	det||clinic-28/NN||the-25/DT	amod||clinic-28/NN||hiv/aids-26/JJ	nn||clinic-28/NN||apex-27/NN	dobj||visited-24/VBD||clinic-28/NN	det||hospital-33/NN||a-30/DT	amod||hospital-33/NN||tertiary-31/JJ	nn||hospital-33/NN||care-32/NN	prep_in||visited-24/VBD||hospital-33/NN	prep_from||visited-24/VBD||march-35/NN	num||march-35/NN||2006-36/CD	aux||march-38/VB||to-37/TO	vmod||carried-9/VBN||march-38/VB	dobj||march-38/VB||2009-39/CD	aids--1||hiv-13||no||analysis of the different spectrum of ois/co-infections were carried out with 204 hiv sero-positive patients (142 males and 62 females) who visited the hiv/aids apex clinic in a tertiary care hospital from march 2006 to march 2009.
det||end-3/NN||the-2/DT	prep_by||comparable-25/JJ||end-3/NN	det||day-8/NN||the-5/DT	amod||day-8/NN||first-6/JJ	nn||day-8/NN||postoperative-7/NN	prep_of||end-3/NN||day-8/NN	det||proportion-11/NN||the-10/DT	nsubj||comparable-25/JJ||proportion-11/NN	nn||responders-14/NNS||treatment-13/NN	prep_of||proportion-11/NN||responders-14/NNS	vmod||responders-14/NNS||based-15/VBN	nn||satisfaction-18/NN||treatment-17/NN	prep_on||based-15/VBN||satisfaction-18/NN	amod||variable-22/NN||primary-20/JJ	amod||variable-22/NN||efficacy-21/JJ	appos||satisfaction-18/NN||variable-22/NN	cop||comparable-25/JJ||was-24/VBD	root||ROOT-0/null||comparable-25/JJ	det||groups-28/NNS||the-27/DT	prep_between||comparable-25/JJ||groups-28/NNS	num||%-31/NN||78.1-30/CD	dep||groups-28/NNS||%-31/NN	dep||%-31/NN||combination-32/NN	dep||%-35/NN||71.9-34/CD	advmod||%-31/NN||%-35/NN	dep||%-31/NN||tramadol-36/NN	dep||tramadol-36/NN||p-38/NN	dep||0.24-40/CD||=-39/SYM	rcmod||p-38/NN||0.24-40/CD	amod||intensity-45/NN||mean-43/JJ	nn||intensity-45/NN||pain-44/NN	nsubjpass||reduced-66/VBN||intensity-45/NN	dep||intensity-45/NN||rated-47/VBN	det||scale-51/NN||a-49/DT	amod||scale-51/NN||numerical-50/JJ	prep_on||rated-47/VBN||scale-51/NN	prep_from||scale-51/NN||0-53/CD	dep||pain-56/NN||=-54/SYM	neg||pain-56/NN||no-55/DT	rcmod||0-53/CD||pain-56/NN	number||=-59/NN||10-58/CD	amod||pain-62/NN||=-59/NN	dep||imaginable-61/JJ||worst-60/JJS	amod||pain-62/NN||imaginable-61/JJ	prep_to||rated-47/VBN||pain-62/NN	aux||reduced-66/VBN||had-64/VBD	auxpass||reduced-66/VBN||been-65/VBN	conj_and||comparable-25/JJ||reduced-66/VBN	number||â-69/CD||1.7-68/CD	num||2.0-71/CD||â-69/CD	number||2.0-71/CD||±-70/CD	prep_to||reduced-66/VBN||2.0-71/CD	det||groups-74/NNS||both-73/DT	prep_for||reduced-66/VBN||groups-74/NNS	pain-62||tramadol-36||yes||by the end of the first postoperative day, the proportion of treatment responders based on treatment satisfaction (primary efficacy variable) was comparable between the groups (78.1% combination, 71.9% tramadol; p = 0.24) and mean pain intensity (rated on a numerical scale from 0 = no pain to 10 = worst imaginable pain) had been reduced to 1.7 â± 2.0 for both groups.
poss||nanoparticles-5/NNS||ironâˆ-1/NNP	nn||nanoparticles-5/NNS||platinum-3/NN	nn||nanoparticles-5/NNS||alloy-4/NN	nsubj||candidates-13/NNS||nanoparticles-5/NNS	amod||nps-8/NN||fept-7/JJ	appos||nanoparticles-5/NNS||nps-8/NN	cop||candidates-13/NNS||are-10/VBP	advmod||promising-12/JJ||extremely-11/RB	amod||candidates-13/NNS||promising-12/JJ	root||ROOT-0/null||candidates-13/NNS	det||generation-17/NN||the-15/DT	amod||generation-17/NN||next-16/JJ	prep_for||candidates-13/NNS||generation-17/NN	prep_of||generation-17/NN||contrastagents-19/NNS	amod||imaging-27/NN||magnetic-21/JJ	nn||imaging-27/NN||resonance-22/NN	nn||imaging-27/NN||mr-24/NN	amod||imaging-27/NN||diagnostic-26/JJ	prep_for||contrastagents-19/NNS||imaging-27/NN	amod||interventions-30/NNS||mr-guided-29/JJ	prep_for||contrastagents-19/NNS||interventions-30/NNS	conj_and||imaging-27/NN||interventions-30/NNS	amod||ablation-34/NN||hyperthermic-33/JJ	prep_including||candidates-13/NNS||ablation-34/NN	amod||cancers-37/NNS||solid-36/JJ	prep_of||ablation-34/NN||cancers-37/NNS	cancers-37||platinum-3||no_rel||ironâˆ’platinum alloy nanoparticles (fept nps) are extremely promising candidates for the next generation of contrastagents for magnetic resonance (mr) diagnostic imaging and mr-guided interventions, including hyperthermic ablation of solid cancers.
det||incidence-2/NN||the-1/DT	nsubj||lower-17/JJR||incidence-2/NN	conj_and||incidence-2/NN||severity-4/NN	nsubj||lower-17/JJR||severity-4/NN	prep_of||incidence-2/NN||pain-6/NN	det||injection-10/NN||the-8/DT	amod||injection-10/NN||propofol-9/JJ	prep_from||pain-6/NN||injection-10/NN	det||group-14/NN||the-12/DT	nn||group-14/NN||combination-13/NN	prep_in||injection-10/NN||group-14/NN	cop||lower-17/JJR||was-15/VBD	advmod||lower-17/JJR||significantly-16/RB	root||ROOT-0/null||lower-17/JJR	prep_than||lower-17/JJR||that-19/DT	det||remifentanil-22/NN||the-21/DT	prep_in||that-19/DT||remifentanil-22/NN	amod||groups-25/NNS||cold-24/JJ	prep_in||that-19/DT||groups-25/NNS	conj_and||remifentanil-22/NN||groups-25/NNS	pain-6||remifentanil-22||yes||the incidence and severity of pain from the propofol injection in the combination group was significantly lower than that in the remifentanil and cold groups.
prep_in||estimated-6/VBN||pakistan-2/NN	expl||estimated-6/VBN||there-4/EX	auxpass||estimated-6/VBN||are-5/VBP	root||ROOT-0/null||estimated-6/VBN	number||million-8/CD||7-9-7/CD	num||carriers-9/NNS||million-8/CD	dobj||estimated-6/VBN||carriers-9/NNS	nsubjpass||estimated-6/VBN||carriers-9/NNS	prep_of||carriers-9/NNS||hepatitisbvirus-11/NNS	appos||hepatitisbvirus-11/NNS||hbv-13/NN	det||rate-18/NN||a-16/DT	nn||rate-18/NN||carrier-17/NN	prep_with||estimated-6/VBN||rate-18/NN	num||%-21/NN||3-5-20/CD	prep_of||rate-18/NN||%-21/NN	hbv-13||hepatitisbvirus-11||no||in pakistan, there are estimated 7-9 million carriers of hepatitisbvirus (hbv) with a carrier rate of 3-5%.
mark||attempts-8/VBZ||as-1/IN	nsubj||attempts-8/VBZ||patients-2/NNS	det||history-5/NN||a-4/DT	prep_with||patients-2/NNS||history-5/NN	prep_of||history-5/NN||suicide-7/NN	advcl||have-37/VB||attempts-8/VBZ	mark||made-11/VBD||before-9/IN	nsubj||made-11/VBD||treatment-10/NN	advcl||attempts-8/VBZ||made-11/VBD	amod||attempts-13/NNS||new-12/JJ	dobj||made-11/VBD||attempts-13/NNS	det||extent-17/NN||a-15/DT	amod||extent-17/NN||lesser-16/JJR	prep_to||made-11/VBD||extent-17/NN	mark||did-19/VBD||than-18/IN	advcl||made-11/VBD||did-19/VBD	dobj||did-19/VBD||patients-20/NNS	nsubj||started-22/VBD||patients-20/NNS	rcmod||patients-20/NNS||started-22/VBD	amod||behaviour-24/NN||such-23/JJ	dobj||started-22/VBD||behaviour-24/NN	prep_in||started-22/VBD||connection-26/NN	prep_with||started-22/VBD||treatment-28/NN	nsubj||have-37/VB||patients-30/NNS	amod||acne-33/NN||severe-32/JJ	prep_with||patients-30/NNS||acne-33/NN	aux||have-37/VB||should-34/MD	neg||have-37/VB||not-35/RB	advmod||have-37/VB||automatically-36/RB	root||ROOT-0/null||have-37/VB	nn||treatment-39/NN||isotretinoin-38/NN	dobj||have-37/VB||treatment-39/NN	vmod||treatment-39/NN||withheld-40/VBN	det||history-44/NN||a-43/DT	prep_because_of||withheld-40/VBN||history-44/NN	amod||suicide-47/NN||attempted-46/VBN	prep_of||history-44/NN||suicide-47/NN	acne-33||isotretinoin-38||yes||as patients with a history of suicide attempts before treatment made new attempts to a lesser extent than did patients who started such behaviour in connection with treatment, patients with severe acne should not automatically have isotretinoin treatment withheld because of a history of attempted suicide.
det||findings-2/NNS||these-1/DT	nsubj||indicate-3/VBP||findings-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||contain-19/VBP||that-4/IN	amod||women-18/NNS||cvl-5/JJ	amod||hiv-8/NN||healthy-7/JJ	prep_from||cvl-5/JJ||hiv-8/NN	appos||hiv-8/NN||+-10/NNP	prep_from||cvl-5/JJ||hiv-13/NN	conj_and||hiv-8/NN||hiv-13/NN	appos||hiv-8/NN||âˆ-15/NN	nsubj||contain-19/VBP||women-18/NNS	ccomp||indicate-3/VBP||contain-19/VBP	amod||mechanisms-24/NNS||innate-20/JJ	conj_and||innate-20/JJ||adaptive-22/JJ	amod||mechanisms-24/NNS||adaptive-22/JJ	nn||mechanisms-24/NNS||defense-23/NN	dobj||contain-19/VBP||mechanisms-24/NNS	nsubj||inhibit-26/VBP||mechanisms-24/NNS	rcmod||mechanisms-24/NNS||inhibit-26/VBP	dobj||inhibit-26/VBP||hivinfection-27/NN	hivinfection-27||hiv-13||no||these findings indicate that cvl from healthy hiv(+) and hiv(âˆ’) women contain innate and adaptive defense mechanisms that inhibit hivinfection.
det||bioactivity-2/NN||the-1/DT	nsubj||greater-20/JJR||bioactivity-2/NN	det||fraction-6/NN||the-4/DT	amod||fraction-6/NN||composite-5/JJ	prep_of||bioactivity-2/NN||fraction-6/NN	prepc_in||fraction-6/NN||enhancing-8/VBG	det||effect-11/NN||the-9/DT	amod||effect-11/NN||antibacterial-10/JJ	dobj||enhancing-8/VBG||effect-11/NN	prep_of||effect-11/NN||oxacillin-13/NN	prep_against||oxacillin-13/NN||methicillin-resistantstaphylococcusaureus-15/NNS	appos||methicillin-resistantstaphylococcusaureus-15/NNS||mrsa-17/NNP	cop||greater-20/JJR||was-19/VBD	root||ROOT-0/null||greater-20/JJR	mark||extract-30/VB||than-21/IN	nsubj||extract-30/VB||that-22/DT	det||monomer-26/NN||the-24/DT	amod||monomer-26/NN||individual-25/JJ	prep_of||that-22/DT||monomer-26/NN	det||hawthorn-29/NN||the-28/DT	prep_of||monomer-26/NN||hawthorn-29/NN	ccomp||greater-20/JJR||extract-30/VB	prep_in||extract-30/VB||vitro-32/NN	methicillin-resistantstaphylococcusaureus-15||oxacillin-13||no_rel||the bioactivity of the composite fraction in enhancing the antibacterial effect of oxacillin against methicillin-resistantstaphylococcusaureus (mrsa) was greater than that of the individual monomer of the hawthorn extract in vitro .
root||ROOT-0/null||objective-1/NN	aux||determine-3/VB||to-2/TO	dep||objective-1/NN||determine-3/VB	dep||objective-1/NN||determine-3/VB	conj_and||determine-3/VB||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||glucosamine-7/NN	prep_of||effect-5/NN||chondroitin-9/NN	conj_or||glucosamine-7/NN||chondroitin-9/NN	det||two-13/CD||the-12/DT	prep_of||effect-5/NN||two-13/CD	conj_or||glucosamine-7/NN||two-13/CD	prep_in||determine-3/VB||combination-15/NN	amod||pain-18/NN||joint-17/JJ	prep_on||combination-15/NN||pain-18/NN	amod||progression-22/NN||radiological-21/JJ	prep_on||determine-3/VB||progression-22/NN	prep_of||progression-22/NN||disease-24/NN	prep_in||determine-3/VB||osteoarthritis-26/NNS	det||hip-29/NN||the-28/DT	prep_of||osteoarthritis-26/NNS||hip-29/NN	prep_of||osteoarthritis-26/NNS||knee-31/NN	conj_or||hip-29/NN||knee-31/NN	pain-18||chondroitin-9||yes||objective to determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee.
det||concepts-3/NNS||the-1/DT	amod||concepts-3/NNS||presented-2/JJ	nsubj||explain-4/VB||concepts-3/NNS	nsubj||provide-16/VB||concepts-3/NNS	root||ROOT-0/null||explain-4/VB	dobj||explain-4/VB||events-5/NNS	vmod||events-5/NNS||preceding-6/VBG	det||manifestation-9/NN||the-7/DT	amod||manifestation-9/NN||clinical-8/JJ	dobj||preceding-6/VBG||manifestation-9/NN	prep_of||manifestation-9/NN||diseases-11/NNS	amod||years-14/NNS||several-13/JJ	agent||preceding-6/VBG||years-14/NNS	conj_and||explain-4/VB||provide-16/VB	det||rationale-18/NN||a-17/DT	dobj||provide-16/VB||rationale-18/NN	det||use-21/NN||the-20/DT	prep_for||rationale-18/NN||use-21/NN	advmod||available-24/JJ||currently-23/RB	amod||vaccines-25/NNS||available-24/JJ	prep_of||use-21/NN||vaccines-25/NNS	aux||protect-27/VB||to-26/TO	vmod||provide-16/VB||protect-27/VB	amod||diseases-31/NNS||certain-29/JJ	amod||diseases-31/NNS||herv-induced-30/JJ	prep_against||protect-27/VB||diseases-31/NNS	advmod||melanoma-34/JJ||especially-33/RB	acomp||protect-27/VB||melanoma-34/JJ	melanoma-34||vaccines-25||no_rel||the presented concepts explain events preceding the clinical manifestation of diseases by several years and provide a rationale for the use of currently available vaccines to protect against certain herv-induced diseases, especially melanoma.
num||type-3/NN||ten-1/CD	amod||type-3/NN||obese-2/JJ	nsubj||-lrb--11/VBD||type-3/NN	num||patients-6/NNS||2-4/CD	amod||patients-6/NNS||diabetic-5/JJ	nsubjpass||infused-8/VBN||patients-6/NNS	auxpass||infused-8/VBN||were-7/VBD	rcmod||type-3/NN||infused-8/VBN	prep_with||infused-8/VBN||insulin-10/NN	root||ROOT-0/null||-lrb--11/VBD	num||units/h-13/NN||2-12/CD	nsubjpass||infused-34/VBN||units/h-13/NN	nsubjpass||served-51/VBN||units/h-13/NN	num||ml-16/NN||100-15/CD	prep_with||units/h-13/NN||ml-16/NN	number||%-19/NN||5-18/CD	amod||-rrb--21/NNS||%-19/NN	nn||-rrb--21/NNS||dextrose/h-20/NN	prep_of||ml-16/NN||-rrb--21/NNS	number||h.-24/CD||4-23/CD	num||8-26/CD||h.-24/CD	quantmod||8-26/CD||another-25/DT	prep_for||-rrb--21/NNS||8-26/CD	num||type-29/NN||6-28/CD	prep_of||ml-16/NN||type-29/NN	conj_and||-rrb--21/NNS||type-29/NN	num||patients-32/NNS||2-30/CD	amod||patients-32/NNS||diabetic-31/JJ	dep||type-29/NN||patients-32/NNS	auxpass||infused-34/VBN||were-33/VBD	ccomp||-lrb--11/VBD||infused-34/VBN	num||ml-37/NN||100-36/CD	prep_with||infused-34/VBN||ml-37/NN	number||%-40/NN||5-39/CD	amod||dextrose/h-41/NN||%-40/NN	prep_of||ml-37/NN||dextrose/h-41/NN	prep_of||ml-37/NN||saline-43/NN	conj_or||dextrose/h-41/NN||saline-43/NN	num||h-46/NN||4-45/CD	prep_for||ml-37/NN||h-46/NN	advmod||infused-34/VBN||respectively-48/RB	ccomp||-lrb--11/VBD||served-51/VBN	conj_and||infused-34/VBN||served-51/VBN	nn||subjects-54/NNS||control-53/NN	prep_as||served-51/VBN||subjects-54/NNS	insulin-10||obese-2||no_rel||ten obese type 2 diabetic patients were infused with insulin -lrb- 2 units/h with 100 ml of 5 % dextrose/h -rrb- for 4 h. another 8 and 6 type 2 diabetic patients were infused with 100 ml of 5 % dextrose/h or saline for 4 h , respectively , and served as control subjects .
nsubj||necessary-3/JJ||it-1/PRP	nsubj||study-5/VB||it-1/PRP	nsubj||focus-9/VB||it-1/PRP	cop||necessary-3/JJ||is-2/VBZ	root||ROOT-0/null||necessary-3/JJ	aux||study-5/VB||to-4/TO	xcomp||necessary-3/JJ||study-5/VB	amod||enzymes-7/NNS||more-6/JJR	dobj||study-5/VB||enzymes-7/NNS	xcomp||necessary-3/JJ||focus-9/VB	conj_and||study-5/VB||focus-9/VB	dobj||focus-9/VB||them-10/PRP	nsubj||quantify-12/VB||them-10/PRP	nsubj||determine-14/VB||them-10/PRP	aux||quantify-12/VB||to-11/TO	xcomp||focus-9/VB||quantify-12/VB	xcomp||focus-9/VB||determine-14/VB	conj_and||quantify-12/VB||determine-14/VB	poss||activity-16/NN||their-15/PRP$	dobj||quantify-12/VB||activity-16/NN	mark||have-21/VB||in-18/IN	dep||have-21/VB||order-19/NN	aux||have-21/VB||to-20/TO	advcl||necessary-3/JJ||have-21/VB	det||correlation-24/NN||a-22/DT	amod||correlation-24/NN||better-23/JJR	dobj||have-21/VB||correlation-24/NN	amod||features-27/NNS||histological-26/JJ	prep_with||correlation-24/NN||features-27/NNS	det||type-30/NN||this-29/DT	prep_in||have-21/VB||type-30/NN	prep_of||type-30/NN||neoplasm-32/NN	enzymes-7||neoplasm-32||no_rel||it is necessary to study more enzymes and focus them to quantify and determine their activity, in order to have a better correlation with histological features in this type of neoplasm.
advmod||occurred-15/VBD||relative-1/JJ	det||state-5/NN||the-3/DT	amod||state-5/NN||dehydrated-4/JJ	prep_to||relative-1/JJ||state-5/NN	det||decrease-10/NN||a-7/DT	number||%-9/NN||6.5-8/CD	amod||decrease-10/NN||%-9/NN	nsubj||occurred-15/VBD||decrease-10/NN	amod||time-14/NN||treadmill-12/JJ	nn||time-14/NN||performance-13/NN	prep_in||decrease-10/NN||time-14/NN	root||ROOT-0/null||occurred-15/VBD	nn||light-18/NN||crystal-17/NN	prep_with||occurred-15/VBD||light-18/NN	mark||resulted-35/VBD||while-20/IN	nsubj||contains-26/VBZ||replenishment-21/NN	nsubj||resulted-35/VBD||replenishment-21/NN	prep_with||replenishment-21/NN||gatorade-23/NN	rcmod||replenishment-21/NN||contains-26/VBZ	dobj||contains-26/VBZ||fructose-27/NN	dobj||contains-26/VBZ||glucose-29/NN	conj_and||fructose-27/NN||glucose-29/NN	dobj||contains-26/VBZ||sodium-31/NN	conj_and||fructose-27/NN||sodium-31/NN	dobj||contains-26/VBZ||potassium-33/NN	conj_and||fructose-27/NN||potassium-33/NN	advcl||occurred-15/VBD||resulted-35/VBD	det||decrease-40/NN||a-37/DT	num||decrease-40/NN||2.1-38/CD	nn||decrease-40/NN||%-39/NN	prep_in||resulted-35/VBD||decrease-40/NN	dehydrated-4||glucose-29||no||relative to the dehydrated state, a 6.5% decrease in treadmill performance time occurred with crystal light, while replenishment with gatorade, which contains fructose, glucose, sodium and potassium, resulted in a 2.1% decrease.
amod||insulin-5/NN||first-1/JJ	conj_and||first-1/JJ||second-phase-4/JJ	amod||insulin-5/NN||second-phase-4/JJ	nsubj||lower-10/JJR||insulin-5/NN	amod||insulin-5/NN||secretion-6/JJ	amod||insulin-5/NN||c-peptide-8/JJ	conj_and||secretion-6/JJ||c-peptide-8/JJ	cop||lower-10/JJR||were-9/VBD	root||ROOT-0/null||lower-10/JJR	nn||+-13/NNS||ab-12/NN	prep_in||lower-10/JJR||+-13/NNS	prepc_compared_with||lower-10/JJR||with-15/IN	poss||type2diabetes-18/NNS||abâˆ-16/NNP	pobj||lower-10/JJR||type2diabetes-18/NNS	type2diabetes-18||insulin-5||yes||first- and second-phase insulin secretion and c-peptide were lower in ab+ compared with abâˆ’ type2diabetes.
nsubj||preserved-9/VBD||attachment-1/NN	amod||chains-5/NNS||neutral-3/JJ	amod||chains-5/NNS||amide-linked-4/JJ	prep_of||attachment-1/NN||chains-5/NNS	amod||chains-8/NNS||thiourea-containing-7/JJ	prep_of||attachment-1/NN||chains-8/NNS	conj_or||chains-5/NNS||chains-8/NNS	root||ROOT-0/null||preserved-9/VBD	det||affinity-12/NN||the-10/DT	amod||affinity-12/NN||moderate-11/JJ	dobj||preserved-9/VBD||affinity-12/NN	dobj||preserved-9/VBD||efficacy-14/NN	conj_and||affinity-12/NN||efficacy-14/NN	det||subtype-19/NN||the-16/DT	amod||subtype-19/NN||a1-17/JJ	nn||subtype-19/NN||ar-18/NN	prep_at||preserved-9/VBD||subtype-19/NN	expl||was-23/VBD||there-22/EX	conj_but||preserved-9/VBD||was-23/VBD	neg||selectivity-25/NN||no-24/DT	nsubj||was-23/VBD||selectivity-25/NN	det||ar-29/NN||the-27/DT	amod||ar-29/NN||a3-28/JJ	prep_for||selectivity-25/NN||ar-29/NN	ar-29||amide--1||no_rel||attachment of neutral amide-linked chains or thiourea-containing chains preserved the moderate affinity and efficacy at the a1 ar subtype, but there was no selectivity for the a3 ar.
amod||physicians-4/NNS||conclusions-1/JJ	nn||physicians-4/NNS||emergency-2/NN	nn||physicians-4/NNS||department-3/NN	nsubj||tend-5/VBP||physicians-4/NNS	nsubj||underestimate-7/VB||physicians-4/NNS	root||ROOT-0/null||tend-5/VBP	aux||underestimate-7/VB||to-6/TO	xcomp||tend-5/VBP||underestimate-7/VB	det||likelihood-9/NN||the-8/DT	dobj||underestimate-7/VB||likelihood-9/NN	amod||bacterialinfection-12/NN||serious-11/JJ	prep_of||likelihood-9/NN||bacterialinfection-12/NN	amod||children-15/NNS||young-14/JJ	prep_in||underestimate-7/VB||children-15/NNS	prep_with||children-15/NNS||fever-17/NN	vmod||children-15/NNS||leading-19/VBG	aux||undertreatment-21/VB||to-20/TO	xcomp||leading-19/VBG||undertreatment-21/VB	prep_with||undertreatment-21/VB||antibiotics-23/NNS	bacterialinfection-12||antibiotics-23||no_rel||conclusions emergency department physicians tend to underestimate the likelihood of serious bacterialinfection in young children with fever, leading to undertreatment with antibiotics.
det||study-7/NN||this-1/DT	amod||study-7/NN||26-week-2/JJ	amod||study-7/NN||double-blind-4/JJ	amod||study-7/NN||parallel-group-6/JJ	root||ROOT-0/null||study-7/NN	vmod||study-7/NN||randomized-8/VBN	amod||patients-10/NNS||655-9/JJ	dobj||randomized-8/VBN||patients-10/NNS	advmod||controlled-13/JJ||inadequately-12/RB	amod||monotherapy-25/NNS||controlled-13/JJ	amod||monotherapy-25/NNS||type2diabetes-14/JJ	num||arms-17/NNS||four-16/CD	prep_to||type2diabetes-14/JJ||arms-17/NNS	num||alogliptin-20/NN||25-18/CD	nn||alogliptin-20/NN||mg-19/NN	nsubj||-lrb--21/VBZ||alogliptin-20/NN	rcmod||arms-17/NNS||-lrb--21/VBZ	amod||monotherapy-25/NNS||a25-22/JJ	amod||monotherapy-25/NNS||-rrb--23/JJ	nn||monotherapy-25/NNS||q.d.-24/NN	prep_with||randomized-8/VBN||monotherapy-25/NNS	number||mg-28/CD||30-27/CD	num||monotherapy-34/NN||mg-28/CD	amod||monotherapy-34/NN||pioglitazone-29/JJ	amod||monotherapy-34/NN||-lrb--30/JJ	amod||monotherapy-34/NN||p30-31/JJ	amod||monotherapy-34/NN||-rrb--32/JJ	nn||monotherapy-34/NN||q.d.-33/NN	prep_with||randomized-8/VBN||monotherapy-34/NN	conj_or||monotherapy-25/NNS||monotherapy-34/NN	num||a12-39/NNS||12.5-37/CD	amod||a12-39/NNS||-lrb--38/JJ	prep_with||randomized-8/VBN||a12-39/NNS	conj_or||monotherapy-25/NNS||a12-39/NNS	num||-rrb--41/NNS||.5-40/CD	dep||a12-39/NNS||-rrb--41/NNS	num||q.d.-46/NN||25-43/CD	nn||q.d.-46/NN||mg-44/NN	nn||q.d.-46/NN||alogliptin-45/NN	prep_with||randomized-8/VBN||q.d.-46/NN	conj_or||monotherapy-25/NNS||q.d.-46/NN	prep||q.d.-46/NN||plus-47/CC	amod||therapy-54/NN||pioglitazone-48/JJ	nn||therapy-54/NN||-lrb--49/NNP	amod||therapy-54/NN||p30-50/JJ	amod||therapy-54/NN||-rrb--51/JJ	nn||therapy-54/NN||q.d.-52/NN	nn||therapy-54/NN||combination-53/NN	pobj||plus-47/CC||therapy-54/NN	type2diabetes-14||pioglitazone-48||yes||this 26-week , double-blind , parallel-group study randomized 655 patients with inadequately controlled type2diabetes to four arms 25 mg alogliptin -lrb- a25 -rrb- q.d. monotherapy , 30 mg pioglitazone -lrb- p30 -rrb- q.d. monotherapy , or 12.5 -lrb- a12 .5 -rrb- or 25 mg alogliptin q.d. plus pioglitazone -lrb- p30 -rrb- q.d. combination therapy .
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-2/PRP	advmod||investigated-4/VBD||further-3/RBR	root||ROOT-0/null||investigated-4/VBD	nn||toxicity-6/NN||dieldrin-5/NN	dobj||investigated-4/VBD||toxicity-6/NN	det||model-12/NN||a-8/DT	amod||model-12/NN||dopaminergic-9/JJ	amod||model-12/NN||neuronal-10/JJ	nn||model-12/NN||cell-11/NN	prep_in||investigated-4/VBD||model-12/NN	amod||cells-20/NNS||parkinson-14/JJ	nn||cells-20/NNS||sdisease-16/NNP	advmod||cells-20/NNS||namely-18/RB	amod||cells-20/NNS||n27-19/JJ	prep_of||model-12/NN||cells-20/NNS	vmod||investigated-4/VBD||using-22/VBG	dep||cytometric-29/JJ||biochemical-23/JJ	conj_and||cytometric-29/JJ||immunochemical-25/JJ	amod||analyses-30/NNS||immunochemical-25/JJ	conj_and||cytometric-29/JJ||flow-28/NN	amod||analyses-30/NNS||flow-28/NN	amod||analyses-30/NNS||cytometric-29/JJ	dobj||using-22/VBG||analyses-30/NNS	parkinson'sdisease--1||dieldrin-5||no_rel||here we further investigated dieldrin toxicity in a dopaminergic neuronal cell model of parkinson'sdisease, namely n27 cells, using biochemical, immunochemical, and flow cytometric analyses.
nsubj||pathogen-14/NN||staphylococcusaureus-1/NNS	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	prep_including||staphylococcusaureus-1/NNS||s.aureus-5/NNS	vmod||s.aureus-5/NNS||-lrb--6/VBG	nn||-rrb--8/NNS||mrsa-7/NN	dobj||-lrb--6/VBG||-rrb--8/NNS	cop||pathogen-14/NN||is-10/VBZ	det||pathogen-14/NN||an-11/DT	amod||pathogen-14/NN||important-12/JJ	amod||pathogen-14/NN||human-13/JJ	root||ROOT-0/null||pathogen-14/NN	nsubj||produces-16/VBZ||pathogen-14/NN	nsubj||causes-22/VBZ||pathogen-14/NN	rcmod||pathogen-14/NN||produces-16/VBZ	det||variety-18/NN||a-17/DT	dobj||produces-16/VBZ||variety-18/NN	prep_of||variety-18/NN||toxins-20/NNS	rcmod||pathogen-14/NN||causes-22/VBZ	conj_and||produces-16/VBZ||causes-22/VBZ	det||range-25/NN||a-23/DT	amod||range-25/NN||wide-24/JJ	dobj||causes-22/VBZ||range-25/NN	prep_of||range-25/NN||infections-27/NNS	amod||infections-31/NNS||soft-tissue-30/JJ	prep_including||produces-16/VBZ||infections-31/NNS	prep_including||produces-16/VBZ||bacteremia-33/NN	conj_and||infections-31/NNS||bacteremia-33/NN	amod||poisoning-38/NN||staphylococcal-36/JJ	nn||poisoning-38/NN||food-37/NN	prep_including||produces-16/VBZ||poisoning-38/NN	conj_and||infections-31/NNS||poisoning-38/NN	mrsa-7||s.aureus-5||no||staphylococcusaureus , including methicillin-resistant s.aureus -lrb- mrsa -rrb- , is an important human pathogen that produces a variety of toxins and causes a wide range of infections , including soft-tissue infections , bacteremia , and staphylococcal food poisoning .
poss||study-2/NN||our-1/PRP$	nsubj||showed-3/VBD||study-2/NN	root||ROOT-0/null||showed-3/VBD	mark||effective-19/JJ||that-4/IN	number||%-6/NN||1-5/CD	amod||tropicamide-7/NN||%-6/NN	nsubj||effective-19/JJ||tropicamide-7/NN	poss||mechanism-13/NN||its-10/PRP$	amod||mechanism-13/NN||parasympathetic-11/JJ	amod||mechanism-13/NN||antagonistic-12/JJ	prep_with||tropicamide-7/NN||mechanism-13/NN	prep_of||mechanism-13/NN||action-15/NN	cop||effective-19/JJ||was-17/VBD	advmod||effective-19/JJ||more-18/RBR	ccomp||showed-3/VBD||effective-19/JJ	prepc_at||effective-19/JJ||inducing-21/VBG	dobj||inducing-21/VBG||pupillarydilation-22/NN	number||%-25/NN||2.5-24/CD	amod||phenylephrine-26/NN||%-25/NN	prep_than||inducing-21/VBG||phenylephrine-26/NN	det||combination-30/NN||the-29/DT	nsubj||effective-41/JJ||combination-30/NN	number||%-33/NN||1-32/CD	amod||tropicamide-34/NN||%-33/NN	prep_of||combination-30/NN||tropicamide-34/NN	number||%-37/NN||2.5-36/CD	amod||phenylephrine-38/NN||%-37/NN	prep_of||combination-30/NN||phenylephrine-38/NN	conj_and||tropicamide-34/NN||phenylephrine-38/NN	cop||effective-41/JJ||was-39/VBD	advmod||effective-41/JJ||more-40/RBR	conj_and||showed-3/VBD||effective-41/JJ	amod||drops-44/NNS||multiple-43/JJ	prep_than||effective-41/JJ||drops-44/NNS	amod||drops-48/NNS||single-46/JJ	nn||drops-48/NNS||eye-47/NN	prep_of||drops-44/NNS||drops-48/NNS	pupillarydilation-22||tropicamide-34||no||our study showed that 1% tropicamide, with its parasympathetic antagonistic mechanism of action, was more effective at inducing pupillarydilation than 2.5% phenylephrine, and the combination of 1% tropicamide and 2.5% phenylephrine was more effective than multiple drops of single eye drops.
prep_after||insulin-11/NN||accounting-2/NN	prep_for||accounting-2/NN||adiposity-4/NN	amod||factors-8/NNS||other-6/JJ	nn||factors-8/NNS||risk-7/NN	nsubj||insulin-11/NN||factors-8/NNS	cop||insulin-11/NN||were-9/VBD	amod||insulin-11/NN||high-10/JJ	root||ROOT-0/null||insulin-11/NN	conj_and||insulin-11/NN||insulinresistance-13/NN	amod||triglycerides-16/NNPS||high-15/JJ	conj_and||insulin-11/NN||triglycerides-16/NNPS	conj_and||insulin-11/NN||smoking-19/NN	nsubj||amenable-22/JJ||factors-21/NNS	nsubj||lifestyle-24/VB||factors-21/NNS	xcomp||insulin-11/NN||amenable-22/JJ	aux||lifestyle-24/VB||to-23/TO	xcomp||amenable-22/JJ||lifestyle-24/VB	dobj||lifestyle-24/VB||intervention-25/NN	triglycerides-16||insulinresistance-13||no_rel||after accounting for adiposity, other risk factors were high insulin, insulinresistance, high triglycerides, and smoking, factors amenable to lifestyle intervention.
nsubj||pathogens-9/NNS||bacillusanthracis-1/NNS	conj_and||bacillusanthracis-1/NNS||francisellatularensis-3/NNS	nsubj||pathogens-9/NNS||francisellatularensis-3/NNS	conj_and||bacillusanthracis-1/NNS||yersiniapestis-6/NNS	nsubj||pathogens-9/NNS||yersiniapestis-6/NNS	cop||pathogens-9/NNS||are-7/VBP	amod||pathogens-9/NNS||bacterial-8/JJ	root||ROOT-0/null||pathogens-9/NNS	nsubj||cause-12/VB||pathogens-9/NNS	nsubjpass||listed-27/VBN||pathogens-9/NNS	aux||cause-12/VB||can-11/MD	rcmod||pathogens-9/NNS||cause-12/VB	dobj||cause-12/VB||anthrax-13/NN	amod||disease-18/NN||lethal-15/JJ	amod||disease-18/NN||acute-16/JJ	amod||disease-18/NN||pneumonic-17/JJ	dobj||cause-12/VB||disease-18/NN	conj_and||anthrax-13/NN||disease-18/NN	dobj||cause-12/VB||bubonicplague-21/NN	conj_and||anthrax-13/NN||bubonicplague-21/NN	advmod||cause-12/VB||respectively-23/RB	auxpass||listed-27/VBN||are-26/VBP	rcmod||pathogens-9/NNS||listed-27/VBN	conj_and||cause-12/VB||listed-27/VBN	amod||category-30/NN||niaid-29/JJ	prep_as||listed-27/VBN||category-30/NN	det||pathogens-33/NNS||a-31/DT	nn||pathogens-33/NNS||priority-32/NN	dobj||listed-27/VBN||pathogens-33/NNS	amod||use-36/NN||possible-35/JJ	prep_for||pathogens-33/NNS||use-36/NN	amod||weapons-39/NNS||biological-38/JJ	prep_as||use-36/NN||weapons-39/NNS	anthrax-13||bacillusanthracis-1||no||bacillusanthracis , francisellatularensis , and yersiniapestis are bacterial pathogens that can cause anthrax, lethal acute pneumonic disease, and bubonicplague, respectively, and are listed as niaid category a priority pathogens for possible use as biological weapons.
advmod||contributing-15/VBG||particularly-1/RB	det||cell-5/NN||the-3/DT	nn||cell-5/NN||t-4/NN	prep_within||contributing-15/VBG||cell-5/NN	nn||infection-8/NN||compartment-6/NN	nn||infection-8/NN||latent-7/NN	nsubj||contributing-15/VBG||infection-8/NN	nsubj||accelerating-18/VBG||infection-8/NN	prep_with||infection-8/NN||humancytomegalovirus-10/NNS	appos||humancytomegalovirus-10/NNS||cmv-12/NN	aux||contributing-15/VBG||is-14/VBZ	root||ROOT-0/null||contributing-15/VBG	prep||contributing-15/VBG||to-16/TO	conj_and||contributing-15/VBG||accelerating-18/VBG	dobj||accelerating-18/VBG||immunosenescence-19/NN	cmv-12||humancytomegalovirus-10||no||particularly within the t cell compartment latent infection with humancytomegalovirus (cmv) is contributing to and accelerating immunosenescence.
mark||shown-5/VBN||although-1/IN	amod||studies-3/NNS||recent-2/JJ	nsubj||shown-5/VBN||studies-3/NNS	aux||shown-5/VBN||have-4/VBP	advcl||suggest-45/VBP||shown-5/VBN	det||decrease-7/NN||a-6/DT	dobj||shown-5/VBN||decrease-7/NN	amod||hepatitis-10/NN||icteric-9/JJ	prep_in||decrease-7/NN||hepatitis-10/NN	prep_after||shown-5/VBN||administration-12/NN	det||types-15/NNS||both-14/DT	prep_of||administration-12/NN||types-15/NNS	nn||³-18/NNS||î-17/NN	prep_of||types-15/NNS||³-18/NNS	parataxis||shown-5/VBN||globulin-20/NN	prep_in||globulin-20/NN||populations-22/NNS	advmod||result-34/NN||where-23/WRB	nsubj||result-34/NN||acquisition-24/NN	prep_of||acquisition-24/NN||hepatitisbvirus-26/NNS	appos||hepatitisbvirus-26/NNS||hbv-28/NN	cop||result-34/NN||is-30/VBZ	advmod||likely-32/JJ||most-31/RBS	amod||result-34/NN||likely-32/JJ	det||result-34/NN||the-33/DT	rcmod||populations-22/NNS||result-34/NN	amod||transmission-37/NN||nonparenteral-36/JJ	prep_of||result-34/NN||transmission-37/NN	det||data-40/NNS||the-39/DT	nsubj||suggest-45/VBP||data-40/NNS	nsubj||decreases-55/VBZ||data-40/NNS	vmod||data-40/NNS||pertaining-41/VBG	aux||parenteral-43/VB||to-42/TO	xcomp||pertaining-41/VBG||parenteral-43/VB	dobj||parenteral-43/VB||exposure-44/NN	root||ROOT-0/null||suggest-45/VBP	mark||hbig-47/VBG||that-46/IN	ccomp||suggest-45/VBP||hbig-47/VBG	dobj||hbig-47/VBG||delays-48/NNS	det||period-51/NN||the-49/DT	nn||period-51/NN||incubation-50/NN	dep||hbig-47/VBG||period-51/NN	prep_of||period-51/NN||hbv-53/NN	conj_and||suggest-45/VBP||decreases-55/VBZ	det||development-57/NN||the-56/DT	dobj||decreases-55/VBZ||development-57/NN	amod||immunity-60/NN||passive-active-59/JJ	prep_of||development-57/NN||immunity-60/NN	hbv-53||hepatitisbvirus-26||no||although recent studies have shown a decrease in icteric hepatitis after administration of both types of î³-globulin in populations where acquisition of hepatitisbvirus (hbv) is most likely the result of nonparenteral transmission, the data pertaining to parenteral exposure suggest that hbig delays the incubation period of hbv and decreases the development of passive-active immunity.
det||results-2/NNS||these-1/DT	nsubj||provide-3/VBP||results-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||evidence-7/NN||molecular-4/JJ	conj_and||molecular-4/JJ||biochemical-6/JJ	amod||evidence-7/NN||biochemical-6/JJ	dobj||provide-3/VBP||evidence-7/NN	mark||caseation-17/VB||that-8/IN	det||development-10/NN||the-9/DT	nsubj||caseation-17/VB||development-10/NN	det||granuloma-15/NN||the-12/DT	amod||granuloma-15/NN||human-13/JJ	nn||granuloma-15/NN||tb-14/NN	prep_of||development-10/NN||granuloma-15/NN	aux||caseation-17/VB||to-16/TO	ccomp||provide-3/VBP||caseation-17/VB	xcomp||provide-3/VBP||caseation-17/VB	dobj||caseation-17/VB||correlates-18/NNS	amod||dysregulation-21/NN||pathogen-mediated-20/JJ	prep_with||caseation-17/VB||dysregulation-21/NN	nn||metabolism-25/NN||host-23/NN	nn||metabolism-25/NN||lipid-24/NN	prep_of||dysregulation-21/NN||metabolism-25/NN	granuloma-15||lipid-24||no_rel||these results provide molecular and biochemical evidence that the development of the human tb granuloma to caseation correlates with pathogen-mediated dysregulation of host lipid metabolism.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||isoniazid-46||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubj||illness-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||illness-9/NN||is-5/VBZ	det||illness-9/NN||a-6/DT	amod||illness-9/NN||severe-7/JJ	nn||illness-9/NN||respiratory-8/NN	root||ROOT-0/null||illness-9/NN	vmod||illness-9/NN||caused-10/VBN	det||virus-14/NN||a-12/DT	nn||virus-14/NN||novel-13/NN	agent||caused-10/VBN||virus-14/NN	det||sarscoronavirus-17/NNS||the-16/DT	appos||virus-14/NN||sarscoronavirus-17/NNS	appos||sarscoronavirus-17/NNS||sars-cov-19/NNP	sars-3||sars-cov-19||no||severeacuterespiratorysyndrome (sars) is a severe respiratory illness caused by a novel virus, the sarscoronavirus (sars-cov).
mark||influence-4/VBP||because-1/IN	nn||rates-3/NNS||testing-2/NN	nsubj||influence-4/VBP||rates-3/NNS	advcl||determined-17/VBD||influence-4/VBP	dobj||influence-4/VBP||interpretation-5/NN	amod||data-8/NNS||reportable-disease-7/JJ	prep_of||interpretation-5/NN||data-8/NNS	dobj||influence-4/VBP||quality-10/NN	conj_and||interpretation-5/NN||quality-10/NN	nn||care-14/NN||cap-12/NN	nn||care-14/NN||patient-13/NN	prep_of||quality-10/NN||care-14/NN	nsubj||determined-17/VBD||we-16/PRP	root||ROOT-0/null||determined-17/VBD	det||proportion-19/NN||the-18/DT	dobj||determined-17/VBD||proportion-19/NN	nsubjpass||tested-25/VBN||proportion-19/NN	nsubjpass||identified-30/VBN||proportion-19/NN	nsubjpass||determined-35/VBN||proportion-19/NN	nn||patients-22/NNS||cap-21/NN	prep_of||proportion-19/NN||patients-22/NNS	auxpass||tested-25/VBN||were-24/VBD	rcmod||proportion-19/NN||tested-25/VBN	amod||spp.-28/NN||coccidioides-27/JJ	prep_for||tested-25/VBN||spp.-28/NN	rcmod||proportion-19/NN||identified-30/VBN	conj_and||tested-25/VBN||identified-30/VBN	xcomp||identified-30/VBN||testing-31/VBG	dobj||testing-31/VBG||predictors-32/NNS	rcmod||proportion-19/NN||determined-35/VBN	conj_and||tested-25/VBN||determined-35/VBN	det||proportion-37/NN||the-36/DT	dobj||determined-35/VBN||proportion-37/NN	nsubj||had-42/VBD||proportion-37/NN	amod||patients-40/NNS||tested-39/JJ	prep_of||proportion-37/NN||patients-40/NNS	rcmod||proportion-37/NN||had-42/VBD	amod||results-45/NNS||positive-43/JJ	nn||results-45/NNS||coccidioidomycosis-44/NN	dobj||had-42/VBD||results-45/NNS	coccidioidomycosis-44||coccidioides-27||no||because testing rates influence interpretation of reportable-disease data and quality of cap patient care, we determined the proportion of cap patients who were tested for coccidioides spp., identified testing predictors, and determined the proportion of tested patients who had positive coccidioidomycosis results.
vmod||used-12/VBD||using-1/VBG	dobj||using-1/VBG||estimates-2/NNS	det||age-5/NN||the-4/DT	prep_of||estimates-2/NNS||age-5/NN	prep_of||age-5/NN||onset-7/NN	prep_of||onset-7/NN||hivinfection-9/NN	nsubj||used-12/VBD||we-11/PRP	root||ROOT-0/null||used-12/VBD	amod||methods-14/NNS||standard-13/JJ	dobj||used-12/VBD||methods-14/NNS	aux||calculate-16/VB||to-15/TO	vmod||used-12/VBD||calculate-16/VB	det||cost-18/NN||the-17/DT	dobj||calculate-16/VB||cost-18/NN	prep_per||cost-18/NN||disability-20/NN	vmod||disability-20/NN||adjusted-21/VBN	nn||year-23/NN||life-22/NN	dobj||adjusted-21/VBN||year-23/NN	appos||year-23/NN||daly-25/NN	vmod||year-23/NN||saved-27/VBN	det||measure-30/NN||a-29/DT	prep_as||saved-27/VBN||measure-30/NN	prep_of||measure-30/NN||cost-effectiveness-32/NNS	det||type-35/NN||each-34/DT	prep_of||cost-effectiveness-32/NNS||type-35/NN	nn||intervention-39/NN||hiv-37/NN	nn||intervention-39/NN||prevention-38/NN	prep_of||type-35/NN||intervention-39/NN	hivinfection-9||hiv-37||no||using estimates of the age of onset of hivinfection, we used standard methods to calculate the cost per disability adjusted life year (daly) saved as a measure of cost-effectiveness of each type of hiv prevention intervention.
det||sensitivity-3/NN||the-1/DT	amod||sensitivity-3/NN||high-2/JJ	nsubjpass||linked-10/VBN||sensitivity-3/NN	prep_of||sensitivity-3/NN||humans-5/NNS	prep_to||humans-5/NNS||thiaminedeficiency-7/NN	auxpass||linked-10/VBN||is-8/VBZ	advmod||linked-10/VBN||probably-9/RB	root||ROOT-0/null||linked-10/VBN	amod||concentrations-15/NNS||low-12/JJ	amod||concentrations-15/NNS||circulating-13/JJ	nn||concentrations-15/NNS||thiamine-14/NN	prep_to||linked-10/VBN||concentrations-15/NNS	amod||contents-20/NNS||low-17/JJ	nn||contents-20/NNS||thdp-18/NN	nn||contents-20/NNS||tissue-19/NN	prep_to||linked-10/VBN||contents-20/NNS	conj_and||concentrations-15/NNS||contents-20/NNS	thiamine-14||thiaminedeficiency-7||no_rel||the high sensitivity of humans to thiaminedeficiency is probably linked to low circulating thiamine concentrations and low thdp tissue contents.
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	polio--1||polioviruses-31||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
nsubj||revealed-2/VBD||studies-1/NNS	root||ROOT-0/null||revealed-2/VBD	mark||appeared-31/VBD||that-3/IN	det||dose-6/NN||a-5/DT	nsubj||mg/kg-11/VBG||dose-6/NN	prep_of||dose-6/NN||25-8/CD	prep_of||dose-6/NN||75-10/CD	conj_and||25-8/CD||75-10/CD	prepc_at||appeared-31/VBD||mg/kg-11/VBG	det||reduction-14/NN||a-12/DT	amod||reduction-14/NN||considerable-13/JJ	nsubjpass||observed-21/VBN||reduction-14/NN	det||extent-17/NN||the-16/DT	prep_in||reduction-14/NN||extent-17/NN	prep_of||extent-17/NN||diarrhoea-19/NN	auxpass||observed-21/VBN||was-20/VBD	ccomp||mg/kg-11/VBG||observed-21/VBN	cc||observed-21/VBN||but-22/CC	det||dose-25/NN||a-24/DT	prep_at||observed-21/VBN||dose-25/NN	num||mg/kg-28/NN||100-27/CD	prep_of||dose-25/NN||mg/kg-28/NN	det||animals-30/NNS||the-29/DT	nsubj||appeared-31/VBD||animals-30/NNS	ccomp||revealed-2/VBD||appeared-31/VBD	advmod||constipated-33/JJ||completely-32/RB	acomp||appeared-31/VBD||constipated-33/JJ	advmod||subjected-35/VBN||when-34/WRB	advcl||appeared-31/VBD||subjected-35/VBN	amod||diarrhoea-39/NN||castoroil-37/JJ	amod||diarrhoea-39/NN||induced-38/JJ	prep_to||subjected-35/VBN||diarrhoea-39/NN	amod||model-43/NN||intestinal-41/JJ	nn||model-43/NN||motility-42/NN	prep_to||subjected-35/VBN||model-43/NN	conj_and||diarrhoea-39/NN||model-43/NN	constipated-33||castoroil-37||yes||studies revealed that at a dose of 25 and 75 mg/kg a considerable reduction in the extent of diarrhoea was observed but at a dose of 100 mg/kg the animals appeared completely constipated when subjected to castoroil induced diarrhoea and intestinal motility model.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||the-3/DT	dobj||report-2/VBP||case-4/NN	det||man-8/NN||a-6/DT	amod||man-8/NN||35-year-old-7/JJ	prep_of||case-4/NN||man-8/NN	det||form-12/NN||a-10/DT	amod||form-12/NN||severe-11/JJ	prep_with||report-2/VBP||form-12/NN	prep_of||form-12/NN||hemophiliaa-14/NN	nsubj||<-17/VBZ||factorviii-16/NNS	parataxis||report-2/VBP||<-17/VBZ	num||%-19/NN||1-18/CD	dobj||<-17/VBZ||%-19/NN	nsubj||suffering-24/VBG||who-22/WP	aux||suffering-24/VBG||was-23/VBD	dep||report-2/VBP||suffering-24/VBG	amod||hemarthrosis-28/NNS||repetitive-26/JJ	amod||hemarthrosis-28/NNS||spontaneous-27/JJ	prep_from||suffering-24/VBG||hemarthrosis-28/NNS	advmod||suffering-24/VBG||especially-30/RB	poss||joints-34/NNS||his-32/PRP$	nn||joints-34/NNS||knee-33/NN	prep_in||suffering-24/VBG||joints-34/NNS	nsubj||become-38/VBN||joints-34/NNS	aux||become-38/VBN||had-36/VBD	advmod||become-38/VBN||consequently-37/RB	rcmod||joints-34/NNS||become-38/VBN	advmod||susceptible-40/JJ||more-39/RBR	acomp||become-38/VBN||susceptible-40/JJ	prep_to||susceptible-40/JJ||bleeding-42/NN	hemophiliaa-14||factorviii-16||yes||we report the case of a 35-year-old man with a severe form of hemophiliaa (factorviii < 1%), who was suffering from repetitive spontaneous hemarthrosis, especially in his knee joints that had consequently become more susceptible to bleeding.
nsubjpass||excluded-9/VBN||subjects-1/NNS	vmod||subjects-1/NNS||receiving-2/VBG	dobj||receiving-2/VBG||thyroxine-3/NN	num||%-6/NN||10.6-5/CD	appos||thyroxine-3/NN||%-6/NN	auxpass||excluded-9/VBN||were-8/VBD	root||ROOT-0/null||excluded-9/VBN	num||%-12/NN||19.3-11/CD	nsubj||had-18/VBD||%-12/NN	vmod||%-12/NN||had-13/VBN	dobj||had-13/VBN||hypertension-14/NN	number||%-17/NN||43-16/CD	amod||hypertension-14/NN||%-17/NN	parataxis||excluded-9/VBN||had-18/VBD	det||history-21/NN||a-19/DT	nn||history-21/NN||family-20/NN	dobj||had-18/VBD||history-21/NN	prep_for||history-21/NN||hypertension-23/NN	hypertension-23||thyroxine-3||no_rel||subjects receiving thyroxine (10.6%) were excluded; 19.3% had hypertension, 43% had a family history for hypertension.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	vitamind-36||multiplesclerosis-40||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
advmod||potentiated-5/VBD||meanwhile-1/RB	amod||knockdown-4/NN||hpebp4-3/JJ	nsubj||potentiated-5/VBD||knockdown-4/NN	root||ROOT-0/null||potentiated-5/VBD	det||chemosensitization-7/NN||the-6/DT	dobj||potentiated-5/VBD||chemosensitization-7/NN	det||rituximab-10/NN||the-9/DT	prep_of||chemosensitization-7/NN||rituximab-10/NN	amod||cells-13/NNS||b-celllymphoma-12/JJ	prep_in||rituximab-10/NN||cells-13/NNS	prepc_by||potentiated-5/VBD||regulating-15/VBG	det||expression-17/NN||the-16/DT	dobj||regulating-15/VBG||expression-17/NN	amod||e-22/NN||bcl-xl-19/JJ	prep_of||expression-17/NN||cycline-21/JJ	amod||e-22/NN||cycline-21/JJ	conj_and||e-22/NN||cycline-21/JJ	prep_of||expression-17/NN||e-22/NN	prep_of||expression-17/NN||p21waf/cip1-24/NNS	conj_and||e-22/NN||p21waf/cip1-24/NNS	prep_of||expression-17/NN||p53-26/NN	conj_and||e-22/NN||p53-26/NN	det||activation-29/NN||the-28/DT	dobj||regulating-15/VBG||activation-29/NN	conj_and||expression-17/NN||activation-29/NN	prep_of||activation-29/NN||caspase-3-31/JJ	prep_of||activation-29/NN||caspase-9-33/JJ	conj_and||caspase-3-31/JJ||caspase-9-33/JJ	b-celllymphoma-12||rituximab-10||yes||meanwhile, hpebp4 knockdown potentiated the chemosensitization of the rituximab in b-celllymphoma cells by regulating the expression of bcl-xl, cycline e, p21waf/cip1 and p53 and the activation of caspase-3 and caspase-9.
prep_in||showed-13/VBD||contrast-2/NN	det||cancers-9/NNS||the-4/DT	amod||cancers-9/NNS||low-5/JJ	nn||cancers-9/NNS||grade-6/NN	nn||cancers-9/NNS||papillary-7/NN	nn||cancers-9/NNS||thyroid-8/NN	nsubj||showed-13/VBD||cancers-9/NNS	appos||cancers-9/NNS||ptc-11/NN	root||ROOT-0/null||showed-13/VBD	amod||epex-15/NN||membranous-14/JJ	dobj||showed-13/VBD||epex-15/NN	neg||ep-icd-20/NN||no-17/DT	amod||ep-icd-20/NN||detectable-18/JJ	amod||ep-icd-20/NN||nuclear-19/JJ	dobj||showed-13/VBD||ep-icd-20/NN	conj_and||epex-15/NN||ep-icd-20/NN	ptc-11||cancers-9||no_rel||in contrast, the low grade papillary thyroid cancers (ptc) showed membranous epex and no detectable nuclear ep-icd.
nsubj||enterovirus-12/NNS||poliovirus-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||poliovirus-1/NNS||agent-5/NN	prep_of||agent-5/NN||poliomyelitis-7/NNP	cop||enterovirus-12/NNS||is-9/VBZ	det||enterovirus-12/NNS||a-10/DT	amod||enterovirus-12/NNS||human-11/JJ	root||ROOT-0/null||enterovirus-12/NNS	det||member-15/NN||a-14/DT	conj_and||enterovirus-12/NNS||member-15/NN	conj_and||enterovirus-12/NNS||member-15/NN	conj_and||member-15/NN||member-15/NN	det||family-18/NN||the-17/DT	prep_of||member-15/NN||family-18/NN	prep_of||family-18/NN||picornaviridae-20/NN	det||viruses-27/NNS||the-23/DT	advmod||rapidly-25/RB||most-24/RBS	advmod||evolving-26/VBG||rapidly-25/RB	amod||viruses-27/NNS||evolving-26/VBG	prep_among||member-15/NN||viruses-27/NNS	vmod||viruses-27/NNS||known-28/VBN	poliomyelitis-7||poliovirus-1||no||poliovirus, the causative agent of poliomyelitis, is a human enterovirus and a member of the family of picornaviridae and among the most rapidly evolving viruses known.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||significant-2/JJ	nsubj||estimated-9/VBD||correlation-3/NN	nsubj||mr-15/VBP||correlation-3/NN	advmod||visible-6/JJ||microscopically-5/RB	amod||droplets-8/NNS||visible-6/JJ	nn||droplets-8/NNS||lipid-7/NN	prep_between||correlation-3/NN||droplets-8/NNS	root||ROOT-0/null||estimated-9/VBD	amod||staining-13/NN||nile-11/JJ	amod||staining-13/NN||red-12/JJ	prep_by||estimated-9/VBD||staining-13/NN	conj_and||estimated-9/VBD||mr-15/VBP	amod||signals-18/NNS||visible-16/JJ	nn||signals-18/NNS||lipid-17/NN	nsubjpass||observed-20/VBN||signals-18/NNS	auxpass||observed-20/VBN||was-19/VBD	ccomp||mr-15/VBP||observed-20/VBN	amod||carcinomas-24/NNS||metastatic-22/JJ	nn||carcinomas-24/NNS||lung-23/NN	prep_in||observed-20/VBN||carcinomas-24/NNS	dep||carcinomas-24/NNS||p-26/VBN	dep||0.01-28/CD||=-27/SYM	ccomp||p-26/VBN||0.01-28/CD	vmod||estimated-9/VBD||indicating-31/VBG	mark||mr-35/VBP||that-32/IN	det||proton-34/NN||the-33/DT	nsubj||mr-35/VBP||proton-34/NN	ccomp||indicating-31/VBG||mr-35/VBP	amod||signals-38/NNS||visible-36/JJ	nn||signals-38/NNS||lipid-37/NN	nsubj||arise-39/VBP||signals-38/NNS	ccomp||mr-35/VBP||arise-39/VBP	amod||droplets-43/NNS||cytoplasmic-41/JJ	nn||droplets-43/NNS||lipid-42/NN	prep_from||arise-39/VBP||droplets-43/NNS	lipid-42||carcinomas-24||no_rel||a significant correlation between microscopically visible lipid droplets estimated by nile red staining and mr visible lipid signals was observed in metastatic lung carcinomas ( p = 0.01), indicating that the proton mr visible lipid signals arise from cytoplasmic lipid droplets.
det||composition-3/NN||the-1/DT	nn||composition-3/NN||lipid-2/NN	nsubjpass||altered-7/VBN||composition-3/NN	prep_of||composition-3/NN||rafts-5/NNS	auxpass||altered-7/VBN||is-6/VBZ	root||ROOT-0/null||altered-7/VBN	nn||models-10/NNS||cell-9/NN	prep_in||altered-7/VBN||models-10/NNS	nsubj||responsible-16/JJ||models-10/NNS	prep_of||models-10/NNS||gaucherdisease-12/NN	aux||responsible-16/JJ||may-14/MD	cop||responsible-16/JJ||be-15/VB	rcmod||models-10/NNS||responsible-16/JJ	amod||lipid-19/NN||impaired-18/VBN	prep_for||responsible-16/JJ||lipid-19/NN	nn||observed-23/NN||protein-21/NN	amod||observed-23/NN||sorting-22/VBG	prep_for||responsible-16/JJ||observed-23/NN	conj_and||lipid-19/NN||observed-23/NN	det||disorder-26/NN||this-25/DT	prep_in||lipid-19/NN||disorder-26/NN	conj_and||altered-7/VBN||consequently-29/RB	dep||consequently-29/RB||pathology-30/RB	gaucherdisease-12||lipid-19||no_rel||the lipid composition of rafts is altered in cell models of gaucherdisease which may be responsible for impaired lipid and protein sorting observed in this disorder, and consequently pathology.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	interleukin-2-6||rheumatoidarthritis-55||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||revealed-2/VBD||studies-1/NNS	root||ROOT-0/null||revealed-2/VBD	mark||appeared-31/VBD||that-3/IN	det||dose-6/NN||a-5/DT	nsubj||mg/kg-11/VBG||dose-6/NN	prep_of||dose-6/NN||25-8/CD	prep_of||dose-6/NN||75-10/CD	conj_and||25-8/CD||75-10/CD	prepc_at||appeared-31/VBD||mg/kg-11/VBG	det||reduction-14/NN||a-12/DT	amod||reduction-14/NN||considerable-13/JJ	nsubjpass||observed-21/VBN||reduction-14/NN	det||extent-17/NN||the-16/DT	prep_in||reduction-14/NN||extent-17/NN	prep_of||extent-17/NN||diarrhoea-19/NN	auxpass||observed-21/VBN||was-20/VBD	ccomp||mg/kg-11/VBG||observed-21/VBN	cc||observed-21/VBN||but-22/CC	det||dose-25/NN||a-24/DT	prep_at||observed-21/VBN||dose-25/NN	num||mg/kg-28/NN||100-27/CD	prep_of||dose-25/NN||mg/kg-28/NN	det||animals-30/NNS||the-29/DT	nsubj||appeared-31/VBD||animals-30/NNS	ccomp||revealed-2/VBD||appeared-31/VBD	advmod||constipated-33/JJ||completely-32/RB	acomp||appeared-31/VBD||constipated-33/JJ	advmod||subjected-35/VBN||when-34/WRB	advcl||appeared-31/VBD||subjected-35/VBN	amod||diarrhoea-39/NN||castoroil-37/JJ	amod||diarrhoea-39/NN||induced-38/JJ	prep_to||subjected-35/VBN||diarrhoea-39/NN	amod||model-43/NN||intestinal-41/JJ	nn||model-43/NN||motility-42/NN	prep_to||subjected-35/VBN||model-43/NN	conj_and||diarrhoea-39/NN||model-43/NN	diarrhoea-39||castoroil-37||no||studies revealed that at a dose of 25 and 75 mg/kg a considerable reduction in the extent of diarrhoea was observed but at a dose of 100 mg/kg the animals appeared completely constipated when subjected to castoroil induced diarrhoea and intestinal motility model.
det||risk-2/NN||the-1/DT	nsubj||increased-8/VBN||risk-2/NN	amod||emergence-6/NN||adefovirdipivoxil-4/JJ	nn||emergence-6/NN||resistance-5/NN	prep_of||risk-2/NN||emergence-6/NN	aux||increased-8/VBN||has-7/VBZ	root||ROOT-0/null||increased-8/VBN	amod||patients-13/NNS||lamivudine-resistant-10/JJ	amod||patients-13/NNS||hepatitisb-11/JJ	amod||patients-13/NNS||infected-12/JJ	prep_in||increased-8/VBN||patients-13/NNS	hepatitisb-11||lamivudine--1||yes||the risk of adefovirdipivoxil resistance emergence has increased in lamivudine-resistant hepatitisb infected patients.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||involved-12/VBN||that-5/IN	amod||capsid-7/NN||hiv-1-6/JJ	nsubjpass||involved-12/VBN||capsid-7/NN	dep||capsid-7/NN||ca-9/MD	auxpass||involved-12/VBN||is-11/VBZ	ccomp||show-4/VBP||involved-12/VBN	prepc_in||involved-12/VBN||facilitating-14/VBG	dobj||facilitating-14/VBG||hivinfection-15/NN	amod||cells-18/NNS||nondividing-17/VBG	prep_of||hivinfection-15/NN||cells-18/NNS	mark||disrupt-25/VB||because-19/IN	amod||changes-21/NNS||aminoacid-20/JJ	nsubj||disrupt-25/VB||changes-21/NNS	advmod||disrupt-25/VB||on-22/RB	aux||disrupt-25/VB||ca-23/MD	advmod||disrupt-25/VB||severely-24/RB	advcl||involved-12/VBN||disrupt-25/VB	det||independence-28/NN||the-26/DT	amod||independence-28/NN||cell-cycle-27/JJ	dobj||disrupt-25/VB||independence-28/NN	prep_of||independence-28/NN||hiv-30/NN	hivinfection-15||hiv-30||no||here, we show that hiv-1 capsid (ca) is involved in facilitating hivinfection of nondividing cells because aminoacid changes on ca severely disrupt the cell-cycle independence of hiv.
nsubj||lower-3/VB||exercise-1/NN	aux||lower-3/VB||can-2/MD	root||ROOT-0/null||lower-3/VB	xcomp||lower-3/VB||circulating-4/VBG	nsubj||responsible-12/JJ||levels-5/NNS	prep_of||levels-5/NNS||estrogen-7/NN	det||hormone-11/NN||the-9/DT	amod||hormone-11/NN||female-10/JJ	appos||estrogen-7/NN||hormone-11/NN	xcomp||circulating-4/VBG||responsible-12/JJ	nn||proliferation-15/NN||tumor-14/NN	prep_for||responsible-12/JJ||proliferation-15/NN	det||form-19/NN||the-17/DT	amod||form-19/NN||estrogen-sensitive-18/JJ	prep_in||proliferation-15/NN||form-19/NN	det||disease-22/NN||the-21/DT	prep_of||form-19/NN||disease-22/NN	tumor-14||hormone-11||no_rel||exercise can lower circulating levels of estrogen, the female hormone responsible for tumor proliferation in the estrogen-sensitive form of the disease.
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||information-5/NN||useful-4/JJ	dobj||provide-3/VBP||information-5/NN	prepc_for||provide-3/VBP||elucidating-7/VBG	det||mechanism-10/NN||the-8/DT	amod||mechanism-10/NN||complicated-9/JJ	dobj||elucidating-7/VBG||mechanism-10/NN	nn||disposition-13/NN||toxin-12/NN	prep_of||mechanism-10/NN||disposition-13/NN	amod||state-16/NN||renaldisease-15/JJ	prep_in||elucidating-7/VBG||state-16/NN	toxin-12||renaldisease-15||no_rel||these findings provide useful information for elucidating the complicated mechanism of toxin disposition in renaldisease state.
det||end-3/NN||the-2/DT	prep_at||superior-10/JJ||end-3/NN	amod||treatment-6/NN||48-week-5/JJ	prep_of||end-3/NN||treatment-6/NN	nsubj||superior-10/JJ||tenofovir-8/NN	nsubj||adefovir-12/VB||tenofovir-8/NN	cop||superior-10/JJ||was-9/VBD	root||ROOT-0/null||superior-10/JJ	aux||adefovir-12/VB||to-11/TO	xcomp||superior-10/JJ||adefovir-12/VB	det||suppression-16/NN||the-14/DT	amod||suppression-16/NN||hbv-dna-15/JJ	prep_at||adefovir-12/VB||suppression-16/NN	nn||rr-20/NN||patients-18/NNS	amod||rr-20/NN||-LSB--19/JJ	prep_in||suppression-16/NN||rr-20/NN	dep||2.59-22/NNS||=-21/SYM	dep||rr-20/NN||2.59-22/NNS	number||%-25/NN||95-24/CD	amod||ci-26/NN||%-25/NN	dep||suppression-16/NN||ci-26/NN	number||.67-29/CD||1.01-6-28/CD	dep||ci-26/NN||.67-29/CD	vmod||ci-26/NN||p-32/VBN	dep||-RSB--35/NNS||=-33/SYM	num||-RSB--35/NNS||0.05-34/CD	ccomp||p-32/VBN||-RSB--35/NNS	hbv--1||tenofovir-8||yes||at the end of 48-week treatment, tenofovir was superior to adefovir at the hbv-dna suppression in patients[rr = 2.59; 95%ci(1.01-6.67), p = 0.05].
prep_in||show-5/VBP||addition-2/NN	nsubj||show-5/VBP||we-4/PRP	root||ROOT-0/null||show-5/VBP	mark||outperforms-10/VBZ||that-6/IN	det||signature-9/NN||the-7/DT	nn||signature-9/NN||dm-8/NN	nsubj||outperforms-10/VBZ||signature-9/NN	nsubj||performs-22/VBZ||signature-9/NN	ccomp||show-5/VBP||outperforms-10/VBZ	amod||signatures-16/NNS||many-11/JJ	advmod||used-13/JJ||widely-12/RB	amod||signatures-16/NNS||used-13/JJ	nn||signatures-16/NNS||breast-14/NN	nn||signatures-16/NNS||cancer-15/NN	dobj||outperforms-10/VBZ||signatures-16/NNS	amod||power-19/NN||predictive-18/JJ	prep_in||outperforms-10/VBZ||power-19/NN	ccomp||show-5/VBP||performs-22/VBZ	conj_and||outperforms-10/VBZ||performs-22/VBZ	acomp||performs-22/VBZ||comparably-23/RB	amod||signatures-27/NNS||other-25/JJ	amod||signatures-27/NNS||proliferation-based-26/JJ	prep_to||comparably-23/RB||signatures-27/NNS	cancer-15||dm-8||no_rel||in addition, we show that the dm signature outperforms many widely used breast cancer signatures in predictive power, and performs comparably to other proliferation-based signatures.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	nsubj||estimate-5/VB||objective-2/NN	nsubj||determine-26/VB||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||estimate-5/VB||to-4/TO	xcomp||was-3/VBD||estimate-5/VB	det||proportion-7/NN||the-6/DT	dobj||estimate-5/VB||proportion-7/NN	prep_of||proportion-7/NN||idus-9/NNS	det||diagnosis-14/NN||a-11/DT	amod||diagnosis-14/NN||late-12/JJ	nn||diagnosis-14/NN||hiv-13/NN	prep_with||idus-9/NNS||diagnosis-14/NN	dep||idus-9/NNS||aids-16/VBZ	dobj||aids-16/VBZ||diagnosis-17/NN	num||months-20/NNS||12-19/CD	prep_within||aids-16/VBZ||months-20/NNS	nn||diagnosis-23/NN||hiv-22/NN	prep_of||months-20/NNS||diagnosis-23/NN	xcomp||was-3/VBD||determine-26/VB	conj_and||estimate-5/VB||determine-26/VB	det||factors-28/NNS||the-27/DT	dobj||determine-26/VB||factors-28/NNS	vmod||factors-28/NNS||associated-29/VBN	nn||progression-32/NN||disease-31/NN	prep_with||associated-29/VBN||progression-32/NN	nn||diagnosis-35/NN||hiv-34/NN	prep_after||associated-29/VBN||diagnosis-35/NN	aids-16||hiv-34||no||our objective was to estimate the proportion of idus with a late hiv diagnosis (aids diagnosis within 12 months of hiv diagnosis) and determine the factors associated with disease progression after hiv diagnosis.
nsubj||are-9/VBP||children-1/NNS	advmod||infected-3/JJ||chronically-2/RB	amod||children-1/NNS||infected-3/JJ	prep_with||infected-3/JJ||hepatitisbvirus-5/NNS	appos||hepatitisbvirus-5/NNS||hbv-7/NN	root||ROOT-0/null||are-9/VBP	amod||risk-12/NN||high-11/JJ	prep_at||are-9/VBP||risk-12/NN	amod||liverdisease-15/NN||progressive-14/JJ	prep_of||risk-12/NN||liverdisease-15/NN	hbv-7||hepatitisbvirus-5||no||children chronically infected with hepatitisbvirus (hbv) are at high risk of progressive liverdisease.
mark||shown-5/VBN||although-1/IN	amod||monotherapy-3/NN||docetaxel-2/JJ	nsubj||shown-5/VBN||monotherapy-3/NN	aux||shown-5/VBN||has-4/VBZ	advcl||controversial-38/JJ||shown-5/VBN	amod||benefits-7/NNS||clinical-6/JJ	dobj||shown-5/VBN||benefits-7/NNS	advmod||treated-10/JJ||previously-9/RB	amod||patients-11/NNS||treated-10/JJ	prep_for||shown-5/VBN||patients-11/NNS	amod||non-smallcelllungcancer-14/NN||advanced-13/VBN	prep_with||patients-11/NNS||non-smallcelllungcancer-14/NN	dep||patients-11/NNS||nsclc-16/JJ	det||efficacy-20/NN||the-19/DT	nsubj||controversial-38/JJ||efficacy-20/NN	nn||chemotherapy-24/NN||salvage-22/NN	amod||chemotherapy-24/NN||docetaxel-23/JJ	prep_of||efficacy-20/NN||chemotherapy-24/NN	amod||patients-27/NNS||elderly-26/JJ	prep_for||chemotherapy-24/NN||patients-27/NNS	prep_for||chemotherapy-24/NN||patients-29/NNS	conj_or||patients-27/NNS||patients-29/NNS	amod||status-33/NN||poor-31/JJ	nn||status-33/NN||performance-32/NN	prep_with||patients-27/NNS||status-33/NN	appos||status-33/NN||ps-35/NN	cop||controversial-38/JJ||is-37/VBZ	root||ROOT-0/null||controversial-38/JJ	non-smallcelllungcancer-14||docetaxel-23||yes||although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-smallcelllungcancer (nsclc), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with poor performance status (ps) is controversial.
nsubj||results-7/VBZ||infection-1/NN	prep_with||infection-1/NN||mycobacteriumtuberculosis-3/NNS	appos||mycobacteriumtuberculosis-3/NNS||mtb-5/NN	root||ROOT-0/null||results-7/VBZ	amod||outcomes-11/NNS||different-9/JJ	amod||outcomes-11/NNS||clinical-10/JJ	prep_in||results-7/VBZ||outcomes-11/NNS	vmod||outcomes-11/NNS||ranging-12/VBG	amod||containment-15/NN||asymptomatic-14/JJ	prep_from||ranging-12/VBG||containment-15/NN	advmod||progressing-18/VBG||rapidly-17/RB	prepc_to||ranging-12/VBG||progressing-18/VBG	dobj||progressing-18/VBG||tuberculosis-19/NNP	appos||tuberculosis-19/NNP||tb-21/NN	tuberculosis-19||mtb-5||no||infection with mycobacteriumtuberculosis ( mtb ) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (tb).
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	ccomp||compared-36/VBN||â-5/VBP	dobj||â-5/VBP||$-6/$	amod||hospital-10/NN||saint-louis-9/JJ	prep_at||$-6/$||hospital-10/NN	nsubjpass||compared-36/VBN||paris-12/NNS	dep||compared-36/VBN||france-14/JJ	num||patients-18/NNS||15-16/CD	nn||patients-18/NNS||african-17/NN	nsubjpass||compared-36/VBN||patients-18/NNS	prep_with||patients-18/NNS||kpd-20/NN	det||period-28/NN||an-22/DT	amod||period-28/NN||average-23/JJ	amod||period-28/NN||10.5-month-24/JJ	amod||period-28/NN||insulin-free-25/JJ	amod||period-28/NN||near-normoglycemic-26/JJ	nn||period-28/NN||remission-27/NN	prep_with||kpd-20/NN||period-28/NN	dep||period-28/NN||mean-30/VB	dobj||mean-30/VB||a1c-31/NNS	number||%-33/NN||6.2-32/CD	amod||a1c-31/NNS||%-33/NN	auxpass||compared-36/VBN||were-35/VBD	root||ROOT-0/null||compared-36/VBN	num||subjects-40/NNS||17-38/CD	nn||subjects-40/NNS||control-39/NN	prep_with||compared-36/VBN||subjects-40/NNS	vmod||subjects-40/NNS||matched-41/VBN	nn||bmi-47/NN||age-43/NN	dep||bmi-47/NN||sex-45/NN	prep_for||matched-41/VBN||bmi-47/NN	nn||origin-51/NN||geographical-50/NN	prep_for||matched-41/VBN||origin-51/NN	conj_and||bmi-47/NN||origin-51/NN	kpd-20||insulin--1||yes||research design and methods â€”at saint-louis hospital, paris, france, 15 african patients with kpd with an average 10.5-month insulin-free near-normoglycemic remission period (mean a1c 6.2%) were compared with 17 control subjects matched for age, sex, bmi, and geographical origin.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||lidocaine-19||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
det||study-3/NN||this-2/DT	prep_in||focused-6/VBD||study-3/NN	nsubj||focused-6/VBD||we-5/PRP	nsubj||define-11/VB||we-5/PRP	root||ROOT-0/null||focused-6/VBD	amod||dcs-9/NN||dermal-8/JJ	prep_on||focused-6/VBD||dcs-9/NN	aux||define-11/VB||to-10/TO	xcomp||focused-6/VBD||define-11/VB	det||model-28/NN||the-12/DT	amod||model-28/NN||in-13/IN	nn||mechanisms-15/NNS||vivo-14/NN	dep||in-13/IN||mechanisms-15/NNS	nn||pathogenesis-19/NNS||metal-17/NN	nn||pathogenesis-19/NNS||allergy-18/NN	prep_of||mechanisms-15/NNS||pathogenesis-19/NNS	det||nickel-23/NN||a-21/DT	nn||nickel-23/NN||mouse-22/NN	prep_in||pathogenesis-19/NNS||nickel-23/NN	appos||nickel-23/NN||ni-25/NN	nn||model-28/NN||allergy-27/NN	dobj||define-11/VB||model-28/NN	allergy-27||allergy-27||no||in this study, we focused on dermal dcs to define the in vivo mechanisms of metal allergy pathogenesis in a mouse nickel (ni) allergy model.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||evaluated-7/VBD||study-4/NN	nsubj||evaluated-7/VBD||we-6/PRP	root||ROOT-0/null||evaluated-7/VBD	det||effect-9/NN||the-8/DT	dobj||evaluated-7/VBD||effect-9/NN	amod||activation-12/NN||dlpfc-11/JJ	prep_of||effect-9/NN||activation-12/NN	dep||evaluated-7/VBD||through-14/IN	pobj||through-14/IN||rtms-15/NNS	amod||control-19/NN||nociceptive-18/JJ	prep_on||evaluated-7/VBD||control-19/NN	det||model-22/NN||a-21/DT	prep_in||control-19/NN||model-22/NN	amod||pain-25/NN||capsaicin-induced-24/JJ	prep_of||model-22/NN||pain-25/NN	pain-25||capsaicin--1||yes||in the present study, we evaluated the effect of dlpfc activation (through rtms) on nociceptive control in a model of capsaicin-induced pain.
vmod||found-12/VBD||using-1/VBG	amod||mice-4/NNS||athymic-2/JJ	amod||mice-4/NNS||nude-3/JJ	dobj||using-1/VBG||mice-4/NNS	det||model-9/NN||an-6/DT	advmod||model-9/NN||in-7/RB	amod||model-9/NN||vivo-8/JJ	prep_as||using-1/VBG||model-9/NN	nsubj||found-12/VBD||we-11/PRP	root||ROOT-0/null||found-12/VBD	mark||reduces-25/VBZ||that-13/IN	csubj||reduces-25/VBZ||feeding-14/VBG	iobj||feeding-14/VBG||animals-15/NNS	det||diet-20/NN||the-16/DT	number||%-18/NN||5-17/CD	amod||diet-20/NN||%-18/NN	amod||diet-20/NN||fishoil-supplemented-19/JJ	dobj||feeding-14/VBG||diet-20/NN	num||weeks-23/NNS||6-22/CD	prep_for||diet-20/NN||weeks-23/NNS	advmod||reduces-25/VBZ||significantly-24/RB	ccomp||found-12/VBD||reduces-25/VBZ	det||growth-27/NN||the-26/DT	dobj||reduces-25/VBZ||growth-27/NN	amod||cells-33/NNS||mcf-7-29/JJ	amod||cells-33/NNS||human-30/JJ	nn||cells-33/NNS||breast-31/NN	nn||cells-33/NNS||cancer-32/NN	prep_of||growth-27/NN||cells-33/NNS	prep_in||growth-27/NN||vivo-35/NN	prep_through||reduces-25/VBZ||inhibition-37/NN	nn||proliferation-41/NN||cancer-39/NN	nn||proliferation-41/NN||cell-40/NN	prep_of||inhibition-37/NN||proliferation-41/NN	prep_through||reduces-25/VBZ||promotion-45/NN	conj_and||inhibition-37/NN||promotion-45/NN	nn||death-48/NN||cell-47/NN	prep_of||promotion-45/NN||death-48/NN	fishoil--1||cancer-39||no_rel||using athymic nude mice as an in vivo model, we found that feeding animals the 5% fishoil-supplemented diet for 6 weeks significantly reduces the growth of mcf-7 human breast cancer cells in vivo through inhibition of cancer cell proliferation as well as promotion of cell death.
amod||participants-3/NNS||attention-control-1/JJ	nn||participants-3/NNS||group-2/NN	nsubj||received-4/VBD||participants-3/NNS	nsubj||hiv/aids-26/VBZ||participants-3/NNS	root||ROOT-0/null||received-4/VBD	num||sessions-8/NNS||six-5/CD	amod||sessions-8/NNS||2-h-6/JJ	nn||sessions-8/NNS||group-7/NN	nsubj||unrelated-17/JJ||sessions-8/NNS	prep_of||sessions-8/NNS||videos-10/NNS	prep_of||sessions-8/NNS||discussion-12/NN	conj_and||videos-10/NNS||discussion-12/NN	nn||issues-16/NNS||msm-14/NN	nn||issues-16/NNS||community-15/NN	prep_of||sessions-8/NNS||issues-16/NNS	xcomp||received-4/VBD||unrelated-17/JJ	nn||use-20/NN||substance-19/NN	prep_to||unrelated-17/JJ||use-20/NN	amod||risk-23/NN||sexual-22/JJ	appos||use-20/NN||risk-23/NN	conj_and||received-4/VBD||hiv/aids-26/VBZ	aids--1||hiv--1||no||attention-control group participants received six 2-h group sessions of videos and discussion of msm community issues unrelated to substance use, sexual risk, and hiv/aids.
nsubj||disease-6/NN||lymedisease-1/NN	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||multi-organ-4/JJ	nn||disease-6/NN||infection-5/NN	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	amod||lato-11/NN||borreliaburgdorferi-9/JJ	amod||lato-11/NN||sensu-10/JJ	agent||caused-7/VBN||lato-11/NN	lymedisease-1||borreliaburgdorferi-9||no||lymedisease is a multi-organ infection disease caused by borreliaburgdorferi sensu lato.
amod||mutants-2/NNS||spontaneous-1/JJ	nsubjpass||isolated-16/VBN||mutants-2/NNS	nsubjpass||found-18/VBN||mutants-2/NNS	prep_of||mutants-2/NNS||mycobacteriumtuberculosis-4/NNS	nsubj||resistant-7/JJ||mycobacteriumtuberculosis-4/NNS	cop||resistant-7/JJ||were-6/VBD	rcmod||mycobacteriumtuberculosis-4/NNS||resistant-7/JJ	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-tuberculosis-10/JJ	prep_to||resistant-7/JJ||drugs-11/NNS	amod||drugs-11/NNS||ethionamide-12/JJ	amod||drugs-11/NNS||isoniazid-14/JJ	conj_and||ethionamide-12/JJ||isoniazid-14/JJ	auxpass||isolated-16/VBN||were-15/VBD	root||ROOT-0/null||isolated-16/VBN	conj_and||isolated-16/VBN||found-18/VBN	prep_to||isolated-16/VBN||map-20/NN	prep_to||isolated-16/VBN||msha-22/NN	det||gene-25/NN||a-24/DT	appos||msha-22/NN||gene-25/NN	vmod||gene-25/NN||encoding-26/VBG	det||enzyme-29/NN||the-27/DT	amod||enzyme-29/NN||first-28/JJ	dobj||encoding-26/VBG||enzyme-29/NN	vmod||enzyme-29/NN||involved-30/VBN	det||biosynthesis-33/NNS||the-32/DT	prep_in||involved-30/VBN||biosynthesis-33/NNS	prep_of||biosynthesis-33/NNS||mycothiol-35/NN	det||thiol-40/NN||a-37/DT	amod||thiol-40/NN||major-38/JJ	amod||thiol-40/NN||low-molecular-weight-39/JJ	appos||mycothiol-35/NN||thiol-40/NN	prep_in||thiol-40/NN||m.tuberculosis-42/NNS	tuberculosis--1||mycobacteriumtuberculosis-4||no||spontaneous mutants of mycobacteriumtuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to msha , a gene encoding the first enzyme involved in the biosynthesis of mycothiol , a major low-molecular-weight thiol in m.tuberculosis .
mark||remain-7/VBP||although-1/IN	amod||laxatives-3/NNS||osmotic-2/JJ	nsubj||remain-7/VBP||laxatives-3/NNS	prep_such_as||laxatives-3/NNS||polyethyleneglycol-6/NN	advcl||appear-17/VBP||remain-7/VBP	xcomp||remain-7/VBP||mainstay-8/NN	amod||agents-12/NNS||several-10/JJ	amod||agents-12/NNS||new-11/JJ	nsubj||target-14/VBP||agents-12/NNS	nsubj||appear-17/VBP||agents-12/NNS	rcmod||agents-12/NNS||target-14/VBP	amod||mechanisms-16/NNS||different-15/JJ	dobj||target-14/VBP||mechanisms-16/NNS	root||ROOT-0/null||appear-17/VBP	xcomp||appear-17/VBP||promising-18/VBG	dep||activator-22/NN||such-19/PDT	amod||activator-22/NN||as-20/IN	amod||activator-22/NN||chloride-channel-21/JJ	dobj||promising-18/VBG||activator-22/NN	appos||activator-22/NN||lubiprostone-24/NN	amod||agonist-29/NN||guanylate-27/JJ	nn||agonist-29/NN||cyclase-28/NN	dobj||promising-18/VBG||agonist-29/NN	conj_and||activator-22/NN||agonist-29/NN	appos||agonist-29/NN||linaclotide-31/NN	amod||agonist-35/NN||5ht4-34/JJ	dobj||promising-18/VBG||agonist-35/NN	conj_and||activator-22/NN||agonist-35/NN	appos||agonist-35/NN||prucalopride-37/NN	amod||î-43/NN||peripherally-41/JJ	amod||î-43/NN||acting-42/JJ	dobj||promising-18/VBG||î-43/NN	conj_and||activator-22/NN||î-43/NN	dep||î-43/NN||1/4-44/CD	amod||antagonists-48/NNS||opioid-46/JJ	nn||antagonists-48/NNS||receptor-47/NN	dep||activator-22/NN||antagonists-48/NNS	dep||antagonists-48/NNS||alvimopan-50/JJ	dep||antagonists-48/NNS||methylnaltrexone-52/JJ	conj_and||alvimopan-50/JJ||methylnaltrexone-52/JJ	amod||constipation-56/NN||opioid-induced-55/JJ	prep_for||antagonists-48/NNS||constipation-56/NN	constipation-56||polyethyleneglycol-6||yes||although osmotic laxatives such as polyethyleneglycol remain mainstay, several new agents that target different mechanisms appear promising such as chloride-channel activator (lubiprostone), guanylate cyclase agonist (linaclotide), 5ht4 agonist (prucalopride), and peripherally acting î¼-opioid receptor antagonists (alvimopan and methylnaltrexone) for opioid-induced constipation.
mark||explored-16/VBN||while-1/IN	amod||therapies-4/NNS||many-2/JJ	nn||therapies-4/NNS||complimentary-3/NN	nsubjpass||explored-16/VBN||therapies-4/NNS	prep_including||therapies-4/NNS||phytoestrogens-7/NNS	prep_including||therapies-4/NNS||blackcohosh-9/NN	conj_and||phytoestrogens-7/NNS||blackcohosh-9/NN	prep_including||therapies-4/NNS||dehydroepiandrosterone-12/NN	conj_and||phytoestrogens-7/NNS||dehydroepiandrosterone-12/NN	aux||explored-16/VBN||have-14/VBP	auxpass||explored-16/VBN||been-15/VBN	advcl||recommended-26/VBN||explored-16/VBN	det||treatment-19/NN||the-18/DT	prep_for||explored-16/VBN||treatment-19/NN	prep_of||treatment-19/NN||hotflashes-21/NNS	nsubjpass||recommended-26/VBN||none-23/NN	aux||recommended-26/VBN||can-24/MD	auxpass||recommended-26/VBN||be-25/VB	root||ROOT-0/null||recommended-26/VBN	det||time-29/NN||this-28/DT	prep_at||recommended-26/VBN||time-29/NN	hotflashes-21||blackcohosh-9||yes||while many complimentary therapies, including phytoestrogens, blackcohosh, and dehydroepiandrosterone, have been explored for the treatment of hotflashes; none can be recommended at this time.
poss||recommendations-2/NNS||their-1/PRP$	nsubj||included-3/VBD||recommendations-2/NNS	root||ROOT-0/null||included-3/VBD	dep||make-12/VB||1-5/LS	det||country-10/NN||every-7/DT	amod||country-10/NN||dengue-8/JJ	amod||country-10/NN||endemic-9/JJ	nsubj||make-12/VB||country-10/NN	aux||make-12/VB||should-11/MD	dep||included-3/VBD||make-12/VB	dobj||make-12/VB||reporting-13/NN	amod||cases-16/NNS||dengue-15/JJ	prep_of||reporting-13/NN||cases-16/NNS	det||government-19/NN||the-18/DT	prep_to||make-12/VB||government-19/NN	amod||government-19/NN||mandatory-20/JJ	dep||developed-30/VBN||2-23/LS	amod||systems-27/NNS||electronic-25/JJ	nn||systems-27/NNS||reporting-26/NN	nsubjpass||developed-30/VBN||systems-27/NNS	nsubjpass||used-32/VBN||systems-27/NNS	aux||developed-30/VBN||should-28/MD	auxpass||developed-30/VBN||be-29/VB	parataxis||make-12/VB||developed-30/VBN	parataxis||make-12/VB||used-32/VBN	conj_and||developed-30/VBN||used-32/VBN	nsubj||include-43/VB||3-35/NNP	amod||data-41/NNS||minimum-38/JJ	nn||data-41/NNS||dengue-39/NN	nn||data-41/NNS||surveillance-40/NN	prep_at||3-35/NNP||data-41/NNS	aux||include-43/VB||should-42/MD	conj_and||included-3/VBD||include-43/VB	dobj||include-43/VB||incidence-44/NN	nn||rates-47/NNS||hospitalization-46/NN	appos||incidence-44/NN||rates-47/NNS	appos||rates-47/NNS||deaths-49/NNS	nn||group-52/NN||age-51/NN	prep_by||include-43/VB||group-52/NN	dep||completed-61/VBN||4-55/LS	amod||studies-58/NNS||additional-57/JJ	nsubjpass||completed-61/VBN||studies-58/NNS	nsubj||check-63/VB||studies-58/NNS	aux||completed-61/VBN||should-59/MD	auxpass||completed-61/VBN||be-60/VB	conj_and||included-3/VBD||completed-61/VBN	aux||check-63/VB||to-62/TO	xcomp||completed-61/VBN||check-63/VB	det||sensitivity-65/NN||the-64/DT	dobj||check-63/VB||sensitivity-65/NN	det||system-68/NN||the-67/DT	prep_of||sensitivity-65/NN||system-68/NN	dep||share-75/VB||5-71/CD	nsubj||share-75/VB||laboratories-73/NNS	aux||share-75/VB||should-74/MD	conj_and||included-3/VBD||share-75/VB	dobj||share-75/VB||expertise-76/NN	dobj||share-75/VB||data-78/NNS	conj_and||expertise-76/NN||data-78/NNS	appos||tests-83/NNS||6-81/CD	dep||expertise-76/NN||tests-83/NNS	nsubj||identify-85/VBP||tests-83/NNS	rcmod||tests-83/NNS||identify-85/VBP	nsubjpass||used-89/VBN||denguevirus-86/NNS	aux||used-89/VBN||should-87/MD	auxpass||used-89/VBN||be-88/VB	ccomp||identify-85/VBP||used-89/VBN	prep_in||used-89/VBN||patients-91/NNS	prep_with||patients-91/NNS||fever-93/NN	num||days-96/NNS||four-95/CD	prep_for||fever-93/NN||days-96/NNS	cc||less-98/JJR||or-97/CC	num||days-96/NNS||less-98/JJR	nn||tests-101/NNS||antibody-100/NN	nsubjpass||used-104/VBN||tests-101/NNS	nsubj||diagnose-109/VB||tests-101/NNS	aux||used-104/VBN||should-102/MD	auxpass||used-104/VBN||be-103/VB	conj_and||included-3/VBD||used-104/VBN	prep_after||used-104/VBN||day-106/NN	num||day-106/NN||4-107/CD	aux||diagnose-109/VB||to-108/TO	xcomp||used-104/VBN||diagnose-109/VB	dobj||diagnose-109/VB||dengue-110/NN	appos||detection-117/NN||7-114/CD	amod||detection-117/NN||early-116/JJ	nsubj||goals-125/NNS||detection-117/NN	conj_and||detection-117/NN||prediction-119/NN	nsubj||goals-125/NNS||prediction-119/NN	amod||outbreaks-122/NNS||dengue-121/JJ	prep_of||prediction-119/NN||outbreaks-122/NNS	aux||goals-125/NNS||should-123/MD	cop||goals-125/NNS||be-124/VB	conj_and||included-3/VBD||goals-125/NNS	amod||systems-129/NNS||national-127/JJ	nn||systems-129/NNS||surveillance-128/NN	prep_for||goals-125/NNS||systems-129/NNS	dengue-121||denguevirus-86||no||their recommendations included (1) every dengue endemic country should make reporting of dengue cases to the government mandatory; (2) electronic reporting systems should be developed and used; (3) at minimum dengue surveillance data should include incidence, hospitalization rates, deaths by age group; (4) additional studies should be completed to check the sensitivity of the system; (5) laboratories should share expertise and data; (6) tests that identify denguevirus should be used in patients with fever for four days or less and antibody tests should be used after day 4 to diagnose dengue; and (7) early detection and prediction of dengue outbreaks should be goals for national surveillance systems.
num||participants-3/NNS||503-2/CD	prep_of||%-19/NN||participants-3/NNS	det||prevalences-7/NNS||the-5/DT	amod||prevalences-7/NNS||overall-6/JJ	nsubj||%-19/NN||prevalences-7/NNS	nn||infection-10/NN||tb-9/NN	prep_of||prevalences-7/NNS||infection-10/NN	prep_of||prevalences-7/NNS||hivinfection-12/NN	conj_and||infection-10/NN||hivinfection-12/NN	amod||co-infection-16/NN||tb/hiv-15/JJ	prep_of||prevalences-7/NNS||co-infection-16/NN	conj_and||infection-10/NN||co-infection-16/NN	cop||%-19/NN||were-17/VBD	num||%-19/NN||57-18/CD	root||ROOT-0/null||%-19/NN	number||%-22/NN||4.2-21/CD	amod||%-19/NN||%-22/NN	conj_and||%-19/NN||%-22/NN	num||%-26/NN||2.2-25/CD	conj_and||%-19/NN||%-26/NN	advmod||%-19/NN||respectively-28/RB	neg||differences-32/NNS||no-30/DT	amod||differences-32/NNS||significant-31/JJ	nsubj||observed-42/JJ||differences-32/NNS	nn||group-35/NN||risk-34/NN	prep_by||differences-32/NNS||group-35/NN	nn||0.05-39/NNP||p-37/NNP	nn||0.05-39/NNP||>-38/NNP	appos||group-35/NN||0.05-39/NNP	cop||observed-42/JJ||were-41/VBD	parataxis||%-19/NN||observed-42/JJ	hivinfection-12||hiv--1||no||of 503 participants, the overall prevalences of tb infection, hivinfection, and tb/hiv co-infection were 57%, 4.2%, and 2.2%, respectively; no significant differences by risk group (p>0.05) were observed.
advmod||observed-34/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-34/VBN||correlation-11/NN	amod||antigen-15/NN||hepatitisb-13/JJ	nn||antigen-15/NN||surface-14/NN	prep_between||correlation-11/NN||antigen-15/NN	appos||antigen-15/NN||hbsag-17/NN	vmod||correlation-11/NN||stimulated-19/VBN	amod||expression-22/NN||il-2-20/JJ	nn||expression-22/NN||gene-21/NN	dobj||stimulated-19/VBN||expression-22/NN	advmod||detectable-25/JJ||as-24/RB	dobj||stimulated-19/VBN||detectable-25/JJ	amod||expression-22/NN||detectable-25/JJ	conj_and||expression-22/NN||detectable-25/JJ	prep_in||detectable-25/JJ||wb-27/NN	amod||titers-32/NNS||specific-30/JJ	nn||titers-32/NNS||antibody-31/NN	dobj||stimulated-19/VBN||titers-32/NNS	conj_and||expression-22/NN||titers-32/NNS	auxpass||observed-34/VBN||was-33/VBD	root||ROOT-0/null||observed-34/VBN	prep_in||observed-34/VBN||donors-36/NNS	vmod||donors-36/NNS||vaccinated-37/VBN	amod||virus-40/NN||hepatitisb-39/JJ	prep_against||vaccinated-37/VBN||virus-40/NN	appos||virus-40/NN||hbv-42/NN	num||months-46/NNS||six-45/CD	prep_between||virus-40/NN||months-46/NNS	num||years-49/NNS||twenty-48/CD	prep_between||virus-40/NN||years-49/NNS	conj_and||months-46/NNS||years-49/NNS	det||tests-52/NNS||the-51/DT	prep_before||vaccinated-37/VBN||tests-52/NNS	il-2-20||hbv-42||no_rel||importantly, a highly significant (p = 0.000009) correlation between hepatitisb surface antigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisb virus (hbv) between six months and twenty years before the tests.
amod||levels-3/NNS||phytanic-1/JJ	nn||levels-3/NNS||acid-2/NN	nsubj||contribute-5/VB||levels-3/NNS	aux||contribute-5/VB||could-4/MD	root||ROOT-0/null||contribute-5/VB	amod||differences-10/NNS||cross-species-7/JJ	conj_and||cross-species-7/JJ||sex-specific-9/JJ	amod||differences-10/NNS||sex-specific-9/JJ	prep_to||contribute-5/VB||differences-10/NNS	amod||transcriptomes-16/NNS||human-12/JJ	conj_and||human-12/JJ||great-14/JJ	amod||transcriptomes-16/NNS||great-14/JJ	nn||transcriptomes-16/NNS||ape-15/NN	prep_in||contribute-5/VB||transcriptomes-16/NNS	advmod||metabolism-23/NN||especially-18/RB	det||metabolism-23/NN||those-19/DT	amod||metabolism-23/NN||related-20/VBN	prep_to||related-20/VBN||lipid-22/NN	appos||transcriptomes-16/NNS||metabolism-23/NN	cross--1||lipid-22||no_rel||phytanic acid levels could contribute to cross-species and sex-specific differences in human and great ape transcriptomes, especially those related to lipid metabolism.
num||studies-3/NNS||two-1/CD	amod||studies-3/NNS||pivotal-2/JJ	nsubj||demonstrated-5/VBN||studies-3/NNS	aux||demonstrated-5/VBN||have-4/VBP	root||ROOT-0/null||demonstrated-5/VBN	det||efficacy-7/NN||the-6/DT	dobj||demonstrated-5/VBN||efficacy-7/NN	prep_of||efficacy-7/NN||fondaparinux-9/NN	det||myocardialinfarction-31/NN||an-11/DT	amod||myocardialinfarction-31/NN||anticoagulant-12/JJ	det||setting-15/NN||the-14/DT	prep_in||anticoagulant-12/JJ||setting-15/NN	prep_of||setting-15/NN||acs-17/NN	advmod||oasis-5-20/JJ||namely-19/RB	conj_and||anticoagulant-12/JJ||oasis-5-20/JJ	amod||myocardialinfarction-31/NN||oasis-5-20/JJ	amod||acs-24/NN||non-st-22/JJ	nn||acs-24/NN||elevation-23/NN	prep_in||oasis-5-20/JJ||acs-24/NN	conj_and||anticoagulant-12/JJ||oasis-6-27/JJ	amod||myocardialinfarction-31/NN||oasis-6-27/JJ	nn||elevation-30/NN||st-29/NN	prep_in||oasis-6-27/JJ||elevation-30/NN	prep_as||demonstrated-5/VBN||myocardialinfarction-31/NN	appos||myocardialinfarction-31/NN||mi-33/NN	myocardialinfarction-31||anticoagulant-12||no_rel||two pivotal studies have demonstrated the efficacy of fondaparinux as an anticoagulant in the setting of acs, namely oasis-5 in non-st elevation acs, and oasis-6 in st elevation myocardialinfarction (mi).
det||prevalence-2/NN||the-1/DT	nsubj||%-7/NN||prevalence-2/NN	prep_of||prevalence-2/NN||isoniazid-resistance-4/NN	cop||%-7/NN||was-5/VBD	num||%-7/NN||14.2-6/CD	root||ROOT-0/null||%-7/NN	dep||%-7/NN||n-9/VBN	dep||21-11/CD||=-10/SYM	ccomp||n-9/VBN||21-11/CD	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-7/NN||ci-16/NN	num||%-20/NN||9.0-20-18/CD	num||%-20/NN||.9-19/CD	appos||ci-16/NN||%-20/NN	det||prevalence-24/NN||the-23/DT	conj_and||%-7/NN||prevalence-24/NN	number||8.8-27/CD||mdr-tb-26/CD	num||%-28/NN||8.8-27/CD	prep_of||prevalence-24/NN||%-28/NN	dep||%-28/NN||n-30/VBN	dep||13-32/CD||=-31/SYM	ccomp||n-30/VBN||13-32/CD	number||%-36/NN||95-35/CD	amod||ci-37/NN||%-36/NN	dep||prevalence-24/NN||ci-37/NN	num||%-41/NN||4.8-14-39/CD	num||%-41/NN||.6-40/CD	appos||ci-37/NN||%-41/NN	tb--1||isoniazid--1||yes||the prevalence of isoniazid-resistance was 14.2% (n = 21) (95%ci, 9.0-20.9%) and the prevalence of mdr-tb 8.8% (n = 13) (95%ci, 4.8-14.6%).
nn||prevention-3/NN||stroke-2/NN	prep_for||associated-21/VBN||prevention-3/NN	prep_in||prevention-3/NN||patients-5/NNS	vmod||patients-5/NNS||suffering-6/VBG	prep_from||suffering-6/VBG||atrialfibrillation-8/NN	nsubjpass||associated-21/VBN||dabigatran-10/NN	vmod||dabigatran-10/NN||administered-11/VBN	det||dose-14/NN||a-13/DT	prep_at||administered-11/VBN||dose-14/NN	number||mg-17/CD||110-16/CD	prep_of||dose-14/NN||mg-17/CD	advmod||daily-19/JJ||twice-18/RB	advmod||mg-17/CD||daily-19/JJ	auxpass||associated-21/VBN||was-20/VBD	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||rates-23/NNS	prep_of||rates-23/NNS||stroke-25/NN	amod||embolism-28/NN||systemic-27/JJ	prep_with||associated-21/VBN||embolism-28/NN	conj_and||rates-23/NNS||embolism-28/NN	nsubj||similar-31/JJ||embolism-28/NN	cop||similar-31/JJ||were-30/VBD	rcmod||embolism-28/NN||similar-31/JJ	prep_to||similar-31/JJ||those-33/DT	vmod||those-33/DT||associated-34/VBN	prep_with||associated-34/VBN||warfarin-36/NN	amod||rates-42/NNS||lower-41/JJR	prep_with||associated-34/VBN||rates-42/NNS	conj_and||warfarin-36/NN||rates-42/NNS	prep_of||rates-42/NNS||hemorrhage-44/NN	stroke-25||warfarin-36||yes||for stroke prevention in patients suffering from atrialfibrillation, dabigatran administered at a dose of 110 mg twice daily was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of hemorrhage.
prep_in||enhanced-7/VBD||summary-2/NN	nsubj||enhanced-7/VBD||c-4/SYM	conj_and||c-4/SYM||ecg-6/NN	nsubj||enhanced-7/VBD||ecg-6/NN	root||ROOT-0/null||enhanced-7/VBD	det||effect-10/NN||the-8/DT	amod||effect-10/NN||antibacterial-9/JJ	dobj||enhanced-7/VBD||effect-10/NN	nn||²-13/NNS||î-12/NN	prep_of||effect-10/NN||²-13/NNS	dep||effect-10/NN||lactamantibiotics-15/NNS	prep_against||lactamantibiotics-15/NNS||mrsa-17/NN	prep_in||enhanced-7/VBD||vitro-19/NN	prep_in||enhanced-7/VBD||in-21/IN	conj_and||vitro-19/NN||in-21/IN	pobj||in-21/IN||vivo-22/NN	nsubjpass||related-27/VBN||vivo-22/NN	aux||related-27/VBN||might-25/MD	auxpass||related-27/VBN||be-26/VB	rcmod||vivo-22/NN||related-27/VBN	det||accumulation-31/NN||the-29/DT	amod||accumulation-31/NN||increased-30/VBN	prep_to||related-27/VBN||accumulation-31/NN	prep_of||accumulation-31/NN||antibiotics-33/NNS	prep_within||antibiotics-33/NNS||mrsa-35/NN	prep_via||mrsa-35/NN||suppression-37/NN	amod||pumpsâ-41/NNS||important-39/JJ	nn||pumpsâ-41/NNS||efflux-40/NN	nn||expression-45/NN||pumpsâ-41/NNS	amod||expression-45/NN||$-42/$	dep||$-42/$||™-43/JJ	nn||expression-45/NN||gene-44/NN	prep_of||suppression-37/NN||expression-45/NN	lactamantibiotics-15||mrsa-35||no_rel||in summary, c and ecg enhanced the antibacterial effect of î²-lactamantibiotics against mrsa in vitro and in vivo , which might be related to the increased accumulation of antibiotics within mrsa via suppression of important efflux pumpsâ€™ gene expression.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||outcome-12/NN||the-9/DT	amod||outcome-12/NN||long-term-10/JJ	nn||outcome-12/NN||treatment-11/NN	dobj||investigate-8/VB||outcome-12/NN	prep_of||outcome-12/NN||lamivudine-14/NN	prepc_in||investigate-8/VB||preventing-16/VBG	nn||reactivation-18/NN||hbv-17/NN	dobj||preventing-16/VBG||reactivation-18/NN	poss||morbidity-22/NN||its-20/PRP$	amod||morbidity-22/NN||associated-21/JJ	dobj||preventing-16/VBG||morbidity-22/NN	conj_and||reactivation-18/NN||morbidity-22/NN	prepc_according_to||preventing-16/VBG||to-24/TO	amod||status-26/NN||hbeag-25/JJ	pobj||preventing-16/VBG||status-26/NN	hbv-17||lamivudine-14||yes||the aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing hbv reactivation and its associated morbidity according to hbeag status.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
nn||fixation-2/NN||formaldehyde-1/NN	nsubj||remains-5/VBZ||fixation-2/NN	conj_and||fixation-2/NN||paraffin-embedding-4/NN	nsubj||remains-5/VBZ||paraffin-embedding-4/NN	root||ROOT-0/null||remains-5/VBZ	det||technique-10/NN||the-6/DT	advmod||used-9/VBN||most-7/RBS	advmod||used-9/VBN||widely-8/RB	amod||technique-10/NN||used-9/VBN	xcomp||remains-5/VBZ||technique-10/NN	amod||specimens-15/NNS||processing-12/VBG	nn||specimens-15/NNS||cancer-13/NN	nn||specimens-15/NNS||tissue-14/NN	prep_for||technique-10/NN||specimens-15/NNS	amod||examination-18/NN||pathologic-17/JJ	prep_for||specimens-15/NNS||examination-18/NN	det||study-21/NN||the-20/DT	prep_for||technique-10/NN||study-21/NN	conj_and||specimens-15/NNS||study-21/NN	nn||morphology-24/NN||tissue-23/NN	prep_of||study-21/NN||morphology-24/NN	amod||preservation-28/NN||archival-27/JJ	prep_for||technique-10/NN||preservation-28/NN	conj_and||specimens-15/NNS||preservation-28/NN	cancer-13||formaldehyde-1||no_rel||formaldehyde fixation and paraffin-embedding remains the most widely used technique for processing cancer tissue specimens for pathologic examination, the study of tissue morphology, and archival preservation.
amod||scores-4/NNS||verbal-1/JJ	amod||scores-4/NNS||analogue-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||need-11/VBP||scores-4/NNS	appos||scores-4/NNS||incidence-6/NN	amod||pain-9/NN||distressing-8/JJ	prep_of||incidence-6/NN||pain-9/NN	ccomp||recorded-28/VBN||need-11/VBP	amod||boluses-14/NNS||supplementary/rescue-13/JJ	prep_of||need-11/VBP||boluses-14/NNS	appos||boluses-14/NNS||dose-16/NN	prep_of||dose-16/NN||bupivacaine-18/NN	vmod||bupivacaine-18/NN||consumed-19/VBN	amod||satisfaction-22/NN||maternal-21/JJ	nsubjpass||recorded-28/VBN||satisfaction-22/NN	amod||scores-26/NNS||neonatal-24/JJ	nn||scores-26/NNS||apgar-25/NN	conj_and||satisfaction-22/NN||scores-26/NNS	nsubjpass||recorded-28/VBN||scores-26/NNS	auxpass||recorded-28/VBN||were-27/VBD	root||ROOT-0/null||recorded-28/VBN	pain-9||bupivacaine-18||yes||verbal analogue pain scores, incidence of distressing pain, need of supplementary/rescue boluses, dose of bupivacaine consumed, maternal satisfaction and neonatal apgar scores were recorded.
det||signature-3/NN||the-1/DT	amod||signature-3/NN||bioenergetic-2/JJ	nsubj||ratio-7/NN||signature-3/NN	cop||ratio-7/NN||is-4/VBZ	det||ratio-7/NN||a-5/DT	nn||ratio-7/NN||protein-6/NN	root||ROOT-0/null||ratio-7/NN	nsubj||provides-16/VBZ||ratio-7/NN	nsubj||serves-25/VBZ||ratio-7/NN	nn||²-10/NNP||î-9/NNP	dep||ratio-7/NN||²-10/NNP	dep||²-10/NNP||f1-atpase/gapdh-12/JJ	rcmod||ratio-7/NN||provides-16/VBZ	det||estimate-18/NN||an-17/DT	dobj||provides-16/VBZ||estimate-18/NN	nn||metabolism-21/NN||glucose-20/NN	prep_of||estimate-18/NN||metabolism-21/NN	prep_in||provides-16/VBZ||tumors-23/NNS	rcmod||ratio-7/NN||serves-25/VBZ	conj_and||provides-16/VBZ||serves-25/VBZ	det||indicator-29/NN||a-27/DT	amod||indicator-29/NN||prognostic-28/JJ	prep_as||serves-25/VBZ||indicator-29/NN	nn||patients-32/NNS||cancer-31/NN	prep_for||indicator-29/NN||patients-32/NNS	tumors-23||glucose-20||no_rel||the bioenergetic signature is a protein ratio (î²-f1-atpase/gapdh), which provides an estimate of glucose metabolism in tumors and serves as a prognostic indicator for cancer patients.
det||study-3/NN||this-2/DT	prep_in||found-5/VBD||study-3/NN	nsubj||found-5/VBD||we-4/PRP	root||ROOT-0/null||found-5/VBD	mark||derived-8/VBD||that-6/IN	nsubj||derived-8/VBD||osteosarcoma-7/NN	ccomp||found-5/VBD||derived-8/VBD	amod||cells-10/NNS||cybrid-9/JJ	nsubj||demonstrated-32/VBN||cells-10/NNS	amod||levels-13/NNS||high-12/JJ	prep_with||cells-10/NNS||levels-13/NNS	nn||g-18/NN||m.-15/NN	num||g-18/NN||3243a-16/CD	nn||g-18/NN||>-17/NN	prep_of||levels-13/NNS||g-18/NN	aux||demonstrated-32/VBN||had-19/VBD	amod||nitrite-21/NN||increased-20/JJ	dobj||demonstrated-32/VBN||nitrite-21/NN	det||no-24/RB||an-23/DT	npadvmod||metabolite-25/JJ||no-24/RB	amod||nitrite-21/NN||metabolite-25/JJ	conj_and||nitrite-21/NN||metabolite-25/JJ	dobj||demonstrated-32/VBN||metabolite-25/JJ	amod||intracellular-29/NN||increased-28/VBN	conj_and||nitrite-21/NN||intracellular-29/NN	dobj||demonstrated-32/VBN||intracellular-29/NN	advmod||intracellular-29/NN||no-30/RB	ccomp||derived-8/VBD||demonstrated-32/VBN	det||probe-37/NN||an-34/DT	neg||probe-37/NN||no-35/RB	amod||probe-37/NN||fluorescent-36/JJ	prep_by||demonstrated-32/VBN||probe-37/NN	appos||probe-37/NN||daf-fm-39/NNP	osteosarcoma-7||nitrite-21||no_rel||in this study we found that osteosarcoma derived cybrid cells with high levels of m.3243a>g had increased nitrite, an no metabolite, and increased intracellular no, demonstrated by an no fluorescent probe (daf-fm).
det||patient-4/NN||a-1/DT	amod||patient-4/NN||43-year-old-2/JJ	amod||patient-4/NN||male-3/JJ	nsubjpass||treated-6/VBN||patient-4/NN	nsubjpass||presented-17/VBN||patient-4/NN	auxpass||treated-6/VBN||was-5/VBD	root||ROOT-0/null||treated-6/VBN	prep_with||treated-6/VBN||metronidazole-8/NN	num||months-11/NNS||2-10/CD	prep_for||treated-6/VBN||months-11/NNS	det||amebicliverabscess-15/NNS||an-14/DT	prep_for||treated-6/VBN||amebicliverabscess-15/NNS	conj_and||treated-6/VBN||presented-17/VBN	amod||signs-20/NNS||neurological-19/JJ	prep_with||presented-17/VBN||signs-20/NNS	prep_with||presented-17/VBN||symptoms-22/NNS	conj_and||signs-20/NNS||symptoms-22/NNS	amebicliverabscess-15||metronidazole-8||no_rel||a 43-year-old male patient was treated with metronidazole for 2 months, for an amebicliverabscess and presented with neurological signs and symptoms.
prep_in||had-11/VBD||comparison-2/NN	det||arm-6/NN||the-4/DT	nn||arm-6/NN||placebo-5/NN	prep_to||comparison-2/NN||arm-6/NN	det||arm-10/NN||the-8/DT	nn||arm-10/NN||ciprofloxacin-9/NN	nsubj||had-11/VBD||arm-10/NN	root||ROOT-0/null||had-11/VBD	amod||nadir-13/NN||lower-12/JJR	dobj||had-11/VBD||nadir-13/NN	amod||count-17/NN||absolute-15/JJ	amod||count-17/NN||neutrophil-16/JJ	prep_of||nadir-13/NN||count-17/NN	prep_during||had-11/VBD||induction-19/NN	prep_with||had-11/VBD||median-21/NN	prep_of||median-21/NN||62-23/CD	dep||median-21/NN||range-25/NN	vmod||range-25/NN||5â-26/VBN	dobj||5â-26/VBN||$-27/$	nn||270-32/NNS||884-29/NNP	nn||270-32/NNS||versus-31/NNP	npadvmod||=-77/RB||270-32/NNS	dep||270-32/NNS||range-34/NN	dep||range-34/NN||14â-35/NNS	dep||14â-35/NNS||$-36/$	nn||ã-40/NN||25,480-38/NNP	npadvmod||=-63/RB||ã-40/NN	num||cells/l-43/NN||109-42/CD	dep||p-62/JJ||cells/l-43/NN	nn||0.01-47/NNP||p-45/NNP	nn||0.01-47/NNP||<-46/NNP	appos||cells/l-43/NN||0.01-47/NNP	amod||risks-51/NNS||greater-50/JJR	appos||cells/l-43/NN||risks-51/NNS	amod||fever-54/NN||experiencing-53/JJ	prep_for||risks-51/NNS||fever-54/NN	num||%-57/NN||50.0-56/CD	dep||risks-51/NNS||%-57/NN	prep||%-57/NN||versus-58/FW	num||%-60/NN||32.7-59/CD	pobj||versus-58/FW||%-60/NN	dep||ã-40/NN||p-62/JJ	dep||0.07-64/CD||=-63/RB	num||$-36/$||0.07-64/CD	nn||p-76/NN||sepsis-68/NNP	num||%-71/NN||50.0-70/CD	dep||p-76/NN||%-71/NN	prep||%-71/NN||versus-72/FW	num||%-74/NN||38.5-73/CD	pobj||versus-72/FW||%-74/NN	prep_clinical||270-32/NNS||p-76/NN	dep||0.22-78/CD||=-77/RB	num||$-27/$||0.22-78/CD	prep_with||had-11/VBD||death-82/NN	conj_and||median-21/NN||death-82/NN	num||%-85/NN||18.9-84/CD	dep||death-82/NN||%-85/NN	num||%-88/NN||5.8-87/CD	prep_versus||%-85/NN||%-88/NN	vmod||%-88/NN||p-90/VBN	dep||0.05-92/CD||=-91/SYM	ccomp||p-90/VBN||0.05-92/CD	sepsis-68||ciprofloxacin-9||no_rel||in comparison to the placebo arm, the ciprofloxacin arm had lower nadir of absolute neutrophil count during induction with median of 62 (range 5â€“884) versus 270 (range 14â€“25,480) ã— 109 cells/l ( p < 0.01), greater risks for experiencing fever (50.0% versus 32.7%, p = 0.07), clinical sepsis (50.0% versus 38.5%, p = 0.22), and death (18.9% versus 5.8%, p = 0.05).
nsubjpass||achieved-7/VBN||treatment-1/NN	amod||hyperglycemia-4/NN||postprandial-3/JJ	prep_of||treatment-1/NN||hyperglycemia-4/NN	aux||achieved-7/VBN||can-5/MD	auxpass||achieved-7/VBN||be-6/VB	root||ROOT-0/null||achieved-7/VBN	agent||achieved-7/VBN||inhibiting-9/VBG	amod||±-12/NNS||intestinal-10/JJ	nn||±-12/NNS||î-11/NN	dobj||inhibiting-9/VBG||±-12/NNS	dep||±-12/NNS||glucosidase-14/NN	det||enzyme-18/NN||the-16/DT	amod||enzyme-18/NN||key-17/JJ	dep||±-12/NNS||enzyme-18/NN	conj_and||glucosidase-14/NN||enzyme-18/NN	amod||digestion-21/NN||oligosaccharide-20/JJ	prep_for||enzyme-18/NN||digestion-21/NN	amod||absorption-25/NN||further-23/JJ	nn||absorption-25/NN||glucose-24/NN	dep||±-12/NNS||absorption-25/NN	conj_and||glucosidase-14/NN||absorption-25/NN	hyperglycemia-4||glucose-24||no||treatment of postprandial hyperglycemia can be achieved by inhibiting intestinal î±-glucosidase, the key enzyme for oligosaccharide digestion and further glucose absorption.
prep_in||reported-8/VBN||particular-2/JJ	nn||atp-5/NN||extracellular-4/NN	nsubjpass||reported-8/VBN||atp-5/NN	nsubj||critical-11/JJ||atp-5/NN	nsubj||stress-18/VB||atp-5/NN	nsubjpass||shown-23/VBN||atp-5/NN	nsubjpass||upregulated-26/VBN||atp-5/NN	aux||reported-8/VBN||has-6/VBZ	auxpass||reported-8/VBN||been-7/VBN	root||ROOT-0/null||reported-8/VBN	aux||critical-11/JJ||to-9/TO	cop||critical-11/JJ||be-10/VB	xcomp||reported-8/VBN||critical-11/JJ	det||response-16/NN||the-13/DT	amod||response-16/NN||epithelial-14/JJ	nn||response-16/NN||cell-15/NN	prep_for||critical-11/JJ||response-16/NN	aux||stress-18/VB||to-17/TO	xcomp||critical-11/JJ||stress-18/VB	aux||shown-23/VBN||has-20/VBZ	advmod||shown-23/VBN||recently-21/RB	auxpass||shown-23/VBN||been-22/VBN	conj_and||reported-8/VBN||shown-23/VBN	aux||upregulated-26/VBN||to-24/TO	auxpass||upregulated-26/VBN||be-25/VB	xcomp||shown-23/VBN||upregulated-26/VBN	prep_in||upregulated-26/VBN||tumors-28/NNS	prep_in||tumors-28/NNS||vivo-30/NN	atp-5||tumors-28||no_rel||in particular, extracellular atp has been reported to be critical for the epithelial cell response to stress and has recently been shown to be upregulated in tumors in vivo .
nn||writers-2/NNS||european-1/NN	nsubj||held-8/VBD||writers-2/NNS	det||1600s-5/NN||the-4/DT	prep_of||writers-2/NNS||1600s-5/NN	prep_to||1600s-5/NN||1700s-7/CD	root||ROOT-0/null||held-8/VBD	dobj||held-8/VBD||views-9/NNS	mark||caused-24/VBD||that-10/IN	amod||health-12/NN||general-11/JJ	nsubj||caused-24/VBD||health-12/NN	amod||injuries-15/NNS||mechanical-14/JJ	conj_and||health-12/NN||injuries-15/NNS	nsubj||caused-24/VBD||injuries-15/NNS	conj_and||health-12/NN||trauma-17/NN	nsubj||caused-24/VBD||trauma-17/NN	amod||changes-22/NNS||sudden-20/JJ	nn||changes-22/NNS||temperature-21/NN	conj_and||health-12/NN||changes-22/NNS	nsubj||caused-24/VBD||changes-22/NNS	dep||changes-22/NNS||all-23/DT	ccomp||held-8/VBD||caused-24/VBD	nn||$-26/NNP||cariesâ-25/NNP	dobj||caused-24/VBD||$-26/NNP	vmod||$-26/NNP||holding-28/VBG	det||belief-31/NN||a-29/DT	amod||belief-31/NN||common-30/JJ	dobj||holding-28/VBG||belief-31/NN	mark||due-35/JJ||that-32/IN	nsubj||due-35/JJ||decay-33/NN	cop||due-35/JJ||was-34/VBD	ccomp||holding-28/VBG||due-35/JJ	nn||agents-38/NNS||chemical-37/NN	prep_to||due-35/JJ||agents-38/NNS	amod||saliva-41/NN||faulty-40/JJ	prep_to||due-35/JJ||saliva-41/NN	conj_and||agents-38/NNS||saliva-41/NN	nn||particles-45/NNS||food-44/NN	prep_to||due-35/JJ||particles-45/NNS	conj_and||agents-38/NNS||particles-45/NNS	chemical-37||caries--1||no_rel||european writers of the 1600s to 1700s held views that general health, mechanical injuries, trauma, and sudden temperature changes all caused cariesâ€”holding a common belief that decay was due to chemical agents, faulty saliva, and food particles.
det||study-5/NN||this-1/DT	amod||study-5/NN||randomized-2/JJ	amod||study-5/NN||controlled-4/JJ	nsubjpass||conducted-14/VBN||study-5/NN	nsubj||compare-16/VB||study-5/NN	dep||study-5/NN||n-7/NN	vmod||n-7/NN||â-8/VBN	dep||256-11/NNS||=-9/SYM	nn||256-11/NNS||â-10/NN	ccomp||â-8/VBN||256-11/NNS	auxpass||conducted-14/VBN||was-13/VBD	root||ROOT-0/null||conducted-14/VBN	aux||compare-16/VB||to-15/TO	xcomp||conducted-14/VBN||compare-16/VB	num||interventions-18/NNS||three-17/CD	dobj||compare-16/VB||interventions-18/NNS	vmod||interventions-18/NNS||designed-19/VBN	aux||promote-21/VB||to-20/TO	xcomp||designed-19/VBN||promote-21/VB	dobj||promote-21/VB||hepatitis-22/NN	det||virus-24/NN||a-23/DT	dep||hepatitis-22/NN||virus-24/NN	appos||virus-24/NN||hav-26/NN	dobj||promote-21/VB||hepatitisbvirus-29/NNS	conj_and||hepatitis-22/NN||hepatitisbvirus-29/NNS	appos||hepatitisbvirus-29/NNS||hbv-31/NN	nn||completion-34/NN||vaccination-33/NN	dep||hepatitisbvirus-29/NNS||completion-34/NN	prep_among||designed-19/VBN||clients-37/NNS	vmod||clients-37/NNS||undergoing-38/VBG	amod||treatment-41/NN||methadone-39/JJ	nn||treatment-41/NN||maintenance-40/NN	dobj||undergoing-38/VBG||treatment-41/NN	appos||treatment-41/NN||mmt-43/NN	nn||angeles-47/NNS||los-46/NN	prep_in||treatment-41/NN||angeles-47/NNS	nn||monica-50/NN||santa-49/NN	prep_in||treatment-41/NN||monica-50/NN	conj_and||angeles-47/NNS||monica-50/NN	hbv-31||hepatitisbvirus-29||no||this randomized, controlled study ( n â =â 256) was conducted to compare three interventions designed to promote hepatitis a virus (hav) and hepatitisbvirus (hbv) vaccination completion, among clients undergoing methadone maintenance treatment (mmt) in los angeles and santa monica.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||inhibited-12/VBD||that-5/IN	amod||acid-8/NN||acetyl-6/JJ	amod||acid-8/NN||salicylic-7/JJ	nsubj||inhibited-12/VBD||acid-8/NN	appos||acid-8/NN||asa-10/NN	ccomp||found-4/VBD||inhibited-12/VBD	amod||inflammation-15/NN||th17-13/JJ	nn||inflammation-15/NN||airway-14/NN	dobj||inhibited-12/VBD||inflammation-15/NN	det||model-20/NN||an-17/DT	nn||model-20/NN||asthma-18/NN	nn||model-20/NN||mouse-19/NN	prep_in||inhibited-12/VBD||model-20/NN	vmod||model-20/NN||induced-21/VBN	agent||induced-21/VBN||sensitization-23/NN	prep_with||induced-21/VBN||lipopolysaccharide-25/NN	appos||lipopolysaccharide-25/NN||lps-27/NN	dep||lipopolysaccharide-25/NN||containing-30/VBG	dobj||containing-30/VBG||allergens-31/NNS	inflammation-15||asa-10||yes||recently, we found that acetyl salicylic acid (asa) inhibited th17 airway inflammation in an asthma mouse model induced by sensitization with lipopolysaccharide (lps)-containing allergens.
nsubj||trial-7/NN||e1684-1/NNS	cop||trial-7/NN||was-2/VBD	det||trial-7/NN||the-3/DT	amod||trial-7/NN||pivotal-4/JJ	amod||trial-7/NN||adjuvant-5/JJ	nn||trial-7/NN||melanoma-6/NN	root||ROOT-0/null||trial-7/NN	prep_for||trial-7/NN||establishment-9/NN	amod||interferon-12/NN||high-dose-11/JJ	prep_of||establishment-9/NN||interferon-12/NN	appos||trial-7/NN||ifn-14/NN	amod||therapy-18/NN||effective-17/JJ	prep_as||trial-7/NN||therapy-18/NN	amod||patients-22/NNS||high-risk-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_of||therapy-18/NN||patients-22/NNS	melanoma-21||ifn-14||yes||e1684 was the pivotal adjuvant melanoma trial for establishment of high-dose interferon (ifn) as effective therapy of high-risk melanoma patients.
amod||viral-2/NNS||dual-1/JJ	nsubj||elevated-5/VBD||viral-2/NNS	conj_and||viral-2/NNS||bacterialinfection-4/NNS	nsubj||elevated-5/VBD||bacterialinfection-4/NNS	root||ROOT-0/null||elevated-5/VBD	det||load-8/NN||the-6/DT	amod||load-8/NN||bacterial-7/JJ	dobj||elevated-5/VBD||load-8/NN	prepc_compared_to||elevated-5/VBD||to-10/TO	pobj||elevated-5/VBD||animals-11/NNS	vmod||animals-11/NNS||infected-12/VBN	prep_with||infected-12/VBN||bacteria-14/NNS	advmod||infected-12/VBN||alone-15/RB	bacterialinfection-4||bacteria-14||no||dual viral and bacterialinfection elevated the bacterial load compared to animals infected with bacteria alone.
advmod||sought-5/VBD||additionally-1/RB	det||study-4/NN||the-3/DT	nsubj||sought-5/VBD||study-4/NN	nsubj||identify-7/VB||study-4/NN	root||ROOT-0/null||sought-5/VBD	aux||identify-7/VB||to-6/TO	xcomp||sought-5/VBD||identify-7/VB	amod||processes-9/NNS||biological-8/JJ	dobj||identify-7/VB||processes-9/NNS	nsubjpass||associated-16/VBN||processes-9/NNS	dobj||identify-7/VB||pathways-11/NNS	conj_and||processes-9/NNS||pathways-11/NNS	nsubjpass||associated-16/VBN||pathways-11/NNS	auxpass||associated-16/VBN||are-13/VBP	advmod||significantly-15/RB||most-14/RBS	advmod||associated-16/VBN||significantly-15/RB	rcmod||processes-9/NNS||associated-16/VBN	amod||metastases-20/NNS||early-18/JJ	amod||metastases-20/NNS||distant-19/JJ	prep_with||associated-16/VBN||metastases-20/NNS	number||5-23/CD||<-22/CD	num||years-24/NNS||5-23/CD	appos||metastases-20/NNS||years-24/NNS	prep_in||metastases-20/NNS||women-27/NNS	amod||receptor-positive-30/JJ||estrogen-29/JJ	amod||breasttumors-35/NNS||receptor-positive-30/JJ	nn||+-33/NNP||er-32/NNP	appos||breasttumors-35/NNS||+-33/NNP	prep_with||women-27/NNS||breasttumors-35/NNS	breasttumors-35||estrogen-29||no||additionally, the study sought to identify biological processes and pathways that are most significantly associated with early distant metastases (<5 years) in women with estrogen receptor-positive (er+) breasttumors.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
amod||plants-3/NNS||transgenic-1/JJ	nn||plants-3/NNS||arabidopsis-2/NNS	nsubj||resistant-16/JJ||plants-3/NNS	vmod||plants-3/NNS||expressing-4/VBG	dobj||expressing-4/VBG||amirnas-5/NNS	vmod||amirnas-5/NNS||designed-6/VBN	aux||target-8/VB||to-7/TO	xcomp||designed-6/VBN||target-8/VB	det||genome-10/NN||the-9/DT	dobj||target-8/VB||genome-10/NN	num||viruses-14/NNS||two-12/CD	amod||viruses-14/NNS||unrelated-13/JJ	prep_of||genome-10/NN||viruses-14/NNS	cop||resistant-16/JJ||were-15/VBD	root||ROOT-0/null||resistant-16/JJ	det||manner-22/NN||a-19/DT	advmod||specific-21/JJ||highly-20/RB	amod||manner-22/NN||specific-21/JJ	prep_in||resistant-16/JJ||manner-22/NN	det||virus-27/NN||the-25/DT	amod||virus-27/NN||appropriate-26/JJ	prep_to||resistant-16/JJ||virus-27/NN	virus-27||viruses-14||no||transgenic arabidopsis plants expressing amirnas designed to target the genome of two unrelated viruses were resistant, in a highly specific manner, to the appropriate virus.
nsubj||measured-2/VBD||we-1/PRP	root||ROOT-0/null||measured-2/VBD	amod||ability-4/NN||binding-3/VBG	dobj||measured-2/VBD||ability-4/NN	amod||a2ars-7/NNS||striatal-6/JJ	prep_of||ability-4/NN||a2ars-7/NNS	vmod||a2ars-7/NNS||using-8/VBG	nn||tomography-11/NN||positron-9/NN	nn||tomography-11/NN||emission-10/NN	dobj||using-8/VBG||tomography-11/NN	appos||tomography-11/NN||pet-13/NN	amod||-RSB--18/NNS||-LSB--16/JJ	amod||-RSB--18/NNS||7-methyl-11c-17/JJ	prep_with||tomography-11/NN||-RSB--18/NNS	dep||-8-23/CD||e-21/LS	prep_of||ability-4/NN||-8-23/CD	conj_and||a2ars-7/NNS||-8-23/CD	dep||--24/VBG||3,4,5-trimethoxystyryl-26/JJ	pobj||--24/VBG||-1,3,7-28/CD	dep||-1,3,7-28/CD||trimethylxanthine-30/NN	amod||tmsx-35/NN||-LSB--32/JJ	nn||tmsx-35/NN||11c-33/NN	nn||tmsx-35/NN||-RSB--34/NN	appos||trimethylxanthine-30/NN||tmsx-35/NN	num||patients-42/NNS||nine-38/CD	amod||patients-42/NNS||drug-naã-39/JJ	amod||patients-42/NNS||¯-40/JJ	nn||patients-42/NNS||ve-41/NN	prep_in||trimethylxanthine-30/NN||patients-42/NNS	prep_with||patients-42/NNS||pd-44/NN	num||patients-48/NNS||seven-46/CD	nn||patients-48/NNS||pd-47/NN	prep_of||ability-4/NN||patients-48/NNS	conj_and||a2ars-7/NNS||patients-48/NNS	amod||dyskinesia-51/NN||mild-50/JJ	prep_with||patients-48/NNS||dyskinesia-51/NN	num||subjects-56/NNS||six-53/CD	amod||subjects-56/NNS||elderly-54/JJ	nn||subjects-56/NNS||control-55/NN	prep_of||ability-4/NN||subjects-56/NNS	conj_and||a2ars-7/NNS||subjects-56/NNS	vmod||subjects-56/NNS||using-57/VBG	dobj||using-57/VBG||pet-58/NN	dyskinesia-51||1--1||no_rel||we measured binding ability of striatal a2ars using positron emission tomography (pet) with [7-methyl-11c]-( e )-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([11c]tmsx) in nine drug-naã¯ve patients with pd, seven pd patients with mild dyskinesia and six elderly control subjects using pet.
det||gene-5/NN||a-1/DT	amod||gene-5/NN||ca2-2/JJ	amod||gene-5/NN||+-3/JJ	nn||gene-5/NN||pump-4/NN	nsubj||present-7/JJ||gene-5/NN	nsubjpass||transcribed-16/VBN||gene-5/NN	cop||present-7/JJ||is-6/VBZ	root||ROOT-0/null||present-7/JJ	prep_in||present-7/JJ||45-9/CD	num||viruses-12/NNS||47-11/CD	prep_of||45-9/CD||viruses-12/NNS	vmod||viruses-12/NNS||tested-13/VBN	auxpass||transcribed-16/VBN||is-15/VBZ	conj_and||present-7/JJ||transcribed-16/VBN	prep_during||transcribed-16/VBN||virusinfection-18/NN	virusinfection-18||viruses-12||no||a ca2+ pump gene is present in 45 of 47 viruses tested and is transcribed during virusinfection.
amod||animals-5/NNS||stz-treated-4/JJ	prep_with_respect_to||characterized-14/VBN||animals-5/NNS	nsubjpass||characterized-14/VBN||mice-7/NNS	vmod||mice-7/NNS||co-injected-8/VBN	nn||trail-12/NN||stz-10/NN	nn||trail-12/NN||+-11/NN	prep_with||co-injected-8/VBN||trail-12/NN	auxpass||characterized-14/VBN||were-13/VBD	root||ROOT-0/null||characterized-14/VBN	dep||levels-19/NNS||1-16/LS	amod||levels-19/NNS||lower-18/JJR	agent||characterized-14/VBN||levels-19/NNS	prep_of||levels-19/NNS||hyperglycemia-21/NN	dep||levels-26/NNS||2-23/LS	amod||levels-26/NNS||higher-25/JJR	agent||characterized-14/VBN||levels-26/NNS	conj_and||levels-19/NNS||levels-26/NNS	nn||weight-29/NN||body-28/NN	prep_of||levels-26/NNS||weight-29/NN	prep_of||levels-26/NNS||insulinemia-31/NN	conj_and||weight-29/NN||insulinemia-31/NN	dep||preservation-37/NN||3-33/LS	det||preservation-37/NN||a-35/DT	amod||preservation-37/NN||partial-36/JJ	agent||characterized-14/VBN||preservation-37/NN	conj_and||levels-19/NNS||preservation-37/NN	amod||islets-40/NNS||pancreatic-39/JJ	prep_of||preservation-37/NN||islets-40/NNS	amod||morphology-43/NN||normal-42/JJ	prep_with||islets-40/NNS||morphology-43/NN	dep||expression-50/NN||4-46/LS	det||expression-50/NN||a-48/DT	amod||expression-50/NN||lower-49/JJR	agent||characterized-14/VBN||expression-50/NN	conj_and||levels-19/NNS||expression-50/NN	det||systemic-53/NN||both-52/DT	prep_of||expression-50/NN||systemic-53/NN	amod||±-56/NNS||tnf-î-55/JJ	appos||systemic-53/NN||±-56/NNS	appos||systemic-53/NN||opg-58/NN	conj_and||±-56/NNS||opg-58/NN	amod||markers-73/NNS||pancreatic-61/JJ	nn||molecule-66/NN||vascular-63/NN	nn||molecule-66/NN||cell-64/NN	nn||molecule-66/NN||adhesion-65/NN	dep||pancreatic-61/JJ||molecule-66/NN	nn||-1-70/NNP||-LSB--67/NNP	nn||-1-70/NNP||vcam-68/NNP	nn||-1-70/NNP||-RSB--69/NNP	dep||molecule-66/NN||-1-70/NNP	amod||markers-73/NNS||inflammatory-72/JJ	prep_of||expression-50/NN||markers-73/NNS	conj_and||systemic-53/NN||markers-73/NNS	stz-10||adhesion-65||no_rel||with respect to stz-treated animals, mice co-injected with stz+trail were characterized by 1 ) lower levels of hyperglycemia, 2 ) higher levels of body weight and insulinemia, 3 ) a partial preservation of pancreatic islets with normal morphology, and 4 ) a lower expression of both systemic (tnf-î± and opg) and pancreatic (vascular cell adhesion molecule [vcam]-1) inflammatory markers.
amod||therapy-3/NN||subcutaneous-1/JJ	nn||therapy-3/NN||insulin-2/NN	nsubj||interfere-6/VB||therapy-3/NN	aux||interfere-6/VB||does-4/VBZ	neg||interfere-6/VB||not-5/RB	root||ROOT-0/null||interfere-6/VB	amod||function-10/NN||venous-8/JJ	amod||function-10/NN||endothelial-9/JJ	prep_with||interfere-6/VB||function-10/NN	prep_in||function-10/NN||type2diabetes-12/CD	advmod||stable-20/JJ||when-13/WRB	nsubj||stable-20/JJ||glycemic-14/NN	nn||control-18/NN||blood-16/NN	nn||control-18/NN||pressure-17/NN	conj_and||glycemic-14/NN||control-18/NN	nsubj||stable-20/JJ||control-18/NN	cop||stable-20/JJ||are-19/VBP	advcl||interfere-6/VB||stable-20/JJ	type2diabetes-12||insulin-2||yes||subcutaneous insulin therapy does not interfere with venous endothelial function in type2diabetes when glycemic and blood pressure control are stable.
amod||prophylaxis-2/NNS||co-trimoxazole-1/JJ	nsubj||reduce-4/VB||prophylaxis-2/NNS	aux||reduce-4/VB||can-3/MD	root||ROOT-0/null||reduce-4/VB	dobj||reduce-4/VB||mortality-5/NN	amod||hivinfection-8/NN||untreated-7/JJ	prep_from||reduce-4/VB||hivinfection-8/NN	prep_in||hivinfection-8/NN||africa-10/NN	mark||occur-14/VBP||whether-12/IN	nsubj||occur-14/VBP||benefits-13/NNS	csubj||unclear-23/JJ||occur-14/VBP	nn||therapy-18/NN||combination-16/NN	amod||therapy-18/NN||antiretroviral-17/JJ	prep_alongside||occur-14/VBP||therapy-18/NN	appos||therapy-18/NN||art-20/NN	cop||unclear-23/JJ||is-22/VBZ	parataxis||reduce-4/VB||unclear-23/JJ	co-trimoxazole-1||hivinfection-8||no_rel||co-trimoxazole prophylaxis can reduce mortality from untreated hivinfection in africa; whether benefits occur alongside combination antiretroviral therapy (art) is unclear.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	tick-borneencephalitis-50||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
nsubj||repair-3/VB||it-1/PRP	nsubj||protect-5/VB||it-1/PRP	aux||repair-3/VB||might-2/MD	ccomp||used-29/VBN||repair-3/VB	conj_and||repair-3/VB||protect-5/VB	ccomp||used-29/VBN||protect-5/VB	amod||cartilage-8/NN||early-6/JJ	nn||cartilage-8/NN||osteoarthritis-7/NNS	dobj||repair-3/VB||cartilage-8/NN	prepc_by||repair-3/VB||delaying-10/VBG	nn||degeneration-12/NN||cartilage-11/NN	dobj||delaying-10/VBG||degeneration-12/NN	prepc_by||repair-3/VB||impairing-14/VBG	conj_and||delaying-10/VBG||impairing-14/VBG	det||function-16/NN||the-15/DT	dobj||impairing-14/VBG||function-16/NN	amod||mediators-19/NNS||inflammatory-18/JJ	prep_of||function-16/NN||mediators-19/NNS	advmod||repair-3/VB||therefore-21/RB	amod||injection-24/NN||intra-articular-23/JJ	nsubjpass||used-29/VBN||injection-24/NN	prep_of||injection-24/NN||celecoxib-26/NN	aux||used-29/VBN||can-27/MD	auxpass||used-29/VBN||be-28/VB	root||ROOT-0/null||used-29/VBN	det||alternative-32/NN||an-31/DT	prep_as||used-29/VBN||alternative-32/NN	det||treatment-36/NN||the-34/DT	amod||treatment-36/NN||current-35/JJ	prep_to||used-29/VBN||treatment-36/NN	prep_of||treatment-36/NN||osteoarthritis-38/NNS	osteoarthritis-38||celecoxib-26||yes||it might repair and protect early osteoarthritis cartilage by delaying cartilage degeneration and impairing the function of inflammatory mediators, therefore, intra-articular injection of celecoxib can be used as an alternative to the current treatment of osteoarthritis.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||rifampicin-17||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
det||chc-4/NN||these-1/DT	nn||chc-4/NN||qualitatively-2/NN	amod||chc-4/NN||differing-3/VBG	nsubjpass||found-7/VBN||chc-4/NN	advmod||found-7/VBN||compounds-5/RB	auxpass||found-7/VBN||were-6/VBD	root||ROOT-0/null||found-7/VBN	amod||classes-11/NNS||various-9/JJ	nn||classes-11/NNS||substance-10/NN	prep_across||found-7/VBN||classes-11/NNS	prep_including||classes-11/NNS||alkanes-13/NNS	appos||alkanes-13/NNS||alkenes-15/NNS	appos||alkanes-13/NNS||mono-17/NN	conj_and||alkenes-15/NNS||mono-17/NN	amod||alkanes-24/NNS||di-20/JJ	conj_and||di-20/JJ||trimethyl-branched-23/JJ	amod||alkanes-24/NNS||trimethyl-branched-23/JJ	appos||alkanes-13/NNS||alkanes-24/NNS	mono-17||alkanes-24||no_rel||these qualitatively differing chc compounds were found across various substance classes including alkanes, alkenes and mono-, di- and trimethyl-branched alkanes.
nsubj||higher-19/JJR||prevalence-1/NN	prep_of||prevalence-1/NN||hpv-3/NNP	num||hpv-3/NNP||16-4/CD	num||hpv-3/NNP||18-6/CD	amod||females-9/NNS||hivpositive-8/JJ	prep_among||prevalence-1/NN||females-9/NNS	num||%-12/NN||32.2-11/CD	dep||prevalence-1/NN||%-12/NN	dep||%-12/NN||n-14/NN	dep||30-16/CD||=-15/SYM	rcmod||n-14/NN||30-16/CD	cop||higher-19/JJR||was-18/VBD	root||ROOT-0/null||higher-19/JJR	amod||females-23/NNS||hiv-21/JJ	amod||females-23/NNS||negative-22/JJ	prep_than||higher-19/JJR||females-23/NNS	num||%-26/NN||9.1-25/CD	dep||females-23/NNS||%-26/NN	dep||%-26/NN||n-28/NN	dep||101-30/CD||=-29/SYM	rcmod||n-28/NN||101-30/CD	hivpositive-8||hiv-21||no||prevalence of hpv 16, 18 among hivpositive females (32.2%; n = 30) was higher than hiv negative females (9.1%; n = 101).
aux||advance-2/VB||to-1/TO	advcl||used-14/VBD||advance-2/VB	poss||understanding-4/NN||our-3/PRP$	dobj||advance-2/VB||understanding-4/NN	det||role-7/NN||the-6/DT	prep_of||understanding-4/NN||role-7/NN	prep_of||role-7/NN||pdi-9/NN	prep_in||advance-2/VB||chlamydiainfection-11/NN	nsubj||used-14/VBD||we-13/PRP	root||ROOT-0/null||used-14/VBD	nn||interference-16/NN||rna-15/NN	dobj||used-14/VBD||interference-16/NN	aux||establish-18/VB||to-17/TO	vmod||used-14/VBD||establish-18/VB	mark||making-30/VBG||that-19/IN	amod||pdi-21/NN||cellular-20/JJ	nsubj||making-30/VBG||pdi-21/NN	cop||making-30/VBG||is-22/VBZ	acomp||making-30/VBG||essential-23/JJ	amod||attachment-26/NN||bacterial-25/JJ	prep_for||essential-23/JJ||attachment-26/NN	prep_to||making-30/VBG||cells-28/NNS	ccomp||establish-18/VB||making-30/VBG	ccomp||making-30/VBG||pdi-31/VB	det||protein-35/NN||the-32/DT	amod||protein-35/NN||only-33/JJ	nn||protein-35/NN||host-34/NN	dobj||pdi-31/VB||protein-35/NN	vmod||protein-35/NN||identified-36/VBN	advmod||necessary-38/JJ||as-37/RB	acomp||identified-36/VBN||necessary-38/JJ	prep_for||identified-36/VBN||attachment-40/NN	amod||species-43/NNS||multiple-42/JJ	prep_of||attachment-40/NN||species-43/NNS	prep_of||species-43/NNS||chlamydia-45/NN	chlamydiainfection-11||chlamydia-45||no||to advance our understanding of the role of pdi in chlamydiainfection, we used rna interference to establish that cellular pdi is essential for bacterial attachment to cells, making pdi the only host protein identified as necessary for attachment of multiple species of chlamydia .
nsubj||analyzed-2/VBD||we-1/PRP	nsubj||analyzed-2/VBD||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	conj_and||analyzed-2/VBD||analyzed-2/VBD	det||relatedness-5/NNS||the-3/DT	amod||relatedness-5/NNS||genetic-4/JJ	dobj||analyzed-2/VBD||relatedness-5/NNS	nn||isolates-9/NNS||blood-7/NN	nn||isolates-9/NNS||culture-8/NN	prep_of||relatedness-5/NNS||isolates-9/NNS	prep_of||isolates-9/NNS||bartonellahenselae-11/NN	num||cats-14/NNS||2-13/CD	prep_from||analyzed-2/VBD||cats-14/NNS	prep_of||cats-14/NNS||patients-16/NNS	prep_with||patients-16/NNS||cat-scratchdisease-18/NN	prep_at||analyzed-2/VBD||admission-20/NN	num||months-24/NNS||12-23/CD	prep_after||analyzed-2/VBD||months-24/NNS	cat-scratchdisease-18||bartonellahenselae-11||no||we analyzed the genetic relatedness of blood culture isolates of bartonellahenselae from 2 cats of patients with cat-scratchdisease at admission and after 12 months.
amod||dye-3/NNS||evans-1/JJ	amod||dye-3/NNS||blue-2/JJ	nsubj||elicits-7/VBZ||dye-3/NNS	appos||dye-3/NNS||eb-5/NN	root||ROOT-0/null||elicits-7/VBZ	det||fluorescence-10/NN||a-8/DT	nn||fluorescence-10/NN||violet-9/NN	dobj||elicits-7/VBZ||fluorescence-10/NN	prep_by||elicits-7/VBZ||excitation-12/NN	prep_at||excitation-12/NN||345-nm-14/NN	prep_at||excitation-12/NN||emission-16/NN	conj_and||345-nm-14/NN||emission-16/NN	prep_at||elicits-7/VBZ||420-nm-18/JJ	det||reddish-brown-22/NN||a-21/DT	nsubj||fluorescence-23/VBP||reddish-brown-22/NN	conj_and||elicits-7/VBZ||fluorescence-23/VBP	prep_by||fluorescence-23/VBP||excitation-25/NN	prep_at||excitation-25/NN||470-nm-27/NN	prep_at||excitation-25/NN||emission-29/NN	conj_and||470-nm-27/NN||emission-29/NN	amod||characteristic-32/NN||515-nm-31/JJ	prep_at||fluorescence-23/VBP||characteristic-32/NN	prep_of||characteristic-32/NN||oxldl-34/NN	advmod||oxldl-34/NN||only-35/RB	evans-1||nm--1||no_rel||evans blue dye (eb) elicits a violet fluorescence by excitation at 345-nm and emission at 420-nm, and a reddish-brown fluorescence by excitation at 470-nm and emission at 515-nm characteristic of oxldl only.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	cd-29||cushingsyndrome-2||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||condition-9/NN||congenitalshortbowelsyndrome-1/NN	appos||congenitalshortbowelsyndrome-1/NN||sbs-3/NN	cop||condition-9/NN||is-5/VBZ	det||condition-9/NN||a-6/DT	advmod||rare-8/JJ||relatively-7/RB	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	advmod||condition-9/NN||as-10/RB	prepc_compared_to||condition-9/NN||to-12/TO	amod||sbs-14/NN||acquired-13/VBN	pobj||condition-9/NN||sbs-14/NN	congenitalshortbowelsyndrome-1||sbs-14||no_rel||congenitalshortbowelsyndrome (sbs) is a relatively rare condition as compared to acquired sbs.
nsubjpass||shown-20/VBN||mycophenolatemofetil-1/NN	nsubj||cause-22/VB||mycophenolatemofetil-1/NN	nn||®-4/NNP||cellceptâ-3/NNP	appos||mycophenolatemofetil-1/NN||®-4/NNP	det||drug-11/NN||a-7/DT	advmod||used-9/VBN||commonly-8/RB	amod||drug-11/NN||used-9/VBN	amod||drug-11/NN||immunosuppressive-10/JJ	appos||mycophenolatemofetil-1/NN||drug-11/NN	amod||transplantation-15/NN||solid-13/JJ	nn||transplantation-15/NN||organ-14/NN	prep_in||drug-11/NN||transplantation-15/NN	aux||shown-20/VBN||has-17/VBZ	advmod||shown-20/VBN||recently-18/RB	auxpass||shown-20/VBN||been-19/VBN	root||ROOT-0/null||shown-20/VBN	aux||cause-22/VB||to-21/TO	xcomp||shown-20/VBN||cause-22/VB	dobj||cause-22/VB||graft-versus-hostdisease-23/NN	dep||graft-versus-hostdisease-23/NN||gvhd-25/VBN	prep_like||cause-22/VB||changes-29/NNS	det||tract-33/NN||the-31/DT	amod||tract-33/NN||gastrointestinal-32/JJ	prep_in||changes-29/NNS||tract-33/NN	gvhd-25||mycophenolatemofetil-1||yes||mycophenolatemofetil (cellceptâ®), a commonly used immunosuppressive drug in solid organ transplantation, has recently been shown to cause graft-versus-hostdisease (gvhd)-like changes in the gastrointestinal tract.
advmod||predicts-5/VBZ||moreover-1/RB	det||model-4/NN||the-3/DT	nsubj||predicts-5/VBZ||model-4/NN	root||ROOT-0/null||predicts-5/VBZ	amod||characteristics-7/NNS||desirable-6/JJ	dobj||predicts-5/VBZ||characteristics-7/NNS	det||protein-11/NN||a-9/DT	nn||protein-11/NN||buffer-10/NN	prep_for||characteristics-7/NNS||protein-11/NN	nsubj||keeps-20/VBZ||protein-11/NN	amod||removal-15/NN||effective-14/JJ	prep_such_as||protein-11/NN||removal-15/NN	prep_of||removal-15/NN||excessiron-17/NN	rcmod||protein-11/NN||keeps-20/VBZ	nn||levels-23/NNS||intracellular-21/NN	nn||levels-23/NNS||clip-22/NN	nsubjpass||introduced-31/VBN||levels-23/NNS	advmod||constant-25/JJ||approximately-24/RB	dep||introduced-31/VBN||constant-25/JJ	advmod||introduced-31/VBN||even-26/RB	advmod||introduced-31/VBN||when-27/WRB	amod||perturbations-29/NNS||large-28/JJ	nsubjpass||introduced-31/VBN||perturbations-29/NNS	auxpass||introduced-31/VBN||are-30/VBP	xcomp||keeps-20/VBZ||introduced-31/VBN	det||source-37/NN||a-34/DT	advmod||available-36/JJ||freely-35/RB	amod||source-37/NN||available-36/JJ	dobj||predicts-5/VBZ||source-37/NN	conj_and||characteristics-7/NNS||source-37/NN	prep_of||source-37/NN||iron-39/NN	nn||starvation-42/NN||iron-41/NN	prep_under||iron-39/NN||starvation-42/NN	excessiron-17||iron-41||no||moreover, the model predicts desirable characteristics for a buffer protein such as effective removal of excessiron, which keeps intracellular clip levels approximately constant even when large perturbations are introduced, and a freely available source of iron under iron starvation.
amod||hemophiliaa-2/NN||severe-1/JJ	nsubjpass||diagnosed-4/VBN||hemophiliaa-2/NN	auxpass||diagnosed-4/VBN||is-3/VBZ	root||ROOT-0/null||diagnosed-4/VBN	det||level-8/NN||a-6/DT	amod||level-8/NN||factorviii-7/JJ	prep_with||diagnosed-4/VBN||level-8/NN	number||1-11/CD||<-10/CD	num||iu/dl-12/NN||1-11/CD	prep_of||level-8/NN||iu/dl-12/NN	hemophiliaa-2||factorviii-7||yes||severe hemophiliaa is diagnosed with a factorviii level of <1 iu/dl.
amod||evidence-2/NN||available-1/JJ	nsubj||shows-8/VBZ||evidence-2/NN	amod||treatment-5/NN||symptomatic-4/JJ	prep_on||evidence-2/NN||treatment-5/NN	prep_of||treatment-5/NN||vomiting-7/NN	root||ROOT-0/null||shows-8/VBZ	det||efficacy-10/NN||the-9/DT	dobj||shows-8/VBZ||efficacy-10/NN	det||molecule-16/NN||the-12/DT	advmod||registered-15/VBN||most-13/RBS	advmod||registered-15/VBN||recently-14/RB	amod||molecule-16/NN||registered-15/VBN	prep_of||efficacy-10/NN||molecule-16/NN	appos||molecule-16/NN||ondansetron-18/NN	det||evaluation-23/NN||a-21/DT	amod||evaluation-23/NN||proper-22/JJ	nsubj||lacking-38/VBG||evaluation-23/NN	amod||drugs-26/NNS||antiemetics-25/JJ	prep_of||evaluation-23/NN||drugs-26/NNS	advmod||used-28/VBN||largely-27/RB	vmod||drugs-26/NNS||used-28/VBN	amod||practice-31/NN||clinical-30/JJ	prep_in||used-28/VBN||practice-31/NN	prep_such_as||evaluation-23/NN||domperidone-35/NN	aux||lacking-38/VBG||is-37/VBZ	conj_but||shows-8/VBZ||lacking-38/VBG	domperidone-35||vomiting-7||no_rel||available evidence on symptomatic treatment of vomiting shows the efficacy of the most recently registered molecule (ondansetron) but a proper evaluation of antiemetics drugs largely used in clinical practice, such as domperidone, is lacking.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||amoxicillin-20||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
nsubjpass||transmitted-10/VBN||borreliaburgdorferi-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||borreliaburgdorferi-1/NNS||agent-5/NN	prep_of||agent-5/NN||lymeborreliosis-7/NNS	auxpass||transmitted-10/VBN||is-9/VBZ	root||ROOT-0/null||transmitted-10/VBN	prep_to||transmitted-10/VBN||humans-12/NNS	det||bite-15/NN||the-14/DT	prep_from||transmitted-10/VBN||bite-15/NN	amod||spp-18/NN||ixodes-17/JJ	prep_of||bite-15/NN||spp-18/NN	lymeborreliosis-7||borreliaburgdorferi-1||no||borreliaburgdorferi , the causative agent of lymeborreliosis, is transmitted to humans from the bite of ixodes spp.
det||warfarin-4/NN||the-1/DT	amod||warfarin-4/NN||anticoagulant-2/JJ	nn||warfarin-4/NN||drug-3/NN	nsubjpass||prescribed-7/VBN||warfarin-4/NN	auxpass||prescribed-7/VBN||is-5/VBZ	advmod||prescribed-7/VBN||widely-6/RB	root||ROOT-0/null||prescribed-7/VBN	prepc_for||prescribed-7/VBN||reducing-9/VBG	det||risk-11/NN||the-10/DT	dobj||reducing-9/VBG||risk-11/NN	prep_of||risk-11/NN||stroke-13/NN	prep_of||risk-11/NN||thrombosis-15/NNS	conj_and||stroke-13/NN||thrombosis-15/NNS	prep_of||risk-11/NN||pulmonaryembolism-17/NN	conj_and||stroke-13/NN||pulmonaryembolism-17/NN	amod||malfunction-21/NN||coronary-20/JJ	prep_of||risk-11/NN||malfunction-21/NN	conj_and||stroke-13/NN||malfunction-21/NN	pulmonaryembolism-17||warfarin-4||yes||the anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonaryembolism, and coronary malfunction.
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	colonystimulatingfactor-15||tumor-10||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
prep_in||similar-24/JJ||patients-2/NNS	advmod||resectable-5/JJ||initially-4/RB	amod||tumors-6/NNS||resectable-5/JJ	prep_with||patients-2/NNS||tumors-6/NNS	det||$-13/NN||â-8/DT	amod||$-13/NN||$-9/$	dep||$-9/$||œresectable-10/JJ	dep||$-9/$||tumor-11/NN	amod||$-13/NN||patientsâ-12/JJ	appos||tumors-6/NNS||$-13/NN	nn||frequencies-17/NNS||resection-16/NN	nsubj||similar-24/JJ||frequencies-17/NNS	conj_and||frequencies-17/NNS||survival-19/NN	nsubj||similar-24/JJ||survival-19/NN	amod||therapy-22/NN||neoadjuvant-21/JJ	prep_after||frequencies-17/NNS||therapy-22/NN	cop||similar-24/JJ||are-23/VBP	root||ROOT-0/null||similar-24/JJ	prep_to||similar-24/JJ||those-26/DT	prep_of||those-26/DT||patients-28/NNS	advmod||tumors-32/NNS||primarily-30/RB	amod||tumors-32/NNS||resected-31/VBN	prep_with||patients-28/NNS||tumors-32/NNS	amod||therapy-35/NN||adjuvant-34/JJ	prep_with||patients-28/NNS||therapy-35/NN	conj_and||tumors-32/NNS||therapy-35/NN	tumor-11||adjuvant-34||no_rel||in patients with initially resectable tumors (â€œresectable tumor patientsâ€?), resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy.
amod||revision-4/NN||mmc-1/JJ	nn||revision-4/NN||needle-2/NN	nn||revision-4/NN||bleb-3/NN	nsubj||appears-5/VBZ||revision-4/NN	nsubj||method-10/NN||revision-4/NN	root||ROOT-0/null||appears-5/VBZ	aux||method-10/NN||to-6/TO	cop||method-10/NN||be-7/VB	det||method-10/NN||an-8/DT	amod||method-10/NN||effective-9/JJ	xcomp||appears-5/VBZ||method-10/NN	aux||revive-12/VB||to-11/TO	vmod||method-10/NN||revive-12/VB	amod||surgery-15/NN||failed-13/JJ	nn||surgery-15/NN||filtration-14/NN	dobj||revive-12/VB||surgery-15/NN	prep_after||revive-12/VB||trabeculectomy-17/NN	prep_in||trabeculectomy-17/NN||patients-19/NNS	amod||glaucoma-22/NN||congenital-21/JJ	prep_with||patients-19/NNS||glaucoma-22/NN	glaucoma-22||mmc-1||yes||mmc needle bleb revision appears to be an effective method to revive failed filtration surgery after trabeculectomy in patients with congenital glaucoma.
nsubjpass||done-21/VBN||hepatitisbsurfaceantigen-1/NN	appos||hepatitisbsurfaceantigen-1/NN||hbsag-3/NN	amod||antigen-8/NN||hepatitisb-6/JJ	nn||antigen-8/NN||envelope-7/NN	appos||hepatitisbsurfaceantigen-1/NN||antigen-8/NN	appos||antigen-8/NN||hbeag-10/NN	conj_and||hepatitisbsurfaceantigen-1/NN||hbv-dna-13/NN	nsubjpass||done-21/VBN||hbv-dna-13/NN	nn||biopsy-17/NN||liver-16/NN	conj_and||hepatitisbsurfaceantigen-1/NN||biopsy-17/NN	nsubjpass||done-21/VBN||biopsy-17/NN	prep_before||biopsy-17/NN||rt-19/NN	auxpass||done-21/VBN||were-20/VBD	root||ROOT-0/null||done-21/VBN	det||patients-24/NNS||all-23/DT	prep_in||done-21/VBN||patients-24/NNS	hbv--1||hepatitisbsurfaceantigen-1||yes||hepatitisbsurfaceantigen (hbsag), hepatitisb envelope antigen (hbeag), hbv-dna, and liver biopsy before rt were done in all patients.
prepc_compared_with||increased-10/VBD||with-2/IN	amod||subjects-4/NNS||healthy-3/JJ	pobj||increased-10/VBD||subjects-4/NNS	amod||levels-8/NNS||serum-6/JJ	amod||levels-8/NNS||non-vldl-tg-7/JJ	nsubj||increased-10/VBD||levels-8/NNS	advmod||increased-10/VBD||significantly-9/RB	root||ROOT-0/null||increased-10/VBD	prep_in||increased-10/VBD||patients-12/NNS	nn||f2-15/NNS||stages-14/NNS	prep_with||increased-10/VBD||f2-15/NNS	amod||ch-c-18/NN||f3-17/JJ	prep_with||increased-10/VBD||ch-c-18/NN	conj_and||f2-15/NNS||ch-c-18/NN	advmod||observed-23/VBD||however-20/RB	nsubj||observed-23/VBD||we-22/PRP	parataxis||increased-10/VBD||observed-23/VBD	neg||difference-26/NN||no-24/DT	amod||difference-26/NN||significant-25/JJ	dobj||observed-23/VBD||difference-26/NN	prep_in||observed-23/VBD||patients-28/NNS	prep_with||observed-23/VBD||livercirrhosis-30/NNS	tg--1||livercirrhosis-30||no_rel||compared with healthy subjects, serum non-vldl-tg levels significantly increased in patients with stages f2 and f3 ch-c; however, we observed no significant difference in patients with livercirrhosis.
amod||numbers-2/NNS||greater-1/JJR	nsubj||sign-12/NN||numbers-2/NNS	nsubj||promote-20/VB||numbers-2/NNS	nsubj||provide-27/VB||numbers-2/NNS	nn||outlets-5/NNS||alcohol-4/NN	prep_of||numbers-2/NNS||outlets-5/NNS	det||community-8/NN||a-7/DT	prep_in||outlets-5/NNS||community-8/NN	aux||sign-12/NN||may-9/MD	cop||sign-12/NN||be-10/VB	det||sign-12/NN||a-11/DT	root||ROOT-0/null||sign-12/NN	amod||constraints-16/NNS||loosened-14/JJ	nn||constraints-16/NNS||normative-15/NN	prep_of||sign-12/NN||constraints-16/NNS	prep_against||constraints-16/NNS||violence-18/NN	conj_and||sign-12/NN||promote-20/VB	xcomp||promote-20/VB||problemdrinking-21/VBG	amod||couples-24/NNS||at-risk-23/JJ	prep_among||problemdrinking-21/VBG||couples-24/NNS	conj_and||sign-12/NN||provide-27/VB	dobj||provide-27/VB||environments-28/NNS	advmod||form-38/VB||where-29/WRB	nsubj||form-38/VB||groups-30/NNS	nsubj||reinforce-41/VB||groups-30/NNS	prep_of||groups-30/NNS||persons-32/NNS	prep_at||persons-32/NNS||risk-34/NN	prep_for||risk-34/NN||ipv-36/NN	aux||form-38/VB||may-37/MD	advcl||provide-27/VB||form-38/VB	advmod||reinforce-41/VB||mutually-40/RB	advcl||provide-27/VB||reinforce-41/VB	conj_and||form-38/VB||reinforce-41/VB	amod||attitudes-43/NNS||ipv-related-42/JJ	dobj||reinforce-41/VB||attitudes-43/NNS	dobj||reinforce-41/VB||norms-45/NNS	conj_and||attitudes-43/NNS||norms-45/NNS	nn||behaviors-49/NNS||problem-48/NN	dobj||reinforce-41/VB||behaviors-49/NNS	conj_and||attitudes-43/NNS||behaviors-49/NNS	problemdrinking-21||alcohol-4||no||greater numbers of alcohol outlets in a community may be a sign of loosened normative constraints against violence, promote problemdrinking among at-risk couples, and provide environments where groups of persons at risk for ipv may form and mutually reinforce ipv-related attitudes, norms, and problem behaviors.
num||onchocerciasis-3/NNS||1987-2/CD	prep_since||relied-6/VBN||onchocerciasis-3/NNS	nsubj||relied-6/VBN||control-4/NN	aux||relied-6/VBN||has-5/VBZ	root||ROOT-0/null||relied-6/VBN	det||donation-9/NN||the-8/DT	prep_on||relied-6/VBN||donation-9/NN	prep_of||donation-9/NN||ivermectin-11/NN	nn||®-14/NNP||mectizanâ-13/NNP	appos||ivermectin-11/NN||®-14/NNP	dep||®-14/NNP||merck-16/NNP	dep||®-14/NNP||co.-18/NNP	conj_and||merck-16/NNP||co.-18/NNP	dep||®-14/NNP||inc.-20/NNP	det||programme-26/NN||the-23/DT	nn||programme-26/NN||mectizan-24/NN	nn||programme-26/NN||donation-25/NN	prep_through||relied-6/VBN||programme-26/NN	onchocerciasis-3||ivermectin-11||yes||since 1987 onchocerciasis control has relied on the donation of ivermectin (mectizanâ®, merck & co., inc.) through the mectizan donation programme.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||amphotericinb-16||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
nsubj||exhibited-17/VBD||five-1/CD	det||antibodies-4/NNS||the-3/DT	prep_of||five-1/CD||antibodies-4/NNS	nsubj||showed-6/VBD||antibodies-4/NNS	rcmod||antibodies-4/NNS||showed-6/VBD	acomp||showed-6/VBD||binding-7/JJ	det||subunit-13/NN||the-9/DT	advmod||conserved-11/JJ||relatively-10/RB	amod||subunit-13/NN||conserved-11/JJ	amod||subunit-13/NN||ha2-12/JJ	prep_to||binding-7/JJ||subunit-13/NN	prep_of||subunit-13/NN||ha-15/NN	root||ROOT-0/null||exhibited-17/VBD	dobj||exhibited-17/VBD||neutralization-18/NN	amod||uptake-21/NN||h5n1-vlp-20/JJ	prep_of||neutralization-18/NN||uptake-21/NN	det||manner-26/NN||a-23/DT	nn||manner-26/NN||dose-24/NN	nn||manner-26/NN||dependant-25/NN	prep_in||exhibited-17/VBD||manner-26/NN	h5n1--1||antibodies-4||no_rel||five of the antibodies which showed binding to the relatively conserved ha2 subunit of ha, exhibited neutralization of h5n1-vlp uptake in a dose dependant manner.
amod||protein-3/NN||pneumococcal-1/JJ	nn||protein-3/NN||surface-2/NN	nsubj||is-8/VBZ||protein-3/NN	det||pspa-6/NN||a-4/DT	dep||protein-3/NN||pspa-6/NN	root||ROOT-0/null||is-8/VBZ	det||antigens-13/NNS||the-10/DT	amod||antigens-13/NNS||best-characterized-11/JJ	amod||antigens-13/NNS||pneumococcal-12/JJ	prep_among||is-8/VBZ||antigens-13/NNS	nsubj||confer-15/VBP||antigens-13/NNS	rcmod||antigens-13/NNS||confer-15/VBP	dobj||confer-15/VBP||protection-16/NN	nn||models-19/NNS||animal-18/NN	prep_in||confer-15/VBP||models-19/NNS	prep_of||models-19/NNS||pneumococcalinfections-21/NNS	mark||such-25/JJ||as-24/IN	parataxis||confer-15/VBP||such-25/JJ	parataxis||alternative-30/NN||such-25/JJ	cop||alternative-30/NN||is-27/VBZ	det||alternative-30/NN||a-28/DT	amod||alternative-30/NN||good-29/JJ	rcmod||antigens-13/NNS||alternative-30/NN	conj_and||confer-15/VBP||alternative-30/NN	det||vaccines-36/NNS||the-32/DT	advmod||available-34/JJ||currently-33/RB	amod||vaccines-36/NNS||available-34/JJ	amod||vaccines-36/NNS||conjugated-35/JJ	prep_for||alternative-30/NN||vaccines-36/NNS	pneumococcalinfections-21||pneumococcal-12||no||pneumococcal surface protein a (pspa) is among the best-characterized pneumococcal antigens that confer protection in animal models of pneumococcalinfections and, as such, is a good alternative for the currently available conjugated vaccines.
det||study-2/NN||this-1/DT	nsubj||evaluated-3/VBN||study-2/NN	root||ROOT-0/null||evaluated-3/VBN	det||effects-5/NNS||the-4/DT	dobj||evaluated-3/VBN||effects-5/NNS	det||program-10/NN||a-7/DT	amod||program-10/NN||progressive-8/JJ	nn||program-10/NN||walking-9/NN	prep_of||effects-5/NNS||program-10/NN	nn||intake-14/NN||glucosamine-12/NN	nn||intake-14/NN||sulphate-13/NN	prep_of||effects-5/NNS||intake-14/NN	conj_and||program-10/NN||intake-14/NN	nn||symptoms-17/NNS||oa-16/NN	prep_on||evaluated-3/VBN||symptoms-17/NNS	amod||participation-21/NN||physical-19/JJ	nn||participation-21/NN||activity-20/NN	conj_and||evaluated-3/VBN||participation-21/NN	prep_in||participation-21/NN||people-23/NNS	amod||moderate-27/JJ||mild-25/JJ	dep||moderate-27/JJ||to-26/TO	amod||hip-28/NN||moderate-27/JJ	prep_with||people-23/NNS||hip-28/NN	nn||oa-31/NN||knee-30/NN	prep_with||people-23/NNS||oa-31/NN	conj_or||hip-28/NN||oa-31/NN	oa-31||glucosamine-12||yes||this study evaluated the effects of a progressive walking program and glucosamine sulphate intake on oa symptoms and physical activity participation in people with mild to moderate hip or knee oa.
advmod||associated-9/VBN||even-1/RB	mark||associated-9/VBN||though-2/IN	nsubjpass||associated-9/VBN||coronavirusinfection-3/NN	prep_of||coronavirusinfection-3/NN||humans-5/NNS	auxpass||associated-9/VBN||is-6/VBZ	neg||associated-9/VBN||not-7/RB	advmod||associated-9/VBN||normally-8/RB	advcl||showed-25/VBD||associated-9/VBN	amod||diseases-12/NNS||severe-11/JJ	prep_with||associated-9/VBN||diseases-12/NNS	det||identification-15/NN||the-14/DT	nsubj||showed-25/VBD||identification-15/NN	det||coronavirus-18/NNS||the-17/DT	prep_of||identification-15/NN||coronavirus-18/NNS	amod||coronavirus-18/NNS||responsible-19/JJ	det||outbreak-22/NN||the-21/DT	prep_for||responsible-19/JJ||outbreak-22/NN	prep_of||outbreak-22/NN||severeacuterespiratorysyndrome-24/NN	root||ROOT-0/null||showed-25/VBD	mark||enter-31/VB||that-26/IN	advmod||pathogenic-28/JJ||highly-27/RB	amod||coronaviruses-29/NNS||pathogenic-28/JJ	nsubj||enter-31/VB||coronaviruses-29/NNS	aux||enter-31/VB||can-30/MD	ccomp||showed-25/VBD||enter-31/VB	det||population-34/NN||the-32/DT	amod||population-34/NN||human-33/JJ	dobj||enter-31/VB||population-34/NN	coronavirusinfection-3||coronavirus-18||no||even though coronavirusinfection of humans is not normally associated with severe diseases, the identification of the coronavirus responsible for the outbreak of severeacuterespiratorysyndrome showed that highly pathogenic coronaviruses can enter the human population.
advmod||consecutive-2/JJ||fifty-1/RB	amod||emb-resistant-6/NN||consecutive-2/JJ	advmod||documented-5/VBN||phenotypically-4/RB	conj_and||consecutive-2/JJ||documented-5/VBN	amod||emb-resistant-6/NN||documented-5/VBN	nsubjpass||analyzed-25/VBN||emb-resistant-6/NN	num||strains-11/NNS||25-8/CD	amod||strains-11/NNS||pansusceptible-9/JJ	nn||strains-11/NNS||m.tuberculosis-10/NN	conj_and||emb-resistant-6/NN||strains-11/NNS	nsubjpass||analyzed-25/VBN||strains-11/NNS	vmod||strains-11/NNS||isolated-12/VBN	num||patients-17/NNS||75-14/CD	amod||patients-17/NNS||different-15/JJ	nn||patients-17/NNS||tb-16/NN	prep_from||isolated-12/VBN||patients-17/NNS	det||period-21/NN||a-19/DT	amod||period-21/NN||four-year-20/JJ	prep_over||patients-17/NNS||period-21/NN	prep_in||period-21/NN||kuwait-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	tb-16||m.tuberculosis-10||no||fifty consecutive and phenotypically documented emb-resistant and 25 pansusceptible m.tuberculosis strains isolated from 75 different tb patients over a four-year period in kuwait were analyzed .
det||spread-2/NN||the-1/DT	nsubj||suggests-23/VBZ||spread-2/NN	det||h1n1influenzavirus-6/NNS||the-4/DT	num||h1n1influenzavirus-6/NNS||2009-5/CD	prep_of||spread-2/NN||h1n1influenzavirus-6/NNS	det||population-9/NN||the-8/DT	prep_in||h1n1influenzavirus-6/NNS||population-9/NN	advmod||population-9/NN||worldwide-10/RB	det||number-17/NN||the-15/DT	amod||number-17/NN||large-16/JJ	prep_in_addition_to||spread-2/NN||number-17/NN	prep_of||number-17/NN||individuals-19/NNS	advmod||vaccinated-21/VBN||already-20/RB	vmod||individuals-19/NNS||vaccinated-21/VBN	root||ROOT-0/null||suggests-23/VBZ	mark||have-32/VBP||that-24/IN	det||proportion-27/NN||a-25/DT	amod||proportion-27/NN||large-26/JJ	nsubj||have-32/VBP||proportion-27/NN	det||population-30/NN||the-29/DT	prep_of||proportion-27/NN||population-30/NN	advmod||have-32/VBP||now-31/RB	ccomp||suggests-23/VBZ||have-32/VBP	amod||antibodies-34/NNS||cross-protective-33/JJ	dobj||have-32/VBP||antibodies-34/NNS	det||virus-38/NN||the-36/DT	num||virus-38/NN||1918-37/CD	prep_against||antibodies-34/NNS||virus-38/NN	advmod||alleviating-41/VBG||greatly-40/RB	vmod||antibodies-34/NNS||alleviating-41/VBG	dobj||alleviating-41/VBG||concerns-42/NNS	dobj||alleviating-41/VBG||fears-44/NNS	conj_and||concerns-42/NNS||fears-44/NNS	det||exposure/release-48/NN||the-46/DT	amod||exposure/release-48/NN||accidental-47/JJ	prep_regarding||concerns-42/NNS||exposure/release-48/NN	det||virus-52/NN||the-50/DT	num||virus-52/NN||1918-51/CD	prep_of||exposure/release-48/NN||virus-52/NN	det||laboratory-55/NN||the-54/DT	prep_from||virus-52/NN||laboratory-55/NN	det||use-58/NN||the-57/DT	prep_of||exposure/release-48/NN||use-58/NN	conj_and||virus-52/NN||use-58/NN	det||virus-61/NN||the-60/DT	prep_of||use-58/NN||virus-61/NN	det||agent-65/NN||a-63/DT	amod||agent-65/NN||bioterrorist-64/JJ	prep_as||virus-61/NN||agent-65/NN	virus-61||antibodies-34||no_rel||the spread of the 2009 h1n1influenzavirus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.
det||review-3/NN||this-2/DT	prep_in||describe-6/VBP||review-3/NN	nsubj||describe-6/VBP||we-5/PRP	root||ROOT-0/null||describe-6/VBP	det||number-8/NN||a-7/DT	dobj||describe-6/VBP||number-8/NN	det||mechanisms-11/NNS||these-10/DT	prep_of||number-8/NN||mechanisms-11/NNS	prep_of||mechanisms-11/NNS||chemoresistance-13/NN	nn||expression-17/NN||abc-15/NN	nn||expression-17/NN||transporter-16/NN	prep_including||describe-6/VBP||expression-17/NN	amod||dehydrogenase-20/JJ||aldehyde-19/JJ	amod||activity-24/NN||dehydrogenase-20/JJ	dep||dehydrogenase-20/JJ||aldh-22/RB	appos||expression-17/NN||activity-24/NN	amod||chemoresistance-31/NN||b-celllymphoma-2-26/JJ	appos||chemoresistance-31/NN||bcl2-28/NNP	amod||chemoresistance-31/NN||related-30/VBN	prep_including||describe-6/VBP||chemoresistance-31/NN	conj_and||expression-17/NN||chemoresistance-31/NN	amod||response-36/NN||enhanced-33/VBN	nn||response-36/NN||dna-34/NN	nn||response-36/NN||damage-35/NN	prep_including||describe-6/VBP||response-36/NN	conj_and||expression-17/NN||response-36/NN	prep_including||describe-6/VBP||activation-38/NN	conj_and||expression-17/NN||activation-38/NN	amod||pathways-42/NNS||key-40/JJ	amod||pathways-42/NNS||signaling-41/JJ	prep_of||activation-38/NN||pathways-42/NNS	aldehyde-19||b-celllymphoma--1||no_rel||in this review, we describe a number of these mechanisms of chemoresistance including abc transporter expression, aldehyde dehydrogenase (aldh) activity, b-celllymphoma-2 (bcl2) related chemoresistance, enhanced dna damage response and activation of key signaling pathways.
nn||intake-2/NN||gluten-1/NN	nsubj||provokes-7/VBZ||intake-2/NN	prep_by||intake-2/NN||patients-4/NNS	prep_with||patients-4/NNS||coeliacdisease-6/NN	root||ROOT-0/null||provokes-7/VBZ	det||reaction-10/NN||a-8/DT	amod||reaction-10/NN||strong-9/JJ	dobj||provokes-7/VBZ||reaction-10/NN	amod||lymphocytes-14/NNS||intestinal-12/JJ	amod||lymphocytes-14/NNS||intraepithelial-13/JJ	prep_by||provokes-7/VBZ||lymphocytes-14/NNS	nsubj||normalises-20/VBZ||lymphocytes-14/NNS	appos||lymphocytes-14/NNS||iels-16/NNS	rcmod||lymphocytes-14/NNS||normalises-20/VBZ	det||diet-24/NN||a-22/DT	amod||diet-24/NN||gluten-free-23/JJ	prep_on||normalises-20/VBZ||diet-24/NN	coeliacdisease-6||gluten-1||no||gluten intake by patients with coeliacdisease provokes a strong reaction by intestinal intraepithelial lymphocytes (iels), which normalises on a gluten-free diet.
prep_following||reaches-6/VBZ||injection-2/NN	nsubj||reaches-6/VBZ||biasp-4/NN	num||biasp-4/NN||30-5/CD	root||ROOT-0/null||reaches-6/VBZ	amod||levels-10/NNS||higher-7/JJR	amod||levels-10/NNS||plasma-8/JJ	nn||levels-10/NNS||insulin-9/NN	dobj||reaches-6/VBZ||levels-10/NNS	advmod||quickly-12/RB||more-11/RBR	advmod||reaches-6/VBZ||quickly-12/RB	amod||premix-15/NN||human-14/JJ	prep_than||reaches-6/VBZ||premix-15/NN	nn||insulin-18/NN||basal-17/NN	prep_than||reaches-6/VBZ||insulin-18/NN	conj_or||premix-15/NN||insulin-18/NN	vmod||reaches-6/VBZ||giving-20/VBG	amod||reduction-22/NN||effective-21/JJ	dobj||giving-20/VBG||reduction-22/NN	amod||hyperglycemia-25/NN||postprandial-24/JJ	prep_of||reduction-22/NN||hyperglycemia-25/NN	hyperglycemia-25||insulin-18||yes||following injection, biasp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia.
nsubj||compared-8/VBD||background-1/NN	nsubj||ifosfamide-20/VBP||background-1/NN	aux||assess-3/VB||to-2/TO	vmod||background-1/NN||assess-3/VB	det||cost-effectiveness-5/NNS||the-4/DT	dobj||assess-3/VB||cost-effectiveness-5/NNS	prep_of||cost-effectiveness-5/NNS||trabectedin-7/NN	root||ROOT-0/null||compared-8/VBD	amod||treatment-11/NN||end-stage-10/JJ	prep_with||compared-8/VBD||treatment-11/NN	appos||treatment-11/NN||est-13/NN	prep_after||compared-8/VBD||failure-16/NN	prep_with||compared-8/VBD||anthracycline-18/NN	conj_and/or||compared-8/VBD||ifosfamide-20/VBP	amod||softtissuesarcoma-23/NN||metastatic-22/JJ	prep_in||ifosfamide-20/VBP||softtissuesarcoma-23/NN	appos||softtissuesarcoma-23/NN||msts-25/NNS	softtissuesarcoma-23||ifosfamide-20||yes||background to assess the cost-effectiveness of trabectedin compared with end-stage treatment (est) after failure with anthracycline and/or ifosfamide in metastatic softtissuesarcoma (msts).
aux||identify-2/VB||to-1/TO	dep||meet-8/VBP||identify-2/VB	conj_and||identify-2/VB||implement-4/VB	dep||meet-8/VBP||implement-4/VB	dobj||identify-2/VB||strategies-5/NNS	det||help-7/NN||that-6/DT	nsubj||meet-8/VBP||help-7/NN	root||ROOT-0/null||meet-8/VBP	nn||requirements-11/NNS||safety-9/NN	nn||requirements-11/NNS||monitoring-10/NN	dobj||meet-8/VBP||requirements-11/NNS	det||context-14/NN||the-13/DT	prep_in||requirements-11/NNS||context-14/NN	det||study-18/NN||an-16/DT	amod||study-18/NN||observational-17/JJ	prep_of||context-14/NN||study-18/NN	amod||treatment-27/NN||artemether-lumefantrine-20/JJ	appos||treatment-27/NN||al-22/NNP	amod||treatment-27/NN||administered-24/VBN	prep_as||administered-24/VBN||first-line-26/NN	prep_for||meet-8/VBP||treatment-27/NN	amod||malaria-30/NN||uncomplicated-29/JJ	prep_for||treatment-27/NN||malaria-30/NN	amod||tanzania-33/NN||rural-32/JJ	prep_in||malaria-30/NN||tanzania-33/NN	malaria-30||lumefantrine--1||yes||to identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (al) administered as first-line treatment for uncomplicated malaria in rural tanzania.
prep_to||diagnosed-12/VBN||date-2/NN	det||majority-6/NN||the-4/DT	amod||majority-6/NN||great-5/JJ	nsubjpass||diagnosed-12/VBN||majority-6/NN	nn||hivinfections-9/NNS||russian-8/NN	prep_of||majority-6/NN||hivinfections-9/NNS	aux||diagnosed-12/VBN||have-10/VBP	auxpass||diagnosed-12/VBN||been-11/VBN	root||ROOT-0/null||diagnosed-12/VBN	prep_among||diagnosed-12/VBN||idus-14/NNS	prep_among||diagnosed-12/VBN||concerns-16/NNS	conj_and||idus-14/NNS||concerns-16/NNS	det||potential-19/NN||the-18/DT	prep_about||idus-14/NNS||potential-19/NN	det||transmission-23/NN||a-21/DT	amod||transmission-23/NN||sexual-22/JJ	prep_for||potential-19/NN||transmission-23/NN	prep_of||transmission-23/NN||hiv-25/NN	det||population-29/NN||the-27/DT	nn||population-29/NN||idu-28/NN	prep_beyond||diagnosed-12/VBN||population-29/NN	aux||increased-31/VBN||have-30/VBP	rcmod||population-29/NN||increased-31/VBN	hivinfections-9||hiv-25||no||to date, the great majority of russian hivinfections have been diagnosed among idus and concerns about the potential for a sexual transmission of hiv beyond the idu population have increased.
nsubj||provides-12/VBZ||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||capecitabine-10/NN	root||ROOT-0/null||provides-12/VBZ	amod||benefits-14/NNS||clinical-13/JJ	dobj||provides-12/VBZ||benefits-14/NNS	prep_to||provides-12/VBZ||patients-16/NNS	amod||cancer-21/NN||erbb2-18/JJ	amod||cancer-21/NN||+-19/JJ	nn||cancer-21/NN||breast-20/NN	prep_with||patients-16/NNS||cancer-21/NN	prep_including||patients-16/NNS||patients-24/NNS	nsubj||develop-26/VBP||patients-24/NNS	rcmod||patients-24/NNS||develop-26/VBP	amod||disease-28/NN||progressive-27/JJ	dobj||develop-26/VBP||disease-28/NN	prep_on||develop-26/VBP||trastuzumab-30/NN	cancer-21||capecitabine-10||no_rel||lapatinib, in combination with chemotherapeuticagents, such as capecitabine, provides clinical benefits to patients with erbb2+ breast cancer, including patients who develop progressive disease on trastuzumab.
amod||scabies-2/NNS||ordinary-1/JJ	nsubjpass||treated-5/VBN||scabies-2/NNS	auxpass||treated-5/VBN||is-3/VBZ	advmod||treated-5/VBN||commonly-4/RB	root||ROOT-0/null||treated-5/VBN	amod||creams-8/NNS||topical-7/JJ	prep_with||treated-5/VBN||creams-8/NNS	prep_such_as||creams-8/NNS||permethrin-11/NN	mark||treated-17/VBN||while-13/IN	amod||scabies-15/NNS||crusted-14/JJ	nsubjpass||treated-17/VBN||scabies-15/NNS	auxpass||treated-17/VBN||is-16/VBZ	advcl||treated-5/VBN||treated-17/VBN	amod||creams-20/NNS||topical-19/JJ	prep_with||treated-17/VBN||creams-20/NNS	prep_in||creams-20/NNS||combination-22/NN	amod||ivermectin-25/NN||oral-24/JJ	prep_with||treated-17/VBN||ivermectin-25/NN	scabies-15||ivermectin-25||yes||ordinary scabies is commonly treated with topical creams such as permethrin, while crusted scabies is treated with topical creams in combination with oral ivermectin.
num||means-3/NNS||one-1/CD	amod||means-3/NNS||recommended-2/VBN	nsubj||therapy-12/NN||means-3/NNS	prepc_of||means-3/NNS||preventing-5/VBG	dobj||preventing-5/VBG||malaria-6/NN	prep_during||preventing-5/VBG||pregnancy-8/NN	cop||therapy-12/NN||is-9/VBZ	amod||therapy-12/NN||intermittent-10/JJ	nn||therapy-12/NN||preventive-11/NN	root||ROOT-0/null||therapy-12/NN	appos||therapy-12/NN||iptp-14/NN	prep_with||therapy-12/NN||sulfadoxine/pyrimethamine-17/NN	appos||sulfadoxine/pyrimethamine-17/NN||sp-19/NN	malaria-6||pyrimethamine--1||no||one recommended means of preventing malaria during pregnancy is intermittent preventive therapy (iptp) with sulfadoxine/pyrimethamine (sp).
nn||options-2/NNS||treatment-1/NN	nsubj||increased-9/VBN||options-2/NNS	prep_for||options-2/NNS||adhd-4/NN	det||netherlands-7/NNS||the-6/DT	prep_in||adhd-4/NN||netherlands-7/NNS	aux||increased-9/VBN||have-8/VBP	root||ROOT-0/null||increased-9/VBN	det||introduction-12/NN||the-11/DT	prep_with||increased-9/VBN||introduction-12/NN	det||formulations-16/NNS||the-14/DT	amod||formulations-16/NNS||extended-release-15/JJ	prep_of||introduction-12/NN||formulations-16/NNS	prep_of||formulations-16/NNS||methylphenidate-18/NN	nn||er-21/NN||mph-20/NN	appos||methylphenidate-18/NN||er-21/NN	nn||®-24/NNP||concertaâ-23/NNP	dep||er-21/NN||®-24/NNP	prep_in||methylphenidate-18/NN||2003-27/CD	prep_of||formulations-16/NNS||atomoxetine-29/NN	conj_and||methylphenidate-18/NN||atomoxetine-29/NN	appos||atomoxetine-29/NN||atx-31/NN	nn||®-34/NNP||stratteraâ-33/NNP	dep||atx-31/NN||®-34/NNP	prep_in||atomoxetine-29/NN||2005-37/CD	nsubj||scarce-49/JJ||data-40/NNS	det||effect-43/NN||the-42/DT	prep_on||data-40/NNS||effect-43/NN	nn||patterns-47/NNS||drug-45/NN	nn||patterns-47/NNS||usage-46/NN	prep_on||effect-43/NN||patterns-47/NNS	cop||scarce-49/JJ||are-48/VBP	conj_but||increased-9/VBN||scarce-49/JJ	adhd-4||atomoxetine-29||yes||treatment options for adhd in the netherlands have increased with the introduction of the extended-release formulations of methylphenidate (mph er, concertaâ®) in 2003 and atomoxetine (atx, stratteraâ®) in 2005, but data on the effect on drug usage patterns are scarce.
det||total-2/NN||a-1/DT	nsubjpass||assigned-27/VBN||total-2/NN	nsubjpass||assigned-27/VBN||total-2/NN	num||men-5/NNS||83-4/CD	prep_of||total-2/NN||men-5/NNS	prep_of||total-2/NN||women-7/NNS	conj_and||men-5/NNS||women-7/NNS	prep_with||men-5/NNS||type2diabetes-9/CD	dep||total-2/NN||aged-11/VBN	number||â-13/CD||56.1-12/CD	num||±-14/NNS||â-13/CD	dobj||aged-11/VBN||±-14/NNS	number||years-16/NNS||7.5-15/CD	amod||±-14/NNS||years-16/NNS	number||35.4-19/CD||bmi-18/CD	num||â-20/NN||35.4-19/CD	npadvmod||±-21/JJ||â-20/NN	dep||years-16/NNS||±-21/JJ	num||kg/m2-23/NNS||4.6-22/CD	dep||years-16/NNS||kg/m2-23/NNS	auxpass||assigned-27/VBN||were-25/VBD	advmod||assigned-27/VBN||randomly-26/RB	root||ROOT-0/null||assigned-27/VBN	conj_or||assigned-27/VBN||assigned-27/VBN	det||diet-33/NN||an-29/DT	amod||diet-33/NN||isocaloric-30/JJ	amod||diet-33/NN||energy-restricted-32/JJ	prep_to||assigned-27/VBN||diet-33/NN	amod||subjects-36/NNS||female-35/JJ	dep||diet-33/NN||subjects-36/NNS	num||subjects-41/NNS||6-37/CD	amod||subjects-41/NNS||mj/day-38/JJ	amod||subjects-41/NNS||male-40/JJ	dep||subjects-36/NNS||subjects-41/NNS	number||mj/day-43/JJ||7-42/CD	amod||subjects-41/NNS||mj/day-43/JJ	det||carbohydrate-48/NN||either-46/DT	amod||carbohydrate-48/NN||standard-47/JJ	prep_of||diet-33/NN||carbohydrate-48/NN	dep||carbohydrate-48/NN||con-50/NN	dep||con-50/NN||carbohydrateproteinfat-52/NN	num||carbohydrateproteinfat-52/NN||531926-53/CD	amod||protein-57/NN||high-56/JJ	prep_of||diet-33/NN||protein-57/NN	conj_or||carbohydrate-48/NN||protein-57/NN	dep||carbohydrate-48/NN||hp-59/NN	dep||hp-59/NN||433322-61/CD	amod||rt-68/NN||supervised-67/JJ	prep_with||assigned-27/VBN||rt-68/NN	prep_without||assigned-27/VBN||rt-68/NN	num||days/week-71/NN||3-70/CD	appos||rt-68/NN||days/week-71/NN	num||weeks-75/NNS||16-74/CD	prep_for||assigned-27/VBN||weeks-75/NNS	carbohydrate-48||type2diabetes-9||no_rel||a total of 83 men and women with type2diabetes (aged 56.1 â± 7.5 years, bmi 35.4 â± 4.6 kg/m2) were randomly assigned to an isocaloric, energy-restricted diet (female subjects 6 mj/day, male subjects 7 mj/day) of either standard carbohydrate (con; carbohydrateproteinfat 531926) or high protein (hp; 433322), with or without supervised rt (3 days/week) for 16 weeks.
det||part-4/NN||this-1/DT	nn||part-4/NN||paper-2/NN	nn||part-4/NN||forms-3/NNS	nsubj||â-21/VBP||part-4/NN	nsubj||changing-38/VBG||part-4/NN	det||review-7/NN||a-6/DT	prep_of||part-4/NN||review-7/NN	advmod||commissioned-11/VBN||â-8/RB	pobj||â-8/RB||$-9/$	vmod||review-7/NN||commissioned-11/VBN	det||initiative-16/NN||the-13/DT	amod||initiative-16/NN||joint-14/JJ	nn||initiative-16/NN||learning-15/NN	agent||commissioned-11/VBN||initiative-16/NN	prep_on||initiative-16/NN||children-18/NNS	prep_on||initiative-16/NN||hiv/aids-20/NNS	conj_and||children-18/NNS||hiv/aids-20/NNS	root||ROOT-0/null||â-21/VBP	dobj||â-21/VBP||$-22/$	amod||studies-26/NNS||qualitative-25/JJ	prep_of||$-22/$||studies-26/NNS	advmod||changed-34/VBN||how-28/WRB	nsubj||changed-34/VBN||families-29/NNS	amod||africa-32/NN||southern-31/JJ	prep_in||families-29/NNS||africa-32/NN	aux||changed-34/VBN||have-33/VBP	prepc_of||studies-26/NNS||changed-34/VBN	aux||changing-38/VBG||are-37/VBP	conj_and||â-21/VBP||changing-38/VBG	det||result-42/NN||a-41/DT	prep_as||changing-38/VBG||result-42/NN	det||impact-45/NN||the-44/DT	prep_of||result-42/NN||impact-45/NN	prep_of||impact-45/NN||hiv-47/NN	prep_of||impact-45/NN||aids-49/NNS	conj_and||hiv-47/NN||aids-49/NNS	aids-49||hiv-47||no||this paper forms part of a review â€” commissioned by the joint learning initiative on children and hiv/aids â€” of qualitative studies of how families in southern africa have changed, and are changing, as a result of the impact of hiv and aids.
advmod||avianinfluenzavirus-3/NNS||highly-1/RB	amod||avianinfluenzavirus-3/NNS||pathogenic-2/JJ	nn||h5n1-7/NNS||avianinfluenzavirus-3/NNS	appos||h5n1-7/NNS||hpai-5/NNP	nsubj||poses-8/VBZ||h5n1-7/NNS	root||ROOT-0/null||poses-8/VBZ	det||threat-11/NN||a-9/DT	amod||threat-11/NN||serious-10/JJ	dobj||poses-8/VBZ||threat-11/NN	amod||animals-14/NNS||domestic-13/JJ	prep_to||poses-8/VBZ||animals-14/NNS	h5n1-7||avianinfluenzavirus-3||no||highly pathogenic avianinfluenzavirus (hpai) h5n1 poses a serious threat to domestic animals.
nn||design-2/NN||research-1/NN	nsubj||pumpâ-10/VBD||design-2/NN	poss||insulin-9/NN||methods-4/NNS	nn||insulin-9/NN||$-6/NNP	num||insulin-9/NN||seventeen-8/CD	conj_and||design-2/NN||insulin-9/NN	nsubj||pumpâ-10/VBD||insulin-9/NN	root||ROOT-0/null||pumpâ-10/VBD	num||adolescents-14/NNS||$-11/$	num||$-11/$||treated-13/CD	nsubj||underwent-17/VBD||adolescents-14/NNS	prep_with||adolescents-14/NNS||type1diabetes-16/CD	ccomp||pumpâ-10/VBD||underwent-17/VBD	num||procedures-21/NNS||two-18/CD	amod||procedures-21/NNS||euglycemic-19/JJ	nn||procedures-21/NNS||clamp-20/NN	dobj||underwent-17/VBD||procedures-21/NNS	det||bolus-26/NNS||a-23/DT	num||bolus-26/NNS||0.2-24/CD	amod||bolus-26/NNS||unit/kg-25/VBG	prep_after||underwent-17/VBD||bolus-26/NNS	preconj||insulinaspart-29/NN||either-28/DT	prep_of||bolus-26/NNS||insulinaspart-29/NN	prep_of||bolus-26/NNS||lispro-31/NN	conj_or||insulinaspart-29/NN||lispro-31/NN	prep_on||insulinaspart-29/NN||day-33/NN	num||day-33/NN||1-34/CD	prep_of||bolus-26/NNS||day-36/NN	conj_and||insulinaspart-29/NN||day-36/NN	num||day-36/NN||4-37/CD	nn||insertion-42/NN||insulin-39/NN	nn||insertion-42/NN||pump-40/NN	nn||insertion-42/NN||site-41/NN	prep_of||day-36/NN||insertion-42/NN	type1diabetes-16||insulin-39||yes||research design and methods â€”seventeen insulin pumpâ€“treated adolescents with type1diabetes underwent two euglycemic clamp procedures after a 0.2 unit/kg bolus of either insulinaspart or lispro on day 1 and day 4 of insulin pump site insertion.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||uncertain-2/JJ	nsubj||motivated-20/VBN||efficacy-3/NN	prep_of||efficacy-3/NN||ondansetron-5/NN	amod||patients-9/NNS||pediatric-7/JJ	amod||patients-9/NNS||neurosurgical-8/JJ	prep_for||ondansetron-5/NN||patients-9/NNS	det||effect-14/NN||the-11/DT	amod||effect-14/NN||possible-12/JJ	amod||effect-14/NN||antiemetic-13/JJ	prep_of||efficacy-3/NN||effect-14/NN	conj_or||ondansetron-5/NN||effect-14/NN	amod||dose-17/NN||small-16/JJ	prep_of||effect-14/NN||dose-17/NN	prep_of||dose-17/NN||propofol-19/NN	root||ROOT-0/null||motivated-20/VBN	dobj||motivated-20/VBN||us-21/PRP	nsubj||evaluate-23/VB||us-21/PRP	aux||evaluate-23/VB||to-22/TO	xcomp||motivated-20/VBN||evaluate-23/VB	det||effect-26/NN||the-24/DT	amod||effect-26/NN||preventive-25/JJ	dobj||evaluate-23/VB||effect-26/NN	det||dose-30/NN||a-28/DT	amod||dose-30/NN||subhypnotic-29/JJ	prep_of||effect-26/NN||dose-30/NN	prep_of||dose-30/NN||propofol-32/NN	prep||evaluate-23/VB||combined-33/VBN	pcomp||combined-33/VBN||with-34/IN	pobj||with-34/IN||dexamethasone-35/NN	amod||vomiting-38/NN||postoperative-37/JJ	prep_on||motivated-20/VBN||vomiting-38/NN	appos||vomiting-38/NN||pov-40/NN	advmod||motivated-20/VBN||especially-43/RB	amod||periods-47/NNS||immediate-45/JJ	nn||periods-47/NNS||postoperative-46/NN	prep_during||especially-43/RB||periods-47/NNS	vomiting-38||ondansetron-5||yes||the uncertain efficacy of ondansetron for pediatric neurosurgical patients or the possible antiemetic effect of small dose of propofol motivated us to evaluate the preventive effect of a subhypnotic dose of propofol combined with dexamethasone on postoperative vomiting (pov), especially during immediate postoperative periods.
nn||virus-3/NN||hepatitis-1/NN	nn||virus-3/NN||e-2/NN	nsubj||factor-11/NN||virus-3/NN	appos||virus-3/NN||hev-5/NN	cop||factor-11/NN||was-7/VBD	det||factor-11/NN||the-8/DT	amod||factor-11/NN||commonest-9/JJ	amod||factor-11/NN||etiological-10/JJ	root||ROOT-0/null||factor-11/NN	prep_for||factor-11/NN||fhf-13/NN	num||cases-16/NNS||50-15/CD	appos||fhf-13/NN||cases-16/NNS	num||%-19/NN||74.6-18/CD	dep||cases-16/NNS||%-19/NN	det||cases-25/NNS||the-23/DT	num||cases-25/NNS||50-24/CD	prep_of||coinfected-37/VBN||cases-25/NNS	nn||infection-28/NN||hev-27/NN	prep_with||cases-25/NNS||infection-28/NN	nsubjpass||coinfected-37/VBN||43-30/CD	num||%-33/NN||64.2-32/CD	appos||43-30/CD||%-33/NN	auxpass||coinfected-37/VBN||were-35/VBD	neg||coinfected-37/VBN||not-36/RB	conj_and||factor-11/NN||coinfected-37/VBN	det||virus-41/NN||any-39/DT	amod||virus-41/NN||other-40/JJ	prep_with||coinfected-37/VBN||virus-41/NN	num||cases-44/NNS||four-43/CD	nsubj||carriers-50/NNS||cases-44/NNS	cop||carriers-50/NNS||were-45/VBD	amod||carriers-50/NNS||hepatitisbvirus-46/JJ	appos||carriers-50/NNS||hbv-48/NN	ccomp||factor-11/NN||carriers-50/NNS	conj_and||factor-11/NN||carriers-50/NNS	nsubj||coinfection-55/VBN||three-53/CD	aux||coinfection-55/VBN||had-54/VBD	conj_and||factor-11/NN||coinfection-55/VBN	prepc_with||coinfection-55/VBN||hepatitis-57/VBG	det||virus-59/NN||a-58/DT	dobj||hepatitis-57/VBG||virus-59/NN	appos||virus-59/NN||hav-61/NN	hbv-48||hepatitisbvirus-46||no||hepatitis e virus (hev) was the commonest etiological factor for fhf (50 cases, 74.6%); of the 50 cases with hev infection, 43 (64.2%) were not coinfected with any other virus, four cases were hepatitisbvirus (hbv) carriers, and three had coinfection with hepatitis a virus (hav).
amod||patients-3/NNS||renal-1/JJ	nn||patients-3/NNS||transplant-2/NN	nsubj||require-10/VB||patients-3/NNS	vmod||patients-3/NNS||prescribed-4/VBN	acomp||prescribed-4/VBN||mycophenolatemofetil-5/JJ	appos||patients-3/NNS||mmf-7/NN	aux||require-10/VB||may-9/MD	root||ROOT-0/null||require-10/VB	dobj||require-10/VB||treatment-11/NN	prep_for||treatment-11/NN||tuberculosis-13/NNP	det||regimen-16/NN||a-15/DT	prep_with||require-10/VB||regimen-16/NN	det||rifampicin-21/NN||the-18/DT	amod||rifampicin-21/NN||tuberculocidal-19/JJ	nn||rifampicin-21/NN||drug-20/NN	prep_including||regimen-16/NN||rifampicin-21/NN	tuberculosis-13||rifampicin-21||yes||renal transplant patients prescribed mycophenolatemofetil (mmf) may require treatment for tuberculosis with a regimen including the tuberculocidal drug rifampicin.
det||study-2/NN||the-1/DT	nsubjpass||made-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||made-4/VBN||was-3/VBD	root||ROOT-0/null||made-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||made-4/VBN||evaluate-6/VB	nn||turnover-8/NN||bone-7/NN	dobj||evaluate-6/VB||turnover-8/NN	nn||patients-14/NNS||systemiclupuserythematosus-10/NNS	appos||patients-14/NNS||sle-12/NN	nsubj||undergoing-15/VBG||patients-14/NNS	prepc_in||evaluate-6/VB||undergoing-15/VBG	amod||therapy-18/NN||long-term-16/JJ	amod||therapy-18/NN||glucocorticoid-17/JJ	dobj||undergoing-15/VBG||therapy-18/NN	systemiclupuserythematosus-10||glucocorticoid-17||no_rel||the study was made to evaluate bone turnover in systemiclupuserythematosus (sle) patients undergoing long-term glucocorticoid therapy.
det||reaction-8/NN||a-1/DT	amod||reaction-8/NN||duplex-2/JJ	amod||reaction-8/NN||real-time-3/JJ	amod||reaction-8/NN||reverse-4/JJ	amod||reaction-8/NN||transcriptase-5/JJ	nn||reaction-8/NN||polymerase-6/NN	nn||reaction-8/NN||chain-7/NN	nsubjpass||improved-14/VBN||reaction-8/NN	appos||reaction-8/NN||rt-pcr-10/NN	advmod||improved-14/VBN||assay-12/RB	auxpass||improved-14/VBN||was-13/VBD	root||ROOT-0/null||improved-14/VBN	amod||detection-17/NN||simultaneous-16/JJ	prep_for||improved-14/VBN||detection-17/NN	advmod||pathogenic-20/JJ||highly-19/RB	amod||influenzavirus-29/NNS||pathogenic-20/JJ	amod||influenzavirus-29/NNS||h5n1-21/JJ	amod||influenzavirus-29/NNS||avianinfluenzavirus-22/JJ	conj_and||avianinfluenzavirus-22/JJ||pandemic-24/JJ	amod||influenzavirus-29/NNS||pandemic-24/JJ	nn||influenzavirus-29/NNS||h1n1-25/NN	appos||influenzavirus-29/NNS||2009-27/CD	prep_of||detection-17/NN||influenzavirus-29/NNS	nsubj||suitable-33/JJ||influenzavirus-29/NNS	cop||suitable-33/JJ||is-32/VBZ	rcmod||influenzavirus-29/NNS||suitable-33/JJ	amod||diagnosis-36/NN||early-35/JJ	prep_for||suitable-33/JJ||diagnosis-36/NN	amod||patients-39/NNS||influenza-like-38/JJ	prep_of||diagnosis-36/NN||patients-39/NNS	amod||surveillance-43/NN||epidemiological-42/JJ	prep_for||suitable-33/JJ||surveillance-43/NN	conj_and||diagnosis-36/NN||surveillance-43/NN	influenza--1||influenzavirus-29||no||a duplex real-time reverse transcriptase polymerase chain reaction (rt-pcr) assay was improved for simultaneous detection of highly pathogenic h5n1 avianinfluenzavirus and pandemic h1n1 (2009) influenzavirus, which is suitable for early diagnosis of influenza-like patients and for epidemiological surveillance.
advmod||reversed-15/VBD||however-1/RB	prep_during||reversed-15/VBD||immunotherapy-4/NN	advmod||no-7/RB||high-6/RB	dep||immunotherapy-4/NN||no-7/RB	amod||inhibition-11/NN||nos2-10/JJ	nsubj||reversed-15/VBD||inhibition-11/NN	nsubj||had-31/VBD||inhibition-11/NN	amod||depletion-14/NN||macrophage-13/JJ	conj_or||inhibition-11/NN||depletion-14/NN	nsubj||reversed-15/VBD||depletion-14/NN	root||ROOT-0/null||reversed-15/VBD	det||ability-17/NN||the-16/DT	dobj||reversed-15/VBD||ability-17/NN	amod||±-22/NNS||il-2-19/JJ	amod||±-22/NNS||/-20/JJ	nn||±-22/NNS||î-21/NN	prep_of||ability-17/NN||±-22/NNS	amod||treatment-25/NN||cd40-24/JJ	dobj||reversed-15/VBD||treatment-25/NN	aux||reduce-27/VB||to-26/TO	parataxis||reversed-15/VBD||reduce-27/VB	vmod||reversed-15/VBD||reduce-27/VB	nn||metastases-29/NNS||lung-28/NN	dobj||reduce-27/VB||metastases-29/NNS	conj_but||reversed-15/VBD||had-31/VBD	neg||effect-33/NN||no-32/DT	dobj||had-31/VBD||effect-33/NN	amod||burden-37/NN||primary-35/JJ	nn||burden-37/NN||tumor-36/NN	prep_on||effect-33/NN||burden-37/NN	il-2-19||metastases-29||no_rel||however, during immunotherapy (high no), nos2 inhibition or macrophage depletion reversed the ability of il-2/î±-cd40 treatment to reduce lung metastases but had no effect on primary tumor burden.
poss||data-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||disrupted-11/VBN||that-4/IN	nsubjpass||disrupted-11/VBN||reconsolidation-5/NN	amod||memories-8/NNS||alcohol-related-7/JJ	prep_of||reconsolidation-5/NN||memories-8/NNS	aux||disrupted-11/VBN||can-9/MD	auxpass||disrupted-11/VBN||be-10/VB	ccomp||indicate-3/VBP||disrupted-11/VBN	det||interval-16/NN||a-13/DT	amod||interval-16/NN||long-14/JJ	amod||interval-16/NN||post-training-15/JJ	prep_after||disrupted-11/VBN||interval-16/NN	det||²-21/NN||that-18/DT	advmod||î-20/JJ||particularly-19/RB	amod||²-21/NN||î-20/JJ	prep_after||disrupted-11/VBN||²-21/NN	conj_and||interval-16/NN||²-21/NN	amod||receptors-24/NNS||adrenergic-23/JJ	nsubj||represent-26/VB||receptors-24/NNS	aux||represent-26/VB||may-25/MD	parataxis||indicate-3/VBP||represent-26/VB	nn||targets-28/NNS||novel-27/NN	dobj||represent-26/VB||targets-28/NNS	prep_for||represent-26/VB||pharmacotherapy-30/NN	prep_of||pharmacotherapy-30/NN||alcoholism-32/NN	prep_in||represent-26/VB||combination-35/NN	amod||therapies-38/NNS||cue-exposure-37/JJ	prep_with||combination-35/NN||therapies-38/NNS	alcoholism-32||alcohol--1||no||our data indicate that reconsolidation of alcohol-related memories can be disrupted after a long post-training interval and that particularly î²-adrenergic receptors may represent novel targets for pharmacotherapy of alcoholism, in combination with cue-exposure therapies.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||analysis-5/NN||a-3/DT	amod||analysis-5/NN||cost-effectiveness-4/JJ	dobj||performed-2/VBD||analysis-5/NN	xcomp||performed-2/VBD||comparing-6/VBG	det||program-10/NN||a-7/DT	amod||program-10/NN||pharmacy-only-8/JJ	amod||program-10/NN||refill-9/JJ	dobj||comparing-6/VBG||program-10/NN	appos||program-10/NN||prp-12/NN	det||form-16/NN||a-15/DT	appos||program-10/NN||form-16/NN	prep_of||form-16/NN||task-shifting-18/NN	det||standard-22/NN||the-21/DT	prep_to||comparing-6/VBG||standard-22/NN	prep_of||standard-22/NN||care-24/NN	appos||care-24/NN||soc-26/NN	det||clinic-32/NN||a-29/DT	amod||clinic-32/NN||large-30/JJ	nn||clinic-32/NN||hiv/aids-31/NNS	prep_at||comparing-6/VBG||clinic-32/NN	prep_in||clinic-32/NN||uganda-34/NN	det||institute-39/NN||the-36/DT	amod||institute-39/NN||infectious-37/JJ	nn||institute-39/NN||diseases-38/NNS	appos||uganda-34/NN||institute-39/NN	appos||institute-39/NN||idi-41/NN	aids--1||hiv--1||no||we performed a cost-effectiveness analysis comparing a pharmacy-only refill program (prp), a form of task-shifting, to the standard of care (soc) at a large hiv/aids clinic in uganda, the infectious diseases institute (idi).
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	glucose-11||obese-17||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nsubjpass||cited-4/VBN||viralinfections-1/NNS	auxpass||cited-4/VBN||are-2/VBP	advmod||cited-4/VBN||frequently-3/RB	dep||examines-20/VBZ||cited-4/VBN	det||factor-9/NN||a-6/DT	amod||factor-9/NN||major-7/JJ	amod||factor-9/NN||environmental-8/JJ	prep_as||cited-4/VBN||factor-9/NN	vmod||factor-9/NN||involved-10/VBN	amod||thyroiditis-13/NNS||subacute-12/JJ	prep_in||involved-10/VBN||thyroiditis-13/NNS	amod||diseases-17/NNS||autoimmune-15/JJ	nn||diseases-17/NNS||thyroid-16/NN	prep_in||involved-10/VBN||diseases-17/NNS	conj_and||thyroiditis-13/NNS||diseases-17/NNS	det||review-19/NN||this-18/DT	nsubj||examines-20/VBZ||review-19/NN	root||ROOT-0/null||examines-20/VBZ	det||data-22/NNS||the-21/DT	nsubj||related-23/VBN||data-22/NNS	xcomp||examines-20/VBZ||related-23/VBN	det||role-26/NN||the-25/DT	prep_to||related-23/VBN||role-26/NN	prep_of||role-26/NN||viruses-28/NNS	det||development-31/NN||the-30/DT	prep_in||viruses-28/NNS||development-31/NN	prep_of||development-31/NN||thyroiditis-33/NNS	viralinfections-1||viruses-28||no||viralinfections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases this review examines the data related to the role of viruses in the development of thyroiditis.
nn||fibrosis-2/NN||liver-1/NN	nsubj||stage-6/NN||fibrosis-2/NN	cop||stage-6/NN||is-3/VBZ	det||stage-6/NN||a-4/DT	amod||stage-6/NN||middle-5/JJ	root||ROOT-0/null||stage-6/NN	det||course-9/NN||the-8/DT	prep_in||stage-6/NN||course-9/NN	amod||infection-15/NN||chronichepatitisbvirus-11/JJ	appos||infection-15/NN||hbv-13/NN	prep_of||course-9/NN||infection-15/NN	nsubj||develop-19/VB||infection-15/NN	nsubj||hepatocellular-24/VB||infection-15/NN	aux||develop-19/VB||will-18/MD	rcmod||infection-15/NN||develop-19/VB	prep_into||develop-19/VB||cirrhosis-21/NNS	advmod||hepatocellular-24/VB||eventually-23/RB	rcmod||infection-15/NN||hepatocellular-24/VB	conj_and||develop-19/VB||hepatocellular-24/VB	dobj||hepatocellular-24/VB||carcinoma-25/NN	appos||carcinoma-25/NN||hcc-27/NN	mark||treated-31/VBN||if-29/IN	neg||treated-31/VBN||not-30/RB	dep||carcinoma-25/NN||treated-31/VBN	det||stage-35/NN||the-33/DT	amod||stage-35/NN||early-34/JJ	prep_at||treated-31/VBN||stage-35/NN	hbv-13||hepatitisbvirus--1||no||liver fibrosis is a middle stage in the course of chronichepatitisbvirus (hbv) infection, which will develop into cirrhosis and eventually hepatocellular carcinoma (hcc) if not treated at the early stage.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||™-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	dobj||seek-29/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohoshextract-34/NN	appos||blackcohoshextract-34/NN||bce-36/NN	aux||relieve-39/VB||to-38/TO	vmod||blackcohoshextract-34/NN||relieve-39/VB	poss||symptoms-42/NNS||their-40/PRP$	amod||symptoms-42/NNS||menopausal-41/JJ	dobj||relieve-39/VB||symptoms-42/NNS	cancer-19||blackcohoshextract-34||no_rel||the womenâ€™s health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohoshextract (bce) to relieve their menopausal symptoms.
num||themes-2/NNS||three-1/CD	nsubj||sketched-4/JJ||themes-2/NNS	cop||sketched-4/JJ||are-3/VBP	root||ROOT-0/null||sketched-4/JJ	dep||sketched-4/JJ||1-6/CD	mark||return-24/VB||as-8/IN	preconj||prevalence-11/NN||both-9/DT	nn||prevalence-11/NN||hiv-10/NN	nsubj||return-24/VB||prevalence-11/NN	amod||increase-15/NN||circular-13/JJ	nn||increase-15/NN||migration-14/NN	conj_and||prevalence-11/NN||increase-15/NN	nsubj||return-24/VB||increase-15/NN	amod||workers-19/NNS||former-17/JJ	nn||workers-19/NNS||migrant-18/NN	appos||prevalence-11/NN||workers-19/NNS	vmod||workers-19/NNS||affected-20/VBN	agent||affected-20/VBN||aids-22/NNS	aux||return-24/VB||may-23/MD	advcl||sketched-4/JJ||return-24/VB	poss||families-27/NNS||their-26/PRP$	prep_to||return-24/VB||families-27/NNS	prep_for||families-27/NNS||care-29/NN	prep_for||families-27/NNS||support-31/NN	conj_and||care-29/NN||support-31/NN	dep||return-24/VB||especially-33/RB	det||end-36/NN||the-35/DT	prep_at||return-24/VB||end-36/NN	prep_of||end-36/NN||life-38/NN	advmod||return-24/VB||often-40/RB	nn||conditions-43/NNS||crisis-42/NN	prep_under||return-24/VB||conditions-43/NNS	aids-22||hiv-10||no||three themes are sketched (1) as both hiv prevalence and circular migration increase, former migrant workers affected by aids may return to their families for care and support, especially at the end of life, often under crisis conditions.
aux||gain-10/VB||should-1/MD	det||virus-3/NN||this-2/DT	nsubj||gain-10/VB||virus-3/NN	cc||influenzavirus-8/VBZ||or-5/CC	det||zoonotic-7/NN||another-6/DT	nsubj||influenzavirus-8/VBZ||zoonotic-7/NN	parataxis||gain-10/VB||influenzavirus-8/VBZ	dep||result-22/VB||gain-10/VB	det||ability-12/NN||the-11/DT	dobj||gain-10/VB||ability-12/NN	amod||transmission-16/NN||sustained-14/JJ	amod||transmission-16/NN||human-to-human-15/JJ	prep_of||gain-10/VB||transmission-16/NN	det||pandemic-20/NN||an-18/DT	nn||pandemic-20/NN||influenza-19/NN	nsubj||result-22/VB||pandemic-20/NN	aux||result-22/VB||could-21/MD	root||ROOT-0/null||result-22/VB	influenza-19||influenzavirus-8||no||should this virus, or another zoonotic influenzavirus, gain the ability of sustained human-to-human transmission, an influenza pandemic could result.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||evidence-4/NN||weak-3/JJ	nsubj||is-2/VBZ||evidence-4/NN	mark||have-12/VB||that-5/IN	nsubj||have-12/VB||children-6/NNS	prep_with||children-6/NNS||fasd-8/NN	prep_with||children-6/NNS||adhd-10/NN	conj_and||fasd-8/NN||adhd-10/NN	aux||have-12/VB||may-11/MD	ccomp||is-2/VBZ||have-12/VB	det||response-15/NN||a-13/DT	amod||response-15/NN||better-14/JJR	dobj||have-12/VB||response-15/NN	aux||dexamphetamine-17/VB||to-16/TO	vmod||response-15/NN||dexamphetamine-17/VB	prep_than||dexamphetamine-17/VB||methylphenidate-19/NN	adhd-10||methylphenidate-19||yes||there is weak evidence that children with fasd and adhd may have a better response to dexamphetamine than methylphenidate.
nsubjpass||observed-7/VBN||electroacupuncture-1/NN	nsubj||reduce-9/VB||electroacupuncture-1/NN	appos||electroacupuncture-1/NN||ea-3/NN	aux||observed-7/VBN||has-5/VBZ	auxpass||observed-7/VBN||been-6/VBN	root||ROOT-0/null||observed-7/VBN	aux||reduce-9/VB||to-8/TO	xcomp||observed-7/VBN||reduce-9/VB	dobj||reduce-9/VB||insulinresistance-10/NN	prep_in||reduce-9/VB||obesity-12/NN	prep_in||reduce-9/VB||diabetes-14/NN	conj_and||obesity-12/NN||diabetes-14/NN	obesity-12||ea-3||no_rel||electroacupuncture (ea) has been observed to reduce insulinresistance in obesity and diabetes.
amod||associations-2/NNS||known-1/VBN	nsubjpass||attributed-10/VBN||associations-2/NNS	nsubjpass||insulinresistance-19/VBD||associations-2/NNS	prep_between||associations-2/NNS||diabetes-4/NN	prep_between||associations-2/NNS||cancer-6/NN	conj_and||diabetes-4/NN||cancer-6/NN	aux||attributed-10/VBN||could-7/MD	advmod||attributed-10/VBN||logically-8/RB	auxpass||attributed-10/VBN||be-9/VB	root||ROOT-0/null||attributed-10/VBN	prep_to||attributed-10/VBN||hyperglycemia-12/NN	appos||hyperglycemia-12/NN||hypersecretion-14/NN	prep_of||hypersecretion-14/NN||insulin-16/NN	conj_and/or||attributed-10/VBN||insulinresistance-19/VBD	hyperglycemia-12||insulin-16||yes||known associations between diabetes and cancer could logically be attributed to hyperglycemia, hypersecretion of insulin, and/or insulinresistance.
nsubj||received-9/VBD||patients-1/NNS	amod||hypertension-4/NN||uncontrolled-3/JJ	prep_with||patients-1/NNS||hypertension-4/NN	amod||risk-8/NN||added-6/VBN	amod||risk-8/NN||cardiovascular-7/JJ	prep_with||patients-1/NNS||risk-8/NN	conj_and||hypertension-4/NN||risk-8/NN	root||ROOT-0/null||received-9/VBD	det||combination-12/NN||a-10/DT	amod||combination-12/NN||fixed-dose-11/JJ	dobj||received-9/VBD||combination-12/NN	amod||mg-16/NN||candesartancilexetil-14/JJ	dep||candesartancilexetil-14/JJ||16-15/CD	prep_of||combination-12/NN||mg-16/NN	nn||mg-20/NN||hctz-18/NN	num||mg-20/NN||12.5-19/CD	prep_of||combination-12/NN||mg-20/NN	conj_and||mg-16/NN||mg-20/NN	nn||group-24/NN||combination-22/NN	nn||group-24/NN||therapy-23/NN	dep||mg-20/NN||group-24/NN	amod||monotherapy-28/NN||high-dose-27/JJ	dobj||received-9/VBD||monotherapy-28/NN	conj_or||combination-12/NN||monotherapy-28/NN	amod||mg-32/NN||candesartancilexetil-30/JJ	dep||candesartancilexetil-30/JJ||32-31/CD	prep_with||monotherapy-28/NN||mg-32/NN	amod||group-36/NN||high-dose-34/JJ	amod||group-36/NN||monotherapy-35/JJ	appos||mg-32/NN||group-36/NN	hypertension-4||candesartancilexetil-30||yes||patients with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination of candesartancilexetil 16 mg and hctz 12.5 mg (combination therapy group) or high-dose monotherapy with candesartancilexetil 32 mg (high-dose monotherapy group).
advmod||reduced-16/VBN||furthermore-1/RB	det||virulence-4/NN||the-3/DT	nsubjpass||reduced-16/VBN||virulence-4/NN	nsubjpass||reduced-29/VBN||virulence-4/NN	det||virus-7/NN||a-6/DT	prep_of||virulence-4/NN||virus-7/NN	vmod||virus-7/NN||lacking-8/VBG	dobj||lacking-8/VBG||c16l-9/NNS	dep||virus-7/NN||vî-11/VBN	dobj||vî-11/VBN||c16-13/NNS	auxpass||reduced-16/VBN||was-15/VBD	root||ROOT-0/null||reduced-16/VBN	det||model-21/NN||a-18/DT	amod||model-21/NN||murine-19/JJ	amod||model-21/NN||intranasal-20/JJ	prep_in||reduced-16/VBN||model-21/NN	prepc_compared_with||reduced-16/VBN||with-23/IN	nn||viruses-25/NNS||control-24/NN	pobj||reduced-16/VBN||viruses-25/NNS	expl||reduced-29/VBN||there-27/EX	auxpass||reduced-29/VBN||were-28/VBD	conj_and||reduced-16/VBN||reduced-29/VBN	nn||titres-31/NNS||virus-30/NN	nsubj||post-infection-37/JJ||titres-31/NNS	amod||days-36/NNS||4â-33/JJ	amod||days-36/NNS||$-34/$	prep_from||titres-31/NNS||days-36/NNS	xcomp||reduced-29/VBN||post-infection-37/JJ	virus-30||viruses-25||no||furthermore, the virulence of a virus lacking c16l (vî”c16) was reduced in a murine intranasal model compared with control viruses and there were reduced virus titres from 4â€…days post-infection.
det||pain-2/NN||the-1/DT	nsubjpass||refractory-4/VBN||pain-2/NN	auxpass||refractory-4/VBN||was-3/VBD	root||ROOT-0/null||refractory-4/VBN	amod||treatment-7/NN||medical-6/JJ	prep_to||refractory-4/VBN||treatment-7/NN	det||block-13/NN||a-10/DT	amod||block-13/NN||bilateral-11/JJ	amod||block-13/NN||sympathetic-12/JJ	nsubj||resulted-18/VBD||block-13/NN	prep_with||block-13/NN||lidocaine-15/NN	prep_with||block-13/NN||triamcinolone-17/NN	conj_and||lidocaine-15/NN||triamcinolone-17/NN	conj_but||refractory-4/VBN||resulted-18/VBD	prep_in||resulted-18/VBD||relief-20/NN	det||pain-23/NN||the-22/DT	prep_from||resulted-18/VBD||pain-23/NN	pain-23||lidocaine-15||yes||the pain was refractory to medical treatment, but a bilateral sympathetic block with lidocaine and triamcinolone resulted in relief from the pain.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||castoroil-2||no||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||indicator-14/NN||that-4/IN	amod||production-7/NN||granulocyte-5/JJ	amod||production-7/NN||colony-stimulatingfactor-6/JJ	nsubj||indicator-14/NN||production-7/NN	amod||leukocytes-10/NNS||lipopolysaccharide-stimulated-9/JJ	prep_by||production-7/NN||leukocytes-10/NNS	cop||indicator-14/NN||is-11/VBZ	det||indicator-14/NN||a-12/DT	amod||indicator-14/NN||useful-13/JJ	ccomp||demonstrate-3/VBP||indicator-14/NN	nn||induction-17/NN||tolerance-16/NN	prep_of||indicator-14/NN||induction-17/NN	amod||patients-21/NNS||surviving-19/VBG	nn||patients-21/NNS||pneumonia-20/NN	prep_in||induction-17/NN||patients-21/NNS	mark||significant-34/JJ||that-23/IN	csubj||significant-34/JJ||measuring-24/VBG	dobj||measuring-24/VBG||camp-25/NN	advmod||leukocytes-29/NNS||freshly-27/RB	amod||leukocytes-29/NNS||isolated-28/VBN	prep_in||camp-25/NN||leukocytes-29/NNS	aux||significant-34/JJ||may-30/MD	advmod||significant-34/JJ||also-31/RB	cop||significant-34/JJ||be-32/VB	advmod||significant-34/JJ||clinically-33/RB	ccomp||demonstrate-3/VBP||significant-34/JJ	conj_and||indicator-14/NN||significant-34/JJ	pneumonia-20||colony-stimulatingfactor-6||no_rel||our results demonstrate that granulocyte colony-stimulatingfactor production by lipopolysaccharide-stimulated leukocytes is a useful indicator of tolerance induction in surviving pneumonia patients and that measuring camp in freshly isolated leukocytes may also be clinically significant.
nsubjpass||caused-14/VBN||plague-1/NNP	appos||plague-1/NNP||one-3/CD	det||diseases-8/NNS||the-5/DT	advmod||devastating-7/JJ||most-6/RBS	amod||diseases-8/NNS||devastating-7/JJ	prep_of||one-3/CD||diseases-8/NNS	amod||history-11/NN||human-10/JJ	prep_in||diseases-8/NNS||history-11/NN	auxpass||caused-14/VBN||is-13/VBZ	root||ROOT-0/null||caused-14/VBN	det||yersiniapestis-18/NNS||the-16/DT	nn||yersiniapestis-18/NNS||bacterium-17/NN	agent||caused-14/VBN||yersiniapestis-18/NNS	plague-1||yersiniapestis-18||no||plague, one of the most devastating diseases in human history, is caused by the bacterium yersiniapestis .
nsubj||consider-2/VBP||we-1/PRP	root||ROOT-0/null||consider-2/VBP	det||opportunities-4/NNS||the-3/DT	dobj||consider-2/VBP||opportunities-4/NNS	prepc_for||consider-2/VBP||improving-6/VBG	det||collection-8/NN||the-7/DT	dobj||improving-6/VBG||collection-8/NN	prep_of||collection-8/NN||data-10/NNS	prep_about||data-10/NNS||men-12/NNS	prep_about||data-10/NNS||families-14/NNS	conj_and||men-12/NNS||families-14/NNS	nn||surveys-17/NNS||household-16/NN	prep_in||improving-6/VBG||surveys-17/NNS	nn||cohorts-20/NNS||population-19/NN	prep_in||improving-6/VBG||cohorts-20/NNS	conj_and||surveys-17/NNS||cohorts-20/NNS	mark||inform-24/VB||in-21/IN	dep||inform-24/VB||order-22/NN	aux||inform-24/VB||to-23/TO	advcl||improving-6/VBG||inform-24/VB	det||design-26/NN||the-25/DT	dobj||inform-24/VB||design-26/NN	dobj||inform-24/VB||evaluation-28/NN	conj_and||design-26/NN||evaluation-28/NN	amod||interventions-31/NNS||family-centred-30/JJ	prep_of||design-26/NN||interventions-31/NNS	prep_for||inform-24/VB||children-33/NNS	vmod||children-33/NNS||affected-34/VBN	agent||affected-34/VBN||hiv-36/NN	agent||affected-34/VBN||aids-38/NNS	conj_and||hiv-36/NN||aids-38/NNS	aids-38||hiv-36||no||we consider the opportunities for improving the collection of data about men and families in household surveys and population cohorts in order to inform the design and evaluation of family-centred interventions for children affected by hiv and aids.
num||lidocaine-3/NN||five-1/CD	nn||lidocaine-3/NN||percent-2/NN	nsubj||medicated-4/VBD||lidocaine-3/NN	root||ROOT-0/null||medicated-4/VBD	nsubj||efficacious-9/NNS||plaster-5/NN	aux||efficacious-9/NNS||has-6/VBZ	cop||efficacious-9/NNS||been-7/VBN	amod||efficacious-9/NNS||proven-8/VBN	ccomp||medicated-4/VBD||efficacious-9/NNS	det||relief-13/NN||the-11/DT	amod||relief-13/NN||symptomatic-12/JJ	prep_for||efficacious-9/NNS||relief-13/NN	prep_of||relief-13/NN||neuropathicpain-15/NN	amod||conditions-19/NNS||diverse-17/JJ	nn||conditions-19/NNS||pain-18/NN	prep_in||efficacious-9/NNS||conditions-19/NNS	nsubjpass||attributed-23/VBN||conditions-19/NNS	aux||attributed-23/VBN||might-21/MD	auxpass||attributed-23/VBN||be-22/VB	rcmod||conditions-19/NNS||attributed-23/VBN	det||symptomatology-28/NN||a-25/DT	amod||symptomatology-28/NN||common-26/JJ	amod||symptomatology-28/NN||localized-27/VBN	prep_to||attributed-23/VBN||symptomatology-28/NN	det||indications-31/NNS||these-30/DT	prep_in||symptomatology-28/NN||indications-31/NNS	advmod||attributed-23/VBN||possibly-33/RB	amod||predictors-36/NNS||common-35/JJ	prep_with||attributed-23/VBN||predictors-36/NNS	nn||success-39/NN||treatment-38/NN	prep_of||predictors-36/NNS||success-39/NN	pain-18||lidocaine-3||yes||five percent lidocaine medicated plaster has been proven efficacious for the symptomatic relief of neuropathicpain in diverse pain conditions which might be attributed to a common localized symptomatology in these indications, possibly with common predictors of treatment success.
num||rats-5/NNS||resultsâ-1/CD	amod||rats-5/NNS||$-2/JJ	nn||rats-5/NNS||zdf-4/NN	nsubj||have-10/VBP||rats-5/NNS	prepc_compared_with||rats-5/NNS||with-7/IN	nn||rats-9/NNS||zcl-8/NN	pobj||rats-5/NNS||rats-9/NNS	root||ROOT-0/null||have-10/VBP	amod||gk-13/NN||lower-11/JJR	amod||gk-13/NN||hepatic-12/JJ	dobj||have-10/VBP||gk-13/NN	nsubj||increased-73/VBD||activity-14/NN	nn||activity-14/NN||-lrb--15/FW	nn||activity-14/NN||11.6-16/FW	nn||activity-14/NN||â-17/FW	nn||activity-14/NN||±-18/FW	nn||activity-14/NN||1.9-19/FW	nn||activity-14/NN||vs.-20/FW	nn||activity-14/NN||32.5-21/FW	nn||activity-14/NN||â-22/FW	nn||activity-14/NN||±-23/FW	nn||activity-14/NN||3.2-24/FW	nn||activity-14/NN||mu/mg-25/FW	nn||activity-14/NN||protein-26/FW	nn||activity-14/NN||-rrb--27/FW	nn||activity-14/NN||marked-29/FW	nn||activity-14/NN||hyperglycemia-30/FW	nn||activity-14/NN||-lrb--31/FW	nn||activity-14/NN||23.9-32/FW	nn||activity-14/NN||â-33/FW	nn||activity-14/NN||±-34/FW	nn||activity-14/NN||1.2-35/FW	nn||activity-14/NN||vs.-36/FW	nn||activity-14/NN||7.4-37/FW	nn||activity-14/NN||â-38/FW	dep||activity-14/NN||±-39/FW	number||-rrb--42/NN||0.3-40/CD	dep||-rrb--42/NN||mmol/l-41/JJ	amod||activity-14/NN||-rrb--42/NN	amod||endogenous-45/NNS||higher-44/JJR	appos||activity-14/NN||endogenous-45/NNS	advmod||activity-14/NN||glucose-46/RB	dep||activity-14/NN||production-47/NN	nn||production-47/NN||-lrb--48/FW	nn||production-47/NN||80-49/FW	nn||production-47/NN||â-50/FW	nn||production-47/NN||±-51/FW	nn||production-47/NN||3-52/FW	nn||production-47/NN||vs.-53/FW	nn||production-47/NN||38-54/FW	nn||production-47/NN||â-55/FW	nn||production-47/NN||±-56/FW	nn||production-47/NN||3-57/FW	nn||production-47/NN||î-58/FW	nn||production-47/NN||1/4-59/FW	nn||production-47/NN||mol-60/FW	nn||production-47/NN||â-61/FW	dep||production-47/NN||·-62/FW	poss||-rrb--71/NN||kgâˆ-63/NNP	number||â-66/NN||1-65/CD	amod||-rrb--71/NN||â-66/NN	punct||-rrb--71/NN||·-67/``	nn||-rrb--71/NN||minâˆ-68/NN	num||-rrb--71/NN||1-70/CD	dep||production-47/NN||-rrb--71/NN	rcmod||gk-13/NN||increased-73/VBD	amod||â-78/NN||glucose-6-phosphatase-74/JJ	nn||â-78/NN||flux-75/NN	nn||â-78/NN||-lrb--76/NN	num||â-78/NN||150-77/CD	iobj||increased-73/VBD||â-78/NN	punct||â-78/NN||±-79/``	nn||â-78/NN||11-80/FW	nn||â-78/NN||vs.-81/FW	nn||â-78/NN||58-82/FW	nn||â-78/NN||â-83/FW	nn||â-78/NN||±-84/FW	nn||â-78/NN||8-85/FW	nn||â-78/NN||î-86/FW	nn||â-78/NN||1/4-87/FW	nn||â-78/NN||mol-88/FW	dep||â-78/NN||â-89/FW	punct||â-78/NN||·-90/''	poss||â-94/NN||kgâˆ-91/NNP	num||â-94/NN||1-93/CD	iobj||increased-73/VBD||â-94/NN	dep||â-94/NN||·-95/SYM	poss||production-113/NN||minâˆ-96/NNP	number||-rrb--99/NN||1-98/CD	amod||production-113/NN||-rrb--99/NN	cc||during-102/IN||and-101/CC	dep||-rrb--99/NN||during-102/IN	det||clamp-105/NN||a-103/DT	amod||clamp-105/NN||hyperglycemic-104/JJ	pobj||during-102/IN||clamp-105/NN	det||failure-108/NN||a-107/DT	appos||clamp-105/NN||failure-108/NN	amod||endogenous-111/NNS||suppress-110/JJ	prep_to||failure-108/NN||endogenous-111/NNS	nn||production-113/NN||glucose-112/NN	iobj||increased-73/VBD||production-113/NN	amod||production-113/NN||-lrb--114/NN	number||-lrb--114/NN||80-115/CD	iobj||increased-73/VBD||â-116/NN	punct||â-116/NN||±-117/``	nn||â-116/NN||7-118/FW	nn||â-116/NN||vs.-119/FW	nn||â-116/NN||âˆ-120/FW	nn||â-116/NN||7-122/FW	nn||â-116/NN||â-123/FW	nn||â-116/NN||±-124/FW	nn||â-116/NN||4-125/FW	nn||â-116/NN||î-126/FW	nn||â-116/NN||1/4-127/FW	nn||â-116/NN||mol-128/FW	dep||â-116/NN||â-129/FW	punct||â-116/NN||·-130/``	poss||â-134/NN||kgâˆ-131/NNP	num||â-134/NN||1-133/CD	dep||â-116/NN||â-134/NN	punct||â-116/NN||·-135/''	poss||incorporation-143/NN||minâˆ-136/NNP	number||-rrb--139/NN||1-138/CD	amod||incorporation-143/NN||-rrb--139/NN	conj_and||-rrb--139/NN||promote-141/JJ	amod||incorporation-143/NN||promote-141/JJ	nn||incorporation-143/NN||glucose-142/NN	dobj||increased-73/VBD||incorporation-143/NN	prep_into||increased-73/VBD||glycogen-145/NN	nn||glycogen-145/NN||-lrb--146/FW	nn||glycogen-145/NN||15-147/FW	nn||glycogen-145/NN||â-148/FW	nn||glycogen-145/NN||±-149/FW	nn||glycogen-145/NN||5-150/FW	nn||glycogen-145/NN||vs.-151/FW	nn||glycogen-145/NN||43-152/FW	nn||glycogen-145/NN||â-153/FW	nn||glycogen-145/NN||±-154/FW	nn||glycogen-145/NN||3-155/FW	dep||glycogen-145/NN||î-156/FW	dep||glycogen-145/NN||1/4-157/CD	xcomp||increased-73/VBD||mol/g-158/VBG	nn||-rrb--160/NNS||liver-159/NN	dobj||mol/g-158/VBG||-rrb--160/NNS	hyperglycemia-30||glucose-142||no||resultsâ $ '' zdf rats compared with zcl rats have lower hepatic gk activity -lrb- 11.6 â ± 1.9 vs. 32.5 â ± 3.2 mu/mg protein -rrb- , marked hyperglycemia -lrb- 23.9 â ± 1.2 vs. 7.4 â ± 0.3 mmol/l -rrb- , higher endogenous glucose production -lrb- 80 â ± 3 vs. 38 â ± 3 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , increased glucose-6-phosphatase flux -lrb- 150 â ± 11 vs. 58 â ± 8 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- , and during a hyperglycemic clamp , a failure to suppress endogenous glucose production -lrb- 80 â ± 7 vs. âˆ ' 7 â ± 4 î 1/4 mol â · kgâˆ ' 1 â · minâˆ ' 1 -rrb- and promote glucose incorporation into glycogen -lrb- 15 â ± 5 vs. 43 â ± 3 î 1/4 mol/g liver -rrb- .
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	amod||number-5/NN||monthly-4/JJ	dobj||measures-3/VBZ||number-5/NN	prep_of||number-5/NN||prescriptions-7/NNS	amod||prophylaxis-10/NNS||antibiotic-9/JJ	prep_for||prescriptions-7/NNS||prophylaxis-10/NNS	vmod||prophylaxis-10/NNS||consisting-11/VBG	det||dose-18/NN||a-13/DT	amod||dose-18/NN||single-14/JJ	number||g-16/CD||3-15/CD	num||dose-18/NN||g-16/CD	amod||dose-18/NN||oral-17/JJ	prep_of||consisting-11/VBG||dose-18/NN	prep_of||dose-18/NN||amoxicillin-20/NNP	det||dose-27/NN||a-22/DT	amod||dose-27/NN||single-23/JJ	number||mg-25/CD||600-24/CD	num||dose-27/NN||mg-25/CD	amod||dose-27/NN||oral-26/JJ	dobj||measures-3/VBZ||dose-27/NN	conj_or||number-5/NN||dose-27/NN	prep_of||dose-27/NN||clindamycin-29/NN	amod||number-33/NN||monthly-32/JJ	dobj||measures-3/VBZ||number-33/NN	conj_and||number-5/NN||number-33/NN	prep_of||number-33/NN||cases-35/NNS	prep_of||cases-35/NNS||infectiveendocarditis-37/NNS	amod||deaths-41/NNS||infectiveendocarditis-39/JJ	amod||deaths-41/NNS||related-40/JJ	prep_of||number-33/NN||deaths-41/NNS	conj_or||cases-35/NNS||deaths-41/NNS	prep_in||deaths-41/NNS||hospital-43/NN	prep_of||number-33/NN||cases-46/NNS	conj_or||cases-35/NNS||cases-46/NNS	prep_of||cases-46/NNS||infectiveendocarditis-48/NNS	det||origin-53/NN||a-50/DT	amod||origin-53/NN||possible-51/JJ	amod||origin-53/NN||oral-52/JJ	prep_with||infectiveendocarditis-48/NNS||origin-53/NN	prep_for||origin-53/NN||streptococci-55/NNS	infectiveendocarditis-48||clindamycin-29||yes||main outcome measures monthly number of prescriptions for antibiotic prophylaxis consisting of a single 3 g oral dose of amoxicillin or a single 600 mg oral dose of clindamycin, and monthly number of cases of infectiveendocarditis, infectiveendocarditis related deaths in hospital, or cases of infectiveendocarditis with a possible oral origin for streptococci.
advmod||determined-33/VBN||secondly-1/RB	nsubjpass||determined-33/VBN||conditions-3/NNS	amod||adsorption-6/NN||maximal-5/JJ	prep_for||conditions-3/NNS||adsorption-6/NN	amod||albumin-10/NN||bovine-8/JJ	nn||albumin-10/NN||serum-9/NN	prep_of||adsorption-6/NN||albumin-10/NN	appos||albumin-10/NN||bsa-12/NN	det||protein-19/NN||a-15/DT	amod||protein-19/NN||recombinant-16/JJ	amod||protein-19/NN||heat-shock-18/JJ	prep_for||conditions-3/NNS||protein-19/NN	conj_or||adsorption-6/NN||protein-19/NN	prep_from||protein-19/NN||mycobacteriumleprae-21/NN	num||kda-hsp-24/NNS||18-23/CD	appos||mycobacteriumleprae-21/NN||kda-hsp-24/NNS	prep_onto||mycobacteriumleprae-21/NN||dodab-covered-27/NN	amod||silica-31/NN||bare-30/JJ	prep_onto||mycobacteriumleprae-21/NN||silica-31/NN	conj_or||dodab-covered-27/NN||silica-31/NN	auxpass||determined-33/VBN||were-32/VBD	root||ROOT-0/null||determined-33/VBN	shock--1||albumin-10||yes||secondly, conditions for maximal adsorption of bovine serum albumin (bsa) or a recombinant, heat-shock protein from mycobacteriumleprae (18 kda-hsp) onto dodab-covered or onto bare silica were determined.
det||study-2/NN||a-1/DT	nsubj||assess-4/VB||study-2/NN	nsubj||identify-23/VB||study-2/NN	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||susceptibility-6/NN||the-5/DT	dobj||assess-4/VB||susceptibility-6/NN	prep_of||susceptibility-6/NN||nursing-8/NN	amod||students-11/NNS||medical-10/JJ	dobj||assess-4/VB||students-11/NNS	conj_and||susceptibility-6/NN||students-11/NNS	prep_towards||students-11/NNS||varicellainfection-13/NN	prepc_by||assess-4/VB||screening-15/VBG	nn||antibodies-18/NNS||igg-17/NN	prep_for||screening-15/VBG||antibodies-18/NNS	prep_against||antibodies-18/NNS||varicellavirus-20/NNS	aux||identify-23/VB||to-22/TO	conj_and||assess-4/VB||identify-23/VB	det||factors-26/NNS||any-24/DT	nn||factors-26/NNS||risk-25/NN	dobj||identify-23/VB||factors-26/NNS	det||same-29/JJ||the-28/DT	prep_for||identify-23/VB||same-29/JJ	varicellainfection-13||varicellavirus-20||no||a study to assess the susceptibility of nursing and medical students towards varicellainfection by screening for igg antibodies against varicellavirus and to identify any risk factors for the same.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	fmn-29||mono--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
det||mutation-4/NN||the-1/DT	amod||mutation-4/NN||dominant-negative-2/JJ	amod||mutation-4/NN||p467l-3/JJ	nsubjpass||identified-16/VBN||mutation-4/NN	amod||³-10/NNP||peroxisome-6/JJ	nn||³-10/NNP||proliferator-7/NN	nn||³-10/NNP||activated-8/NNP	nn||³-10/NNP||receptor-î-9/NNP	prep_in||mutation-4/NN||³-10/NNP	nn||³-13/NNP||pparî-12/NNP	appos||mutation-4/NN||³-13/NNP	auxpass||identified-16/VBN||was-15/VBD	root||ROOT-0/null||identified-16/VBN	amod||patients-19/NNS||insulin-resistant-18/JJ	prep_in||identified-16/VBN||patients-19/NNS	prep_with||identified-16/VBN||hyperglycemia-21/NN	prep_with||identified-16/VBN||lipodystrophy-23/NN	conj_and||hyperglycemia-21/NN||lipodystrophy-23/NN	insulin--1||hyperglycemia-21||no_rel||the dominant-negative p467l mutation in peroxisome proliferator activated receptor-î³ (pparî³) was identified in insulin-resistant patients with hyperglycemia and lipodystrophy.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||monitor-8/VB||aim-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||monitor-8/VB||to-7/TO	xcomp||was-6/VBD||monitor-8/VB	nn||markers-10/NNS||hbv-9/NN	dobj||monitor-8/VB||markers-10/NNS	nn||antigen-14/NN||hbv-12/NN	nn||antigen-14/NN||surface-13/NN	prep_in||monitor-8/VB||antigen-14/NN	appos||antigen-14/NN||hbsag-16/NN	amod||patients-20/NNS||negative/anti-hbcab-positive-19/JJ	dep||antigen-14/NN||patients-20/NNS	vmod||patients-20/NNS||treated-21/VBN	det||inhibitor-26/NN||a-23/DT	amod||inhibitor-26/NN||tnfî-24/JJ	amod||inhibitor-26/NN||±-25/JJ	prep_with||treated-21/VBN||inhibitor-26/NN	amod||arthritides-29/NNS||inflammatory-28/JJ	prep_for||inhibitor-26/NN||arthritides-29/NNS	hbv-12||hbsag-16||yes||the aim of our study was to monitor hbv markers in hbv surface antigen (hbsag)-negative/anti-hbcab-positive patients treated with a tnfî± inhibitor for inflammatory arthritides.
det||focus-2/NN||the-1/DT	nsubj||is-7/VBZ||focus-2/NN	det||work-6/NN||the-4/DT	amod||work-6/NN||presented-5/JJ	prep_of||focus-2/NN||work-6/NN	root||ROOT-0/null||is-7/VBZ	prepc_on||is-7/VBZ||detecting-9/VBG	dobj||detecting-9/VBG||differences-10/NNS	nn||expression-13/NN||gene-12/NN	prep_in||differences-10/NNS||expression-13/NN	amod||individuals-16/NNS||healthy-15/JJ	prep_between||expression-13/NN||individuals-16/NNS	prep_between||expression-13/NN||adjuvant-18/NN	conj_and||individuals-16/NNS||adjuvant-18/NN	amod||patients-23/NNS||metastatic-20/JJ	nn||patients-23/NNS||breast-21/NN	nn||patients-23/NNS||cancer-22/NN	prep_between||expression-13/NN||patients-23/NNS	conj_and||individuals-16/NNS||patients-23/NNS	neg||quantification-28/NN||not-25/RB	det||quantification-28/NN||an-26/DT	amod||quantification-28/NN||accurate-27/JJ	appos||expression-13/NN||quantification-28/NN	det||differences-31/NNS||these-30/DT	prep_of||differences-10/NNS||differences-31/NNS	cancer-22||adjuvant-18||no_rel||the focus of the presented work is on detecting differences in gene expression between healthy individuals and adjuvant and metastatic breast cancer patients, not an accurate quantification of these differences.
nn||loads-3/NNS||ebv-1/NN	nn||loads-3/NNS||dna-2/NN	nsubj||ã-8/NN||loads-3/NNS	cop||ã-8/NN||were-4/VBD	amod||ã-8/NN||detectable-5/JJ	prep_from||detectable-5/JJ||8.0-7/CD	root||ROOT-0/null||ã-8/NN	number||1.3-12/CD||102-10/CD	dep||1.3-12/CD||to-11/TO	num||ã-13/NN||1.3-12/CD	dep||ã-8/NN||ã-13/NN	num||copies/ml-16/NN||108-15/CD	conj_and||ã-8/NN||copies/ml-16/NN	amod||disease-20/NN||post-transplant-18/JJ	nn||disease-20/NN||lymphoproliferative-19/NN	prep_in||copies/ml-16/NN||disease-20/NN	dep||ã-8/NN||n-22/VBN	dep||5-24/CD||=-23/SYM	ccomp||n-22/VBN||5-24/CD	num||ã-28/NN||1.5-27/CD	conj_and||ã-8/NN||ã-28/NN	number||2.0-32/CD||103-30/CD	dep||2.0-32/CD||to-31/TO	num||ã-33/NN||2.0-32/CD	dep||ã-28/NN||ã-33/NN	num||copies/ml-36/NN||105-35/CD	conj_and||ã-8/NN||copies/ml-36/NN	prep_in||copies/ml-36/NN||infectiousmononucleosis-38/NNS	dep||ã-8/NN||n-40/VBN	dep||7-42/CD||=-41/SYM	ccomp||n-40/VBN||7-42/CD	num||ã-46/NN||7.5-45/CD	conj_and||ã-8/NN||ã-46/NN	number||1.1-50/CD||104-48/CD	dep||1.1-50/CD||to-49/TO	num||ã-51/NN||1.1-50/CD	dep||ã-46/NN||ã-51/NN	num||copies/ml-54/NN||105-53/CD	conj_and||ã-8/NN||copies/ml-54/NN	amod||syndrome-58/NN||ebv-associated-56/JJ	amod||syndrome-58/NN||haemophagocytic-57/JJ	prep_in||copies/ml-54/NN||syndrome-58/NN	dep||ã-8/NN||n-60/VBN	dep||1-62/CD||=-61/SYM	ccomp||n-60/VBN||1-62/CD	number||ã-66/CD||2.0-65/CD	conj_and||ã-8/NN||ã-66/CD	number||5.6-70/CD||102-68/CD	dep||5.6-70/CD||to-69/TO	dep||ã-66/CD||5.6-70/CD	dep||5.6-70/CD||ã-71/NN	num||copies/ml-74/NN||103-73/CD	conj_and||ã-8/NN||copies/ml-74/NN	amod||patients-77/NNS||hiv-infected-76/JJ	prep_in||copies/ml-74/NN||patients-77/NNS	dep||ã-8/NN||n-79/VBN	dep||12-81/CD||=-80/SYM	ccomp||n-79/VBN||12-81/CD	number||ã-86/CD||2.0-85/CD	conj_and||ã-8/NN||ã-86/CD	number||9.1-90/CD||102-88/CD	dep||9.1-90/CD||to-89/TO	num||ã-91/NNS||9.1-90/CD	dep||ã-86/CD||ã-91/NNS	number||copies/ml-94/JJ||104-93/CD	amod||ã-86/CD||copies/ml-94/JJ	det||sample-98/NN||the-96/DT	nn||sample-98/NN||population-97/NN	prep_in||ã-86/CD||sample-98/NN	dep||ã-86/CD||n-100/VBN	dep||218-102/CD||=-101/SYM	ccomp||n-100/VBN||218-102/CD	infectiousmononucleosis-38||ebv-1||no||ebv dna loads were detectable from 8.0 ã— 102 to 1.3 ã— 108 copies/ml in post-transplant lymphoproliferative disease (n = 5), 1.5 ã— 103 to 2.0 ã— 105 copies/ml in infectiousmononucleosis (n = 7), 7.5 ã— 104 to 1.1 ã— 105 copies/ml in ebv-associated haemophagocytic syndrome (n = 1), 2.0 ã— 102 to 5.6 ã— 103 copies/ml in hiv-infected patients (n = 12), and 2.0 ã— 102 to 9.1 ã— 104 copies/ml in the population sample (n = 218).
amod||insertions-2/NNS||nucleotide-1/JJ	nsubj||cause-13/VBP||insertions-2/NNS	det||gene-12/NN||the-4/DT	amod||light-6/JJ||ferritin-5/JJ	amod||gene-12/NN||light-6/JJ	nn||gene-12/NN||chain-7/NN	appos||gene-12/NN||ftl-9/NN	amod||gene-12/NN||polypeptide-11/JJ	prep_in||insertions-2/NNS||gene-12/NN	ccomp||characterized-19/VBD||cause-13/VBP	advmod||cause-13/VBP||hereditaryferritinopathy-14/RB	det||disease-18/NN||a-16/DT	amod||disease-18/NN||neurodegenerative-17/JJ	nsubj||characterized-19/VBD||disease-18/NN	root||ROOT-0/null||characterized-19/VBD	amod||accumulation-22/NN||abnormal-21/JJ	prep_by||characterized-19/VBD||accumulation-22/NN	prep_of||accumulation-22/NN||ferritin-24/NN	prep_of||accumulation-22/NN||iron-26/NN	conj_and||ferritin-24/NN||iron-26/NN	det||system-31/NN||the-28/DT	amod||system-31/NN||central-29/JJ	amod||system-31/NN||nervous-30/JJ	prep_in||characterized-19/VBD||system-31/NN	iron-26||hereditaryferritinopathy-14||no_rel||nucleotide insertions in the ferritin light chain (ftl) polypeptide gene cause hereditaryferritinopathy, a neurodegenerative disease characterized by abnormal accumulation of ferritin and iron in the central nervous system.
det||discovery-2/NN||the-1/DT	nsubj||suggests-22/VBZ||discovery-2/NN	mark||uncoupled-15/VBN||that-3/IN	det||induction-5/NN||the-4/DT	nsubjpass||uncoupled-15/VBN||induction-5/NN	amod||responses-12/NNS||pro-inflammatory-7/JJ	conj_and||pro-inflammatory-7/JJ||type-9/NN	amod||responses-12/NNS||type-9/NN	amod||responses-12/NNS||i-10/JJ	nn||responses-12/NNS||ifn-11/NN	prep_of||induction-5/NN||responses-12/NNS	aux||uncoupled-15/VBN||can-13/MD	auxpass||uncoupled-15/VBN||be-14/VB	dep||discovery-2/NN||uncoupled-15/VBN	amod||manipulation-18/NN||pharmacological-17/JJ	prep_through||uncoupled-15/VBN||manipulation-18/NN	amod||acidification-21/NN||endolysosomal-20/JJ	prep_of||manipulation-18/NN||acidification-21/NN	root||ROOT-0/null||suggests-22/VBZ	amod||avenues-24/NNS||new-23/JJ	dobj||suggests-22/VBZ||avenues-24/NNS	amod||intervention-28/NN||potential-26/JJ	amod||intervention-28/NN||therapeutic-27/JJ	prep_for||suggests-22/VBZ||intervention-28/NN	prep_against||intervention-28/NN||inflammations-30/NNS	prep_against||intervention-28/NN||sepsis-32/NN	conj_and||inflammations-30/NNS||sepsis-32/NN	ifn-11||inflammations-30||no_rel||the discovery that the induction of pro-inflammatory and type i ifn responses can be uncoupled through pharmacological manipulation of endolysosomal acidification suggests new avenues for potential therapeutic intervention against inflammations and sepsis.
amod||dlpfc-rtms-2/NNS||left-1/JJ	nsubj||min-9/VBP||dlpfc-rtms-2/NNS	vmod||dlpfc-rtms-2/NNS||delivered-3/VBN	advmod||delivered-3/VBN||either-4/RB	prep_at||delivered-3/VBN||10-6/CD	prep_at||delivered-3/VBN||20â-8/CD	conj_and||10-6/CD||20â-8/CD	root||ROOT-0/null||min-9/VBP	mark||decreased-14/VBD||after-10/IN	nn||application-12/NN||capsaicin-11/NN	nsubj||decreased-14/VBD||application-12/NN	advmod||decreased-14/VBD||significantly-13/RB	advcl||min-9/VBP||decreased-14/VBD	amod||pain-16/NN||spontaneous-15/JJ	dobj||decreased-14/VBD||pain-16/NN	det||hands-19/NNS||both-18/DT	prep_in||decreased-14/VBD||hands-19/NNS	pain-16||capsaicin-11||yes||left dlpfc-rtms delivered either at 10 and 20â min after capsaicin application significantly decreased spontaneous pain in both hands.
det||findings-2/NNS||these-1/DT	nsubj||are-3/VBP||findings-2/NNS	nsubj||indicate-14/VBP||findings-2/NNS	nsubj||open-39/VB||findings-2/NNS	root||ROOT-0/null||are-3/VBP	prep_in||are-3/VBP||contrast-5/NN	det||wisdom-9/NN||the-7/DT	amod||wisdom-9/NN||conventional-8/JJ	prep_to||contrast-5/NN||wisdom-9/NN	det||ufd-12/NN||the-11/DT	prep_concerning||wisdom-9/NN||ufd-12/NN	conj_and||are-3/VBP||indicate-14/VBP	det||concept-17/NN||a-15/DT	amod||concept-17/NN||new-16/JJ	dobj||indicate-14/VBP||concept-17/NN	aux||target-19/VB||to-18/TO	vmod||indicate-14/VBP||target-19/VB	det||protein-21/NN||a-20/DT	dobj||target-19/VB||protein-21/NN	dobj||target-19/VB||protein-21/NN	conj_and||protein-21/NN||protein-21/NN	det||system-25/NN||the-23/DT	amod||system-25/NN||ubiquitin-proteasome-24/JJ	prep_into||protein-21/NN||system-25/NN	appos||system-25/NN||ups-27/NNS	advmod||protein-21/NN||thus-30/RB	amod||presentation-35/NN||enhanced-32/JJ	nn||presentation-35/NN||mhc-i-33/NN	nn||presentation-35/NN||antigen-34/NN	prep_for||protein-21/NN||presentation-35/NN	aux||open-39/VB||might-38/MD	conj_and||are-3/VBP||open-39/VB	prt||open-39/VB||up-40/RP	amod||possibilities-42/NNS||new-41/JJ	dobj||open-39/VB||possibilities-42/NNS	det||development-45/NN||the-44/DT	prep_in||possibilities-42/NNS||development-45/NN	nn||vaccines-48/NNS||tumor-47/NN	prep_of||development-45/NN||vaccines-48/NNS	tumor-47||vaccines-48||no_rel||these findings are in contrast to the conventional wisdom concerning the ufd and indicate a new concept to target a protein into the ubiquitin-proteasome system (ups) and thus for enhanced mhc-i antigen presentation, and might open up new possibilities in the development of tumor vaccines.
nn||evidence-5/NN||human-1/NN	conj_and||human-1/NN||animal-3/NN	nn||evidence-5/NN||animal-3/NN	nn||evidence-5/NN||model-4/NN	nsubj||suggests-6/VBZ||evidence-5/NN	root||ROOT-0/null||suggests-6/VBZ	mark||play-12/VBP||that-7/IN	amod||cells-11/NNS||cd4-8/JJ	amod||cells-11/NNS||+-9/JJ	nn||cells-11/NNS||t-10/NN	nsubj||play-12/VBP||cells-11/NNS	ccomp||suggests-6/VBZ||play-12/VBP	det||role-15/NN||a-13/DT	amod||role-15/NN||critical-14/JJ	dobj||play-12/VBP||role-15/NN	det||control-18/NN||the-17/DT	prep_in||role-15/NN||control-18/NN	amod||infection-25/NN||chronichepatitisc-20/JJ	nn||infection-25/NN||virus-21/NN	appos||infection-25/NN||hcv-23/NN	prep_of||control-18/NN||infection-25/NN	chronichepatitisc-20||hcv-23||no||human and animal model evidence suggests that cd4+ t cells play a critical role in the control of chronichepatitisc virus (hcv) infection.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||decipher-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||decipher-8/VB||to-7/TO	xcomp||was-6/VBD||decipher-8/VB	det||role-11/NN||the-9/DT	amod||role-11/NN||specific-10/JJ	dobj||decipher-8/VB||role-11/NN	amod||stimulation-14/NN||ecb-system-13/JJ	prep_of||role-11/NN||stimulation-14/NN	amod||endotoxaemia-17/NN||metabolic-16/JJ	dobj||decipher-8/VB||endotoxaemia-17/NN	conj_or||role-11/NN||endotoxaemia-17/NN	det||onset-20/NN||the-19/DT	prep_in||endotoxaemia-17/NN||onset-20/NN	prep_of||onset-20/NN||glucoseintolerance-22/NN	amod||inflammation-25/NN||metabolic-24/JJ	prep_of||onset-20/NN||inflammation-25/NN	conj_and||glucoseintolerance-22/NN||inflammation-25/NN	amod||metabolism-29/NN||altered-27/JJ	nn||metabolism-29/NN||lipid-28/NN	prep_of||onset-20/NN||metabolism-29/NN	conj_and||glucoseintolerance-22/NN||metabolism-29/NN	inflammation-25||lipid-28||no_rel||the aim of this study was to decipher the specific role of ecb-system stimulation or metabolic endotoxaemia in the onset of glucoseintolerance, metabolic inflammation and altered lipid metabolism.
det||bacillusanthracis-3/NNS||the-1/DT	amod||bacillusanthracis-3/NNS||anthrax-causing-2/JJ	nsubj||experienced-4/VBD||bacillusanthracis-3/NNS	root||ROOT-0/null||experienced-4/VBD	det||changes-8/NNS||the-5/DT	amod||changes-8/NNS||similar-6/JJ	nn||changes-8/NNS||lifestyle-7/NN	dobj||experienced-4/VBD||changes-8/NNS	anthrax--1||bacillusanthracis-3||no||the anthrax-causing bacillusanthracis experienced the similar lifestyle changes.
amod||fibers-3/NNS||viscous-1/JJ	nn||fibers-3/NNS||dietary-2/NN	nsubj||blunt-4/VB||fibers-3/NNS	root||ROOT-0/null||blunt-4/VB	det||rise-7/NN||the-5/DT	amod||rise-7/NN||postprandial-6/JJ	dobj||blunt-4/VB||rise-7/NN	prep_in||blunt-4/VB||bloodglucose-9/NN	advmod||known-21/VBN||however-11/RB	poss||effect-13/NN||their-12/PRP$	nsubjpass||known-21/VBN||effect-13/NN	prep_on||effect-13/NN||type2diabetes-15/NN	prep_on||effect-13/NN||obesity-17/NN	conj_and||type2diabetes-15/NN||obesity-17/NN	auxpass||known-21/VBN||are-18/VBP	neg||known-21/VBN||not-19/RB	advmod||known-21/VBN||entirely-20/RB	parataxis||blunt-4/VB||known-21/VBN	type2diabetes-15||rise-7||no_rel||viscous dietary fibers blunt the postprandial rise in bloodglucose, however their effect on type2diabetes and obesity are not entirely known.
nsubj||exhibited-2/VBD||vh.cr-1/NN	root||ROOT-0/null||exhibited-2/VBD	amod||protection-13/NN||dose-dependent-3/JJ	amod||300â-8/NNS||100â-5/JJ	amod||300â-8/NNS||$-6/$	dep||mg/kg-11/JJ||300â-8/NNS	amod||300â-8/NNS||$-9/$	number||$-9/$||‰-10/CD	dep||protection-13/NN||mg/kg-11/JJ	dobj||exhibited-2/VBD||protection-13/NN	amod||diarrhea-16/NN||castoroil-induced-15/JJ	prep_against||protection-13/NN||diarrhea-16/NN	prep_in||exhibited-2/VBD||mice-18/NNS	diarrhea-16||castoroil--1||no||vh.cr exhibited dose-dependent (100â€“300â€‰mg/kg) protection against castoroil-induced diarrhea in mice.
amod||cells-2/NNS||epithelial-1/JJ	nsubjpass||grown-29/VBN||cells-2/NNS	nsubjpass||treated-36/VBN||cells-2/NNS	amod||brushings-5/NNS||bronchial-4/JJ	prep_from||cells-2/NNS||brushings-5/NNS	prep_of||brushings-5/NNS||normal-7/JJ	dep||normal-7/JJ||n-9/VBN	dep||8-11/CD||=-10/SYM	ccomp||n-9/VBN||8-11/CD	prep_of||brushings-5/NNS||asthma-14/NN	conj_and||normal-7/JJ||asthma-14/NN	dep||asthma-14/NN||n-16/VBN	dep||8-18/CD||=-17/SYM	ccomp||n-16/VBN||8-18/CD	amod||subjects-27/NNS||copd-21/JJ	dep||copd-21/JJ||n-23/VBN	dep||8-25/CD||=-24/SYM	ccomp||n-23/VBN||8-25/CD	prep_of||brushings-5/NNS||subjects-27/NNS	conj_and||normal-7/JJ||subjects-27/NNS	auxpass||grown-29/VBN||were-28/VBD	root||ROOT-0/null||grown-29/VBN	amod||cultures-33/NNS||air-liquid-31/JJ	nn||cultures-33/NNS||interface-32/NN	prep_in||grown-29/VBN||cultures-33/NNS	conj_and||grown-29/VBN||treated-36/VBN	nn||smoke-39/NN||cigarette-38/NN	prep_with||treated-36/VBN||smoke-39/NN	ccomp||treated-36/VBN||extract-40/VB	appos||th2-45/NN||cse-42/NN	amod||th2-45/NN||and/or-44/JJ	dobj||extract-40/VB||th2-45/NN	amod||il-13-47/JJ||cytokine-46/JJ	amod||th2-45/NN||il-13-47/JJ	conj_and||grown-29/VBN||followed-49/VBN	conj_and||treated-36/VBN||followed-49/VBN	nn||infection-52/NN||mp-51/NN	prep_by||followed-49/VBN||infection-52/NN	prep_by||followed-49/VBN||treatment-54/NN	conj_and||infection-52/NN||treatment-54/NN	nn||albuterol-59/NN||î-56/NN	nn||albuterol-59/NN||²-57/NNP	amod||albuterol-59/NN||2-agonists-58/JJ	prep_with||followed-49/VBN||albuterol-59/NN	conj_and||grown-29/VBN||formoterol-61/JJ	conj_and||treated-36/VBN||formoterol-61/JJ	quantmod||seven-65/CD||up-63/IN	dep||seven-65/CD||to-64/TO	num||days-66/NNS||seven-65/CD	prep_for||formoterol-61/JJ||days-66/NNS	asthma-14||formoterol-61||yes||epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and copd (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (cse) and/or th2 cytokine il-13, followed by mp infection and treatment with î²2-agonists albuterol and formoterol for up to seven days.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	type2diabetes-15||insulin-22||yes||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
advmod||therapeutics-10/NNS||thus-1/RB	amod||modulators-6/NNS||gabab-3/JJ	nn||modulators-6/NNS||receptor-4/NN	amod||modulators-6/NNS||positive-5/JJ	nsubj||therapeutics-10/NNS||modulators-6/NNS	aux||therapeutics-10/NNS||could-7/MD	cop||therapeutics-10/NNS||be-8/VB	amod||therapeutics-10/NNS||useful-9/JJ	root||ROOT-0/null||therapeutics-10/NNS	det||treatment-13/NN||the-12/DT	prep_for||therapeutics-10/NNS||treatment-13/NN	amod||aspects-16/NNS||different-15/JJ	prep_of||treatment-13/NN||aspects-16/NNS	prep_of||aspects-16/NNS||nicotinedependence-18/NN	prepc_by||therapeutics-10/NNS||facilitating-20/VBG	nn||cessation-22/NN||smoking-21/NN	dobj||facilitating-20/VBG||cessation-22/NN	amod||intake-26/NN||decreasing-24/VBG	nn||intake-26/NN||nicotine-25/NN	prep_by||facilitating-20/VBG||intake-26/NN	prepc_by||therapeutics-10/NNS||preventing-28/VBG	conj_and||facilitating-20/VBG||preventing-28/VBG	acomp||preventing-28/VBG||relapse-29/JJ	prep_to||relapse-29/JJ||smoking-31/NN	prep_in||smoking-31/NN||humans-33/NNS	nicotinedependence-18||nicotine-25||no||thus, gabab receptor positive modulators could be useful therapeutics for the treatment of different aspects of nicotinedependence by facilitating smoking cessation by decreasing nicotine intake and preventing relapse to smoking in humans.
nsubj||developed-2/VBD||we-1/PRP	root||ROOT-0/null||developed-2/VBD	dobj||developed-2/VBD||rules-3/NNS	aux||guide-5/VB||to-4/TO	vmod||developed-2/VBD||guide-5/VB	dobj||guide-5/VB||frequency-6/NN	amod||monitoring-11/NN||cd4-8/JJ	nn||monitoring-11/NN||cell-9/NN	nn||monitoring-11/NN||count-10/NN	prep_of||frequency-6/NN||monitoring-11/NN	prep_in||monitoring-11/NN||hivinfection-13/NN	prepc_before||guide-5/VB||starting-15/VBG	amod||therapy-17/NN||antiretroviral-16/JJ	dobj||starting-15/VBG||therapy-17/NN	dobj||validated-21/VBD||therapy-17/NN	nsubj||validated-21/VBD||we-20/PRP	rcmod||therapy-17/NN||validated-21/VBD	advmod||validated-21/VBD||retrospectively-22/RB	prep_in||validated-21/VBD||patients-24/NNS	det||study-30/NN||the-26/DT	amod||study-30/NN||swiss-27/JJ	nn||study-30/NN||hiv-28/NN	nn||study-30/NN||cohort-29/NN	prep_from||patients-24/NNS||study-30/NN	hivinfection-13||hiv-28||no||we developed rules to guide frequency of cd4 cell count monitoring in hivinfection before starting antiretroviral therapy, which we validated retrospectively in patients from the swiss hiv cohort study.
num||characteristics-4/NNS||six-1/CD	nn||characteristics-4/NNS||baseline-2/NN	nn||characteristics-4/NNS||participant-3/NN	nsubjpass||designated-6/VBN||characteristics-4/NNS	nsubj||participantsâ-60/VBZ||characteristics-4/NNS	auxpass||designated-6/VBN||were-5/VBD	root||ROOT-0/null||designated-6/VBN	amod||predictors-9/NNS||putative-8/JJ	prep_as||designated-6/VBN||predictors-9/NNS	nn||response-12/NN||treatment-11/NN	prep_of||predictors-9/NNS||response-12/NN	appos||response-12/NN||1-14/CD	dep||response-12/NN||gender-16/NN	appos||gender-16/NN||2-19/CD	dep||gender-16/NN||education-21/NN	dep||use-27/NN||3-24/LS	amod||use-27/NN||internet-26/VBN	appos||education-21/NN||use-27/NN	amod||sociodemographics-30/NNS||competence-28/JJ	dep||use-27/NN||sociodemographics-30/NNS	appos||sociodemographics-30/NNS||4-34/CD	amod||consumption-39/NN||mean-36/JJ	amod||consumption-39/NN||weekly-37/JJ	nn||consumption-39/NN||alcohol-38/NN	dep||sociodemographics-30/NNS||consumption-39/NN	appos||consumption-39/NN||5-42/CD	amod||help-46/NN||prior-44/JJ	amod||help-46/NN||professional-45/JJ	dep||consumption-39/NN||help-46/NN	nn||problems-49/NNS||alcohol-48/NN	prep_for||help-46/NN||problems-49/NNS	dep||problems-49/NNS||level-51/NN	prep_of||level-51/NN||problemdrinking-53/VBG	dep||participantsâ-60/VBZ||6-58/CD	conj_and||designated-6/VBN||participantsâ-60/VBZ	dep||expectancies-63/NNS||$-61/$	num||expectancies-63/NNS||™-62/CD	dobj||participantsâ-60/VBZ||expectancies-63/NNS	amod||interventions-66/NNS||web-based-65/JJ	prep_of||expectancies-63/NNS||interventions-66/NNS	prep_for||interventions-66/NNS||problemdrinking-68/VBG	problemdrinking-68||alcohol-48||no||six baseline participant characteristics were designated as putative predictors of treatment response (1) gender, (2) education, (3) internet use competence (sociodemographics), (4) mean weekly alcohol consumption, (5) prior professional help for alcohol problems (level of problemdrinking), and (6) participantsâ€™ expectancies of web-based interventions for problemdrinking.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	insulin--1||type2diabetes--1||no_rel||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
nn||department-2/NN||emergency-1/NN	nsubjpass||treated-15/VBN||department-2/NN	dep||treated-15/VBN||ed-4/NN	nsubjpass||treated-15/VBN||patients-6/NNS	amod||thromboembolism-9/NN||venous-8/JJ	prep_with||patients-6/NNS||thromboembolism-9/NN	appos||patients-6/NNS||vte-11/NN	auxpass||treated-15/VBN||are-13/VBP	advmod||treated-15/VBN||eventually-14/RB	root||ROOT-0/null||treated-15/VBN	det||dose-19/NN||a-17/DT	amod||dose-19/NN||standard-18/JJ	prep_with||treated-15/VBN||dose-19/NN	prep_of||dose-19/NN||warfarin-21/NN	det||fact-24/NN||the-23/DT	prep_despite||treated-15/VBN||fact-24/NN	mark||known-31/VBN||that-25/IN	det||number-27/NN||a-26/DT	nsubjpass||known-31/VBN||number-27/NN	nsubj||sensitive-34/JJ||number-27/NN	nsubj||warfarin-36/VB||number-27/NN	nsubj||experience-39/VB||number-27/NN	prep_of||number-27/NN||patients-29/NNS	auxpass||known-31/VBN||are-30/VBP	ccomp||treated-15/VBN||known-31/VBN	aux||sensitive-34/JJ||to-32/TO	cop||sensitive-34/JJ||be-33/VB	xcomp||known-31/VBN||sensitive-34/JJ	aux||warfarin-36/VB||to-35/TO	xcomp||sensitive-34/JJ||warfarin-36/VB	aux||experience-39/VB||may-38/MD	ccomp||treated-15/VBN||experience-39/VB	conj_and||known-31/VBN||experience-39/VB	amod||inrs-41/NNS||supra-therapeutic-40/JJ	dobj||experience-39/VB||inrs-41/NNS	amod||events-45/NNS||adverse-43/JJ	amod||events-45/NNS||bleeding-44/VBG	dobj||experience-39/VB||events-45/NNS	conj_and||inrs-41/NNS||events-45/NNS	thromboembolism-9||warfarin-36||yes||emergency department (ed) patients with venous thromboembolism (vte) are eventually treated with a standard dose of warfarin despite the fact that a number of patients are known to be sensitive to warfarin and may experience supra-therapeutic inrs and adverse bleeding events.
amod||spraying-4/NNS||indoor-1/JJ	amod||spraying-4/NNS||residual-2/JJ	nn||spraying-4/NNS||insecticide-3/NN	nsubjpass||used-18/VBN||spraying-4/NNS	appos||spraying-4/NNS||irs-6/NN	amod||nets-12/NNS||long-lasting-9/JJ	amod||nets-12/NNS||insecticide-10/JJ	amod||nets-12/NNS||treated-11/JJ	conj_and||spraying-4/NNS||nets-12/NNS	nsubjpass||used-18/VBN||nets-12/NNS	appos||nets-12/NNS||llins-14/NNS	auxpass||used-18/VBN||are-16/VBP	advmod||used-18/VBN||commonly-17/RB	root||ROOT-0/null||used-18/VBN	advmod||used-18/VBN||together-19/RB	advmod||inconsistent-36/JJ||even-20/RB	mark||inconsistent-36/JJ||though-21/IN	nsubj||inconsistent-36/JJ||evidence-22/NN	mark||confer-26/VBP||that-23/IN	amod||combinations-25/NNS||such-24/JJ	nsubj||confer-26/VBP||combinations-25/NNS	dep||evidence-22/NN||confer-26/VBP	amod||protection-28/NN||greater-27/JJR	dobj||confer-26/VBP||protection-28/NN	prep_against||confer-26/VBP||malaria-30/NN	det||method-33/NN||either-32/DT	prep_than||malaria-30/NN||method-33/NN	advmod||inconsistent-36/JJ||alone-34/RB	cop||inconsistent-36/JJ||is-35/VBZ	advcl||used-18/VBN||inconsistent-36/JJ	insecticide-10||malaria-30||no_rel||indoor residual insecticide spraying (irs) and long-lasting insecticide treated nets (llins) are commonly used together even though evidence that such combinations confer greater protection against malaria than either method alone is inconsistent.
nsubjpass||thought-4/VBN||this-1/DT	nsubj||represent-6/VB||this-1/DT	auxpass||thought-4/VBN||was-2/VBD	advmod||thought-4/VBN||initially-3/RB	root||ROOT-0/null||thought-4/VBN	aux||represent-6/VB||to-5/TO	xcomp||thought-4/VBN||represent-6/VB	det||allergicreaction-8/NN||an-7/DT	dobj||represent-6/VB||allergicreaction-8/NN	aux||dicloxacillin-10/VB||to-9/TO	vmod||allergicreaction-8/NN||dicloxacillin-10/VB	prep_in||dicloxacillin-10/VB||someone-12/NN	det||history-16/NN||a-14/DT	amod||history-16/NN||previous-15/JJ	prep_with||dicloxacillin-10/VB||history-16/NN	nn||hypersensitivity-19/NN||penicillin-18/NN	prep_of||history-16/NN||hypersensitivity-19/NN	allergicreaction-8||hypersensitivity-19||no||this was initially thought to represent an allergicreaction to dicloxacillin in someone with a previous history of penicillin hypersensitivity.
nn||fdc-2/NN||repaglinide/metformin-1/NN	nsubj||represents-3/VBZ||fdc-2/NN	root||ROOT-0/null||represents-3/VBZ	det||option-6/NN||a-4/DT	amod||option-6/NN||new-5/JJ	dobj||represents-3/VBZ||option-6/NN	det||pursuit-9/NN||the-8/DT	prep_in||option-6/NN||pursuit-9/NN	prepc_of||pursuit-9/NN||achieving-11/VBG	nn||targets-13/NNS||glucose-12/NN	dobj||achieving-11/VBG||targets-13/NNS	prepc_of||pursuit-9/NN||reducing-15/VBG	conj_and||achieving-11/VBG||reducing-15/VBG	nn||risk-17/NN||vascular-16/NN	dobj||reducing-15/VBG||risk-17/NN	prep_in||risk-17/NN||type2diabetes-19/CD	det||advantage-23/NN||the-22/DT	prep_with||reducing-15/VBG||advantage-23/NN	prepc_of||advantage-23/NN||improving-25/VBG	dobj||improving-25/VBG||adherence-26/NN	type2diabetes-19||metformin--1||yes||repaglinide/metformin fdc represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type2diabetes, with the advantage of improving adherence.
nn||samples-2/NNS||water-1/NN	nsubjpass||collected-11/VBN||samples-2/NNS	nsubj||detect-16/VB||samples-2/NNS	amod||areas-7/NNS||different-4/JJ	amod||areas-7/NNS||cholera-5/JJ	amod||areas-7/NNS||endemic-6/JJ	prep_from||samples-2/NNS||areas-7/NNS	prep_in||areas-7/NNS||sudan-9/NN	auxpass||collected-11/VBN||were-10/VBD	root||ROOT-0/null||collected-11/VBN	det||aim-14/NN||the-13/DT	prep_with||collected-11/VBN||aim-14/NN	aux||detect-16/VB||to-15/TO	xcomp||collected-11/VBN||detect-16/VB	preconj||v.cholerae-18/JJ||both-17/DT	amod||species-21/NNS||v.cholerae-18/JJ	conj_and||v.cholerae-18/JJ||acanthamoeba-20/JJ	amod||species-21/NNS||acanthamoeba-20/JJ	dobj||detect-16/VB||species-21/NNS	amod||samples-26/NNS||same-23/JJ	amod||samples-26/NNS||natural-24/JJ	nn||samples-26/NNS||water-25/NN	prep_from||detect-16/VB||samples-26/NNS	nn||-rrb--33/NNP||polymerase-28/NN	nn||-rrb--33/NNP||chain-29/NN	nn||-rrb--33/NNP||reaction-30/NN	nn||-rrb--33/NNP||-lrb--31/NNP	nn||-rrb--33/NNP||pcr-32/NNP	prep_by||detect-16/VB||-rrb--33/NNP	cholera-5||v.cholerae-18||no||water samples from different cholera endemic areas in sudan were collected with the aim to detect both v.cholerae and acanthamoeba species from same natural water samples by polymerase chain reaction -lrb- pcr -rrb- .
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||mesothelioma-33||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
det||end-3/NN||this-2/DT	prep_to||made-26/VBN||end-3/NN	amod||amplification-7/NN||single-5/JJ	nn||amplification-7/NN||genome-6/NN	nsubj||made-26/VBN||amplification-7/NN	appos||amplification-7/NN||sga-9/NN	conj_and||amplification-7/NN||sequencing-12/NN	nsubj||made-26/VBN||sequencing-12/NN	amod||evolution-24/NN||hiv-1-14/JJ	det||context-17/NN||the-16/DT	prep_within||hiv-1-14/JJ||context-17/NN	det||model-20/NN||a-19/DT	prep_of||context-17/NN||model-20/NN	amod||virus-23/NN||random-22/JJ	prep_of||model-20/NN||virus-23/NN	prep_of||sequencing-12/NN||evolution-24/NN	aux||made-26/VBN||has-25/VBZ	root||ROOT-0/null||made-26/VBN	acomp||made-26/VBN||possible-27/JJ	det||time-31/NN||the-29/DT	amod||time-31/NN||first-30/JJ	prep_for||made-26/VBN||time-31/NN	det||identification-34/NN||an-32/DT	amod||identification-34/NN||unambiguous-33/JJ	dep||time-31/NN||identification-34/NN	nn||viruses-37/NNS||transmitted/founder-36/NN	prep_of||identification-34/NN||viruses-37/NNS	det||estimation-41/NN||a-39/DT	amod||estimation-41/NN||precise-40/JJ	prep_for||made-26/VBN||estimation-41/NN	conj_and||time-31/NN||estimation-41/NN	poss||numbers-44/NNS||their-43/PRP$	prep_of||estimation-41/NN||numbers-44/NNS	virus-23||viruses-37||no||to this end, single genome amplification (sga) and sequencing of hiv-1 within the context of a model of random virus evolution has made possible for the first time an unambiguous identification of transmitted/founder viruses and a precise estimation of their numbers.
det||study-2/NN||this-1/DT	nsubj||defined-3/VBD||study-2/NN	root||ROOT-0/null||defined-3/VBD	det||dose-6/NN||a-4/DT	amod||dose-6/NN||tolerable-5/JJ	dobj||defined-3/VBD||dose-6/NN	prep_of||dose-6/NN||olaparib-8/NN	prep_in||defined-3/VBD||combination-10/NN	prep_with||defined-3/VBD||dacarbazine-12/NN	expl||were-16/VBD||there-15/EX	conj_but||defined-3/VBD||were-16/VBD	neg||responses-18/NNS||no-17/DT	nsubj||were-16/VBD||responses-18/NNS	amod||patients-22/NNS||chemonaive-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_in||responses-18/NNS||patients-22/NNS	vmod||responses-18/NNS||demonstrating-24/VBG	neg||advantage-27/NN||no-25/DT	amod||advantage-27/NN||clinical-26/JJ	dobj||demonstrating-24/VBG||advantage-27/NN	amod||dacarbazine-30/NN||single-agent-29/JJ	prep_over||advantage-27/NN||dacarbazine-30/NN	det||doses-33/NNS||these-32/DT	prep_at||demonstrating-24/VBG||doses-33/NNS	melanoma-21||dacarbazine-30||yes||this study defined a tolerable dose of olaparib in combination with dacarbazine, but there were no responses in chemonaive melanoma patients, demonstrating no clinical advantage over single-agent dacarbazine at these doses.
nn||species-2/NNS||brucella-1/NN	nsubj||agents-6/NNS||species-2/NNS	cop||agents-6/NNS||are-3/VBP	det||agents-6/NNS||the-4/DT	amod||agents-6/NNS||causative-5/JJ	root||ROOT-0/null||agents-6/NNS	prep_of||agents-6/NNS||one-8/CD	det||brucellosis-15/NNS||the-10/DT	advmod||zoonotic-13/JJ||most-11/RBS	amod||zoonotic-13/JJ||prevalent-12/JJ	amod||brucellosis-15/NNS||zoonotic-13/JJ	nn||brucellosis-15/NNS||diseases-14/NNS	prep_of||agents-6/NNS||brucellosis-15/NNS	brucellosis-15||brucella-1||no||brucella species are the causative agents of one of the most prevalent zoonotic diseases brucellosis.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||solvate-16/NN||compound-3/NN	amod||·-6/NNS||c16h20n4o3sâ-5/JJ	appos||compound-3/NN||·-6/NNS	num||h2o-11/NNS||0.25-7/CD	amod||h2o-11/NNS||ch4oâ-8/JJ	nn||h2o-11/NNS||·-9/NNP	num||h2o-11/NNS||0.25-10/CD	dep||·-6/NNS||h2o-11/NNS	cop||solvate-16/NN||is-13/VBZ	det||solvate-16/NN||a-14/DT	amod||solvate-16/NN||hydrate/methanol-15/JJ	root||ROOT-0/null||solvate-16/NN	prep_of||solvate-16/NN||torasemide-18/NN	det||drug-22/NN||a-20/DT	amod||drug-22/NN||diuretic-21/JJ	appos||torasemide-18/NN||drug-22/NN	vmod||drug-22/NN||used-23/VBN	det||treatment-26/NN||the-25/DT	prep_in||used-23/VBN||treatment-26/NN	prep_of||treatment-26/NN||hypertension-28/NN	hypertension-28||torasemide-18||yes||the title compound, c16h20n4o3sâ·0.25ch4oâ·0.25h2o, is a hydrate/methanol solvate of torasemide, a diuretic drug used in the treatment of hypertension.
amod||anticoagulation-2/NN||oral-1/JJ	nsubj||prevents-3/VBZ||anticoagulation-2/NN	root||ROOT-0/null||prevents-3/VBZ	dobj||prevents-3/VBZ||strokes-4/NNS	prep_in||strokes-4/NNS||patients-6/NNS	prep_with||patients-6/NNS||atrialfibrillation-8/NN	nsubj||remain-14/VBP||reasons-12/NNS	prep_for||receive-26/VBP||reasons-12/NNS	rcmod||reasons-12/NNS||remain-14/VBP	acomp||remain-14/VBP||unclear-15/JJ	mwe||than-18/IN||less-17/JJR	quantmod||40-19/CD||than-18/IN	num||%-20/NN||40-19/CD	nsubj||receive-26/VBP||%-20/NN	det||patients-23/NNS||all-22/DT	prep_of||%-20/NN||patients-23/NNS	prep_with||patients-23/NNS||atrialfibrillation-25/NN	conj_but||prevents-3/VBZ||receive-26/VBP	dobj||receive-26/VBP||warfarin-27/NN	strokes-4||warfarin-27||yes||oral anticoagulation prevents strokes in patients with atrialfibrillation but, for reasons that remain unclear, less than 40% of all patients with atrialfibrillation receive warfarin.
nsubj||conducted-5/VBD||we-1/PRP	advmod||conducted-5/VBD||therefore-3/RB	root||ROOT-0/null||conducted-5/VBD	det||evaluation-8/NN||a-6/DT	amod||evaluation-8/NN||comprehensive-7/JJ	dobj||conducted-5/VBD||evaluation-8/NN	advmod||resistant-11/JJ||inh-10/RB	amod||levels-54/NNS||resistant-11/JJ	amod||strains-13/NNS||m.tuberculosis-12/JJ	nn||n-15/NN||strains-13/NNS	amod||n-15/NN||-lrb--14/JJ	npadvmod||resistant-11/JJ||n-15/NN	dep||-rrb--18/NNS||=-16/SYM	num||-rrb--18/NNS||224-17/CD	dep||n-15/NN||-rrb--18/NNS	npadvmod||south-21/RB||three-20/CD	advmod||countries-23/NNS||south-21/RB	amod||countries-23/NNS||american-22/JJ	prep_from||resistant-11/JJ||countries-23/NNS	amod||burden-26/NN||high-25/JJ	prep_with||resistant-11/JJ||burden-26/NN	prep_of||burden-26/NN||drug-28/NN	amod||levels-54/NNS||resistant-29/JJ	advmod||resistant-29/JJ||tb-30/RB	aux||characterize-32/VB||to-31/TO	xcomp||resistant-29/JJ||characterize-32/VB	dobj||characterize-32/VB||mutations-33/NNS	nn||g-36/NN||kat-35/NN	prep_in||characterize-32/VB||g-36/NN	xcomp||resistant-29/JJ||ahp-38/VB	conj_and||characterize-32/VB||ahp-38/VB	dep||ahp-38/VB||c-39/SYM	xcomp||resistant-29/JJ||inh-41/VB	conj_and||characterize-32/VB||inh-41/VB	det||loci-44/NN||a-42/DT	nn||loci-44/NN||gene-43/NN	dobj||inh-41/VB||loci-44/NN	conj_and||characterize-32/VB||correlate-46/VB	conj_and||inh-41/VB||correlate-46/VB	amod||concentrations-50/NNS||minimal-48/JJ	nn||concentrations-50/NNS||inhibitory-49/NN	prep_with||correlate-46/VB||concentrations-50/NNS	amod||levels-54/NNS||-lrb--51/JJ	amod||levels-54/NNS||mic-52/JJ	nn||levels-54/NNS||-rrb--53/NN	prep_of||evaluation-8/NN||levels-54/NNS	amod||family-58/NN||spoligotype-56/JJ	nn||family-58/NN||strain-57/NN	prep_of||evaluation-8/NN||family-58/NN	conj_and||levels-54/NNS||family-58/NN	tb-30||inh-41||yes||we , therefore , conducted a comprehensive evaluation of inh resistant m.tuberculosis strains -lrb- n = 224 -rrb- from three south american countries with high burden of drug resistant tb to characterize mutations in kat g , ahp c and inh a gene loci and correlate with minimal inhibitory concentrations -lrb- mic -rrb- levels and spoligotype strain family .
det||diversity-3/NN||the-1/DT	amod||diversity-3/NN||high-2/JJ	nsubj||caused-13/VBN||diversity-3/NN	nn||variants-6/NNS||hiv-5/NN	prep_of||diversity-3/NN||variants-6/NNS	vmod||variants-6/NNS||driving-7/VBG	det||epidemic-11/NN||the-8/DT	amod||epidemic-11/NN||global-9/JJ	nn||epidemic-11/NN||aids-10/NNS	dobj||driving-7/VBG||epidemic-11/NN	aux||caused-13/VBN||has-12/VBZ	root||ROOT-0/null||caused-13/VBN	acomp||caused-13/VBN||many-14/JJ	aux||doubt-16/VB||to-15/TO	xcomp||many-14/JJ||doubt-16/VB	mark||possible-25/JJ||whether-17/IN	det||vaccine-20/NN||an-18/DT	amod||vaccine-20/NN||effective-19/JJ	nsubj||possible-25/JJ||vaccine-20/NN	det||virus-23/NN||the-22/DT	prep_against||vaccine-20/NN||virus-23/NN	cop||possible-25/JJ||is-24/VBZ	ccomp||doubt-16/VB||possible-25/JJ	aids-10||hiv-5||no||the high diversity of hiv variants driving the global aids epidemic has caused many to doubt whether an effective vaccine against the virus is possible.
poss||findings-2/NNS||its-1/PRP$	nsubj||contribute-4/VB||findings-2/NNS	aux||contribute-4/VB||may-3/MD	root||ROOT-0/null||contribute-4/VB	det||identification-7/NN||the-6/DT	prep_in||contribute-4/VB||identification-7/NN	amod||individuals-11/NNS||higher-9/JJR	nn||individuals-11/NNS||risk-10/NN	prep_of||identification-7/NN||individuals-11/NNS	prep_for||individuals-11/NNS||diabetes-13/NN	prep_for||individuals-11/NNS||cardiovasculardisease-15/NN	conj_and||diabetes-13/NN||cardiovasculardisease-15/NN	det||comprehension-19/NN||a-17/DT	amod||comprehension-19/NN||better-18/JJR	prep_with||contribute-4/VB||comprehension-19/NN	det||intercorrelation-23/NN||the-21/DT	amod||intercorrelation-23/NN||complex-22/JJ	prep_about||comprehension-19/NN||intercorrelation-23/NN	nn||metabolism-28/NN||adiposity-25/NN	prep_between||intercorrelation-23/NN||glucose-27/NN	conj_and||metabolism-28/NN||glucose-27/NN	prep_between||intercorrelation-23/NN||metabolism-28/NN	prep_between||intercorrelation-23/NN||vasculardisease-30/NN	conj_and||metabolism-28/NN||vasculardisease-30/NN	cardiovasculardisease-15||glucose-27||no_rel||its findings may contribute in the identification of higher risk individuals for diabetes and cardiovasculardisease with a better comprehension about the complex intercorrelation between adiposity, glucose metabolism and vasculardisease.
nsubjpass||implicated-22/VBN||bacteria-1/NNS	advmod||bacteria-1/NNS||particularly-3/RB	conj_and||bacteria-1/NNS||particularly-3/RB	nsubjpass||implicated-22/VBN||particularly-3/RB	nn||pylori-5/NNS||helicobacter-4/NN	dep||bacteria-1/NNS||pylori-5/NNS	conj_and||bacteria-1/NNS||viruses-8/NNS	nsubjpass||implicated-22/VBN||viruses-8/NNS	prep_such_as||viruses-8/NNS||members-11/NNS	det||family-15/NN||the-13/DT	amod||family-15/NN||humanpapillomavirus-14/JJ	prep_of||members-11/NNS||family-15/NN	prep_of||members-11/NNS||hepatitisb-17/NN	conj_and||family-15/NN||hepatitisb-17/NN	prep_of||members-11/NNS||c-19/SYM	conj_and||family-15/NN||c-19/SYM	auxpass||implicated-22/VBN||are-20/VBP	advmod||implicated-22/VBN||strongly-21/RB	root||ROOT-0/null||implicated-22/VBN	amod||factors-25/NNS||etiological-24/JJ	prep_as||implicated-22/VBN||factors-25/NNS	amod||cancers-28/NNS||certain-27/JJ	prep_in||factors-25/NNS||cancers-28/NNS	hepatitisb-17||viruses-8||no||bacteria, particularly helicobacter pylori , and viruses such as members of the humanpapillomavirus family and hepatitisb and c are strongly implicated as etiological factors in certain cancers.
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||varicella-zostervirus-1||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
nsubjpass||evidenced-8/VBN||lymeneuroborreliosis-1/NNS	poss||$-4/$||â-3/PRP$	conj_or||lymeneuroborreliosis-1/NNS||$-4/$	nsubjpass||evidenced-8/VBN||$-4/$	number||$-6/CD||œneurologicallymediseaseâ-5/CD	num||$-4/$||$-6/CD	auxpass||evidenced-8/VBN||was-7/VBD	root||ROOT-0/null||evidenced-8/VBN	prep_in||evidenced-8/VBN||2-10/CD	num||patients-13/NNS||23-12/CD	prep_of||2-10/CD||patients-13/NNS	vmod||patients-13/NNS||submitted-14/VBN	amod||criteria-17/NNS||strict-16/JJ	prep_to||submitted-14/VBN||criteria-17/NNS	nn||selection-20/NN||case-19/NN	prep_for||criteria-17/NNS||selection-20/NN	det||centers-23/NNS||the-22/DT	prep_of||selection-20/NN||centers-23/NNS	nn||control-26/NN||disease-25/NN	prep_for||centers-23/NNS||control-26/NN	prep_for||centers-23/NNS||prevention-28/NN	conj_and||control-26/NN||prevention-28/NN	xcomp||submitted-14/VBN||employing-29/VBG	det||test-32/NN||a-30/DT	amod||test-32/NN||two-tier-31/JJ	dobj||employing-29/VBG||test-32/NN	aux||detect-34/VB||to-33/TO	vmod||employing-29/VBG||detect-34/VB	dobj||detect-34/VB||antibodies-35/NNS	prep_to||detect-34/VB||borreliaburgdorferi-37/NNS	det||institution-41/NN||a-39/DT	amod||institution-41/NN||single-40/JJ	prep_at||borreliaburgdorferi-37/NNS||institution-41/NN	neurologicallymedisease--1||borreliaburgdorferi-37||no||lymeneuroborreliosis or â€œneurologicallymediseaseâ€? was evidenced in 2 of 23 patients submitted to strict criteria for case selection of the centers for disease control and prevention employing a two-tier test to detect antibodies to borreliaburgdorferi at a single institution.
mark||recognised-19/VBN||although-1/IN	amod||infections-3/NNS||polymicrobial-2/JJ	nsubjpass||recognised-19/VBN||infections-3/NNS	vmod||infections-3/NNS||caused-5/VBN	agent||caused-5/VBN||combinations-7/NNS	prep_of||combinations-7/NNS||viruses-9/NNS	prep_of||combinations-7/NNS||bacteria-11/NNS	conj_and||viruses-9/NNS||bacteria-11/NNS	prep_of||combinations-7/NNS||fungi-13/NNS	conj_and||viruses-9/NNS||fungi-13/NNS	prep_of||combinations-7/NNS||parasites-15/NNS	conj_and||viruses-9/NNS||parasites-15/NNS	aux||recognised-19/VBN||are-17/VBP	auxpass||recognised-19/VBN||being-18/VBG	advcl||known-26/VBN||recognised-19/VBN	amod||frequency-22/NN||increasing-21/VBG	prep_with||recognised-19/VBN||frequency-22/NN	nsubjpass||known-26/VBN||little-24/RB	auxpass||known-26/VBN||is-25/VBZ	root||ROOT-0/null||known-26/VBN	det||occurrence-29/NN||the-28/DT	prep_about||known-26/VBN||occurrence-29/NN	amod||diversity-32/NN||within-species-31/JJ	prep_of||occurrence-29/NN||diversity-32/NN	prep_in||diversity-32/NN||bacterialinfections-34/NNS	det||bases-40/NNS||the-36/DT	amod||bases-40/NNS||molecular-37/JJ	conj_and||molecular-37/JJ||evolutionary-39/JJ	amod||bases-40/NNS||evolutionary-39/JJ	prep_of||occurrence-29/NN||bases-40/NNS	conj_and||diversity-32/NN||bases-40/NNS	det||diversity-43/NN||this-42/DT	prep_of||bases-40/NNS||diversity-43/NN	bacterialinfections-34||bacteria-11||no||although polymicrobial infections, caused by combinations of viruses, bacteria, fungi and parasites, are being recognised with increasing frequency, little is known about the occurrence of within-species diversity in bacterialinfections and the molecular and evolutionary bases of this diversity.
det||interview-4/NN||the-2/DT	amod||interview-4/NN||same-3/JJ	prep_in||conduct-8/VB||interview-4/NN	nsubj||conduct-8/VB||we-6/PRP	aux||conduct-8/VB||will-7/MD	root||ROOT-0/null||conduct-8/VB	amod||exercises-10/NNS||preference-elicitation-9/JJ	dobj||conduct-8/VB||exercises-10/NNS	vmod||exercises-10/NNS||using-11/VBG	det||thermometer-14/NN||the-12/DT	nn||thermometer-14/NN||feeling-13/NN	dobj||using-11/VBG||thermometer-14/NN	aux||identify-16/VB||to-15/TO	vmod||using-11/VBG||identify-16/VB	det||utilities-18/NNS||the-17/DT	dobj||identify-16/VB||utilities-18/NNS	mark||place-21/VBP||that-19/IN	nsubj||place-21/VBP||patients-20/NNS	ccomp||identify-16/VB||place-21/VBP	prepc_on||place-21/VBP||taking-23/VBG	dobj||taking-23/VBG||medication-24/NN	dep||medication-24/NN||warfarin-26/NN	dep||medication-24/NN||aspirin-28/NN	conj_and||warfarin-26/NN||aspirin-28/NN	prepc_on||place-21/VBP||having-33/VBG	conj_and||taking-23/VBG||having-33/VBG	det||stroke-36/NN||a-34/DT	amod||stroke-36/NN||mild-35/JJ	dobj||having-33/VBG||stroke-36/NN	det||stroke-40/NN||a-38/DT	amod||stroke-40/NN||severe-39/JJ	dobj||having-33/VBG||stroke-40/NN	conj_and||stroke-36/NN||stroke-40/NN	det||bleed-45/NN||a-43/DT	amod||bleed-45/NN||major-44/JJ	dobj||having-33/VBG||bleed-45/NN	conj_and||stroke-36/NN||bleed-45/NN	stroke-40||warfarin-26||yes||in the same interview, we will conduct preference-elicitation exercises using the feeling thermometer to identify the utilities that patients place on taking medication (warfarin and aspirin), and on having a mild stroke, a severe stroke, and a major bleed.
prep_after||considered-9/VBN||treatment-2/NN	prep_with||treatment-2/NN||gabapentin-4/NN	num||patients-7/NNS||16-6/CD	nsubjpass||considered-9/VBN||patients-7/NNS	auxpass||considered-9/VBN||were-8/VBD	root||ROOT-0/null||considered-9/VBN	dep||considered-9/VBN||responders-11/NNS	prep_with||considered-9/VBN||decrease-15/NN	prep_in||decrease-15/NN||pain-17/NN	mwe||than-20/IN||greater-19/JJR	quantmod||50-21/CD||than-20/IN	num||%-22/NN||50-21/CD	prep_of||pain-17/NN||%-22/NN	prepc_as||%-22/NN||evaluated-24/VBN	amod||scale-28/NN||visual-26/JJ	amod||scale-28/NN||analogue-27/JJ	prep_by||evaluated-24/VBN||scale-28/NN	appos||%-22/NN||vas-30/NN	pain-17||gabapentin-4||yes||after treatment with gabapentin, 16 patients were considered 'responders', with decrease in pain of greater than 50% as evaluated by visual analogue scale (vas).
det||lack-4/NN||this-1/DT	nn||lack-4/NN||study-2/NN	nn||lack-4/NN||shows-3/NNS	nsubj||ca-44/MD||lack-4/NN	amod||activity-8/NN||co2-6/JJ	nn||activity-8/NN||hydration-7/NN	prep_of||lack-4/NN||activity-8/NN	det||protein-12/NN||a-10/DT	amod||protein-12/NN||recombinant-11/JJ	prep_in||activity-8/NN||protein-12/NN	vmod||protein-12/NN||expressed-13/VBN	det||gene-16/NN||a-15/DT	prep_from||expressed-13/VBN||gene-16/NN	vmod||gene-16/NN||predicted-17/VBN	aux||encode-19/VB||to-18/TO	xcomp||predicted-17/VBN||encode-19/VB	det||³-22/NN||a-20/DT	nn||³-22/NN||î-21/NN	dobj||encode-19/VB||³-22/NN	amod||anhydrase-25/NN||carbonic-24/JJ	dep||cross-31/VBP||anhydrase-25/NN	nn||brasilense-28/NN||a.-27/NN	prep_in||anhydrase-25/NN||brasilense-28/NN	mark||cross-31/VBP||although-29/IN	nsubj||cross-31/VBP||it-30/PRP	dep||lack-4/NN||cross-31/VBP	ccomp||cross-31/VBP||reacts-32/VBZ	amod||antibody-35/NN||anti-cam-34/JJ	prep_with||reacts-32/VBZ||antibody-35/NN	vmod||antibody-35/NN||raised-36/VBN	det||³-42/NN||a-38/DT	advmod||characterized-40/JJ||well-39/RB	amod||³-42/NN||characterized-40/JJ	nn||³-42/NN||î-41/NN	prep_against||raised-36/VBN||³-42/NN	root||ROOT-0/null||ca-44/MD	cross-31||ca-44||no_rel||this study shows lack of co2 hydration activity in a recombinant protein expressed from a gene predicted to encode a î ³ - carbonic anhydrase in a. brasilense although it cross reacts with anti-cam antibody raised against a well characterized î ³ - ca .
det||index-4/NN||the-1/DT	amod||index-4/NN||overall-2/JJ	nn||index-4/NN||plaque-3/NN	nsubj||1.38-12/CD||index-4/NN	prep_for||index-4/NN||patients-6/NNS	nsubj||therapy-10/NN||patients-6/NNS	cop||therapy-10/NN||were-8/VBD	amod||therapy-10/NN||post-antineoplastic-9/JJ	rcmod||patients-6/NNS||therapy-10/NN	cop||1.38-12/CD||was-11/VBD	root||ROOT-0/null||1.38-12/CD	dep||â-19/VBP||sd-14/NN	amod||sd-14/NN||0.25-16/CD	nsubj||â-19/VBP||n-18/NN	dep||1.38-12/CD||â-19/VBP	dobj||â-19/VBP||$-20/$	number||=-22/CD||‰-21/CD	num||$-20/$||=-22/CD	dep||â-19/VBP||â-23/VB	dobj||â-23/VB||$-24/$	number||189-26/CD||‰-25/CD	num||$-24/$||189-26/CD	antineoplastic--1||plaque-3||no_rel||the overall plaque index for patients who were post-antineoplastic therapy was 1.38 (sd, 0.25; n â€‰=â€‰189).
det||aminosalicylates-2/NNS||the-1/DT	nsubjpass||considered-14/VBN||aminosalicylates-2/NNS	dep||aminosalicylates-2/NNS||5-asa-4/JJ	advmod||referred-7/NN||also-6/RB	dep||5-asa-4/JJ||referred-7/NN	dep||referred-7/NN||to-8/TO	advmod||mesalamine-based-10/JJ||as-9/RB	amod||agents-11/NNS||mesalamine-based-10/JJ	dep||referred-7/NN||agents-11/NNS	auxpass||considered-14/VBN||are-13/VBP	root||ROOT-0/null||considered-14/VBN	prep_as||considered-14/VBN||first-line-16/NN	det||maintenance-19/NN||the-18/DT	prep_in||considered-14/VBN||maintenance-19/NN	prep_of||maintenance-19/NN||remission-21/NN	amod||moderate-25/JJ||mild-23/JJ	dep||moderate-25/JJ||to-24/TO	amod||ulcerativecolitis-26/NNS||moderate-25/JJ	prep_of||remission-21/NN||ulcerativecolitis-26/NNS	appos||ulcerativecolitis-26/NNS||uc-28/NN	ulcerativecolitis-26||5-asa-4||yes||the aminosalicylates (5-asa; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerativecolitis (uc).
det||study-2/NN||this-1/DT	nsubj||first-5/JJ||study-2/NN	cop||first-5/JJ||is-3/VBZ	det||first-5/JJ||the-4/DT	root||ROOT-0/null||first-5/JJ	det||uae-8/NN||the-7/DT	prep_in||first-5/JJ||uae-8/NN	aux||report-10/VB||to-9/TO	vmod||uae-8/NN||report-10/VB	amod||levels-13/NNS||such-11/JJ	amod||levels-13/NNS||high-12/JJ	dobj||report-10/VB||levels-13/NNS	prep_of||levels-13/NNS||resistance-15/NN	amod||drugs-18/NNS||anti-tb-17/JJ	prep_to||report-10/VB||drugs-18/NNS	num||%-21/NN||27.7-20/CD	nsubj||are-30/VBP||%-21/NN	nsubj||achieve-35/VB||%-21/NN	amod||drugs-24/NNS||anti-tuberculosis-23/JJ	prep_for||%-21/NN||drugs-24/NNS	prep_such_as||drugs-24/NNS||isoniazid-27/NN	prep_such_as||drugs-24/NNS||pyrazinamide-29/NN	conj_and||isoniazid-27/NN||pyrazinamide-29/NN	parataxis||first-5/JJ||are-30/VBP	amod||significance-33/NN||great-32/JJ	prep_of||are-30/VBP||significance-33/NN	aux||achieve-35/VB||to-34/TO	xcomp||are-30/VBP||achieve-35/VB	amod||treatment-37/NN||proper-36/JJ	dobj||achieve-35/VB||treatment-37/NN	prep_in||achieve-35/VB||m.tuberculosisinfections-39/NNS	prep_in||m.tuberculosisinfections-39/NNS||future-41/NN	tuberculosis--1||pyrazinamide-29||yes||this study is the first in the uae to report such high levels of resistance to anti-tb drugs ; 27.7 % for anti-tuberculosis drugs such as isoniazid and pyrazinamide are of great significance to achieve proper treatment in m.tuberculosisinfections in future .
poss||series-4/NN||our-1/PRP$	advmod||large-3/JJ||relatively-2/RB	amod||series-4/NN||large-3/JJ	nsubj||suggested-5/VBD||series-4/NN	nsubj||responsive-79/JJ||series-4/NN	nsubj||pyridoxine-81/VB||series-4/NN	root||ROOT-0/null||suggested-5/VBD	mark||challenging-15/JJ||that-6/IN	amod||diagnosis-8/NN||clinical-7/JJ	nsubj||challenging-15/JJ||diagnosis-8/NN	amod||dependent-11/JJ||pyridoxine-10/JJ	amod||epilepsy-12/NN||dependent-11/JJ	prep_of||diagnosis-8/NN||epilepsy-12/NN	aux||challenging-15/JJ||can-13/MD	cop||challenging-15/JJ||be-14/VB	ccomp||suggested-5/VBD||challenging-15/JJ	mark||response-24/NN||because-16/IN	dep||response-24/NN||i-18/NNP	expl||response-24/NN||there-20/EX	aux||response-24/NN||may-21/MD	cop||response-24/NN||be-22/VB	det||response-24/NN||some-23/DT	ccomp||challenging-15/JJ||response-24/NN	amod||drugs-27/NNS||antiepileptic-26/JJ	prep_to||response-24/NN||drugs-27/NNS	nsubj||instant-45/JJ||ii-30/NN	nsubj||obvious-47/JJ||ii-30/NN	prep_in||ii-30/NN||infants-33/NNS	nn||pathology-36/NN||multisystem-35/NN	prep_with||infants-33/NNS||pathology-36/NN	det||response-39/NN||the-38/DT	appos||pathology-36/NN||response-39/NN	aux||pyridoxine-41/VB||to-40/TO	vmod||response-39/NN||pyridoxine-41/VB	aux||instant-45/JJ||may-42/MD	neg||instant-45/JJ||not-43/RB	cop||instant-45/JJ||be-44/VB	parataxis||response-24/NN||instant-45/JJ	parataxis||response-24/NN||obvious-47/JJ	conj_and||instant-45/JJ||obvious-47/JJ	dep||challenging-15/JJ||iii-51/NN	amod||abnormalities-55/NNS||structural-53/JJ	nn||abnormalities-55/NNS||brain-54/NN	nsubj||co-exist-57/VB||abnormalities-55/NNS	nsubjpass||considered-60/VBN||abnormalities-55/NNS	aux||co-exist-57/VB||may-56/MD	ccomp||suggested-5/VBD||co-exist-57/VB	conj_and||challenging-15/JJ||co-exist-57/VB	auxpass||considered-60/VBN||be-59/VB	conj_and||challenging-15/JJ||considered-60/VBN	conj_and||co-exist-57/VB||considered-60/VBN	amod||cause-62/NN||sufficient-61/JJ	dobj||considered-60/VBN||cause-62/NN	prep_of||cause-62/NN||epilepsy-64/NN	mark||consequence-72/NN||whereas-66/IN	det||fits-68/NNS||the-67/DT	nsubj||consequence-72/NN||fits-68/NNS	aux||consequence-72/NN||may-69/MD	cop||consequence-72/NN||be-70/VB	det||consequence-72/NN||a-71/DT	advcl||considered-60/VBN||consequence-72/NN	nn||deficiency-75/NN||antiquitin-74/NN	prep_of||consequence-72/NN||deficiency-75/NN	cop||responsive-79/JJ||are-77/VBP	advmod||responsive-79/JJ||then-78/RB	conj_and||suggested-5/VBD||responsive-79/JJ	aux||pyridoxine-81/VB||to-80/TO	xcomp||responsive-79/JJ||pyridoxine-81/VB	fits-68||pyridoxine-81||yes||our relatively large series suggested that clinical diagnosis of pyridoxine dependent epilepsy can be challenging because (i) there may be some response to antiepileptic drugs; (ii) in infants with multisystem pathology, the response to pyridoxine may not be instant and obvious; and (iii) structural brain abnormalities may co-exist and be considered sufficient cause of epilepsy, whereas the fits may be a consequence of antiquitin deficiency and are then responsive to pyridoxine.
nn||numbers-3/NNS||c.-1/NN	nn||numbers-3/NNS||leptum-2/NN	nsubjpass||reduced-8/VBN||numbers-3/NNS	conj_and||numbers-3/NNS||diversity-5/NN	nsubjpass||reduced-8/VBN||diversity-5/NN	auxpass||reduced-8/VBN||were-6/VBD	advmod||reduced-8/VBN||significantly-7/RB	root||ROOT-0/null||reduced-8/VBN	preconj||cd-11/NN||both-10/DT	prep_in||reduced-8/VBN||cd-11/NN	prep_in||reduced-8/VBN||uc-13/NN	conj_and||cd-11/NN||uc-13/NN	vmod||cd-11/NN||suggesting-14/VBG	mark||noted-17/VBD||that-15/IN	nsubj||noted-17/VBD||alterations-16/NNS	ccomp||suggesting-14/VBG||noted-17/VBD	cop||specific-20/JJ||were-18/VBD	neg||specific-20/JJ||not-19/RB	ccomp||noted-17/VBD||specific-20/JJ	num||disease-23/NN||one-22/CD	prep_to||specific-20/JJ||disease-23/NN	cd-11||uc-13||no_rel||c. leptum numbers and diversity were significantly reduced in both cd and uc suggesting that alterations noted were not specific to one disease .
mark||have-8/VBP||as-1/IN	nsubj||have-8/VBP||patients-2/NNS	amod||sepsis-5/NN||severe-4/JJ	prep_with||patients-2/NNS||sepsis-5/NN	prep_with||patients-2/NNS||septicshock-7/NN	conj_and||sepsis-5/NN||septicshock-7/NN	advcl||¥-19/VBD||have-8/VBP	det||vd-11/NN||an-9/DT	amod||vd-11/NN||increased-10/VBN	dobj||have-8/VBP||vd-11/NN	det||dose-15/NN||a-13/DT	amod||dose-15/NN||first-14/JJ	nsubj||¥-19/VBD||dose-15/NN	nn||‰-18/NNS||â-17/NN	prep_of||dose-15/NN||‰-18/NNS	root||ROOT-0/null||¥-19/VBD	num||mg/kg-21/NN||25-20/CD	nsubjpass||required-30/VBN||mg/kg-21/NN	nsubj||reach-32/VB||mg/kg-21/NN	amod||weight-25/NN||total-23/JJ	nn||weight-25/NN||body-24/NN	appos||mg/kg-21/NN||weight-25/NN	prep_of||mg/kg-21/NN||amikacin-28/NN	auxpass||required-30/VBN||is-29/VBZ	ccomp||¥-19/VBD||required-30/VBN	aux||reach-32/VB||to-31/TO	xcomp||required-30/VBN||reach-32/VB	amod||concentrations-35/NNS||therapeutic-33/JJ	nn||concentrations-35/NNS||peak-34/NN	dobj||reach-32/VB||concentrations-35/NNS	sepsis-5||amikacin-28||yes||as patients with severe sepsis and septicshock have an increased vd, a first dose of â‰¥ 25 mg/kg (total body weight) of amikacin is required to reach therapeutic peak concentrations.
amod||excursions-3/NNS||increased-1/VBN	nn||excursions-3/NNS||glucose-2/NN	nsubjpass||suggested-9/VBN||excursions-3/NNS	amod||hyperglycaemia-6/NN||postprandial-5/JJ	conj_and||excursions-3/NNS||hyperglycaemia-6/NN	nsubjpass||suggested-9/VBN||hyperglycaemia-6/NN	aux||suggested-9/VBN||have-7/VBP	auxpass||suggested-9/VBN||been-8/VBN	root||ROOT-0/null||suggested-9/VBN	amod||factors-13/NNS||unique-11/JJ	nn||factors-13/NNS||risk-12/NN	prep_as||suggested-9/VBN||factors-13/NNS	prep_for||factors-13/NNS||cardiovasculardisease-15/NN	appos||cardiovasculardisease-15/NN||cvd-17/NN	prep_as||suggested-9/VBN||mortality-20/NN	conj_and||factors-13/NNS||mortality-20/NN	prep_in||mortality-20/NN||patients-22/NNS	prep_with||patients-22/NNS||diabetesmellitus-24/NNS	hyperglycaemia-6||glucose-2||no||increased glucose excursions and postprandial hyperglycaemia have been suggested as unique risk factors for cardiovasculardisease (cvd) and mortality in patients with diabetesmellitus.
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	insulinresistance-19||glucose-30||no_rel||research design and methodsâ€” to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
det||inducer-6/NN||the-2/DT	advmod||used-4/VBN||clinically-3/RB	amod||inducer-6/NN||used-4/VBN	nn||inducer-6/NN||differentiation-5/NN	prep_unlike||target-44/VB||inducer-6/NN	advmod||inducer-6/NN||all-7/DT	dep||inducer-6/NN||trans-9/NNS	vmod||trans-9/NNS||retinoicacid-10/VBN	amod||shows-13/NNS||tenovin-6-12/JJ	nsubj||target-44/VB||shows-13/NNS	vmod||shows-13/NNS||limited-14/VBN	dobj||limited-14/VBN||effects-15/NNS	prepc_on||limited-14/VBN||promyelocyticleukemiaâ-17/VBG	dobj||promyelocyticleukemiaâ-17/VBG||$-18/$	amod||±-23/NNS||retinoicacid-20/JJ	nn||±-23/NNS||receptor-21/NN	nn||±-23/NNS||î-22/NN	npadvmod||that-39/RB||±-23/NNS	number||±-26/CD||pml-rar-î-25/CD	dep||±-23/NNS||±-26/CD	nn||formation-33/NN||stability-28/NN	conj_and||stability-28/NN||promyelocyticleukemia-30/NN	nn||formation-33/NN||promyelocyticleukemia-30/NN	amod||formation-33/NN||nuclear-31/JJ	nn||formation-33/NN||body-32/NN	dep||±-26/CD||formation-33/NN	amod||cells-36/NNS||nb4-35/JJ	prep_in||±-26/CD||cells-36/NNS	appos||cells-36/NNS||suggesting-38/NNP	dep||tenovin-6-40/CD||that-39/RB	num||$-18/$||tenovin-6-40/CD	aux||target-44/VB||does-41/VBZ	neg||target-44/VB||not-42/RB	advmod||target-44/VB||directly-43/RB	root||ROOT-0/null||target-44/VB	amod||activity-47/NN||pml-rar-î-45/JJ	amod||activity-47/NN||±-46/JJ	dobj||target-44/VB||activity-47/NN	promyelocyticleukemia-30||retinoicacid-20||yes||unlike the clinically used differentiation inducer all- trans retinoicacid, tenovin-6 shows limited effects on promyelocyticleukemiaâ€“retinoicacid receptor î± (pml-rar-î±) stability and promyelocyticleukemia nuclear body formation in nb4 cells, suggesting that tenovin-6 does not directly target pml-rar-î± activity.
det||extract-3/NN||the-1/DT	nn||extract-3/NN||ethanol-2/NN	nsubjpass||indicated-19/VBN||extract-3/NN	nsubj||possess-21/VB||extract-3/NN	det||smith-13/NN||the-5/DT	amod||smith-13/NN||rhizome-6/JJ	nn||zerumbet-9/NN||zingiber-8/NN	prep_of||rhizome-6/JJ||zerumbet-9/NN	appos||smith-13/NN||l.-11/NN	prep_from||extract-3/NN||smith-13/NN	appos||smith-13/NN||eezzr-15/NN	aux||indicated-19/VBN||has-17/VBZ	auxpass||indicated-19/VBN||been-18/VBN	root||ROOT-0/null||indicated-19/VBN	aux||possess-21/VB||to-20/TO	xcomp||indicated-19/VBN||possess-21/VB	det||property-24/NN||an-22/DT	amod||property-24/NN||insulin-like-23/JJ	dobj||possess-21/VB||property-24/NN	prepc_by||possess-21/VB||ameliorating-26/VBG	dobj||ameliorating-26/VBG||hyperglycemia-27/NN	prep_in||ameliorating-26/VBG||diabetes-29/NN	hyperglycemia-27||insulin--1||yes||the ethanol extract from the rhizome of zingiber zerumbet (l.) smith (eezzr) has been indicated to possess an insulin-like property by ameliorating hyperglycemia in diabetes.
amod||measures-3/NNS||secondary-1/JJ	nn||measures-3/NNS||outcome-2/NN	nsubj||consistency-6/NN||measures-3/NNS	cop||consistency-6/NN||were-4/VBD	amod||consistency-6/NN||stool-5/JJ	root||ROOT-0/null||consistency-6/NN	vmod||consistency-6/NN||using-7/VBG	det||frequency-12/NN||the-8/DT	amod||frequency-12/NN||bristol-9/JJ	amod||frequency-12/NN||stool-10/JJ	nn||frequency-12/NN||scale-11/NN	dobj||using-7/VBG||frequency-12/NN	prep_of||frequency-12/NN||episodes-14/NNS	amod||incontinence-17/NN||faecal-16/JJ	prep_of||episodes-14/NNS||incontinence-17/NN	dobj||using-7/VBG||pain-19/NN	conj_and||frequency-12/NN||pain-19/NN	prep_during||pain-19/NN||defecation-21/NN	dobj||using-7/VBG||frequency-23/NN	conj_and||frequency-12/NN||frequency-23/NN	prep_of||frequency-23/NN||abdominalpain-25/NN	dobj||using-7/VBG||frequency-27/NN	conj_and||frequency-12/NN||frequency-27/NN	amod||effects-30/NNS||adverse-29/JJ	prep_of||frequency-27/NN||effects-30/NNS	dep||effects-30/NNS||nausea-32/NN	dep||effects-30/NNS||diarrhoea-34/NN	conj_and||nausea-32/NN||diarrhoea-34/NN	amod||taste-37/NN||bad-36/JJ	dep||effects-30/NNS||taste-37/NN	conj_and||nausea-32/NN||taste-37/NN	dobj||using-7/VBG||frequency-41/NN	conj_and||frequency-12/NN||frequency-41/NN	prep_of||frequency-41/NN||intake-43/NN	prep_of||intake-43/NN||bisacodyl-45/NN	diarrhoea-34||bisacodyl-45||no||secondary outcome measures were stool consistency using the bristol stool scale frequency of episodes of faecal incontinence, pain during defecation, frequency of abdominalpain, frequency of adverse effects (nausea, diarrhoea and bad taste), and frequency of intake of bisacodyl.
amod||analyses-2/NNS||multiallelic-1/JJ	nsubj||showed-10/VBD||analyses-2/NNS	prepc_of||analyses-2/NNS||carrying-4/VBG	nn||alleles-6/NNS||risk-5/NN	dobj||carrying-4/VBG||alleles-6/NNS	amod||genes-9/NNS||multiple-8/JJ	prep_for||carrying-4/VBG||genes-9/NNS	root||ROOT-0/null||showed-10/VBD	dobj||showed-10/VBD||correlations-11/NNS	prep_between||correlations-11/NNS||number-13/NN	nn||alleles-16/NNS||risk-15/NN	prep_of||number-13/NN||alleles-16/NNS	prep_of||number-13/NN||type2diabetes-18/NNS	conj_and||alleles-16/NNS||type2diabetes-18/NNS	amod||secretion-22/NN||impaired-20/VBN	nn||secretion-22/NN||insulin-21/NN	prep_between||correlations-11/NNS||secretion-22/NN	conj_and||number-13/NN||secretion-22/NN	amod||subjects-25/NNS||normoglycemic-24/JJ	prep_in||secretion-22/NN||subjects-25/NNS	dep||secretion-22/NN||p-27/VBN	dep||0.006-29/CD||=-28/SYM	ccomp||p-27/VBN||0.006-29/CD	ccomp||p-27/VBN||0.0001-31/CD	conj_and||0.006-29/CD||0.0001-31/CD	prep_for||p-27/VBN||type2diabetes-33/NN	prep_for||p-27/VBN||air-35/NN	conj_and||type2diabetes-33/NN||air-35/NN	advmod||p-27/VBN||respectively-37/RB	vmod||showed-10/VBD||supporting-40/VBG	det||hypothesis-42/NNS||the-41/DT	dobj||supporting-40/VBG||hypothesis-42/NNS	mark||influence-48/VBP||that-43/IN	nsubj||influence-48/VBP||many-44/JJ	det||genes-47/NNS||these-46/DT	prep_of||many-44/JJ||genes-47/NNS	ccomp||supporting-40/VBG||influence-48/VBP	nn||risk-50/NN||diabetes-49/NN	dobj||influence-48/VBP||risk-50/NN	prepc_by||influence-48/VBP||affecting-52/VBG	nn||secretion-54/NN||insulin-53/NN	dobj||affecting-52/VBG||secretion-54/NN	type2diabetes-33||insulin-53||yes||multiallelic analyses of carrying risk alleles for multiple genes showed correlations between number of risk alleles and type2diabetes and impaired insulin secretion in normoglycemic subjects ( p = 0.006 and 0.0001 for type2diabetes and air, respectively), supporting the hypothesis that many of these genes influence diabetes risk by affecting insulin secretion.
nn||propofol-2/NN||microemulsion-1/NN	nsubjpass||developed-4/VBN||propofol-2/NN	nsubj||avoid-6/VB||propofol-2/NN	auxpass||developed-4/VBN||was-3/VBD	root||ROOT-0/null||developed-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||developed-4/VBN||avoid-6/VB	det||effects-9/NNS||these-7/DT	nn||effects-9/NNS||side-8/NN	dobj||avoid-6/VB||effects-9/NNS	nsubj||is-18/VBZ||incidence-11/NN	conj_and||incidence-11/NN||severity-13/NN	nsubj||is-18/VBZ||severity-13/NN	prep_of||incidence-11/NN||pain-15/NN	prep_on||pain-15/NN||injection-17/NN	conj_but||developed-4/VBN||is-18/VBZ	dep||than-20/IN||higher-19/JJR	advmod||is-18/VBZ||than-20/IN	nn||propofol-24/NN||lipid-22/NN	nn||propofol-24/NN||emulsion-23/NN	prep_with||is-18/VBZ||propofol-24/NN	pain-15||propofol-24||yes||microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||artemether--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
det||report-3/NN||this-2/DT	prep_in||describe-6/VBP||report-3/NN	nsubj||describe-6/VBP||we-5/PRP	root||ROOT-0/null||describe-6/VBP	det||rapid-8/JJ||a-7/DT	dobj||describe-6/VBP||rapid-8/JJ	amod||nanoparticle-12/NN||simple-10/JJ	nn||nanoparticle-12/NN||gold-11/NN	dobj||describe-6/VBP||nanoparticle-12/NN	conj_and||rapid-8/JJ||nanoparticle-12/NN	appos||rapid-8/JJ||np-14/NN	prep||rapid-8/JJ||based-17/VBN	amod||assay-20/NN||genomic-18/JJ	nn||assay-20/NN||microarray-19/NN	npadvmod||from-30/IN||assay-20/NN	amod||identification-23/NN||specific-22/JJ	prep_for||assay-20/NN||identification-23/NN	amod||h5n1-26/NNS||avianinfluenzavirus-25/JJ	prep_of||identification-23/NN||h5n1-26/NNS	poss||discrimination-29/NN||its-28/PRP$	prep_of||identification-23/NN||discrimination-29/NN	conj_and||h5n1-26/NNS||discrimination-29/NN	pcomp||based-17/VBN||from-30/IN	amod||influenza-33/NN||other-31/JJ	amod||influenza-33/NN||major-32/JJ	pobj||from-30/IN||influenza-33/NN	det||strains-36/NNS||a-34/DT	nn||strains-36/NNS||virus-35/NN	dep||influenza-33/NN||strains-36/NNS	dep||influenza-33/NN||h1n1-38/NNS	appos||h1n1-38/NNS||h3n2-40/NNS	h5n1-26||avianinfluenzavirus-25||no||in this report, we describe a rapid and simple gold nanoparticle (np)-based genomic microarray assay for specific identification of avianinfluenzavirus h5n1 and its discrimination from other major influenza a virus strains (h1n1, h3n2).
mark||used-30/VBN||although-1/IN	amod||strategies-4/NNS||established-2/JJ	amod||strategies-4/NNS||therapeutic-3/JJ	nsubjpass||used-30/VBN||strategies-4/NNS	nsubj||treat-32/VB||strategies-4/NNS	amod||control-10/NN||appropriate-8/JJ	nn||control-10/NN||bloodglucose-9/NN	prep_such_as||strategies-4/NNS||control-10/NN	nn||control-14/NN||blood-12/NN	nn||control-14/NN||pressure-13/NN	appos||control-10/NN||control-14/NN	prepc_with||control-14/NN||reninâ-16/VBG	dobj||reninâ-16/VBG||$-17/$	advmod||with-26/IN||angiotensin-19/RB	nn||blockade-21/NN||system-20/NN	npadvmod||with-26/IN||blockade-21/NN	cc||lowering-25/NNP||and-23/CC	dep||lowering-25/NNP||lipid-24/RB	dep||blockade-21/NN||lowering-25/NNP	dep||statins-27/CD||with-26/IN	num||$-17/$||statins-27/CD	auxpass||used-30/VBN||are-29/VBP	advcl||increased-49/VBN||used-30/VBN	aux||treat-32/VB||to-31/TO	xcomp||used-30/VBN||treat-32/VB	dobj||treat-32/VB||diabetes-33/NN	det||contribution-36/NN||the-35/DT	nsubj||increased-49/VBN||contribution-36/NN	amod||end-stagekidneydisease-39/NN||diabetic-38/JJ	prep_of||contribution-36/NN||end-stagekidneydisease-39/NN	det||number-43/NN||the-41/DT	amod||number-43/NN||total-42/JJ	prep_to||end-stagekidneydisease-39/NN||number-43/NN	prep_of||number-43/NN||cases-45/NNS	vmod||cases-45/NNS||requiring-46/VBG	dobj||requiring-46/VBG||hemodialysis-47/NNS	aux||increased-49/VBN||has-48/VBZ	root||ROOT-0/null||increased-49/VBN	advmod||increased-49/VBN||tremendously-50/RB	det||decades-55/NNS||the-52/DT	amod||decades-55/NNS||past-53/JJ	num||decades-55/NNS||two-54/CD	prep_in||increased-49/VBN||decades-55/NNS	glucose--1||end-stagekidneydisease-39||no_rel||although established therapeutic strategies, such as appropriate bloodglucose control, blood pressure control with reninâ€“angiotensin system blockade, and lipid lowering with statins, are used to treat diabetes, the contribution of diabetic end-stagekidneydisease to the total number of cases requiring hemodialysis has increased tremendously in the past two decades.
nsubjpass||categorised-6/VBN||half-1/NN	nsubjpass||expected-13/VBN||half-1/NN	nsubj||have-15/VB||half-1/NN	det||vegans-4/NNS||the-3/DT	prep_of||half-1/NN||vegans-4/NNS	auxpass||categorised-6/VBN||were-5/VBD	root||ROOT-0/null||categorised-6/VBN	amod||deficient-9/NN||vitaminb12-8/JJ	prep_as||categorised-6/VBN||deficient-9/NN	aux||expected-13/VBN||would-11/MD	auxpass||expected-13/VBN||be-12/VB	conj_and||categorised-6/VBN||expected-13/VBN	aux||have-15/VB||to-14/TO	xcomp||expected-13/VBN||have-15/VB	det||risk-18/NN||a-16/DT	amod||risk-18/NN||higher-17/JJR	dobj||have-15/VB||risk-18/NN	prepc_of||risk-18/NN||developing-20/VBG	amod||symptoms-22/NNS||clinical-21/JJ	dobj||developing-20/VBG||symptoms-22/NNS	vmod||symptoms-22/NNS||related-23/VBN	prep_to||related-23/VBN||vitaminb12deficiency-25/CD	vitaminb12deficiency-25||vitaminb12-8||yes||half of the vegans were categorised as vitaminb12 deficient and would be expected to have a higher risk of developing clinical symptoms related to vitaminb12deficiency.
nsubj||binding-6/VBD||redistribution-1/NN	nsubj||ubiquitinated-16/VBD||redistribution-1/NN	amod||dna-5/NN||nuclear-3/JJ	nn||dna-5/NN||tar-4/NN	prep_of||redistribution-1/NN||dna-5/NN	root||ROOT-0/null||binding-6/VBD	dobj||binding-6/VBD||protein-7/NN	advmod||binding-6/VBD||43-8/CD	dep||binding-6/VBD||tdp-43-10/JJ	det||cytoplasm-14/NN||the-13/DT	prep_to||binding-6/VBD||cytoplasm-14/NN	conj_and||binding-6/VBD||ubiquitinated-16/VBD	dobj||ubiquitinated-16/VBD||inclusions-17/NNS	amod||neurons-21/NNS||spinal-19/JJ	nn||neurons-21/NNS||motor-20/NN	prep_of||inclusions-17/NNS||neurons-21/NNS	amod||cells-24/NNS||glial-23/JJ	nsubj||characteristic-26/JJ||cells-24/NNS	cop||characteristic-26/JJ||is-25/VBZ	conj_and||binding-6/VBD||characteristic-26/JJ	prep_of||characteristic-26/JJ||amyotrophiclateralsclerosis-28/NNS	appos||amyotrophiclateralsclerosis-28/NNS||als-30/NN	advmod||characteristic-26/JJ||pathology-32/RB	tar-4||als-30||no_rel||redistribution of nuclear tar dna binding protein 43 (tdp-43) to the cytoplasm and ubiquitinated inclusions of spinal motor neurons and glial cells is characteristic of amyotrophiclateralsclerosis (als) pathology.
nsubj||suggest-2/VBP||we-1/PRP	root||ROOT-0/null||suggest-2/VBP	mark||site-8/NN||that-3/IN	det||stomata-5/NN||these-4/DT	nsubj||site-8/NN||stomata-5/NN	cop||site-8/NN||are-6/VBP	det||site-8/NN||the-7/DT	ccomp||suggest-2/VBP||site-8/NN	nsubj||negotiate-17/VB||site-8/NN	prep_of||site-8/NN||retention-10/NN	amod||fibres-13/NNS||long-12/JJ	prep_of||retention-10/NN||fibres-13/NNS	aux||negotiate-17/VB||can-15/MD	neg||negotiate-17/VB||not-16/RB	rcmod||site-8/NN||negotiate-17/VB	nsubj||leading-19/JJ||them-18/PRP	xcomp||negotiate-17/VB||leading-19/JJ	nn||pathology-24/NN||inflammation-21/NN	conj_and||inflammation-21/NN||pleural-23/NN	nn||pathology-24/NN||pleural-23/NN	prep_to||leading-19/JJ||pathology-24/NN	prep_including||pathology-24/NN||mesothelioma-26/NN	inflammation-21||fibres-13||no_rel||we suggest that these stomata are the site of retention of long fibres which cannot negotiate them leading to inflammation and pleural pathology including mesothelioma.
nsubj||created-2/VBD||we-1/PRP	nsubj||saline-44/VBP||we-1/PRP	root||ROOT-0/null||created-2/VBD	det||model-5/NN||an-3/DT	nn||model-5/NN||animal-4/NN	dobj||created-2/VBD||model-5/NN	prep_of||model-5/NN||comorbidity-7/NN	prep_of||comorbidity-7/NN||nicotineaddiction-9/NN	prep_of||comorbidity-7/NN||schizophrenia-11/NN	conj_and||nicotineaddiction-9/NN||schizophrenia-11/NN	prepc_by||created-2/VBD||injecting-13/VBG	amod||rats-16/NNS||male-14/JJ	amod||rats-16/NNS||sprague-dawley-15/JJ	dobj||injecting-13/VBG||rats-16/NNS	prep_with||injecting-13/VBG||nicotine-18/NN	num||mg/kg-21/NN||0.40-20/CD	dep||nicotine-18/NN||mg/kg-21/NN	amod||-RSB--26/NNS||subcutaneously-23/JJ	amod||-RSB--26/NNS||-LSB--24/JJ	nn||-RSB--26/NNS||sc-25/NN	appos||mg/kg-21/NN||-RSB--26/NNS	prep_with||injecting-13/VBG||saline-29/NN	conj_or||nicotine-18/NN||saline-29/NN	prep_in||injecting-13/VBG||combination-32/NN	prep_with||combination-32/NN||phencyclidine-34/NN	dep||phencyclidine-34/NN||pcp-36/NN	num||mg/kg-39/NN||3.0-38/CD	appos||pcp-36/NN||mg/kg-39/NN	appos||pcp-36/NN||sc-41/NN	conj_or||created-2/VBD||saline-44/VBP	advmod||saline-44/VBP||daily-45/RB	num||days-49/NNS||14-47/CD	amod||days-49/NNS||consecutive-48/JJ	prep_for||saline-44/VBP||days-49/NNS	nicotineaddiction-9||nicotine-18||no||we created an animal model of comorbidity of nicotineaddiction and schizophrenia by injecting male sprague-dawley rats with nicotine (0.40 mg/kg, subcutaneously[sc]) or saline, in combination with phencyclidine (pcp, 3.0 mg/kg, sc) or saline daily for 14 consecutive days.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	mouthulcers-27||antibody--1||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	virus-44||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
nsubj||observed-4/VBN||we-1/PRP	aux||observed-4/VBN||have-2/VBP	advmod||observed-4/VBN||previously-3/RB	root||ROOT-0/null||observed-4/VBN	mark||improved-14/VBD||that-5/IN	prep_in||improved-14/VBD||vivo-7/NN	nsubj||improved-14/VBD||administration-8/NN	det||inhibitor-11/NN||an-10/DT	prep_of||administration-8/NN||inhibitor-11/NN	prep_of||inhibitor-11/NN||nitricoxide-13/NN	ccomp||observed-4/VBN||improved-14/VBD	det||response-16/NN||the-15/DT	dobj||improved-14/VBD||response-16/NN	prep_to||improved-14/VBD||bcg-18/NN	nn||mice-22/NNS||bladdertumor-20/NN	nn||mice-22/NNS||bearing-21/NN	prep_of||bcg-18/NN||mice-22/NNS	bladdertumor-20||bcg-18||yes||we have previously observed that in vivo administration of an inhibitor of nitricoxide improved the response to bcg of bladdertumor bearing mice.
nsubjpass||found-12/VBN||four-1/CD	dep||four-1/CD||b245-3/NNP	dep||b245-3/NNP||b376-5/NNP	dep||b245-3/NNP||b1581-7/JJ	dep||b245-3/NNP||b1789-9/JJ	conj_and||b1581-7/JJ||b1789-9/JJ	auxpass||found-12/VBN||were-11/VBD	root||ROOT-0/null||found-12/VBN	det||ability-15/NN||the-14/DT	prep_with||found-12/VBN||ability-15/NN	aux||inhibit-18/VB||to-16/TO	advmod||inhibit-18/VB||potently-17/RB	vmod||ability-15/NN||inhibit-18/VB	nn||rna-20/NN||hbv-19/NN	dobj||inhibit-18/VB||rna-20/NN	iobj||inhibit-18/VB||rna-20/NN	dobj||inhibit-18/VB||dna-22/NN	iobj||inhibit-18/VB||dna-22/NN	conj_and||rna-20/NN||dna-22/NN	nn||antigen-25/NN||surface-24/NN	dobj||inhibit-18/VB||antigen-25/NN	iobj||inhibit-18/VB||antigen-25/NN	conj_and||rna-20/NN||antigen-25/NN	appos||antigen-25/NN||hbsag-27/NN	amod||antigen-31/NN||e-30/JJ	appos||antigen-25/NN||antigen-31/NN	appos||antigen-31/NN||hbeag-33/NN	nn||antigen-37/NN||core-36/NN	dobj||inhibit-18/VB||antigen-37/NN	iobj||inhibit-18/VB||antigen-37/NN	conj_and||rna-20/NN||antigen-37/NN	dep||rna-20/NN||hbcag-39/VBG	dep||rna-20/NN||expression-41/NN	nn||genotypes-44/NNS||hbv-43/NN	prep_in||expression-41/NN||genotypes-44/NNS	dep||genotypes-44/NNS||a-45/SYM	dep||genotypes-44/NNS||b-47/SYM	conj_and||a-45/SYM||b-47/SYM	dep||genotypes-44/NNS||c-49/SYM	conj_and||a-45/SYM||c-49/SYM	dep||genotypes-44/NNS||d-51/SYM	conj_and||a-45/SYM||d-51/SYM	dep||genotypes-44/NNS||i-53/JJ	conj_and||a-45/SYM||i-53/JJ	det||genotype-58/NN||a-55/DT	advmod||identified-57/JJ||newly-56/RB	amod||genotype-58/NN||identified-57/JJ	appos||ability-15/NN||genotype-58/NN	amod||cells-62/NNS||huh7-61/JJ	prep_in||ability-15/NN||cells-62/NNS	prep_in||ability-15/NN||mice-65/NNS	conj_and||cells-62/NNS||mice-65/NNS	hbv-43||hbsag-27||yes||four (b245, b376, b1581 and b1789) were found with the ability to potently inhibit hbv rna, dna, surface antigen (hbsag), e antigen (hbeag) and core antigen (hbcag) expression in hbv genotypes a, b, c, d and i (a newly identified genotype) in huh7 cells and in mice.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||lipids-53||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
mark||reached-11/VBN||after-1/IN	det||concentration-6/NN||the-2/DT	nn||concentration-6/NN||target-3/NN	nn||concentration-6/NN||effect-4/NN	nn||concentration-6/NN||site-5/NN	nsubjpass||reached-11/VBN||concentration-6/NN	prep_of||concentration-6/NN||remifentanil-8/NN	aux||reached-11/VBN||had-9/VBD	auxpass||reached-11/VBN||been-10/VBN	advcl||controlled-15/VBD||reached-11/VBN	det||target-14/NN||the-13/DT	nsubj||controlled-15/VBD||target-14/NN	root||ROOT-0/null||controlled-15/VBD	nsubjpass||started-20/VBN||infusion-16/NN	prep_of||infusion-16/NN||propofol-18/NN	auxpass||started-20/VBN||was-19/VBD	dep||controlled-15/VBD||started-20/VBN	amod||pain-23/NN||propofol-induced-22/JJ	nsubjpass||recorded-25/VBN||pain-23/NN	auxpass||recorded-25/VBN||was-24/VBD	dep||controlled-15/VBD||recorded-25/VBN	conj_and||started-20/VBN||recorded-25/VBN	pain-23||propofol-18||yes||after the target effect site concentration of remifentanil had been reached, the target controlled infusion of propofol was started and propofol-induced pain was recorded.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-5/NN||no-3/DT	amod||association-5/NN||significant-4/JJ	nsubj||was-2/VBD||association-5/NN	prep_with||association-5/NN||diabetesmellitus-7/NNS	det||occurrence-10/NN||the-9/DT	prep_with||diabetesmellitus-7/NNS||occurrence-10/NN	prep_of||occurrence-10/NN||uti-12/NN	amod||resistant-15/JJ||ciprofloxacin-14/JJ	amod||coli-17/NNS||resistant-15/JJ	nn||coli-17/NNS||e.-16/NN	prep_with||uti-12/NN||coli-17/NNS	uti-12||ciprofloxacin-14||yes||there was no significant association with diabetesmellitus with the occurrence of uti with ciprofloxacin resistant e. coli .
amod||chemotherapeuticagents-2/NNS||many-1/JJ	nsubj||promote-3/VBP||chemotherapeuticagents-2/NNS	root||ROOT-0/null||promote-3/VBP	nn||death-6/NN||tumor-4/NN	nn||death-6/NN||cell-5/NN	dobj||promote-3/VBP||death-6/NN	prepc_by||promote-3/VBP||activating-8/VBG	det||pathway-11/NN||the-9/DT	amod||pathway-11/NN||intrinsic-10/JJ	dobj||activating-8/VBG||pathway-11/NN	prep_of||pathway-11/NN||apoptosis-13/NNS	chemotherapeuticagents-2||tumor-4||no_rel||many chemotherapeuticagents promote tumor cell death by activating the intrinsic pathway of apoptosis.
advmod||demonstrated-30/VBN||finally-1/RB	det||role-4/NN||a-3/DT	nsubjpass||demonstrated-30/VBN||role-4/NN	det||microflora-7/NN||the-6/DT	prep_for||role-4/NN||microflora-7/NN	prepc_in||microflora-7/NN||mediating-9/VBG	det||hyperglycemia-12/NN||the-10/DT	amod||hyperglycemia-12/NN||fasting-11/JJ	dobj||mediating-9/VBG||hyperglycemia-12/NN	det||response-18/NN||the-16/DT	amod||response-18/NN||excessive-17/JJ	dobj||mediating-9/VBG||response-18/NN	conj_negcc||hyperglycemia-12/NN||response-18/NN	det||load-22/NN||a-20/DT	nn||load-22/NN||glucose-21/NN	prep_to||response-18/NN||load-22/NN	amod||mice-28/NNS||12-week-old-25/JJ	amod||mice-28/NNS||gal-3-26/JJ	nn||mice-28/NNS||ko-27/NN	prep_of||response-18/NN||mice-28/NNS	auxpass||demonstrated-30/VBN||was-29/VBD	root||ROOT-0/null||demonstrated-30/VBN	agent||demonstrated-30/VBN||administration-32/NN	prep_of||administration-32/NN||antibiotics-34/NNS	hyperglycemia-12||glucose-21||no||finally, a role for the microflora in mediating the fasting hyperglycemia, but not the excessive response to a glucose load, of 12-week-old gal-3 ko mice was demonstrated by administration of antibiotics.
det||goal-2/NN||the-1/DT	nsubj||was-3/VBD||goal-2/NN	nsubj||include-5/VB||goal-2/NN	root||ROOT-0/null||was-3/VBD	aux||include-5/VB||to-4/TO	xcomp||was-3/VBD||include-5/VB	det||representation-11/NN||a-6/DT	amod||representation-11/NN||comprehensive-7/JJ	advmod||redundant-10/JJ||minimally-9/RB	conj_and||comprehensive-7/JJ||redundant-10/JJ	amod||representation-11/NN||redundant-10/JJ	dobj||include-5/VB||representation-11/NN	det||bacteria-14/NNS||the-13/DT	prep_of||representation-11/NN||bacteria-14/NNS	nsubj||reside-17/VB||bacteria-14/NNS	advmod||reside-17/VB||regularly-16/RB	rcmod||bacteria-14/NNS||reside-17/VB	det||cavity-22/NN||the-19/DT	amod||cavity-22/NN||human-20/JJ	amod||cavity-22/NN||oral-21/JJ	prep_in||reside-17/VB||cavity-22/NN	amod||classification-26/NN||computationally-24/JJ	amod||classification-26/NN||robust-25/JJ	prep_with||cavity-22/NN||classification-26/NN	det||level-29/NN||the-28/DT	prep_at||reside-17/VB||level-29/NN	prep_of||level-29/NN||species-31/NNS	prep_of||level-29/NN||genus-33/NNS	conj_and||species-31/NNS||genus-33/NNS	cavity-22||bacteria-14||no||the goal was to include a comprehensive and minimally redundant representation of the bacteria that regularly reside in the human oral cavity with computationally robust classification at the level of species and genus.
nsubjpass||reviewed-33/VBN||statements-1/NNS	det||effects-4/NNS||the-3/DT	prep_regarding||statements-1/NNS||effects-4/NNS	amod||use-9/NN||preoperative-6/JJ	nn||use-9/NN||somatostatin-7/NN	nn||use-9/NN||analog-8/NN	prep_of||effects-4/NNS||use-9/NN	amod||outcomes-13/NNS||pituitary-11/JJ	amod||outcomes-13/NNS||surgical-12/JJ	prep_on||use-9/NN||outcomes-13/NNS	poss||effects-16/NNS||their-15/PRP$	prep_of||effects-4/NNS||effects-16/NNS	conj_and||use-9/NN||effects-16/NNS	nn||control-21/NN||hormone-18/NN	conj_and||hormone-18/NN||symptom-20/NN	nn||control-21/NN||symptom-20/NN	prep_on||effects-16/NNS||control-21/NN	prep_in||control-21/NN||carcinoidsyndrome-23/NN	det||efficacy-27/NN||the-26/DT	prep_of||effects-4/NNS||efficacy-27/NN	conj_and||use-9/NN||efficacy-27/NN	amod||intervals-31/NNS||extended-29/JJ	nn||intervals-31/NNS||dosing-30/NN	prep_of||efficacy-27/NN||intervals-31/NNS	auxpass||reviewed-33/VBN||were-32/VBD	root||ROOT-0/null||reviewed-33/VBN	carcinoidsyndrome-23||hormone-18||no_rel||statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoidsyndrome, and the efficacy of extended dosing intervals were reviewed.
det||study-2/NN||this-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||are-36/VBP||that-4/IN	advmod||established-9/VBN||when-5/WRB	det||collaboration-7/NN||a-6/DT	nsubjpass||established-9/VBN||collaboration-7/NN	nsubj||strengthen-11/VB||collaboration-7/NN	auxpass||established-9/VBN||is-8/VBZ	advcl||are-36/VBP||established-9/VBN	aux||strengthen-11/VB||to-10/TO	xcomp||established-9/VBN||strengthen-11/VB	amod||systems-14/NNS||existing-12/JJ	nn||systems-14/NNS||health-13/NN	dobj||strengthen-11/VB||systems-14/NNS	prepc_in_addition_to||established-9/VBN||providing-19/VBG	amod||services-21/NNS||hiv/aids-20/JJ	dobj||providing-19/VBG||services-21/NNS	det||setting-24/NN||a-23/DT	prep_in||providing-19/VBG||setting-24/NN	prep_in||delivered-33/VBN||setting-24/NN	amod||care-30/NN||other-27/JJ	amod||care-30/NN||primary-28/JJ	nn||care-30/NN||health-29/NN	nsubjpass||delivered-33/VBN||care-30/NN	aux||delivered-33/VBN||is-31/VBZ	auxpass||delivered-33/VBN||being-32/VBG	rcmod||setting-24/NN||delivered-33/VBN	expl||are-36/VBP||there-35/EX	ccomp||shows-3/VBZ||are-36/VBP	amod||effects-38/NNS||positive-37/JJ	nsubj||are-36/VBP||effects-38/NNS	neg||only-40/JJ||not-39/RB	preconj||are-36/VBP||only-40/JJ	amod||services-43/NNS||hiv/aids-42/JJ	prep_on||are-36/VBP||services-43/NNS	amod||services-51/NNS||many-48/JJ	amod||services-51/NNS||other-49/JJ	amod||services-51/NNS||essential-50/JJ	prep_on||are-36/VBP||services-51/NNS	conj_and||services-43/NNS||services-51/NNS	aids--1||hiv--1||no||this study shows that when a collaboration is established to strengthen existing health systems, in addition to providing hiv/aids services in a setting in which other primary health care is being delivered, there are positive effects not only on hiv/aids services, but also on many other essential services.
amod||risks-4/NNS||gastrointestinal-3/JJ	prep_because_of||propose-30/VBP||risks-4/NNS	nn||complications-8/NNS||ulcer-7/NN	prep_including||risks-4/NNS||complications-8/NNS	amod||risks-12/NNS||cardiovascular-11/JJ	conj_and||risks-4/NNS||risks-12/NNS	prep_because_of||propose-30/VBP||risks-12/NNS	nn||events-18/NNS||hypertension-15/NN	conj_and||hypertension-15/NN||thrombotic-17/JJ	nn||events-18/NNS||thrombotic-17/JJ	prep_including||risks-12/NNS||events-18/NNS	vmod||events-18/NNS||associated-19/VBN	amod||anti-inflammatorydrugs-22/NNS||nonsteroidal-21/JJ	prep_with||associated-19/VBN||anti-inflammatorydrugs-22/NNS	num||nsaids-24/NNS||-LSB--23/CD	npadvmod||-RSB--25/JJ||nsaids-24/NNS	amod||anti-inflammatorydrugs-22/NNS||-RSB--25/JJ	det||guidelines-29/NNS||these-28/DT	nsubj||propose-30/VBP||guidelines-29/NNS	root||ROOT-0/null||propose-30/VBP	dobj||propose-30/VBP||acetaminophen-31/NN	det||anti-inflammatoryagents-36/NNS||the-33/DT	amod||anti-inflammatoryagents-36/NNS||first-34/JJ	nn||anti-inflammatoryagents-36/NNS||choice-35/NN	prep_as||propose-30/VBP||anti-inflammatoryagents-36/NNS	ulcer-7||anti-inflammatoryagents-36||no_rel||because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatorydrugs [nsaids]), these guidelines propose acetaminophen as the first choice anti-inflammatoryagents.
nsubj||â-2/VBP||results-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	det||patients-8/NNS||the-5/DT	advmod||obese-7/JJ||morbidly-6/RB	amod||patients-8/NNS||obese-7/JJ	nsubj||had-11/VBD||patients-8/NNS	prep_with||patients-8/NNS||diabetes-10/NN	rcmod||$-3/$||had-11/VBD	advmod||higher-13/JJR||significantly-12/RB	amod||levels-14/NNS||higher-13/JJR	dobj||had-11/VBD||levels-14/NNS	prep_of||levels-14/NNS||oxldl-16/NN	prepc_compared_with||had-11/VBD||with-18/IN	det||patients-22/NNS||the-19/DT	advmod||obese-21/JJ||morbidly-20/RB	amod||patients-22/NNS||obese-21/JJ	pobj||had-11/VBD||patients-22/NNS	amod||glucose-26/NN||normal-24/JJ	nn||glucose-26/NN||fasting-25/NN	prep_with||patients-22/NNS||glucose-26/NN	det||subjects-30/NNS||the-28/DT	nn||subjects-30/NNS||control-29/NN	prep_with||patients-22/NNS||subjects-30/NNS	conj_and||glucose-26/NN||subjects-30/NNS	advmod||lower-33/JJR||significantly-32/RB	amod||levels-34/NNS||lower-33/JJR	pobj||had-11/VBD||levels-34/NNS	conj_and||patients-22/NNS||levels-34/NNS	amod||antibodies-38/NNS||igm-36/JJ	amod||antibodies-38/NNS||anti-oxldl-37/JJ	prep_of||levels-34/NNS||antibodies-38/NNS	obese-21||glucose-26||no_rel||results â€”the morbidly obese patients with diabetes had significantly higher levels of oxldl compared with the morbidly obese patients with normal fasting glucose and the control subjects and significantly lower levels of igm anti-oxldl antibodies.
amod||administration-6/NN||objective-1/JJ	nn||administration-6/NN||â-2/NN	nn||administration-6/NN||$-3/NN	nn||administration-6/NN||bedtime-5/NN	nsubj||prevents-17/VBZ||administration-6/NN	nsubj||causes-21/VBZ||administration-6/NN	num||mg-9/NN||5.0-8/CD	prep_of||administration-6/NN||mg-9/NN	det||terbutaline-16/NN||the-11/DT	nn||terbutaline-16/NN||î-12/NN	punct||terbutaline-16/NN||²-13/``	amod||terbutaline-16/NN||2-adrenergic-14/JJ	nn||terbutaline-16/NN||agonist-15/NN	prep_of||mg-9/NN||terbutaline-16/NN	root||ROOT-0/null||prevents-17/VBZ	amod||hypoglycemia-19/NN||nocturnal-18/JJ	dobj||prevents-17/VBZ||hypoglycemia-19/NN	conj_but||prevents-17/VBZ||causes-21/VBZ	nn||hyperglycemia-23/NN||morning-22/NN	dobj||causes-21/VBZ||hyperglycemia-23/NN	prep_in||causes-21/VBZ||type1diabetes-25/CD	terbutaline-16||type1diabetes-25||no_rel||objective â€”bedtime administration of 5.0 mg of the î²2-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type1diabetes.
nsubj||consistent-4/JJ||epsteinbarrvirus-1/NNS	advmod||consistent-4/JJ||serology-2/RB	cop||consistent-4/JJ||was-3/VBD	root||ROOT-0/null||consistent-4/JJ	amod||epsteinbarrvirusinfection-7/NN||recent-6/JJ	prep_with||consistent-4/JJ||epsteinbarrvirusinfection-7/NN	epsteinbarrvirusinfection-7||epsteinbarrvirus-1||no||epsteinbarrvirus serology was consistent with recent epsteinbarrvirusinfection.
nsubj||decreased-2/VBD||vitamine-1/NN	root||ROOT-0/null||decreased-2/VBD	nn||risk-4/NN||pneumonia-3/NN	dobj||decreased-2/VBD||risk-4/NN	num||%-7/NN||69-6/CD	prep_by||decreased-2/VBD||%-7/NN	num||%-10/NN||95-9/CD	nsubj||ci-11/VBP||%-10/NN	parataxis||decreased-2/VBD||ci-11/VBP	num||%-13/NN||43-12/CD	dobj||ci-11/VBP||%-13/NN	num||%-16/NN||83-15/CD	prep_to||ci-11/VBP||%-16/NN	prep_among||decreased-2/VBD||participants-19/NNS	nsubj||had-21/VBD||participants-19/NNS	nsubj||exercised-28/VBN||participants-19/NNS	rcmod||participants-19/NNS||had-21/VBD	det||exposure-24/NN||the-22/DT	amod||exposure-24/NN||least-23/JJS	dobj||had-21/VBD||exposure-24/NN	prep_to||exposure-24/NN||smoking-26/NN	rcmod||participants-19/NNS||exercised-28/VBN	conj_and||had-21/VBD||exercised-28/VBN	nn||time-31/NN||leisure-30/NN	prep_during||exercised-28/VBN||time-31/NN	vitamine-1||pneumonia-3||no_rel||vitamine decreased pneumonia risk by 69% (95% ci 43% to 83%) among participants who had the least exposure to smoking and exercised during leisure time.
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
nsubj||increased-19/VBD||stimulation-1/NN	amod||-rrb--12/NN||vvec-3/JJ	prep_with||vvec-3/JJ||extracellular-5/NN	amod||-rrb--12/NN||atp-6/JJ	number||100-8/CD||-lrb--7/CD	num||-rrb--12/NN||100-8/CD	amod||-rrb--12/NN||î-9/JJ	num||-rrb--12/NN||1/4-10/CD	nn||-rrb--12/NN||m-11/NN	prep_of||stimulation-1/NN||-rrb--12/NN	advmod||-lrb--14/JJ||dramatically-13/RB	amod||-rrb--12/NN||-lrb--14/JJ	advmod||increased-19/VBD||up-15/RB	amod||-rrb--18/NNS||ten-fold-17/JJ	prep_to||up-15/RB||-rrb--18/NNS	root||ROOT-0/null||increased-19/VBD	nn||formation-23/NN||migration-20/NN	conj_and||migration-20/NN||tube-22/NN	nn||formation-23/NN||tube-22/NN	dobj||increased-19/VBD||formation-23/NN	prep_on||increased-19/VBD||matrigel-25/NN	advmod||observed-36/JJ||however-27/RB	neg||effects-31/NNS||no-29/DT	amod||effects-31/NNS||significant-30/JJ	nsubj||observed-36/JJ||effects-31/NNS	nn||proliferation-34/NN||cell-33/NN	prep_on||effects-31/NNS||proliferation-34/NN	cop||observed-36/JJ||were-35/VBD	parataxis||increased-19/VBD||observed-36/JJ	tb--1||inh--1||yes||stimulation of vvec with extracellular atp -lrb- 100 î 1/4 m -rrb- dramatically -lrb- up to ten-fold -rrb- increased migration and tube formation on matrigel ; however , no significant effects on cell proliferation were observed .
advmod||bear-16/VBP||however-1/RB	prep_in||bear-16/VBP||terms-4/NNS	det||constitution-12/NN||the-6/DT	amod||constitution-12/NN||countryâ-7/JJ	amod||constitution-12/NN||$-8/$	number||s-10/CD||™-9/CD	num||$-8/$||s-10/CD	amod||constitution-12/NN||quasi-federal-11/JJ	prep_of||terms-4/NNS||constitution-12/NN	amod||governments-15/NNS||provincial-14/JJ	nsubj||bear-16/VBP||governments-15/NNS	nsubj||have-27/VBP||governments-15/NNS	root||ROOT-0/null||bear-16/VBP	det||responsibility-19/NN||the-17/DT	amod||responsibility-19/NN||main-18/JJ	dobj||bear-16/VBP||responsibility-19/NN	prep_for||bear-16/VBP||provision-21/NN	nn||care-24/NN||health-23/NN	prep_of||provision-21/NN||care-24/NN	conj_and||bear-16/VBP||have-27/VBP	det||amount-30/NN||a-28/DT	amod||amount-30/NN||certain-29/JJ	dobj||have-27/VBP||amount-30/NN	prep_of||amount-30/NN||autonomy-32/NN	advmod||implemented-43/VBN||therefore-34/RB	nsubjpass||implemented-43/VBN||choice-35/NN	det||way-38/NN||the-37/DT	prep_in||choice-35/NN||way-38/NN	poss||programmes-41/NNS||their-39/PRP$	nn||programmes-41/NNS||hiv/aids-40/NNS	dep||way-38/NN||programmes-41/NNS	auxpass||implemented-43/VBN||are-42/VBP	conj_and||bear-16/VBP||implemented-43/VBN	aids--1||hiv--1||no||however, in terms of the countryâ€™s quasi-federal constitution, provincial governments bear the main responsibility for provision of health care, and have a certain amount of autonomy and therefore choice in the way their hiv/aids programmes are implemented.
nsubjpass||shown-14/VBN||combinations-1/NNS	nsubj||active-18/JJ||combinations-1/NNS	nsubj||mantle-24/VB||combinations-1/NNS	prep_of||combinations-1/NNS||bendamustine-3/NN	prep_with||bendamustine-3/NN||mitoxantrone-5/NN	prep_with||bendamustine-3/NN||rituximab-7/NN	conj_and||mitoxantrone-5/NN||rituximab-7/NN	prep_with||bendamustine-3/NN||rituximab-10/NN	conj_and||mitoxantrone-5/NN||rituximab-10/NN	advmod||shown-14/VBN||alone-11/RB	aux||shown-14/VBN||have-12/VBP	auxpass||shown-14/VBN||been-13/VBN	root||ROOT-0/null||shown-14/VBN	aux||active-18/JJ||to-15/TO	cop||active-18/JJ||be-16/VB	advmod||active-18/JJ||highly-17/RB	xcomp||shown-14/VBN||active-18/JJ	amod||lymphomas-22/NNS||relapsed/refractory-20/JJ	nn||lymphomas-22/NNS||indolent-21/NN	prep_in||active-18/JJ||lymphomas-22/NNS	xcomp||shown-14/VBN||mantle-24/VB	conj_and||active-18/JJ||mantle-24/VB	nn||lymphomas-26/NNS||cell-25/NN	dobj||mantle-24/VB||lymphomas-26/NNS	xcomp||mantle-24/VB||achieving-27/VBG	advmod||lasting-29/JJ||long-28/RB	amod||remissions-31/NNS||lasting-29/JJ	amod||remissions-31/NNS||complete-30/JJ	dobj||achieving-27/VBG||remissions-31/NNS	lymphomas-26||mitoxantrone-5||yes||combinations of bendamustine with mitoxantrone and rituximab and with rituximab alone have been shown to be highly active in relapsed/refractory indolent lymphomas and mantle cell lymphomas achieving long lasting complete remissions.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	metastasis-17||antibody-56||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
aux||investigate-2/VB||to-1/TO	csubj||synthase-11/VBD||investigate-2/VB	csubj||synthase-11/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandine-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandine-7/NN	appos||prostaglandine-7/NN||pge-9/NN	root||ROOT-0/null||synthase-11/VBD	conj_and||synthase-11/VBD||synthase-11/VBD	dobj||synthase-11/VBD||1-12/CD	dep||1-12/CD||mpges-1-14/JJ	dobj||synthase-11/VBD||cyclooxygenase-17/NN	conj_and||1-12/CD||cyclooxygenase-17/NN	appos||cyclooxygenase-17/NN||cox-19/NN	nn||biopsies-23/NNS||muscle-22/NN	prep_in||cyclooxygenase-17/NN||biopsies-23/NNS	prep_from||synthase-11/VBD||patients-25/NNS	prep_with||patients-25/NNS||polymyositis-27/NNS	prep_with||patients-25/NNS||dermatomyositis-29/NNS	conj_or||polymyositis-27/NNS||dermatomyositis-29/NNS	amod||treatment-35/NN||conventional-33/JJ	nn||treatment-35/NN||immunosuppressive-34/NN	prep_after||synthase-11/VBD||treatment-35/NN	prep_before||synthase-11/VBD||treatment-35/NN	prostaglandine-7||dermatomyositis-29||no_rel||to investigate the expression of microsomal prostaglandine (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
det||interest-2/NN||the-1/DT	nsubjpass||recommended-7/VBN||interest-2/NN	det||case-5/NN||this-4/DT	prep_of||interest-2/NN||case-5/NN	auxpass||recommended-7/VBN||is-6/VBZ	root||ROOT-0/null||recommended-7/VBN	det||existence-10/NN||the-9/DT	prep_in||recommended-7/VBN||existence-10/NN	num||pathogens-14/NNS||two-12/CD	amod||pathogens-14/NNS||responsible-13/JJ	prep_of||existence-10/NN||pathogens-14/NNS	det||paucity-17/NN||the-16/DT	prep_in||recommended-7/VBN||paucity-17/NN	conj_and||existence-10/NN||paucity-17/NN	det||oflungabscess-21/NNS||the-19/DT	nn||oflungabscess-21/NNS||development-20/NN	prep_of||paucity-17/NN||oflungabscess-21/NNS	det||patient-24/NN||a-23/DT	prep_in||oflungabscess-21/NNS||patient-24/NN	prep_with||patient-24/NN||vap-26/NN	det||treatment-31/NN||the-29/DT	amod||treatment-31/NN||successful-30/JJ	prep_in||recommended-7/VBN||treatment-31/NN	conj_and||existence-10/NN||treatment-31/NN	det||patient-34/NN||the-33/DT	prep_of||treatment-31/NN||patient-34/NN	det||combination-37/NN||the-36/DT	prep_with||recommended-7/VBN||combination-37/NN	amod||drainage-40/NN||controlled-39/VBN	prep_of||combination-37/NN||drainage-40/NN	det||therapy-47/NN||the-42/DT	amod||therapy-47/NN||abscess-43/JJ	conj_and||abscess-43/JJ||appropriate-45/JJ	amod||therapy-47/NN||appropriate-45/JJ	amod||therapy-47/NN||antibiotic-46/JJ	prep_of||drainage-40/NN||therapy-47/NN	oflungabscess-21||antibiotic-46||no_rel||the interest of this case is recommended in the existence of two responsible pathogens, the paucity of the development oflungabscess in a patient with vap, and the successful treatment of the patient with the combination of controlled drainage of the abscess and appropriate antibiotic therapy.
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||find-17/VB||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	amod||incidence-5/NN||increased-4/VBN	dobj||demonstrated-3/VBD||incidence-5/NN	amod||pancreatitis-8/NNS||acute-7/JJ	prep_of||incidence-5/NN||pancreatitis-8/NNS	prep_in||pancreatitis-8/NNS||diabetic-10/NN	amod||patients-13/NNS||nondiabetic-12/JJ	prep_versus||diabetic-10/NN||patients-13/NNS	aux||find-17/VB||did-15/VBD	neg||find-17/VB||not-16/RB	conj_but||demonstrated-3/VBD||find-17/VB	det||association-19/NN||an-18/DT	dobj||find-17/VB||association-19/NN	det||use-22/NN||the-21/DT	prep_between||association-19/NN||use-22/NN	dep||sitagliptin-26/JJ||exenatide-24/JJ	amod||pancreatitis-29/NNS||sitagliptin-26/JJ	conj_and||sitagliptin-26/JJ||acute-28/JJ	amod||pancreatitis-29/NNS||acute-28/JJ	prep_of||use-22/NN||pancreatitis-29/NNS	pancreatitis-29||sitagliptin-26||no_rel||our study demonstrated increased incidence of acute pancreatitis in diabetic versus nondiabetic patients but did not find an association between the use of exenatide or sitagliptin and acute pancreatitis.
prep_in||requires-12/VBZ||hemophiliaa-2/NN	amod||prophylaxis-5/NNS||routine-4/JJ	nsubj||requires-12/VBZ||prophylaxis-5/NNS	nsubj||lead-18/VB||prophylaxis-5/NNS	amod||factorviii-8/NNS||exogenous-7/JJ	prep_with||prophylaxis-5/NNS||factorviii-8/NNS	appos||factorviii-8/NNS||fviii-10/NNP	root||ROOT-0/null||requires-12/VBZ	amod||injections-15/NNS||frequent-13/JJ	amod||injections-15/NNS||intravenous-14/JJ	dobj||requires-12/VBZ||injections-15/NNS	aux||lead-18/VB||can-17/MD	conj_and||requires-12/VBZ||lead-18/VB	det||development-21/NN||the-20/DT	prep_to||lead-18/VB||development-21/NN	amod||alloantibodies-24/NNS||anti-fviii-23/JJ	prep_of||development-21/NN||alloantibodies-24/NNS	num||inhibitors-27/NNS||fviii-26/CD	appos||alloantibodies-24/NNS||inhibitors-27/NNS	hemophiliaa-2||factorviii-8||yes||in hemophiliaa, routine prophylaxis with exogenous factorviii (fviii) requires frequent intravenous injections and can lead to the development of anti-fviii alloantibodies (fviii inhibitors).
nsubj||drug-6/NN||alminoprofen-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||non-steroid-4/JJ	amod||drug-6/NN||anti-inflammatory-5/JJ	root||ROOT-0/null||drug-6/NN	dep||drug-6/NN||nsaid-8/VBN	vmod||drug-6/NN||used-10/VBN	det||analgesic-13/JJ||an-12/DT	prep_as||used-10/VBN||analgesic-13/JJ	prep_for||analgesic-13/JJ||rheumatism-15/NN	rheumatism-15||analgesic-13||no_rel||alminoprofen is a non-steroid anti-inflammatory drug (nsaid) used as an analgesic for rheumatism.
nsubj||antipsychoticdrug-5/NN||aripiprazole-1/NN	cop||antipsychoticdrug-5/NN||is-2/VBZ	det||antipsychoticdrug-5/NN||an-3/DT	amod||antipsychoticdrug-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychoticdrug-5/NN	vmod||antipsychoticdrug-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	amod||disorders-12/NNS||psychiatric-11/JJ	prep_of||treatment-9/NN||disorders-12/NNS	nn||depressivedisorder-20/NN||schizophrenia-15/NN	prep_such_as||disorders-12/NNS||bipolardisorder-17/NN	conj_and||depressivedisorder-20/NN||bipolardisorder-17/NN	prep_such_as||disorders-12/NNS||major-19/JJ	amod||depressivedisorder-20/NN||major-19/JJ	conj_and||depressivedisorder-20/NN||major-19/JJ	prep_such_as||disorders-12/NNS||depressivedisorder-20/NN	prep_such_as||disorders-12/NNS||autism-22/NN	conj_and||depressivedisorder-20/NN||autism-22/NN	schizophrenia-15||antipsychoticdrug-5||no_rel||aripiprazole is an atypical antipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||used-8/VBN||that-4/IN	nsubjpass||used-8/VBN||bufalin-5/NN	nsubj||treat-10/VB||bufalin-5/NN	aux||used-8/VBN||could-6/MD	auxpass||used-8/VBN||be-7/VB	ccomp||suggest-3/VBP||used-8/VBN	aux||treat-10/VB||to-9/TO	xcomp||used-8/VBN||treat-10/VB	acomp||treat-10/VB||inflammatory-11/JJ	acomp||treat-10/VB||autoimmunediseases-13/JJ	conj_and||inflammatory-11/JJ||autoimmunediseases-13/JJ	advmod||hyperactivated-19/VBN||where-14/WRB	nsubjpass||hyperactivated-19/VBN||ifn-15/NN	conj_or||ifn-15/NN||tnf-17/NN	nsubjpass||hyperactivated-19/VBN||tnf-17/NN	auxpass||hyperactivated-19/VBN||are-18/VBP	advcl||treat-10/VB||hyperactivated-19/VBN	autoimmunediseases-13||ifn-15||no||these findings suggest that bufalin could be used to treat inflammatory and autoimmunediseases where ifn or tnf are hyperactivated.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
nsubj||indicate-6/VBP||studies-1/NNS	amod||contexts-4/NNS||different-3/JJ	prep_from||studies-1/NNS||contexts-4/NNS	advmod||indicate-6/VBP||worldwide-5/RB	root||ROOT-0/null||indicate-6/VBP	mark||manifest-10/VBP||that-7/IN	amod||patients-9/NNS||hivpositive-8/JJ	nsubj||manifest-10/VBP||patients-9/NNS	ccomp||indicate-6/VBP||manifest-10/VBP	amod||behavior-13/NN||high-risk-11/JJ	amod||behavior-13/NN||sexual-12/JJ	nsubj||characterized-14/VBD||behavior-13/NN	ccomp||manifest-10/VBP||characterized-14/VBD	nn||intentions-17/NNS||fertility-16/NN	prep_by||characterized-14/VBD||intentions-17/NNS	amod||partners-21/NNS||multiple-19/JJ	amod||partners-21/NNS||sexual-20/JJ	appos||intentions-17/NNS||partners-21/NNS	prep_by||characterized-14/VBD||non-use-23/NN	conj_and||intentions-17/NNS||non-use-23/NN	prep_of||non-use-23/NN||contraceptives-25/NNS	prep_by||characterized-14/VBD||non-disclosure-27/NN	conj_and||intentions-17/NNS||non-disclosure-27/NN	nn||status-30/NN||hiv-29/NN	prep_of||non-disclosure-27/NN||status-30/NN	poss||partners-34/NNS||their-32/PRP$	nn||partners-34/NNS||sex-33/NN	prep_to||characterized-14/VBD||partners-34/NNS	hivpositive-8||hiv-29||no||studies from different contexts worldwide indicate that hivpositive patients manifest high-risk sexual behavior characterized by fertility intentions, multiple sexual partners, non-use of contraceptives and non-disclosure of hiv status to their sex partners.
nsubj||produced-3/VBD||sp-1/NN	nsubjpass||affected-27/VBN||sp-1/NN	advmod||produced-3/VBD||also-2/RB	root||ROOT-0/null||produced-3/VBD	amod||potentials-7/NNS||cortical-4/JJ	amod||potentials-7/NNS||evoked-5/JJ	nn||potentials-7/NNS||eeg-6/NN	nsubj||consistent-8/JJ||potentials-7/NNS	xcomp||produced-3/VBD||consistent-8/JJ	nn||mediation-12/NN||aî-10/NN	nn||mediation-12/NN||´-11/NN	prep_with||consistent-8/JJ||mediation-12/NN	prep_of||amplitude-15/NN||mediation-12/NN	det||amplitude-15/NN||the-14/DT	nsubjpass||correlated-20/VBN||amplitude-15/NN	auxpass||correlated-20/VBN||was-18/VBD	advmod||correlated-20/VBN||directly-19/RB	rcmod||mediation-12/NN||correlated-20/VBN	nn||intensity-23/NN||pain-22/NN	prep_with||correlated-20/VBN||intensity-23/NN	auxpass||affected-27/VBN||was-25/VBD	neg||affected-27/VBN||not-26/RB	conj_but||produced-3/VBD||affected-27/VBN	amod||capsaicin-30/NN||topical-29/JJ	agent||affected-27/VBN||capsaicin-30/NN	pain-22||capsaicin-30||yes||sp also produced cortical evoked eeg potentials consistent with aî´ mediation, the amplitude of which was directly correlated with pain intensity but was not affected by topical capsaicin.
det||average-3/NN||the-1/DT	amod||average-3/NN||mean-2/JJ	nsubj||â-13/NNS||average-3/NN	prep_of||average-3/NN||intensity-5/NN	prep_of||intensity-5/NN||pain-7/NN	det||patients-10/NNS||these-9/DT	prep_in||pain-7/NN||patients-10/NNS	cop||â-13/NNS||was-11/VBD	num||â-13/NNS||7.5-12/CD	root||ROOT-0/null||â-13/NNS	number||2.2-15/CD||±-14/CD	num||â-13/NNS||2.2-15/CD	amod||patients-18/NNS||few-17/JJ	nsubj||used-19/VBD||patients-18/NNS	parataxis||â-13/NNS||used-19/VBD	dobj||used-19/VBD||alcohol-20/NN	num||%-23/NN||4-22/CD	appos||alcohol-20/NN||%-23/NN	dobj||used-19/VBD||opium-26/NN	conj_and||alcohol-20/NN||opium-26/NN	num||%-29/NN||1-28/CD	appos||opium-26/NN||%-29/NN	dobj||used-19/VBD||cigarette-32/NN	conj_and||alcohol-20/NN||cigarette-32/NN	num||%-35/NN||10-34/CD	appos||alcohol-20/NN||%-35/NN	pain-7||opium-26||yes||the mean average of intensity of pain in these patients was 7.5â±2.2; few patients used alcohol (4%), opium (1%) and cigarette (10%).
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	det||effects-4/NNS||the-3/DT	dobj||determine-2/VB||effects-4/NNS	amod||supplementation-7/NN||combined-6/JJ	prep_of||determine-2/VB||supplementation-7/NN	prep_with||determine-2/VB||chromium-9/NN	appos||chromium-9/NN||cr-11/NN	prep_with||determine-2/VB||vitamins-14/NNS	conj_and||chromium-9/NN||vitamins-14/NNS	dep||determine-2/VB||c-15/SYM	dep||>-28/VBZ||e-17/SYM	amod||stress-20/NN||oxidative-19/JJ	prep_on||>-28/VBZ||stress-20/NN	prep_in||stress-20/NN||type2diabetes-22/CD	amod||subjects-25/NNS||adult-24/JJ	nsubj||>-28/VBZ||subjects-25/NNS	prep_with||subjects-25/NNS||hba1c-27/CD	conj_and||determine-2/VB||>-28/VBZ	num||%-30/NN||8.5-29/CD	dobj||>-28/VBZ||%-30/NN	chromium-9||type2diabetes-22||no_rel||to determine the effects of combined supplementation with chromium (cr) and vitamins c and e on oxidative stress in type2diabetes, adult subjects with hba1c >8.5%.
nn||number-2/NN||otu-1/NN	nsubjpass||reduced-5/VBN||number-2/NN	auxpass||reduced-5/VBN||was-3/VBD	advmod||reduced-5/VBN||significantly-4/RB	root||ROOT-0/null||reduced-5/VBN	prep_in||reduced-5/VBN||cd-7/NN	num||±-11/NNP||7.7-9/CD	nn||±-11/NNP||â-10/NNP	dep||cd-7/NN||±-11/NNP	num||±-11/NNP||3.7-12/CD	nn||sd-16/NNP||meanâ-14/NNP	nn||sd-16/NNP||±-15/NNP	appos||±-11/NNP||sd-16/NNP	prep_in||reduced-5/VBN||uc-19/NN	conj_and||cd-7/NN||uc-19/NN	num||3.0-24/NNS||9.0-21/CD	nn||3.0-24/NNS||â-22/NNP	nn||3.0-24/NNS||±-23/NN	appos||cd-7/NN||3.0-24/NNS	prepc_compared_to||reduced-5/VBN||to-27/TO	pobj||reduced-5/VBN||hc-28/NN	num||2.2-33/NNS||11.9-30/CD	nn||2.2-33/NNS||â-31/NNP	nn||2.2-33/NNS||±-32/NN	appos||hc-28/NN||2.2-33/NNS	dep||hc-28/NN||p-36/VBN	dep||0.0005-38/CD||=-37/SYM	ccomp||p-36/VBN||0.0005-38/CD	uc-19||cd-7||no_rel||otu number was significantly reduced in cd (7.7â±3.7, meanâ±sd) and uc (9.0â±3.0) compared to hc (11.9â±2.2) (p=0.0005).
amod||children-2/NNS||sixty-1/JJ	nsubj||received-16/VBD||children-2/NNS	nn||syndrome-7/NN||autism-4/NN	conj_or||autism-4/NN||asperger-6/NN	nn||syndrome-7/NN||asperger-6/NN	prep_with||children-2/NNS||syndrome-7/NN	dep||old-14/JJ||3â-9/RB	num||years-13/NNS||$-10/$	num||$-10/$||11-12/CD	npadvmod||old-14/JJ||years-13/NNS	dep||children-2/NNS||old-14/JJ	root||ROOT-0/null||received-16/VBD	num||months-19/NNS||3-18/CD	prep_for||received-16/VBD||months-19/NNS	amod||months-19/NNS||placebo-20/JJ	amod||months-19/NNS||bumetanide-22/JJ	conj_or||placebo-20/JJ||bumetanide-22/JJ	dep||months-19/NNS||1â-24/VBG	dobj||1â-24/VBG||$-25/$	number||mg-27/CD||‰-26/CD	num||$-25/$||mg-27/CD	advmod||1â-24/VBG||daily-28/RB	prepc_followed_by||received-16/VBD||by-32/IN	amod||wash-34/NN||1-month-33/JJ	pobj||received-16/VBD||wash-34/NN	dep||wash-34/NN||out-35/RP	autism-4||bumetanide-22||no_rel||sixty children with autism or asperger syndrome (3â€“11 years old) received for 3 months placebo or bumetanide (1â€‰mg daily), followed by 1-month wash out.
advmod||started-10/VBD||then-1/RB	det||team-6/NN||the-3/DT	nn||team-6/NN||nutrition-4/NN	nn||team-6/NN||support-5/NN	nsubj||started-10/VBD||team-6/NN	nsubj||estimated-13/VBD||team-6/NN	appos||team-6/NN||nst-8/NN	root||ROOT-0/null||started-10/VBD	dobj||started-10/VBD||intervention-11/NN	conj_and||started-10/VBD||estimated-13/VBD	det||patient-15/NN||the-14/DT	poss||malnutrition-17/NN||patient-15/NN	dobj||estimated-13/VBD||malnutrition-17/NN	poss||weight-21/NN||her-19/PRP$	nn||weight-21/NN||body-20/NN	prep_from||estimated-13/VBD||weight-21/NN	number||kg-24/CD||30.1-23/CD	dep||weight-21/NN||kg-24/CD	nn||index-29/NN||body-27/NN	nn||index-29/NN||mass-28/NN	prep_from||estimated-13/VBD||index-29/NN	conj_and||weight-21/NN||index-29/NN	appos||index-29/NN||bmi-31/NN	appos||index-29/NN||13.9-34/NNP	amod||thickness-39/NN||triceps-37/JJ	amod||thickness-39/NN||skinfold-38/JJ	prep_from||estimated-13/VBD||thickness-39/NN	conj_and||weight-21/NN||thickness-39/NN	appos||thickness-39/NN||tsf-41/NN	number||mm-45/CD||3.5-44/CD	dep||thickness-39/NN||mm-45/CD	nn||circumference-49/NN||arm-48/NN	prep_from||estimated-13/VBD||circumference-49/NN	conj_and||weight-21/NN||circumference-49/NN	appos||circumference-49/NN||ac-51/NN	number||cm-55/CD||17.2-54/CD	dep||circumference-49/NN||cm-55/CD	nn||albumin-59/NN||serum-58/NN	prep_from||estimated-13/VBD||albumin-59/NN	conj_and||weight-21/NN||albumin-59/NN	num||g/dl-62/NN||2.6-61/CD	appos||albumin-59/NN||g/dl-62/NN	malnutrition-17||tsf-41||no_rel||then, the nutrition support team (nst) started intervention and estimated the patient's malnutrition from her body weight (30.1 kg), body mass index (bmi) (13.9), triceps skinfold thickness (tsf) (3.5 mm), arm circumference (ac) (17.2 cm) and serum albumin (2.6 g/dl).
nsubjpass||accepted-3/VBN||dacarbazine-1/NN	auxpass||accepted-3/VBN||was-2/VBD	root||ROOT-0/null||accepted-3/VBN	det||treatment-7/NN||the-5/DT	amod||treatment-7/NN||standard-6/JJ	prep_as||accepted-3/VBN||treatment-7/NN	prep_for||treatment-7/NN||melanoma-9/NN	det||1970s-12/NNS||the-11/DT	prep_in||accepted-3/VBN||1970s-12/NNS	prepc_despite||remained-26/VBD||inducing-16/VBG	det||survival-19/NN||an-17/DT	amod||survival-19/NN||overall-18/JJ	dobj||inducing-16/VBG||survival-19/NN	quantmod||7.4-22/CD||approximately-21/RB	num||months-23/NNS||7.4-22/CD	prep_of||survival-19/NN||months-23/NNS	nsubj||remained-26/VBD||it-25/PRP	conj_and||accepted-3/VBN||remained-26/VBD	advmod||remained-26/VBD||so-27/RB	prep||so-27/RB||until-28/IN	advmod||recently-30/RB||relatively-29/RB	pobj||until-28/IN||recently-30/RB	melanoma-9||dacarbazine-1||yes||dacarbazine was accepted as the standard treatment for melanoma in the 1970s, and despite inducing an overall survival of approximately 7.4 months, it remained so until relatively recently.
nn||samples-2/NNS||csf-1/NN	nsubjpass||analyzed-9/VBN||samples-2/NNS	prep_from||samples-2/NNS||aids-4/NNS	amod||patients-7/NNS||hiv-negative-6/JJ	prep_from||samples-2/NNS||patients-7/NNS	conj_and||aids-4/NNS||patients-7/NNS	auxpass||analyzed-9/VBN||were-8/VBD	root||ROOT-0/null||analyzed-9/VBN	aids-4||hiv--1||no||csf samples from aids and hiv-negative patients were analyzed.
mark||contain-9/VBP||since-1/IN	amod||tract-4/NN||female-2/JJ	amod||tract-4/NN||reproductive-3/JJ	nn||secretions-8/NNS||tract-4/NN	appos||secretions-8/NNS||frt-6/NN	nsubj||contain-9/VBP||secretions-8/NNS	advcl||hypothesized-16/VBZ||contain-9/VBP	det||spectrum-11/NN||a-10/DT	dobj||contain-9/VBP||spectrum-11/NN	prep_of||spectrum-11/NN||antimicrobials-13/NNS	nsubj||hypothesized-16/VBZ||we-15/PRP	root||ROOT-0/null||hypothesized-16/VBZ	mark||inhibit-31/VBP||that-17/IN	nsubj||inhibit-31/VBP||cvl-18/NN	amod||hiv-21/NN||healthy-20/JJ	prep_from||cvl-18/NN||hiv-21/NN	appos||hiv-21/NN||+-23/NNP	poss||women-30/NNS||âˆ-27/NNP	prep_from||cvl-18/NN||women-30/NNS	conj_and||hiv-21/NN||women-30/NNS	ccomp||hypothesized-16/VBZ||inhibit-31/VBP	dobj||inhibit-31/VBP||hivinfection-32/NN	hivinfection-32||hiv-21||no||since female reproductive tract (frt) secretions contain a spectrum of antimicrobials, we hypothesized that cvl from healthy hiv(+) and (âˆ’) women inhibit hivinfection.
amod||-rrb--4/NNS||methicillin-resistantstaphylococcusaureus-1/JJ	amod||-rrb--4/NNS||-lrb--2/JJ	nn||-rrb--4/NNS||mrsa-3/NN	nsubj||-lrb--8/VBD||-rrb--4/NNS	amod||s.aureus-7/NNS||methicillin-sensitive-6/JJ	conj_and||-rrb--4/NNS||s.aureus-7/NNS	nsubj||-lrb--8/VBD||s.aureus-7/NNS	root||ROOT-0/null||-lrb--8/VBD	nn||-rrb--10/NNP||mssa-9/NNP	nsubjpass||used-12/VBN||-rrb--10/NNP	auxpass||used-12/VBN||were-11/VBD	ccomp||-lrb--8/VBD||used-12/VBN	prep_in||used-12/VBN||vitro-14/NN	prep_in||used-12/VBN||for-16/IN	conj_and||vitro-14/NN||for-16/IN	amod||mice-18/NNS||infecting-17/VBG	pobj||for-16/IN||mice-18/NNS	mark||studied-25/VBN||while-20/IN	amod||infection-23/NN||natural-21/JJ	nn||infection-23/NN||mssa-22/NN	nsubjpass||studied-25/VBN||infection-23/NN	auxpass||studied-25/VBN||was-24/VBD	advcl||used-12/VBN||studied-25/VBN	prep_in||studied-25/VBN||humans-27/NNS	mrsa-3||s.aureus-7||no||methicillin-resistantstaphylococcusaureus -lrb- mrsa -rrb- and methicillin-sensitive s.aureus -lrb- mssa -rrb- were used in vitro and for infecting mice , while natural mssa infection was studied in humans .
det||purpose-2/NN||the-1/DT	nsubj||was-8/VBD||purpose-2/NN	nsubj||evaluate-10/VB||purpose-2/NN	det||study-7/NN||this-4/DT	nn||study-7/NN||multicenter-5/NN	nn||study-7/NN||spanish-6/NN	prep_of||purpose-2/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||evaluate-10/VB||to-9/TO	xcomp||was-8/VBD||evaluate-10/VB	det||response-12/NN||the-11/DT	dobj||evaluate-10/VB||response-12/NN	amod||methylphenidate-15/NN||immediate-release-14/JJ	prep_to||evaluate-10/VB||methylphenidate-15/NN	prep_by||evaluate-10/VB||children-17/NNS	prep_by||evaluate-10/VB||adults-19/NNS	conj_and||children-17/NNS||adults-19/NNS	vmod||children-17/NNS||diagnosed-20/VBN	prep_with||diagnosed-20/VBN||attention-deficit/hyperactivitydisorder-22/NN	dep||attention-deficit/hyperactivitydisorder-22/NN||adhd-24/VBN	aux||obtain-31/VB||to-30/TO	prep_by||evaluate-10/VB||obtain-31/VB	conj_and||children-17/NNS||obtain-31/VB	vmod||children-17/NNS||obtain-31/VB	dobj||obtain-31/VB||information-32/NN	amod||patterns-36/NNS||current-34/JJ	nn||patterns-36/NNS||therapy-35/NN	prep_on||obtain-31/VB||patterns-36/NNS	nn||characteristics-39/NNS||safety-38/NN	prep_on||obtain-31/VB||characteristics-39/NNS	conj_and||patterns-36/NNS||characteristics-39/NNS	adhd-24||methylphenidate-15||yes||the purpose of this multicenter spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivitydisorder (adhd), as well as to obtain information on current therapy patterns and safety characteristics.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||used-5/VBD||that-3/IN	advmod||used-5/VBD||currently-4/RB	ccomp||found-2/VBD||used-5/VBD	amod||methods-7/NNS||culture-based-6/JJ	nsubj||miss-9/VB||methods-7/NNS	aux||miss-9/VB||may-8/MD	ccomp||used-5/VBD||miss-9/VB	det||proportion-12/NN||a-10/DT	amod||proportion-12/NN||substantial-11/JJ	dobj||miss-9/VB||proportion-12/NN	prep_of||proportion-12/NN||campylobacterinfections-14/NNS	amod||testing-19/NN||additional-17/JJ	amod||testing-19/NN||serological-18/JJ	nsubjpass||considered-24/VBN||testing-19/NN	prep_for||testing-19/NN||campylobacter-21/NN	aux||considered-24/VBN||should-22/MD	auxpass||considered-24/VBN||be-23/VB	conj_and||found-2/VBD||considered-24/VBN	campylobacterinfections-14||campylobacter-21||no||we found that currently used culture-based methods may miss a substantial proportion of campylobacterinfections, and additional serological testing for campylobacter should be considered.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	det||trial-6/NN||a-3/DT	amod||trial-6/NN||16-week-4/JJ	nn||trial-6/NN||intervention-5/NN	dobj||performed-2/VBD||trial-6/NN	det||diet-12/NN||a-8/DT	amod||diet-12/NN||hypocaloric-9/JJ	amod||diet-12/NN||low-fat-11/JJ	prep_of||trial-6/NN||diet-12/NN	dobj||performed-2/VBD||10-14/CD	conj_plus||trial-6/NN||10-14/CD	advmod||ezetimibe-16/JJ||mg/day-15/RB	amod||10-14/CD||ezetimibe-16/JJ	dep||10-14/CD||n-18/VBN	dep||15-20/CD||=-19/SYM	ccomp||n-18/VBN||15-20/CD	det||diet-27/NN||a-23/DT	amod||diet-27/NN||hypocaloric-24/JJ	amod||diet-27/NN||low-fat-26/JJ	conj_plus||trial-6/NN||diet-27/NN	conj_versus||10-14/CD||diet-27/NN	amod||diet-27/NN||alone-28/RB	dep||trial-6/NN||n-30/VBN	dep||10-32/CD||=-31/SYM	ccomp||n-30/VBN||10-32/CD	amod||triglyceride-36/NN||intrahepatic-35/JJ	prep_on||performed-2/VBD||triglyceride-36/NN	appos||triglyceride-36/NN||ihtg-38/NN	amod||triglyceride-36/NN||content-40/JJ	vmod||triglyceride-36/NN||plasma-42/VBN	amod||subjects-67/NNS||high-43/JJ	dep||$-45/$||sensitivityâ-44/RB	dep||subjects-67/NNS||$-45/$	npadvmod||in-65/RB||c-reactive-47/NN	advmod||c-reactive-47/NN||protein-48/RB	pobj||protein-48/RB||hs-crp-50/NN	appos||hs-crp-50/NN||adipocytokines-53/NNS	amod||concentrations-57/NNS||fetuin-a-56/JJ	pobj||protein-48/RB||concentrations-57/NNS	conj_and||hs-crp-50/NN||concentrations-57/NNS	conj_and||hs-crp-50/NN||apolipoprotein-59/NNS	conj_and||concentrations-57/NNS||apolipoprotein-59/NNS	appos||concentrations-57/NNS||apo-61/NN	amod||kinetics-64/NNS||b-100-63/JJ	dep||concentrations-57/NNS||kinetics-64/NNS	dep||obese-66/CD||in-65/RB	num||$-45/$||obese-66/CD	dobj||plasma-42/VBN||subjects-67/NNS	obese-66||fat--1||no_rel||we performed a 16-week intervention trial of a hypocaloric, low-fat diet plus 10 mg/day ezetimibe ( n = 15) versus a hypocaloric, low-fat diet alone ( n = 10) on intrahepatic triglyceride (ihtg) content, plasma high sensitivityâ€“c-reactive protein (hs-crp), adipocytokines, and fetuin-a concentrations and apolipoprotein (apo)b-100 kinetics in obese subjects.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mtb-24||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-28/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||lowbackpain-16/NN||chronic-15/JJ	prep_in||activity-13/NN||lowbackpain-16/NN	appos||lowbackpain-16/NN||cbp-18/NN	nn||osteoarthritis-23/NNS||knee-22/NN	prep_in||treatment-6/NN||osteoarthritis-23/NNS	appos||effects-2/NNS||oa-25/NN	auxpass||investigated-28/VBN||were-27/VBD	root||ROOT-0/null||investigated-28/VBN	xcomp||investigated-28/VBN||using-29/VBG	amod||fmri-31/NNS||serial-30/JJ	dobj||using-29/VBG||fmri-31/NNS	dep||fmri-31/NNS||contrasting-33/VBG	dobj||contrasting-33/VBG||fmri-34/NNS	advmod||weeks-40/NNS||before-36/RB	conj_and||before-36/RB||after-38/IN	advmod||weeks-40/NNS||after-38/IN	pobj||after-38/IN||two-39/CD	prep_between||fmri-34/NNS||weeks-40/NNS	prep_of||fmri-34/NNS||treatment-42/NN	lowbackpain-16||lidocaine-8||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic lowbackpain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
det||extent-2/NN||the-1/DT	nsubj||different-11/JJ||extent-2/NN	nn||pattern-8/NN||mrsa-4/NN	conj_and||mrsa-4/NN||drug-6/NN	nn||pattern-8/NN||drug-6/NN	nn||pattern-8/NN||resistance-7/NN	prep_of||extent-2/NN||pattern-8/NN	cop||different-11/JJ||was-9/VBD	advmod||different-11/JJ||significantly-10/RB	root||ROOT-0/null||different-11/JJ	amod||samples-14/NNS||various-13/JJ	prep_among||different-11/JJ||samples-14/NNS	prep_of||samples-14/NNS||s.aureus-16/NNS	dep||different-11/JJ||positive-18/JJ	ccomp||positive-18/JJ||isolates-19/VBZ	mrsa-4||s.aureus-16||no||the extent of mrsa and drug resistance pattern was significantly different among various samples of s.aureus - positive isolates .
advmod||showed-5/VBD||furthermore-1/RB	det||subpopulations-4/NNS||both-3/DT	nsubj||showed-5/VBD||subpopulations-4/NNS	root||ROOT-0/null||showed-5/VBD	amod||sensitivity-7/NN||similar-6/JJ	dobj||showed-5/VBD||sensitivity-7/NN	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-melanoma-10/JJ	prep_to||showed-5/VBD||drugs-11/NNS	prep_to||showed-5/VBD||dacarbazine-13/NN	conj_and||drugs-11/NNS||dacarbazine-13/NN	prep_to||showed-5/VBD||lexatumumab-15/NN	conj_and||drugs-11/NNS||lexatumumab-15/NN	melanoma--1||dacarbazine-13||yes||furthermore, both subpopulations showed similar sensitivity to the anti-melanoma drugs, dacarbazine and lexatumumab.
mark||overshadowed-10/VBN||although-1/IN	det||mortality-3/NN||the-2/DT	nsubjpass||overshadowed-10/VBN||mortality-3/NN	amod||mortality-3/NN||attributable-4/JJ	prep_to||attributable-4/JJ||cancer-6/NN	prep_in||cancer-6/NN||type2diabetes-8/CD	auxpass||overshadowed-10/VBN||is-9/VBZ	advcl||suggest-22/VBP||overshadowed-10/VBN	agent||overshadowed-10/VBN||that-12/DT	amod||cardiovasculardisease-15/JJ||due-13/JJ	dep||cardiovasculardisease-15/JJ||to-14/TO	amod||that-12/DT||cardiovasculardisease-15/JJ	amod||data-18/NNS||emerging-17/VBG	nsubj||suggest-22/VBP||data-18/NNS	amod||studies-21/NNS||epidemiologic-20/JJ	prep_from||data-18/NNS||studies-21/NNS	root||ROOT-0/null||suggest-22/VBP	mark||confer-27/VB||that-23/IN	nn||therapy-25/NN||insulin-24/NN	nsubj||confer-27/VB||therapy-25/NN	aux||confer-27/VB||may-26/MD	ccomp||suggest-22/VBP||confer-27/VB	amod||risk-29/NN||added-28/VBN	dobj||confer-27/VB||risk-29/NN	prep_for||risk-29/NN||cancer-31/NN	advmod||mediated-34/VBN||perhaps-33/RB	vmod||cancer-31/NN||mediated-34/VBN	agent||mediated-34/VBN||signaling-36/VBG	det||receptor-45/NN||the-38/DT	amod||receptor-45/NN||igf-1-39/JJ	amod||factor-1-43/NN||insulin-like-41/JJ	nn||factor-1-43/NN||growth-42/NN	appos||receptor-45/NN||factor-1-43/NN	prep_through||signaling-36/VBG||receptor-45/NN	type2diabetes-8||insulin-24||yes||although the mortality attributable to cancer in type2diabetes is overshadowed by that due to cardiovasculardisease, emerging data from epidemiologic studies suggest that insulin therapy may confer added risk for cancer, perhaps mediated by signaling through the igf-1 (insulin-like growth factor-1) receptor.
det||studies-4/NNS||the-1/DT	nn||studies-4/NNS||afm-2/NN	nn||studies-4/NNS||morphological-3/NN	nsubj||revealed-5/VBD||studies-4/NNS	root||ROOT-0/null||revealed-5/VBD	mark||occurred-9/VBD||that-6/IN	amod||phenomena-8/NNS||pile-up-7/JJ	nsubj||occurred-9/VBD||phenomena-8/NNS	ccomp||revealed-5/VBD||occurred-9/VBD	det||sides-12/NNS||both-11/DT	prep_on||occurred-9/VBD||sides-12/NNS	det||scratches-15/NNS||the-14/DT	prep_of||sides-12/NNS||scratches-15/NNS	vmod||scratches-15/NNS||formed-16/VBN	det||epilayers-20/NNS||the-18/DT	nn||epilayers-20/NNS||gan-19/NN	prep_on||formed-16/VBN||epilayers-20/NNS	gan-19||pile--1||no_rel||the afm morphological studies revealed that pile-up phenomena occurred on both sides of the scratches formed on the gan epilayers.
det||proportion-3/NN||a-1/DT	amod||proportion-3/NN||significant-2/JJ	nsubj||common-34/JJ||proportion-3/NN	nsubj||leads-36/VBZ||proportion-3/NN	prep_of||proportion-3/NN||patients-5/NNS	amod||virus-8/NN||chronichepatitisc-7/JJ	prep_with||patients-5/NNS||virus-8/NN	appos||virus-8/NN||hcv-10/NN	nsubj||develop-13/VB||infection-12/NN	nsubj||require-26/VB||infection-12/NN	rcmod||virus-8/NN||develop-13/VB	dobj||develop-13/VB||livercirrhosis-14/NNS	dobj||develop-13/VB||complications-16/NNS	conj_and||livercirrhosis-14/NNS||complications-16/NNS	amod||liverdisease-19/NN||end-stage-18/JJ	prep_of||livercirrhosis-14/NNS||liverdisease-19/NN	number||three-23/CD||two-21/CD	dep||three-23/CD||to-22/TO	num||decades-24/NNS||three-23/CD	prep_over||develop-13/VB||decades-24/NNS	rcmod||virus-8/NN||require-26/VB	conj_and||develop-13/VB||require-26/VB	nn||transplantation-28/NN||liver-27/NN	dobj||require-26/VB||transplantation-28/NN	advmod||common-34/JJ||however-30/RB	nsubj||common-34/JJ||reinfection-32/NN	cop||common-34/JJ||is-33/VBZ	root||ROOT-0/null||common-34/JJ	conj_and||common-34/JJ||leads-36/VBZ	amod||events-40/NNS||further-38/JJ	amod||events-40/NNS||adverse-39/JJ	prep_to||leads-36/VBZ||events-40/NNS	prep_under||leads-36/VBZ||immunosuppression-42/NN	chronichepatitisc-7||hcv-10||no||a significant proportion of patients with chronichepatitisc virus (hcv) infection develop livercirrhosis and complications of end-stage liverdisease over two to three decades and require liver transplantation, however, reinfection is common and leads to further adverse events under immunosuppression.
amod||rats-3/NNS||male-1/JJ	nn||rats-3/NNS||wistar-2/NN	nsubj||received-7/VBD||rats-3/NNS	amod||livercirrhosis-6/NNS||thioacetamide-induced-5/JJ	prep_with||rats-3/NNS||livercirrhosis-6/NNS	root||ROOT-0/null||received-7/VBD	dobj||received-7/VBD||slv329-8/NNS	dobj||received-7/VBD||vehicle-10/NN	conj_or||slv329-8/NNS||vehicle-10/NN	dobj||received-7/VBD||furosemide-12/NN	conj_or||slv329-8/NNS||furosemide-12/NN	num||weeks-15/NNS||12-14/CD	prep_for||received-7/VBD||weeks-15/NNS	livercirrhosis-6||furosemide-12||yes||male wistar rats with thioacetamide-induced livercirrhosis received slv329, vehicle or furosemide for 12 weeks.
nsubj||interesting-4/JJ||it-1/PRP	nsubj||investigate-6/VB||it-1/PRP	aux||interesting-4/JJ||will-2/MD	cop||interesting-4/JJ||be-3/VB	root||ROOT-0/null||interesting-4/JJ	aux||investigate-6/VB||to-5/TO	xcomp||interesting-4/JJ||investigate-6/VB	mark||has-22/VBZ||whether-7/IN	nsubjpass||used-15/VBN||mefloquine-8/NN	nsubj||has-22/VBZ||mefloquine-8/NN	auxpass||used-15/VBN||is-11/VBZ	advmod||used-15/VBN||widely-12/RB	conj_and||widely-12/RB||effectively-14/RB	advmod||used-15/VBN||effectively-14/RB	rcmod||mefloquine-8/NN||used-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||used-15/VBN||treatment-18/NN	prep_of||treatment-18/NN||malaria-20/NN	ccomp||investigate-6/VB||has-22/VBZ	det||impact-24/NN||an-23/DT	dobj||has-22/VBZ||impact-24/NN	prep_on||impact-24/NN||schistosomiasis-26/NNS	prep_in||schistosomiasis-26/NNS||areas-28/NNS	advmod||co-exist-34/VB||where-29/WRB	det||malaria-31/NN||both-30/DT	nsubj||co-exist-34/VB||malaria-31/NN	conj_and||malaria-31/NN||schistosomiasis-33/NNS	nsubj||co-exist-34/VB||schistosomiasis-33/NNS	advcl||interesting-4/JJ||co-exist-34/VB	malaria-31||mefloquine-8||yes||it will be interesting to investigate whether mefloquine, which is widely and effectively used for the treatment of malaria, has an impact on schistosomiasis in areas where both malaria and schistosomiasis co-exist.
amod||load-2/NN||proviral-1/JJ	nsubj||correlated-3/VBD||load-2/NN	nsubj||correlated-3/VBD||load-2/NN	root||ROOT-0/null||correlated-3/VBD	conj_negcc||correlated-3/VBD||correlated-3/VBD	amod||antibodies-6/NNS||anti-env-5/JJ	prep_with||correlated-3/VBD||antibodies-6/NNS	amod||carriers-9/NNS||asymptomatic-8/JJ	prep_in||antibodies-6/NNS||carriers-9/NNS	dep||antibodies-6/NNS||r-11/VBN	dep||0.76-13/CD||=-12/SYM	ccomp||r-11/VBN||0.76-13/CD	prep_in||correlated-3/VBD||ham/tsp-19/NN	ham--1||antibodies-6||no_rel||proviral load correlated with anti-env antibodies in asymptomatic carriers ( r = 0.76), but not in ham/tsp.
prepc_based_on||care-71/VBP||on-2/IN	amod||appraisal-6/NN||intensive-3/JJ	amod||appraisal-6/NN||prior-4/JJ	nn||appraisal-6/NN||situation-5/NN	pobj||care-71/VBP||appraisal-6/NN	conj_and||appraisal-6/NN||consultation-8/NN	pobj||care-71/VBP||consultation-8/NN	det||set-12/NN||a-10/DT	amod||set-12/NN||multi-faceted-11/JJ	nsubj||care-71/VBP||set-12/NN	prep_of||set-12/NN||interventions-14/NNS	vmod||interventions-14/NNS||combining-15/VBG	nn||appraisal-17/NN||situation-16/NN	dobj||combining-15/VBG||appraisal-17/NN	aux||inform-19/VB||to-18/TO	vmod||combining-15/VBG||inform-19/VB	dobj||inform-19/VB||planning-20/NN	amod||dialogue-24/NN||sustained-22/VBN	nn||dialogue-24/NN||policy-23/NN	dep||interventions-14/NNS||dialogue-24/NN	nn||levels-29/NNS||union-26/NN	conj_and||union-26/NN||state-28/NN	nn||levels-29/NNS||state-28/NN	prep_at||dialogue-24/NN||levels-29/NNS	dep||interventions-14/NNS||development-31/NN	prep_of||development-31/NN||policy-33/NN	prep_of||development-31/NN||legislation-35/NN	conj_and||policy-33/NN||legislation-35/NN	appos||interventions-14/NNS||development-37/NN	amod||plans-41/NNS||strategic-39/JJ	nn||plans-41/NNS||action-40/NN	prep_of||development-37/NN||plans-41/NNS	appos||interventions-14/NNS||establishment-43/NN	amod||committee-50/NN||intersectoral-45/JJ	amod||committee-50/NN||national-46/JJ	amod||committee-50/NN||mental-47/JJ	nn||committee-50/NN||health-48/NN	nn||committee-50/NN||implementation-49/NN	prep_of||establishment-43/NN||committee-50/NN	appos||interventions-14/NNS||establishment-52/NN	amod||system-58/NN||national-54/JJ	amod||system-58/NN||mental-55/JJ	nn||system-58/NN||health-56/NN	nn||system-58/NN||coordination-57/NN	prep_of||establishment-52/NN||system-58/NN	appos||interventions-14/NNS||integration-60/NN	amod||health-63/NN||mental-62/JJ	prep_of||integration-60/NN||health-63/NN	amod||care-66/NN||primary-65/JJ	prep_into||health-63/NN||care-66/NN	appos||interventions-14/NNS||strengthening-68/NN	prep_of||strengthening-68/NN||primary-secondary-70/NN	root||ROOT-0/null||care-71/VBP	dobj||care-71/VBP||liaison-72/NN	dobj||care-71/VBP||rationalisation-74/NN	conj_and||liaison-72/NN||rationalisation-74/NN	dobj||care-71/VBP||strengthening-76/NN	conj_and||liaison-72/NN||strengthening-76/NN	amod||system-80/NN||secondary-78/JJ	nn||system-80/NN||care-79/NN	prep_of||liaison-72/NN||system-80/NN	vmod||care-71/VBP||ensuring-82/VBG	amod||supply-84/NN||adequate-83/JJ	dobj||ensuring-82/VBG||supply-84/NN	prep_of||supply-84/NN||medicines-86/NNS	dobj||ensuring-82/VBG||use-88/NN	conj_and||supply-84/NN||use-88/NN	amod||guidelines-92/NNS||good-90/JJ	nn||guidelines-92/NNS||practice-91/NN	prep_of||use-88/NN||guidelines-92/NNS	nn||systems-96/NNS||health-94/NN	nn||systems-96/NNS||information-95/NN	prep_of||use-88/NN||systems-96/NNS	conj_and||guidelines-92/NNS||systems-96/NNS	dobj||ensuring-82/VBG||development-98/NN	conj_and||supply-84/NN||development-98/NN	prep_of||development-98/NN||services-100/NNS	prep_for||services-100/NNS||people-102/NNS	prep_with||people-102/NNS||intellectualdisability-104/NN	dobj||ensuring-82/VBG||establishment-106/NN	conj_and||supply-84/NN||establishment-106/NN	amod||mechanism-109/NN||formal-108/JJ	prep_of||establishment-106/NN||mechanism-109/NN	amod||liaison-112/NN||close-111/JJ	prep_for||mechanism-109/NN||liaison-112/NN	det||services-117/NNS||the-114/DT	amod||services-117/NNS||mental-115/JJ	nn||services-117/NNS||health-116/NN	prep_between||liaison-112/NN||services-117/NNS	amod||governmental-120/NNS||other-119/JJ	dobj||ensuring-82/VBG||governmental-120/NNS	conj_and||supply-84/NN||governmental-120/NNS	amod||sectors-125/NNS||non-governmental-122/JJ	conj_and||non-governmental-122/JJ||traditional-124/JJ	amod||sectors-125/NNS||traditional-124/JJ	conj_and||supply-84/NN||sectors-125/NNS	conj_and||governmental-120/NNS||sectors-125/NNS	amod||promotion-129/NN||mental-127/JJ	nn||promotion-129/NN||health-128/NN	conj_and||supply-84/NN||promotion-129/NN	conj_and||governmental-120/NNS||promotion-129/NN	nn||prevention-132/NN||suicide-131/NN	conj_and||supply-84/NN||prevention-132/NN	conj_and||governmental-120/NNS||prevention-132/NN	conj_and||supply-84/NN||research-135/NN	conj_and||governmental-120/NNS||research-135/NN	conj_and||governmental-120/NNS||development-137/NN	conj_and||research-135/NN||development-137/NN	intellectualdisability-104||inform-19||no_rel||based on intensive prior situation appraisal and consultation, a multi-faceted set of interventions combining situation appraisal to inform planning; sustained policy dialogue at union and state levels; development of policy and legislation, development of strategic action plans, establishment of intersectoral national mental health implementation committee, establishment of national mental health coordination system, integration of mental health into primary care, strengthening of primary-secondary care liaison, rationalisation and strengthening of secondary care system, ensuring adequate supply of medicines, use of good practice guidelines and health information systems, development of services for people with intellectualdisability, establishment of formal mechanism for close liaison between the mental health services and other governmental, non-governmental and traditional sectors, mental health promotion, suicide prevention, and research and development.
amod||treatment-2/NN||adefovirdipivoxil-1/JJ	nsubj||improved-5/VBN||treatment-2/NN	aux||improved-5/VBN||has-3/VBZ	advmod||improved-5/VBN||significantly-4/RB	root||ROOT-0/null||improved-5/VBN	det||outcome-7/NN||the-6/DT	dobj||improved-5/VBN||outcome-7/NN	nn||infection-13/NN||chronichepatitisbvirus-9/NNP	appos||infection-13/NN||hbv-11/NN	prep_of||outcome-7/NN||infection-13/NN	hbv-11||hepatitisbvirus--1||no||adefovirdipivoxil treatment has significantly improved the outcome of chronichepatitisbvirus (hbv) infection.
advmod||show-9/VBP||here-1/RB	vmod||show-9/VBP||using-3/VBG	amod||analysis-6/NN||novel-4/JJ	amod||analysis-6/NN||statistical-5/JJ	dobj||using-3/VBG||analysis-6/NN	nsubj||show-9/VBP||we-8/PRP	root||ROOT-0/null||show-9/VBP	mark||exist-15/VBP||that-10/IN	amod||abnormalities-14/NNS||subtle-11/JJ	conj_but||subtle-11/JJ||significant-13/JJ	amod||abnormalities-14/NNS||significant-13/JJ	nsubj||exist-15/VBP||abnormalities-14/NNS	ccomp||show-9/VBP||exist-15/VBP	det||composition-18/NN||the-17/DT	prep_in||exist-15/VBP||composition-18/NN	prep_of||composition-18/NN||fattyacids-20/NNS	appos||fattyacids-20/NNS||fas-22/NN	amod||acid-27/NN||docosapentaenoic-26/JJ	prep_including||exist-15/VBP||acid-27/NN	num||-3-31/NN||225-29/CD	nn||-3-31/NN||n-30/NN	appos||acid-27/NN||-3-31/NN	appos||acid-27/NN||one-34/CD	det||fas-39/NN||the-36/DT	amod||fas-39/NN||omega-3-37/JJ	amod||fas-39/NN||polyunsaturated-38/JJ	prep_of||one-34/CD||fas-39/NN	vmod||fas-39/NN||found-41/VBN	det||cortex-46/NN||the-43/DT	amod||cortex-46/NN||post-mortem-44/JJ	nn||cortex-46/NN||frontopolar-45/NN	prep_in||found-41/VBN||cortex-46/NN	appos||cortex-46/NN||fpc-48/NN	prep_of||cortex-46/NN||subjects-51/NNS	prep_with||found-41/VBN||bipolar-53/NNP	amod||depressivedisorders-56/NNS||major-55/JJ	prep_with||found-41/VBN||depressivedisorders-56/NNS	conj_or||bipolar-53/NNP||depressivedisorders-56/NNS	mark||in-60/IN||although-58/IN	dep||in-60/IN||not-59/RB	advcl||exist-15/VBP||in-60/IN	pobj||in-60/IN||those-61/DT	prep_with||those-61/DT||schizophrenia-63/NN	schizophrenia-63||omega-3-37||no_rel||here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fattyacids (fas), including docosapentaenoic acid (225 n -3), one of the omega-3 polyunsaturated fas, found in the post-mortem frontopolar cortex (fpc) of subjects with bipolar or major depressivedisorders, although not in those with schizophrenia.
amod||sequencing-3/NN||454-1/JJ	amod||sequencing-3/NN||parallel-2/JJ	nsubj||allowed-20/VBN||sequencing-3/NN	det||dna-7/NN||the-5/DT	amod||dna-7/NN||amplified-6/JJ	prep_of||sequencing-3/NN||dna-7/NN	vmod||dna-7/NN||followed-8/VBN	nn||search-11/NN||similarity-10/NN	agent||followed-8/VBN||search-11/NN	det||data-15/NNS||the-13/DT	amod||data-15/NNS||sequenced-14/JJ	prep_of||search-11/NN||data-15/NNS	det||database-19/NN||an-17/DT	nn||database-19/NN||rrna-18/NN	prep_against||data-15/NNS||database-19/NN	root||ROOT-0/null||allowed-20/VBN	dobj||allowed-20/VBN||us-21/PRP	nsubj||identify-23/VB||us-21/PRP	aux||identify-23/VB||to-22/TO	xcomp||allowed-20/VBN||identify-23/VB	dobj||identify-23/VB||v.cholerae-24/NN	det||cause-27/NN||the-26/DT	appos||v.cholerae-24/NN||cause-27/NN	prep_of||cause-27/NN||cholera-29/NN	det||children-34/NNS||all-32/DT	num||children-34/NNS||nine-33/CD	prep_in||identify-23/VB||children-34/NNS	nn||species-42/NNS||day-36/NN	num||day-36/NN||0-37/CD	advmod||predominant-41/JJ||as-40/RB	conj_and||day-36/NN||predominant-41/JJ	nn||species-42/NNS||predominant-41/JJ	prep_at||identify-23/VB||species-42/NNS	num||children-45/NNS||six-44/CD	prep_in||allowed-20/VBN||children-45/NNS	prep||allowed-20/VBN||accounting-47/VBG	pcomp||accounting-47/VBG||for-48/IN	num||%-50/NN||35-49/CD	pobj||for-48/IN||%-50/NN	det||microbiota-55/NN||the-52/DT	amod||microbiota-55/NN||total-53/JJ	nn||microbiota-55/NN||gut-54/NN	prep_of||%-50/NN||microbiota-55/NN	det||average-58/NN||an-57/DT	prep_on||microbiota-55/NN||average-58/NN	predet||children-63/NNS||all-60/PDT	det||children-63/NNS||the-61/DT	num||children-63/NNS||nine-62/CD	prep_in||average-58/NN||children-63/NNS	cholera-29||v.cholerae-24||no||454 parallel sequencing of the amplified dna followed by similarity search of the sequenced data against an rrna database allowed us to identify v.cholerae , the cause of cholera , in all nine children at day 0 , and as predominant species in six children , accounting for 35 % of the total gut microbiota on an average in all the nine children .
nsubj||constructed-3/VBN||we-1/PRP	aux||constructed-3/VBN||have-2/VBP	dep||take-52/VB||constructed-3/VBN	det||model-5/NN||a-4/DT	dobj||constructed-3/VBN||model-5/NN	prep_of||model-5/NN||hivinfection-7/NN	mark||types-13/VBZ||that-8/IN	nsubj||types-13/VBZ||differentiates-9/NNS	nsubj||used-17/VBN||differentiates-9/NNS	det||hla-12/NN||these-11/DT	prep_between||differentiates-9/NNS||hla-12/NN	ccomp||constructed-3/VBN||types-13/VBZ	aux||used-17/VBN||have-16/VBP	ccomp||constructed-3/VBN||used-17/VBN	conj_and||types-13/VBZ||used-17/VBN	amod||estimates-19/NNS||reported-18/VBN	dobj||used-17/VBN||estimates-19/NNS	det||number-22/NN||the-21/DT	prep_of||estimates-19/NNS||number-22/NN	prep_of||number-22/NN||people-24/NNS	vmod||people-24/NNS||infected-25/VBN	prep_with||infected-25/VBN||hiv-27/NN	det||rates-31/NNS||the-29/DT	amod||rates-31/NNS||different-30/JJ	prep_with||infected-25/VBN||rates-31/NNS	conj_and||hiv-27/NN||rates-31/NNS	prep_of||rates-31/NNS||progression-33/NN	aux||acquiredimmunodeficiencysyndrome-35/VB||to-34/TO	xcomp||infected-25/VBN||acquiredimmunodeficiencysyndrome-35/VB	dobj||acquiredimmunodeficiencysyndrome-35/VB||aids-37/NNS	nsubj||provide-40/VB||aids-37/NNS	aux||provide-40/VB||to-39/TO	xcomp||acquiredimmunodeficiencysyndrome-35/VB||provide-40/VB	det||estimate-44/NN||a-41/DT	dep||bound-43/VBN||lower-42/JJR	amod||estimate-44/NN||bound-43/VBN	dobj||provide-40/VB||estimate-44/NN	det||length-47/NN||the-46/DT	prep_on||provide-40/VB||length-47/NN	prep_of||length-47/NN||time-49/NN	nsubj||take-52/VB||it-50/PRP	nsubj||impose-56/VB||it-50/PRP	aux||take-52/VB||would-51/MD	root||ROOT-0/null||take-52/VB	prep_for||take-52/VB||hiv-54/NN	aux||impose-56/VB||to-55/TO	xcomp||take-52/VB||impose-56/VB	amod||change-59/NN||major-57/JJ	amod||change-59/NN||genetic-58/JJ	dobj||impose-56/VB||change-59/NN	prep_in||impose-56/VB||humans-61/NNS	aids-37||hiv-54||no||we have constructed a model of hivinfection that differentiates between these hla types, and have used reported estimates of the number of people infected with hiv and the different rates of progression to acquiredimmunodeficiencysyndrome (aids) to provide a lower bound estimate on the length of time it would take for hiv to impose major genetic change in humans.
nn||onset-3/NN||schizophrenia-2/NN	prep_after||treated-7/VBN||onset-3/NN	nsubjpass||treated-7/VBN||he-5/PRP	auxpass||treated-7/VBN||was-6/VBD	root||ROOT-0/null||treated-7/VBN	prep_in||treated-7/VBN||sequence-10/NN	prep_with||treated-7/VBN||olanzapine-13/NN	prep_with||treated-7/VBN||amisulpride-15/NN	conj_and||olanzapine-13/NN||amisulpride-15/NN	prep_with||treated-7/VBN||aripiprazole-17/NN	conj_and||olanzapine-13/NN||aripiprazole-17/NN	olanzapine-13||schizophrenia-2||no_rel||after schizophrenia onset, he was treated, in sequence, with olanzapine, amisulpride and aripiprazole.
num||strain-2/NN||one-1/CD	nsubj||promising-8/JJ||strain-2/NN	appos||strain-2/NN||m44-4/NNP	aux||promising-8/JJ||was-6/VBD	advmod||promising-8/JJ||particularly-7/RB	root||ROOT-0/null||promising-8/JJ	poss||activity-11/NN||its-10/PRP$	prep_since||promising-8/JJ||activity-11/NN	vmod||activity-11/NN||counteracted-12/VBN	det||effect-15/NN||the-13/DT	amod||effect-15/NN||protective-14/JJ	dobj||counteracted-12/VBN||effect-15/NN	prep_of||effect-15/NN||ledgf/p75-17/NNS	dep||ledgf/p75-17/NNS||overexpressed-18/VBN	nn||cells-21/NNS||aml-20/NN	prep_in||overexpressed-18/VBN||cells-21/NNS	dep||ledgf/p75-17/NNS||acted-23/VBN	conj_and||overexpressed-18/VBN||acted-23/VBN	advmod||acted-23/VBN||synergistically-24/RB	det||daunorubicin-29/NN||the-26/DT	amod||daunorubicin-29/NN||anthracycline-27/JJ	amod||daunorubicin-29/NN||anticancerdrug-28/VBG	prep_with||acted-23/VBN||daunorubicin-29/NN	nn||cells-32/NNS||aml-31/NN	prep_in||daunorubicin-29/NN||cells-32/NNS	dep||ledgf/p75-17/NNS||protected-35/VBN	conj_and||overexpressed-18/VBN||protected-35/VBN	dobj||protected-35/VBN||cardiomyoblasts-36/NNS	det||effect-40/NN||the-38/DT	amod||effect-40/NN||toxic-39/JJ	prep_against||protected-35/VBN||effect-40/NN	prep_of||effect-40/NN||anthracyclines-42/NNS	aml-31||daunorubicin-29||yes||one strain (m44) was particularly promising since its activity counteracted the protective effect of ledgf/p75 overexpressed in aml cells, acted synergistically with the anthracycline anticancerdrug daunorubicin in aml cells, and protected cardiomyoblasts against the toxic effect of anthracyclines.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	num||timings-8/NNS||three-6/CD	amod||timings-8/NNS||premeal-7/JJ	prep_of||effect-4/NN||timings-8/NNS	amod||insulin-11/NN||rapid-acting-10/JJ	prep_of||timings-8/NNS||insulin-11/NN	amod||excursions-15/NNS||postprandial-13/JJ	nn||excursions-15/NNS||glucose-14/NN	prep_on||assess-2/VB||excursions-15/NNS	prep_in||excursions-15/NNS||type1diabetes-17/CD	type1diabetes-17||insulin-11||yes||to assess the effect of three premeal timings of rapid-acting insulin on postprandial glucose excursions in type1diabetes.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	atorvastatin-21||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
prep_in||fails-15/VBZ||areas-2/NNS	amod||resistance-6/NN||widespread-4/JJ	amod||resistance-6/NN||sulfadoxine-pyrimethamine-5/JJ	prep_of||areas-2/NNS||resistance-6/NN	amod||treatment-9/NN||intermittent-8/JJ	nsubj||fails-15/VBZ||treatment-9/NN	nsubj||prevent-17/VB||treatment-9/NN	nsubj||exacerbate-25/VB||treatment-9/NN	prep_in||treatment-9/NN||pregnancy-11/NN	appos||treatment-9/NN||iptp-13/NN	root||ROOT-0/null||fails-15/VBZ	aux||prevent-17/VB||to-16/TO	xcomp||fails-15/VBZ||prevent-17/VB	amod||malaria-19/NN||placental-18/JJ	dobj||prevent-17/VB||malaria-19/NN	appos||malaria-19/NN||pm-21/NN	aux||exacerbate-25/VB||may-24/MD	conj_and||fails-15/VBZ||exacerbate-25/VB	nn||infections-28/NNS||drug-26/NN	nn||infections-28/NNS||resistant-27/NN	dobj||exacerbate-25/VB||infections-28/NNS	malaria-19||pyrimethamine--1||yes||in areas of widespread sulfadoxine-pyrimethamine resistance, intermittent treatment in pregnancy (iptp) fails to prevent placental malaria (pm) and may exacerbate drug resistant infections.
det||receptor-8/NN||the-1/DT	amod||receptor-8/NN||insulin-like-2/JJ	nn||receptor-8/NN||growth-3/NN	nn||receptor-8/NN||factor-4/NN	num||receptor-8/NN||1-5/CD	nn||receptor-8/NN||tyrosine-6/NN	nn||receptor-8/NN||kinase-7/NN	nsubjpass||shown-22/VBN||receptor-8/NN	nsubj||play-24/VB||receptor-8/NN	dep||receptor-8/NN||igf-1r-10/JJ	det||receptor-17/NN||the-13/DT	amod||receptor-17/NN||chemokine-14/JJ	amod||receptor-17/NN||g-protein-15/JJ	nn||receptor-17/NN||coupled-16/NN	conj_and||receptor-8/NN||receptor-17/NN	nsubjpass||shown-22/VBN||receptor-17/NN	nsubj||play-24/VB||receptor-17/NN	appos||receptor-17/NN||cxcr4-19/NNS	aux||shown-22/VBN||have-20/VBP	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||play-24/VB||to-23/TO	xcomp||shown-22/VBN||play-24/VB	det||role-27/NN||an-25/DT	amod||role-27/NN||important-26/JJ	dobj||play-24/VB||role-27/NN	nn||metastasis-31/NNS||breast-29/NN	nn||metastasis-31/NNS||cancer-30/NN	prep_in||play-24/VB||metastasis-31/NNS	tyrosine-6||metastasis-31||no_rel||the insulin-like growth factor 1 tyrosine kinase receptor (igf-1r) and the chemokine g-protein coupled receptor, cxcr4 have been shown to play an important role in breast cancer metastasis.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	prep_of||efficacy-10/NN||ketorolac-12/NNP	prep_of||efficacy-10/NN||paracetamol-14/NNP	conj_and||ketorolac-12/NNP||paracetamol-14/NNP	prep_of||efficacy-10/NN||paracetamol-17/NNP	conj_and||ketorolac-12/NNP||paracetamol-17/NNP	dobj||compare-8/VB||morphine-19/NN	conj_plus||efficacy-10/NN||morphine-19/NN	nn||relief-22/NN||pain-21/NN	prep_on||morphine-19/NN||relief-22/NN	prep_after||compare-8/VB||thyroidectomy-24/NN	pain-21||paracetamol-17||yes||the aim of this study was to compare the efficacy of ketorolac, paracetamol, and paracetamol plus morphine on pain relief after thyroidectomy.
nsubj||liverdisease-5/NN||hepatitisc-1/NN	cop||liverdisease-5/NN||is-2/VBZ	det||liverdisease-5/NN||a-3/DT	amod||liverdisease-5/NN||fatal-4/JJ	root||ROOT-0/null||liverdisease-5/NN	vmod||liverdisease-5/NN||caused-6/VBN	det||virus-10/NN||the-8/DT	amod||virus-10/NN||hepatitisc-9/JJ	agent||caused-6/VBN||virus-10/NN	hepatitisc-9||hepatitiscvirus--1||no||hepatitisc is a fatal liverdisease caused by the hepatitisc virus.
det||series-3/NN||a-2/DT	prep_following||found-12/VBN||series-3/NN	prep_of||series-3/NN||studies-5/NNS	prep_in||studies-5/NNS||patients-7/NNS	prep_with||patients-7/NNS||non-vibriocholera-9/NN	nsubjpass||found-12/VBN||it-10/PRP	auxpass||found-12/VBN||was-11/VBD	root||ROOT-0/null||found-12/VBN	mark||had-16/VBD||that-13/IN	det||patients-15/NNS||these-14/DT	nsubj||had-16/VBD||patients-15/NNS	ccomp||found-12/VBN||had-16/VBD	amod||concentrations-18/NNS||large-17/JJ	dobj||had-16/VBD||concentrations-18/NNS	prep_of||concentrations-18/NNS||escherichiacoli-20/NNS	det||bowel-24/NN||the-22/DT	amod||bowel-24/NN||small-23/JJ	prep_in||escherichiacoli-20/NNS||bowel-24/NN	prep_of||concentrations-18/NNS||stools-26/NNS	conj_and||escherichiacoli-20/NNS||stools-26/NNS	nsubj||produced-28/VBD||stools-26/NNS	nsubj||had-34/VBD||stools-26/NNS	rcmod||stools-26/NNS||produced-28/VBD	amod||enterotoxins-31/NNS||cholera-29/JJ	amod||enterotoxins-31/NNS||toxin-like-30/JJ	dobj||produced-28/VBD||enterotoxins-31/NNS	rcmod||stools-26/NNS||had-34/VBD	conj_and||produced-28/VBD||had-34/VBD	amod||abnormalities-39/NNS||fluid-35/JJ	conj_and||fluid-35/JJ||electrolyte-37/JJ	amod||abnormalities-39/NNS||electrolyte-37/JJ	nn||abnormalities-39/NNS||transport-38/NN	dobj||had-34/VBD||abnormalities-39/NNS	det||bowel-43/NN||the-41/DT	amod||bowel-43/NN||small-42/JJ	prep_in||abnormalities-39/NNS||bowel-43/NN	amod||bowel-43/NN||similar-44/JJ	prep_to||similar-44/JJ||patients-46/NNS	amod||cholera-49/NN||documented-48/VBN	prep_with||patients-46/NNS||cholera-49/NN	cholera-49||vibriocholera--1||no||following a series of studies in patients with non-vibriocholera it was found that these patients had large concentrations of escherichiacoli in the small bowel and stools which produced cholera toxin-like enterotoxins, and had fluid and electrolyte transport abnormalities in the small bowel similar to patients with documented cholera.
aux||compare-2/VB||to-1/TO	csubj||urinarytractinfections-16/VBZ||compare-2/VB	det||effectiveness-4/NN||the-3/DT	nsubj||extract-7/VB||effectiveness-4/NN	prep_of||effectiveness-4/NN||cranberry-6/NN	ccomp||compare-2/VB||extract-7/VB	amod||trimethoprim-10/NN||low-dose-9/JJ	prep_with||extract-7/VB||trimethoprim-10/NN	det||prevention-13/NN||the-12/DT	prep_in||trimethoprim-10/NN||prevention-13/NN	prep_of||prevention-13/NN||recurrent-15/NN	root||ROOT-0/null||urinarytractinfections-16/VBZ	dobj||urinarytractinfections-16/VBZ||utis-18/NNS	amod||women-22/NNS||older-21/JJR	prep_in||urinarytractinfections-16/VBZ||women-22/NNS	utis-18||trimethoprim-10||yes||to compare the effectiveness of cranberry extract with low-dose trimethoprim in the prevention of recurrent urinarytractinfections (utis) in older women.
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||‰-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||‰-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||‰-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||‰-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||‰-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||‰-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9â€‰mmâ€‰hg and bedtime hbp was 129.7â±13.8/74.7â±10.1â€‰mmâ€‰hg, whereas cbp was 135.6â±15.4/77.6â±10.9â€‰mmâ€‰hg.
advmod||tested-4/VBD||therefore-1/RB	nsubj||tested-4/VBD||we-3/PRP	root||ROOT-0/null||tested-4/VBD	det||model-9/NN||an-7/DT	amod||model-9/NN||established-8/JJ	prep_in||tested-4/VBD||model-9/NN	amod||feed-13/NN||enhanced-11/JJ	nn||feed-13/NN||cholesterol-12/NN	prep_of||model-9/NN||feed-13/NN	prep_in||feed-13/NN||rabbits-15/NNS	det||effects-18/NNS||the-17/DT	appos||rabbits-15/NNS||effects-18/NNS	prep_of||effects-18/NNS||hypercholesterolemia-20/NN	prep_on||hypercholesterolemia-20/NN||vasospasm-22/NN	prep_after||tested-4/VBD||sah-24/NN	prepc_by||tested-4/VBD||using-26/VBG	amod||angiograms-32/NNS||computed-27/JJ	nn||angiograms-32/NNS||tomography-28/NN	appos||angiograms-32/NNS||ct-30/NN	dobj||using-26/VBG||angiograms-32/NNS	det||artery-37/NN||the-34/DT	nn||artery-37/NN||rabbit-35/NN	nn||artery-37/NN||basilar-36/NN	prep_of||angiograms-32/NNS||artery-37/NN	prep_in||tested-43/VBD||addition-40/NN	nsubj||tested-43/VBD||we-42/PRP	parataxis||tested-4/VBD||tested-43/VBD	det||effects-45/NNS||the-44/DT	dobj||tested-43/VBD||effects-45/NNS	prep_of||effects-45/NNS||vitamine-47/NN	det||conditions-50/NNS||these-49/DT	prep_on||tested-43/VBD||conditions-50/NNS	nsubjpass||studied-56/VBN||conditions-50/NNS	aux||studied-56/VBN||have-53/VBP	neg||studied-56/VBN||not-54/RB	auxpass||studied-56/VBN||been-55/VBN	rcmod||conditions-50/NNS||studied-56/VBN	prt||studied-56/VBN||up-57/RP	prep||studied-56/VBN||to-58/TO	pobj||to-58/TO||now-59/RB	hypercholesterolemia-20||cholesterol-12||no||therefore, we tested, in an established model of enhanced cholesterol feed in rabbits, the effects of hypercholesterolemia on vasospasm after sah by using computed tomography (ct) angiograms of the rabbit basilar artery; in addition, we tested the effects of vitamine on these conditions, which have not been studied up to now.
nn||factors-2/NNS||risk-1/NN	nsubj||significant-42/JJ||factors-2/NNS	prep_such_as||factors-2/NNS||age-5/NN	nn||status-8/NN||smoking-7/NN	prep_such_as||factors-2/NNS||status-8/NN	conj_and||age-5/NN||status-8/NN	amod||cholesterol-11/NN||total-10/JJ	prep_such_as||factors-2/NNS||cholesterol-11/NN	conj_and||age-5/NN||cholesterol-11/NN	amod||levels-17/NNS||high-13/JJ	nn||levels-17/NNS||density-14/NN	nn||levels-17/NNS||lipoprotein-15/NN	nn||levels-17/NNS||cholesterol-16/NN	prep_such_as||factors-2/NNS||levels-17/NNS	conj_and||age-5/NN||levels-17/NNS	vmod||significant-42/JJ||qualifying-19/VBG	dobj||qualifying-19/VBG||event-20/NN	det||syndrome-25/NN||the-22/DT	amod||syndrome-25/NN||acute-23/JJ	amod||syndrome-25/NN||coronary-24/JJ	prep_for||qualifying-19/VBG||syndrome-25/NN	appos||syndrome-25/NN||revascularization-27/NN	appos||revascularization-27/NN||history-29/NN	prep_of||history-29/NN||stroke-31/NN	prep_of||history-29/NN||diabetes-33/NN	conj_or||stroke-31/NN||diabetes-33/NN	nn||grade-36/NN||angina-35/NN	nsubj||significant-42/JJ||grade-36/NN	conj_and||grade-36/NN||treatment-38/NN	nsubj||significant-42/JJ||treatment-38/NN	prep_with||grade-36/NN||pravastatin-40/NN	cop||significant-42/JJ||were-41/VBD	root||ROOT-0/null||significant-42/JJ	prep_for||significant-42/JJ||development-44/NN	preconj||first-47/JJ||both-46/DT	prep_of||development-44/NN||first-47/JJ	amod||events-51/NNS||subsequent-49/JJ	nn||events-51/NNS||mi-50/NN	prep_of||development-44/NN||events-51/NNS	conj_and||first-47/JJ||events-51/NNS	tuberculosis--1||m. tuberculosis--1||no||risk factors such as age , smoking status , total cholesterol and high density lipoprotein cholesterol levels , qualifying event for the acute coronary syndrome , revascularization , history of stroke or diabetes , angina grade and treatment with pravastatin were significant for development of both first and subsequent mi events .
nsubj||includes-5/VBZ||treatment-1/NN	prep_of||treatment-1/NN||thalassemia-3/NNP	amod||thalassemia-3/NNP||major-4/JJ	root||ROOT-0/null||includes-5/VBZ	amod||transfusions-8/NNS||regular-6/JJ	nn||transfusions-8/NNS||rbc-7/NN	dobj||includes-5/VBZ||transfusions-8/NNS	nn||chelation-11/NN||iron-10/NN	dobj||includes-5/VBZ||chelation-11/NN	conj_and||transfusions-8/NNS||chelation-11/NN	dobj||includes-5/VBZ||management-13/NN	conj_and||transfusions-8/NNS||management-13/NN	amod||complications-16/NNS||secondary-15/JJ	prep_of||management-13/NN||complications-16/NNS	prep_of||complications-16/NNS||ironoverload-18/NN	ironoverload-18||iron-10||no||treatment of thalassemia major includes regular rbc transfusions, iron chelation and management of secondary complications of ironoverload.
advmod||comparable-32/JJ||however-1/RB	det||differences-6/NNS||the-4/DT	amod||differences-6/NNS||large-5/JJ	prep_despite||comparable-32/JJ||differences-6/NNS	vmod||differences-6/NNS||observed-7/VBN	det||responses-13/NNS||the-9/DT	dep||vitro-11/NN||in-10/IN	amod||responses-13/NNS||vitro-11/NN	amod||responses-13/NNS||cell-death-12/JJ	prep_in||observed-7/VBN||responses-13/NNS	vmod||responses-13/NNS||associated-14/VBN	prep_with||associated-14/VBN||3brp-16/CD	num||3brp-16/CD||ia-18/CD	prep_with||associated-14/VBN||5-fu-20/CD	conj_and||3brp-16/CD||5-fu-20/CD	nsubj||comparable-32/JJ||the-22/DT	amod||activities-27/NNS||vivo-24/JJ	nn||activities-27/NNS||tumor-25/NN	nn||activities-27/NNS||regression-26/NN	prep_in||the-22/DT||activities-27/NNS	det||agents-30/NNS||these-29/DT	prep_of||activities-27/NNS||agents-30/NNS	cop||comparable-32/JJ||were-31/VBD	root||ROOT-0/null||comparable-32/JJ	5-fu-20||tumor-25||no_rel||however, despite the large differences observed in the in vitro cell-death responses associated with 3brp, ia and 5-fu, the in vivo tumor regression activities of these agents were comparable.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||similar-2/JJ	nsubj||observed-5/JJ||effect-3/NN	cop||observed-5/JJ||was-4/VBD	root||ROOT-0/null||observed-5/JJ	prepc_in||observed-5/JJ||circulating-7/VBG	amod||cells-11/NNS||hcv-specific-8/JJ	amod||cells-11/NNS||cd8-9/JJ	nn||cells-11/NNS||t-10/NN	dobj||circulating-7/VBG||cells-11/NNS	amod||co-expression-17/NN||increased-13/VBN	amod||co-expression-17/NN||pd-1-14/JJ	amod||co-expression-17/NN||/-15/JJ	amod||co-expression-17/NN||ctla-4-16/JJ	prep_with||circulating-7/VBG||co-expression-17/NN	prep_during||observed-5/JJ||acutehepatitisc-19/NN	acutehepatitisc-19||hcv--1||no||a similar effect was observed in circulating hcv-specific cd8 t cells with increased pd-1/ctla-4 co-expression during acutehepatitisc.
nn||agitation-2/NN||emergence-1/NN	nsubjpass||prevented-10/VBN||agitation-2/NN	amod||anesthesia-5/NN||sevoflurane-4/JJ	prep_after||agitation-2/NN||anesthesia-5/NN	prep_in||anesthesia-5/NN||children-7/NNS	aux||prevented-10/VBN||can-8/MD	auxpass||prevented-10/VBN||be-9/VB	root||ROOT-0/null||prevented-10/VBN	agent||prevented-10/VBN||midazolam-12/NN	agitation-2||midazolam-12||yes||emergence agitation after sevoflurane anesthesia in children can be prevented by midazolam.
aux||assess-2/VB||to-1/TO	dep||bimatoprost-33/VBP||assess-2/VB	det||effect-5/NN||the-3/DT	amod||effect-5/NN||additive-4/JJ	dobj||assess-2/VB||effect-5/NN	prep_of||effect-5/NN||dorzolamidehydrochloride-7/NN	number||%-9/NN||2-8/CD	amod||dorzolamidehydrochloride-7/NN||%-9/NN	det||pressure-14/NN||the-11/DT	amod||pressure-14/NN||diurnal-12/JJ	amod||pressure-14/NN||intraocular-13/JJ	prep_on||assess-2/VB||pressure-14/NN	dep||bimatoprost-33/VBP||iop-16/VB	nn||haemodynamics-21/NNS||curve-18/NN	conj_and||curve-18/NN||retrobulbar-20/NN	nn||haemodynamics-21/NNS||retrobulbar-20/NN	nsubj||bimatoprost-33/VBP||haemodynamics-21/NNS	prep_in||haemodynamics-21/NNS||patients-23/NNS	amod||open-angleglaucoma-26/NN||primary-25/JJ	prep_with||patients-23/NNS||open-angleglaucoma-26/NN	dep||patients-23/NNS||poag-28/VBG	vmod||patients-23/NNS||treated-30/VBN	prep_with||treated-30/VBN||morning-dosed-32/JJ	root||ROOT-0/null||bimatoprost-33/VBP	num||%-35/NN||0.03-34/CD	dobj||bimatoprost-33/VBP||%-35/NN	open-angleglaucoma-26||bimatoprost-33||yes||to assess the additive effect of dorzolamidehydrochloride 2% on the diurnal intraocular pressure (iop) curve and retrobulbar haemodynamics in patients with primary open-angleglaucoma (poag) treated with morning-dosed bimatoprost 0.03%.
amod||virus-2/NN||hepatitisc-1/JJ	nsubj||agent-9/NN||virus-2/NN	appos||virus-2/NN||hcv-4/NN	cop||agent-9/NN||is-6/VBZ	det||agent-9/NN||the-7/DT	amod||agent-9/NN||etiological-8/JJ	root||ROOT-0/null||agent-9/NN	det||majority-12/NN||the-11/DT	prep_for||agent-9/NN||majority-12/NN	prep_of||majority-12/NN||cases-14/NNS	prep_of||cases-14/NNS||non-a-16/NN	appos||non-a-16/NN||non-bhepatitis-18/NNS	non-a-16||non-bhepatitis-18||no||hepatitisc virus (hcv) is the etiological agent for the majority of cases of non-a, non-bhepatitis.
aux||identify-2/VB||to-1/TO	advcl||undertaken-29/VBN||identify-2/VB	det||variations-5/NNS||the-3/DT	amod||variations-5/NNS||genetic-4/JJ	dobj||identify-2/VB||variations-5/NNS	vmod||variations-5/NNS||associated-6/VBN	nn||intolerance-9/NN||aspirin-8/NN	prep_with||associated-6/VBN||intolerance-9/NN	prep_in||intolerance-9/NN||asthmatics-11/NNS	det||stage-15/NN||the-13/DT	amod||stage-15/NN||first-14/JJ	nsubjpass||undertaken-29/VBN||stage-15/NN	amod||study-19/NN||genome-wide-17/JJ	nn||study-19/NN||association-18/NN	prep_of||stage-15/NN||study-19/NN	num||polymorphisms-24/NNS||109,365-21/CD	amod||polymorphisms-24/NNS||single-22/JJ	nn||polymorphisms-24/NNS||nucleotide-23/NN	prep_with||study-19/NN||polymorphisms-24/NNS	appos||polymorphisms-24/NNS||snps-26/NNS	auxpass||undertaken-29/VBN||was-28/VBD	root||ROOT-0/null||undertaken-29/VBN	det||cohort-43/NN||a-31/DT	amod||cohort-43/NN||korean-32/JJ	amod||cohort-43/NN||aia-33/JJ	dep||cohort-43/NN||nâ-35/NN	num||â-39/NN||$-36/$	number||=-38/CD||š-37/CD	num||$-36/$||=-38/CD	dep||nâ-35/NN||â-39/NN	dep||â-39/NN||$-40/$	num||$-40/$||š80-41/CD	prep_in||undertaken-29/VBN||cohort-43/NN	nn||subjects-58/NNS||aspirin-tolerant-45/NN	nn||subjects-58/NNS||asthma-46/NN	dep||subjects-58/NNS||ata-48/NN	appos||ata-48/NN||nâ-50/NN	num||â-54/NN||$-51/$	number||=-53/CD||š-52/CD	num||$-51/$||=-53/CD	dep||nâ-50/NN||â-54/NN	dep||ata-48/NN||$-55/$	num||$-55/$||š100-56/CD	prep_in||undertaken-29/VBN||subjects-58/NNS	conj_and||cohort-43/NN||subjects-58/NNS	prep_as||cohort-43/NN||controls-60/NNS	asthmatics-11||aspirin-8||no||to identify the genetic variations associated with aspirin intolerance in asthmatics, the first stage of genome-wide association study with 109,365 single nucleotide polymorphisms (snps) was undertaken in a korean aia (nâ€š=â€š80) cohort and aspirin-tolerant asthma (ata, nâ€š=â€š100) subjects as controls.
nn||swans-5/NNS||adult-1/NN	amod||mute-4/JJ||healthy-3/JJ	amod||swans-5/NNS||mute-4/JJ	nsubjpass||infected-8/VBN||swans-5/NNS	auxpass||infected-8/VBN||were-6/VBD	advmod||infected-8/VBN||experimentally-7/RB	root||ROOT-0/null||infected-8/VBN	advmod||pathogenic-11/JJ||highly-10/RB	amod||avianinfluenzavirus-12/NNS||pathogenic-11/JJ	prep_with||infected-8/VBN||avianinfluenzavirus-12/NNS	amod||h5n1-20/NNS||a-13/DT	punct||cygnus-16/JJ||/-14/:	dep||cygnus-16/JJ||cygnus-15/NNS	dep||a-13/DT||cygnus-16/JJ	punct||cygnus-16/JJ||/-17/:	amod||h5n1-20/NNS||germany/r65/2006-18/JJ	nn||h5n1-20/NNS||subtype-19/NN	dep||avianinfluenzavirus-12/NNS||h5n1-20/NNS	h5n1-20||avianinfluenzavirus-12||no||adult, healthy mute swans were experimentally infected with highly pathogenic avianinfluenzavirus a/ cygnus cygnus /germany/r65/2006 subtype h5n1.
amod||studies-2/NNS||few-1/JJ	nsubj||assessed-4/VBN||studies-2/NNS	aux||assessed-4/VBN||have-3/VBP	root||ROOT-0/null||assessed-4/VBN	det||efficacy-6/NN||the-5/DT	dobj||assessed-4/VBN||efficacy-6/NN	prep_of||efficacy-6/NN||carbohydrate-8/NN	vmod||carbohydrate-8/NN||counting-9/VBG	prep_in||counting-9/VBG||type1diabetes-11/CD	nsubj||validated-16/VBN||none-14/NN	aux||validated-16/VBN||have-15/VBP	conj_and||assessed-4/VBN||validated-16/VBN	poss||efficacy-18/NN||its-17/PRP$	dobj||validated-16/VBN||efficacy-18/NN	prep_in||validated-16/VBN||patients-20/NNS	nsubjpass||treated-23/VBN||patients-20/NNS	auxpass||treated-23/VBN||are-22/VBP	rcmod||patients-20/NNS||treated-23/VBN	amod||subcutaneous-26/JJ||continuous-25/JJ	amod||infusion-28/NN||subcutaneous-26/JJ	nn||infusion-28/NN||insulin-27/NN	prep_with||treated-23/VBN||infusion-28/NN	appos||infusion-28/NN||csii-30/NNP	type1diabetes-11||insulin-27||yes||few studies have assessed the efficacy of carbohydrate counting in type1diabetes, and none have validated its efficacy in patients who are treated with continuous subcutaneous insulin infusion (csii).
nsubjpass||found-5/VBN||zinc-1/NN	nsubjpass||associated-8/VBN||zinc-1/NN	advmod||found-5/VBN||difficiency-2/RB	aux||found-5/VBN||has-3/VBZ	auxpass||found-5/VBN||been-4/VBN	root||ROOT-0/null||found-5/VBN	aux||associated-8/VBN||to-6/TO	auxpass||associated-8/VBN||be-7/VB	xcomp||found-5/VBN||associated-8/VBN	amod||episodes-11/NNS||severe-10/JJ	prep_with||associated-8/VBN||episodes-11/NNS	amod||diarrhea-14/NN||acute-13/JJ	prep_of||episodes-11/NNS||diarrhea-14/NN	zinc-1||diarrhea-14||no_rel||zinc difficiency has been found to be associated with severe episodes of acute diarrhea.
det||growth-2/NN||the-1/DT	nsubj||relaxed-11/VBD||growth-2/NN	amod||wells-7/NNS||ingan/gan-4/JJ	amod||wells-7/NNS||multiple-5/JJ	nn||wells-7/NNS||quantum-6/NN	prep_of||growth-2/NN||wells-7/NNS	det||stress-10/NN||these-9/DT	prep_on||wells-7/NNS||stress-10/NN	root||ROOT-0/null||relaxed-11/VBD	amod||templates-15/NNS||low-12/JJ	nn||templates-15/NNS||defect-13/NN	nn||templates-15/NNS||density-14/NN	nsubj||improves-16/VBZ||templates-15/NNS	ccomp||relaxed-11/VBD||improves-16/VBZ	det||efficiency-20/NN||the-17/DT	amod||efficiency-20/NN||internal-18/JJ	nn||efficiency-20/NN||quantum-19/NN	dobj||improves-16/VBZ||efficiency-20/NN	num||%-23/NN||15-22/CD	prep_by||improves-16/VBZ||%-23/NN	det||wells-29/NNS||the-25/DT	amod||wells-29/NNS||cyan-green-26/JJ	amod||wells-29/NNS||multiple-27/JJ	nn||wells-29/NNS||quantum-28/NN	prep_for||%-23/NN||wells-29/NNS	gan--1||wells-29||no_rel||the growth of ingan/gan multiple quantum wells on these stress relaxed low defect density templates improves the internal quantum efficiency by 15% for the cyan-green multiple quantum wells.
nn||users-2/NNS||drug-1/NN	nsubj||have-3/VBP||users-2/NNS	ccomp||expressed-17/VBD||have-3/VBP	det||vulnerability-7/NN||an-4/DT	amod||vulnerability-7/NN||increased-5/VBN	nn||vulnerability-7/NN||hivinfection-6/NN	dobj||have-3/VBP||vulnerability-7/NN	prepc_compared_to||vulnerability-7/NN||to-9/TO	det||population-12/NN||the-10/DT	amod||population-12/NN||general-11/JJ	pobj||vulnerability-7/NN||population-12/NN	det||population-16/NN||this-14/DT	amod||population-16/NN||specific-15/JJ	nsubj||expressed-17/VBD||population-16/NN	root||ROOT-0/null||expressed-17/VBD	amod||doubts-19/NNS||relevant-18/JJ	dobj||expressed-17/VBD||doubts-19/NNS	nn||transmission-22/NN||hiv-21/NN	prep_about||doubts-19/NNS||transmission-22/NN	amod||levels-28/NNS||high-27/JJ	dobj||expressed-17/VBD||levels-28/NNS	conj_and||doubts-19/NNS||levels-28/NNS	amod||behavior-31/NN||risky-30/JJ	prep_of||levels-28/NNS||behavior-31/NN	hivinfection-6||hiv-21||no||drug users have an increased hivinfection vulnerability compared to the general population, this specific population expressed relevant doubts about hiv transmission, as well as high levels of risky behavior.
amod||therapy-3/NN||mefloquine-artesunate-1/JJ	nn||therapy-3/NN||combination-2/NN	nsubj||one-8/CD||therapy-3/NN	amod||falciparummalaria-6/NN||uncomplicated-5/JJ	prep_for||therapy-3/NN||falciparummalaria-6/NN	cop||one-8/CD||is-7/VBZ	root||ROOT-0/null||one-8/CD	det||treatments-11/NNS||the-10/DT	prep_of||one-8/CD||treatments-11/NNS	vmod||treatments-11/NNS||used-12/VBN	nn||children-15/NNS||african-14/NN	prep_in||used-12/VBN||children-15/NNS	falciparummalaria-6||mefloquine--1||yes||mefloquine-artesunate combination therapy for uncomplicated falciparummalaria is one of the treatments used in african children.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	prep_such_as||disorders-27/NNS||disseminatedintravascularcoagulation-30/NN	appos||disseminatedintravascularcoagulation-30/NN||dic-32/NN	prep_such_as||disorders-27/NNS||shock-35/NN	conj_and||disseminatedintravascularcoagulation-30/NN||shock-35/NN	prep_such_as||disorders-27/NNS||pancreatitis-38/NNS	conj_and||disseminatedintravascularcoagulation-30/NN||pancreatitis-38/NNS	dic-32||pancreatitis-38||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminatedintravascularcoagulation (dic), shock, and pancreatitis.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||study-6/NN||a-3/DT	amod||study-6/NN||longitudinal-4/JJ	nn||study-6/NN||qualitative-5/NN	dobj||conducted-2/VBD||study-6/NN	prep_with||conducted-2/VBD||people-8/NNS	vmod||people-8/NNS||living-9/VBG	prep_with||living-9/VBG||hiv-11/NN	ccomp||living-9/VBG||using-12/VBG	dobj||using-12/VBG||art-13/NN	nsubjpass||provided-17/VBN||art-13/NN	auxpass||provided-17/VBN||were-16/VBD	rcmod||art-13/NN||provided-17/VBN	nn||education-20/NN||adherence-19/NN	prep_with||provided-17/VBN||education-20/NN	ccomp||living-9/VBG||counselling-22/VBG	conj_and||using-12/VBG||counselling-22/VBG	dobj||counselling-22/VBG||support-23/NN	det||organisation-28/NN||a-25/DT	amod||organisation-28/NN||ugandan-26/JJ	amod||organisation-28/NN||nongovernmental-27/JJ	prep_by||counselling-22/VBG||organisation-28/NN	det||organisation-33/NN||the-30/DT	nn||organisation-33/NN||aids-31/NNS	nn||organisation-33/NN||support-32/NN	appos||organisation-28/NN||organisation-33/NN	appos||organisation-33/NN||taso-35/NNP	aids-31||hiv-11||no||we conducted a longitudinal qualitative study with people living with hiv using art, who were provided with adherence education and counselling support by a ugandan nongovernmental organisation, the aids support organisation (taso).
nsubj||has-2/VBZ||eslicarbazepine-1/NN	root||ROOT-0/null||has-2/VBZ	amod||affinity-4/NN||similar-3/JJ	dobj||has-2/VBZ||affinity-4/NN	amod||channels-8/NNS||inactivated-6/JJ	nn||channels-8/NNS||sodium-7/NN	prep_to||affinity-4/NN||channels-8/NNS	dep||affinity-4/NN||channels-10/NNS	advmod||neurons-14/NNS||just-12/RB	amod||neurons-14/NNS||activated-13/VBN	prep_in||channels-10/NNS||neurons-14/NNS	advmod||carbamazepine-17/JJ||as-16/RB	amod||affinity-4/NN||carbamazepine-17/JJ	amod||affinity-4/NN||greater-20/JJR	conj_and||carbamazepine-17/JJ||greater-20/JJR	advmod||has-2/VBZ||efficacy-21/RB	nn||models-24/NNS||animal-23/NN	prep_in||has-2/VBZ||models-24/NNS	prep_of||models-24/NNS||seizure-26/NN	prep_than||seizure-26/NN||oxcarbazepine-28/NN	seizure-26||oxcarbazepine-28||no_rel||eslicarbazepine has similar affinity to inactivated sodium channels (channels in just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than oxcarbazepine.
nsubj||increased-8/VBD||offspring-1/NN	conj_negcc||offspring-1/NN||controls-5/NNS	nsubj||increased-8/VBD||controls-5/NNS	advmod||increased-8/VBD||significantly-7/RB	root||ROOT-0/null||increased-8/VBD	dobj||increased-8/VBD||isi-9/NN	prep_in||increased-8/VBD||response-11/NN	det||intervention-15/NN||an-13/DT	nn||intervention-15/NN||exercise-14/NN	prep_to||increased-8/VBD||intervention-15/NN	vmod||increased-8/VBD||indicating-17/VBG	mark||modulated-24/JJ||that-18/IN	nn||sensitivity-20/NN||insulin-19/NN	nsubj||modulated-24/JJ||sensitivity-20/NN	cop||modulated-24/JJ||is-21/VBZ	advmod||modulated-24/JJ||more-22/RBR	advmod||modulated-24/JJ||highly-23/RB	ccomp||indicating-17/VBG||modulated-24/JJ	amod||activity-27/NN||physical-26/JJ	prep_by||modulated-24/JJ||activity-27/NN	prep_in||activity-27/NN||daughters-29/NNS	prep_of||daughters-29/NNS||patients-31/NNS	prep_with||patients-31/NNS||type2diabetes-33/CD	dep||modulated-24/JJ||than-34/IN	prep_in||modulated-24/JJ||women-36/NNS	neg||history-40/NN||no-38/DT	nn||history-40/NN||family-39/NN	prep_with||women-36/NNS||history-40/NN	det||disease-43/NN||the-42/DT	prep_of||history-40/NN||disease-43/NN	insulin-19||type2diabetes-33||no_rel||offspring, but not controls, significantly increased isi in response to an exercise intervention, indicating that insulin sensitivity is more highly modulated by physical activity in daughters of patients with type2diabetes than in women with no family history of the disease.
amod||cultures-3/NNS||fdk-1/JJ	amod||cultures-3/NNS||primary-2/JJ	nsubjpass||used-29/VBN||cultures-3/NNS	nsubj||n-14/VBP||atopicdermatitis-5/NNS	appos||atopicdermatitis-5/NNS||n-7/NN	dep||11-9/CD||=-8/SYM	rcmod||n-7/NN||11-9/CD	amod||controls-12/NNS||non-atopic-11/JJ	dep||n-7/NN||controls-12/NNS	parataxis||used-29/VBN||n-14/VBP	dep||7-16/CD||=-15/SYM	ccomp||n-14/VBP||7-16/CD	advmod||treatment-27/NN||before-18/RB	conj_and||before-18/RB||after-20/IN	advmod||treatment-27/NN||after-20/IN	nn||gamma-22/NN||interferon-21/NN	pobj||after-20/IN||gamma-22/NN	nn||³-25/NNP||ifn-î-24/NNP	appos||gamma-22/NN||³-25/NNP	nsubjpass||used-29/VBN||treatment-27/NN	auxpass||used-29/VBN||were-28/VBD	root||ROOT-0/null||used-29/VBN	amod||analysis-32/NN||microarray-31/JJ	prep_for||used-29/VBN||analysis-32/NN	amod||rt-pcr-35/NN||quantitative-34/JJ	prep_for||used-29/VBN||rt-pcr-35/NN	conj_and||analysis-32/NN||rt-pcr-35/NN	atopicdermatitis-5||atopic--1||no||fdk primary cultures (atopicdermatitis, n = 11; non-atopic controls, n = 7) before and after interferon gamma (ifn-î³) treatment were used for microarray analysis and quantitative rt-pcr.
nsubj||disease-8/NN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	cop||disease-8/NN||is-5/VBZ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||complex-7/JJ	root||ROOT-0/null||disease-8/NN	vmod||disease-8/NN||characterized-9/VBN	amod||hyperglycemia-12/NN||chronic-11/JJ	agent||characterized-9/VBN||hyperglycemia-12/NN	det||factor-17/NN||a-14/DT	amod||factor-17/NN||known-15/VBN	nn||factor-17/NN||risk-16/NN	appos||hyperglycemia-12/NN||factor-17/NN	amod||atherosclerosis-20/NNS||accelerated-19/JJ	prep_for||factor-17/NN||atherosclerosis-20/NNS	prep_for||factor-17/NN||vasculardisease-22/NN	conj_and||atherosclerosis-20/NNS||vasculardisease-22/NN	atherosclerosis-20||dm-3||no_rel||diabetesmellitus (dm) is a complex disease characterized by chronic hyperglycemia, a known risk factor for accelerated atherosclerosis and vasculardisease.
nsubj||thromboembolism-20/VBP||conclusions-1/NNS	det||findings-3/NNS||these-2/DT	nsubj||contribute-4/VBP||findings-3/NNS	rcmod||conclusions-1/NNS||contribute-4/VBP	amod||evidence-7/NN||emerging-6/VBG	prep_to||contribute-4/VBP||evidence-7/NN	mark||carries-14/VBZ||that-8/IN	det||oralcontraceptive-11/NN||the-9/DT	amod||oralcontraceptive-11/NN||combined-10/VBN	nsubj||carries-14/VBZ||oralcontraceptive-11/NN	vmod||oralcontraceptive-11/NN||containing-12/VBG	dobj||containing-12/VBG||drospirenone-13/NN	ccomp||evidence-7/NN||carries-14/VBZ	det||risk-17/NN||a-15/DT	amod||risk-17/NN||higher-16/JJR	dobj||carries-14/VBZ||risk-17/NN	prep_of||risk-17/NN||venous-19/NNS	root||ROOT-0/null||thromboembolism-20/VBP	mark||do-22/VBP||than-21/IN	advcl||thromboembolism-20/VBP||do-22/VBP	dobj||do-22/VBP||formulations-23/NNS	vmod||formulations-23/NNS||containing-24/VBG	acomp||containing-24/VBG||levonorgestrel-25/JJ	thromboembolism-20||levonorgestrel-25||no||conclusions these findings contribute to emerging evidence that the combined oralcontraceptive containing drospirenone carries a higher risk of venous thromboembolism than do formulations containing levonorgestrel.
amod||disposal-4/NN||impaired-1/VBN	amod||disposal-4/NN||insulin-dependent-2/JJ	nn||disposal-4/NN||glucose-3/NN	nsubj||harbinger-11/NN||disposal-4/NN	prep_in||disposal-4/NN||muscle-6/NN	prep_in||disposal-4/NN||fat-8/NN	conj_and||muscle-6/NN||fat-8/NN	cop||harbinger-11/NN||is-9/VBZ	det||harbinger-11/NN||a-10/DT	root||ROOT-0/null||harbinger-11/NN	prep_of||harbinger-11/NN||type2diabetes-13/CD	amod||models-17/NNS||murine-16/JJ	nsubj||conspicuous-26/JJ||models-17/NNS	amod||insulinresistance-20/NN||selective-19/JJ	prep_of||models-17/NNS||insulinresistance-20/NN	det||sites-24/NNS||these-22/DT	num||sites-24/NNS||two-23/CD	prep_at||insulinresistance-20/NN||sites-24/NNS	cop||conspicuous-26/JJ||are-25/VBP	conj_but||harbinger-11/NN||conspicuous-26/JJ	poss||failure-29/NN||their-28/PRP$	prep_by||conspicuous-26/JJ||failure-29/NN	aux||cause-31/VB||to-30/TO	vmod||failure-29/NN||cause-31/VB	dobj||cause-31/VB||hyperglycemia-32/NN	hyperglycemia-32||insulin--1||yes||impaired insulin-dependent glucose disposal in muscle and fat is a harbinger of type2diabetes, but murine models of selective insulinresistance at these two sites are conspicuous by their failure to cause hyperglycemia.
prep_in||have-10/VBP||contrast-2/NN	det||organization-6/NN||this-4/DT	nn||organization-6/NN||tetrapolar-5/NN	prep_to||contrast-2/NN||organization-6/NN	nn||gattii-9/NNS||cryptococcusneoformans/cryptococcus-8/NNS	nsubj||have-10/VBP||gattii-9/NNS	root||ROOT-0/null||have-10/VBP	det||system-14/NN||a-11/DT	nn||system-14/NN||bipolar-12/NNP	nn||system-14/NN||mating-13/NN	dobj||have-10/VBP||system-14/NN	det||locus-20/NNS||a-17/DT	amod||locus-20/NNS||single-18/JJ	amod||locus-20/NNS||biallelic-19/JJ	nsubj||governs-21/VBZ||locus-20/NNS	conj_and||have-10/VBP||governs-21/VBZ	amod||reproduction-23/NN||sexual-22/JJ	dobj||governs-21/VBZ||reproduction-23/NN	cryptococcusneoformans--1||cryptococcus--1||no||in contrast to this tetrapolar organization, cryptococcusneoformans/cryptococcus gattii have a bipolar mating system, and a single biallelic locus governs sexual reproduction.
nsubj||drug-10/NN||arsenictrioxide-1/NN	det||trisenox-6/NN||the-3/DT	nn||trisenox-6/NN||trade-4/NN	nn||trisenox-6/NN||name-5/NN	appos||arsenictrioxide-1/NN||trisenox-6/NN	cop||drug-10/NN||is-8/VBZ	det||drug-10/NN||a-9/DT	root||ROOT-0/null||drug-10/NN	vmod||drug-10/NN||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||promyleocytic-15/JJ||acute-14/JJ	amod||leukemia-16/NN||promyleocytic-15/JJ	dobj||treat-13/VB||leukemia-16/NN	appos||leukemia-16/NN||apl-18/NN	apl-18||arsenictrioxide-1||yes||arsenictrioxide, the trade name trisenox, is a drug used to treat acute promyleocytic leukemia (apl).
nsubj||reported-2/VBD||we-1/PRP	dep||reduces-25/VBZ||reported-2/VBD	mark||difluoromethylornithine-15/VBN||that-3/IN	nsubj||difluoromethylornithine-15/VBN||administration-4/NN	num||%-7/NN||1-6/CD	prep_of||administration-4/NN||%-7/NN	dep||î-12/NN||d-8/SYM	prep||d-8/SYM||l-10/IN	dep||difluoromethylornithine-15/VBN||î-12/NN	num||î-12/NN||±-13/CD	ccomp||reported-2/VBD||difluoromethylornithine-15/VBN	amod||-rrb--18/NNS||-lrb--16/JJ	nn||-rrb--18/NNS||dfmo-17/NN	dobj||difluoromethylornithine-15/VBN||-rrb--18/NNS	prep_to||difluoromethylornithine-15/VBN||mice-20/NNS	vmod||mice-20/NNS||infected-21/VBN	nn||pylori-24/NNS||h.-23/NN	prep_with||infected-21/VBN||pylori-24/NNS	root||ROOT-0/null||reduces-25/VBZ	iobj||reduces-25/VBZ||gastritis-26/NNS	dobj||attributed-32/VBD||gastritis-26/NNS	iobj||reduces-25/VBZ||colonization-28/NNS	conj_and||gastritis-26/NNS||colonization-28/NNS	dobj||attributed-32/VBD||colonization-28/NNS	nsubj||attributed-32/VBD||we-31/PRP	rcmod||gastritis-26/NNS||attributed-32/VBD	amod||host-35/NN||enhanced-34/JJ	prep_to||attributed-32/VBD||host-35/NN	amod||response-37/NN||immune-36/JJ	dobj||reduces-25/VBZ||response-37/NN	prep_due_to||response-37/NN||inhibition-40/NN	amod||decarboxylase-44/NN||macrophage-42/JJ	nn||decarboxylase-44/NN||ornithine-43/NN	prep_of||inhibition-40/NN||decarboxylase-44/NN	nn||-rrb--47/NNP||-lrb--45/NNP	nn||-rrb--47/NNP||odc-46/NNP	nsubj||reduces-25/VBZ||-rrb--47/NNP	det||enzyme-51/NN||the-49/DT	amod||enzyme-51/NN||rate-limiting-50/JJ	appos||-rrb--47/NNP||enzyme-51/NN	amod||biosynthesis-54/NNS||polyamine-53/JJ	prep_in||enzyme-51/NN||biosynthesis-54/NNS	gastritis-26||enzyme-51||no_rel||we reported that administration of 1 % d , l - î ± - difluoromethylornithine -lrb- dfmo -rrb- to mice infected with h. pylori reduces gastritis and colonization , which we attributed to enhanced host immune response due to inhibition of macrophage ornithine decarboxylase -lrb- odc -rrb- , the rate-limiting enzyme in polyamine biosynthesis .
det||trial-2/NN||the-1/DT	nsubj||trial-12/NN||trial-2/NN	cop||trial-12/NN||was-3/VBD	det||trial-12/NN||a-4/DT	amod||trial-12/NN||prospective-5/JJ	amod||trial-12/NN||randomized-7/JJ	amod||trial-12/NN||double-blind-9/JJ	amod||trial-12/NN||placebo-controlled-10/JJ	nn||trial-12/NN||intervention-11/NN	root||ROOT-0/null||trial-12/NN	vmod||trial-12/NN||enrolling-13/VBG	dobj||enrolling-13/VBG||patients-14/NNS	prep_with||enrolling-13/VBG||hypercholesterolemia-16/NN	dep||hypercholesterolemia-16/NN||defined-18/VBN	det||‰-25/NN||a-20/DT	amod||‰-25/NN||baseline-21/JJ	amod||‰-25/NN||total-22/JJ	nn||‰-25/NN||cholesterol-23/NN	nn||‰-25/NN||â-24/NN	prep_as||defined-18/VBN||‰-25/NN	vmod||‰-25/NN||¥-26/VBG	num||100â-39/NNS||200â-27/CD	amod||100â-39/NNS||$-28/$	number||mg/dl-30/CD||‰-29/CD	num||$-28/$||mg/dl-30/CD	amod||100â-39/NNS||and/or-31/JJ	nn||100â-39/NNS||baseline-32/NN	nn||100â-39/NNS||low-density-33/NN	nn||100â-39/NNS||lipoprotein-34/NN	nn||100â-39/NNS||cholesterol-35/NN	nn||100â-39/NNS||â-36/NN	amod||100â-39/NNS||‰-37/JJ	nn||100â-39/NNS||¥-38/NN	dobj||¥-26/VBG||100â-39/NNS	npadvmod||mg/dl-42/JJ||$-40/$	num||$-40/$||‰-41/CD	amod||100â-39/NNS||mg/dl-42/JJ	hypercholesterolemia-16||cholesterol-35||no||the trial was a prospective, randomized, double-blind placebo-controlled intervention trial enrolling patients with hypercholesterolemia (defined as a baseline total cholesterol â‰¥200â€‰mg/dl and/or baseline low-density lipoprotein cholesterol â‰¥100â€‰mg/dl).
det||decrease-2/NN||this-1/DT	nsubj||attributable-5/JJ||decrease-2/NN	cop||attributable-5/JJ||was-3/VBD	advmod||attributable-5/JJ||mainly-4/RB	root||ROOT-0/null||attributable-5/JJ	prep_to||attributable-5/JJ||treatment-7/NN	amod||patients-10/NNS||hiv/aids-9/JJ	prep_of||treatment-7/NN||patients-10/NNS	advmod||active-13/JJ||highly-12/RB	amod||therapy-15/NN||active-13/JJ	amod||therapy-15/NN||antiretroviral-14/JJ	prep_with||attributable-5/JJ||therapy-15/NN	appos||therapy-15/NN||haart-17/NN	aids--1||hiv--1||no||this decrease was mainly attributable to treatment of hiv/aids patients with highly active antiretroviral therapy (haart).
prep_since||supported-8/VBN||2003-2/CD	det||fund-6/NN||the-4/DT	amod||fund-6/NN||global-5/JJ	nsubj||supported-8/VBN||fund-6/NN	aux||supported-8/VBN||has-7/VBZ	root||ROOT-0/null||supported-8/VBN	det||scale-up-10/NN||the-9/DT	dobj||supported-8/VBN||scale-up-10/NN	prep_of||scale-up-10/NN||hiv/aids-12/NNS	prep_of||scale-up-10/NN||tuberculosis-14/NNP	conj_and||hiv/aids-12/NNS||tuberculosis-14/NNP	nn||control-17/NN||malaria-16/NN	prep_of||scale-up-10/NN||control-17/NN	conj_and||hiv/aids-12/NNS||control-17/NN	amod||countries-23/NNS||low-19/JJ	conj_and||low-19/JJ||middle-income-22/JJ	amod||countries-23/NNS||middle-income-22/JJ	prep_in||supported-8/VBN||countries-23/NNS	aids--1||hiv--1||no||since 2003, the global fund has supported the scale-up of hiv/aids, tuberculosis and malaria control in low- and middle-income countries.
nsubj||mediate-3/VB||capsaicin-1/NN	aux||mediate-3/VB||can-2/MD	root||ROOT-0/null||mediate-3/VB	det||sensation-8/NN||a-4/DT	amod||sensation-8/NN||painful-5/JJ	amod||sensation-8/NN||burning-7/JJ	dobj||mediate-3/VB||sensation-8/NN	det||gut-12/NN||the-10/DT	amod||gut-12/NN||human-11/JJ	prep_in||mediate-3/VB||gut-12/NN	det||vanilloid-1-18/NN||the-14/DT	amod||vanilloid-1-18/NN||transient-15/JJ	nn||vanilloid-1-18/NN||receptor-16/NN	nn||vanilloid-1-18/NN||potential-17/NN	prep_via||gut-12/NN||vanilloid-1-18/NN	appos||vanilloid-1-18/NN||trpv1-20/NNP	painful-5||capsaicin-1||yes||capsaicin can mediate a painful, burning sensation in the human gut via the transient receptor potential vanilloid-1 (trpv1).
nsubj||present-8/VBP||patients-1/NNS	vmod||patients-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||valproicacid-4/NN	appos||patients-1/NNS||vpa-6/NN	root||ROOT-0/null||present-8/VBP	det||incidence-11/NN||a-9/DT	amod||incidence-11/NN||high-10/JJ	dobj||present-8/VBP||incidence-11/NN	prep_of||incidence-11/NN||non-alcoholicfattyliverdisease-13/NN	dep||non-alcoholicfattyliverdisease-13/NN||nafld-15/JJ	advmod||%-20/NN||around-18/RB	num||%-20/NN||61-19/CD	appos||non-alcoholicfattyliverdisease-13/NN||%-20/NN	liverdisease--1||valproicacid-4||no||patients treated with valproicacid (vpa) present a high incidence of non-alcoholicfattyliverdisease (nafld) (around 61%).
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||yes||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	tick-borneencephalitis-50||viruses-29||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
amod||studies-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||effective-12/JJ||that-5/IN	nsubj||effective-12/JJ||naproxen-6/NN	conj_and||naproxen-6/NN||ibuprofen-8/NN	nsubj||effective-12/JJ||ibuprofen-8/NN	cop||effective-12/JJ||are-9/VBP	advmod||effective-12/JJ||significantly-10/RB	advmod||effective-12/JJ||more-11/RBR	ccomp||shown-4/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||pain-16/NN||oa-15/NN	dobj||reducing-14/VBG||pain-16/NN	mark||acetaminophen-19/NN||than-17/IN	cop||acetaminophen-19/NN||is-18/VBZ	ccomp||effective-12/JJ||acetaminophen-19/NN	nsubj||has-27/VBZ||acetaminophen-19/NN	det||therapy-24/NN||the-21/DT	amod||therapy-24/NN||traditional-22/JJ	amod||therapy-24/NN||first-line-23/JJ	appos||acetaminophen-19/NN||therapy-24/NN	rcmod||acetaminophen-19/NN||has-27/VBZ	neg||activity-31/NN||no-28/DT	amod||activity-31/NN||apparent-29/JJ	amod||activity-31/NN||anti-inflammatory-30/JJ	dobj||has-27/VBZ||activity-31/NN	det||joints-34/NNS||the-33/DT	prep_in||activity-31/NN||joints-34/NNS	oa-15||naproxen-6||yes||clinical studies have shown that naproxen and ibuprofen are significantly more effective at reducing oa pain than is acetaminophen, the traditional first-line therapy, which has no apparent anti-inflammatory activity in the joints.
aux||determine-2/VB||to-1/TO	advcl||isolated-32/VBD||determine-2/VB	det||characteristics-5/NNS||the-3/DT	nn||characteristics-5/NNS||transmission-4/NN	dobj||determine-2/VB||characteristics-5/NNS	amod||strains-8/NNS||m.tuberculosis-7/JJ	prep_of||characteristics-5/NNS||strains-8/NNS	vmod||strains-8/NNS||isolated-9/VBN	prep_in||isolated-9/VBN||beijing-11/NN	prep_in||isolated-9/VBN||china-13/NN	conj_and||beijing-11/NN||china-13/NN	poss||relationships-18/NNS||their-16/PRP$	amod||relationships-18/NNS||genetic-17/JJ	prep_in||isolated-9/VBN||relationships-18/NNS	conj_and||beijing-11/NN||relationships-18/NNS	advmod||characteristics-5/NNS||especially-20/RB	dep||characteristics-5/NNS||those-21/DT	amod||strains-25/NNS||beijing-23/VBG	nn||strains-25/NNS||family-24/NN	prep_among||those-21/DT||strains-25/NNS	amod||strains-31/NNS||260â-27/JJ	amod||strains-31/NNS||$-28/$	dep||$-28/$||‰-29/JJ	nn||strains-31/NNS||m.tuberculosis-30/NN	nsubj||isolated-32/VBD||strains-31/NNS	root||ROOT-0/null||isolated-32/VBD	prep_from||isolated-32/VBD||patients-34/NNS	xcomp||isolated-32/VBD||presenting-35/VBG	nsubjpass||analyzed-38/VBN||pulmonarytuberculosis-36/NNS	auxpass||analyzed-38/VBN||were-37/VBD	dep||presenting-35/VBG||analyzed-38/VBN	agent||analyzed-38/VBN||spoligotyping-40/VBG	agent||analyzed-38/VBN||examining-44/VBG	conj_and||spoligotyping-40/VBG||examining-44/VBG	num||loci-47/NNS||22-45/CD	nn||loci-47/NNS||vntr-46/NN	dobj||examining-44/VBG||loci-47/NNS	det||presence/absence-50/NN||the-49/DT	nsubj||6110-53/CD||presence/absence-50/NN	prep||presence/absence-50/NN||of-51/IN	cop||6110-53/CD||is-52/VBZ	dep||presenting-35/VBG||6110-53/CD	conj_and||analyzed-38/VBN||6110-53/CD	det||region-57/NN||the-55/DT	nn||region-57/NN||ntf-56/NN	prep_in||6110-53/CD||region-57/NN	prep_in||6110-53/CD||rd105-59/NNS	conj_and||region-57/NN||rd105-59/NNS	prep_in||6110-53/CD||rd181-61/NNS	conj_and||region-57/NN||rd181-61/NNS	pulmonarytuberculosis-36||m.tuberculosis-30||no||to determine the transmission characteristics of m.tuberculosis strains isolated in beijing , china , and their genetic relationships , especially those among beijing family strains , 260â $ ‰ m.tuberculosis strains isolated from patients presenting pulmonarytuberculosis were analyzed by spoligotyping , and by examining 22 vntr loci and the presence/absence of is 6110 in the ntf region , rd105 and rd181 .
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||man-3/NN||a-1/DT	amod||man-3/NN||29-year-old-2/JJ	nsubjpass||readmitted-26/VBN||man-3/NN	vmod||man-3/NN||suffering-4/VBG	prep_from||suffering-4/VBG||dyspnea-6/NN	amod||effusion-10/NN||eosinophilic-8/JJ	amod||effusion-10/NN||pleural-9/JJ	prep_from||suffering-4/VBG||effusion-10/NN	conj_and||dyspnea-6/NN||effusion-10/NN	prepc_after||suffering-4/VBG||being-12/VBG	prep_on||being-12/VBG||warfarin-14/NN	amod||thromboembolism-17/NN||pulmonary-16/JJ	prep_for||warfarin-14/NN||thromboembolism-17/NN	det||period-20/NN||a-19/DT	prep_for||being-12/VBG||period-20/NN	num||month-23/NN||one-22/CD	prep_of||period-20/NN||month-23/NN	auxpass||readmitted-26/VBN||was-25/VBD	root||ROOT-0/null||readmitted-26/VBN	poss||hospital-29/NN||our-28/PRP$	prep_to||readmitted-26/VBN||hospital-29/NN	thromboembolism-17||warfarin-14||yes||a 29-year-old man suffering from dyspnea and eosinophilic pleural effusion after being on warfarin for pulmonary thromboembolism for a period of one month, was readmitted to our hospital.
mwe||than-2/IN||more-1/JJR	quantmod||50-3/CD||than-2/IN	num||%-4/NN||50-3/CD	nsubj||ribavirin-25/VBZ||%-4/NN	amod||viruses-7/NNS||hepatitisc-6/JJ	prep_of||%-4/NN||viruses-7/NNS	appos||viruses-7/NNS||hcv-9/NN	amod||patients-13/NNS||infected-12/JJ	nsubj||respond-16/VB||patients-13/NNS	aux||respond-16/VB||do-14/VBP	neg||respond-16/VB||not-15/RB	parataxis||ribavirin-25/VBZ||respond-16/VB	det||interferon-20/NN||the-18/DT	amod||interferon-20/NN||classical-19/JJ	prep_to||respond-16/VB||interferon-20/NN	appos||interferon-20/NN||ifn-22/NN	punct||respond-16/VB||/-24/:	root||ROOT-0/null||ribavirin-25/VBZ	dep||ribavirin-25/VBZ||rbv-27/NN	nn||therapy-30/NN||combination-29/NN	dobj||ribavirin-25/VBZ||therapy-30/NN	hepatitisc-6||viruses-7||no||more than 50% of hepatitisc viruses (hcv)-infected patients do not respond to the classical interferon (ifn)/ribavirin (rbv) combination therapy.
nsubj||disease-5/NN||leprosy-1/NNP	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||infectious-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	agent||caused-6/VBN||mycobacteriumleprae-8/NN	leprosy-1||mycobacteriumleprae-8||no||leprosy is an infectious disease caused by mycobacteriumleprae .
det||streptococcuspyogenes-4/NNS||the-1/DT	amod||streptococcuspyogenes-4/NNS||gram-positive-2/JJ	nn||streptococcuspyogenes-4/NNS||bacterium-3/NN	nsubj||pathogen-8/NN||streptococcuspyogenes-4/NNS	cop||pathogen-8/NN||is-5/VBZ	det||pathogen-8/NN||a-6/DT	amod||pathogen-8/NN||common-7/JJ	root||ROOT-0/null||pathogen-8/NN	prep_of||pathogen-8/NN||humans-10/NNS	nsubj||causes-12/VBZ||humans-10/NNS	rcmod||humans-10/NNS||causes-12/VBZ	amod||infections-14/NNS||invasive-13/JJ	dobj||causes-12/VBZ||infections-14/NNS	amod||syndrome-17/NN||toxic-shock-16/JJ	dobj||causes-12/VBZ||syndrome-17/NN	conj_and||infections-14/NNS||syndrome-17/NN	dobj||causes-12/VBZ||rheumaticfever-19/NN	conj_and||infections-14/NNS||rheumaticfever-19/NN	dobj||causes-12/VBZ||necrotizingfasciitis-21/NNS	conj_and||infections-14/NNS||necrotizingfasciitis-21/NNS	amod||diseases-24/NNS||other-23/JJ	dobj||causes-12/VBZ||diseases-24/NNS	conj_and||infections-14/NNS||diseases-24/NNS	rheumaticfever-19||streptococcuspyogenes-4||no||the gram-positive bacterium streptococcuspyogenes is a common pathogen of humans that causes invasive infections, toxic-shock syndrome, rheumaticfever, necrotizingfasciitis and other diseases.
det||period-3/NN||this-2/DT	prep_during||â-10/VBP||period-3/NN	det||number-7/NN||the-5/DT	amod||number-7/NN||estimated-6/VBN	nsubj||â-10/VBP||number-7/NN	prep_of||number-7/NN||s.aureus-9/NNS	root||ROOT-0/null||â-10/VBP	dobj||â-10/VBP||$-11/$	amod||hospitalizations-14/NNS||related-13/JJ	npadvmod||more-31/JJR||hospitalizations-14/NNS	amod||hospitalizations-14/NNS||increased-15/JJ	num||%-17/NN||62-16/CD	dep||hospitalizations-14/NNS||%-17/NN	number||477,927-22/CD||294,570-20/CD	dep||477,927-22/CD||to-21/TO	prep_from||hospitalizations-14/NNS||477,927-22/CD	det||number-27/NN||the-25/DT	amod||number-27/NN||estimated-26/JJ	conj_and||hospitalizations-14/NNS||number-27/NN	npadvmod||more-31/JJR||number-27/NN	amod||hospitalizations-30/NNS||mrsa-related-29/JJ	prep_of||number-27/NN||hospitalizations-30/NNS	dep||doubled-33/CD||more-31/JJR	prep||more-31/JJR||than-32/IN	num||$-11/$||doubled-33/CD	number||278,203-38/CD||127,036-36/CD	dep||278,203-38/CD||to-37/TO	prep_from||â-10/VBP||278,203-38/CD	mrsa--1||s.aureus-9||no||during this period , the estimated number of s.aureus â $ `` related hospitalizations increased 62 % , from 294,570 to 477,927 , and the estimated number of mrsa-related hospitalizations more than doubled , from 127,036 to 278,203 .
vmod||develops-12/VBZ||fixed-1/VBN	det||bottom-4/NN||the-3/DT	prep_on||fixed-1/VBN||bottom-4/NN	det||substrate-7/NN||the-6/DT	prep_to||fixed-1/VBN||substrate-7/NN	det||gel-11/NN||the-9/DT	amod||gel-11/NN||tubular-10/JJ	nsubj||develops-12/VBZ||gel-11/NN	root||ROOT-0/null||develops-12/VBZ	amod||stress-14/NN||inhomogeneous-13/JJ	dobj||develops-12/VBZ||stress-14/NN	prep_during||develops-12/VBZ||swelling-16/VBG	nsubj||gives-19/VBZ||swelling-16/VBG	rcmod||swelling-16/VBG||gives-19/VBZ	dobj||gives-19/VBZ||rise-20/NN	prepc_to||gives-19/VBZ||buckling-22/VBG	dobj||buckling-22/VBG||instability-23/NN	rise-20||swelling-16||no_rel||fixed on the bottom to the substrate, the tubular gel develops inhomogeneous stress during swelling, which gives rise to buckling instability.
det||study-4/NN||the-2/DT	amod||study-4/NN||cross-sectional-3/JJ	prep_in||investigated-7/VBD||study-4/NN	nsubj||investigated-7/VBD||we-6/PRP	root||ROOT-0/null||investigated-7/VBD	det||linkage-9/NN||the-8/DT	dobj||investigated-7/VBD||linkage-9/NN	det||snp-13/NN||the-11/DT	nn||snp-13/NN||candidate-12/NN	prep_between||linkage-9/NN||snp-13/NN	amod||snp-13/NN||rs1051295-14/JJ	amod||snp-13/NN||t2d-16/JJ	conj_and||rs1051295-14/JJ||t2d-16/JJ	prepc_by||investigated-7/VBD||comparing-18/VBG	prepc_by||investigated-7/VBD||comparing-18/VBG	conj_and||comparing-18/VBG||comparing-18/VBG	amod||function-20/NN||beta-cell-19/JJ	dobj||comparing-18/VBG||function-20/NN	nn||sensitivity-23/NN||insulin-22/NN	dobj||comparing-18/VBG||sensitivity-23/NN	conj_and||function-20/NN||sensitivity-23/NN	amod||genotypes-26/NNS||rs1051295-25/JJ	prep_among||function-20/NN||genotypes-26/NNS	det||population-30/NN||a-28/DT	amod||population-30/NN||general-29/JJ	prep_in||comparing-18/VBG||population-30/NN	num||subjects-33/NNS||1051-32/CD	prep_of||population-30/NN||subjects-33/NNS	prepc_at||comparing-18/VBG||fasting-35/VBG	nn||loading-39/NN||glucose-38/NN	prep_after||comparing-18/VBG||loading-39/NN	amod||tests-44/NNS||oral-41/JJ	nn||tests-44/NNS||glucose-42/NN	nn||tests-44/NNS||tolerance-43/NN	dep||loading-39/NN||tests-44/NNS	appos||tests-44/NNS||ogtt-46/NN	num||subjects-53/NNS||84-49/CD	amod||subjects-53/NNS||fasting-50/VBG	nn||subjects-53/NNS||glucose-51/NN	amod||subjects-53/NNS||impaired-52/VBN	prep_in||loading-39/NN||subjects-53/NNS	amod||traits-58/NNS||several-56/JJ	amod||traits-58/NNS||t2d-related-57/JJ	prep_in||loading-39/NN||traits-58/NNS	conj_and||subjects-53/NNS||traits-58/NNS	t2d-16||insulin-22||yes||in the cross-sectional study, we investigated the linkage between the candidate snp rs1051295 and t2d by comparing beta-cell function and insulin sensitivity among rs1051295 genotypes in a general population of 1051 subjects at fasting and after glucose loading (oral glucose tolerance tests, ogtt) in 84 fasting glucose impaired subjects, and several t2d-related traits.
det||aminosalicylates-2/NNS||the-1/DT	nsubjpass||considered-14/VBN||aminosalicylates-2/NNS	dep||aminosalicylates-2/NNS||5-asa-4/JJ	advmod||referred-7/NN||also-6/RB	dep||5-asa-4/JJ||referred-7/NN	dep||referred-7/NN||to-8/TO	advmod||mesalamine-based-10/JJ||as-9/RB	amod||agents-11/NNS||mesalamine-based-10/JJ	dep||referred-7/NN||agents-11/NNS	auxpass||considered-14/VBN||are-13/VBP	root||ROOT-0/null||considered-14/VBN	prep_as||considered-14/VBN||first-line-16/NN	det||maintenance-19/NN||the-18/DT	prep_in||considered-14/VBN||maintenance-19/NN	prep_of||maintenance-19/NN||remission-21/NN	amod||moderate-25/JJ||mild-23/JJ	dep||moderate-25/JJ||to-24/TO	amod||ulcerativecolitis-26/NNS||moderate-25/JJ	prep_of||remission-21/NN||ulcerativecolitis-26/NNS	appos||ulcerativecolitis-26/NNS||uc-28/NN	ulcerativecolitis-26||mesalamine--1||yes||the aminosalicylates (5-asa; also referred to as mesalamine-based agents) are considered as first-line in the maintenance of remission of mild to moderate ulcerativecolitis (uc).
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	insulin-59||cancer-54||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
det||best-3/JJS||the-2/DT	prep_to||is-9/VBZ||best-3/JJS	poss||knowledge-6/NN||our-5/PRP$	prep_of||best-3/JJS||knowledge-6/NN	expl||is-9/VBZ||there-8/EX	root||ROOT-0/null||is-9/VBZ	neg||report-11/NN||no-10/DT	nsubj||is-9/VBZ||report-11/NN	det||use-14/NN||the-13/DT	prep_of||report-11/NN||use-14/NN	amod||beads-17/NNS||antibiotic-cement-16/JJ	prep_of||use-14/NN||beads-17/NNS	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||surgical-20/JJ	prep_in||beads-17/NNS||treatment-21/NN	det||epiduralabscess-24/NNS||an-23/DT	prep_of||treatment-21/NN||epiduralabscess-24/NNS	epiduralabscess-24||antibiotic--1||no_rel||to the best of our knowledge, there is no report of the use of antibiotic-cement beads in the surgical treatment of an epiduralabscess.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubj||had-7/VBD||plus-5/NN	advmod||had-7/VBD||assay-6/RB	root||ROOT-0/null||had-7/VBD	det||sensitivity-9/NN||a-8/DT	dobj||had-7/VBD||sensitivity-9/NN	num||%-12/NN||95.3-11/CD	prep_of||sensitivity-9/NN||%-12/NN	num||%-15/NN||100-14/CD	prep_of||sensitivity-9/NN||%-15/NN	conj_and||%-12/NN||%-15/NN	num||%-19/NN||94.4-18/CD	prep_of||sensitivity-9/NN||%-19/NN	conj_and||%-12/NN||%-19/NN	nn||resistance-22/NN||inh-21/NN	prep_for||had-7/VBD||resistance-22/NN	nn||resistance-25/NN||rif-24/NN	prep_for||had-7/VBD||resistance-25/NN	conj_and||resistance-22/NN||resistance-25/NN	prep_for||had-7/VBD||mdr-tb-28/NN	conj_and||resistance-22/NN||mdr-tb-28/NN	advmod||had-7/VBD||respectively-30/RB	tb--1||inh-21||yes||the genotypeâ® mtbdr plus assay had a sensitivity of 95.3%, 100%, and 94.4% for inh resistance, rif resistance, and mdr-tb, respectively.
amod||vaccines-9/NNS||immunization-1/JJ	amod||swine-6/NNS||1918-like-3/JJ	conj_and||1918-like-3/JJ||classical-5/JJ	amod||swine-6/NNS||classical-5/JJ	prep_with||immunization-1/JJ||swine-6/NNS	amod||vaccines-9/NNS||h1n1-7/JJ	nn||vaccines-9/NNS||virus-8/NN	nsubj||results-10/VBZ||vaccines-9/NNS	root||ROOT-0/null||results-10/VBZ	amod||antibodies-13/NNS||cross-protective-12/JJ	prep_in||results-10/VBZ||antibodies-13/NNS	det||influenza-19/NN||the-15/DT	num||h1n1-17/NNS||2009-16/CD	npadvmod||pandemic-18/JJ||h1n1-17/NNS	amod||influenza-19/NN||pandemic-18/JJ	prep_against||antibodies-13/NNS||influenza-19/NN	xcomp||results-10/VBZ||indicating-21/VBG	amod||similarities-23/NNS||antigenic-22/JJ	dobj||indicating-21/VBG||similarities-23/NNS	det||viruses-26/NNS||these-25/DT	prep_among||indicating-21/VBG||viruses-26/NNS	influenza-19||antibodies-13||no_rel||immunization with 1918-like and classical swine h1n1 virus vaccines results in cross-protective antibodies against the 2009 h1n1 pandemic influenza, indicating antigenic similarities among these viruses.
amod||conjugates-4/NNS||vivo-2/JJ	nn||conjugates-4/NNS||antibody-3/NN	prep_in||caused-5/VBD||conjugates-4/NNS	root||ROOT-0/null||caused-5/VBD	dobj||caused-5/VBD||suppression-6/NN	amod||growth-11/NN||human-8/JJ	nn||growth-11/NN||lovo-9/NN	nn||growth-11/NN||tumour-10/NN	prep_of||suppression-6/NN||growth-11/NN	amod||nih-14/NN||immunodeficient-13/JJ	prep_in||caused-5/VBD||nih-14/NN	nn||mice-16/NNS||iii-15/NN	nsubj||caused-5/VBD||mice-16/NNS	amod||doses-35/NNS||similar-18/JJ	det||therapy-23/NN||the-20/DT	amod||therapy-23/NN||commercial-21/JJ	amod||therapy-23/NN||photodynamic-22/JJ	prep_to||similar-18/JJ||therapy-23/NN	appos||therapy-23/NN||pdt-25/NN	nn||doses-35/NNS||agent-27/NN	amod||doses-35/NNS||photofrinâ-28/JJ	amod||doses-35/NNS||®-29/JJ	conj_but||®-29/JJ||at-32/IN	amod||doses-35/NNS||at-32/IN	amod||doses-35/NNS||administered-33/JJ	nn||doses-35/NNS||photosensitizer-34/NN	appos||mice-16/NNS||doses-35/NNS	nsubj||lower-44/JJR||doses-35/NNS	cop||lower-44/JJR||were-37/VBD	mwe||than-39/IN||more-38/JJR	quantmod||two-40/CD||than-39/IN	num||orders-41/NNS||two-40/CD	npadvmod||lower-44/JJR||orders-41/NNS	prep_of||orders-41/NNS||magnitude-43/NN	rcmod||doses-35/NNS||lower-44/JJR	immunodeficient-13||photosensitizer-34||no_rel||in vivo antibody conjugates caused suppression of human lovo tumour growth in immunodeficient nih iii mice, similar to the commercial photodynamic therapy (pdt) agent photofrinâ®, but at administered photosensitizer doses that were more than two orders of magnitude lower.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||assess-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||efficacy-11/NN||the-10/DT	dobj||assess-9/VB||efficacy-11/NN	amod||lamivudine-14/NN||prophylactic-13/JJ	prep_of||efficacy-11/NN||lamivudine-14/NN	prepc_in||assess-9/VB||reducing-16/VBG	det||incidence-18/NN||the-17/DT	dobj||reducing-16/VBG||incidence-18/NN	dobj||reducing-16/VBG||severity-20/NN	conj_and||incidence-18/NN||severity-20/NN	nn||reactivation-23/NN||hbv-22/NN	prep_of||incidence-18/NN||reactivation-23/NN	amod||patients-28/NNS||post-operative-25/JJ	nn||patients-28/NNS||breast-26/NN	nn||patients-28/NNS||cancer-27/NN	prep_in||reducing-16/VBG||patients-28/NNS	vmod||patients-28/NNS||undergoing-29/VBG	amod||chemotherapy-32/NN||adjuvant-30/JJ	amod||chemotherapy-32/NN||doxorubicin-containing-31/JJ	dobj||undergoing-29/VBG||chemotherapy-32/NN	hbv-22||lamivudine-14||yes||the purpose of the current study was to assess the efficacy of prophylactic lamivudine in reducing the incidence and severity of hbv reactivation in post-operative breast cancer patients undergoing adjuvant doxorubicin-containing chemotherapy.
det||results-3/NNS||the-1/DT	amod||results-3/NNS||impressive-2/JJ	nsubj||make-13/VBP||results-3/NNS	det||trial-8/NN||this-5/DT	amod||trial-8/NN||recent-6/JJ	amod||trial-8/NN||randomized-7/JJ	prep_of||results-3/NNS||trial-8/NN	amod||studies-12/NNS||other-10/JJ	amod||studies-12/NNS||observational-11/JJ	prep_of||results-3/NNS||studies-12/NNS	conj_and||trial-8/NN||studies-12/NNS	root||ROOT-0/null||make-13/VBP	det||argument-16/NN||a-14/DT	amod||argument-16/NN||strong-15/JJ	dobj||make-13/VBP||argument-16/NN	det||use-19/NN||the-18/DT	prep_for||argument-16/NN||use-19/NN	prep_of||use-19/NN||bivalirudin-21/NN	dobj||make-13/VBP||heparin-24/NN	conj_negcc||argument-16/NN||heparin-24/NN	prep||heparin-24/NN||plus-25/CC	nn||inhibitors-28/NNS||gp-26/NN	nn||inhibitors-28/NNS||iib/iiia-27/NN	pobj||plus-25/CC||inhibitors-28/NNS	det||majority-32/NN||the-30/DT	amod||majority-32/NN||great-31/JJ	prep_for||inhibitors-28/NNS||majority-32/NN	prep_of||majority-32/NN||patients-34/NNS	prep_with||make-13/VBP||ami-36/NN	vmod||ami-36/NN||treated-37/VBN	amod||pci-40/NN||primary-39/JJ	prep_with||treated-37/VBN||pci-40/NN	ami-36||heparin-24||yes||the impressive results of this recent randomized trial and other observational studies make a strong argument for the use of bivalirudin rather than heparin plus gp iib/iiia inhibitors for the great majority of patients with ami treated with primary pci.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	insulin-50||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
nsubj||affects-5/VBZ||denguevirus-1/NNS	appos||denguevirus-1/NNS||denv-3/NNP	root||ROOT-0/null||affects-5/VBZ	quantmod||half-7/PDT||over-6/IN	num||population-13/NN||half-7/PDT	det||population-13/NN||the-8/DT	amod||population-13/NN||worldâ-9/JJ	amod||population-13/NN||$-10/$	number||s-12/CD||™-11/CD	num||$-10/$||s-12/CD	dobj||affects-5/VBZ||population-13/NN	num||countries-16/NNS||112-15/CD	prep_in||affects-5/VBZ||countries-16/NNS	nsubj||arthropod-27/NN||denguefever-19/NN	appos||denguefever-19/NN||df-21/NN	cop||arthropod-27/NN||is-23/VBZ	det||arthropod-27/NN||the-24/DT	amod||arthropod-27/NN||second-25/JJ	dep||second-25/JJ||largest-26/JJS	conj_and||affects-5/VBZ||arthropod-27/NN	vmod||arthropod-27/NN||borne-28/VBN	amod||hazard-31/NN||infectious-29/JJ	amod||hazard-31/NN||global-30/JJ	dobj||borne-28/VBN||hazard-31/NN	prep_after||borne-28/VBN||malaria-33/NN	prep_with||borne-28/VBN||complications-35/NNS	prep_like||complications-35/NNS||denguehemorrhagicfever-37/NN	appos||denguehemorrhagicfever-37/NN||dhf-39/NN	prep_like||complications-35/NNS||dengueshocksyndrome-42/NN	conj_and||denguehemorrhagicfever-37/NN||dengueshocksyndrome-42/NN	appos||denguehemorrhagicfever-37/NN||dss-44/NN	prep||borne-28/VBN||accounting-47/VBG	pcomp||accounting-47/VBG||for-48/IN	amod||morbidity-50/NN||significant-49/JJ	pobj||for-48/IN||morbidity-50/NN	nn||world-over-53/NN||mortality-52/NN	pobj||for-48/IN||world-over-53/NN	conj_and||morbidity-50/NN||world-over-53/NN	dengueshocksyndrome-42||denguevirus-1||no||denguevirus (denv) affects over half the worldâ€™s population in 112 countries, and denguefever (df) is the second largest arthropod borne infectious global hazard after malaria with complications like denguehemorrhagicfever (dhf) and dengueshocksyndrome (dss), accounting for significant morbidity and mortality world-over.
det||research-3/NN||this-2/DT	prep_in||designed-5/VBD||research-3/NN	nsubj||designed-5/VBD||we-4/PRP	nsubj||implemented-7/VBD||we-4/PRP	root||ROOT-0/null||designed-5/VBD	conj_and||designed-5/VBD||implemented-7/VBD	det||oidr-9/NN||the-8/DT	dobj||implemented-7/VBD||oidr-9/NN	advmod||implemented-7/VBD||reflectometry-10/RB	xcomp||implemented-7/VBD||measuring-11/VBG	dobj||measuring-11/VBG||system-12/NN	det||source-21/NN||a-14/DT	amod||source-21/NN||650â-15/JJ	amod||source-21/NN||$-16/$	number||nm-18/CD||‰-17/CD	num||$-16/$||nm-18/CD	nn||source-21/NN||diode-19/NN	nn||source-21/NN||laser-20/NN	prep_with||measuring-11/VBG||source-21/NN	nn||physicians-24/NNS||aid-23/NN	prep_to||source-21/NN||physicians-24/NNS	prepc_in||measuring-11/VBG||diagnosing-26/VBG	det||squamouscellcarcinomas-28/NNS||both-27/DT	dobj||diagnosing-26/VBG||squamouscellcarcinomas-28/NNS	appos||squamouscellcarcinomas-28/NNS||scc-30/NN	dobj||diagnosing-26/VBG||basalcellcarcinomas-33/NNS	conj_and||squamouscellcarcinomas-28/NNS||basalcellcarcinomas-33/NNS	appos||basalcellcarcinomas-33/NNS||bcc-35/NN	basalcellcarcinomas-33||nm-18||no_rel||in this research we designed and implemented the oidr reflectometry measuring system with a 650â€‰ nm diode laser source to aid physicians in diagnosing both squamouscellcarcinomas (scc) and basalcellcarcinomas(bcc).
nsubj||diseases-9/NNS||priondiseases-1/NNS	conj_or||priondiseases-1/NNS||transmissiblespongiformencephalopathies-3/NNS	nsubj||diseases-9/NNS||transmissiblespongiformencephalopathies-3/NNS	appos||priondiseases-1/NNS||tses-5/NNS	cop||diseases-9/NNS||are-7/VBP	amod||diseases-9/NNS||fatal-8/JJ	root||ROOT-0/null||diseases-9/NNS	vmod||diseases-9/NNS||associated-10/VBN	det||conversion-13/NN||the-12/DT	prep_with||associated-10/VBN||conversion-13/NN	det||prionprotein-17/NN||the-15/DT	amod||prionprotein-17/NN||cellular-16/JJ	prep_of||conversion-13/NN||prionprotein-17/NN	dep||prionprotein-17/NN||prpc-19/JJ	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||abnormal-23/JJ	prep_to||associated-10/VBN||prionprotein-24/NN	dep||prionprotein-24/NN||prpsc-26/JJ	transmissiblespongiformencephalopathies-3||prionprotein-24||no||priondiseases or transmissiblespongiformencephalopathies (tses) are fatal diseases associated with the conversion of the cellular prionprotein (prpc) to the abnormal prionprotein (prpsc).
nsubjpass||found-9/VBN||differences-1/NNS	nsubjpass||found-9/VBN||differences-1/NNS	amod||sequence-4/NN||nucleotide-3/JJ	prep_in||differences-1/NNS||sequence-4/NN	amod||env-7/NN||herv-w-6/JJ	prep_of||sequence-4/NN||env-7/NN	auxpass||found-9/VBN||were-8/VBD	root||ROOT-0/null||found-9/VBN	conj_and||found-9/VBN||found-9/VBN	prep_between||found-9/VBN||patients-11/NNS	prep_with||patients-11/NNS||sz-13/NN	prep_with||patients-11/NNS||bd-15/NN	conj_and||sz-13/NN||bd-15/NN	prepc_as||found-9/VBN||compared-17/VBN	pcomp||compared-17/VBN||with-18/IN	pobj||with-18/IN||hc-19/NN	prep_between||found-9/VBN||sz-25/NN	prep_between||found-9/VBN||bd-27/NN	conj_and||sz-25/NN||bd-27/NN	sz-25||hc-19||no_rel||differences in nucleotide sequence of herv-w env were found between patients with sz and bd as compared with hc, as well as between sz and bd.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
amod||therapy-4/NN||weekly-1/JJ	amod||therapy-4/NN||low-dose-2/JJ	amod||therapy-4/NN||docetaxel-3/JJ	nsubj||provides-5/VBZ||therapy-4/NN	nsubj||provides-5/VBZ||therapy-4/NN	root||ROOT-0/null||provides-5/VBZ	conj_or||provides-5/VBZ||provides-5/VBZ	det||alternative-8/NN||a-6/DT	amod||alternative-8/NN||reasonable-7/JJ	dobj||provides-5/VBZ||alternative-8/NN	amod||treatment-12/NN||nsclc-10/JJ	nn||treatment-12/NN||salvage-11/NN	prep_for||provides-5/VBZ||treatment-12/NN	amod||patients-16/NNS||pretreated-14/JJ	amod||patients-16/NNS||elderly-15/JJ	prep_in||treatment-12/NN||patients-16/NNS	prep_in||provides-5/VBZ||patients-19/NNS	det||ps-23/NN||a-21/DT	amod||ps-23/NN||reduced-22/VBN	prep_with||patients-19/NNS||ps-23/NN	nsclc-10||docetaxel-3||yes||weekly low-dose docetaxel therapy provides a reasonable alternative for nsclc salvage treatment in pretreated elderly patients or in patients with a reduced ps.
cc||therapy-3/VBZ||and-1/CC	nsubj||therapy-3/VBZ||ribavirin-2/NNP	root||ROOT-0/null||therapy-3/VBZ	amod||virus-6/NN||chronichepatitisc-5/JJ	prep_for||therapy-3/VBZ||virus-6/NN	chronichepatitisc-5||ribavirin-2||yes||and ribavirin therapy for chronichepatitisc virus.
nsubjpass||associated-4/VBN||irondeficiency-1/NN	nsubj||statusepilepticus-42/VBZ||irondeficiency-1/NN	auxpass||associated-4/VBN||was-2/VBD	advmod||associated-4/VBN||neither-3/RB	root||ROOT-0/null||associated-4/VBN	det||risk-8/NN||an-6/DT	amod||risk-8/NN||increased-7/VBN	prep_with||associated-4/VBN||risk-8/NN	amod||seizures-11/NNS||acute-10/JJ	prep_of||risk-8/NN||seizures-11/NNS	num||cases-18/NNS||45/133-13/CD	number||33.8-15/CD||-LSB--14/CD	dep||%-16/NN||33.8-15/CD	dep||cases-18/NNS||%-16/NN	nn||cases-18/NNS||-RSB--17/NN	nsubj||deficient-21/NN||cases-18/NNS	cop||deficient-21/NN||were-19/VBD	nn||deficient-21/NN||iron-20/NN	dep||risk-8/NN||deficient-21/NN	prepc_compared_to||deficient-21/NN||to-23/TO	num||â-36/NNS||36/133-24/CD	number||27.1-26/CD||-LSB--25/CD	dep||%-27/NN||27.1-26/CD	dep||â-36/NNS||%-27/NN	amod||â-36/NNS||-RSB--28/JJ	nn||â-36/NNS||controls-29/NNS	dep||â-36/NNS||p-31/NN	nn||â-36/NNS||â-32/NN	num||â-36/NNS||$-33/$	number||=-35/CD||š-34/CD	num||$-33/$||=-35/CD	pobj||deficient-21/NN||â-36/NNS	dep||deficient-21/NN||$-37/$	num||$-37/$||š0-38/CD	num||$-37/$||.230-39/CD	conj_nor||associated-4/VBN||statusepilepticus-42/VBZ	nsubj||affect-47/VB||it-44/PRP	aux||affect-47/VB||did-45/VBD	neg||affect-47/VB||not-46/RB	conj_and||associated-4/VBN||affect-47/VB	dobj||affect-47/VB||seizure-48/NN	advmod||affect-47/VB||semiology-49/RB	irondeficiency-1||iron-20||yes||irondeficiency was neither associated with an increased risk of acute seizures (45/133[33.8%] cases were iron deficient compared to 36/133[27.1%] controls, p â€š=â€š0.230) nor statusepilepticus and it did not affect seizure semiology.
nn||organization-2/NN||gene-1/NN	nsubj||similar-16/JJ||organization-2/NN	nsubj||different-25/JJ||organization-2/NN	det||spacer-6/NN||the-4/DT	amod||spacer-6/NN||intergenic-5/JJ	prep_of||organization-2/NN||spacer-6/NN	det||rrna-10/NN||the-8/DT	amod||rrna-10/NN||16s-9/JJ	prep_between||spacer-6/NN||rrna-10/NN	det||rrna-14/NN||the-12/DT	amod||rrna-14/NN||23s-13/JJ	prep_between||spacer-6/NN||rrna-14/NN	conj_and||rrna-10/NN||rrna-14/NN	cop||similar-16/JJ||was-15/VBD	root||ROOT-0/null||similar-16/JJ	prep_to||similar-16/JJ||that-18/DT	amod||species-23/NNS||other-20/JJ	nn||species-23/NNS||tbrf-21/NN	nn||species-23/NNS||borrelia-22/NN	prep_of||that-18/DT||species-23/NNS	conj_and||similar-16/JJ||different-25/JJ	det||species-30/NN||the-27/DT	amod||species-30/NN||lymedisease-28/JJ	nn||species-30/NN||borrelia-29/NN	prep_from||different-25/JJ||species-30/NN	lymedisease-28||borrelia-29||no||gene organization of the intergenic spacer between the 16s rrna and the 23s rrna was similar to that of other tbrf borrelia species and different from the lymedisease borrelia species.
nsubj||pathogen-9/NN||denguevirus-1/NNS	appos||denguevirus-1/NNS||denv-3/NNP	cop||pathogen-9/NN||is-5/VBZ	det||pathogen-9/NN||a-6/DT	amod||pathogen-9/NN||serious-7/JJ	amod||pathogen-9/NN||mosquito-borne-8/JJ	root||ROOT-0/null||pathogen-9/NN	vmod||pathogen-9/NN||causing-10/VBG	vmod||pathogen-9/NN||causing-10/VBG	conj_or||causing-10/VBG||causing-10/VBG	amod||burden-14/NN||significant-11/JJ	amod||burden-14/NN||global-12/JJ	nn||burden-14/NN||disease-13/NN	dobj||causing-10/VBG||burden-14/NN	preconj||causing-10/VBG||either-16/CC	amod||denguefever-19/NN||classic-18/JJ	prep_as||causing-10/VBG||denguefever-19/NN	appos||denguefever-19/NN||df-21/NN	poss||denguehemorrhagicfever-29/NN||its-25/PRP$	advmod||severe-27/JJ||most-26/RBS	amod||denguehemorrhagicfever-29/NN||severe-27/JJ	amod||denguehemorrhagicfever-29/NN||manifestation-28/JJ	prep_in||causing-10/VBG||denguehemorrhagicfever-29/NN	appos||denguehemorrhagicfever-29/NN||dhf-31/NN	denguehemorrhagicfever-29||denguevirus-1||no||denguevirus (denv) is a serious mosquito-borne pathogen causing significant global disease burden, either as classic denguefever (df) or in its most severe manifestation denguehemorrhagicfever (dhf).
nsubj||factor-8/NN||hyperhomocysteinemia-1/NN	nsubj||develop-16/VB||hyperhomocysteinemia-1/NN	cop||factor-8/NN||is-4/VBZ	det||factor-8/NN||an-5/DT	amod||factor-8/NN||independent-6/JJ	nn||factor-8/NN||risk-7/NN	rcmod||hyperhomocysteinemia-1/NN||factor-8/NN	amod||vasculardisease-11/NN||atherosclerotic-10/JJ	prep_for||factor-8/NN||vasculardisease-11/NN	prep_for||factor-8/NN||thromboembolism-13/NN	conj_and||vasculardisease-11/NN||thromboembolism-13/NN	aux||develop-16/VB||may-15/MD	root||ROOT-0/null||develop-16/VB	amod||patients-19/NNS||hcv-infected-18/JJ	prep_in||develop-16/VB||patients-19/NNS	mark||enzyme-28/VBP||although-20/IN	amod||transferase-24/NN||altered-21/JJ	amod||transferase-24/NN||alanine-22/JJ	amod||transferase-24/NN||amino-23/JJ	nsubj||enzyme-28/VBP||transferase-24/NN	appos||transferase-24/NN||alt-26/NN	advcl||develop-16/VB||enzyme-28/VBP	nsubjpass||associated-32/VBN||levels-29/NNS	auxpass||associated-32/VBN||are-30/VBP	advmod||associated-32/VBN||generally-31/RB	ccomp||enzyme-28/VBP||associated-32/VBN	prep_with||associated-32/VBN||damage-34/NN	nn||cells-37/NNS||liver-36/NN	prep_to||associated-32/VBN||cells-37/NNS	enzyme-28||vasculardisease-11||no_rel||hyperhomocysteinemia, which is an independent risk factor for atherosclerotic vasculardisease and thromboembolism , may develop in hcv-infected patients although altered alanine amino transferase (alt) enzyme levels are generally associated with damage to liver cells.
advmod||had-21/VBD||however-1/RB	nsubj||had-21/VBD||children-3/NNS	prep_with||children-3/NNS||heredity-5/NN	prep_for||heredity-5/NN||allergies-7/NNS	prep_with||children-3/NNS||presence-10/NN	conj_and||heredity-5/NN||presence-10/NN	amod||smoke-14/NN||secondhand-12/JJ	nn||smoke-14/NN||tobacco-13/NN	prep_of||presence-10/NN||smoke-14/NN	poss||year-18/NN||their-16/PRP$	amod||year-18/NN||first-17/JJ	prep_during||smoke-14/NN||year-18/NN	prep_in||year-18/NN||life-20/NN	root||ROOT-0/null||had-21/VBD	advmod||odds-24/NNS||highly-22/RB	amod||odds-24/NNS||increased-23/VBN	dobj||had-21/VBD||odds-24/NNS	prepc_of||odds-24/NNS||developing-26/VBG	det||allergy-28/NN||an-27/DT	dobj||developing-26/VBG||allergy-28/NN	aux||sought-31/VBN||having-30/VBG	prepc_of||odds-24/NNS||sought-31/VBN	conj_and||developing-26/VBG||sought-31/VBN	amod||care-33/NN||medical-32/JJ	dobj||sought-31/VBN||care-33/NN	amod||symptoms-37/NNS||allergic-36/JJ	prep_due_to||sought-31/VBN||symptoms-37/NNS	num||years-40/NNS||4-39/CD	prep_at||symptoms-37/NNS||years-40/NNS	prep_of||years-40/NNS||age-42/NN	allergies-7||allergy-28||no||however, children with heredity for allergies and with presence of secondhand tobacco smoke during their first year in life had highly increased odds of developing an allergy and having sought medical care due to allergic symptoms at 4 years of age.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	pain-30||nsaids-57||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
det||pattern-2/NN||the-1/DT	nsubj||§-8/VBD||pattern-2/NN	nn||mortality-5/NN||childhood-4/NN	prep_of||pattern-2/NN||mortality-5/NN	prep_in||mortality-5/NN||manhiã-7/NNP	root||ROOT-0/null||§-8/VBD	det||area-10/NN||a-9/DT	nsubj||typical-12/JJ||area-10/NN	cop||typical-12/JJ||is-11/VBZ	ccomp||§-8/VBD||typical-12/JJ	prepc_of||typical-12/JJ||developing-14/VBG	dobj||developing-14/VBG||countries-15/NNS	advmod||causes-24/NNS||where-16/WRB	nsubj||causes-24/NNS||malaria-17/NN	conj_and||malaria-17/NN||pneumonia-19/NN	nsubj||causes-24/NNS||pneumonia-19/NN	conj_and||malaria-17/NN||hiv/aids-21/NNS	nsubj||causes-24/NNS||hiv/aids-21/NNS	cop||causes-24/NNS||are-22/VBP	amod||causes-24/NNS||important-23/JJ	rcmod||countries-15/NNS||causes-24/NNS	prep_of||causes-24/NNS||death-26/NN	aids--1||hiv--1||no||the pattern of childhood mortality in manhiã§a area is typical of developing countries where malaria, pneumonia and hiv/aids are important causes of death.
det||qrt-pcr-3/NN||the-1/DT	amod||qrt-pcr-3/NN||same-2/JJ	nsubjpass||used-6/VBN||qrt-pcr-3/NN	nsubj||compare-8/VB||qrt-pcr-3/NN	advmod||used-6/VBN||assay-4/RB	auxpass||used-6/VBN||was-5/VBD	root||ROOT-0/null||used-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||used-6/VBN||compare-8/VB	dobj||compare-8/VB||trpv1â-9/NNS	nsubjpass||found-36/VBN||$-10/$	num||expression-13/NN||4-12/CD	npadvmod||doubled-29/RB||expression-13/NN	dep||controls-16/NNS||between-14/IN	amod||controls-16/NNS||healthy-15/JJ	dep||expression-13/NN||controls-16/NNS	nn||hyposensitive-19/NN||patients-18/NNS	dep||expression-13/NN||hyposensitive-19/NN	conj_and||controls-16/NNS||hyposensitive-19/NN	nn||pain-23/NN||capsaicin-21/NN	nn||stimuli-26/NNS||pain-23/NN	conj_and||pain-23/NN||thermal-25/JJ	nn||stimuli-26/NNS||thermal-25/JJ	prep_to||controls-16/NNS||stimuli-26/NNS	punct||controls-16/NNS||an-27/,	advmod||controls-16/NNS||almost-28/RB	dep||up-regulation-30/CD||doubled-29/RB	num||$-10/$||up-regulation-30/CD	det||gene-34/NN||the-32/DT	amod||gene-34/NN||trpv1-33/JJ	prep_of||$-10/$||gene-34/NN	auxpass||found-36/VBN||was-35/VBD	rcmod||trpv1â-9/NNS||found-36/VBN	det||subjects-40/NNS||the-38/DT	amod||subjects-40/NNS||pathological-39/JJ	prep_in||found-36/VBN||subjects-40/NNS	pain-23||capsaicin-21||yes||the same qrt-pcr assay was used to compare trpv1â€“4 expression between healthy controls and patients hyposensitive to capsaicin, pain and thermal stimuli an almost doubled up-regulation of the trpv1 gene was found in the pathological subjects.
nsubjpass||reported-18/VBN||infliximab-1/NN	nsubj||effective-21/JJ||infliximab-1/NN	det||factor-6/NN||an-3/DT	amod||factor-6/NN||anti-tumor-4/JJ	nn||factor-6/NN||necrosis-5/NNS	appos||infliximab-1/NN||factor-6/NN	appos||factor-6/NN||tnf-8/NN	advmod||±-12/JJ||î-11/RB	amod||antibody-14/NN||±-12/JJ	amod||antibody-14/NN||monoclonal-13/JJ	dep||factor-6/NN||antibody-14/NN	aux||reported-18/VBN||has-16/VBZ	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	aux||effective-21/JJ||to-19/TO	cop||effective-21/JJ||be-20/VB	xcomp||reported-18/VBN||effective-21/JJ	amod||uveoretinitis-24/NNS||refractory-23/JJ	prep_in||effective-21/JJ||uveoretinitis-24/NNS	prepc_in||effective-21/JJ||behã-26/VBG	nn||et-28/NNP||§-27/NNP	dep||sdisease-30/JJ||et-28/NNP	dep||behã-26/VBG||sdisease-30/JJ	antibody-14||tumor--1||no_rel||infliximab, an anti-tumor necrosis factor (tnf)-î± monoclonal antibody, has been reported to be effective in refractory uveoretinitis in behã§et'sdisease.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
aux||describe-2/VB||to-1/TO	dep||pathogen-26/NN||describe-2/VB	det||characteristics-5/NNS||the-3/DT	amod||characteristics-5/NNS||clinical-4/JJ	dobj||describe-2/VB||characteristics-5/NNS	dobj||describe-2/VB||diagnosis-7/NN	conj_and||characteristics-5/NNS||diagnosis-7/NN	dobj||describe-2/VB||treatment-10/NN	conj_and||characteristics-5/NNS||treatment-10/NN	amod||ampicillinsodium-13/NN||intravitreal-12/JJ	prep_with||describe-2/VB||ampicillinsodium-13/NN	det||case-18/NN||a-15/DT	amod||case-18/NN||postoperative-16/JJ	nn||case-18/NN||endophthalmitis-17/NNS	prep_of||ampicillinsodium-13/NN||case-18/NN	amod||uberis-22/NNS||streptococcus-21/JJ	prep_due_to||case-18/NN||uberis-22/NNS	det||pathogen-26/NN||an-24/DT	amod||pathogen-26/NN||environmental-25/JJ	root||ROOT-0/null||pathogen-26/NN	advmod||seen-28/VBN||commonly-27/RB	vmod||pathogen-26/NN||seen-28/VBN	amod||cases-31/NNS||mastitis-30/JJ	prep_in||seen-28/VBN||cases-31/NNS	amod||cows-34/NNS||lactating-33/VBG	prep_of||cases-31/NNS||cows-34/NNS	ampicillinsodium-13||endophthalmitis-17||no_rel||to describe the clinical characteristics, diagnosis, and treatment with intravitreal ampicillinsodium of a postoperative endophthalmitis case due to streptococcus uberis ; an environmental pathogen commonly seen in mastitis cases of lactating cows.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||lidocaine-30||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
amod||analysis-4/NN||multivariate-1/JJ	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubjpass||performed-6/VBN||analysis-4/NN	nsubj||assess-8/VB||analysis-4/NN	auxpass||performed-6/VBN||was-5/VBD	root||ROOT-0/null||performed-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||performed-6/VBN||assess-8/VB	advmod||associated-12/VBN||how-9/WRB	nsubjpass||associated-12/VBN||religion-10/NN	auxpass||associated-12/VBN||was-11/VBD	ccomp||assess-8/VB||associated-12/VBN	prep_with||associated-12/VBN||perceptions-14/NNS	prep_about||perceptions-14/NNS||hiv-16/NN	nn||treatment-19/NN||hiv-18/NN	prep_about||perceptions-14/NNS||treatment-19/NN	conj_and||hiv-16/NN||treatment-19/NN	prep_about||perceptions-14/NNS||people-22/NNS	conj_and||hiv-16/NN||people-22/NNS	xcomp||associated-12/VBN||living-23/VBG	prep_with||living-23/VBG||hiv/aids-25/NNS	aids--1||hiv-18||no||multivariate logistic regression analysis was performed to assess how religion was associated with perceptions about hiv, hiv treatment, and people living with hiv/aids.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	prep_for||assessed-2/VBD||knowledge-4/NN	prep_about||assessed-2/VBD||aging-6/NN	prep_about||assessed-2/VBD||hiv/aids-8/NNS	conj_and||aging-6/NN||hiv/aids-8/NNS	prep_among||assessed-2/VBD||clinicians-11/NNS	nn||district-14/NN||kampala-13/NN	prep_in||clinicians-11/NNS||district-14/NN	appos||district-14/NN||uganda-16/NN	aids--1||hiv--1||no||we assessed for knowledge about aging and hiv/aids, among clinicians in kampala district, uganda.
prep_in||beneficial-8/JJ||contrast-2/NN	nsubj||beneficial-8/JJ||aprotinin-4/NN	aux||beneficial-8/JJ||might-5/MD	advmod||beneficial-8/JJ||probably-6/RB	cop||beneficial-8/JJ||be-7/VB	root||ROOT-0/null||beneficial-8/JJ	amod||surgery-13/NN||high-10/JJ	nn||surgery-13/NN||risk-11/NN	amod||surgery-13/NN||cardiac-12/JJ	prep_in||beneficial-8/JJ||surgery-13/NN	mark||reduces-16/VBZ||as-14/IN	nsubj||reduces-16/VBZ||it-15/PRP	advcl||beneficial-8/JJ||reduces-16/VBZ	dobj||reduces-16/VBZ||risk-17/NN	nn||complications-22/NNS||transfusion-19/NN	conj_and||transfusion-19/NN||bleeding-21/NN	nn||complications-22/NNS||bleeding-21/NN	prep_of||risk-17/NN||complications-22/NNS	bleeding-21||aprotinin-4||yes||in contrast, aprotinin might probably be beneficial in high risk cardiac surgery as it reduces risk of transfusion and bleeding complications.
det||effect-2/NN||the-1/DT	nsubjpass||evaluated-27/VBN||effect-2/NN	det||extract-6/NN||the-4/DT	nn||extract-6/NN||ethanol-5/NN	prep_of||effect-2/NN||extract-6/NN	det||motility-9/NN||the-8/DT	prep_on||extract-6/NN||motility-9/NN	det||git-12/NN||the-11/DT	prep_of||motility-9/NN||git-12/NN	prep_in||git-12/NN||mice-14/NNS	vmod||mice-14/NNS||using-15/VBG	det||method-19/NN||the-16/DT	nn||method-19/NN||charcoal-17/NN	nn||method-19/NN||plug-18/NN	dobj||using-15/VBG||method-19/NN	amod||diarrhoea-23/NN||castoroil-21/JJ	nn||diarrhoea-23/NN||induced-22/NN	dobj||using-15/VBG||diarrhoea-23/NN	conj_and||method-19/NN||diarrhoea-23/NN	prep_in||method-19/NN||rats-25/NNS	auxpass||evaluated-27/VBN||was-26/VBD	root||ROOT-0/null||evaluated-27/VBN	diarrhoea-23||castoroil-21||no||the effect of the ethanol extract on the motility of the git in mice using the charcoal plug method and castoroil induced diarrhoea in rats was evaluated.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||alpha-tocopherol-2||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â€“69 years using a 2 ã— 2 factorial design.
det||emergence-3/NN||the-1/DT	amod||emergence-3/NN||recent-2/JJ	nsubj||raised-12/VBN||emergence-3/NN	det||influenzavirus-7/NNS||the-5/DT	amod||influenzavirus-7/NNS||h5n1-6/JJ	prep_of||emergence-3/NN||influenzavirus-7/NNS	nn||reservoirs-10/NNS||avian-9/NN	prep_from||influenzavirus-7/NNS||reservoirs-10/NNS	aux||raised-12/VBN||has-11/VBZ	root||ROOT-0/null||raised-12/VBN	dobj||raised-12/VBN||concern-13/NN	amod||strains-17/NNS||future-15/JJ	nn||strains-17/NNS||influenza-16/NN	prep_about||raised-12/VBN||strains-17/NNS	amod||virulence-20/NN||high-19/JJ	prep_of||strains-17/NNS||virulence-20/NN	nsubj||infect-25/VB||virulence-20/NN	amod||virulence-20/NN||emerging-21/VBG	aux||infect-25/VB||could-23/MD	advmod||infect-25/VB||easily-24/RB	rcmod||virulence-20/NN||infect-25/VB	dobj||infect-25/VB||humans-26/NNS	h5n1-6||influenzavirus-7||no||the recent emergence of the h5n1 influenzavirus from avian reservoirs has raised concern about future influenza strains of high virulence emerging that could easily infect humans.
nsubj||television-17/NN||resources-1/NNS	prep_of||resources-1/NNS||information-3/NN	prep_from||available-15/JJ||information-3/NN	nn||behaviors-9/NNS||knowledge-6/NN	conj_and||knowledge-6/NN||risk-8/NN	nn||behaviors-9/NNS||risk-8/NN	nsubj||available-15/JJ||behaviors-9/NNS	vmod||behaviors-9/NNS||related-10/VBN	prep_to||related-10/VBN||hiv/aids-12/NNS	cop||available-15/JJ||was-13/VBD	advmod||available-15/JJ||most-14/RBS	rcmod||information-3/NN||available-15/JJ	cop||television-17/NN||were-16/VBD	root||ROOT-0/null||television-17/NN	num||%-20/NN||58.6-19/CD	appos||television-17/NN||%-20/NN	prep_among||television-17/NN||msm-23/NN	prepc_followed_by||television-17/NN||by-26/IN	amod||partner-28/NN||sexual-27/JJ	pobj||television-17/NN||partner-28/NN	num||%-31/NN||51.6-30/CD	appos||partner-28/NN||%-31/NN	nn||material-35/NN||publicity-34/NN	pobj||television-17/NN||material-35/NN	conj_and||partner-28/NN||material-35/NN	num||%-38/NN||51.0-37/CD	appos||material-35/NN||%-38/NN	pobj||television-17/NN||internet-41/NN	conj_and||partner-28/NN||internet-41/NN	num||%-44/NN||48.7-43/CD	appos||internet-41/NN||%-44/NN	aids--1||hiv--1||no||resources of information from which knowledge and risk behaviors related to hiv/aids was most available were television (58.6%) among msm, followed by sexual partner (51.6%), publicity material (51.0%) and internet (48.7%).
nsubj||shows-2/VBZ||this-1/DT	root||ROOT-0/null||shows-2/VBZ	amod||potential-4/NN||great-3/JJ	dobj||shows-2/VBZ||potential-4/NN	det||treatment-7/NN||the-6/DT	prep_in||potential-4/NN||treatment-7/NN	amod||carcinoma-10/NN||androgen-independent-9/JJ	prep_of||treatment-7/NN||carcinoma-10/NN	prep_of||carcinoma-10/NN||prostate-12/NN	nn||nanosuspensions-15/NNS||oridonin-14/NN	prep_by||shows-2/VBZ||nanosuspensions-15/NNS	carcinoma-10||androgen--1||no_rel||this shows great potential in the treatment of androgen-independent carcinoma of prostate by oridonin nanosuspensions.
advmod||observed-34/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-34/VBN||correlation-11/NN	amod||antigen-15/NN||hepatitisb-13/JJ	nn||antigen-15/NN||surface-14/NN	prep_between||correlation-11/NN||antigen-15/NN	appos||antigen-15/NN||hbsag-17/NN	vmod||correlation-11/NN||stimulated-19/VBN	amod||expression-22/NN||il-2-20/JJ	nn||expression-22/NN||gene-21/NN	dobj||stimulated-19/VBN||expression-22/NN	advmod||detectable-25/JJ||as-24/RB	dobj||stimulated-19/VBN||detectable-25/JJ	amod||expression-22/NN||detectable-25/JJ	conj_and||expression-22/NN||detectable-25/JJ	prep_in||detectable-25/JJ||wb-27/NN	amod||titers-32/NNS||specific-30/JJ	nn||titers-32/NNS||antibody-31/NN	dobj||stimulated-19/VBN||titers-32/NNS	conj_and||expression-22/NN||titers-32/NNS	auxpass||observed-34/VBN||was-33/VBD	root||ROOT-0/null||observed-34/VBN	prep_in||observed-34/VBN||donors-36/NNS	vmod||donors-36/NNS||vaccinated-37/VBN	prep_against||vaccinated-37/VBN||hepatitisbvirus-39/NNS	appos||hepatitisbvirus-39/NNS||hbv-41/NN	num||months-45/NNS||six-44/CD	prep_between||hepatitisbvirus-39/NNS||months-45/NNS	num||years-48/NNS||twenty-47/CD	prep_between||hepatitisbvirus-39/NNS||years-48/NNS	conj_and||months-45/NNS||years-48/NNS	det||tests-51/NNS||the-50/DT	prep_before||vaccinated-37/VBN||tests-51/NNS	hbv-41||hepatitisbvirus-39||no||importantly, a highly significant (p = 0.000009) correlation between hepatitisb surface antigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisbvirus (hbv) between six months and twenty years before the tests.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mark||approach-8/VBP||whether-3/IN	det||transfer-7/NN||an-4/DT	amod||transfer-7/NN||antiangiogenic-5/JJ	nn||transfer-7/NN||gene-6/NN	nsubj||approach-8/VBP||transfer-7/NN	ccomp||investigated-2/VBD||approach-8/VBP	xcomp||approach-8/VBP||using-9/VBG	det||beauty-12/NN||the-10/DT	amod||beauty-12/NN||sleeping-11/VBG	dobj||using-9/VBG||beauty-12/NN	appos||beauty-12/NN||sb-14/NN	nn||system-17/NN||transposon-16/NN	nsubjpass||used-20/VBN||system-17/NN	nsubj||inhibit-22/VB||system-17/NN	aux||used-20/VBN||could-18/MD	auxpass||used-20/VBN||be-19/VB	rcmod||beauty-12/NN||used-20/VBN	aux||inhibit-22/VB||to-21/TO	xcomp||used-20/VBN||inhibit-22/VB	nsubj||metastatic-26/JJ||growth-23/NN	prep_of||growth-23/NN||colorectaltumors-25/NNS	xcomp||inhibit-22/VB||metastatic-26/JJ	det||liver-29/NN||the-28/DT	prep_to||metastatic-26/JJ||liver-29/NN	colorectaltumors-25||sb-14||no_rel||we investigated whether an antiangiogenic gene transfer approach using the sleeping beauty (sb) transposon system could be used to inhibit growth of colorectaltumors metastatic to the liver.
mark||use-14/VBP||although-1/IN	amod||groups-4/NNS||different-3/JJ	prep_in||use-14/VBP||groups-4/NNS	det||severeacuterespiratorysyndrome-coronavirus-8/NNS||the-6/DT	amod||severeacuterespiratorysyndrome-coronavirus-8/NNS||coronaviruses-7/JJ	nsubj||use-14/VBP||severeacuterespiratorysyndrome-coronavirus-8/NNS	appos||severeacuterespiratorysyndrome-coronavirus-8/NNS||sars-cov-10/NNP	conj_and||severeacuterespiratorysyndrome-coronavirus-8/NNS||nl63-13/NNS	nsubj||use-14/VBP||nl63-13/NNS	advcl||enzyme-21/VBP||use-14/VBP	det||receptor-17/NN||the-15/DT	amod||receptor-17/NN||same-16/JJ	dobj||use-14/VBP||receptor-17/NN	nn||converting-20/NNP||angiotensin-19/NNP	nsubj||enzyme-21/VBP||converting-20/NNP	root||ROOT-0/null||enzyme-21/VBP	dep||enzyme-21/VBP||ace-23/VB	dobj||enzyme-21/VBP||-2-25/CD	prep_for||enzyme-21/VBP||entry-28/NN	det||cell-32/NN||the-30/DT	nn||cell-32/NN||host-31/NN	prep_into||entry-28/NN||cell-32/NN	severeacuterespiratorysyndrome--1||coronaviruses-7||no||although in different groups, the coronaviruses severeacuterespiratorysyndrome-coronavirus (sars-cov) and nl63 use the same receptor, angiotensin converting enzyme (ace)-2, for entry into the host cell.
nsubj||‰-13/VBP||subjects-1/NNS	npadvmod||-LSB--5/JJ||resistant-3/NN	npadvmod||-LSB--5/JJ||hypertension-4/NN	amod||â-12/NN||-LSB--5/JJ	nn||â-12/NN||clinic-6/NN	nn||â-12/NN||blood-7/NN	nn||â-12/NN||pressure-8/NN	discourse||â-12/NN||bp-10/UH	prep_with||subjects-1/NNS||â-12/NN	root||ROOT-0/null||‰-13/VBP	dep||‰-13/VBP||¥-14/SYM	num||mm-16/NN||140/90-15/CD	npadvmod||hg-17/RB||mm-16/NN	advmod||‰-13/VBP||hg-17/RB	poss||‰-20/NN||â-19/PRP$	prep_on||‰-13/VBP||‰-20/NN	dep||medications-24/NNS||¥-21/SYM	num||medications-24/NNS||3-22/CD	amod||medications-24/NNS||antihypertensive-23/JJ	dep||‰-20/NN||medications-24/NNS	det||diuretic-29/NN||a-27/DT	amod||diuretic-29/NN||thiazide-28/JJ	prep_including||‰-13/VBP||diuretic-29/NN	nn||-LSB--32/NN||osa-31/NN	prep_including||‰-13/VBP||-LSB--32/NN	conj_and||diuretic-29/NN||-LSB--32/NN	vmod||diuretic-29/NN||defined-33/VBN	mark||â-41/VBP||as-34/IN	det||index-37/NN||an-35/DT	nn||index-37/NN||apneahypopnea-36/NN	nsubj||â-41/VBP||index-37/NN	discourse||index-37/NN||ahi-39/UH	advcl||defined-33/VBN||â-41/VBP	dep||15-44/CD||‰-42/SYM	punct||15-44/CD||¥-43/:	dep||â-41/VBP||15-44/CD	advmod||had-46/VBD||-RSB--45/RB	dep||15-44/CD||had-46/VBD	amod||polysomnography-50/NN||full-47/JJ	amod||polysomnography-50/NN||diagnostic-48/JJ	dobj||had-46/VBD||polysomnography-50/NN	cc||8-53/CD||and-52/CC	num||weeks-54/NNS||8-53/CD	prep_before||had-46/VBD||weeks-54/NNS	mark||added-65/VBN||after-55/IN	nsubjpass||added-65/VBN||spironolactone-56/NN	dep||spironolactone-56/NN||25â-58/VBG	dobj||25â-58/VBG||$-59/$	num||$-59/$||50-61/CD	advmod||25â-58/VBG||mg/day-62/RB	auxpass||added-65/VBN||was-64/VBD	advcl||had-46/VBD||added-65/VBN	poss||therapy-70/NN||their-67/PRP$	amod||therapy-70/NN||ongoing-68/JJ	nn||therapy-70/NN||antihypertensive-69/NN	prep_to||added-65/VBN||therapy-70/NN	hypertension-4||spironolactone-56||yes||subjects with resistant hypertension [clinic blood pressure (bp) â‰¥140/90 mm hg on â‰¥3 antihypertensive medications, including a thiazide diuretic and osa [defined as an apneahypopnea index (ahi) â‰¥ 15] had full diagnostic, polysomnography before and 8 weeks after spironolactone (25â€“50 mg/day) was added to their ongoing antihypertensive therapy.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||safety-4/NN||the-3/DT	dobj||compare-2/VB||safety-4/NN	dobj||compare-2/VB||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	amod||ointment-10/NN||loteprednoletabonate-8/JJ	amod||ointment-10/NN||ophthalmic-9/JJ	prep_of||safety-4/NN||ointment-10/NN	number||%-12/NN||0.5-11/CD	amod||ointment-10/NN||%-12/NN	amod||ointment-15/NN||le-14/JJ	appos||ointment-10/NN||ointment-15/NN	det||formulation-22/NN||a-18/DT	amod||formulation-22/NN||new-19/JJ	amod||formulation-22/NN||topical-20/JJ	nn||formulation-22/NN||ointment-21/NN	appos||ointment-10/NN||formulation-22/NN	prep_with||compare-2/VB||vehicle-25/NN	det||treatment-28/NN||the-27/DT	prep_for||vehicle-25/NN||treatment-28/NN	prep_of||treatment-28/NN||inflammation-30/NN	prep_of||treatment-28/NN||pain-32/NN	conj_and||inflammation-30/NN||pain-32/NN	nn||surgery-35/NN||cataract-34/NN	prep_following||vehicle-25/NN||surgery-35/NN	cataract-34||loteprednoletabonate-8||no_rel||to compare the safety and efficacy of loteprednoletabonate ophthalmic ointment 0.5% (le ointment), a new topical ointment formulation, with vehicle for the treatment of inflammation and pain following cataract surgery.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	dobj||evaluate-2/VB||barriers-3/NNS	vmod||barriers-3/NNS||preventing-4/VBG	amod||women-6/NNS||pregnant-5/JJ	dobj||preventing-4/VBG||women-6/NNS	prepc_from||preventing-4/VBG||using-8/VBG	amod||nets-10/NNS||insecticide-treated-9/JJ	dobj||using-8/VBG||nets-10/NNS	appos||nets-10/NNS||itn-12/NN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||presumptive-16/NN	nsubj||promoting-36/VBG||treatment-17/NN	appos||treatment-17/NN||ipt-19/NN	amod||sp-24/NN||sulphadoxine-pyrimethamine-22/JJ	prep_with||treatment-17/NN||sp-24/NN	num||years-27/NNS||5-26/CD	dep||sp-24/NN||years-27/NNS	det||launch-30/NN||the-29/DT	prep_after||sp-24/NN||launch-30/NN	det||strategy-35/NN||the-32/DT	amod||strategy-35/NN||national-33/JJ	nn||strategy-35/NN||malaria-34/NN	prep_of||launch-30/NN||strategy-35/NN	conj_and||evaluate-2/VB||promoting-36/VBG	det||measures-38/NNS||these-37/DT	dobj||promoting-36/VBG||measures-38/NNS	prep_in||promoting-36/VBG||kenya-40/NN	malaria-34||pyrimethamine--1||yes||to evaluate barriers preventing pregnant women from using insecticide-treated nets (itn) and intermittent presumptive treatment (ipt) with sulphadoxine-pyrimethamine (sp) 5 years after the launch of the national malaria strategy promoting these measures in kenya.
amod||status-2/NN||hiv/aids-1/JJ	nsubjpass||known-4/VBN||status-2/NN	auxpass||known-4/VBN||was-3/VBD	ccomp||reported-19/VBD||known-4/VBN	amod||children-11/NNS||68-6/CD	num||%-9/NN||17.4-8/CD	appos||children-11/NNS||%-9/NN	agent||known-4/VBN||children-11/NNS	nn||caretakers-18/NNS||93-13/CD	num||%-16/NN||29-15/CD	appos||caretakers-18/NNS||%-16/NN	nsubj||reported-19/VBD||caretakers-18/NNS	root||ROOT-0/null||reported-19/VBD	xcomp||reported-19/VBD||knowing-20/VBG	det||child-22/NN||the-21/DT	poss||status-48/NN||child-22/NN	amod||status-48/NN||serostatus-24/JJ	num||years-26/NNS||two-25/CD	npadvmod||serostatus-24/JJ||years-26/NNS	poss||survey-30/NN||our-29/PRP$	prep_prior_to||serostatus-24/JJ||survey-30/NN	appos||survey-30/NN||180-32/CD	mark||told-44/VBN||180-32/CD	num||%-35/NN||46.2-34/CD	appos||180-32/CD||%-35/NN	nsubj||said-38/VBD||respondents-37/NNS	rcmod||180-32/CD||said-38/VBD	det||child-41/NN||the-40/DT	nsubjpass||told-44/VBN||child-41/NN	aux||told-44/VBN||should-42/MD	auxpass||told-44/VBN||be-43/VB	ccomp||said-38/VBD||told-44/VBN	nn||hiv/aids-47/NNS||his/her-46/NN	prep_about||told-44/VBN||hiv/aids-47/NNS	dobj||knowing-20/VBG||status-48/NN	advmod||older-52/JJR||when-49/WRB	nsubj||older-52/JJR||he/she-50/NN	cop||older-52/JJR||is-51/VBZ	rcmod||child-22/NN||older-52/JJR	ccomp||status-48/NN||older-52/JJR	num||years-55/NNS||14-54/CD	prep_than||older-52/JJR||years-55/NNS	prep_of||years-55/NNS||age-57/NN	aids--1||hiv--1||no||hiv/aids status was known by 68 (17.4%) children, 93 (29%) caretakers reported knowing the child's serostatus two years prior to our survey, 180 (46.2%) respondents said that the child should be told about his/her hiv/aids status when he/she is older than 14 years of age.
amod||concentration-3/NN||endogenous-1/JJ	nn||concentration-3/NN||formaldehyde-2/NN	nsubj||increased-4/VBD||concentration-3/NN	root||ROOT-0/null||increased-4/VBD	advmod||increased-4/VBD||significantly-5/RB	det||lines-12/NNS||the-7/DT	amod||lines-12/NNS||cultured-8/JJ	nn||lines-12/NNS||breast-9/NN	nn||lines-12/NNS||cancer-10/NN	nn||lines-12/NNS||cell-11/NN	prep_in||increased-4/VBD||lines-12/NNS	prep_in||lines-12/NNS||vitro-14/NNP	det||marrow-19/NN||the-17/DT	nn||marrow-19/NN||bone-18/NN	prep_in||increased-4/VBD||marrow-19/NN	prepc_of||marrow-19/NN||breast-21/VBG	amod||model-26/NN||mrmt-1-22/JJ	nn||model-26/NN||bone-23/NN	nn||model-26/NN||cancer-24/NN	nn||model-26/NN||pain-25/NN	dobj||breast-21/VBG||model-26/NN	prep_in||breast-21/VBG||rats-28/NNS	prep_in||breast-21/VBG||tissues-31/NNS	conj_and||rats-28/NNS||tissues-31/NNS	nn||cancer-34/NN||breast-33/NN	prep_from||tissues-31/NNS||cancer-34/NN	nn||patients-38/NNS||lung-36/NN	nn||patients-38/NNS||cancer-37/NN	prep_from||tissues-31/NNS||patients-38/NNS	conj_and||cancer-34/NN||patients-38/NNS	prep_in||breast-21/VBG||vivo-40/NN	cancer-37||formaldehyde-2||no_rel||endogenous formaldehyde concentration increased significantly in the cultured breast cancer cell lines in vitro , in the bone marrow of breast mrmt-1 bone cancer pain model in rats and in tissues from breast cancer and lung cancer patients in vivo .
amod||prophylaxis-8/NNS||mefloquine-1/JJ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||marketed-4/JJ	nn||drug-6/NN||anti-malaria-5/NN	appos||prophylaxis-8/NNS||drug-6/NN	nsubj||has-9/VBZ||prophylaxis-8/NNS	root||ROOT-0/null||has-9/VBZ	det||risk-12/NN||a-10/DT	amod||risk-12/NN||high-11/JJ	dobj||has-9/VBZ||risk-12/NN	prepc_of||risk-12/NN||causing-14/VBG	amod||events-16/NNS||adverse-15/JJ	dobj||causing-14/VBG||events-16/NNS	malaria--1||mefloquine-1||yes||mefloquine (a marketed anti-malaria drug) prophylaxis has a high risk of causing adverse events.
ccomp||insulinresistance-22/VBP||the-2/NN	dep||appears-9/VBZ||freet4.tsh-5/VBG	nsubj||appears-9/VBZ||product-8/NN	nsubj||predictor-15/NN||product-8/NN	rcmod||the-2/NN||appears-9/VBZ	aux||predictor-15/NN||to-10/TO	cop||predictor-15/NN||be-11/VB	det||predictor-15/NN||an-12/DT	advmod||stronger-14/JJR||even-13/RB	amod||predictor-15/NN||stronger-14/JJR	xcomp||appears-9/VBZ||predictor-15/NN	dep||the-2/NN||of-16/IN	pobj||of-16/IN||dap-17/NN	nsubj||insulinresistance-22/VBP||independently-19/NNP	prep_of||independently-19/NNP||homa-21/NN	root||ROOT-0/null||insulinresistance-22/VBP	dobj||insulinresistance-22/VBP||index-23/NN	dobj||insulinresistance-22/VBP||obesity-25/NN	conj_and||index-23/NN||obesity-25/NN	obesity-25||tsh--1||no_rel||" the ""freet4.tsh"" product appears to be an even stronger predictor of dap, independently of homa insulinresistance index and obesity."
aux||determine-2/VB||to-1/TO	advcl||tested-16/VBD||determine-2/VB	nn||prevalence-4/NN||hiv-3/NN	dobj||determine-2/VB||prevalence-4/NN	dobj||determine-2/VB||place-6/NN	conj_and||prevalence-4/NN||place-6/NN	prep_of||prevalence-4/NN||exposure-8/NN	amod||migrants-11/NNS||illegal-10/JJ	prep_for||determine-2/VB||migrants-11/NNS	prep_in||migrants-11/NNS||italy-13/NN	nsubj||tested-16/VBD||we-15/PRP	root||ROOT-0/null||tested-16/VBD	num||migrants-20/NNS||3,003-17/CD	amod||migrants-20/NNS||illegal-18/JJ	nn||migrants-20/NNS||adult-19/NN	dobj||tested-16/VBD||migrants-20/NNS	prep_for||tested-16/VBD||hiv-22/NN	nsubj||hivpositive-30/JJ||29-24/CD	num||%-27/NN||0.97-26/CD	appos||29-24/CD||%-27/NN	cop||hivpositive-30/JJ||were-29/VBD	parataxis||tested-16/VBD||hivpositive-30/JJ	hivpositive-30||hiv-22||no||to determine hiv prevalence and place of exposure for illegal migrants in italy, we tested 3,003 illegal adult migrants for hiv; 29 (0.97%) were hivpositive.
nsubj||examine-2/VBP||we-1/PRP	root||ROOT-0/null||examine-2/VBP	dobj||examine-2/VBP||relationships-3/NNS	nn||trends-6/NNS||market-5/NN	prep_between||relationships-3/NNS||trends-6/NNS	nn||organization-10/NN||world-8/NN	nn||organization-10/NN||health-9/NN	nsubj||hiv/aids-14/VBZ||organization-10/NN	nsubj||unitaid-71/VBD||organization-10/NN	dep||organization-10/NN||who-12/WP	conj_and||examine-2/VBP||hiv/aids-14/VBZ	nn||guidelines-16/NNS||treatment-15/NN	dobj||hiv/aids-14/VBZ||guidelines-16/NNS	nsubj||prequalification-19/VBP||guidelines-16/NNS	rcmod||guidelines-16/NNS||prequalification-19/VBP	dobj||prequalification-19/VBP||programme-20/NN	nsubj||prequal-23/VBP||who-22/WP	dep||programme-20/NN||prequal-23/VBP	amod||states-27/NNS||united-26/VBN	dobj||prequalification-19/VBP||states-27/NNS	conj_and||programme-20/NN||states-27/NNS	dep||states-27/NNS||us-29/PRP	dep||programme-20/NN||food-31/NN	nn||administration-34/NN||drug-33/NN	dobj||prequalification-19/VBP||administration-34/NN	conj_and||programme-20/NN||administration-34/NN	appos||administration-34/NN||fda-36/NN	dep||administration-34/NN||approvals-38/NNS	amod||policies-42/NNS||procurement-41/JJ	dobj||hiv/aids-14/VBZ||policies-42/NNS	conj_and||guidelines-16/NNS||policies-42/NNS	nsubj||prequalification-19/VBP||policies-42/NNS	det||fund-46/NN||the-44/DT	amod||fund-46/NN||global-45/JJ	prep_of||policies-42/NNS||fund-46/NN	aux||fight-48/VB||to-47/TO	vmod||fund-46/NN||fight-48/VB	dobj||fight-48/VB||aids-49/NNS	appos||aids-49/NNS||tuberculosis-51/NNP	dobj||fight-48/VB||malaria-54/NN	conj_and||aids-49/NNS||malaria-54/NN	appos||malaria-54/NN||gfatm-56/NNP	nsubj||plan-63/NN||us-59/PRP	poss||plan-63/NN||president-60/NN	nn||plan-63/NN||emergency-62/NN	xcomp||fight-48/VB||plan-63/NN	nn||relief-66/NN||aids-65/NNS	prep_for||plan-63/NN||relief-66/NN	appos||relief-66/NN||pepfar-68/NN	conj_and||examine-2/VBP||unitaid-71/VBD	conj_and||hiv/aids-14/VBZ||unitaid-71/VBD	aids-65||hiv--1||no||we examine relationships between market trends and world health organization (who) hiv/aids treatment guidelines; who prequalification programme (who prequal) and united states (us) food and drug administration (fda) approvals; and procurement policies of the global fund to fight aids, tuberculosis, and malaria (gfatm), us president's emergency plan for aids relief (pepfar) and unitaid.
det||development-2/NN||the-1/DT	nsubj||step-24/NN||development-2/NN	cc||logic-5/CD||or-4/CC	num||gate-6/NN||logic-5/CD	prep_of||development-2/NN||gate-6/NN	prepc_based_on||gate-6/NN||on-8/IN	amod||strategy-10/NN||dual-aptamer-9/JJ	pobj||gate-6/NN||strategy-10/NN	num||signals-15/NNS||two-12/CD	amod||signals-15/NNS||chemical-13/JJ	nn||signals-15/NNS||input-14/NN	pobj||gate-6/NN||signals-15/NNS	conj_and||strategy-10/NN||signals-15/NNS	dep||gate-6/NN||prpres-17/JJ	dep||gate-6/NN||gdn-hcl-19/JJ	conj_and||prpres-17/JJ||gdn-hcl-19/JJ	cop||step-24/NN||is-21/VBZ	det||step-24/NN||an-22/DT	amod||step-24/NN||important-23/JJ	root||ROOT-0/null||step-24/NN	det||design-27/NN||the-26/DT	prep_toward||step-24/NN||design-27/NN	amod||diagnosis-30/NN||priondiseases-29/JJ	prep_of||design-27/NN||diagnosis-30/NN	nn||systems-33/NNS||therapy-32/NN	prep_of||design-27/NN||systems-33/NNS	conj_and||diagnosis-30/NN||systems-33/NNS	chemical-13||priondiseases-29||no_rel||the development of or logic gate based on dual-aptamer strategy and two chemical input signals (prpres and gdn-hcl) is an important step toward the design of priondiseases diagnosis and therapy systems.
amod||pufa-3/NN||fishoil-1/JJ	amod||pufa-3/NN||n-3-2/JJ	nsubjpass||consumed-9/VBN||pufa-3/NN	amod||daily-6/NN||3g-5/JJ	appos||pufa-3/NN||daily-6/NN	auxpass||consumed-9/VBN||were-8/VBD	root||ROOT-0/null||consumed-9/VBN	prep_during||consumed-9/VBN||5weeks-11/NNS	vmod||5weeks-11/NNS||separated-12/VBN	det||period-18/NN||a-14/DT	num||period-18/NN||5-15/CD	nn||period-18/NN||week-16/NN	nn||period-18/NN||washout-17/NN	agent||separated-12/VBN||period-18/NN	det||placebo-22/NN||a-20/DT	amod||placebo-22/NN||cross-over-21/JJ	prep_in||separated-12/VBN||placebo-22/NN	vmod||placebo-22/NN||controlled-23/VBN	dobj||controlled-23/VBN||study-24/NN	num||middle-29/NN||40-27/CD	amod||middle-29/NN||healthy-28/JJ	prep_including||controlled-23/VBN||middle-29/NN	vmod||middle-29/NN||aged-30/VBN	amod||subjects-33/NNS||elderly-32/JJ	prep_to||aged-30/VBN||subjects-33/NNS	cross--1||fishoil-1||no_rel||fishoil n-3 pufa (3g daily) were consumed during 5weeks separated by a 5 week washout period in a cross-over placebo controlled study, including 40 healthy middle aged to elderly subjects.
det||essence-2/NN||the-1/DT	nsubj||is-6/VBZ||essence-2/NN	poss||research-5/NN||our-4/PRP$	prep_of||essence-2/NN||research-5/NN	root||ROOT-0/null||is-6/VBZ	mark||characterized-28/VBN||that-7/IN	nsubjpass||characterized-28/VBN||patients-8/NNS	nsubjpass||characterized-28/VBN||patients-8/NNS	prep_with||patients-8/NNS||t1dm-10/NN	prep_with||patients-8/NNS||ht-12/NN	conj_and||t1dm-10/NN||ht-12/NN	prep_with||patients-8/NNS||microalbuminuria-15/NN	conj_and||t1dm-10/NN||microalbuminuria-15/NN	discourse||microalbuminuria-15/NN||ma-17/UH	conj_and||t1dm-10/NN||diabeticretinopathy-20/NN	conj_and||microalbuminuria-15/NN||diabeticretinopathy-20/NN	discourse||microalbuminuria-15/NN||dr-22/UH	appos||patients-8/NNS||ma/dr-25/NN	auxpass||characterized-28/VBN||are-27/VBP	ccomp||is-6/VBZ||characterized-28/VBN	ccomp||is-6/VBZ||characterized-28/VBN	conj_and||characterized-28/VBN||characterized-28/VBN	det||level-33/NN||a-30/DT	advmod||higher-32/JJR||significantly-31/RB	amod||level-33/NN||higher-32/JJR	agent||characterized-28/VBN||level-33/NN	prep_of||level-33/NN||vegf-35/NN	num||â-38/NN||340.23-37/CD	dep||vegf-35/NN||â-38/NN	punct||â-38/NN||±-39/:	npadvmod||â-41/RB||93.22-40/CD	prep||â-38/NN||â-41/RB	pobj||â-41/RB||$-42/$	num||$-42/$||‰-43/CD	advmod||â-41/RB||pgâ-44/RB	num||$-48/$||$-45/$	number||mlâ-47/CD||‰-46/CD	num||$-45/$||mlâ-47/CD	pobj||â-41/RB||$-48/$	num||$-48/$||1-50/CD	nn||serum-54/NN||blood-53/NN	prep_in||characterized-28/VBN||serum-54/NN	prep_in||serum-54/NN||comparison-56/NN	det||group-59/NN||the-58/DT	prep_with||characterized-28/VBN||group-59/NN	amod||patients-62/NNS||t1dm-61/JJ	prep_of||group-59/NN||patients-62/NNS	prep_without||characterized-28/VBN||ht-64/FW	prep_without||characterized-28/VBN||ma/dr-66/FW	conj_and||ht-64/FW||ma/dr-66/FW	num||â-69/NN||183.6-68/CD	dep||characterized-28/VBN||â-69/NN	punct||â-69/NN||±-70/:	num||â-72/NN||96.6-71/CD	dep||â-69/NN||â-72/NN	num||$-76/NNS||$-73/$	number||pgâ-75/CD||‰-74/CD	num||$-73/$||pgâ-75/CD	dep||â-72/NN||$-76/NNS	punct||â-69/NN||‰-77/:	dep||â-69/NN||mlâ-78/VBN	dobj||mlâ-78/VBN||$-79/$	num||$-79/$||1-81/CD	amod||controls-86/NNS||healthy-85/JJ	prep_with||characterized-28/VBN||controls-86/NNS	num||â-89/NN||145.32-88/CD	dep||controls-86/NNS||â-89/NN	punct||â-89/NN||±-90/:	npadvmod||â-92/RB||75.58-91/CD	prep||â-89/NN||â-92/RB	pobj||â-92/RB||$-93/$	num||$-93/$||‰-94/CD	advmod||â-92/RB||pgâ-95/RB	num||$-99/$||$-96/$	number||mlâ-98/CD||‰-97/CD	num||$-96/$||mlâ-98/CD	pobj||â-92/RB||$-99/$	num||$-99/$||1-101/CD	dr-22||essence-2||no_rel||the essence of our research is that patients with t1dm and ht and with microalbuminuria (ma) and diabeticretinopathy (dr) (ma/dr) are characterized by a significantly higher level of vegf (340.23â±93.22â€‰pgâ€‰mlâ€“1) in blood serum in comparison with the group of t1dm patients without ht and ma/dr (183.6â±96.6â€‰pgâ€‰mlâ€“1) and with healthy controls (145.32â±75.58â€‰pgâ€‰mlâ€“1).
nsubj||had-2/VBD||trimethoprim-1/NN	nsubj||had-20/VBD||trimethoprim-1/NN	root||ROOT-0/null||had-2/VBD	det||advantage-6/NN||a-3/DT	advmod||limited-5/JJ||very-4/RB	amod||advantage-6/NN||limited-5/JJ	dobj||had-2/VBD||advantage-6/NN	nn||extract-9/NNS||cranberry-8/NN	prep_over||advantage-6/NN||extract-9/NNS	det||prevention-12/NN||the-11/DT	prep_in||had-2/VBD||prevention-12/NN	amod||utis-15/NNS||recurrent-14/JJ	prep_of||prevention-12/NN||utis-15/NNS	amod||women-18/NNS||older-17/JJR	prep_in||utis-15/NNS||women-18/NNS	conj_and||had-2/VBD||had-20/VBD	amod||effects-23/NNS||more-21/JJR	amod||effects-23/NNS||adverse-22/JJ	dobj||had-20/VBD||effects-23/NNS	utis-15||trimethoprim-1||yes||trimethoprim had a very limited advantage over cranberry extract in the prevention of recurrent utis in older women and had more adverse effects.
nsubj||disease-10/NN||infectiousbursaldisease-1/NN	appos||infectiousbursaldisease-1/NN||ibd-3/NN	cop||disease-10/NN||is-5/VBZ	det||disease-10/NN||a-6/DT	advmod||contagious-8/JJ||highly-7/RB	amod||disease-10/NN||contagious-8/JJ	nn||disease-10/NN||immunosuppressive-9/NN	root||ROOT-0/null||disease-10/NN	amod||chickens-13/NNS||young-12/JJ	prep_in||disease-10/NN||chickens-13/NNS	vmod||chickens-13/NNS||caused-14/VBN	amod||virus-17/NN||infectiousbursaldisease-16/JJ	agent||caused-14/VBN||virus-17/NN	appos||virus-17/NN||ibdv-19/NNP	infectiousbursaldisease-16||ibdv-19||no||infectiousbursaldisease (ibd) is a highly contagious immunosuppressive disease in young chickens caused by infectiousbursaldisease virus (ibdv).
nsubjpass||recruited-26/VBN||patients-1/NNS	amod||ulcerativecolitis-4/NNS||established-3/VBN	prep_with||patients-1/NNS||ulcerativecolitis-4/NNS	appos||ulcerativecolitis-4/NNS||uc-6/NN	amod||cd-13/NNS||crohn-9/JJ	amod||cd-13/NNS||sdisease-11/JJ	prep_with||patients-1/NNS||cd-13/NNS	conj_and||ulcerativecolitis-4/NNS||cd-13/NNS	nsubj||residents-19/NNS||cd-13/NNS	cop||residents-19/NNS||were-17/VBD	amod||residents-19/NNS||permanent-18/JJ	rcmod||cd-13/NNS||residents-19/NNS	det||districts-23/NNS||these-21/DT	amod||districts-23/NNS||adjoining-22/JJ	prep_of||residents-19/NNS||districts-23/NNS	auxpass||recruited-26/VBN||were-25/VBD	root||ROOT-0/null||recruited-26/VBN	nn||registries-29/NNS||hospital-28/NN	prep_from||recruited-26/VBN||registries-29/NNS	amod||clinics-32/NNS||out-patient-31/JJ	prep_from||recruited-26/VBN||clinics-32/NNS	conj_and||registries-29/NNS||clinics-32/NNS	cd-13||ulcerativecolitis-4||no_rel||patients with established ulcerativecolitis (uc) and crohn'sdisease (cd), who were permanent residents of these adjoining districts, were recruited from hospital registries and out-patient clinics.
amod||responses-3/NNS||ifn-î-1/JJ	amod||responses-3/NNS||³-2/JJ	nsubjpass||measured-15/VBN||responses-3/NNS	nsubjpass||measured-15/VBN||responses-3/NNS	det||mtb-6/NN||the-5/DT	prep_to||responses-3/NNS||mtb-6/NN	amod||mtb-6/NN||antigens-7/JJ	amod||mtb-6/NN||esat-6-9/JJ	conj_and||antigens-7/JJ||esat-6-9/JJ	amod||mtb-6/NN||cfp-10-11/JJ	conj_and||antigens-7/JJ||cfp-10-11/JJ	amod||mtb-6/NN||ppd-13/JJ	conj_and||antigens-7/JJ||ppd-13/JJ	auxpass||measured-15/VBN||were-14/VBD	root||ROOT-0/null||measured-15/VBN	conj_and||measured-15/VBN||measured-15/VBN	det||assay-20/NN||an-17/DT	amod||assay-20/NN||enzyme-linked-18/JJ	nn||assay-20/NN||immunospot-19/NN	agent||measured-15/VBN||assay-20/NN	amod||elispot-24/NN||ifn-î-22/JJ	amod||elispot-24/NN||³-23/JJ	appos||assay-20/NN||elispot-24/NN	prep_at||assay-20/NN||presentation-27/NN	prep_at||measured-15/VBN||one-30/CD	num||one-30/CD||two-32/CD	prep_at||measured-15/VBN||six-34/CD	conj_and||one-30/CD||six-34/CD	pobj||measured-15/VBN||months-35/NNS	prepc_after||measured-15/VBN||starting-37/VBG	amod||treatment-39/NN||anti-tuberculous-38/JJ	dobj||starting-37/VBG||treatment-39/NN	amod||children-42/NNS||hiv-infected-41/JJ	prep_in||starting-37/VBG||children-42/NNS	amod||tb-47/NN||definite-44/JJ	conj_or||definite-44/JJ||probable-46/JJ	amod||tb-47/NN||probable-46/JJ	prep_with||children-42/NNS||tb-47/NN	tuberculous--1||mtb-6||no||ifn-î³ responses to the mtb antigens, esat-6, cfp-10 and ppd were measured by an enzyme-linked immunospot assay (ifn-î³ elispot) at presentation and at one, two and six months after starting anti-tuberculous treatment in hiv-infected children with definite or probable tb.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
nn||culture-3/NN||tissue-2/NN	prep_in||inhibited-10/VBD||culture-3/NN	amod||acid-5/NN||phosphonoacetic-4/JJ	nsubj||inhibited-10/VBD||acid-5/NN	appos||acid-5/NN||paa-7/NN	advmod||inhibited-10/VBD||specifically-9/RB	root||ROOT-0/null||inhibited-10/VBD	nn||synthesis-12/NN||dna-11/NN	dobj||inhibited-10/VBD||synthesis-12/NN	prep_of||synthesis-12/NN||humancytomegalovirus-14/NNS	appos||humancytomegalovirus-14/NNS||cmv-16/NN	amod||cmv-20/NN||murine-19/JJ	prep_of||synthesis-12/NN||cmv-20/NN	conj_and||humancytomegalovirus-14/NNS||cmv-20/NN	nn||cmv-23/NN||simian-22/NN	prep_of||synthesis-12/NN||cmv-23/NN	conj_and||humancytomegalovirus-14/NNS||cmv-23/NN	prep_of||synthesis-12/NN||epstein-barrvirus-25/NNS	conj_and||humancytomegalovirus-14/NNS||epstein-barrvirus-25/NNS	amod||saimiri-29/NNS||herpesvirus-28/JJ	prep_of||synthesis-12/NN||saimiri-29/NNS	conj_and||humancytomegalovirus-14/NNS||saimiri-29/NNS	cmv-23||humancytomegalovirus-14||no||in tissue culture phosphonoacetic acid (paa) specifically inhibited dna synthesis of humancytomegalovirus (cmv), murine cmv, simian cmv, epstein-barrvirus, and herpesvirus saimiri.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
aux||investigate-2/VB||to-1/TO	advcl||tested-41/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-38/VBN||when-31/WRB	nsubjpass||recognized-38/VBN||acquiredimmunedeficiencysyndrome-32/NN	appos||acquiredimmunedeficiencysyndrome-32/NN||aids-34/NNS	auxpass||recognized-38/VBN||was-36/VBD	advmod||recognized-38/VBN||first-37/RB	advcl||investigate-2/VB||recognized-38/VBN	nsubj||tested-41/VBD||we-40/PRP	root||ROOT-0/null||tested-41/VBD	dobj||tested-41/VBD||sera-42/NN	amod||women-46/NNS||310-44/JJ	amod||women-46/NNS||pregnant-45/JJ	prep_from||tested-41/VBD||women-46/NNS	nsubj||participated-48/VBD||women-46/NNS	rcmod||women-46/NNS||participated-48/VBD	det||project-53/NN||the-50/DT	amod||project-53/NN||collaborative-51/JJ	amod||project-53/NN||perinatal-52/JJ	prep_in||participated-48/VBD||project-53/NN	det||1959-1964-57/NN||the-55/DT	nn||1959-1964-57/NN||period-56/NN	prep_during||participated-48/VBD||1959-1964-57/NN	prep_for||1959-1964-57/NN||hiv-59/NN	prep_for||1959-1964-57/NN||htlv-iantibody-61/NN	conj_and||hiv-59/NN||htlv-iantibody-61/NN	acquiredimmunedeficiencysyndrome-32||hiv-59||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquiredimmunedeficiencysyndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-iantibody.
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||‰-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	t2d-52||insulin-46||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â ‰ $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
det||search-3/NN||a-1/DT	amod||search-3/NN||medline-2/JJ	nsubj||reveal-9/VB||search-3/NN	det||literature-6/NN||the-5/DT	prep_of||search-3/NN||literature-6/NN	aux||reveal-9/VB||did-7/VBD	neg||reveal-9/VB||not-8/RB	root||ROOT-0/null||reveal-9/VB	det||report-11/NN||any-10/DT	dobj||reveal-9/VB||report-11/NN	prep_of||report-11/NN||keratomalacia-13/NN	det||feature-18/NN||the-15/DT	amod||feature-18/NN||initial-16/JJ	amod||feature-18/NN||presenting-17/JJ	prep_as||reveal-9/VB||feature-18/NN	nn||acquiredimmunedeficiencysyndrome-22/NN||hiv-20/NN	nn||acquiredimmunedeficiencysyndrome-22/NN||/-21/NN	prep_of||feature-18/NN||acquiredimmunedeficiencysyndrome-22/NN	acquiredimmunedeficiencysyndrome-22||hiv-20||no||a medline search of the literature did not reveal any report of keratomalacia as the initial presenting feature of hiv/ acquiredimmunedeficiencysyndrome.
nsubj||reviewed-3/VBN||we-1/PRP	advmod||reviewed-3/VBN||retrospectively-2/RB	root||ROOT-0/null||reviewed-3/VBN	poss||data-5/NNS||our-4/PRP$	dobj||reviewed-3/VBN||data-5/NNS	prep_of||data-5/NNS||patients-7/NNS	amod||genotype-10/NN||chronichepatitisc-9/JJ	prep_with||reviewed-3/VBN||genotype-10/NN	num||genotype-10/NN||1-11/CD	vmod||genotype-10/NN||treated-12/VBN	amod||±-16/NNP||pegylated-14/JJ	nn||±-16/NNP||interferon-î-15/NNS	prep_with||treated-12/VBN||±-16/NNP	prep_with||treated-12/VBN||ribavirin-18/NNP	conj_and||±-16/NNP||ribavirin-18/NNP	chronichepatitisc-9||ribavirin-18||yes||we retrospectively reviewed our data of patients with chronichepatitisc genotype 1 treated with pegylated interferon-î± and ribavirin.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	speed-30||cataract-45||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
nsubjpass||associated-3/VBN||oxaliplatin/docetaxel-1/NN	auxpass||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	advmod||less-6/JJR||significantly-5/RB	amod||toxicity-12/NN||less-6/JJR	det||grade-9/NN||any-8/DT	dep||less-6/JJR||grade-9/NN	amod||toxicity-12/NN||renal-11/JJ	prep_with||associated-3/VBN||toxicity-12/NN	num||%-15/NN||56-14/CD	dep||toxicity-12/NN||%-15/NN	vmod||%-15/NN||vs-16/VBN	num||%-18/NN||11-17/CD	dobj||vs-16/VBN||%-18/NN	det||fatigue-23/NN||any-21/DT	nn||fatigue-23/NN||grade-22/NN	prep_with||associated-3/VBN||fatigue-23/NN	conj_and||toxicity-12/NN||fatigue-23/NN	num||%-26/NN||81-25/CD	dep||fatigue-23/NN||%-26/NN	vmod||%-26/NN||vs-27/VBN	num||%-29/NN||59-28/CD	dobj||vs-27/VBN||%-29/NN	amod||alopecia-33/NN||complete-32/JJ	prep_with||associated-3/VBN||alopecia-33/NN	conj_and||toxicity-12/NN||alopecia-33/NN	num||%-36/NN||76-35/CD	dep||alopecia-33/NN||%-36/NN	dep||%-36/NN||vs-37/NN	num||%-39/NN||27-38/CD	dep||vs-37/NN||%-39/NN	det||leukopenia-44/NN||any-42/DT	nn||leukopenia-44/NN||grade-43/NN	conj_and||toxicity-12/NN||leukopenia-44/NN	conj_and||alopecia-33/NN||leukopenia-44/NN	num||%-47/NN||84-46/CD	dep||leukopenia-44/NN||%-47/NN	vmod||%-47/NN||vs-48/VBN	num||%-50/NN||61-49/CD	dobj||vs-48/VBN||%-50/NN	nn||leukopenia-55/NN||grade-53/NN	num||leukopenia-55/NN||3/4-54/CD	conj_and||toxicity-12/NN||leukopenia-55/NN	conj_and||alopecia-33/NN||leukopenia-55/NN	num||%-58/NN||44-57/CD	dep||leukopenia-55/NN||%-58/NN	vmod||%-58/NN||vs-59/VBN	num||%-61/NN||14-60/CD	dobj||vs-59/VBN||%-61/NN	prep_with||associated-3/VBN||neutropenia-64/NN	conj_and||toxicity-12/NN||neutropenia-64/NN	num||%-67/NN||56-66/CD	dep||neutropenia-64/NN||%-67/NN	vmod||%-67/NN||vs-68/VBN	num||%-70/NN||27-69/CD	dobj||vs-68/VBN||%-70/NN	neutropenia-64||docetaxel--1||no||oxaliplatin/docetaxel was associated with significantly less (any grade) renal toxicity (56% vs 11%), any grade fatigue (81% vs 59%), complete alopecia (76% vs 27%), any grade leukopenia (84% vs 61%) and grade 3/4 leukopenia (44% vs 14%) and neutropenia (56% vs 27%).
nsubjpass||regulated-9/VBN||iii-2/NN	num||%-6/NN||40-5/CD	prep_over||iii-2/NN||%-6/NN	auxpass||regulated-9/VBN||were-7/VBD	advmod||regulated-9/VBN||similarly-8/RB	root||ROOT-0/null||regulated-9/VBN	prep_in||regulated-9/VBN||vitro-11/NN	prep_in||vitro-11/NN||response-13/NN	preconj||treatment-19/NN||both-15/DT	nn||treatment-19/NN||influenzavirusinfection-16/NN	conj_and||influenzavirusinfection-16/NN||interferon-18/NN	nn||treatment-19/NN||interferon-18/NN	prep_to||regulated-9/VBN||treatment-19/NN	interferon-18||virusinfection--1||no_rel||(iii) over 40% were similarly regulated in vitro in response to both influenzavirusinfection and interferon treatment.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||chloroquine-18||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
nn||abnormalities-2/NNS||glucose-1/NN	nsubjpass||documented-4/VBN||abnormalities-2/NNS	auxpass||documented-4/VBN||were-3/VBD	root||ROOT-0/null||documented-4/VBN	num||%-7/NN||71-6/CD	prep_in||documented-4/VBN||%-7/NN	nn||type2diabetes-10/NNS||patients-9/NNS	prep_of||%-7/NN||type2diabetes-10/NNS	num||%-13/NN||29-12/CD	prep_in||documented-4/VBN||%-13/NN	amod||glucose-17/NN||impaired-15/VBN	amod||glucose-17/NN||fasting-16/JJ	appos||%-13/NN||glucose-17/NN	appos||glucose-17/NN||ifg-19/NN	num||%-23/NN||58-22/CD	prep_in||glucose-17/NN||%-23/NN	prep_in||glucose-17/NN||impairedglucosetolerance-26/NN	conj_and||%-23/NN||impairedglucosetolerance-26/NN	appos||%-23/NN||igt-28/NN	num||%-32/NN||37.5-31/CD	prep_in||glucose-17/NN||%-32/NN	type2diabetes-10||glucose-17||no_rel||glucose abnormalities were documented in 71% of patients type2diabetes in 29%, impaired fasting glucose (ifg) in 58%, and impairedglucosetolerance (igt) in 37.5%.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	rheumatoidarthritis-55||dm-48||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
prepc_based_on||divided-19/VBN||on-2/IN	amod||symptoms-4/NNS||clinical-3/JJ	pobj||divided-19/VBN||symptoms-4/NNS	nn||hormone-10/NN||t4-6/NN	conj_and||t4-6/NN||thyroid-8/NN	nn||hormone-10/NN||thyroid-8/NN	nn||hormone-10/NN||stimulating-9/NN	appos||symptoms-4/NNS||hormone-10/NN	appos||symptoms-4/NNS||tsh-12/NN	dep||symptoms-4/NNS||concentration-14/NN	num||dogs-17/NNS||1,339-16/CD	nsubjpass||divided-19/VBN||dogs-17/NNS	auxpass||divided-19/VBN||were-18/VBD	root||ROOT-0/null||divided-19/VBN	num||groups-22/NNS||six-21/CD	prep_into||divided-19/VBN||groups-22/NNS	npadvmod||hypothyroid-25/JJ||group-23/NN	num||group-23/NN||1-24/CD	amod||groups-22/NNS||hypothyroid-25/JJ	dep||groups-22/NNS||n-27/VBN	dep||149-29/CD||=-28/SYM	ccomp||n-27/VBN||149-29/CD	dep||groups-22/NNS||group-32/NN	num||thyroiditis-35/NNS||2-33/CD	amod||thyroiditis-35/NNS||subclinical-34/JJ	dep||group-32/NN||thyroiditis-35/NNS	dep||groups-22/NNS||n-37/VBN	dep||110-39/CD||=-38/SYM	ccomp||n-37/VBN||110-39/CD	dep||groups-22/NNS||group-42/NN	num||group-42/NN||3-43/CD	amod||group-42/NN||suspicious-44/JJ	nn||illness-48/NN||non-46/NN	amod||illness-48/NN||thyroidal-47/JJ	prep_for||suspicious-44/JJ||illness-48/NN	dep||illness-48/NN||n-50/VBN	dep||691-52/CD||=-51/SYM	ccomp||n-50/VBN||691-52/CD	nn||euthyroid-58/NN||group-55/NN	num||euthyroid-58/NN||4-56/CD	nn||euthyroid-58/NN||biochemical-57/NN	dep||illness-48/NN||euthyroid-58/NN	dep||euthyroid-58/NN||n-60/VBN	dep||138-62/CD||=-61/SYM	ccomp||n-60/VBN||138-62/CD	dep||groups-22/NNS||group-65/NN	num||group-65/NN||5-66/CD	vmod||group-65/NN||hypothyroid-67/VBN	dobj||hypothyroid-67/VBN||dogs-68/NNS	nn||therapy-71/NN||substitution-70/NN	prep_under||hypothyroid-67/VBN||therapy-71/NN	dep||therapy-71/NN||n-73/VBN	dep||141-75/CD||=-74/SYM	ccomp||n-73/VBN||141-75/CD	dep||therapy-71/NN||group-78/NN	num||dogs-81/NNS||6-79/CD	amod||dogs-81/NNS||healthy-80/JJ	dep||group-78/NN||dogs-81/NNS	dep||group-78/NN||n-83/VBN	dep||110-85/CD||=-84/SYM	ccomp||n-83/VBN||110-85/CD	hypothyroid-67||t4-6||yes||based on clinical symptoms, t4 and thyroid stimulating hormone (tsh) concentration, 1,339 dogs were divided into six groups group 1 hypothyroid (n = 149); group 2 subclinical thyroiditis (n = 110); group 3 suspicious for non thyroidal illness (n = 691); group 4 biochemical euthyroid (n = 138); group 5 hypothyroid dogs under substitution therapy (n = 141); group 6 healthy dogs (n = 110).
nsubj||demonstration-5/NN||this-1/DT	cop||demonstration-5/NN||is-2/VBZ	det||demonstration-5/NN||the-3/DT	amod||demonstration-5/NN||first-4/JJ	root||ROOT-0/null||demonstration-5/NN	mark||induces-8/VBZ||that-6/IN	nsubj||induces-8/VBZ||stroke-7/NN	ccomp||demonstration-5/NN||induces-8/VBZ	amod||changes-10/NNS||immediate-9/JJ	dobj||induces-8/VBZ||changes-10/NNS	det||timing-13/NN||the-12/DT	prep_in||induces-8/VBZ||timing-13/NN	amod||secretion-17/NN||pineal-15/JJ	nn||secretion-17/NN||melatonin-16/NN	prep_of||timing-13/NN||secretion-17/NN	vmod||induces-8/VBZ||indicating-19/VBG	mark||impacts-26/VBZ||that-20/IN	amod||infarction-25/NNS||cortical-21/JJ	conj_and||cortical-21/JJ||basal-23/JJ	amod||infarction-25/NNS||basal-23/JJ	nn||infarction-25/NNS||ganglia-24/NN	nsubj||impacts-26/VBZ||infarction-25/NNS	ccomp||indicating-19/VBG||impacts-26/VBZ	det||timing-28/NN||the-27/DT	dobj||impacts-26/VBZ||timing-28/NN	nn||rhythms-31/NNS||melatonin-30/NN	prep_of||timing-28/NN||rhythms-31/NNS	melatonin-30||infarction-25||no_rel||this is the first demonstration that stroke induces immediate changes in the timing of pineal melatonin secretion, indicating that cortical and basal ganglia infarction impacts the timing of melatonin rhythms.
det||strength-2/NN||the-1/DT	nsubj||led-17/VBD||strength-2/NN	det||evidence-5/NN||the-4/DT	prep_of||strength-2/NN||evidence-5/NN	vmod||evidence-5/NN||linking-6/VBG	advmod||linking-6/VBG||concurrency-7/RB	aux||hiv-9/VB||to-8/TO	xcomp||linking-6/VBG||hiv-9/VB	nn||severity-11/NN||epidemic-10/NN	dobj||hiv-9/VB||severity-11/NN	amod||africa-16/NN||southern-13/JJ	conj_and||southern-13/JJ||eastern-15/JJ	amod||africa-16/NN||eastern-15/JJ	prep_in||hiv-9/VB||africa-16/NN	root||ROOT-0/null||led-17/VBD	det||programme-22/NN||the-18/DT	amod||programme-22/NN||joint-19/JJ	amod||programme-22/NN||united-20/JJ	nn||programme-22/NN||nations-21/NNS	dobj||led-17/VBD||programme-22/NN	prep_on||programme-22/NN||hiv/aids-24/NNS	det||community-30/NN||the-26/DT	amod||community-30/NN||southern-27/JJ	nn||community-30/NN||african-28/NN	nn||community-30/NN||development-29/NN	prep_on||programme-22/NN||community-30/NN	conj_and||hiv/aids-24/NNS||community-30/NN	prep_in||led-17/VBD||2006-32/CD	aux||conclude-34/VB||to-33/TO	vmod||led-17/VBD||conclude-34/VB	mark||drivers-57/NNS||that-35/IN	amod||rates-37/NNS||high-36/JJ	nsubj||drivers-57/NNS||rates-37/NNS	amod||partnerships-41/NNS||concurrent-39/JJ	amod||partnerships-41/NNS||sexual-40/JJ	prep_of||rates-37/NNS||partnerships-41/NNS	vmod||rates-37/NNS||combined-43/VBN	amod||rates-46/NNS||low-45/JJ	prep_with||combined-43/VBN||rates-46/NNS	amod||circumcision-49/NN||male-48/JJ	nn||use-53/NN||circumcision-49/NN	conj_and||circumcision-49/NN||infrequent-51/JJ	nn||use-53/NN||infrequent-51/JJ	nn||use-53/NN||condom-52/NN	prep_of||rates-46/NNS||use-53/NN	cop||drivers-57/NNS||are-55/VBP	amod||drivers-57/NNS||major-56/JJ	ccomp||conclude-34/VB||drivers-57/NNS	det||epidemic-61/NN||the-59/DT	nn||epidemic-61/NN||aids-60/NNS	prep_of||drivers-57/NNS||epidemic-61/NN	amod||africa-64/NN||southern-63/JJ	prep_in||epidemic-61/NN||africa-64/NN	aids-60||hiv-9||no||the strength of the evidence linking concurrency to hiv epidemic severity in southern and eastern africa led the joint united nations programme on hiv/aids and the southern african development community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the aids epidemic in southern africa.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
csubj||humanimmunodeficiencyvirus-8/VBZ||aged-1/VBN	csubj||remained-39/VBD||aged-1/VBN	dep||old-6/JJ||>-3/RB	num||years-5/NNS||50â-4/CD	npadvmod||old-6/JJ||years-5/NNS	dep||humanimmunodeficiencyvirus-8/VBZ||old-6/JJ	root||ROOT-0/null||humanimmunodeficiencyvirus-8/VBZ	dobj||humanimmunodeficiencyvirus-8/VBZ||hiv-10/NN	nsubj||segment-16/NN||patients-12/NNS	cop||segment-16/NN||are-13/VBP	det||segment-16/NN||the-14/DT	amod||segment-16/NN||fastest-growing-15/JJ	rcmod||hiv-10/NN||segment-16/NN	det||population-20/NN||the-18/DT	amod||population-20/NN||hiv-infected-19/JJ	prep_of||segment-16/NN||population-20/NN	det||usa-23/NN||the-22/DT	prep_in||population-20/NN||usa-23/NN	amod||therapy-27/NN||antiretroviral-26/JJ	prep_despite||increased-37/VBN||therapy-27/NN	amod||disorder-31/NN||hiv-associated-29/JJ	nn||disorder-31/NN||neurocognitive-30/NN	nsubj||increased-37/VBN||disorder-31/NN	appos||disorder-31/NN||hand-33/NN	advmod||increased-37/VBN||prevalence-35/RB	aux||increased-37/VBN||has-36/VBZ	rcmod||hiv-10/NN||increased-37/VBN	conj_and||segment-16/NN||increased-37/VBN	conj_or||humanimmunodeficiencyvirus-8/VBZ||remained-39/VBD	det||same-41/JJ||the-40/DT	xcomp||remained-39/VBD||same-41/JJ	det||group-44/NN||this-43/DT	prep_among||remained-39/VBD||group-44/NN	hiv---1||humanimmunodeficiencyvirus-8||no||aged (>50â years old) humanimmunodeficiencyvirus (hiv) patients are the fastest-growing segment of the hiv-infected population in the usa and despite antiretroviral therapy, hiv-associated neurocognitive disorder (hand) prevalence has increased or remained the same among this group.
nsubj||â-2/VBP||objective-1/NN	ccomp||associated-22/VBN||â-2/VBP	dobj||â-2/VBP||$-3/$	mark||one-9/CD||because-5/IN	amod||muscle-7/NN||skeletal-6/JJ	nsubj||one-9/CD||muscle-7/NN	cop||one-9/CD||is-8/VBZ	advcl||â-2/VBP||one-9/CD	det||tissues-13/NNS||the-11/DT	nn||tissues-13/NNS||target-12/NN	prep_of||one-9/CD||tissues-13/NNS	prep_for||tissues-13/NNS||insulin-15/NN	amod||mass-19/NN||skeletal-17/JJ	nn||mass-19/NN||muscle-18/NN	nsubjpass||associated-22/VBN||mass-19/NN	aux||associated-22/VBN||might-20/MD	auxpass||associated-22/VBN||be-21/VB	root||ROOT-0/null||associated-22/VBN	prep_with||associated-22/VBN||type2diabetes-24/CD	type2diabetes-24||insulin-15||yes||objective â€”because skeletal muscle is one of the target tissues for insulin, skeletal muscle mass might be associated with type2diabetes.
nsubj||increased-8/VBD||animals-1/NNS	vmod||animals-1/NNS||primed-2/VBN	prep||primed-2/VBN||with-3/IN	nsubj||showed-5/VBD||afro-1-4/JJ	parataxis||primed-2/VBN||showed-5/VBD	dobj||showed-5/VBD||i-6/FW	root||ROOT-0/null||increased-8/VBD	amod||production-11/NN||ag85b-specific-9/JJ	amod||production-11/NN||ifn-gamma-10/JJ	dobj||increased-8/VBD||production-11/NN	det||assay-15/NN||the-13/DT	nn||assay-15/NN||wba-14/NN	prep_in||production-11/NN||assay-15/NN	amod||pg/ml-20/NN||median-17/JJ	amod||pg/ml-20/NN||>-18/JJ	num||pg/ml-20/NN||400-19/CD	dep||assay-15/NN||pg/ml-20/NN	num||animals-23/NNS||6-22/CD	prep_for||pg/ml-20/NN||animals-23/NNS	num||week-26/NN||one-25/CD	dep||assay-15/NN||week-26/NN	det||boost-30/NN||the-28/DT	amod||boost-30/NN||first-29/JJ	prep_after||increased-8/VBD||boost-30/NN	amod||tb-antigens-33/NNS||adenoviral-delivered-32/JJ	prep_with||boost-30/NN||tb-antigens-33/NNS	prep||increased-8/VBD||as-34/IN	prep||increased-8/VBD||compared-35/VBN	pcomp||compared-35/VBN||to-36/TO	pobj||to-36/TO||animals-37/NNS	vmod||animals-37/NNS||primed-38/VBN	prep_with||primed-38/VBN||bcg-40/NN	number||200-43/CD||<-42/CD	num||pg/ml-44/NNS||200-43/CD	appos||bcg-40/NN||pg/ml-44/NNS	dobj||primed-38/VBN||ii-47/NN	amod||proliferation-52/NN||stronger-49/JJR	nn||proliferation-52/NN||t-50/NN	nn||proliferation-52/NN||cell-51/NN	npadvmod||primed-38/VBN||proliferation-52/NN	det||subset-59/NN||the-54/DT	amod||subset-59/NN||cd8alpha/alpha-55/JJ	amod||subset-59/NN||+-56/JJ	nn||subset-59/NN||t-57/NN	nn||subset-59/NN||cell-58/NN	prep_in||primed-38/VBN||subset-59/NN	amod||index-62/NN||proliferative-61/JJ	dep||subset-59/NN||index-62/NN	num||%-64/NN||17-63/CD	dep||index-62/NN||%-64/NN	prepc_as||subset-59/NN||compared-67/VBN	pcomp||compared-67/VBN||to-68/TO	amod||animals-70/NNS||bcg-primed-69/JJ	pobj||to-68/TO||animals-70/NNS	amod||index-73/NN||proliferative-72/JJ	dep||subset-59/NN||index-73/NN	number||%-75/NN||5-74/CD	amod||index-73/NN||%-75/NN	amod||cells-80/NNS||cd8alpha/alpha-77/JJ	amod||cells-80/NNS||+-78/JJ	nn||cells-80/NNS||t-79/NN	prep_in||index-73/NN||cells-80/NNS	tb--1||bcg-40||no||animals primed with afro-1 showed i) increased ag85b-specific ifn-gamma production in the wba assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered tb-antigens as compared to animals primed with bcg (<200 pg/ml), ii) stronger t cell proliferation in the cd8alpha/alpha+ t cell subset (proliferative index 17%) as compared to bcg-primed animals (proliferative index 5% in cd8alpha/alpha+ t cells).
nn||serotype-2/NN||salmonellaenterica-1/NN	nsubj||cause-8/NN||serotype-2/NN	advmod||a-4/DT||paratyphi-3/RB	amod||serotype-2/NN||a-4/DT	cop||cause-8/NN||is-5/VBZ	det||cause-8/NN||a-6/DT	amod||cause-8/NN||human-restricted-7/JJ	root||ROOT-0/null||cause-8/NN	prep_of||cause-8/NN||paratyphoidfever-10/NN	prep||cause-8/NN||accounting-12/VBG	pcomp||accounting-12/VBG||for-13/IN	pcomp||for-13/IN||up-14/RB	det||fifth-17/NN||a-16/DT	prep_to||up-14/RB||fifth-17/NN	det||cases-20/NNS||all-19/DT	prep_of||fifth-17/NN||cases-20/NNS	prep_of||cases-20/NNS||entericfever-22/NN	prep_in||entericfever-22/NN||asia-24/NN	paratyphoidfever-10||salmonellaenterica-1||no||salmonellaenterica serotype paratyphi a is a human-restricted cause of paratyphoidfever, accounting for up to a fifth of all cases of entericfever in asia.
nsubj||showed-27/VBD||cell-1/NN	amod||cell-1/NN||swelling-2/VBG	auxpass||increased-4/VBN||was-3/VBD	rcmod||cell-1/NN||increased-4/VBN	nn||-rrb--10/NNS||ammonia-6/NNP	nn||-rrb--10/NNS||-lrb--7/NNP	number||%-9/NN||43-8/CD	amod||-rrb--10/NNS||%-9/NN	agent||increased-4/VBN||-rrb--10/NNS	agent||increased-4/VBN||cytokines-13/NNS	conj_and||-rrb--10/NNS||cytokines-13/NNS	vmod||cytokines-13/NNS||-lrb--14/VBG	num||%-16/NN||37-15/CD	dobj||-lrb--14/VBG||%-16/NN	advmod||-lrb--14/VBG||-rrb--17/RB	num||co-treatment-22/NN||24-19/CD	amod||co-treatment-22/NN||h.-20/JJ	amod||co-treatment-22/NN||simultaneous-21/JJ	prep_at||-lrb--14/VBG||co-treatment-22/NN	prep_with||co-treatment-22/NN||cytokines-24/NNS	prep_with||co-treatment-22/NN||ammonia-26/NN	conj_and||cytokines-24/NNS||ammonia-26/NN	root||ROOT-0/null||showed-27/VBD	neg||swelling-30/NN||no-28/DT	amod||swelling-30/NN||additional-29/JJ	dobj||showed-27/VBD||swelling-30/NN	swelling-30||ammonia-26||no_rel||cell swelling was increased by ammonia -lrb- 43 % -rrb- and by cytokines -lrb- 37 % -rrb- at 24 h. simultaneous co-treatment with cytokines and ammonia showed no additional swelling .
nn||polysaccharides-2/NNS||capsular-1/NN	nsubj||factor-10/NN||polysaccharides-2/NNS	nsubj||form-14/VBP||polysaccharides-2/NNS	appos||polysaccharides-2/NNS||cps-4/NN	cop||factor-10/NN||are-6/VBP	det||factor-10/NN||a-7/DT	amod||factor-10/NN||major-8/JJ	nn||factor-10/NN||virulence-9/NN	root||ROOT-0/null||factor-10/NN	prep_in||factor-10/NN||meningococcalinfections-12/NNS	conj_and||factor-10/NN||form-14/VBP	det||basis-16/NN||the-15/DT	dobj||form-14/VBP||basis-16/NN	nn||designation-19/NN||serogroup-18/NN	prep_for||form-14/VBP||designation-19/NN	amod||vaccines-22/NNS||protective-21/JJ	prep_for||form-14/VBP||vaccines-22/NNS	conj_and||designation-19/NN||vaccines-22/NNS	meningococcalinfections-12||vaccines-22||no_rel||capsular polysaccharides (cps) are a major virulence factor in meningococcalinfections and form the basis for serogroup designation and protective vaccines.
aux||report-2/VB||to-1/TO	root||ROOT-0/null||report-2/VB	det||case-5/NN||a-3/DT	amod||case-5/NN||first-4/JJ	dobj||report-2/VB||case-5/NN	amod||bp-9/NN||bullouspemphigoid-7/JJ	prep_of||case-5/NN||bp-9/NN	amod||fluorescein-13/NN||intravenous-12/JJ	prep_following||bp-9/NN||fluorescein-13/NN	amod||angiography-16/NN||fundus-15/JJ	prep_for||fluorescein-13/NN||angiography-16/NN	fluorescein-13||bullouspemphigoid-7||no_rel||to report a first case of bullouspemphigoid (bp) following intravenous fluorescein for fundus angiography.
nsubj||candidate-8/NN||humanimmunodeficiencyvirus-1/NNS	appos||humanimmunodeficiencyvirus-1/NNS||hiv-3/NN	cop||candidate-8/NN||is-5/VBZ	det||candidate-8/NN||a-6/DT	amod||candidate-8/NN||prime-7/JJ	root||ROOT-0/null||candidate-8/NN	aux||impose-10/VB||to-9/TO	vmod||candidate-8/NN||impose-10/VB	amod||selection-13/NN||such-11/JJ	amod||selection-13/NN||genetic-12/JJ	dobj||impose-10/VB||selection-13/NN	vmod||selection-13/NN||owing-14/VBG	det||number-18/NN||the-16/DT	amod||number-18/NN||vast-17/JJ	prep_to||owing-14/VBG||number-18/NN	prep_of||number-18/NN||people-20/NNS	nsubj||infects-22/VBZ||it-21/PRP	rcmod||people-20/NNS||infects-22/VBZ	det||susceptibility-26/NN||the-24/DT	amod||susceptibility-26/NN||varying-25/VBG	dobj||impose-10/VB||susceptibility-26/NN	conj_and||selection-13/NN||susceptibility-26/NN	amod||types-35/NNS||different-28/JJ	amod||types-35/NNS||human-29/JJ	nn||types-35/NNS||leucocyte-30/NN	nn||types-35/NNS||antigen-31/NN	appos||types-35/NNS||hla-33/NN	prep_of||susceptibility-26/NN||types-35/NNS	amod||progression-38/NN||hivdisease-37/JJ	prep_to||types-35/NNS||progression-38/NN	hivdisease-37||hiv-3||no||humanimmunodeficiencyvirus (hiv) is a prime candidate to impose such genetic selection owing to the vast number of people it infects and the varying susceptibility of different human leucocyte antigen (hla) types to hivdisease progression.
det||zn-3/NN||a-1/DT	amod||zn-3/NN||size-controlled-2/JJ	nsubjpass||used-10/VBN||zn-3/NN	nsubj||explain-16/VB||zn-3/NN	discourse||zn-3/NN||oh-5/UH	number||template-8/JJ||2-7/CD	amod||zn-3/NN||template-8/JJ	auxpass||used-10/VBN||is-9/VBZ	root||ROOT-0/null||used-10/VBN	det||study-14/NN||a-12/DT	nn||study-14/NN||case-13/NN	prep_as||used-10/VBN||study-14/NN	aux||explain-16/VB||to-15/TO	xcomp||used-10/VBN||explain-16/VB	det||strategy-19/NN||the-17/DT	amod||strategy-19/NN||chemical-18/JJ	dobj||explain-16/VB||strategy-19/NN	nsubjpass||executed-23/VBN||strategy-19/NN	aux||executed-23/VBN||can-21/MD	auxpass||executed-23/VBN||be-22/VB	rcmod||strategy-19/NN||executed-23/VBN	advmod||engineering-26/VBG||chemically-25/RB	prepc_to||executed-23/VBN||engineering-26/VBG	amod||cavities-29/NNS||various-27/JJ	nn||cavities-29/NNS||nanoscale-28/NN	dobj||engineering-26/VBG||cavities-29/NNS	chemically-25||cavities-29||no_rel||a size-controlled zn(oh)2 template is used as a case study to explain the chemical strategy that can be executed to chemically engineering various nanoscale cavities.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||male-5/NN||a-3/DT	amod||male-5/NN||37-year-old-4/JJ	dobj||report-2/VBP||male-5/NN	prep_with||report-2/VBP||hivinfection-7/NN	nsubj||developed-9/VBD||hivinfection-7/NN	nsubj||recovered-17/VBD||hivinfection-7/NN	rcmod||hivinfection-7/NN||developed-9/VBD	dobj||developed-9/VBD||prca-10/NN	num||weeks-12/NNS||6-11/CD	npadvmod||developed-9/VBD||weeks-12/NNS	prepc_after||developed-9/VBD||commencing-14/VBG	dobj||commencing-14/VBG||zidovudine-15/NN	rcmod||hivinfection-7/NN||recovered-17/VBD	conj_and||developed-9/VBD||recovered-17/VBD	amod||cessation-19/NN||following-18/JJ	dobj||recovered-17/VBD||cessation-19/NN	det||drug-22/NN||the-21/DT	prep_of||cessation-19/NN||drug-22/NN	hivinfection-7||zidovudine-15||yes||we report a 37-year-old male with hivinfection who developed prca 6 weeks after commencing zidovudine and recovered following cessation of the drug.
det||trial-3/NN||each-2/DT	prep_in||numerically-27/RB||trial-3/NN	dep||trial-3/NN||comprising-4/VBG	det||glucose-10/NN||the-5/DT	amod||fasting-8/JJ||meta-analysis-6/NNP	amod||glucose-10/NN||fasting-8/JJ	nn||glucose-10/NN||plasma-9/NN	dobj||comprising-4/VBG||glucose-10/NN	dep||trial-3/NN||confirmed-12/VBN	conj_and||comprising-4/VBG||confirmed-12/VBN	acomp||confirmed-12/VBN||overall-13/JJ	acomp||confirmed-12/VBN||nocturnal-15/JJ	conj_and||overall-13/JJ||nocturnal-15/JJ	amod||hypoglycaemia-24/NN||-lrb--16/NN	number||-lrb--16/NN||00.01-17/CD	amod||hypoglycaemia-24/NN||â-18/JJ	amod||hypoglycaemia-24/NN||$-19/$	num||$-19/$||05.59-21/CD	nn||hypoglycaemia-24/NN||h-22/NN	nn||hypoglycaemia-24/NN||-rrb--23/NN	nsubj||numerically-27/RB||hypoglycaemia-24/NN	nsubj||lower-30/JJR||hypoglycaemia-24/NN	cop||numerically-27/RB||were-25/VBD	advmod||numerically-27/RB||all-26/RB	root||ROOT-0/null||numerically-27/RB	advmod||lower-30/JJR||significantly-29/RB	conj_or||numerically-27/RB||lower-30/JJR	nn||degludec-33/NN||insulin-32/NN	prep_with||lower-30/JJR||degludec-33/NN	prep||numerically-27/RB||vs.-34/NN	dep||vs.-34/NN||insulinglargine-35/NN	hypoglycaemia-24||glucose-10||yes||in each trial comprising the meta-analysis , fasting plasma glucose and confirmed overall and nocturnal -lrb- 00.01 â $ `` 05.59 h -rrb- hypoglycaemia were all numerically or significantly lower with insulin degludec vs. insulinglargine .
nn||design-2/NN||research-1/NN	dep||conducted-8/VBD||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	dep||conducted-8/VBD||$-5/NNP	nsubj||conducted-8/VBD||we-7/PRP	root||ROOT-0/null||conducted-8/VBD	amod||studies-10/NNS||case-control-9/JJ	dobj||conducted-8/VBD||studies-10/NNS	num||adults-13/NNS||764-12/CD	prep_in||conducted-8/VBD||adults-13/NNS	num||samples-18/NNS||two-16/CD	amod||samples-18/NNS||independent-17/JJ	prep_from||adults-13/NNS||samples-18/NNS	num||individuals-25/NNS||289-20/CD	amod||individuals-25/NNS||nonobese-21/JJ	conj_and||nonobese-21/JJ||485-23/JJ	amod||individuals-25/NNS||485-23/JJ	amod||individuals-25/NNS||obese-24/JJ	prep_of||samples-18/NNS||individuals-25/NNS	num||children-30/NNS||240-28/CD	amod||children-30/NNS||overweight/obese-29/JJ	prep_in||conducted-8/VBD||children-30/NNS	conj_and||adults-13/NNS||children-30/NNS	vmod||children-30/NNS||undergoing-31/VBG	amod||testing-35/NN||oral-32/JJ	nn||testing-35/NN||glucose-33/NN	nn||testing-35/NN||tolerance-34/NN	dobj||undergoing-31/VBG||testing-35/NN	appos||testing-35/NN||ogtt-37/NN	obese-24||glucose-33||no_rel||research design and methodsâ€” we conducted case-control studies in 764 adults (from two independent samples of 289 nonobese and 485 obese individuals) and 240 overweight/obese children undergoing oral glucose tolerance testing (ogtt).
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	cardiovasculardisease-34||fat--1||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
amod||evidence-2/NN||available-1/JJ	nsubj||suggests-3/VBZ||evidence-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||lengthen-12/VB||that-4/IN	amod||mg-7/NN||dronedarone-5/JJ	dep||dronedarone-5/JJ||400-6/CD	nsubj||lengthen-12/VB||mg-7/NN	nsubj||decrease-17/VB||mg-7/NN	advmod||twice-9/JJ||orally-8/RB	amod||mg-7/NN||twice-9/JJ	advmod||lengthen-12/VB||daily-10/RB	aux||lengthen-12/VB||can-11/MD	ccomp||suggests-3/VBZ||lengthen-12/VB	det||time-14/NN||the-13/DT	dobj||lengthen-12/VB||time-14/NN	prep||lengthen-12/VB||to-15/TO	ccomp||suggests-3/VBZ||decrease-17/VB	conj_and||lengthen-12/VB||decrease-17/VB	det||recurrence-20/NN||the-18/DT	amod||recurrence-20/NN||overall-19/JJ	dobj||decrease-17/VB||recurrence-20/NN	prep_of||recurrence-20/NN||atrialfibrillation-22/NN	prepc_compared_with||decrease-17/VB||with-24/IN	pobj||decrease-17/VB||placebo-25/NN	dronedarone-5||atrialfibrillation-22||no_rel||available evidence suggests that dronedarone 400 mg orally twice daily can lengthen the time to and decrease the overall recurrence of atrialfibrillation compared with placebo.
nn||manifestations-2/NNS||ocular-1/NN	root||ROOT-0/null||manifestations-2/NNS	aux||occur-4/VB||can-3/MD	rcmod||manifestations-2/NNS||occur-4/VB	quantmod||50-8/CD||up-6/IN	dep||50-8/CD||to-7/TO	num||%-9/NN||50-8/CD	prep_in||occur-4/VB||%-9/NN	prep_of||%-9/NN||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	punct||manifestations-2/NNS||/-15/:	dep||manifestations-2/NNS||acquired-16/VBD	amod||patients-22/NNS||immunedeficiency-17/JJ	nn||patients-22/NNS||syndrome-18/NN	appos||patients-22/NNS||aids-20/NNS	nsubj||presentation-31/NN||patients-22/NNS	nn||involvement-26/NN||posterior-24/NN	nn||involvement-26/NN||segment-25/NN	conj_and||patients-22/NNS||involvement-26/NN	nsubj||presentation-31/NN||involvement-26/NN	cop||presentation-31/NN||is-27/VBZ	det||presentation-31/NN||the-28/DT	advmod||common-30/JJ||most-29/RBS	amod||presentation-31/NN||common-30/JJ	ccomp||acquired-16/VBD||presentation-31/NN	aids-20||hiv-13||no||ocular manifestations can occur in up to 50% of humanimmunodeficiencyvirus (hiv)/acquired immunedeficiency syndrome (aids) patients and posterior segment involvement is the most common presentation.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	interferon--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
det||cancer-2/NN||the-1/DT	nsubj||stem-3/VBP||cancer-2/NN	root||ROOT-0/null||stem-3/VBP	nn||theory-5/NN||cell-4/NN	nsubj||suggests-6/VBZ||theory-5/NN	ccomp||stem-3/VBP||suggests-6/VBZ	nsubj||persist-8/VB||cscs-7/NNS	nsubj||cause-16/VB||cscs-7/NNS	ccomp||suggests-6/VBZ||persist-8/VB	prep_in||persist-8/VB||tumors-10/NNS	det||population-14/NN||a-12/DT	amod||population-14/NN||distinct-13/JJ	prep_as||tumors-10/NNS||population-14/NN	ccomp||suggests-6/VBZ||cause-16/VB	conj_and||persist-8/VB||cause-16/VB	dobj||cause-16/VB||relapse-17/NN	dobj||cause-16/VB||metastasis-19/NNS	conj_and||relapse-17/NN||metastasis-19/NNS	prepc_by||cause-16/VB||giving-21/VBG	dobj||giving-21/VBG||rise-22/NN	amod||tumors-25/NNS||new-24/JJ	prep_to||giving-21/VBG||tumors-25/NNS	rise-22||cancer-2||no_rel||the cancer stem cell theory suggests cscs persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors.
amod||baseline-2/NN||cortisol-1/JJ	nsubj||predictors-21/NNS||baseline-2/NN	appos||baseline-2/NN||acth-4/NN	appos||baseline-2/NN||pct-6/NN	conj_and||acth-4/NN||pct-6/NN	amod||ii-9/NN||apache-8/JJ	appos||baseline-2/NN||ii-9/NN	conj_and||acth-4/NN||ii-9/NN	nn||scores-12/NNS||sepsis-11/NN	conj_and||acth-4/NN||scores-12/NNS	conj_and||ii-9/NN||scores-12/NNS	appos||baseline-2/NN||shock-15/NN	conj_and||acth-4/NN||shock-15/NN	prep_on||shock-15/NN||admission-17/NN	cop||predictors-21/NNS||were-19/VBD	amod||predictors-21/NNS||independent-20/JJ	root||ROOT-0/null||predictors-21/NNS	nn||diagnosis-24/NN||sepsis-23/NN	prep_of||predictors-21/NNS||diagnosis-24/NN	prep_upon||predictors-21/NNS||admission-26/NN	shock-15||cortisol-1||yes||cortisol baseline, acth, pct, apache ii and sepsis scores, and shock on admission, were independent predictors of sepsis diagnosis upon admission.
det||regions-3/NNS||the-1/DT	amod||regions-3/NNS||endemic-2/JJ	nsubj||evolved-6/VBD||regions-3/NNS	prep_of||regions-3/NNS||mexico-5/NN	root||ROOT-0/null||evolved-6/VBD	amod||states-10/NNS||high-8/JJ	amod||states-10/NNS||onchocerciasis-endemic-9/JJ	prep_from||evolved-6/VBD||states-10/NNS	det||interruption-13/NN||the-12/DT	prep_to||evolved-6/VBD||interruption-13/NN	prep_of||interruption-13/NN||transmission-15/NN	det||strategies-19/NNS||the-18/DT	prep_due_to||evolved-6/VBD||strategies-19/NNS	vmod||strategies-19/NNS||followed-20/VBN	det||msh-23/NN||the-22/DT	agent||followed-20/VBN||msh-23/NN	prepc_based_on||evolved-6/VBD||on-26/IN	pobj||evolved-6/VBD||treatment-27/NN	prep_with||treatment-27/NN||ivermectin-29/NN	onchocerciasis--1||ivermectin-29||yes||the endemic regions of mexico evolved from high onchocerciasis-endemic states to the interruption of transmission due to the strategies followed by the msh, based on treatment with ivermectin.
advmod||observed-23/VBN||finally-1/RB	prepc_compared_with||observed-23/VBN||with-4/IN	det||patients-7/NNS||the-5/DT	amod||patients-7/NNS||chronichepatitisb-6/JJ	pobj||observed-23/VBN||patients-7/NNS	amod||rate-10/NN||similar-9/JJ	nsubjpass||observed-23/VBN||rate-10/NN	nn||reactivation-13/NN||hbv-12/NN	prep_of||rate-10/NN||reactivation-13/NN	amod||withdrawal-16/NN||lamivudine-15/JJ	prep_after||reactivation-13/NN||withdrawal-16/NN	prep_after||reactivation-13/NN||development-18/NN	conj_and||withdrawal-16/NN||development-18/NN	amod||mutation-21/NN||ymdd-20/JJ	prep_of||reactivation-13/NN||mutation-21/NN	auxpass||observed-23/VBN||was-22/VBD	root||ROOT-0/null||observed-23/VBN	nn||patients-26/NNS||nhl-25/NN	prep_in||observed-23/VBN||patients-26/NNS	hbv-12||lamivudine-15||yes||finally, compared with the chronichepatitisb patients, similar rate of hbv reactivation after lamivudine withdrawal and development of ymdd mutation was observed in nhl patients.
det||associations-2/NNS||the-1/DT	nsubj||vary-46/VB||associations-2/NNS	prep_with||associations-2/NNS||age-4/NN	conj_and||associations-2/NNS||nulliparity-6/NN	nsubj||vary-46/VB||nulliparity-6/NN	appos||nulliparity-6/NN||parity-8/NN	conj_and||associations-2/NNS||age-10/NN	nsubj||vary-46/VB||age-10/NN	prep_at||age-10/NN||menopause-12/NN	conj_and||associations-2/NNS||type-14/NN	nsubj||vary-46/VB||type-14/NN	prep_of||type-14/NN||menopause-16/NN	nn||intake-19/NN||alcohol-18/NN	conj_and||associations-2/NNS||intake-19/NN	nsubj||vary-46/VB||intake-19/NN	amod||index-24/NN||adult-21/JJ	nn||index-24/NN||body-22/NN	nn||index-24/NN||mass-23/NN	appos||intake-19/NN||index-24/NN	appos||index-24/NN||bmi-26/NN	conj_and||associations-2/NNS||bmi-29/NN	nsubj||vary-46/VB||bmi-29/NN	prep_at||bmi-29/NN||age-31/NN	num||age-31/NN||18-32/CD	nn||history-35/NN||family-34/NN	conj_and||associations-2/NNS||history-35/NN	nsubj||vary-46/VB||history-35/NN	nn||cancer-38/NN||breast-37/NN	prep_of||history-35/NN||cancer-38/NN	amod||history-41/NN||personal-40/JJ	conj_and||associations-2/NNS||history-41/NN	nsubj||vary-46/VB||history-41/NN	prep_of||history-41/NN||benignbreastdisease-43/NN	aux||vary-46/VB||did-44/VBD	neg||vary-46/VB||not-45/RB	root||ROOT-0/null||vary-46/VB	prep_by||vary-46/VB||subtype-48/NN	dep||subtype-48/NN||p-50/NN	nn||¥-55/NNP||het-52/NN	nn||¥-55/NNP||â-53/NN	nn||¥-55/NNP||‰-54/NNP	dep||p-50/NN||¥-55/NNP	num||¥-55/NNP||0.08-56/CD	alcohol-18||benignbreastdisease-43||no_rel||the associations with age, nulliparity, parity, age at menopause, type of menopause, alcohol intake, adult body mass index (bmi), bmi at age 18, family history of breast cancer and personal history of benignbreastdisease did not vary by subtype ( p -het â‰¥ 0.08).
advmod||assessed-23/VBN||therefore-1/RB	aux||gain-4/VB||to-3/TO	csubjpass||assessed-23/VBN||gain-4/VB	amod||insights-6/NNS||preliminary-5/JJ	dobj||gain-4/VB||insights-6/NNS	det||status-10/NN||the-8/DT	amod||status-10/NN||vitamind-9/JJ	prep_into||gain-4/VB||status-10/NN	prep_of||status-10/NN||infants-12/NNS	amod||bangladesh-15/NN||rural-14/JJ	prep_in||infants-12/NNS||bangladesh-15/NN	amod||bangladesh-15/NN||25-17/CD	discourse||bangladesh-15/NN||oh-19/UH	dep||bangladesh-15/NN||d-21/SYM	auxpass||assessed-23/VBN||was-22/VBD	root||ROOT-0/null||assessed-23/VBN	det||group-26/NN||a-25/DT	prep_in||assessed-23/VBN||group-26/NN	amod||participants-30/NNS||community-sampled-28/JJ	nn||participants-30/NNS||control-29/NN	prep_of||group-26/NN||participants-30/NNS	det||study-35/NN||a-32/DT	nn||study-35/NN||pneumonia-33/NN	amod||study-35/NN||case-control-34/JJ	prep_in||assessed-23/VBN||study-35/NN	amod||sylhet-38/NN||rural-37/JJ	prep_in||study-35/NN||sylhet-38/NN	appos||sylhet-38/NN||bangladesh-40/NN	amod||n-44/NN||25â-42/JJ	amod||n-44/NN||°-43/JJ	appos||bangladesh-40/NN||n-44/NN	det||season-50/NN||the-47/DT	nn||season-50/NN||winter-48/NN	amod||season-50/NN||dry-49/JJ	prep_during||assessed-23/VBN||season-50/NN	appos||season-50/NN||january-february-52/NN	vitamind-9||pneumonia-33||no_rel||therefore, to gain preliminary insights into the vitamind status of infants in rural bangladesh, 25(oh)d was assessed in a group of community-sampled control participants in a pneumonia case-control study in rural sylhet, bangladesh (25â°n) during the winter dry season (january-february).
det||hypermuscularity-3/NN||the-1/DT	amod||hypermuscularity-3/NN||marked-2/JJ	nsubj||reduces-10/VBZ||hypermuscularity-3/NN	prep_in||hypermuscularity-3/NN||mice-5/NNS	amod||deficiency-9/NN||constitutive-7/JJ	nn||deficiency-9/NN||myostatin-8/NN	prep_with||mice-5/NNS||deficiency-9/NN	root||ROOT-0/null||reduces-10/VBZ	amod||accumulation-12/NN||fat-11/JJ	dobj||reduces-10/VBZ||accumulation-12/NN	dobj||reduces-10/VBZ||hyperglycemia-14/NN	conj_and||accumulation-12/NN||hyperglycemia-14/NN	vmod||accumulation-12/NN||induced-15/VBN	amod||feeding-18/NN||high-fat-17/JJ	agent||induced-15/VBN||feeding-18/NN	nsubj||unclear-23/JJ||it-21/PRP	cop||unclear-23/JJ||is-22/VBZ	conj_but||reduces-10/VBZ||unclear-23/JJ	mark||has-38/VBZ||whether-24/IN	det||increase-27/NN||the-25/DT	amod||increase-27/NN||smaller-26/JJR	nsubj||has-38/VBZ||increase-27/NN	nn||mass-30/NN||muscle-29/NN	prep_in||increase-27/NN||mass-30/NN	vmod||mass-30/NN||caused-31/VBN	amod||loss-34/NN||postdevelopmental-33/JJ	agent||caused-31/VBN||loss-34/NN	nn||activity-37/NN||myostatin-36/NN	prep_of||loss-34/NN||activity-37/NN	ccomp||unclear-23/JJ||has-38/VBZ	amod||effects-41/NNS||beneficial-39/JJ	amod||effects-41/NNS||metabolic-40/JJ	dobj||has-38/VBZ||effects-41/NNS	amod||feeding-44/NN||high-fat-43/JJ	prep_during||has-38/VBZ||feeding-44/NN	fat-11||hyperglycemia-14||no_rel||the marked hypermuscularity in mice with constitutive myostatin deficiency reduces fat accumulation and hyperglycemia induced by high-fat feeding, but it is unclear whether the smaller increase in muscle mass caused by postdevelopmental loss of myostatin activity has beneficial metabolic effects during high-fat feeding.
dep||induced-2/VBD||ht-29-1/JJ	root||ROOT-0/null||induced-2/VBD	advmod||induced-2/VBD||autophagy-3/RB	prep_in||induced-2/VBD||response-5/NN	prep_to||induced-2/VBD||5-fu-7/JJ	nn||inhibited-11/NNS||cq-10/NN	prep_to||induced-2/VBD||inhibited-11/NNS	conj_and||5-fu-7/JJ||inhibited-11/NNS	det||induction-13/NN||this-12/DT	nsubj||induced-2/VBD||induction-13/NN	det||mechanism-17/NN||a-15/DT	amod||mechanism-17/NN||possible-16/JJ	appos||induction-13/NN||mechanism-17/NN	det||potentiation-20/NN||the-19/DT	prep_of||mechanism-17/NN||potentiation-20/NN	det||effect-24/NN||the-22/DT	amod||effect-24/NN||anti-cancer-23/JJ	prep_of||potentiation-20/NN||effect-24/NN	prep_of||effect-24/NN||5-fu-26/CD	5-fu-26||cancer--1||no_rel||ht-29 induced autophagy in response to 5-fu, and cq inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-fu.
det||data-2/NNS||these-1/DT	nsubj||open-3/VBP||data-2/NNS	root||ROOT-0/null||open-3/VBP	amod||perspectives-5/NNS||new-4/JJ	dobj||open-3/VBP||perspectives-5/NNS	det||possibility-8/NN||the-7/DT	prep_on||open-3/VBP||possibility-8/NN	aux||use-10/VB||to-9/TO	vmod||possibility-8/NN||use-10/VB	xcomp||use-10/VB||sap-11/VB	det||component-16/NN||a-13/DT	amod||component-16/NN||potential-14/JJ	nn||component-16/NN||vaccine-15/NN	prep_as||sap-11/VB||component-16/NN	vmod||component-16/NN||inducing-17/VBG	amod||antibodies-20/NNS||functional-18/JJ	amod||antibodies-20/NNS||cross-reacting-19/JJ	dobj||inducing-17/VBG||antibodies-20/NNS	vmod||antibodies-20/NNS||interfering-21/VBG	prep_with||interfering-21/VBG||streptococcalinfections-23/NNS	streptococcalinfections-23||antibodies-20||no_rel||these data open new perspectives on the possibility to use sap as a potential vaccine component inducing functional cross-reacting antibodies interfering with streptococcalinfections.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||‰-53/NNS||â-52/JJ	appos||$-42/$||‰-53/NNS	conj_and||$-47/$||‰-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	carbohydrate-12||type2diabetes-35||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â€“9, 10â€“19, and â‰¥20 years).
ccomp||evoked-15/VBD||short-2/JJ	number||ms-5/CD||60-4/CD	dep||short-2/JJ||ms-5/CD	amod||pulses-11/NNS||high-8/JJ	nn||pulses-11/NNS||intensity-9/NN	nn||pulses-11/NNS||laser-10/NN	nsubj||evoked-15/VBD||pulses-11/NNS	appos||pulses-11/NNS||sp-13/NN	ccomp||evoked-40/VBD||evoked-15/VBD	xcomp||evoked-15/VBD||monomodal-16/VB	dobj||monomodal-16/VB||pricking-19/NN	dep||pricking-19/NN||pain-22/NN	nsubjpass||enhanced-26/VBN||pain-22/NN	auxpass||enhanced-26/VBN||was-24/VBD	neg||enhanced-26/VBN||not-25/RB	rcmod||pain-22/NN||enhanced-26/VBN	amod||capsaicin-29/NN||topical-28/JJ	agent||enhanced-26/VBN||capsaicin-29/NN	advmod||longer-32/JJR||whereas-31/RB	amod||pricking-19/NN||longer-32/JJR	amod||pulses-36/NNS||lower-34/JJR	nn||pulses-36/NNS||power-35/NN	nsubj||evoked-40/VBD||pulses-36/NNS	appos||pulses-36/NNS||lp-38/NN	root||ROOT-0/null||evoked-40/VBD	xcomp||evoked-40/VBD||monomodal-41/VB	dobj||monomodal-41/VB||burning-44/NN	iobj||monomodal-41/VB||burning-44/NN	dep||burning-44/NN||pain-47/NN	nsubjpass||enhanced-50/VBN||pain-47/NN	auxpass||enhanced-50/VBN||was-49/VBD	rcmod||pain-47/NN||enhanced-50/VBN	amod||capsaicin-53/NN||topical-52/JJ	agent||enhanced-50/VBN||capsaicin-53/NN	pain-47||capsaicin-53||yes||" short (60 ms), high intensity laser pulses (sp) evoked monomodal ""pricking"" pain which was not enhanced by topical capsaicin, whereas longer, lower power pulses (lp) evoked monomodal ""burning"" pain which was enhanced by topical capsaicin."
det||sequence-4/NN||the-1/DT	amod||sequence-4/NN||primary-2/JJ	amod||sequence-4/NN||aminoacid-3/JJ	nsubjpass||searched-13/VBN||sequence-4/NN	det||proteome-11/JJ||the-6/DT	amod||proteome-11/JJ||hepatitisbvirus-7/JJ	appos||proteome-11/JJ||hbv-9/NN	prep_of||sequence-4/NN||proteome-11/JJ	auxpass||searched-13/VBN||was-12/VBD	root||ROOT-0/null||searched-13/VBN	nn||spots-16/NNS||identity-15/NN	prep_for||searched-13/VBN||spots-16/NNS	det||proteome-20/NN||the-18/DT	amod||proteome-20/NN||human-19/JJ	prep_in||spots-16/NNS||proteome-20/NN	agent||searched-13/VBN||using-22/VBG	det||database-27/NN||the-23/DT	nn||database-27/NN||protein-24/NN	nn||database-27/NN||information-25/NN	nn||database-27/NN||resource-26/NN	dobj||using-22/VBG||database-27/NN	hbv-9||hepatitisbvirus-7||no||the primary aminoacid sequence of the hepatitisbvirus (hbv) proteome was searched for identity spots in the human proteome by using the protein information resource database.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||pyrimethamine-28||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â€“6 months after artemetherâ€“lumefantrine (al) replaced sulfadoxineâ€“pyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||telmisartan-7||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
nsubj||results-2/VBZ||cholera-1/NN	root||ROOT-0/null||results-2/VBZ	dobj||results-2/VBZ||expulsion-3/NN	amod||bacteria-7/NNS||major-5/JJ	amod||bacteria-7/NNS||commensal-6/JJ	prep_of||expulsion-3/NN||bacteria-7/NNS	nn||bacteroidetes-10/NNS||phyla-9/NN	prep_of||bacteria-7/NNS||bacteroidetes-10/NNS	prep_of||bacteria-7/NNS||firmicutes-12/NNS	conj_and||bacteroidetes-10/NNS||firmicutes-12/NNS	prep_of||bacteria-7/NNS||actinobacteria-15/NN	conj_and||bacteroidetes-10/NNS||actinobacteria-15/NN	dobj||results-2/VBZ||increase-18/NN	conj_and||expulsion-3/NN||increase-18/NN	amod||proteobacteria-21/NN||harmful-20/JJ	prep_of||increase-18/NN||proteobacteria-21/NN	aux||colonize-23/VB||to-22/TO	vmod||results-2/VBZ||colonize-23/VB	det||gut-25/NN||the-24/DT	dobj||colonize-23/VB||gut-25/NN	amod||states-30/NNS||acute-27/JJ	conj_and||acute-27/JJ||convalescence-29/JJ	amod||states-30/NNS||convalescence-29/JJ	prep_during||colonize-23/VB||states-30/NNS	cholera-1||bacteria-7||no||cholera results expulsion of major commensal bacteria of phyla bacteroidetes, firmicutes, and actinobacteria, and increase of harmful proteobacteria to colonize the gut during acute and convalescence states.
det||group-5/NN||the-2/DT	amod||group-5/NN||prophylactic-3/JJ	nn||group-5/NN||lamivudine-4/NN	prep_in||was-8/VBD||group-5/NN	expl||was-8/VBD||there-7/EX	root||ROOT-0/null||was-8/VBD	advmod||less-10/JJR||significantly-9/RB	amod||hbv-11/NN||less-10/JJR	nsubj||was-8/VBD||hbv-11/NN	dep||hbv-11/NN||reactivation-12/NN	num||patient-15/NN||1-14/CD	nsubj||vs-20/VBP||patient-15/NN	num||%-18/NN||2-17/CD	appos||patient-15/NN||%-18/NN	dep||hbv-11/NN||vs-20/VBP	num||patients-22/NNS||20-21/CD	dobj||vs-20/VBP||patients-22/NNS	num||%-25/NN||16-24/CD	appos||patients-22/NNS||%-25/NN	dep||patients-22/NNS||p-28/NN	dep||0.002-30/CD||=-29/SYM	rcmod||p-28/NN||0.002-30/CD	amod||disruption-34/NN||less-33/JJR	nsubj||was-8/VBD||disruption-34/NN	conj_and||hbv-11/NN||disruption-34/NN	prep_of||disruption-34/NN||chemotherapy-36/NN	num||vs-39/NN||7-38/CD	nsubj||p-42/VBP||vs-39/NN	number||%-41/NN||14-40/CD	amod||vs-39/NN||%-41/NN	dep||hbv-11/NN||p-42/VBP	dep||0.04-44/CD||=-43/SYM	ccomp||p-42/VBP||0.04-44/CD	amod||hepatitis-50/NN||less-48/JJR	amod||hepatitis-50/NN||severe-49/JJ	nsubj||was-8/VBD||hepatitis-50/NN	conj_and||hbv-11/NN||hepatitis-50/NN	num||vs-53/NN||0-52/CD	dep||hepatitis-50/NN||vs-53/NN	num||%-55/NN||17-54/CD	nsubj||0.002-58/CD||%-55/NN	vmod||%-55/NN||p-56/VBN	dep||0.002-58/CD||=-57/SYM	rcmod||vs-53/NN||0.002-58/CD	hbv-11||lamivudine-4||yes||in the prophylactic lamivudine group, there was significantly less hbv reactivation (1 patient (2%) vs 20 patients (16%); p =0.002), less disruption of chemotherapy (7 vs 14% p =0.04), and less severe hepatitis (0 vs 17% p =0.002).
det||safety-2/NN||the-1/DT	nsubjpass||demonstrated-31/VBN||safety-2/NN	conj_and||safety-2/NN||effectiveness-4/NN	nsubjpass||demonstrated-31/VBN||effectiveness-4/NN	prep_of||safety-2/NN||lacosamide-6/NN	det||drug-10/NN||an-8/DT	amod||drug-10/NN||antiepileptic-9/JJ	appos||safety-2/NN||drug-10/NN	nsubj||enhances-16/VBZ||drug-10/NN	appos||drug-10/NN||aed-12/NN	advmod||enhances-16/VBZ||selectively-15/RB	rcmod||drug-10/NN||enhances-16/VBZ	det||inactivation-19/NN||the-17/DT	amod||inactivation-19/NN||slow-18/JJ	dobj||enhances-16/VBZ||inactivation-19/NN	amod||channels-23/NNS||voltage-gated-21/JJ	nn||channels-23/NNS||sodium-22/NN	prep_of||inactivation-19/NN||channels-23/NNS	prepc_without||enhances-16/VBZ||affecting-25/VBG	amod||inactivation-27/NN||rapid-26/JJ	dobj||affecting-25/VBG||inactivation-27/NN	aux||demonstrated-31/VBN||has-29/VBZ	auxpass||demonstrated-31/VBN||been-30/VBN	root||ROOT-0/null||demonstrated-31/VBN	amod||trials-38/NNS||randomized-33/JJ	amod||trials-38/NNS||double-blind-35/JJ	amod||trials-38/NNS||placebo-controlled-37/JJ	prep_in||demonstrated-31/VBN||trials-38/NNS	prep_in||demonstrated-31/VBN||adults-40/NNS	amod||epilepticseizures-43/NNS||focal-42/JJ	prep_with||adults-40/NNS||epilepticseizures-43/NNS	epilepticseizures-43||lacosamide-6||yes||the safety and effectiveness of lacosamide, an antiepileptic drug (aed) that selectively enhances the slow inactivation of voltage-gated sodium channels without affecting rapid inactivation, has been demonstrated in randomized, double-blind, placebo-controlled trials in adults with focal epilepticseizures.
nsubj||antispasmodics-9/VBZ||objective-1/NN	nsubj||peppermintoil-12/JJ||objective-1/NN	aux||determine-3/VB||to-2/TO	vmod||objective-1/NN||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||fibre-7/NN	root||ROOT-0/null||antispasmodics-9/VBZ	conj_and||antispasmodics-9/VBZ||peppermintoil-12/JJ	det||treatment-15/NN||the-14/DT	prep_in||peppermintoil-12/JJ||treatment-15/NN	prep_of||treatment-15/NN||irritablebowelsyndrome-17/NN	fibre-7||irritablebowelsyndrome-17||no_rel||objective to determine the effect of fibre, antispasmodics, and peppermintoil in the treatment of irritablebowelsyndrome.
advmod||brought-13/VBD||moreover-1/RB	nsubj||brought-13/VBD||data-3/NNS	det||interaction-6/NN||the-5/DT	prep_on||data-3/NNS||interaction-6/NN	prep_of||interaction-6/NN||microbiota-8/NN	prep_with||microbiota-8/NN||food-10/NN	prep_with||microbiota-8/NN||obesity-12/NN	conj_and||food-10/NN||obesity-12/NN	root||ROOT-0/null||brought-13/VBD	amod||hypothesis-15/NNS||new-14/JJ	dobj||brought-13/VBD||hypothesis-15/NNS	det||relationship-20/NN||the-17/DT	amod||relationship-20/NN||obesity/fat-18/JJ	nn||relationship-20/NN||diet-19/NN	prep_for||brought-13/VBD||relationship-20/NN	prep_with||brought-13/VBD||inflammation-22/NN	obesity-12||fat--1||no_rel||moreover, data on the interaction of microbiota with food and obesity brought new hypothesis for the obesity/fat diet relationship with inflammation.
det||results-2/NNS||these-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||used-12/VBN||that-4/IN	amod||plasmablasts-8/NNS||bcg-specific-5/JJ	amod||plasmablasts-8/NNS||igg-secreting-6/JJ	amod||plasmablasts-8/NNS||peripheral-7/JJ	nsubjpass||used-12/VBN||plasmablasts-8/NNS	nsubj||improve-18/VB||plasmablasts-8/NNS	nsubj||facilitate-32/VB||plasmablasts-8/NNS	aux||used-12/VBN||could-9/MD	auxpass||used-12/VBN||be-10/VB	advmod||used-12/VBN||successfully-11/RB	ccomp||suggest-3/VBP||used-12/VBN	det||biomarker-16/NN||a-14/DT	amod||biomarker-16/NN||host-specific-15/JJ	prep_as||used-12/VBN||biomarker-16/NN	aux||improve-18/VB||to-17/TO	xcomp||used-12/VBN||improve-18/VB	dobj||improve-18/VB||diagnosis-19/NN	amod||tb-22/NN||active-21/JJ	prep_of||diagnosis-19/NN||tb-22/NN	advmod||improve-18/VB||particularly-24/RB	prep_in||improve-18/VB||people-26/NNS	nsubj||hivpositive-29/JJ||people-26/NNS	cop||hivpositive-29/JJ||are-28/VBP	rcmod||people-26/NNS||hivpositive-29/JJ	xcomp||used-12/VBN||facilitate-32/VB	conj_and||improve-18/VB||facilitate-32/VB	dobj||facilitate-32/VB||administration-33/NN	amod||treatment-36/NN||effective-35/JJ	prep_of||administration-33/NN||treatment-36/NN	prep_to||facilitate-32/VB||patients-38/NNS	tb-22||bcg--1||yes||these results suggest that bcg-specific igg-secreting peripheral plasmablasts could be successfully used as a host-specific biomarker to improve diagnosis of active tb, particularly in people who are hivpositive, and facilitate administration of effective treatment to patients.
advmod||enhanced-13/VBD||conversely-1/RB	nn||inhibition-4/NN||sirna-3/NN	nsubj||enhanced-13/VBD||inhibition-4/NN	amod||expression-9/NN||socs1-6/JJ	conj_and||socs1-6/JJ||socs3-8/JJ	amod||expression-9/NN||socs3-8/JJ	prep_of||inhibition-4/NN||expression-9/NN	nn||cells-12/NNS||melanoma-11/NN	prep_in||expression-9/NN||cells-12/NNS	root||ROOT-0/null||enhanced-13/VBD	poss||responsiveness-15/NNS||their-14/PRP$	dobj||enhanced-13/VBD||responsiveness-15/NNS	nn||stimulation-18/NN||interferon-17/NN	prep_to||enhanced-13/VBD||stimulation-18/NN	melanoma-11||interferon-17||yes||conversely, sirna inhibition of socs1 and socs3 expression in melanoma cells enhanced their responsiveness to interferon stimulation.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||compare-8/VB||objective-2/NN	det||trial-5/NN||this-4/DT	prep_of||objective-2/NN||trial-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||regimen-10/NN||cisplatin-plus-vinorelbine-9/JJ	dobj||compare-8/VB||regimen-10/NN	amod||regimen-13/NN||cisplatin-plus-gemcitabine-12/JJ	prep_with||compare-8/VB||regimen-13/NN	prep_in||regimen-13/NN||patients-15/NNS	nn||non-smallcelllungcancer-19/NN||stage-17/NN	amod||non-smallcelllungcancer-19/NN||iiib-iv-18/JJ	prep_with||patients-15/NNS||non-smallcelllungcancer-19/NN	dep||non-smallcelllungcancer-19/NN||nsclc-21/JJ	non-smallcelllungcancer-19||vinorelbine--1||yes||the objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage iiib-iv non-smallcelllungcancer (nsclc).
det||patient-4/NN||the-1/DT	amod||patient-4/NN||hiv-1-2/JJ	amod||patient-4/NN||+-3/JJ	nsubj||taking-9/VBG||patient-4/NN	nsubjpass||treated-14/VBN||patient-4/NN	vmod||patient-4/NN||studied-5/VBN	advmod||studied-5/VBN||here-6/RB	aux||taking-9/VBG||was-7/VBD	neg||taking-9/VBG||not-8/RB	root||ROOT-0/null||taking-9/VBG	amod||drugs-11/NNS||antiretroviral-10/JJ	dobj||taking-9/VBG||drugs-11/NNS	auxpass||treated-14/VBN||was-13/VBD	conj_and||taking-9/VBG||treated-14/VBN	amod||lymphoplasmacytoidlymphoma-18/NN||pre-existing-16/JJ	amod||lymphoplasmacytoidlymphoma-18/NN||low-grade-17/JJ	prep_for||treated-14/VBN||lymphoplasmacytoidlymphoma-18/NN	nsubj||using-26/VBG||depletion-20/NN	amod||cells-25/NNS||cd20-22/JJ	nn||cells-25/NNS||+-23/NNP	nn||cells-25/NNS||b-24/NNP	prep_of||depletion-20/NN||cells-25/NNS	agent||treated-14/VBN||using-26/VBG	dobj||using-26/VBG||rituximab-27/NN	lymphoplasmacytoidlymphoma-18||rituximab-27||no_rel||the hiv-1+ patient studied here was not taking antiretroviral drugs and was treated for pre-existing low-grade lymphoplasmacytoidlymphoma by depletion of cd20+ b cells using rituximab.
prep_in||explored-19/VBN||addition-2/NN	amod||tests-5/NNS||immunological-4/JJ	nsubjpass||explored-19/VBN||tests-5/NNS	nsubj||identify-21/VB||tests-5/NNS	det||detection-8/NN||the-7/DT	prep_for||tests-5/NNS||detection-8/NN	amod||antigens-11/NNS||m.tuberculosis-10/JJ	prep_of||detection-8/NN||antigens-11/NNS	prep_of||detection-8/NN||antibodies-13/NNS	conj_and||antigens-11/NNS||antibodies-13/NNS	det||antigens-16/NNS||the-15/DT	prep_to||antigens-11/NNS||antigens-16/NNS	aux||explored-19/VBN||have-17/VBP	auxpass||explored-19/VBN||been-18/VBN	root||ROOT-0/null||explored-19/VBN	aux||identify-21/VB||to-20/TO	xcomp||explored-19/VBN||identify-21/VB	dobj||identify-21/VB||individuals-22/NNS	prep_at||identify-21/VB||risk-24/NN	amod||-rrb--35/NNS||developing-26/VBG	advmod||-rrb--35/NNS||tb-27/RB	conj_or||tb-27/RB||with-29/IN	advmod||-rrb--35/NNS||with-29/IN	nn||ltbi-34/NNS||latent-30/NN	nn||ltbi-34/NNS||tb-31/NN	nn||ltbi-34/NNS||infection-32/NN	amod||ltbi-34/NNS||-lrb--33/JJ	pobj||with-29/IN||ltbi-34/NNS	prep_of||risk-24/NN||-rrb--35/NNS	tb-31||m.tuberculosis-10||no||in addition , immunological tests for the detection of m.tuberculosis antigens and antibodies to the antigens have been explored to identify individuals at risk of developing tb or with latent tb infection -lrb- ltbi -rrb- .
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||discomfort-4/NN||ocular-3/NN	dobj||assess-2/VB||discomfort-4/NN	prep_upon||assess-2/VB||instillation-6/NN	amod||preference-9/NN||patient-8/JJ	prep_upon||assess-2/VB||preference-9/NN	conj_and||instillation-6/NN||preference-9/NN	prep_for||preference-9/NN||brinzolamide/timolol-11/NN	amod||dorzolamide/timolol-14/JJ||relative-12/JJ	dep||dorzolamide/timolol-14/JJ||to-13/TO	amod||preference-9/NN||dorzolamide/timolol-14/JJ	prep_in||preference-9/NN||patients-17/NNS	prep_with||patients-17/NNS||open-angleglaucoma-19/NN	prep_with||patients-17/NNS||ocularhypertension-21/NN	conj_or||open-angleglaucoma-19/NN||ocularhypertension-21/NN	open-angleglaucoma-19||brinzolamide--1||yes||to assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angleglaucoma or ocularhypertension.
nsubj||available-11/JJ||information-1/NN	nsubjpass||analysed-16/VBN||information-1/NN	det||replication-4/NN||the-3/DT	prep_on||information-1/NN||replication-4/NN	nn||viruses-7/NNS||viralhaemorrhagicfever-6/NN	prep_of||replication-4/NN||viruses-7/NNS	cop||available-11/JJ||is-8/VBZ	neg||available-11/JJ||not-9/RB	advmod||available-11/JJ||readily-10/RB	root||ROOT-0/null||available-11/JJ	aux||analysed-16/VBN||has-13/VBZ	neg||analysed-16/VBN||never-14/RB	auxpass||analysed-16/VBN||been-15/VBN	conj_and||available-11/JJ||analysed-16/VBN	det||approach-20/NN||a-18/DT	amod||approach-20/NN||comparative-19/JJ	prep_in||analysed-16/VBN||approach-20/NN	viralhaemorrhagicfever-6||viruses-7||no||information on the replication of viralhaemorrhagicfever viruses is not readily available and has never been analysed in a comparative approach.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mycobacteriumtuberculosis-22||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
nsubj||diseases-5/NNS||priondiseases-1/NNS	cop||diseases-5/NNS||are-2/VBP	amod||diseases-5/NNS||fatal-3/JJ	nn||diseases-5/NNS||neurodegenerative-4/NN	root||ROOT-0/null||diseases-5/NNS	vmod||diseases-5/NNS||associated-6/VBN	det||conversion-9/NN||the-8/DT	prep_with||associated-6/VBN||conversion-9/NN	amod||prionprotein-12/NN||cellular-11/JJ	prep_of||conversion-9/NN||prionprotein-12/NN	dep||prionprotein-12/NN||prpc-14/JJ	det||system-20/NN||the-17/DT	amod||system-20/NN||central-18/JJ	amod||system-20/NN||nervous-19/JJ	prep_in||prionprotein-12/NN||system-20/NN	det||isoform-24/NN||the-22/DT	amod||isoform-24/NN||infectious-23/JJ	prep_into||associated-6/VBN||isoform-24/NN	dep||isoform-24/NN||prpsc-26/JJ	priondiseases-1||prionprotein-12||no||priondiseases are fatal neurodegenerative diseases associated with the conversion of cellular prionprotein (prpc) in the central nervous system into the infectious isoform (prpsc).
prepc_based_on||become-18/VBN||on-2/IN	det||results-4/NNS||the-3/DT	pobj||become-18/VBN||results-4/NNS	amod||trials-8/NNS||several-6/JJ	amod||trials-8/NNS||randomized-7/JJ	prep_of||results-4/NNS||trials-8/NNS	nsubj||become-18/VBN||abciximab-10/NN	prep_with||abciximab-10/NN||uh-12/NN	prep_with||abciximab-10/NN||aspirin-14/NN	conj_and||uh-12/NN||aspirin-14/NN	prep_with||abciximab-10/NN||clopidogrel-16/NN	conj_and||uh-12/NN||clopidogrel-16/NN	aux||become-18/VBN||have-17/VBP	root||ROOT-0/null||become-18/VBN	det||therapy-22/NN||a-19/DT	amod||therapy-22/NN||standard-20/JJ	nn||therapy-22/NN||adjunctive-21/NN	xcomp||become-18/VBN||therapy-22/NN	amod||pci-25/NN||primary-24/JJ	prep_with||become-18/VBN||pci-25/NN	prep_for||pci-25/NN||ami-27/NN	ami-27||aspirin-14||yes||based on the results of several randomized trials, abciximab with uh, aspirin and clopidogrel have become a standard adjunctive therapy with primary pci for ami.
det||organizations-2/NNS||these-1/DT	nsubj||include-3/VBP||organizations-2/NNS	root||ROOT-0/null||include-3/VBP	det||center-5/NN||the-4/DT	dobj||include-3/VBP||center-5/NN	amod||-rrb--12/NNP||hiv/aids-7/JJ	nn||-rrb--12/NNP||vaccine-8/NN	nn||-rrb--12/NNP||immunology-9/NN	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||chavi-11/NNP	prep_for||center-5/NN||-rrb--12/NNP	det||network-17/NN||the-14/DT	amod||network-17/NN||immune-15/JJ	nn||network-17/NN||tolerance-16/NN	dobj||include-3/VBP||network-17/NN	conj_and||center-5/NN||network-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||itn-19/NNP	dep||network-17/NN||-rrb--20/NNP	det||hiv-23/NN||the-22/DT	dobj||include-3/VBP||hiv-23/NN	conj_and||center-5/NN||hiv-23/NN	nn||-rrb--29/NNP||vaccine-24/NN	nn||-rrb--29/NNP||trials-25/NNS	nn||-rrb--29/NNP||network-26/NN	nn||-rrb--29/NNP||-lrb--27/NNP	nn||-rrb--29/NNP||hvtn-28/NNP	dep||hiv-23/NN||-rrb--29/NNP	det||program-36/NN||the-31/DT	amod||program-36/NN||u.s.-32/JJ	amod||program-36/NN||military-33/JJ	nn||program-36/NN||hiv-34/NN	nn||program-36/NN||research-35/NN	dobj||include-3/VBP||program-36/NN	conj_and||center-5/NN||program-36/NN	amod||-rrb--39/NNS||-lrb--37/JJ	nn||-rrb--39/NNS||mhrp-38/NN	dep||program-36/NN||-rrb--39/NNS	det||network-43/NN||the-42/DT	dobj||include-3/VBP||network-43/NN	conj_and||center-5/NN||network-43/NN	amod||donors-47/NNS||pancreatic-45/JJ	nn||donors-47/NNS||organ-46/NN	prep_for||network-43/NN||donors-47/NNS	nn||-rrb--52/NN||diabetes-49/NN	nn||-rrb--52/NN||-lrb--50/NNP	amod||-rrb--52/NN||npod-51/JJ	prep_with||include-3/VBP||-rrb--52/NN	aids--1||hiv-34||no||these organizations include the center for hiv/aids vaccine immunology -lrb- chavi -rrb- , the immune tolerance network -lrb- itn -rrb- , the hiv vaccine trials network -lrb- hvtn -rrb- , the u.s. military hiv research program -lrb- mhrp -rrb- , and the network for pancreatic organ donors with diabetes -lrb- npod -rrb- .
det||ha117-4/NNS||the-1/DT	nn||ha117-4/NNS||novel-2/NN	nn||ha117-4/NNS||gene-3/NN	nsubj||gene-12/NN||ha117-4/NNS	cop||gene-12/NN||is-5/VBZ	det||gene-12/NN||a-6/DT	nn||gene-12/NN||multidrug-7/NN	nn||gene-12/NN||resistance-8/NN	appos||gene-12/NN||mdr-10/NN	root||ROOT-0/null||gene-12/NN	vmod||gene-12/NN||expressed-13/VBN	amod||cells-17/NNS||all-transretinoicacid-resistant-15/JJ	amod||cells-17/NNS||hl-60-16/JJ	agent||expressed-13/VBN||cells-17/NNS	hl--1||all-transretinoicacid--1||no_rel||the novel gene ha117 is a multidrug resistance (mdr) gene expressed by all-transretinoicacid-resistant hl-60 cells.
det||organization-4/NN||the-1/DT	nn||organization-4/NN||world-2/NN	nn||organization-4/NN||health-3/NN	nsubj||estimated-6/VBN||organization-4/NN	aux||estimated-6/VBN||has-5/VBZ	root||ROOT-0/null||estimated-6/VBN	mark||develop-12/VBP||that-7/IN	number||million-9/CD||8-8/CD	nsubj||develop-12/VBP||million-9/CD	prep_of||million-9/CD||people-11/NNS	ccomp||estimated-6/VBN||develop-12/VBP	amod||tb-14/NN||active-13/JJ	dobj||develop-12/VBP||tb-14/NN	det||year-16/NN||every-15/DT	tmod||develop-12/VBP||year-16/NN	det||situation-19/NN||the-18/DT	nsubjpass||complicated-21/VBN||situation-19/NN	auxpass||complicated-21/VBN||is-20/VBZ	ccomp||estimated-6/VBN||complicated-21/VBN	conj_and||develop-12/VBP||complicated-21/VBN	det||increase-24/NN||an-23/DT	agent||complicated-21/VBN||increase-24/NN	amod||strains-27/NNS||mycobacteriumtuberculosis-26/JJ	prep_of||increase-24/NN||strains-27/NNS	amod||strains-27/NNS||resistant-28/JJ	prep_to||resistant-28/JJ||drugs-30/NNS	vmod||drugs-30/NNS||used-31/VBN	nn||mdr-35/NN||antitubercular-33/NN	nn||mdr-35/NN||therapy-34/NN	prep_in||used-31/VBN||mdr-35/NN	amod||strains-27/NNS||xdr-tb-37/JJ	conj_and||resistant-28/JJ||xdr-tb-37/JJ	tb-14||antitubercular-33||yes||the world health organization has estimated that 8 million of people develop active tb every year and the situation is complicated by an increase of mycobacteriumtuberculosis strains resistant to drugs used in antitubercular therapy mdr and xdr-tb.
nn||toxin-2/NN||cholera-1/NN	nsubj||factors-16/NNS||toxin-2/NN	appos||toxin-2/NN||ct-4/NN	amod||pili-8/NNS||toxin-co-regulated-7/JJ	conj_and||toxin-2/NN||pili-8/NNS	nsubj||factors-16/NNS||pili-8/NNS	appos||pili-8/NNS||tcp-10/NN	cop||factors-16/NNS||are-12/VBP	det||factors-16/NNS||the-13/DT	amod||factors-16/NNS||major-14/JJ	nn||factors-16/NNS||virulence-15/NN	root||ROOT-0/null||factors-16/NNS	nsubj||contribute-23/VBP||factors-16/NNS	amod||strains-21/NNS||vibriocholeraeo1-18/JJ	conj_and||vibriocholeraeo1-18/JJ||o139-20/JJ	amod||strains-21/NNS||o139-20/JJ	prep_of||factors-16/NNS||strains-21/NNS	rcmod||factors-16/NNS||contribute-23/VBP	det||pathogenesis-26/NNS||the-25/DT	prep_to||contribute-23/VBP||pathogenesis-26/NNS	prep_of||pathogenesis-26/NNS||disease-28/NN	amod||pandemics-32/NNS||devastating-30/JJ	nn||pandemics-32/NNS||cholera-31/NN	prep_during||contribute-23/VBP||pandemics-32/NNS	cholera-31||vibriocholeraeo1-18||no||cholera toxin (ct) and toxin-co-regulated pili (tcp) are the major virulence factors of vibriocholeraeo1 and o139 strains that contribute to the pathogenesis of disease during devastating cholera pandemics.
nsubj||one-24/CD||ifih1-1/NNS	dep||ifih1-1/NNS||interferon-3/NN	vmod||interferon-3/NN||induced-4/VBN	prep_with||induced-4/VBN||helicase-6/NN	dep||domain-8/NN||c-7/SYM	dep||helicase-6/NN||domain-8/NN	num||domain-8/NN||1-9/CD	advmod||known-13/VBN||also-12/RB	vmod||ifih1-1/NNS||known-13/VBN	prep_as||known-13/VBN||mda5-15/NNS	amod||protein-19/NN||melanoma-17/JJ	amod||protein-19/NN||differentiation-associated-18/JJ	dep||mda5-15/NNS||protein-19/NN	dep||protein-19/NN||5-20/CD	cop||one-24/CD||is-23/VBZ	root||ROOT-0/null||one-24/CD	det||family-27/NN||a-26/DT	prep_of||one-24/CD||family-27/NN	nn||proteins-30/NNS||intracellular-29/NN	prep_of||family-27/NN||proteins-30/NNS	vmod||proteins-30/NNS||known-31/VBN	aux||recognise-33/VB||to-32/TO	xcomp||known-31/VBN||recognise-33/VB	amod||rna-35/NN||viral-34/JJ	dobj||recognise-33/VB||rna-35/NN	xcomp||known-31/VBN||mediate-37/VB	conj_and||recognise-33/VB||mediate-37/VB	det||response-41/NN||the-38/DT	amod||response-41/NN||innate-39/JJ	amod||response-41/NN||immune-40/JJ	dobj||mediate-37/VB||response-41/NN	melanoma-17||interferon-3||yes||ifih1 (interferon induced with helicase c domain 1), also known as mda5 (melanoma differentiation-associated protein 5), is one of a family of intracellular proteins known to recognise viral rna and mediate the innate immune response.
det||discovery-2/NN||the-1/DT	nsubj||suggests-22/VBZ||discovery-2/NN	mark||uncoupled-15/VBN||that-3/IN	det||induction-5/NN||the-4/DT	nsubjpass||uncoupled-15/VBN||induction-5/NN	amod||responses-12/NNS||pro-inflammatory-7/JJ	conj_and||pro-inflammatory-7/JJ||type-9/NN	amod||responses-12/NNS||type-9/NN	amod||responses-12/NNS||i-10/JJ	nn||responses-12/NNS||ifn-11/NN	prep_of||induction-5/NN||responses-12/NNS	aux||uncoupled-15/VBN||can-13/MD	auxpass||uncoupled-15/VBN||be-14/VB	dep||discovery-2/NN||uncoupled-15/VBN	amod||manipulation-18/NN||pharmacological-17/JJ	prep_through||uncoupled-15/VBN||manipulation-18/NN	amod||acidification-21/NN||endolysosomal-20/JJ	prep_of||manipulation-18/NN||acidification-21/NN	root||ROOT-0/null||suggests-22/VBZ	amod||avenues-24/NNS||new-23/JJ	dobj||suggests-22/VBZ||avenues-24/NNS	amod||intervention-28/NN||potential-26/JJ	amod||intervention-28/NN||therapeutic-27/JJ	prep_for||suggests-22/VBZ||intervention-28/NN	prep_against||intervention-28/NN||inflammations-30/NNS	prep_against||intervention-28/NN||sepsis-32/NN	conj_and||inflammations-30/NNS||sepsis-32/NN	sepsis-32||ifn-11||no_rel||the discovery that the induction of pro-inflammatory and type i ifn responses can be uncoupled through pharmacological manipulation of endolysosomal acidification suggests new avenues for potential therapeutic intervention against inflammations and sepsis.
det||report-2/NN||this-1/DT	nsubj||describes-3/VBZ||report-2/NN	root||ROOT-0/null||describes-3/VBZ	number||old-6/JJ||3-4/CD	npadvmod||old-6/JJ||year-5/NN	amod||girl-7/NN||old-6/JJ	dobj||describes-3/VBZ||girl-7/NN	det||presentation-11/NN||the-9/DT	amod||presentation-11/NN||unusual-10/JJ	prep_with||describes-3/VBZ||presentation-11/NN	nn||juvenileidiopathicarthritis-14/NNS||polyarticular-13/NN	prep_of||presentation-11/NN||juvenileidiopathicarthritis-14/NNS	appos||juvenileidiopathicarthritis-14/NNS||jia-16/NN	amod||citrullinated-20/JJ||anti-cyclic-19/JJ	amod||antibodies-25/NNS||citrullinated-20/JJ	nn||antibodies-25/NNS||peptide-21/NN	appos||antibodies-25/NNS||anti-ccp-23/NN	prep_with||describes-3/VBZ||antibodies-25/NNS	det||factor-30/NN||a-27/DT	amod||factor-30/NN||positive-28/JJ	amod||factor-30/NN||rheumatoid-29/JJ	prep_with||describes-3/VBZ||factor-30/NN	conj_and||antibodies-25/NNS||factor-30/NN	appos||factor-30/NN||rf-32/NN	jia-16||antibodies-25||no_rel||this report describes 3 year old girl with the unusual presentation of polyarticular juvenileidiopathicarthritis (jia) with anti-cyclic citrullinated peptide (anti-ccp) antibodies and a positive rheumatoid factor (rf).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||infiltration-13/NN||pre-incisional-12/JJ	prep_of||effect-10/NN||infiltration-13/NN	prep_of||infiltration-13/NN||tonsils-15/NNS	prep_with||tonsils-15/NNS||dexamethasone-17/NN	det||incidence-20/NN||the-19/DT	prep_on||dexamethasone-17/NN||incidence-20/NN	prep_on||dexamethasone-17/NN||severity-22/NN	conj_and||incidence-20/NN||severity-22/NN	prep_of||incidence-20/NN||postoperativepain-24/NN	prep_of||incidence-20/NN||vomiting-26/NN	conj_and||postoperativepain-24/NN||vomiting-26/NN	prep_in||evaluate-8/VB||children-28/NNS	vmod||children-28/NNS||undergoing-29/VBG	advmod||undergoing-29/VBG||tonsillectomy-30/RB	amod||anesthesia-33/NN||general-32/JJ	prep_under||undergoing-29/VBG||anesthesia-33/NN	vomiting-26||dexamethasone-17||yes||the aim of this study was to evaluate the effect of pre-incisional infiltration of tonsils with dexamethasone on the incidence and severity of postoperativepain and vomiting in children undergoing tonsillectomy under general anesthesia.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tuberculosis-28||rif-19||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
amod||offspring-2/NN||sedentary-1/JJ	nsubj||insulin-resistant-10/JJ||offspring-2/NN	prep_of||offspring-2/NN||patients-4/NNS	prep_with||patients-4/NNS||type2diabetes-6/CD	cop||insulin-resistant-10/JJ||are-7/VBP	advmod||insulin-resistant-10/JJ||often-8/RB	advmod||insulin-resistant-10/JJ||more-9/RBR	root||ROOT-0/null||insulin-resistant-10/JJ	prep_than||insulin-resistant-10/JJ||persons-12/NNS	neg||history-16/NN||no-14/DT	nn||history-16/NN||family-15/NN	prep_with||persons-12/NNS||history-16/NN	prep_of||history-16/NN||diabetes-18/NN	advmod||are-31/VBP||when-21/WRB	amod||offspring-25/NN||active-22/JJ	conj_or||active-22/JJ||fit-24/JJ	amod||offspring-25/NN||fit-24/JJ	nsubj||are-31/VBP||offspring-25/NN	amod||patients-30/NNS||type-27/NN	number||type-27/NN||2-28/CD	amod||patients-30/NNS||diabetic-29/JJ	prep_of||offspring-25/NN||patients-30/NNS	advcl||evident-42/JJ||are-31/VBP	prepc_compared_with||are-31/VBP||with-33/IN	amod||persons-35/NNS||non-diabetic-34/JJ	pobj||are-31/VBP||persons-35/NNS	nsubj||evident-42/JJ||differences-37/NNS	prep_in||differences-37/NNS||insulinresistance-39/NN	cop||evident-42/JJ||are-40/VBP	advmod||evident-42/JJ||less-41/RBR	conj_but||insulin-resistant-10/JJ||evident-42/JJ	insulin--1||insulinresistance-39||no_rel||sedentary offspring of patients with type2diabetes are often more insulin-resistant than persons with no family history of diabetes, but when active or fit offspring of type 2 diabetic patients are compared with non-diabetic persons, differences in insulinresistance are less evident.
nsubj||causes-7/VBZ||aquafol-1/NN	det||propofol-5/NN||a-3/DT	nn||propofol-5/NN||microemulsion-4/NN	appos||aquafol-1/NN||propofol-5/NN	root||ROOT-0/null||causes-7/VBZ	advmod||severe-9/JJ||more-8/RBR	amod||pain-12/NN||severe-9/JJ	conj_and||severe-9/JJ||frequent-11/JJ	amod||pain-12/NN||frequent-11/JJ	dobj||causes-7/VBZ||pain-12/NN	prep_on||causes-7/VBZ||injection-14/NN	prep_than||injection-14/NN||propofol-16/NN	pain-12||propofol-16||yes||aquafol, a microemulsion propofol, causes more severe and frequent pain on injection than propofol.
aux||address-2/VB||to-1/TO	advcl||initiated-7/VBD||address-2/VB	det||issue-4/NN||this-3/DT	dobj||address-2/VB||issue-4/NN	nsubj||initiated-7/VBD||we-6/PRP	nsubj||assessed-19/VBD||we-6/PRP	root||ROOT-0/null||initiated-7/VBD	det||study-11/NN||a-8/DT	nn||study-11/NN||candidate-9/NN	nn||study-11/NN||gene-10/NN	dobj||initiated-7/VBD||study-11/NN	det||study-17/NN||the-13/DT	amod||study-17/NN||amish-14/JJ	nn||study-17/NN||family-15/NN	nn||study-17/NN||diabetes-16/NN	prep_within||initiated-7/VBD||study-17/NN	conj_and||initiated-7/VBD||assessed-19/VBD	det||association-21/NN||the-20/DT	dobj||assessed-19/VBD||association-21/NN	nn||variants-25/NNS||taste-23/NN	nn||variants-25/NNS||receptor-24/NN	prep_of||association-21/NN||variants-25/NNS	prep_with||assessed-19/VBD||indicators-27/NNS	nn||dysregulation-30/NN||glucose-29/NN	prep_of||indicators-27/NNS||dysregulation-30/NN	det||diagnosis-34/NN||a-33/DT	prep_including||assessed-19/VBD||diagnosis-34/NN	amod||levels-39/NNS||type2diabetesmellitus-36/JJ	conj_and||type2diabetesmellitus-36/JJ||high-38/JJ	amod||levels-39/NNS||high-38/JJ	prep_of||diagnosis-34/NN||levels-39/NNS	prep_of||levels-39/NNS||bloodglucose-41/NN	prep_of||levels-39/NNS||insulin-43/NN	conj_and||bloodglucose-41/NN||insulin-43/NN	det||test-49/NN||an-45/DT	amod||test-49/NN||oral-46/JJ	nn||test-49/NN||glucose-47/NN	nn||test-49/NN||tolerance-48/NN	prep_during||assessed-19/VBD||test-49/NN	type2diabetesmellitus-36||insulin-43||yes||to address this issue, we initiated a candidate gene study within the amish family diabetes study and assessed the association of taste receptor variants with indicators of glucose dysregulation, including a diagnosis of type2diabetesmellitus and high levels of bloodglucose and insulin during an oral glucose tolerance test.
det||concentrations-2/NNS||the-1/DT	nsubj||compounds-5/VBZ||concentrations-2/NNS	prep_of||concentrations-2/NNS||antioxidant-4/NN	root||ROOT-0/null||compounds-5/VBZ	advmod||phenolics-7/NNS||namely-6/RB	dobj||compounds-5/VBZ||phenolics-7/NNS	nsubjpass||correlated-31/VBN||phenolics-7/NNS	dobj||compounds-5/VBZ||carotenoids-9/NNS	conj_and||phenolics-7/NNS||carotenoids-9/NNS	nsubjpass||correlated-31/VBN||carotenoids-9/NNS	dobj||compounds-5/VBZ||flavonoids-11/NNS	conj_and||phenolics-7/NNS||flavonoids-11/NNS	nsubjpass||correlated-31/VBN||flavonoids-11/NNS	dobj||compounds-5/VBZ||tocopherols-13/NNS	conj_and||phenolics-7/NNS||tocopherols-13/NNS	nsubjpass||correlated-31/VBN||tocopherols-13/NNS	vmod||phenolics-7/NNS||estimated-14/VBN	det||oil-18/NN||the-16/DT	nn||oil-18/NN||seed-17/NN	prep_in||estimated-14/VBN||oil-18/NN	vmod||oil-18/NN||increased-19/VBN	acomp||increased-19/VBN||due-20/JJ	amod||proline-23/NN||foliar-applied-22/JJ	prep_to||due-20/JJ||proline-23/NN	nn||conditions-27/NNS||water-25/NN	nn||conditions-27/NNS||deficit-26/NN	prep_under||increased-19/VBN||conditions-27/NNS	auxpass||correlated-31/VBN||was-29/VBD	advmod||correlated-31/VBN||positively-30/RB	rcmod||phenolics-7/NNS||correlated-31/VBN	det||dpph-36/NN||the-33/DT	amod||dpph-36/NN||enhanced-34/JJ	nn||dpph-36/NN||oil-35/NN	nn||activity-40/NN||dpph-36/NN	amod||radical-38/JJ||free-37/JJ	amod||activity-40/NN||radical-38/JJ	nn||activity-40/NN||scavenging-39/NN	prep_with||correlated-31/VBN||activity-40/NN	deficit-26||phenolics-7||no_rel||the concentrations of antioxidant compounds namely phenolics, carotenoids, flavonoids and tocopherols estimated in the seed oil increased due to foliar-applied proline under water deficit conditions that was positively correlated with the enhanced oil dpph free radical scavenging activity.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	det||therapy-9/NN||a-6/DT	amod||therapy-9/NN||4-week-7/JJ	nn||therapy-9/NN||adjunctive-8/NN	prep_of||effect-4/NN||therapy-9/NN	amod||exe-13/NN||exenatide-11/JJ	prep_of||therapy-9/NN||exe-13/NN	dep||exe-13/NN||5â-16/NNS	nn||metformin-57/NN||$-17/$	num||î-20/NN||10-19/CD	npadvmod||response-37/RB||î-20/NN	num||b.i.d.-23/NNP||1/4-21/CD	nn||b.i.d.-23/NNP||g-22/NNP	npadvmod||in-36/IN||b.i.d.-23/NNP	conj_or||b.i.d.-23/NNP||sitagliptin-26/NN	npadvmod||in-36/IN||sitagliptin-26/NN	appos||sitagliptin-26/NN||sita-28/NNP	num||mg-32/NN||100-31/CD	npadvmod||once-33/RB||mg-32/NN	dep||sitagliptin-26/NN||once-33/RB	dep||once-33/RB||daily-34/RB	advmod||î-20/NN||in-36/IN	dep||+-56/CD||response-37/RB	det||challenge-43/NN||a-39/DT	amod||challenge-43/NN||standardized-40/JJ	nn||challenge-43/NN||breakfast-41/NN	nn||challenge-43/NN||meal-42/NN	prep_to||response-37/RB||challenge-43/NN	num||men-46/NNS||48-45/CD	prep_in||response-37/RB||men-46/NNS	prep_in||response-37/RB||women-48/NNS	conj_or||men-46/NNS||women-48/NNS	amod||insulinglargine-52/NN||type2diabetes-50/JJ	nn||insulinglargine-52/NN||receiving-51/NN	prep_with||men-46/NNS||insulinglargine-52/NN	appos||insulinglargine-52/NN||glar-54/NN	num||$-17/$||+-56/CD	dep||5â-16/NNS||metformin-57/NN	dep||exe-13/NN||met-59/VBN	type2diabetes-50||exenatide-11||yes||to assess the effect of a 4-week adjunctive therapy of exenatide (exe) (5â€“10 î¼g b.i.d.) or sitagliptin (sita) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type2diabetes receiving insulinglargine (glar) + metformin (met).
poss||aim-2/NN||our-1/PRP$	nsubj||was-3/VBD||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||establish-5/VB||to-4/TO	ccomp||was-3/VBD||establish-5/VB	amod||assays-8/NNS||virus-specific-6/JJ	amod||assays-8/NNS||serological-7/JJ	dobj||establish-5/VB||assays-8/NNS	aux||determine-11/VB||to-10/TO	ccomp||was-3/VBD||determine-11/VB	conj_and||establish-5/VB||determine-11/VB	det||prevalence-13/NN||the-12/DT	dobj||determine-11/VB||prevalence-13/NN	nn||g-16/NN||immunoglobulin-15/NN	prep_of||prevalence-13/NN||g-16/NN	appos||g-16/NN||igg-18/NN	det||viruses-23/NNS||these-21/DT	num||viruses-23/NNS||three-22/CD	prep_against||determine-11/VB||viruses-23/NNS	det||population-27/NN||the-25/DT	amod||population-27/NN||general-26/JJ	prep_in||viruses-23/NNS||population-27/NN	virus--1||viruses-23||no||our aim was to establish virus-specific serological assays and to determine the prevalence of immunoglobulin g (igg) against these three viruses in the general population.
num||patients-2/NNS||six-1/CD	nsubj||had-7/VBD||patients-2/NNS	amod||results-6/NNS||discordant-4/JJ	nn||results-6/NNS||test-5/NN	prep_with||patients-2/NNS||results-6/NNS	root||ROOT-0/null||had-7/VBD	preconj||tst-14/NN||either-8/DT	dep||tst-14/NN||1-10/LS	det||tst-14/NN||a-12/DT	amod||tst-14/NN||negative-13/JJ	dobj||had-7/VBD||tst-14/NN	amod||igra-17/NN||positive-16/JJ	dobj||had-7/VBD||igra-17/NN	conj_and||tst-14/NN||igra-17/NN	prep_in||tst-14/NN||combination-19/NN	det||history-23/NN||a-21/DT	amod||history-23/NN||medical-22/JJ	prep_with||combination-19/NN||history-23/NN	nn||exposure-26/NN||tuberculosis-25/NNP	prep_of||history-23/NN||exposure-26/NN	nn||â-29/NN||n-28/NN	dep||combination-19/NN||â-29/NN	nsubj||â-33/VBP||$-30/$	number||=-32/CD||‰-31/CD	num||$-30/$||=-32/CD	rcmod||â-29/NN||â-33/VBP	dobj||â-33/VBP||$-34/$	number||1-36/CD||‰-35/CD	num||$-34/$||1-36/CD	dep||tst-44/NN||2-40/LS	det||tst-44/NN||a-42/DT	amod||tst-44/NN||positive-43/JJ	prep_in||tst-14/NN||tst-44/NN	conj_or||combination-19/NN||tst-44/NN	amod||igra-47/NN||negative-46/JJ	conj_or||combination-19/NN||igra-47/NN	conj_and||tst-44/NN||igra-47/NN	prep_in||tst-44/NN||combination-49/NN	nn||vaccination-52/NN||bcg-51/NN	prep_with||combination-49/NN||vaccination-52/NN	nn||â-55/NN||n-54/NN	dep||combination-49/NN||â-55/NN	nsubj||â-59/VBP||$-56/$	number||=-58/CD||‰-57/CD	num||$-56/$||=-58/CD	rcmod||â-55/NN||â-59/VBP	dobj||â-59/VBP||$-60/$	number||3-62/CD||‰-61/CD	num||$-60/$||3-62/CD	det||history-67/NN||a-65/DT	amod||history-67/NN||medical-66/JJ	dobj||had-7/VBD||history-67/NN	conj_or||tst-14/NN||history-67/NN	nn||exposure-70/NN||tuberculosis-69/NNP	prep_of||history-67/NN||exposure-70/NN	nn||â-73/NN||n-72/NN	dep||history-67/NN||â-73/NN	nsubj||â-77/VBP||$-74/$	number||=-76/CD||‰-75/CD	num||$-74/$||=-76/CD	rcmod||â-73/NN||â-77/VBP	dobj||â-77/VBP||$-78/$	number||2-80/CD||‰-79/CD	num||$-78/$||2-80/CD	tuberculosis-69||bcg-51||no||six patients with discordant test results had either (1) a negative tst and positive igra in combination with a medical history of tuberculosis exposure ( n â€‰=â€‰1) or (2) a positive tst and negative igra in combination with bcg vaccination ( n â€‰=â€‰3) or a medical history of tuberculosis exposure ( n â€‰=â€‰2).
det||goal-3/NN||the-1/DT	amod||goal-3/NN||primary-2/JJ	nsubj||reducing-16/VBG||goal-3/NN	prep_of||goal-3/NN||therapy-5/NN	prep_in||therapy-5/NN||patients-7/NNS	prep_with||patients-7/NNS||hypercholesterolemia-9/NN	prep_with||patients-7/NNS||coronaryheartdisease-11/NN	conj_and||hypercholesterolemia-9/NN||coronaryheartdisease-11/NN	appos||goal-3/NN||chd-13/NN	aux||reducing-16/VBG||is-15/VBZ	root||ROOT-0/null||reducing-16/VBG	nn||cholesterol-19/NN||low-density-17/NN	nn||cholesterol-19/NN||lipoprotein-18/NN	dobj||reducing-16/VBG||cholesterol-19/NN	dep||cholesterol-19/NN||ldl-c-21/JJ	hypercholesterolemia-9||cholesterol-19||no||the primary goal of therapy in patients with hypercholesterolemia and coronaryheartdisease (chd) is reducing low-density lipoprotein cholesterol (ldl-c).
nsubj||finding-5/NN||insulinresistance-1/NN	nsubjpass||manifested-14/VBN||insulinresistance-1/NN	cop||finding-5/NN||is-2/VBZ	det||finding-5/NN||a-3/DT	amod||finding-5/NN||common-4/JJ	root||ROOT-0/null||finding-5/NN	amod||kidneydisease-8/NN||chronic-7/JJ	prep_in||finding-5/NN||kidneydisease-8/NN	appos||kidneydisease-8/NN||ckd-10/NN	auxpass||manifested-14/VBN||is-13/VBZ	conj_and||finding-5/NN||manifested-14/VBN	amod||hyperglycemia-18/NN||mild-16/JJ	amod||hyperglycemia-18/NN||fasting-17/VBG	agent||manifested-14/VBN||hyperglycemia-18/NN	amod||testing-23/NN||abnormal-20/JJ	nn||testing-23/NN||glucose-21/NN	nn||testing-23/NN||tolerance-22/NN	agent||manifested-14/VBN||testing-23/NN	conj_and||hyperglycemia-18/NN||testing-23/NN	hyperglycemia-18||glucose-21||no||insulinresistance is a common finding in chronic kidneydisease (ckd) and is manifested by mild fasting hyperglycemia and abnormal glucose tolerance testing.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bacilluscalmette-guerin-24||no||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
nsubjpass||associated-3/VBN||insulinresistance-1/NN	auxpass||associated-3/VBN||is-2/VBZ	root||ROOT-0/null||associated-3/VBN	amod||dysfunction-6/NN||endothelial-5/JJ	prep_with||associated-3/VBN||dysfunction-6/NN	advmod||remains-27/VBZ||however-8/RB	det||relationship-12/NN||the-10/DT	amod||relationship-12/NN||mechanistic-11/JJ	nsubj||remains-27/VBZ||relationship-12/NN	det||abnormalities-15/NNS||these-14/DT	prep_between||relationship-12/NN||abnormalities-15/NNS	det||role-18/NN||the-17/DT	prep_between||relationship-12/NN||role-18/NN	conj_and||abnormalities-15/NNS||role-18/NN	amod||insulin-22/NN||impaired-20/VBN	amod||insulin-22/NN||endothelial-21/JJ	prep_of||role-18/NN||insulin-22/NN	vmod||insulin-22/NN||signaling-23/VBG	prep||signaling-23/VBG||versus-24/CC	amod||insulinresistance-26/NN||global-25/JJ	pobj||versus-24/CC||insulinresistance-26/NN	parataxis||associated-3/VBN||remains-27/VBZ	acomp||remains-27/VBZ||unclear-28/JJ	insulin-22||insulinresistance-26||no_rel||insulinresistance is associated with endothelial dysfunction; however, the mechanistic relationship between these abnormalities and the role of impaired endothelial insulin signaling versus global insulinresistance remains unclear.
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	tb-24||bcg-1||yes||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
det||objective-3/NN||the-1/DT	nn||objective-3/NN||study-2/NN	nsubj||was-4/VBD||objective-3/NN	nsubj||explore-6/VB||objective-3/NN	root||ROOT-0/null||was-4/VBD	aux||explore-6/VB||to-5/TO	xcomp||was-4/VBD||explore-6/VB	det||mechanism-9/NN||the-7/DT	amod||mechanism-9/NN||immunomodulatory-8/JJ	dobj||explore-6/VB||mechanism-9/NN	prep_of||mechanism-9/NN||action-11/NN	amod||2b-15/NNS||ifn-î-13/JJ	amod||2b-15/NNS||±-14/JJ	prep_for||action-11/NN||2b-15/NNS	prepc_by||explore-6/VB||measuring-17/VBG	amod||cell-21/NN||serum-18/JJ	amod||cell-21/NN||regulatory-19/JJ	nn||cell-21/NN||t-20/NN	dobj||measuring-17/VBG||cell-21/NN	appos||cell-21/NN||treg-23/NN	nn||²-30/NNP||serum-26/NNP	nn||²-30/NNP||transforming-27/NNP	nn||²-30/NNP||growth-28/NN	nn||²-30/NNP||factor-î-29/NNP	dobj||measuring-17/VBG||²-30/NNP	conj_and||cell-21/NN||²-30/NNP	nn||²-33/NNP||tgf-î-32/NNP	appos||²-30/NNP||²-33/NNP	amod||-10-40/NN||interleukin-36/JJ	appos||-10-40/NN||il-38/NN	dobj||measuring-17/VBG||-10-40/NN	conj_and||cell-21/NN||-10-40/NN	amod||levels-44/NNS||autoantibody-43/JJ	dobj||measuring-17/VBG||levels-44/NNS	conj_and||cell-21/NN||levels-44/NNS	prep_in||levels-44/NNS||patients-46/NNS	prep_with||patients-46/NNS||melanoma-48/NN	vmod||cell-21/NN||treated-49/VBN	det||phase-53/NN||the-51/DT	nn||phase-53/NN||induction-52/NN	prep_with||treated-49/VBN||phase-53/NN	det||regimen-60/NN||the-55/DT	amod||regimen-60/NN||high-dose-56/JJ	nn||regimen-60/NN||ifn-î-57/NNP	nn||regimen-60/NN||±-58/NNP	amod||regimen-60/NN||2b-59/JJ	prep_of||phase-53/NN||regimen-60/NN	melanoma-48||ifn--1||yes||the study objective was to explore the immunomodulatory mechanism of action for ifn-î± 2b by measuring serum regulatory t cell (treg), serum transforming growth factor-î² (tgf-î²), interleukin (il)-10, and autoantibody levels in patients with melanoma treated with the induction phase of the high-dose ifn-î± 2b regimen.
nsubjpass||known-4/VBN||it-1/PRP	auxpass||known-4/VBN||is-2/VBZ	advmod||known-4/VBN||well-3/RB	root||ROOT-0/null||known-4/VBN	mark||has-7/VBZ||that-5/IN	nsubj||has-7/VBZ||pioglitazone-6/NN	ccomp||known-4/VBN||has-7/VBZ	det||effect-10/NN||an-8/DT	amod||effect-10/NN||anti-atherosclerotic-9/JJ	dobj||has-7/VBZ||effect-10/NN	mark||unclear-15/JJ||although-12/IN	nsubj||unclear-15/JJ||it-13/PRP	cop||unclear-15/JJ||is-14/VBZ	advcl||has-7/VBZ||unclear-15/JJ	mark||induces-18/VBZ||if-16/IN	nsubj||induces-18/VBZ||hyperinsulinemia-17/NN	advcl||unclear-15/JJ||induces-18/VBZ	amod||changes-20/NNS||atherogenic-19/JJ	dobj||induces-18/VBZ||changes-20/NNS	preconj||directly-23/RB||either-22/DT	dep||induces-18/VBZ||directly-23/RB	dep||induces-18/VBZ||indirectly-25/RB	conj_or||directly-23/RB||indirectly-25/RB	det||promotion-29/NN||the-28/DT	prep_by||induces-18/VBZ||promotion-29/NN	prep_of||promotion-29/NN||obesity-31/NN	pioglitazone-6||obesity-31||no_rel||it is well known that pioglitazone has an anti-atherosclerotic effect, although it is unclear if hyperinsulinemia induces atherogenic changes, either directly or indirectly, by the promotion of obesity.
prepc_compared_to||had-24/VBD||to-2/TO	det||study-5/NN||an-3/DT	amod||study-5/NN||earlier-4/JJR	pobj||had-24/VBD||study-5/NN	nn||mg-9/NN||gabapentin-7/NN	num||mg-9/NN||900-8/CD	prep_of||study-5/NN||mg-9/NN	amod||pain-13/NN||acute-11/JJ	nn||pain-13/NN||zoster-12/NN	prep_for||mg-9/NN||pain-13/NN	conj_and||study-5/NN||allodynia-15/NN	nsubj||followed-17/VBD||allodynia-15/NN	pobj||had-24/VBD||allodynia-15/NN	rcmod||allodynia-15/NN||followed-17/VBD	det||protocol-21/NN||a-18/DT	advmod||identical-20/JJ||nearly-19/RB	amod||protocol-21/NN||identical-20/JJ	dobj||followed-17/VBD||protocol-21/NN	nsubj||had-24/VBD||pregabalin-23/NN	nsubjpass||tolerated-33/VBN||pregabalin-23/NN	root||ROOT-0/null||had-24/VBD	det||effect-27/NN||a-25/DT	amod||effect-27/NN||similar-26/JJ	dobj||had-24/VBD||effect-27/NN	prep_on||effect-27/NN||pain-29/NN	auxpass||tolerated-33/VBN||was-31/VBD	advmod||tolerated-33/VBN||well-32/RB	conj_and||had-24/VBD||tolerated-33/VBN	neg||difference-37/NN||no-36/DT	prep_with||tolerated-33/VBN||difference-37/NN	prep_from||difference-37/NN||placebo-39/NN	prep_on||placebo-39/NN||sleepiness-41/NNS	pain-29||gabapentin-7||yes||compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	hormone-12||cushingsyndrome-2||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nn||physicians-2/NNS||family-1/NN	nsubj||received-3/VBD||physicians-2/NNS	root||ROOT-0/null||received-3/VBD	nn||education-6/NN||insulin-4/NN	nn||education-6/NN||initiation/titration-5/NN	nsubj||cardâ-13/VBD||education-6/NN	det||â-10/NN||a-8/DT	amod||â-10/NN||physician-specific-9/JJ	appos||education-6/NN||â-10/NN	amod||â-10/NN||$-11/$	dep||$-11/$||˜report-12/JJ	ccomp||received-3/VBD||cardâ-13/VBD	dobj||cardâ-13/VBD||$-14/$	num||$-14/$||™-15/CD	det||characteristics-18/NNS||the-17/DT	prep_on||cardâ-13/VBD||characteristics-18/NNS	poss||population-25/NN||their-20/PRP$	amod||population-25/NN||type2diabetes-21/JJ	appos||population-25/NN||t2dm-23/NNP	prep_of||characteristics-18/NNS||population-25/NN	det||registry-29/NN||a-28/DT	prep_on||cardâ-13/VBD||registry-29/NN	conj_and||characteristics-18/NNS||registry-29/NN	amod||patients-32/NNS||insulin-eligible-31/JJ	prep_of||registry-29/NN||patients-32/NNS	det||workshop-35/NN||a-34/DT	prep_at||cardâ-13/VBD||workshop-35/NN	type2diabetes-21||insulin-4||yes||family physicians received insulin initiation/titration education, a physician-specific â€˜report cardâ€™ on the characteristics of their type2diabetes (t2dm) population, and a registry of insulin-eligible patients at a workshop.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatic-37||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
amod||levels-14/NNS||serum-1/JJ	amod||levels-14/NNS||interleukin-8-2/JJ	dep||interleukin-8-2/JJ||il-8-4/JJ	conj_and||interleukin-8-2/JJ||interferon-alpha-7/JJ	amod||levels-14/NNS||interferon-alpha-7/JJ	dep||interferon-alpha-7/JJ||ifn-9/NN	nn||±-12/NNS||î-11/NN	dep||ifn-9/NN||±-12/NNS	nsubjpass||estimated-17/VBN||levels-14/NNS	aux||estimated-17/VBN||have-15/VBP	auxpass||estimated-17/VBN||been-16/VBN	root||ROOT-0/null||estimated-17/VBN	det||total-20/NN||a-19/DT	prep_from||estimated-17/VBN||total-20/NN	num||individuals-23/NNS||88-22/CD	prep_of||total-20/NN||individuals-23/NNS	prep_of||individuals-30/NNS||individuals-23/NNS	nsubj||individuals-30/NNS||19-26/CD	cop||individuals-30/NNS||were-27/VBD	amod||individuals-30/NNS||disease-free-28/JJ	amod||individuals-30/NNS||healthy-29/JJ	rcmod||individuals-23/NNS||individuals-30/NNS	nsubj||patients-35/NNS||69-33/CD	cop||patients-35/NNS||were-34/VBD	conj_and||estimated-17/VBN||patients-35/NNS	nn||goitre-39/NN||thyroid-37/NN	nn||goitre-39/NN||diseases-38/NNS	prep_with||patients-35/NNS||goitre-39/NN	dep||goitre-39/NN||n-41/VBN	dep||21-43/CD||=-42/SYM	ccomp||n-41/VBN||21-43/CD	prep_with||patients-35/NNS||autoimmunediseases-46/NNS	conj_and||goitre-39/NN||autoimmunediseases-46/NNS	dep||autoimmunediseases-46/NNS||n-48/VBN	dep||16-50/CD||=-49/SYM	ccomp||n-48/VBN||16-50/CD	prep_with||patients-35/NNS||carcinomas-54/NNS	conj_and||goitre-39/NN||carcinomas-54/NNS	dep||carcinomas-54/NNS||n-56/VBN	dep||32-58/CD||=-57/SYM	ccomp||n-56/VBN||32-58/CD	autoimmunediseases-46||ifn-9||no||serum interleukin-8 (il-8) and interferon-alpha (ifn- î± ) levels have been estimated from a total of 88 individuals of which 19 were disease-free healthy individuals, and 69 were patients with thyroid diseases goitre ( n = 21), autoimmunediseases ( n = 16), and carcinomas ( n = 32).
det||rates-3/NNS||the-1/DT	nn||rates-3/NNS||incidence-2/NN	nsubj||0.69-5/CD||rates-3/NNS	cop||0.69-5/CD||were-4/VBD	root||ROOT-0/null||0.69-5/CD	punct||100,000-7/CD||/-6/:	dep||0.69-5/CD||100,000-7/CD	number||%-10/NN||95-9/CD	amod||ci-11/NN||%-10/NN	dep||100,000-7/CD||ci-11/NN	num||/-14/NNS||0.44-0-12/CD	num||/-14/NNS||.94-13/CD	dep||ci-11/NN||/-14/NNS	dep||ci-11/NN||100,000-15/CD	prep_for||100,000-7/CD||uc-18/CD	prep_for||100,000-7/CD||0.09-20/CD	conj_and||uc-18/CD||0.09-20/CD	punct||100,000-7/CD||/-21/:	dep||0.69-5/CD||100,000-22/CD	num||%-25/NN||95-24/CD	dep||0.69-5/CD||%-25/NN	vmod||%-25/NN||ci-26/VBN	number||.18-28/CD||0.002-0-27/CD	num||/-29/NNP||.18-28/CD	dobj||ci-26/VBN||/-29/NNP	num||/-29/NNP||100,000-30/CD	prep_for||0.69-5/CD||cd-33/NN	cd-33||uc-18||no_rel||the incidence rates were 0.69/100,000 (95% ci 0.44-0.94/100,000) for uc and 0.09/100,000 (95% ci 0.002-0.18/100,000) for cd.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	alcohol-22||hyperuricaemia-14||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
det||question-4/NN||the-1/DT	amod||question-4/NN||key-2/JJ	amod||question-4/NN||operational-3/JJ	nsubj||is-6/VBZ||question-4/NN	advmod||is-6/VBZ||now-5/RB	root||ROOT-0/null||is-6/VBZ	mark||added-11/VBN||whether-7/IN	nsubjpass||added-11/VBN||primaquine-8/NN	nsubj||artemisinin-13/VB||primaquine-8/NN	aux||added-11/VBN||should-9/MD	auxpass||added-11/VBN||be-10/VB	ccomp||is-6/VBZ||added-11/VBN	aux||artemisinin-13/VB||to-12/TO	xcomp||added-11/VBN||artemisinin-13/VB	nn||treatments-15/NNS||combination-14/NN	dobj||artemisinin-13/VB||treatments-15/NNS	det||treatment-18/NN||the-17/DT	prep_for||artemisinin-13/VB||treatment-18/NN	prep_of||treatment-18/NN||falciparummalaria-20/NN	aux||reduce-22/VB||to-21/TO	vmod||artemisinin-13/VB||reduce-22/VB	advmod||reduce-22/VB||further-23/RBR	det||transmissibility-25/NN||the-24/DT	dobj||reduce-22/VB||transmissibility-25/NN	det||infection-29/NN||the-27/DT	amod||infection-29/NN||treated-28/JJ	prep_of||transmissibility-25/NN||infection-29/NN	falciparummalaria-20||primaquine-8||yes||the key operational question now is whether primaquine should be added to artemisinin combination treatments for the treatment of falciparummalaria to reduce further the transmissibility of the treated infection.
aux||study-2/VB||to-1/TO	advcl||mg-46/VBP||study-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||potential-4/JJ	dobj||study-2/VB||efficacy-5/NN	dobj||study-2/VB||tolerability-7/NN	conj_and||efficacy-5/NN||tolerability-7/NN	det||formula-12/NN||a-9/DT	amod||formula-12/NN||natural-10/JJ	amod||formula-12/NN||multiherbal-11/JJ	prep_of||efficacy-5/NN||formula-12/NN	appos||formula-12/NN||immumax-14/NN	xcomp||study-2/VB||containing-16/VBG	amod||mg-19/NN||echinaceaextract-17/JJ	dep||echinaceaextract-17/JJ||120-18/CD	dobj||containing-16/VBG||mg-19/NN	amod||powder-22/NN||garlic-21/JJ	nsubj||mg-46/VBP||powder-22/NN	num||mg-24/NN||100-23/CD	dep||powder-22/NN||mg-24/NN	nn||oil-28/NN||nigella-26/NN	nn||oil-28/NN||sativa-27/NN	conj_and||powder-22/NN||oil-28/NN	nsubj||mg-46/VBP||oil-28/NN	num||mg-30/NN||200-29/CD	dep||oil-28/NN||mg-30/NN	nn||ginseng-34/NN||panax-33/NN	conj_and||powder-22/NN||ginseng-34/NN	nsubj||mg-46/VBP||ginseng-34/NN	number||50-36/CD||extract-35/CD	num||mg-37/NNP||50-36/CD	dep||ginseng-34/NN||mg-37/NNP	nn||mg-41/NN||vitaminc-39/NNP	num||mg-41/NN||50-40/CD	dep||ginseng-34/NN||mg-41/NN	conj_plus||mg-37/NNP||mg-41/NN	amod||7.5-45/NN||elemental-43/JJ	nn||7.5-45/NN||zinc-44/NN	dep||ginseng-34/NN||7.5-45/NN	conj_and||mg-37/NNP||7.5-45/NN	root||ROOT-0/null||mg-46/VBP	det||treatment-49/NN||the-48/DT	prep_in||mg-46/VBP||treatment-49/NN	prep_of||treatment-49/NN||patients-51/NNS	vmod||patients-51/NNS||suffering-52/VBG	det||commoncold-55/NN||the-54/DT	prep_from||suffering-52/VBG||commoncold-55/NN	commoncold-55||echinaceaextract-17||yes||to study the potential efficacy and tolerability of a natural multiherbal formula (immumax) containing echinaceaextract 120 mg, garlic powder 100 mg, nigella sativa oil 200 mg, and panax ginseng extract 50 mg plus vitaminc 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the commoncold.
advmod||observed-4/VBD||surprisingly-1/RB	nsubj||observed-4/VBD||we-3/PRP	root||ROOT-0/null||observed-4/VBD	dobj||observed-4/VBD||inhibition-5/NN	prep_of||inhibition-5/NN||rsvinfection-7/NN	amod||lines-12/NNS||immortalized-9/JJ	amod||lines-12/NNS||epithelial-10/JJ	nn||lines-12/NNS||cell-11/NN	prep_in||observed-4/VBD||lines-12/NNS	nsubjpass||shown-16/VBN||lines-12/NNS	nsubjpass||related-19/VBN||lines-12/NNS	nsubjpass||charged-26/VBN||lines-12/NNS	auxpass||shown-16/VBN||was-15/VBD	rcmod||lines-12/NNS||shown-16/VBN	aux||related-19/VBN||to-17/TO	auxpass||related-19/VBN||be-18/VB	xcomp||shown-16/VBN||related-19/VBN	prep_to||related-19/VBN||interactions-21/NNS	prep_between||interactions-21/NNS||pam3csk4-23/CD	advmod||charged-26/VBN||negatively-25/RB	xcomp||shown-16/VBN||charged-26/VBN	conj_and||related-19/VBN||charged-26/VBN	dobj||charged-26/VBN||glycosaminoglycans-27/NNS	det||cells-30/NNS||these-29/DT	prep_on||charged-26/VBN||cells-30/NNS	nsubjpass||known-34/VBN||cells-30/NNS	auxpass||known-34/VBN||are-33/VBP	rcmod||cells-30/NNS||known-34/VBN	dobj||known-34/VBN||targets-35/NNS	prep_for||known-34/VBN||binding-37/VBG	amod||rsv-43/NN||laboratory-adapted-39/JJ	conj_negcc||laboratory-adapted-39/JJ||wild-type-42/JJ	amod||rsv-43/NN||wild-type-42/JJ	prep_of||binding-37/VBG||rsv-43/NN	rsvinfection-7||rsv-43||no||surprisingly, we observed inhibition of rsvinfection in immortalized epithelial cell lines, which was shown to be related to interactions between pam3csk4 and negatively charged glycosaminoglycans on these cells, which are known targets for binding of laboratory-adapted but not wild-type rsv.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	fat--1||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
num||specimens-3/NNS||33-2/CD	prep_of||%-27/NN||specimens-3/NNS	amod||results-7/NNS||concurrent-5/JJ	nn||results-7/NNS||dst-6/NN	prep_with||specimens-3/NNS||results-7/NNS	nsubj||%-27/NN||sensitivity-9/NN	det||assay-13/NN||the-11/DT	amod||assay-13/NN||mods-12/JJ	prep_of||sensitivity-9/NN||assay-13/NN	prep_for||assay-13/NN||detection-15/NN	prep_of||detection-15/NN||resistance-17/NN	prep_to||resistance-17/NN||isoniazid-19/NN	prep_to||resistance-17/NN||rifampin-21/NN	conj_and||isoniazid-19/NN||rifampin-21/NN	prep_to||resistance-17/NN||mdr-tb-24/NN	conj_and||isoniazid-19/NN||mdr-tb-24/NN	cop||%-27/NN||was-25/VBD	num||%-27/NN||88-26/CD	root||ROOT-0/null||%-27/NN	num||%-30/NN||95-29/CD	npadvmod||ci-31/JJ||%-30/NN	dep||68â-33/NNS||ci-31/JJ	dep||%-27/NN||68â-33/NNS	dep||%-37/NN||$-34/$	num||$-34/$||97-36/CD	amod||68â-33/NNS||%-37/NN	num||%-41/NN||96-40/CD	conj_and||%-27/NN||%-41/NN	num||%-44/NN||95-43/CD	npadvmod||ci-45/JJ||%-44/NN	dep||79â-47/NNS||ci-45/JJ	dep||%-41/NN||79â-47/NNS	dep||%-51/NN||$-48/$	num||$-48/$||100-50/CD	amod||79â-47/NNS||%-51/NN	num||%-56/NN||91-55/CD	conj_and||%-27/NN||%-56/NN	num||%-59/NN||95-58/CD	npadvmod||ci-60/JJ||%-59/NN	dep||72â-62/NNS||ci-60/JJ	dep||%-56/NN||72â-62/NNS	dep||%-66/NN||$-63/$	num||$-63/$||99-65/CD	amod||72â-62/NNS||%-66/NN	advmod||%-27/NN||respectively-69/RB	nsubj||%-74/NN||specificity-71/NN	cop||%-74/NN||was-72/VBD	num||%-74/NN||89-73/CD	parataxis||%-27/NN||%-74/NN	num||%-77/NN||95-76/CD	npadvmod||ci-78/JJ||%-77/NN	dep||52â-80/NNS||ci-78/JJ	dep||%-74/NN||52â-80/NNS	dep||%-84/NN||$-81/$	num||$-81/$||100-83/CD	amod||52â-80/NNS||%-84/NN	num||%-88/NN||89-87/CD	parataxis||%-27/NN||%-88/NN	conj_and||%-74/NN||%-88/NN	num||%-91/NN||95-90/CD	npadvmod||ci-92/JJ||%-91/NN	dep||52â-94/NNS||ci-92/JJ	dep||%-88/NN||52â-94/NNS	dep||%-98/NN||$-95/$	num||$-95/$||100-97/CD	amod||52â-94/NNS||%-98/NN	num||%-103/NN||90-102/CD	parataxis||%-27/NN||%-103/NN	conj_and||%-74/NN||%-103/NN	num||%-106/NN||95-105/CD	npadvmod||ci-107/JJ||%-106/NN	dep||56â-109/NNS||ci-107/JJ	dep||%-103/NN||56â-109/NNS	dep||%-113/NN||$-110/$	num||$-110/$||100-112/CD	amod||56â-109/NNS||%-113/NN	advmod||%-74/NN||respectively-116/RB	tb--1||rifampin-21||yes||of 33 specimens with concurrent dst results, sensitivity of the mods assay for detection of resistance to isoniazid, rifampin, and mdr-tb was 88% (95% ci, 68â€“97%), 96% (95% ci, 79â€“100%), and 91% (95% ci, 72â€“99%), respectively; specificity was 89% (95% ci, 52â€“100%), 89% (95% ci, 52â€“100%), and 90% (95% ci, 56â€“100%), respectively.
nsubjpass||shown-7/VBN||hydrogensulfide-1/NN	nsubj||have-9/VB||hydrogensulfide-1/NN	appos||hydrogensulfide-1/NN||h2s-3/NNP	aux||shown-7/VBN||has-5/VBZ	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||have-9/VB||to-8/TO	xcomp||shown-7/VBN||have-9/VB	amod||effects-11/NNS||cytoprotective-10/JJ	dep||sdisease-21/JJ||effects-11/NNS	prep_in||effects-11/NNS||models-13/NNS	prep_of||models-13/NNS||hypertension-15/NN	prep_of||models-13/NNS||ischemia/reperfusion-17/NN	conj_and||hypertension-15/NN||ischemia/reperfusion-17/NN	prep_of||models-13/NNS||alzheimer-19/NN	conj_and||hypertension-15/NN||alzheimer-19/NN	dep||have-9/VB||sdisease-21/JJ	hydrogensulfide-1||ischemia--1||no_rel||hydrogensulfide (h2s) has been shown to have cytoprotective effects in models of hypertension, ischemia/reperfusion and alzheimer'sdisease.
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||quinine-15||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
amod||naive-3/JJ||temozolomide-2/JJ	amod||gbm-4/NN||naive-3/JJ	prep_for||treatment-18/NN||gbm-4/NN	nn||patients-9/NNS||astrocytoma-6/NN	nn||patients-9/NNS||grade-7/NN	nn||patients-9/NNS||iii-8/NN	conj_and||gbm-4/NN||patients-9/NNS	prep_for||treatment-18/NN||patients-9/NNS	nn||progression-12/NN||disease-11/NN	prep_with||gbm-4/NN||progression-12/NN	nsubj||treatment-18/NN||temozolomide-14/NN	cop||treatment-18/NN||is-15/VBZ	advmod||treatment-18/NN||still-16/RB	det||treatment-18/NN||the-17/DT	root||ROOT-0/null||treatment-18/NN	nn||outside-21/NN||choice-20/NN	prep_of||treatment-18/NN||outside-21/NN	amod||studies-24/NNS||clinical-23/JJ	prep_of||outside-21/NN||studies-24/NNS	astrocytoma-6||temozolomide-14||yes||for temozolomide naive gbm and astrocytoma grade iii patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies.
det||importance-2/NN||the-1/DT	nsubj||stem-6/VBP||importance-2/NN	nsubj||leaves-8/VBZ||importance-2/NN	nn||cordifolia-5/NN||tinospora-4/NN	prep_of||importance-2/NN||cordifolia-5/NN	root||ROOT-0/null||stem-6/VBP	conj_and||stem-6/VBP||leaves-8/VBZ	nsubjpass||investigated-11/VBN||extract-9/NNP	auxpass||investigated-11/VBN||was-10/VBD	ccomp||leaves-8/VBZ||investigated-11/VBN	poss||effect-16/NN||its-13/PRP$	amod||effect-16/NN||possible-14/JJ	nn||effect-16/NN||hepatoprotective-15/NN	prep_for||investigated-11/VBN||effect-16/NN	amod||mice-21/NNS||swiss-18/JJ	amod||mice-21/NNS||albino-19/JJ	amod||mice-21/NNS||male-20/JJ	prep_in||investigated-11/VBN||mice-21/NNS	amod||toxicity-26/NN||lead-23/JJ	amod||toxicity-26/NN||nitrate-24/JJ	amod||toxicity-26/NN||induced-25/JJ	prep_against||mice-21/NNS||toxicity-26/NN	albino-19||nitrate-24||no_rel||the importance of tinospora cordifolia stem and leaves extract was investigated for its possible hepatoprotective effect in swiss albino male mice against lead nitrate induced toxicity.
nsubj||factor-6/NN||hypoglycaemia-1/NN	cop||factor-6/NN||is-2/VBZ	det||factor-6/NN||an-3/DT	amod||factor-6/NN||independent-4/JJ	nn||factor-6/NN||risk-5/NN	root||ROOT-0/null||factor-6/NN	prep_for||factor-6/NN||death-8/NN	amod||malaria-11/NN||severe-10/JJ	prep_in||death-8/NN||malaria-11/NN	det||effect-17/NN||a-13/DT	amod||effect-17/NN||recognized-14/VBN	amod||effect-17/NN||adverse-15/JJ	nn||effect-17/NN||treatment-16/NN	prep_for||factor-6/NN||effect-17/NN	conj_and||death-8/NN||effect-17/NN	amod||quinine-20/NN||parenteral-19/JJ	prep_of||effect-17/NN||quinine-20/NN	malaria-11||quinine-20||yes||hypoglycaemia is an independent risk factor for death in severe malaria and a recognized adverse treatment effect of parenteral quinine.
det||study-5/NN||this-2/DT	nn||study-5/NN||retrospective-3/NN	amod||study-5/NN||cross-sectional-4/JJ	prep_in||evaluated-26/VBN||study-5/NN	det||value-8/NN||the-6/DT	amod||value-8/NN||prognostic-7/JJ	nsubjpass||evaluated-26/VBN||value-8/NN	amod||parameters-16/NNS||basic-10/JJ	amod||parameters-16/NNS||cerebrospinal-11/JJ	nn||parameters-16/NNS||fluid-12/NN	appos||parameters-16/NNS||csf-14/NN	prep_of||value-8/NN||parameters-16/NNS	prep_in||parameters-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||bacterialmeningitis-20/NNS	prep_with||patients-18/NNS||viralmeningoencephalitis-22/NNS	conj_and||bacterialmeningitis-20/NNS||viralmeningoencephalitis-22/NNS	prep_with||patients-18/NNS||leptomeningealmetastases-24/NNS	conj_and||bacterialmeningitis-20/NNS||leptomeningealmetastases-24/NNS	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	meningitis--1||viral--1||no_rel||in this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (csf) parameters in patients with bacterialmeningitis, viralmeningoencephalitis and leptomeningealmetastases were evaluated.
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	ebvinfection-26||epstein-barrvirus-4||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-11/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||ipti-sp-9/NN	root||ROOT-0/null||reduces-11/VBZ	nn||morbidity-13/NN||malaria-12/NN	dobj||reduces-11/VBZ||morbidity-13/NN	number||%-19/NN||20-15/CD	dep||%-19/NN||%-16/NN	dep||%-19/NN||to-17/TO	number||%-19/NN||33-18/CD	prep_by||reduces-11/VBZ||%-19/NN	malaria-12||pyrimethamine--1||no||intermittent preventive treatment in infants with sulphadoxine-pyrimethamine (ipti-sp) reduces malaria morbidity by 20% to 33%.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
det||study-2/NN||the-1/DT	nsubjpass||performed-5/VBN||study-2/NN	aux||performed-5/VBN||will-3/MD	auxpass||performed-5/VBN||be-4/VB	root||ROOT-0/null||performed-5/VBN	det||study-9/NN||a-7/DT	amod||study-9/NN||dose-escalation-8/JJ	prep_as||performed-5/VBN||study-9/NN	vmod||study-9/NN||evaluating-10/VBG	det||dose-15/NN||the-11/DT	amod||dose-15/NN||optimal-12/JJ	nn||dose-15/NN||carbon-13/NN	nn||dose-15/NN||ion-14/NN	dobj||evaluating-10/VBG||dose-15/NN	prep_with||dose-15/NN||respect-17/NN	nn||control-22/NN||toxicity-19/NN	conj_and||toxicity-19/NN||tumor-21/NN	nn||control-22/NN||tumor-21/NN	prep_to||evaluating-10/VBG||control-22/NN	ion-14||tumor-21||no_rel||the study will be performed as a dose-escalation study evaluating the optimal carbon ion dose with respect to toxicity and tumor control.
vmod||possible-16/JJ||using-1/VBG	dobj||using-1/VBG||algorithms-2/NNS	aux||shut-4/VB||to-3/TO	vmod||using-1/VBG||shut-4/VB	prt||shut-4/VB||off-5/RP	det||pump-8/NN||the-6/DT	nn||pump-8/NN||insulin-7/NN	dobj||shut-4/VB||pump-8/NN	tmod||predicted-12/VBN||pump-8/NN	advmod||predicted-12/VBN||when-9/WRB	nsubjpass||predicted-12/VBN||hypoglycemia-10/NN	auxpass||predicted-12/VBN||is-11/VBZ	rcmod||pump-8/NN||predicted-12/VBN	nsubj||possible-16/JJ||it-14/PRP	nsubj||prevent-18/VB||it-14/PRP	cop||possible-16/JJ||is-15/VBZ	root||ROOT-0/null||possible-16/JJ	aux||prevent-18/VB||to-17/TO	xcomp||possible-16/JJ||prevent-18/VB	dobj||prevent-18/VB||hypoglycemia-19/NN	num||%-22/NN||75-21/CD	prep_on||prevent-18/VB||%-22/NN	prep_of||%-22/NN||nights-24/NNS	tmod||predicted-36/VBN||nights-24/NNS	num||%-27/NN||84-26/CD	dep||nights-24/NNS||%-27/NN	prep_of||%-27/NN||events-29/NNS	advmod||predicted-36/VBN||when-31/WRB	nsubjpass||predicted-36/VBN||it-32/PRP	nsubj||occur-38/VB||it-32/PRP	aux||predicted-36/VBN||would-33/MD	advmod||predicted-36/VBN||otherwise-34/RB	auxpass||predicted-36/VBN||be-35/VB	rcmod||nights-24/NNS||predicted-36/VBN	aux||occur-38/VB||to-37/TO	xcomp||predicted-36/VBN||occur-38/VB	insulin-7||hypoglycemia-19||no_rel||using algorithms to shut off the insulin pump when hypoglycemia is predicted, it is possible to prevent hypoglycemia on 75% of nights (84% of events) when it would otherwise be predicted to occur.
amod||research-2/NN||future-1/JJ	nsubj||investigate-4/VB||research-2/NN	aux||investigate-4/VB||should-3/MD	root||ROOT-0/null||investigate-4/VB	dobj||contributing-8/VBG||what-5/WP	nsubj||contributing-8/VBG||factors-6/NNS	aux||contributing-8/VBG||are-7/VBP	ccomp||investigate-4/VB||contributing-8/VBG	amod||charges-12/NNS||rising-10/VBG	nn||charges-12/NNS||inpatient-11/NN	prep_to||contributing-8/VBG||charges-12/NNS	amod||patients-15/NNS||hiv/aids-14/JJ	prep_among||charges-12/NNS||patients-15/NNS	aids--1||hiv--1||no||future research should investigate what factors are contributing to rising inpatient charges among hiv/aids patients.
det||pain-3/NN||the-1/DT	nn||pain-3/NN||injection-2/NN	nsubj||frequent-8/JJ||pain-3/NN	nsubj||difficult-10/JJ||pain-3/NN	nsubj||prevent-12/VB||pain-3/NN	nn||propofol-6/NN||microemulsion-5/NN	prep_of||pain-3/NN||propofol-6/NN	cop||frequent-8/JJ||is-7/VBZ	root||ROOT-0/null||frequent-8/JJ	conj_and||frequent-8/JJ||difficult-10/JJ	aux||prevent-12/VB||to-11/TO	xcomp||frequent-8/JJ||prevent-12/VB	pain-3||propofol-6||yes||the injection pain of microemulsion propofol is frequent and difficult to prevent.
nsubj||detrimental-4/JJ||this-1/DT	aux||detrimental-4/JJ||could-2/MD	cop||detrimental-4/JJ||be-3/VB	root||ROOT-0/null||detrimental-4/JJ	det||setting-7/NN||the-6/DT	prep_in||detrimental-4/JJ||setting-7/NN	amod||cerebralischemia-10/NN||delayed-9/VBN	prep_of||setting-7/NN||cerebralischemia-10/NN	appos||cerebralischemia-10/NN||dci-12/NN	advmod||vulnerable-20/JJ||when-15/WRB	det||tissue-18/NN||the-16/DT	nn||tissue-18/NN||brain-17/NN	nsubj||vulnerable-20/JJ||tissue-18/NN	cop||vulnerable-20/JJ||is-19/VBZ	rcmod||cerebralischemia-10/NN||vulnerable-20/JJ	amod||reductions-23/NNS||further-22/JJ	prep_to||vulnerable-20/JJ||reductions-23/NNS	nn||delivery-26/NN||oxygen-25/NN	prep_in||reductions-23/NNS||delivery-26/NN	prep_to||vulnerable-20/JJ||increases-28/NNS	conj_or||reductions-23/NNS||increases-28/NNS	prep_in||increases-28/NNS||demand-30/NN	cerebralischemia-10||oxygen-25||no_rel||this could be detrimental in the setting of delayed cerebralischemia (dci), when the brain tissue is vulnerable to further reductions in oxygen delivery or increases in demand.
nsubjpass||reported-39/VBN||conclusion-1/NN	amod||exposure-6/NN||short-term-2/JJ	advmod||single-dose-5/JJ||mostly-4/RB	amod||exposure-6/NN||single-dose-5/JJ	nsubjpass||associated-20/VBN||exposure-6/NN	prep_to||exposure-6/NN||asa-8/NN	det||treatment-11/NN||the-10/DT	prep_for||asa-8/NN||treatment-11/NN	prep_of||treatment-11/NN||pain-13/NN	prep_of||treatment-11/NN||fever-15/NN	conj_or||pain-13/NN||fever-15/NN	prep_of||treatment-11/NN||colds-18/NNS	conj_or||pain-13/NN||colds-18/NNS	auxpass||associated-20/VBN||was-19/VBD	rcmod||conclusion-1/NN||associated-20/VBN	det||increase-26/NN||a-22/DT	amod||increase-26/NN||small-23/JJ	conj_but||small-23/JJ||significant-25/JJ	amod||increase-26/NN||significant-25/JJ	prep_with||associated-20/VBN||increase-26/NN	det||risk-29/NN||the-28/DT	prep_in||increase-26/NN||risk-29/NN	prep_of||risk-29/NN||dyspepsia-31/NN	advmod||reported-39/VBN||relative-32/JJ	amod||complications-37/NNS||placebo.no-34/JJ	amod||complications-37/NNS||serious-35/JJ	nn||complications-37/NNS||gi-36/NN	prep_to||relative-32/JJ||complications-37/NNS	auxpass||reported-39/VBN||were-38/VBD	root||ROOT-0/null||reported-39/VBN	pain-13||asa-8||yes||conclusion short-term, mostly single-dose exposure to asa for the treatment of pain, fever, or colds was associated with a small but significant increase in the risk of dyspepsia relative to placebo.no serious gi complications were reported.
det||availability-3/NN||the-2/DT	prep_despite||continues-11/VBZ||availability-3/NN	amod||vaccines-6/NNS||specific-5/JJ	prep_of||availability-3/NN||vaccines-6/NNS	prep_of||availability-3/NN||antiviraldrugs-8/NNS	conj_and||vaccines-6/NNS||antiviraldrugs-8/NNS	nsubj||continues-11/VBZ||influenza-10/NN	nsubj||impose-13/VB||influenza-10/NN	root||ROOT-0/null||continues-11/VBZ	aux||impose-13/VB||to-12/TO	xcomp||continues-11/VBZ||impose-13/VB	det||toll-16/NN||a-14/DT	amod||toll-16/NN||heavy-15/JJ	dobj||impose-13/VB||toll-16/NN	amod||health-19/NN||human-18/JJ	prep_on||toll-16/NN||health-19/NN	advmod||impose-13/VB||worldwide-20/RB	influenza-10||antiviraldrugs-8||no_rel||despite the availability of specific vaccines and antiviraldrugs, influenza continues to impose a heavy toll on human health worldwide.
neg||differences-4/NNS||no-1/DT	amod||differences-4/NNS||significant-2/JJ	amod||differences-4/NNS||ethnic-3/JJ	nsubjpass||detected-6/VBN||differences-4/NNS	auxpass||detected-6/VBN||were-5/VBD	root||ROOT-0/null||detected-6/VBN	amod||status-9/NN||node-8/JJ	prep_for||detected-6/VBN||status-9/NN	nn||type-12/NN||tumour-11/NN	prep_for||detected-6/VBN||type-12/NN	conj_or||status-9/NN||type-12/NN	nn||size-15/NN||tumour-14/NN	prep_for||detected-6/VBN||size-15/NN	conj_or||status-9/NN||size-15/NN	amod||receptor-21/NN||human-17/JJ	nn||receptor-21/NN||epidermal-18/NN	nn||receptor-21/NN||growth-19/NN	nn||receptor-21/NN||factor-20/NN	prep_for||detected-6/VBN||receptor-21/NN	conj_or||status-9/NN||receptor-21/NN	nn||receptor-26/NN||oestrogen-23/NN	conj_and||oestrogen-23/NN||progesterone-25/NN	nn||receptor-26/NN||progesterone-25/NN	prep_for||detected-6/VBN||receptor-26/NN	conj_or||status-9/NN||receptor-26/NN	appos||receptor-26/NN||er/pr-28/NN	dep||receptor-26/NN||status-30/NN	prep_for||detected-6/VBN||survival-33/NN	conj_or||status-9/NN||survival-33/NN	oestrogen-23||tumour-14||no_rel||no significant ethnic differences were detected for node status, tumour type, tumour size, human epidermal growth factor receptor, oestrogen and progesterone receptor (er/pr) status, or survival.
det||findings-2/NNS||these-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	det||prevalence-6/NN||an-4/DT	amod||prevalence-6/NN||high-5/JJ	dobj||show-3/VBP||prevalence-6/NN	prep_of||prevalence-6/NN||rotavirusinfections-8/NNS	prep_among||show-3/VBP||children-10/NNS	vmod||children-10/NNS||admitted-11/VBN	prep_to||admitted-11/VBN||hospital-13/NN	amod||gastroenteritis-16/NNS||acute-15/JJ	prep_for||admitted-11/VBN||gastroenteritis-16/NNS	vmod||gastroenteritis-16/NNS||caused-17/VBN	amod||strains-21/NNS||different-19/JJ	nn||strains-21/NNS||rotavirus-20/NNS	agent||caused-17/VBN||strains-21/NNS	vmod||strains-21/NNS||circulating-22/VBG	det||area-25/NN||the-24/DT	prep_in||circulating-22/VBG||area-25/NN	vmod||area-25/NN||studied-26/VBN	rotavirusinfections-8||rotavirus-20||yes||these findings show an high prevalence of rotavirusinfections among children admitted to hospital for acute gastroenteritis caused by different rotavirus strains circulating in the area studied.
det||risk-2/NN||the-1/DT	nsubj||remained-5/VBD||risk-2/NN	prep_for||risk-2/NN||dka-4/NN	root||ROOT-0/null||remained-5/VBD	advmod||different-7/JJ||significantly-6/RB	acomp||remained-5/VBD||different-7/JJ	prep_after||remained-5/VBD||adjustment-9/NN	prep_for||adjustment-9/NN||age-11/NN	nn||onset-14/NN||diabetes-13/NN	prep_at||remained-5/VBD||onset-14/NN	nn||duration-17/NN||diabetes-16/NN	prep_at||remained-5/VBD||duration-17/NN	conj_and||onset-14/NN||duration-17/NN	prep_at||remained-5/VBD||a1c-19/NNS	conj_and||onset-14/NN||a1c-19/NNS	nn||dose-22/NN||insulin-21/NN	prep_at||remained-5/VBD||dose-22/NN	conj_and||onset-14/NN||dose-22/NN	prep_at||remained-5/VBD||sex-24/NN	conj_and||onset-14/NN||sex-24/NN	nn||background-28/NN||migration-27/NN	prep_at||remained-5/VBD||background-28/NN	conj_and||onset-14/NN||background-28/NN	parataxis||remained-5/VBD||p-30/VB	number||0.015-32/CD||=-31/CD	dobj||p-30/VB||0.015-32/CD	nn||ratio-35/NN||odds-34/NNS	appos||0.015-32/CD||ratio-35/NN	num||-RSB--43/NNS||1.357-36/CD	number||1.062-38/CD||-LSB--37/CD	num||-RSB--43/NNS||1.062-38/CD	amod||-RSB--43/NNS||â-39/JJ	num||-RSB--43/NNS||$-40/$	num||$-40/$||1.734-42/CD	dep||ratio-35/NN||-RSB--43/NNS	insulin-21||dka-4||no_rel||the risk for dka remained significantly different after adjustment for age at diabetes onset, diabetes duration, a1c, insulin dose, sex, and migration background ( p = 0.015, odds ratio 1.357 [1.062â€“1.734]).
det||model-4/NN||this-2/DT	nn||model-4/NN||animal-3/NN	prep_in||elevated-12/VBN||model-4/NN	nn||dna-8/NN||serum-6/NN	nn||dna-8/NN||hbv-7/NN	nsubjpass||elevated-12/VBN||dna-8/NN	conj_and||dna-8/NN||hbsag-10/NN	nsubjpass||elevated-12/VBN||hbsag-10/NN	auxpass||elevated-12/VBN||were-11/VBD	root||ROOT-0/null||elevated-12/VBN	prep_in||elevated-12/VBN||accordance-14/NN	nn||growth-17/NN||tumor-16/NN	prep_with||elevated-12/VBN||growth-17/NN	hbv-7||hbsag-10||yes||in this animal model, serum hbv dna and hbsag were elevated in accordance with tumor growth.
prep_in||ranged-13/VBD||subjects-2/NNS	amod||transmission-5/NN||multivariant-4/JJ	prep_with||subjects-2/NNS||transmission-5/NN	det||number-9/NN||the-7/DT	amod||number-9/NN||minimum-8/JJ	nsubj||ranged-13/VBD||number-9/NN	amod||viruses-12/NNS||transmitted-11/JJ	prep_of||number-9/NN||viruses-12/NNS	root||ROOT-0/null||ranged-13/VBD	number||10-17/CD||2-15/CD	dep||10-17/CD||to-16/TO	prep_from||ranged-13/VBD||10-17/CD	amod||recombination-20/NN||viral-19/JJ	prep_with||ranged-13/VBD||recombination-20/NN	amod||recombination-20/NN||leading-21/VBG	amod||shuffling-27/NN||rapid-23/JJ	conj_and||rapid-23/JJ||extensive-25/JJ	amod||shuffling-27/NN||extensive-25/JJ	amod||shuffling-27/NN||genetic-26/JJ	prep_to||recombination-20/NN||shuffling-27/NN	nn||lineages-30/NNS||virus-29/NN	prep_among||shuffling-27/NN||lineages-30/NNS	virus-29||viruses-12||no||in subjects with multivariant transmission, the minimum number of transmitted viruses ranged from 2 to 10 with viral recombination leading to rapid and extensive genetic shuffling among virus lineages.
advmod||is-4/VBZ||however-1/RB	expl||is-4/VBZ||there-3/EX	root||ROOT-0/null||is-4/VBZ	amod||data-6/NNS||minimal-5/JJ	nsubj||is-4/VBZ||data-6/NNS	amod||aerosol-9/NN||influenzavirus-8/JJ	prep_on||data-6/NNS||aerosol-9/NN	amod||aerosol-9/NN||shedding-10/VBG	det||infectiousness-13/NNS||the-12/DT	nsubj||is-4/VBZ||infectiousness-13/NNS	conj_and||data-6/NNS||infectiousness-13/NNS	amod||aerosols-16/NNS||exhaled-15/JJ	prep_of||infectiousness-13/NNS||aerosols-16/NNS	nsubj||is-4/VBZ||none-19/NN	conj_and||data-6/NNS||none-19/NN	det||impact-22/NN||the-21/DT	prep_on||none-19/NN||impact-22/NN	prep_of||impact-22/NN||facemasks-24/NNS	amod||aerosol-27/NN||viral-26/JJ	prep_on||facemasks-24/NNS||aerosol-27/NN	vmod||aerosol-27/NN||shedding-28/VBG	prep_from||shedding-28/VBG||patients-30/NNS	amod||influenza-33/NN||seasonal-32/JJ	prep_with||patients-30/NNS||influenza-33/NN	influenza-33||influenzavirus-8||no||however, there is minimal data on influenzavirus aerosol shedding, the infectiousness of exhaled aerosols, and none on the impact of facemasks on viral aerosol shedding from patients with seasonal influenza.
det||aliskiren-3/NN||the-2/DT	prep_in||received-23/VBD||aliskiren-3/NN	det||evaluation-6/NN||the-5/DT	prep_in||aliskiren-3/NN||evaluation-6/NN	prep_of||evaluation-6/NN||proteinuria-8/NN	nn||study-14/NN||diabetes-10/NNP	appos||study-14/NN||avoid-12/NNP	prep_in||proteinuria-8/NN||study-14/NN	num||patients-18/NNS||599-16/CD	amod||patients-18/NNS||hypertensive-17/JJ	nsubj||received-23/VBD||patients-18/NNS	prep_with||patients-18/NNS||type2diabetes-20/NN	prep_with||patients-18/NNS||nephropathy-22/NN	conj_and||type2diabetes-20/NN||nephropathy-22/NN	root||ROOT-0/null||received-23/VBD	num||months-25/NNS||6-24/CD	dobj||received-23/VBD||months-25/NNS	prep_of||months-25/NNS||aliskiren-27/NN	num||mg-30/NN||150-29/CD	dep||months-25/NNS||mg-30/NN	advmod||titrated-32/VBN||daily-31/RB	vmod||mg-30/NN||titrated-32/VBN	number||mg-35/CD||300-34/CD	prep_to||titrated-32/VBN||mg-35/CD	advmod||titrated-32/VBN||daily-36/RB	num||months-39/NNS||3-38/CD	prep_after||titrated-32/VBN||months-39/NNS	nn||therapy-51/NN||placebo-42/NN	dep||therapy-51/NN||added-43/VBN	num||losartan-47/NN||100-45/CD	nn||losartan-47/NN||mg-46/NN	prep_to||added-43/VBN||losartan-47/NN	amod||antihypertensive-50/JJ||optimal-49/JJ	conj_and||added-43/VBN||antihypertensive-50/JJ	dep||therapy-51/NN||antihypertensive-50/JJ	dobj||received-23/VBD||therapy-51/NN	conj_or||months-25/NNS||therapy-51/NN	type2diabetes-20||antihypertensive-50||no_rel||in the aliskiren in the evaluation of proteinuria in diabetes (avoid) study, 599 hypertensive patients with type2diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy.
nsubj||investigated-2/VBD||we-1/PRP	nsubj||found-30/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||regulation-4/NN||the-3/DT	dobj||investigated-2/VBD||regulation-4/NN	amod||cells-12/NNS||hmgb-1-6/JJ	amod||blood-10/NN||human-8/JJ	amod||blood-10/NN||peripheral-9/JJ	prep_in||hmgb-1-6/JJ||blood-10/NN	nn||cells-12/NNS||mononuclear-11/NN	prep_of||regulation-4/NN||cells-12/NNS	appos||cells-12/NNS||pbmcs-14/NNS	prep_following||cells-12/NNS||stimulation-17/NN	det||superantigen-21/NN||the-19/DT	amod||superantigen-21/NN||staphylococcal-20/JJ	prep_with||stimulation-17/NN||superantigen-21/NN	amod||toxin-1-24/JJ||toxicshocksyndrome-23/JJ	amod||stimulation-17/NN||toxin-1-24/JJ	dep||cells-12/NNS||tsst-1-26/JJ	conj_and||investigated-2/VBD||found-30/VBD	nsubj||tsst-1-32/JJ||that-31/DT	xcomp||found-30/VBD||tsst-1-32/JJ	conj_and||investigated-2/VBD||like-34/IN	prep_like||investigated-2/VBD||lps-35/NN	vmod||lps-35/NN||induced-37/VBN	det||secretion-39/NN||the-38/DT	dobj||induced-37/VBN||secretion-39/NN	prep_of||secretion-39/NN||hmgb-1-41/CD	amod||pbmc-44/NN||human-43/JJ	prep_from||induced-37/VBN||pbmc-44/NN	toxin--1||toxicshocksyndrome-23||no_rel||we investigated the regulation of hmgb-1 in human peripheral blood mononuclear cells (pbmcs) following stimulation with the staphylococcal superantigen, toxicshocksyndrome toxin-1 (tsst-1), and found that tsst-1, like lps, induced the secretion of hmgb-1 from human pbmc.
nsubj||enzyme-7/NN||katg-1/NN	cop||enzyme-7/NN||is-2/VBZ	advmod||enzyme-7/NN||also-3/RB	det||enzyme-7/NN||the-4/DT	amod||enzyme-7/NN||key-5/JJ	amod||enzyme-7/NN||mycobacterial-6/JJ	root||ROOT-0/null||enzyme-7/NN	amod||enzyme-7/NN||responsible-8/JJ	det||activation-11/NN||the-10/DT	prep_for||responsible-8/JJ||activation-11/NN	det||isoniazid-17/NN||the-13/DT	amod||isoniazid-17/NN||first-line-14/JJ	nn||isoniazid-17/NN||tuberculosis-15/NNP	nn||isoniazid-17/NN||drug-16/NN	prep_of||activation-11/NN||isoniazid-17/NN	tuberculosis-15||isoniazid-17||yes||katg is also the key mycobacterial enzyme responsible for the activation of the first-line tuberculosis drug isoniazid.
prepc_based_on||divided-19/VBN||on-2/IN	amod||symptoms-4/NNS||clinical-3/JJ	pobj||divided-19/VBN||symptoms-4/NNS	nn||hormone-10/NN||t4-6/NN	conj_and||t4-6/NN||thyroid-8/NN	nn||hormone-10/NN||thyroid-8/NN	nn||hormone-10/NN||stimulating-9/NN	appos||symptoms-4/NNS||hormone-10/NN	appos||symptoms-4/NNS||tsh-12/NN	dep||symptoms-4/NNS||concentration-14/NN	num||dogs-17/NNS||1,339-16/CD	nsubjpass||divided-19/VBN||dogs-17/NNS	auxpass||divided-19/VBN||were-18/VBD	root||ROOT-0/null||divided-19/VBN	num||groups-22/NNS||six-21/CD	prep_into||divided-19/VBN||groups-22/NNS	npadvmod||hypothyroid-25/JJ||group-23/NN	num||group-23/NN||1-24/CD	amod||groups-22/NNS||hypothyroid-25/JJ	dep||groups-22/NNS||n-27/VBN	dep||149-29/CD||=-28/SYM	ccomp||n-27/VBN||149-29/CD	dep||groups-22/NNS||group-32/NN	num||thyroiditis-35/NNS||2-33/CD	amod||thyroiditis-35/NNS||subclinical-34/JJ	dep||group-32/NN||thyroiditis-35/NNS	dep||groups-22/NNS||n-37/VBN	dep||110-39/CD||=-38/SYM	ccomp||n-37/VBN||110-39/CD	dep||groups-22/NNS||group-42/NN	num||group-42/NN||3-43/CD	amod||group-42/NN||suspicious-44/JJ	nn||illness-48/NN||non-46/NN	amod||illness-48/NN||thyroidal-47/JJ	prep_for||suspicious-44/JJ||illness-48/NN	dep||illness-48/NN||n-50/VBN	dep||691-52/CD||=-51/SYM	ccomp||n-50/VBN||691-52/CD	nn||euthyroid-58/NN||group-55/NN	num||euthyroid-58/NN||4-56/CD	nn||euthyroid-58/NN||biochemical-57/NN	dep||illness-48/NN||euthyroid-58/NN	dep||euthyroid-58/NN||n-60/VBN	dep||138-62/CD||=-61/SYM	ccomp||n-60/VBN||138-62/CD	dep||groups-22/NNS||group-65/NN	num||group-65/NN||5-66/CD	vmod||group-65/NN||hypothyroid-67/VBN	dobj||hypothyroid-67/VBN||dogs-68/NNS	nn||therapy-71/NN||substitution-70/NN	prep_under||hypothyroid-67/VBN||therapy-71/NN	dep||therapy-71/NN||n-73/VBN	dep||141-75/CD||=-74/SYM	ccomp||n-73/VBN||141-75/CD	dep||therapy-71/NN||group-78/NN	num||dogs-81/NNS||6-79/CD	amod||dogs-81/NNS||healthy-80/JJ	dep||group-78/NN||dogs-81/NNS	dep||group-78/NN||n-83/VBN	dep||110-85/CD||=-84/SYM	ccomp||n-83/VBN||110-85/CD	hypothyroid-67||t4-6||yes||based on clinical symptoms, t4 and thyroid stimulating hormone (tsh) concentration, 1,339 dogs were divided into six groups group 1 hypothyroid (n = 149); group 2 subclinical thyroiditis (n = 110); group 3 suspicious for non thyroidal illness (n = 691); group 4 biochemical euthyroid (n = 138); group 5 hypothyroid dogs under substitution therapy (n = 141); group 6 healthy dogs (n = 110).
det||review-2/NN||the-1/DT	nsubjpass||built-4/VBN||review-2/NN	auxpass||built-4/VBN||is-3/VBZ	root||ROOT-0/null||built-4/VBN	det||search-11/NN||a-6/DT	amod||search-11/NN||systematic-7/JJ	amod||search-11/NN||pubmed-8/JJ	conj_and||pubmed-8/JJ||medline-10/JJ	amod||search-11/NN||medline-10/JJ	prep_on||built-4/VBN||search-11/NN	prep_for||search-11/NN||publications-13/NNS	det||words-17/NNS||the-15/DT	amod||words-17/NNS||key-16/JJ	nn||receptor-19/NN||words-17/NNS	amod||receptor-19/NN||glp-1-18/JJ	prep_with||publications-13/NNS||receptor-19/NN	amod||receptor-19/NN||agonist-20/JJ	amod||receptor-19/NN||exenatide-22/JJ	conj_and||agonist-20/JJ||exenatide-22/JJ	amod||receptor-19/NN||liraglutide-24/JJ	conj_and||agonist-20/JJ||liraglutide-24/JJ	amod||receptor-19/NN||type2diabetesmellitus-26/JJ	conj_and||agonist-20/JJ||type2diabetesmellitus-26/JJ	advmod||publications-13/NNS||up-27/RB	prep_to||up-27/RB||january-29/NNP	num||january-29/NNP||2009-30/CD	type2diabetesmellitus-26||exenatide-22||yes||the review is built on a systematic pubmed and medline search for publications with the key words glp-1 receptor agonist, exenatide, liraglutide and type2diabetesmellitus up to january 2009.
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||yes||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
amod||lamivudine-2/NN||prophylactic-1/JJ	nsubj||reduced-4/VBD||lamivudine-2/NN	advmod||reduced-4/VBD||significantly-3/RB	root||ROOT-0/null||reduced-4/VBD	det||incidence-6/NN||the-5/DT	dobj||reduced-4/VBD||incidence-6/NN	dobj||reduced-4/VBD||severity-8/NN	conj_and||incidence-6/NN||severity-8/NN	nn||reactivation-11/NN||hbv-10/NN	prep_of||incidence-6/NN||reactivation-11/NN	nn||patients-15/NNS||breast-13/NN	nn||patients-15/NNS||cancer-14/NN	prep_in||reduced-4/VBD||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	amod||adjuvant-18/NN||anthracycline-based-17/JJ	dobj||undergoing-16/VBG||adjuvant-18/NN	advmod||undergoing-16/VBG||chemotherapy-19/RB	hbv-10||lamivudine-2||yes||prophylactic lamivudine significantly reduced the incidence and severity of hbv reactivation in breast cancer patients undergoing anthracycline-based adjuvant chemotherapy.
nn||profiles-3/NNS||dsp-1/NN	nn||profiles-3/NNS||toxin-2/NN	nsubj||showed-4/VBD||profiles-3/NNS	root||ROOT-0/null||showed-4/VBD	det||presence-6/NN||the-5/DT	dobj||showed-4/VBD||presence-6/NN	amod||oa-10/NN||okadaicacid-8/JJ	prep_of||presence-6/NN||oa-10/NN	prep_in||oa-10/NN||three-13/CD	dobj||showed-4/VBD||ytx-16/NN	conj_and||presence-6/NN||ytx-16/NN	prep_in||ytx-16/NN||four-18/CD	num||samples-22/NNS||nine-21/CD	prep_out_of||showed-4/VBD||samples-22/NNS	nsubjpass||analyzed-25/VBN||samples-22/NNS	auxpass||analyzed-25/VBN||were-24/VBD	rcmod||samples-22/NNS||analyzed-25/VBN	agent||analyzed-25/VBN||lc-ms/ms-27/NNS	oa-10||okadaicacid-8||no_rel||dsp toxin profiles showed the presence of okadaicacid (oa) in three, and ytx in four out of nine samples that were analyzed by lc-ms/ms.
nn||propofol-2/NN||microemulsion-1/NN	nsubj||produces-3/VBZ||propofol-2/NN	root||ROOT-0/null||produces-3/VBZ	advmod||frequent-5/JJ||more-4/RBR	amod||pain-8/NN||frequent-5/JJ	conj_and||frequent-5/JJ||severe-7/JJ	amod||pain-8/NN||severe-7/JJ	dobj||produces-3/VBZ||pain-8/NN	prep_upon||produces-3/VBZ||injection-10/NN	nn||propofol-14/NN||lipid-12/NN	nn||propofol-14/NN||emulsion-13/NN	prep_than||injection-10/NN||propofol-14/NN	pain-8||propofol-14||yes||microemulsion propofol produces more frequent and severe pain upon injection than lipid emulsion propofol.
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||remifentanil-13||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	collagen-38||eia-72||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
amod||mice-3/NNS||swiss-1/JJ	nn||mice-3/NNS||albino-2/NN	nsubjpass||divided-8/VBN||mice-3/NNS	det||sex-6/NN||either-5/DT	prep_of||mice-3/NNS||sex-6/NN	auxpass||divided-8/VBN||were-7/VBD	root||ROOT-0/null||divided-8/VBN	num||groups-11/NNS||five-10/CD	prep_into||divided-8/VBN||groups-11/NNS	vmod||groups-11/NNS||-lrb--12/VBG	nn||group-15/NN||five/group-13/NN	nn||group-15/NN||-rrb--14/NN	dobj||-lrb--12/VBG||group-15/NN	nsubj||served-17/VBD||i-16/FW	nsubj||received-21/VBD||i-16/FW	rcmod||group-15/NN||served-17/VBD	prep_as||served-17/VBD||control-19/NN	rcmod||group-15/NN||received-21/VBD	conj_and||served-17/VBD||received-21/VBD	nn||-lrb--23/NNS||vehicle-22/NN	dobj||received-21/VBD||-lrb--23/NNS	number||%-25/NN||1-24/CD	amod||tween-26/NN||%-25/NN	dep||group-15/NN||tween-26/NN	number||-rrb--28/CD||80-27/CD	dep||group-15/NN||-rrb--28/CD	det||dose-31/NN||a-30/DT	prep_at||-rrb--28/CD||dose-31/NN	prep_of||dose-31/NN||10-33/CD	vmod||-rrb--28/CD||ml/kg-34/VBG	advmod||ml/kg-34/VBG||orally-35/RB	nn||ii-38/NN||group-37/NN	dep||group-15/NN||ii-38/NN	dep||ii-38/NN||served-39/VBN	prep_as||served-39/VBN||standard-41/NN	dep||ii-38/NN||received-43/VBN	conj_and||served-39/VBN||received-43/VBN	dobj||received-43/VBN||loperamide-44/NN	det||dose-47/NN||the-46/DT	prep_at||received-43/VBN||dose-47/NN	prep_of||dose-47/NN||3-49/CD	dep||received-43/VBN||mg/kg-50/VBG	advmod||mg/kg-50/VBG||orally-51/RB	dep||group-15/NN||groups-53/NNS	nsubj||served-59/VBD||iii-54/NN	nsubj||received-64/VBD||iii-54/NN	conj_and||iii-54/NN||iv-56/NN	nsubj||served-59/VBD||iv-56/NN	conj_and||iii-54/NN||v-58/NN	nsubj||served-59/VBD||v-58/NN	rcmod||groups-53/NNS||served-59/VBD	nn||groups-62/NNS||test-61/NN	prep_as||served-59/VBD||groups-62/NNS	rcmod||groups-53/NNS||received-64/VBD	conj_and||served-59/VBD||received-64/VBD	det||extract-70/NN||the-65/DT	number||%-67/NN||80-66/CD	amod||extract-70/NN||%-67/NN	amod||extract-70/NN||meoh-68/JJ	nn||extract-70/NN||leaf-69/NN	dobj||received-64/VBD||extract-70/NN	nn||aurea-73/NN||c.-72/NN	prep_of||extract-70/NN||aurea-73/NN	prep_at||received-64/VBD||doses-75/NNS	prep_of||doses-75/NNS||100-77/CD	num||100-77/CD||200-79/CD	prep_of||doses-75/NNS||400-81/CD	conj_and||100-77/CD||400-81/CD	amod||orally-83/NN||mg/kg-82/JJ	dep||group-15/NN||orally-83/NN	amod||group-15/NN||respectively-85/RB	vehicle-22||albino-2||no_rel||swiss albino mice of either sex were divided into five groups -lrb- five/group -rrb- group i served as control and received vehicle -lrb- 1 % tween 80 -rrb- at a dose of 10 ml/kg orally ; group ii served as standard and received loperamide at the dose of 3 mg/kg orally ; groups iii , iv and v served as test groups and received the 80 % meoh leaf extract of c. aurea at doses of 100 , 200 and 400 mg/kg orally , respectively .
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||users-4/NNS||drug-3/NN	poss||knowledge-6/NN||users-4/NNS	dobj||assess-2/VB||knowledge-6/NN	prep_of||knowledge-6/NN||hiv/aids-8/NNS	det||association-12/NN||the-10/DT	amod||association-12/NN||possible-11/JJ	dobj||assess-2/VB||association-12/NN	conj_and||knowledge-6/NN||association-12/NN	nn||testing-17/NN||knowledge-14/NN	conj_and||knowledge-14/NN||hiv-16/NN	nn||testing-17/NN||hiv-16/NN	prep_between||association-12/NN||testing-17/NN	aids--1||hiv-16||no||to assess drug users' knowledge of hiv/aids and the possible association between knowledge and hiv testing.
det||subjects-4/NNS||these-2/DT	amod||subjects-4/NNS||obese-3/JJ	prep_in||associated-9/VBN||subjects-4/NNS	nsubjpass||associated-9/VBN||sc-cav-1-6/JJ	auxpass||associated-9/VBN||was-7/VBD	advmod||associated-9/VBN||also-8/RB	root||ROOT-0/null||associated-9/VBN	prepc_with||associated-9/VBN||fasting-11/VBG	dobj||fasting-11/VBG||triglycerides-12/NNPS	dep||triglycerides-12/NNPS||r-14/SYM	dep||-0.50-16/CD||=-15/SYM	ccomp||p-18/VBP||-0.50-16/CD	rcmod||r-14/SYM||p-18/VBP	number||0.0001-20/CD||<-19/CD	dobj||p-18/VBP||0.0001-20/CD	obese-3||triglycerides-12||no_rel||in these obese subjects, sc-cav-1 was also associated with fasting triglycerides (r = -0.50, p < 0.0001).
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hl-8||bleomycin-15||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
mark||associated-15/VBN||while-1/IN	amod||plasminogenactivator-4/NN||increased-2/VBN	amod||plasminogenactivator-4/NN||urokinase-type-3/JJ	nsubjpass||associated-15/VBN||plasminogenactivator-4/NN	appos||plasminogenactivator-4/NN||upa-6/NN	vmod||plasminogenactivator-4/NN||expression-8/VBG	nn||tissue-12/NN||breast-10/NN	nn||tissue-12/NN||cancer-11/NN	prep_in||expression-8/VBG||tissue-12/NN	auxpass||associated-15/VBN||is-13/VBZ	advmod||associated-15/VBN||directly-14/RB	advcl||suggests-22/VBZ||associated-15/VBN	amod||prognosis-18/NN||poor-17/JJ	prep_with||associated-15/VBN||prognosis-18/NN	amod||evidence-21/NN||recent-20/JJ	nsubj||suggests-22/VBZ||evidence-21/NN	root||ROOT-0/null||suggests-22/VBZ	mark||suppress-27/VB||that-23/IN	nn||overexpression-25/NN||upa-24/NN	nsubj||suppress-27/VB||overexpression-25/NN	nsubj||prolong-31/VB||overexpression-25/NN	aux||suppress-27/VB||may-26/MD	ccomp||suggests-22/VBZ||suppress-27/VB	nn||growth-29/NN||tumor-28/NN	dobj||suppress-27/VB||growth-29/NN	ccomp||suggests-22/VBZ||prolong-31/VB	conj_and||suppress-27/VB||prolong-31/VB	dobj||prolong-31/VB||survival-32/NN	cancer-11||upa-24||no_rel||while increased urokinase-type plasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||determine-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||reproducibility-11/NN||the-9/DT	amod||reproducibility-11/NN||inter-study-10/JJ	dobj||determine-8/VB||reproducibility-11/NN	amod||cmr-15/NN||adenosine-13/JJ	nn||cmr-15/NN||stress-14/NN	prep_of||reproducibility-11/NN||cmr-15/NN	prep_in||cmr-15/NN||patients-17/NNS	amod||cad-21/NN||symptomatic-19/JJ	amod||cad-21/NN||multi-vessel-20/JJ	prep_with||determine-8/VB||cad-21/NN	prep_with||determine-8/VB||those-23/DT	conj_and||cad-21/NN||those-23/DT	amod||risk-26/NN||low-25/JJ	prep_at||determine-8/VB||risk-26/NN	prep_for||risk-26/NN||cad-28/NN	adenosine-13||cad-28||no_rel||the purpose of this study was to determine the inter-study reproducibility of adenosine stress cmr in patients with symptomatic multi-vessel cad and those at low risk for cad.
nn||infection-2/NN||anthrax-1/NN	nsubjpass||associated-4/VBN||infection-2/NN	auxpass||associated-4/VBN||is-3/VBZ	root||ROOT-0/null||associated-4/VBN	amod||sequelae-8/NN||devastating-6/JJ	amod||sequelae-8/NN||cardiovascular-7/JJ	prep_with||associated-4/VBN||sequelae-8/NN	xcomp||associated-4/VBN||suggesting-10/VBG	amod||effects-13/NNS||unfavorable-11/JJ	amod||effects-13/NNS||cardiovascular-12/JJ	dobj||suggesting-10/VBG||effects-13/NNS	prep_of||effects-13/NNS||toxins-15/NNS	vmod||toxins-15/NNS||originated-16/VBN	prep_from||originated-16/VBN||bacillusanthracis-18/NNS	advmod||lethal-20/JJ||namely-19/RB	dep||bacillusanthracis-18/NNS||lethal-20/JJ	amod||toxins-23/NNS||edema-22/JJ	dep||bacillusanthracis-18/NNS||toxins-23/NNS	conj_and||lethal-20/JJ||toxins-23/NNS	anthrax-1||bacillusanthracis-18||no||anthrax infection is associated with devastating cardiovascular sequelae, suggesting unfavorable cardiovascular effects of toxins originated from bacillusanthracis namely lethal and edema toxins.
det||total-2/NN||a-1/DT	nsubj||underwent-27/VBD||total-2/NN	num||adolescents-6/NNS||24-4/CD	amod||adolescents-6/NNS||obese-5/JJ	prep_of||total-2/NN||adolescents-6/NNS	prep_with||adolescents-6/NNS||ngt-8/NN	conj_and||total-2/NN||13-10/CD	nsubj||underwent-27/VBD||13-10/CD	prep_with||13-10/CD||ifg-12/NN	conj_and||total-2/NN||29-14/CD	nsubj||underwent-27/VBD||29-14/CD	prep_with||29-14/CD||igt-16/NN	conj_and||total-2/NN||11-18/CD	nsubj||underwent-27/VBD||11-18/CD	amod||ifg/igt-21/NN||combined-20/JJ	prep_with||11-18/CD||ifg/igt-21/NN	conj_and||total-2/NN||30-24/CD	nsubj||underwent-27/VBD||30-24/CD	prep_with||30-24/CD||type2diabetes-26/CD	root||ROOT-0/null||underwent-27/VBD	dobj||underwent-27/VBD||evaluation-28/NN	amod||production-32/NN||hepatic-30/JJ	nn||production-32/NN||glucose-31/NN	prep_of||evaluation-28/NN||production-32/NN	amod||glucose-37/NN||-LSB--34/JJ	nn||glucose-37/NN||6,6-2h2-35/NN	nn||glucose-37/NN||-RSB--36/NN	appos||production-32/NN||glucose-37/NN	amod||disposal-42/NN||insulin-stimulated-40/JJ	nn||disposal-42/NN||glucose-41/NN	appos||production-32/NN||disposal-42/NN	dep||disposal-42/NN||r-44/SYM	dep||r-44/SYM||d-45/SYM	amod||clamp-48/NN||euglycemic-47/JJ	appos||r-44/SYM||clamp-48/NN	amod||secretion-56/NN||first-51/JJ	conj_and||first-51/JJ||second-phase-54/JJ	amod||secretion-56/NN||second-phase-54/JJ	nn||secretion-56/NN||insulin-55/NN	appos||production-32/NN||secretion-56/NN	conj_and||disposal-42/NN||secretion-56/NN	amod||clamp-59/NN||hyperglycemic-58/JJ	appos||secretion-56/NN||clamp-59/NN	nn||composition-63/NN||body-62/NN	appos||production-32/NN||composition-63/NN	conj_and||disposal-42/NN||composition-63/NN	amod||absorptiometry-67/NN||dual-energy-65/JJ	amod||absorptiometry-67/NN||x-ray-66/JJ	appos||composition-63/NN||absorptiometry-67/NN	amod||adiposity-71/NN||abdominal-70/JJ	appos||production-32/NN||adiposity-71/NN	conj_and||disposal-42/NN||adiposity-71/NN	dep||adiposity-71/NN||computed-73/VBN	advmod||computed-73/VBN||tomography-74/RB	amod||oxidation-79/NN||substrate-78/JJ	appos||production-32/NN||oxidation-79/NN	conj_and||disposal-42/NN||oxidation-79/NN	amod||calorimetry-82/NN||indirect-81/JJ	appos||oxidation-79/NN||calorimetry-82/NN	type2diabetes-26||insulin-55||yes||a total of 24 obese adolescents with ngt, 13 with ifg, 29 with igt, 11 with combined ifg/igt, and 30 with type2diabetes underwent evaluation of hepatic glucose production ([6,6-2h2]glucose), insulin-stimulated glucose disposal ( r d, euglycemic clamp), first- and second-phase insulin secretion (hyperglycemic clamp), body composition (dual-energy x-ray absorptiometry), abdominal adiposity (computed tomography), and substrate oxidation (indirect calorimetry).
nn||aspiration-3/NN||bone-1/NN	nn||aspiration-3/NN||marrow-2/NN	nsubjpass||performed-7/VBN||aspiration-3/NN	conj_and||aspiration-3/NN||biopsy-5/NN	nsubjpass||performed-7/VBN||biopsy-5/NN	auxpass||performed-7/VBN||were-6/VBD	root||ROOT-0/null||performed-7/VBN	det||result-10/NN||the-9/DT	nsubj||revealed-11/VBD||result-10/NN	conj_and||performed-7/VBN||revealed-11/VBD	amod||organisms-14/NNS||numerous-12/JJ	nn||organisms-14/NNS||intracellular-13/NN	nsubj||consistent-15/JJ||organisms-14/NNS	xcomp||revealed-11/VBD||consistent-15/JJ	prep_with||consistent-15/JJ||histoplasmacapsulatum-17/NN	advmod||made-27/VBN||therefore-19/RB	det||diagnosis-22/NN||the-21/DT	nsubjpass||made-27/VBN||diagnosis-22/NN	amod||histoplasmosis-25/NNS||disseminated-24/JJ	prep_of||diagnosis-22/NN||histoplasmosis-25/NNS	auxpass||made-27/VBN||was-26/VBD	parataxis||performed-7/VBN||made-27/VBN	histoplasmosis-25||histoplasmacapsulatum-17||no||bone marrow aspiration and biopsy were performed and the result revealed numerous intracellular organisms consistent with histoplasmacapsulatum; therefore, the diagnosis of disseminated histoplasmosis was made.
amod||procedures-3/NNS||invasive-1/JJ	amod||procedures-3/NNS||medical-2/JJ	nsubjpass||associated-27/VBN||procedures-3/NNS	nn||contact-6/NN||household-5/NN	appos||procedures-3/NNS||contact-6/NN	amod||carriers-12/NNS||hepatitisbvirus-8/JJ	appos||carriers-12/NNS||hbv-10/NN	prep_with||contact-6/NN||carriers-12/NNS	nn||care-15/NN||body-14/NN	conj_and||procedures-3/NNS||care-15/NN	nsubjpass||associated-27/VBN||care-15/NN	nn||treatments-18/NNS||beauty-17/NN	conj_and||procedures-3/NNS||treatments-18/NNS	conj_and||care-15/NN||treatments-18/NNS	conj_and||procedures-3/NNS||lack-21/NN	nsubjpass||associated-27/VBN||lack-21/NN	nn||vaccination-24/NN||hbv-23/NN	prep_of||lack-21/NN||vaccination-24/NN	auxpass||associated-27/VBN||were-25/VBD	advmod||associated-27/VBN||independently-26/RB	root||ROOT-0/null||associated-27/VBN	prep_with||associated-27/VBN||ahb-29/NN	hbv-23||hepatitisbvirus-8||no||invasive medical procedures, household contact with hepatitisbvirus (hbv) carriers, body care and beauty treatments, and lack of hbv vaccination were independently associated with ahb.
amod||agents-4/NNS||recommended-1/VBN	amod||agents-4/NNS||parenteral-2/JJ	nn||agents-4/NNS||anticoagulant-3/NN	nsubj||include-16/VBP||agents-4/NNS	amod||indications-7/NNS||different-6/JJ	prep_with||agents-4/NNS||indications-7/NNS	det||prevention-10/NN||the-9/DT	prep_for||indications-7/NNS||prevention-10/NN	prep_for||indications-7/NNS||treatment-12/NN	conj_and||prevention-10/NN||treatment-12/NN	amod||thromboembolism-15/NN||venous-14/JJ	prep_of||prevention-10/NN||thromboembolism-15/NN	root||ROOT-0/null||include-16/VBP	dobj||include-16/VBP||unfractionatedheparin-17/NN	amod||heparins-20/NNS||low-molecular-weight-19/JJ	dobj||include-16/VBP||heparins-20/NNS	conj_and||unfractionatedheparin-17/NN||heparins-20/NNS	dobj||include-16/VBP||fondaparinux-22/NN	conj_and||unfractionatedheparin-17/NN||fondaparinux-22/NN	thromboembolism-15||heparins-20||yes||recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionatedheparin, low-molecular-weight heparins and fondaparinux.
nsubj||found-10/VBD||comparison-1/NN	det||status-5/NN||the-3/DT	amod||status-5/NN||replicative-4/JJ	prep_of||comparison-1/NN||status-5/NN	det||viruses-9/NNS||the-7/DT	num||viruses-9/NNS||two-8/CD	prep_of||status-5/NN||viruses-9/NNS	root||ROOT-0/null||found-10/VBD	amod||load-14/NN||low-11/JJ	nn||load-14/NN||hbv-12/NN	amod||load-14/NN||viral-13/JJ	dobj||found-10/VBD||load-14/NN	det||patients-18/NNS||all-16/DT	amod||patients-18/NNS||co-infected-17/JJ	prep_in||found-10/VBD||patients-18/NNS	amod||patients-18/NNS||as-19/IN	prepc_compared_to||found-10/VBD||to-21/TO	pobj||found-10/VBD||patients-22/NNS	amod||infection-26/NN||single-24/JJ	nn||infection-26/NN||hbv-25/NN	prep_with||patients-22/NNS||infection-26/NN	hbv-25||viruses-9||no||comparison of the replicative status of the two viruses found low hbv viral load in all co-infected patients as compared to patients with single hbv infection.
amod||results-3/NNS||exenatide-1/JJ	nn||results-3/NNS||qw-2/NN	nsubj||tolerated-20/VBD||results-3/NNS	amod||coverage-6/NN||24-hour-5/JJ	prep_in||results-3/NNS||coverage-6/NN	nsubjpass||known-12/VBN||coverage-6/NN	nsubj||improve-14/VB||coverage-6/NN	nsubj||remain-18/VB||coverage-6/NN	amod||concentrations-9/NNS||exenatide-8/JJ	prep_with||coverage-6/NN||concentrations-9/NNS	auxpass||known-12/VBN||are-11/VBP	rcmod||coverage-6/NN||known-12/VBN	aux||improve-14/VB||to-13/TO	xcomp||known-12/VBN||improve-14/VB	amod||control-16/NN||glycemic-15/JJ	dobj||improve-14/VB||control-16/NN	xcomp||known-12/VBN||remain-18/VB	conj_and||improve-14/VB||remain-18/VB	advmod||remain-18/VB||well-19/RB	root||ROOT-0/null||tolerated-20/VBD	prep_in||tolerated-20/VBD||patients-22/NNS	prep_with||tolerated-20/VBD||type2diabetesmellitus-24/CD	type2diabetesmellitus-24||exenatide-8||yes||exenatide qw results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type2diabetesmellitus.
prep_in||deregulated-7/VBG||fact-2/NN	nn||transporters-5/NNS||sugar-4/NN	nsubj||deregulated-7/VBG||transporters-5/NNS	aux||deregulated-7/VBG||are-6/VBP	root||ROOT-0/null||deregulated-7/VBG	nn||cells-10/NNS||cancer-9/NN	prep_in||deregulated-7/VBG||cells-10/NNS	mark||incorporate-13/VB||so-11/IN	nsubj||incorporate-13/VB||they-12/PRP	advcl||deregulated-7/VBG||incorporate-13/VB	amod||amounts-15/NNS||higher-14/JJR	dobj||incorporate-13/VB||amounts-15/NNS	prep_of||amounts-15/NNS||sugar-17/NN	amod||cells-20/NNS||normal-19/JJ	prep_than||incorporate-13/VB||cells-20/NNS	sugar-17||cancer-9||no_rel||in fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of sugar than normal cells.
nn||results-3/NNS||hiv-1/NN	nn||results-3/NNS||test-2/NN	nsubjpass||obtained-5/VBN||results-3/NNS	auxpass||obtained-5/VBN||were-4/VBD	root||ROOT-0/null||obtained-5/VBN	num||patients-8/NNS||498-7/CD	prep_for||obtained-5/VBN||patients-8/NNS	prep_of||hivpositive-15/JJ||patients-8/NNS	num||%-13/NN||33.7-12/CD	nsubj||hivpositive-15/JJ||%-13/NN	cop||hivpositive-15/JJ||were-14/VBD	rcmod||patients-8/NNS||hivpositive-15/JJ	hivpositive-15||hiv-1||no||hiv test results were obtained for 498 patients, of which 33.7% were hivpositive.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||association-4/NN||an-3/DT	nsubj||was-2/VBD||association-4/NN	prep_between||association-4/NN||strength-6/NN	prep_of||strength-6/NN||analgesic-8/NN	prep_of||strength-6/NN||intensity-10/NN	conj_and||analgesic-8/NN||intensity-10/NN	prep_of||association-4/NN||pain-12/NN	advmod||intense-14/JJ||more-13/RBR	dep||resulted-16/VBD||intense-14/JJ	nsubj||resulted-16/VBD||pain-15/NN	dep||was-2/VBD||resulted-16/VBD	det||drug-20/NN||a-18/DT	amod||drug-20/NN||stronger-19/JJR	prep_in||resulted-16/VBD||drug-20/NN	pain-15||analgesic-8||no_rel||there was an association between strength of analgesic and intensity of pain more intense pain resulted in a stronger drug.
nsubj||causes-2/VBZ||varicella-zostervirus-1/NNS	nsubj||shingles-8/VBZ||varicella-zostervirus-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||chickenpox-3/NN	amod||infection-6/NN||primary-5/JJ	prep_upon||causes-2/VBZ||infection-6/NN	conj_and||causes-2/VBZ||shingles-8/VBZ	prep_after||shingles-8/VBZ||reactivation-10/NN	shingles-8||varicella-zostervirus-1||no||varicella-zostervirus causes chickenpox upon primary infection and shingles after reactivation.
amod||outcomes-2/NNS||secondary-1/JJ	nsubj||include-3/VBP||outcomes-2/NNS	root||ROOT-0/null||include-3/VBP	det||proportion-5/NN||the-4/DT	dobj||include-3/VBP||proportion-5/NN	dobj||‰-14/VBZ||proportion-5/NN	amod||users-9/NNS||new-7/JJ	nn||users-9/NNS||statin-8/NN	prep_of||proportion-5/NN||users-9/NNS	nn||â-13/NN||exhibit-11/NN	nn||â-13/NN||adherence-12/NN	nsubj||‰-14/VBZ||â-13/NN	rcmod||proportion-5/NN||‰-14/VBZ	number||80-16/CD||¥-15/CD	num||%-17/NN||80-16/CD	dobj||‰-14/VBZ||%-17/NN	dobj||‰-14/VBZ||persistence-20/NN	conj_and||%-17/NN||persistence-20/NN	nn||use-23/NN||statin-22/NN	prep_with||persistence-20/NN||use-23/NN	statin-22||secondary-1||no_rel||secondary outcomes include the proportion of new statin users who exhibit adherence â‰¥80%, and persistence with statin use.
det||study-3/NN||this-2/DT	prep_in||attempted-6/VBD||study-3/NN	nsubj||attempted-6/VBD||we-5/PRP	nsubj||assess-8/VB||we-5/PRP	root||ROOT-0/null||attempted-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||attempted-6/VBD||assess-8/VB	dobj||assess-8/VB||simvastatin-9/NN	dobj||assess-8/VB||simvastatin-9/NN	conj_and||simvastatin-9/NN||simvastatin-9/NN	advmod||used-12/VBN||widely-11/RB	vmod||simvastatin-9/NN||used-12/VBN	det||drug-16/NN||a-14/DT	amod||drug-16/NN||cholesterol-lowering-15/JJ	prep_as||used-12/VBN||drug-16/NN	preconj||simvastatin-9/NN||both-18/DT	det||agent-22/NN||a-20/DT	amod||agent-22/NN||single-21/JJ	prep_as||simvastatin-9/NN||agent-22/NN	nsubj||$-29/VBG||combination-25/NN	amod||analogsâ-28/NNS||purine-27/JJ	prep_with||combination-25/NN||analogsâ-28/NNS	prepc_in||simvastatin-9/NN||$-29/VBG	nn||$-34/NNS||fludarabine-31/NN	conj_and||fludarabine-31/NN||cladribineâ-33/NN	nn||$-34/NNS||cladribineâ-33/NN	dobj||$-29/VBG||$-34/NNS	prep_in||$-29/VBG||terms-37/NNS	poss||effect-40/NN||its-39/PRP$	prep_of||terms-37/NNS||effect-40/NN	prep_on||effect-40/NN||apoptosis-42/NNS	nn||damage-45/NN||dna-44/NN	prep_on||effect-40/NN||damage-45/NN	conj_and||apoptosis-42/NNS||damage-45/NN	nn||cells-48/NNS||cll-47/NN	prep_of||effect-40/NN||cells-48/NNS	cll-47||fludarabine-31||yes||in this study, we attempted to assess simvastatin, widely used as a cholesterol-lowering drug, both as a single agent and in combination with purine analogsâ€”fludarabine and cladribineâ€”in terms of its effect on apoptosis and dna damage of cll cells.
det||rat-6/NN||the-1/DT	amod||rat-6/NN||goto-kakizaki-2/JJ	nn||rat-6/NN||gk-4/NN	nsubj||model-17/NN||rat-6/NN	cop||model-17/NN||is-7/VBZ	det||model-17/NN||a-8/DT	amod||type2diabetes-12/NNS||well-studied-9/JJ	amod||type2diabetes-12/NNS||non-obese-10/JJ	amod||type2diabetes-12/NNS||spontaneous-11/JJ	nn||model-17/NN||type2diabetes-12/NNS	appos||type2diabetes-12/NNS||t2d-14/NNP	nn||model-17/NN||animal-16/NN	root||ROOT-0/null||model-17/NN	vmod||model-17/NN||characterized-18/VBN	amod||secretion-23/NN||impaired-20/VBN	amod||secretion-23/NN||glucose-stimulated-21/JJ	nn||secretion-23/NN||insulin-22/NN	agent||characterized-18/VBN||secretion-23/NN	appos||secretion-23/NN||gsis-25/NNS	det||cells-31/NNS||the-28/DT	amod||cells-31/NNS||pancreatic-29/JJ	amod||cells-31/NNS||beta-30/JJ	prep_in||secretion-23/NN||cells-31/NNS	type2diabetes-12||insulin-22||yes||the goto-kakizaki (gk) rat is a well-studied non-obese spontaneous type2diabetes (t2d) animal model characterized by impaired glucose-stimulated insulin secretion (gsis) in the pancreatic beta cells.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-16/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||pregnancy-7/NN	appos||pregnancy-7/NN||iptp-9/NN	prep_with||pregnancy-7/NN||sulphadoxine-pyrimethamine-12/NN	appos||treatment-3/NN||sp-14/NN	root||ROOT-0/null||reduces-16/VBZ	det||incidence-18/NN||the-17/DT	dobj||reduces-16/VBZ||incidence-18/NN	amod||birth-weight-21/NN||low-20/JJ	prep_of||incidence-18/NN||birth-weight-21/NN	amod||delivery-24/NN||pre-term-23/JJ	prep_of||incidence-18/NN||delivery-24/NN	conj_and||birth-weight-21/NN||delivery-24/NN	amod||growth-retardation-27/NN||intrauterine-26/JJ	prep_of||incidence-18/NN||growth-retardation-27/NN	conj_and||birth-weight-21/NN||growth-retardation-27/NN	amod||anaemia-30/NN||maternal-29/JJ	prep_of||incidence-18/NN||anaemia-30/NN	conj_and||birth-weight-21/NN||anaemia-30/NN	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in pregnancy (iptp) with sulphadoxine-pyrimethamine (sp) reduces the incidence of low birth-weight, pre-term delivery, intrauterine growth-retardation and maternal anaemia.
det||mito-mice-3/NN||the-2/DT	prep_in||induced-10/VBN||mito-mice-3/NN	nsubj||induced-10/VBN||accumulation-5/NN	nn||mtdna-9/NN||î-7/NN	prep_of||accumulation-5/NN||mtdna-9/NN	root||ROOT-0/null||induced-10/VBN	amod||defects-13/NNS||mitochondrial-11/JJ	nn||defects-13/NNS||respiration-12/NN	dobj||induced-10/VBN||defects-13/NNS	amod||tissues-16/NNS||various-15/JJ	prep_in||defects-13/NNS||tissues-16/NNS	vmod||induced-10/VBN||resulting-18/VBG	amod||phenotypes-22/NNS||mitochondrial-20/JJ	nn||phenotypes-22/NNS||disease-21/NN	prep_in||resulting-18/VBG||phenotypes-22/NNS	amod||weight-28/NN||low-26/JJ	nn||weight-28/NN||body-27/NN	prep_such_as||phenotypes-22/NNS||weight-28/NN	amod||acidosis-31/NNS||lactic-30/JJ	prep_such_as||phenotypes-22/NNS||acidosis-31/NNS	conj_and||weight-28/NN||acidosis-31/NNS	prep_such_as||phenotypes-22/NNS||ischemia-33/NN	conj_and||weight-28/NN||ischemia-33/NN	prep_such_as||phenotypes-22/NNS||myopathy-35/NN	conj_and||weight-28/NN||myopathy-35/NN	nn||block-38/NN||heart-37/NN	prep_such_as||phenotypes-22/NNS||block-38/NN	conj_and||weight-28/NN||block-38/NN	prep_such_as||phenotypes-22/NNS||deafness-40/NNS	conj_and||weight-28/NN||deafness-40/NNS	prep_such_as||phenotypes-22/NNS||maleinfertility-42/NN	conj_and||weight-28/NN||maleinfertility-42/NN	prep_such_as||phenotypes-22/NNS||renalfailure-45/NN	conj_and||weight-28/NN||renalfailure-45/NN	maleinfertility-42||mito--1||no_rel||in the mito-mice, accumulation of î”mtdna induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, maleinfertility, and renalfailure.
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	celiac-16||gluten-25||no||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
det||use-3/NN||the-1/DT	amod||use-3/NN||combined-2/VBN	nsubjpass||associated-23/VBN||use-3/NN	prep_of||use-3/NN||propofol-5/NN	prep_of||use-3/NN||remifentanil-7/NN	conj_and||propofol-5/NN||remifentanil-7/NN	det||infusion-11/NN||a-9/DT	amod||infusion-11/NN||continuous-10/JJ	prep_as||use-3/NN||infusion-11/NN	prep_as||use-3/NN||infusion-11/NN	conj_and||infusion-11/NN||infusion-11/NN	prep_before||infusion-11/NN||performance-13/NN	det||block-16/NN||the-15/DT	prep_of||performance-13/NN||block-16/NN	amod||surgery-21/NN||lengthy-19/JJ	amod||surgery-21/NN||vitreo-retinal-20/JJ	prep_during||infusion-11/NN||surgery-21/NN	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||incidence-27/NN||a-25/DT	amod||incidence-27/NN||lower-26/JJR	prep_with||associated-23/VBN||incidence-27/NN	amod||discomfort-30/NN||patient-29/JJ	prep_of||incidence-27/NN||discomfort-30/NN	nn||pain-33/NN||breakthrough-32/NN	prep_of||incidence-27/NN||pain-33/NN	conj_and||discomfort-30/NN||pain-33/NN	amod||movement-37/NN||patient-36/JJ	prep_of||incidence-27/NN||movement-37/NN	conj_and||discomfort-30/NN||movement-37/NN	amod||degree-41/NN||high-40/JJ	prep_along_with||incidence-27/NN||degree-41/NN	prepc_of||degree-41/NN||surgeonsâ-43/VBG	nn||stability-49/NN||$-44/$	number||satisfaction-46/CD||™-45/CD	num||$-44/$||satisfaction-46/CD	conj_and||$-44/$||hemodynamic-48/JJ	nn||stability-49/NN||hemodynamic-48/JJ	dobj||surgeonsâ-43/VBG||stability-49/NN	pain-33||propofol-5||yes||the combined use of propofol and remifentanil as a continuous infusion before performance of the block and during lengthy vitreo-retinal surgery was associated with a lower incidence of patient discomfort, breakthrough pain, and patient movement along with high degree of surgeonsâ€™ satisfaction and hemodynamic stability.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||formoterol-16||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
nn||control-2/NN||vector-1/NN	nsubj||relies-3/VBZ||control-2/NN	nsubj||reduce-12/VB||control-2/NN	root||ROOT-0/null||relies-3/VBZ	det||use-6/NN||the-5/DT	prep_on||relies-3/VBZ||use-6/NN	amod||chemicals-9/NNS||insecticide-8/JJ	prep_of||use-6/NN||chemicals-9/NNS	aux||reduce-12/VB||to-10/TO	advmod||reduce-12/VB||significantly-11/RB	xcomp||relies-3/VBZ||reduce-12/VB	det||number-14/NN||the-13/DT	dobj||reduce-12/VB||number-14/NN	nn||vectors-17/NNS||malaria-16/NN	prep_of||number-14/NN||vectors-17/NNS	prepc_by||reduce-12/VB||targeting-19/VBG	det||portion-21/NN||that-20/DT	dobj||targeting-19/VBG||portion-21/NN	det||population-25/NN||the-23/DT	amod||population-25/NN||female-24/JJ	prep_of||portion-21/NN||population-25/NN	nsubj||takes-27/VBZ||population-25/NN	nsubj||rests-32/VBZ||population-25/NN	rcmod||population-25/NN||takes-27/VBZ	nn||meals-29/NNS||blood-28/NN	dobj||takes-27/VBZ||meals-29/NNS	advmod||rests-32/VBZ||subsequently-31/RB	rcmod||population-25/NN||rests-32/VBZ	conj_and||takes-27/VBZ||rests-32/VBZ	advmod||rests-32/VBZ||indoors-33/RB	chemicals-9||malaria-16||no_rel||vector control relies on the use of insecticide chemicals to significantly reduce the number of malaria vectors by targeting that portion of the female population that takes blood meals and subsequently rests indoors.
amod||thromboembolism-2/NN||venous-1/JJ	nsubj||complication-8/NN||thromboembolism-2/NN	cop||complication-8/NN||is-3/VBZ	det||complication-8/NN||a-4/DT	advmod||frequently-6/RB||relatively-5/RB	advmod||occurring-7/VBG||frequently-6/RB	amod||complication-8/NN||occurring-7/VBG	root||ROOT-0/null||complication-8/NN	advmod||ill-11/JJ||critically-10/RB	amod||patients-12/NNS||ill-11/JJ	prep_in||complication-8/NN||patients-12/NNS	vmod||patients-12/NNS||admitted-13/VBN	det||icu-16/NN||the-15/DT	prep_to||admitted-13/VBN||icu-16/NN	amod||treatment-19/NN||prophylactic-18/JJ	prep_despite||admitted-13/VBN||treatment-19/NN	amod||heparin-25/NN||subcutaneous-21/JJ	amod||heparin-25/NN||low-22/JJ	amod||heparin-25/NN||molecular-23/JJ	nn||heparin-25/NN||weight-24/NN	prep_with||admitted-13/VBN||heparin-25/NN	thromboembolism-2||heparin-25||yes||venous thromboembolism is a relatively frequently occurring complication in critically ill patients admitted to the icu despite prophylactic treatment with subcutaneous low molecular weight heparin.
det||total-2/NN||a-1/DT	nsubjpass||tested-15/VBN||total-2/NN	num||children-6/NNS||4,726-4/CD	amod||children-6/NNS||healthy-5/JJ	dep||younger-7/JJR||children-6/NNS	prep_of||total-2/NN||younger-7/JJR	num||years-10/NNS||15-9/CD	prep_than||younger-7/JJR||years-10/NNS	amod||illness-13/NN||influenza-like-12/JJ	prep_with||years-10/NNS||illness-13/NN	auxpass||tested-15/VBN||were-14/VBD	root||ROOT-0/null||tested-15/VBN	prep_for||tested-15/VBN||influenzaviruses-17/NNS	amod||reaction-22/NN||real-time-19/JJ	nn||reaction-22/NN||polymerase-20/NN	nn||reaction-22/NN||chain-21/NN	agent||tested-15/VBN||reaction-22/NN	det||winters-25/NNS||the-24/DT	prep_in||reaction-22/NN||winters-25/NNS	prep_of||winters-25/NNS||2007-2008-27/CD	prep_of||winters-25/NNS||2008-2009-29/CD	conj_and||2007-2008-27/CD||2008-2009-29/CD	prep_in||tested-15/VBN||italy-31/NN	influenza--1||influenzaviruses-17||no||a total of 4,726 healthy children younger than 15 years with influenza-like illness were tested for influenzaviruses by real-time polymerase chain reaction in the winters of 2007-2008 and 2008-2009 in italy.
det||prionprotein-2/NN||the-1/DT	nsubj||plays-6/VBZ||prionprotein-2/NN	appos||prionprotein-2/NN||prnp/prp-4/NN	root||ROOT-0/null||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||crucial-8/JJ	dobj||plays-6/VBZ||role-9/NN	prep_in||role-9/NN||transmissiblespongiformencephalopathies-11/NNS	appos||transmissiblespongiformencephalopathies-11/NNS||tses-13/NNS	amod||disease-17/NN||creutzfeldt-jakob-16/JJ	prep_like||plays-6/VBZ||disease-17/NN	appos||disease-17/NN||cjd-19/NN	amod||disease-26/NN||scrapie-22/JJ	conj_and||scrapie-22/JJ||mad-24/JJ	amod||disease-26/NN||mad-24/JJ	nn||disease-26/NN||cow-25/NN	appos||disease-17/NN||disease-26/NN	prionprotein-2||scrapie-22||no_rel||the prionprotein (prnp/prp) plays a crucial role in transmissiblespongiformencephalopathies (tses) like creutzfeldt-jakob disease (cjd), scrapie and mad cow disease.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||uncertain-3/JJ	mark||increases-8/VBZ||whether-4/IN	nsubj||increases-8/VBZ||use-5/NN	nsubj||decreases-21/VBZ||use-5/NN	prep_of||use-5/NN||insulin-7/NN	ccomp||remains-2/VBZ||increases-8/VBZ	nn||risk-10/NN||cancer-9/NN	dobj||increases-8/VBZ||risk-10/NN	poss||effect-14/NN||its-13/PRP$	prep_because_of||risk-10/NN||effect-14/NN	nn||growth-17/NN||cell-16/NN	prep_on||increases-8/VBZ||growth-17/NN	prep_on||increases-8/VBZ||proliferation-19/NN	conj_and||growth-17/NN||proliferation-19/NN	ccomp||remains-2/VBZ||decreases-21/VBZ	conj_or||increases-8/VBZ||decreases-21/VBZ	nn||risk-23/NN||cancer-22/NN	dobj||decreases-21/VBZ||risk-23/NN	poss||effect-28/NN||its-26/PRP$	amod||effect-28/NN||glucose-lowering-27/JJ	prep_because_of||risk-23/NN||effect-28/NN	cancer-22||insulin-7||no_rel||it remains uncertain whether use of insulin increases cancer risk because of its effect on cell growth and proliferation or decreases cancer risk because of its glucose-lowering effect.
amod||trial-3/NN||randomized-1/JJ	amod||trial-3/NN||controlled-2/JJ	nsubj||randomized-14/VBD||trial-3/NN	nsubj||risperidone-16/VB||trial-3/NN	appos||participants-8/NNS||50-6/CD	prep_with||trial-3/NN||participants-8/NNS	det||diagnosis-11/NN||a-10/DT	prep_with||participants-8/NNS||diagnosis-11/NN	prep_of||diagnosis-11/NN||schizophrenia-13/NN	root||ROOT-0/null||randomized-14/VBD	aux||risperidone-16/VB||to-15/TO	xcomp||randomized-14/VBD||risperidone-16/VB	dobj||risperidone-16/VB||lai-17/NN	amod||medication-22/NN||oral-19/JJ	amod||medication-22/NN||atypical-20/JJ	amod||medication-22/NN||antipsychotic-21/JJ	dobj||risperidone-16/VB||medication-22/NN	conj_or||lai-17/NN||medication-22/NN	schizophrenia-13||antipsychotic-21||no_rel||randomized controlled trial with (50) participants with a diagnosis of schizophrenia randomized to risperidone lai or oral atypical antipsychotic medication.
amod||âˆ-3/NN||trex1-2/JJ	poss||âˆ-6/NN||âˆ-3/NN	amod||âˆ-6/NN||/-5/JJ	poss||cells-9/NNS||âˆ-6/NN	nn||cells-9/NNS||mouse-8/NN	prep_in||accumulated-29/VBN||cells-9/NNS	amod||cells-15/NNS||human-11/JJ	amod||cells-15/NNS||cd4-12/JJ	amod||cells-15/NNS||+-13/JJ	nn||cells-15/NNS||t-14/NN	conj_and||cells-9/NNS||cells-15/NNS	prep_in||accumulated-29/VBN||cells-15/NNS	conj_and||cells-9/NNS||macrophages-17/NNS	conj_and||cells-15/NNS||macrophages-17/NNS	prep_in||inhibited-22/VBN||which-19/WDT	nsubjpass||inhibited-22/VBN||trex1-20/NNS	auxpass||inhibited-22/VBN||was-21/VBD	dep||cells-9/NNS||inhibited-22/VBN	nn||interference-25/NN||rna-24/NN	agent||inhibited-22/VBN||interference-25/NN	amod||hivdna-28/NN||cytosolic-27/JJ	nsubj||accumulated-29/VBN||hivdna-28/NN	root||ROOT-0/null||accumulated-29/VBN	nsubj||induced-33/VBN||hivinfection-32/NN	nsubj||spreading-42/VBG||hivinfection-32/NN	conj_and||accumulated-29/VBN||induced-33/VBN	nn||ifn-36/NN||type-34/FW	nn||ifn-36/NN||i-35/FW	dobj||induced-33/VBN||ifn-36/NN	nsubj||inhibited-38/VBD||ifn-36/NN	rcmod||ifn-36/NN||inhibited-38/VBD	nn||replication-40/NN||hiv-39/NN	dobj||inhibited-38/VBD||replication-40/NN	conj_and||accumulated-29/VBN||spreading-42/VBG	conj_and||induced-33/VBN||spreading-42/VBG	hivinfection-32||hiv-39||no||in trex1 âˆ’/âˆ’ mouse cells and human cd4+ t cells and macrophages in which trex1 was inhibited by rna interference, cytosolic hivdna accumulated, and hivinfection induced type i ifn that inhibited hiv replication and spreading.
nsubj||factor-8/NN||hyperhomocysteinemia-1/NN	nsubj||develop-16/VB||hyperhomocysteinemia-1/NN	cop||factor-8/NN||is-4/VBZ	det||factor-8/NN||an-5/DT	amod||factor-8/NN||independent-6/JJ	nn||factor-8/NN||risk-7/NN	rcmod||hyperhomocysteinemia-1/NN||factor-8/NN	amod||vasculardisease-11/NN||atherosclerotic-10/JJ	prep_for||factor-8/NN||vasculardisease-11/NN	prep_for||factor-8/NN||thromboembolism-13/NN	conj_and||vasculardisease-11/NN||thromboembolism-13/NN	aux||develop-16/VB||may-15/MD	root||ROOT-0/null||develop-16/VB	amod||patients-19/NNS||hcv-infected-18/JJ	prep_in||develop-16/VB||patients-19/NNS	mark||enzyme-28/VBP||although-20/IN	amod||transferase-24/NN||altered-21/JJ	amod||transferase-24/NN||alanine-22/JJ	amod||transferase-24/NN||amino-23/JJ	nsubj||enzyme-28/VBP||transferase-24/NN	appos||transferase-24/NN||alt-26/NN	advcl||develop-16/VB||enzyme-28/VBP	nsubjpass||associated-32/VBN||levels-29/NNS	auxpass||associated-32/VBN||are-30/VBP	advmod||associated-32/VBN||generally-31/RB	ccomp||enzyme-28/VBP||associated-32/VBN	prep_with||associated-32/VBN||damage-34/NN	nn||cells-37/NNS||liver-36/NN	prep_to||associated-32/VBN||cells-37/NNS	thromboembolism-13||alanine-22||no_rel||hyperhomocysteinemia, which is an independent risk factor for atherosclerotic vasculardisease and thromboembolism , may develop in hcv-infected patients although altered alanine amino transferase (alt) enzyme levels are generally associated with damage to liver cells.
agent||determined-13/VBN||using-2/VBG	amod||analysis-4/NN||spectroscopic-3/JJ	dobj||using-2/VBG||analysis-4/NN	det||structures-7/NNS||the-6/DT	nsubjpass||determined-13/VBN||structures-7/NNS	det||constituents-11/NNS||these-9/DT	amod||constituents-11/NNS||pure-10/JJ	prep_of||structures-7/NNS||constituents-11/NNS	auxpass||determined-13/VBN||were-12/VBD	root||ROOT-0/null||determined-13/VBN	num||lignans-16/NNS||three-15/CD	prep_as||determined-13/VBN||lignans-16/NNS	num||steroids-19/NNS||four-18/CD	prep_as||determined-13/VBN||steroids-19/NNS	conj_and||lignans-16/NNS||steroids-19/NNS	num||benzenoids-22/NNS||ten-21/CD	prep_as||determined-13/VBN||benzenoids-22/NNS	conj_and||lignans-16/NNS||benzenoids-22/NNS	ten-21||steroids-19||no_rel||by using spectroscopic analysis, the structures of these pure constituents were determined as three lignans, four steroids and ten benzenoids.
mark||associated-26/VBN||whilst-1/IN	nsubjpass||associated-26/VBN||three-2/CD	prep_of||three-2/CD||these-4/DT	amod||oxygenase-1-7/NN||heme-6/JJ	appos||these-4/DT||oxygenase-1-7/NN	dep||oxygenase-1-7/NN||ho-1-9/JJ	appos||these-4/DT||aquaporin-1-12/JJ	conj_and||oxygenase-1-7/NN||aquaporin-1-12/JJ	dep||aquaporin-1-12/JJ||aqp-1-14/JJ	number||2-19/CD||b-cellcll/lymphoma-18/CD	appos||these-4/DT||2-19/CD	conj_and||oxygenase-1-7/NN||2-19/CD	dep||2-19/CD||bcl-2-21/JJ	aux||associated-26/VBN||have-23/VBP	advmod||associated-26/VBN||already-24/RB	auxpass||associated-26/VBN||been-25/VBN	advcl||suggests-37/VBZ||associated-26/VBN	amod||renoprotection-29/NN||epo-induced-28/JJ	prep_with||associated-26/VBN||renoprotection-29/NN	det||study-32/NN||this-31/DT	nsubj||suggests-37/VBZ||study-32/NN	det||time-36/NN||the-34/DT	amod||time-36/NN||first-35/JJ	prep_for||study-32/NN||time-36/NN	root||ROOT-0/null||suggests-37/VBZ	amod||m-39/NN||carboxypeptidase-38/JJ	dobj||suggests-37/VBZ||m-39/NN	nsubj||play-57/VB||m-39/NN	appos||m-39/NN||cpm-41/NN	amod||iv-46/NN||dipeptidyl-44/JJ	nn||iv-46/NN||peptidase-45/NN	dobj||suggests-37/VBZ||iv-46/NN	conj_and||m-39/NN||iv-46/NN	nsubj||play-57/VB||iv-46/NN	appos||iv-46/NN||dppiv-48/NNP	dobj||suggests-37/VBZ||cytoglobin-52/NN	conj_and||m-39/NN||cytoglobin-52/NN	nsubj||play-57/VB||cytoglobin-52/NN	appos||m-39/NN||cygb-54/NN	aux||play-57/VB||to-56/TO	xcomp||suggests-37/VBZ||play-57/VB	det||role-59/NN||a-58/DT	dobj||play-57/VB||role-59/NN	det||process-62/NN||this-61/DT	prep_in||role-59/NN||process-62/NN	b-cellcll--1||cpm-41||yes||whilst three of these, heme oxygenase-1 (ho-1), aquaporin-1 (aqp-1), and b-cellcll/lymphoma 2 (bcl-2) have already been associated with epo-induced renoprotection, this study for the first time suggests carboxypeptidase m (cpm), dipeptidyl peptidase iv (dppiv), and cytoglobin (cygb) to play a role in this process.
amod||prick-3/NN||titrated-1/JJ	nn||prick-3/NN||skin-2/NN	nsubj||indicated-17/VBD||prick-3/NN	vmod||prick-3/NN||testing-4/VBG	amod||responses-9/NNS||wheal-6/JJ	conj_and||wheal-6/JJ||flare-8/JJ	amod||responses-9/NNS||flare-8/JJ	prep_with||testing-4/VBG||responses-9/NNS	advmod||testing-4/VBG||up-10/RB	det||dilution-14/NN||an-12/DT	nn||dilution-14/NN||enoxaparin-13/NN	prep_to||up-10/RB||dilution-14/NN	prep_of||dilution-14/NN||110.000-16/CD	root||ROOT-0/null||indicated-17/VBD	det||mechanism-21/NN||a-18/DT	amod||mechanism-21/NN||probable-19/JJ	amod||mechanism-21/NN||allergic-20/JJ	dobj||indicated-17/VBD||mechanism-21/NN	det||anaphylaxis-25/NNS||the-23/DT	amod||anaphylaxis-25/NNS||enoxaparin-induced-24/JJ	prep_of||mechanism-21/NN||anaphylaxis-25/NNS	anaphylaxis-25||enoxaparin-13||no_rel||titrated skin prick testing with wheal and flare responses up to an enoxaparin dilution of 110.000 indicated a probable allergic mechanism of the enoxaparin-induced anaphylaxis.
num||years-2/NNS||ten-1/CD	tmod||diagnosed-7/VBN||years-2/NNS	advmod||years-2/NNS||previously-3/RB	nsubjpass||diagnosed-7/VBN||he-4/PRP	nsubjpass||treated-12/VBN||he-4/PRP	aux||diagnosed-7/VBN||had-5/VBD	auxpass||diagnosed-7/VBN||been-6/VBN	root||ROOT-0/null||diagnosed-7/VBN	nn||infection-10/NN||hbv-9/NN	prep_with||diagnosed-7/VBN||infection-10/NN	conj_and||diagnosed-7/VBN||treated-12/VBN	prep_with||treated-12/VBN||lamivudine-14/NN	num||mg/day-17/NN||100-16/CD	appos||lamivudine-14/NN||mg/day-17/NN	hbv-9||lamivudine-14||yes||ten years previously he had been diagnosed with hbv infection and treated with lamivudine (100 mg/day).
nsubj||potential-7/JJ||study-1/NN	nsubj||inactivate-9/VB||study-1/NN	nsubj||produce-37/VB||study-1/NN	prepc_of||study-1/NN||hppâ-3/VBG	dobj||hppâ-3/VBG||$-4/$	num||$-4/$||™-5/CD	cop||potential-7/JJ||s-6/VBZ	root||ROOT-0/null||potential-7/JJ	aux||inactivate-9/VB||to-8/TO	xcomp||potential-7/JJ||inactivate-9/VB	amod||viruses-11/NNS||foodborne-10/JJ	dobj||inactivate-9/VB||viruses-11/NNS	aux||defined-13/VBN||has-12/VBZ	rcmod||viruses-11/NNS||defined-13/VBN	amod||levels-16/NNS||general-14/JJ	nn||levels-16/NNS||pressure-15/NN	dobj||defined-13/VBN||levels-16/NNS	vmod||levels-16/NNS||required-17/VBN	aux||inactivate-19/VB||to-18/TO	xcomp||required-17/VBN||inactivate-19/VB	xcomp||inactivate-19/VB||hepatitis-20/VBG	det||virus-22/NN||a-21/DT	dobj||hepatitis-20/VBG||virus-22/NN	amod||surrogates-25/NNS||norovirus-24/JJ	dobj||hepatitis-20/VBG||surrogates-25/NNS	conj_and||virus-22/NN||surrogates-25/NNS	amod||norovirus-29/NNS||human-28/JJ	dobj||hepatitis-20/VBG||norovirus-29/NNS	conj_and||virus-22/NN||norovirus-29/NNS	dobj||inactivate-19/VB||itself-30/PRP	prep_within||inactivate-9/VB||foods-32/NNS	prep_such_as||foods-32/NNS||shellfish-35/NN	xcomp||potential-7/JJ||produce-37/VB	conj_and||inactivate-9/VB||produce-37/VB	virus-22||viruses-11||no||study of hppâ€™s potential to inactivate foodborne viruses has defined general pressure levels required to inactivate hepatitis a virus, norovirus surrogates, and human norovirus itself within foods such as shellfish and produce.
amod||patients-3/NNS||chronic-1/JJ	nn||patients-3/NNS||hbv-2/NN	nsubjpass||treated-5/VBN||patients-3/NNS	nsubjpass||examined-9/VBN||patients-3/NNS	auxpass||treated-5/VBN||were-4/VBD	root||ROOT-0/null||treated-5/VBN	prep_with||treated-5/VBN||adefovirdipivoxil-7/NN	conj_and||treated-5/VBN||examined-9/VBN	nn||loads-14/NNS||serum-11/NN	nn||loads-14/NNS||hbv-12/NN	nn||loads-14/NNS||dna-13/NN	prep_for||examined-9/VBN||loads-14/NNS	appos||loads-14/NNS||cytokines-16/NNS	nn||helper-20/NN||t-19/NN	nsubj||cytokine-29/VBP||helper-20/NN	appos||helper-20/NN||th1-22/NNP	conj_and||helper-20/NN||2-25/CD	nsubj||cytokine-29/VBP||2-25/CD	appos||2-25/CD||th2-27/NNP	conj_and||treated-5/VBN||cytokine-29/VBP	xcomp||cytokine-29/VBP||producing-30/VBG	nn||cells-32/NNS||t-31/NN	dobj||producing-30/VBG||cells-32/NNS	num||weeks-35/NNS||104-34/CD	prep_during||producing-30/VBG||weeks-35/NNS	det||treatment-38/NN||the-37/DT	prep_of||weeks-35/NNS||treatment-38/NN	hbv-12||adefovirdipivoxil-7||yes||chronic hbv patients were treated with adefovirdipivoxil and examined for serum hbv dna loads, cytokines, and t helper (th1) and 2 (th2) cytokine producing t cells during 104 weeks of the treatment.
advmod||recognizing-6/VBG||thus-1/RB	nn||cells-5/NNS||t-3/NN	nn||cells-5/NNS||reg-4/NN	nsubj||recognizing-6/VBG||cells-5/NNS	nsubj||restrict-12/VB||cells-5/NNS	root||ROOT-0/null||recognizing-6/VBG	amod||antigens-8/NNS||mtb-derived-7/JJ	dobj||recognizing-6/VBG||antigens-8/NNS	advmod||recognizing-6/VBG||specifically-9/RB	advmod||restrict-12/VB||potently-11/RB	conj_and||recognizing-6/VBG||restrict-12/VB	amod||responses-15/NNS||protective-13/JJ	amod||responses-15/NNS||immune-14/JJ	dobj||restrict-12/VB||responses-15/NNS	prep_during||restrict-12/VB||tuberculosis-17/NNP	tuberculosis-17||mtb--1||no||thus, t reg cells recognizing mtb-derived antigens specifically and potently restrict protective immune responses during tuberculosis.
nsubj||recorded-2/VBD||we-1/PRP	root||ROOT-0/null||recorded-2/VBD	nn||time-4/NN||onset-3/NN	iobj||recorded-2/VBD||time-4/NN	det||block-8/NN||the-6/DT	amod||block-8/NN||sensory-7/JJ	prep_of||time-4/NN||block-8/NN	nn||time-11/NN||end-10/NN	appos||block-8/NN||time-11/NN	det||block-15/NN||the-13/DT	amod||block-15/NN||sensory-14/JJ	prep_of||time-11/NN||block-15/NN	appos||block-15/NN||presence-17/NN	det||block-21/NN||the-19/DT	nn||block-21/NN||motor-20/NN	prep_of||presence-17/NN||block-21/NN	det||time-24/NN||the-23/DT	dobj||recorded-2/VBD||time-24/NN	advmod||reported-29/VBD||when-25/WRB	det||patient-27/NN||the-26/DT	nsubj||reported-29/VBD||patient-27/NN	advmod||reported-29/VBD||verbally-28/RB	advcl||recorded-2/VBD||reported-29/VBD	amod||pain-31/NN||tourniquet-30/JJ	dobj||reported-29/VBD||pain-31/NN	amod||pain-34/NN||surgical-33/JJ	dobj||reported-29/VBD||pain-34/NN	conj_and||pain-31/NN||pain-34/NN	appos||pain-31/NN||duration-36/NN	amod||tolerance-39/NN||tourniquet-38/JJ	prep_of||duration-36/NN||tolerance-39/NN	amod||consumption-42/NN||fentanyl-41/JJ	appos||pain-31/NN||consumption-42/NN	det||operation-45/NN||the-44/DT	prep_during||consumption-42/NN||operation-45/NN	appos||pain-31/NN||time-47/NN	amod||requirement-51/NN||first-49/JJ	amod||requirement-51/NN||analgesic-50/JJ	prep_to||time-47/NN||requirement-51/NN	nn||values-54/NNS||methemoglobin-53/NN	appos||pain-31/NN||values-54/NNS	amod||minutes-57/NNS||60â-56/JJ	prep_at||values-54/NNS||minutes-57/NNS	amod||conditions-60/NNS||operative-59/JJ	prep_at||values-54/NNS||conditions-60/NNS	conj_and||minutes-57/NNS||conditions-60/NNS	amod||consumption-64/NN||24-hour-62/JJ	amod||consumption-64/NN||analgesic-63/JJ	prep_at||values-54/NNS||consumption-64/NN	conj_and||minutes-57/NNS||consumption-64/NN	nn||time-67/NN||discharge-66/NN	prep_at||values-54/NNS||time-67/NN	conj_and||minutes-57/NNS||time-67/NN	amod||parameters-71/NNS||hemodynamic-70/JJ	prep_at||values-54/NNS||parameters-71/NNS	conj_and||minutes-57/NNS||parameters-71/NNS	pain-34||fentanyl-41||yes||we recorded onset time of the sensory block, end time of the sensory block, presence of the motor block, the time when the patient verbally reported tourniquet pain and surgical pain, duration of tourniquet tolerance, fentanyl consumption during the operation, time to first analgesic requirement, methemoglobin values at 60â minutes, operative conditions, 24-hour analgesic consumption, discharge time, and hemodynamic parameters.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||key-14/JJ||that-4/IN	det||combination-6/NN||a-5/DT	nsubj||key-14/JJ||combination-6/NN	amod||genes-11/NNS||suppressed-8/JJ	conj_and||suppressed-8/JJ||up-regulated-10/JJ	amod||genes-11/NNS||up-regulated-10/JJ	prep_of||combination-6/NN||genes-11/NNS	aux||key-14/JJ||may-12/MD	cop||key-14/JJ||be-13/VB	ccomp||suggest-3/VBP||key-14/JJ	prepc_in||key-14/JJ||determining-16/VBG	dobj||determining-16/VBG||development-17/NN	amod||immunity-20/NN||protective-19/JJ	prep_of||development-17/NN||immunity-20/NN	prep_to||determining-16/VBG||tb-22/NN	vmod||tb-22/NN||induced-23/VBN	agent||induced-23/VBN||vaccination-25/NN	prep_with||induced-23/VBN||bcg-27/NN	tb-22||bcg-27||yes||our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to tb induced by vaccination with bcg.
det||aim-2/NN||the-1/DT	nsubj||is-7/VBZ||aim-2/NN	nsubj||analyze-9/VB||aim-2/NN	det||work-6/NN||the-4/DT	amod||work-6/NN||present-5/JJ	prep_of||aim-2/NN||work-6/NN	root||ROOT-0/null||is-7/VBZ	aux||analyze-9/VB||to-8/TO	xcomp||is-7/VBZ||analyze-9/VB	det||profile-14/NN||the-10/DT	amod||fluid-12/JJ||cerebrospinal-11/JJ	amod||profile-14/NN||fluid-12/JJ	amod||profile-14/NN||proteomic-13/JJ	dobj||analyze-9/VB||profile-14/NN	vmod||profile-14/NN||trying-16/VBG	aux||find-18/VB||to-17/TO	xcomp||trying-16/VBG||find-18/VB	amod||biomarkers-20/NNS||possible-19/JJ	dobj||find-18/VB||biomarkers-20/NNS	det||effects-23/NNS||the-22/DT	prep_of||biomarkers-20/NNS||effects-23/NNS	prep_of||effects-23/NNS||hypertension-25/NN	det||blood-28/NN||the-27/DT	prep_of||hypertension-25/NN||blood-28/NN	aux||csf-30/VB||to-29/TO	vmod||find-18/VB||csf-30/VB	nn||disruption-32/NN||barrier-31/NN	dobj||csf-30/VB||disruption-32/NN	det||brain-35/NN||the-34/DT	prep_in||disruption-32/NN||brain-35/NN	poss||participation-38/NN||their-37/PRP$	dobj||csf-30/VB||participation-38/NN	conj_and||disruption-32/NN||participation-38/NN	det||²-44/NN||the-40/DT	nn||²-44/NN||cholesterol-41/NN	conj_and||cholesterol-41/NN||î-43/NN	nn||²-44/NN||î-43/NN	prep_in||participation-38/NN||²-44/NN	amod||metabolism-47/NN||amyloid-46/JJ	dep||participation-38/NN||metabolism-47/NN	amod||processes-50/NNS||inflammatory-49/JJ	dep||participation-38/NN||processes-50/NNS	conj_and||metabolism-47/NN||processes-50/NNS	cholesterol-41||hypertension-25||no_rel||the aim of the present work is to analyze the cerebrospinal fluid proteomic profile, trying to find possible biomarkers of the effects of hypertension of the blood to csf barrier disruption in the brain and their participation in the cholesterol and î² -amyloid metabolism and inflammatory processes.
amod||oxidase-2/NN||xanthine-1/JJ	nsubjpass||implicated-14/VBN||oxidase-2/NN	poss||products-5/NNS||its-4/PRP$	conj_and||oxidase-2/NN||products-5/NNS	nsubjpass||implicated-14/VBN||products-5/NNS	amod||acid-8/NN||uric-7/JJ	appos||oxidase-2/NN||acid-8/NN	appos||oxidase-2/NN||ros-10/NN	conj_and||acid-8/NN||ros-10/NN	aux||implicated-14/VBN||have-12/VBP	auxpass||implicated-14/VBN||been-13/VBN	root||ROOT-0/null||implicated-14/VBN	det||pathogenesis-17/NNS||the-16/DT	prep_in||implicated-14/VBN||pathogenesis-17/NNS	prep_of||pathogenesis-17/NNS||cardiovasculardisease-19/NN	prep_such_as||pathogenesis-17/NNS||hypertension-23/NN	xanthine-1||cardiovasculardisease-19||no_rel||xanthine oxidase and its products, uric acid and ros, have been implicated in the pathogenesis of cardiovasculardisease, such as hypertension.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||children-6/NNS||2227-4/CD	nn||children-6/NNS||ghanaian-5/NN	dobj||included-3/VBD||children-6/NNS	nsubjpass||given-16/VBN||children-6/NNS	dep||children-6/NNS||3â-8/VBN	num||months-12/NNS||$-9/$	num||$-9/$||59-11/CD	tmod||3â-8/VBN||months-12/NNS	auxpass||given-16/VBN||were-15/VBD	rcmod||children-6/NNS||given-16/VBN	amod||bimonthly-21/NNS||sulphadoxine-pyrimethamine-17/JJ	discourse||bimonthly-21/NNS||sp-19/UH	dobj||given-16/VBN||bimonthly-21/NNS	dobj||given-16/VBN||artesunate-23/NN	dobj||given-16/VBN||amodiaquine-25/NN	conj_plus||artesunate-23/NN||amodiaquine-25/NN	mark||aq-29/VBP||as-27/IN	nsubj||aq-29/VBP||+-28/PRP	dep||amodiaquine-25/NN||aq-29/VBP	dep||amodiaquine-25/NN||monthly-31/JJ	dep||amodiaquine-25/NN||bimonthly-33/JJ	conj_or||monthly-31/JJ||bimonthly-33/JJ	dobj||given-16/VBN||placebo-36/NN	conj_or||artesunate-23/NN||placebo-36/NN	advmod||spanning-41/VBG||monthly-37/JJ	num||months-40/NNS||six-39/CD	prep_for||monthly-37/JJ||months-40/NNS	vmod||placebo-36/NN||spanning-41/VBG	det||season-45/NN||the-42/DT	nn||season-45/NN||malaria-43/NN	nn||season-45/NN||transmission-44/NN	dobj||spanning-41/VBG||season-45/NN	malaria-43||pyrimethamine--1||yes||the study included 2227 ghanaian children (3â€“59 months) who were given sulphadoxine-pyrimethamine (sp) bimonthly, artesunate plus amodiaquine (as+aq) monthly or bimonthly, or placebo monthly for six months spanning the malaria transmission season.
det||role-2/NN||the-1/DT	nsubj||study-15/VBP||role-2/NN	prep_of||role-2/NN||vitamine-4/NN	amod||warrants-13/NNS||susceptibility-6/JJ	prep_to||susceptibility-6/JJ||pneumonia-8/NN	advmod||active-11/JJ||physically-10/RB	amod||nonsmokers-12/NNS||active-11/JJ	prep_in||pneumonia-8/NN||nonsmokers-12/NNS	prep_in||vitamine-4/NN||warrants-13/NNS	advmod||study-15/VBP||further-14/RB	root||ROOT-0/null||study-15/VBP	pneumonia-8||vitamine-4||no_rel||the role of vitamine in susceptibility to pneumonia in physically active nonsmokers warrants further study.
nsubj||present-2/VBP||we-1/PRP	dep||necrosis-17/VBZ||present-2/VBP	det||case-4/NN||the-3/DT	dobj||present-2/VBP||case-4/NN	det||man-8/NN||a-6/DT	amod||man-8/NN||40-year-old-7/JJ	prep_of||case-4/NN||man-8/NN	amod||rheumatoidarthritis-11/NNS||severe-10/JJ	prep_with||present-2/VBP||rheumatoidarthritis-11/NNS	auxpass||treated-13/VBN||being-12/VBG	vmod||rheumatoidarthritis-11/NNS||treated-13/VBN	amod||anti-tumor-16/NN||high-dose-15/JJ	prep_with||treated-13/VBN||anti-tumor-16/NN	root||ROOT-0/null||necrosis-17/VBZ	nn||î-19/NN||factor-18/NN	dobj||necrosis-17/VBZ||î-19/NN	amod||therapy-21/NN||±-20/JJ	nsubj||necrosis-17/VBZ||therapy-21/NN	nsubj||developed-27/VBD||therapy-21/NN	appos||therapy-21/NN||adalimumab-23/NN	rcmod||therapy-21/NN||developed-27/VBD	amod||lymphoma-29/NN||simultaneous-28/JJ	dobj||developed-27/VBD||lymphoma-29/NN	nn||cancer-32/NN||breast-31/NN	dobj||developed-27/VBD||cancer-32/NN	conj_and||lymphoma-29/NN||cancer-32/NN	nn||metastases-36/NNS||lymph-34/NN	nn||metastases-36/NNS||node-35/NN	prep_with||lymphoma-29/NN||metastases-36/NNS	rheumatoidarthritis-11||adalimumab-23||yes||we present the case of a 40-year-old man with severe rheumatoidarthritis being treated with high-dose anti-tumor necrosis factor î± therapy (adalimumab), who developed simultaneous lymphoma and breast cancer with lymph node metastases.
amod||history-2/NN||parental-1/JJ	nsubjpass||associated-7/VBN||history-2/NN	prep_of||history-2/NN||type2diabetes-4/CD	auxpass||associated-7/VBN||was-5/VBD	advmod||associated-7/VBN||independently-6/RB	root||ROOT-0/null||associated-7/VBN	prep_with||associated-7/VBN||age-9/NN	prep_at||associated-7/VBN||onset-11/NN	prep_of||onset-11/NN||type1diabetes-13/NNS	nn||ratio-16/NN||odds-15/NNS	dep||type1diabetes-13/NNS||ratio-16/NN	num||-LSB--18/NNS||1.02-17/CD	dep||ratio-16/NN||-LSB--18/NNS	number||%-20/NN||95-19/CD	amod||-LSB--18/NNS||%-20/NN	advmod||-LSB--18/NNS||ci-21/RB	num||â-23/NN||1.01-22/CD	pobj||ci-21/RB||â-23/NN	num||-RSB--27/NNS||$-24/$	num||$-24/$||1.03-26/CD	dep||-LSB--18/NNS||-RSB--27/NNS	prep_of||onset-11/NN||bmi-30/NN	conj_and||type1diabetes-13/NNS||bmi-30/NN	num||-LSB--33/NNS||1.07-32/CD	dep||bmi-30/NN||-LSB--33/NNS	num||â-35/NN||1.02-34/CD	dep||-LSB--33/NNS||â-35/NN	num||-RSB--39/NNS||$-36/$	num||$-36/$||1.12-38/CD	dep||â-35/NN||-RSB--39/NNS	prep_of||onset-11/NN||triglycerides-42/NNPS	conj_and||type1diabetes-13/NNS||triglycerides-42/NNPS	num||-LSB--45/NNS||1.18-44/CD	dep||triglycerides-42/NNPS||-LSB--45/NNS	num||â-47/NN||1.03-46/CD	dep||-LSB--45/NNS||â-47/NN	num||-RSB--51/NNS||$-48/$	num||$-48/$||1.35-50/CD	dep||â-47/NN||-RSB--51/NNS	nn||dose-56/NN||insulin-55/NN	prep_of||onset-11/NN||dose-56/NN	conj_and||type1diabetes-13/NNS||dose-56/NN	prep_per||dose-56/NN||kilogram-58/NN	num||-LSB--61/NNS||1.63-60/CD	dep||type1diabetes-13/NNS||-LSB--61/NNS	num||â-63/NN||1.04-62/CD	dep||-LSB--61/NNS||â-63/NN	num||-RSB--67/NNS||$-64/$	num||$-64/$||2.54-66/CD	dep||â-63/NN||-RSB--67/NNS	type1diabetes-13||insulin-55||yes||parental history of type2diabetes was independently associated with age at onset of type1diabetes (odds ratio 1.02 [95% ci 1.01â€“1.03]), bmi (1.07 [1.02â€“1.12]), triglycerides (1.18 [1.03â€“1.35]), and insulin dose per kilogram (1.63 [1.04â€“2.54]).
nsubjpass||assessed-3/VBN||pain-1/NN	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	det||scale-7/NN||a-5/DT	amod||scale-7/NN||four-point-6/JJ	prep_on||assessed-3/VBN||scale-7/NN	amod||injection-11/NN||microemulsion-9/JJ	amod||injection-11/NN||propofol-10/JJ	prep_during||assessed-3/VBN||injection-11/NN	pain-1||propofol-10||yes||pain was assessed on a four-point scale during microemulsion propofol injection.
det||conservation-2/NN||the-1/DT	nsubj||suggest-13/VBP||conservation-2/NN	nsubj||highlight-23/VB||conservation-2/NN	det||ires-5/NNS||this-4/DT	prep_of||conservation-2/NN||ires-5/NNS	poss||properties-8/NNS||its-7/PRP$	prep_of||conservation-2/NN||properties-8/NNS	conj_and||ires-5/NNS||properties-8/NNS	advmod||evolving-11/VBG||rapidly-10/RB	amod||viruses-12/NNS||evolving-11/VBG	prep_in||properties-8/NNS||viruses-12/NNS	root||ROOT-0/null||suggest-13/VBP	det||role-16/NN||an-14/DT	amod||role-16/NN||important-15/JJ	dobj||suggest-13/VBP||role-16/NN	det||cycle-21/NN||the-18/DT	nn||cycle-21/NN||virus-19/NN	nn||cycle-21/NN||life-20/NN	prep_in||role-16/NN||cycle-21/NN	conj_and||suggest-13/VBP||highlight-23/VB	det||target-28/NN||an-24/DT	amod||target-28/NN||attractive-25/JJ	amod||target-28/NN||new-26/JJ	amod||target-28/NN||therapeutic-27/JJ	dobj||highlight-23/VB||target-28/NN	virus-19||viruses-12||no||the conservation of this ires and its properties in rapidly evolving viruses suggest an important role in the virus life cycle and highlight an attractive new therapeutic target.
det||organs-2/NNS||all-1/DT	nsubjpass||affected-5/VBN||organs-2/NNS	aux||affected-5/VBN||can-3/MD	auxpass||affected-5/VBN||be-4/VB	root||ROOT-0/null||affected-5/VBN	agent||affected-5/VBN||complications-7/NNS	prep_of||complications-7/NNS||hiv/aids-9/NNS	det||eye-13/NN||the-12/DT	prep_including||complications-7/NNS||eye-13/NN	aids--1||hiv--1||no||all organs can be affected by complications of hiv/aids, including the eye.
mark||substantiated-10/VBN||while-1/IN	det||efficacy-3/NN||the-2/DT	nsubjpass||substantiated-10/VBN||efficacy-3/NN	conj_and||efficacy-3/NN||safety-5/NN	nsubjpass||substantiated-10/VBN||safety-5/NN	prep_of||efficacy-3/NN||lidocaine-7/NN	aux||substantiated-10/VBN||have-8/VBP	auxpass||substantiated-10/VBN||been-9/VBN	advcl||has-22/VBZ||substantiated-10/VBN	det||reliability-13/NN||the-12/DT	nsubj||has-22/VBZ||reliability-13/NN	amod||arrhythmias-16/NNS||warning-15/VBG	prep_of||reliability-13/NN||arrhythmias-16/NNS	prep_as||arrhythmias-16/NNS||predictors-18/NNS	amod||ventricularfibrillation-21/NN||primary-20/JJ	prep_for||predictors-18/NNS||ventricularfibrillation-21/NN	root||ROOT-0/null||has-22/VBZ	neg||has-22/VBZ||not-23/RB	ventricularfibrillation-21||lidocaine-7||yes||while the efficacy and safety of lidocaine have been substantiated, the reliability of warning arrhythmias as predictors for primary ventricularfibrillation has not.
prep_in||demonstrated-11/VBD||contrast-2/NN	det||nucleus-7/NN||the-4/DT	nn||nucleus-7/NN||hpg-5/NN	nn||nucleus-7/NN||arcuate-6/NN	nsubj||demonstrated-11/VBD||nucleus-7/NN	appos||nucleus-7/NN||arc-9/NN	root||ROOT-0/null||demonstrated-11/VBD	det||increase-14/NN||a-12/DT	amod||increase-14/NN||10-fold-13/JJ	dobj||demonstrated-11/VBD||increase-14/NN	amod||mrna-17/NN||kiss1-16/JJ	prep_in||demonstrated-11/VBD||mrna-17/NN	nn||days-22/NNS||10-19/CD	conj_and||10-19/CD||30-21/CD	nn||days-22/NNS||30-21/CD	prep_between||mrna-17/NN||days-22/NNS	preconj||females-25/NNS||both-24/DT	prep_in||days-22/NNS||females-25/NNS	prep_in||days-22/NNS||males-27/NNS	conj_and||females-25/NNS||males-27/NNS	vmod||demonstrated-11/VBD||suggesting-29/VBG	mark||center-36/NN||that-30/IN	det||arc-32/NN||the-31/DT	nsubj||center-36/NN||arc-32/NN	cop||center-36/NN||is-33/VBZ	det||center-36/NN||a-34/DT	amod||center-36/NN||significant-35/JJ	ccomp||suggesting-29/VBG||center-36/NN	nn||expression-42/NN||sex-38/NN	amod||expression-42/NN||steroid-independent-39/JJ	amod||expression-42/NN||pubertal-40/JJ	nn||expression-42/NN||kisspeptin-41/NN	prep_for||center-36/NN||expression-42/NN	steroid--1||arc-32||no_rel||in contrast, the hpg arcuate nucleus (arc) demonstrated a 10-fold increase in kiss1 mrna between 10 and 30 days in both females and males, suggesting that the arc is a significant center for sex steroid-independent pubertal kisspeptin expression.
det||comparison-3/NN||the-2/DT	prep_in||prevalent-24/JJ||comparison-3/NN	prep_of||comparison-3/NN||individuals-5/NNS	prep_with||individuals-5/NNS||lada-7/NN	prep_with||individuals-5/NNS||type2diabetes-9/NNS	conj_and||lada-7/NN||type2diabetes-9/NNS	advmod||prevalent-24/JJ||all-11/DT	det||need-14/NN||the-13/DT	prep_without||all-11/DT||need-14/NN	prep_for||need-14/NN||insulin-16/NN	nsubj||prevalent-24/JJ||markers-18/NNS	nsubj||pronounced-26/JJ||markers-18/NNS	amod||syndrome-21/NN||metabolic-20/JJ	prep_of||markers-18/NNS||syndrome-21/NN	cop||prevalent-24/JJ||were-22/VBD	advmod||prevalent-24/JJ||equally-23/RB	root||ROOT-0/null||prevalent-24/JJ	conj_and||prevalent-24/JJ||pronounced-26/JJ	type2diabetes-9||insulin-16||yes||in the comparison of individuals with lada and type2diabetes, all without the need for insulin, markers of metabolic syndrome were equally prevalent and pronounced.
det||study-2/NN||this-1/DT	nsubj||links-3/VBZ||study-2/NN	nsubj||suggests-15/VBZ||study-2/NN	root||ROOT-0/null||links-3/VBZ	amod||consumption-6/NN||chronic-4/JJ	amod||consumption-6/NN||maternal-5/JJ	dobj||links-3/VBZ||consumption-6/NN	det||hfd-9/NN||a-8/DT	prep_of||consumption-6/NN||hfd-9/NN	amod||apoptosis-13/NNS||fetal-11/JJ	amod||apoptosis-13/NNS||hepatic-12/JJ	prep_with||links-3/VBZ||apoptosis-13/NNS	conj_and||links-3/VBZ||suggests-15/VBZ	mark||replicated-24/VBN||that-16/IN	det||maternal-20/NN||a-17/DT	advmod||pathological-19/JJ||potentially-18/RB	amod||maternal-20/NN||pathological-19/JJ	nsubjpass||replicated-24/VBN||maternal-20/NN	amod||milieu-22/JJ||fattyacid-21/JJ	amod||maternal-20/NN||milieu-22/JJ	auxpass||replicated-24/VBN||is-23/VBZ	ccomp||suggests-15/VBZ||replicated-24/VBN	det||fetalcirculation-28/NN||the-26/DT	amod||fetalcirculation-28/NN||developing-27/VBG	prep_in||replicated-24/VBN||fetalcirculation-28/NN	det||primate-32/NN||the-30/DT	nn||primate-32/NN||nonhuman-31/NN	prep_in||fetalcirculation-28/NN||primate-32/NN	fetalcirculation-28||fattyacid-21||no_rel||this study links chronic maternal consumption of a hfd with fetal hepatic apoptosis and suggests that a potentially pathological maternal fattyacid milieu is replicated in the developing fetalcirculation in the nonhuman primate.
mark||recommended-5/VBN||although-1/IN	nsubjpass||recommended-5/VBN||walking-2/NN	auxpass||recommended-5/VBN||is-3/VBZ	advmod||recommended-5/VBN||commonly-4/RB	advcl||used-23/VBN||recommended-5/VBN	prepc_for||recommended-5/VBN||reducing-7/VBG	dobj||reducing-7/VBG||pain-8/NN	prepc_for||recommended-5/VBN||increasing-10/VBG	conj_and||reducing-7/VBG||increasing-10/VBG	amod||function-12/NN||physical-11/JJ	dobj||increasing-10/VBG||function-12/NN	prep_in||increasing-10/VBG||people-14/NNS	prep_with||people-14/NNS||oa-16/NN	amod||sulphate-19/NN||glucosamine-18/JJ	nsubjpass||used-23/VBN||sulphate-19/NN	nsubj||alleviate-25/VB||sulphate-19/NN	nsubj||slow-28/VB||sulphate-19/NN	aux||used-23/VBN||has-20/VBZ	advmod||used-23/VBN||also-21/RB	auxpass||used-23/VBN||been-22/VBN	root||ROOT-0/null||used-23/VBN	aux||alleviate-25/VB||to-24/TO	xcomp||used-23/VBN||alleviate-25/VB	dobj||alleviate-25/VB||pain-26/NN	xcomp||used-23/VBN||slow-28/VB	conj_and||alleviate-25/VB||slow-28/VB	det||progression-30/NN||the-29/DT	dobj||slow-28/VB||progression-30/NN	prep_of||progression-30/NN||oa-32/NN	oa-32||glucosamine-18||yes||although walking is commonly recommended for reducing pain and increasing physical function in people with oa, glucosamine sulphate has also been used to alleviate pain and slow the progression of oa.
poss||results-2/NNS||our-1/PRP$	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||inhibited-7/VBD||that-4/IN	nsubj||inhibited-7/VBD||anthocyanins-5/NNS	advmod||inhibited-7/VBD||significantly-6/RB	ccomp||showed-3/VBD||inhibited-7/VBD	amod||mediators-10/NNS||lps-induced-8/JJ	amod||mediators-10/NNS||pro-inflammatory-9/JJ	dobj||inhibited-7/VBD||mediators-10/NNS	prep_such_as||mediators-10/NNS||nitricoxide-14/NN	discourse||nitricoxide-14/NN||no-16/UH	prep_such_as||mediators-10/NNS||prostaglandine2-19/NNS	conj_and||nitricoxide-14/NN||prostaglandine2-19/NNS	amod||cytokines-23/NNS||pro-inflammatory-22/JJ	nsubj||necrosis-26/VBZ||cytokines-23/NNS	prep_including||cytokines-23/NNS||tumor-25/NN	conj_and||showed-3/VBD||necrosis-26/VBZ	dobj||necrosis-26/VBZ||factor-27/NN	appos||factor-27/NN||tnf-29/NN	nn||±-33/NN||î-32/NN	dep||factor-27/NN||±-33/NN	dep||factor-27/NN||interleukin-35/NN	conj_and||±-33/NN||interleukin-35/NN	appos||±-33/NN||il-37/NN	num||²-41/NNS||-1-39/CD	nn||²-41/NNS||î-40/NN	dep||±-33/NN||²-41/NNS	amod||cytotoxicity-45/NN||significant-44/JJ	prep_without||necrosis-26/VBZ||cytotoxicity-45/NN	tumor-25||nitricoxide-14||no_rel||our results showed that anthocyanins significantly inhibited lps-induced pro-inflammatory mediators, such as nitricoxide (no) and prostaglandine2, and pro-inflammatory cytokines including tumor necrosis factor (tnf)-î± and interleukin (il)-1î², without significant cytotoxicity.
nsubj||limit-4/VB||nutritional-1/NNP	nsubj||impair-16/VB||nutritional-1/NNP	advmod||limit-4/VB||irondeficiency-2/RB	aux||limit-4/VB||may-3/MD	root||ROOT-0/null||limit-4/VB	nn||availability-6/NN||iron-5/NN	dobj||limit-4/VB||availability-6/NN	det||parasite-10/NN||the-8/DT	nn||parasite-10/NN||malaria-9/NN	prep_to||limit-4/VB||parasite-10/NN	vmod||parasite-10/NN||reducing-11/VBG	nn||risk-13/NN||infection-12/NN	dobj||reducing-11/VBG||risk-13/NN	conj_and/or||limit-4/VB||impair-16/VB	nn||immunity-18/NN||host-17/NN	dobj||impair-16/VB||immunity-18/NN	advmod||increasing-20/VBG||thereby-19/RB	vmod||immunity-18/NN||increasing-20/VBG	det||risk-22/NN||this-21/DT	dobj||increasing-20/VBG||risk-22/NN	irondeficiency-2||iron-5||yes||nutritional irondeficiency may limit iron availability to the malaria parasite reducing infection risk, and/or impair host immunity thereby increasing this risk.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â€“44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â€“67.7%).
nsubj||examine-2/VBP||we-1/PRP	root||ROOT-0/null||examine-2/VBP	dobj||examine-2/VBP||relationships-3/NNS	nn||trends-6/NNS||market-5/NN	prep_between||relationships-3/NNS||trends-6/NNS	nn||organization-10/NN||world-8/NN	nn||organization-10/NN||health-9/NN	nsubj||hiv/aids-14/VBZ||organization-10/NN	nsubj||unitaid-71/VBD||organization-10/NN	dep||organization-10/NN||who-12/WP	conj_and||examine-2/VBP||hiv/aids-14/VBZ	nn||guidelines-16/NNS||treatment-15/NN	dobj||hiv/aids-14/VBZ||guidelines-16/NNS	nsubj||prequalification-19/VBP||guidelines-16/NNS	rcmod||guidelines-16/NNS||prequalification-19/VBP	dobj||prequalification-19/VBP||programme-20/NN	nsubj||prequal-23/VBP||who-22/WP	dep||programme-20/NN||prequal-23/VBP	amod||states-27/NNS||united-26/VBN	dobj||prequalification-19/VBP||states-27/NNS	conj_and||programme-20/NN||states-27/NNS	dep||states-27/NNS||us-29/PRP	dep||programme-20/NN||food-31/NN	nn||administration-34/NN||drug-33/NN	dobj||prequalification-19/VBP||administration-34/NN	conj_and||programme-20/NN||administration-34/NN	appos||administration-34/NN||fda-36/NN	dep||administration-34/NN||approvals-38/NNS	amod||policies-42/NNS||procurement-41/JJ	dobj||hiv/aids-14/VBZ||policies-42/NNS	conj_and||guidelines-16/NNS||policies-42/NNS	nsubj||prequalification-19/VBP||policies-42/NNS	det||fund-46/NN||the-44/DT	amod||fund-46/NN||global-45/JJ	prep_of||policies-42/NNS||fund-46/NN	aux||fight-48/VB||to-47/TO	vmod||fund-46/NN||fight-48/VB	dobj||fight-48/VB||aids-49/NNS	appos||aids-49/NNS||tuberculosis-51/NNP	dobj||fight-48/VB||malaria-54/NN	conj_and||aids-49/NNS||malaria-54/NN	appos||malaria-54/NN||gfatm-56/NNP	nsubj||plan-63/NN||us-59/PRP	poss||plan-63/NN||president-60/NN	nn||plan-63/NN||emergency-62/NN	xcomp||fight-48/VB||plan-63/NN	nn||relief-66/NN||aids-65/NNS	prep_for||plan-63/NN||relief-66/NN	appos||relief-66/NN||pepfar-68/NN	conj_and||examine-2/VBP||unitaid-71/VBD	conj_and||hiv/aids-14/VBZ||unitaid-71/VBD	aids-65||hiv--1||no||we examine relationships between market trends and world health organization (who) hiv/aids treatment guidelines; who prequalification programme (who prequal) and united states (us) food and drug administration (fda) approvals; and procurement policies of the global fund to fight aids, tuberculosis, and malaria (gfatm), us president's emergency plan for aids relief (pepfar) and unitaid.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	painful-10||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
nsubj||disease-5/NN||smallpox-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||acute-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	agent||caused-6/VBN||infection-8/NN	prep_with||caused-6/VBN||variolavirus-10/NNS	nsubj||had-13/VBN||variolavirus-10/NNS	aux||had-13/VBN||has-12/VBZ	rcmod||variolavirus-10/NNS||had-13/VBN	amod||effects-15/NNS||historic-14/JJ	dobj||had-13/VBN||effects-15/NNS	det||population-19/NN||the-17/DT	amod||population-19/NN||human-18/JJ	prep_on||had-13/VBN||population-19/NN	poss||virulence-23/NN||its-22/PRP$	prep_due_to||population-19/NN||virulence-23/NN	prep_due_to||population-19/NN||infectivity-25/NN	conj_and||virulence-23/NN||infectivity-25/NN	smallpox-1||variolavirus-10||no||smallpox is an acute disease caused by infection with variolavirus that has had historic effects on the human population due to its virulence and infectivity.
det||symptoms-5/NNS||the-1/DT	amod||symptoms-5/NNS||anemia-associated-2/JJ	conj_and||anemia-associated-2/JJ||gastrointestinal-4/JJ	amod||symptoms-5/NNS||gastrointestinal-4/JJ	nsubj||resolved-6/VBD||symptoms-5/NNS	root||ROOT-0/null||resolved-6/VBD	advmod||resolved-6/VBD||completely-7/RB	det||patients-10/NNS||all-9/DT	prep_in||resolved-6/VBD||patients-10/NNS	nn||injection-13/NN||intramuscular-12/NN	prep_after||resolved-6/VBD||injection-13/NN	prep_of||injection-13/NN||cobalamin-15/NN	mark||remained-20/VBD||whereas-17/IN	amod||symptoms-19/NNS||neurological-18/JJ	nsubj||remained-20/VBD||symptoms-19/NNS	advcl||resolved-6/VBD||remained-20/VBD	prep_in||remained-20/VBD||some-22/DT	cobalamin-15||anemia--1||no_rel||the anemia-associated and gastrointestinal symptoms resolved completely in all patients after intramuscular injection of cobalamin, whereas neurological symptoms remained in some.
poss||study-4/NN||our-2/PRP$	amod||study-4/NN||present-3/JJ	prep_in||discovered-7/VBD||study-4/NN	nsubj||discovered-7/VBD||we-6/PRP	root||ROOT-0/null||discovered-7/VBD	mark||disrupted-20/VBN||that-8/IN	amod||domain-10/NN||nuclear-9/JJ	nsubjpass||disrupted-20/VBN||domain-10/NN	num||domain-10/NN||10-11/CD	appos||domain-10/NN||nd10-13/NNP	amod||cells-17/NNS||human-16/JJ	prep_of||domain-10/NN||cells-17/NNS	auxpass||disrupted-20/VBN||was-18/VBD	neg||disrupted-20/VBN||not-19/RB	ccomp||discovered-7/VBD||disrupted-20/VBN	amod||cmv-23/NN||murine-22/JJ	agent||disrupted-20/VBN||cmv-23/NN	appos||cmv-23/NN||mcmv-25/NNP	mark||disrupted-36/VBN||that-28/IN	det||nd10-30/NN||the-29/DT	nsubjpass||disrupted-36/VBN||nd10-30/NN	nn||cells-33/NNS||mouse-32/NN	prep_of||nd10-30/NN||cells-33/NNS	auxpass||disrupted-36/VBN||was-34/VBD	neg||disrupted-36/VBN||not-35/RB	ccomp||discovered-7/VBD||disrupted-36/VBN	conj_and||disrupted-20/VBN||disrupted-36/VBN	agent||disrupted-36/VBN||hcmv-38/NNP	mark||colocalized-53/VBD||although-40/IN	det||protein-43/NN||the-41/DT	amod||protein-43/NN||nd10-disrupting-42/JJ	nsubj||colocalized-53/VBD||protein-43/NN	amod||protein-46/NN||immediate-early-45/JJ	appos||protein-43/NN||protein-46/NN	num||protein-46/NN||1-47/CD	appos||protein-46/NN||ie1-49/NNP	advmod||colocalized-53/VBD||also-52/RB	advcl||disrupted-36/VBN||colocalized-53/VBD	prep_with||colocalized-53/VBD||nd10-55/CD	amod||infections-58/NNS||cross-species-57/JJ	prep_in||colocalized-53/VBD||infections-58/NNS	cmv-23||hcmv-38||no||in our present study, we discovered that nuclear domain 10 (nd10) of human cells was not disrupted by murine cmv (mcmv) and that the nd10 of mouse cells was not disrupted by hcmv, although the nd10-disrupting protein, immediate-early protein 1 (ie1), also colocalized with nd10 in cross-species infections.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	nsubj||mdd-9/VBP||cross-sectionally-3/NN	num||individuals-6/NNS||1,435-5/CD	prep_in||cross-sectionally-3/NN||individuals-6/NNS	prep_with||individuals-6/NNS||lifetime-8/NN	ccomp||investigated-2/VBD||mdd-9/VBP	det||impact-11/NN||the-10/DT	dobj||mdd-9/VBP||impact-11/NN	nn||abuse-14/NN||childhood-13/NN	prep_of||impact-11/NN||abuse-14/NN	parataxis||mdd-9/VBP||ca-16/MD	parataxis||events-21/NNS||ca-16/MD	amod||events-21/NNS||recent-19/JJ	nn||events-21/NNS||life-20/NN	ccomp||investigated-2/VBD||events-21/NNS	conj_and||mdd-9/VBP||events-21/NNS	nn||levels-25/NNS||serum-23/NN	nn||levels-25/NNS||bdnf-24/NN	prep_on||events-21/NNS||levels-25/NNS	conj_and||mdd-9/VBP||assessed-27/VBN	conj_and||events-21/NNS||assessed-27/VBN	mark||moderated-35/VBN||whether-28/IN	det||impact-30/NN||the-29/DT	nsubjpass||moderated-35/VBN||impact-30/NN	det||events-33/NNS||these-32/DT	prep_of||impact-30/NN||events-33/NNS	auxpass||moderated-35/VBN||was-34/VBD	ccomp||assessed-27/VBN||moderated-35/VBN	det||polymorphism-40/NN||the-37/DT	amod||polymorphism-40/NN||bdnf-38/JJ	amod||polymorphism-40/NN||val66met-39/JJ	agent||moderated-35/VBN||polymorphism-40/NN	cross--1||ca-16||no_rel||we investigated cross-sectionally in 1,435 individuals with lifetime mdd the impact of childhood abuse (ca) and recent life events on serum bdnf levels and assessed whether the impact of these events was moderated by the bdnf val66met polymorphism.
nsubjpass||caused-3/VBN||commoncold-1/NN	auxpass||caused-3/VBN||is-2/VBZ	root||ROOT-0/null||caused-3/VBN	det||variety-6/NN||a-5/DT	agent||caused-3/VBN||variety-6/NN	amod||viruses-9/NNS||respiratory-8/JJ	prep_of||variety-6/NN||viruses-9/NNS	commoncold-1||viruses-9||no||commoncold is caused by a variety of respiratory viruses.
amod||results-3/NNS||objective-1/JJ	det||results-3/NNS||the-2/DT	nsubjpass||investigated-45/VBN||results-3/NNS	nsubj||examine-49/VB||results-3/NNS	det||survey-8/NN||a-5/DT	amod||survey-8/NN||prospective-6/JJ	amod||survey-8/NN||post-marketing-7/JJ	prep_of||results-3/NNS||survey-8/NN	nsubjpass||conducted-11/VBN||survey-8/NN	nsubj||assess-13/VB||survey-8/NN	auxpass||conducted-11/VBN||was-10/VBD	rcmod||survey-8/NN||conducted-11/VBN	aux||assess-13/VB||to-12/TO	xcomp||conducted-11/VBN||assess-13/VB	det||safety-15/NN||the-14/DT	dobj||assess-13/VB||safety-15/NN	dobj||assess-13/VB||efficacy-17/NN	conj_and||safety-15/NN||efficacy-17/NN	det||mg-31/NN||the-19/DT	amod||mg-31/NN||b-adrenergicreceptorantagonist-20/JJ	nn||²-23/NNS||î-22/NN	dep||mg-31/NN||²-23/NNS	dep||²-23/NNS||blocker-25/NN	nn||mg-31/NN||artistâ-27/NNP	nn||mg-31/NN||®-28/NNP	nn||mg-31/NN||tablets-29/NNP	num||mg-31/NN||10-30/CD	prep_of||safety-15/NN||mg-31/NN	amod||carvedilol-35/NN||20mg-33/JJ	appos||mg-31/NN||carvedilol-35/NN	prep_in||carvedilol-35/NN||patients-38/NNS	prep_with||patients-38/NNS||hypertension-40/NN	prep_in||hypertension-40/NN||japan-42/NN	auxpass||investigated-45/VBN||were-44/VBD	root||ROOT-0/null||investigated-45/VBN	prep_in||investigated-45/VBN||order-47/NN	aux||examine-49/VB||to-48/TO	xcomp||investigated-45/VBN||examine-49/VB	det||safety-51/NN||the-50/DT	dobj||examine-49/VB||safety-51/NN	dobj||examine-49/VB||efficacy-53/NN	conj_and||safety-51/NN||efficacy-53/NN	det||drug-56/NN||the-55/DT	prep_of||safety-51/NN||drug-56/NN	amod||treatment-59/NN||long-term-58/JJ	prep_during||examine-49/VB||treatment-59/NN	num||months-62/NNS||18-61/CD	appos||treatment-59/NN||months-62/NNS	hypertension-40||carvedilol-35||yes||objective the results of a prospective post-marketing survey that was conducted to assess the safety and efficacy of the b-adrenergicreceptorantagonist (î²-blocker) artistâ® tablets 10 mg, 20mg (carvedilol) in patients with hypertension in japan, were investigated in order to examine the safety and efficacy of the drug during long-term treatment (18 months).
nsubjpass||used-5/VBN||today-1/NN	tmod||used-5/VBN||today-1/NN	nsubjpass||used-5/VBN||macrolides-3/NNS	auxpass||used-5/VBN||are-4/VBP	root||ROOT-0/null||used-5/VBN	det||treatment-9/NN||the-7/DT	amod||treatment-9/NN||primary-8/JJ	prep_in||used-5/VBN||treatment-9/NN	nn||infection-13/NN||m.-11/NN	nn||infection-13/NN||pneumoniae-12/NN	prep_of||treatment-9/NN||infection-13/NN	pneumoniae-12||macrolides-3||no_rel||today , macrolides are used in the primary treatment of m. pneumoniae infection .
det||decrease-4/NN||a-1/DT	amod||decrease-4/NN||borderline-2/JJ	amod||decrease-4/NN||significant-3/JJ	nsubjpass||observed-9/VBN||decrease-4/NN	nn||risk-7/NN||cvd-6/NN	prep_in||decrease-4/NN||risk-7/NN	auxpass||observed-9/VBN||was-8/VBD	root||ROOT-0/null||observed-9/VBN	prep_in||observed-9/VBN||subjects-11/NNS	nn||levels-14/NNS||cholesterol-13/NN	prep_with||observed-9/VBN||levels-14/NNS	number||‰-16/CD||â-15/CD	num||200-18/CD||‰-16/CD	number||200-18/CD||¥-17/CD	npadvmod||mg/dl-19/JJ||200-18/CD	amod||levels-14/NNS||mg/dl-19/JJ	parataxis||observed-9/VBN||hradditve-21/VB	dep||0.77-23/CD||=-22/SYM	ccomp||ci-27/VBP||0.77-23/CD	num||%-26/NN||95-25/CD	nsubj||ci-27/VBP||%-26/NN	ccomp||hradditve-21/VB||ci-27/VBP	number||1.03-30/CD||0.58-28/CD	dep||1.03-30/CD||to-29/TO	dobj||ci-27/VBP||1.03-30/CD	det||study-35/NN||the-33/DT	amod||study-35/NN||epic-potsdam-34/JJ	prep_in||observed-9/VBN||study-35/NN	cholesterol-13||cvd-6||no_rel||a borderline significant decrease in cvd risk was observed in subjects with cholesterol levels â‰¥200 mg/dl (hradditve = 0.77, 95% ci 0.58 to 1.03) in the epic-potsdam study.
amod||production-2/NN||excessive-1/JJ	nsubjpass||thought-16/VBN||production-2/NN	nsubj||underlie-18/VB||production-2/NN	prep_of||production-2/NN||nitricoxide-4/NN	discourse||nitricoxide-4/NN||no-6/UH	amod||synthase-11/NN||inducible-9/JJ	neg||synthase-11/NN||no-10/DT	prep_by||nitricoxide-4/NN||synthase-11/NN	appos||production-2/NN||inos-13/NNS	auxpass||thought-16/VBN||is-15/VBZ	root||ROOT-0/null||thought-16/VBN	aux||underlie-18/VB||to-17/TO	xcomp||thought-16/VBN||underlie-18/VB	det||dysfunction-21/NN||the-19/DT	nn||dysfunction-21/NN||vascular-20/NN	dobj||underlie-18/VB||dysfunction-21/NN	amod||hypotension-24/NN||systemic-23/JJ	appos||dysfunction-21/NN||hypotension-24/NN	nsubj||characterize-29/VBP||hypotension-24/NN	nn||failure-27/NN||organ-26/NN	appos||dysfunction-21/NN||failure-27/NN	conj_and||hypotension-24/NN||failure-27/NN	nsubj||characterize-29/VBP||failure-27/NN	rcmod||hypotension-24/NN||characterize-29/VBP	dobj||characterize-29/VBP||endotoxicshock-30/NN	nitricoxide-4||endotoxicshock-30||no_rel||excessive production of nitricoxide (no) by inducible no synthase (inos) is thought to underlie the vascular dysfunction, systemic hypotension and organ failure that characterize endotoxicshock.
det||prevalence-2/NN||the-1/DT	nsubj||%-18/NN||prevalence-2/NN	prep_of||prevalence-2/NN||lipoatrophy-4/NN	amod||glucose-8/NN||impaired-6/VBN	amod||glucose-8/NN||fasting-7/JJ	appos||lipoatrophy-4/NN||glucose-8/NN	appos||glucose-8/NN||impairedglucosetolerance-10/NN	appos||glucose-8/NN||hyperlactataemia-12/NN	conj_and||impairedglucosetolerance-10/NN||hyperlactataemia-12/NN	appos||glucose-8/NN||hypertriglyceridaemia-15/NN	conj_and||impairedglucosetolerance-10/NN||hypertriglyceridaemia-15/NN	cop||%-18/NN||were-16/VBD	num||%-18/NN||34-17/CD	root||ROOT-0/null||%-18/NN	num||%-21/NN||19-20/CD	conj_and||%-18/NN||%-21/NN	num||%-24/NN||4-23/CD	conj_and||%-18/NN||%-24/NN	num||%-27/NN||32-26/CD	conj_and||%-18/NN||%-27/NN	num||%-31/NN||23-30/CD	conj_and||%-18/NN||%-31/NN	advmod||%-18/NN||respectively-32/RB	impairedglucosetolerance-10||glucose-8||no_rel||the prevalence of lipoatrophy, impaired fasting glucose, impairedglucosetolerance, hyperlactataemia, and hypertriglyceridaemia were 34%, 19%, 4%, 32%, and 23% respectively.
nsubj||tgf-î-4/VBD||addition-1/NN	prep_of||addition-1/NN||exogenous-3/NNS	root||ROOT-0/null||tgf-î-4/VBD	acomp||tgf-î-4/VBD||²-5/JJ	amod||mortality-14/NN||h5n1-7/JJ	dep||$-9/$||influenzavirusâ-8/RB	dep||mortality-14/NN||$-9/$	num||$-9/$||infected-11/NNS	quantmod||infected-11/NNS||mice-12/IN	quantmod||infected-11/NNS||delayed-13/JJ	prep_to||²-5/JJ||mortality-14/NN	amod||titers-18/NNS||reduced-16/VBN	amod||titers-18/NNS||viral-17/JJ	prep_to||²-5/JJ||titers-18/NNS	conj_and||mortality-14/NN||titers-18/NNS	mark||increased-31/VBD||whereas-19/IN	nsubj||increased-31/VBD||neutralization-20/NN	nn||²-23/NNP||tgf-î-22/NNP	prep_of||neutralization-20/NN||²-23/NNP	prep_during||²-23/NNP||h5n1-25/NNS	amod||infection-30/NN||pandemic-27/JJ	num||infection-30/NN||2009-28/CD	amod||infection-30/NN||h1n1-29/JJ	prep_during||²-23/NNP||infection-30/NN	conj_and||h5n1-25/NNS||infection-30/NN	advcl||tgf-î-4/VBD||increased-31/VBD	dobj||increased-31/VBD||morbidity-32/NN	h5n1-25||influenzavirus--1||no||addition of exogenous tgf-î² to h5n1 influenzavirusâ€“infected mice delayed mortality and reduced viral titers whereas neutralization of tgf-î² during h5n1 and pandemic 2009 h1n1 infection increased morbidity.
prep_in||approach-16/NN||conclusion-2/NN	amod||silencing-5/NN||allele-preferential-4/JJ	nsubj||approach-16/NN||silencing-5/NN	nn||genes-10/NNS||collagen-7/NN	nn||genes-10/NNS||type-8/NN	nn||genes-10/NNS||i-9/NN	prep_of||silencing-5/NN||genes-10/NNS	aux||approach-16/NN||may-11/MD	cop||approach-16/NN||be-12/VB	det||approach-16/NN||a-13/DT	amod||approach-16/NN||future-14/JJ	amod||approach-16/NN||therapeutic-15/JJ	root||ROOT-0/null||approach-16/NN	prep_for||approach-16/NN||oi-18/NN	collagen-7||oi-18||no_rel||in conclusion, allele-preferential silencing of collagen type i genes may be a future therapeutic approach for oi.
det||patients-2/NNS||the-1/DT	nsubj||group-8/NN||patients-2/NNS	cop||group-8/NN||were-3/VBD	amod||group-8/NN||divided-4/VBN	num||groups-7/NNS||5-6/CD	prep_into||divided-4/VBN||groups-7/NNS	root||ROOT-0/null||group-8/NN	dep||diabetic-12/NN||1-10/LS	dep||group-8/NN||diabetic-12/NN	amod||levels-16/NNS||normal-14/JJ	amod||levels-16/NNS||glycemic-15/JJ	prep_with||diabetic-12/NN||levels-16/NNS	aux||american-19/VB||to-18/TO	dep||n-27/VBN||american-19/VB	nn||criteria-22/NNS||diabetes-20/NN	nn||criteria-22/NNS||association-21/NN	dobj||american-19/VB||criteria-22/NNS	amod||patients-25/NNS||in-hospital-24/JJ	prep_for||american-19/VB||patients-25/NNS	prep_according||levels-16/NNS||n-27/VBN	dep||123-29/CD||=-28/SYM	ccomp||n-27/VBN||123-29/CD	conj_and||group-8/NN||group-32/NN	dep||diabetics-36/NNS||2-34/LS	dep||group-32/NN||diabetics-36/NNS	prep_with||diabetics-36/NNS||hyperglycemia-38/NN	dep||group-32/NN||n-40/VBN	dep||76-42/CD||=-41/SYM	ccomp||n-40/VBN||76-42/CD	conj_and||group-8/NN||group-45/NN	dep||non-diabetics-49/NNS||3-47/LS	dep||group-45/NN||non-diabetics-49/NNS	prep_with||non-diabetics-49/NNS||hyperglycemia-51/NN	dep||group-45/NN||n-53/VBN	dep||225-55/CD||=-54/SYM	ccomp||n-53/VBN||225-55/CD	conj_and||group-8/NN||group-58/NN	dep||diabetics-62/NNS||4-60/LS	dep||group-58/NN||diabetics-62/NNS	dep||group-58/NN||non-diabetics-64/NNS	conj_and||diabetics-62/NNS||non-diabetics-64/NNS	amod||hyperglycemia-67/NN||persistent-66/JJ	prep_with||diabetics-62/NNS||hyperglycemia-67/NN	num||days-71/NNS||3-69/CD	amod||days-71/NNS||consecutive-70/JJ	prep_during||hyperglycemia-67/NN||days-71/NNS	dep||group-58/NN||n-73/VBN	dep||57-75/CD||=-74/SYM	ccomp||n-73/VBN||57-75/CD	conj_and||group-8/NN||group-78/NN	appos||group-78/NN||5-80/CD	dep||group-78/NN||those-82/DT	amod||control-86/NN||normal-84/JJ	nn||control-86/NN||glucose-85/NN	prep_with||group-78/NN||control-86/NN	dep||control-86/NN||n-88/VBN	dep||298-90/NNS||=-89/SYM	ccomp||n-88/VBN||298-90/NNS	hyperglycemia-67||glucose-85||no||the patients were divided into 5 groups group (1) diabetic with normal glycemic levels according to american diabetes association criteria for in-hospital patients (n = 123); group (2) diabetics with hyperglycemia (n = 76); group (3) non-diabetics with hyperglycemia (n = 225); group (4)diabetics and non-diabetics with persistent hyperglycemia during 3 consecutive days (n = 57) and group (5) those with normal glucose control (n = 298).
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipids-32||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
nsubjpass||increased-22/VBN||hypertension-1/NN	conj_and||hypertension-1/NN||triglycerides-3/NN	nsubjpass||increased-22/VBN||triglycerides-3/NN	conj_and||hypertension-1/NN||insulinresistance-5/NN	nsubjpass||increased-22/VBN||insulinresistance-5/NN	dep||hypertension-1/NN||determined-7/VBN	amod||assessment-11/NN||homeostasis-9/JJ	nn||assessment-11/NN||model-10/NN	prep_by||determined-7/VBN||assessment-11/NN	prep_of||assessment-11/NN||insulinresistance-13/NN	amod||protein-17/NN||c-reactive-16/JJ	conj_and||hypertension-1/NN||protein-17/NN	nsubjpass||increased-22/VBN||protein-17/NN	dep||protein-17/NN||crp-19/VBN	auxpass||increased-22/VBN||were-21/VBD	root||ROOT-0/null||increased-22/VBN	prep_in||increased-22/VBN||sle-24/NN	parataxis||increased-22/VBN||p-26/VB	num||0.01-28/CD||<-27/CD	dobj||p-26/VB||0.01-28/CD	mark||differ-43/VB||while-30/IN	nn||lipoprotein-37/NN||smoking-31/NN	dep||lipoprotein-37/NN||ldl-33/NN	amod||lipoprotein-37/NN||high-35/JJ	nn||lipoprotein-37/NN||density-36/NN	nsubj||differ-43/VB||lipoprotein-37/NN	appos||lipoprotein-37/NN||hdl-39/NN	aux||differ-43/VB||did-41/VBD	neg||differ-43/VB||not-42/RB	advcl||increased-22/VBN||differ-43/VB	prep_between||differ-43/VB||groups-45/NNS	sle-24||triglycerides-3||no_rel||hypertension, triglycerides and insulinresistance (determined by homeostasis model assessment of insulinresistance) and c-reactive protein (crp) were increased in sle ( p < 0.01) while smoking, ldl, high density lipoprotein (hdl) did not differ between groups.
amod||mutants-2/NNS||spontaneous-1/JJ	nsubjpass||isolated-16/VBN||mutants-2/NNS	nsubjpass||found-18/VBN||mutants-2/NNS	prep_of||mutants-2/NNS||mycobacteriumtuberculosis-4/NNS	nsubj||resistant-7/JJ||mycobacteriumtuberculosis-4/NNS	cop||resistant-7/JJ||were-6/VBD	rcmod||mycobacteriumtuberculosis-4/NNS||resistant-7/JJ	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-tuberculosis-10/JJ	prep_to||resistant-7/JJ||drugs-11/NNS	amod||drugs-11/NNS||ethionamide-12/JJ	amod||drugs-11/NNS||isoniazid-14/JJ	conj_and||ethionamide-12/JJ||isoniazid-14/JJ	auxpass||isolated-16/VBN||were-15/VBD	root||ROOT-0/null||isolated-16/VBN	conj_and||isolated-16/VBN||found-18/VBN	prep_to||isolated-16/VBN||map-20/NN	prep_to||isolated-16/VBN||msha-22/NN	det||gene-25/NN||a-24/DT	appos||msha-22/NN||gene-25/NN	vmod||gene-25/NN||encoding-26/VBG	det||enzyme-29/NN||the-27/DT	amod||enzyme-29/NN||first-28/JJ	dobj||encoding-26/VBG||enzyme-29/NN	vmod||enzyme-29/NN||involved-30/VBN	det||biosynthesis-33/NNS||the-32/DT	prep_in||involved-30/VBN||biosynthesis-33/NNS	prep_of||biosynthesis-33/NNS||mycothiol-35/NN	det||thiol-40/NN||a-37/DT	amod||thiol-40/NN||major-38/JJ	amod||thiol-40/NN||low-molecular-weight-39/JJ	appos||mycothiol-35/NN||thiol-40/NN	prep_in||thiol-40/NN||m.tuberculosis-42/NNS	tuberculosis--1||ethionamide-12||yes||spontaneous mutants of mycobacteriumtuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to msha , a gene encoding the first enzyme involved in the biosynthesis of mycothiol , a major low-molecular-weight thiol in m.tuberculosis .
amod||abnormalities-2/NNS||metabolic-1/JJ	nsubj||common-4/JJ||abnormalities-2/NNS	nsubj||occur-16/VB||abnormalities-2/NNS	cop||common-4/JJ||are-3/VBP	root||ROOT-0/null||common-4/JJ	det||course-7/NN||the-6/DT	prep_throughout||common-4/JJ||course-7/NN	nn||infection-13/NN||humanimmunodeficiencyvirus-9/NNP	appos||infection-13/NN||hiv-11/NN	prep_of||course-7/NN||infection-13/NN	aux||occur-16/VB||may-15/MD	conj_and||common-4/JJ||occur-16/VB	dep||effects-27/NNS||either-17/RB	prep_due_to||either-17/RB||hivinfection-20/NN	conj_or||either-17/RB||as-22/IN	dep||effects-27/NNS||as-22/IN	det||result-24/NN||a-23/DT	pobj||as-22/IN||result-24/NN	prep_of||result-24/NN||side-26/NN	dobj||occur-16/VB||effects-27/NNS	amod||therapy-30/NN||antiretroviral-29/JJ	prep_of||effects-27/NNS||therapy-30/NN	hivinfection-20||humanimmunodeficiencyvirus-9||no||metabolic abnormalities are common throughout the course of humanimmunodeficiencyvirus (hiv) infection and may occur either due to hivinfection or as a result of side effects of antiretroviral therapy.
amod||access-2/NN||reliable-1/JJ	nsubj||improve-7/VB||access-2/NN	amod||services-5/NNS||basic-4/JJ	prep_to||access-2/NN||services-5/NNS	aux||improve-7/VB||can-6/MD	root||ROOT-0/null||improve-7/VB	det||community-9/NN||a-8/DT	poss||resilience-11/NN||community-9/NN	dobj||improve-7/VB||resilience-11/NN	prep_to||improve-7/VB||hiv/aids-13/NNS	aids--1||basic-4||no_rel||reliable access to basic services can improve a community's resilience to hiv/aids.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	prep_of||role-4/NN||variation-6/NN	amod||genes-10/NNS||putative-8/JJ	nn||genes-10/NNS||psychosis-9/NNS	prep_in||variation-6/NN||genes-10/NNS	vmod||variation-6/NN||coding-11/VBG	prep_for||coding-11/VBG||elements-13/NNS	det||system-18/NN||the-15/DT	amod||system-18/NN||white-16/JJ	nn||system-18/NN||matter-17/NN	prep_of||elements-13/NNS||system-18/NN	agent||coding-11/VBG||examining-20/VBG	det||contribution-22/NN||the-21/DT	dobj||examining-20/VBG||contribution-22/NN	amod||variation-25/NN||genotypic-24/JJ	prep_of||contribution-22/NN||variation-25/NN	num||polymorphisms-29/NNS||three-27/CD	amod||polymorphisms-29/NNS||single-nucleotide-28/JJ	prep_in||variation-6/NN||polymorphisms-29/NNS	dep||variation-6/NN||snps-31/NNS	dep||variation-6/NN||neuregulin-33/NN	num||neuregulin-33/NN||1-34/CD	appos||neuregulin-33/NN||nrg1-36/NNP	amod||rs2857766-46/NNS||snp8nrg221533-38/JJ	amod||oligodendrocytes-41/JJ||myelin-40/JJ	amod||rs2857766-46/NNS||oligodendrocytes-41/JJ	nn||rs2857766-46/NNS||glycoprotein-42/NN	appos||rs2857766-46/NNS||mog-44/NN	dep||variation-6/NN||rs2857766-46/NNS	prep_of||role-4/NN||cnp-48/NN	conj_and||variation-6/NN||cnp-48/NN	appos||cnp-48/NN||rs2070106-50/NNP	num||ice-56/NN||one-53/CD	amod||ice-56/NN||haplotype-54/JJ	nn||ice-56/NN||hap-55/NN	conj_and||variation-6/NN||ice-56/NN	conj_and||cnp-48/NN||ice-56/NN	appos||ice-56/NN||decode-58/NN	amod||volume-63/NN||white-61/JJ	nn||volume-63/NN||matter-62/NN	prep_to||investigated-2/VBD||volume-63/NN	prep_in||volume-63/NN||patients-65/NNS	prep_with||investigated-2/VBD||psychoticdisorder-67/NN	poss||relatives-71/NNS||their-69/PRP$	amod||relatives-71/NNS||unaffected-70/JJ	prep_with||investigated-2/VBD||relatives-71/NNS	conj_and||psychoticdisorder-67/NN||relatives-71/NNS	psychosis-9||ice-56||no_rel||we investigated the role of variation in putative psychosis genes coding for elements of the white matter system by examining the contribution of genotypic variation in three single-nucleotide polymorphisms (snps) neuregulin 1 ( nrg1 ) snp8nrg221533, myelin oligodendrocytes glycoprotein (mog) rs2857766 and cnp (rs2070106) and one haplotype hap ice (decode) to white matter volume in patients with psychoticdisorder and their unaffected relatives.
vmod||identified-20/VBN||guided-1/VBN	nn||analysis-6/NN||gene-3/NN	nn||analysis-6/NN||expression-4/NN	nn||analysis-6/NN||array-5/NN	nsubj||interrogating-11/VBG||analysis-6/NN	det||screen-10/NN||a-8/DT	amod||screen-10/NN||phenotypic-9/JJ	conj_and||analysis-6/NN||screen-10/NN	nsubj||interrogating-11/VBG||screen-10/NN	agent||guided-1/VBN||interrogating-11/VBG	det||collection-13/NN||a-12/DT	dobj||interrogating-11/VBG||collection-13/NN	amod||derivatives-16/NNS||3,7-diamino-phenothiazinium-15/JJ	prep_of||collection-13/NN||derivatives-16/NNS	nsubj||identified-20/VBN||we-18/PRP	aux||identified-20/VBN||have-19/VBP	root||ROOT-0/null||identified-20/VBN	det||methyleneblue-23/NN||the-21/DT	amod||methyleneblue-23/NN||redox-drug-22/JJ	dobj||identified-20/VBN||methyleneblue-23/NN	appos||methyleneblue-23/NN||mb-25/NN	vmod||methyleneblue-23/NN||used-28/VBN	dep||used-28/VBN||clinically-29/RB	det||treatment-33/NN||the-31/DT	amod||treatment-33/NN||infusional-32/JJ	prep_for||clinically-29/RB||treatment-33/NN	prep_of||treatment-33/NN||methemoglobinemia-35/NN	det||modulator-40/NN||a-38/DT	amod||modulator-40/NN||negative-39/JJ	prep_as||identified-20/VBN||modulator-40/NN	nn||expression-46/NN||heat-42/NN	nn||expression-46/NN||shock-43/NN	nn||expression-46/NN||response-44/NN	nn||expression-46/NN||gene-45/NN	prep_of||modulator-40/NN||expression-46/NN	amod||cells-51/NNS||human-48/JJ	amod||cells-51/NNS||metastatic-49/JJ	nn||cells-51/NNS||melanoma-50/NN	prep_in||expression-46/NN||cells-51/NNS	methemoglobinemia-35||methyleneblue-23||yes||guided by gene expression array analysis and a phenotypic screen interrogating a collection of 3,7-diamino-phenothiazinium derivatives, we have identified the redox-drug methyleneblue (mb), used clinically for the infusional treatment of methemoglobinemia, as a negative modulator of heat shock response gene expression in human metastatic melanoma cells.
det||study-4/NN||this-1/DT	amod||study-4/NN||prospective-2/JJ	nn||study-4/NN||cohort-3/NN	nsubj||conducted-5/VBD||study-4/NN	root||ROOT-0/null||conducted-5/VBD	prep_in||conducted-5/VBD||zambia-7/NN	vmod||zambia-7/NN||evaluated-8/VBN	det||safety-10/NN||the-9/DT	dobj||evaluated-8/VBN||safety-10/NN	prep_of||safety-10/NN||artemether-lumefantrine-12/NN	appos||artemether-lumefantrine-12/NN||al-14/NNP	amod||women-18/NNS||pregnant-17/JJ	prep_in||evaluated-8/VBN||women-18/NNS	prep_with||evaluated-8/VBN||malaria-20/NN	malaria-20||lumefantrine--1||yes||this prospective cohort study conducted in zambia evaluated the safety of artemether-lumefantrine (al) in pregnant women with malaria.
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||calciumchannelblocker-153/NN||a-152/DT	appos||nicardipine-150/NN||calciumchannelblocker-153/NN	det||prevention-157/NN||the-156/DT	prep_in||nicardipine-150/NN||prevention-157/NN	prep_of||prevention-157/NN||vasospasm-159/NN	vmod||zoledronate-127/NN||hydrocortisone-162/VB	conj_and||prevent-134/VB||hydrocortisone-162/VB	aux||prevent-164/VB||to-163/TO	xcomp||hydrocortisone-162/VB||prevent-164/VB	dobj||prevent-164/VB||hyponatraemia-165/NN	amod||hemorrhage-168/NN||sub-arachnoid-167/JJ	prep_after||prevent-164/VB||hemorrhage-168/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calciumchannelblocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
aux||identify-2/VB||to-1/TO	csubj||change-10/VBP||identify-2/VB	det||tree-6/NN||a-3/DT	amod||tree-6/NN||simple-4/JJ	nn||tree-6/NN||decision-5/NN	dobj||identify-2/VB||tree-6/NN	xcomp||identify-2/VB||using-7/VBG	amod||symptom-9/NN||early-8/JJ	dobj||using-7/VBG||symptom-9/NN	root||ROOT-0/null||change-10/VBP	aux||predict-12/VB||to-11/TO	xcomp||change-10/VBP||predict-12/VB	dobj||predict-12/VB||response-13/NN	aux||atypical-15/VB||to-14/TO	vmod||predict-12/VB||atypical-15/VB	amod||therapy-17/NN||antipsychotic-16/JJ	dobj||atypical-15/VB||therapy-17/NN	prep_in||atypical-15/VB||patients-19/NNS	amod||manual-25/NN||diagnostic-22/JJ	conj_and||diagnostic-22/JJ||statistical-24/JJ	amod||manual-25/NN||statistical-24/JJ	dep||schizophrenia-34/NN||manual-25/NN	amod||edition-28/NN||fourth-27/JJ	appos||manual-25/NN||edition-28/NN	appos||manual-25/NN||text-30/NN	amod||text-30/NN||revised-31/JJ	amod||schizophrenia-34/NN||chronic-33/JJ	prep_with||patients-19/NNS||schizophrenia-34/NN	schizophrenia-34||antipsychotic-16||no_rel||to identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (diagnostic and statistical manual, fourth edition, text revised) chronic schizophrenia.
amod||oxymorphone-2/NN||oral-1/JJ	nsubj||formulation-6/NN||oxymorphone-2/NN	cop||formulation-6/NN||is-3/VBZ	det||formulation-6/NN||a-4/DT	amod||formulation-6/NN||new-5/JJ	root||ROOT-0/null||formulation-6/NN	det||opioid-11/NN||an-8/DT	amod||opioid-11/NN||existing-9/VBG	amod||opioid-11/NN||parenteral-10/JJ	prep_of||formulation-6/NN||opioid-11/NN	nsubj||become-14/VBN||opioid-11/NN	aux||become-14/VBN||has-13/VBZ	rcmod||opioid-11/NN||become-14/VBN	acomp||become-14/VBN||available-15/JJ	det||treatment-18/NN||the-17/DT	prep_for||become-14/VBN||treatment-18/NN	amod||postoperative-23/NN||significant-20/JJ	nn||postoperative-23/NN||pain-21/NN	amod||postoperative-23/NN||acute-22/JJ	prep_of||treatment-18/NN||postoperative-23/NN	amod||arthritis-26/NN||chronic-25/JJ	prep_of||treatment-18/NN||arthritis-26/NN	conj_and||postoperative-23/NN||arthritis-26/NN	amod||back-30/NN||chronic-28/JJ	amod||back-30/NN||low-29/JJ	prep_of||treatment-18/NN||back-30/NN	conj_and||postoperative-23/NN||back-30/NN	amod||pain-35/NN||chronic-33/JJ	nn||pain-35/NN||cancer-34/NN	prep_of||treatment-18/NN||pain-35/NN	conj_and||postoperative-23/NN||pain-35/NN	pain-35||oxymorphone-2||yes||oral oxymorphone is a new formulation of an existing parenteral opioid that has become available for the treatment of significant pain acute postoperative, chronic arthritis, chronic low back, and chronic cancer pain.
det||model-4/NN||the-1/DT	amod||model-4/NN||rhesus-2/JJ	nn||model-4/NN||macaque-3/NN	nsubj||resembles-9/VBZ||model-4/NN	prep_of||model-4/NN||glutensensitivity-6/NN	dep||only-8/RB||not-7/RB	advmod||resembles-9/VBZ||only-8/RB	root||ROOT-0/null||resembles-9/VBZ	det||histopathology-11/NN||the-10/DT	xcomp||resembles-9/VBZ||histopathology-11/NN	prep_of||histopathology-11/NN||cd-13/NN	nsubj||provide-18/VB||it-15/PRP	advmod||provide-18/VB||also-16/RB	aux||provide-18/VB||may-17/MD	conj_but||resembles-9/VBZ||provide-18/VB	det||model-20/NN||a-19/DT	dobj||provide-18/VB||model-20/NN	prepc_for||provide-18/VB||studying-22/VBG	amod||permeability-24/NN||intestinal-23/JJ	dobj||studying-22/VBG||permeability-24/NN	prep_in||studying-22/VBG||states-26/NNS	amod||integrity-29/NN||epithelial-28/JJ	prep_of||states-26/NNS||integrity-29/NN	prep_of||states-26/NNS||disrepair-31/NN	conj_and||integrity-29/NN||disrepair-31/NN	cd-13||glutensensitivity-6||no_rel||the rhesus macaque model of glutensensitivity not only resembles the histopathology of cd but it also may provide a model for studying intestinal permeability in states of epithelial integrity and disrepair.
nsubj||determine-3/VBP||to-2/TO	root||ROOT-0/null||determine-3/VBP	det||incidence-5/NN||the-4/DT	nsubj||isolates-11/VBZ||incidence-5/NN	nn||mycobacterial-10/NN||mycobacteriumtuberculosiscomplex-7/NN	conj_and||mycobacteriumtuberculosiscomplex-7/NN||non-tuberculous-9/JJ	nn||mycobacterial-10/NN||non-tuberculous-9/JJ	prep_of||incidence-5/NN||mycobacterial-10/NN	ccomp||determine-3/VBP||isolates-11/VBZ	det||setting-15/NN||the-13/DT	amod||setting-15/NN||routine-14/JJ	prep_in||isolates-11/VBZ||setting-15/NN	det||hospital-20/NN||a-17/DT	amod||hospital-20/NN||large-18/JJ	amod||hospital-20/NN||general-19/JJ	prep_of||setting-15/NN||hospital-20/NN	vmod||hospital-20/NN||using-21/VBG	punct||hospital-20/NN||an-22/,	dep||hospital-20/NN||in-house-25/NN	nn||method-32/NN||multiplex-28/NN	nn||method-32/NN||polymerase-29/NN	nn||method-32/NN||chain-30/NN	nn||method-32/NN||reaction-31/NN	dep||hospital-20/NN||method-32/NN	aux||establish-35/VB||to-34/TO	dep||hospital-20/NN||establish-35/VB	conj_and||method-32/NN||establish-35/VB	vmod||method-32/NN||establish-35/VB	det||paradigm-37/NN||a-36/DT	dobj||establish-35/VB||paradigm-37/NN	det||identification-41/NN||the-39/DT	amod||identification-41/NN||definitive-40/JJ	prep_for||establish-35/VB||identification-41/NN	prep_of||identification-41/NN||mycobacteria-43/NN	vmod||mycobacteria-43/NN||isolated-44/VBN	xcomp||isolated-44/VBN||using-45/VBG	amod||equipment-47/NN||semi-automated-46/JJ	dobj||using-45/VBG||equipment-47/NN	tuberculous--1||mycobacteriumtuberculosiscomplex-7||no||" to determine the incidence of mycobacteriumtuberculosiscomplex and non-tuberculous mycobacterial isolates in the routine setting of a large general hospital using an ""in-house"" multiplex polymerase chain reaction method and to establish a paradigm for the definitive identification of mycobacteria isolated using semi-automated equipment."
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	impairedglucosetolerance-29||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	nn||samples-4/NNS||ebc-3/NN	dobj||collected-2/VBD||samples-4/NNS	prep_from||collected-2/VBD||children-6/NNS	prep_from||collected-2/VBD||adolescents-8/NNS	conj_and||children-6/NNS||adolescents-8/NNS	prep_including||collected-2/VBD||38-11/CD	amod||asthma-14/NN||severe-13/JJ	prep_with||38-11/CD||asthma-14/NN	prep_with||38-11/CD||46-16/CD	conj_and||asthma-14/NN||46-16/CD	amod||asthma-19/NN||mild-to-moderate-18/JJ	prep_with||46-16/CD||asthma-19/NN	num||controls-24/NNS||16-21/CD	amod||controls-24/NNS||healthy-22/JJ	amod||controls-24/NNS||adolescent-23/JJ	prep_with||38-11/CD||controls-24/NNS	conj_and||asthma-14/NN||controls-24/NNS	det||concentration-28/NN||the-27/DT	nsubjpass||quantified-33/VBN||concentration-28/NN	amod||constituents-31/NNS||ionic-30/JJ	prep_of||concentration-28/NN||constituents-31/NNS	auxpass||quantified-33/VBN||was-32/VBD	conj_and||collected-2/VBD||quantified-33/VBN	xcomp||quantified-33/VBN||using-34/VBG	nn||chromatography-36/NN||ion-35/NN	dobj||using-34/VBG||chromatography-36/NN	ion-35||asthma-19||no_rel||we collected ebc samples from children and adolescents, including 38 with severe asthma, 46 with mild-to-moderate asthma and 16 healthy adolescent controls, and the concentration of ionic constituents was quantified using ion chromatography.
nn||terms-2/NNS||search-1/NN	nsubj||included-3/VBD||terms-2/NNS	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||dyslipidemia-4/NN	dobj||included-3/VBD||obesity-6/NN	conj_and||dyslipidemia-4/NN||obesity-6/NN	dobj||included-3/VBD||tobacco-8/NN	conj_and||dyslipidemia-4/NN||tobacco-8/NN	dobj||included-3/VBD||hypertension-10/NN	conj_and||dyslipidemia-4/NN||hypertension-10/NN	dobj||included-3/VBD||diabetesmellitus-13/NNS	conj_and||dyslipidemia-4/NN||diabetesmellitus-13/NNS	tobacco-8||hypertension-10||no_rel||search terms included dyslipidemia, obesity, tobacco, hypertension, and diabetesmellitus.
root||ROOT-0/null||ustekinumabâ-1/VBG	dobj||ustekinumabâ-1/VBG||$-2/$	num||$-2/$||™-3/CD	cop||safety-5/NN||s-4/VBZ	aux||ustekinumabâ-1/VBG||safety-5/NN	cc||efficacy-7/RB||and-6/CC	dep||safety-5/NN||efficacy-7/RB	aux||evaluated-10/VBN||has-8/VBZ	auxpass||evaluated-10/VBN||been-9/VBN	ccomp||efficacy-7/RB||evaluated-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||evaluated-10/VBN||treatment-13/NN	amod||plaquepsoriasis-16/NNS||moderate-to-severe-15/JJ	prep_of||treatment-13/NN||plaquepsoriasis-16/NNS	num||phase-19/NN||3-18/CD	prep_in||evaluated-10/VBN||phase-19/NN	vmod||phase-19/NN||iii-20/VBN	amod||trials-22/NNS||clinical-21/JJ	dobj||iii-20/VBN||trials-22/NNS	number||placebo-controlled-25/JJ||2-24/CD	aux||ustekinumabâ-1/VBG||placebo-controlled-25/JJ	conj_and||safety-5/NN||placebo-controlled-25/JJ	dep||safety-5/NN||phoenix-27/VB	dobj||phoenix-27/VB||1-28/CD	dobj||phoenix-27/VB||2-30/CD	conj_and||1-28/CD||2-30/CD	number||comparator-controlled-35/JJ||1-34/CD	aux||ustekinumabâ-1/VBG||comparator-controlled-35/JJ	conj_and||safety-5/NN||comparator-controlled-35/JJ	dep||safety-5/NN||accept-37/VB	nsubj||ustekinumabâ-1/VBG||study-39/NN	nsubj||proved-41/VBD||which-40/WDT	nsubj||failed-50/VBD||which-40/WDT	nsubj||unresponsive-60/JJ||which-40/WDT	nsubj||phototherapy-62/VB||which-40/WDT	nsubj||unable-66/JJ||which-40/WDT	nsubj||use-68/VB||which-40/WDT	ccomp||study-39/NN||proved-41/VBD	acomp||proved-41/VBD||advantageous-42/JJ	prep_in||advantageous-42/JJ||patients-44/NNS	nsubj||treatment-naive-47/JJ||patients-44/NNS	cop||treatment-naive-47/JJ||were-46/VBD	rcmod||patients-44/NNS||treatment-naive-47/JJ	advmod||failed-50/VBD||previously-49/RB	ccomp||study-39/NN||failed-50/VBD	conj_or||proved-41/VBD||failed-50/VBD	amod||medications-53/NNS||other-51/JJ	nn||medications-53/NNS||immunosuppressive-52/NN	dobj||failed-50/VBD||medications-53/NNS	prep_including||medications-53/NNS||cyclosporine-55/NN	prep_including||medications-53/NNS||methotrexate-57/NN	conj_or||cyclosporine-55/NN||methotrexate-57/NN	cop||unresponsive-60/JJ||were-59/VBD	ccomp||study-39/NN||unresponsive-60/JJ	conj_or||proved-41/VBD||unresponsive-60/JJ	aux||phototherapy-62/VB||to-61/TO	xcomp||unresponsive-60/JJ||phototherapy-62/VB	cop||unable-66/JJ||were-65/VBD	ccomp||study-39/NN||unable-66/JJ	conj_or||proved-41/VBD||unable-66/JJ	aux||use-68/VB||to-67/TO	xcomp||unable-66/JJ||use-68/VB	xcomp||unable-66/JJ||tolerate-70/VB	conj_or||use-68/VB||tolerate-70/VB	amod||therapies-72/NNS||other-71/JJ	dobj||use-68/VB||therapies-72/NNS	plaquepsoriasis-16||methotrexate-57||no_rel||ustekinumabâ€™s safety and efficacy has been evaluated for the treatment of moderate-to-severe plaquepsoriasis in 3 phase iii clinical trials, 2 placebo-controlled (phoenix 1 and 2), and 1 comparator-controlled (accept) study which proved advantageous in patients who were treatment-naive, previously failed other immunosuppressive medications including cyclosporine or methotrexate, were unresponsive to phototherapy, or were unable to use or tolerate other therapies.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||capsid-14/VBD||that-5/IN	amod||aminoacids-7/NNS||several-6/JJ	nsubj||capsid-14/VBD||aminoacids-7/NNS	det||surface-10/NN||the-9/DT	prep_on||aminoacids-7/NNS||surface-10/NN	det||jcvirus-13/NNS||the-12/DT	prep_of||surface-10/NN||jcvirus-13/NNS	ccomp||show-4/VBP||capsid-14/VBD	nn||vp1-16/NNS||protein-15/NN	nsubj||display-17/VBP||vp1-16/NNS	ccomp||capsid-14/VBD||display-17/VBP	amod||evolution-19/NN||accelerated-18/VBN	dobj||display-17/VBP||evolution-19/NN	amod||sequences-22/NNS||viral-21/JJ	prep_in||display-17/VBP||sequences-22/NNS	vmod||sequences-22/NNS||isolated-23/VBN	nn||patients-26/NNS||pml-25/NN	prep_from||isolated-23/VBN||patients-26/NNS	prep_in||display-17/VBP||sequences-30/NNS	conj_negcc||sequences-22/NNS||sequences-30/NNS	vmod||sequences-30/NNS||isolated-31/VBN	amod||subjects-34/NNS||healthy-33/JJ	prep_from||isolated-31/VBN||subjects-34/NNS	pml-25||jcvirus-13||no||here, we show that several aminoacids on the surface of the jcvirus capsid protein vp1 display accelerated evolution in viral sequences isolated from pml patients but not in sequences isolated from healthy subjects.
aux||prevent-2/VB||to-1/TO	advcl||added-23/VBN||prevent-2/VB	dobj||prevent-2/VB||hyperinsulinemia-3/NN	nsubj||cause-7/VB||hyperinsulinemia-3/NN	aux||cause-7/VB||may-6/MD	rcmod||hyperinsulinemia-3/NN||cause-7/VB	dobj||cause-7/VB||atherosclerosis-8/NNS	nsubjpass||added-23/VBN||thiazolidinediones-10/NNS	appos||thiazolidinediones-10/NNS||tzds-12/NNS	advmod||known-16/VBN||also-15/RB	vmod||thiazolidinediones-10/NNS||known-16/VBN	nn||sensitizers-19/NNS||insulin-18/NN	prep_as||known-16/VBN||sensitizers-19/NNS	auxpass||added-23/VBN||are-21/VBP	advmod||added-23/VBN||often-22/RB	root||ROOT-0/null||added-23/VBN	det||regimen-27/NN||the-25/DT	amod||regimen-27/NN||therapeutic-26/JJ	prep_to||added-23/VBN||regimen-27/NN	prep_of||regimen-27/NN||patients-29/NNS	prep_with||added-23/VBN||type2diabetes-31/NNS	nsubj||receiving-34/VBG||type2diabetes-31/NNS	aux||receiving-34/VBG||are-33/VBP	rcmod||type2diabetes-31/NNS||receiving-34/VBG	dobj||receiving-34/VBG||insulin-35/NN	atherosclerosis-8||insulin-35||no_rel||to prevent hyperinsulinemia, which may cause atherosclerosis, thiazolidinediones (tzds), also known as insulin sensitizers, are often added to the therapeutic regimen of patients with type2diabetes who are receiving insulin.
mark||develop-4/VB||in-1/IN	dep||develop-4/VB||order-2/NN	aux||develop-4/VB||to-3/TO	advcl||cloned-45/VBN||develop-4/VB	det||nonviral-11/NN||a-5/DT	advmod||administered-7/VBN||systemically-6/RB	amod||nonviral-11/NN||administered-7/VBN	amod||nonviral-11/NN||safe-8/JJ	conj_and||safe-8/JJ||effective-10/JJ	amod||nonviral-11/NN||effective-10/JJ	dobj||develop-4/VB||nonviral-11/NN	nn||system-14/NN||gene-12/NN	nn||system-14/NN||delivery-13/NN	dep||nonviral-11/NN||system-14/NN	prep_against||system-14/NN||avianinfluenzavirus-16/NNS	nsubj||induced-21/VBN||avianinfluenzavirus-16/NNS	appos||avianinfluenzavirus-16/NNS||aiv-18/NN	rcmod||avianinfluenzavirus-16/NNS||induced-21/VBN	amod||expression-23/NN||cytokine-22/JJ	dobj||induced-21/VBN||expression-23/NN	det||gene-30/NN||the-25/DT	nn||gene-30/NN||hemagglutinin-26/NN	appos||gene-30/NN||h5-28/NNP	appos||nonviral-11/NN||gene-30/NN	prep_of||gene-30/NN||aiv-32/NN	nsubjpass||cloned-45/VBN||a/ck/malaysia-34/NN	nsubjpass||formulated-55/VBN||a/ck/malaysia-34/NN	punct||h5n1-38/NN||/-35/:	num||h5n1-38/NN||5858/04-36/CD	dep||a/ck/malaysia-34/NN||h5n1-38/NN	amod||protein-43/NN||green-41/JJ	amod||protein-43/NN||fluorescent-42/JJ	dep||a/ck/malaysia-34/NN||protein-43/NN	conj_and||h5n1-38/NN||protein-43/NN	auxpass||cloned-45/VBN||were-44/VBD	root||ROOT-0/null||cloned-45/VBN	det||pires-50/NNS||a-47/DT	amod||pires-50/NNS||coexpression-48/JJ	nn||pires-50/NNS||vector-49/NN	prep_into||cloned-45/VBN||pires-50/NNS	dep||pires-50/NNS||piregfp-h5-52/JJ	conj_and||cloned-45/VBN||formulated-55/VBN	xcomp||formulated-55/VBN||using-56/VBG	amod||synthesis-58/NN||green-57/JJ	dobj||using-56/VBG||synthesis-58/NN	amod||nanoparticles-61/NNS||silver-60/JJ	prep_of||synthesis-58/NN||nanoparticles-61/NNS	appos||nanoparticles-61/NNS||agnps-63/NNS	prep_with||using-56/VBG||poly-66/NN	dep||poly-66/NN||ethyleneglycol-68/JJ	conj_and||cloned-45/VBN||transfected-71/VBN	conj_and||formulated-55/VBN||transfected-71/VBN	amod||cells-75/NNS||primary-73/JJ	amod||cells-75/NNS||duodenal-74/JJ	prep_into||transfected-71/VBN||cells-75/NNS	vmod||cells-75/NNS||taken-76/VBN	amod||embryos-81/NNS||18-day-old-78/JJ	amod||embryos-81/NNS||specific-pathogen-free-79/JJ	nn||embryos-81/NNS||chick-80/NN	prep_from||taken-76/VBN||embryos-81/NNS	h5n1-38||avianinfluenzavirus-16||no||in order to develop a systemically administered safe and effective nonviral gene delivery system against avianinfluenzavirus (aiv) that induced cytokine expression, the hemagglutinin (h5) gene of aiv, a/ck/malaysia/5858/04 (h5n1) and green fluorescent protein were cloned into a coexpression vector pires (piregfp-h5) and formulated using green synthesis of silver nanoparticles (agnps) with poly(ethyleneglycol) and transfected into primary duodenal cells taken from 18-day-old specific-pathogen-free chick embryos.
det||outcome-3/NN||the-1/DT	amod||outcome-3/NN||primary-2/JJ	nsubj||time-6/NN||outcome-3/NN	cop||time-6/NN||was-4/VBD	det||time-6/NN||the-5/DT	root||ROOT-0/null||time-6/NN	vmod||time-6/NN||spent-7/VBN	prep_in||spent-7/VBN||hypoglycemia-9/NN	amod||<-14/NNS||interstitial-11/JJ	nn||<-14/NNS||glucose-12/NN	nn||<-14/NNS||concentration-13/NN	dep||mg/dl-16/JJ||<-14/NNS	number||mg/dl-16/JJ||63-15/CD	dep||hypoglycemia-9/NN||mg/dl-16/JJ	det||period-20/NN||a-19/DT	prep_over||hypoglycemia-9/NN||period-20/NN	num||weeks-23/NNS||26-22/CD	prep_of||period-20/NN||weeks-23/NNS	hypoglycemia-9||glucose-12||yes||the primary outcome was the time spent in hypoglycemia (interstitial glucose concentration <63 mg/dl) over a period of 26 weeks.
poss||patient-2/NN||our-1/PRP$	nsubj||responded-3/VBD||patient-2/NN	root||ROOT-0/null||responded-3/VBD	advmod||responded-3/VBD||well-4/RB	prep_to||well-4/RB||treatment-6/NN	nn||intervals-11/NNS||levothyroxine-8/NN	conj_and||levothyroxine-8/NN||qt-10/NN	nn||intervals-11/NNS||qt-10/NN	prep_with||responded-3/VBD||intervals-11/NNS	vmod||intervals-11/NNS||normalized-12/VBN	nsubjpass||abolished-16/VBN||ventriculartachycardia-14/NN	auxpass||abolished-16/VBN||was-15/VBD	conj_and||responded-3/VBD||abolished-16/VBN	num||months-18/NNS||two-17/CD	npadvmod||abolished-16/VBN||months-18/NNS	amod||therapy-21/NN||levothyroxine-20/JJ	prep_after||abolished-16/VBN||therapy-21/NN	ventriculartachycardia-14||levothyroxine-20||no_rel||our patient responded well to treatment with levothyroxine and qt intervals normalized and ventriculartachycardia was abolished two months after levothyroxine therapy.
aux||investigate-2/VB||to-1/TO	advcl||kept-39/VBD||investigate-2/VB	mark||affects-8/VBZ||if-3/IN	amod||deficiency-7/NN||total-4/JJ	amod||deficiency-7/NN||pgc-1î-5/JJ	amod||deficiency-7/NN||±-6/JJ	nsubj||affects-8/VBZ||deficiency-7/NN	advcl||investigate-2/VB||affects-8/VBZ	dobj||affects-8/VBZ||atherosclerosis-9/NNS	nsubj||kept-39/VBD||we-11/PRP	prep||kept-39/VBD||compared-12/VBN	amod||âˆ-14/NN||apoe-13/JJ	poss||âˆ-17/NN||âˆ-14/NN	amod||âˆ-17/NN||/-16/JJ	poss||âˆ-21/NN||âˆ-17/NN	amod||±-20/JJ||pgc-1î-19/JJ	amod||âˆ-21/NN||±-20/JJ	pobj||compared-12/VBN||âˆ-21/NN	punct||âˆ-24/VB||/-23/:	parataxis||kept-39/VBD||âˆ-24/VB	conj_and||âˆ-24/VB||apoe-27/VB	parataxis||kept-39/VBD||apoe-27/VB	poss||+-35/NNS||âˆ-28/NNP	nn||âˆ-31/NNP||/-30/NNP	poss||+-35/NNS||âˆ-31/NNP	amod||+-35/NNS||pgc-1î-33/JJ	amod||+-35/NNS||±-34/JJ	dobj||apoe-27/VB||+-35/NNS	iobj||apoe-27/VB||+-35/NNS	punct||âˆ-24/VB||/-36/:	amod||mice-38/NNS||+-37/JJ	nsubj||kept-39/VBD||mice-38/NNS	root||ROOT-0/null||kept-39/VBD	det||diet-44/NN||a-41/DT	amod||diet-44/NN||high-42/JJ	nn||diet-44/NN||cholesterol-43/NN	prep_on||kept-39/VBD||diet-44/NN	cholesterol-43||atherosclerosis-9||no_rel||to investigate if total pgc-1î± deficiency affects atherosclerosis, we compared apoe âˆ’/âˆ’ pgc-1î± âˆ’/âˆ’ and apoe âˆ’/âˆ’ pgc-1î± +/+ mice kept on a high cholesterol diet.
mark||offered-6/VBN||since-1/IN	amod||cross-protection-3/NN||limited-2/JJ	nsubjpass||offered-6/VBN||cross-protection-3/NN	aux||offered-6/VBN||would-4/MD	auxpass||offered-6/VBN||be-5/VB	advcl||taken-18/VBN||offered-6/VBN	nn||types-9/NNS||hpv-8/NN	prep_between||offered-6/VBN||types-9/NNS	nsubjpass||taken-18/VBN||heterogeneity-11/NN	amod||distribution-15/NN||hpv-13/JJ	amod||distribution-15/NN||type-specific-14/JJ	prep_in||heterogeneity-11/NN||distribution-15/NN	aux||taken-18/VBN||should-16/MD	auxpass||taken-18/VBN||be-17/VB	root||ROOT-0/null||taken-18/VBN	prep_into||taken-18/VBN||account-20/NN	advmod||predicting-22/VBG||when-21/WRB	advcl||taken-18/VBN||predicting-22/VBG	det||effect-24/NN||the-23/DT	dobj||predicting-22/VBG||effect-24/NN	amod||vaccines-28/NNS||current-26/JJ	amod||vaccines-28/NNS||prophylactic-27/JJ	prep_of||effect-24/NN||vaccines-28/NNS	advcl||taken-18/VBN||forming-30/VBG	conj_and||predicting-22/VBG||forming-30/VBG	det||basic-32/JJ||the-31/DT	dobj||forming-30/VBG||basic-32/JJ	det||vaccines-36/NNS||the-34/DT	amod||vaccines-36/NNS||second-generation-35/JJ	prep_for||forming-30/VBG||vaccines-36/NNS	vmod||vaccines-36/NNS||targeted-37/VBN	amod||regions-40/NNS||specific-39/JJ	prep_to||targeted-37/VBN||regions-40/NNS	cross--1||basic-32||no_rel||since limited cross-protection would be offered between hpv types, heterogeneity in hpv type-specific distribution should be taken into account when predicting the effect of current prophylactic vaccines and forming the basic for the second-generation vaccines targeted to specific regions.
det||search-2/NN||a-1/DT	nsubj||rises-5/VBZ||search-2/NN	prep_for||search-2/NN||antibody-4/NN	root||ROOT-0/null||rises-5/VBZ	amod||antigens-8/NNS||viral-7/JJ	prep_to||rises-5/VBZ||antigens-8/NNS	amod||epstein-barrvirus-12/CD||other-9/JJ	quantmod||epstein-barrvirus-12/CD||than-10/IN	dep||epstein-barrvirus-12/CD||to-11/TO	nsubjpass||carried-20/VBN||epstein-barrvirus-12/CD	det||agent-16/NN||the-14/DT	amod||agent-16/NN||causative-15/JJ	appos||epstein-barrvirus-12/CD||agent-16/NN	aux||carried-20/VBN||has-18/VBZ	auxpass||carried-20/VBN||been-19/VBN	rcmod||antigens-8/NNS||carried-20/VBN	prt||carried-20/VBN||out-21/RP	amod||samples-25/NNS||serial-23/JJ	nn||samples-25/NNS||serum-24/NN	prep_in||carried-20/VBN||samples-25/NNS	num||patients-28/NNS||82-27/CD	prep_from||carried-20/VBN||patients-28/NNS	prep_with||patients-28/NNS||infectiousmononucleosis-30/NNS	appos||infectiousmononucleosis-30/NNS||im-32/NN	infectiousmononucleosis-30||epstein-barrvirus-12||no||a search for antibody rises to viral antigens other than to epstein-barrvirus, the causative agent, has been carried out in serial serum samples from 82 patients with infectiousmononucleosis (im).
nsubj||suggest-2/VBP||experiments-1/NNS	root||ROOT-0/null||suggest-2/VBP	mark||viruses-6/VBZ||that-3/IN	nn||inactivates-5/NNS||hpp-4/NN	nsubj||viruses-6/VBZ||inactivates-5/NNS	ccomp||suggest-2/VBP||viruses-6/VBZ	prep_via||viruses-6/VBZ||denaturation-8/NN	nsubj||render-13/VBP||denaturation-8/NN	amod||proteins-11/NNS||capsid-10/JJ	prep_of||denaturation-8/NN||proteins-11/NNS	rcmod||denaturation-8/NN||render-13/VBP	det||virus-15/NN||the-14/DT	nsubj||incapable-16/JJ||virus-15/NN	xcomp||render-13/VBP||incapable-16/JJ	prep_of||incapable-16/JJ||binding-18/JJ	poss||receptor-21/NN||its-20/PRP$	prep_to||binding-18/JJ||receptor-21/NN	det||surface-24/NN||the-23/DT	prep_on||receptor-21/NN||surface-24/NN	poss||cell-28/NN||its-26/PRP$	nn||cell-28/NN||host-27/NN	prep_of||surface-24/NN||cell-28/NN	virus-15||viruses-6||no||experiments suggest that hpp inactivates viruses via denaturation of capsid proteins which render the virus incapable of binding to its receptor on the surface of its host cell.
nn||patients-2/NNS||emf-1/NN	nsubj||showed-3/VBD||patients-2/NNS	root||ROOT-0/null||showed-3/VBD	amod||frequency-5/NN||greater-4/JJR	dobj||showed-3/VBD||frequency-5/NN	dobj||showed-3/VBD||reactivity-7/NN	conj_and||frequency-5/NN||reactivity-7/NN	nn||antibodies-10/NNS||igg-9/NN	prep_of||frequency-5/NN||antibodies-10/NNS	amod||proteins-13/NNS||myocardial-12/JJ	prep_against||showed-3/VBD||proteins-13/NNS	amod||weights-16/NNS||molecular-15/JJ	prep_of||proteins-13/NNS||weights-16/NNS	num||kd-18/NN||35-17/CD	dobj||showed-3/VBD||kd-18/NN	num||kd-21/NN||42-20/CD	appos||kd-18/NN||kd-21/NN	num||kd-24/NN||70-23/CD	appos||kd-18/NN||kd-24/NN	conj_and||kd-21/NN||kd-24/NN	nn||values-27/NNS||p-26/NN	nsubj||<-28/VBZ||values-27/NNS	dep||kd-21/NN||<-28/VBZ	dobj||<-28/VBZ||0.01-29/CD	dobj||<-28/VBZ||<-31/NNP	conj_and||0.01-29/CD||<-31/NNP	num||<-31/NNP||0.01-32/CD	dobj||<-28/VBZ||<-34/NNP	conj_and||0.01-29/CD||<-34/NNP	num||<-34/NNP||0.05-35/CD	advmod||<-28/VBZ||respectively-36/RB	kd-24||antibodies-10||no_rel||emf patients showed greater frequency and reactivity of igg antibodies against myocardial proteins of molecular weights 35 kd, 42 kd and 70 kd ( p values <0.01, <0.01 and <0.05 respectively).
amod||â-2/NN||objective-1/JJ	nsubj||was-10/VBD||â-2/NN	nsubj||examine-12/VB||â-2/NN	dep||â-2/NN||$-3/$	det||purpose-6/NN||the-5/DT	dep||â-2/NN||purpose-6/NN	det||study-9/NN||this-8/DT	prep_of||purpose-6/NN||study-9/NN	root||ROOT-0/null||was-10/VBD	aux||examine-12/VB||to-11/TO	xcomp||was-10/VBD||examine-12/VB	det||effect-14/NN||the-13/DT	dobj||examine-12/VB||effect-14/NN	prep_of||effect-14/NN||type-16/NN	nn||analog-19/NN||insulin-18/NN	prep_of||type-16/NN||analog-19/NN	prep_of||type-16/NN||age-21/NN	conj_and||analog-19/NN||age-21/NN	nn||site-24/NN||insertion-23/NN	prep_of||effect-14/NN||site-24/NN	det||characteristics-28/NNS||the-26/DT	amod||characteristics-28/NNS||pharmacodynamic-27/JJ	prep_on||examine-12/VB||characteristics-28/NNS	det||bolus-33/NNS||a-30/DT	amod||bolus-33/NNS||standard-31/JJ	nn||bolus-33/NNS||insulin-32/NN	prep_of||characteristics-28/NNS||bolus-33/NNS	prep_in||bolus-33/NNS||youth-35/NN	amod||therapy-41/NN||type1diabetes-37/JJ	nn||therapy-41/NN||receiving-38/NN	nn||therapy-41/NN||insulin-39/NN	nn||therapy-41/NN||pump-40/NN	prep_with||examine-12/VB||therapy-41/NN	type1diabetes-37||insulin-39||yes||objective â€”the purpose of this study was to examine the effect of type of insulin analog and age of insertion site on the pharmacodynamic characteristics of a standard insulin bolus in youth with type1diabetes receiving insulin pump therapy.
nsubj||inhibited-25/VBD||amitriptyline-1/NNP	dep||amitriptyline-1/NNP||5-3/CD	num||mg/kg-6/NN||10-5/CD	appos||5-3/CD||mg/kg-6/NN	conj_and||amitriptyline-1/NNP||maprotiline-9/NN	nsubj||inhibited-25/VBD||maprotiline-9/NN	dep||maprotiline-9/NN||10-11/CD	num||mg/kg-14/NN||20-13/CD	appos||10-11/CD||mg/kg-14/NN	conj_and||amitriptyline-1/NNP||fluvoxamine-17/NN	nsubj||inhibited-25/VBD||fluvoxamine-17/NN	dep||amitriptyline-1/NNP||20-19/CD	num||mg/kg-22/NN||30-21/CD	dep||amitriptyline-1/NNP||mg/kg-22/NN	conj_and||20-19/CD||mg/kg-22/NN	advmod||inhibited-25/VBD||effectively-24/RB	root||ROOT-0/null||inhibited-25/VBD	nn||induction-27/NN||pain-26/NN	dobj||inhibited-25/VBD||induction-27/NN	vmod||induction-27/NN||caused-28/VBN	det||phase-32/NN||the-30/DT	amod||phase-32/NN||second-31/JJ	agent||caused-28/VBN||phase-32/NN	det||test-36/NN||the-34/DT	nn||test-36/NN||formalin-35/NN	prep_of||phase-32/NN||test-36/NN	pain-26||maprotiline-9||yes||amitriptyline (5, 10 mg/kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by the second phase of the formalin test.
poss||study-2/NN||our-1/PRP$	nsubj||focuses-3/VBZ||study-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||level-9/NN||the-5/DT	amod||level-9/NN||cellular-6/JJ	conj_and||cellular-6/JJ||molecular-8/JJ	amod||level-9/NN||molecular-8/JJ	prep_at||focuses-3/VBZ||level-9/NN	nsubjpass||mediated-15/VBN||level-9/NN	nsubjpass||mediated-15/VBN||level-9/NN	amod||effects-12/NNS||ethanol-induced-11/JJ	prep_on||level-9/NN||effects-12/NNS	auxpass||mediated-15/VBN||are-14/VBP	rcmod||level-9/NN||mediated-15/VBN	rcmod||level-9/NN||mediated-15/VBN	conj_and||mediated-15/VBN||mediated-15/VBN	det||receptor-19/NN||the-17/DT	amod||receptor-19/NN||mu-opioid-18/JJ	prep_through||mediated-15/VBN||receptor-19/NN	dep||mediated-15/VBN||mop-21/VB	det||effects-26/NNS||the-25/DT	prep_on||mediated-15/VBN||effects-26/NNS	prep_of||effects-26/NNS||naltrexone-28/NN	det||antagonist-32/NN||a-30/DT	amod||antagonist-32/NN||well-known-31/JJ	appos||naltrexone-28/NN||antagonist-32/NN	nsubj||used-37/JJ||antagonist-32/NN	nsubj||prevent-40/VB||antagonist-32/NN	prep_at||antagonist-32/NN||mop-34/NNP	cop||used-37/JJ||is-36/VBZ	rcmod||antagonist-32/NN||used-37/JJ	advmod||used-37/JJ||clinically-38/RB	aux||prevent-40/VB||to-39/TO	xcomp||used-37/JJ||prevent-40/VB	dobj||prevent-40/VB||relapse-41/NN	prep_in||prevent-40/VB||alcoholism-43/NN	alcoholism-43||ethanol--1||no||our study focuses at the cellular and molecular level on ethanol-induced effects that are mediated through the mu-opioid receptor (mop) and on the effects of naltrexone, a well-known antagonist at mop that is used clinically to prevent relapse in alcoholism.
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||lumefantrine--1||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
mark||enhance-4/VB||because-1/IN	nsubj||enhance-4/VB||iron-2/NN	aux||enhance-4/VB||can-3/MD	advcl||examined-12/VBD||enhance-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||oxidative-6/JJ	dobj||enhance-4/VB||effects-7/NNS	prep_of||effects-7/NNS||lead-9/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	mark||-LSB--19/VB||whether-13/IN	nsubj||-LSB--19/VB||polymorphisms-14/NNS	nsubj||transferrin-25/VB||polymorphisms-14/NNS	nsubj||heme-32/VB||polymorphisms-14/NNS	nn||genes-18/NNS||iron-16/NN	nn||genes-18/NNS||metabolism-17/NN	prep_in||polymorphisms-14/NNS||genes-18/NNS	ccomp||examined-12/VBD||-LSB--19/VB	dobj||-LSB--19/VB||hemochromatosis-20/NNS	appos||hemochromatosis-20/NNS||hfe-22/NN	ccomp||examined-12/VBD||transferrin-25/VB	conj_and||-LSB--19/VB||transferrin-25/VB	appos||c2-29/NNS||tf-27/NN	dobj||transferrin-25/VB||c2-29/NNS	ccomp||examined-12/VBD||heme-32/VB	conj_and||-LSB--19/VB||heme-32/VB	amod||susceptibility-39/NN||oxygenase-1-33/JJ	dep||oxygenase-1-33/JJ||hmox-1-35/JJ	amod||susceptibility-39/NN||-RSB--37/JJ	nn||susceptibility-39/NN||increase-38/NN	dobj||heme-32/VB||susceptibility-39/NN	det||effects-42/NNS||the-41/DT	prep_to||heme-32/VB||effects-42/NNS	prep_of||effects-42/NNS||lead-44/NN	nn||interval-47/NN||qt-46/NN	nsubj||community-dwelling-50/VBG||interval-47/NN	prep_in||interval-47/NN||613-49/CD	prepc_on||heme-32/VB||community-dwelling-50/VBG	amod||men-52/NNS||older-51/JJR	dobj||community-dwelling-50/VBG||men-52/NNS	hemochromatosis-20||iron-16||no||because iron can enhance the oxidative effects of lead, we examined whether polymorphisms in iron metabolism genes [hemochromatosis ( hfe ), transferrin ( tf ) c2, and heme oxygenase-1 ( hmox-1 )] increase susceptibility to the effects of lead on qt interval in 613 community-dwelling older men.
nsubj||occurs-5/VBZ||magnesiumdeficiency-1/NN	prep_in||magnesiumdeficiency-1/NN||pregnancy-3/NN	advmod||occurs-5/VBZ||frequently-4/RB	root||ROOT-0/null||occurs-5/VBZ	amod||intake-11/NN||inadequate-8/JJ	conj_or||inadequate-8/JJ||low-10/JJ	amod||intake-11/NN||low-10/JJ	prep_because_of||occurs-5/VBZ||intake-11/NN	prep_of||intake-11/NN||magnesium-13/NN	magnesiumdeficiency-1||magnesium-13||yes||magnesiumdeficiency in pregnancy frequently occurs because of inadequate or low intake of magnesium.
root||ROOT-0/null||herein-1/VB	nsubj||document-4/VB||we-3/PRP	ccomp||herein-1/VB||document-4/VB	mark||provides-14/VBZ||that-5/IN	det||signature-8/NN||the-6/DT	amod||signature-8/NN||bioenergetic-7/JJ	nsubj||provides-14/VBZ||signature-8/NN	amod||cells-13/NNS||isogenic-10/JJ	nn||cells-13/NNS||colon-11/NN	nn||cells-13/NNS||cancer-12/NN	prep_of||signature-8/NN||cells-13/NNS	ccomp||document-4/VB||provides-14/VBZ	det||gauge-16/NN||a-15/DT	dobj||provides-14/VBZ||gauge-16/NN	aux||predict-18/VB||to-17/TO	vmod||gauge-16/NN||predict-18/VB	det||response-21/NN||the-19/DT	amod||response-21/NN||cell-death-20/JJ	dobj||predict-18/VB||response-21/NN	det||inhibitors-25/NNS||the-23/DT	amod||inhibitors-25/NNS||metabolic-24/JJ	prep_to||predict-18/VB||inhibitors-25/NNS	amod||3brp-29/NNS||3-bromopyruvate-27/JJ	prep_to||predict-18/VB||3brp-29/NNS	conj_and||inhibitors-25/NNS||3brp-29/NNS	amod||ia-34/NN||iodoacetate-32/JJ	prep_to||predict-18/VB||ia-34/NN	conj_and||inhibitors-25/NNS||ia-34/NN	det||anti-metabolite-39/NN||the-38/DT	prep_to||predict-18/VB||anti-metabolite-39/NN	conj_and||inhibitors-25/NNS||anti-metabolite-39/NN	prep_to||predict-18/VB||5-fluorouracil-41/NN	conj_and||inhibitors-25/NNS||5-fluorouracil-41/NN	dep||inhibitors-25/NNS||5-fu-43/JJ	5-fu-43||cancer-12||no_rel||herein, we document that the bioenergetic signature of isogenic colon cancer cells provides a gauge to predict the cell-death response to the metabolic inhibitors, 3-bromopyruvate (3brp) and iodoacetate (ia), and the anti-metabolite, 5-fluorouracil (5-fu).
mark||increased-2/VBD||while-1/IN	advcl||suggests-21/VBZ||increased-2/VBD	amod||expression-7/NN||urokinase-typeplasminogenactivator-3/JJ	appos||expression-7/NN||upa-5/NN	nsubjpass||associated-14/VBN||expression-7/NN	nn||tissue-11/NN||breast-9/NN	nn||tissue-11/NN||cancer-10/NN	prep_in||expression-7/NN||tissue-11/NN	auxpass||associated-14/VBN||is-12/VBZ	advmod||associated-14/VBN||directly-13/RB	ccomp||increased-2/VBD||associated-14/VBN	amod||prognosis-17/NN||poor-16/JJ	prep_with||associated-14/VBN||prognosis-17/NN	amod||evidence-20/NN||recent-19/JJ	nsubj||suggests-21/VBZ||evidence-20/NN	root||ROOT-0/null||suggests-21/VBZ	mark||suppress-26/VB||that-22/IN	nn||overexpression-24/NN||upa-23/NN	nsubj||suppress-26/VB||overexpression-24/NN	nsubj||prolong-30/VB||overexpression-24/NN	aux||suppress-26/VB||may-25/MD	ccomp||suggests-21/VBZ||suppress-26/VB	nn||growth-28/NN||tumor-27/NN	dobj||suppress-26/VB||growth-28/NN	ccomp||suggests-21/VBZ||prolong-30/VB	conj_and||suppress-26/VB||prolong-30/VB	dobj||prolong-30/VB||survival-31/NN	urokinase-typeplasminogenactivator-3||tumor-27||no_rel||while increased urokinase-typeplasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||formoterol--1||no||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
det||patients-2/NNS||both-1/DT	nsubj||taking-4/VBG||patients-2/NNS	aux||taking-4/VBG||were-3/VBD	root||ROOT-0/null||taking-4/VBG	det||lamotrigine-8/NN||the-5/DT	amod||lamotrigine-8/NN||anti-seizure-6/JJ	nn||lamotrigine-8/NN||medication-7/NN	dobj||taking-4/VBG||lamotrigine-8/NN	prep_with||taking-4/VBG||nothing-10/NN	advmod||nothing-10/NN||else-11/RB	prep_in||nothing-10/NN||common-13/JJ	seizure--1||lamotrigine-8||yes||both patients were taking the anti-seizure medication lamotrigine with nothing else in common.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||aims-4/VBZ||study-3/NN	nsubj||demonstrate-6/VB||study-3/NN	root||ROOT-0/null||aims-4/VBZ	aux||demonstrate-6/VB||to-5/TO	xcomp||aims-4/VBZ||demonstrate-6/VB	mark||induces-13/VBZ||that-7/IN	det||formaldehyde-12/NN||the-8/DT	amod||formaldehyde-12/NN||tumor-9/JJ	amod||formaldehyde-12/NN||tissue-derived-10/JJ	nn||formaldehyde-12/NN||endogenous-11/NNS	nsubj||induces-13/VBZ||formaldehyde-12/NN	ccomp||demonstrate-6/VB||induces-13/VBZ	nn||pain-16/NN||bone-14/NN	nn||pain-16/NN||cancer-15/NN	dobj||induces-13/VBZ||pain-16/NN	amod||activation-19/NN||trpv1-18/JJ	prep_via||pain-16/NN||activation-19/NN	nn||environment-23/NN||tumor-21/NN	amod||environment-23/NN||acidic-22/JJ	prep_under||induces-13/VBZ||environment-23/NN	tumor-21||formaldehyde-12||no_rel||the present study aims to demonstrate that the tumor tissue-derived endogenous formaldehyde induces bone cancer pain via trpv1 activation under tumor acidic environment.
det||use-2/NN||the-1/DT	nsubj||reduces-14/VBZ||use-2/NN	amod||cream-5/NN||pimecrolimus-4/JJ	prep_of||use-2/NN||cream-5/NN	det||sign-9/NN||the-7/DT	amod||sign-9/NN||first-8/JJ	prep_for||cream-5/NN||sign-9/NN	prep_of||use-2/NN||symptoms-11/NNS	conj_and||cream-5/NN||symptoms-11/NNS	prep_of||symptoms-11/NNS||atopiceczema-13/NN	root||ROOT-0/null||reduces-14/VBZ	det||occurrence-16/NN||the-15/DT	dobj||reduces-14/VBZ||occurrence-16/NN	prep_of||occurrence-16/NN||flares-18/NNS	mark||defined-20/VBN||as-19/IN	dep||flares-18/NNS||defined-20/VBN	det||need-23/NN||the-22/DT	prep_by||defined-20/VBN||need-23/NN	amod||corticosteroids-26/NNS||topical-25/JJ	prep_for||need-23/NN||corticosteroids-26/NNS	atopiceczema-13||pimecrolimus-4||yes||the use of pimecrolimus cream for the first sign and symptoms of atopiceczema reduces the occurrence of flares as defined by the need for topical corticosteroids.
det||study-3/NN||a-1/DT	amod||study-3/NN||12-week-2/JJ	nsubj||assessed-4/VBD||study-3/NN	root||ROOT-0/null||assessed-4/VBD	det||efficacy-6/NN||the-5/DT	dobj||assessed-4/VBD||efficacy-6/NN	dobj||assessed-4/VBD||safety-8/NN	conj_and||efficacy-6/NN||safety-8/NN	det||agent-14/NN||a-10/DT	amod||agent-14/NN||new-11/JJ	amod||agent-14/NN||oral-12/JJ	amod||agent-14/NN||antidiabetic-13/JJ	prep_of||efficacy-6/NN||agent-14/NN	appos||agent-14/NN||imeglimin-16/NN	amod||therapy-20/NN||add-on-19/JJ	prep_as||assessed-4/VBD||therapy-20/NN	amod||patients-23/NNS||type2diabetes-22/JJ	prep_in||therapy-20/NN||patients-23/NNS	advmod||controlled-25/VBN||inadequately-24/RB	amod||patients-23/NNS||controlled-25/VBN	prep_with||assessed-4/VBD||metformin-27/NN	advmod||assessed-4/VBD||alone-28/RB	type2diabetes-22||metformin-27||yes||a 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type2diabetes patients inadequately controlled with metformin alone.
det||cause-3/NN||the-1/DT	amod||cause-3/NN||main-2/JJ	nsubjpass||represented-5/VBN||cause-3/NN	auxpass||represented-5/VBN||is-4/VBZ	root||ROOT-0/null||represented-5/VBN	agent||represented-5/VBN||autoimmunethyroiditis-7/NNS	nsubjpass||thought-20/VBN||mutations-10/NNS	nsubj||responsible-23/JJ||mutations-10/NNS	nn||proteins-14/NNS||genes-12/NNS	amod||proteins-14/NNS||encoding-13/VBG	prep_in||mutations-10/NNS||proteins-14/NNS	vmod||proteins-14/NNS||involved-15/VBN	prep_in||involved-15/VBN||tsh-17/NN	advmod||thought-20/VBN||pathway-18/RB	auxpass||thought-20/VBN||are-19/VBP	conj_but||represented-5/VBN||thought-20/VBN	aux||responsible-23/JJ||to-21/TO	cop||responsible-23/JJ||be-22/VB	xcomp||thought-20/VBN||responsible-23/JJ	prep_for||responsible-23/JJ||sh-25/NN	advmod||responsible-23/JJ||particularly-27/RB	prep_in||responsible-23/JJ||cases-29/NNS	vmod||cases-29/NNS||arising-30/VBG	amod||settings-33/NNS||familial-32/JJ	prep_in||arising-30/VBG||settings-33/NNS	autoimmunethyroiditis-7||tsh-17||no_rel||the main cause is represented by autoimmunethyroiditis, but mutations in genes encoding proteins involved in tsh pathway are thought to be responsible for sh, particularly in cases arising in familial settings.
amod||administration-2/NN||early-1/JJ	nsubj||able-19/JJ||administration-2/NN	nsubj||increase-21/VB||administration-2/NN	prep_of||administration-2/NN||norepinephrine-4/NN	vmod||norepinephrine-4/NN||aimed-5/VBN	advmod||achieving-8/VBG||rapidly-7/RB	prepc_at||aimed-5/VBN||achieving-8/VBG	det||pressure-12/NN||a-9/DT	amod||pressure-12/NN||sufficient-10/JJ	nn||pressure-12/NN||perfusion-11/NN	dobj||achieving-8/VBG||pressure-12/NN	advmod||hypotensive-15/JJ||severely-14/RB	amod||patients-17/NNS||hypotensive-15/JJ	amod||patients-17/NNS||septic-shock-16/JJ	prep_in||achieving-8/VBG||patients-17/NNS	cop||able-19/JJ||is-18/VBZ	root||ROOT-0/null||able-19/JJ	aux||increase-21/VB||to-20/TO	xcomp||able-19/JJ||increase-21/VB	amod||output-23/NN||cardiac-22/JJ	dobj||increase-21/VB||output-23/NN	det||increase-26/NN||an-25/DT	prep_through||increase-21/VB||increase-26/NN	amod||preload-29/NN||cardiac-28/JJ	prep_in||increase-26/NN||preload-29/NN	amod||contractility-32/NN||cardiac-31/JJ	prep_in||increase-26/NN||contractility-32/NN	conj_and||preload-29/NN||contractility-32/NN	shock--1||norepinephrine-4||yes||early administration of norepinephrine aimed at rapidly achieving a sufficient perfusion pressure in severely hypotensive septic-shock patients is able to increase cardiac output through an increase in cardiac preload and cardiac contractility.
det||results-3/NNS||the-1/DT	amod||results-3/NNS||overall-2/JJ	nsubj||show-11/VBP||results-3/NNS	prep_of||results-3/NNS||uri-5/NN	prep_of||results-3/NNS||lri-7/NN	conj_and||uri-5/NN||lri-7/NN	prep_of||results-3/NNS||ip-10/NN	conj_and||uri-5/NN||ip-10/NN	root||ROOT-0/null||show-11/VBP	amod||correlation-13/NN||clear-12/JJ	iobj||show-11/VBP||correlation-13/NN	amod||pm10-19/NNS||so2-15/JJ	conj_and||so2-15/JJ||co-17/NN	amod||pm10-19/NNS||co-17/NN	prep_with||correlation-13/NN||pm10-19/NNS	prep_with||correlation-13/NN||o3-21/NNS	conj_and||pm10-19/NNS||o3-21/NNS	iobj||show-11/VBP||pm10-24/NNS	conj_and||correlation-13/NN||pm10-24/NNS	advmod||pm10-24/NNS||respectively-26/RB	det||etw4-30/NN||the-29/DT	iobj||show-11/VBP||etw4-30/NN	conj_and||correlation-13/NN||etw4-30/NN	amod||temperature-33/NN||effective-32/JJ	appos||etw4-30/NN||temperature-33/NN	predet||the-37/DT||all-36/PDT	prep_for||etw4-30/NN||the-37/DT	num||groups-40/NNS||three-38/CD	nn||groups-40/NNS||disease-39/NN	dobj||show-11/VBP||groups-40/NNS	o3-21||uri-5||no_rel||the overall results of uri, lri, and ip show clear correlation with so2 and co, pm10 and o3, and pm10, respectively, and the etw4 (effective temperature) for all the three disease groups.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||determine-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	dobj||determine-9/VB||relationship-10/NN	nn||activity-13/NN||disease-12/NN	prep_between||relationship-10/NN||activity-13/NN	amod||markers-16/NNS||systemic-15/JJ	dobj||determine-9/VB||markers-16/NNS	conj_and||relationship-10/NN||markers-16/NNS	nn||degradation-19/NN||cartilage-18/NN	prep_of||markers-16/NNS||degradation-19/NN	amod||telopeptides-24/NNS||urinary-21/JJ	amod||telopeptides-24/NNS||c-terminal-22/JJ	amod||telopeptides-24/NNS||cross-linking-23/JJ	dobj||determine-9/VB||telopeptides-24/NNS	conj_and||relationship-10/NN||telopeptides-24/NNS	nn||collagen-28/NN||type-26/NN	nn||collagen-28/NN||ii-27/NN	prep_of||telopeptides-24/NNS||collagen-28/NN	appos||collagen-28/NN||uctx-ii-30/NNP	nn||degradation-35/NN||bone-34/NN	dobj||determine-9/VB||degradation-35/NN	conj_and||relationship-10/NN||degradation-35/NN	advmod||telopeptides-40/NNS||urinary-37/RB	amod||telopeptides-40/NNS||c-terminal-38/JJ	amod||telopeptides-40/NNS||cross-linking-39/JJ	dobj||determine-9/VB||telopeptides-40/NNS	conj_and||relationship-10/NN||telopeptides-40/NNS	nn||collagen-44/NN||type-42/FW	nn||collagen-44/NN||i-43/FW	prep_of||telopeptides-40/NNS||collagen-44/NN	appos||collagen-44/NN||uctx-i-46/NNP	amod||progression-50/NN||structural-49/JJ	dobj||determine-9/VB||progression-50/NN	conj_and||relationship-10/NN||progression-50/NN	prep_of||progression-50/NN||osteoarthritis-52/NNS	appos||osteoarthritis-52/NNS||oa-54/NN	amod||efficacy-59/NN||potential-57/JJ	amod||efficacy-59/NN||therapeutic-58/JJ	dobj||determine-9/VB||efficacy-59/NN	conj_and||relationship-10/NN||efficacy-59/NN	nn||collagen-63/NN||type-61/NN	nn||collagen-63/NN||ii-62/NN	prep_of||efficacy-59/NN||collagen-63/NN	appos||collagen-63/NN||collii-65/NNP	prep_in||determine-9/VB||combination-68/NN	prep_with||determine-9/VB||glucosamine-70/NN	prep_with||determine-9/VB||chondroitinsulfate-72/NN	conj_and||glucosamine-70/NN||chondroitinsulfate-72/NN	appos||glucosamine-70/NN||gc-74/NN	osteoarthritis-52||glucosamine-70||yes||the purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary c-terminal cross-linking telopeptides of type ii collagen (uctx-ii), and bone degradation, urinary c-terminal cross-linking telopeptides of type i collagen (uctx-i), structural progression of osteoarthritis (oa) and potential therapeutic efficacy of type ii collagen (collii) in combination with glucosamine and chondroitinsulfate (gc).
amod||charges-3/NNS||hiv/aids-1/JJ	nn||charges-3/NNS||inpatient-2/NN	nsubj||increased-4/VBD||charges-3/NNS	root||ROOT-0/null||increased-4/VBD	prepc_after||increased-4/VBD||adjusting-6/VBG	prep_for||adjusting-6/VBG||inflation-8/NN	amod||studies-11/NNS||earlier-10/JJR	prep_despite||adjusting-6/VBG||studies-11/NNS	nsubj||showed-13/VBD||studies-11/NNS	rcmod||studies-11/NNS||showed-13/VBD	det||decline-15/NN||a-14/DT	dobj||showed-13/VBD||decline-15/NN	aids--1||hiv--1||no||hiv/aids inpatient charges increased after adjusting for inflation despite earlier studies that showed a decline.
det||work-2/NN||this-1/DT	nsubj||shows-3/VBZ||work-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||ameliorated-22/VBN||that-4/IN	nsubjpass||ameliorated-22/VBN||resistance-5/NN	nsubjpass||bypassed-24/VBN||resistance-5/NN	prep_to||resistance-5/NN||dr-7/NN	amod||death-12/NN||fludarabine-induced-10/JJ	nn||death-12/NN||cell-11/NN	conj_and||resistance-5/NN||death-12/NN	nsubjpass||ameliorated-22/VBN||death-12/NN	amod||cells-15/NNS||leukaemic-14/JJ	prep_in||death-12/NN||cells-15/NNS	vmod||cells-15/NNS||isolated-16/VBN	nn||patients-19/NNS||cll-18/NN	prep_from||isolated-16/VBN||patients-19/NNS	aux||ameliorated-22/VBN||can-20/MD	auxpass||ameliorated-22/VBN||be-21/VB	ccomp||shows-3/VBZ||ameliorated-22/VBN	ccomp||shows-3/VBZ||bypassed-24/VBN	conj_or||ameliorated-22/VBN||bypassed-24/VBN	det||treatment-28/NN||the-26/DT	amod||treatment-28/NN||combined-27/VBN	agent||ameliorated-22/VBN||treatment-28/NN	prep_with||treatment-28/NN||quercetin-30/NN	cll-18||fludarabine--1||yes||this work shows that resistance to dr- and fludarabine-induced cell death in leukaemic cells isolated from cll patients can be ameliorated or bypassed by the combined treatment with quercetin.
advmod||identical-20/JJ||however-1/RB	det||prevalence-4/NN||the-3/DT	nsubj||identical-20/JJ||prevalence-4/NN	prep_of||prevalence-4/NN||borreliaburgdorferi-6/NNS	det||bacterium-9/NN||the-8/DT	appos||borreliaburgdorferi-6/NNS||bacterium-9/NN	nsubj||causes-11/VBZ||bacterium-9/NN	rcmod||bacterium-9/NN||causes-11/VBZ	acomp||causes-11/VBZ||lymedisease-12/JJ	det||vector-17/NN||the-15/DT	nn||vector-17/NN||tick-16/NN	prep_in||causes-11/VBZ||vector-17/NN	cop||identical-20/JJ||is-18/VBZ	advmod||identical-20/JJ||nearly-19/RB	root||ROOT-0/null||identical-20/JJ	det||regions-24/NNS||the-22/DT	num||regions-24/NNS||2-23/CD	prep_in||identical-20/JJ||regions-24/NNS	lymedisease-12||borreliaburgdorferi-6||no||however, the prevalence of borreliaburgdorferi , the bacterium that causes lymedisease, in the tick vector is nearly identical in the 2 regions.
num||patients-2/NNS||six-1/CD	nsubj||had-7/VBD||patients-2/NNS	amod||results-6/NNS||discordant-4/JJ	nn||results-6/NNS||test-5/NN	prep_with||patients-2/NNS||results-6/NNS	root||ROOT-0/null||had-7/VBD	preconj||tst-14/NN||either-8/DT	dep||tst-14/NN||1-10/LS	det||tst-14/NN||a-12/DT	amod||tst-14/NN||negative-13/JJ	dobj||had-7/VBD||tst-14/NN	amod||igra-17/NN||positive-16/JJ	dobj||had-7/VBD||igra-17/NN	conj_and||tst-14/NN||igra-17/NN	prep_in||tst-14/NN||combination-19/NN	det||history-23/NN||a-21/DT	amod||history-23/NN||medical-22/JJ	prep_with||combination-19/NN||history-23/NN	nn||exposure-26/NN||tuberculosis-25/NNP	prep_of||history-23/NN||exposure-26/NN	nn||â-29/NN||n-28/NN	dep||combination-19/NN||â-29/NN	nsubj||â-33/VBP||$-30/$	number||=-32/CD||‰-31/CD	num||$-30/$||=-32/CD	rcmod||â-29/NN||â-33/VBP	dobj||â-33/VBP||$-34/$	number||1-36/CD||‰-35/CD	num||$-34/$||1-36/CD	dep||tst-44/NN||2-40/LS	det||tst-44/NN||a-42/DT	amod||tst-44/NN||positive-43/JJ	prep_in||tst-14/NN||tst-44/NN	conj_or||combination-19/NN||tst-44/NN	amod||igra-47/NN||negative-46/JJ	conj_or||combination-19/NN||igra-47/NN	conj_and||tst-44/NN||igra-47/NN	prep_in||tst-44/NN||combination-49/NN	nn||vaccination-52/NN||bcg-51/NN	prep_with||combination-49/NN||vaccination-52/NN	nn||â-55/NN||n-54/NN	dep||combination-49/NN||â-55/NN	nsubj||â-59/VBP||$-56/$	number||=-58/CD||‰-57/CD	num||$-56/$||=-58/CD	rcmod||â-55/NN||â-59/VBP	dobj||â-59/VBP||$-60/$	number||3-62/CD||‰-61/CD	num||$-60/$||3-62/CD	det||history-67/NN||a-65/DT	amod||history-67/NN||medical-66/JJ	dobj||had-7/VBD||history-67/NN	conj_or||tst-14/NN||history-67/NN	nn||exposure-70/NN||tuberculosis-69/NNP	prep_of||history-67/NN||exposure-70/NN	nn||â-73/NN||n-72/NN	dep||history-67/NN||â-73/NN	nsubj||â-77/VBP||$-74/$	number||=-76/CD||‰-75/CD	num||$-74/$||=-76/CD	rcmod||â-73/NN||â-77/VBP	dobj||â-77/VBP||$-78/$	number||2-80/CD||‰-79/CD	num||$-78/$||2-80/CD	tuberculosis-69||bcg-51||no||six patients with discordant test results had either (1) a negative tst and positive igra in combination with a medical history of tuberculosis exposure ( n â€‰=â€‰1) or (2) a positive tst and negative igra in combination with bcg vaccination ( n â€‰=â€‰3) or a medical history of tuberculosis exposure ( n â€‰=â€‰2).
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	polio--1||polioviruses-31||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
nsubjpass||used-9/VBN||hydroxyethylstarch-1/NN	nsubj||induce-16/VB||hydroxyethylstarch-1/NN	appos||hydroxyethylstarch-1/NN||hes-3/NN	auxpass||used-9/VBN||is-7/VBZ	advmod||used-9/VBN||widely-8/RB	rcmod||hydroxyethylstarch-1/NN||used-9/VBN	nn||replacement-13/NN||blood-11/NN	nn||replacement-13/NN||volume-12/NN	prep_for||used-9/VBN||replacement-13/NN	aux||induce-16/VB||can-15/MD	root||ROOT-0/null||induce-16/VB	advmod||induce-16/VB||coagulopathy-17/RB	coagulopathy-17||hes-3||no||hydroxyethylstarch (hes), which is widely used for blood volume replacement, can induce coagulopathy.
amod||model-5/NN||castoroil-2/JJ	amod||model-5/NN||induced-3/JJ	nn||model-5/NN||diarrhea-4/NN	prep_in||reduced-33/VBD||model-5/NN	det||extract-12/NN||the-7/DT	number||%-9/NN||80-8/CD	amod||extract-12/NN||%-9/NN	nn||extract-12/NN||methanol-10/NN	nn||extract-12/NN||leaf-11/NN	nsubj||reduced-33/VBD||extract-12/NN	nn||aurea-15/NN||c.-14/NN	prep_of||extract-12/NN||aurea-15/NN	prep_at||aurea-15/NN||100-17/CD	num||100-17/CD||200-19/CD	prep_at||aurea-15/NN||400-21/CD	conj_and||100-17/CD||400-21/CD	amod||aurea-15/NN||mg/kg-22/JJ	det||drug-26/NN||the-24/DT	amod||drug-26/NN||standard-25/JJ	amod||aurea-15/NN||drug-26/NN	conj_and||mg/kg-22/JJ||drug-26/NN	advmod||drug-26/NN||loperamide-27/RB	number||3-29/CD||-lrb--28/CD	num||-rrb--31/NNS||3-29/CD	amod||-rrb--31/NNS||mg/kg-30/JJ	dep||mg/kg-22/JJ||-rrb--31/NNS	advmod||reduced-33/VBD||significantly-32/RB	root||ROOT-0/null||reduced-33/VBD	det||time-35/NN||the-34/DT	dobj||reduced-33/VBD||time-35/NN	prep_of||time-35/NN||onset-37/NN	prep_of||onset-37/NN||diarrhea-39/NN	det||frequency-42/NN||the-41/DT	prep_of||time-35/NN||frequency-42/NN	conj_and||onset-37/NN||frequency-42/NN	nn||number-47/NN||defecation-44/NN	nn||number-47/NN||-lrb--45/NNP	amod||number-47/NN||total-46/JJ	prep_of||frequency-42/NN||number-47/NN	amod||-rrb--51/NNS||faecal-49/JJ	nn||-rrb--51/NNS||output-50/NN	prep_of||frequency-42/NN||-rrb--51/NNS	prep_of||time-35/NN||weight-53/NN	conj_and||onset-37/NN||weight-53/NN	prep_of||weight-53/NN||faeces-55/NNS	diarrhea-39||loperamide-27||no||in castoroil induced diarrhea model , the 80 % methanol leaf extract of c. aurea at 100 , 200 and 400 mg/kg and the standard drug loperamide -lrb- 3 mg/kg -rrb- significantly reduced the time of onset of diarrhea , the frequency of defecation -lrb- total number of faecal output -rrb- and weight of faeces .
amod||testing-3/NN||one-off-1/JJ	nn||testing-3/NN||mtb/rif-2/NN	nsubj||detected-4/VBD||testing-3/NN	root||ROOT-0/null||detected-4/VBD	dobj||detected-4/VBD||933-5/CD	amod||·-8/NNS||90â-7/JJ	dep||933-5/CD||·-8/NNS	num||%-10/NN||3-9/CD	dep||·-8/NNS||%-10/NN	num||cases-15/NNS||1033-13/CD	amod||cases-15/NNS||culture-confirmed-14/JJ	prep_of||933-5/CD||cases-15/NNS	prep_of||cases-15/NNS||tuberculosis-17/NNP	prepc_compared_with||detected-4/VBD||with-20/IN	pobj||detected-4/VBD||699-21/NNP	amod||·-24/NNS||67â-23/JJ	dep||699-21/NNP||·-24/NNS	num||%-26/NN||1-25/CD	dep||·-24/NNS||%-26/NN	prep_of||699-21/NNP||1041-29/CD	prep_for||699-21/NNP||microscopy-31/NN	tuberculosis-17||mtb--1||no||one-off mtb/rif testing detected 933 (90â·3%) of 1033 culture-confirmed cases of tuberculosis, compared with 699 (67â·1%) of 1041 for microscopy.
mark||has-4/VBZ||although-1/IN	det||method-3/NN||the-2/DT	nsubj||has-4/VBZ||method-3/NN	advcl||shown-10/VBN||has-4/VBZ	poss||limitations-6/NNS||its-5/PRP$	dobj||has-4/VBZ||limitations-6/NNS	nsubjpass||shown-10/VBN||it-8/PRP	nsubj||feasible-13/JJ||it-8/PRP	nsubjpass||provided-15/VBN||it-8/PRP	auxpass||shown-10/VBN||was-9/VBD	root||ROOT-0/null||shown-10/VBN	aux||feasible-13/JJ||to-11/TO	cop||feasible-13/JJ||be-12/VB	xcomp||shown-10/VBN||feasible-13/JJ	conj_and||shown-10/VBN||provided-15/VBN	dobj||provided-15/VBN||estimates-16/NNS	det||impact-19/NN||the-18/DT	prep_of||estimates-16/NNS||impact-19/NN	nn||use-22/NN||alcohol-21/NN	prep_of||impact-19/NN||use-22/NN	det||outcome-26/NN||the-24/DT	nn||outcome-26/NN||mortality-25/NN	prep_on||provided-15/VBN||outcome-26/NN	prep_of||outcome-26/NN||hiv/aids-28/NNS	aids--1||hiv--1||no||although the method has its limitations, it was shown to be feasible and provided estimates of the impact of alcohol use on the mortality outcome of hiv/aids.
nsubj||added-2/VBD||aliskiren-1/NN	nsubj||losartan-4/VB||aliskiren-1/NN	nsubj||tolerated-13/JJ||aliskiren-1/NN	root||ROOT-0/null||added-2/VBD	aux||losartan-4/VB||to-3/TO	xcomp||added-2/VBD||losartan-4/VB	amod||albuminuria-6/NN||reduced-5/VBN	dobj||losartan-4/VB||albuminuria-6/NN	amod||dysfunction-9/NN||renal-8/JJ	dobj||losartan-4/VB||dysfunction-9/NN	conj_and||albuminuria-6/NN||dysfunction-9/NN	cop||tolerated-13/JJ||was-11/VBD	advmod||tolerated-13/JJ||well-12/RB	conj_and||added-2/VBD||tolerated-13/JJ	prep_except_for||independent-23/JJ||hyperkalemia-17/NN	appos||hyperkalemia-17/NN||stage-19/NN	num||stage-19/NN||3-20/CD	dep||tolerated-13/JJ||independent-23/JJ	amod||stage-27/NN||baseline-25/JJ	nn||stage-27/NN||ckd-26/NN	prep_of||independent-23/JJ||stage-27/NN	prep_in||stage-27/NN||patients-29/NNS	prep_with||patients-29/NNS||type2diabetes-31/NNS	appos||type2diabetes-31/NNS||hypertension-33/NN	conj_and||added-2/VBD||nephropathy-36/JJ	conj_and||tolerated-13/JJ||nephropathy-36/JJ	nephropathy-36||losartan-4||no_rel||aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline ckd stage in patients with type2diabetes, hypertension, and nephropathy.
poss||aim-2/NN||our-1/PRP$	nsubj||was-3/VBD||aim-2/NN	nsubj||evaluate-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||evaluate-5/VB||to-4/TO	xcomp||was-3/VBD||evaluate-5/VB	det||prevalence-7/NN||the-6/DT	dobj||evaluate-5/VB||prevalence-7/NN	amod||infection-11/NN||occult-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_of||prevalence-7/NN||infection-11/NN	det||donations-17/NNS||the-13/DT	amod||donations-17/NNS||hbsag-14/JJ	amod||donations-17/NNS||negative/antihbc-15/JJ	amod||donations-17/NNS||positive-16/JJ	prep_among||infection-11/NN||donations-17/NNS	det||region-23/NN||a-19/DT	advmod||prevalent-22/JJ||highly-20/RB	advmod||prevalent-22/JJ||hiv-21/RB	amod||region-23/NN||prevalent-22/JJ	prep_from||evaluate-5/VB||region-23/NN	prep_of||region-23/NN||india-25/NN	hbv-10||hbsag-14||yes||our aim was to evaluate the prevalence of occult hbv infection among the hbsag negative/antihbc positive donations from a highly hiv prevalent region of india.
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||iron-36||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â€“8 wks.
det||bortezomib-4/NN||the-1/DT	amod||bortezomib-4/NN||proteasome-2/JJ	nn||bortezomib-4/NN||inhibitor-3/NN	nsubj||improved-6/VBN||bortezomib-4/NN	aux||improved-6/VBN||has-5/VBZ	root||ROOT-0/null||improved-6/VBN	det||survival-8/NN||the-7/DT	dobj||improved-6/VBN||survival-8/NN	prep_of||survival-8/NN||patients-10/NNS	prep_with||improved-6/VBN||multiplemyeloma-12/NN	amod||peripheralneuropathy-15/NN||bortezomib-induced-14/JJ	nsubj||emerged-20/VBN||peripheralneuropathy-15/NN	appos||peripheralneuropathy-15/NN||bipn-17/NN	aux||emerged-20/VBN||has-19/VBZ	conj_but||improved-6/VBN||emerged-20/VBN	det||complication-25/NN||a-22/DT	amod||complication-25/NN||serious-23/JJ	amod||complication-25/NN||potential-24/JJ	prep_as||emerged-20/VBN||complication-25/NN	det||therapy-28/NN||this-27/DT	prep_of||complication-25/NN||therapy-28/NN	multiplemyeloma-12||bortezomib-4||yes||the proteasome inhibitor bortezomib has improved the survival of patients with multiplemyeloma but bortezomib-induced peripheralneuropathy (bipn) has emerged as a serious potential complication of this therapy.
mark||disease-8/NN||though-1/IN	nn||syndrome-3/NN||austrian-2/NN	nsubj||disease-8/NN||syndrome-3/NN	cop||disease-8/NN||is-4/VBZ	det||disease-8/NN||a-5/DT	advmod||rare-7/JJ||clinically-6/RB	amod||disease-8/NN||rare-7/JJ	advcl||aggressive-17/JJ||disease-8/NN	det||evolution-11/NN||the-10/DT	nsubjpass||aggressive-17/JJ||evolution-11/NN	nsubjpass||associated-19/VBN||evolution-11/NN	amod||endocarditis-14/NNS||pneumococcal-13/JJ	prep_of||evolution-11/NN||endocarditis-14/NNS	auxpass||aggressive-17/JJ||is-15/VBZ	cop||aggressive-17/JJ||is-15/VBZ	advmod||aggressive-17/JJ||very-16/RB	root||ROOT-0/null||aggressive-17/JJ	conj_and||aggressive-17/JJ||associated-19/VBN	amod||mortality-22/NN||high-21/JJ	prep_with||associated-19/VBN||mortality-22/NN	amod||recognition-26/NN||early-25/JJ	nsubj||important-37/JJ||recognition-26/NN	nsubj||reduce-39/VB||recognition-26/NN	prep_for||recognition-26/NN||evidence-28/NN	amod||lesion-31/NN||endocardial-30/JJ	prep_of||evidence-28/NN||lesion-31/NN	prep_in||lesion-31/NN||patients-33/NNS	prep_with||patients-33/NNS||pneumococcalmeningitis-35/NNS	cop||important-37/JJ||is-36/VBZ	conj_and||aggressive-17/JJ||important-37/JJ	aux||reduce-39/VB||to-38/TO	xcomp||important-37/JJ||reduce-39/VB	det||complications-41/NNS||the-40/DT	dobj||reduce-39/VB||complications-41/NNS	nn||rate-44/NN||mortality-43/NN	dobj||reduce-39/VB||rate-44/NN	conj_and||complications-41/NNS||rate-44/NN	pneumococcalmeningitis-35||pneumococcal-13||no||though austrian syndrome is a clinically rare disease, the evolution of pneumococcal endocarditis is very aggressive and associated with high mortality, and early recognition for evidence of endocardial lesion in patients with pneumococcalmeningitis is important to reduce the complications and mortality rate.
det||data-2/NNS||these-1/DT	nsubj||able-9/JJ||data-2/NNS	nsubj||explain-11/VB||data-2/NNS	aux||able-9/JJ||may-3/MD	prep_in||able-9/JJ||part-6/NN	cop||able-9/JJ||be-8/VB	root||ROOT-0/null||able-9/JJ	aux||explain-11/VB||to-10/TO	xcomp||able-9/JJ||explain-11/VB	det||use-14/NN||the-12/DT	amod||use-14/NN||traditional-13/JJ	dobj||explain-11/VB||use-14/NN	amod||plants-18/NNS||tannin-containing-16/JJ	amod||plants-18/NNS||medicinal-17/JJ	prep_of||use-14/NN||plants-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||explain-11/VB||treatment-21/NN	det||variety-24/NN||a-23/DT	prep_of||treatment-21/NN||variety-24/NN	prep_of||variety-24/NN||inflammatorydiseases-26/NNS	prep_including||explain-11/VB||inflammatoryboweldisease-29/NN	prep_including||explain-11/VB||celiacdisease-31/NN	conj_and||inflammatoryboweldisease-29/NN||celiacdisease-31/NN	prep_including||explain-11/VB||rheumatoidarthritis-34/NNS	conj_and||inflammatoryboweldisease-29/NN||rheumatoidarthritis-34/NNS	tannin--1||inflammatoryboweldisease-29||no_rel||these data may, in part, be able to explain the traditional use of tannin-containing medicinal plants for the treatment of a variety of inflammatorydiseases, including inflammatoryboweldisease, celiacdisease, and rheumatoidarthritis.
amod||iron-2/NN||internalized-1/JJ	nsubjpass||transported-4/VBN||iron-2/NN	nsubjpass||ironâ-13/VBN||iron-2/NN	auxpass||transported-4/VBN||is-3/VBZ	root||ROOT-0/null||transported-4/VBN	prep_to||transported-4/VBN||mitochondria-6/NN	det||synthesis-9/NN||the-8/DT	prep_for||transported-4/VBN||synthesis-9/NN	prep_of||synthesis-9/NN||haem-11/NN	conj_or||transported-4/VBN||ironâ-13/VBN	num||clusters-17/NNS||$-14/$	num||$-14/$||sulfur-16/CD	dobj||ironâ-13/VBN||clusters-17/NNS	nsubj||parts-22/NNS||clusters-17/NNS	cop||parts-22/NNS||are-20/VBP	amod||parts-22/NNS||integral-21/JJ	rcmod||clusters-17/NNS||parts-22/NNS	amod||metalloproteins-25/NNS||several-24/JJ	prep_of||parts-22/NNS||metalloproteins-25/NNS	nsubjpass||stored-30/VBN||excessiron-28/NN	nsubjpass||detoxified-32/VBN||excessiron-28/NN	auxpass||stored-30/VBN||is-29/VBZ	conj_and||transported-4/VBN||stored-30/VBN	conj_and||transported-4/VBN||detoxified-32/VBN	conj_and||stored-30/VBN||detoxified-32/VBN	amod||ferritin-35/NN||cytosolic-34/JJ	prep_in||stored-30/VBN||ferritin-35/NN	excessiron-28||iron-2||no||internalized iron is transported to mitochondria for the synthesis of haem or ironâ€“sulfur clusters, which are integral parts of several metalloproteins, and excessiron is stored and detoxified in cytosolic ferritin.
nn||patients-2/NNS||patients-1/NNS	nsubj||carvedilol-naive-4/JJ||patients-2/NNS	nsubj||had-6/VBD||patients-2/NNS	cop||carvedilol-naive-4/JJ||were-3/VBD	root||ROOT-0/null||carvedilol-naive-4/JJ	conj_and||carvedilol-naive-4/JJ||had-6/VBD	amod||hypertension-8/NN||essential-7/JJ	dobj||had-6/VBD||hypertension-8/NN	amod||hypertension-12/NN||renal-10/JJ	amod||hypertension-12/NN||parenchymal-11/JJ	dobj||had-6/VBD||hypertension-12/NN	conj_or||hypertension-8/NN||hypertension-12/NN	hypertension-12||carvedilol--1||yes||patients patients were carvedilol-naive and had essential hypertension or renal parenchymal hypertension.
amod||viruses-5/NNS||arthropod-borne-1/JJ	amod||viruses-5/NNS||arbo-3/JJ	nsubjpass||transmitted-10/VBN||viruses-5/NNS	prep_such_as||viruses-5/NNS||wnv-8/NN	auxpass||transmitted-10/VBN||are-9/VBP	root||ROOT-0/null||transmitted-10/VBN	prep_to||transmitted-10/VBN||vertebrates-12/NNS	det||probes-17/NNS||an-14/DT	amod||probes-17/NNS||infectious-15/JJ	nn||probes-17/NNS||mosquito-16/NN	prep_as||vertebrates-12/NNS||probes-17/NNS	det||skin-19/NN||the-18/DT	nsubjpass||transmitted-10/VBN||skin-19/NN	prep_for||skin-19/NN||blood-21/NN	vmod||transmitted-10/VBN||depositing-23/VBG	det||virus-25/NN||the-24/DT	dobj||depositing-23/VBG||virus-25/NN	dobj||depositing-23/VBG||saliva-27/NN	conj_and||virus-25/NN||saliva-27/NN	det||skin-30/NN||the-29/DT	prep_into||depositing-23/VBG||skin-30/NN	prep_into||depositing-23/VBG||circulation-32/NN	conj_and||skin-30/NN||circulation-32/NN	virus-25||viruses-5||no||arthropod-borne (arbo)viruses such as wnv are transmitted to vertebrates as an infectious mosquito probes the skin for blood, depositing the virus and saliva into the skin and circulation.
nsubj||factors-28/NNS||female-1/NN	dep||female-1/NN||p-3/VBN	dep||0.037-5/CD||=-4/SYM	ccomp||p-3/VBN||0.037-5/CD	amod||allergies-9/NNS||preexisting-8/VBG	conj_and||female-1/NN||allergies-9/NNS	nsubj||factors-28/NNS||allergies-9/NNS	dep||allergies-9/NNS||p-11/VBN	dep||0.004-13/CD||=-12/SYM	ccomp||p-11/VBN||0.004-13/CD	amod||level-17/NN||lower-16/JJR	conj_and||female-1/NN||level-17/NN	nsubj||factors-28/NNS||level-17/NN	amod||dehydrogenase-20/NN||lactate-19/JJ	prep_of||level-17/NN||dehydrogenase-20/NN	dep||female-1/NN||p-22/VBN	dep||0.003-24/CD||=-23/SYM	ccomp||p-22/VBN||0.003-24/CD	cop||factors-28/NNS||were-26/VBD	nn||factors-28/NNS||risk-27/NN	root||ROOT-0/null||factors-28/NNS	number||1/2-31/CD||grade-30/CD	num||hypersensitivityreactions-32/NNS||1/2-31/CD	prep_for||factors-28/NNS||hypersensitivityreactions-32/NNS	amod||count-37/NN||higher-35/JJR	amod||count-37/NN||neutrophil-36/JJ	nsubj||were-52/VBD||count-37/NN	dep||count-37/NN||p-39/VBN	dep||0.043-41/CD||=-40/SYM	ccomp||p-39/VBN||0.043-41/CD	amod||count-46/NN||lower-44/JJR	nn||count-46/NN||monocyte-45/NN	conj_and||count-37/NN||count-46/NN	nsubj||were-52/VBD||count-46/NN	dep||count-46/NN||p-48/VBN	dep||0.007-50/CD||=-49/SYM	ccomp||p-48/VBN||0.007-50/CD	conj_and||factors-28/NNS||were-52/VBD	number||3/4-55/CD||grade-54/CD	num||reactions-56/NNS||3/4-55/CD	prep_for||were-52/VBD||reactions-56/NNS	allergies-9||hypersensitivityreactions-32||no||female (p=0.037), preexisting allergies (p=0.004) and lower level of lactate dehydrogenase (p=0.003) were risk factors for grade 1/2 hypersensitivityreactions, and higher neutrophil count (p=0.043) and lower monocyte count (p=0.007) were for grade 3/4 reactions.
advmod||review-3/VBP||here-1/RB	nsubj||review-3/VBP||we-2/PRP	root||ROOT-0/null||review-3/VBP	det||data-6/NN||the-4/DT	amod||data-6/NN||available-5/JJ	dobj||review-3/VBP||data-6/NN	prep_on||review-3/VBP||levetiracetam-8/NN	det||population-13/NN||the-10/DT	amod||population-13/NN||pediatric-11/JJ	nn||population-13/NN||epilepsy-12/NN	prep_in||levetiracetam-8/NN||population-13/NN	epilepsy-12||levetiracetam-8||yes||here we review the available data on levetiracetam in the pediatric epilepsy population.
nsubj||reduced-9/VBD||conclusions-1/NNS	det||regimen-7/NN||an-2/DT	amod||regimen-7/NN||olmesartanmedoxomilâ-3/JJ	amod||regimen-7/NN||±-4/JJ	nn||regimen-7/NN||hctz-5/NN	nn||regimen-7/NN||treatment-6/NN	dep||conclusions-1/NNS||regimen-7/NN	advmod||reduced-9/VBD||significantly-8/RB	root||ROOT-0/null||reduced-9/VBD	dobj||reduced-9/VBD||bp-10/NN	prep_from||reduced-9/VBD||baseline-12/NN	prep_in||reduced-9/VBD||patients-14/NNS	prep_with||patients-14/NNS||hypertension-16/NN	prep_with||patients-14/NNS||type2diabetes-18/NNS	conj_and||hypertension-16/NN||type2diabetes-18/NNS	hypertension-16||olmesartanmedoxomil--1||yes||conclusions an olmesartanmedoxomilâ±hctz treatment regimen significantly reduced bp from baseline in patients with hypertension and type2diabetes.
det||challenge-2/NN||a-1/DT	nsubj||is-9/VBZ||challenge-2/NN	nsubj||develop-11/VB||challenge-2/NN	nn||research-8/NN||tuberculosis-4/NNP	appos||research-8/NN||tb-6/NN	prep_in||challenge-2/NN||research-8/NN	root||ROOT-0/null||is-9/VBZ	aux||develop-11/VB||to-10/TO	xcomp||is-9/VBZ||develop-11/VB	det||test-15/NN||a-12/DT	amod||test-15/NN||new-13/JJ	amod||test-15/NN||immunological-14/JJ	dobj||develop-11/VB||test-15/NN	nsubj||help-18/VB||test-15/NN	aux||help-18/VB||can-17/MD	rcmod||test-15/NN||help-18/VB	ccomp||help-18/VB||distinguish-19/VB	prep_among||distinguish-19/VB||subjects-22/NNS	amod||subjects-22/NNS||responsive-23/JJ	nn||gold-27/NN||quantiferon-25/NN	nn||gold-27/NN||tb-26/NN	prep_to||responsive-23/JJ||gold-27/NN	prep_in||gold-27/NN||tube-29/NN	appos||subjects-22/NNS||qft-it-31/NN	dobj||distinguish-19/VB||those-34/DT	nsubj||able-37/JJ||those-34/DT	nsubj||control-39/VB||those-34/DT	cop||able-37/JJ||are-36/VBP	rcmod||those-34/DT||able-37/JJ	aux||control-39/VB||to-38/TO	xcomp||able-37/JJ||control-39/VB	nn||replication-41/NN||mtb-40/NN	dobj||control-39/VB||replication-41/NN	amod||ltbi-44/NNS||remote-43/JJ	dep||replication-41/NN||ltbi-44/NNS	amod||infection-47/NN||recent-46/JJ	dep||replication-41/NN||infection-47/NN	conj_and||ltbi-44/NNS||infection-47/NN	amod||tb-50/NN||past-49/JJ	dep||replication-41/NN||tb-50/NN	conj_and||ltbi-44/NNS||tb-50/NN	prep_from||control-39/VB||those-53/DT	nsubj||can-55/MD||those-53/DT	rcmod||those-53/DT||can-55/MD	neg||can-55/MD||not-56/RB	amod||disease-60/NN||active-58/JJ	nn||disease-60/NN||tb-59/NN	appos||those-53/DT||disease-60/NN	tb-59||mtb-40||no||a challenge in tuberculosis (tb) research is to develop a new immunological test that can help distinguish, among subjects responsive to quantiferon tb gold in tube (qft-it), those who are able to control mtb replication (remote ltbi, recent infection and past tb) from those who cannot (active tb disease).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||rif-19||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||used-17/VBN||that-3/IN	vmod||used-17/VBN||owing-4/VBG	prep_to||owing-4/VBG||complexity-6/NN	nn||metabolism-9/NN||iron-8/NN	prep_of||complexity-6/NN||metabolism-9/NN	prep_in||metabolism-9/NN||ckd-11/NN	nsubjpass||used-17/VBN||stfr-13/NN	aux||used-17/VBN||can-14/MD	neg||used-17/VBN||not-15/RB	auxpass||used-17/VBN||be-16/VB	ccomp||conclude-2/VBP||used-17/VBN	det||marker-21/NN||a-19/DT	amod||marker-21/NN||reliable-20/JJ	prep_as||used-17/VBN||marker-21/NN	prep_of||marker-21/NN||irondeficiencyanemia-23/NN	irondeficiencyanemia-23||iron-8||yes||we conclude that owing to complexity of iron metabolism in ckd, stfr can not be used as a reliable marker of irondeficiencyanemia.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	collagen-15||virusinfection-29||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
amod||function-2/NN||visual-1/JJ	nsubjpass||analyzed-12/VBN||function-2/NN	amod||function-5/NN||anteriorpituitary-4/JJ	conj_and||function-2/NN||function-5/NN	nsubjpass||analyzed-12/VBN||function-5/NN	nn||rates-10/NNS||tumor-8/NN	nn||rates-10/NNS||control-9/NN	conj_and||function-2/NN||rates-10/NNS	nsubjpass||analyzed-12/VBN||rates-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	det||series-15/NN||the-14/DT	prep_for||analyzed-12/VBN||series-15/NN	anteriorpituitary-4||tumor-8||no_rel||visual function, anteriorpituitary function, and tumor control rates were analyzed for the series.
advmod||frequent-10/JJ||however-1/RB	det||âˆ-4/NN||the-3/DT	poss||variant-7/NN||âˆ-4/NN	amod||variant-7/NN||336a-6/JJ	nsubj||frequent-10/JJ||variant-7/NN	cop||frequent-10/JJ||was-8/VBD	advmod||frequent-10/JJ||more-9/RBR	root||ROOT-0/null||frequent-10/JJ	amod||patients-13/NNS||htlv-1-infected-12/JJ	prep_in||frequent-10/JJ||patients-13/NNS	amod||tropicalspasticparaparesis-17/NNS||-LSB--14/JJ	amod||tropicalspasticparaparesis-17/NNS||htlv-1-associatedmyelopathy-15/JJ	amod||tropicalspasticparaparesis-17/NNS||/-16/JJ	dep||patients-13/NNS||tropicalspasticparaparesis-17/NNS	appos||tropicalspasticparaparesis-17/NNS||ham/tsp-19/NN	quantmod||$-23/$||80â-22/RB	num||%-25/NN||$-23/$	num||$-23/$||š-24/CD	appos||tropicalspasticparaparesis-17/NNS||%-25/NN	amod||asymptomatic-28/JJ||healthy-27/JJ	amod||carriers-30/NNS||asymptomatic-28/JJ	amod||carriers-30/NNS||htlv-1-29/JJ	appos||tropicalspasticparaparesis-17/NNS||carriers-30/NNS	amod||-RSB--36/NNS||90â-32/JJ	dep||%-35/NN||$-33/$	num||$-33/$||š-34/CD	amod||-RSB--36/NNS||%-35/NN	appos||tropicalspasticparaparesis-17/NNS||-RSB--36/NNS	mark||70â-43/NNS||than-37/IN	det||group-41/NN||the-39/DT	nn||group-41/NN||control-40/NN	prep_in||70â-43/NNS||group-41/NN	dep||-RSB--36/NNS||70â-43/NNS	dep||%-46/NN||$-44/$	num||$-44/$||š-45/CD	amod||70â-43/NNS||%-46/NN	dep||70â-43/NNS||-LSB--48/FW	dep||70â-43/NNS||p-49/NN	dep||0.0197-51/CD||=-50/SYM	rcmod||p-49/NN||0.0197-51/CD	nn||ratio-54/NN||odds-53/NNS	appos||tropicalspasticparaparesis-17/NNS||ratio-54/NN	cc||=-58/NNP||or-56/CC	dep||ratio-54/NN||=-58/NNP	num||=-58/NNP||2.511-59/CD	num||=-58/NNP||95â-61/CD	dep||%-64/NN||$-62/$	num||$-62/$||š-63/CD	amod||interval-66/NN||%-64/NN	nn||interval-66/NN||confidence-65/NN	nsubj||=-70/VBZ||interval-66/NN	discourse||interval-66/NN||ci-68/UH	rcmod||=-58/NNP||=-70/VBZ	num||â-72/NNS||1.218-71/CD	dobj||=-70/VBZ||â-72/NNS	num||â-72/NNS||$-73/$	num||$-73/$||5.179-75/CD	ham--1||htlv-1-29||no||however, the âˆ’336a variant was more frequent in htlv-1-infected patients [htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp), 80â€š%; healthy asymptomatic htlv-1 carriers, 90â€š%] than in the control group (70â€š%) [ p =0.0197, odds ratio (or)=2.511, 95â€š% confidence interval (ci)=1.218â€“5.179).
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	insulin--1||obesity-4||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
nn||propofol-2/NN||microemulsion-1/NN	nsubjpass||developed-4/VBN||propofol-2/NN	nsubj||avoid-6/VB||propofol-2/NN	auxpass||developed-4/VBN||was-3/VBD	root||ROOT-0/null||developed-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||developed-4/VBN||avoid-6/VB	det||effects-9/NNS||these-7/DT	nn||effects-9/NNS||side-8/NN	dobj||avoid-6/VB||effects-9/NNS	nsubj||is-18/VBZ||incidence-11/NN	conj_and||incidence-11/NN||severity-13/NN	nsubj||is-18/VBZ||severity-13/NN	prep_of||incidence-11/NN||pain-15/NN	prep_on||pain-15/NN||injection-17/NN	conj_but||developed-4/VBN||is-18/VBZ	dep||than-20/IN||higher-19/JJR	advmod||is-18/VBZ||than-20/IN	nn||propofol-24/NN||lipid-22/NN	nn||propofol-24/NN||emulsion-23/NN	prep_with||is-18/VBZ||propofol-24/NN	pain-15||propofol-24||yes||microemulsion propofol was developed to avoid these side effects but incidence and severity of pain on injection is higher than with lipid emulsion propofol.
nsubj||have-12/VBP||fluticasone/salmeterol-1/NN	conj_and||fluticasone/salmeterol-1/NN||budesonide/formoterol-3/NN	nsubj||have-12/VBP||budesonide/formoterol-3/NN	det||products-10/NNS||the-5/DT	advmod||available-7/JJ||currently-6/RB	amod||products-10/NNS||available-7/JJ	nn||products-10/NNS||ics/laba-8/NN	nn||products-10/NNS||combination-9/NN	appos||fluticasone/salmeterol-1/NN||products-10/NNS	root||ROOT-0/null||have-12/VBP	amod||efficacy-14/NN||similar-13/JJ	dobj||have-12/VBP||efficacy-14/NN	dobj||have-12/VBP||tolerability-16/NN	conj_and||efficacy-14/NN||tolerability-16/NN	prepc_based_on||have-12/VBP||on-18/IN	det||meta-analysis-21/NNS||a-19/DT	amod||meta-analysis-21/NNS||recent-20/JJ	pobj||have-12/VBP||meta-analysis-21/NNS	nn||trials-24/NNS||asthma-23/NN	prep_of||meta-analysis-21/NNS||trials-24/NNS	asthma-23||salmeterol--1||yes||fluticasone/salmeterol and budesonide/formoterol, the currently available ics/laba combination products, have similar efficacy and tolerability based on a recent meta-analysis of asthma trials.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	poss||lymphoma-19/NN||non-hodgkin-17/NN	prep_in||antibody-15/NN||lymphoma-19/NN	amod||lupuserythematosus-22/NNS||systemic-21/JJ	prep_in||antibody-15/NN||lupuserythematosus-22/NNS	conj_and||lymphoma-19/NN||lupuserythematosus-22/NNS	appos||lupuserythematosus-22/NNS||sle-24/NN	poss||mechanism-29/NN||its-28/PRP$	nsubj||remains-34/VBZ||mechanism-29/NN	prep_of||mechanism-29/NN||action-31/NN	prep_on||action-31/NN||b-cells-33/NNS	conj_but||is-9/VBZ||remains-34/VBZ	acomp||remains-34/VBZ||elusive-35/JJ	antibody-15||sle-24||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin's lymphoma and systemic lupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
num||snps-2/NNS||three-1/CD	nsubj||showed-10/VBD||snps-2/NNS	nsubjpass||selected-27/VBN||snps-2/NNS	det||gene-6/NN||the-4/DT	amod||gene-6/NN||il2ra/cd25-5/JJ	prep_within||snps-2/NNS||gene-6/NN	advmod||showed-10/VBD||previously-9/RB	rcmod||snps-2/NNS||showed-10/VBD	dobj||showed-10/VBD||evidence-11/NN	det||association-14/NN||an-13/DT	prep_of||evidence-11/NN||association-14/NN	det||ra-17/NN||either-16/DT	prep_with||showed-10/VBD||ra-17/NN	prep_with||showed-10/VBD||ms-19/NN	conj_or||ra-17/NN||ms-19/NN	nn||dm-24/NN||type-22/NN	num||dm-24/NN||1-23/CD	prep_with||showed-10/VBD||dm-24/NN	conj_or||ra-17/NN||dm-24/NN	auxpass||selected-27/VBN||were-26/VBD	root||ROOT-0/null||selected-27/VBN	prep_for||selected-27/VBN||genotyping-29/VBG	nn||cases-33/NNS||uk-31/NN	nn||cases-33/NNS||jia-32/NN	prep_in||genotyping-29/VBG||cases-33/NNS	dep||genotyping-29/VBG||n-35/VBN	dep||654-37/CD||=-36/SYM	ccomp||n-35/VBN||654-37/CD	prep_for||selected-27/VBN||controls-40/NNS	conj_and||genotyping-29/VBG||controls-40/NNS	dep||controls-40/NNS||n-42/VBN	dep||3,849-44/CD||=-43/SYM	ccomp||n-42/VBN||3,849-44/CD	jia-32||dm-24||no_rel||three snps within the il2ra/cd25 gene, that previously showed evidence of an association with either ra, ms, or type 1 dm, were selected for genotyping in uk jia cases (n = 654) and controls (n = 3,849).
det||progress-4/NN||the-2/DT	amod||progress-4/NN||recent-3/JJ	prep_despite||remains-15/VBZ||progress-4/NN	amod||therapies-10/NNS||interferon-6/JJ	appos||therapies-10/NNS||ifn-8/NN	prep_in||progress-4/NN||therapies-10/NNS	prep_for||progress-4/NN||chronichepatitisc-12/NN	nsubj||remains-15/VBZ||livercirrhosis-14/NNS	root||ROOT-0/null||remains-15/VBZ	xcomp||remains-15/VBZ||refractory-16/JJ	chronichepatitisc-12||ifn-8||yes||despite the recent progress in interferon (ifn) therapies for chronichepatitisc, livercirrhosis remains refractory.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||outcomes-5/NNS||the-4/DT	prep_on||report-2/VBP||outcomes-5/NNS	num||patients-11/NNS||21-7/CD	amod||patients-11/NNS||consecutive-8/JJ	amod||patients-11/NNS||gastric-9/JJ	nn||patients-11/NNS||cancer-10/NN	prep_of||outcomes-5/NNS||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_off||treated-12/VBN||protocol-14/NN	amod||carboplatin-17/NNS||adjuvant-16/JJ	prep_with||treated-12/VBN||carboplatin-17/NNS	dep||carboplatin-17/NNS||area-19/NN	det||ã-25/NN||the-21/DT	nn||ã-25/NN||curve-22/NN	num||ã-25/NN||5-23/CD	nn||ã-25/NN||mg/ml-24/NN	prep_under||area-19/NN||ã-25/NN	dep||ã-25/NN||min-27/NN	prep_with||treated-12/VBN||paclitaxel-30/NN	conj_and||carboplatin-17/NNS||paclitaxel-30/NN	quantmod||$-33/$||175â-32/RB	num||mg/m2-36/NNS||$-33/$	num||$-33/$||200-35/CD	dep||paclitaxel-30/NN||mg/m2-36/NNS	det||weeks-40/NNS||every-38/DT	num||weeks-40/NNS||3-39/CD	tmod||treated-12/VBN||weeks-40/NNS	prepc_followed_by||treated-12/VBN||by-43/IN	amod||analogs-46/NNS||concurrent-44/JJ	nn||analogs-46/NNS||pyrimidine-45/NN	pobj||treated-12/VBN||analogs-46/NNS	dep||â-51/FW||either-48/DT	nn||â-51/FW||capecitabine-49/FW	nn||â-51/FW||1,600-50/FW	dep||analogs-46/NNS||â-51/FW	num||mg/m2/day-55/NNS||$-52/$	num||$-52/$||2,000-54/CD	dep||â-51/FW||mg/m2/day-55/NNS	num||patients-58/NNS||17-57/CD	prep_in||mg/m2/day-55/NNS||patients-58/NNS	number||200-62/CD||5fu-61/CD	num||mg/m2/day-63/NNS||200-62/CD	dep||â-51/FW||mg/m2/day-63/NNS	conj_or||mg/m2/day-55/NNS||mg/m2/day-63/NNS	num||patients-66/NNS||4-65/CD	prep_in||mg/m2/day-63/NNS||patients-66/NNS	pobj||treated-12/VBN||radiation-69/NN	conj_and||analogs-46/NNS||radiation-69/NN	dep||analogs-46/NNS||45â-71/NNS	dep||45â-71/NNS||$-72/$	num||$-72/$||50.4-74/CD	dep||$-72/$||gy-75/NN	cancer-10||carboplatin-17||no_rel||we report on the outcomes of 21 consecutive gastric cancer patients treated off protocol with adjuvant carboplatin (area under the curve 5 mg/ml ã— min) and paclitaxel (175â€“200 mg/m2) every 3 weeks, followed by concurrent pyrimidine analogs (either capecitabine 1,600â€“2,000 mg/m2/day in 17 patients, or 5fu 200 mg/m2/day in 4 patients) and radiation (45â€“50.4 gy).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	nn||variation-9/NN||virus-7/NN	amod||variation-9/NN||strain-related-8/JJ	dobj||investigated-6/VBD||variation-9/NN	prep_in||variation-9/NN||persistence-11/NN	prep_in||persistence-11/NN||water-13/NN	num||duck-17/NN||nine-15/CD	amod||duck-17/NN||wild-16/JJ	prep_for||investigated-6/VBD||duck-17/NN	vmod||duck-17/NN||isolated-18/VBN	nn||viruses-20/NNS||ia-19/NN	dobj||isolated-18/VBN||viruses-20/NNS	num||subtypes-23/NNS||three-22/CD	prep_of||viruses-20/NNS||subtypes-23/NNS	dep||subtypes-23/NNS||h3n8-25/NNS	dep||subtypes-23/NNS||h4n6-27/NNS	conj_and||h3n8-25/NNS||h4n6-27/NNS	dep||subtypes-23/NNS||h8n4-30/NNS	conj_and||h3n8-25/NNS||h8n4-30/NNS	virus-7||viruses-20||no||in this study, we investigated virus strain-related variation in persistence in water for nine wild duck isolated ia viruses of three subtypes (h3n8, h4n6, and h8n4).
aux||study-2/VB||to-1/TO	advcl||mg-46/VBP||study-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||potential-4/JJ	dobj||study-2/VB||efficacy-5/NN	dobj||study-2/VB||tolerability-7/NN	conj_and||efficacy-5/NN||tolerability-7/NN	det||formula-12/NN||a-9/DT	amod||formula-12/NN||natural-10/JJ	amod||formula-12/NN||multiherbal-11/JJ	prep_of||efficacy-5/NN||formula-12/NN	appos||formula-12/NN||immumax-14/NN	xcomp||study-2/VB||containing-16/VBG	amod||mg-19/NN||echinaceaextract-17/JJ	dep||echinaceaextract-17/JJ||120-18/CD	dobj||containing-16/VBG||mg-19/NN	amod||powder-22/NN||garlic-21/JJ	nsubj||mg-46/VBP||powder-22/NN	num||mg-24/NN||100-23/CD	dep||powder-22/NN||mg-24/NN	nn||oil-28/NN||nigella-26/NN	nn||oil-28/NN||sativa-27/NN	conj_and||powder-22/NN||oil-28/NN	nsubj||mg-46/VBP||oil-28/NN	num||mg-30/NN||200-29/CD	dep||oil-28/NN||mg-30/NN	nn||ginseng-34/NN||panax-33/NN	conj_and||powder-22/NN||ginseng-34/NN	nsubj||mg-46/VBP||ginseng-34/NN	number||50-36/CD||extract-35/CD	num||mg-37/NNP||50-36/CD	dep||ginseng-34/NN||mg-37/NNP	nn||mg-41/NN||vitaminc-39/NNP	num||mg-41/NN||50-40/CD	dep||ginseng-34/NN||mg-41/NN	conj_plus||mg-37/NNP||mg-41/NN	amod||7.5-45/NN||elemental-43/JJ	nn||7.5-45/NN||zinc-44/NN	dep||ginseng-34/NN||7.5-45/NN	conj_and||mg-37/NNP||7.5-45/NN	root||ROOT-0/null||mg-46/VBP	det||treatment-49/NN||the-48/DT	prep_in||mg-46/VBP||treatment-49/NN	prep_of||treatment-49/NN||patients-51/NNS	vmod||patients-51/NNS||suffering-52/VBG	det||commoncold-55/NN||the-54/DT	prep_from||suffering-52/VBG||commoncold-55/NN	commoncold-55||echinaceaextract-17||yes||to study the potential efficacy and tolerability of a natural multiherbal formula (immumax) containing echinaceaextract 120 mg, garlic powder 100 mg, nigella sativa oil 200 mg, and panax ginseng extract 50 mg plus vitaminc 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the commoncold.
prep_in||associated-34/VBN||patients-2/NNS	amod||inflammation-5/NN||acute-4/JJ	prep_without||patients-2/NNS||inflammation-5/NN	nn||irondeficiency-8/NN||overt-7/NN	prep_without||patients-2/NNS||irondeficiency-8/NN	conj_and||inflammation-5/NN||irondeficiency-8/NN	dep||<-13/NNS||c-10/SYM	amod||<-13/NNS||reactive-11/JJ	nn||<-13/NNS||protein-12/NN	dep||inflammation-5/NN||<-13/NNS	amod||mg/dl-15/NN||1â-14/JJ	dep||<-13/NNS||mg/dl-15/NN	nn||>-18/NNS||ferritin-17/NN	dep||<-13/NNS||>-18/NNS	conj_and||mg/dl-15/NN||>-18/NNS	amod||ng/ml-20/NN||30â-19/JJ	dep||mg/dl-15/NN||ng/ml-20/NN	dep||mg/dl-15/NN||nâ-22/NN	num||â-26/NN||$-23/$	number||=-25/CD||‰-24/CD	num||$-23/$||=-25/CD	dep||nâ-22/NN||â-26/NN	num||â-26/NN||$-27/$	number||86-29/CD||‰-28/CD	num||$-27/$||86-29/CD	nsubjpass||associated-34/VBN||hepcidin-32/NN	auxpass||associated-34/VBN||was-33/VBD	root||ROOT-0/null||associated-34/VBN	amod||volume-39/NN||lower-36/JJR	amod||volume-39/NN||mean-37/JJ	nn||volume-39/NN||corpuscular-38/NN	prep_with||associated-34/VBN||volume-39/NN	dep||volume-39/NN||pâ-41/VBN	dobj||pâ-41/VBN||$-42/$	number||=-44/CD||‰-43/CD	num||$-42/$||=-44/CD	dep||pâ-41/VBN||â-45/VB	dobj||â-45/VB||$-46/$	number||0.002-48/CD||‰-47/CD	num||$-46/$||0.002-48/CD	xcomp||associated-34/VBN||suggesting-51/VBG	mark||contributed-54/VBD||that-52/IN	nsubj||contributed-54/VBD||it-53/PRP	ccomp||suggesting-51/VBG||contributed-54/VBD	amod||erythropoiesis-57/NNS||iron-restricted-56/JJ	prep_to||contributed-54/VBD||erythropoiesis-57/NNS	irondeficiency-8||iron--1||yes||in patients without acute inflammation and overt irondeficiency (c reactive protein <1â mg/dl and ferritin >30â ng/ml; nâ€‰=â€‰86), hepcidin was associated with lower mean corpuscular volume (pâ€‰=â€‰0.002), suggesting that it contributed to iron-restricted erythropoiesis.
nsubj||homeostasis-4/VBZ||disruption-1/NN	prep_of||disruption-1/NN||er-3/NN	ccomp||approved-29/VBD||homeostasis-4/VBZ	dobj||homeostasis-4/VBZ||results-5/NNS	nn||stress-8/NN||er-7/NN	prep_in||results-5/NNS||stress-8/NN	nsubj||cause-14/NN||stress-8/NN	cop||cause-14/NN||is-11/VBZ	det||cause-14/NN||a-12/DT	amod||cause-14/NN||major-13/JJ	rcmod||stress-8/NN||cause-14/NN	nn||death-17/NN||cell-16/NN	prep_of||cause-14/NN||death-17/NN	prep_in||death-17/NN||cells-19/NNS	vmod||cells-19/NNS||exposed-20/VBN	det||bortezomib-25/NN||the-22/DT	amod||bortezomib-25/NN||proteasome-23/JJ	nn||bortezomib-25/NN||inhibitor-24/NN	prep_to||exposed-20/VBN||bortezomib-25/NN	det||anti-cancerdrug-28/NN||an-27/DT	nsubj||approved-29/VBD||anti-cancerdrug-28/NN	root||ROOT-0/null||approved-29/VBD	prep_for||approved-29/VBD||treatment-31/NN	nn||lymphoma-37/NN||multiplemyeloma-33/NN	conj_and||multiplemyeloma-33/NN||mantle-35/NN	nn||lymphoma-37/NN||mantle-35/NN	nn||lymphoma-37/NN||cell-36/NN	prep_of||treatment-31/NN||lymphoma-37/NN	multiplemyeloma-33||bortezomib-25||yes||disruption of er homeostasis results in er stress, which is a major cause of cell death in cells exposed to the proteasome inhibitor bortezomib, an anti-cancerdrug approved for treatment of multiplemyeloma and mantle cell lymphoma.
agent||identified-12/VBN||contrast-2/NN	nsubjpass||identified-12/VBN||changes-4/NNS	prep_in||changes-4/NNS||17-6/CD	num||species-10/NNS||12-8/CD	nn||species-10/NNS||lipid-9/NN	prep_in||changes-4/NNS||species-10/NNS	conj_and||17-6/CD||species-10/NNS	auxpass||identified-12/VBN||were-11/VBD	root||ROOT-0/null||identified-12/VBN	det||amygdala-18/NN||the-14/DT	nn||amygdala-18/NN||parkinson-15/NN	amod||amygdala-18/NN||sdisease-17/JJ	prep_in||identified-12/VBN||amygdala-18/NN	nn||cortex-22/NN||anterior-20/NN	nn||cortex-22/NN||cingulate-21/NN	prep_in||identified-12/VBN||cortex-22/NN	conj_and||amygdala-18/NN||cortex-22/NN	advmod||identified-12/VBN||respectively-24/RB	prepc_compared_to||identified-12/VBN||to-27/TO	pobj||identified-12/VBN||controls-28/NNS	dep||controls-28/NNS||none-30/NN	nsubj||remained-33/VBD||which-32/WDT	prepc_of||none-30/NN||remained-33/VBD	acomp||remained-33/VBD||significant-34/JJ	amod||analysis-39/NN||false-36/JJ	nn||analysis-39/NN||discovery-37/NN	nn||analysis-39/NN||rate-38/NN	prep_after||remained-33/VBD||analysis-39/NN	lipid-9||parkinson'sdisease--1||no_rel||by contrast, changes in 17 and 12 lipid species were identified in the parkinson'sdisease amygdala and anterior cingulate cortex, respectively, compared to controls; none of which remained significant after false discovery rate analysis.
det||suppression-3/NN||the-1/DT	amod||suppression-3/NN||entecavir-induced-2/JJ	nsubjpass||accompanied-8/VBN||suppression-3/NN	nn||replication-6/NN||hbv-5/NN	prep_of||suppression-3/NN||replication-6/NN	auxpass||accompanied-8/VBN||was-7/VBD	root||ROOT-0/null||accompanied-8/VBN	det||increase-12/NN||a-10/DT	amod||increase-12/NN||rapid-11/JJ	agent||accompanied-8/VBN||increase-12/NN	det||number-15/NN||the-14/DT	prep_in||increase-12/NN||number-15/NN	amod||cells-18/NNS||th17-17/JJ	prep_of||number-15/NN||cells-18/NNS	advmod||accompanied-8/VBN||together-20/RB	det||decrease-23/NN||a-22/DT	prep_with||accompanied-8/VBN||decrease-23/NN	amod||cells-26/NNS||treg-25/VBG	prep_in||decrease-23/NN||cells-26/NNS	nsubj||lead-29/VBP||cells-26/NNS	rcmod||cells-26/NNS||lead-29/VBP	det||reduction-33/NN||a-31/DT	amod||reduction-33/NN||significant-32/JJ	prep_to||lead-29/VBP||reduction-33/NN	amod||ratios-36/NNS||treg/th17-35/JJ	prep_of||reduction-33/NN||ratios-36/NNS	hbv-5||entecavir--1||yes||the entecavir-induced suppression of hbv replication was accompanied by a rapid increase in the number of th17 cells, together with a decrease in treg cells, which lead to a significant reduction of treg/th17 ratios.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	tumors-28||antibodies-20||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	advmod||report-3/VBP||yet-4/RB	det||reovirus-7/NNS||another-5/DT	amod||reovirus-7/NNS||melaka-like-6/JJ	dobj||report-3/VBP||reovirus-7/NNS	dep||reovirus-7/NNS||named-9/VBN	nn||virus-11/NN||kampar-10/NN	dobj||named-9/VBN||virus-11/NN	amod||reovirus-7/NNS||isolated-13/VBN	det||swab-17/NN||the-15/DT	nn||swab-17/NN||throat-16/NN	prep_from||isolated-13/VBN||swab-17/NN	nsubj||suffering-33/VBG||swab-17/NN	det||patient-24/NN||a-19/DT	number||old-22/JJ||54-20/CD	npadvmod||old-22/JJ||year-21/NN	amod||patient-24/NN||old-22/JJ	amod||patient-24/NN||male-23/JJ	prep_of||swab-17/NN||patient-24/NN	nn||malaysia-30/NN||kampar-26/NN	dep||malaysia-30/NN||perak-28/NN	prep_in||patient-24/NN||malaysia-30/NN	aux||suffering-33/VBG||was-32/VBD	rcmod||swab-17/NN||suffering-33/VBG	amod||fever-36/NN||high-35/JJ	prep_from||suffering-33/VBG||fever-36/NN	amod||respiratorydisease-39/NN||acute-38/JJ	prep_from||suffering-33/VBG||respiratorydisease-39/NN	conj_and||fever-36/NN||respiratorydisease-39/NN	prep_from||suffering-33/VBG||vomiting-41/NN	conj_and||fever-36/NN||vomiting-41/NN	det||time-44/NN||the-43/DT	prep_at||suffering-33/VBG||time-44/NN	prep_of||time-44/NN||virusisolation-46/NN	virusisolation-46||respiratorydisease-39||no_rel||here we report yet another melaka-like reovirus (named kampar virus) isolated from the throat swab of a 54 year old male patient in kampar, perak, malaysia who was suffering from high fever, acute respiratorydisease and vomiting at the time of virusisolation.
nn||cisplatin-3/NN||background-1/NN	nn||cisplatin-3/NN||liposomal-2/NN	nsubj||formulation-7/NN||cisplatin-3/NN	cop||formulation-7/NN||is-4/VBZ	det||formulation-7/NN||a-5/DT	amod||formulation-7/NN||new-6/JJ	root||ROOT-0/null||formulation-7/NN	vmod||formulation-7/NN||developed-8/VBN	aux||reduce-10/VB||to-9/TO	xcomp||developed-8/VBN||reduce-10/VB	det||toxicity-13/NN||the-11/DT	amod||toxicity-13/NN||systemic-12/JJ	dobj||reduce-10/VB||toxicity-13/NN	prep_of||toxicity-13/NN||cisplatin-15/NN	mark||improving-18/VBG||while-16/IN	advmod||improving-18/VBG||simultaneously-17/RB	advcl||reduce-10/VB||improving-18/VBG	det||targeting-20/NN||the-19/DT	dobj||improving-18/VBG||targeting-20/NN	det||drug-23/NN||the-22/DT	prep_of||targeting-20/NN||drug-23/NN	det||tumor-27/NN||the-25/DT	amod||tumor-27/NN||primary-26/JJ	prep_to||improving-18/VBG||tumor-27/NN	prep_to||improving-18/VBG||metastases-30/NNS	conj_and||tumor-27/NN||metastases-30/NNS	amod||time-34/NN||increasing-32/VBG	nn||time-34/NN||circulation-33/NN	prep_by||improving-18/VBG||time-34/NN	det||fluids-38/NNS||the-36/DT	nn||fluids-38/NNS||body-37/NN	prep_in||time-34/NN||fluids-38/NNS	prep_in||time-34/NN||tissues-40/NNS	conj_and||fluids-38/NNS||tissues-40/NNS	metastases-30||cisplatin-15||no_rel||background liposomal cisplatin is a new formulation developed to reduce the systemic toxicity of cisplatin while simultaneously improving the targeting of the drug to the primary tumor and to metastases by increasing circulation time in the body fluids and tissues.
det||analysis-4/NN||the-1/DT	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubj||showed-5/VBD||analysis-4/NN	root||ROOT-0/null||showed-5/VBD	mark||associated-9/VBN||that-6/IN	nsubjpass||associated-9/VBN||fetuin-a-7/NN	nsubjpass||associated-9/VBN||fetuin-a-7/NN	auxpass||associated-9/VBN||were-8/VBD	ccomp||showed-5/VBD||associated-9/VBN	ccomp||showed-5/VBD||associated-9/VBN	conj_or||associated-9/VBN||associated-9/VBN	amod||homa-ir-12/NN||elevated-11/JJ	prep_with||associated-9/VBN||homa-ir-12/NN	nn||insulin-16/NN||fasting-14/NN	nn||insulin-16/NN||serum-15/NN	prep_with||associated-9/VBN||insulin-16/NN	conj_and||homa-ir-12/NN||insulin-16/NN	preconj||associated-9/VBN||both-17/DT	det||participants-20/NNS||the-19/DT	prep_among||associated-9/VBN||participants-20/NNS	prep||participants-20/NNS||with-21/IN	prep_without||associated-9/VBN||type2diabetes-24/NNS	det||analysis-29/NN||the-26/DT	amod||analysis-29/NN||full-27/JJ	amod||analysis-29/NN||adjusted-28/JJ	prep_in||type2diabetes-24/NNS||analysis-29/NN	type2diabetes-24||insulin-16||yes||the logistic regression analysis showed that fetuin-a were associated with elevated homa-ir and fasting serum insulin both among the participants with or without type2diabetes in the full adjusted analysis.
advmod||viruses-7/VBZ||influenza-1/RB	det||pdm09-6/NNS||a-2/DT	appos||pdm09-6/NNS||h1n1-4/NNP	nsubj||viruses-7/VBZ||pdm09-6/NNS	root||ROOT-0/null||viruses-7/VBZ	xcomp||viruses-7/VBZ||cause-8/VB	advmod||cause-8/VB||sporadically-9/RB	advmod||severe-11/JJ||very-10/RB	amod||disease-12/NN||severe-11/JJ	dobj||cause-8/VB||disease-12/NN	amod||outcomes-16/NNS||fatal-14/JJ	amod||outcomes-16/NNS||clinical-15/JJ	prep_including||disease-12/NN||outcomes-16/NNS	vmod||outcomes-16/NNS||associated-17/VBN	prep_with||associated-17/VBN||pneumonia-19/NN	prep_with||associated-17/VBN||viremia-21/NN	conj_and||pneumonia-19/NN||viremia-21/NN	prep_with||associated-17/VBN||myocarditis-23/NNS	conj_and||pneumonia-19/NN||myocarditis-23/NNS	viremia-21||viruses-7||no||influenza a(h1n1)pdm09 viruses cause sporadically very severe disease including fatal clinical outcomes associated with pneumonia, viremia and myocarditis.
nsubjpass||prescribed-3/VBN||antibiotics-1/NNS	auxpass||prescribed-3/VBN||were-2/VBD	root||ROOT-0/null||prescribed-3/VBN	advmod||prescribed-3/VBN||acutely-4/RB	num||%-7/NN||66-6/CD	prep_in||prescribed-3/VBN||%-7/NN	appos||%-7/NN||359/543-9/CD	prep_of||%-7/NN||children-12/NNS	prep_with||children-12/NNS||urinarytractinfection-14/NN	num||%-17/NN||69-16/CD	prep_in||prescribed-3/VBN||%-17/NN	conj_and||%-7/NN||%-17/NN	appos||%-17/NN||366/533-19/CD	prep_with||%-17/NN||pneumonia-22/NN	num||%-26/NN||81-25/CD	prep_in||prescribed-3/VBN||%-26/NN	conj_and||%-7/NN||%-26/NN	appos||%-26/NN||52/64-28/CD	prep_with||%-26/NN||bacteraemia-31/NN	antibiotics-1||bacteraemia-31||no_rel||antibiotics were prescribed acutely in 66% (359/543) of children with urinarytractinfection, 69% (366/533) with pneumonia, and 81% (52/64) with bacteraemia.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	neg||differences-4/NNS||no-3/DT	nsubj||were-2/VBD||differences-4/NNS	amod||mortality-7/NN||in-hospital-6/JJ	prep_in||differences-4/NNS||mortality-7/NN	prep_in||differences-4/NNS||reinfarction-9/NN	conj_or||mortality-7/NN||reinfarction-9/NN	amod||revascularization-14/NN||urgent-11/JJ	nn||revascularization-14/NN||target-12/NN	nn||revascularization-14/NN||vessel-13/NN	prep_in||differences-4/NNS||revascularization-14/NN	conj_or||mortality-7/NN||revascularization-14/NN	prep_in||differences-4/NNS||stroke-16/NN	conj_or||mortality-7/NN||stroke-16/NN	amod||thrombosis-22/NNS||acute-18/JJ	conj_or||acute-18/JJ||subacute-20/JJ	amod||thrombosis-22/NNS||subacute-20/JJ	nn||thrombosis-22/NNS||stent-21/NN	prep_in||differences-4/NNS||thrombosis-22/NNS	conj_or||mortality-7/NN||thrombosis-22/NNS	mark||showed-28/VBD||while-24/IN	nsubj||showed-28/VBD||group-25/NN	num||patients-27/NNS||1-26/CD	dep||group-25/NN||patients-27/NNS	advcl||were-2/VBD||showed-28/VBD	det||incidence-31/NN||a-29/DT	amod||incidence-31/NN||lower-30/JJR	nsubj||-rrb--49/NN||incidence-31/NN	amod||complications-35/NNS||major-33/JJ	amod||complications-35/NNS||bleeding-34/VBG	prep_of||incidence-31/NN||complications-35/NNS	vmod||complications-35/NNS||-lrb--36/VBG	nn||scale-38/NN||acuity-37/NN	dobj||-lrb--36/VBG||scale-38/NN	num||scale-38/NN||1.1-39/CD	prep||-lrb--36/VBG||vs.-40/FW	num||%-42/NN||4.0-41/CD	pobj||vs.-40/FW||%-42/NN	nn||â-45/NN||p-44/NN	appos||%-42/NN||â-45/NN	dep||-rrb--49/NN||=-46/SYM	nn||-rrb--49/NN||â-47/NN	num||-rrb--49/NN||0.035-48/CD	ccomp||showed-28/VBD||-rrb--49/NN	det||length-53/NN||a-51/DT	amod||length-53/NN||shorter-52/JJR	nsubj||stay-56/VBP||length-53/NN	prep_of||length-53/NN||hospital-55/NN	advcl||were-2/VBD||stay-56/VBP	conj_and||showed-28/VBD||stay-56/VBP	number||3.5-58/CD||-lrb--57/CD	num||â-62/NN||3.5-58/CD	nn||â-62/NN||â-59/NN	nn||â-62/NN||â-60/NN	num||â-62/NN||±-61/CD	dobj||stay-56/VBP||â-62/NN	dobj||â-77/NN||1.7-63/CD	prep||1.7-63/CD||vs.-64/FW	amod||â-67/NN||4.0-65/JJ	nn||â-67/NN||â-66/NN	pobj||vs.-64/FW||â-67/NN	amod||â-75/NN||±-68/JJ	nn||â-75/NN||â-69/NN	num||â-75/NN||1.6-70/CD	nn||â-75/NN||â-71/NN	nn||â-75/NN||days-72/NNS	dep||â-75/NN||p-74/NN	nsubj||â-77/NN||â-75/NN	dep||â-77/NN||=-76/SYM	rcmod||â-62/NN||â-77/NN	num||-rrb--79/NNS||0.002-78/CD	npadvmod||as-80/RB||-rrb--79/NNS	advmod||stay-56/VBP||as-80/RB	prepc_compared_with||stay-56/VBP||with-82/IN	pobj||stay-56/VBP||heparin-83/NN	vmod||heparin-83/NN||treated-84/VBN	dobj||treated-84/VBN||patients-85/NNS	thrombosis-22||heparin-83||no_rel||there were no differences in in-hospital mortality , reinfarction , urgent target vessel revascularization , stroke or acute or subacute stent thrombosis , while group 1 patients showed a lower incidence of major bleeding complications -lrb- acuity scale 1.1 vs. 4.0 % , p â = â 0.035 -rrb- and a shorter length of hospital stay -lrb- 3.5 â â ± â 1.7 vs. 4.0 â â ± â 1.6 â days , p â = â 0.002 -rrb- as compared with heparin treated patients .
advmod||observed-23/VBN||finally-1/RB	prepc_compared_with||observed-23/VBN||with-4/IN	det||patients-7/NNS||the-5/DT	amod||patients-7/NNS||chronichepatitisb-6/JJ	pobj||observed-23/VBN||patients-7/NNS	amod||rate-10/NN||similar-9/JJ	nsubjpass||observed-23/VBN||rate-10/NN	nn||reactivation-13/NN||hbv-12/NN	prep_of||rate-10/NN||reactivation-13/NN	amod||withdrawal-16/NN||lamivudine-15/JJ	prep_after||reactivation-13/NN||withdrawal-16/NN	prep_after||reactivation-13/NN||development-18/NN	conj_and||withdrawal-16/NN||development-18/NN	amod||mutation-21/NN||ymdd-20/JJ	prep_of||reactivation-13/NN||mutation-21/NN	auxpass||observed-23/VBN||was-22/VBD	root||ROOT-0/null||observed-23/VBN	nn||patients-26/NNS||nhl-25/NN	prep_in||observed-23/VBN||patients-26/NNS	hbv-12||lamivudine-15||yes||finally, compared with the chronichepatitisb patients, similar rate of hbv reactivation after lamivudine withdrawal and development of ymdd mutation was observed in nhl patients.
amod||association-2/NN||significant-1/JJ	nsubjpass||noted-44/VBN||association-2/NN	appos||association-2/NN||p-4/NNP	number||0.001-6/CD||<-5/CD	num||p-4/NNP||0.001-6/CD	amod||use-10/NN||prior-9/JJ	prep_of||association-2/NN||use-10/NN	prep_of||use-10/NN||antibiotics-12/NNS	prep_in||antibiotics-12/NNS||males-14/NNS	conj_and||association-2/NN||uti-16/NN	nsubjpass||noted-44/VBN||uti-16/NN	prep_in||uti-16/NN||adults-18/NNS	amod||surgery-21/NN||gynaecological-20/JJ	conj_and||association-2/NN||surgery-21/NN	nsubjpass||noted-44/VBN||surgery-21/NN	prep_in||surgery-21/NN||females-23/NNS	amod||uropathy-26/NN||obstructive-25/JJ	conj_and||association-2/NN||uropathy-26/NN	nsubjpass||noted-44/VBN||uropathy-26/NN	prep_in||uropathy-26/NN||males-28/NNS	amod||uti-31/NN||complicated-30/JJ	conj_and||association-2/NN||uti-31/NN	nsubjpass||noted-44/VBN||uti-31/NN	prep_in||uti-31/NN||females-33/NNS	det||occurrence-36/NN||the-35/DT	prep_with||females-33/NNS||occurrence-36/NN	prep_of||occurrence-36/NN||uti-38/NN	amod||resistant-41/JJ||ciprofloxacin-40/JJ	amod||escherichiacoli-42/NNS||resistant-41/JJ	prep_with||uti-38/NN||escherichiacoli-42/NNS	auxpass||noted-44/VBN||was-43/VBD	root||ROOT-0/null||noted-44/VBN	uti-38||ciprofloxacin-40||yes||significant association ( p <0.001) of prior use of antibiotics in males, uti in adults, gynaecological surgery in females, obstructive uropathy in males and complicated uti in females with the occurrence of uti with ciprofloxacin resistant escherichiacoli was noted.
det||combination-3/NN||the-1/DT	amod||combination-3/NN||olmesartan/amlodipine-2/JJ	nsubj||demonstrated-5/VBN||combination-3/NN	aux||demonstrated-5/VBN||has-4/VBZ	root||ROOT-0/null||demonstrated-5/VBN	amod||efficacy-7/NN||greater-6/JJR	dobj||demonstrated-5/VBN||efficacy-7/NN	poss||monotherapies-11/NNS||its-9/PRP$	nn||monotherapies-11/NNS||component-10/NN	prep_than||demonstrated-5/VBN||monotherapies-11/NNS	prepc_in||demonstrated-5/VBN||reducing-13/VBG	dobj||reducing-13/VBG||bp-14/NN	prep_in||reducing-13/VBG||patients-16/NNS	amod||hypertension-19/NN||mild-to-severe-18/JJ	prep_with||patients-16/NNS||hypertension-19/NN	hypertension-19||amlodipine--1||yes||the olmesartan/amlodipine combination has demonstrated greater efficacy than its component monotherapies in reducing bp in patients with mild-to-severe hypertension.
det||contrary-3/NN||the-2/DT	prep_on||tgf-î-40/VBZ||contrary-3/NN	amod||injections-7/NNS||triple-5/JJ	nn||injections-7/NNS||i.p.-6/NN	nsubj||tgf-î-40/VBZ||injections-7/NNS	num||hours-10/NNS||24-9/CD	npadvmod||apart-11/RB||hours-10/NNS	advmod||injections-7/NNS||apart-11/RB	num||î-15/NN||10-14/CD	prep_of||injections-7/NNS||î-15/NN	num||ejhe-18/NN||1/4-16/CD	nn||ejhe-18/NN||g-17/NN	nsubj||increased-19/VBD||ejhe-18/NN	rcmod||î-15/NN||increased-19/VBD	advmod||ifn-î-21/JJ||significantly-20/RB	amod||production-23/NN||ifn-î-21/JJ	amod||production-23/NN||³-22/JJ	dobj||increased-19/VBD||production-23/NN	det||p-28/NN||the-25/DT	amod||p-28/NN||spleen-26/JJ	amod||p-28/NN||-lrb--27/JJ	prep_in||increased-19/VBD||p-28/NN	vmod||p-28/NN||<-29/VBG	num||-rrb--31/NNS||0.02-30/CD	dobj||<-29/VBG||-rrb--31/NNS	mark||increased-35/VBD||while-32/IN	advmod||ejhe-wr-34/NN||only-33/RB	nsubj||increased-35/VBD||ejhe-wr-34/NN	advcl||<-29/VBG||increased-35/VBD	advmod||ifn-î-37/JJ||significantly-36/RB	amod||³-38/NNS||ifn-î-37/JJ	dobj||increased-35/VBD||³-38/NNS	root||ROOT-0/null||tgf-î-40/VBZ	number||1-42/CD||²-41/CD	dobj||tgf-î-40/VBZ||1-42/CD	amod||<-47/NNS||il-17-44/JJ	amod||<-47/NNS||-lrb--45/JJ	nn||<-47/NNS||p-46/NN	dobj||tgf-î-40/VBZ||<-47/NNS	conj_and||1-42/CD||<-47/NNS	dep||<-47/NNS||0.03-48/CD	num||production-52/NN||0.005-50/CD	amod||production-52/NN||-rrb--51/JJ	dep||<-47/NNS||production-52/NN	det||microenvironment-56/NN||the-54/DT	nn||microenvironment-56/NN||tumor-55/NN	prep_within||production-52/NN||microenvironment-56/NN	amod||fibrosarcoma-59/NN||meth-a-58/JJ	prep_of||microenvironment-56/NN||fibrosarcoma-59/NN	meth--1||tumor-55||no_rel||on the contrary , triple i.p. injections , 24 hours apart ; of 10 î 1/4 g ejhe increased significantly ifn-î ³ production in the spleen -lrb- p < 0.02 -rrb- while only ejhe-wr increased significantly ifn-î ³ , tgf-î ² 1 and il-17 -lrb- p < 0.03 - 0.005 -rrb- production within the tumor microenvironment of meth-a fibrosarcoma .
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	nn||weakness-36/NN||muscle-35/NN	conj_and||disorder-29/NN||weakness-36/NN	nn||failure-39/NN||growth-38/NN	appos||weakness-36/NN||failure-39/NN	amod||seizures-42/NNS||hypocalcemic-41/JJ	conj_and||disorder-29/NN||seizures-42/NNS	amod||infancy-45/NN||early-44/JJ	prep_in||seizures-42/NNS||infancy-45/NN	amod||findings-49/NNS||radiographic-48/JJ	conj_and||disorder-29/NN||findings-49/NNS	prep_of||findings-49/NNS||rickets-51/NNS	rickets-51||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscle weakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
nn||design-2/NN||research-1/NN	nsubj||pumpâ-10/VBD||design-2/NN	poss||insulin-9/NN||methods-4/NNS	nn||insulin-9/NN||$-6/NNP	num||insulin-9/NN||seventeen-8/CD	conj_and||design-2/NN||insulin-9/NN	nsubj||pumpâ-10/VBD||insulin-9/NN	root||ROOT-0/null||pumpâ-10/VBD	num||adolescents-14/NNS||$-11/$	num||$-11/$||treated-13/CD	nsubj||underwent-17/VBD||adolescents-14/NNS	prep_with||adolescents-14/NNS||type1diabetes-16/CD	ccomp||pumpâ-10/VBD||underwent-17/VBD	num||procedures-21/NNS||two-18/CD	amod||procedures-21/NNS||euglycemic-19/JJ	nn||procedures-21/NNS||clamp-20/NN	dobj||underwent-17/VBD||procedures-21/NNS	det||bolus-26/NNS||a-23/DT	num||bolus-26/NNS||0.2-24/CD	amod||bolus-26/NNS||unit/kg-25/VBG	prep_after||underwent-17/VBD||bolus-26/NNS	preconj||insulinaspart-29/NN||either-28/DT	prep_of||bolus-26/NNS||insulinaspart-29/NN	prep_of||bolus-26/NNS||lispro-31/NN	conj_or||insulinaspart-29/NN||lispro-31/NN	prep_on||insulinaspart-29/NN||day-33/NN	num||day-33/NN||1-34/CD	prep_of||bolus-26/NNS||day-36/NN	conj_and||insulinaspart-29/NN||day-36/NN	num||day-36/NN||4-37/CD	nn||insertion-42/NN||insulin-39/NN	nn||insertion-42/NN||pump-40/NN	nn||insertion-42/NN||site-41/NN	prep_of||day-36/NN||insertion-42/NN	type1diabetes-16||lispro-31||yes||research design and methods â€”seventeen insulin pumpâ€“treated adolescents with type1diabetes underwent two euglycemic clamp procedures after a 0.2 unit/kg bolus of either insulinaspart or lispro on day 1 and day 4 of insulin pump site insertion.
nsubj||enzyme-10/NN||glucokinase-1/NN	appos||glucokinase-1/NN||gck-3/NN	cop||enzyme-10/NN||is-5/VBZ	det||enzyme-10/NN||the-6/DT	amod||enzyme-10/NN||key-7/JJ	nn||enzyme-10/NN||glucose-8/NN	nn||enzyme-10/NN||phosphorylation-9/NN	root||ROOT-0/null||enzyme-10/NN	nsubj||attracted-13/VBN||enzyme-10/NN	nsubj||regulates-40/VBZ||enzyme-10/NN	aux||attracted-13/VBN||has-12/VBZ	rcmod||enzyme-10/NN||attracted-13/VBN	amod||attention-15/NN||considerable-14/JJ	dobj||attracted-13/VBN||attention-15/NN	det||gene-19/NN||a-17/DT	nn||gene-19/NN||candidate-18/NN	prep_as||attracted-13/VBN||gene-19/NN	amod||t2d-23/NNS||type2diabetes-21/JJ	prep_for||gene-19/NN||t2d-23/NNS	vmod||t2d-23/NNS||based-25/VBN	poss||function-29/NN||its-27/PRP$	amod||function-29/NN||enzyme-28/JJ	prep_on||based-25/VBN||function-29/NN	det||step-34/NN||the-31/DT	amod||step-34/NN||first-32/JJ	amod||step-34/NN||rate-limiting-33/JJ	prep_as||based-25/VBN||step-34/NN	det||pathway-38/NN||the-36/DT	amod||pathway-38/NN||glycolysis-37/JJ	prep_in||step-34/NN||pathway-38/NN	rcmod||enzyme-10/NN||regulates-40/VBZ	conj_and||attracted-13/VBN||regulates-40/VBZ	amod||secretion-43/NN||glucose-stimulated-41/JJ	nn||secretion-43/NN||insulin-42/NN	dobj||regulates-40/VBZ||secretion-43/NN	t2d-23||insulin-42||yes||glucokinase ( gck ) is the key glucose phosphorylation enzyme which has attracted considerable attention as a candidate gene for type2diabetes (t2d) based on its enzyme function as the first rate-limiting step in the glycolysis pathway and regulates glucose-stimulated insulin secretion.
mark||higher-6/JJR||although-1/IN	amod||prevalence-3/NN||hbsag-2/VBG	nsubj||higher-6/JJR||prevalence-3/NN	cop||higher-6/JJR||is-4/VBZ	advmod||higher-6/JJR||much-5/RB	advcl||high-29/JJ||higher-6/JJR	prep_among||higher-6/JJR||subjects-8/NNS	nsubj||hivpositive-11/JJ||subjects-8/NNS	cop||hivpositive-11/JJ||are-10/VBP	rcmod||subjects-8/NNS||hivpositive-11/JJ	num||%-14/NN||14.0-13/CD	dep||subjects-8/NNS||%-14/NN	num||%-17/NN||4.3-16/CD	dep||subjects-8/NNS||%-17/NN	conj_versus||%-14/NN||%-17/NN	det||prevalence-21/NN||the-20/DT	nsubj||high-29/JJ||prevalence-21/NN	nsubj||warrant-32/VB||prevalence-21/NN	prepc_of||prevalence-21/NN||hbsag-23/VBG	amod||subjects-27/NNS||hiv-25/JJ	amod||subjects-27/NNS||negative-26/JJ	prep_in||hbsag-23/VBG||subjects-27/NNS	cop||high-29/JJ||is-28/VBZ	root||ROOT-0/null||high-29/JJ	advmod||high-29/JJ||enough-30/RB	aux||warrant-32/VB||to-31/TO	xcomp||high-29/JJ||warrant-32/VB	det||recommendation-34/NN||a-33/DT	dobj||warrant-32/VB||recommendation-34/NN	aux||screen-36/VB||to-35/TO	vmod||recommendation-34/NN||screen-36/VB	det||clients-38/NNS||all-37/DT	dobj||screen-36/VB||clients-38/NNS	nn||centers-41/NNS||vct-40/NN	prep_at||screen-36/VB||centers-41/NNS	nn||status-45/NN||hiv-44/NN	prep_irrespective_of||screen-36/VB||status-45/NN	hivpositive-11||hiv-44||no||although hbsag prevalence is much higher among subjects who are hivpositive (14.0% versus 4.3%), the prevalence of hbsag in hiv negative subjects is high enough to warrant a recommendation to screen all clients at vct centers irrespective of hiv status.
amod||titers-3/NNS||anti-tax-1/JJ	nn||titers-3/NNS||antibody-2/NN	nsubj||higher-6/JJR||titers-3/NNS	cop||higher-6/JJR||were-4/VBD	advmod||higher-6/JJR||also-5/RB	root||ROOT-0/null||higher-6/JJR	dep||higher-6/JJR||p-8/NNP	number||0.0005-10/CD||<-9/CD	num||p-8/NNP||0.0005-10/CD	det||ham/tsp-14/NN||the-13/DT	prep_in||higher-6/JJR||ham/tsp-14/NN	prepc_compared_to||higher-6/JJR||to-16/TO	det||carriers-20/NNS||the-17/DT	amod||carriers-20/NNS||asymptomatic-18/JJ	num||carriers-20/NNS||htlv-i-19/CD	pobj||higher-6/JJR||carriers-20/NNS	antibody-2||ham--1||no_rel||anti-tax antibody titers were also higher ( p < 0.0005) in the ham/tsp compared to the asymptomatic htlv-i carriers.
amod||sleepapnea-2/NN||obstructive-1/JJ	nsubj||common-4/JJ||sleepapnea-2/NN	cop||common-4/JJ||is-3/VBZ	root||ROOT-0/null||common-4/JJ	prep_in||common-4/JJ||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	poss||association-12/NN||its-11/PRP$	nsubjpass||examined-19/VBN||association-12/NN	prep_with||association-12/NN||insulin-14/NN	prep_with||association-12/NN||insulinresistance-16/NN	conj_and||insulin-14/NN||insulinresistance-16/NN	aux||examined-19/VBN||has-17/VBZ	auxpass||examined-19/VBN||been-18/VBN	conj_and||common-4/JJ||examined-19/VBN	amod||studies-22/NNS||cross-sectional-21/JJ	prep_in||examined-19/VBN||studies-22/NNS	insulin-14||sleepapnea-2||no_rel||obstructive sleepapnea is common in patients with type2diabetes, and its association with insulin and insulinresistance has been examined in cross-sectional studies.
det||±-3/NN||the-1/DT	nn||±-3/NN||î-2/NN	root||ROOT-0/null||±-3/NN	amod||bartonella-7/NN||proteobacterial-5/JJ	nn||bartonella-7/NN||genus-6/NN	nsubj||comprises-8/VBZ||bartonella-7/NN	dep||±-3/NN||comprises-8/VBZ	num||species-10/NNS||21-9/CD	dobj||comprises-8/VBZ||species-10/NNS	nsubj||cause-12/VBP||species-10/NNS	rcmod||species-10/NNS||cause-12/VBP	amod||bacteremia-15/NN||host-specific-13/JJ	amod||bacteremia-15/NN||intraerythrocytic-14/JJ	dobj||cause-12/VBP||bacteremia-15/NN	prep_as||cause-12/VBP||hallmark-17/NN	prep_of||hallmark-17/NN||infection-19/NN	poss||reservoirs-24/NNS||their-21/PRP$	amod||reservoirs-24/NNS||respective-22/JJ	amod||reservoirs-24/NNS||mammalian-23/JJ	prep_in||infection-19/NN||reservoirs-24/NNS	det||bartonellaquintana-30/NN||the-27/DT	amod||bartonellaquintana-30/NN||human-specific-28/JJ	nn||bartonellaquintana-30/NN||pathogens-29/NNS	prep_including||cause-12/VBP||bartonellaquintana-30/NN	prep_including||cause-12/VBP||bartonellabacilliformis-32/NNS	conj_and||bartonellaquintana-30/NN||bartonellabacilliformis-32/NNS	nsubj||cause-34/VBP||bartonellabacilliformis-32/NNS	rcmod||bartonellabacilliformis-32/NNS||cause-34/VBP	dobj||cause-34/VBP||trenchfever-35/NN	dobj||cause-34/VBP||oroyafever-37/NN	conj_and||trenchfever-35/NN||oroyafever-37/NN	advmod||cause-34/VBP||respectively-39/RB	trenchfever-35||bartonellaquintana-30||no||the î±-proteobacterial genus bartonella comprises 21 species that cause host-specific intraerythrocytic bacteremia as hallmark of infection in their respective mammalian reservoirs, including the human-specific pathogens bartonellaquintana and bartonellabacilliformis that cause trenchfever and oroyafever, respectively.
nsubj||provides-2/VBZ||this-1/DT	root||ROOT-0/null||provides-2/VBZ	dobj||provides-2/VBZ||analogy-3/NN	amod||proteins-6/NNS||membrane-associated-5/JJ	prep_with||provides-2/VBZ||proteins-6/NNS	vmod||proteins-6/NNS||mediating-7/VBG	det||build-up-9/NN||the-8/DT	dobj||mediating-7/VBG||build-up-9/NN	prep_of||build-up-9/NN||â-11/NN	amod||build-up-9/NN||$-12/$	dep||$-12/$||œvirus-13/JJ	vmod||build-up-9/NN||factoriesâ-14/VBN	dobj||factoriesâ-14/VBN||$-15/$	quantmod||cells-17/CD||in-16/IN	num||$-15/$||cells-17/CD	vmod||$-15/$||infected-18/VBN	amod||viruses-23/NNS||diverse-20/JJ	amod||viruses-23/NNS||positive-strand-21/JJ	nn||viruses-23/NNS||rna-22/NN	prep_with||infected-18/VBN||viruses-23/NNS	amod||viruses-26/NNS||alpha-like-25/JJ	dep||viruses-23/NNS||viruses-26/NNS	amod||viruses-29/NNS||picorna-like-28/JJ	dep||viruses-23/NNS||viruses-29/NNS	conj_and||viruses-26/NNS||viruses-29/NNS	dep||viruses-23/NNS||flaviviruses-31/NNS	conj_and||viruses-26/NNS||flaviviruses-31/NNS	dep||viruses-23/NNS||nidoviruses-34/NNS	conj_and||viruses-26/NNS||nidoviruses-34/NNS	amod||viruses-39/NNS||negative-strand-37/JJ	nn||viruses-39/NNS||rna-38/NN	prep_with||infected-18/VBN||viruses-39/NNS	conj_and||viruses-23/NNS||viruses-39/NNS	appos||viruses-23/NNS||bunyaviruses-41/NNS	virus--1||viruses-39||no||this provides analogy with membrane-associated proteins mediating the build-up of â€œvirus factoriesâ€? in cells infected with diverse positive-strand rna viruses (alpha-like viruses, picorna-like viruses, flaviviruses, and nidoviruses) and negative-strand rna viruses (bunyaviruses).
nsubj||provides-12/VBZ||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||capecitabine-10/NN	root||ROOT-0/null||provides-12/VBZ	amod||benefits-14/NNS||clinical-13/JJ	dobj||provides-12/VBZ||benefits-14/NNS	prep_to||provides-12/VBZ||patients-16/NNS	amod||cancer-21/NN||erbb2-18/JJ	amod||cancer-21/NN||+-19/JJ	nn||cancer-21/NN||breast-20/NN	prep_with||patients-16/NNS||cancer-21/NN	prep_including||patients-16/NNS||patients-24/NNS	nsubj||develop-26/VBP||patients-24/NNS	rcmod||patients-24/NNS||develop-26/VBP	amod||disease-28/NN||progressive-27/JJ	dobj||develop-26/VBP||disease-28/NN	prep_on||develop-26/VBP||trastuzumab-30/NN	cancer-21||trastuzumab-30||no_rel||lapatinib, in combination with chemotherapeuticagents, such as capecitabine, provides clinical benefits to patients with erbb2+ breast cancer, including patients who develop progressive disease on trastuzumab.
det||enzymes-3/NNS||the-1/DT	amod||enzymes-3/NNS||immobilized-2/JJ	nsubj||retained-4/VBD||enzymes-3/NNS	root||ROOT-0/null||retained-4/VBD	num||%-6/NN||58.1-5/CD	dobj||retained-4/VBD||%-6/NN	poss||activities-10/NNS||their-8/PRP$	amod||activities-10/NNS||initial-9/JJ	prep_of||%-6/NN||activities-10/NNS	num||uses-14/NNS||ten-12/CD	amod||uses-14/NNS||consecutive-13/JJ	prep_after||retained-4/VBD||uses-14/NNS	enzymes-3||ten-12||no_rel||the immobilized enzymes retained 58.1% of their initial activities after ten consecutive uses.
num||patients-2/NNS||nine-1/CD	npadvmod||seropositive-3/JJ||patients-2/NNS	root||ROOT-0/null||seropositive-3/JJ	prep_for||seropositive-3/JJ||hepatitisb-5/NN	dep||received-8/VBD||e-6/SYM	nsubj||received-8/VBD||antigen-7/NN	dep||seropositive-3/JJ||received-8/VBD	nn||monotherapy-10/NN||entecavir-9/NN	nsubjpass||analyzed-34/VBN||monotherapy-10/NN	num||months-13/NNS||12-12/CD	prep_for||monotherapy-10/NN||months-13/NNS	det||percentages-16/NNS||the-15/DT	prep_for||monotherapy-10/NN||percentages-16/NNS	conj_and||months-13/NNS||percentages-16/NNS	prep_of||percentages-16/NNS||tregs-18/NNS	amod||cells-21/NNS||th17-20/JJ	prep_of||percentages-16/NNS||cells-21/NNS	conj_and||tregs-18/NNS||cells-21/NNS	det||productions-28/NNS||the-25/DT	amod||productions-28/NNS||hbv-specific-26/JJ	amod||productions-28/NNS||il-17-27/JJ	prep_of||percentages-16/NNS||productions-28/NNS	conj_and||tregs-18/NNS||productions-28/NNS	det||patients-31/NNS||these-30/DT	prep_in||productions-28/NNS||patients-31/NNS	auxpass||analyzed-34/VBN||were-32/VBD	advmod||analyzed-34/VBN||longitudinally-33/RB	ccomp||received-8/VBD||analyzed-34/VBN	hepatitisb-5||entecavir-9||yes||nine patients seropositive for hepatitisb e antigen received entecavir monotherapy for 12 months and the percentages of tregs and th17 cells as well as the hbv-specific il-17 productions in these patients were longitudinally analyzed.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||investigate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||investigate-9/VB||to-8/TO	xcomp||was-7/VBD||investigate-9/VB	det||role-11/NN||the-10/DT	dobj||investigate-9/VB||role-11/NN	prep_of||role-11/NN||mmp-8-13/JJ	dep||mmp-8-13/JJ||collagenase-2-15/JJ	det||model-20/NN||an-18/DT	nn||model-20/NN||arthritis-19/NN	prep_in||investigate-9/VB||model-20/NN	arthritis-19||collagenase--1||no_rel||the aim of the present study was to investigate the role of mmp-8 (collagenase-2) in an arthritis model.
det||prevalences-2/NNS||the-1/DT	nsubj||33.1-24/NNP||prevalences-2/NNS	amod||antibody-6/NN||anti-hbv-4/JJ	nn||antibody-6/NN||core-5/NN	prep_of||prevalences-2/NNS||antibody-6/NN	dep||antibody-6/NN||anti-hbc-8/JJ	prep_of||prevalences-2/NNS||hepatitisbvirussurfaceantigen-11/NN	conj_and||antibody-6/NN||hepatitisbvirussurfaceantigen-11/NN	appos||hepatitisbvirussurfaceantigen-11/NN||hbsag-13/NN	amod||antibody-19/NN||anti-hbv-17/JJ	nn||antibody-19/NN||surface-18/NN	prep_of||prevalences-2/NNS||antibody-19/NN	conj_and||antibody-6/NN||antibody-19/NN	appos||antibody-19/NN||anti-hbs-21/NNS	cop||33.1-24/NNP||were-23/VBD	root||ROOT-0/null||33.1-24/NNP	conj_and||33.1-24/NNP||10.4-26/CD	num||%-30/NN||56.1-29/CD	conj_and||33.1-24/NNP||%-30/NN	advmod||33.1-24/NNP||respectively-32/RB	hbv--1||hepatitisbvirussurfaceantigen-11||yes||the prevalences of anti-hbv core antibody (anti-hbc), hepatitisbvirussurfaceantigen (hbsag), and anti-hbv surface antibody (anti-hbs) were 33.1, 10.4, and 56.1%, respectively.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||man-3/NN||a-1/DT	amod||man-3/NN||65-year-old-2/JJ	nsubjpass||referred-7/VBN||man-3/NN	prep_with||man-3/NN||diabetes-5/NN	auxpass||referred-7/VBN||was-6/VBD	root||ROOT-0/null||referred-7/VBN	nsubj||lasting-16/VBG||cornealabscess-9/NNS	amod||cornealabscess-9/NNS||unresponsive-10/JJ	amod||treatment-15/NN||antibiotic-12/JJ	conj_and||antibiotic-12/JJ||antifungal-14/JJ	amod||treatment-15/NN||antifungal-14/JJ	prep_to||unresponsive-10/JJ||treatment-15/NN	prepc_for||referred-7/VBN||lasting-16/VBG	num||weeks-18/NNS||6-17/CD	tmod||lasting-16/VBG||weeks-18/NNS	antibiotic-12||cornealabscess-9||no_rel||a 65-year-old man with diabetes was referred for cornealabscess unresponsive to antibiotic and antifungal treatment lasting 6 weeks.
nsubj||dna-10/NN||temozolomide-1/NN	appos||temozolomide-1/NN||tmz-3/NN	cop||dna-10/NN||is-5/VBZ	det||dna-10/NN||a-6/DT	amod||dna-10/NN||new-7/JJ	amod||dna-10/NN||second-8/JJ	nn||dna-10/NN||generation-9/NN	root||ROOT-0/null||dna-10/NN	vmod||dna-10/NN||alkylating-11/VBG	dobj||alkylating-11/VBG||agent-12/NN	nsubj||become-15/VBN||agent-12/NN	aux||become-15/VBN||has-14/VBZ	rcmod||agent-12/NN||become-15/VBN	xcomp||become-15/VBN||part-16/NN	amod||paradigms-21/NNS||malignant-18/JJ	nn||paradigms-21/NNS||astrocytoma-19/NN	nn||paradigms-21/NNS||management-20/NN	prep_of||part-16/NN||paradigms-21/NNS	poss||efficacy-26/NN||its-24/PRP$	amod||efficacy-26/NN||proven-25/JJ	prep_because_of||paradigms-21/NNS||efficacy-26/NN	xcomp||become-15/VBN||ease-28/NN	conj_and||part-16/NN||ease-28/NN	prep_of||ease-28/NN||administration-30/NN	amod||profile-35/NN||favorable-33/JJ	nn||profile-35/NN||toxicity-34/NN	xcomp||become-15/VBN||profile-35/NN	conj_and||part-16/NN||profile-35/NN	astrocytoma-19||tmz-3||yes||temozolomide (tmz) is a new second generation dna alkylating agent that has become part of malignant astrocytoma management paradigms because of its proven efficacy, ease of administration, and favorable toxicity profile.
nsubj||feasible-20/JJ||detection-1/NN	prep_of||detection-1/NN||acutehivinfection-3/NN	appos||detection-1/NN||ahi-5/NN	num||testing-12/NN||pooled-8/CD	amod||testing-12/NN||nucleic-9/JJ	amod||testing-12/NN||acid-10/JJ	nn||testing-12/NN||amplification-11/NN	prep_with||detection-1/NN||testing-12/NN	appos||testing-12/NN||naat-14/NN	nn||testing-18/NN||hiv-17/NN	prep_following||testing-12/NN||testing-18/NN	cop||feasible-20/JJ||is-19/VBZ	root||ROOT-0/null||feasible-20/JJ	acutehivinfection-3||hiv-17||no||detection of acutehivinfection (ahi) with pooled nucleic acid amplification testing (naat) following hiv testing is feasible.
det||study-2/NN||this-1/DT	nsubjpass||interpreted-21/VBN||study-2/NN	dep||study-2/NN||aimed-3/VBN	prepc_at||aimed-3/VBN||exploring-5/VBG	amod||choices-8/NNS||infant-6/JJ	amod||choices-8/NNS||feeding-7/VBG	dobj||exploring-5/VBG||choices-8/NNS	advmod||breastfeeding-11/JJ||how-10/WRB	dep||study-2/NN||breastfeeding-11/JJ	conj_and||aimed-3/VBN||breastfeeding-11/JJ	det||risk-14/NN||the-13/DT	conj_and||study-2/NN||risk-14/NN	nsubjpass||interpreted-21/VBN||risk-14/NN	nn||transmission-17/NN||hiv-16/NN	prep_of||risk-14/NN||transmission-17/NN	prep_through||transmission-17/NN||breastfeeding-19/NN	auxpass||interpreted-21/VBN||was-20/VBD	root||ROOT-0/null||interpreted-21/VBN	amod||mothers-24/NNS||hivpositive-23/JJ	prep_among||interpreted-21/VBN||mothers-24/NNS	poss||counselors-27/NNS||their-26/PRP$	prep_among||interpreted-21/VBN||counselors-27/NNS	conj_and||mothers-24/NNS||counselors-27/NNS	amod||programs-30/NNS||pmtct-29/JJ	prep_in||interpreted-21/VBN||programs-30/NNS	amod||ababa-33/NN||addis-32/JJ	prep_in||programs-30/NNS||ababa-33/NN	appos||ababa-33/NN||ethiopia-35/NN	hivpositive-23||hiv-16||no||this study aimed at exploring infant feeding choices and how breastfeeding and the risk of hiv transmission through breastfeeding was interpreted among hivpositive mothers and their counselors in pmtct programs in addis ababa, ethiopia.
amod||type-3/NN||male-1/JJ	amod||type-3/NN||wild-2/JJ	nsubj||capable-11/JJ||type-3/NN	dep||capable-11/JJ||wt-5/NN	amod||mice-8/NNS||c57bl/6-7/JJ	nsubj||capable-11/JJ||mice-8/NNS	cop||capable-11/JJ||are-9/VBP	advmod||capable-11/JJ||less-10/RBR	root||ROOT-0/null||capable-11/JJ	prepc_of||capable-11/JJ||clearing-13/VBG	dobj||clearing-13/VBG||bacteria-14/NNS	dobj||clearing-13/VBG||surviving-16/VBG	conj_and||bacteria-14/NNS||surviving-16/VBG	prep_from||clearing-13/VBG||bacterialpneumonia-18/NN	prep_than||clearing-13/VBG||females-20/NNS	bacterialpneumonia-18||bacteria-14||no||male wild type (wt) c57bl/6 mice are less capable of clearing bacteria and surviving from bacterialpneumonia than females.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-42/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-42/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-42/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-41/NN||oral-39/JJ	nn||bowel-41/NN||sodiumphosphate-40/NN	prep_after||acute-35/VB||bowel-41/NN	prep_to||related-23/VBN||preparation-42/NN	nsubj||resolved-45/VBN||preparation-42/NN	rcmod||preparation-42/NN||resolved-45/VBN	advmod||resolved-45/VBN||rapidly-46/RB	nn||gluconate-49/NN||calcium-48/NN	prep_after||resolved-45/VBN||gluconate-49/NN	advmod||resolved-45/VBN||intravenously-50/RB	calcium-48||hypocalcemia-25||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodiumphosphate bowel preparation, which resolved rapidly after calcium gluconate intravenously.
det||data-2/NNS||these-1/DT	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||produce-7/VBP||that-4/IN	det||ad-dele1b55-6/NN||the-5/DT	nsubj||produce-7/VBP||ad-dele1b55-6/NN	ccomp||indicate-3/VBP||produce-7/VBP	amod||effects-10/NNS||combinatory-8/JJ	nn||effects-10/NNS||antitumor-9/NN	dobj||produce-7/VBP||effects-10/NNS	det||irrespective-14/NN||a-12/DT	amod||irrespective-14/NN||chemotherapeuticagent-13/JJ	prep_with||produce-7/VBP||irrespective-14/NN	det||schedule-18/NN||the-16/DT	nn||schedule-18/NN||administration-17/NN	prep_of||irrespective-14/NN||schedule-18/NN	det||effects-22/NNS||the-21/DT	nsubj||depend-23/VBP||effects-22/NNS	conj_but||indicate-3/VBP||depend-23/VBP	det||agent-26/NN||an-25/DT	prep_on||depend-23/VBP||agent-26/NN	amod||carcinoma-29/NN||esophageal-28/JJ	prep_in||agent-26/NN||carcinoma-29/NN	chemotherapeuticagent-13||carcinoma-29||no_rel||these data indicate that the ad-dele1b55 produce combinatory antitumor effects with a chemotherapeuticagent irrespective of the administration schedule, but the effects depend on an agent in esophageal carcinoma.
amod||sensitivities-2/NNS||analytical-1/JJ	nsubj||reduce-10/VB||sensitivities-2/NNS	prep_for||sensitivities-2/NNS||hbsag-4/NN	number||1-7/CD||>-6/CD	num||iu/ml-8/NN||1-7/CD	prep_of||hbsag-4/NN||iu/ml-8/NN	advmod||reduce-10/VB||significantly-9/RB	root||ROOT-0/null||reduce-10/VB	det||length-12/NN||the-11/DT	dobj||reduce-10/VB||length-12/NN	det||period-17/NN||the-14/DT	amod||period-17/NN||hbsag-15/JJ	amod||period-17/NN||positive-16/JJ	prep_of||length-12/NN||period-17/NN	nsubj||renders-19/VBZ||period-17/NN	rcmod||period-17/NN||renders-19/VBZ	nsubj||reliable-22/JJ||them-20/PRP	advmod||reliable-22/JJ||less-21/RBR	xcomp||renders-19/VBZ||reliable-22/JJ	prepc_for||renders-19/VBZ||detecting-24/VBG	vmod||detecting-24/VBG||hbsag-25/VBG	amod||infections-29/NNS||asymptomatic-27/JJ	nn||infections-29/NNS||hbv-28/NN	prep_in||hbsag-25/VBG||infections-29/NNS	hbv-28||hbsag-25||yes||analytical sensitivities for hbsag of >1 iu/ml significantly reduce the length of the hbsag positive period which renders them less reliable for detecting hbsag in asymptomatic hbv infections.
amod||control-2/NN||efficient-1/JJ	nsubj||requires-8/VBZ||control-2/NN	prep_of||control-2/NN||tuberculosis-4/NNP	appos||tuberculosis-4/NNP||tb-6/NN	dep||mycobacteriumbovis-20/VBZ||requires-8/VBZ	dobj||requires-8/VBZ||development-9/NN	prep_of||development-9/NN||strategies-11/NNS	nsubj||enhance-14/VB||strategies-11/NNS	aux||enhance-14/VB||can-13/MD	rcmod||strategies-11/NNS||enhance-14/VB	dobj||enhance-14/VB||efficacy-15/NN	det||vaccine-19/NN||the-17/DT	amod||vaccine-19/NN||existing-18/VBG	prep_of||efficacy-15/NN||vaccine-19/NN	root||ROOT-0/null||mycobacteriumbovis-20/VBZ	amod||guerin-23/NN||bacille-21/JJ	nn||guerin-23/NN||calmette-22/NN	nsubj||mycobacteriumbovis-20/VBZ||guerin-23/NN	appos||guerin-23/NN||bcg-25/NN	tb-6||bcg-25||yes||efficient control of tuberculosis (tb) requires development of strategies that can enhance efficacy of the existing vaccine mycobacteriumbovis bacille calmette guerin (bcg).
amod||cells-4/NNS||hes-induced-1/JJ	nn||cells-4/NNS||t-2/NN	nn||cells-4/NNS||reg-3/NN	nsubj||suppressed-5/VBD||cells-4/NNS	root||ROOT-0/null||suppressed-5/VBD	preconj||suppressed-5/VBD||both-6/DT	amod||proliferation-11/NN||vitro-8/JJ	nn||proliferation-11/NN||effector-9/NN	nn||proliferation-11/NN||cell-10/NN	prep_in||suppressed-5/VBD||proliferation-11/NN	amod||inflammation-17/NN||vivo-14/JJ	amod||inflammation-17/NN||allergic-15/JJ	amod||inflammation-17/NN||airway-16/JJ	prep_in||suppressed-5/VBD||inflammation-17/NN	conj_and||proliferation-11/NN||inflammation-17/NN	hes--1||inflammation-17||no_rel||hes-induced t reg cells suppressed both in vitro effector cell proliferation and in vivo allergic airway inflammation.
aux||determine-2/VB||to-1/TO	advcl||tested-36/VBN||determine-2/VB	det||role-4/NN||the-3/DT	dobj||determine-2/VB||role-4/NN	amod||degradation-7/NN||metabolic-6/JJ	prep_of||role-4/NN||degradation-7/NN	det||mechanism-10/NN||a-9/DT	prep_as||determine-2/VB||mechanism-10/NN	amod||resistance-13/NN||acaricide-12/JJ	prep_for||mechanism-10/NN||resistance-13/NN	amod||mites-16/NNS||scabies-15/JJ	prep_in||determine-2/VB||mites-16/NNS	nsubjpass||tested-36/VBN||pbo-18/NN	appos||pbo-18/NN||piperonylbutoxide-20/NN	conj_and||pbo-18/NN||def-23/NN	nsubjpass||tested-36/VBN||def-23/NN	amod||phosphorotrithioate-26/NN||s,s,s-tributyl-25/JJ	appos||def-23/NN||phosphorotrithioate-26/NN	conj_and||pbo-18/NN||dem-29/NNP	nsubjpass||tested-36/VBN||dem-29/NNP	amod||maleate-32/NN||diethyl-31/JJ	appos||pbo-18/NN||maleate-32/NN	auxpass||tested-36/VBN||were-34/VBD	advmod||tested-36/VBN||first-35/RB	root||ROOT-0/null||tested-36/VBN	amod||activity-39/NN||synergistic-38/JJ	prep_for||tested-36/VBN||activity-39/NN	prep_with||tested-36/VBN||permethrin-41/NN	det||bioassay-44/NN||a-43/DT	prep_in||permethrin-41/NN||bioassay-44/NN	nn||killing-47/NN||mite-46/NN	prep_of||bioassay-44/NN||killing-47/NN	scabies-15||piperonylbutoxide-20||yes||to determine the role of metabolic degradation as a mechanism for acaricide resistance in scabies mites, pbo (piperonylbutoxide), def (s,s,s-tributyl phosphorotrithioate) and dem (diethyl maleate) were first tested for synergistic activity with permethrin in a bioassay of mite killing.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-15/VBN||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulfadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	auxpass||recommended-15/VBN||is-14/VBZ	root||ROOT-0/null||recommended-15/VBN	dobj||low-29/JJ||who-17/WP	advmod||high-24/JJ||where-18/WRB	nn||incidence-20/NN||malaria-19/NN	nsubj||high-24/JJ||incidence-20/NN	nsubj||sp-26/JJ||incidence-20/NN	prep_in||incidence-20/NN||infancy-22/NN	cop||high-24/JJ||is-23/VBZ	advcl||low-29/JJ||high-24/JJ	conj_and||high-24/JJ||sp-26/JJ	advcl||low-29/JJ||sp-26/JJ	nsubj||low-29/JJ||resistance-27/NN	cop||low-29/JJ||is-28/VBZ	agent||recommended-15/VBN||low-29/JJ	malaria-19||pyrimethamine--1||yes||intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine (sp) is recommended by who where malaria incidence in infancy is high and sp resistance is low.
nsubjpass||diagnosed-3/VBN||type2diabetes-1/NNS	auxpass||diagnosed-3/VBN||was-2/VBD	root||ROOT-0/null||diagnosed-3/VBN	mark||â-9/VBN||if-4/IN	amod||glucose-7/NN||fasting-5/JJ	nn||glucose-7/NN||plasma-6/NN	nsubjpass||â-9/VBN||glucose-7/NN	auxpass||â-9/VBN||was-8/VBD	advcl||diagnosed-3/VBN||â-9/VBN	nn||126-12/NNP||‰-10/NNP	nn||126-12/NNP||¥-11/NNP	nsubj||mg/dl-13/JJ||126-12/NNP	xcomp||â-9/VBN||mg/dl-13/JJ	mark||taking-18/VBG||if-15/IN	nsubj||taking-18/VBG||participants-16/NNS	aux||taking-18/VBG||were-17/VBD	advcl||diagnosed-3/VBN||taking-18/VBG	conj_or||â-9/VBN||taking-18/VBG	amod||medication-21/NN||oral-19/JJ	amod||medication-21/NN||hypoglycemic-20/JJ	dobj||taking-18/VBG||medication-21/NN	dobj||taking-18/VBG||insulin-23/NN	conj_or||medication-21/NN||insulin-23/NN	type2diabetes-1||insulin-23||yes||type2diabetes was diagnosed if fasting plasma glucose was â‰¥126 mg/dl or if participants were taking oral hypoglycemic medication or insulin.
nn||ebvinfection-2/NN||recurrent-1/NN	nsubjpass||demonstrated-4/VBN||ebvinfection-2/NN	auxpass||demonstrated-4/VBN||was-3/VBD	root||ROOT-0/null||demonstrated-4/VBN	det||presence-7/NN||the-6/DT	agent||demonstrated-4/VBN||presence-7/NN	amod||antibodies-13/NNS||anti-ebv-9/JJ	amod||antibodies-13/NNS||early-10/JJ	nn||antibodies-13/NNS||antigen-11/NN	nn||antibodies-13/NNS||igm-12/NN	prep_of||presence-7/NN||antibodies-13/NNS	amod||antibodies-19/NNS||anti-ebv-15/JJ	amod||antibodies-19/NNS||nuclear-16/JJ	nn||antibodies-19/NNS||antigen-17/NN	nn||antibodies-19/NNS||igg-18/NN	prep_of||presence-7/NN||antibodies-19/NNS	conj_and||antibodies-13/NNS||antibodies-19/NNS	ebvinfection-2||ebv--1||no||recurrent ebvinfection was demonstrated by the presence of anti-ebv early antigen igm antibodies and anti-ebv nuclear antigen igg antibodies.
nn||action-4/NN||absorption-1/NN	conj_and||absorption-1/NN||hypoglycemic-3/JJ	nn||action-4/NN||hypoglycemic-3/JJ	nsubjpass||delayed-12/VBN||action-4/NN	amod||dosages-7/NNS||increasing-6/VBG	prep_of||action-4/NN||dosages-7/NNS	prep_of||dosages-7/NNS||lispro-9/NN	auxpass||delayed-12/VBN||are-10/VBP	advmod||delayed-12/VBN||critically-11/RB	root||ROOT-0/null||delayed-12/VBN	amod||subjects-15/NNS||obese-14/JJ	prep_in||delayed-12/VBN||subjects-15/NNS	prep_with||subjects-15/NNS||type2diabetes-17/CD	type2diabetes-17||lispro-9||yes||absorption and hypoglycemic action of increasing dosages of lispro are critically delayed in obese subjects with type2diabetes.
det||models-4/NNS||both-2/DT	nn||models-4/NNS||mouse-3/NN	nsubj||exhibiting-5/VBG||models-4/NNS	prepc_despite||are-24/VBP||exhibiting-5/VBG	amod||influx-9/NN||increased-6/VBN	amod||influx-9/NN||in-vivo-7/JJ	nn||influx-9/NN||calcium-8/NN	dobj||exhibiting-5/VBG||influx-9/NN	det||stage-13/NN||an-11/DT	amod||stage-13/NN||early-12/JJ	prep_at||exhibiting-5/VBG||stage-13/NN	det||development-16/NN||the-15/DT	prep_in||stage-13/NN||development-16/NN	det||cardiomyopathy-19/NN||the-18/DT	prep_of||development-16/NN||cardiomyopathy-19/NN	prep_before||exhibiting-5/VBG||leftventricularhypertrophy-21/NN	expl||are-24/VBP||there-23/EX	root||ROOT-0/null||are-24/VBP	amod||differences-27/NNS||distinct-25/JJ	amod||differences-27/NNS||phenotypical-26/JJ	nsubj||are-24/VBP||differences-27/NNS	det||models-31/NNS||the-29/DT	num||models-31/NNS||2-30/CD	prep_between||differences-27/NNS||models-31/NNS	prep_in||models-31/NNS||terms-33/NNS	nn||rates-36/NNS||heart-35/NN	prep_of||terms-33/NNS||rates-36/NNS	prep_of||terms-33/NNS||hemodynamics-38/NNS	conj_and||rates-36/NNS||hemodynamics-38/NNS	prep_of||terms-33/NNS||responses-40/NNS	conj_and||rates-36/NNS||responses-40/NNS	nn||inhibitors-44/NNS||calcium-42/NN	nn||inhibitors-44/NNS||channel-43/NN	prep_to||rates-36/NNS||inhibitors-44/NNS	calcium-42||cardiomyopathy-19||no_rel||despite both mouse models exhibiting increased in-vivo calcium influx at an early stage in the development of the cardiomyopathy before leftventricularhypertrophy, there are distinct phenotypical differences between the 2 models in terms of heart rates, hemodynamics and responses to calcium channel inhibitors.
det||number-3/NN||a-1/DT	amod||number-3/NN||considerable-2/JJ	nsubj||responded-13/VBD||number-3/NN	amod||patients-6/NNS||asthmatic-5/JJ	prep_of||number-3/NN||patients-6/NNS	neg||history-9/NN||no-8/DT	prep_with||patients-6/NNS||history-9/NN	nn||intolerance-12/NN||aspirin-11/NN	prep_of||history-9/NN||intolerance-12/NN	root||ROOT-0/null||responded-13/VBD	det||challenge-18/NN||the-15/DT	nn||challenge-18/NN||inhalation-16/NN	nn||challenge-18/NN||aspirin-17/NN	prep_to||responded-13/VBD||challenge-18/NN	asthmatic-5||aspirin-17||no||a considerable number of asthmatic patients with no history of aspirin intolerance responded to the inhalation aspirin challenge.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	amod||outcomes-4/NNS||various-3/JJ	dobj||evaluate-2/VB||outcomes-4/NNS	amod||treatment-8/NN||short-course-6/JJ	nn||treatment-8/NN||cyclosporine-7/NN	prep_of||outcomes-4/NNS||treatment-8/NN	amod||psoriasis-11/NNS||severe-10/JJ	prep_for||treatment-8/NN||psoriasis-11/NNS	aux||describe-15/VB||to-14/TO	conj_and||evaluate-2/VB||describe-15/VB	poss||use-18/NN||dermatologists-16/NNS	dobj||describe-15/VB||use-18/NN	det||rule-21/NN||the-20/DT	prep_of||use-18/NN||rule-21/NN	prep_of||rule-21/NN||tens-23/NNS	psoriasis-11||cyclosporine-7||yes||to evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the rule of tens.
det||level-2/NN||the-1/DT	nsubj||change-11/VB||level-2/NN	amod||diversity-5/NN||viral-4/JJ	prep_of||level-2/NN||diversity-5/NN	det||individual-9/NN||an-7/DT	amod||individual-9/NN||hiv-infected-8/JJ	prep_in||diversity-5/NN||individual-9/NN	aux||change-11/VB||can-10/MD	root||ROOT-0/null||change-11/VB	det||course-14/NN||the-13/DT	prep_during||change-11/VB||course-14/NN	prep_of||course-14/NN||hivinfection-16/NN	xcomp||change-11/VB||reflecting-18/VBG	dobj||reflecting-18/VBG||mutagenesis-19/NNS	amod||replication-22/NN||viral-21/JJ	prep_during||reflecting-18/VBG||replication-22/NN	prep_during||reflecting-18/VBG||selection-24/NN	conj_and||replication-22/NN||selection-24/NN	amod||variants-27/NNS||viral-26/JJ	prep_of||replication-22/NN||variants-27/NNS	amod||pressures-33/NNS||immune-29/JJ	conj_and||immune-29/JJ||other-31/JJ	amod||pressures-33/NNS||other-31/JJ	amod||pressures-33/NNS||selective-32/JJ	prep_by||reflecting-18/VBG||pressures-33/NNS	hivinfection-16||hiv--1||no||the level of viral diversity in an hiv-infected individual can change during the course of hivinfection, reflecting mutagenesis during viral replication and selection of viral variants by immune and other selective pressures.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	oa-13||glucosamine-42||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
nsubj||described-3/VBD||we-1/PRP	advmod||described-3/VBD||previously-2/RB	root||ROOT-0/null||described-3/VBD	det||pseudoknot-7/NN||an-4/DT	amod||pseudoknot-7/NN||unusual-5/JJ	amod||pseudoknot-7/NN||three-stemmed-6/JJ	dobj||described-3/VBD||pseudoknot-7/NN	nsubj||stimulated-19/VBN||pseudoknot-7/NN	det||coronavirus-14/NNS||the-9/DT	amod||coronavirus-14/NNS||severeacuterespiratorysyndrome-10/JJ	appos||coronavirus-14/NNS||sars-12/NNS	prep_from||pseudoknot-7/NN||coronavirus-14/NNS	appos||pseudoknot-7/NN||cov-16/NN	rcmod||pseudoknot-7/NN||stimulated-19/VBN	num||prf-21/NN||-1-20/CD	dobj||stimulated-19/VBN||prf-21/NN	sars-12||coronavirus-14||no||we previously described an unusual three-stemmed pseudoknot from the severeacuterespiratorysyndrome (sars) coronavirus (cov) that stimulated -1 prf.
nsubj||leads-8/VBZ||conclusions-1/NNS	prepc_compared_with||conclusions-1/NNS||with-3/IN	pobj||conclusions-1/NNS||insulinglargine-4/NN	nn||degludec-7/NN||insulin-6/NN	appos||insulinglargine-4/NN||degludec-7/NN	root||ROOT-0/null||leads-8/VBZ	prep_to||leads-8/VBZ||improvements-10/NNS	det||status-17/NN||both-12/DT	amod||status-17/NN||mental-13/JJ	conj_and||mental-13/JJ||physical-15/JJ	amod||status-17/NN||physical-15/JJ	nn||status-17/NN||health-16/NN	prep_in||improvements-10/NNS||status-17/NN	prep_for||status-17/NN||patients-19/NNS	amod||therapy-24/NN||type2diabetes-21/JJ	amod||therapy-24/NN||initiating-22/JJ	nn||therapy-24/NN||insulin-23/NN	prep_with||patients-19/NNS||therapy-24/NN	type2diabetes-21||insulin-23||yes||conclusions compared with insulinglargine, insulin degludec leads to improvements in both mental and physical health status for patients with type2diabetes initiating insulin therapy.
nsubjpass||trained-8/VBN||volunteers-1/NNS	dep||volunteers-1/NNS||one-3/CD	prep_per||one-3/CD||village-5/NN	auxpass||trained-8/VBN||were-7/VBD	root||ROOT-0/null||trained-8/VBN	prepc_on||trained-8/VBN||using-10/VBG	dobj||using-10/VBG||rdts-11/NNS	prep_for||rdts-11/NNS||diagnosis-13/NN	prep_for||rdts-11/NNS||artesunate-15/NN	conj_and||diagnosis-13/NN||artesunate-15/NN	dobj||using-10/VBG||sulphadoxine-pyrimethamine-17/NN	conj_plus||rdts-11/NNS||sulphadoxine-pyrimethamine-17/NN	prepc_for||sulphadoxine-pyrimethamine-17/NN||treating-19/VBG	nn||patients-21/NNS||malaria-20/NN	dobj||treating-19/VBG||patients-21/NNS	dobj||using-10/VBG||referral-26/NN	conj_and||rdts-11/NNS||referral-26/NN	amod||cases-31/NNS||severe-28/JJ	conj_and||severe-28/JJ||non-malaria-30/JJ	amod||cases-31/NNS||non-malaria-30/JJ	prep_of||referral-26/NN||cases-31/NNS	malaria-20||pyrimethamine--1||no||volunteers (one per village) were trained on using rdts for diagnosis and artesunate plus sulphadoxine-pyrimethamine for treating malaria patients, as well as referral of severe and non-malaria cases.
amod||anticoagulation-2/NN||oral-1/JJ	nsubj||prevents-3/VBZ||anticoagulation-2/NN	root||ROOT-0/null||prevents-3/VBZ	dobj||prevents-3/VBZ||strokes-4/NNS	prep_in||strokes-4/NNS||patients-6/NNS	prep_with||patients-6/NNS||atrialfibrillation-8/NN	nsubj||remain-14/VBP||reasons-12/NNS	prep_for||receive-26/VBP||reasons-12/NNS	rcmod||reasons-12/NNS||remain-14/VBP	acomp||remain-14/VBP||unclear-15/JJ	mwe||than-18/IN||less-17/JJR	quantmod||40-19/CD||than-18/IN	num||%-20/NN||40-19/CD	nsubj||receive-26/VBP||%-20/NN	det||patients-23/NNS||all-22/DT	prep_of||%-20/NN||patients-23/NNS	prep_with||patients-23/NNS||atrialfibrillation-25/NN	conj_but||prevents-3/VBZ||receive-26/VBP	dobj||receive-26/VBP||warfarin-27/NN	atrialfibrillation-25||warfarin-27||yes||oral anticoagulation prevents strokes in patients with atrialfibrillation but, for reasons that remain unclear, less than 40% of all patients with atrialfibrillation receive warfarin.
amod||regions-4/NNS||multiple-2/JJ	amod||regions-4/NNS||geographic-3/JJ	prep_across||-lrb--14/VBD||regions-4/NNS	amod||rates-7/NNS||high-6/JJ	nsubj||-lrb--14/VBD||rates-7/NNS	amod||resistance-10/NN||antimicrobial-9/JJ	prep_of||rates-7/NNS||resistance-10/NN	amod||agents-13/NNS||multiple-12/JJ	prep_to||resistance-10/NN||agents-13/NNS	root||ROOT-0/null||-lrb--14/VBD	nsubj||limited-28/VBN||e.g.-15/NNP	dep||-rrb--26/JJ||sulfonamides-16/JJ	amod||e.g.-15/NNP||tetracycline-18/JJ	conj_and||-rrb--26/JJ||tetracycline-18/JJ	amod||e.g.-15/NNP||chloramphenicol-20/JJ	conj_and||-rrb--26/JJ||chloramphenicol-20/JJ	amod||e.g.-15/NNP||ampicillin-22/JJ	conj_and||-rrb--26/JJ||ampicillin-22/JJ	amod||e.g.-15/NNP||trimethoprim-sulfamethoxazole-25/JJ	conj_and||-rrb--26/JJ||trimethoprim-sulfamethoxazole-25/JJ	amod||e.g.-15/NNP||-rrb--26/JJ	aux||limited-28/VBN||have-27/VBP	ccomp||-lrb--14/VBD||limited-28/VBN	det||choices-30/NNS||the-29/DT	dobj||limited-28/VBN||choices-30/NNS	amod||therapy-34/NN||empiric-32/JJ	amod||therapy-34/NN||antimicrobial-33/JJ	prep_for||limited-28/VBN||therapy-34/NN	vmod||therapy-34/NN||required-35/VBN	aux||manage-37/VB||to-36/TO	xcomp||required-35/VBN||manage-37/VB	dobj||manage-37/VB||shigellainfections-38/NNS	xcomp||required-35/VBN||reduce-40/VB	conj_and||manage-37/VB||reduce-40/VB	amod||excretion-42/NN||fecal-41/JJ	dobj||reduce-40/VB||excretion-42/NN	det||dominance-56/NN||the-44/DT	amod||dominance-56/NN||bacteria-45/NNS	number||8-47/CD||-lsb--46/CD	dep||bacteria-45/NNS||8-47/CD	number||-rsb--50/CD||10-49/CD	dep||8-47/CD||-rsb--50/CD	prep_with||-rsb--50/CD||descriptions-52/NNS	amod||species-55/NNS||shifting-54/VBG	prep_of||descriptions-52/NNS||species-55/NNS	prep_of||excretion-42/NN||dominance-56/NN	prep_of||excretion-42/NN||changes-58/NNS	conj_and||dominance-56/NN||changes-58/NNS	amod||susceptibility-61/NN||antimicrobial-60/JJ	prep_in||changes-58/NNS||susceptibility-61/NN	dep||-rsb--66/JJ||-lsb--62/NNP	num||-lsb--62/NNP||10-63/CD	num||-lsb--62/NNP||11-65/CD	amod||susceptibility-61/NN||-rsb--66/JJ	shigellainfections-38||bacteria-45||no||across multiple geographic regions , high rates of antimicrobial resistance to multiple agents -lrb- e.g. sulfonamides , tetracycline , chloramphenicol , ampicillin , and trimethoprim-sulfamethoxazole -rrb- have limited the choices for empiric antimicrobial therapy required to manage shigellainfections and reduce fecal excretion of the bacteria -lsb- 8 - 10 -rsb- with descriptions of shifting species dominance and changes in antimicrobial susceptibility -lsb- 10 , 11 -rsb- .
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||carried-5/VBN||study-3/NN	nsubj||investigate-8/VB||study-3/NN	nsubj||methicillin-26/VB||study-3/NN	auxpass||carried-5/VBN||was-4/VBD	root||ROOT-0/null||carried-5/VBN	prt||carried-5/VBN||out-6/RP	aux||investigate-8/VB||to-7/TO	xcomp||carried-5/VBN||investigate-8/VB	amod||activity-12/NN||vitro-11/JJ	prep_in||investigate-8/VB||activity-12/NN	amod||antibiotics-15/NNS||conventional-14/JJ	prep_of||activity-12/NN||antibiotics-15/NNS	advmod||prescribed-17/VBN||routinely-16/RB	vmod||antibiotics-15/NNS||prescribed-17/VBN	amod||resistant-20/JJ||methicillin-19/JJ	amod||-rrb--24/NNS||resistant-20/JJ	amod||-rrb--24/NNS||s.aureus-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||mrsa-23/NN	prep_for||prescribed-17/VBN||-rrb--24/NNS	xcomp||carried-5/VBN||methicillin-26/VB	conj_and||investigate-8/VB||methicillin-26/VB	amod||s.aureus-28/JJ||sensitive-27/JJ	amod||infections-32/NNS||s.aureus-28/JJ	amod||infections-32/NNS||-lrb--29/JJ	nn||infections-32/NNS||mssa-30/NN	nn||infections-32/NNS||-rrb--31/NN	dobj||methicillin-26/VB||infections-32/NNS	det||northwest-35/NN||the-34/DT	prep_in||methicillin-26/VB||northwest-35/NN	nsubjpass||recommended-45/VBN||northwest-35/NN	nn||agents-42/NNS||iran-37/NN	conj_and||iran-37/NN||other-39/JJ	nn||agents-42/NNS||other-39/JJ	num||agents-42/NNS||alternating-40/CD	amod||agents-42/NNS||therapeutic-41/JJ	prep_of||northwest-35/NN||agents-42/NNS	auxpass||recommended-45/VBN||are-44/VBP	rcmod||northwest-35/NN||recommended-45/VBN	nn||organisms-49/NNS||gram-47/NN	amod||organisms-49/NNS||positive-48/JJ	prep_for||recommended-45/VBN||organisms-49/NNS	mrsa-23||s.aureus-28||no||the present study was carried out to investigate in - vitro activity of conventional antibiotics routinely prescribed for methicillin resistant s.aureus -lrb- mrsa -rrb- and methicillin sensitive s.aureus -lrb- mssa -rrb- infections in the northwest of iran and other alternating therapeutic agents which are recommended for gram positive organisms .
prep_in||demonstrated-8/VBN||line-2/NN	prep_with||line-2/NN||this-4/DT	nsubjpass||demonstrated-8/VBN||bisphosphonates-6/NNS	nsubj||effective-12/JJ||bisphosphonates-6/NNS	auxpass||demonstrated-8/VBN||are-7/VBP	root||ROOT-0/null||demonstrated-8/VBN	aux||effective-12/JJ||to-9/TO	cop||effective-12/JJ||be-10/VB	advmod||effective-12/JJ||particularly-11/RB	xcomp||demonstrated-8/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||growth-16/NN||breasttumour-15/NN	dobj||reducing-14/VBG||growth-16/NN	advmod||used-18/VBN||when-17/WRB	advcl||effective-12/JJ||used-18/VBN	prep_in||used-18/VBN||combination-20/NN	prep_with||used-18/VBN||agents-22/NNS	nsubj||target-25/VBP||agents-22/NNS	advmod||target-25/VBP||directly-24/RB	rcmod||agents-22/NNS||target-25/VBP	nn||cells-27/NNS||cancer-26/NN	dobj||target-25/VBP||cells-27/NNS	cancer-26||bisphosphonates-6||no_rel||in line with this, bisphosphonates are demonstrated to be particularly effective at reducing breasttumour growth when used in combination with agents that directly target cancer cells.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	nsubj||investigate-8/VB||goal-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||underpinnings-11/NNS||the-9/DT	amod||underpinnings-11/NNS||molecular-10/JJ	dobj||investigate-8/VB||underpinnings-11/NNS	vmod||underpinnings-11/NNS||associated-12/VBN	det||behavior-18/NN||the-14/DT	advmod||aggressive-16/JJ||relatively-15/RB	amod||behavior-18/NN||aggressive-16/JJ	amod||behavior-18/NN||clinical-17/JJ	prep_with||associated-12/VBN||behavior-18/NN	nn||cancer-21/NN||prostate-20/NN	prep_of||behavior-18/NN||cancer-21/NN	appos||cancer-21/NN||pca-23/NN	nn||american-27/NN||african-26/NN	prep_in||cancer-21/NN||american-27/NN	appos||american-27/NN||aa-29/NN	prepc_compared_to||associated-12/VBN||to-32/TO	amod||american-34/NN||caucasian-33/JJ	pobj||associated-12/VBN||american-34/NN	dep||american-34/NN||ca-36/MD	dep||american-34/NN||patients-38/NNS	vmod||patients-38/NNS||using-39/VBG	det||approach-42/NN||a-40/DT	amod||approach-42/NN||genome-wide-41/JJ	dobj||using-39/VBG||approach-42/NN	cancer-21||ca-36||no_rel||the goal of our study was to investigate the molecular underpinnings associated with the relatively aggressive clinical behavior of prostate cancer (pca) in african american (aa) compared to caucasian american (ca) patients using a genome-wide approach.
det||incidence-4/NN||the-2/DT	amod||incidence-4/NN||increasing-3/VBG	prep_with||develop-42/VB||incidence-4/NN	nn||cancer-7/NN||breast-6/NN	prep_of||incidence-4/NN||cancer-7/NN	advmod||cancer-7/NN||worldwide-8/RB	prep_in||worldwide-8/RB||particular-11/JJ	nn||asia-14/NN||southeast-13/NN	prep_in||incidence-4/NN||asia-14/NN	prep_including||incidence-4/NN||korea-17/NN	det||use-23/NN||the-21/DT	amod||use-23/NN||common-22/JJ	conj_and||incidence-4/NN||use-23/NN	prep_with||develop-42/VB||use-23/NN	prep_of||use-23/NN||anthracyclines-25/NNS	det||adjuvant-28/NN||the-27/DT	prep_in||anthracyclines-25/NNS||adjuvant-28/NN	amod||settings-31/NNS||metastatic-30/JJ	prep_in||anthracyclines-25/NNS||settings-31/NNS	conj_and||adjuvant-28/NN||settings-31/NNS	det||occurrence-34/NN||the-33/DT	nsubj||develop-42/VB||occurrence-34/NN	amod||reactivation-40/NNS||hepatitisbvirus-36/JJ	appos||reactivation-40/NNS||hbv-38/NN	prep_of||occurrence-34/NN||reactivation-40/NNS	aux||develop-42/VB||may-41/MD	root||ROOT-0/null||develop-42/VB	det||population-46/NN||this-44/DT	amod||population-46/NN||patient-45/JJ	prep_in||develop-42/VB||population-46/NN	hbv-38||hepatitisbvirus-36||no||with the increasing incidence of breast cancer worldwide, in particular in southeast asia (including korea), and the common use of anthracyclines in the adjuvant and metastatic settings, the occurrence of hepatitisbvirus (hbv) reactivation may develop in this patient population.
quantmod||70-2/CD||approximately-1/RB	num||%-3/NN||70-2/CD	nsubj||express-6/VBP||%-3/NN	prep_of||%-3/NN||breasttumors-5/NNS	root||ROOT-0/null||express-6/VBP	det||receptor-9/NN||the-7/DT	nn||receptor-9/NN||estrogen-8/NN	dobj||express-6/VBP||receptor-9/NN	appos||receptor-9/NN||er-11/NN	breasttumors-5||estrogen-8||yes||approximately 70% of breasttumors express the estrogen receptor (er).
amod||enzyme-2/NN||insulin-degrading-1/JJ	nsubj||peptidase-10/NN||enzyme-2/NN	appos||enzyme-2/NN||ide-4/NN	cop||peptidase-10/NN||is-6/VBZ	det||peptidase-10/NN||a-7/DT	amod||sensitive-9/JJ||thiol-8/JJ	amod||peptidase-10/NN||sensitive-9/JJ	root||ROOT-0/null||peptidase-10/NN	nsubj||degrades-12/VBZ||peptidase-10/NN	nsubjpass||linked-22/VBN||peptidase-10/NN	rcmod||peptidase-10/NN||degrades-12/VBZ	nn||²-17/NNS||insulin-13/NN	conj_and||insulin-13/NN||amyloid-15/JJ	nn||²-17/NNS||amyloid-15/JJ	nn||²-17/NNS||î-16/NN	dobj||degrades-12/VBZ||²-17/NNS	aux||linked-22/VBN||has-20/VBZ	auxpass||linked-22/VBN||been-21/VBN	rcmod||peptidase-10/NN||linked-22/VBN	conj_and||degrades-12/VBZ||linked-22/VBN	nn||sdisease-28/NN||type2diabetesmellitus-24/NN	conj_and||type2diabetesmellitus-24/NN||alzheimer-26/NN	nn||sdisease-28/NN||alzheimer-26/NN	prep_to||linked-22/VBN||sdisease-28/NN	type2diabetesmellitus-24||insulin-13||yes||insulin-degrading enzyme (ide) is a thiol sensitive peptidase that degrades insulin and amyloid î², and has been linked to type2diabetesmellitus and alzheimer'sdisease.
nsubj||sequelae-12/NN||acuterheumaticfever-1/NN	appos||acuterheumaticfever-1/NN||arf-3/NN	amod||disease-8/NN||rheumatic-6/JJ	nn||disease-8/NN||heart-7/NN	conj_and||acuterheumaticfever-1/NN||disease-8/NN	nsubj||sequelae-12/NN||disease-8/NN	cop||sequelae-12/NN||are-9/VBP	amod||sequelae-12/NN||serious-10/JJ	amod||sequelae-12/NN||autoimmune-11/JJ	root||ROOT-0/null||sequelae-12/NN	prep_to||sequelae-12/NN||infections-14/NNS	prep_with||infections-14/NNS||streptococcuspyogenes-16/NNS	acuterheumaticfever-1||streptococcuspyogenes-16||no||acuterheumaticfever (arf) and rheumatic heart disease are serious autoimmune sequelae to infections with streptococcuspyogenes .
det||authors-2/NNS||the-1/DT	nsubj||report-3/VBP||authors-2/NNS	root||ROOT-0/null||report-3/VBP	det||case-5/NN||a-4/DT	nsubj||due-8/JJ||case-5/NN	prep_of||case-5/NN||pericarditis-7/NNS	xcomp||report-3/VBP||due-8/JJ	amod||therapy-12/NN||alpha-10/JJ	nn||therapy-12/NN||interferon-11/NN	prep_to||due-8/JJ||therapy-12/NN	prep_for||therapy-12/NN||chronichepatitisc-14/NN	det||woman-19/NN||a-17/DT	amod||woman-19/NN||young-18/JJ	prep_in||due-8/JJ||woman-19/NN	amod||pathology-23/NN||previous-21/JJ	amod||pathology-23/NN||cardiac-22/JJ	prep_without||report-3/VBP||pathology-23/NN	chronichepatitisc-14||interferon-11||yes||the authors report a case of pericarditis due to alpha interferon therapy for chronichepatitisc, in a young woman without previous cardiac pathology.
det||activity-2/NN||the-1/DT	nsubjpass||thought-18/VBN||activity-2/NN	nsubj||determinant-23/NN||activity-2/NN	amod||dehydrogenase-5/NN||dihydropyrimidine-4/JJ	prep_of||activity-2/NN||dehydrogenase-5/NN	appos||dehydrogenase-5/NN||dpd-7/NN	det||enzyme-12/NN||the-10/DT	amod||enzyme-12/NN||key-11/JJ	appos||activity-2/NN||enzyme-12/NN	amod||catabolism-15/NN||pyrimidine-14/JJ	prep_of||enzyme-12/NN||catabolism-15/NN	auxpass||thought-18/VBN||is-17/VBZ	root||ROOT-0/null||thought-18/VBN	aux||determinant-23/NN||to-19/TO	cop||determinant-23/NN||be-20/VB	det||determinant-23/NN||an-21/DT	amod||determinant-23/NN||important-22/JJ	xcomp||thought-18/VBN||determinant-23/NN	det||occurrence-26/NN||the-25/DT	prep_for||determinant-23/NN||occurrence-26/NN	amod||reactions-30/NNS||severe-28/JJ	amod||reactions-30/NNS||toxic-29/JJ	prep_of||occurrence-26/NN||reactions-30/NNS	prep_to||reactions-30/NNS||5-fluorouracil-32/NN	nsubj||one-39/CD||5-fluorouracil-32/NN	dep||5-fluorouracil-32/NN||5-fu-34/JJ	cop||one-39/CD||is-38/VBZ	rcmod||5-fluorouracil-32/NN||one-39/CD	det||chemotherapeuticagents-45/NNS||the-41/DT	advmod||prescribed-44/VBN||most-42/RBS	advmod||prescribed-44/VBN||commonly-43/RB	amod||chemotherapeuticagents-45/NNS||prescribed-44/VBN	prep_of||one-39/CD||chemotherapeuticagents-45/NNS	det||treatment-48/NN||the-47/DT	prep_for||chemotherapeuticagents-45/NNS||treatment-48/NN	amod||cancers-51/NNS||solid-50/JJ	prep_of||treatment-48/NN||cancers-51/NNS	cancers-51||5-fluorouracil-32||no_rel||the activity of dihydropyrimidine dehydrogenase (dpd), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-fu), which is one of the most commonly prescribed chemotherapeuticagents for the treatment of solid cancers.
amod||treatment-2/NN||subsequent-1/JJ	nsubj||suppressed-7/VBD||treatment-2/NN	prep_of||treatment-2/NN||neurons-4/NNS	vmod||neurons-4/NNS||containing-5/VBG	advmod||containing-5/VBG||stably-6/RB	root||ROOT-0/null||suppressed-7/VBD	dobj||suppressed-7/VBD||virus-8/NN	prep_with||suppressed-7/VBD||forskolin-10/NN	vmod||forskolin-10/NN||resulted-11/VBN	prep_in||resulted-11/VBN||reactivation-13/NN	det||viruses-16/NNS||both-15/DT	prep_of||reactivation-13/NN||viruses-16/NNS	virus-8||viruses-16||no||subsequent treatment of neurons containing stably suppressed virus with forskolin resulted in reactivation of both viruses.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||examine-5/VB||to-4/TO	ccomp||was-3/VBD||examine-5/VB	det||relationship-7/NN||the-6/DT	dobj||examine-5/VB||relationship-7/NN	amod||indexes-10/NNS||common-9/JJ	nsubj||using-23/VBG||indexes-10/NNS	amod||glycemia-13/NN||postprandial-12/JJ	prep_of||indexes-10/NNS||glycemia-13/NN	amod||hyperglycemia-16/NN||overall-15/JJ	prep_of||indexes-10/NNS||hyperglycemia-16/NN	conj_and||glycemia-13/NN||hyperglycemia-16/NN	nn||variability-19/NN||glucose-18/NN	prep_of||indexes-10/NNS||variability-19/NN	conj_and||glycemia-13/NN||variability-19/NN	prep_of||indexes-10/NNS||a1c-22/NNS	conj_and||glycemia-13/NN||a1c-22/NNS	prepc_among||examine-5/VB||using-23/VBG	amod||measures-26/NNS||detailed-24/JJ	nn||measures-26/NNS||glucose-25/NN	dobj||using-23/VBG||measures-26/NNS	vmod||measures-26/NNS||obtained-27/VBN	amod||life-30/NN||everyday-29/JJ	prep_during||obtained-27/VBN||life-30/NN	aux||study-33/VB||to-32/TO	ccomp||was-3/VBD||study-33/VB	conj_and||examine-5/VB||study-33/VB	dobj||provide-40/VBP||which-34/WDT	amod||values-36/NNS||bloodglucose-35/JJ	nsubj||provide-40/VBP||values-36/NNS	det||day-39/NN||the-38/DT	prep_of||values-36/NNS||day-39/NN	ccomp||study-33/VB||provide-40/VBP	det||prediction-43/NN||the-41/DT	amod||prediction-43/NN||strongest-42/JJS	dobj||provide-40/VBP||prediction-43/NN	prep_of||prediction-43/NN||a1c-45/CD	hyperglycemia-16||glucose-25||no||our objective was to examine the relationship among common indexes of postprandial glycemia, overall hyperglycemia, glucose variability, and a1c using detailed glucose measures obtained during everyday life and to study which bloodglucose values of the day provide the strongest prediction of a1c.
nsubj||inducer-15/NN||rifampicin-1/NN	det||component-5/NN||a-3/DT	amod||component-5/NN||critical-4/JJ	appos||rifampicin-1/NN||component-5/NN	nn||therapy-11/NN||tuberculosis-7/NNP	appos||therapy-11/NN||tb-9/NN	prep_of||component-5/NN||therapy-11/NN	cop||inducer-15/NN||is-12/VBZ	det||inducer-15/NN||a-13/DT	amod||inducer-15/NN||potent-14/JJ	root||ROOT-0/null||inducer-15/NN	nn||activity-19/NN||cyp-17/NN	nn||activity-19/NN||enzyme-18/NN	prep_of||inducer-15/NN||activity-19/NN	tuberculosis-7||rifampicin-1||yes||rifampicin, a critical component of tuberculosis (tb) therapy is a potent inducer of cyp enzyme activity.
amod||monitoring-2/NN||detailed-1/JJ	nsubj||contribute-18/VB||monitoring-2/NN	det||arsenic-6/NN||the-4/DT	amod||arsenic-6/NN||therapeutic-5/JJ	prep_of||monitoring-2/NN||arsenic-6/NN	poss||metabolites-9/NNS||its-8/PRP$	prep_of||monitoring-2/NN||metabolites-9/NNS	conj_and||arsenic-6/NN||metabolites-9/NNS	amod||specimens-13/NNS||various-11/JJ	amod||specimens-13/NNS||accessible-12/JJ	prep_in||metabolites-9/NNS||specimens-13/NNS	nn||patients-16/NNS||apl-15/NN	prep_of||specimens-13/NNS||patients-16/NNS	aux||contribute-18/VB||can-17/MD	root||ROOT-0/null||contribute-18/VB	prepc_to||contribute-18/VB||improving-20/VBG	dobj||improving-20/VBG||treatment-21/NN	advmod||improving-20/VBG||efficacy-22/RB	prepc_to||contribute-18/VB||minimizing-24/VBG	conj_and||improving-20/VBG||minimizing-24/VBG	amod||effects-27/NNS||arsenic-induced-25/JJ	nn||effects-27/NNS||side-26/NN	dobj||minimizing-24/VBG||effects-27/NNS	apl-15||arsenic-6||yes||detailed monitoring of the therapeutic arsenic and its metabolites in various accessible specimens of apl patients can contribute to improving treatment efficacy and minimizing arsenic-induced side effects.
det||hemagglutinin-6/NN||the-1/DT	amod||hemagglutinin-6/NN||main-2/JJ	amod||hemagglutinin-6/NN||influenzavirus-3/JJ	nn||hemagglutinin-6/NN||surface-4/NN	nn||hemagglutinin-6/NN||glycoprotein-5/NN	nsubjpass||shown-18/VBN||hemagglutinin-6/NN	nsubj||susceptible-22/JJ||hemagglutinin-6/NN	appos||hemagglutinin-6/NN||ha-8/NN	advmod||pathogenic-12/JJ||highly-11/RB	amod||avianinfluenzaviruses-13/NNS||pathogenic-12/JJ	prep_of||hemagglutinin-6/NN||avianinfluenzaviruses-13/NNS	appos||avianinfluenzaviruses-13/NNS||hpaiv-15/NNP	auxpass||shown-18/VBN||was-17/VBD	root||ROOT-0/null||shown-18/VBN	aux||susceptible-22/JJ||to-19/TO	cop||susceptible-22/JJ||be-20/VB	advmod||susceptible-22/JJ||more-21/RBR	xcomp||shown-18/VBN||susceptible-22/JJ	amod||treatment-26/NN||acidic-24/JJ	nn||treatment-26/NN||ph-25/NN	prep_to||susceptible-22/JJ||treatment-26/NN	prep_than||treatment-26/NN||that-28/DT	amod||avianinfluenzaviruses-34/NNS||human-30/JJ	conj_or||human-30/JJ||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||low-32/JJ	amod||avianinfluenzaviruses-34/NNS||pathogenic-33/JJ	prep_of||that-28/DT||avianinfluenzaviruses-34/NNS	avianinfluenza--1||influenzaviruses--1||no||the main influenzavirus surface glycoprotein hemagglutinin (ha) of highly pathogenic avianinfluenzaviruses (hpaiv) was shown to be more susceptible to acidic ph treatment than that of human or low pathogenic avianinfluenzaviruses.
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	tumour-49||fibre-42||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
nsubjpass||used-5/VBN||arsenictrioxide-1/NN	aux||used-5/VBN||has-2/VBZ	auxpass||used-5/VBN||been-3/VBN	advmod||used-5/VBN||successfully-4/RB	root||ROOT-0/null||used-5/VBN	det||therapeutic-8/JJ||a-7/DT	prep_as||used-5/VBN||therapeutic-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||therapeutic-8/JJ||treatment-11/NN	prep_of||treatment-11/NN||acutepromyelocyticleukemia-13/NN	appos||acutepromyelocyticleukemia-13/NN||apl-15/NN	apl-15||arsenictrioxide-1||yes||arsenictrioxide has been successfully used as a therapeutic in the treatment of acutepromyelocyticleukemia (apl).
det||patients-5/NNS||the-2/DT	num||patients-5/NNS||67-3/CD	amod||patients-5/NNS||b-celllymphoma-4/JJ	nsubj||received-7/VBD||patients-5/NNS	prep_in||had-21/VBD||patients-5/NNS	rcmod||patients-5/NNS||received-7/VBD	advmod||received-7/VBD||chemotherapy-8/RB	num||patients-11/NNS||36-10/CD	nsubj||had-21/VBD||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_with||treated-12/VBN||rituximab-14/NN	quantmod||3-18/CD||at-16/IN	mwe||at-16/IN||least-17/JJS	pobj||at-16/IN||least-17/JJS	num||cycles-19/NNS||3-18/CD	appos||patients-11/NNS||cycles-19/NNS	root||ROOT-0/null||had-21/VBD	det||os-24/NN||a-22/DT	amod||os-24/NN||mean-23/JJ	dobj||had-21/VBD||os-24/NN	num||months-27/NNS||72-26/CD	prep_of||os-24/NN||months-27/NNS	num||%-30/NN||95-29/CD	dep||months-27/NNS||%-30/NN	dep||%-30/NN||ci-31/NN	num||ci-31/NN||62-81-32/CD	num||months-36/NNS||62-35/CD	prep_versus||months-27/NNS||months-36/NNS	num||%-39/NN||95-38/CD	dep||months-36/NNS||%-39/NN	dep||%-39/NN||ci-40/NN	num||ci-40/NN||47-76-41/CD	prep_for||months-36/NNS||patients-44/NNS	amod||treatment-47/NN||rituximab-46/JJ	prep_without||had-21/VBD||treatment-47/NN	dep||treatment-47/NN||p-49/VBN	dep||0.021-51/CD||=-50/SYM	ccomp||p-49/VBN||0.021-51/CD	b-celllymphoma-4||rituximab-46||yes||in the 67 b-celllymphoma patients who received chemotherapy, 36 patients treated with rituximab (at least 3 cycles) had a mean os of 72 months (95% ci 62-81) versus 62 months (95% ci 47-76) for patients without rituximab treatment (p = 0.021).
num||groups-3/NNS||two-1/CD	nn||groups-3/NNS||treatment-2/NN	nsubjpass||compared-11/VBN||groups-3/NNS	amod||patients-7/NNS||resuscitated-5/JJ	nn||patients-7/NNS||trauma-6/NN	prep_of||groups-3/NNS||patients-7/NNS	prep_in||patients-7/NNS||cardiacarrest-9/NN	auxpass||compared-11/VBN||were-10/VBD	root||ROOT-0/null||compared-11/VBN	det||patients-16/NNS||the-13/DT	amod||patients-16/NNS||epinephrine-14/JJ	nn||patients-16/NNS||group-15/NN	prep_in||compared-11/VBN||patients-16/NNS	dep||patients-16/NNS||received-17/VBN	amod||mg-20/NN||epinephrine-18/JJ	amod||mg-20/NN||1â-19/JJ	nsubj||iv-21/VB||mg-20/NN	ccomp||received-17/VBN||iv-21/VB	det||min-24/NN||every-22/DT	amod||min-24/NN||3â-23/JJ	dobj||iv-21/VB||min-24/NN	advmod||iv-21/VB||only-25/RB	det||vasopressin-29/NN||the-28/DT	prep_in||iv-21/VB||vasopressin-29/NN	nn||patients-31/NNS||group-30/NN	nsubj||received-33/VBD||patients-31/NNS	advmod||received-33/VBD||first-32/RB	rcmod||vasopressin-29/NN||received-33/VBD	amod||hhs-35/NN||hypertonic-34/JJ	dobj||received-33/VBD||hhs-35/NN	nn||vasopressin-38/NN||arginine-37/NN	dobj||received-33/VBD||vasopressin-38/NN	conj_and||hhs-35/NN||vasopressin-38/NN	num||units-40/NNS||40-39/CD	npadvmod||iv-41/JJ||units-40/NNS	amod||hhs-35/NN||iv-41/JJ	advmod||received-33/VBD||only-42/RB	dep||patients-16/NNS||followed-44/VBN	conj_or||received-17/VBN||followed-44/VBN	amod||mg-48/NN||epinephrine-46/JJ	amod||mg-48/NN||1â-47/JJ	prep_by||followed-44/VBN||mg-48/NN	det||min-51/NN||every-49/DT	amod||min-51/NN||3â-50/JJ	dobj||received-17/VBN||min-51/NN	prep_until||received-17/VBN||cessation-53/NN	prep_of||cessation-53/NN||cpr-55/NN	cardiacarrest-9||epinephrine-46||yes||two treatment groups of resuscitated trauma patients in cardiacarrest were compared in the epinephrine group patients received epinephrine 1â mg iv every 3â min only; in the vasopressin group patients first received hypertonic hhs and arginine vasopressin 40 units iv only or followed by epinephrine 1â mg every 3â min until cessation of cpr.
nsubjpass||shown-12/VBN||reduction-1/NN	amod||layer-6/NN||retinal-3/JJ	nn||layer-6/NN||nerve-4/NN	nn||layer-6/NN||fibre-5/NN	prep_of||reduction-1/NN||layer-6/NN	dep||reduction-1/NN||rnfl-8/JJ	advmod||shown-12/VBN||thickness-10/RB	auxpass||shown-12/VBN||was-11/VBD	root||ROOT-0/null||shown-12/VBN	prep_as||shown-12/VBN||part-14/NN	det||process-18/NN||the-16/DT	amod||process-18/NN||neurodegenerative-17/JJ	prep_of||part-14/NN||process-18/NN	det||range-21/NN||a-20/DT	prep_in||shown-12/VBN||range-21/NN	amod||pathologies-25/NNS||different-23/JJ	nn||pathologies-25/NNS||neurodegenerative-24/NN	prep_of||range-21/NN||pathologies-25/NNS	amod||disease-31/NN||alzheimerâ-27/JJ	dep||alzheimerâ-27/JJ||$-28/$	number||s-30/CD||²-29/CD	num||$-28/$||s-30/CD	prep_including||pathologies-25/NNS||disease-31/NN	appos||disease-31/NN||ad-33/NN	amod||parkinsonâ-37/NNS||idiopathic-36/JJ	prep_including||pathologies-25/NNS||parkinsonâ-37/NNS	conj_and||disease-31/NN||parkinsonâ-37/NNS	num||disease-41/NN||$-38/$	number||s-40/CD||™-39/CD	num||$-38/$||s-40/CD	dep||parkinsonâ-37/NNS||disease-41/NN	appos||disease-41/NN||pd-43/NN	nn||ataxia-47/NN||spinocerebellar-46/NN	prep_including||pathologies-25/NNS||ataxia-47/NN	conj_and||disease-31/NN||ataxia-47/NN	appos||ataxia-47/NN||sca-49/NN	amod||atrophy-54/NN||multiple-52/JJ	nn||atrophy-54/NN||system-53/NN	prep_including||pathologies-25/NNS||atrophy-54/NN	conj_and||disease-31/NN||atrophy-54/NN	appos||atrophy-54/NN||msa-56/NN	msa-56||sca-49||no_rel||reduction of retinal nerve fibre layer (rnfl) thickness was shown as part of the neurodegenerative process in a range of different neurodegenerative pathologies including alzheimerâ€²s disease (ad), idiopathic parkinsonâ€™s disease (pd), spinocerebellar ataxia (sca) and multiple system atrophy (msa).
advmod||identified-4/VBD||here-1/RB	nsubj||identified-4/VBD||we-3/PRP	root||ROOT-0/null||identified-4/VBD	amod||translocations-6/NNS||recurrent-5/JJ	dobj||identified-4/VBD||translocations-6/NNS	det||/-11/NN||the-8/DT	amod||/-11/NN||multiplemyeloma-9/JJ	amod||/-11/NN||oncogene-1-10/JJ	prep_involving||translocations-6/NNS||/-11/NN	vmod||/-11/NN||interferon-12/VBN	amod||locus-18/NNS||regulatory-13/JJ	amod||locus-18/NNS||factor-4-14/JJ	amod||locus-18/NNS||irf4-16/JJ	dobj||interferon-12/VBN||locus-18/NNS	prep_in||locus-18/NNS||ptcls-20/NNS	multiplemyeloma-9||interferon-12||yes||here, we identified recurrent translocations involving the multiplemyeloma oncogene-1/interferon regulatory factor-4 ( irf4 ) locus in ptcls.
amod||rates-3/NNS||reported-1/VBN	nn||rates-3/NNS||prevalence-2/NN	nsubj||vary-6/VBP||rates-3/NNS	prep_of||rates-3/NNS||ca-mrsa-5/NN	root||ROOT-0/null||vary-6/VBP	advmod||vary-6/VBP||widely-7/RB	prep_among||vary-6/VBP||studies-9/NNS	advmod||vary-6/VBP||largely-11/RB	det||definitions-16/NNS||the-14/DT	amod||definitions-16/NNS||different-15/JJ	prep_because_of||vary-6/VBP||definitions-16/NNS	vmod||definitions-16/NNS||employed-17/VBN	amod||settings-20/NNS||different-19/JJ	prep_because_of||vary-6/VBP||settings-20/NNS	conj_and||definitions-16/NNS||settings-20/NNS	prep_in||performed-27/VBN||settings-20/NNS	det||studies-24/NNS||the-23/DT	nsubjpass||performed-27/VBN||studies-24/NNS	aux||performed-27/VBN||have-25/VBP	auxpass||performed-27/VBN||been-26/VBN	rcmod||settings-20/NNS||performed-27/VBN	mrsa--1||ca--1||no_rel||reported prevalence rates of ca-mrsa vary widely among studies, largely because of the different definitions employed and different settings in which the studies have been performed.
amod||stimulation-2/NN||insulin-induced-1/JJ	nsubjpass||reduced-12/VBN||stimulation-2/NN	amod||uptake-6/NN||hepatic-4/JJ	nn||uptake-6/NN||glucose-5/NN	prep_of||stimulation-2/NN||uptake-6/NN	amod||synthesis-10/NN||hepatic-8/JJ	nn||synthesis-10/NN||glycogen-9/NN	prep_of||stimulation-2/NN||synthesis-10/NN	conj_and||uptake-6/NN||synthesis-10/NN	auxpass||reduced-12/VBN||are-11/VBP	root||ROOT-0/null||reduced-12/VBN	prep_in||reduced-12/VBN||people-14/NNS	amod||presumably-25/NNS||type2diabetes-16/JJ	advmod||presumably-25/NNS||primarily-17/RB	amod||uptake-21/NN||decreased-20/VBN	prep_due_to||presumably-25/NNS||uptake-21/NN	prep_of||uptake-21/NN||extracellular-23/NN	nn||presumably-25/NNS||glucose-24/NN	prep_with||reduced-12/VBN||presumably-25/NNS	amod||activation-29/NN||inadequate-28/JJ	prep_because_of||presumably-25/NNS||activation-29/NN	amod||glucokinase-32/NN||hepatic-31/JJ	prep_of||activation-29/NN||glucokinase-32/NN	type2diabetes-16||glucose-24||no_rel||insulin-induced stimulation of hepatic glucose uptake and hepatic glycogen synthesis are reduced in people with type2diabetes primarily due to decreased uptake of extracellular glucose presumably because of inadequate activation of hepatic glucokinase.
det||research-3/NN||the-1/DT	amod||research-3/NN||proposed-2/VBN	nsubj||seeks-4/VBZ||research-3/NN	nsubj||answer-6/VB||research-3/NN	dep||explain-23/VB||seeks-4/VBZ	aux||answer-6/VB||to-5/TO	xcomp||seeks-4/VBZ||answer-6/VB	det||questions-9/NNS||the-7/DT	amod||questions-9/NNS||following-8/JJ	nsubj||i-10/VBZ||questions-9/NNS	parataxis||answer-6/VB||i-10/VBZ	advmod||assessed-13/VBN||when-12/WRB	advcl||answer-6/VB||assessed-13/VBN	advmod||assessed-13/VBN||systematically-14/RB	aux||explain-23/VB||do-16/VBP	nsubj||explain-23/VB||patients-17/NNS	conj_and||patients-17/NNS||clinicians-20/NNS	nsubj||explain-23/VB||clinicians-20/NNS	dep||patients-17/NNS||preferences-22/NNS	root||ROOT-0/null||explain-23/VB	det||utilization-25/NN||the-24/DT	dobj||explain-23/VB||utilization-25/NN	prep_of||utilization-25/NN||warfarin-27/NN	aux||prevent-29/VB||to-28/TO	vmod||explain-23/VB||prevent-29/VB	dobj||prevent-29/VB||strokes-30/NNS	vmod||strokes-30/NNS||associated-31/VBN	prep_with||associated-31/VBN||atrialfibrillation-33/NN	strokes-30||warfarin-27||yes||the proposed research seeks to answer the following questions i) when assessed systematically, do patients' and clinicians' preferences explain the utilization of warfarin to prevent strokes associated with atrialfibrillation?
det||addition-2/NN||the-1/DT	nsubj||shortens-9/VBZ||addition-2/NN	nsubj||shortens-9/VBZ||addition-2/NN	prep_of||addition-2/NN||acetaminophen-4/NN	aux||lidocaine-6/VB||to-5/TO	vmod||acetaminophen-4/NN||lidocaine-6/VB	prep_for||lidocaine-6/VB||ivra-8/NN	root||ROOT-0/null||shortens-9/VBZ	conj_but||shortens-9/VBZ||shortens-9/VBZ	det||time-12/NN||the-10/DT	nn||time-12/NN||onset-11/NN	dobj||shortens-9/VBZ||time-12/NN	amod||block-15/NN||sensory-14/JJ	prep_of||shortens-9/VBZ||block-15/NN	nn||pain-19/NN||delays-17/NNS	nn||pain-19/NN||tourniquet-18/NN	prep_of||shortens-9/VBZ||pain-19/NN	conj_and||block-15/NN||pain-19/NN	amod||time-21/NN||onset-20/JJ	dep||block-15/NN||time-21/NN	neg||shortens-9/VBZ||not-24/RB	prep_with||shortens-9/VBZ||ketorolac-26/NN	pain-19||lidocaine-6||yes||the addition of acetaminophen to lidocaine for ivra shortens the onset time of sensory block and delays tourniquet pain onset time, but not with ketorolac.
amod||prevalence-2/NN||conflicting-1/VBG	nsubjpass||reported-25/VBN||prevalence-2/NN	advmod||identified-5/JJ||newly-4/RB	amod||ki-6/NN||identified-5/JJ	prep_of||prevalence-2/NN||ki-6/NN	appos||ki-6/NN||kipyv-8/NNP	prep_of||prevalence-2/NN||wu-11/NN	conj_and||ki-6/NN||wu-11/NN	appos||wu-11/NN||wupyv-13/NNP	amod||polyomaviruses-22/NNS||merkel-16/JJ	nn||polyomaviruses-22/NNS||cell-17/NN	nn||polyomaviruses-22/NNS||carcinoma-18/NN	appos||polyomaviruses-22/NNS||mcpyv-20/NNP	prep_of||prevalence-2/NN||polyomaviruses-22/NNS	conj_and||ki-6/NN||polyomaviruses-22/NNS	aux||reported-25/VBN||have-23/VBP	auxpass||reported-25/VBN||been-24/VBN	root||ROOT-0/null||reported-25/VBN	nsubj||ranging-34/VBG||progressivemultifocalleukoencephalopathy-27/NN	appos||progressivemultifocalleukoencephalopathy-27/NN||pml-29/NN	amod||samples-32/NNS||patient-31/JJ	dep||progressivemultifocalleukoencephalopathy-27/NN||samples-32/NNS	prepc_in||reported-25/VBN||ranging-34/VBG	prep_from||ranging-34/VBG||0-36/CD	num||%-39/NN||14.3-38/CD	prep_to||ranging-34/VBG||%-39/NN	pml-29||polyomaviruses-22||no||conflicting prevalence of newly identified ki(kipyv), wu(wupyv) and merkel cell carcinoma(mcpyv) polyomaviruses have been reported in progressivemultifocalleukoencephalopathy(pml) patient samples, ranging from 0 to 14.3%.
det||evidence-4/NN||the-2/DT	amod||evidence-4/NN||previous-3/JJ	prep_with||seems-13/VBZ||evidence-4/NN	prepc_in||evidence-4/NN||influenza-6/VBG	num||viruses-10/NNS||a-7/SYM	conj_and||a-7/SYM||b-9/SYM	num||viruses-10/NNS||b-9/SYM	dobj||influenza-6/VBG||viruses-10/NNS	nsubj||seems-13/VBZ||it-12/PRP	root||ROOT-0/null||seems-13/VBZ	mark||has-17/VBZ||that-14/IN	advmod||recombination-16/NN||homologous-15/RB	nsubj||has-17/VBZ||recombination-16/NN	ccomp||seems-13/VBZ||has-17/VBZ	amod||effect-21/NN||minimal-18/JJ	conj_or||minimal-18/JJ||no-20/DT	amod||effect-21/NN||no-20/DT	dobj||has-17/VBZ||effect-21/NN	amod||evolution-24/NN||influenzavirus-23/JJ	prep_on||effect-21/NN||evolution-24/NN	influenza-6||influenzavirus-23||no||with the previous evidence in influenza a and b viruses, it seems that homologous recombination has minimal or no effect on influenzavirus evolution.
nsubjpass||adopted-7/VBN||artemether/lumefantrine-1/NN	appos||artemether/lumefantrine-1/NN||al-3/NNP	aux||adopted-7/VBN||has-5/VBZ	auxpass||adopted-7/VBN||been-6/VBN	root||ROOT-0/null||adopted-7/VBN	det||treatment-10/NN||the-9/DT	prep_as||adopted-7/VBN||treatment-10/NN	prep_of||treatment-10/NN||choice-12/NN	amod||malaria-15/NN||uncomplicated-14/JJ	prep_for||adopted-7/VBN||malaria-15/NN	prep_in||malaria-15/NN||kenya-17/NN	amod||countries-20/NNS||other-19/JJ	prep_for||adopted-7/VBN||countries-20/NNS	conj_and||malaria-15/NN||countries-20/NNS	det||region-23/NN||the-22/DT	prep_in||countries-20/NNS||region-23/NN	malaria-15||artemether--1||yes||artemether/lumefantrine (al) has been adopted as the treatment of choice for uncomplicated malaria in kenya and other countries in the region.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	advmod||propose-2/VBP||thus-3/RB	mark||glucocorticoid-8/VBD||that-4/IN	nn||compromises-7/NNS||gr-5/NN	nn||compromises-7/NNS||haploinsufficiency-6/NN	nsubj||glucocorticoid-8/VBD||compromises-7/NNS	dep||revealed-22/VBD||glucocorticoid-8/VBD	dobj||glucocorticoid-8/VBD||sensitivity-9/NN	aux||represent-12/VB||may-11/MD	ccomp||propose-2/VBP||represent-12/VB	conj_and||revealed-22/VBD||represent-12/VB	det||cause-16/NN||a-13/DT	amod||cause-16/NN||novel-14/JJ	amod||cause-16/NN||genetic-15/JJ	dobj||represent-12/VB||cause-16/NN	amod||hypercortisolism-19/NN||subclinical-18/JJ	prep_of||cause-16/NN||hypercortisolism-19/NN	advmod||revealed-22/VBD||incidentally-21/RB	ccomp||propose-2/VBP||revealed-22/VBD	amod||adrenalhyperplasia-24/NN||bilateral-23/JJ	dobj||revealed-22/VBD||adrenalhyperplasia-24/NN	amod||hypertension-27/NN||mineralocorticoid-independent-26/JJ	dobj||revealed-22/VBD||hypertension-27/NN	conj_and||adrenalhyperplasia-24/NN||hypertension-27/NN	glucocorticoid-8||adrenalhyperplasia-24||no_rel||we propose thus that gr haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenalhyperplasia and mineralocorticoid-independent hypertension.
nsubj||zoonosis-4/NNS||qfever-1/NN	cop||zoonosis-4/NNS||is-2/VBZ	det||zoonosis-4/NNS||a-3/DT	ccomp||found-14/VBD||zoonosis-4/NNS	vmod||zoonosis-4/NNS||caused-5/VBN	agent||caused-5/VBN||coxiellaburnetii-7/NNS	det||bacterium-12/NN||an-9/DT	amod||bacterium-12/NN||obligate-10/JJ	nn||bacterium-12/NN||intracellular-11/NN	nsubj||found-14/VBD||bacterium-12/NN	advmod||found-14/VBD||typically-13/RB	root||ROOT-0/null||found-14/VBD	amod||cells-17/NNS||myeloid-16/JJ	prep_in||found-14/VBD||cells-17/NNS	qfever-1||coxiellaburnetii-7||no||qfever is a zoonosis caused by coxiellaburnetii , an obligate intracellular bacterium typically found in myeloid cells.
nsubj||generated-2/VBD||we-1/PRP	root||ROOT-0/null||generated-2/VBD	iobj||generated-2/VBD||seven-3/CD	advmod||stable-5/JJ||genetically-4/RB	amod||clade-7/NN||stable-5/JJ	amod||clade-7/NN||recombinant-6/JJ	iobj||generated-2/VBD||clade-7/NN	number||a/turkey/15-9/CD||2.2-8/CD	num||/-10/NNS||a/turkey/15-9/CD	iobj||generated-2/VBD||/-10/NNS	amod||influenzaviruses-15/NNS||06-like-11/JJ	appos||influenzaviruses-15/NNS||h5n1-13/NNP	dobj||generated-2/VBD||influenzaviruses-15/NNS	xcomp||generated-2/VBD||carrying-16/VBG	aux||mutations-18/VB||na-17/TO	xcomp||carrying-16/VBG||mutations-18/VB	dep||mutations-18/VB||located-19/VBN	preconj||located-19/VBN||either-20/CC	det||residues-24/NNS||the-22/DT	nn||residues-24/NNS||framework-23/NN	prep_in||located-19/VBN||residues-24/NNS	dep||residues-24/NNS||e119a-26/NNS	appos||e119a-26/NNS||h274y-28/NNS	appos||e119a-26/NNS||n294s-30/NNS	advmod||proximity-35/RB||close-34/RB	amod||site-41/NN||proximity-35/RB	det||enzyme-39/NN||the-37/DT	amod||enzyme-39/NN||na-38/JJ	prep_to||proximity-35/RB||enzyme-39/NN	amod||site-41/NN||active-40/JJ	prep_in||located-19/VBN||site-41/NN	conj_or||residues-24/NNS||site-41/NN	dep||site-41/NN||v116a-43/NNS	appos||v116a-43/NNS||i117v-45/NNS	appos||v116a-43/NNS||k150n-47/NNS	appos||v116a-43/NNS||y252h-49/NNS	h5n1-13||influenzaviruses-15||no||we generated seven genetically stable recombinant clade 2.2 a/turkey/15/06-like (h5n1) influenzaviruses carrying na mutations located either in the framework residues (e119a, h274y, n294s) or in close proximity to the na enzyme active site (v116a, i117v, k150n, y252h).
prep_in||demonstrated-17/VBD||type1diabetes-2/CD	prepc_compared_with||demonstrated-17/VBD||with-5/IN	pobj||demonstrated-17/VBD||insulinglargine-6/NN	nsubj||demonstrated-17/VBD||ly2605541-8/NNS	nsubj||lowered-39/VBD||ly2605541-8/NNS	det||novel-11/NN||a-10/DT	appos||ly2605541-8/NNS||novel-11/NN	amod||insulin-15/NN||long-acting-13/JJ	amod||insulin-15/NN||basal-14/JJ	appos||novel-11/NN||insulin-15/NN	root||ROOT-0/null||demonstrated-17/VBD	amod||improvements-19/NNS||greater-18/JJR	dobj||demonstrated-17/VBD||improvements-19/NNS	amod||control-22/NN||glycemic-21/JJ	prep_in||demonstrated-17/VBD||control-22/NN	amod||hypoglycemia-26/NN||increased-24/VBN	amod||hypoglycemia-26/NN||total-25/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-26/NN	conj_and||control-22/NN||hypoglycemia-26/NN	amod||hypoglycemia-31/NN||reduced-29/VBN	amod||hypoglycemia-31/NN||nocturnal-30/JJ	prep_in||demonstrated-17/VBD||hypoglycemia-31/NN	conj_and||control-22/NN||hypoglycemia-31/NN	amod||weight-37/NN||reduced-36/VBN	prep_in||demonstrated-17/VBD||weight-37/NN	conj_and||control-22/NN||weight-37/NN	conj_and||demonstrated-17/VBD||lowered-39/VBD	amod||doses-42/NNS||mealtime-40/JJ	nn||doses-42/NNS||insulin-41/NN	dobj||lowered-39/VBD||doses-42/NNS	type1diabetes-2||insulin-41||yes||in type1diabetes, compared with insulinglargine, ly2605541, a novel, long-acting basal insulin, demonstrated greater improvements in glycemic control, increased total hypoglycemia, and reduced nocturnal hypoglycemia, as well as reduced weight and lowered mealtime insulin doses.
det||patient-3/NN||each-2/DT	prep_in||graded-12/JJ||patient-3/NN	nsubj||graded-12/JJ||pain-5/NN	nsubj||mild-16/JJ||pain-5/NN	nsubj||moderate-18/JJ||pain-5/NN	nsubj||severe-21/JJ||pain-5/NN	amod||injection-10/NN||microemulsion-7/JJ	amod||injection-10/NN||propofol-8/JJ	nn||injection-10/NN||solution-9/NN	prep_on||pain-5/NN||injection-10/NN	cop||graded-12/JJ||was-11/VBD	root||ROOT-0/null||graded-12/JJ	prep_as||graded-12/JJ||none-14/NN	conj_or||graded-12/JJ||mild-16/JJ	conj_or||graded-12/JJ||moderate-18/JJ	conj_or||graded-12/JJ||severe-21/JJ	pain-5||propofol-8||yes||in each patient, pain on microemulsion propofol solution injection was graded as none, mild, moderate, or severe.
det||response-4/NN||an-1/DT	amod||response-4/NN||early-2/JJ	amod||response-4/NN||virological-3/JJ	nsubj||leads-19/VBZ||response-4/NN	appos||response-4/NN||evr-6/NN	det||start-10/NN||the-9/DT	prep_after||response-4/NN||start-10/NN	amod||treatment-16/NN||interferon-12/JJ	appos||treatment-16/NN||ifn-14/NN	prep_of||start-10/NN||treatment-16/NN	prep_for||treatment-16/NN||chronichepatitisc-18/NN	root||ROOT-0/null||leads-19/VBZ	det||outcome-24/NN||a-21/DT	amod||outcome-24/NN||successful-22/JJ	amod||outcome-24/NN||virological-23/JJ	prep_to||leads-19/VBZ||outcome-24/NN	chronichepatitisc-18||interferon-12||yes||an early virological response (evr) after the start of interferon (ifn) treatment for chronichepatitisc leads to a successful virological outcome.
advmod||shown-5/VBN||hiv-1/RB	nsubjpass||shown-5/VBN||itself-2/PRP	aux||shown-5/VBN||has-3/VBZ	auxpass||shown-5/VBN||been-4/VBN	root||ROOT-0/null||shown-5/VBN	aux||increase-7/VB||to-6/TO	ccomp||shown-5/VBN||increase-7/VB	dobj||increase-7/VB||lipogenesis-8/NNS	det||liver-11/NN||the-10/DT	prep_in||increase-7/VB||liver-11/NN	aux||alter-14/VB||to-13/TO	ccomp||shown-5/VBN||alter-14/VB	conj_and||increase-7/VB||alter-14/VB	det||profile-17/NN||the-15/DT	nn||profile-17/NN||lipid-16/NN	dobj||alter-14/VB||profile-17/NN	mark||increases-33/VBZ||while-19/IN	det||presence-21/NN||the-20/DT	nsubj||increases-33/VBZ||presence-21/NN	amod||habits-24/NNS||unsafe-23/JJ	prep_of||presence-21/NN||habits-24/NNS	prep_of||presence-21/NN||addiction-26/NN	conj_and||habits-24/NNS||addiction-26/NN	prep_of||presence-21/NN||comorbidities-28/NNS	conj_and||habits-24/NNS||comorbidities-28/NNS	amod||diseases-32/NNS||aids-related-31/JJ	prep_of||presence-21/NN||diseases-32/NNS	conj_and||habits-24/NNS||diseases-32/NNS	advcl||shown-5/VBN||increases-33/VBZ	advmod||increases-33/VBZ||substantially-34/RB	det||risk-36/NN||the-35/DT	dobj||increases-33/VBZ||risk-36/NN	prep_of||risk-36/NN||cardiovasculardisease-38/NN	appos||cardiovasculardisease-38/NN||cvd-40/NN	det||population-45/NN||the-43/DT	amod||population-45/NN||hiv-infected-44/JJ	prep_in||cardiovasculardisease-38/NN||population-45/NN	aids--1||hiv-1||no||hiv itself has been shown to increase lipogenesis in the liver and to alter the lipid profile, while the presence of unsafe habits, addiction, comorbidities, and aids-related diseases increases substantially the risk of cardiovasculardisease (cvd) in the hiv-infected population.
det||article-2/NN||this-1/DT	nsubj||focuses-3/VBZ||article-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||determination-6/NN||the-5/DT	prep_on||focuses-3/VBZ||determination-6/NN	nn||species-9/NNS||arsenic-8/NN	prep_of||determination-6/NN||species-9/NNS	nn||samples-12/NNS||saliva-11/NN	prep_in||species-9/NNS||samples-12/NNS	nn||patients-15/NNS||apl-14/NN	prep_from||focuses-3/VBZ||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	nn||treatment-18/NN||arsenic-17/NN	dobj||undergoing-16/VBG||treatment-18/NN	apl-14||arsenic-17||yes||this article focuses on the determination of arsenic species in saliva samples from apl patients undergoing arsenic treatment.
amod||evidence-2/NN||more-1/JJR	nsubjpass||needed-4/VBN||evidence-2/NN	auxpass||needed-4/VBN||is-3/VBZ	root||ROOT-0/null||needed-4/VBN	det||safety-7/NN||the-6/DT	prep_on||needed-4/VBN||safety-7/NN	prep_of||safety-7/NN||primaquine-9/NN	advmod||administered-11/VBN||when-10/WRB	advcl||needed-4/VBN||administered-11/VBN	prepc_without||administered-11/VBN||screening-13/VBG	prep_for||screening-13/VBG||g6pddeficiency-15/CD	aux||inform-17/VB||to-16/TO	xcomp||screening-13/VBG||inform-17/VB	amod||approaches-22/NNS||individual-18/JJ	conj_and||individual-18/JJ||mass-20/JJ	amod||approaches-22/NNS||mass-20/JJ	nn||approaches-22/NNS||treatment-21/NN	dobj||inform-17/VB||approaches-22/NNS	det||context-25/NN||the-24/DT	prep_in||approaches-22/NNS||context-25/NN	nn||programmes-29/NNS||malaria-27/NN	nn||programmes-29/NNS||elimination-28/NN	prep_of||context-25/NN||programmes-29/NNS	malaria-27||primaquine-9||yes||more evidence is needed on the safety of primaquine when administered without screening for g6pddeficiency to inform individual and mass treatment approaches in the context of malaria elimination programmes.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	nn||samples-4/NNS||ebc-3/NN	dobj||collected-2/VBD||samples-4/NNS	prep_from||collected-2/VBD||children-6/NNS	prep_from||collected-2/VBD||adolescents-8/NNS	conj_and||children-6/NNS||adolescents-8/NNS	prep_including||collected-2/VBD||38-11/CD	amod||asthma-14/NN||severe-13/JJ	prep_with||38-11/CD||asthma-14/NN	prep_with||38-11/CD||46-16/CD	conj_and||asthma-14/NN||46-16/CD	amod||asthma-19/NN||mild-to-moderate-18/JJ	prep_with||46-16/CD||asthma-19/NN	num||controls-24/NNS||16-21/CD	amod||controls-24/NNS||healthy-22/JJ	amod||controls-24/NNS||adolescent-23/JJ	prep_with||38-11/CD||controls-24/NNS	conj_and||asthma-14/NN||controls-24/NNS	det||concentration-28/NN||the-27/DT	nsubjpass||quantified-33/VBN||concentration-28/NN	amod||constituents-31/NNS||ionic-30/JJ	prep_of||concentration-28/NN||constituents-31/NNS	auxpass||quantified-33/VBN||was-32/VBD	conj_and||collected-2/VBD||quantified-33/VBN	xcomp||quantified-33/VBN||using-34/VBG	nn||chromatography-36/NN||ion-35/NN	dobj||using-34/VBG||chromatography-36/NN	ion-35||asthma-19||no_rel||we collected ebc samples from children and adolescents, including 38 with severe asthma, 46 with mild-to-moderate asthma and 16 healthy adolescent controls, and the concentration of ionic constituents was quantified using ion chromatography.
det||genotype-4/NN||the-1/DT	amod||genotype-4/NN||rs707922-2/JJ	nn||genotype-4/NN||tt-3/NN	nsubjpass||associated-7/VBN||genotype-4/NN	auxpass||associated-7/VBN||was-5/VBD	advmod||associated-7/VBN||significantly-6/RB	root||ROOT-0/null||associated-7/VBN	amod||plasma-10/NN||elevated-9/JJ	prep_with||associated-7/VBN||plasma-10/NN	amod||levels-17/NNS||total-11/JJ	conj_and||total-11/JJ||ldl-14/JJ	amod||levels-17/NNS||ldl-14/JJ	nn||levels-17/NNS||cholesterol-16/NN	dep||plasma-10/NN||levels-17/NNS	dep||plasma-10/NN||pâ-19/VBN	dobj||pâ-19/VBN||$-20/$	number||=-22/CD||š-21/CD	num||$-20/$||=-22/CD	dep||pâ-19/VBN||â-23/VB	dobj||â-23/VB||$-24/$	num||$-24/$||š0-25/CD	num||$-24/$||.006-26/CD	dep||pâ-19/VBN||pâ-28/VB	conj_and||â-23/VB||pâ-28/VB	dobj||pâ-28/VB||$-29/$	number||=-31/CD||š-30/CD	num||$-29/$||=-31/CD	dep||pâ-28/VB||â-32/VB	dobj||â-32/VB||$-33/$	number||.009-35/CD||š0-34/CD	num||$-33/$||.009-35/CD	advmod||$-33/$||respectively-37/RB	amod||patients-41/NNS||t2d-40/JJ	prep_in||plasma-10/NN||patients-41/NNS	t2d-40||cholesterol-16||no_rel||the rs707922 tt genotype was significantly associated with elevated plasma total- and ldl- cholesterol levels (pâ€š=â€š0.006 and pâ€š=â€š0.009, respectively) in t2d patients.
nn||studies-2/NNS||animal-1/NN	nsubj||report-3/VBP||studies-2/NNS	root||ROOT-0/null||report-3/VBP	mark||observed-50/VBN||that-4/IN	amod||changes-6/NNS||persistent-5/JJ	nsubjpass||observed-50/VBN||changes-6/NNS	amod||e.g.-12/NNP||nociception-associated-8/JJ	amod||e.g.-12/NNP||molecular-9/JJ	nn||e.g.-12/NNP||expression-10/NN	nn||e.g.-12/NNP||-lrb--11/NNP	prep_including||changes-6/NNS||e.g.-12/NNP	amod||-rrb--18/NN||neurokinin-1-13/JJ	advmod||nk-1-15/JJ||-lrb--14/RB	amod||-rrb--18/NN||nk-1-15/JJ	nn||-rrb--18/NN||-rrb--16/NN	nn||-rrb--18/NN||receptors-17/NNS	dep||e.g.-12/NNP||-rrb--18/NN	prep_including||changes-6/NNS||activation-20/NN	conj_and||e.g.-12/NNP||activation-20/NN	nn||-lrb--25/NNS||signal-22/NN	nn||-lrb--25/NNS||transduction-23/NN	nn||-lrb--25/NNS||cascades-24/NN	prep_of||activation-20/NN||-lrb--25/NNS	det||kinase-30/NN||the-28/DT	nn||kinase-30/NN||protein-29/NN	prep_such_as||activation-20/NN||kinase-30/NN	det||-rsb--34/NN||a-31/DT	amod||-rsb--34/NN||-lsb--32/JJ	nn||-rsb--34/NN||pka-33/NN	dep||kinase-30/NN||-rsb--34/NN	amod||-rrb--43/NNS||c-amp-responsive-36/JJ	nn||-rrb--43/NNS||element-37/NN	amod||-rrb--43/NNS||binding-38/JJ	amod||-rrb--43/NNS||-lsb--39/JJ	amod||-rrb--43/NNS||creb-40/JJ	amod||-rrb--43/NNS||-rsb--41/JJ	nn||-rrb--43/NNS||cascade-42/NN	dep||activation-20/NN||-rrb--43/NNS	amod||neurons-48/NNS||spinal-46/JJ	amod||neurons-48/NNS||psdc-47/JJ	prep_in||activation-20/NN||neurons-48/NNS	auxpass||observed-50/VBN||are-49/VBP	ccomp||report-3/VBP||observed-50/VBN	amod||stimulation-54/NN||visceral-52/JJ	nn||stimulation-54/NN||pain-53/NN	prep_following||observed-50/VBN||stimulation-54/NN	pain-53||amp--1||no_rel||animal studies report that persistent changes including nociception-associated molecular expression -lrb- e.g. neurokinin-1 -lrb- nk-1 -rrb- receptors -rrb- and activation of signal transduction cascades -lrb- such as the protein kinase a -lsb- pka -rsb- - c-amp-responsive element binding -lsb- creb -rsb- cascade -rrb- - in spinal psdc neurons are observed following visceral pain stimulation .
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	nsubj||is-2/VBZ||evidence-3/NN	mark||participate-9/VB||that-4/IN	amod||women-6/NNS||hiv-positive-5/JJ	nsubj||participate-9/VB||women-6/NNS	aux||participate-9/VB||do-7/VBP	neg||participate-9/VB||not-8/RB	ccomp||is-2/VBZ||participate-9/VB	advmod||participate-9/VB||sufficiently-10/RB	amod||screening-14/NN||cervical-12/JJ	nn||screening-14/NN||cancer-13/NN	prep_in||sufficiently-10/RB||screening-14/NN	prep_in||participate-9/VB||italy-16/NN	advmod||higher-25/JJR||where-18/WRB	amod||cancer-20/NN||cervical-19/JJ	nsubj||higher-25/JJR||cancer-20/NN	cop||higher-25/JJR||is-21/VBZ	mwe||than-23/IN||more-22/JJR	quantmod||10-fold-24/CD||than-23/IN	npadvmod||higher-25/JJR||10-fold-24/CD	advcl||is-2/VBZ||higher-25/JJR	prep_in||higher-25/JJR||women-27/NNS	prep_with||women-27/NNS||aids-29/NNS	prep||higher-25/JJR||than-30/IN	pcomp||than-30/IN||in-31/IN	det||population-34/NN||the-32/DT	amod||population-34/NN||general-33/JJ	pobj||in-31/IN||population-34/NN	aids-29||hiv--1||no||there is evidence that hiv-positive women do not participate sufficiently in cervical cancer screening in italy, where cervical cancer is more than 10-fold higher in women with aids than in the general population.
amod||studies-2/NNS||further-1/JJ	nsubjpass||required-4/VBN||studies-2/NNS	nsubj||define-6/VB||studies-2/NNS	auxpass||required-4/VBN||are-3/VBP	root||ROOT-0/null||required-4/VBN	aux||define-6/VB||to-5/TO	xcomp||required-4/VBN||define-6/VB	amod||strategies-8/NNS||setting-specific-7/JJ	dobj||define-6/VB||strategies-8/NNS	aux||reduce-10/VB||to-9/TO	dep||define-6/VB||reduce-10/VB	dobj||reduce-10/VB||mortality-11/NN	amod||bacteraemia-14/NN||s.aureus-13/JJ	prep_from||reduce-10/VB||bacteraemia-14/NN	dep||reduce-10/VB||prevent-16/VB	nn||transmission-18/NN||mrsa-17/NN	dobj||prevent-16/VB||transmission-18/NN	aux||define-22/VB||to-21/TO	dep||define-6/VB||define-22/VB	conj_and||reduce-10/VB||define-22/VB	det||burden-24/NN||the-23/DT	dobj||define-22/VB||burden-24/NN	nn||disease-27/NN||s.aureus-26/NNS	prep_of||burden-24/NN||disease-27/NN	prep_of||burden-24/NN||emergence-29/NN	conj_and||disease-27/NN||emergence-29/NN	nn||resistance-32/NN||drug-31/NN	prep_of||disease-27/NN||resistance-32/NN	det||world-36/NN||the-34/DT	amod||world-36/NN||developing-35/VBG	prep_throughout||define-22/VB||world-36/NN	mrsa-17||s.aureus-26||no||further studies are required to define setting-specific strategies to reduce mortality from s.aureus bacteraemia , prevent mrsa transmission , and to define the burden of s.aureus disease and emergence of drug resistance throughout the developing world .
amod||patients-2/NNS||forty-eight-1/JJ	nsubjpass||enrolled-18/VBN||patients-2/NNS	nsubjpass||treated-24/VBN||patients-2/NNS	nn||ve-6/NNP||chemo-naã-4/NNP	nn||ve-6/NNP||¯-5/NNP	prep_with||patients-2/NNS||ve-6/NNP	advmod||confirmed-9/VBN||histologically-8/RB	vmod||ve-6/NNP||confirmed-9/VBN	advmod||ve-6/NNP||locally-11/RB	amod||cancer-16/NN||advanced-12/VBN	conj_or||advanced-12/VBN||metastatic-14/JJ	amod||cancer-16/NN||metastatic-14/JJ	amod||cancer-16/NN||gastric-15/JJ	dep||ve-6/NNP||cancer-16/NN	auxpass||enrolled-18/VBN||were-17/VBD	root||ROOT-0/null||enrolled-18/VBN	det||study-21/NN||the-20/DT	prep_for||enrolled-18/VBN||study-21/NN	auxpass||treated-24/VBN||were-23/VBD	conj_and||enrolled-18/VBN||treated-24/VBN	nn||chemotherapy-27/NN||combination-26/NN	prep_with||treated-24/VBN||chemotherapy-27/NN	amod||mg/m2-31/NNS||paclitaxel-29/JJ	dep||paclitaxel-29/JJ||175-30/CD	prep_of||chemotherapy-27/NN||mg/m2-31/NNS	prep_of||chemotherapy-27/NN||cisplatin-33/NN	conj_and||mg/m2-31/NNS||cisplatin-33/NN	num||mg/m2-35/NNS||75-34/CD	dobj||enrolled-18/VBN||mg/m2-35/NNS	prep_for||enrolled-18/VBN||maximum-37/NN	num||cycles-40/NNS||six-39/CD	prep_of||maximum-37/NN||cycles-40/NNS	prepc_after||enrolled-18/VBN||obtaining-42/VBG	dobj||obtaining-42/VBG||specimen-43/NN	prep_for||obtaining-42/VBG||atp-cra-45/NN	cancer-16||paclitaxel-29||no_rel||forty-eight patients with chemo-naã¯ve, histologically confirmed, locally advanced or metastatic gastric cancer were enrolled for the study and were treated with combination chemotherapy of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2 for maximum of six cycles after obtaining specimen for atp-cra.
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||role-4/NN||the-3/DT	dobj||review-2/VB||role-4/NN	prep_of||role-4/NN||tmz-6/NN	det||management-9/NN||the-8/DT	prep_in||review-2/VB||management-9/NN	amod||astrocytomas-12/NNS||malignant-11/JJ	prep_of||management-9/NN||astrocytomas-12/NNS	nn||grades-17/NNS||world-14/NN	nn||grades-17/NNS||health-15/NN	nn||grades-17/NNS||organization-16/NN	nsubj||iii-18/VBP||grades-17/NNS	nsubj||iv-20/VBP||grades-17/NNS	dep||management-9/NN||iii-18/VBP	dep||management-9/NN||iv-20/VBP	conj_and||iii-18/VBP||iv-20/VBP	advmod||diagnosed-24/JJ||newly-23/RB	amod||astrocytomas-34/NNS||diagnosed-24/JJ	dep||diagnosed-24/JJ||n-26/NN	conj_and||diagnosed-24/JJ||recurrent-29/JJ	amod||astrocytomas-34/NNS||recurrent-29/JJ	dep||recurrent-29/JJ||r-31/NN	amod||astrocytomas-34/NNS||anaplastic-33/JJ	prep_including||management-9/NN||astrocytomas-34/NNS	appos||astrocytomas-34/NNS||aa-36/NN	prep_including||management-9/NN||glioblastomas-39/NNS	conj_and||astrocytomas-34/NNS||glioblastomas-39/NNS	astrocytomas-34||tmz-6||yes||to review the role of tmz in the management of malignant astrocytomas (world health organization grades iii and iv) including newly diagnosed (n) and recurrent (r) anaplastic astrocytomas (aa) and glioblastomas.
nn||options-2/NNS||treatment-1/NN	nsubj||better-12/JJR||options-2/NNS	prep_for||options-2/NNS||women-4/NNS	amod||cancer-8/NN||early-stage-6/JJ	nn||cancer-8/NN||breast-7/NN	prep_with||women-4/NNS||cancer-8/NN	aux||better-12/JJR||have-9/VBP	neg||better-12/JJR||never-10/RB	cop||better-12/JJR||been-11/VBN	root||ROOT-0/null||better-12/JJR	det||addition-16/NN||the-15/DT	nsubj||tool-26/NN||addition-16/NN	prep_of||addition-16/NN||bisphosphonates-18/NNS	amod||therapy-21/NN||adjuvant-20/JJ	prep_to||bisphosphonates-18/NNS||therapy-21/NN	cop||tool-26/NN||is-22/VBZ	det||tool-26/NN||a-23/DT	amod||tool-26/NN||valuable-24/JJ	amod||tool-26/NN||new-25/JJ	conj_and||better-12/JJR||tool-26/NN	amod||tool-26/NN||capable-27/JJ	advmod||improving-30/VBG||substantially-29/RB	amod||outcomes-32/NNS||improving-30/VBG	amod||outcomes-32/NNS||clinical-31/JJ	prep_of||capable-27/JJ||outcomes-32/NNS	det||women-35/NNS||these-34/DT	prep_for||outcomes-32/NNS||women-35/NNS	cancer-8||adjuvant-20||no_rel||treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women.
quantmod||52.6-3/CD||total-2/JJ	num||%-4/NN||52.6-3/CD	prep_in||positive-12/JJ||%-4/NN	appos||%-4/NN||2409/4584-6/CD	det||samples-10/NNS||the-9/DT	prep_of||%-4/NN||samples-10/NNS	cop||positive-12/JJ||were-11/VBD	root||ROOT-0/null||positive-12/JJ	prep_for||positive-12/JJ||influenzavirus-14/NNS	num||%-16/NN||64-15/CD	nsubj||positive-12/JJ||%-16/NN	appos||%-16/NN||2066/3212-18/CD	cc||25-22/CD||and-21/CC	num||%-23/NN||25-22/CD	prep_during||%-16/NN||%-23/NN	appos||%-16/NN||343/1372-25/CD	vmod||%-16/NN||pre/post-27/VBG	det||epidemic-30/NN||an-28/DT	nn||epidemic-30/NN||influenza-29/NN	dobj||pre/post-27/VBG||epidemic-30/NN	influenza-29||influenzavirus-14||no||in total 52.6% (2409/4584) of the samples were positive for influenzavirus 64% (2066/3212) during and 25% (343/1372) pre/post an influenza epidemic.
amod||studies-4/NNS||previous-1/JJ	amod||studies-4/NNS||genome-wide-2/JJ	nn||studies-4/NNS||association-3/NN	nsubj||confirmed-10/VBN||studies-4/NNS	amod||genes-8/NNS||type2diabetes-6/JJ	nn||genes-8/NNS||susceptibility-7/NN	prep_for||studies-4/NNS||genes-8/NNS	aux||confirmed-10/VBN||have-9/VBP	root||ROOT-0/null||confirmed-10/VBN	mark||associated-31/VBN||that-11/IN	det||variant-14/NN||a-12/DT	amod||variant-14/NN||common-13/JJ	nsubjpass||associated-31/VBN||variant-14/NN	appos||variant-14/NN||rs9939609-16/NNS	det||mass-21/NN||the-19/DT	amod||mass-21/NN||fat-20/JJ	prep_in||variant-14/NN||mass-21/NN	advmod||region-29/NN||obesity-23/RB	amod||region-29/NN||associated-24/JJ	appos||region-29/NN||fto-26/NN	nn||region-29/NN||gene-28/NN	prep_in||variant-14/NN||region-29/NN	conj_and||mass-21/NN||region-29/NN	auxpass||associated-31/VBN||is-30/VBZ	ccomp||confirmed-10/VBN||associated-31/VBN	nn||index-35/NN||body-33/NN	nn||index-35/NN||mass-34/NN	prep_with||associated-31/VBN||index-35/NN	appos||index-35/NN||bmi-37/NN	nn||children-41/NNS||european-40/NN	prep_in||index-35/NN||children-41/NNS	prep_in||index-35/NN||adults-43/NNS	conj_and||children-41/NNS||adults-43/NNS	type2diabetes-6||fat-20||no_rel||previous genome-wide association studies for type2diabetes susceptibility genes have confirmed that a common variant, rs9939609, in the fat mass and obesity associated ( fto ) gene region is associated with body mass index (bmi) in european children and adults.
amod||dna-2/NN||francisellatularensis-1/JJ	nsubjpass||found-4/VBN||dna-2/NN	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	det||biopsy-8/NN||the-6/DT	nn||biopsy-8/NN||skin-7/NN	prep_in||found-4/VBN||biopsy-8/NN	det||serology-11/NN||the-10/DT	nsubj||showed-12/VBD||serology-11/NN	conj_and||found-4/VBN||showed-12/VBD	nsubj||consistent-14/JJ||titres-13/NNS	xcomp||showed-12/VBD||consistent-14/JJ	prep_with||consistent-14/JJ||tularaemia-16/NN	tularaemia-16||francisellatularensis-1||no||francisellatularensis dna was found in the skin biopsy and the serology showed titres consistent with tularaemia.
advmod||enteroviruses-4/NNS||only-1/RB	num||enteroviruses-4/NNS||three-2/CD	amod||enteroviruses-4/NNS||other-3/JJ	nsubjpass||detected-18/VBN||enteroviruses-4/NNS	advmod||enteroviruses-4/NNS||namely-6/RB	conj_and||enteroviruses-4/NNS||namely-6/RB	nsubjpass||detected-18/VBN||namely-6/RB	amod||b4-9/NNS||coxsackievirus-7/JJ	nn||b4-9/NNS||type-8/NN	dep||enteroviruses-4/NNS||b4-9/NNS	amod||b5-13/NNS||coxsackievirus-11/JJ	nn||b5-13/NNS||type-12/NN	conj_and||enteroviruses-4/NNS||b5-13/NNS	nsubjpass||detected-18/VBN||b5-13/NNS	conj_and||enteroviruses-4/NNS||enterovirus-15/NNS	nsubjpass||detected-18/VBN||enterovirus-15/NNS	num||enterovirus-15/NNS||71-16/CD	auxpass||detected-18/VBN||were-17/VBD	root||ROOT-0/null||detected-18/VBN	advmod||cases-21/NNS||am-20/RB	prep_among||detected-18/VBN||cases-21/NNS	prep_in||cases-21/NNS||kuwait-23/NN	enterovirus-15||enteroviruses-4||no||only three other enteroviruses, namely coxsackievirus type b4, coxsackievirus type b5 and enterovirus 71 were detected among am cases in kuwait.
root||ROOT-0/null||objective-1/NN	aux||determine-3/VB||to-2/TO	dep||objective-1/NN||determine-3/VB	dep||objective-1/NN||determine-3/VB	conj_and||determine-3/VB||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||glucosamine-7/NN	prep_of||effect-5/NN||chondroitin-9/NN	conj_or||glucosamine-7/NN||chondroitin-9/NN	det||two-13/CD||the-12/DT	prep_of||effect-5/NN||two-13/CD	conj_or||glucosamine-7/NN||two-13/CD	prep_in||determine-3/VB||combination-15/NN	amod||pain-18/NN||joint-17/JJ	prep_on||combination-15/NN||pain-18/NN	amod||progression-22/NN||radiological-21/JJ	prep_on||determine-3/VB||progression-22/NN	prep_of||progression-22/NN||disease-24/NN	prep_in||determine-3/VB||osteoarthritis-26/NNS	det||hip-29/NN||the-28/DT	prep_of||osteoarthritis-26/NNS||hip-29/NN	prep_of||osteoarthritis-26/NNS||knee-31/NN	conj_or||hip-29/NN||knee-31/NN	osteoarthritis-26||glucosamine-7||yes||objective to determine the effect of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in osteoarthritis of the hip or knee.
amod||toxin-3/NN||bacillusanthracis-1/JJ	amod||toxin-3/NN||lethal-2/JJ	nsubj||factor-11/NN||toxin-3/NN	nsubj||contributes-15/VBZ||toxin-3/NN	appos||toxin-3/NN||lt-5/NN	cop||factor-11/NN||is-7/VBZ	det||factor-11/NN||a-8/DT	amod||factor-11/NN||key-9/JJ	nn||factor-11/NN||virulence-10/NN	root||ROOT-0/null||factor-11/NN	prep_of||factor-11/NN||anthrax-13/NN	conj_and||factor-11/NN||contributes-15/VBZ	advmod||contributes-15/VBZ||significantly-16/RB	det||pathology-21/NN||the-18/DT	advmod||pathology-21/NN||in-19/RB	amod||pathology-21/NN||vivo-20/JJ	prep_to||contributes-15/VBZ||pathology-21/NN	anthrax-13||bacillusanthracis-1||no||bacillusanthracis lethal toxin (lt) is a key virulence factor of anthrax and contributes significantly to the in vivo pathology.
det||fraction-5/NN||the-1/DT	amod||fraction-5/NN||ethyl-2/JJ	amod||fraction-5/NN||acetate-3/JJ	amod||fraction-5/NN||soluble-4/JJ	nsubj||sinensis-12/VBZ||fraction-5/NN	det||extract-9/NN||the-7/DT	nn||extract-9/NN||methanol-8/NN	prep_of||fraction-5/NN||extract-9/NN	prep_of||extract-9/NN||h.-11/NN	root||ROOT-0/null||sinensis-12/VBZ	amod||-rrb--15/NNS||-lrb--13/JJ	nn||-rrb--15/NNS||easf-14/NN	nsubj||attenuated-16/VBD||-rrb--15/NNS	ccomp||sinensis-12/VBZ||attenuated-16/VBD	dobj||attenuated-16/VBD||amnesia-17/NN	vmod||amnesia-17/NN||induced-18/VBN	agent||induced-18/VBN||scopolamine-20/NN	agent||induced-18/VBN||aging-22/NN	conj_and||scopolamine-20/NN||aging-22/NN	amnesia-17||scopolamine-20||no||the ethyl acetate soluble fraction of the methanol extract of h. sinensis -lrb- easf -rrb- attenuated amnesia induced by scopolamine and aging .
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
nsubjpass||characterized-6/VBN||type2diabetesmellitus-1/NNS	nsubjpass||accompanied-23/VBN||type2diabetesmellitus-1/NNS	appos||type2diabetesmellitus-1/NNS||t2dm-3/NNP	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	agent||characterized-6/VBN||defects-8/NNS	preconj||sensitivity-12/NN||both-10/DT	nn||sensitivity-12/NN||insulin-11/NN	prep_in||defects-8/NNS||sensitivity-12/NN	amod||secretion-16/NN||glucose-stimulated-14/JJ	nn||secretion-16/NN||insulin-15/NN	prep_in||defects-8/NNS||secretion-16/NN	conj_and||sensitivity-12/NN||secretion-16/NN	appos||sensitivity-12/NN||gsis-18/NNS	auxpass||accompanied-23/VBN||is-21/VBZ	advmod||accompanied-23/VBN||often-22/RB	conj_and||characterized-6/VBN||accompanied-23/VBN	agent||accompanied-23/VBN||obesity-25/NN	type2diabetesmellitus-1||insulin-15||yes||type2diabetesmellitus (t2dm) is characterized by defects in both insulin sensitivity and glucose-stimulated insulin secretion (gsis) and is often accompanied by obesity.
nsubjpass||diagnosed-4/VBN||calciphylaxis-1/NNS	aux||diagnosed-4/VBN||has-2/VBZ	auxpass||diagnosed-4/VBN||been-3/VBN	root||ROOT-0/null||diagnosed-4/VBN	prepc_after||diagnosed-4/VBN||receiving-6/VBG	dobj||receiving-6/VBG||anticoagulation-7/NN	prep_with||receiving-6/VBG||phenprocoumon-9/NN	det||event-13/NN||a-11/DT	amod||event-13/NN||single-12/JJ	prep_after||receiving-6/VBG||event-13/NN	prep_of||event-13/NN||pulmonaryembolism-15/NN	pulmonaryembolism-15||phenprocoumon-9||yes||calciphylaxis has been diagnosed after receiving anticoagulation with phenprocoumon after a single event of pulmonaryembolism.
nn||identification-2/NN||species-1/NN	nsubj||seems-12/VBZ||identification-2/NN	nsubj||important-15/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--11/NN||the-7/DT	amod||-rrb--11/NN||mycobacteriumtuberculosiscomplex-8/JJ	amod||-rrb--11/NN||-lrb--9/JJ	nn||-rrb--11/NN||mtc-10/NN	prep_to||belonging-5/VBG||-rrb--11/NN	root||ROOT-0/null||seems-12/VBZ	aux||important-15/JJ||to-13/TO	cop||important-15/JJ||be-14/VB	xcomp||seems-12/VBZ||important-15/JJ	det||treatment-19/NN||the-17/DT	amod||treatment-19/NN||appropriate-18/JJ	prep_for||important-15/JJ||treatment-19/NN	prep_of||treatment-19/NN||patients-21/NNS	mark||resistant-28/JJ||since-23/IN	nn||bovis-25/NNS||m.-24/NN	nsubj||resistant-28/JJ||bovis-25/NNS	cop||resistant-28/JJ||is-26/VBZ	advmod||resistant-28/JJ||naturally-27/RB	advcl||important-15/JJ||resistant-28/JJ	det||drug-37/NN||a-30/DT	amod||drug-37/NN||first-31/JJ	nn||drug-37/NN||line-32/NN	amod||drug-37/NN||anti-tuberculosis-33/JJ	nn||drug-37/NN||-lrb--34/NNP	nn||drug-37/NN||tb-35/NN	nn||drug-37/NN||-rrb--36/NN	prep_to||resistant-28/JJ||drug-37/NN	appos||drug-37/NN||pyrazinamide-39/NN	mark||susceptible-49/JJ||while-41/IN	nsubj||susceptible-49/JJ||most-42/JJS	det||members-47/NNS||the-44/DT	amod||members-47/NNS||other-45/JJ	nn||members-47/NNS||mtc-46/NN	prep_of||most-42/JJS||members-47/NNS	cop||susceptible-49/JJ||are-48/VBP	advcl||resistant-28/JJ||susceptible-49/JJ	det||agent-53/NN||this-51/DT	amod||agent-53/NN||antimicrobial-52/JJ	prep_to||susceptible-49/JJ||agent-53/NN	tb-35||mycobacteriumtuberculosiscomplex-8||no||species identification of isolates belonging to the mycobacteriumtuberculosiscomplex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
advmod||recommended-6/VBN||therefore-1/RB	nn||ferritin-4/NN||serum-3/NN	nsubjpass||recommended-6/VBN||ferritin-4/NN	nsubj||use-13/VB||ferritin-4/NN	auxpass||recommended-6/VBN||is-5/VBZ	root||ROOT-0/null||recommended-6/VBN	det||index-11/NN||a-8/DT	advmod||adequate-10/JJ||more-9/RBR	amod||index-11/NN||adequate-10/JJ	prep_as||recommended-6/VBN||index-11/NN	aux||use-13/VB||to-12/TO	xcomp||recommended-6/VBN||use-13/VB	amod||screening-16/NN||irondeficiency-15/JJ	prep_for||use-13/VB||screening-16/NN	nn||purposes-19/NNS||planning-18/NN	prep_for||use-13/VB||purposes-19/NNS	conj_and||screening-16/NN||purposes-19/NNS	nn||supplementation-22/NN||iron-21/NN	prep_for||screening-16/NN||supplementation-22/NN	prep_among||use-13/VB||them-24/PRP	irondeficiency-15||iron-21||yes||therefore, serum ferritin is recommended as a more adequate index to use for irondeficiency screening and planning purposes for iron supplementation among them.
det||cohort-6/NN||a-1/DT	amod||cohort-6/NN||12-matched-2/JJ	amod||cohort-6/NN||new-3/JJ	nn||cohort-6/NN||insulin-4/NN	nn||cohort-6/NN||user-5/NN	nsubjpass||selected-31/VBN||cohort-6/NN	prep_on||cohort-6/NN||age-8/NN	nn||±-11/NNS||â-10/NN	dep||age-8/NN||±-11/NNS	num||years-13/NNS||3-12/CD	dep||±-11/NNS||years-13/NNS	amod||status-17/NN||smoking-16/VBG	prep_on||cohort-6/NN||status-17/NN	conj_and||age-8/NN||status-17/NN	prep_on||cohort-6/NN||likelihood-20/NN	conj_and||age-8/NN||likelihood-20/NN	prepc_of||likelihood-20/NN||initiating-22/VBG	nn||therapy-24/NN||insulin-23/NN	dobj||initiating-22/VBG||therapy-24/NN	dep||selected-31/VBN||â-26/VB	num||0.05-28/CD||±-27/CD	dobj||â-26/VB||0.05-28/CD	auxpass||selected-31/VBN||was-30/VBD	root||ROOT-0/null||selected-31/VBN	det||cohort-34/NN||a-33/DT	prep_from||selected-31/VBN||cohort-34/NN	num||patients-38/NNS||4,623-36/CD	amod||patients-38/NNS||chinese-37/JJ	prep_of||cohort-34/NN||patients-38/NNS	prep_with||selected-31/VBN||type2diabetes-40/JJ	prep_with||selected-31/VBN||free-42/JJ	conj_and||type2diabetes-40/JJ||free-42/JJ	prep_of||free-42/JJ||cancer-44/NN	prep_with||selected-31/VBN||naive-47/JJ	conj_and||type2diabetes-40/JJ||naive-47/JJ	prep_to||naive-47/JJ||insulin-49/NN	prep_at||insulin-49/NN||enrollment-51/NN	type2diabetes-40||insulin-49||yes||a 12-matched new insulin user cohort on age (â±3 years), smoking status, and likelihood of initiating insulin therapy (â±0.05) was selected from a cohort of 4,623 chinese patients with type2diabetes, free of cancer, and naive to insulin at enrollment.
det||risk-2/NN||the-1/DT	nsubjpass||characterized-24/VBN||risk-2/NN	amod||events-7/NNS||nsaid-related-4/JJ	amod||events-7/NNS||upper-5/JJ	nn||events-7/NNS||gi-6/NN	prep_of||risk-2/NN||events-7/NNS	prep_such_as||risk-2/NN||dyspepsia-11/NN	prep_such_as||risk-2/NN||pepticulcer-13/NN	conj_or||dyspepsia-11/NN||pepticulcer-13/NN	prep_such_as||risk-2/NN||complications-15/NNS	conj_and||dyspepsia-11/NN||complications-15/NNS	prep_such_as||complications-15/NNS||perforation-18/NN	prep_such_as||complications-15/NNS||bleeding-20/NN	conj_or||perforation-18/NN||bleeding-20/NN	auxpass||characterized-24/VBN||is-22/VBZ	advmod||characterized-24/VBN||well-23/RB	root||ROOT-0/null||characterized-24/VBN	dyspepsia-11||nsaid--1||no_rel||the risk of nsaid-related upper gi events, such as dyspepsia or pepticulcer and complications such as perforation or bleeding, is well characterized.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	glucose-11||type2diabetes-34||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||srnas-4/NNS||64-3/CD	dobj||identified-2/VBD||srnas-4/NNS	prep_in||srnas-4/NNS||shigella-6/NN	nsubjpass||validated-11/VBN||shigella-6/NN	auxpass||validated-11/VBN||were-9/VBD	advmod||validated-11/VBN||experimentally-10/RB	rcmod||shigella-6/NN||validated-11/VBN	amod||bacteria-14/NNS||other-13/JJ	prep_in||validated-11/VBN||bacteria-14/NNS	prepc_based_on||validated-11/VBN||on-16/IN	nn||conservation-18/NN||sequence-17/NN	pobj||validated-11/VBN||conservation-18/NN	shigella-6||bacteria-14||no||we identified 64 srnas in shigella, which were experimentally validated in other bacteria based on sequence conservation.
amod||hyperglycemia-2/NN||postprandial-1/JJ	nsubjpass||characterized-6/VBN||hyperglycemia-2/NN	prep_in||hyperglycemia-2/NN||type2diabetes-4/CD	auxpass||characterized-6/VBN||is-5/VBZ	root||ROOT-0/null||characterized-6/VBN	amod||secretion-10/NN||impaired-8/VBN	nn||secretion-10/NN||insulin-9/NN	agent||characterized-6/VBN||secretion-10/NN	agent||characterized-6/VBN||action-12/NN	conj_and||secretion-10/NN||action-12/NN	amod||effectiveness-16/NN||decreased-14/VBN	nn||effectiveness-16/NN||glucose-15/NN	appos||action-12/NN||effectiveness-16/NN	amod||suppression-19/NN||defective-18/JJ	appos||action-12/NN||suppression-19/NN	conj_and||effectiveness-16/NN||suppression-19/NN	nn||secretion-22/NN||glucagon-21/NN	prep_of||suppression-19/NN||secretion-22/NN	hyperglycemia-2||insulin-9||yes||postprandial hyperglycemia in type2diabetes is characterized by impaired insulin secretion and action, decreased glucose effectiveness and defective suppression of glucagon secretion.
advmod||used-27/VBN||however-1/RB	mark||susceptible-7/JJ||because-3/IN	nsubj||susceptible-7/JJ||ferrets-4/NNS	cop||susceptible-7/JJ||are-5/VBP	advmod||susceptible-7/JJ||naturally-6/RB	advcl||used-27/VBN||susceptible-7/JJ	prep_to||susceptible-7/JJ||infection-9/NN	prep_with||infection-9/NN||humaninfluenzaviruses-11/NNS	mark||resembles-17/VBZ||because-13/IN	det||state-16/NN||the-14/DT	nn||state-16/NN||disease-15/NN	nsubj||resembles-17/VBZ||state-16/NN	conj_and||susceptible-7/JJ||resembles-17/VBZ	advcl||used-27/VBN||resembles-17/VBZ	xcomp||resembles-17/VBZ||that-18/DT	prep_of||that-18/DT||humaninfluenza-20/NN	det||animals-23/NNS||these-22/DT	nsubjpass||used-27/VBN||animals-23/NNS	nsubj||study-32/VB||animals-23/NNS	aux||used-27/VBN||have-24/VBP	auxpass||used-27/VBN||been-25/VBN	advmod||used-27/VBN||widely-26/RB	root||ROOT-0/null||used-27/VBN	det||model-30/NN||a-29/DT	prep_as||used-27/VBN||model-30/NN	aux||study-32/VB||to-31/TO	xcomp||used-27/VBN||study-32/VB	amod||pathogenesis-34/NNS||influenzavirus-33/JJ	dobj||study-32/VB||pathogenesis-34/NNS	humaninfluenza-20||influenzavirus-33||no||however, because ferrets are naturally susceptible to infection with humaninfluenzaviruses and because the disease state resembles that of humaninfluenza, these animals have been widely used as a model to study influenzavirus pathogenesis.
nsubj||viruses-13/VBZ||melanogaster-1/NN	prep_to||melanogaster-1/NN||chikungunya-3/NN	appos||chikungunya-3/NN||togaviridae-5/NN	det||crosse-9/NN||la-8/DT	prep_to||melanogaster-1/NN||crosse-9/NN	conj_and||chikungunya-3/NN||crosse-9/NN	appos||chikungunya-3/NN||bunyaviridae-11/NN	root||ROOT-0/null||viruses-13/VBZ	chikungunya-3||bunyaviridae-11||no||melanogaster to chikungunya ( togaviridae ) and la crosse ( bunyaviridae ) viruses.
amod||antibodies-2/NNS||plexina4-1/JJ	nsubj||labeled-3/VBD||antibodies-2/NNS	root||ROOT-0/null||labeled-3/VBD	dobj||labeled-3/VBD||fibers-4/NNS	det||septum-8/NN||the-6/DT	amod||septum-8/NN||lateral-7/JJ	prep_in||labeled-3/VBD||septum-8/NN	nn||accumbens-11/NNS||nucleus-10/NN	appos||septum-8/NN||accumbens-11/NNS	amod||nuclei-15/NNS||several-13/JJ	amod||nuclei-15/NNS||thalamic-14/JJ	appos||septum-8/NN||nuclei-15/NNS	nn||reticulata-20/NN||substantia-17/NN	nn||reticulata-20/NN||nigra-18/NN	nn||reticulata-20/NN||pars-19/NNS	appos||septum-8/NN||reticulata-20/NN	nn||incerta-23/NN||zona-22/NN	appos||septum-8/NN||incerta-23/NN	amod||region-27/NN||pontine-25/JJ	nn||region-27/NN||reticular-26/NN	appos||septum-8/NN||region-27/NN	amod||nuclei-36/NNS||several-33/JJ	amod||nuclei-36/NNS||cranial-34/JJ	nn||nuclei-36/NNS||nerve-35/NN	prep_in||labeled-3/VBD||nuclei-36/NNS	conj_and||septum-8/NN||nuclei-36/NNS	zona-22||antibodies-2||no_rel||plexina4 antibodies labeled fibers in the lateral septum, nucleus accumbens, several thalamic nuclei, substantia nigra pars reticulata, zona incerta, pontine reticular region, as well as in several cranial nerve nuclei.
amod||stimulation-2/NN||insulin-induced-1/JJ	nsubjpass||reduced-12/VBN||stimulation-2/NN	amod||uptake-6/NN||hepatic-4/JJ	nn||uptake-6/NN||glucose-5/NN	prep_of||stimulation-2/NN||uptake-6/NN	amod||synthesis-10/NN||hepatic-8/JJ	nn||synthesis-10/NN||glycogen-9/NN	prep_of||stimulation-2/NN||synthesis-10/NN	conj_and||uptake-6/NN||synthesis-10/NN	auxpass||reduced-12/VBN||are-11/VBP	root||ROOT-0/null||reduced-12/VBN	prep_in||reduced-12/VBN||people-14/NNS	amod||presumably-25/NNS||type2diabetes-16/JJ	advmod||presumably-25/NNS||primarily-17/RB	amod||uptake-21/NN||decreased-20/VBN	prep_due_to||presumably-25/NNS||uptake-21/NN	prep_of||uptake-21/NN||extracellular-23/NN	nn||presumably-25/NNS||glucose-24/NN	prep_with||reduced-12/VBN||presumably-25/NNS	amod||activation-29/NN||inadequate-28/JJ	prep_because_of||presumably-25/NNS||activation-29/NN	amod||glucokinase-32/NN||hepatic-31/JJ	prep_of||activation-29/NN||glucokinase-32/NN	insulin--1||type2diabetes-16||no_rel||insulin-induced stimulation of hepatic glucose uptake and hepatic glycogen synthesis are reduced in people with type2diabetes primarily due to decreased uptake of extracellular glucose presumably because of inadequate activation of hepatic glucokinase.
mark||improve-4/VB||in-1/IN	dep||improve-4/VB||order-2/NN	aux||improve-4/VB||to-3/TO	advcl||treating-15/VBG||improve-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||systemic-6/JJ	dobj||improve-4/VB||effects-7/NNS	amod||therapy-10/NN||adjuvant-9/JJ	prep_of||effects-7/NNS||therapy-10/NN	nsubj||treating-15/VBG||we-12/PRP	aux||treating-15/VBG||have-13/VBP	aux||treating-15/VBG||been-14/VBN	root||ROOT-0/null||treating-15/VBG	dobj||treating-15/VBG||patients-16/NNS	amod||cancer-20/NN||resected-18/JJ	amod||cancer-20/NN||gastric-19/JJ	prep_with||patients-16/NNS||cancer-20/NN	prep_with||treating-15/VBG||carboplatin-22/NN	prep_with||treating-15/VBG||paclitaxel-24/NN	conj_and||carboplatin-22/NN||paclitaxel-24/NN	vmod||carboplatin-22/NN||followed-25/VBN	amod||analogue-28/NN||fluoropyrimidine-27/JJ	agent||followed-25/VBN||analogue-28/NN	agent||followed-25/VBN||radiation-30/NN	conj_and||analogue-28/NN||radiation-30/NN	cancer-20||adjuvant-9||no_rel||in order to improve the systemic effects of adjuvant therapy, we have been treating patients with resected gastric cancer with carboplatin and paclitaxel followed by fluoropyrimidine analogue and radiation.
nsubjpass||found-3/VBN||it-1/PRP	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	mark||%-11/NN||that-4/IN	nsubj||%-11/NN||reduction-5/NN	det||inflammation-8/NN||the-7/DT	prep_in||reduction-5/NN||inflammation-8/NN	cop||%-11/NN||was-9/VBD	num||%-11/NN||90.01-10/CD	ccomp||found-3/VBN||%-11/NN	prep_with||%-11/NN||indomethacin-13/NN	num||%-16/NN||3.10-15/CD	ccomp||found-3/VBN||%-16/NN	conj_and||%-11/NN||%-16/NN	prep_with||%-16/NN||pm-i-18/NN	num||%-21/NN||41.56-20/CD	ccomp||found-3/VBN||%-21/NN	conj_and||%-11/NN||%-21/NN	prep_with||%-21/NN||pm-ii-23/NN	num||%-26/NN||45.87-25/CD	ccomp||found-3/VBN||%-26/NN	conj_and||%-11/NN||%-26/NN	prep_with||%-26/NN||pm-iii-28/NN	num||%-31/NN||49.76-30/CD	ccomp||found-3/VBN||%-31/NN	conj_and||%-11/NN||%-31/NN	prep_with||%-31/NN||pm-iv-33/NNP	inflammation-8||indomethacin-13||yes||it was found that reduction in the inflammation was 90.01% with indomethacin, 3.10% with pm-i, 41.56% with pm-ii, 45.87% with pm-iii and 49.76% with pm-iv.
aux||determine-2/VB||to-1/TO	advcl||lesions-19/VBZ||determine-2/VB	det||effect-4/NN||the-3/DT	dobj||determine-2/VB||effect-4/NN	amod||treatment-10/NN||chondroitinsulphate-6/JJ	appos||treatment-10/NN||cs-8/NN	prep_of||effect-4/NN||treatment-10/NN	nn||loss-14/NN||cartilage-12/NN	nn||loss-14/NN||volume-13/NN	prep_on||treatment-10/NN||loss-14/NN	amod||marrow-18/NN||subchondral-16/JJ	nn||marrow-18/NN||bone-17/NN	nsubj||lesions-19/VBZ||marrow-18/NN	root||ROOT-0/null||lesions-19/VBZ	dobj||lesions-19/VBZ||bml-21/NN	dobj||lesions-19/VBZ||synovitis-24/NNS	conj_and||bml-21/NN||synovitis-24/NNS	nn||symptoms-27/NNS||disease-26/NN	dobj||lesions-19/VBZ||symptoms-27/NNS	conj_and||bml-21/NN||symptoms-27/NNS	prep_in||lesions-19/VBZ||patients-29/NNS	nn||osteoarthritis-32/NNS||knee-31/NN	prep_with||patients-29/NNS||osteoarthritis-32/NNS	appos||osteoarthritis-32/NNS||oa-34/NN	osteoarthritis-32||chondroitinsulphate-6||yes||to determine the effect of chondroitinsulphate (cs) treatment on cartilage volume loss, subchondral bone marrow lesions (bml), synovitis and disease symptoms in patients with knee osteoarthritis (oa).
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	cyclophosphamide-50||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â€“4, vincristine 0.4 mg/m2/day on days 1â€“4, doxorubicin 10 mg/m2/day on days 1â€“4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â€“6).
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-11/VBN||treatment-3/NN	amod||ulphadoxine-pyrimethamine-6/NN||s-5/JJ	prep_with||treatment-3/NN||ulphadoxine-pyrimethamine-6/NN	appos||treatment-3/NN||sp-8/NN	auxpass||recommended-11/VBN||is-10/VBZ	root||ROOT-0/null||recommended-11/VBN	prepc_for||recommended-11/VBN||reducing-13/VBG	det||risk-15/NN||the-14/DT	dobj||reducing-13/VBG||risk-15/NN	prep_of||risk-15/NN||malaria-17/NN	prep_in||malaria-17/NN||pregnancy-19/NN	poss||consequences-22/NNS||its-21/PRP$	prep_of||risk-15/NN||consequences-22/NNS	conj_and||malaria-17/NN||consequences-22/NNS	prep_on||consequences-22/NNS||mothers-24/NNS	prep_on||consequences-22/NNS||babies-26/NNS	conj_and||mothers-24/NNS||babies-26/NNS	appos||mothers-24/NNS||iptp-sp-28/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment with s ulphadoxine-pyrimethamine (sp) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (iptp-sp).
det||hand-4/NN||the-2/DT	amod||hand-4/NN||other-3/JJ	prep_on||shown-22/VBN||hand-4/NN	det||era-9/NN||the-7/DT	amod||era-9/NN||stent-8/JJ	prep_in||shown-22/VBN||era-9/NN	nsubjpass||shown-22/VBN||bivalirudin-11/NN	nsubj||provide-24/VB||bivalirudin-11/NN	det||inhibitor-17/NN||a-13/DT	amod||inhibitor-17/NN||semi-synthetic-14/JJ	amod||inhibitor-17/NN||direct-15/JJ	nn||inhibitor-17/NN||thrombin-16/NN	appos||bivalirudin-11/NN||inhibitor-17/NN	aux||shown-22/VBN||has-19/VBZ	advmod||shown-22/VBN||recently-20/RB	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||provide-24/VB||to-23/TO	xcomp||shown-22/VBN||provide-24/VB	amod||efficacy-26/NN||similar-25/JJ	dobj||provide-24/VB||efficacy-26/NN	amod||bleeding-29/NN||less-28/JJR	prep_with||provide-24/VB||bleeding-29/NN	prepc_compared_with||bleeding-29/NN||with-31/IN	pobj||bleeding-29/NN||unfractionatedheparin-32/NN	prep||unfractionatedheparin-32/NN||plus-33/CC	amod||inhibitors-37/NNS||platelet-34/JJ	nn||inhibitors-37/NNS||gp-35/NN	nn||inhibitors-37/NNS||iib/iiia-36/NN	pobj||plus-33/CC||inhibitors-37/NNS	nn||patients-40/NNS||ami-39/NN	prep_in||inhibitors-37/NNS||patients-40/NNS	vmod||patients-40/NNS||treated-41/VBN	amod||pci-44/NN||primary-43/JJ	prep_with||treated-41/VBN||pci-44/NN	bleeding-29||thrombin-16||yes||on the other hand, in the stent era, bivalirudin, a semi-synthetic direct thrombin inhibitor, has recently been shown to provide similar efficacy with less bleeding compared with unfractionatedheparin plus platelet gp iib/iiia inhibitors in ami patients treated with primary pci.
det||rin-8/NN||the-1/DT	amod||rin-8/NN||current-2/JJ	nn||rin-8/NN||vaccine-3/NN	dep||rin-8/NN||bacille-5/NN	num||rin-8/NN||calmette-guã-6/CD	nn||rin-8/NN||©-7/NNP	nsubj||protect-19/VB||rin-8/NN	appos||rin-8/NN||bcg-10/NN	advmod||employed-15/VBN||albeit-13/IN	advmod||albeit-13/IN||widely-14/RB	vmod||rin-8/NN||employed-15/VBN	aux||protect-19/VB||does-17/VBZ	neg||protect-19/VB||not-18/RB	root||ROOT-0/null||protect-19/VB	amod||disease-23/NN||adult-21/JJ	amod||disease-23/NN||pulmonary-22/JJ	prep_against||protect-19/VB||disease-23/NN	amod||vaccines-27/NNS||new-26/JJ	nsubjpass||needed-30/VBN||vaccines-27/NNS	nsubj||reduce-32/VB||vaccines-27/NNS	auxpass||needed-30/VBN||are-28/VBP	advmod||needed-30/VBN||urgently-29/RB	conj_and||protect-19/VB||needed-30/VBN	aux||reduce-32/VB||to-31/TO	xcomp||needed-30/VBN||reduce-32/VB	det||incidence-34/NN||the-33/DT	dobj||reduce-32/VB||incidence-34/NN	prep_of||incidence-34/NN||tb-36/NN	advmod||reduce-32/VB||worldwide-37/RB	tb-36||bcg-10||yes||the current vaccine, bacille calmette-guã©rin (bcg), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of tb worldwide.
amod||prevalence-2/NN||conflicting-1/VBG	nsubjpass||reported-25/VBN||prevalence-2/NN	advmod||identified-5/JJ||newly-4/RB	amod||ki-6/NN||identified-5/JJ	prep_of||prevalence-2/NN||ki-6/NN	appos||ki-6/NN||kipyv-8/NNP	prep_of||prevalence-2/NN||wu-11/NN	conj_and||ki-6/NN||wu-11/NN	appos||wu-11/NN||wupyv-13/NNP	amod||polyomaviruses-22/NNS||merkel-16/JJ	nn||polyomaviruses-22/NNS||cell-17/NN	nn||polyomaviruses-22/NNS||carcinoma-18/NN	appos||polyomaviruses-22/NNS||mcpyv-20/NNP	prep_of||prevalence-2/NN||polyomaviruses-22/NNS	conj_and||ki-6/NN||polyomaviruses-22/NNS	aux||reported-25/VBN||have-23/VBP	auxpass||reported-25/VBN||been-24/VBN	root||ROOT-0/null||reported-25/VBN	nsubj||ranging-34/VBG||progressivemultifocalleukoencephalopathy-27/NN	appos||progressivemultifocalleukoencephalopathy-27/NN||pml-29/NN	amod||samples-32/NNS||patient-31/JJ	dep||progressivemultifocalleukoencephalopathy-27/NN||samples-32/NNS	prepc_in||reported-25/VBN||ranging-34/VBG	prep_from||ranging-34/VBG||0-36/CD	num||%-39/NN||14.3-38/CD	prep_to||ranging-34/VBG||%-39/NN	progressivemultifocalleukoencephalopathy-27||polyomaviruses-22||no||conflicting prevalence of newly identified ki(kipyv), wu(wupyv) and merkel cell carcinoma(mcpyv) polyomaviruses have been reported in progressivemultifocalleukoencephalopathy(pml) patient samples, ranging from 0 to 14.3%.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
prep_since||implemented-27/VBN||2003-2/CD	amod||schemes-7/NNS||new-4/JJ	amod||schemes-7/NNS||social-5/JJ	nn||schemes-7/NNS||assistance-6/NN	nsubjpass||implemented-27/VBN||schemes-7/NNS	cc||decentralization-14/NN||and-9/CC	advmod||importantly-12/RB||more-11/RBR	dep||decentralization-14/NN||importantly-12/RB	ccomp||implemented-27/VBN||decentralization-14/NN	amod||treatment-17/NN||routine-16/JJ	prep_of||decentralization-14/NN||treatment-17/NN	prep_of||decentralization-14/NN||care-19/NN	conj_and||treatment-17/NN||care-19/NN	nn||stations-23/NNS||community-21/NN	nn||stations-23/NNS||health-22/NN	prep_to||decentralization-14/NN||stations-23/NNS	auxpass||implemented-27/VBN||were-25/VBD	advmod||implemented-27/VBN||progressively-26/RB	root||ROOT-0/null||implemented-27/VBN	amod||areas-30/NNS||rural-29/JJ	prep_in||implemented-27/VBN||areas-30/NNS	advmod||affected-32/VBN||most-31/RBS	vmod||areas-30/NNS||affected-32/VBN	det||epidemic-36/NN||the-34/DT	amod||epidemic-36/NN||hiv/aids-35/JJ	agent||affected-32/VBN||epidemic-36/NN	aids--1||hiv--1||no||since 2003, new social assistance schemes, and, more importantly, decentralization of routine treatment and care to community health stations, were progressively implemented in rural areas most affected by the hiv/aids epidemic.
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	det||basis-5/NN||a-4/DT	dobj||provide-3/VBP||basis-5/NN	nsubj||improve-13/VB||basis-5/NN	det||use-8/NN||the-7/DT	prep_for||basis-5/NN||use-8/NN	nn||peel-11/NN||onion-10/NN	prep_of||use-8/NN||peel-11/NN	aux||improve-13/VB||to-12/TO	xcomp||provide-3/VBP||improve-13/VB	nn||insensitivity-15/NN||insulin-14/NN	dobj||improve-13/VB||insensitivity-15/NN	prep_in||improve-13/VB||type2diabetes-17/CD	type2diabetes-17||insulin-14||yes||these findings provide a basis for the use of onion peel to improve insulin insensitivity in type2diabetes.
nsubj||promising-15/VBG||capecitabine-1/NN	conj_plus||capecitabine-1/NN||docetaxel-3/NN	nsubj||promising-15/VBG||docetaxel-3/NN	appos||docetaxel-3/NN||xt-5/NN	conj_and||capecitabine-1/NN||trastuzumab-8/NN	nsubj||promising-15/VBG||trastuzumab-8/NN	prep_with||trastuzumab-8/NN||xt-10/NN	appos||xt-10/NN||hxt-12/NN	aux||promising-15/VBG||are-14/VBP	root||ROOT-0/null||promising-15/VBG	amod||regimens-17/NNS||non-anthracycline-16/JJ	dobj||promising-15/VBG||regimens-17/NNS	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||preoperative-20/JJ	prep_for||promising-15/VBG||treatment-21/NN	prep_of||treatment-21/NN||women-23/NNS	amod||cancer-29/NN||her2-negative-25/JJ	conj_and||her2-negative-25/JJ||her2-positive-27/JJ	amod||cancer-29/NN||her2-positive-27/JJ	nn||cancer-29/NN||breast-28/NN	prep_with||women-23/NNS||cancer-29/NN	advmod||promising-15/VBG||respectively-31/RB	cancer-29||docetaxel-3||no_rel||capecitabine plus docetaxel (xt) and trastuzumab with xt (hxt) are promising non-anthracycline regimens for the preoperative treatment of women with her2-negative and her2-positive breast cancer, respectively.
det||length-2/NN||neither-1/DT	nsubj||predictor-13/NN||length-2/NN	amod||infection-10/NN||stay-4/JJ	conj_nor||stay-4/JJ||methicillin-resistantstaphylococcusaureus-6/JJ	amod||infection-10/NN||methicillin-resistantstaphylococcusaureus-6/JJ	nn||infection-10/NN||-lrb--7/NN	nn||infection-10/NN||mrsa-8/NN	nn||infection-10/NN||-rrb--9/NN	prep_of||length-2/NN||infection-10/NN	cop||predictor-13/NN||was-11/VBD	det||predictor-13/NN||a-12/DT	root||ROOT-0/null||predictor-13/NN	amod||bacteriuria-16/NN||s.aureus-15/JJ	prep_of||predictor-13/NN||bacteriuria-16/NN	prep_of||predictor-13/NN||death-18/NN	conj_or||bacteriuria-16/NN||death-18/NN	methicillin-resistantstaphylococcusaureus-6||s.aureus-15||no||neither length of stay nor methicillin-resistantstaphylococcusaureus -lrb- mrsa -rrb- infection was a predictor of s.aureus bacteriuria or death .
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	chloroquine-38||malaria-104||no_rel||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
nsubjpass||shown-8/VBN||sitagliptin-1/NN	nsubj||improve-10/VB||sitagliptin-1/NN	aux||shown-8/VBN||has-2/VBZ	amod||studies-6/NNS||several-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_in||shown-8/VBN||studies-6/NNS	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||improve-10/VB||to-9/TO	xcomp||shown-8/VBN||improve-10/VB	amod||control-12/NN||metabolic-11/JJ	dobj||improve-10/VB||control-12/NN	prep_in||improve-10/VB||type2diabetes-14/NNS	appos||type2diabetes-14/NNS||both-16/DT	advmod||used-18/VBN||when-17/WRB	advcl||improve-10/VB||used-18/VBN	prep_as||used-18/VBN||monotherapy-20/NN	advmod||used-23/VBN||when-22/WRB	advcl||improve-10/VB||used-23/VBN	conj_and||used-18/VBN||used-23/VBN	prep_in||used-23/VBN||combination-25/NN	prep_with||used-23/VBN||metformin-27/NN	prep_with||used-23/VBN||sulfonylurea-29/NN	conj_or||metformin-27/NN||sulfonylurea-29/NN	prep_with||used-23/VBN||thiazolidinediones-31/NNS	conj_or||metformin-27/NN||thiazolidinediones-31/NNS	prep_with||used-23/VBN||insulin-33/NN	conj_or||metformin-27/NN||insulin-33/NN	type2diabetes-14||metformin-27||yes||sitagliptin has in several clinical studies been shown to improve metabolic control in type2diabetes, both when used as monotherapy and when used in combination with metformin, sulfonylurea, thiazolidinediones or insulin.
nsubj||complication-9/NN||heparin-inducedthrombocytopenia-1/NN	dep||heparin-inducedthrombocytopenia-1/NN||hit-3/VBN	cop||complication-9/NN||is-5/VBZ	det||complication-9/NN||an-6/DT	amod||complication-9/NN||immunoglobulin-mediated-7/JJ	amod||complication-9/NN||serious-8/JJ	root||ROOT-0/null||complication-9/NN	nn||therapy-12/NN||heparin-11/NN	prep_of||complication-9/NN||therapy-12/NN	vmod||complication-9/NN||characterized-13/VBN	nn||risk-18/NN||thrombocytopenia-15/NN	conj_and||thrombocytopenia-15/NN||high-17/JJ	nn||risk-18/NN||high-17/JJ	agent||characterized-13/VBN||risk-18/NN	prep_for||risk-18/NN||venous-20/NNS	amod||hit-24/NN||arterial-22/JJ	nn||hit-24/NN||thrombosis-23/NNS	prep_for||risk-18/NN||hit-24/NN	conj_and||venous-20/NNS||hit-24/NN	nn||syndrome-27/NN||thrombosis-26/NNS	prep_for||risk-18/NN||syndrome-27/NN	conj_and||venous-20/NNS||syndrome-27/NN	dep||complication-9/NN||hitts-29/VBZ	hit-24||heparin-11||no||heparin-inducedthrombocytopenia (hit) is an immunoglobulin-mediated serious complication of heparin therapy characterized by thrombocytopenia and high risk for venous and arterial thrombosis hit and thrombosis syndrome (hitts).
poss||case-2/NN||our-1/PRP$	nsubj||report-6/NN||case-2/NN	cop||report-6/NN||is-3/VBZ	det||report-6/NN||the-4/DT	amod||report-6/NN||second-5/JJ	root||ROOT-0/null||report-6/NN	amod||dhs-9/NN||ebv-associated-8/JJ	prep_of||report-6/NN||dhs-9/NN	nsubj||suggests-12/VBZ||dhs-9/NN	rcmod||dhs-9/NN||suggests-12/VBZ	mark||contribute-16/VB||that-13/IN	nsubj||contribute-16/VB||ebvinfection-14/NN	aux||contribute-16/VB||may-15/MD	ccomp||suggests-12/VBZ||contribute-16/VB	det||pathogenesis-19/NNS||the-18/DT	prep_to||contribute-16/VB||pathogenesis-19/NNS	prep_of||pathogenesis-19/NNS||ahs-21/UH	det||patients-25/NNS||a-23/DT	amod||patients-25/NNS||few-24/JJ	prep_in||contribute-16/VB||patients-25/NNS	ebvinfection-14||ebv--1||no||our case is the second report of ebv-associated dhs, which suggests that ebvinfection may contribute to the pathogenesis of ahs in a few patients.
amod||investigators-2/NNS||early-1/JJ	nsubj||suggested-3/VBD||investigators-2/NNS	root||ROOT-0/null||suggested-3/VBD	mark||preceded-13/VBN||that-4/IN	nsubjpass||preceded-13/VBN||ventricularfibrillation-5/NN	nn||failure-8/NN||heart-7/NN	prep_without||ventricularfibrillation-5/NN||failure-8/NN	prep_in||failure-8/NN||acutemyocardialinfarction-10/NN	auxpass||preceded-13/VBN||was-11/VBD	advmod||preceded-13/VBN||reliably-12/RB	ccomp||suggested-3/VBD||preceded-13/VBN	amod||arrhythmias-16/NNS||warning-15/VBG	agent||preceded-13/VBN||arrhythmias-16/NNS	mark||avoid-28/VB||that-19/IN	nsubj||avoid-28/VB||suppression-20/NN	amod||arrhythmias-23/NNS||such-22/JJ	prep_of||suppression-20/NN||arrhythmias-23/NNS	amod||lidocaine-26/NN||intravenous-25/JJ	prep_with||arrhythmias-23/NNS||lidocaine-26/NN	aux||avoid-28/VB||could-27/MD	ccomp||suggested-3/VBD||avoid-28/VB	conj_and||preceded-13/VBN||avoid-28/VB	det||need-30/NN||the-29/DT	dobj||avoid-28/VB||need-30/NN	prep_for||need-30/NN||resuscitation-32/NN	ventricularfibrillation-5||lidocaine-26||yes||early investigators suggested that ventricularfibrillation without heart failure in acutemyocardialinfarction was reliably preceded by warning arrhythmias, and that suppression of such arrhythmias with intravenous lidocaine could avoid the need for resuscitation.
nn||toxin-3/NN||anthrax-1/NN	amod||toxin-3/NN||lethal-2/JJ	nsubj||toxin-11/NN||toxin-3/NN	appos||toxin-3/NN||lt-5/NN	cop||toxin-11/NN||is-7/VBZ	det||toxin-11/NN||a-8/DT	amod||toxin-11/NN||bipartite-9/JJ	amod||toxin-11/NN||protease-containing-10/JJ	root||ROOT-0/null||toxin-11/NN	det||determinant-16/NN||a-13/DT	amod||determinant-16/NN||key-14/JJ	nn||determinant-16/NN||virulence-15/NN	conj_and||toxin-11/NN||determinant-16/NN	prep_of||determinant-16/NN||bacillusanthracis-18/NNS	anthrax-1||bacillusanthracis-18||no||anthrax lethal toxin (lt) is a bipartite protease-containing toxin and a key virulence determinant of bacillusanthracis .
det||empyema-2/NN||an-1/DT	nsubjpass||created-4/VBN||empyema-2/NN	auxpass||created-4/VBN||was-3/VBD	root||ROOT-0/null||created-4/VBN	det||injection-8/NN||the-6/DT	amod||injection-8/NN||intrapleural-7/JJ	prep_via||created-4/VBN||injection-8/NN	amod||bacteria-11/NNS||escherichiacoli-10/JJ	prep_of||injection-8/NN||bacteria-11/NNS	appos||bacteria-11/NNS||atcc-13/NN	num||atcc-13/NN||35218-14/CD	det||space-19/NN||the-17/DT	amod||space-19/NN||pleural-18/JJ	prep_into||created-4/VBN||space-19/NN	amod||rabbits-24/NNS||new-21/JJ	amod||rabbits-24/NNS||zealand-22/JJ	amod||rabbits-24/NNS||white-23/JJ	prep_of||space-19/NN||rabbits-24/NNS	empyema-2||bacteria-11||no||an empyema was created via the intrapleural injection of escherichiacoli bacteria (atcc 35218) into the pleural space of new zealand white rabbits.
amod||monitoring-3/NN||adequate-2/JJ	prep_with||reduces-10/VBZ||monitoring-3/NN	nn||adherence-6/NN||patient-5/NN	conj_and||monitoring-3/NN||adherence-6/NN	prep_with||reduces-10/VBZ||adherence-6/NN	amod||treatment-9/NN||cyclosporine-8/JJ	nsubj||reduces-10/VBZ||treatment-9/NN	nsubj||improves-17/VBZ||treatment-9/NN	nsubj||tolerated-23/JJ||treatment-9/NN	root||ROOT-0/null||reduces-10/VBZ	det||severity-12/NN||the-11/DT	dobj||reduces-10/VBZ||severity-12/NN	amod||psoriasis-15/NNS||severe-14/JJ	prep_of||severity-12/NN||psoriasis-15/NNS	conj_and||reduces-10/VBZ||improves-17/VBZ	dobj||improves-17/VBZ||qol-18/NN	cop||tolerated-23/JJ||is-21/VBZ	advmod||tolerated-23/JJ||appropriately-22/RB	conj_and||reduces-10/VBZ||tolerated-23/JJ	parataxis||reduces-10/VBZ||leading-25/VBG	amod||satisfaction-29/NN||high-27/JJ	nn||satisfaction-29/NN||patient-28/NN	prep_to||leading-25/VBG||satisfaction-29/NN	psoriasis-15||cyclosporine-8||yes||with adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves qol, and is appropriately tolerated; leading to high patient satisfaction.
det||form-2/NN||the-1/DT	nsubj||vary-9/VB||form-2/NN	det||biomarkers-7/NN||the-4/DT	nn||biomarkers-7/NN||prostate-5/NN	nn||biomarkers-7/NN||cancer-6/NN	prep_of||form-2/NN||biomarkers-7/NN	aux||vary-9/VB||can-8/MD	root||ROOT-0/null||vary-9/VB	prep_from||vary-9/VB||metabolites-11/NNS	nn||products-14/NNS||chemical-13/NN	prep_from||vary-9/VB||products-14/NNS	conj_and||metabolites-11/NNS||products-14/NNS	amod||metabolites-11/NNS||present-15/JJ	nn||fluid-18/NN||body-17/NN	prep_in||present-15/JJ||fluid-18/NN	prep_to||vary-9/VB||genes-20/NNS	prep_to||vary-9/VB||proteins-22/NNS	conj_and||genes-20/NNS||proteins-22/NNS	det||tissues-26/NNS||the-24/DT	nn||tissues-26/NNS||prostate-25/NN	prep_in||genes-20/NNS||tissues-26/NNS	cancer-6||chemical-13||no_rel||the form of the prostate cancer biomarkers can vary from metabolites and chemical products present in body fluid to genes and proteins in the prostate tissues.
nsubj||is-9/VBZ||epratuzumab-1/NN	det||antibody-7/NN||a-3/DT	amod||antibody-7/NN||humanized-4/JJ	amod||antibody-7/NN||anti-cd22-5/JJ	nn||antibody-7/NN||monoclonal-6/NN	appos||epratuzumab-1/NN||antibody-7/NN	root||ROOT-0/null||is-9/VBZ	prep_under||is-9/VBZ||investigation-11/NN	det||antibody-15/NN||a-13/DT	amod||antibody-15/NN||therapeutic-14/JJ	prep_as||investigation-11/NN||antibody-15/NN	poss||lymphoma-19/NNS||non-hodgkin-17/NN	prep_in||antibody-15/NN||lymphoma-19/NNS	prep_in||antibody-15/NN||systemiclupuserythematosus-21/NNS	conj_and||lymphoma-19/NNS||systemiclupuserythematosus-21/NNS	appos||lymphoma-19/NNS||sle-23/NN	poss||mechanism-28/NN||its-27/PRP$	nsubj||remains-33/VBZ||mechanism-28/NN	prep_of||mechanism-28/NN||action-30/NN	prep_on||action-30/NN||b-cells-32/NNS	conj_but||is-9/VBZ||remains-33/VBZ	acomp||remains-33/VBZ||elusive-34/JJ	systemiclupuserythematosus-21||antibody-15||no_rel||epratuzumab, a humanized anti-cd22 monoclonal antibody, is under investigation as a therapeutic antibody in non-hodgkin's lymphoma and systemiclupuserythematosus (sle), but its mechanism of action on b-cells remains elusive.
num||years-2/NNS||ten-1/CD	tmod||diagnosed-7/VBN||years-2/NNS	advmod||years-2/NNS||previously-3/RB	nsubjpass||diagnosed-7/VBN||he-4/PRP	nsubjpass||treated-12/VBN||he-4/PRP	aux||diagnosed-7/VBN||had-5/VBD	auxpass||diagnosed-7/VBN||been-6/VBN	root||ROOT-0/null||diagnosed-7/VBN	nn||infection-10/NN||hbv-9/NN	prep_with||diagnosed-7/VBN||infection-10/NN	conj_and||diagnosed-7/VBN||treated-12/VBN	prep_with||treated-12/VBN||lamivudine-14/NN	num||mg/day-17/NN||100-16/CD	appos||lamivudine-14/NN||mg/day-17/NN	hbv-9||lamivudine-14||yes||ten years previously he had been diagnosed with hbv infection and treated with lamivudine (100 mg/day).
nsubj||ovarian-10/VBP||a2780cis-1/NNS	appos||a2780cis-1/NNS||cisplatin-resistant-3/NN	conj_and||a2780cis-1/NNS||a2780-6/NNS	nsubj||ovarian-10/VBP||a2780-6/NNS	dep||a2780-6/NNS||cisplatin-sensitive-8/JJ	root||ROOT-0/null||ovarian-10/VBP	nn||lines-13/NNS||carcinoma-11/NN	nn||lines-13/NNS||cell-12/NN	nsubjpass||used-15/VBN||lines-13/NNS	auxpass||used-15/VBN||were-14/VBD	ccomp||ovarian-10/VBP||used-15/VBN	carcinoma-11||cisplatin--1||no_rel||a2780cis (cisplatin-resistant) and a2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||protein-10/VBZ||that-5/IN	nsubj||protein-10/VBZ||hepatitisbvirus-6/NNS	appos||hepatitisbvirus-6/NNS||hbv-8/NN	ccomp||shown-4/VBN||protein-10/VBZ	nsubj||leading-25/VBG||x-11/SYM	appos||x-11/SYM||hbx-13/NN	det||protein-18/NN||a-16/DT	amod||protein-18/NN||regulatory-17/JJ	appos||x-11/SYM||protein-18/NN	prep_of||protein-18/NN||hbv-20/NN	amod||stat1-23/NNS||activates-22/JJ	appos||x-11/SYM||stat1-23/NNS	dep||protein-10/VBZ||leading-25/VBG	dep||i-28/NN||type-27/NN	amod||production-33/NN||i-28/NN	nn||production-33/NN||interferon-29/NN	appos||production-33/NN||ifn-31/NN	prep_to||leading-25/VBG||production-33/NN	hbv-20||hepatitisbvirus-6||no||we have previously shown that hepatitisbvirus (hbv) protein x (hbx), a regulatory protein of hbv, activates stat1, leading to type i interferon (ifn) production.
advmod||was-8/VBD||therefore-1/RB	det||aim-4/NN||the-3/DT	nsubj||was-8/VBD||aim-4/NN	nsubj||assess-10/VB||aim-4/NN	det||study-7/NN||this-6/DT	prep_of||aim-4/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||assess-10/VB||to-9/TO	xcomp||was-8/VBD||assess-10/VB	det||effectiveness-12/NN||the-11/DT	dobj||assess-10/VB||effectiveness-12/NN	amod||-rrb--43/NN||chloroquine-14/JJ	nn||strains-18/NNS||p.-16/NN	nn||strains-18/NNS||vivax-17/NN	prep_against||chloroquine-14/JJ||strains-18/NNS	prep_in||strains-18/NNS||one-20/CD	det||areas-25/NNS||the-22/DT	amod||areas-25/NNS||malaria-23/JJ	amod||areas-25/NNS||endemic-24/JJ	prep_of||one-20/CD||areas-25/NNS	nn||district-31/NN||ethiopia-27/NN	advmod||district-31/NN||namely-29/RB	nn||district-31/NN||halaba-30/NN	prep_of||areas-25/NNS||district-31/NN	vmod||strains-18/NNS||located-33/VBN	amod||nations-36/NNS||south-35/JJ	prep_in||located-33/VBN||nations-36/NNS	prep_in||located-33/VBN||nationalities-38/NNS	conj_and||nations-36/NNS||nationalities-38/NNS	nn||-rrb--43/NN||peoples-39/NNS	nn||-rrb--43/NN||region-40/NN	amod||-rrb--43/NN||-lrb--41/VBG	nn||-rrb--43/NN||snnpr-42/NN	prep_of||effectiveness-12/NN||-rrb--43/NN	amod||ethiopia-46/NN||south-45/JJ	prep_of||effectiveness-12/NN||ethiopia-46/NN	num||patients-50/NNS||87-48/CD	nn||patients-50/NNS||malaria-49/NN	prep_among||ethiopia-46/NN||patients-50/NNS	vmod||patients-50/NNS||enrolled-51/VBN	det||study-54/NN||the-53/DT	prep_in||enrolled-51/VBN||study-54/NN	quantmod||80-57/CD||only-56/RB	appos||study-54/NN||80-57/CD	prep_of||80-57/CD||them-59/PRP	vmod||80-57/CD||completed-60/VBN	det||follow-up-63/NN||the-61/DT	amod||follow-up-63/NN||28-days-62/JJ	dobj||completed-60/VBN||follow-up-63/NN	malaria-49||chloroquine-14||yes||therefore , the aim of this study was to assess the effectiveness of chloroquine against p. vivax strains in one of the malaria endemic areas of ethiopia , namely halaba district , located in south nations and nationalities peoples region -lrb- snnpr -rrb- of south ethiopia among 87 malaria patients enrolled in the study , only 80 of them completed the 28-days follow-up .
det||advances-3/NNS||the-2/DT	prep_despite||remains-19/VBZ||advances-3/NNS	det||treatment-6/NN||the-5/DT	prep_in||advances-3/NNS||treatment-6/NN	nn||infection-12/NN||chronichepatitisbvirus-8/NNP	appos||infection-12/NN||hbv-10/NN	prep_of||treatment-6/NN||infection-12/NN	nn||transplantation-15/NN||liver-14/NN	nsubj||remains-19/VBZ||transplantation-15/NN	appos||transplantation-15/NN||lt-17/NN	root||ROOT-0/null||remains-19/VBZ	det||hope-22/NN||the-20/DT	amod||hope-22/NN||only-21/JJ	xcomp||remains-19/VBZ||hope-22/NN	amod||patients-25/NNS||many-24/JJ	prep_for||hope-22/NN||patients-25/NNS	amod||liverdiseases-28/NNS||end-stage-27/JJ	prep_with||remains-19/VBZ||liverdiseases-28/NNS	vmod||liverdiseases-28/NNS||resulting-29/VBG	prep_from||resulting-29/VBG||hbv-31/NN	hbv-31||hepatitisbvirus--1||no||despite the advances in the treatment of chronichepatitisbvirus (hbv) infection, liver transplantation (lt) remains the only hope for many patients with end-stage liverdiseases resulting from hbv.
nsubj||close-2/VBP||we-1/PRP	nsubj||ameliorate-11/VB||we-1/PRP	root||ROOT-0/null||close-2/VBP	det||recommendations-6/NNS||the-4/DT	amod||recommendations-6/NNS||following-5/JJ	prep_with||close-2/VBP||recommendations-6/NNS	amod||families-9/NNS||strengthening-8/JJ	prep_for||recommendations-6/NNS||families-9/NNS	aux||ameliorate-11/VB||to-10/TO	xcomp||close-2/VBP||ameliorate-11/VB	det||effects-13/NNS||the-12/DT	dobj||ameliorate-11/VB||effects-13/NNS	prep_of||effects-13/NNS||hiv-15/NN	prep_of||effects-13/NNS||aids-17/NNS	conj_and||hiv-15/NN||aids-17/NNS	prep_on||ameliorate-11/VB||children-19/NNS	aids-17||hiv-15||no||we close with the following recommendations for strengthening families to ameliorate the effects of hiv and aids on children.
amod||levels-2/NNS||treg-1/VBG	nsubj||shifted-3/VBD||levels-2/NNS	root||ROOT-0/null||shifted-3/VBD	prep_in||shifted-3/VBD||patients-5/NNS	prep_with||shifted-3/VBD||melanoma-7/NN	vmod||melanoma-7/NN||treated-8/VBN	amod||2b-12/NNS||ifn-î-10/JJ	amod||2b-12/NNS||±-11/JJ	prep_with||treated-8/VBN||2b-12/NNS	mark||made-33/VBN||although-14/IN	neg||conclusions-17/NNS||no-15/DT	nn||conclusions-17/NNS||firm-16/NN	nsubjpass||made-33/VBN||conclusions-17/NNS	det||role-20/NN||the-19/DT	prep_regarding||conclusions-17/NNS||role-20/NN	prep_of||role-20/NN||tregs-22/NNS	det||marker-25/NN||a-24/DT	prep_as||tregs-22/NNS||marker-25/NN	nn||response-28/NN||treatment-27/NN	prep_of||marker-25/NN||response-28/NN	prep_of||marker-25/NN||outcome-30/NN	conj_or||response-28/NN||outcome-30/NN	aux||made-33/VBN||can-31/MD	auxpass||made-33/VBN||be-32/VB	advcl||treated-8/VBN||made-33/VBN	prep_at||made-33/VBN||present-35/JJ	melanoma-7||ifn--1||yes||treg levels shifted in patients with melanoma treated with ifn-î± 2b, although no firm conclusions regarding the role of tregs as a marker of treatment response or outcome can be made at present.
det||review-2/NN||this-1/DT	nsubj||seeks-3/VBZ||review-2/NN	nsubj||synthesise-5/VB||review-2/NN	root||ROOT-0/null||seeks-3/VBZ	aux||synthesise-5/VB||to-4/TO	xcomp||seeks-3/VBZ||synthesise-5/VB	poss||data-8/NNS||our-6/PRP$	amod||data-8/NNS||new-7/JJ	dobj||synthesise-5/VB||data-8/NNS	amod||nanotubes-12/NNS||multi-walled-10/JJ	nn||nanotubes-12/NNS||carbon-11/NN	prep_with||synthesise-5/VB||nanotubes-12/NNS	appos||nanotubes-12/NNS||cnt-14/NN	det||hypothesis-18/NNS||that-17/DT	prep_with||synthesise-5/VB||hypothesis-18/NNS	det||behaviour-21/NN||the-20/DT	prep_for||hypothesis-18/NNS||behaviour-21/NN	amod||fibres-24/NNS||long-23/JJ	prep_of||behaviour-21/NN||fibres-24/NNS	det||lung-27/NN||the-26/DT	prep_in||fibres-24/NNS||lung-27/NN	poss||retention-30/NN||their-29/PRP$	prep_with||synthesise-5/VB||retention-30/NN	conj_and||hypothesis-18/NNS||retention-30/NN	det||pleura-34/NN||the-32/DT	amod||pleura-34/NN||parietal-33/JJ	prep_in||retention-30/NN||pleura-34/NN	vmod||retention-30/NN||leading-35/VBG	det||initiation-38/NN||the-37/DT	prep_to||leading-35/VBG||initiation-38/NN	nn||pathology-43/NN||inflammation-40/NN	conj_and||inflammation-40/NN||pleural-42/NN	nn||pathology-43/NN||pleural-42/NN	prep_of||initiation-38/NN||pathology-43/NN	prep_such_as||retention-30/NN||mesothelioma-46/NN	inflammation-40||fibres-24||no_rel||this review seeks to synthesise our new data with multi-walled carbon nanotubes (cnt) with that hypothesis for the behaviour of long fibres in the lung and their retention in the parietal pleura leading to the initiation of inflammation and pleural pathology such as mesothelioma.
nsubj||agents-13/NNS||dengueviruses-1/NNS	amod||members-4/NNS||mosquito-borne-3/JJ	appos||dengueviruses-1/NNS||members-4/NNS	det||family-8/NN||the-6/DT	amod||family-8/NN||flaviviridae-7/JJ	prep_of||members-4/NNS||family-8/NN	cop||agents-13/NNS||are-10/VBP	det||agents-13/NNS||the-11/DT	amod||agents-13/NNS||causative-12/JJ	root||ROOT-0/null||agents-13/NNS	prep_of||agents-13/NNS||denguefever-15/NN	poss||complications-19/NNS||its-17/PRP$	amod||complications-19/NNS||associated-18/VBN	conj_and||agents-13/NNS||complications-19/NNS	conj_and||agents-13/NNS||denguehaemorrhagicfever-21/NN	conj_and||complications-19/NNS||denguehaemorrhagicfever-21/NN	conj_and||agents-13/NNS||dengueshocksyndrome-23/NN	conj_and||complications-19/NNS||dengueshocksyndrome-23/NN	denguehaemorrhagicfever-21||dengueviruses-1||no||dengueviruses, mosquito-borne members of the flaviviridae family, are the causative agents of denguefever and its associated complications, denguehaemorrhagicfever and dengueshocksyndrome.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||fat--1||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
det||study-5/NN||this-2/DT	nn||study-5/NN||retrospective-3/NN	amod||study-5/NN||cross-sectional-4/JJ	prep_in||evaluated-26/VBN||study-5/NN	det||value-8/NN||the-6/DT	amod||value-8/NN||prognostic-7/JJ	nsubjpass||evaluated-26/VBN||value-8/NN	amod||parameters-16/NNS||basic-10/JJ	amod||parameters-16/NNS||cerebrospinal-11/JJ	nn||parameters-16/NNS||fluid-12/NN	appos||parameters-16/NNS||csf-14/NN	prep_of||value-8/NN||parameters-16/NNS	prep_in||parameters-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||bacterialmeningitis-20/NNS	prep_with||patients-18/NNS||viralmeningoencephalitis-22/NNS	conj_and||bacterialmeningitis-20/NNS||viralmeningoencephalitis-22/NNS	prep_with||patients-18/NNS||leptomeningealmetastases-24/NNS	conj_and||bacterialmeningitis-20/NNS||leptomeningealmetastases-24/NNS	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	basic-10||leptomeningealmetastases-24||no_rel||in this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (csf) parameters in patients with bacterialmeningitis, viralmeningoencephalitis and leptomeningealmetastases were evaluated.
det||study-2/NN||this-1/DT	nsubj||evaluate-4/VB||study-2/NN	aux||evaluate-4/VB||will-3/MD	root||ROOT-0/null||evaluate-4/VB	nn||therapy-8/NN||novel-5/NN	nn||therapy-8/NN||stem/progenitor-6/NN	nn||therapy-8/NN||cell-7/NN	dobj||evaluate-4/VB||therapy-8/NN	nn||treatment-12/NN||combination-10/NN	nn||treatment-12/NN||cytokine-11/NN	prep_with||evaluate-4/VB||treatment-12/NN	det||analogue-17/NN||the-14/DT	amod||analogue-17/NN||long-acting-15/JJ	nn||analogue-17/NN||erythropoietin-16/NN	prep_of||treatment-12/NN||analogue-17/NN	prep_of||treatment-12/NN||darbepoetin-19/NN	conj_and||analogue-17/NN||darbepoetin-19/NN	amod||colony-stimulatingfactor-23/NN||granulocyte-22/JJ	prep_of||treatment-12/NN||colony-stimulatingfactor-23/NN	conj_and||analogue-17/NN||colony-stimulatingfactor-23/NN	dep||analogue-17/NN||g-csf-25/JJ	prep_in||evaluate-4/VB||patients-28/NNS	prep_with||patients-28/NNS||acutemyocardialinfarction-30/NN	colony-stimulatingfactor-23||acutemyocardialinfarction-30||no_rel||this study will evaluate novel stem/progenitor cell therapy with combination cytokine treatment of the long-acting erythropoietin analogue, darbepoetin, and granulocyte colony-stimulatingfactor (g-csf) in patients with acutemyocardialinfarction.
amod||studies-2/NNS||previous-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||exhibit-10/VB||that-5/IN	nsubj||exhibit-10/VB||geminiviruses-6/NNS	nn||viruses-9/NNS||rna-8/NN	conj_and||geminiviruses-6/NNS||viruses-9/NNS	nsubj||exhibit-10/VB||viruses-9/NNS	ccomp||shown-4/VBN||exhibit-10/VB	amod||frequencies-13/NNS||similar-11/JJ	nn||frequencies-13/NNS||mutation-12/NN	dobj||exhibit-10/VB||frequencies-13/NNS	mark||replicated-18/VBN||although-15/IN	nsubjpass||replicated-18/VBN||geminiviruses-16/NNS	auxpass||replicated-18/VBN||are-17/VBP	advcl||shown-4/VBN||replicated-18/VBN	nn||polymerases-22/NNS||host-20/NN	nn||polymerases-22/NNS||dna-21/NN	agent||replicated-18/VBN||polymerases-22/NNS	nn||viruses-25/NNS||rna-24/NN	agent||replicated-18/VBN||viruses-25/NNS	conj_and||polymerases-22/NNS||viruses-25/NNS	poss||rna-polymerase-32/NN||their-27/PRP$	amod||rna-polymerase-32/NN||own-28/JJ	amod||rna-polymerase-32/NN||virus-encoded-29/JJ	amod||rna-polymerase-32/NN||error-prone-30/JJ	amod||rna-polymerase-32/NN||rna-dependent-31/JJ	agent||replicated-18/VBN||rna-polymerase-32/NN	virus--1||viruses-25||no||previous studies have shown that geminiviruses and rna viruses exhibit similar mutation frequencies, although geminiviruses are replicated by host dna polymerases and rna viruses by their own virus-encoded error-prone rna-dependent rna-polymerase.
num||purpura-4/NN||henoch-schã-1/CD	amod||purpura-4/NN||¶-2/JJ	nn||purpura-4/NN||nlein-3/NN	nsubj||syndrome-11/NN||purpura-4/NN	cop||syndrome-11/NN||is-5/VBZ	det||syndrome-11/NN||a-6/DT	amod||syndrome-11/NN||common-7/JJ	amod||syndrome-11/NN||immunoglobulin-8/JJ	amod||syndrome-11/NN||a-mediated-9/JJ	amod||syndrome-11/NN||vasculitic-10/JJ	root||ROOT-0/null||syndrome-11/NN	prep_in||syndrome-11/NN||children-13/NNS	vmod||children-13/NNS||characterized-15/VBN	amod||rash-18/NN||purpuric-17/JJ	agent||characterized-15/VBN||rash-18/NN	agent||characterized-15/VBN||arthritis-20/NN	conj_and||rash-18/NN||arthritis-20/NN	agent||characterized-15/VBN||abdominalpain-22/NN	conj_and||rash-18/NN||abdominalpain-22/NN	arthritis-20||immunoglobulin-8||no_rel||henoch-schã¶nlein purpura is a common immunoglobulin a-mediated vasculitic syndrome in children, characterized by purpuric rash, arthritis and abdominalpain.
amod||ulceration-3/NN||methotrexate-induced-1/JJ	nn||ulceration-3/NN||cutaneous-2/NN	nsubjpass||reported-7/VBN||ulceration-3/NN	aux||reported-7/VBN||has-4/VBZ	advmod||reported-7/VBN||rarely-5/RB	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||patients-9/NNS	prep_with||patients-9/NNS||mycosisfungoides-11/NNS	mycosisfungoides-11||methotrexate--1||yes||methotrexate-induced cutaneous ulceration has rarely been reported in patients with mycosisfungoides.
advmod||eradicate-8/VB||currently-1/RB	neg||therapy-5/NN||no-3/DT	amod||therapy-5/NN||licensed-4/JJ	nsubj||eradicate-8/VB||therapy-5/NN	aux||eradicate-8/VB||can-6/MD	advmod||eradicate-8/VB||thoroughly-7/RB	root||ROOT-0/null||eradicate-8/VB	dobj||eradicate-8/VB||hepatitisbvirus-9/NNS	appos||hepatitisbvirus-9/NNS||hbv-11/NN	det||body-15/NN||the-14/DT	prep_from||eradicate-8/VB||body-15/NN	amod||±-20/NNS||interferon-18/JJ	nn||±-20/NNS||î-19/NN	prep_including||eradicate-8/VB||±-20/NNS	prep_including||eradicate-8/VB||inhibitors-22/NNS	conj_and||±-20/NNS||inhibitors-22/NNS	nn||reverse-transcription-25/NN||hbv-24/NN	prep_of||±-20/NNS||reverse-transcription-25/NN	hbv-24||hepatitisbvirus-9||no||currently, no licensed therapy can thoroughly eradicate hepatitisbvirus (hbv) from the body, including interferon î± and inhibitors of hbv reverse-transcription.
advmod||caused-5/VBN||usually-1/RB	nn||retropharyngealabscesses-3/NNS||tuberculous-2/NNS	nsubjpass||caused-5/VBN||retropharyngealabscesses-3/NNS	auxpass||caused-5/VBN||are-4/VBP	root||ROOT-0/null||caused-5/VBN	det||invasion-9/NN||the-7/DT	amod||invasion-9/NN||direct-8/JJ	agent||caused-5/VBN||invasion-9/NN	det||bacteria-12/NNS||the-11/DT	prep_of||invasion-9/NN||bacteria-12/NNS	det||spine-15/NN||the-14/DT	prep_from||caused-5/VBN||spine-15/NN	nn||ligament-19/NN||anterior-17/NN	amod||ligament-19/NN||longitudinal-18/JJ	prep_via||spine-15/NN||ligament-19/NN	det||spine-22/NN||the-21/DT	prep_of||ligament-19/NN||spine-22/NN	retropharyngealabscesses-3||bacteria-12||no||usually tuberculous retropharyngealabscesses are caused by the direct invasion of the bacteria from the spine via anterior longitudinal ligament of the spine.
det||presence-2/NN||the-1/DT	nsubj||increases-9/VBZ||presence-2/NN	amod||genotypes-6/NNS||multiple-4/JJ	nn||genotypes-6/NNS||borrelia-5/NN	prep_of||presence-2/NN||genotypes-6/NNS	prep_in||genotypes-6/NNS||ticks-8/NNS	root||ROOT-0/null||increases-9/VBZ	det||probability-11/NN||the-10/DT	dobj||increases-9/VBZ||probability-11/NN	mark||infected-17/VBN||that-12/IN	det||person-14/NN||a-13/DT	nsubjpass||infected-17/VBN||person-14/NN	aux||infected-17/VBN||will-15/MD	auxpass||infected-17/VBN||be-16/VB	ccomp||increases-9/VBZ||infected-17/VBN	mwe||than-20/IN||more-19/JJR	quantmod||one-21/CD||than-20/IN	num||genotype-22/NN||one-21/CD	prep_with||infected-17/VBN||genotype-22/NN	nn||burgdorferi-25/NNS||b.-24/NN	prep_of||genotype-22/NN||burgdorferi-25/NNS	advmod||increasing-28/VBG||potentially-27/RB	xcomp||infected-17/VBN||increasing-28/VBG	det||risks-30/NNS||the-29/DT	dobj||increasing-28/VBG||risks-30/NNS	amod||lymedisease-33/NN||disseminated-32/JJ	prep_of||risks-30/NNS||lymedisease-33/NN	lymedisease-33||borrelia-5||no||the presence of multiple borrelia genotypes in ticks increases the probability that a person will be infected with more than one genotype of b. burgdorferi , potentially increasing the risks of disseminated lymedisease .
nsubjpass||achieved-8/VBN||safety-1/NN	nn||transmission-6/NN||hbv-5/NN	prep_with_respect_to||safety-1/NN||transmission-6/NN	auxpass||achieved-8/VBN||was-7/VBD	root||ROOT-0/null||achieved-8/VBN	advmod||achieved-8/VBN||even-9/RB	det||development-13/NN||the-12/DT	prep_prior_to||achieved-8/VBN||development-13/NN	amod||tests-17/NNS||sensitive-15/JJ	nn||tests-17/NNS||screening-16/NN	prep_of||development-13/NN||tests-17/NNS	prep_for||achieved-8/VBN||hbsag-19/NN	mark||predicted-24/VBN||as-21/IN	aux||predicted-24/VBN||can-22/MD	auxpass||predicted-24/VBN||be-23/VB	advcl||achieved-8/VBN||predicted-24/VBN	prep||predicted-24/VBN||given-25/VBN	det||load-29/NN||the-26/DT	amod||load-29/NN||initial-27/JJ	nn||load-29/NN||virus-28/NN	pobj||given-25/VBN||load-29/NN	det||influence-32/NN||the-31/DT	pobj||given-25/VBN||influence-32/NN	conj_and||load-29/NN||influence-32/NN	prep_of||influence-32/NN||factors-34/NNS	vmod||factors-34/NNS||affecting-35/VBG	dobj||affecting-35/VBG||removal-36/NN	dobj||affecting-35/VBG||inactivation-38/NN	conj_and||removal-36/NN||inactivation-38/NN	hbv-5||hbsag-19||yes||safety with respect to hbv transmission was achieved even prior to the development of sensitive screening tests for hbsag, as can be predicted given the initial virus load and the influence of factors affecting removal and inactivation.
nsubj||drug-8/NN||epinephrine-1/NN	vmod||epinephrine-1/NN||administered-3/VBN	advmod||administered-3/VBN||immediately-4/RB	cop||drug-8/NN||is-6/VBZ	det||drug-8/NN||the-7/DT	root||ROOT-0/null||drug-8/NN	prep_of||drug-8/NN||choice-10/NN	amod||anaphylaxis-13/NNS||acute-12/JJ	prep_for||choice-10/NN||anaphylaxis-13/NNS	anaphylaxis-13||epinephrine-1||yes||epinephrine, administered immediately, is the drug of choice for acute anaphylaxis.
poss||study-2/NN||our-1/PRP$	nsubj||showed-3/VBD||study-2/NN	root||ROOT-0/null||showed-3/VBD	mark||feasible-11/JJ||that-4/IN	amod||adherence-6/NN||good-5/JJ	nsubj||feasible-11/JJ||adherence-6/NN	amod||survival-9/NN||improved-8/VBN	conj_and||adherence-6/NN||survival-9/NN	nsubj||feasible-11/JJ||survival-9/NN	cop||feasible-11/JJ||are-10/VBP	ccomp||showed-3/VBD||feasible-11/JJ	nn||programmes-15/NNS||community-13/NN	nn||programmes-15/NNS||hiv/aids-14/NNS	prep_in||feasible-11/JJ||programmes-15/NNS	prep_such_as||programmes-15/NNS||that-18/DT	prep_of||that-18/DT||taso-20/NN	appos||taso-20/NN||uganda-22/NN	aids--1||hiv--1||no||our study showed that good adherence and improved survival are feasible in community hiv/aids programmes such as that of taso, uganda.
nsubj||worked-2/VBD||doctors-1/NNS	root||ROOT-0/null||worked-2/VBD	amod||clinics-8/NNS||urban-4/JJ	conj_and||urban-4/JJ||peri-urban-6/NN	amod||clinics-8/NNS||peri-urban-6/NN	nn||clinics-8/NNS||hiv/aids-7/NNS	prep_in||worked-2/VBD||clinics-8/NNS	prep_in||worked-2/VBD||peru-10/NN	advmod||are-24/VBP||where-12/WRB	quantmod||70-14/CD||almost-13/RB	num||%-15/NN||70-14/CD	nsubj||are-24/VBP||%-15/NN	det||nation-18/NN||the-17/DT	poss||patients-21/NNS||nation-18/NN	nn||patients-21/NNS||hiv-20/NN	prep_of||%-15/NN||patients-21/NNS	prep_in||%-15/NN||need-23/NN	advcl||worked-2/VBD||are-24/VBP	prep_on||are-24/VBP||treatment-26/NN	aids--1||hiv-20||no||doctors worked in urban and peri-urban hiv/aids clinics in peru, where almost 70% of the nation's hiv patients in need are on treatment.
nsubjpass||optimized-32/VBN||proportions-1/NNS	num||enzymes-6/NNS||six-3/CD	amod||enzymes-6/NNS||core-4/JJ	amod||enzymes-6/NNS||fungal-5/JJ	prep_of||proportions-1/NNS||enzymes-6/NNS	nn||²-15/NNPS||cbh1-8/NNPS	dep||²-15/NNPS||cbh2-10/NNPS	dep||²-15/NNPS||eg1-12/NNPS	dep||²-15/NNPS||î-14/NNP	dep||enzymes-6/NNS||²-15/NNPS	dep||²-15/NNPS||glucosidase-17/NN	det||xylosidase-29/NN||a-19/DT	amod||xylosidase-29/NN||gh10-20/JJ	advmod||1,4-xylanase-23/JJ||endo-î-21/RB	advmod||1,4-xylanase-23/JJ||²-22/RB	amod||xylosidase-29/NN||1,4-xylanase-23/JJ	advmod||²-27/JJ||î-26/RB	conj_and||1,4-xylanase-23/JJ||²-27/JJ	amod||xylosidase-29/NN||²-27/JJ	appos||glucosidase-17/NN||xylosidase-29/NN	auxpass||optimized-32/VBN||were-31/VBD	root||ROOT-0/null||optimized-32/VBN	det||loading-37/NN||a-34/DT	amod||loading-37/NN||fixed-35/VBN	nn||loading-37/NN||enzyme-36/NN	prep_at||optimized-32/VBN||loading-37/NN	num||glucan-41/NN||15-39/CD	amod||glucan-41/NN||mg/g-40/VBG	prep_of||loading-37/NN||glucan-41/NN	prep_for||glucan-41/NN||release-43/NN	prep_of||release-43/NN||glc-45/NN	prep_of||release-43/NN||xyl-47/NN	conj_and||glc-45/NN||xyl-47/NN	det||combinations-50/NNS||all-49/DT	prep_from||glucan-41/NN||combinations-50/NNS	num||feedstocks-54/NNS||five-52/CD	amod||feedstocks-54/NNS||biomass-53/JJ	prep_of||combinations-50/NNS||feedstocks-54/NNS	nn||stover-57/NN||corn-56/NN	nsubj||dried-63/VBD||stover-57/NN	appos||stover-57/NN||switchgrass-59/NNS	appos||switchgrass-59/NNS||miscanthus-61/NNS	dep||glucan-41/NN||dried-63/VBD	poss||grains-66/NNS||distillers-64/NNS	dobj||dried-63/VBD||grains-66/NNS	prep||grains-66/NNS||plus-67/CC	amod||-RSB--71/NNP||solubles-68/JJ	amod||-RSB--71/NNP||-LSB--69/VBG	nn||-RSB--71/NNP||ddgs-70/NNS	pobj||plus-67/CC||-RSB--71/NNP	pobj||plus-67/CC||poplar-73/NNP	conj_and||-RSB--71/NNP||poplar-73/NNP	vmod||glucan-41/NN||subjected-75/VBN	num||pretreatments-79/NNS||three-77/CD	amod||pretreatments-79/NNS||alkaline-78/JJ	prep_to||subjected-75/VBN||pretreatments-79/NNS	dep||pretreatments-79/NNS||afex-81/VB	dep||pretreatments-79/NNS||dilute-83/VB	conj_and||afex-81/VB||dilute-83/VB	amod||-RSB--89/NN||base-84/JJ	amod||-RSB--89/NN||-LSB--85/JJ	number||%-87/NN||0.25-86/CD	amod||-RSB--89/NN||%-87/NN	nn||-RSB--89/NN||naoh-88/NN	dobj||dilute-83/VB||-RSB--89/NN	dep||pretreatments-79/NNS||alkaline-91/VB	conj_and||afex-81/VB||alkaline-91/VB	amod||-RSB--95/NNS||peroxide-92/JJ	amod||-RSB--95/NNS||-LSB--93/JJ	nn||-RSB--95/NNS||ap-94/NN	dobj||alkaline-91/VB||-RSB--95/NNS	enzyme-36||endo--1||no_rel||proportions of six core fungal enzymes (cbh1, cbh2, eg1, î²-glucosidase, a gh10 endo-î²1,4-xylanase, and î²-xylosidase) were optimized at a fixed enzyme loading of 15 mg/g glucan for release of glc and xyl from all combinations of five biomass feedstocks (corn stover, switchgrass, miscanthus , dried distillers' grains plus solubles [ddgs] and poplar) subjected to three alkaline pretreatments (afex, dilute base [0.25% naoh] and alkaline peroxide [ap]).
nsubj||receiving-3/VBG||patients-2/NNS	prepc_in||had-17/VBD||receiving-3/VBG	dobj||receiving-3/VBG||dacarbazine-4/NN	amod||chemotherapy-7/NN||first-line-6/JJ	prep_as||receiving-3/VBG||chemotherapy-7/NN	amod||melanoma-10/NN||metastatic-9/JJ	prep_for||chemotherapy-7/NN||melanoma-10/NN	det||addition-13/NN||the-12/DT	nsubj||had-17/VBD||addition-13/NN	amod||bosentan-16/NN||high-dose-15/JJ	prep_of||addition-13/NN||bosentan-16/NN	root||ROOT-0/null||had-17/VBD	neg||effect-19/NN||no-18/DT	dobj||had-17/VBD||effect-19/NN	prep_on||effect-19/NN||time-21/NN	nn||progression-24/NN||tumor-23/NN	prep_to||had-17/VBD||progression-24/NN	amod||parameters-28/NNS||other-26/JJ	nn||parameters-28/NNS||efficacy-27/NN	prep_to||had-17/VBD||parameters-28/NNS	conj_or||progression-24/NN||parameters-28/NNS	dacarbazine-4||tumor-23||no_rel||in patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.
nsubj||shown-3/VBN||we-1/PRP	aux||shown-3/VBN||have-2/VBP	root||ROOT-0/null||shown-3/VBN	mark||reduced-19/VBD||that-4/IN	nsubj||reduced-19/VBD||rgcs-5/NNS	vmod||rgcs-5/NNS||exposed-6/VBN	prep_to||exposed-6/VBN||hypoxia-8/NN	num||%-11/NN||1-10/CD	appos||hypoxia-8/NN||%-11/NN	nn||display-18/NN||hypoxia-14/NN	amod||display-18/NN||mimetic-15/JJ	amod||display-18/NN||cobalt-16/JJ	nn||display-18/NN||chloride-17/NN	prep_to||exposed-6/VBN||display-18/NN	conj_or||hypoxia-8/NN||display-18/NN	ccomp||shown-3/VBN||reduced-19/VBD	dobj||reduced-19/VBD||expression-20/NN	prep_of||expression-20/NN||prdx6-22/CD	amod||expression-26/NN||higher-24/JJR	nn||expression-26/NN||ros-25/NN	prep_with||reduced-19/VBD||expression-26/NN	prep_with||reduced-19/VBD||activation-28/NN	conj_and||expression-26/NN||activation-28/NN	prep_of||activation-28/NN||nf-îºb-30/NN	cobalt-16||hypoxia-14||no_rel||we have shown that rgcs exposed to hypoxia (1%) or hypoxia mimetic cobalt chloride display reduced expression of prdx6 with higher ros expression and activation of nf-îºb.
amod||studies-2/NNS||several-1/JJ	nsubj||demonstrated-15/VBN||studies-2/NNS	nsubj||associated-28/VBN||studies-2/NNS	num||studies-9/NNS||three-5/CD	amod||studies-9/NNS||double-blind-6/JJ	amod||studies-9/NNS||placebo-controlled-8/JJ	prep_including||studies-2/NNS||studies-9/NNS	amod||analyses-12/NNS||intent-to-treat-11/JJ	prep_with||studies-9/NNS||analyses-12/NNS	aux||demonstrated-15/VBN||have-14/VBP	root||ROOT-0/null||demonstrated-15/VBN	det||efficacy-17/NN||the-16/DT	dobj||demonstrated-15/VBN||efficacy-17/NN	amod||tablets-21/NNS||modafinil-19/JJ	amod||tablets-21/NNS||film-coated-20/JJ	prep_of||efficacy-17/NN||tablets-21/NNS	prepc_in||demonstrated-15/VBN||reducing-23/VBG	dobj||reducing-23/VBG||symptoms-24/NNS	prep_of||symptoms-24/NNS||adhd-26/NN	conj_and||demonstrated-15/VBN||associated-28/VBN	nn||behaviors-30/NNS||problem-29/NN	dobj||associated-28/VBN||behaviors-30/NNS	prep_in||associated-28/VBN||children-32/NNS	prep_in||associated-28/VBN||adolescents-34/NNS	conj_and||children-32/NNS||adolescents-34/NNS	adhd-26||modafinil-19||yes||several studies, including three double-blind, placebo-controlled studies with intent-to-treat analyses, have demonstrated the efficacy of modafinil film-coated tablets in reducing symptoms of adhd and associated problem behaviors in children and adolescents.
nsubjpass||performed-3/VBN||bioassay-1/NN	auxpass||performed-3/VBN||were-2/VBD	root||ROOT-0/null||performed-3/VBN	prep_on||performed-3/VBN||adults-5/NNS	vmod||adults-5/NNS||collected-6/VBN	det||field-9/NN||the-8/DT	prep_from||collected-6/VBN||field-9/NN	aux||assess-11/VB||to-10/TO	xcomp||collected-6/VBN||assess-11/VB	det||susceptibility-13/NN||the-12/DT	dobj||assess-11/VB||susceptibility-13/NN	nn||vectors-16/NNS||malaria-15/NN	prep_of||susceptibility-13/NN||vectors-16/NNS	amod||papers-19/NNS||insecticide-impregnated-18/JJ	prep_to||assess-11/VB||papers-19/NNS	dep||performed-3/VBN||permethrin-21/VB	num||%-23/NN||0.75-22/CD	dobj||permethrin-21/VB||%-23/NN	dep||performed-3/VBN||delthamethrin-25/VB	conj_and||permethrin-21/VB||delthamethrin-25/VB	num||%-27/NN||0.05-26/CD	dobj||delthamethrin-25/VB||%-27/NN	dep||performed-3/VBN||ddt-29/VB	conj_and||permethrin-21/VB||ddt-29/VB	num||%-31/NN||4-30/CD	dobj||ddt-29/VB||%-31/NN	dep||performed-3/VBN||bendiocarb-34/VB	conj_and||permethrin-21/VB||bendiocarb-34/VB	num||%-36/NN||0.1-35/CD	dobj||bendiocarb-34/VB||%-36/NN	amod||guidelines-40/NNS||whopes-39/JJ	prep_following||performed-3/VBN||guidelines-40/NNS	ddt-29||malaria-15||no_rel||bioassay were performed on adults collected from the field to assess the susceptibility of malaria vectors to insecticide-impregnated papers (permethrin 0.75%, delthamethrin 0.05%, ddt 4%, and bendiocarb 0.1%) following whopes guidelines.
amod||type-6/NN||human-1/JJ	nn||type-6/NN||t-2/NN	nn||type-6/NN||cell-3/NN	nn||type-6/NN||leukemia-4/NN	nn||type-6/NN||virus-5/NN	nsubj||agent-14/NN||type-6/NN	dep||type-6/NN||1-7/CD	dep||type-6/NN||htlv-1-9/JJ	cop||agent-14/NN||is-11/VBZ	det||agent-14/NN||the-12/DT	amod||agent-14/NN||etiologic-13/JJ	root||ROOT-0/null||agent-14/NN	amod||leukemia-19/NN||adult-16/JJ	nn||leukemia-19/NN||t-17/NN	nn||leukemia-19/NN||cell-18/NN	prep_of||agent-14/NN||leukemia-19/NN	appos||leukemia-19/NN||atl-21/NN	det||disorder-26/NN||the-24/DT	amod||disorder-26/NN||neurological-25/JJ	conj_and||agent-14/NN||disorder-26/NN	amod||tropicalspasticparaparesis-29/NNS||htlv-1-associatedmyelopathy-27/JJ	amod||tropicalspasticparaparesis-29/NNS||/-28/JJ	dep||disorder-26/NN||tropicalspasticparaparesis-29/NNS	appos||tropicalspasticparaparesis-29/NNS||ham/tsp-31/NN	htlv-1-associatedmyelopathy-27||htlv-1-9||no||human t cell leukemia virus type 1 (htlv-1) is the etiologic agent of adult t cell leukemia (atl) and the neurological disorder htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||participated-8/VBN||background-1/NN	nsubj||received-19/VBD||background-1/NN	num||years-4/NNS||20-3/CD	prep_for||background-1/NN||years-4/NNS	appos||years-4/NNS||china-6/NN	aux||participated-8/VBN||has-7/VBZ	root||ROOT-0/null||participated-8/VBN	num||projects-13/NNS||267-10/CD	amod||projects-13/NNS||international-11/JJ	nn||projects-13/NNS||cooperation-12/NN	prep_in||participated-8/VBN||projects-13/NNS	det||epidemic-17/NN||the-15/DT	amod||epidemic-17/NN||hiv/aids-16/JJ	prep_against||projects-13/NNS||epidemic-17/NN	conj_and||participated-8/VBN||received-19/VBD	number||1/4-21/CD||âˆ-20/CD	dobj||received-19/VBD||1/4-21/CD	number||million-23/CD||526-22/CD	num||usd-24/NN||million-23/CD	npadvmod||received-19/VBD||usd-24/NN	quantmod||40-27/CD||over-26/IN	num||organizations-29/NNS||40-27/CD	amod||organizations-29/NNS||international-28/JJ	prep_from||received-19/VBD||organizations-29/NNS	aids--1||hiv--1||no||background for 20 years, china has participated in 267 international cooperation projects against the hiv/aids epidemic and received âˆ¼526 million usd from over 40 international organizations.
amod||therapy-2/NN||artemisinin-combination-1/JJ	nsubjpass||recommended-7/VBN||therapy-2/NN	appos||therapy-2/NN||act-4/NN	auxpass||recommended-7/VBN||is-6/VBZ	root||ROOT-0/null||recommended-7/VBN	amod||treatment-10/NN||first-line-9/JJ	prep_as||recommended-7/VBN||treatment-10/NN	prep_of||treatment-10/NN||falciparummalaria-12/NN	det||world-15/NN||the-14/DT	prep_throughout||recommended-7/VBN||world-15/NN	amod||combinations-19/NNS||fixed-dose-18/JJ	nsubjpass||preferred-21/VBN||combinations-19/NNS	auxpass||preferred-21/VBN||are-20/VBP	conj_and||recommended-7/VBN||preferred-21/VBN	agent||preferred-21/VBN||who-23/WP	mark||added-34/VBN||whether-25/IN	det||dose-29/NN||a-26/DT	amod||dose-29/NN||single-27/JJ	amod||dose-29/NN||gametocytocidal-28/JJ	nsubjpass||added-34/VBN||dose-29/NN	prep_of||dose-29/NN||primaquine-31/NN	aux||added-34/VBN||should-32/MD	auxpass||added-34/VBN||be-33/VB	csubj||unknown-36/JJ||added-34/VBN	cop||unknown-36/JJ||is-35/VBZ	parataxis||recommended-7/VBN||unknown-36/JJ	falciparummalaria-12||primaquine-31||yes||artemisinin-combination therapy (act) is recommended as first-line treatment of falciparummalaria throughout the world, and fixed-dose combinations are preferred by who; whether a single gametocytocidal dose of primaquine should be added is unknown.
amod||management-2/NN||obstetric-1/JJ	nsubj||focuses-6/VBZ||management-2/NN	amod||pre-eclampsia-5/NN||severe-4/JJ	prep_of||management-2/NN||pre-eclampsia-5/NN	root||ROOT-0/null||focuses-6/VBZ	amod||management-9/NN||medical-8/JJ	prep_on||focuses-6/VBZ||management-9/NN	nn||pressure-12/NN||blood-11/NN	prep_of||management-9/NN||pressure-12/NN	prep_of||management-9/NN||prevention-14/NN	conj_and||pressure-12/NN||prevention-14/NN	prep_of||management-9/NN||seizures-16/NNS	vmod||seizures-16/NNS||using-17/VBG	dobj||using-17/VBG||magnesiumsulfate-18/NN	det||cure-23/NN||the-21/DT	amod||cure-23/NN||ultimate-22/JJ	nsubj||remains-24/VBZ||cure-23/NN	conj_but||focuses-6/VBZ||remains-24/VBZ	xcomp||remains-24/VBZ||delivery-25/NN	det||fetus-28/NN||the-27/DT	prep_of||delivery-25/NN||fetus-28/NN	prep_of||delivery-25/NN||placenta-30/NN	conj_and||fetus-28/NN||placenta-30/NN	pre-eclampsia-5||magnesiumsulfate-18||yes||obstetric management of severe pre-eclampsia focuses on medical management of blood pressure and prevention of seizures using magnesiumsulfate, but the ultimate cure remains delivery of the fetus and placenta.
nsubjpass||associated-3/VBN||aceruloplasminemia-1/NN	auxpass||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	amod||brain-6/NN||severe-5/JJ	prep_with||associated-3/VBN||brain-6/NN	nn||ironoverload-9/NN||liver-8/NN	prep_with||associated-3/VBN||ironoverload-9/NN	conj_and||brain-6/NN||ironoverload-9/NN	advmod||increased-21/VBN||where-11/WRB	amod||expression-14/NN||hepatic-12/JJ	nn||expression-14/NN||mrna-13/NN	nsubjpass||increased-21/VBN||expression-14/NN	det||hepcidin-19/NN||the-16/DT	nn||hepcidin-19/NN||iron-17/NN	nn||hepcidin-19/NN||hormone-18/NN	prep_of||expression-14/NN||hepcidin-19/NN	auxpass||increased-21/VBN||was-20/VBD	rcmod||brain-6/NN||increased-21/VBN	amod||brain-6/NN||corresponding-23/JJ	det||degree-26/NN||the-25/DT	prep_to||corresponding-23/JJ||degree-26/NN	prep_of||degree-26/NN||ironoverload-28/NN	ironoverload-28||iron-17||no||aceruloplasminemia was associated with severe brain and liver ironoverload, where hepatic mrna expression of the iron hormone hepcidin was increased, corresponding to the degree of ironoverload.
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	tumor-57||fattyacids-55||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâ€“reacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
det||introduction-3/NN||the-2/DT	prep_with||is-21/VBZ||introduction-3/NN	amod||therapy-7/NN||artemisinin-based-5/JJ	nn||therapy-7/NN||combination-6/NN	prep_of||introduction-3/NN||therapy-7/NN	appos||therapy-7/NN||act-9/NN	prep_for||therapy-7/NN||treatment-12/NN	prep_of||treatment-12/NN||malaria-14/NN	amod||settings-18/NNS||many-16/JJ	amod||settings-18/NNS||low-resource-17/JJ	prep_in||malaria-14/NN||settings-18/NNS	expl||is-21/VBZ||there-20/EX	root||ROOT-0/null||is-21/VBZ	nsubj||is-21/VBZ||need-22/NN	aux||target-24/VB||to-23/TO	vmod||need-22/NN||target-24/VB	dobj||target-24/VB||treatment-25/NN	prep_to||target-24/VB||patients-27/NNS	prep_with||target-24/VB||parasitologically-29/NN	vmod||parasitologically-29/NN||confirmed-30/VBN	dobj||confirmed-30/VBN||malaria-31/NN	prep_in||confirmed-30/VBN||order-33/NN	aux||improve-35/VB||to-34/TO	vmod||confirmed-30/VBN||improve-35/VB	dobj||improve-35/VB||quality-36/NN	prep_of||quality-36/NN||care-38/NN	vmod||confirmed-30/VBN||reduce-40/VB	conj_and||improve-35/VB||reduce-40/VB	prt||reduce-40/VB||over-41/RP	dobj||reduce-40/VB||consumption-42/NN	prep_of||consumption-42/NN||anti-malarials-44/NNS	vmod||confirmed-30/VBN||reduce-46/VB	conj_and||improve-35/VB||reduce-46/VB	nn||pressure-48/NN||drug-47/NN	dobj||reduce-46/VB||pressure-48/NN	advmod||turn-51/VB||in-50/RB	vmod||confirmed-30/VBN||turn-51/VB	conj_and||improve-35/VB||turn-51/VB	nn||development-53/NN||delay-52/NN	dobj||turn-51/VB||development-53/NN	dobj||turn-51/VB||spread-55/NN	conj_and||development-53/NN||spread-55/NN	nn||resistance-58/NN||drug-57/NN	prep_of||development-53/NN||resistance-58/NN	anti-malarials-44||malaria-31||no_rel||with the introduction of artemisinin-based combination therapy (act) for treatment of malaria in many low-resource settings, there is need to target treatment to patients with parasitologically confirmed malaria in order to improve quality of care, reduce over consumption of anti-malarials, reduce drug pressure and in turn delay development and spread of drug resistance.
amod||studies-2/NNS||further-1/JJ	nsubjpass||needed-4/VBN||studies-2/NNS	nsubj||investigate-6/VB||studies-2/NNS	auxpass||needed-4/VBN||are-3/VBP	root||ROOT-0/null||needed-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||needed-4/VBN||investigate-6/VB	det||safety-8/NN||the-7/DT	dobj||investigate-6/VB||safety-8/NN	dobj||investigate-6/VB||efficiency-10/NN	conj_and||safety-8/NN||efficiency-10/NN	amod||contraception-13/NN||hormonal-12/JJ	prep_of||safety-8/NN||contraception-13/NN	prep_in||investigate-6/VB||women-15/NNS	vmod||women-15/NNS||living-16/VBG	prep_with||living-16/VBG||hiv/aids-18/NNS	aids--1||hiv--1||no||further studies are needed to investigate the safety and efficiency of hormonal contraception in women living with hiv/aids.
det||strategies-4/NNS||the-2/DT	nn||strategies-4/NNS||prevention-3/NN	prep_of||involve-7/VBP||strategies-4/NNS	nsubj||involve-7/VBP||primordial-6/JJ	root||ROOT-0/null||involve-7/VBP	dobj||involve-7/VBP||improvement-8/NN	amod||status-11/NN||socioeconomic-10/JJ	prep_in||improvement-8/NN||status-11/NN	prep_in||improvement-8/NN||literacy-13/NN	conj_and||status-11/NN||literacy-13/NN	amod||financing-17/NN||adequate-15/JJ	nn||financing-17/NN||healthcare-16/NN	dobj||involve-7/VBP||financing-17/NN	conj_and||improvement-8/NN||financing-17/NN	amod||insurance-21/NN||public-19/JJ	nn||insurance-21/NN||health-20/NN	conj_and||improvement-8/NN||insurance-21/NN	conj_and||financing-17/NN||insurance-21/NN	amod||programme-27/NN||effective-23/JJ	amod||programme-27/NN||national-24/JJ	amod||programme-27/NN||cvd-25/JJ	nn||programme-27/NN||control-26/NN	appos||financing-17/NN||programme-27/NN	nn||policies-31/NNS||smoking-29/NN	nn||policies-31/NNS||control-30/NN	appos||financing-17/NN||policies-31/NNS	amod||control-34/NN||legislative-33/JJ	appos||financing-17/NN||control-34/NN	amod||fats-37/NNS||saturated-36/JJ	prep_of||control-34/NN||fats-37/NNS	amod||fats-40/NNS||trans-39/JJ	appos||financing-17/NN||fats-40/NNS	appos||financing-17/NN||salt-42/NN	conj_and||fats-40/NNS||salt-42/NN	appos||financing-17/NN||alcohol-44/NN	conj_and||fats-40/NNS||alcohol-44/NN	dobj||involve-7/VBP||development-47/NN	conj_and||improvement-8/NN||development-47/NN	prep_of||development-47/NN||facilities-49/NNS	prepc_for||involve-7/VBP||increasing-51/VBG	amod||activity-53/NN||physical-52/JJ	dobj||increasing-51/VBG||activity-53/NN	amod||planning-57/NN||better-55/JJR	amod||planning-57/NN||urban-56/JJ	prep_through||increasing-51/VBG||planning-57/NN	prep_through||increasing-51/VBG||school-based-59/NN	conj_and||planning-57/NN||school-based-59/NN	nn||interventions-62/NNS||worksite-61/NN	prep_through||increasing-51/VBG||interventions-62/NNS	conj_and||planning-57/NN||interventions-62/NNS	fats-40||cvd-25||no_rel||of the prevention strategies, primordial involve improvement in socioeconomic status and literacy, adequate healthcare financing and public health insurance, effective national cvd control programme, smoking control policies, legislative control of saturated fats, trans fats, salt and alcohol, and development of facilities for increasing physical activity through better urban planning and school-based and worksite interventions.
root||ROOT-0/null||objectives-1/NNS	aux||study-3/VB||to-2/TO	vmod||objectives-1/NNS||study-3/VB	det||effects-5/NNS||the-4/DT	dobj||study-3/VB||effects-5/NNS	prep_of||effects-5/NNS||metformin-7/NN	det||incidence-10/NN||the-9/DT	prep_on||study-3/VB||incidence-10/NN	amod||deficiency-14/NN||vitamin-12/JJ	amod||deficiency-14/NN||b-12-13/JJ	prep_of||incidence-10/NN||deficiency-14/NN	number||150-17/CD||<-16/CD	num||pmol/l-18/NNS||150-17/CD	appos||objectives-1/NNS||pmol/l-18/NNS	amod||concentrations-22/NNS||low-21/JJ	conj_and||objectives-1/NNS||concentrations-22/NNS	nn||b-12-25/NN||vitamin-24/NN	prep_of||concentrations-22/NNS||b-12-25/NN	num||pmol/l-28/NN||150-220-27/CD	appos||concentrations-22/NNS||pmol/l-28/NN	amod||concentrations-35/NNS||folate-32/JJ	conj_and||folate-32/JJ||homocysteine-34/JJ	amod||concentrations-35/NNS||homocysteine-34/JJ	conj_and||objectives-1/NNS||concentrations-35/NNS	prep_in||concentrations-35/NNS||patients-37/NNS	prep_with||objectives-1/NNS||type2diabetes-39/NNS	vmod||type2diabetes-39/NNS||receiving-40/VBG	dobj||receiving-40/VBG||treatment-41/NN	prep_with||receiving-40/VBG||insulin-43/NN	type2diabetes-39||metformin-7||yes||objectives to study the effects of metformin on the incidence of vitamin b-12 deficiency (<150 pmol/l), low concentrations of vitamin b-12 (150-220 pmol/l), and folate and homocysteine concentrations in patients with type2diabetes receiving treatment with insulin.
nsubj||has-25/VBZ||identification-1/NN	prepc_of||identification-1/NN||neutralizing-3/VBG	dobj||neutralizing-3/VBG||antibodies-4/NNS	prep_with||antibodies-4/NNS||specificity-6/NN	det||mutation-11/NN||the-9/DT	amod||mutation-11/NN||traditional-10/JJ	prep_away_from||neutralizing-3/VBG||mutation-11/NN	amod||mutation-11/NN||prone-12/JJ	amod||regions-14/NNS||antigenic-13/JJ	dep||prone-12/JJ||regions-14/NNS	det||regions-19/NNS||the-17/DT	amod||regions-19/NNS||conserved-18/JJ	prep_against||regions-14/NNS||regions-19/NNS	prep_of||regions-19/NNS||hemagglutinin-21/NN	amod||influenzavirus-24/NNS||h5n1-23/JJ	prep_from||hemagglutinin-21/NN||influenzavirus-24/NNS	root||ROOT-0/null||has-25/VBZ	det||potential-27/NN||the-26/DT	dobj||has-25/VBZ||potential-27/NN	aux||provide-29/VB||to-28/TO	vmod||potential-27/NN||provide-29/VB	det||option-32/NN||a-30/DT	amod||option-32/NN||therapeutic-31/JJ	dobj||provide-29/VB||option-32/NN	nsubjpass||developed-36/VBN||option-32/NN	aux||developed-36/VBN||can-34/MD	auxpass||developed-36/VBN||be-35/VB	rcmod||option-32/NN||developed-36/VBN	prep_ahead_of||developed-36/VBN||time-39/NN	prep_in||time-39/NN||preparation-41/NN	det||pandemic-45/NN||a-43/DT	amod||pandemic-45/NN||possible-44/JJ	prep_for||developed-36/VBN||pandemic-45/NN	amod||viruses-49/NNS||h5n1-48/JJ	prep_due_to||pandemic-45/NN||viruses-49/NNS	h5n1-48||antibodies-4||no_rel||identification of neutralizing antibodies with specificity away from the traditional mutation prone antigenic regions, against the conserved regions of hemagglutinin from h5n1 influenzavirus has the potential to provide a therapeutic option which can be developed ahead of time in preparation for a possible pandemic due to h5n1 viruses.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||aripiprazole-66||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
root||ROOT-0/null||hereditary-1/VBG	amod||deficiency-5/NN||combined-2/VBN	amod||deficiency-5/NN||vitamink-dependent-3/JJ	nn||deficiency-5/NN||clottingfactors-4/NN	dobj||hereditary-1/VBG||deficiency-5/NN	dep||deficiency-5/NN||vkcfd-7/VBN	cop||bleedingdisorder-13/NN||is-9/VBZ	det||bleedingdisorder-13/NN||a-10/DT	amod||bleedingdisorder-13/NN||rare-11/JJ	amod||bleedingdisorder-13/NN||congenital-12/JJ	aux||hereditary-1/VBG||bleedingdisorder-13/NN	vmod||bleedingdisorder-13/NN||resulting-14/VBG	amod||levels-18/NNS||variably-16/JJ	amod||levels-18/NNS||decreased-17/VBN	prep_from||resulting-14/VBG||levels-18/NNS	amod||ii-21/NN||coagulationfactors-20/JJ	prep_of||levels-18/NNS||ii-21/NN	prep_of||levels-18/NNS||vii-23/NN	conj_and||ii-21/NN||vii-23/NN	prep_of||levels-18/NNS||ix-25/NN	conj_and||ii-21/NN||ix-25/NN	prep_of||levels-18/NNS||x-27/SYM	conj_and||ii-21/NN||x-27/SYM	amod||anticoagulants-32/NNS||natural-31/JJ	aux||hereditary-1/VBG||anticoagulants-32/NNS	conj_and||bleedingdisorder-13/NN||anticoagulants-32/NNS	dep||anticoagulants-32/NNS||protein-33/NN	nsubj||hereditary-1/VBG||c-34/SYM	nn||s-37/NNS||protein-36/NN	appos||c-34/SYM||s-37/NNS	nn||z.-40/NN||protein-39/NN	appos||c-34/SYM||z.-40/NN	conj_and||s-37/NNS||z.-40/NN	bleedingdisorder-13||anticoagulants-32||no_rel||hereditary combined vitamink-dependent clottingfactors deficiency (vkcfd) is a rare congenital bleedingdisorder resulting from variably decreased levels of coagulationfactors ii, vii, ix and x as well as natural anticoagulants protein c, protein s and protein z.
det||results-2/NNS||the-1/DT	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	amod||level-5/NN||intermediate-4/JJ	dobj||indicate-3/VBP||level-5/NN	prep_of||level-5/NN||endemicity-7/NN	nn||infection-10/NN||hbv-9/NN	prep_of||endemicity-7/NN||infection-10/NN	nn||community-13/NN||dhaka-12/NN	prep_in||infection-10/NN||community-13/NN	advmod||higher-17/JJR||much-16/RB	prep_with||indicate-3/VBP||higher-17/JJR	amod||higher-17/JJR||prevalence-18/JJ	nn||members-21/NNS||family-20/NN	prep_among||prevalence-18/JJ||members-21/NNS	amod||individuals-25/NNS||hbsag-23/JJ	amod||individuals-25/NNS||positive-24/JJ	prep_of||members-21/NNS||individuals-25/NNS	advmod||prevalence-28/JJ||low-27/RB	amod||higher-17/JJR||prevalence-28/JJ	conj_but||prevalence-18/JJ||prevalence-28/JJ	nn||infections-31/NNS||hcv-30/NN	prep_of||higher-17/JJR||infections-31/NNS	advmod||indicating-34/VBG||clearly-33/RB	vmod||higher-17/JJR||indicating-34/VBG	dobj||indicating-34/VBG||need-35/NN	amod||vaccination-39/NN||universal-37/JJ	nn||vaccination-39/NN||hepatitisb-38/NN	prep_for||higher-17/JJR||vaccination-39/NN	hbv-9||hbsag-23||yes||the results indicate intermediate level of endemicity of hbv infection in dhaka community, with much higher prevalence among family members of hbsag positive individuals but low prevalence of hcv infections, clearly indicating need for universal hepatitisb vaccination.
nsubj||³-6/NN||pneumophila-1/NN	cop||³-6/NN||is-2/VBZ	det||³-6/NN||a-3/DT	amod||³-6/NN||gram-negative-4/JJ	nn||³-6/NN||î-5/NN	root||ROOT-0/null||³-6/NN	conj_and||³-6/NN||proteobacterium-8/NN	det||agent-12/NN||the-10/DT	amod||agent-12/NN||causative-11/JJ	conj_and||³-6/NN||agent-12/NN	prep_of||agent-12/NN||legionnaires-14/NNS	dep||legionnaires-14/NNS||disease-16/NN	det||form-19/NN||a-18/DT	appos||legionnaires-14/NNS||form-19/NN	nn||pneumonia-22/NN||epidemic-21/NN	prep_of||form-19/NN||pneumonia-22/NN	legionnaires'disease--1||pneumophila-1||no||pneumophila is a gram-negative î³-proteobacterium and the causative agent of legionnaires'disease, a form of epidemic pneumonia.
det||patients-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||patients-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	amod||debridement-7/NN||surgical-6/JJ	agent||treated-4/VBN||debridement-7/NN	vmod||debridement-7/NN||followed-8/VBN	det||combination-11/NN||a-10/DT	agent||followed-8/VBN||combination-11/NN	nsubj||died-31/VBD||combination-11/NN	prep_of||combination-11/NN||antibiotics-13/NNS	dep||combination-11/NN||ceftazidime-16/NN	appos||ceftazidime-16/NN||amoxy-clavulanicacid-18/NN	appos||ceftazidime-16/NN||co-trimoxazole-20/NN	conj_and||amoxy-clavulanicacid-18/NN||co-trimoxazole-20/NN	appos||ceftazidime-16/NN||doxycycline-22/NN	conj_and||amoxy-clavulanicacid-18/NN||doxycycline-22/NN	num||months-26/NNS||six-25/CD	prep_for||ceftazidime-16/NN||months-26/NNS	prepc_except_for||months-26/NNS||for-28/IN	pobj||months-26/NNS||one-29/CD	rcmod||combination-11/NN||died-31/VBD	acomp||died-31/VBD||due-32/JJ	aux||fulminant-34/VB||to-33/TO	xcomp||due-32/JJ||fulminant-34/VB	dobj||fulminant-34/VB||septicemia-35/NN	septicemia-35||ceftazidime-16||no_rel||all patients were treated by surgical debridement followed by a combination of antibiotics; (ceftazidime, amoxy-clavulanicacid, co-trimoxazole and doxycycline) for six months except for one who died due to fulminant septicemia.
nsubjpass||found-3/VBN||praziquantel-1/NN	nsubj||effective-7/JJ||praziquantel-1/NN	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	aux||effective-7/JJ||to-4/TO	cop||effective-7/JJ||be-5/VB	advmod||effective-7/JJ||very-6/RB	xcomp||found-3/VBN||effective-7/JJ	advmod||complete-11/JJ||sometimes-10/RB	amod||worms-12/NNS||complete-11/JJ	nsubjpass||recovered-16/VBN||worms-12/NNS	aux||recovered-16/VBN||could-13/MD	neg||recovered-16/VBN||not-14/RB	auxpass||recovered-16/VBN||be-15/VB	conj_but||found-3/VBN||recovered-16/VBN	det||feces-19/NNS||the-18/DT	prep_from||recovered-16/VBN||feces-19/NNS	prep_after||recovered-16/VBN||treatment-21/NN	advmod||due-24/JJ||probably-23/RB	acomp||recovered-16/VBN||due-24/JJ	det||dissolution-27/NN||the-26/DT	prep_to||due-24/JJ||dissolution-27/NN	det||proglottids-30/NNS||the-29/DT	prep_of||dissolution-27/NN||proglottids-30/NNS	worms-12||praziquantel-1||yes||praziquantel was found to be very effective, but sometimes complete worms could not be recovered from the feces after treatment, probably due to the dissolution of the proglottids.
nsubj||remains-5/VBZ||quinine-1/NN	appos||quinine-1/NN||qn-3/NN	root||ROOT-0/null||remains-5/VBZ	det||drug-10/NN||the-6/DT	amod||drug-10/NN||first-7/JJ	nn||drug-10/NN||line-8/NN	nn||drug-10/NN||anti-malarial-9/NN	xcomp||remains-5/VBZ||drug-10/NN	det||treatment-13/NN||the-12/DT	prep_for||drug-10/NN||treatment-13/NN	amod||malaria-16/NN||complicated-15/JJ	prep_of||treatment-13/NN||malaria-16/NN	prep_in||malaria-16/NN||europe-18/NN	prep_in||malaria-16/NN||africa-20/NN	conj_and||europe-18/NN||africa-20/NN	malaria-16||quinine-1||yes||quinine (qn) remains the first line anti-malarial drug for the treatment of complicated malaria in europe and africa.
amod||infection-5/NNS||humantcelllymphotropicvirustype1-1/JJ	dep||infection-5/NNS||htlv-1-3/JJ	nsubj||lead-7/VB||infection-5/NNS	aux||lead-7/VB||can-6/MD	root||ROOT-0/null||lead-7/VB	prep_to||lead-7/VB||development-9/NN	amod||leukemia/lymphoma-14/NN||adult-11/JJ	nn||leukemia/lymphoma-14/NN||t-12/NN	nn||leukemia/lymphoma-14/NN||cell-13/NN	prep_of||development-9/NN||leukemia/lymphoma-14/NN	appos||leukemia/lymphoma-14/NN||atl-16/NN	amod||tropicalspasticparaparesis-21/NNS||htlv-1-associatedmyelopathy-19/JJ	amod||tropicalspasticparaparesis-21/NNS||/-20/JJ	prep_of||development-9/NN||tropicalspasticparaparesis-21/NNS	conj_or||leukemia/lymphoma-14/NN||tropicalspasticparaparesis-21/NNS	appos||leukemia/lymphoma-14/NN||ham/tsp-23/NN	det||subset-27/NN||a-26/DT	prep_in||lead-7/VB||subset-27/NN	amod||subjects-30/NNS||infected-29/JJ	prep_of||subset-27/NN||subjects-30/NNS	tropicalspasticparaparesis-21||humantcelllymphotropicvirustype1-1||no||humantcelllymphotropicvirustype1 (htlv-1) infection can lead to development of adult t cell leukemia/lymphoma (atl) or htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) in a subset of infected subjects.
mark||shown-5/VBN||although-1/IN	amod||monotherapy-3/NN||docetaxel-2/JJ	nsubj||shown-5/VBN||monotherapy-3/NN	aux||shown-5/VBN||has-4/VBZ	advcl||controversial-38/JJ||shown-5/VBN	amod||benefits-7/NNS||clinical-6/JJ	dobj||shown-5/VBN||benefits-7/NNS	advmod||treated-10/JJ||previously-9/RB	amod||patients-11/NNS||treated-10/JJ	prep_for||shown-5/VBN||patients-11/NNS	amod||non-smallcelllungcancer-14/NN||advanced-13/VBN	prep_with||patients-11/NNS||non-smallcelllungcancer-14/NN	dep||patients-11/NNS||nsclc-16/JJ	det||efficacy-20/NN||the-19/DT	nsubj||controversial-38/JJ||efficacy-20/NN	nn||chemotherapy-24/NN||salvage-22/NN	amod||chemotherapy-24/NN||docetaxel-23/JJ	prep_of||efficacy-20/NN||chemotherapy-24/NN	amod||patients-27/NNS||elderly-26/JJ	prep_for||chemotherapy-24/NN||patients-27/NNS	prep_for||chemotherapy-24/NN||patients-29/NNS	conj_or||patients-27/NNS||patients-29/NNS	amod||status-33/NN||poor-31/JJ	nn||status-33/NN||performance-32/NN	prep_with||patients-27/NNS||status-33/NN	appos||status-33/NN||ps-35/NN	cop||controversial-38/JJ||is-37/VBZ	root||ROOT-0/null||controversial-38/JJ	nsclc-16||docetaxel-23||yes||although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-smallcelllungcancer (nsclc), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with poor performance status (ps) is controversial.
nsubj||disease-9/NN||porcinecontagiouspleuropneumonia-1/NN	appos||porcinecontagiouspleuropneumonia-1/NN||pcp-3/NN	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||a-6/DT	advmod||contagious-8/JJ||highly-7/RB	amod||disease-9/NN||contagious-8/JJ	root||ROOT-0/null||disease-9/NN	nsubjpass||caused-12/VBN||disease-9/NN	nsubjpass||characterized-19/VBN||disease-9/NN	auxpass||caused-12/VBN||is-11/VBZ	rcmod||disease-9/NN||caused-12/VBN	agent||caused-12/VBN||actinobacilluspleuropneumoniae-14/NN	appos||actinobacilluspleuropneumoniae-14/NN||app-16/NN	rcmod||disease-9/NN||characterized-19/VBN	conj_and||caused-12/VBN||characterized-19/VBN	amod||fibrinous-22/NNS||severe-21/JJ	prep_by||characterized-19/VBN||fibrinous-22/NNS	vmod||fibrinous-22/NNS||necrotizing-23/VBG	amod||pleuropneumonia-25/NN||hemorrhagic-24/JJ	dobj||necrotizing-23/VBG||pleuropneumonia-25/NN	nsubj||threat-31/NN||pleuropneumonia-25/NN	cop||threat-31/NN||is-28/VBZ	det||threat-31/NN||a-29/DT	amod||threat-31/NN||severe-30/JJ	rcmod||pleuropneumonia-25/NN||threat-31/NN	det||industry-35/NN||the-33/DT	nn||industry-35/NN||swine-34/NNS	prep_to||threat-31/NN||industry-35/NN	porcinecontagiouspleuropneumonia-1||actinobacilluspleuropneumoniae-14||no||porcinecontagiouspleuropneumonia (pcp) is a highly contagious disease that is caused by actinobacilluspleuropneumoniae (app) and characterized by severe fibrinous necrotizing hemorrhagic pleuropneumonia, which is a severe threat to the swine industry.
prep_since||administered-14/VBN||1986-2/CD	nsubjpass||administered-14/VBN||interferon-alfa-4/NN	dep||interferon-alfa-4/NN||ifn-6/NN	nn||±-9/NNS||î-8/NN	dep||ifn-6/NN||±-9/NNS	advmod||administered-14/VBN||monotherapy-11/RB	aux||administered-14/VBN||has-12/VBZ	auxpass||administered-14/VBN||been-13/VBN	root||ROOT-0/null||administered-14/VBN	prep_for||administered-14/VBN||patients-16/NNS	prep_with||patients-16/NNS||chronichepatitisc-18/NN	appos||chronichepatitisc-18/NN||chc-20/NN	chronichepatitisc-18||interferon--1||yes||since 1986, interferon-alfa (ifn- î± ) monotherapy has been administered for patients with chronichepatitisc (chc).
det||observational-3/NN||a-1/DT	amod||observational-3/NN||prospective-2/JJ	nsubj||assessed-5/VBD||observational-3/NN	advmod||assessed-5/VBD||registry-4/RB	root||ROOT-0/null||assessed-5/VBD	amod||experience-8/NN||real-6/JJ	nn||experience-8/NN||world-7/NN	dobj||assessed-5/VBD||experience-8/NN	nn||monotherapy-11/NN||caspofungin-10/NN	prep_with||assessed-5/VBD||monotherapy-11/NN	nn||therapy-14/NN||combination-13/NN	prep_with||assessed-5/VBD||therapy-14/NN	conj_or||monotherapy-11/NN||therapy-14/NN	det||treatment-20/NN||the-16/DT	amod||treatment-20/NN||initial-17/JJ	conj_or||initial-17/JJ||salvage-19/NN	amod||treatment-20/NN||salvage-19/NN	prep_for||monotherapy-11/NN||treatment-20/NN	amod||aspergillosis-26/NNS||proven-22/JJ	conj_or||proven-22/JJ||probable-24/JJ	amod||aspergillosis-26/NNS||probable-24/JJ	nn||aspergillosis-26/NNS||invasive-25/NN	prep_of||monotherapy-11/NN||aspergillosis-26/NNS	appos||aspergillosis-26/NNS||ia-28/NN	aspergillosis-26||caspofungin-10||yes||a prospective observational registry assessed real world experience with caspofungin monotherapy or combination therapy for the initial or salvage treatment of proven or probable invasive aspergillosis (ia).
det||group-3/NN||the-1/DT	nn||group-3/NN||patient-2/NN	nsubj||consisted-4/VBD||group-3/NN	root||ROOT-0/null||consisted-4/VBD	num||patients-7/NNS||180-6/CD	prep_of||consisted-4/VBD||patients-7/NNS	amod||disease-11/NN||active-9/JJ	nn||disease-11/NN||tb-10/NN	prep_with||patients-7/NNS||disease-11/NN	dep||disease-11/NN||culture-positive-13/JJ	prep_for||culture-positive-13/JJ||mtb-15/NN	num||contacts-20/NNS||50-18/CD	nn||contacts-20/NNS||screening-19/NN	prep_of||consisted-4/VBD||contacts-20/NNS	conj_and||patients-7/NNS||contacts-20/NNS	amod||response-23/NN||ltbi-positive-22/JJ	prep_with||contacts-20/NNS||response-23/NN	det||test-27/NN||the-25/DT	amod||test-27/NN||qft-2g-26/JJ	prep_to||consisted-4/VBD||test-27/NN	tb-10||mtb-15||no||the patient group consisted of 180 patients with active tb disease (culture-positive for mtb) and 50 screening contacts with ltbi-positive response to the qft-2g test.
nsubj||encompasses-5/VBZ||cutaneouslupuserythematosus-1/NNS	appos||cutaneouslupuserythematosus-1/NNS||cle-3/NN	root||ROOT-0/null||encompasses-5/VBZ	det||variety-7/NN||a-6/DT	dobj||encompasses-5/VBZ||variety-7/NN	prep_of||variety-7/NN||lesions-9/NNS	nsubjpass||refractory-13/VBN||lesions-9/NNS	aux||refractory-13/VBN||may-11/MD	auxpass||refractory-13/VBN||be-12/VB	rcmod||lesions-9/NNS||refractory-13/VBN	prep_to||refractory-13/VBN||systemic-15/NNS	prep_to||refractory-13/VBN||topicalagents-17/NNS	conj_or||systemic-15/NNS||topicalagents-17/NNS	cutaneouslupuserythematosus-1||topicalagents-17||no_rel||cutaneouslupuserythematosus (cle) encompasses a variety of lesions that may be refractory to systemic or topicalagents.
prep_in||found-10/VBN||addition-2/NN	det||âˆ-5/NN||the-4/DT	poss||allele-8/NN||âˆ-5/NN	amod||allele-8/NN||139a-7/JJ	nsubjpass||found-10/VBN||allele-8/NN	nsubjpass||associated-13/VBN||allele-8/NN	auxpass||found-10/VBN||was-9/VBD	root||ROOT-0/null||found-10/VBN	aux||associated-13/VBN||to-11/TO	auxpass||associated-13/VBN||be-12/VB	xcomp||found-10/VBN||associated-13/VBN	prep_with||associated-13/VBN||protection-15/NN	prep_against||associated-13/VBN||htlv-1infection-17/JJ	parataxis||associated-13/VBN||p-19/VB	number||0.0037-21/CD||=-20/CD	dobj||p-19/VB||0.0037-21/CD	dobj||p-19/VB||=-24/NNP	conj_or||0.0037-21/CD||=-24/NNP	num||=-24/NNP||0.3758-25/CD	num||=-24/NNP||95â-27/CD	dep||%-30/NN||$-28/$	num||$-28/$||š-29/CD	amod||â-34/NNS||%-30/NN	nn||â-34/NNS||ci-31/NN	amod||â-34/NNS||=-32/JJ	num||â-34/NNS||0.1954-33/CD	dep||=-24/NNP||â-34/NNS	num||â-34/NNS||$-35/$	num||$-35/$||0.7229-37/CD	advmod||compared-47/VBN||when-39/WRB	det||patients-42/NNS||the-40/DT	amod||patients-42/NNS||htlv-1-infected-41/JJ	nsubjpass||compared-47/VBN||patients-42/NNS	det||whole-45/NN||a-44/DT	prep_as||patients-42/NNS||whole-45/NN	auxpass||compared-47/VBN||were-46/VBD	advcl||associated-13/VBN||compared-47/VBN	det||group-51/NN||the-49/DT	amod||group-51/NN||healthy-control-50/JJ	prep_with||compared-47/VBN||group-51/NN	htlv-1infection-17||htlv-1--1||no||in addition, the âˆ’139a allele was found to be associated with protection against htlv-1infection ( p =0.0037, or=0.3758, 95â€š% ci=0.1954â€“0.7229) when the htlv-1-infected patients as a whole were compared with the healthy-control group.
aux||characterize-2/VB||to-1/TO	csubj||randomized-38/VBD||characterize-2/VB	det||amount-4/NN||the-3/DT	dobj||characterize-2/VB||amount-4/NN	amod||hypoglycemia-7/NN||nocturnal-6/JJ	prep_of||amount-4/NN||hypoglycemia-7/NN	conj_and||characterize-2/VB||evaluate-9/VB	csubj||randomized-38/VBD||evaluate-9/VB	dobj||evaluate-9/VB||factors-10/NNS	vmod||factors-10/NNS||associated-11/VBN	amod||hypoglycemia-14/NN||nocturnal-13/JJ	prep_with||associated-11/VBN||hypoglycemia-14/NN	vmod||hypoglycemia-14/NN||assessed-15/VBN	amod||monitoring-19/NN||continuous-17/JJ	nn||monitoring-19/NN||glucose-18/NN	prep_with||assessed-15/VBN||monitoring-19/NN	appos||monitoring-19/NN||cgm-21/NN	prep_in||monitoring-19/NN||adults-24/NNS	prep_in||monitoring-19/NN||children-26/NNS	conj_and||adults-24/NNS||children-26/NNS	prep_with||assessed-15/VBN||type1diabetes-28/NNS	nsubj||participated-30/VBD||type1diabetes-28/NNS	rcmod||type1diabetes-28/NNS||participated-30/VBD	det||cgm-37/NN||the-32/DT	amod||cgm-37/NN||juvenile-33/JJ	nn||cgm-37/NN||diabetes-34/NN	nn||cgm-37/NN||research-35/NN	nn||cgm-37/NN||foundation-36/NN	prep_in||participated-30/VBD||cgm-37/NN	root||ROOT-0/null||randomized-38/VBD	amod||trial-40/NN||clinical-39/JJ	dobj||randomized-38/VBD||trial-40/NN	glucose-18||hypoglycemia-14||no_rel||to characterize the amount of nocturnal hypoglycemia and evaluate factors associated with nocturnal hypoglycemia assessed with continuous glucose monitoring (cgm) in adults and children with type1diabetes who participated in the juvenile diabetes research foundation cgm randomized clinical trial.
nn||rigidity-2/NN||flexor-1/NN	nsubj||increased-3/VBD||rigidity-2/NN	nsubj||decreased-57/VBD||rigidity-2/NN	root||ROOT-0/null||increased-3/VBD	amod||positivity-6/NN||hydrogen-breath-test-5/JJ	prep_before||increased-3/VBD||positivity-6/NN	amod||overgrowth-11/NN||small-8/JJ	amod||overgrowth-11/NN||intestinal-9/JJ	amod||overgrowth-11/NN||bacterial-10/JJ	prep_for||positivity-6/NN||overgrowth-11/NN	nsubj||p-27/VBP||208-13/CD	appos||208-13/CD||28â-15/NNP	num||28â-15/NNP||$-16/$	num||$-16/$||388-18/CD	nn||ã-21/FW||nm-20/FW	dep||208-13/CD||ã-21/FW	dep||208-13/CD||10âˆ-23/NNS	dep||208-13/CD||3-25/CD	parataxis||increased-32/VBN||p-27/VBP	dep||.02-29/CD||=-28/SYM	ccomp||p-27/VBP||.02-29/CD	vmod||positivity-6/NN||increased-32/VBN	advmod||increased-32/VBN||further-33/RBR	prep||increased-32/VBN||during-34/IN	dep||positivity-6/NN||171-36/VBN	dep||171-36/VBN||67â-38/NNP	num||67â-38/NNP||$-39/$	num||$-39/$||274-41/CD	dep||171-36/VBN||p-44/VBN	dep||.001-46/CD||=-45/SYM	ccomp||p-44/VBN||.001-46/CD	dep||positivity-6/NN||15â-49/VBN	num||months-53/NNS||$-50/$	num||$-50/$||31-52/CD	tmod||15â-49/VBN||months-53/NNS	conj_and||increased-3/VBD||decreased-57/VBD	nsubj||p-67/VBP||136-59/CD	appos||136-59/CD||6â-61/NNP	num||6â-61/NNP||$-62/$	num||$-62/$||267-64/CD	parataxis||increased-3/VBD||p-67/VBP	dep||.04-69/CD||=-68/SYM	ccomp||p-67/VBP||.04-69/CD	prep_after||increased-3/VBD||restoration-72/NN	prep_of||restoration-72/NN||negativity-74/NN	dep||restoration-72/NN||32â-76/VBN	num||months-80/NNS||$-77/$	num||$-77/$||41-79/CD	tmod||32â-76/VBN||months-80/NNS	rigidity-2||nm-20||no_rel||flexor rigidity increased before hydrogen-breath-test positivity for small intestinal bacterial overgrowth (208 (28â€“388) nm ã— 10âˆ’3, p = .02), increased further during (171 (67â€“274), p = .001) (15â€“31 months), and decreased (136 (6â€“267), p = .04) after restoration of negativity (32â€“41 months).
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fat--1||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
nsubj||observed-2/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	amod||agreement-4/NN||strong-3/JJ	dobj||observed-2/VBD||agreement-4/NN	prep_between||agreement-4/NN||dna-6/NN	prep_from||observed-2/VBD||breasttumors-8/NNS	amod||tissue-12/NN||normal-10/JJ	amod||tissue-12/NN||lymphatic-11/JJ	prep_from||observed-2/VBD||tissue-12/NN	conj_and||breasttumors-8/NNS||tissue-12/NN	det||genotyping-15/NN||the-14/DT	prep_in||observed-2/VBD||genotyping-15/NN	prep_of||genotyping-15/NN||polymorphisms-17/NNS	num||enzymes-21/NNS||three-19/CD	amod||enzymes-21/NNS||tamoxifen-metabolizing-20/JJ	prep_in||polymorphisms-17/NNS||enzymes-21/NNS	breasttumors-8||tamoxifen--1||yes||we observed strong agreement between dna from breasttumors and normal lymphatic tissue in the genotyping of polymorphisms in three tamoxifen-metabolizing enzymes.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||looks-4/VBZ||study-3/NN	root||ROOT-0/null||looks-4/VBZ	det||aspects-7/NNS||some-6/DT	prep_at||looks-4/VBZ||aspects-7/NNS	prep_of||aspects-7/NNS||disability-9/NN	vmod||disability-9/NN||associated-10/VBN	num||disorders-14/NNS||7-12/CD	amod||disorders-14/NNS||psychiatric-13/JJ	prep_with||associated-10/VBN||disorders-14/NNS	nsubj||obsessiveâ-24/VBZ||schizophrenia-15/NN	amod||affectivedisorder-18/NN||bipolar-17/JJ	appos||schizophrenia-15/NN||affectivedisorder-18/NN	appos||schizophrenia-15/NN||anxietydisorders-20/NNS	appos||schizophrenia-15/NN||depression-22/NN	rcmod||disorders-14/NNS||obsessiveâ-24/VBZ	dobj||obsessiveâ-24/VBZ||$-25/$	advmod||alcohol-42/CD||compulsive-27/RB	dep||mental-33/JJ||disorder-28/JJ	conj_and||mental-33/JJ||dementia-30/JJ	amod||disorders-36/NNS||dementia-30/JJ	amod||disorders-36/NNS||mental-33/JJ	conj_and||mental-33/JJ||behavioural-35/JJ	amod||disorders-36/NNS||behavioural-35/JJ	npadvmod||alcohol-42/CD||disorders-36/NNS	det||use-40/NN||the-39/DT	prep_due_to||alcohol-42/CD||use-40/NN	prep||use-40/NN||of-41/IN	num||$-25/$||alcohol-42/CD	alcohol-42||anxietydisorders-20||no_rel||the present study looks at some aspects of disability associated with 7 psychiatric disorders schizophrenia, bipolar affectivedisorder, anxietydisorders, depression, obsessiveâ€“compulsive disorder, dementia, and mental and behavioural disorders due to the use of alcohol.
mark||similar-11/JJ||although-1/IN	amod||scores-4/NNS||mean-2/JJ	nn||scores-4/NNS||pain-3/NN	nsubj||similar-11/JJ||scores-4/NNS	det||labor-7/NN||the-6/DT	prep_throughout||scores-4/NNS||labor-7/NN	prep_throughout||scores-4/NNS||delivery-9/NN	conj_and||labor-7/NN||delivery-9/NN	cop||similar-11/JJ||were-10/VBD	advcl||required-21/VBD||similar-11/JJ	det||groups-14/NNS||both-13/DT	prep_in||similar-11/JJ||groups-14/NNS	amod||patients-17/NNS||more-16/JJR	nsubj||required-21/VBD||patients-17/NNS	amod||group-20/NN||fentanyl-19/JJ	prep_in||patients-17/NNS||group-20/NN	root||ROOT-0/null||required-21/VBD	amod||boluses-23/NNS||supplementary-22/JJ	dobj||required-21/VBD||boluses-23/NNS	mark||significant-27/JJ||though-24/IN	neg||significant-27/JJ||not-25/RB	advmod||significant-27/JJ||statistically-26/RB	advcl||required-21/VBD||significant-27/JJ	pain-3||fentanyl-19||yes||although mean pain scores throughout the labor and delivery were similar in both groups, more patients in fentanyl group required supplementary boluses though not statistically significant.
nsubj||analog-6/NN||lamivudine-1/NN	cop||analog-6/NN||is-2/VBZ	det||analog-6/NN||a-3/DT	amod||analog-6/NN||synthetic-4/JJ	nn||analog-6/NN||nucleoside-5/NN	root||ROOT-0/null||analog-6/NN	det||action-10/NN||a-8/DT	amod||action-10/NN||potent-9/JJ	prep_with||analog-6/NN||action-10/NN	nn||replication-13/NN||hbv-12/NN	prep_on||action-10/NN||replication-13/NN	hbv-12||lamivudine-1||yes||lamivudine is a synthetic nucleoside analog with a potent action on hbv replication.
prep||excluded-20/VBN||given-1/VBN	det||insulin-4/NN||the-2/DT	amod||insulin-4/NN||low-3/JJ	pobj||given-1/VBN||insulin-4/NN	nn||levels-7/NNS||glucose-6/NN	pobj||given-1/VBN||levels-7/NNS	conj_and||insulin-4/NN||levels-7/NNS	amod||fasting-10/NN||prolonged-9/JJ	prep_after||insulin-4/NN||fasting-10/NN	nn||action-15/NN||hyperglycemia-12/NN	conj_and||hyperglycemia-12/NN||insulin-14/NN	nn||action-15/NN||insulin-14/NN	nsubjpass||excluded-20/VBN||action-15/NN	nsubj||intramuscular-31/VBP||action-15/NN	nn||se-17/FW||per-16/FW	advmod||excluded-20/VBN||se-17/FW	aux||excluded-20/VBN||can-18/MD	auxpass||excluded-20/VBN||be-19/VB	root||ROOT-0/null||excluded-20/VBN	amod||mechanisms-23/NNS||underlying-22/VBG	prep_as||excluded-20/VBN||mechanisms-23/NNS	vmod||mechanisms-23/NNS||pointing-25/VBG	amod||ffa-29/NN||elevated-27/JJ	nn||ffa-29/NN||plasma-28/NN	prep_toward||pointing-25/VBG||ffa-29/NN	conj_and/or||excluded-20/VBN||intramuscular-31/VBP	amod||accumulation-33/NN||fat-32/JJ	dobj||intramuscular-31/VBP||accumulation-33/NN	amod||causes-36/NNS||possible-35/JJ	prep_as||intramuscular-31/VBP||causes-36/NNS	det||reduction-40/NN||the-38/DT	amod||reduction-40/NN||observed-39/JJ	prep_for||causes-36/NNS||reduction-40/NN	amod||capacity-43/NN||mitochondrial-42/JJ	prep_in||reduction-40/NN||capacity-43/NN	hyperglycemia-12||insulin-14||yes||given the low insulin and glucose levels after prolonged fasting, hyperglycemia and insulin action per se can be excluded as underlying mechanisms, pointing toward elevated plasma ffa and/or intramuscular fat accumulation as possible causes for the observed reduction in mitochondrial capacity.
amod||services-4/NNS||non-hiv/aids-2/JJ	nn||services-4/NNS||health-3/NN	prep_for||increased-31/VBD||services-4/NNS	nn||lab-7/NN||tb-6/NN	nsubj||tests-8/VBZ||lab-7/NN	nsubj||diagnoses-20/VBZ||lab-7/NN	parataxis||increased-31/VBD||tests-8/VBZ	number||1.19-10/CD||-lrb--9/CD	dobj||tests-8/VBZ||1.19-10/CD	num||%-13/NN||95-12/CD	appos||1.19-10/CD||%-13/NN	dep||-rrb--18/JJ||c.i.-14/NNP	num||c.i.-14/NNP||0.25-15/CD	num||c.i.-14/NNP||2.14-17/CD	amod||%-13/NN||-rrb--18/JJ	conj_and||tests-8/VBZ||diagnoses-20/VBZ	parataxis||increased-31/VBD||diagnoses-20/VBZ	number||0.34-22/CD||-lrb--21/CD	dobj||diagnoses-20/VBZ||0.34-22/CD	num||%-25/NN||95-24/CD	nsubj||increased-31/VBD||%-25/NN	dep||-rrb--30/JJ||c.i.-26/NNP	num||c.i.-26/NNP||0.05-27/CD	num||c.i.-26/NNP||0.64-29/CD	amod||%-25/NN||-rrb--30/JJ	root||ROOT-0/null||increased-31/VBD	advmod||increased-31/VBD||significantly-32/RB	aids--1||hiv--1||no||for non-hiv/aids health services , tb lab tests -lrb- 1.19 , 95 % c.i. 0.25 , 2.14 -rrb- and diagnoses -lrb- 0.34 , 95 % c.i. 0.05 , 0.64 -rrb- increased significantly .
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||activities-6/NNS||the-4/DT	amod||activities-6/NNS||antibacterial-5/JJ	dobj||examined-3/VBD||activities-6/NNS	det||containing-10/NN||a-8/DT	nn||containing-10/NN||triclosan-9/NN	prep_of||activities-6/NNS||containing-10/NN	appos||containing-10/NN||seal-12/NNP	appos||containing-10/NN||protect-14/NNP	conj_and||seal-12/NNP||protect-14/NNP	det||desensitizer-20/NN||a-17/DT	nn||desensitizer-20/NN||benzalconium-18/NN	nn||desensitizer-20/NN||containing-19/NN	appos||containing-10/NN||desensitizer-20/NN	amod||prime-23/NN||micro-22/JJ	appos||desensitizer-20/NN||prime-23/NN	det||fluoride-27/NN||a-26/DT	appos||containing-10/NN||fluoride-27/NN	vmod||fluoride-27/NN||containing-28/VBG	advmod||paste-30/JJ||prophilaxy-29/RB	acomp||containing-28/VBG||paste-30/JJ	nn||desensitizer-33/NN||sultan-32/NN	appos||fluoride-27/NN||desensitizer-33/NN	num||fluoride-37/NN||two-36/CD	appos||containing-10/NN||fluoride-37/NN	dep||fluoride-37/NN||containing-38/VBG	dobj||containing-38/VBG||varnishes-39/NNS	amod||shealth-42/NN||cavity-41/JJ	dep||fluoride-37/NN||shealth-42/NN	nn||ez-45/NN||ultra-44/NN	dep||fluoride-37/NN||ez-45/NN	conj_and||shealth-42/NN||ez-45/NN	det||primer-52/NN||a-49/DT	amod||primer-52/NN||dentin-50/JJ	nn||primer-52/NN||bonding-51/NN	prep_of||activities-6/NNS||primer-52/NN	conj_and||containing-10/NN||primer-52/NN	det||bond-55/NN||all-54/DT	appos||primer-52/NN||bond-55/NN	cavity-41||fluoride-37||yes||this study examined the antibacterial activities of a triclosan containing (seal & protect), a benzalconium containing desensitizer (micro prime), a fluoride containing prophilaxy paste (sultan desensitizer), two fluoride containing varnishes (cavity shealth and ultra ez), and a dentin bonding primer (all bond).
det||bioactivity-2/NN||the-1/DT	nsubj||greater-20/JJR||bioactivity-2/NN	det||fraction-6/NN||the-4/DT	amod||fraction-6/NN||composite-5/JJ	prep_of||bioactivity-2/NN||fraction-6/NN	prepc_in||fraction-6/NN||enhancing-8/VBG	det||effect-11/NN||the-9/DT	amod||effect-11/NN||antibacterial-10/JJ	dobj||enhancing-8/VBG||effect-11/NN	prep_of||effect-11/NN||oxacillin-13/NN	prep_against||oxacillin-13/NN||methicillin-resistantstaphylococcusaureus-15/NNS	appos||methicillin-resistantstaphylococcusaureus-15/NNS||mrsa-17/NNP	cop||greater-20/JJR||was-19/VBD	root||ROOT-0/null||greater-20/JJR	mark||extract-30/VB||than-21/IN	nsubj||extract-30/VB||that-22/DT	det||monomer-26/NN||the-24/DT	amod||monomer-26/NN||individual-25/JJ	prep_of||that-22/DT||monomer-26/NN	det||hawthorn-29/NN||the-28/DT	prep_of||monomer-26/NN||hawthorn-29/NN	ccomp||greater-20/JJR||extract-30/VB	prep_in||extract-30/VB||vitro-32/NN	methicillin-resistantstaphylococcusaureus-15||antibacterial-10||no_rel||the bioactivity of the composite fraction in enhancing the antibacterial effect of oxacillin against methicillin-resistantstaphylococcusaureus (mrsa) was greater than that of the individual monomer of the hawthorn extract in vitro .
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||compare-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||compare-6/VB||to-5/TO	xcomp||conducted-4/VBN||compare-6/VB	det||efficacy-8/NN||the-7/DT	dobj||compare-6/VB||efficacy-8/NN	det||combination-11/NN||a-10/DT	prep_of||efficacy-8/NN||combination-11/NN	prep_of||combination-11/NN||ondansetron-13/NN	prep_of||combination-11/NN||dexamethasone-15/NN	conj_and||ondansetron-13/NN||dexamethasone-15/NN	prep_with||compare-6/VB||that-17/DT	nn||analgesia-36/NN||metoclopramide-19/NN	conj_and||metoclopramide-19/NN||dexamethasone-21/JJ	nn||analgesia-36/NN||dexamethasone-21/JJ	prep_for||dexamethasone-21/JJ||prevention-23/NN	prepc_of||prevention-23/NN||postoperativenauseaandvomiting-25/VBG	dobj||postoperativenauseaandvomiting-25/VBG||ponv-27/NNP	amod||patients-31/NNS||gynecologic-30/JJ	prep_in||ponv-27/NNP||patients-31/NNS	vmod||patients-31/NNS||receiving-32/VBG	amod||analgesia-36/NN||fentanyl-33/JJ	amod||analgesia-36/NN||iv-patient-34/JJ	amod||analgesia-36/NN||controlled-35/VBN	prep_of||that-17/DT||analgesia-36/NN	ponv-27||metoclopramide-19||yes||this study was conducted to compare the efficacy of a combination of ondansetron and dexamethasone with that of metoclopramide and dexamethasone for prevention of postoperativenauseaandvomiting (ponv) in gynecologic patients receiving fentanyl iv-patient controlled analgesia.
det||findings-2/NNS||these-1/DT	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||modulate-8/VB||that-4/IN	nsubj||modulate-8/VB||pde5inhibitors-5/NNS	nsubj||enhance-13/VB||pde5inhibitors-5/NNS	aux||modulate-8/VB||may-6/MD	advmod||modulate-8/VB||effectively-7/RB	ccomp||suggest-3/VBP||modulate-8/VB	dobj||modulate-8/VB||btb-9/NN	advmod||modulate-8/VB||permeability-10/RB	ccomp||suggest-3/VBP||enhance-13/VB	conj_and||modulate-8/VB||enhance-13/VB	nn||efficacy-17/NN||delivery-14/NN	conj_and||delivery-14/NN||therapeutic-16/JJ	nn||efficacy-17/NN||therapeutic-16/JJ	dobj||enhance-13/VB||efficacy-17/NN	amod||antibodies-20/NNS||monoclonal-19/JJ	prep_of||efficacy-17/NN||antibodies-20/NNS	amod||metastases-24/NNS||hard-to-treat-22/JJ	nn||metastases-24/NNS||brain-23/NN	prep_in||antibodies-20/NNS||metastases-24/NNS	amod||tumors-28/NNS||different-26/JJ	amod||tumors-28/NNS||primary-27/JJ	prep_from||enhance-13/VB||tumors-28/NNS	nsubj||metastasized-31/VBN||tumors-28/NNS	aux||metastasized-31/VBN||had-30/VBD	rcmod||tumors-28/NNS||metastasized-31/VBN	det||brain-34/NN||the-33/DT	prep_to||metastasized-31/VBN||brain-34/NN	pde5inhibitors-5||metastases-24||no_rel||these findings suggest that pde5inhibitors may effectively modulate btb permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.
mark||associated-15/VBN||while-1/IN	amod||plasminogenactivator-4/NN||increased-2/VBN	amod||plasminogenactivator-4/NN||urokinase-type-3/JJ	nsubjpass||associated-15/VBN||plasminogenactivator-4/NN	appos||plasminogenactivator-4/NN||upa-6/NN	vmod||plasminogenactivator-4/NN||expression-8/VBG	nn||tissue-12/NN||breast-10/NN	nn||tissue-12/NN||cancer-11/NN	prep_in||expression-8/VBG||tissue-12/NN	auxpass||associated-15/VBN||is-13/VBZ	advmod||associated-15/VBN||directly-14/RB	advcl||suggests-22/VBZ||associated-15/VBN	amod||prognosis-18/NN||poor-17/JJ	prep_with||associated-15/VBN||prognosis-18/NN	amod||evidence-21/NN||recent-20/JJ	nsubj||suggests-22/VBZ||evidence-21/NN	root||ROOT-0/null||suggests-22/VBZ	mark||suppress-27/VB||that-23/IN	nn||overexpression-25/NN||upa-24/NN	nsubj||suppress-27/VB||overexpression-25/NN	nsubj||prolong-31/VB||overexpression-25/NN	aux||suppress-27/VB||may-26/MD	ccomp||suggests-22/VBZ||suppress-27/VB	nn||growth-29/NN||tumor-28/NN	dobj||suppress-27/VB||growth-29/NN	ccomp||suggests-22/VBZ||prolong-31/VB	conj_and||suppress-27/VB||prolong-31/VB	dobj||prolong-31/VB||survival-32/NN	cancer-11||upa-24||no_rel||while increased urokinase-type plasminogenactivator (upa) expression in breast cancer tissue is directly associated with poor prognosis, recent evidence suggests that upa overexpression may suppress tumor growth and prolong survival.
nsubj||had-6/VBD||one-1/CD	det||women-5/NNS||every-3/DT	num||women-5/NNS||three-4/CD	prep_in||one-1/CD||women-5/NNS	root||ROOT-0/null||had-6/VBD	dobj||had-6/VBD||anaemia-7/NN	dobj||had-6/VBD||deficiency-9/NN	conj_and||anaemia-7/NN||deficiency-9/NN	prep_of||anaemia-7/NN||folicacid-11/NN	mark||had-17/VBD||while-12/IN	nsubj||had-17/VBD||one-13/CD	det||two-16/CD||every-15/DT	prep_in||one-13/CD||two-16/CD	advcl||had-6/VBD||had-17/VBD	dobj||had-17/VBD||irondeficiency-18/NN	vmod||had-17/VBD||suggesting-20/VBG	mark||constitute-28/VBP||that-21/IN	nsubj||constitute-28/VBP||deficiencies-22/NNS	preconj||folicacid-25/NN||both-24/DT	prep_of||deficiencies-22/NNS||folicacid-25/NN	prep_of||deficiencies-22/NNS||iron-27/NN	conj_and||folicacid-25/NN||iron-27/NN	ccomp||suggesting-20/VBG||constitute-28/VBP	det||deficiencies-32/NNS||the-29/DT	amod||deficiencies-32/NNS||major-30/JJ	nn||deficiencies-32/NNS||micronutrient-31/NN	dobj||constitute-28/VBP||deficiencies-32/NNS	nn||women-35/NNS||ethiopian-34/NN	prep_in||deficiencies-32/NNS||women-35/NNS	irondeficiency-18||iron-27||yes||one in every three women had anaemia and deficiency of folicacid while one in every two had irondeficiency, suggesting that deficiencies of both folicacid and iron constitute the major micronutrient deficiencies in ethiopian women.
nsubj||agonist-6/NN||methadone-1/NN	nsubjpass||recommended-10/VBN||methadone-1/NN	cop||agonist-6/NN||is-2/VBZ	det||agonist-6/NN||a-3/DT	amod||agonist-6/NN||âµ-opioid-4/JJ	nn||agonist-6/NN||receptor-5/NN	root||ROOT-0/null||agonist-6/NN	auxpass||recommended-10/VBN||is-8/VBZ	advmod||recommended-10/VBN||commonly-9/RB	conj_and||agonist-6/NN||recommended-10/VBN	prep_for||recommended-10/VBN||treatment-12/NN	prep_of||treatment-12/NN||opioiddependence-14/NN	prep_during||recommended-10/VBN||pregnancy-16/NN	opioiddependence-14||opioid--1||no||methadone is a âµ-opioid receptor agonist and is commonly recommended for treatment of opioiddependence during pregnancy.
advmod||viruses-3/NNS||most-1/RBS	amod||viruses-3/NNS||enteric-2/JJ	nsubj||produce-4/VBP||viruses-3/NNS	root||ROOT-0/null||produce-4/VBP	dobj||produce-4/VBP||diseases-5/NNS	nsubj||distinct-9/JJ||diseases-5/NNS	cop||distinct-9/JJ||are-7/VBP	neg||distinct-9/JJ||not-8/RB	rcmod||diseases-5/NNS||distinct-9/JJ	amod||pathogens-12/NNS||other-11/JJ	prep_from||distinct-9/JJ||pathogens-12/NNS	amod||diagnostics-16/NNS||current-15/JJ	nsubjpass||limited-18/VBN||diagnostics-16/NNS	auxpass||limited-18/VBN||is-17/VBZ	conj_and||produce-4/VBP||limited-18/VBN	prep_in||limited-18/VBN||breadth-20/NN	prep_in||limited-18/VBN||sensitivity-22/NN	conj_and||breadth-20/NN||sensitivity-22/NN	vmod||breadth-20/NN||required-23/VBN	aux||advance-25/VB||to-24/TO	xcomp||required-23/VBN||advance-25/VB	nn||schemes-28/NNS||virus-26/NN	nn||schemes-28/NNS||detection-27/NN	dobj||advance-25/VB||schemes-28/NNS	nn||strategies-32/NNS||disease-30/NN	nn||strategies-32/NNS||intervention-31/NN	prep_for||advance-25/VB||strategies-32/NNS	virus-26||viruses-3||no||most enteric viruses produce diseases that are not distinct from other pathogens, and current diagnostics is limited in breadth and sensitivity required to advance virus detection schemes for disease intervention strategies.
nsubj||report-5/NN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	aux||demonstrate-7/VB||to-6/TO	vmod||report-5/NN||demonstrate-7/VB	det||effects-9/NNS||the-8/DT	dobj||demonstrate-7/VB||effects-9/NNS	amod||polymorphisms-13/NNS||cyp2b6-11/JJ	amod||polymorphisms-13/NNS||g516t-12/JJ	prep_of||effects-9/NNS||polymorphisms-13/NNS	nn||efavirenz-16/NN||plasma-15/NN	prep_on||demonstrate-7/VB||efavirenz-16/NN	nn||concentrations-19/NNS||nevirapine-18/NN	prep_on||demonstrate-7/VB||concentrations-19/NNS	conj_and||efavirenz-16/NN||concentrations-19/NNS	advmod||co-administered-21/VBN||when-20/WRB	advcl||demonstrate-7/VB||co-administered-21/VBN	prep_with||co-administered-21/VBN||rifampicin-23/NN	amod||adults-28/NNS||hiv/tb-25/JJ	amod||adults-28/NNS||co-infected-26/JJ	nn||adults-28/NNS||thai-27/NN	prep_in||rifampicin-23/NN||adults-28/NNS	tb--1||rifampicin-23||yes||this is the first report to demonstrate the effects of cyp2b6 g516t polymorphisms on plasma efavirenz and nevirapine concentrations when co-administered with rifampicin in hiv/tb co-infected thai adults.
amod||dcs-2/NN||human-1/JJ	nsubj||phagocytose-4/VB||dcs-2/NN	nsubj||induce-10/VB||dcs-2/NN	aux||phagocytose-4/VB||can-3/MD	root||ROOT-0/null||phagocytose-4/VB	amod||cells-7/NNS||enterovirus-infected-5/JJ	amod||cells-7/NNS||pancreatic-6/JJ	dobj||phagocytose-4/VB||cells-7/NNS	advmod||induce-10/VB||subsequently-9/RB	conj_and||phagocytose-4/VB||induce-10/VB	amod||responses-13/NNS||innate-11/JJ	amod||responses-13/NNS||antiviral-12/JJ	dobj||induce-10/VB||responses-13/NNS	prep_such_as||responses-13/NNS||induction-17/NN	prep_of||induction-17/NN||rlhs-19/NNS	antiviral-12||enterovirus--1||no_rel||human dcs can phagocytose enterovirus-infected pancreatic cells and subsequently induce innate antiviral responses, such as induction of rlhs.
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	tumor-57||nitrite-14||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâ€“reacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	cholesterol-3||virus-17||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
nsubj||aim-2/VBP||we-1/PRP	nsubj||analyze-4/VB||we-1/PRP	root||ROOT-0/null||aim-2/VBP	aux||analyze-4/VB||to-3/TO	xcomp||aim-2/VBP||analyze-4/VB	amod||functioning-6/NN||neurocognitive-5/JJ	dobj||analyze-4/VB||functioning-6/NN	amod||patients-10/NNS||school-aged-8/JJ	nn||patients-10/NNS||cystinosis-9/NNS	prep_of||functioning-6/NN||patients-10/NNS	vmod||patients-10/NNS||treated-11/VBN	prep_with||treated-11/VBN||cysteamine-13/NN	mark||identify-17/VB||in-14/IN	dep||identify-17/VB||order-15/NN	aux||identify-17/VB||to-16/TO	advcl||treated-11/VBN||identify-17/VB	amod||deficits-19/NNS||specific-18/JJ	dobj||identify-17/VB||deficits-19/NNS	nsubj||lead-22/VB||deficits-19/NNS	aux||lead-22/VB||can-21/MD	rcmod||deficits-19/NNS||lead-22/VB	prepc_to||lead-22/VB||learning-24/VBG	dobj||learning-24/VBG||difficulties-25/NNS	cystinosis-9||cysteamine-13||yes||we aim to analyze neurocognitive functioning of school-aged cystinosis patients treated with cysteamine in order to identify specific deficits that can lead to learning difficulties.
det||decline-2/NN||a-1/DT	nsubj||indicates-11/VBZ||decline-2/NN	nn||sensitivity-6/NN||body-4/NN	nn||sensitivity-6/NN||insulin-5/NN	prep_in||decline-2/NN||sensitivity-6/NN	advmod||healthy-9/JJ||apparently-8/RB	amod||individuals-10/NNS||healthy-9/JJ	prep_in||sensitivity-6/NN||individuals-10/NNS	root||ROOT-0/null||indicates-11/VBZ	det||risk-14/NN||a-12/DT	amod||risk-14/NN||high-13/JJ	dobj||indicates-11/VBZ||risk-14/NN	aux||develop-16/VB||to-15/TO	vmod||risk-14/NN||develop-16/VB	dobj||develop-16/VB||type2diabetes-17/NNS	type2diabetes-17||insulin-5||yes||a decline in body insulin sensitivity in apparently healthy individuals indicates a high risk to develop type2diabetes.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	obese-17||leucine-22||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
nsubj||induce-4/VB||dha-1/NN	aux||induce-4/VB||can-2/MD	advmod||induce-4/VB||strongly-3/RB	root||ROOT-0/null||induce-4/VB	dobj||induce-4/VB||apoptosis-5/NNS	amod||cells-11/NNS||human-7/JJ	amod||cells-11/NNS||mcf-7-8/JJ	nn||cells-11/NNS||breast-9/NN	nn||cells-11/NNS||cancer-10/NN	prep_in||apoptosis-5/NNS||cells-11/NNS	preconj||induce-4/VB||both-12/DT	prep_in||induce-4/VB||vitro-14/NNP	prep_in||induce-4/VB||vivo-17/NN	conj_and||vitro-14/NNP||vivo-17/NN	cancer-10||dha-1||no_rel||dha can strongly induce apoptosis in human mcf-7 breast cancer cells both in vitro and in vivo .
nsubj||effective-4/JJ||caspofungin-1/NN	nsubj||tolerated-7/JJ||caspofungin-1/NN	cop||effective-4/JJ||was-2/VBD	dep||effective-4/JJ||both-3/DT	root||ROOT-0/null||effective-4/JJ	advmod||tolerated-7/JJ||well-6/RB	conj_and||effective-4/JJ||tolerated-7/JJ	amod||groups-11/NNS||high-risk-9/JJ	nn||groups-11/NNS||patient-10/NN	prep_among||effective-4/JJ||groups-11/NNS	prep_such_as||groups-11/NNS||those-14/DT	amod||malignancies-19/NNS||neutropenia-16/JJ	conj_and||neutropenia-16/JJ||active-18/JJ	amod||malignancies-19/NNS||active-18/JJ	prep_with||those-14/DT||malignancies-19/NNS	caspofungin-1||neutropenia-16||no_rel||caspofungin was both effective and well tolerated among high-risk patient groups such as those with neutropenia and active malignancies.
det||combination-2/NN||the-1/DT	nsubj||provide-17/VBP||combination-2/NN	nn||recruitment-5/NN||community-4/NN	prep_of||combination-2/NN||recruitment-5/NN	prep_of||combination-2/NN||acasi-7/NNS	conj_and||recruitment-5/NN||acasi-7/NNS	amod||testing-10/NN||rapid-9/JJ	prep_of||combination-2/NN||testing-10/NN	conj_and||recruitment-5/NN||testing-10/NN	det||study-16/NN||a-12/DT	amod||study-16/NN||linked-13/VBN	amod||study-16/NN||diagnostic-14/JJ	nn||study-16/NN||accuracy-15/NN	prep_of||combination-2/NN||study-16/NN	conj_and||recruitment-5/NN||study-16/NN	root||ROOT-0/null||provide-17/VBP	amod||methods-19/NNS||enhanced-18/VBN	dobj||provide-17/VBP||methods-19/NNS	prepc_for||provide-17/VBP||conducting-21/VBG	dobj||conducting-21/VBG||blood-22/NN	vmod||blood-22/NN||borne-23/VBN	nn||studies-26/NNS||virus-24/NN	amod||studies-26/NNS||sero-prevalence-25/JJ	dobj||borne-23/VBN||studies-26/NNS	prep_in||borne-23/VBN||idus-28/NNS	virus-24||idus-28||yes||the combination of community recruitment, acasi, rapid testing and a linked diagnostic accuracy study provide enhanced methods for conducting blood borne virus sero-prevalence studies in idus.
advmod||studied-14/VBN||furthermore-1/RB	det||role-4/NN||the-3/DT	nsubjpass||studied-14/VBN||role-4/NN	prep_of||role-4/NN||hyperglycemia-6/NNP	prep_of||role-4/NN||hyperinsulinemia-8/NNP	conj_versus||hyperglycemia-6/NNP||hyperinsulinemia-8/NNP	amod||disposal-12/NN||exenatide-mediated-10/JJ	nn||disposal-12/NN||glucose-11/NN	prep_in||hyperglycemia-6/NNP||disposal-12/NN	auxpass||studied-14/VBN||was-13/VBD	root||ROOT-0/null||studied-14/VBN	hyperglycemia-6||glucose-11||no||furthermore, the role of hyperglycemia versus hyperinsulinemia in exenatide-mediated glucose disposal was studied.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||cidofovir-27||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||measured-9/VBD||we-8/PRP	rcmod||$-6/$||measured-9/VBD	amod||circumference-11/NN||waist-10/JJ	dobj||measured-9/VBD||circumference-11/NN	nn||pressure-14/NN||blood-13/NN	dobj||measured-9/VBD||pressure-14/NN	conj_and||circumference-11/NN||pressure-14/NN	nn||concentrations-21/NNS||glucose-16/NN	conj_and||glucose-16/NN||insulin-18/NN	nn||concentrations-21/NNS||insulin-18/NN	conj_and||glucose-16/NN||lipid-20/NN	nn||concentrations-21/NNS||lipid-20/NN	dobj||measured-9/VBD||concentrations-21/NNS	conj_and||circumference-11/NN||concentrations-21/NNS	det||prevalence-25/NN||the-24/DT	dobj||measured-9/VBD||prevalence-25/NN	conj_and||circumference-11/NN||prevalence-25/NN	amod||syndrome-28/NN||metabolic-27/JJ	prep_of||prevalence-25/NN||syndrome-28/NN	amod||panel-36/NN||national-30/JJ	nn||panel-36/NN||cholesterol-31/NN	nn||panel-36/NN||education-32/NN	nn||panel-36/NN||program-33/NN	nn||panel-36/NN||adult-34/NN	nn||panel-36/NN||treatment-35/NN	dep||syndrome-28/NN||panel-36/NN	dep||syndrome-28/NN||definition-38/NN	conj_iii||panel-36/NN||definition-38/NN	num||men-42/NNS||1,492-41/CD	prep_in||measured-9/VBD||men-42/NNS	prep_in||measured-9/VBD||women-44/NNS	conj_and||men-42/NNS||women-44/NNS	vmod||men-42/NNS||aged-45/VBN	dobj||aged-45/VBN||26â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||32-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_in||aged-45/VBN||delhi-52/NNS	poss||weight-57/NN||delhi-52/NNS	appos||delhi-52/NNS||india-54/NN	nsubjpass||recorded-61/VBN||weight-57/NN	conj_and||weight-57/NN||height-59/NN	nsubjpass||recorded-61/VBN||height-59/NN	auxpass||recorded-61/VBN||were-60/VBD	rcmod||delhi-52/NNS||recorded-61/VBN	det||months-64/NNS||every-62/DT	num||months-64/NNS||6-63/CD	tmod||recorded-61/VBN||months-64/NNS	prep_throughout||recorded-61/VBN||infancy-66/NN	dep||infancy-66/NN||0â-68/NNS	num||years-72/NNS||$-69/$	num||$-69/$||2-71/CD	dep||0â-68/NNS||years-72/NNS	prep_throughout||recorded-61/VBN||childhood-75/NN	conj_and||infancy-66/NN||childhood-75/NN	dep||childhood-75/NN||2â-77/NNS	num||years-81/NNS||$-78/$	num||$-78/$||11-80/CD	dep||2â-77/NNS||years-81/NNS	prep_throughout||recorded-61/VBN||adolescence-85/NN	conj_and||infancy-66/NN||adolescence-85/NN	num||yearsâ-88/NNS||11-87/CD	dep||adolescence-85/NN||yearsâ-88/NNS	dep||yearsâ-88/NNS||$-89/$	dep||$-89/$||adult-91/NN	delhi-52||lipid-20||no_rel||research design and methods â€”we measured waist circumference, blood pressure, glucose, insulin and lipid concentrations, and the prevalence of metabolic syndrome (national cholesterol education program adult treatment panel iii definition) in 1,492 men and women aged 26â€“32 years in delhi, india, whose weight and height were recorded every 6 months throughout infancy (0â€“2 years), childhood (2â€“11 years), and adolescence (11 yearsâ€“adult).
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||chloroquine-18||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
nsubj||suggests-10/VBZ||demonstration-1/NN	prep_of||demonstration-1/NN||persistence-3/NN	prep_of||demonstration-1/NN||function-5/NN	conj_and||persistence-3/NN||function-5/NN	amod||cells-9/NNS||insulin-producing-7/JJ	amod||cells-9/NNS||pancreatic-8/JJ	prep_of||persistence-3/NN||cells-9/NNS	root||ROOT-0/null||suggests-10/VBZ	det||possibility-12/NN||the-11/DT	dobj||suggests-10/VBZ||possibility-12/NN	prep_in||î-25/VBP||possibility-12/NN	det||state-16/NN||a-14/DT	amod||state-16/NN||steady-15/JJ	prep_of||possibility-12/NN||state-16/NN	prep_of||state-16/NN||turnover-18/NN	nsubj||î-25/VBP||stimuli-21/NNS	aux||enhance-23/VB||to-22/TO	vmod||stimuli-21/NNS||enhance-23/VB	dobj||enhance-23/VB||endogenous-24/NNS	rcmod||possibility-12/NN||î-25/VBP	amod||cells-27/NNS||²-26/JJ	nsubj||approach-33/NN||cells-27/NNS	aux||approach-33/NN||could-28/MD	cop||approach-33/NN||be-29/VB	det||approach-33/NN||a-30/DT	amod||approach-33/NN||viable-31/JJ	amod||approach-33/NN||therapeutic-32/JJ	ccomp||î-25/VBP||approach-33/NN	det||number-37/NN||a-35/DT	amod||number-37/NN||significant-36/JJ	prep_in||approach-33/NN||number-37/NN	prep_of||number-37/NN||patients-39/NNS	prep_with||patients-39/NNS||type1diabetes-41/CD	advmod||approach-33/NN||even-43/RB	prep_for||approach-33/NN||those-45/DT	amod||duration-48/NN||chronic-47/JJ	prep_with||those-45/DT||duration-48/NN	type1diabetes-41||insulin--1||yes||demonstration of persistence and function of insulin-producing pancreatic cells suggests the possibility of a steady state of turnover in which stimuli to enhance endogenous î² cells could be a viable therapeutic approach in a significant number of patients with type1diabetes, even for those with chronic duration.
amod||rate-2/NN||goitre-1/JJ	nsubjpass||measured-37/VBN||rate-2/NN	nsubjpass||compared-39/VBN||rate-2/NN	nn||hormone-6/NN||serum-4/NN	amod||hormone-6/NN||thyroid-stimulating-5/JJ	appos||rate-2/NN||hormone-6/NN	appos||hormone-6/NN||tsh-8/NN	appos||rate-2/NN||thyroxine-11/NN	conj_and||hormone-6/NN||thyroxine-11/NN	appos||thyroxine-11/NN||t4-13/NNP	nn||antibody-18/NN||thyroid-16/NN	nn||antibody-18/NN||peroxidase-17/NN	appos||rate-2/NN||antibody-18/NN	conj_and||hormone-6/NN||antibody-18/NN	appos||antibody-18/NN||tpoab-20/NN	nn||antibody-24/NN||thyroglobulin-23/NN	appos||rate-2/NN||antibody-24/NN	conj_and||hormone-6/NN||antibody-24/NN	appos||antibody-24/NN||tgab-26/NN	advmod||iodine-31/JJ||urinary-30/RB	amod||concentration-32/NN||iodine-31/JJ	appos||rate-2/NN||concentration-32/NN	conj_and||hormone-6/NN||concentration-32/NN	appos||concentration-32/NN||uic-34/NN	auxpass||measured-37/VBN||were-36/VBD	root||ROOT-0/null||measured-37/VBN	conj_and||measured-37/VBN||compared-39/VBN	det||goitrous-42/NNS||the-41/DT	prep_between||measured-37/VBN||goitrous-42/NNS	dep||goitrous-42/NNS||n-44/VBN	dep||478-46/CD||=-45/SYM	ccomp||n-44/VBN||478-46/CD	det||participants-56/NNS||the-49/DT	amod||participants-56/NNS||non-goitrous-50/JJ	dep||non-goitrous-50/JJ||n-52/VBN	dep||2,045-54/CD||=-53/SYM	ccomp||n-52/VBN||2,045-54/CD	prep_between||measured-37/VBN||participants-56/NNS	conj_and||goitrous-42/NNS||participants-56/NNS	goitre-1||t4-13||yes||goitre rate, serum thyroid-stimulating hormone (tsh), thyroxine (t4), thyroid peroxidase antibody (tpoab), thyroglobulin antibody (tgab), and urinary iodine concentration (uic) were measured and compared between the goitrous (n=478) and the non-goitrous (n=2,045) participants.
advmod||pathogenic-2/JJ||highly-1/RB	amod||avianinfluenzavirus-3/NNS||pathogenic-2/JJ	nsubjpass||isolated-9/VBN||avianinfluenzavirus-3/NNS	det||subtype-7/NN||the-5/DT	amod||subtype-7/NN||h5n1-6/JJ	prep_of||avianinfluenzavirus-3/NNS||subtype-7/NN	auxpass||isolated-9/VBN||was-8/VBD	root||ROOT-0/null||isolated-9/VBN	prep_from||isolated-9/VBN||specimens-11/NNS	det||birds-15/NNS||the-13/DT	amod||birds-15/NNS||affected-14/VBN	prep_of||specimens-11/NNS||birds-15/NNS	h5n1-6||avianinfluenzavirus-3||no||highly pathogenic avianinfluenzavirus of the h5n1 subtype was isolated from specimens of the affected birds.
nn||artesunate-2/NN||intramuscular-1/NN	nsubj||superior-5/JJ||artesunate-2/NN	nsubj||intramuscular-7/VB||artesunate-2/NN	aux||superior-5/JJ||may-3/MD	cop||superior-5/JJ||be-4/VB	root||ROOT-0/null||superior-5/JJ	aux||intramuscular-7/VB||to-6/TO	xcomp||superior-5/JJ||intramuscular-7/VB	dobj||intramuscular-7/VB||artemether-8/NN	det||treatment-11/NN||the-10/DT	prep_for||intramuscular-7/VB||treatment-11/NN	amod||malaria-14/NN||severe-13/JJ	prep_of||treatment-11/NN||malaria-14/NN	prep_in||malaria-14/NN||adults-16/NNS	malaria-14||artemether-8||yes||intramuscular artesunate may be superior to intramuscular artemether for the treatment of severe malaria in adults.
det||role-2/NN||the-1/DT	nsubj||has-33/VBZ||role-2/NN	nsubjpass||determined-36/VBN||role-2/NN	advmod||dosed-5/JJ||lower-4/RBR	amod||glioma-31/NN||dosed-5/JJ	conj_or||dosed-5/JJ||dose-dense-7/JJ	amod||glioma-31/NN||dose-dense-7/JJ	conj_or||dosed-5/JJ||continuous-10/JJ	amod||glioma-31/NN||continuous-10/JJ	nn||glioma-31/NN||regimen-11/NN	nn||combination-16/NN||drug-15/NN	prep_with||glioma-31/NN||combination-16/NN	prep_without||glioma-31/NN||combination-16/NN	det||role-19/NN||the-18/DT	conj_and||combination-16/NN||role-19/NN	prep_with||glioma-31/NN||role-19/NN	prep_without||glioma-31/NN||role-19/NN	prep_of||role-19/NN||temozolomide-21/NN	advmod||diagnosed-24/JJ||newly-23/RB	amod||iii-27/NN||diagnosed-24/JJ	amod||iii-27/NN||astrocytoma-25/JJ	nn||iii-27/NN||grade-26/NN	prep_for||temozolomide-21/NN||iii-27/NN	prep_of||role-2/NN||low-29/JJ	conj_and||glioma-31/NN||low-29/JJ	nn||glioma-31/NN||grade-30/NN	prep_of||role-2/NN||glioma-31/NN	prep_of||role-2/NN||glioma-31/NN	conj_or||glioma-31/NN||glioma-31/NN	advmod||has-33/VBZ||still-32/RB	root||ROOT-0/null||has-33/VBZ	aux||determined-36/VBN||to-34/TO	auxpass||determined-36/VBN||be-35/VB	xcomp||has-33/VBZ||determined-36/VBN	astrocytoma-25||temozolomide-21||yes||the role of lower dosed, dose-dense, or continuous regimen with or without drug combination and the role of temozolomide for newly diagnosed astrocytoma grade iii and low grade glioma still has to be determined.
nsubjpass||introduced-14/VBN||mallards-1/NNS	amod||platyrhynchos-4/NNS||anas-3/JJ	appos||mallards-1/NNS||platyrhynchos-4/NNS	advmod||infected-7/VBN||recently-6/RB	vmod||mallards-1/NNS||infected-7/VBN	amod||viruses-12/NNS||h5n2-9/JJ	conj_or||h5n2-9/JJ||h7n3-11/JJ	amod||viruses-12/NNS||h7n3-11/JJ	prep_with||infected-7/VBN||viruses-12/NNS	auxpass||introduced-14/VBN||were-13/VBD	root||ROOT-0/null||introduced-14/VBN	det||mallards-20/NNS||a-16/DT	nn||mallards-20/NNS||room-17/NN	nn||mallards-20/NNS||housing-18/NN	amod||mallards-20/NNS||other-19/JJ	prep_into||introduced-14/VBN||mallards-20/NNS	prep||introduced-14/VBN||plus-21/CC	pobj||plus-21/CC||chickens-22/NNS	pobj||plus-21/CC||blackbirds-24/NNS	conj_and||chickens-22/NNS||blackbirds-24/NNS	pobj||plus-21/CC||rats-26/NNS	conj_and||chickens-22/NNS||rats-26/NNS	pobj||plus-21/CC||pigeons-28/NNS	conj_and||chickens-22/NNS||pigeons-28/NNS	nsubjpass||assessed-33/VBN||transmission-31/NN	auxpass||assessed-33/VBN||was-32/VBD	conj_and||introduced-14/VBN||assessed-33/VBN	agent||assessed-33/VBN||monitoring-35/VBG	dobj||monitoring-35/VBG||virus-36/NN	amod||virus-36/NN||shedding-37/VBG	appos||virus-36/NN||ducks-39/NNS	dobj||monitoring-35/VBG||seroconversion-42/NN	conj_or||virus-36/NN||seroconversion-42/NN	amod||species-45/NNS||other-44/JJ	appos||seroconversion-42/NN||species-45/NNS	det||weeks-51/NNS||the-48/DT	amod||weeks-51/NNS||following-49/JJ	num||weeks-51/NNS||4-50/CD	prep_over||seroconversion-42/NN||weeks-51/NNS	virus-36||viruses-12||no||mallards ( anas platyrhynchos ) recently infected with h5n2 or h7n3 viruses were introduced into a room housing other mallards plus chickens, blackbirds, rats and pigeons, and transmission was assessed by monitoring virus shedding (ducks) or seroconversion (other species) over the following 4 weeks.
nsubj||increased-7/VBD||bortezomib-1/NN	vmod||bortezomib-1/NN||used-2/VBN	amod||treatment-5/NN||first-line-4/JJ	prep_as||used-2/VBN||treatment-5/NN	advmod||increased-7/VBD||significantly-6/RB	root||ROOT-0/null||increased-7/VBD	nn||deposition-9/NN||collagen-8/NN	dobj||increased-7/VBD||deposition-9/NN	prep_in||increased-7/VBD||patients-11/NNS	nn||lesions-16/NNS||multiplemyeloma-13/NN	conj_and||multiplemyeloma-13/NN||osteolytic-15/NN	nn||lesions-16/NNS||osteolytic-15/NN	prep_with||increased-7/VBD||lesions-16/NNS	det||addition-20/NN||the-19/DT	nsubj||inhibited-28/VBD||addition-20/NN	det||transiently-27/NN||a-22/DT	amod||transiently-27/NN||glucocorticoid-23/JJ	det||treatment-26/NN||the-25/DT	prep_to||glucocorticoid-23/JJ||treatment-26/NN	prep_of||addition-20/NN||transiently-27/NN	conj_but||increased-7/VBD||inhibited-28/VBD	det||effect-31/NN||the-29/DT	amod||effect-31/NN||positive-30/JJ	dobj||inhibited-28/VBD||effect-31/NN	prep_of||effect-31/NN||bortezomib-33/NN	vmod||inhibited-28/VBD||suggesting-35/VBG	mark||result-39/VB||that-36/IN	nsubj||result-39/VB||bortezomib-37/NN	aux||result-39/VB||may-38/MD	ccomp||suggesting-35/VBG||result-39/VB	amod||healing-42/NN||better-41/JJR	prep_in||result-39/VB||healing-42/NN	amod||lesions-45/NNS||osteolytic-44/JJ	prep_of||healing-42/NN||lesions-45/NNS	advmod||used-47/VBN||when-46/WRB	advcl||result-39/VB||used-47/VBN	prep_without||used-47/VBN||glucocorticoids-49/NNS	prep_in||glucocorticoids-49/NNS||patients-51/NNS	nsubj||obtained-54/VBN||patients-51/NNS	aux||obtained-54/VBN||have-53/VBP	rcmod||patients-51/NNS||obtained-54/VBN	dobj||obtained-54/VBN||remission-55/NN	det||therapy-59/NN||a-57/DT	amod||therapy-59/NN||previous-58/JJ	prep_with||obtained-54/VBN||therapy-59/NN	multiplemyeloma-13||bortezomib-37||yes||bortezomib used as first-line treatment significantly increased collagen deposition in patients with multiplemyeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy.
prepc_compared_with||increased-16/VBN||with-2/IN	det||controls-5/NNS||the-3/DT	amod||controls-5/NNS||healthy-4/JJ	pobj||increased-16/VBN||controls-5/NNS	det||level-10/NN||the-7/DT	amod||level-10/NN||plasma-8/JJ	amod||level-10/NN||il-21-9/JJ	nsubjpass||increased-16/VBN||level-10/NN	nsubjpass||decreased-22/VBN||level-10/NN	amod||patients-13/NNS||chronichepatitisb-12/JJ	prep_in||level-10/NN||patients-13/NNS	auxpass||increased-16/VBN||was-14/VBD	advmod||increased-16/VBN||significantly-15/RB	root||ROOT-0/null||increased-16/VBN	amod||carriers-20/NNS||chronic-18/JJ	nn||carriers-20/NNS||hbv-19/NN	prep_in||increased-16/VBN||carriers-20/NNS	conj_and||increased-16/VBN||decreased-22/VBN	amod||hepatitisb-25/JJ||inactive-24/JJ	amod||carriers-31/NNS||hepatitisb-25/JJ	nn||carriers-31/NNS||surface-26/NN	nn||carriers-31/NNS||antigen-27/NN	appos||carriers-31/NNS||hbsag-29/NN	prep_in||decreased-22/VBN||carriers-31/NNS	nn||0.05-35/NNP||p-33/NNP	nn||0.05-35/NNP||<-34/NNP	appos||carriers-31/NNS||0.05-35/NNP	hbv-19||hbsag-29||yes||compared with the healthy controls, the plasma il-21 level in chronichepatitisb patients was significantly increased in chronic hbv carriers and decreased in inactive hepatitisb surface antigen (hbsag) carriers (p<0.05).
advmod||defines-14/VBZ||thus-1/RB	det||capability-4/NN||the-3/DT	nsubj||defines-14/VBZ||capability-4/NN	amod||t-cells-9/NNS||hiv-specific-6/JJ	amod||t-cells-9/NNS||cd8-7/JJ	amod||t-cells-9/NNS||+-8/JJ	prep_of||capability-4/NN||t-cells-9/NNS	advmod||express-12/JJ||rapidly-11/RB	amod||perforin-13/NN||express-12/JJ	prep_to||t-cells-9/NNS||perforin-13/NN	root||ROOT-0/null||defines-14/VBZ	det||correlate-17/NN||a-15/DT	nn||correlate-17/NN||novel-16/NN	dobj||defines-14/VBZ||correlate-17/NN	prep_of||correlate-17/NN||control-19/NN	prep_in||control-19/NN||hivinfection-21/NN	hivinfection-21||hiv--1||no||thus, the capability of hiv-specific cd8+ t-cells to rapidly express perforin defines a novel correlate of control in hivinfection.
poss||results-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||considered-8/VBN||that-4/IN	nsubjpass||considered-8/VBN||lamivudine-5/NN	nsubj||prevent-19/VB||lamivudine-5/NN	aux||considered-8/VBN||should-6/MD	auxpass||considered-8/VBN||be-7/VB	ccomp||demonstrate-3/VBP||considered-8/VBN	advmod||considered-8/VBN||preemptively-9/RB	det||chemotherapy-12/NN||the-11/DT	prep_before||considered-8/VBN||chemotherapy-12/NN	det||patients-17/NNS||all-14/DT	amod||patients-17/NNS||hbsag-positive-15/JJ	nn||patients-17/NNS||nhl-16/NN	prep_for||chemotherapy-12/NN||patients-17/NNS	aux||prevent-19/VB||to-18/TO	xcomp||considered-8/VBN||prevent-19/VB	nn||reactivation-21/NN||hbv-20/NN	dobj||prevent-19/VB||reactivation-21/NN	prep_regardless_of||hbeag-26/VBG||pre-chemotherapy-25/NN	xcomp||considered-8/VBN||hbeag-26/VBG	dobj||hbeag-26/VBG||status-27/NN	hbv-20||hbsag--1||yes||our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all hbsag-positive nhl patients to prevent hbv reactivation, regardless of pre-chemotherapy hbeag status.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||lumefantrine--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
nsubj||been-3/VBN||he-1/PRP	aux||been-3/VBN||has-2/VBZ	root||ROOT-0/null||been-3/VBN	amod||drugs-6/NNS||anti-tuberculous-5/JJ	prep_on||been-3/VBN||drugs-6/NNS	dep||drugs-6/NNS||isoniazid-8/NN	appos||isoniazid-8/NN||rifampin-10/NN	num||year-14/NN||1-13/CD	prep_for||been-3/VBN||year-14/NN	poss||encephalitis-18/NN||his-16/PRP$	amod||encephalitis-18/NN||tuberculous-17/JJ	prep_for||year-14/NN||encephalitis-18/NN	tuberculous-17||isoniazid-8||yes||he has been on anti-tuberculous drugs (isoniazid, rifampin) for 1 year for his tuberculous encephalitis.
amod||diodes-5/NNS||phosphor-free-1/JJ	amod||diodes-5/NNS||apple-white-2/JJ	amod||diodes-5/NNS||light-3/JJ	nn||diodes-5/NNS||emitting-4/NN	nsubjpass||fabricated-8/VBN||diodes-5/NNS	aux||fabricated-8/VBN||have-6/VBP	auxpass||fabricated-8/VBN||been-7/VBN	root||ROOT-0/null||fabricated-8/VBN	xcomp||fabricated-8/VBN||using-9/VBG	det||wells-16/NNS||a-10/DT	amod||wells-16/NNS||dual-11/JJ	amod||wells-16/NNS||stacked-12/JJ	amod||wells-16/NNS||ingan/gan-13/JJ	amod||wells-16/NNS||multiple-14/JJ	nn||wells-16/NNS||quantum-15/NN	dobj||using-9/VBG||wells-16/NNS	vmod||wells-16/NNS||comprising-17/VBG	det||set-21/NN||a-19/DT	amod||set-21/NN||lower-20/JJR	prep_of||comprising-17/VBG||set-21/NN	amod||wavelength-24/NN||long-23/JJ	prep_of||set-21/NN||wavelength-24/NN	vmod||comprising-17/VBG||emitting-25/VBG	amod||nanostructures-27/NNS||indium-rich-26/JJ	dobj||emitting-25/VBG||nanostructures-27/NNS	vmod||nanostructures-27/NNS||incorporated-28/VBN	amod||wells-32/NNS||multiple-30/JJ	nn||wells-32/NNS||quantum-31/NN	prep_in||incorporated-28/VBN||wells-32/NNS	det||set-36/NN||an-34/DT	amod||set-36/NN||upper-35/JJ	nsubj||emitting-39/VBG||set-36/NN	prep_of||set-36/NN||cyan-green-38/NN	prepc_with||incorporated-28/VBN||emitting-39/VBG	amod||wells-42/NNS||multiple-40/JJ	nn||wells-42/NNS||quantum-41/NN	dobj||emitting-39/VBG||wells-42/NNS	gan--1||wells-42||no_rel||phosphor-free apple-white light emitting diodes have been fabricated using a dual stacked ingan/gan multiple quantum wells comprising of a lower set of long wavelength emitting indium-rich nanostructures incorporated in multiple quantum wells with an upper set of cyan-green emitting multiple quantum wells.
det||rate-5/NN||the-1/DT	amod||rate-5/NN||minimum-2/JJ	amod||rate-5/NN||effective-3/JJ	nn||rate-5/NN||infusion-4/NN	nsubj||bupivacaine-9/VBP||rate-5/NN	num||%-8/NN||0.125-7/CD	prep_of||rate-5/NN||%-8/NN	root||ROOT-0/null||bupivacaine-9/VBP	prep_for||bupivacaine-9/VBP||cfnb-11/NN	mark||appears-14/VBZ||after-12/IN	nsubj||appears-14/VBZ||tkr-13/NN	nsubj||ml/h-18/NN||tkr-13/NN	advcl||bupivacaine-9/VBP||appears-14/VBZ	aux||ml/h-18/NN||to-15/TO	cop||ml/h-18/NN||be-16/VB	num||ml/h-18/NN||4-17/CD	xcomp||appears-14/VBZ||ml/h-18/NN	prepc_according_to||ml/h-18/NN||to-20/TO	det||scores-24/NNS||the-21/DT	amod||scores-24/NNS||vas-22/JJ	nn||scores-24/NNS||pain-23/NN	pobj||ml/h-18/NN||scores-24/NNS	pain-23||bupivacaine-9||yes||the minimum effective infusion rate of 0.125% bupivacaine for cfnb after tkr appears to be 4 ml/h according to the vas pain scores.
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hodgkinlymphoma-6||dacarbazine-19||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
nsubj||seems-14/VBZ||conclusions-1/NNS	nsubj||be-16/VB||conclusions-1/NNS	det||risk-3/NN||the-2/DT	nsubj||thromboembolism-7/VBP||risk-3/NN	amod||venous-6/NNS||non-fatal-5/JJ	prep_of||risk-3/NN||venous-6/NNS	rcmod||conclusions-1/NNS||thromboembolism-7/VBP	prep_among||thromboembolism-7/VBP||users-9/NNS	prep_of||users-9/NNS||oralcontraceptives-11/NNS	vmod||oralcontraceptives-11/NNS||containing-12/VBG	dobj||containing-12/VBG||drospirenone-13/NN	root||ROOT-0/null||seems-14/VBZ	aux||be-16/VB||to-15/TO	xcomp||seems-14/VBZ||be-16/VB	advmod||that-19/DT||twice-18/RB	prep_around||be-16/VB||that-19/DT	prep_of||that-19/DT||users-21/NNS	prep_of||users-21/NNS||oralcontraceptives-23/NNS	vmod||oralcontraceptives-23/NNS||containing-24/VBG	acomp||containing-24/VBG||levonorgestrel-25/JJ	mark||taken-38/VBN||after-27/IN	det||effects-29/NNS||the-28/DT	nsubjpass||taken-38/VBN||effects-29/NNS	amod||confounders-32/NNS||potential-31/JJ	prep_of||effects-29/NNS||confounders-32/NNS	amod||biases-35/NNS||prescribing-34/VBG	prep_of||effects-29/NNS||biases-35/NNS	conj_and||confounders-32/NNS||biases-35/NNS	aux||taken-38/VBN||have-36/VBP	auxpass||taken-38/VBN||been-37/VBN	advcl||seems-14/VBZ||taken-38/VBN	prep_into||taken-38/VBN||account-40/NN	thromboembolism-7||drospirenone-13||no||conclusions the risk of non-fatal venous thromboembolism among users of oralcontraceptives containing drospirenone seems to be around twice that of users of oralcontraceptives containing levonorgestrel, after the effects of potential confounders and prescribing biases have been taken into account.
nsubj||included-8/VBD||factors-1/NNS	vmod||factors-1/NNS||related-2/VBN	det||reappearance-5/NN||the-4/DT	prep_to||related-2/VBN||reappearance-5/NN	prep_of||reappearance-5/NN||vivaxmalaria-7/NN	root||ROOT-0/null||included-8/VBD	amod||dosage-12/NN||inadequate-9/JJ	amod||dosage-12/NN||total-10/JJ	nn||dosage-12/NN||primaquine-11/NN	dobj||included-8/VBD||dosage-12/NN	vmod||dosage-12/NN||received-13/VBN	xcomp||received-13/VBN||-lrb--14/VBG	num||-rrb--18/NNS||<-15/CD	num||-rrb--18/NNS||2.75-16/CD	amod||-rrb--18/NNS||mg/kg-17/JJ	nsubj||‰-24/VB||-rrb--18/NNS	appos||-rrb--18/NNS||duration-20/NN	nn||â-23/NN||fever-22/NN	prep_of||duration-20/NN||â-23/NN	ccomp||-lrb--14/VBG||‰-24/VB	amod||days-27/NNS||$-25/$	number||$-25/$||2-26/CD	tmod||‰-24/VB||days-27/NNS	prep_before||‰-24/VB||initiation-29/NN	prep_of||initiation-29/NN||treatment-31/NN	nn||count-34/NN||parasite-33/NN	dep||‰-24/VB||count-34/NN	nn||¥-39/NNP||admission-36/NN	nn||¥-39/NNP||â-37/NN	nn||¥-39/NNP||‰-38/NNP	prep_on||count-34/NN||¥-39/NNP	num||¥-39/NNP||10,000-40/CD	punct||count-34/NN||/-41/:	dep||count-34/NN||âµl-42/NN	amod||vivax-46/NN||multiple-44/JJ	nn||vivax-46/NN||p.-45/NN	appos||âµl-42/NN||vivax-46/NN	amod||infection-49/NN||genotype-48/JJ	dep||âµl-42/NN||infection-49/NN	dobj||included-8/VBD||presence-52/NN	conj_and||dosage-12/NN||presence-52/NN	nn||infection-56/NN||p.-54/NN	nn||infection-56/NN||falciparum-55/NN	prep_of||presence-52/NN||infection-56/NN	det||period-60/NN||the-58/DT	nn||period-60/NN||follow-up-59/NN	prep_during||infection-56/NN||period-60/NN	vivaxmalaria-7||primaquine-11||yes||factors related to the reappearance of vivaxmalaria included inadequate total primaquine dosage received -lrb- < 2.75 mg/kg -rrb- , duration of fever â ‰ $ 2 days before initiation of treatment , parasite count on admission â ‰ ¥ 10,000 / âµl , multiple p. vivax - genotype infection , and presence of p. falciparum infection during the follow-up period .
det||agents-4/NNS||the-1/DT	amod||agents-4/NNS||oral-2/JJ	amod||agents-4/NNS||chondroprotective-3/JJ	nsubj||make-10/VBP||agents-4/NNS	prep_such_as||agents-4/NNS||glucosamine-7/NN	prep_such_as||agents-4/NNS||chondroitinsulfate-9/NN	conj_and||glucosamine-7/NN||chondroitinsulfate-9/NN	root||ROOT-0/null||make-10/VBP	det||patients-12/NNS||the-11/DT	nsubj||alleviate-13/VB||patients-12/NNS	ccomp||make-10/VBP||alleviate-13/VB	poss||pain-15/NN||their-14/PRP$	dobj||alleviate-13/VB||pain-15/NN	amod||effects-18/NNS||adverse-17/JJ	prep_without||alleviate-13/VB||effects-18/NNS	pain-15||chondroitinsulfate-9||yes||the oral chondroprotective agents such as glucosamine and chondroitinsulfate make the patients alleviate their pain without adverse effects.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	bacterialmeningitis-30||glucose-7||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||propofol-14||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
det||phase-3/NN||the-1/DT	amod||phase-3/NN||first-2/JJ	nsubj||occurred-4/VBD||phase-3/NN	root||ROOT-0/null||occurred-4/VBD	prep_between||occurred-4/VBD||1973-6/CD	prep_between||occurred-4/VBD||1982-8/CD	conj_and||1973-6/CD||1982-8/CD	prep_during||located-16/VBN||which-10/WDT	det||foci-12/NN||the-11/DT	nsubjpass||located-16/VBN||foci-12/NN	prep_of||foci-12/NN||hfrs-14/NNS	auxpass||located-16/VBN||was-15/VBD	dep||occurred-4/VBD||located-16/VBN	det||shandong-20/NN||the-18/DT	amod||shandong-20/NN||south-19/JJ	prep_in||located-16/VBN||shandong-20/NN	det||peak-24/NN||the-22/DT	nn||peak-24/NN||epidemic-23/NN	nsubj||occurred-25/VBD||peak-24/NN	dep||occurred-4/VBD||occurred-25/VBD	conj_and||located-16/VBN||occurred-25/VBD	det||fall-28/NN||the-27/DT	prep_in||occurred-25/VBD||fall-28/NN	prep_in||occurred-25/VBD||winter-30/NN	conj_and||fall-28/NN||winter-30/NN	xcomp||occurred-25/VBD||presenting-32/VBG	det||transmission-41/NN||a-33/DT	amod||transmission-41/NN||seasonal-34/JJ	amod||transmission-41/NN||characteristic-35/JJ	prep_of||characteristic-35/JJ||hantaanvirus-37/NNS	appos||hantaanvirus-37/NNS||htnv-39/NNP	dobj||presenting-32/VBG||transmission-41/NN	hfrs-14||hantaanvirus-37||no||the first phase occurred between 1973 and 1982 during which the foci of hfrs was located in the south shandong and the epidemic peak occurred in the fall and winter, presenting a seasonal characteristic of hantaanvirus (htnv) transmission.
nsubj||studied-2/VBD||we-1/PRP	nsubj||found-17/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	amod||alterations-4/NNS||microcircuit-3/JJ	dobj||studied-2/VBD||alterations-4/NNS	det||cortex-8/NN||the-6/DT	amod||cortex-8/NN||prefrontal-7/JJ	prep_in||studied-2/VBD||cortex-8/NN	det||model-13/NN||the-10/DT	amod||model-13/NN||valproicacid-11/JJ	nn||model-13/NN||rat-12/NN	prep_in||cortex-8/NN||model-13/NN	prep_of||model-13/NN||autism-15/NN	conj_and||studied-2/VBD||found-17/VBD	mark||connected-25/VBN||that-18/IN	det||neurons-23/NNS||the-19/DT	nn||neurons-23/NNS||layer-20/NN	num||neurons-23/NNS||5-21/CD	nn||neurons-23/NNS||pyramidal-22/NN	nsubjpass||connected-25/VBN||neurons-23/NNS	auxpass||connected-25/VBN||are-24/VBP	ccomp||found-17/VBD||connected-25/VBN	advmod||neighbouring-29/JJ||significantly-27/RB	advmod||neighbouring-29/JJ||more-28/RBR	amod||neurons-30/NNS||neighbouring-29/JJ	prep_to||connected-25/VBN||neurons-30/NNS	prep||connected-25/VBN||than-31/IN	pcomp||than-31/IN||in-32/IN	pobj||in-32/IN||controls-33/NNS	valproicacid-11||autism-15||no_rel||we studied microcircuit alterations in the prefrontal cortex in the valproicacid rat model of autism and found that the layer 5 pyramidal neurons are connected to significantly more neighbouring neurons than in controls.
num||cities-5/NNS||two-2/CD	amod||cities-5/NNS||neighboring-3/JJ	nn||cities-5/NNS||german-4/NN	prep_in||recorded-23/VBN||cities-5/NNS	amod||factors-10/NNS||prevalence-7/JJ	conj_and||prevalence-7/JJ||additional-9/JJ	amod||factors-10/NNS||additional-9/JJ	nsubjpass||recorded-23/VBN||factors-10/NNS	det||development-13/NN||the-12/DT	prep_of||factors-10/NNS||development-13/NN	prep_of||development-13/NN||bp-onj-15/NNP	nn||patients-18/NNS||multiplemyeloma-17/NN	prep_in||bp-onj-15/NNP||patients-18/NNS	amod||therapy-21/NN||bisphosphonates-20/JJ	prep_with||patients-18/NNS||therapy-21/NN	auxpass||recorded-23/VBN||were-22/VBD	root||ROOT-0/null||recorded-23/VBN	xcomp||recorded-23/VBN||using-24/VBG	det||retrospective-26/NN||a-25/DT	dobj||using-24/VBG||retrospective-26/NN	appos||retrospective-26/NN||rs-28/NN	amod||study-32/NN||cross-sectional-31/JJ	dobj||using-24/VBG||study-32/NN	conj_and||retrospective-26/NN||study-32/NN	appos||study-32/NN||css-34/NN	dep||retrospective-26/NN||design-36/NN	cross--1||bisphosphonates-20||no_rel||in two neighboring german cities, prevalence and additional factors of the development of bp-onj in multiplemyeloma patients with bisphosphonates therapy were recorded using a retrospective (rs) and cross-sectional study (css) design.
nn||fibre-2/NN||conclusion-1/NN	nsubj||effective-11/JJ||fibre-2/NN	conj_and||fibre-2/NN||antispasmodics-4/NNS	nsubj||effective-11/JJ||antispasmodics-4/NNS	conj_and||fibre-2/NN||peppermintoil-7/NN	nsubj||effective-11/JJ||peppermintoil-7/NN	cop||effective-11/JJ||were-8/VBD	det||effective-11/JJ||all-9/DT	advmod||effective-11/JJ||more-10/RBR	root||ROOT-0/null||effective-11/JJ	prep_than||effective-11/JJ||placebo-13/NN	det||treatment-16/NN||the-15/DT	prep_in||effective-11/JJ||treatment-16/NN	prep_of||treatment-16/NN||irritablebowelsyndrome-18/NN	irritablebowelsyndrome-18||fibre-2||no_rel||conclusion fibre, antispasmodics, and peppermintoil were all more effective than placebo in the treatment of irritablebowelsyndrome.
prep_in||started-10/VBD||response-2/NN	det||cancer-7/NN||the-4/DT	amod||cancer-7/NN||exacerbated-5/JJ	nn||cancer-7/NN||prostate-6/NN	prep_to||response-2/NN||cancer-7/NN	nsubj||started-10/VBD||we-9/PRP	root||ROOT-0/null||started-10/VBD	det||therapy-12/NN||a-11/DT	dobj||started-10/VBD||therapy-12/NN	det||administration-15/NN||the-14/DT	prep_involving||therapy-12/NN||administration-15/NN	num||weight-20/NN||8-17/CD	amod||weight-20/NN||mg/kg-18/JJ	nn||weight-20/NN||body-19/NN	prep_of||administration-15/NN||weight-20/NN	prep_of||weight-20/NN||dexamethasone-22/NN	num||mg/m2-25/NNS||55-24/CD	prep_of||administration-15/NN||mg/m2-25/NNS	conj_and||weight-20/NN||mg/m2-25/NNS	prep_of||mg/m2-25/NNS||docetaxel-27/NN	det||weeks-30/NNS||every-28/DT	num||weeks-30/NNS||3-29/CD	tmod||started-10/VBD||weeks-30/NNS	cancer-7||dexamethasone-22||no_rel||in response to the exacerbated prostate cancer, we started a therapy involving the administration of 8 mg/kg body weight of dexamethasone and 55 mg/m2 of docetaxel every 3 weeks.
amod||virus-7/NN||incurable-2/JJ	conj_but||incurable-2/JJ||treatable-4/JJ	amod||virus-7/NN||treatable-4/JJ	amod||virus-7/NN||herpes-5/JJ	amod||virus-7/NN||simplex-6/JJ	prep_including||halve-18/VB||virus-7/NN	appos||virus-7/NN||hsv-9/NN	num||ulcers-12/NNS||-2-11/CD	nsubj||halve-18/VB||ulcers-12/NNS	det||calculation-16/NN||the-14/DT	nn||calculation-16/NN||effectiveness-15/NN	prep_in||ulcers-12/NNS||calculation-16/NN	aux||halve-18/VB||would-17/MD	root||ROOT-0/null||halve-18/VB	det||proportion-20/NN||the-19/DT	dobj||halve-18/VB||proportion-20/NN	prep_of||proportion-20/NN||ulcers-22/NNS	dep||ulcers-22/NNS||cured-23/VBN	advmod||treated-26/VBN||correctly-25/RB	dep||ulcers-22/NNS||treated-26/VBN	conj_or||cured-23/VBN||treated-26/VBN	det||reduction-30/NN||this-29/DT	nsubjpass||countered-34/VBN||reduction-30/NN	aux||countered-34/VBN||could-31/MD	auxpass||countered-34/VBN||be-32/VB	advmod||countered-34/VBN||entirely-33/RB	conj_but||halve-18/VB||countered-34/VBN	agent||countered-34/VBN||including-36/VBG	amod||treatment-39/NN||episodic-37/JJ	amod||treatment-39/NN||antiviral-38/JJ	dobj||including-36/VBG||treatment-39/NN	det||guidelines-43/NNS||the-41/DT	amod||guidelines-43/NNS||national-42/JJ	prep_in||including-36/VBG||guidelines-43/NNS	antiviral-38||ulcers-22||no_rel||including incurable but treatable herpes simplex virus (hsv)-2 ulcers in the effectiveness calculation would halve the proportion of ulcers cured or correctly treated, but this reduction could be entirely countered by including episodic antiviral treatment in the national guidelines.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
det||phenomenon-5/NN||a-2/DT	amod||phenomenon-5/NN||well-recognized-3/JJ	amod||phenomenon-5/NN||clinical-4/JJ	prep_as||called-30/VBN||phenomenon-5/NN	amod||detectable-8/JJ||persistent-7/JJ	amod||replication-28/NN||detectable-8/JJ	amod||replication-28/NN||viral-9/JJ	amod||replication-28/NN||genome-10/JJ	prep_in||genome-10/JJ||liver-12/NN	prep_in||genome-10/JJ||sera-14/NN	conj_or||liver-12/NN||sera-14/NN	det||absence-17/NN||the-16/DT	prep_in||liver-12/NN||absence-17/NN	amod||markers-21/NNS||other-19/JJ	amod||markers-21/NNS||serological-20/JJ	prep_of||absence-17/NN||markers-21/NNS	amod||hepatitisbvirus-24/NNS||active-23/JJ	prep_for||markers-21/NNS||hepatitisbvirus-24/NNS	appos||hepatitisbvirus-24/NNS||hbv-26/NN	nsubjpass||called-30/VBN||replication-28/NN	auxpass||called-30/VBN||is-29/VBZ	root||ROOT-0/null||called-30/VBN	amod||infection-33/NN||occult-31/JJ	nn||infection-33/NN||hbv-32/NN	dobj||called-30/VBN||infection-33/NN	hbv-32||hepatitisbvirus-24||no||as a well-recognized clinical phenomenon, persistent detectable viral genome in liver or sera in the absence of other serological markers for active hepatitisbvirus (hbv) replication is called occult hbv infection.
nn||disorders-3/NNS||alcohol-1/NN	nn||disorders-3/NNS||use-2/NN	nsubj||affect-6/VBP||disorders-3/NNS	conj_and||disorders-3/NNS||alcoholdependency-5/NN	nsubj||affect-6/VBP||alcoholdependency-5/NN	root||ROOT-0/null||affect-6/VBP	dobj||affect-6/VBP||millions-7/NNS	prep_of||millions-7/NNS||individuals-9/NNS	advmod||affect-6/VBP||worldwide-10/RB	alcoholdependency-5||alcohol-1||no||alcohol use disorders and alcoholdependency affect millions of individuals worldwide.
